{
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "text_answer": "  To determine if the statement Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant is entailed or contradicted by the given trials we need to calculate the emesisfree days for each group and then compare the ratio of emesisfree days between the two groups  From the given trials we have  1 Aprepitant group 13 participants with",
        "label": "Entailment"
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "text_answer": "  The statement Only 2 patients in the primary trial did not have Recurrencefree Survival is not directly entailed or contradicted by the provided trial information The trial results only state that 98 out of 100 participants had Recurrencefree Survival but it does not specify how many did not have Recurrencefree Survival or their reasons for not having it Therefore the statement cannot be definitively determined",
        "label": "Contradiction"
    },
    "b03bae0b-6811-4c4d-a265-98c0f4ae7f1f": {
        "text_answer": "  The statement patients who have received gabapentin or herceptin treatment in the past year are not eligible for the secondary clinical trial but can participate in the primary clinical trial is a contradiction to the information provided in the trials inclusion and exclusion criteria  In the secondary trial the exclusion criteria state that no prior gabapentin or pregabalin is required for participation However the statement provided states that patients who have received gabapentin",
        "label": "Contradiction"
    },
    "1b2048ba-33c8-43d1-8d8f-bca70ca8d80c": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial the dosages of PF06647020 for Intervention 1 and Intervention 2 are 02 mgkg and 05 mgkg respectively In the secondary trial the dosages of ALT801 for Intervention 1 and Intervention 2 are 0",
        "label": "Entailment"
    },
    "f398c658-74cb-4d2b-894c-d785e4dde994": {
        "text_answer": "  The statement the primary clinical trial and secondary clinical trial utilize different metrics for assessing outcomes is entailed in the given trials as follows  1 In the primary clinical trial the outcome measures are the percentage of participants experiencing any treatment emergent adverse events and serious treatment emergent adverse events 2 In the secondary clinical trial the outcome measures are the number of participants with objective response  Both trials assess different outcomes using different metrics hence",
        "label": "Entailment"
    },
    "d4b54b4a-d675-4d59-b489-2c1a025b2b4e": {
        "text_answer": "  The statement patients with a clinically speculated diagnosis of an inoperable nonsmall cell lung cancer or small cell lung cancer are eligible for the primary clinical trial is entailed in the trials inclusion criteria since nonsmall cell lung cancer and small cell lung cancer are explicitly listed as eligible tumor types",
        "label": "Entailment"
    },
    "ad00f90a-b69d-4df4-a9f8-d495ac080b38": {
        "text_answer": "  The statement in comparison to patients on aprepitant in the primary clinical trial those given the placebo intervention were two times more likely to undergo emesis can be verified by calculating the ratio of the number of participants who experienced emesis in each group and comparing it to the stated ratio of 2  From the given results we have   Number of participants on aprepitant who experienced emesis 0  Number of",
        "label": "Entailment"
    },
    "7308389a-7cde-4cf2-8f68-cefff152645c": {
        "text_answer": "  The statement there were no occurrences of urinary tract infections among the participants of the primary clinical trial is contradictory to the information provided in the trials as one occurrence of urinary tract infection was reported 150 or 200 Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "d88cc7fc-34dc-4e86-a3a0-50192a316624": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials   In the primary trial high risk breast lesions including atypia or atypical hyperplasia are excluded Malignant ductal carcinoma in situ is considered a high risk breast lesion so it would be excluded from the primary trial  However in the secondary trial patients with a history of breast cancer including ductal carcinoma in",
        "label": "Entailment"
    },
    "36eb6a9f-5a3a-4f8f-b242-e669aeaa3547": {
        "text_answer": "  The statement participation in the primary clinical trial is not allowed for patients with visible tumors in both breasts is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information provided However the criteria do exclude patients with active or metastatic cancer which could include those with visible tumors in both breasts Thus it is safe to assume that the statement is",
        "label": "Entailment"
    },
    "b9e11a69-3cd1-4669-93ae-b644cbd40e71": {
        "text_answer": "  The statement is contradictory to the trials inclusion criteria The trial only accepts patients with metastatic breast cancer colorectal cancer with Kras or BRAF mutations esophageal andor gastric cancer cisplatinrefractory unresectable germ cell tumors or any tumor type with CCND1 amplification CDK46 mutation CCND2 amplification or any",
        "label": "Entailment"
    },
    "57eb42a8-0c1b-4358-b024-0579811b3db3": {
        "text_answer": "  The statement is entailed in the trials as both trials involve testing interventions on specific study groups In the primary trial the interventions are different radiation therapies Hydrophor and MediHoney applied to the skin during radiation therapy In contrast the secondary trial involves testing different doses 90 mg and 110 mg of the same treatment PF05212384 in combination with docetaxel for",
        "label": "Entailment"
    },
    "885733b0-a998-4f2c-b131-e58b2008a8a2": {
        "text_answer": "  The statement the primary clinical trial is designed for patients who exhibit optimal levels of vitamin d but such patients may be disqualified from the secondary clinical trial is neither entailed nor contradicted by the given trial information  Explanation  The primary clinical trial includes postmenopausal women with early stage breast cancer who have low vitamin D levels 40 ngml and will be treated with an aromatase inhibitor",
        "label": "Entailment"
    },
    "b8f0039d-f476-4aa1-a522-751d93e45147": {
        "text_answer": "  The statement results are available for the cohort on lbh589 and lapatinib in the primary clinical trial is a contradiction based on the information provided in the trials The trial results 1 and 2 only mention the combination of LBH589 with Capecitabine but there is no information about the combination of LBH589 and Lapatinib in the primary trial Therefore the statement is not entailed",
        "label": "Contradiction"
    },
    "c6aa83b0-88fb-475a-8b38-e330d2bdf332": {
        "text_answer": "  The statement partial or complete response is a partial or complete response to treatment the primary trial and the secondary trial adminster their interventions orally is entailed in the given trials as both trials involve administering interventions orally and the term partial or complete response refers to the response of the participants to the treatment",
        "label": "Entailment"
    },
    "b590614e-03b9-4e7b-91e9-940058316465": {
        "text_answer": "  The statement patients diagnosed with 23 cerebral metastases are ineligible for the secondary clinical trial but they may qualify for the primary clinical trial is neither entailed in the primary trial nor contradictory to it   The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is for patients with cerebral metastases from a histologically confirmed extracerebral site with one to",
        "label": "Entailment"
    },
    "4a73eb98-e69d-4116-bbed-7e1b6458aa61": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections of 120 milligrams every 4 weeks which translates to 03 grams per month 120 mg  4288 gmol  4   In contrast the secondary trial does not involve denosumab injections but rather the use",
        "label": "Entailment"
    },
    "eaf2bb85-799b-47e9-af79-4fc7a54f0fcd": {
        "text_answer": "  The statement is entailed in the trials as described In the trials the dosage of enzalutamide for cohort 1 is 80 mg two 40 mg capsules and for cohort 2 it is 160 mg four 40 mg capsules Therefore the dosage for cohort 2 is indeed double the dosage for cohort 1",
        "label": "Entailment"
    },
    "1692ad17-057d-4d84-bc1b-f9fa773288b2": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial involves an intraosseous injection of fluciclatide while the secondary trial involves an intravenous administration of chloroquine for the first cohort Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "f3918549-5e15-44e3-b35b-f7f361845792": {
        "text_answer": "  The statement in the primary clinical trial all observed adverse events were attributed to members of both cohorts not exclusively those in cohort 1 is not directly entailed or contradicted by the given data in the trials  The trials only provide the number and percentage of adverse events for each cohort but they do not specify which adverse events were shared between the cohorts or unique to each cohort Therefore based on",
        "label": "Contradiction"
    },
    "d46fad97-64a3-4553-a586-0dd9878009ec": {
        "text_answer": "  The statement distinct patient clusters are required for the secondary clinical trial and the primary clinical trial is not directly entailed or contradicted by the given trial results   The trials address different outcomes and drugs and the patient clusters may or may not be distinct depending on various factors such as inclusion and exclusion criteria disease conditions and study designs The trial results only provide information about the percentage of participants with a response within 10 days of first dose of den",
        "label": "Contradiction"
    },
    "be4814f1-b515-4744-8df9-293327502949": {
        "text_answer": "  The primary trial includes patients with a breast tumor 1 cm in diameter HR HER2 and the secondary trial includes patients with measurable disease but the size of the breast tumor is not specified in the secondary trial Therefore the statement about patients with a breast tumor 28 mm in diameter being eligible for both trials cannot be definitively determined based on the given information  However it is important to note that the primary trial has",
        "label": "Entailment"
    },
    "039ef0fd-7ea1-4820-b08f-99cf35009bc3": {
        "text_answer": "  The statement patients receiving warfarinfounded treatments are barred from the primary clinical trial yet they may still be suitable for the secondary clinical trial is a contradiction based on the provided inclusion and exclusion criteria for both trials  In the primary trial patients receiving warfarin are explicitly excluded However in the secondary trial lowdose warfarin less than or equal to 1 mgday is permitted Therefore",
        "label": "Contradiction"
    },
    "2945688b-8ee8-43ce-8ed3-30c0a4fdf489": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial mentions cabergoline being given orally PO while the secondary trial mentions pixantrone being given intravenously IV The statement suggests that the intervention in the primary trial is given topically which is not the case",
        "label": "Entailment"
    },
    "a6eb92cc-e789-4ced-a40c-166bebb09a67": {
        "text_answer": "  The statement There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs is not directly related to the information provided about the trials regarding the completion of a spine MRI study at diagnosis Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "5461003b-2108-4302-96ad-d843b5b9e938": {
        "text_answer": "  The statement zero adverse events were documented in both cohorts of the primary clinical trial is entailed in the given trials data since the data reports Total 060 000 for both Adverse Events 1 and Adverse Events 2 This means that no adverse events were documented in either cohort which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "0b343459-5c78-4c51-b71b-bfc5aa6d0c6a": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials   In the primary trial the reflexology intervention lasted for 10 weeks In the secondary trial both the placebo and vitamin D interventions lasted for 24 weeks The statement suggests that the intervention in the secondary trial concludes 20 weeks earlier than the intervention in the primary trial which is not the case Therefore the statement is contradictory",
        "label": "Entailment"
    },
    "1be9e4b6-a9e2-42b2-9131-4d7557ccd568": {
        "text_answer": "  The statement is a contradiction to the given trials   Explanation   The primary trial involves patients receiving denosumab injections every 4 weeks while the secondary trial does not mention anything about denosumab injections Instead it describes two interventions related to lymphoscintigraphy using a handheld gamma camera and standard gamma probes Therefore the statement that patients in the secondary trial undergo l",
        "label": "Contradiction"
    },
    "fb4df065-adca-4ce7-9059-bda1cc4ca1be": {
        "text_answer": "  The statement is entailed in the given trials as neither trial reported any adverse events in more than 10 of the participants In both trials the percentage of participants with adverse events was less than 1 Therefore the statement is a valid conclusion based on the provided data",
        "label": "Entailment"
    },
    "5a286769-0146-41da-8daa-af8c7169023a": {
        "text_answer": "  The statement patients with recent history within the last three years of pulmonary embolism will not be permitted to participate in the primary clinical trial but might be considered for the secondary clinical trial upon review by the investigator is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However it can be inferred that patients with a history of thrombotic or embolic events such as a stroke and",
        "label": "Entailment"
    },
    "c926dbb4-ab16-46dc-a2be-8d04563ce9d0": {
        "text_answer": "  The statement the secondary trial and the primary trial recorded an equal number of aes is contradictory to the given data   In the primary trial there were no adverse events reported out of 17 participants In contrast in the secondary trial there were 11 adverse events reported out of 25 participants Therefore the statement is contradictory to the given data",
        "label": "Contradiction"
    },
    "69b11fe6-3c14-4ac6-a664-916dc341700f": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial patients undergo mastectomy surgery and are not specified to receive any particular intervention after surgery   In the secondary trial there are two interventions for the HR subgroup In intervention 1 patients receive MM121 and Paclitaxel The MM121 is given as a 2 week",
        "label": "Entailment"
    },
    "e688cf8e-7082-43f3-803c-7489148f3cac": {
        "text_answer": "  The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is for patients with advanced or metast",
        "label": "Entailment"
    },
    "306374f7-40f9-45d5-a7cf-6cece3889a04": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   In the given trial the doses of eribulin and docetaxel are specified for each intervention The dose of eribulin for cohort 1 patients is 14mgm2 and the dose of docetaxel for cohort 2 patients is 75mgm2   To",
        "label": "Entailment"
    },
    "c616276b-e187-44ee-a2fb-93704f1a64cc": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement all patients in the primary clinical trial reported experiencing at least one adverse event while those in the secondary clinical trial completed it without any adverse events is contradicted by the data provided in the trials   In the primary clinical trial no adverse events were reported out of a total of 42 patients In contrast in the secondary clinical trial",
        "label": "Contradiction"
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "text_answer": "  The statement There were no patients with recorded Aes in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is entailed in the given trials data   Explanation   The statement is entailed because the primary trial had no recorded adverse events 042 and the secondary trial had at least one adverse event for every patient 10000 This means that the",
        "label": "Contradiction"
    },
    "e7f5c09e-9d3d-4081-a926-9f89647a0e3b": {
        "text_answer": "  The statement patients regardless of their gender having a solid tumor that is either locally advanced or metastatic may participate in both phases of the primary clinical trial is entailed in the given inclusion criteria for both Phase 1 and Phase 2 of the trial   The inclusion criteria for both phases state that participants must have a solid tumor that is locally advanced andor metastatic Therefore the statement is a logical consequence of the given inclusion",
        "label": "Entailment"
    },
    "687b9bc0-7328-4ecc-9bae-6b63f2df3cdb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial zoledronic acid in Intervention 1 is given intravenously but the other interventions and placebos are not specified for their route of administration   In the secondary trial some of the interventions granisetron hydrochloride dexamethasone and palonosetron hydrochloride",
        "label": "Entailment"
    },
    "55c1905d-0e17-41b6-89ba-c29df13d2e30": {
        "text_answer": "  The statement each patient in cohort 1 of the primary clinical trial that experienced infections and fever were the only ones is a contradiction to the given data in the Trials   Explanation  The statement implies that no other patients in cohort 1 experienced any other adverse events besides infections and fever However the data in Trial 1 shows that one patient experienced death NOS which is not mentioned in",
        "label": "Contradiction"
    },
    "1e213f71-5def-460d-b18e-aa58dbbe4463": {
        "text_answer": "  The primary clinical trial is not conducting trials with a dietary intervention as per the given information Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "e26430d8-c773-4770-b298-429c286fd5d3": {
        "text_answer": "  The statement patients diagnosed with leukemia irrespective of their cytogenic presentation are eligible for all cohorts of the primary clinical trial is not entailed in the given inclusion and exclusion criteria The criteria only specify eligibility based on breast cancer type age gender cancerfree status and treatment history Leukemia is not mentioned as a permitted or excluded condition Therefore the statement is contradictory to",
        "label": "Contradiction"
    },
    "67b66f39-48c2-495c-9ab0-0beefd9cdcef": {
        "text_answer": "  The statement is entailed in the trials as both GBM and gynecological cancer patient groups undergo 18FFDG and 18FFPPRGD2 PETCT or PETMRI imaging at specified time points with the same radiotracer doses Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "30234b84-2f15-4ea8-b7ed-af5f4ea40e9c": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve preoperative intravenous administration of Dexamethasone The statement also mentions that the participants have benign testicular neoplasms which is a nonmetastasizing neoplasm that arises from the testis and includes representative examples such as benign Sertoli cell tumor thecoma and fibroma",
        "label": "Entailment"
    },
    "2c9e275c-18ef-471f-8ec9-1d73bfb27e20": {
        "text_answer": "  The statement the severity of symptoms in patients in the primary clinical trial who did not receive paclitaxel infusions was milder than those who did receive paclitaxel infusions is not directly entailed in the given trial results   The trial results only provide the aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline for Arm I Cryotherapy and Arm",
        "label": "Contradiction"
    },
    "4fb8207e-292f-4f97-9587-bf028abd57be": {
        "text_answer": "  The statement All Infections and Infestations cases in the primary trial were for patients in cohort 1 does not directly entail or contradict the given information about the adverse events in the primary and secondary trials However it does provide additional context that may help interpret the data The statement does not affect the reported adverse event rates or their proportions in each trial Therefore the statement is neither entailed nor contradictory to the given information",
        "label": "Entailment"
    },
    "3426bc8a-b9c6-451e-aa76-25e1fc8bff69": {
        "text_answer": "  The statement increase travel for leisure or visit with people is a question about how often a person thought about increasing their travel for leisure or for visiting with people is neither entailed nor contradicted by the information provided in the primary or secondary trials The trials only provide information about the interventions being administered to the study participants and do not mention anything about their thoughts or behaviors regarding travel or visiting people",
        "label": "Entailment"
    },
    "c4620792-b333-4232-ba8e-62595917256f": {
        "text_answer": "  The statement is a contradiction to the given trials In the primary trial both interventions include Anastrozole but in the secondary trial Anastrozole is absent from Intervention 1",
        "label": "Contradiction"
    },
    "a68e6309-12b7-445f-837b-ce8cef67a882": {
        "text_answer": "  The statement eating disorders were not common for the primary trial candidates is not directly related to the adverse events listed in the trial data The statement about eating disorders being uncommon is not entailed or contradicted by the information provided in the trial data regarding adverse events The trial data only reports on various physical and laboratory adverse events and does not mention eating disorders",
        "label": "Contradiction"
    },
    "f81c0c12-c161-4e90-91e4-65a2b255d1c2": {
        "text_answer": "  The statement is not entailed in the trials as given   The primary trial is measuring the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial is measuring the change in total sleep time in minutes as assessed by polysomnography PSG before and after the first cycle of Lenalidomide treatment These outcomes are not directly related to each other",
        "label": "Contradiction"
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "text_answer": "  The statement 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrencefree Survival compared to the 67 from the NaCl 09 3mL group is a contradiction of the given trials  The trials provide the number of participants analyzed in each group and their Recurrencefree Survival rates However they do not directly provide the number of participants who",
        "label": "Contradiction"
    },
    "71db6876-7205-4e4b-9a89-949045f26ab9": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of which vaccine is given to which cohort in the trials provided for the Intervention 1 Adult Cancer Patients and Intervention 2 Healthy Volunteers The statement only mentions that Intervention 1 receives the pneumococcus vaccine and Intervention 2 receives the influenza vaccine but the trials do not necessarily follow this exact arrangement Therefore the statement",
        "label": "Contradiction"
    },
    "037ef54b-03fa-49f8-ae4b-ea645d268ea9": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both cohorts received the same dose of Cetuximab but cohort 1 had an additional Collaborative Care Intervention However the trial information clearly states that cohort 1 received a lower dose of Cetuximab 12 mgkg compared to cohort 2a 20",
        "label": "Entailment"
    },
    "889268e5-7b76-4c17-b567-bd828a9abf3e": {
        "text_answer": "  The statement numerous instances of cardiac and psychiatric aes were remarked during the primary clinical trial and the secondary clinical trial with only a few other types of aes reported is not entailed in the given trials data as there is no mention of the number or type of cardiac and psychiatric adverse events in the trials data provided However the statement is not contradicted by the data either as the trials data does not report the absence of cardiac and",
        "label": "Contradiction"
    },
    "2f7bf983-b072-4d3e-96fb-718475ef0fd2": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial uses a transdermal patch for intervention administration not mentioned in the statement while the secondary trial uses a sublingual method which is different from the primary trials administration method and is stated in the trial description",
        "label": "Entailment"
    },
    "0279dc49-0833-4673-8fb7-a7101a16fa14": {
        "text_answer": "  The statement candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial is entailed in the given trials as follows  1 The primary trial includes candidates with an ECOG score of 0 to 2 An ECOG score of 1 falls within this range 2 The secondary trial includes candidates with an ECOG score of 02 OR Karnofsky 6",
        "label": "Entailment"
    },
    "9126bd66-8ee7-47a5-84e2-0269efe06362": {
        "text_answer": "  The statement adults are excluded from the primary clinical trial but they are specifically eligible for the secondary clinical trial is contradictory based on the provided information   In the primary clinical trial adults postmenopausal women are included as long as they meet the specified criteria In contrast in the secondary clinical trial adults women are specifically mentioned as eligible for participation Therefore the statement is contradictory as adults are included in",
        "label": "Entailment"
    },
    "1b56f68b-a4b1-433c-a634-73ff99fce7aa": {
        "text_answer": "  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is not directly related to the given information about the box dosing unit Therefore the statement cannot be determined to be entailed or contradicted based on the provided trials alone  However the statement box dosing unit is a dosing unit equal to the amount of active ingredients",
        "label": "Contradiction"
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "text_answer": "  The statement Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial is entailed in the inclusion criteria of the trial   Explanation   The inclusion criteria state that patients with histologically proven DCIS are eligible for the trial The statement in question specifically mentions patients with DCIS who are considering AI therapy which is exactly what the inclusion criteria allow Therefore the statement is ent",
        "label": "Entailment"
    },
    "0a0a9bd9-b3d0-4af8-b09a-f0e3a1684ef0": {
        "text_answer": "  The statement a history of gabapentin or pregabalin use is not a disqualifying factor for the secondary trial but compromises eligibility for the primary trial is a statement of difference between the inclusion criteria of the two trials   In the primary trial a history of gabapentin or pregabalin use is a disqualifying factor In contrast in the secondary trial a history of gabapentin or pregabalin use is not",
        "label": "Entailment"
    },
    "462f7871-9216-4b37-af39-1fb32b2bbf84": {
        "text_answer": "  The statement the primary clinical trial does not admit patients who previously had serious anaphylactic reactions to trastuzumab is entailed in the trials exclusion criteria as stated History of grade 3 or 4 allergic reactions attributed to trastuzumab Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "548ed40c-ccf4-4250-9fd9-c870bcc61b17": {
        "text_answer": "  The statement engagement in regular physical activity is not a required component of the intervention for participants in the primary clinical trial is entailed in the given trial description The trial description specifies that engagement in regular physical activity is not a required component of the intervention for certain patient populations Therefore the statement is an accurate reflection of the information provided in the trial description",
        "label": "Entailment"
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "text_answer": "  The statement In total there are less cases of anemia in the primary trial than in the secondary trial is entailed in the trials as the number of anemia cases in the primary trial is 000 or 0 out of 37 while in the secondary trial it is 430 or 4 out of 93 Therefore the primary trial has fewer cases of anemia than the secondary trial",
        "label": "Entailment"
    },
    "098f7c20-8543-4de6-b236-341c4cdea28e": {
        "text_answer": "  The statement from the primary trial it was found that 13 of participants having her2 primary breast cancer developed imagable her2 metastases post their treatment with her2targeted petct 89zrtrastuzumab is entailed in the trial results 1 as the trial reports that 13 of participants developed imagable her2 metastases after undergoing HER2",
        "label": "Entailment"
    },
    "9d2b4df6-e802-437f-a844-61e944365df0": {
        "text_answer": "  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is not directly related to the adverse event data provided in the trials The statement in the question is about a specific question in the WHODAS 20 36item version selfadministered questionnaire and does not entail or contradict the information given in the trials regarding adverse events",
        "label": "Entailment"
    },
    "a02a0c3b-3c6c-45ce-a382-636abd7e1bef": {
        "text_answer": "  The statement in the primary clinical trial the outcomes from the placebo arm suggest superior overall response rate than the Arm A intervention however in the secondary clinical trial the zoledronic acid cohort recorded a shorter time to first onstudy SRE compared to the denosumab cohort is not directly entailed in the given trials as they address different outcome measures and patient populations  The primary trial compares Arm A and Arm B",
        "label": "Contradiction"
    },
    "a9f8fa09-52b6-4a39-b62b-3685f41d6c6e": {
        "text_answer": "  The statement is entailed in the trials as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion of the involved breast at three separate time points during the surgical procedures The statement about lipodystrophy being a disorder characterized by abnormal loss or redistribution of adip",
        "label": "Entailment"
    },
    "f5a3b01c-743a-4d70-81c8-a5671272d1e0": {
        "text_answer": "  The statement milliunit is a quantity equivalent to the one thousandth unit 10e3 unit is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "af9986f4-5f0c-4b8c-b02a-05ae6f7f4d1b": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we first need to calculate the percentage of responders participants with a decrease in GFS in each group  ERpositive Luminal B group 131 to 492 25th to 75th percentile Triple Negative group 67 to 352 ",
        "label": "Entailment"
    },
    "fe0af3be-4bf7-4e28-ad4c-81082e2ebfbd": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there is a comparison between two interventions one with CBTI and placebo and the other with CBTI and Armodafinil In the Armodafinil group patients receive Armodafinil daily for 47 days with a varying dosage throughout the treatment period   In contrast the secondary trial involves two different dos",
        "label": "Contradiction"
    },
    "b54c2b24-79e2-4561-bd18-ba18479cd7a3": {
        "text_answer": "  The statement was 1p19q deletion analysis performed is neither entailed nor contradicted by the information provided in the trials   The primary trial focuses on the use of oral pregabalin for treating patients while the secondary trial describes the treatment regimen for patients with Acute Myeloid Leukemia AML using Depocyt and HDMTX There is no mention of 1p19q delet",
        "label": "Entailment"
    },
    "52174f7c-e29a-4fc5-b116-eeb9ee0ecc34": {
        "text_answer": "  The statement ability to wash your back is a question about an individuals ability to wash their back is neither entailed nor contradicted by the information provided in the trials   The statement is not entailed because it does not directly relate to the adverse events mentioned in the trials   The statement is not contradicted because there is no information in the trials that suggests an individuals ability to wash their back is related to the occurrence of ad",
        "label": "Entailment"
    },
    "1f5d055f-5dde-400d-bbad-687e79830586": {
        "text_answer": "  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed in the given trials as they do not provide sufficient information to make that determination The trials only report the number and percentage of patients who experienced specific adverse events in each trial The statement makes a generalization about the absence of adverse events for all patients in both trials which is not explicitly stated in the trials Therefore",
        "label": "Contradiction"
    },
    "f4e8530b-843b-422e-8db4-c02378c66512": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive seven different types of drugs doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate and vinorelbine tartrate and undergo surgery In contrast the secondary trial participants receive only two different drugs everol",
        "label": "Entailment"
    },
    "0c561a05-4615-4578-aff2-745d9c9761c0": {
        "text_answer": "  To determine if the statement is entailed in the trials or if it is a contradiction we need to compare the percentage of participants with a decrease in the growth factor signature GFS between the ERpositive Luminal B and Triple Negative groups  According to the results provided the percentage of participants with a decrease in GFS in the ERpositive Luminal B group was 286 131",
        "label": "Entailment"
    },
    "1e5ed892-07f9-409a-bc45-edd43978e9b1": {
        "text_answer": "  The statement have not received treatment is a response indicating that an individual has not been treated for cancer is not directly related to the information provided in the trials However based on the information given the statement does not contradict the trials as the trials do not mention anything about the cancer treatment status of the patients in the intervention or control groups Therefore the statement is neutral with respect to the trials  Regarding the trials the statement Only cohort ",
        "label": "Entailment"
    },
    "7774f54f-4f08-4c6d-8fa4-af4979ba5bac": {
        "text_answer": "  The statement patients with a TNBC tumor of 18cm in diameter are eligible for both the primary trial and the secondary trial is contradictory to the given trials inclusion criteria  Explanation  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the primary trial explicitly states that patients with a tumor larger than 1 cm",
        "label": "Entailment"
    },
    "cfce111d-8810-4915-98ee-1e280271de10": {
        "text_answer": "  The statement participants in the primary clinical trial are administered pembrolizumab with a frequency that is double of that given sunitinib in the secondary clinical trial is entailed in the trials   Explanation   In the primary trial pembrolizumab is given every 3 weeks Q3W while in the secondary trial sunitinib is given on continuous dosing regimens with",
        "label": "Entailment"
    },
    "5861703f-56fc-4e31-ba4e-d97400d71d99": {
        "text_answer": "  The statement is entailed in the Trials since both trials recorded zero cases of febrile neutropenia and cholelithiasis",
        "label": "Entailment"
    },
    "4c5fcde7-b882-4ea3-96ba-275af987ea60": {
        "text_answer": "  The statement for every case of hypertension and pancreatectomy there were three cases of hepatotoxicity is a ratio statement expressing a relationship between three different types of adverse events in the trial   To verify whether this statement is entailed in the given data we need to check if the number of cases of hypertension and pancreatectomy is equal to one third of the number of cases of hepatot",
        "label": "Entailment"
    },
    "83c63591-6cde-4635-8d33-61dad15c7a21": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not provide sufficient information about the type of carcinoma being studied or the dosing frequency of sunitinib for the secondary trial The statement makes a specific assumption about the type of carcinoma being spiradenocylindrocarcinoma and arising in a spiradenocylindroma which is not mentioned in the trials Additionally the statement makes a comparison between the dosing frequency",
        "label": "Contradiction"
    },
    "ef245c6c-7858-45cd-a0fd-d272e7aae585": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there is no mention of myalgias being administered to any group In fact both groups receive normal saline injections which is not associated with myalgias   In the secondary trial myalgias are mentioned as a symptom experienced by patients with vitamin D deficiency but there is no information provided regarding any intervention involving myalgias  ",
        "label": "Contradiction"
    },
    "87a7f86a-e915-4ea9-a2ba-c8e4d37dfa15": {
        "text_answer": "  The statement working at a desk or table is a question about an individuals ability to work at a desk or table is neither entailed nor contradicted by the information provided in the Trials The Trials focus on the inclusion and exclusion criteria for patients participating in clinical trials for breast cancer treatment The statement is not directly related to the Trials and does not entail or contradict any information provided  Regarding the statements relation to the Tri",
        "label": "Entailment"
    },
    "aad4638b-6c8d-4f55-bf3f-5a3e9d74ef50": {
        "text_answer": "  The statement individuals with quantifiable tumor growth in both breasts can participate in the primary clinical trial is contradictory to the inclusion criteria of the trial The trial only includes individuals with unilateral breast cancer Therefore individuals with quantifiable tumor growth in both breasts do not meet the inclusion criteria and cannot participate in the trial",
        "label": "Entailment"
    },
    "ad66bfcf-7359-41c6-b4f8-694ed27fbc8e": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials report on the Maximum Tolerated Dose MTD of different interventions but they do not provide the same MTD value for comparison The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or Maximum Feasible Dose of MM111 The statement only ment",
        "label": "Contradiction"
    },
    "89c0759c-7a7e-4c65-b98e-841d2ca21808": {
        "text_answer": "  The statement patients with a histologicallycytologically confirmed diagnosis of advanced stage and metastatic melanoma or pancreatic cancer are qualified to participate in the primary clinical trial is not explicitly stated in the given inclusion criteria However it is mentioned that patients with Adenocarcinoma or carcinoma of unknown primary site are eligible for the trial While melanoma is not specifically listed it is a type of carcinoma",
        "label": "Entailment"
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "text_answer": "  The statement less than 5 of patients in the primary trial suffered AEs is entailed by the given trial data since the total number of adverse events is 2 and the total number of patients is 35 Therefore the percentage of patients suffering from adverse events is indeed less than 5",
        "label": "Entailment"
    },
    "1669453c-bb8e-437d-b5e2-98600980d7d3": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the same administration schedule for tremelimumab and the same optional extended treatment for durvalumab The only difference between the interventions is the dosage of durvalumab given in each monthly injection 03 mgkg vs 1 mgkg Therefore the statement accurately reflects the variations between the two interventions",
        "label": "Entailment"
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive CUDC101 at a dosage of 275 mgm2 but the frequency of administration differs cohort 1 receives the infusion for 5 days every 14 days while cohort 2 receives the infusion for 3 days every 28 days Although the dosage is the same cohort 1 is indeed administer",
        "label": "Entailment"
    },
    "72c54a84-aa51-4250-ba38-3646a07391b9": {
        "text_answer": "  The statement tumour lysis syndrome was a condition suffered by multiple patients participating in the primary clinical trial as well as the secondary clinical trial is not directly entailed or contradicted by the given data   The data provided only lists various adverse events and their frequencies in each trial Tumour lysis syndrome is not mentioned as an adverse event in either trial Therefore the statement cannot be determined to be entailed or contradicted based on the given",
        "label": "Contradiction"
    },
    "ab957edd-8a87-49e2-a7cf-0a55fb30c54f": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given trials we need to examine the information provided in the intervention section of the primary clinical trial for MM111  The statement is the method of administration dosage or schedule is not distinguished in the intervention section of the primary clinical trial  Lets check the intervention section of the primary clinical trial for MM111  No specific information",
        "label": "Entailment"
    },
    "884486ed-0e11-41be-9792-d2765bd977a2": {
        "text_answer": "  The statement every individual in the first cohort of the primary clinical trial experienced some form of adverse event is not directly entailed in the given trial results   The trial results only provide the number of participants with serious and nonserious adverse events for each dose level but they do not indicate that every participant in the first cohort which consists of 3 participants experienced an adverse event Therefore the statement is not entailed",
        "label": "Contradiction"
    },
    "a77a5845-0747-4291-b6de-4903e453ae6a": {
        "text_answer": "  The statement a greater number of patients in the secondary clinical trial were documented as having experienced adverse events AEs compared to patients in the primary clinical trial is entailed in the given data   Explanation  The statement requires that there be a greater number of patients in the secondary trial who experienced AEs compared to the primary trial The data provided shows that the number of patients with AEs in the secondary trial is 12 out of",
        "label": "Entailment"
    },
    "19738717-25bb-443f-8c7f-050bbc0c7a06": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial measure the Change in Ki67 Expression in Tumors is a contradiction to the information provided in the trials   The primary trial measures tumor response using RECIST criteria but it does not mention anything about Ki67 expression The secondary trial mentions several types of correlative studies including laboratory biomarker analysis but Ki67 expression is not specifically mentioned in the provided results",
        "label": "Contradiction"
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "text_answer": "  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the trials exclusion criteria as stated in the text provided Therefore the statement is entailed",
        "label": "Entailment"
    },
    "bffa5810-1ace-45e0-bf6d-6a3d35d6d4d7": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials explicitly state that xrays transendocardial injections CT scans and MRIs are excluded from the interventions",
        "label": "Entailment"
    },
    "264b1943-377e-4466-ad48-b4ba143f6bdb": {
        "text_answer": "  The statement We cannot compare the adverse events in the primary trial and the secondary trial as they do not appear to have been recorded for the primary trial is entailed in the given information The primary trial does not have any recorded adverse events listed while the secondary trial has several adverse events listed Therefore it is not possible to make a comparison between the two trials based on the provided data",
        "label": "Entailment"
    },
    "a6dad239-adab-48d2-b63a-0325c718ddf9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement mentions asthma as the most encountered adverse event but the trials do not report any cases of asthma among the adverse events listed Instead the primary trial reports a total of 3 adverse events out of 12 patients 2500 with no mention of asthma The secondary trial reports no adverse events for the given condition",
        "label": "Contradiction"
    },
    "2f813222-a2b6-488e-96e6-f1a3d8713550": {
        "text_answer": "  The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is not entailed in the given trial results   The trial results state that there were 24 treatmentemergent adverse events among the 25 participants analyzed not 35 patients Therefore the statement is a contradiction to the",
        "label": "Contradiction"
    },
    "2b58a234-e92e-475b-a0c9-a947776bf332": {
        "text_answer": "  The statement any patient that has been under the treatment involving antineoplastic chemotherapy androgens estrogens or progestogens in the last month before study initiation are dismissed from the primary clinical trial is entailed in the trials exclusion criteria   The trials exclusion criteria state that any patient currently receiving or planning to receive antineoplastic chemotherapy androgens estrogens or progestog",
        "label": "Entailment"
    },
    "c179c437-ffe9-4120-9390-58d88fb596f3": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The statement suggests that the intervention is uniform for both breast cancer and ovarianperitoneal cancer patients but the trials specify different dosing regimens for each cancer type Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "ce185781-5c8f-4849-b96c-734228f2a323": {
        "text_answer": "  The statement recombinants is an individual cell or organisms which carries recombinant DNA is not directly related to the inclusion and exclusion criteria provided in the primary or secondary trials Therefore it cannot be determined if the statement is entailed in the trials or not  Regarding the eligibility of patients with stage 4 cancer the primary trial includes patients with stage IIbIIIIV breast cancer while the secondary trial excludes patients",
        "label": "Entailment"
    },
    "2717fbc9-ffe5-419f-8c2d-ac9505f7cd01": {
        "text_answer": "  The statement is entailed in the Trials with Contradiction   Explanation  The primary trial and the secondary trial have different sets of inclusion and exclusion criteria The primary trial requires written informed consent while the secondary trial does not mention it as a criterion Therefore the statement that the secondary trial and the primary trial do not share any inclusion or exclusion criteria including the requirement to provide written informed consent is correct However",
        "label": "Entailment"
    },
    "1f77bf31-ae19-4adc-9af1-4c982718bbf6": {
        "text_answer": "  The statement is contradictory to the primary trial as the primary trial does apply a cycle to the intervention specifically a 21day cycle for each treatment administration The secondary trial on the other hand does not mention a cycle in the description of the intervention itself but rather mentions a predetermined 4week interval for imaging in the context of breast cancer surgery The primary trials cycle length is not mentioned in the statement making it contrad",
        "label": "Entailment"
    },
    "1672004b-d668-4441-95b4-eaab6fd70818": {
        "text_answer": "  The statement that a 384 month old patient with histologically verified diagnosis of stage III breast cancer absolute neutrophil count of 1807 x 106l platelet count of 79 x 104l hemoglobin level of 9 gdl and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial",
        "label": "Entailment"
    },
    "91afbc39-fae6-483e-8b8d-dc4ce8d0ea5c": {
        "text_answer": "  The statement the patient with the longest PFS in the primary clinical trial survived for 7 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "dbe6803f-8c85-45d2-a9b8-1bbd0e772733": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site Therefore intervention 1 using more substantial amounts of tc99m sulfur colloid than intervention 2 is not entailed in the trials",
        "label": "Contradiction"
    },
    "12279abc-fae3-49d8-ac68-95ed47f4de12": {
        "text_answer": "  The statement the serious adverse reactions were reported more frequently in the adverse events section of the primary clinical trial compared to the secondary clinical trial is a contradiction to the given data   The data shows that there were no serious adverse reactions reported in both trials for Adverse Event 1 Therefore it cannot be determined which trial had more serious adverse reactions based on the given information Additionally there is no information provided about Adverse Event 2 in",
        "label": "Contradiction"
    },
    "df141af2-f34d-4e16-aee3-72c015ccc995": {
        "text_answer": "  The statement none of the patients receiving the placebo intervention in the primary clinical trial experienced emesis is entailed in the trial results 2 as it reports that there were 0 participants in the placebo group who experienced emesis during the study period",
        "label": "Entailment"
    },
    "0dfa4e06-e226-4d46-be1f-90249c1f34d4": {
        "text_answer": "  The statement a higher number of patients in the secondary clinical trial were documented to have chest pain compared to those in the primary clinical trial is not mentioned in the given trials data Therefore it cannot be determined if the statement is entailed in the trials or contradictory to them The trials only provide data on adverse events for each trial not specific symptoms or conditions like chest pain",
        "label": "Entailment"
    },
    "44ccb908-9444-4137-a227-c47b65207de7": {
        "text_answer": "  The statement 9335 patients in the primary trial and the secondary trial suffered from infections during the study period is not entailed in the given trials as there is no common adverse event listed as Infections in both trials with the same percentage The primary trial reports 3125 patients 826 suffered from infections while the secondary trial reports 4000 patients 615",
        "label": "Contradiction"
    },
    "3e7895ff-0e1a-40d9-830d-bab9c5b59706": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive a combination of various types of treatments including chemotherapy targeted therapy and hormonal therapy as well as surgical procedures   In contrast the secondary trial only mentions the use of two specific oral medications everolimus and exemestane for postmenopausal women with oestrogen receptor positive locally advanced or metast",
        "label": "Entailment"
    },
    "172e14bc-4f23-4d47-9e94-1d65291ef090": {
        "text_answer": "  The statement there is no single common inclusion criteria between the secondary trial and the primary trial is entailed in the given trials as follows  Common inclusion criteria in both trials 1 Age 18 years or more  Different inclusion criteria in primary trial 1 Women histologically diagnosed with carcinoma of the breast 2 Women with nonpalpable malignant lesions requiring image guided localization 3 Undergoing",
        "label": "Contradiction"
    },
    "21f268fa-899c-43ab-a7c2-78c0f940f014": {
        "text_answer": "  The statement is entailed in the trials as it accurately identifies the difference in dosing between the two interventions The statement specifically mentions the lower dose of durvalumab in intervention 1 03 mgkg compared to intervention 2 1 mgkg which is consistent with the information provided in the trials",
        "label": "Entailment"
    },
    "448d6b4e-e05a-4971-9aea-cabeb8ce2c00": {
        "text_answer": "  The statement individuals suffering from bilateral noncancerous breast lesions are eligible for the primary clinical trial is contradictory to the inclusion criteria of the trial The trial only includes individuals with unilateral breast cancer and lymphedema in the ipsilateral upper extremity Therefore individuals with bilateral noncancerous breast lesions do not meet the eligibility criteria for this specific clinical trial",
        "label": "Entailment"
    },
    "bae24418-25bc-4334-be92-d7f341ac3f14": {
        "text_answer": "  The statement is entailed in the primary trial as ER and PR positivity are inclusion criteria for both trials However it is important to note that the statement does not mention anything about HER2neu negativity being a requirement for both trials but it is a commonality between the two trials inclusion criteria Therefore the statement is partially entailed in the trials  The statement is also entailed in the secondary trial as ER and PR positivity are inclusion",
        "label": "Entailment"
    },
    "d6cc1a08-fbff-4ef1-b44f-6bc1b1ed0ef2": {
        "text_answer": "  The statement more instances of palpitations pericardial effusions and abdominal pains were documented in the primary clinical trial compared to the secondary one is a comparison statement To verify this statement we need to compare the number of instances of these adverse events between the two trials  From the given data we can see that the primary trial had a total of 106 participants and recorded 11 instances of palpitations",
        "label": "Entailment"
    },
    "4763223f-0ecd-4d19-a9ee-d466648ce4ea": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference in interventions between the two cohorts in terms of the specific drugs and dosages administered The first cohort receives sunitinib at starting doses of 25 mg to 375 mg daily while the second cohort receives bevacizumab at a dose of 10 mgkg This aligns with the information provided in the trials",
        "label": "Entailment"
    },
    "2771bac1-0b7c-4049-9971-6c3129efb634": {
        "text_answer": "  The statement every patient in the primary trial is receives a dose of 01 to 16 milligram fentanyl sublingual spray during radiation therapy is contradictory to the information provided in the trial description   The trial description only mentions the use of Vorinostat and Radiation Therapy for all participants with no mention of Fentanyl spray being administered during the trial",
        "label": "Contradiction"
    },
    "d9682530-105c-4e04-a26b-5d5985aac260": {
        "text_answer": "  The statement stage 4 cancer patients are excluded from the secondary clinical trial but may participate in the primary clinical trial is entailed in the given trials as follows  In the primary trial the inclusion criteria state that patients with a histologically verified diagnosis of stage IIbIIIIV breast cancer are eligible However the exclusion criteria for the primary trial state that patients with a documented hypersensitivity to filgrastim pegfilgrastim",
        "label": "Entailment"
    },
    "28e1ae2b-668d-48c5-a17b-169460475af0": {
        "text_answer": "  The statement the primary clinical trial involved the administration of the biopath nanoparticle delivery system to thirteen participants is not explicitly stated in the provided information However it can be inferred that the vaccine being administered is a GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine with QS",
        "label": "Entailment"
    },
    "f00c0288-b56a-45b4-9908-1c679e5043e8": {
        "text_answer": "  Lets analyze the given trials to determine if the statement is entailed or contradicted  First lets calculate the total amount of MCS110 and PDR001 each patient receives in both interventions  INTERVENTION 1  MCS110 1 mgkg Q3W every 3 weeks  PDR001 100 mg Q3W ",
        "label": "Entailment"
    },
    "13311b5b-36d8-455d-bf27-8a5adf1c913e": {
        "text_answer": "  The statement is entailed in the Trials The secondary trial has uniform inclusionexclusion specifications for all participants while the primary trial has different eligibility norms for its two study cohorts Phase I and Phase II",
        "label": "Entailment"
    },
    "6938fd4c-78be-4e24-b385-835d2be9f3c1": {
        "text_answer": "  The statement more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 5040 hours after the surgery is not directly entailed in the given trials as the trials do not provide information about the number of participants in each cohort who experienced pathologic complete response after approximately 5040 hours after the surgery The trials only report the number of",
        "label": "Contradiction"
    },
    "56bdbd86-0233-4eb9-bc63-0199e196966b": {
        "text_answer": "  The statement less than 087 of the primary trial participants had a reduction in circulating tumor cells following weeks of highdose chemotherapy with purged autologous stem cell products is a contradiction to the results presented in the trial   The trial reports that Number of participants with reduction in CTCs following highdose chemotherapy with purged autologous stem cell products was not specified in the results for the",
        "label": "Contradiction"
    },
    "adb18104-31a9-4eef-817b-0ab742bd4093": {
        "text_answer": "  The statement all patients treated with gtx024 1mg in the primary trial gained lean body mass over a 10 year period is not entailed in the given trials as the trials only report the change in lean body mass from baseline to 4 months and do not provide any information about the lean body mass over a 10 year period Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "20ee9640-9334-41a2-b8aa-62cc27aeab70": {
        "text_answer": "  The statement All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is a comparison of the dosages of ALT801 between the two trials However the statement does not provide enough information to make a definitive entailment or contradiction judgment as it does not specify the dosages used in the secondary trial for each participant  To make a definitive judgment we would need to compare the",
        "label": "Entailment"
    },
    "ff78e7a6-b997-49b3-be7f-2604a1e00308": {
        "text_answer": "  The statement arimidex is used frequently in both the primary and secondary trials is not directly entailed in the given trials as the trials only mention the use of Anastrozole in the primary trial and the potential use of HER2targeted PETCT with 89Zrtrastuzumab and 89Zrpertuzumab in the secondary trial Arimidex and Anastrozole are the same",
        "label": "Contradiction"
    },
    "076f0bbd-6b10-44e1-a7c6-9853d9457509": {
        "text_answer": "  The statement specify another form of birth control that was used is not directly entailed nor contradictory to the information provided in the primary trial description The trial description focuses on the administration of Sunitinib and Capecitabine their dosing schedules and monitoring for toxicity It does not mention any specific form of birth control used by the participants Therefore the statement is neither entailed nor contradictory to the trial description",
        "label": "Contradiction"
    },
    "b79be25a-c0ac-442e-adaf-821e42a3349b": {
        "text_answer": "  The statement benign ciliary body neoplasm is a nonmetastasizing neoplasm that arises from the ciliary body Representative examples include leiomyoma and adenoma of the ciliary epithelium is not directly entailed in the given inclusion and exclusion criteria for the primary or secondary trials   The statement describes a type of benign neoplasm that arises from the ciliary body of the eye",
        "label": "Contradiction"
    },
    "be30d480-b4d8-4768-8244-3a3d267418d2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial does not mention any separate inclusion standards for age groups 1850 and 50 respectively Therefore the statement is incorrect  The secondary trial does not have any mention of agespecific inclusion criteria The statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "4d1b524f-e8d8-4444-bc99-6631e049fde8": {
        "text_answer": "  The statement hispanic patients without any state residence restrictions can take part in the primary clinical trial is not explicitly stated in the provided inclusion and exclusion criteria for the primary clinical trial Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information given However the criteria do not mention any residence restrictions for Hispanic patients so it can be inferred that there are no residence restrictions mentioned for this patient population Thus the statement",
        "label": "Entailment"
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "text_answer": "  The statement None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes is in agreement with the results presented in Trials 1 and 2 Both trials report that none of the participants in their respective cohorts Normal Vitamin D Levels and Lownormal Vitamin D Levels showed a discernible pattern for gene expression Therefore the statement is ent",
        "label": "Entailment"
    },
    "ddee09ab-2af9-4c93-a64e-58371896a08e": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial receives twice the dose of alt801 compared to cohort 2 is entailed in the trials if  0040 mgkgdose  0015 mgkgdose  Given that the statement is true it is entailed in the trials",
        "label": "Entailment"
    },
    "93118a13-cb16-4c4d-8f7a-ad0cb815e179": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial data provided includes instances of cardiac related Adverse Events AE for cohort 1 The statement correctly describes the pairedend sequencing method and does not contradict any information provided in the trials",
        "label": "Entailment"
    },
    "4eb2221b-a478-4b64-bed8-230e4eab958d": {
        "text_answer": "  The statement over 20 of participants in the primary clinical trial encountered adverse events is contradictory to the given data The total number of adverse events reported was 2 and the total number of participants was 35 Therefore the percentage of participants who encountered adverse events is 571 which is less than 20",
        "label": "Entailment"
    },
    "49e76af6-53c7-458d-a091-0aa8edf2f2aa": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants in each group who demonstrated a decrease in the Growth Factor Signature GFS   According to the trials in the ERpositive Luminal B group 131 to 492 of participants with a mean of 286 demonstrated a decrease in GFS In",
        "label": "Entailment"
    },
    "c4a67b84-c8c7-4922-a5fb-5fb9a1a3160a": {
        "text_answer": "  The statement grade 2 follicular lymphoma is a follicular lymphoma which contains 615 centroblasts per 40x highpower microscopic field is not directly related to the interventions in the primary or secondary trials Both trials administer their interventions orally Vitamin B12 sublingually and memantine or placebo by mouth but the statement about the type and grade of follic",
        "label": "Entailment"
    },
    "4e832d71-c3c2-4209-9a57-8bd40ed3b08a": {
        "text_answer": "  The statement were clinical genomics performed is not entailed in the given trials as there is no information provided in the trials regarding clinical genomics being performed or not The trials only provide information about the interventions used in each group",
        "label": "Contradiction"
    },
    "4a06c463-8c8b-454e-9664-bac7871cbb95": {
        "text_answer": "  The statement the outcome measures for the primary clinical trial and the secondary clinical trial are completely different is entailed in the given trials as follows  1 In the primary clinical trial the outcome measures are the percentage of participants with any treatmentemergent adverse events TEAEs and serious TEAEs in the TNBC Target Population HRHER2 mBC Population Metastatic Urothelial Cancer ",
        "label": "Entailment"
    },
    "adf1424b-3b15-478f-acab-72d4217db886": {
        "text_answer": "  The statement at least one patient in the primary trial suffered several different adverse events is entailed in the given data as there are multiple distinct adverse events reported in the trial each with at least one occurrence The statement about impedance conductivity is not related to the given trials data and does not entail or contradict the statement about adverse events in the trial",
        "label": "Entailment"
    },
    "31ad3c14-faaa-42e1-93aa-d9f9b8687cae": {
        "text_answer": "  The statement is not entailed in the trials provided as there is no mention of osteitis fibrosa cystica or hyperparathyroidism in either the primary or secondary trials The trials only discuss adverse events related to HER2specific T cell therapy and trastuzumab emtansine treatment",
        "label": "Contradiction"
    },
    "396273f3-1e8f-4aa7-a50e-4c36c243748b": {
        "text_answer": "  The statement over 320 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as the number of patients with infections is different in each trial However it is not contradictory either since the statement allows for a possibility that fewer than 3 patients in each trial had infections Therefore the statement is neither entailed nor contradictory based on the given information",
        "label": "Contradiction"
    },
    "50171a05-0f3d-434e-a43d-9310a845fa3f": {
        "text_answer": "  The statement Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial is not directly entailed in the given trials as the trials do not provide sufficient information to make a definitive comparison between the two trials regarding the frequency of all adverse events However the statement is not contradictory to the trials as well since the trials do not mention the occurrence or nonoccur",
        "label": "Contradiction"
    },
    "c8a83ca7-bc34-4afe-9323-7439ed841bca": {
        "text_answer": "  The statement more than 42 patients across both batches of the primary clinical trial demonstrated a pathologic complete response in breast and axillary lymph nodes almost 7 months following the surgical process is not directly entailed in the given trial results However it is not contradictory either as the results do not provide sufficient information to determine whether more than 42 patients achieved a pathologic complete response or not The trial results only report",
        "label": "Contradiction"
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "text_answer": "  To determine if the statement the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab  Capecitabine cohort is entailed in the trials we need to compare the percentage of participants with disease progression or death between the two groups  The percentage of participants with disease progression or death in the Bevacizumab cohort was 117 11 out",
        "label": "Entailment"
    },
    "c67afffa-bf41-4562-bf5e-1ba035fe653c": {
        "text_answer": "  The statement biliary colic and clostridium difficile colitis are less prevalent in the secondary trial compared to the primary trial is entailed in the given trials   Explanation   The statement is entailed because the prevalence of biliary colic in the primary trial is 328 1122 and in the secondary trial it is 167 16",
        "label": "Entailment"
    },
    "7b860f15-132f-423e-ac6d-1c73f7a2d0d5": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial In the secondary trial the intervention includes Depocyt liposomal cytarabine and Highdose Methotrexate HDMTX which contradicts the statement that depocyt together with hdmtx are not used in the secondary trials patient treatment Therefore the statement is contradictory to the information provided in the",
        "label": "Contradiction"
    },
    "fba4a92c-e18b-4029-b3bd-4b967db7faa1": {
        "text_answer": "  The statement 1000 mcg of talazoparib is given daily to several participants involved in the primary clinical trial is not directly entailed in the given trial description The trial description mentions that talazoparib is one of the potential treatments in the study but it does not specify the exact dosage or frequency for all participants Therefore the statement is neither entailed nor contradicted by the trial description",
        "label": "Contradiction"
    },
    "3cbea791-dc12-4c0e-b672-031b43c49bf2": {
        "text_answer": "  The statement is not entailed in the given trials as there is no information provided in the trials regarding the presence or absence of ring chromosome 12 in the cohorts The trials only report the occurrence of various adverse events in each cohort",
        "label": "Contradiction"
    },
    "50b6f969-8637-47a1-ab63-9067b009bd2c": {
        "text_answer": "  The statement every patient in the primary trial is receives a dose of 1 to 10 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information The trial only mentions the use of Vorinostat and Radiation Therapy for the patients with no mention of the use of Fentanyl sublingual spray during radiation therapy",
        "label": "Contradiction"
    },
    "aca44925-657c-47d1-9325-f3933deee650": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial did not report any aes and neither did the candidates in cohort 1 is entailed in the given information if the trials data is represented as follows  Trials         name Primary Clinical Trial     cohorts                 name Cohort 1         aes",
        "label": "Entailment"
    },
    "f074cadc-99e3-4603-8095-aa09822d174d": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment These are two distinct outcomes being measured in separate trials  The statement correctly",
        "label": "Entailment"
    },
    "6146e7c3-2c76-4881-88bd-1c547c9f732a": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000 mg of talazoparib daily as part of the intervention is not directly entailed in the given trial description The trial description specifies that patients are eligible for the trial if they are older than 70 years and have been diagnosed with certain types of cancer and that they are assessable for the primary outcome measure It also mentions that patients may be included before",
        "label": "Contradiction"
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "text_answer": "  The statement children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trial explicitly excludes children as eligible participants The secondary trial does not mention anything about childrens eligibility either including or excluding them Therefore the statement is neither entailed nor contradicted by the given trials criteria",
        "label": "Entailment"
    },
    "9b50ab6a-abe0-4082-8ebc-0cc297945062": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points in both intervention groups Therefore the statement that only catheterbased interventions are performed without the use of any form of angiography is not entailed in the trials",
        "label": "Contradiction"
    },
    "964f8275-1095-4d48-953d-8d77152cecb8": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 specify that participants will be injected with less than 10 mCi of 18FFPPRGD2 for their PETCT or PETMRI scans Therefore all groups in both interventions receive equal doses of 18FFPPRGD2 as part of their imaging procedures",
        "label": "Entailment"
    },
    "2ceabe21-98c6-44e3-9cb2-03d3e73124a7": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria as the primary trial explicitly excludes participants who have used nicotine within the last 5 years smokers while the secondary trial does not mention nicotine use as an exclusion criterion but only mentions alcohol consumption as a limitation with a limit of 5 drinks per day Therefore a person who smokes but consumes less than 5 alcoholic drinks per day could potentially qualify for",
        "label": "Entailment"
    },
    "47485ca0-43cb-4525-9417-a8222961e1cd": {
        "text_answer": "  The statement complete absences of swelling hypothermia and confusion were observed in the aes reports from both the primary and secondary clinical trials is entailed in the given data if we focus only on Adverse Events 1 since the statement mentions in the aes reports and were observed The data states that there were no occurrences of Adverse Event 1 in both trials which implies a complete absence of these adverse events",
        "label": "Entailment"
    },
    "1ee86f9f-6119-4cce-a036-324aea1fb251": {
        "text_answer": "  The statement is contradictory to the trials provided   The primary trial states that participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks not 500 milligrams injected daily   The secondary trial states that lymphoscintigraphy involves injection of 04 to 10 mCi of radioactive Tc99M sul",
        "label": "Entailment"
    },
    "1d8450d1-ac32-4f98-ac75-1d6e212b0879": {
        "text_answer": "  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not directly related to the genetic finding met gene mutation negative Therefore this statement does not entail or contradict the given trials information  However its important to note that the statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is not necessarily contradictory to the",
        "label": "Entailment"
    },
    "9c180516-eca4-490b-b661-b47c625e3ab9": {
        "text_answer": "  The statement within the adverse events of both the primary and secondary clinical trials only one fatality was documented is entailed in the given trials as follows  1 The primary trial had one fatality not otherwise specified out of a total of 9 subjects 2 The secondary trial had no fatalities not otherwise specified out of a total of 201 subjects  Therefore the total number of fatalities across",
        "label": "Entailment"
    },
    "2df3c784-8e32-4d92-9770-63087b7c7f62": {
        "text_answer": "  The statement ability to get up from kneeling is a question about an individuals ability to get up from kneeling is neither entailed nor contradicted by the information provided in the primary trial The trial focuses on the comparison of two different chemotherapy regimens Arm A NabPaclitaxel  Gemcitabine and Arm B NabPaclitaxel  Carboplatin and their effects on participants",
        "label": "Entailment"
    },
    "100d5efd-de88-4127-b6c1-cb870fff9e82": {
        "text_answer": "  The statement extent of hyperperfusion is a determination of the amount of area that is hyperperfused is not directly related to the adverse event data provided in the primary and secondary trials Therefore the statement cannot be determined to be entailed or contradicted based on the given information alone  However it is important to note that the statement itself is not false as it accurately describes the concept of hyperperfusion and its measurement The trials only provide information",
        "label": "Entailment"
    },
    "038bc748-0ea5-4d83-b799-b986177f9dbf": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there are two interventions Arm 1 with placebo and CBTI and Arm 2 with CBTI and Armodafinil In Arm 2 of the primary trial Armodafinil is given daily for 47 days with a varying dosage However the statement incorrectly asserts that only three cohorts in the primary",
        "label": "Contradiction"
    },
    "63a60028-ee0a-4f47-a8f2-b5edf081579a": {
        "text_answer": "  The statement patients with considerable cardiovascular impairment are allowed to participate in the primary clinical trial is contradictory to the exclusion criteria in the primary trial The exclusion criteria state that patients with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that",
        "label": "Entailment"
    },
    "b11dea7c-ef4b-4042-9267-40934719c44e": {
        "text_answer": "  The statement is a contradiction of the primary trial data The primary trial reported no anaemia cases 000 while the secondary trial reported anaemia cases in over 2 of participants 234 Therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "a56ade78-3385-4789-b86a-3aef67188d2c": {
        "text_answer": "  The statement difficulty paying attention to things is a question about whether an individual has difficulty paying attention to things is not directly related to the trials provided The trials only report the number of adverse events for a specific condition difficulty paying attention to things is a symptom not a condition and the statement does not make any claims about the trials or their results Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "ad271913-e4a5-4a4a-9b0a-d3ae24415a54": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The statement suggests that trabectedin is administered orally once daily but the actual intervention in the trial is an intravenous infusion of 13 mgm2 on Day 2",
        "label": "Entailment"
    },
    "bb01dea7-5b49-41b7-997b-70cc1e980226": {
        "text_answer": "  The given statement atypical carcinoid tumor is a carcinoid tumor characterized by a high mitotic rate often associated with the presence of necrosis and nuclear pleomorphism is not related to the information provided in the trials   Regarding the cognitive function trials the statement does not entail or contradict the information given The trials only report the mean standardized scores and standard deviations for cognitive function in two different groups of",
        "label": "Entailment"
    },
    "776b3152-7fa5-480d-8235-cd6e472bf0a6": {
        "text_answer": "  The statement is entailed in the given trials as follows  The statement adverse events were not reported in the primary clinical trial is entailed by the fact that the number of adverse events reported in the primary trial is 0 out of 25 which is less than the number of patients in the trial  The statement any recorded adverse event had an impact on less than 30 of patients excluding skin infections is",
        "label": "Entailment"
    },
    "5099ee2b-f5ea-47be-ba1e-ce2e4462a0c5": {
        "text_answer": "  The statement luer valve device is a valve that incorporates a luer fitting is not related to the inclusion or exclusion criteria of either the primary or secondary trials Therefore it is neither entailed nor contradictory to the trials criteria  Regarding the statement Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and",
        "label": "Entailment"
    },
    "37257ef8-1772-4b94-9bb9-0433a83b83fe": {
        "text_answer": "  The statement palpable masses sequence number is an identifier that describes the relative position of palpable masses data within a series is not related to the inclusion and exclusion criteria of the primary or secondary trials Therefore it is neither entailed nor contradicted by the information provided in the trials  Regarding the inclusion and exclusion criteria the statement Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are",
        "label": "Entailment"
    },
    "e50a24aa-fbee-4cf7-b91b-661c5173c787": {
        "text_answer": "  The statement Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial is an independent condition and is not directly related to the inclusion and exclusion criteria provided for the primary and secondary trials   The statement about tsukamurellaceae is not related to the trials and their inclusionexclusion criteria at all Therefore the statement about tsukamurellaceae is neither entailed nor contradictory to the",
        "label": "Entailment"
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "text_answer": "  The statement less than 10 patients in the primary trial suffered AEs is not directly entailed or contradicted by the given information in the trials   The trials report that 2 out of 35 patients experienced adverse events which is equivalent to 571 However the statement only mentions that less than 10 patients suffered AEs but it does not specify an exact number Therefore the statement is neither entailed",
        "label": "Contradiction"
    },
    "146a72f6-cba2-4056-94a2-21d2e05ac04e": {
        "text_answer": "  The statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is contradictory to the information provided in the Trials   In the first trial there was one instance of increased pleural effusion out of 13 patients 769 In the second trial there was one instance of increased pleural effusion out of 4 patients 2500 However",
        "label": "Entailment"
    },
    "2cf5335c-74b8-4122-bf27-caf0cdf94b8a": {
        "text_answer": " The primary trial does not provide sufficient information to determine if the statement is entailed in the trials or not The trials only report the mean number of hot flashes per 24 hours for each group but they do not report the number of treatment emergent adverse events or serious treatment emergent adverse events for each group Therefore it is not possible to make a definitive statement about which group had lesser adverse events based on the given information",
        "label": "Entailment"
    },
    "6432c266-a7b8-4cda-b5b8-7fd13cb023fb": {
        "text_answer": "  The statement the groups in the primary clinical trial differed significantly in their results and the reflexology group and control group in the secondary clinical trial generated divergent results is not directly entailed in the given trials as there is no comparison of the primary and secondary trials in the statement However it can be inferred that the primary trial results showed a difference between the two algorithms while the secondary trial results showed a difference between the reflexology and control groups These",
        "label": "Contradiction"
    },
    "8d1ad83d-8298-46fe-971d-3fadc862bd5e": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORR between the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 058",
        "label": "Entailment"
    },
    "a378ea56-7b9b-4ee9-b304-ff9597744fb7": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on the use of 18FFDG and 18FFPPRGD2 in patients with glioblastoma multiforme and gynecological cancers and do not mention any specific conditions related to nonneoplastic thymus disorders However there is no contradiction to the statement as well as the trials do not exclude patients with nonneopl",
        "label": "Contradiction"
    },
    "1060fd94-b24c-43cb-884e-b10f70e0ea23": {
        "text_answer": "  The statement picalm gene rearrangement is a molecular abnormality indicating rearrangement of the picalm gene is not directly related to the given trial criteria Therefore it cannot be determined if the statement is entailed or contradicted based on the information provided in the trial description  However the statement does not contradict the trial criteria as there is no mention of picalm gene rearrangement as an exclusion criterion",
        "label": "Entailment"
    },
    "1c13e304-89af-4ef5-95c6-cabc803d81b8": {
        "text_answer": "  The statement Every participant in the primary trial receives the same intervention is entailed in both trials as stated However the statement indeterminate extranodal tumor extension is a response is not mentioned in either trial Therefore it is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "65f90fcc-a7ce-4d52-b010-b8e482c02f9c": {
        "text_answer": "  The statement lifethreatening adverse events were absent in the first cohort of the primary clinical trial is entailed in the trial results as no serious adverse events which include lifethreatening events were reported in the first cohort with 3 participants",
        "label": "Entailment"
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "text_answer": "  The statement the primary trial only has a single adverse event recorded for its patient cohort is entailed in the given information if we consider the Trials data as a whole However it is important to note that the statement only applies to the specific trial with the patient cohort size of 29 and the single recorded adverse event Therefore it may not be entailed in every trial within the Trials dataset  Explanation ",
        "label": "Entailment"
    },
    "47d5620b-1b48-4a55-920f-35879c6e85eb": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trials Both Intervention 1 and Intervention 2 include the administration of doxorubicin cyclophosphamide and docetaxel to the patients Therefore the statement that all patients in the primary clinical trial are not given any doses of docetaxel doxorubicin and cyclophosphamide is contradictory to the information given in",
        "label": "Entailment"
    },
    "b0b78244-40a7-46d4-888d-1ccfe70d3645": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the use of doxorubicin and cyclophosphamide in the initial phase of treatment but the frequency of docetaxel administration differs between the two interventions In Intervention 1 docetaxel is given every 3 weeks for 4 cycles while in Intervention 2 docetaxel is given on Day 2 of",
        "label": "Entailment"
    },
    "840c7b65-e801-4dec-b9dd-b97680e5e3ba": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary clinical trial is not applying immunooncology techniques as there is no mention of any immunotherapies or cancer treatment in the interventions   The secondary clinical trial is using acupuncture which is not a form of chemotherapy or immunooncology therapy   Therefore the statement is contradictory to the information provided",
        "label": "Contradiction"
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "text_answer": "  The statement More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery is not directly entailed in the given trials as they only provide the number of participants who achieved pathologic complete response in each arm of the study The trials do not provide the total number of participants who achieved pathologic complete response across both arms However",
        "label": "Contradiction"
    },
    "ffa844c8-752d-48df-aa7a-e0ba58305b12": {
        "text_answer": "  The statement ret gene translocation is a cytogenetic abnormality that refers to any translocation involving the ret gene Any cancer patient diagnosed with either Epilepsy thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is not explicitly stated in the given trials inclusion and exclusion criteria However it can be inferred that patients with epilepsy thalasemic syndromes",
        "label": "Entailment"
    },
    "012a3705-05f7-4a26-adf2-1ae4244bd576": {
        "text_answer": "  The statement is not entailed in the given trials as there is no direct comparison or relation between the dosage of oral pregabalin in the primary trial 150 mg twice daily and the interventions in the secondary trial Liposomal Cytarabine and Highdose Methotrexate The statement mentions a different dosage of pregabalin 300 mg every 2 weeks which is not present in the",
        "label": "Contradiction"
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "text_answer": "  The statement None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups but they do not provide information about the distribution of pain intensity scores or the number of patients who experienced the worst pain imaginable at any point during the 10week study period",
        "label": "Contradiction"
    },
    "fd88904b-8a23-46ad-b337-3c7eef4e7bef": {
        "text_answer": "  The statement patients with a history of pulmonary embolisms are disqualified from participating in the secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for the secondary trial However it is mentioned in the exclusion criteria for the primary trial that Inability to safely undergo general anesthesia andor perioperative care related to vascularized lymph node transfer is an exclusion criterion",
        "label": "Entailment"
    },
    "7a831a11-8edd-42ef-81e7-fd8bca5ca0cc": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive the same amount of radiation therapy and a SPECT scan is performed on each patient at baseline and 6 months followup Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "7e791f30-68d4-4a11-86e4-c2e88d737913": {
        "text_answer": "  The statement There were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial is a contradiction to the given trials as there were no cases of nausea reported in either trial and the number of cases for Infection and Asymmetry were lower in the secondary trial compared to the primary trial Therefore the statement is contradictory to the given trials  Regarding the second part of the statement ",
        "label": "Contradiction"
    },
    "ff07ae9a-9106-443b-b584-a7522ec3f71d": {
        "text_answer": "  The statement is contradictory to the secondary trial information In the secondary trial the intervention is not specified to include Suramin and Paclitaxel but rather patients undergoing mastectomy surgery Therefore the statement that Suramin and Paclitaxel are administered to all patients in the primary trial is not entailed in the secondary trial information",
        "label": "Contradiction"
    },
    "1e47ae4a-c57b-47fa-9b85-1b15ebdbf1fc": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials   The primary trial includes patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent no evidence of metastatic disease",
        "label": "Contradiction"
    },
    "871378d6-a6e5-461c-af83-d82fe8f44f4e": {
        "text_answer": "  The statement sutterella is a genus of aerobic gram negative rod shaped bacterium assigned to the phylum proteobacteria and the family alicaligenaceae is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial The statement is about a bacterial genus while the trial criteria are related to breast cancer and hormonal treatment eligibility There is no connection between the two",
        "label": "Entailment"
    },
    "3c06901b-29be-43be-8da7-c23d80cc4d89": {
        "text_answer": "  The statement the occurrence of disease progression or death was more prevalent in the bevacizumab cohort in contrast to the bevacizumab  capecitabine cohort in the primary clinical trial is not directly entailed in the given trial data   The trial data only provides the percentage of participants with disease progression or death in each cohort during the maintenance phase of the study The statement makes a",
        "label": "Contradiction"
    },
    "e115652e-6728-47a8-bc2e-1866a7c257ec": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement none of the cohorts in the primary clinical trial undergo any invasive operation or receive neratinib is consistent with the information provided in the trials description   The first cohort is described as Phase 2 Triple ve which typically refers to a trial for patients with triple negative breast cancer who do not have HER2",
        "label": "Entailment"
    },
    "2aa1c4f5-a46c-4004-9a8a-52e2ac476181": {
        "text_answer": "  The statement Only 4 different types of adverse events affected patients in the primary trial all of which were in cohort 2 is not directly entailed in the given trials as the trials do not provide information about the types of adverse events that affected patients in cohort 1 However the statement is not contradictory to the trials as well since the trials only report the number and frequency of adverse events for each type and cohort",
        "label": "Contradiction"
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "text_answer": "  The statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed in the given trial description   Explanation   The trial description specifies that participants will receive epirubicin cyclophosphamide docetaxel and trastuzumab during the course of the study Each of these drugs is distinct so the statement that participants receive 4 different drugs is a logical",
        "label": "Entailment"
    },
    "b9f262d7-23e5-42d1-9020-0e516ce3505c": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial employs hormonal approaches as a form of intervention with Estring and Testosterone Cream The secondary trial does not employ hormonal approaches as a form of intervention but rather tests the effectiveness of acupuncture  Therefore the statement that the primary clinical trial employs hormonal approaches as a form of intervention while the secondary clinical trial is testing the effectiveness of",
        "label": "Entailment"
    },
    "0b5e78d7-d717-41d0-98e5-564eda711bec": {
        "text_answer": "  The statement severe insomnia patients are barred from participating in both the primary and secondary clinical trials is entailed in the given trials as follows  In the primary trial severe insomnia is not explicitly mentioned as an exclusion criterion However it can be inferred that patients with uncontrolled intercurrent illness including psychiatric illness are excluded Severe insomnia can be considered a type of psychiatric illness and thus",
        "label": "Entailment"
    },
    "d201eee8-33d1-4ae4-9540-b37fa07536e0": {
        "text_answer": "  The statement people having extreme obesity can be accepted in the primary clinical trial is entailed in the given inclusion criteria as the trial includes individuals with a BMI of 25 kgm2 or greater and weight 400 lbs This definition falls under the category of extreme obesity Therefore the statement is entailed in the trials inclusion criteria",
        "label": "Entailment"
    },
    "d9d5a341-26ba-4f5d-a730-14561dea5c17": {
        "text_answer": "  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is not directly related to the given trials as they do not provide enough information to determine if there is tumor progression present after initial treatment or not The trials only report the occurrence of specific adverse events Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "b9a1b80e-4c45-4a78-962b-13dfe98ab56c": {
        "text_answer": "  The statement is a contradiction to the primary trial data The primary trial reported 04 000 acute myocardial infarctions while the statement claims that 2 participants out of 73 had this adverse event This is a clear contradiction to the reported data in the primary trial The secondary trial data does not affect the validity of this comparison as it has a much larger sample size and no acute myocard",
        "label": "Contradiction"
    },
    "c8bd9404-6d9c-4048-9d19-639aefd4ab08": {
        "text_answer": "  The statement Hypokalemic patients are excluded from the primary trial but hyperkalemic patients may be eligible for the secondary trial and the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials  Explanation  The statement mentions hypokalemia and hyperkalemia which refer to low and high potassium levels in the blood respectively The primary trial excludes patients with potass",
        "label": "Entailment"
    },
    "973b8d05-863f-4978-a197-bd08355b7834": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not mention anything about radiation therapy being given to the patients so it cannot be determined if the statement is entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "0bc7c5c7-6e64-4eee-ba84-e2168d64a8ef": {
        "text_answer": "  The statement knob device is a handle usually attached to a shaft allowing manual rotation of the shaft is not related to the inclusion or exclusion criteria of either the primary or secondary trials Therefore it is neither entailed nor contradictory to the trials criteria  Regarding the trials criteria the statement that Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer",
        "label": "Entailment"
    },
    "4318ce37-10b6-4318-868e-f533a1fd000e": {
        "text_answer": "  The statement is entailed in the trial results as stated in the following text Percentage of Patients With HER2 Primary Breast Cancer Who Develop Imagable HER2 Metastases is the outcome measurement in the trial The trial armgroup HER2targeted PETCT describes the intervention where participants receive HER2targeted PETCT using 89Zrtrastuzumab The",
        "label": "Entailment"
    },
    "d0bcf0db-e64d-4aff-a63b-ba3571ebfad4": {
        "text_answer": "  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial criteria do not mention anything about CBT Cognitive Behavioral Therapy treatments being prohibited or allowed The secondary trial criteria do not mention CBT at all   However the statement",
        "label": "Contradiction"
    },
    "e0c92d00-132b-4e76-ba59-2fa14e67bf53": {
        "text_answer": "  The statement adverse events were a common occurrence among participants in the primary clinical trial is not directly entailed nor contradicted by the information provided in the trial results The trial results focus on the recurrencefree survival rates for patients with stage I and II disease who received systemic chemotherapy with or without maintenance therapy The statement about adverse events is not explicitly mentioned in the trial results but it is a common assumption for clinical trials involving chemotherapy Therefore",
        "label": "Contradiction"
    },
    "c39031be-e4dd-4943-a3fe-97164ac7a5e9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as the secondary trial involves the use of ibrutinib and MEDI4736 in combination not protonbeam therapy and capecitabine",
        "label": "Entailment"
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "text_answer": "  The statement is entailed in the trials as follows  The statement The only types of AEs observed in patients from the secondary trial were Eyelid oedema and Chest pain no AEs were recorded in the primary trial is entailed by the given data because  1 The statement mentions that only Eyelid oedema and Chest pain were observed in the secondary trial and no AEs were recorded in the primary trial",
        "label": "Entailment"
    },
    "a7efab48-443a-4728-a4b5-0c837052aab7": {
        "text_answer": "  The statement is entailed in the given trials as Perjeta pertuzumab is mentioned in the secondary trial as a novel radiotracer used in HER2targeted PETCT but it is not mentioned as a part of the treatment intervention in either the primary or secondary trials Therefore the statement that perjeta while utilized in the primary trial is not a part of the secondary trials treatment protocol is entailed",
        "label": "Entailment"
    },
    "e16eb398-b70e-42d2-90d5-d17172fda47f": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial compares two different interventions one with navelbine and the other with carboplatin Paraplatin is not mentioned in the trial description at all Therefore the statement that every intervention within the primary clinical trial employs the same quantity of paraplatin is contradictory to the facts presented",
        "label": "Entailment"
    },
    "ce896357-cc87-4eb3-b588-61c1f99fc5f4": {
        "text_answer": "  The statement patients in the primary clinical trial who underwent topical cryotherapy reported higher symptom severity than those who did not undergo the treatment is contradicted by the trial results   The results show that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 while the median aAUCpa for the Arm II Control group was ",
        "label": "Contradiction"
    },
    "3d081c7c-10e8-490f-8943-260f27175c56": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is a contradiction to the inclusion criteria of the trial as stated in the text  The reason being the statement suggests that patients with a history of severe anaphylactic reactions to trastuzumab or nonresponse to trastuzumab treatments are eligible for the",
        "label": "Contradiction"
    },
    "54aa7f2d-b774-4530-ad47-3848ca093433": {
        "text_answer": "  The statement patients in cohort 2 of the primary trial reported higher rates of neutropenia as compared to patients in cohort 1 of the secondary trial both groups receiving the same doses of empegfilgrastim is not directly entailed in the provided trial data   The primary trial reports the mean duration of neutropenia CTCAE grade 34 for two different doses of empegfil",
        "label": "Contradiction"
    },
    "024c2c6d-e462-439c-baa2-a8639cd68d30": {
        "text_answer": "  The statement There were no patients with recorded AEs in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is entailed in the given data   Explanation   The statement is entailed in the data because the primary trial has a total of 0 adverse events out of 42 patients 000 while the secondary trial has a total of 12 adverse events out",
        "label": "Contradiction"
    },
    "d8e5f1e2-76e1-405a-9920-c21c7f105eb2": {
        "text_answer": "  The statement is entailed in the trials In both trials Herceptin trastuzumab is administered at a dose of 2 mgkg per week for the continuation phase In the primary trial this dose is given in combination with docetaxel or paclitaxel In the secondary trial Herceptin is given as a single agent at a dose of 4 mgkg in Cycle 5 and then 2 mg",
        "label": "Entailment"
    },
    "1ecd0f33-cffb-4c0e-917f-6ae5f8570183": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial reported adverse events for infection asymmetry and deflation with a total of 131 323 for all three The secondary trial however reported no adverse events for any category Therefore it is contradictory to state that the secondary trial had a higher incidence of infection asymmetry and nausea than the primary trial",
        "label": "Contradiction"
    },
    "c71fced3-2da3-4471-a72f-0dec2e7bbb02": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial participants receive alpha lipoic acid orally three times daily with a baseline dose of 100 mg and dose escalation until a maximum tolerated dose is found This means that the amount of alpha lipoic acid administered to participants in the primary trial varies and is not consistently the same throughout the study  In contrast in the secondary trial participants in Cohort",
        "label": "Entailment"
    },
    "decd387b-7da2-4f7b-8f32-4e009d9f6ee5": {
        "text_answer": "  The statement more than 3333 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days of the study is not directly entailed in the given trial data   The trials only provide the number of participants with pathologic complete response in each arm of the study but they do not provide the total number of participants in both arms who",
        "label": "Contradiction"
    },
    "41b2eac1-36a4-4cd8-a163-c7ab7b3636ee": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that the weekly administration of MM121 and Paclitaxel in the secondary trial is less than that of the primary trial but the patients in the secondary trial receive more Herceptin not mentioned in the statement and Docetaxel contradictory to the statement   However the primary trial does",
        "label": "Entailment"
    },
    "72d1b9c7-56d4-487c-8170-752c86b764ec": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does involve a drugbased treatment PF06647020 with different dosages while the secondary trial does not mention any drugbased treatment at all Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Entailment"
    },
    "ae1b63ed-25c5-484a-8221-3bee0af17594": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity both from cohort 2 is not directly stated in the provided trial results However it can be inferred from the information given   The trial results indicate that there were 6 participants in each cohort and the statement mentions that both Incidences of Doselimiting Toxicity occurred in cohort",
        "label": "Entailment"
    },
    "365dc837-fcfb-49f6-8dc3-bb74a0f60507": {
        "text_answer": "  The statement is entailed in the given trials as follows  The primary trial involves the following interventions 1 Neoadjuvant Therapy Adjuvant Therapy 2 doxorubicin hydrochloride Given IV 3 cyclophosphamide Given PO 4 paclitaxel Given IV 5 filgrastim Given SC 6 capecitabine Given PO",
        "label": "Entailment"
    },
    "517f5131-6807-4537-ae4c-308be1f98d17": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The statement There were more adverse events observed in the secondary trial than in the primary trial is contradictory to the given data because the data shows that there were no adverse events in both trials for Adverse Event 1 and the number of participants in the secondary trial is greater than that of the primary trial However having no adverse events in the primary",
        "label": "Contradiction"
    },
    "ce29883b-654b-4124-ac60-40ff13cb9f3e": {
        "text_answer": "  The statement any patients with a welldocumented allergy to cefuroxime or nitrofurantoin can participate in both the primary and secondary trials is neither entailed in the primary trials inclusion or exclusion criteria nor contradictory to it   The primary trial does not mention any specific allergies as exclusion criteria and the secondary trials exclusion criteria do not include cefuroxime or nitrofurantoin",
        "label": "Entailment"
    },
    "4b9aeee6-6ad8-477a-a09a-15fd52c8fec8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial all patients receive a single injection at the beginning of the study while in the secondary trial participants in the intervention group receive 12 weekly subcutaneous injections Therefore the statement that candidates for the secondary trial study group receive 3 weekly subcutaneous injections whereas the primary trial participants only receive a single injection at the beginning of the study is incorrect",
        "label": "Entailment"
    },
    "48206c2e-1f24-4248-8c06-bfac596dcaa5": {
        "text_answer": "  The statement is entailed in the given trials as neither the primary nor the secondary trial includes Xrays transendocardial injections CT scans or MRIs as part of the interventions Additionally arthroscopic surgery is not mentioned in either trial",
        "label": "Entailment"
    },
    "fdc63af9-e802-4ef7-8f6d-bec415bf2537": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the number of participants in each group and their recurrencefree survival percentages but they do not directly provide the data needed to calculate the difference in recurrencefree survival between the two groups as a percentage Therefore it is not possible to determine if the statement is entailed or contradicted based on the information given in the trials",
        "label": "Contradiction"
    },
    "437fedde-1e69-4514-ac5f-d8d532497280": {
        "text_answer": "  The statement The only AE recorded in the primary trial was Stomatitis drug accountability assessment test code is a character or string that represents the short code name of the drug is not directly entailed in the given information in the Trials data However the statement The only AE recorded in the primary trial was Stomatitis is entailed in the data as stated in the Adverse Events 1 section The second part of the statement about",
        "label": "Contradiction"
    },
    "957f4300-757b-40ee-926c-3c7deae05ade": {
        "text_answer": "  The statement individuals who have a severe anaphylactic history to trastuzumab are excluded from the primary clinical trial is entailed in the trials exclusion criteria The trial explicitly states that Patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study While the statement provided is more specific and mentions severe anaphylactic history it is a",
        "label": "Entailment"
    },
    "da5c1eb1-b093-45cf-b607-e40504be981b": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial participants in Intervention 2 received armodafinil daily for 47 days but in the secondary trial armodafinil is not mentioned at all Additionally the statement incorrectly assumes that all patients in the secondary trial receive a consistent dose of PDR001 100 mg Q3W but Intervention 2 in the secondary trial administers a higher",
        "label": "Entailment"
    },
    "56f41ab4-6a20-4593-af47-b5cab9dabdd2": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trial descriptions   In the primary trial patients receive 2 injections at the beginning of the study INTERVENTION 1 Baseline while in the secondary trial patients in INTERVENTION 1 do not receive any information about the number of injections they receive However the statement suggests that patients in the secondary trial receive 6 daily injections which is",
        "label": "Entailment"
    },
    "35c16ab6-47c9-48ed-b92d-967b89df4869": {
        "text_answer": "  The statement colon nonhodgkin lymphoma is an extranodal nonhodgkin lymphoma that arises from the colon The majority are bcell nonhodgkin lymphomas is not directly related to the adverse events data provided in the primary and secondary trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However",
        "label": "Entailment"
    },
    "4d702550-2f94-46be-92f2-ea6659c69ddb": {
        "text_answer": "  The statement in the primary clinical trial all patients get a dose of no less than 20mg of mcs110 every three weeks is contradictory to the given trials as none of the interventions in the trials specify a dose of 20mg or more of MCS110 every three weeks for all patients The trials only specify doses of 1mgkg or 3mgkg of MCS110 every three",
        "label": "Contradiction"
    },
    "490ea7b9-ad4e-4741-8dce-65a050f9a776": {
        "text_answer": "  The statement all participants in the primary clinical trial showed partial or no response by the 24th week is a contradiction to the trial results   The trial results indicate that at Week 12 there were 4 participants with partial response PR and at Week 24 there were 4 participants with partial response Therefore there were participants in the trial who showed a partial response beyond the 12th week   H",
        "label": "Contradiction"
    },
    "20de5f49-227b-4d5f-9a4e-868354842985": {
        "text_answer": "  The statement a woman who has experienced quadrantectomy may not be eligible for the secondary trial or the primary trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However it can be inferred that a woman who has undergone a quadrantectomy may not be eligible for the primary trial as it mentions patients who have not undergone autologous tissue breast reconstruction and intend to undergo implant only breast reconstruction",
        "label": "Entailment"
    },
    "55220fb9-bef7-4c72-bf60-982c0ec903e6": {
        "text_answer": "  The woman who has undergone a mastectomy can be suitable for the primary clinical trial if she meets all the inclusion criteria and none of the exclusion criteria The statement does not explicitly mention anything about the womans eligibility for the secondary clinical trial However the secondary clinical trial has its own set of inclusion and exclusion criteria that the woman must meet to be eligible Therefore the statement does not entail or contradict the information provided in the trials",
        "label": "Entailment"
    },
    "9bd55a1f-e5dc-4620-ba52-73b4bf792459": {
        "text_answer": "  The statement individuals with a history of pulmonary embolisms and current breast implants are allowed to participate in the primary clinical trial is not explicitly stated in the inclusion or exclusion criteria for the primary trial However the exclusion criteria do not mention breast implants or a history of pulmonary embolisms as reasons for exclusion Therefore based on the information provided it appears that individuals with a history of pulmonary embolisms and",
        "label": "Entailment"
    },
    "a9d72bc6-9396-4a8a-986a-e64587f02e9e": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial does state that radiation therapy is being administered to both groups but the statement asserts that it is not Therefore the statement is contradictory to the information provided",
        "label": "Entailment"
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "text_answer": "  The statement The most common adverse event in the secondary trial was Anaemia there were no recorded AEs in the primary trial is a contradiction   Explanation   The statement implies that Anaemia was the most frequent adverse event in the secondary trial and that there were no adverse events at all in the primary trial However the data provided in the trials shows that there were no adverse events of any kind in the",
        "label": "Contradiction"
    },
    "75cd8c4d-e0e6-4db0-8157-a76ac5bcf555": {
        "text_answer": "  The statement was kras mutation analysis performed is a question is neither entailed nor contradicted by the given trials as there is no information in the trials regarding KRAS mutation analysis The trials only report the occurrence of various adverse events in two separate cohorts",
        "label": "Entailment"
    },
    "b52201dd-cbd7-4b92-8aae-3d8da980f4a1": {
        "text_answer": "  The statement is entailed in the Trials as the dosage of Denosumab in Intervention 1 of the primary trial is 120 mg Q4W quarterly which is lower than the dosage of Tamoxifen in Intervention 1 of the secondary trial which is 10 mg once daily for 21 days per month approximately 30 mgmonth Therefore the dosage of Denos",
        "label": "Entailment"
    },
    "5a17f44e-b8ba-4598-96e3-992b0022b5ca": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial involves the use of several pharmaceutical interventions including epirubicin cyclophosphamide docetaxel and trastuzumab Therefore the statement that the trial involves no pharmaceutical intervention is incorrect",
        "label": "Contradiction"
    },
    "3559fa92-e0d7-4e4f-9b1f-7f087fbff0d1": {
        "text_answer": "  The primary clinical trial description mentions that patients undergo breast reconstruction using a Contour Profile Tissue Expander which involves the use of xrays during the surgical procedure for placement and positioning of the expander The secondary clinical trial description mentions the use of a NOGA Myostar injection catheter for administering injections to the left ventricle which typically involves the use of fluoroscopy xray or CT scan for",
        "label": "Entailment"
    },
    "0433b29d-6509-420d-ba83-4ddcf8907e2b": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any Aes sixteen is a natural number greater than 15 and less than 17 and the quantity that it denotes is not directly related to each other The first part of the statement is about the number of adverse events reported in a trial while the second part is about the definition and properties of the number sixteen Therefore the statement is neither entailed nor contradictory based on",
        "label": "Entailment"
    },
    "ec5c7b6f-dfae-4681-9b8f-4f0b3635d232": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials only provide information about the dosage and frequency of MCS1110 and PDR001 administered to the patients but they do not explicitly state the total amount of MCS110 or PDR001 each patient receives over a certain period However we can calculate the total amount of MCS110 and PDR001 each patient receives based on the given",
        "label": "Contradiction"
    },
    "06ec7728-efe1-408c-afa8-a6b679a9cd57": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the Trials with Entailment or Contradiction we need to refer to the provided information in the clinical trial In this case the statement is that details regarding the mode of administration dosage or cycle are absent in the intervention sector of the primary clinical trial  Lets examine the trial data provided to see if this statement is entailed or contradicted  Trial Title",
        "label": "Entailment"
    },
    "cffc1c21-5e4d-485a-a167-32841ff01f4c": {
        "text_answer": "  The statement moderately better is a subjective response indicating that something is moderately better is not entailed in the given trials as they do not provide any information related to the subjective response or comparison between the interventions in terms of being moderately better or not The primary trial is about the use of Contour Profile Tissue Expander and Placebo in breast reconstruction while the secondary trial is about the use of AlloMSCs and Placebo in",
        "label": "Contradiction"
    },
    "9dd13c76-10e0-4dd0-ad16-42d135f6c2c5": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial experienced multiple moderate adverse events is a contradiction to the information given in the trials data which states Total 0147 000 The trials data indicates that there were no adverse events reported in cohort 1 while the statement suggests that there were multiple moderate adverse events",
        "label": "Contradiction"
    },
    "f6bfaa2d-0171-4bbe-a65c-0e3b217ac61f": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial intervention is Radioembolization using TheraSpheres while the secondary trial intervention is based on ibrutinib and MEDI4736 which are not related to Radioembolization or TheraSpheres",
        "label": "Entailment"
    },
    "bf140d08-90da-4fb4-90da-b86a87b5bb07": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as there is no mention of agespecific inclusionexclusion criteria in either the primary or secondary trials Both trials have their own distinct sets of inclusion and exclusion criteria that apply to all participants regardless of age",
        "label": "Contradiction"
    },
    "8ee8670b-6200-4309-8fd6-545572945b7c": {
        "text_answer": "  The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is a contradiction to the given results   The results state that there were 24 participants with treatmentemergent adverse events not 35 The statement is contradictory to the results",
        "label": "Contradiction"
    },
    "64f9b5b3-cd20-4b90-94b5-14e08a9999f0": {
        "text_answer": "  The statement chest pain has been more frequently observed in patients participating in the secondary clinical trial than in those in the primary clinical trial is not directly entailed or contradicted by the given data   The data provided only mentions the occurrence of adverse events for each trial but it does not specify if chest pain is among those events Therefore we cannot make a definitive conclusion about the frequency of chest pain based on the given information alone",
        "label": "Contradiction"
    },
    "f99f83b0-66dd-4c77-b422-113e0cb758bf": {
        "text_answer": "  The statement every one of the 61 cervical cancer patients in the initial cohort of the primary clinical trial complied with their screenings before the intervention commenced is not entailed in the trials provided The trials only report the percentage of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention No information is given about the screening status of individual patients including the number of patients",
        "label": "Contradiction"
    },
    "02addfef-d1b3-4e62-865c-aa0bd1ddfab4": {
        "text_answer": "  The statement the secondary trial and the primary trial share at least one inclusion criteria is entailed in the given trials as both trials include patients who are 18 years of age or older Therefore the statement is true  Regarding the second part of the statement tandem mass tag 10plex is a tandem mass tag reagent preparation containing ten distinct isotope substitutions it is not related to the trials and their inclusion",
        "label": "Entailment"
    },
    "8cd22d45-e829-47df-8ae1-cb50a163fc27": {
        "text_answer": "  The statement is not entailed in the given trials as they address different interventions for different patient populations The primary trial deals with the use of oral pregabalin while the secondary trial involves the use of intravenous HighDose Methotrexate and Intrathecal Liposomal Cytarabine Therefore the statement is neither entailed nor contradictory to the given trials",
        "label": "Contradiction"
    },
    "27950c75-7035-435a-a7df-6f7abd504d30": {
        "text_answer": "  The statement is not directly entailed in the given information about the primary trial interventions The statement is about an optical condition called ametropia which is not related to the interventions described in the primary trial The trial interventions are for Phase 2 studies one for a PR negative ER negative and HER cohort and the other for a HER2 cohort The statement about ametropia does not mention any connection",
        "label": "Contradiction"
    },
    "eec36c42-c1fb-45c8-9db9-82f10f4f7af7": {
        "text_answer": "  The statement is entailed in the trials as both trials report changes in a specific body part over a certain time frame The primary trial measures changes in pain intensity of the participants pain episodes at various time points after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine over a 9month period Both trials involve assessing changes in a specific body part pain intensity in the primary trial and BMD in the",
        "label": "Entailment"
    },
    "902a36e5-a751-44c6-9844-465aaa0f1d75": {
        "text_answer": "  The statement several adverse events were reported in over 30 of participants in both the primary clinical trial and the secondary clinical trial is contradictory to the given data   The primary trial had one adverse event reported in 1 out of 208 participants 048 and none in the secondary trial with 34 participants 000 No adverse event was reported in more than 3",
        "label": "Contradiction"
    },
    "8f319cf4-ec84-4f34-a4d8-2af54adbaab9": {
        "text_answer": "  The given statement sars coronavirus 2 b1128 is a variant lineage of sars coronavirus 2 that is the ancestor for the p1 and p2 lineages 1000 of cohort 1 of the primary trial suffered some kind of adverse event is not directly entailed in the provided trial data The trial data only reports the number of participants with serious and nonserious",
        "label": "Contradiction"
    },
    "0f42fd08-8cba-4861-a89c-bf898270ea29": {
        "text_answer": "  The statement Both interventions in the primary trial include the same dose of Paraplatin is not directly related to the information provided about the globular region of a protein Therefore the statement does not entail or contradict the information given in the trials The trials only mention the interventions and the drugs used in each arm but they do not provide any information about the doses of Paraplatin specifically",
        "label": "Entailment"
    },
    "5a378399-ff09-418f-8797-9e122617d8d6": {
        "text_answer": "  The statement having dealt with postmenopausal adenocarcinoma or serious psychiatric conditions in the last 6 months does not affect an individuals eligibility for the primary clinical trial is contradictory to the trials exclusion criteria The trial explicitly states that individuals with a history of significant psychiatric disorders are excluded from participating Therefore the statement is not entailed in the trials criteria",
        "label": "Contradiction"
    },
    "894b1c21-f4ab-4145-ac19-9f973184b5bd": {
        "text_answer": "  Both trials measure the outcome of patients with cancer but they use different outcome measures The primary trial measures tumor diameter while the secondary trial measures the number of participants with solid tumor response based on RECIST 11 criteria Therefore the statement is contradictory as the trials do not use the same metric for quantifying their results",
        "label": "Entailment"
    },
    "097ca9f3-901b-4072-b2d5-2e36f5bfccf0": {
        "text_answer": "  The statement candidates for the primary clinical trial are given an intervention that does not contain talazoparib is a contradiction to the given trial description The trial description includes patients who may receive various types of cancer treatments but it does not specify that talazoparib is a component of the intervention for any of the eligible patient groups Therefore the statement that the intervention does not contain talazoparib is not entailed by the trial description",
        "label": "Contradiction"
    },
    "f27c4b19-1479-48ea-92a0-28da5256b7b8": {
        "text_answer": "  The statement patients with a diagnosis of 23 cerebral metastases within the brainstem will be ineligible for the secondary clinical trial however this diagnosis might not necessarily disqualify them for the primary clinical trial is not explicitly stated in either the primary or secondary trial information provided  However based on the information given it can be inferred that patients with cerebral metastases within the brainstem are ineligible",
        "label": "Entailment"
    },
    "6582c5f8-507a-459d-82e4-b0b8e80be34d": {
        "text_answer": "  The statement is entailed in the trials as described The trials specify different dosages for breast cancer patients 1000 mcgday and ovarianperitoneal cancer patients ranging from 25 mcgday to 1100 mcgday but with a starting dose of 25 mcgday The statement correctly identifies that the breast cancer patients receive a higher daily dose 1000",
        "label": "Entailment"
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both cohorts received the same dose of Cetuximab but cohort 1 had an additional Collaborative Care Intervention However the trial information clearly states that cohort 1 received a lower dose of Cetuximab 12 mgkg compared to cohort 2a 20",
        "label": "Entailment"
    },
    "232cfca0-08b4-45e3-ac2a-01ce31ecb857": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials description The trials description focuses on the intervention and control groups of a study for African American patients receiving palliative care and the statement discusses a different anatomical concept the gray commissure in the spinal cord There is no connection between the two",
        "label": "Entailment"
    },
    "fa23fd31-c7c2-4887-a982-174f355a2035": {
        "text_answer": "  The statement 3636 of the primary trial patients suffered an increase in Blood bilirubin is entailed in the given trial data as it is explicitly stated that 1 out of 11 patients 909 experienced an increase in Blood bilirubin Therefore the statement is entailed in the trial data  The statement about pedal spasms is not related to the trial data and is not entailed or contrad",
        "label": "Entailment"
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "text_answer": "  The statement Both interventions in the primary trial include trastuzumab is entailed in the given information since trastuzumab is mentioned as a component in both interventions Arm 1 Herceptin and Arm 2 HerceptinTrastuzumab",
        "label": "Entailment"
    },
    "0164b2f8-a87d-4bb8-8487-6eb1f65b9804": {
        "text_answer": "  The statement Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention is not directly stated in the provided trial results However the statement does not contradict the information given in the results as well The trial results only provide the percentage of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention for both the",
        "label": "Entailment"
    },
    "e0c8ebce-a242-4619-9e96-7a80e6d157dd": {
        "text_answer": "  The statement the primary trial recorded 11 more adverse events than the secondary trial is entailed in the given trials as the secondary trial reported 11 adverse events in total while the primary trial reported none Therefore the primary trial recorded 11 fewer adverse events than the secondary trial but the statement 11 more is the opposite of that so it is entailed with the contradiction However the statement is not directly ent",
        "label": "Entailment"
    },
    "de91b720-a7f8-4c27-8182-f642de29ddee": {
        "text_answer": "  The statement candidates undergoing treatments based on warfarin are not permitted for the primary clinical trial but their participation in the secondary clinical trial might still be possible is a contradiction to the exclusion criteria in the primary trial as it states that Patients who require use of coumarinderivative anticoagulants such as warfarin are excluded However in the secondary trial the exclusion criteria do not mention warfarin",
        "label": "Contradiction"
    },
    "91e178f6-c6ec-426d-8799-629c2f512038": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the number of participants in each group and their recurrencefree survival percentages but they do not directly provide the recurrencefree survival data for each group to calculate the difference between them Therefore it is not possible to determine if the statement is entailed or contradicted based on the given information",
        "label": "Contradiction"
    },
    "0aab1829-69a6-4db5-ae99-78b1f9c9cbc0": {
        "text_answer": "  The statement laserassisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial is entailed in the given trials as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell for perfusion monitoring at three separate time points during",
        "label": "Entailment"
    },
    "f83654b1-c44c-40eb-a7b1-91db95cb71f6": {
        "text_answer": "  The statement is entailed in the trials as the trials provide information about the specific adverse events observed in each trial The statement mentions that certain adverse events were more commonly seen in the primary trial than in the secondary trial The trials indeed show that the adverse events of Recurrent malignancies Graftversushost disease Infection and Altered mental status were more frequent in the primary trial while none of these events were reported in the",
        "label": "Entailment"
    },
    "a0294da5-368d-4341-9084-1d42b995be34": {
        "text_answer": "  The statement no adverse events were documented for cohort 1 patients in the primary clinical trial is entailed in the given trials as both trials report 03 000 for the total number of adverse events and for each specific adverse event listed Therefore the statement is a logical consequence of the trials data",
        "label": "Contradiction"
    },
    "079d70f0-b586-466d-aeb0-38f67273c1c6": {
        "text_answer": "  The statement both the secondary and primary clinical trials do not employ the number of participants with treatmentemergent adverse events as the metric for their study outcomes is not directly entailed in the given information from the trials   The primary trial reports the change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial reports the change in isothiocyanate in urine samples as assessed at baseline and after",
        "label": "Contradiction"
    },
    "8ef9ed3d-ab31-4ef7-be9a-113b31e3ed2a": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on pCR rates and do not provide information on qualityoflife assessments However the statement implies a comparison of pCR rates between different trials and cohorts which is indirectly related to the trials The statement is not contradictory to the trials as it does not contain any conflicting information  Therefore the statement is neither entailed nor contradictory to the trials",
        "label": "Contradiction"
    },
    "13d66853-9b8a-4d79-b0d9-884c8d744acd": {
        "text_answer": "  The statement usually have considerable trouble concentrating is a response indicating that an individual usually has or had considerable difficulty concentrating is not entailed in the given trials as they have completely unrelated outcome measurements The primary trials focus on the percentage of participants with treatmentemergent adverse events in different populations while the secondary trials report the number of participants with objective response to talazoparib in breast and ovarianperitoneal cancer patients",
        "label": "Contradiction"
    },
    "4cc838c3-caee-492c-8092-c74844d68cd1": {
        "text_answer": "  The statement is entailed in the Trials as both trials mention the requirement for a certain performance status for candidate selection However they use different scoring systems for assessing performance status Therefore the statement is entailed in the Trials with the qualification that they use different performance status scoring systems for their respective trials",
        "label": "Entailment"
    },
    "51d7f113-1dba-48f0-9e5c-1f16bfcd5394": {
        "text_answer": "  The statement the primary clinical trial noted zero cases of hepatotoxicity is contradictory to the information provided in the Trials data as there were actually three cases of hepatotoxicity reported 3750 Therefore the statement is contradictory to the given data  The statement while there were multiple cases of hypertension and pancreatectomy is entailed in the data as there was one case",
        "label": "Entailment"
    },
    "87c5ee7a-a65a-4633-9efc-b51e2956db27": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials as the trials do not provide information about the number of participants in each cohort Arm II and Arm III The statement only mentions the total number of participants analyzed in the study which is reported in both trials Therefore the statement is neutral with respect to the given trials",
        "label": "Entailment"
    },
    "21ae5802-04f7-4f06-86d6-9ee8ee9cdd84": {
        "text_answer": "  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race or ethnic origin or cancer type however for the secondary trial they must have Her2neu breast cancer is a contradiction to the information provided in the inclusion criteria for both trials  In the primary trial the inclusion criteria state that females of all racial and ethnic origins who are scheduled to receive the first cycle of a single intraven",
        "label": "Contradiction"
    },
    "eef90c1d-1b9c-459e-a895-47b9012a8d1a": {
        "text_answer": "  The statement having an eating disorder was not a frequent condition among the primary clinical trial candidates is not directly entailed or contradicted by the given adverse events data The data only reports various adverse events observed during the trial but it does not provide information about the prevalence of eating disorders among the candidates before or during the trial",
        "label": "Contradiction"
    },
    "bcfd2c0f-411a-462a-acd8-7dcd6818c1c6": {
        "text_answer": "  The statement is contradictory to the given trials   The primary trial involves the use of FMX and MM398 while the secondary trial involves the use of lapatinib and paclitaxel Although both trials have a similar dosage schedule every 2 weeks for the primary trial and every 4 weeks for the secondary trial they differ in the pharmaceutical regimes and administration techniques used Additionally the primary trial uses FMX",
        "label": "Entailment"
    },
    "2dc8c214-bbe5-49b7-a48e-0945fddcd9da": {
        "text_answer": "  The statement is entailed in the Trials Both trials include docetaxel as part of their interventions In the primary trial docetaxel is given in the form of CarboplatinNabPaclitaxel In the secondary trial docetaxel is given as part of the docetaxel  lapatinib regimen Therefore the statement that the primary clinical trial and the secondary trial administer docetax",
        "label": "Entailment"
    },
    "e41035c2-246d-43a1-b2d4-5ff9af1f789e": {
        "text_answer": "  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed in the given trials data as it contradicts the information provided The trials data states that there were no adverse events in both cohorts 1 and 2 with a total of 0 adverse events out of 60 patients in each cohort Therefore",
        "label": "Contradiction"
    },
    "f9ac9b4b-4033-416b-b66c-0ecf23a9a06c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial reports one instance of mucositis oral 133 but the statement claims that the primary trial observed more instances of mucositis oral than the secondary trial However the secondary trial reports no instances of mucositis oral 000  Regarding epileptic seizures and thromboembolic events neither trial reports any",
        "label": "Contradiction"
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "text_answer": "  The statement Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial is a contradiction based on the given trials inclusion and exclusion criteria  Explanation  In the primary trial patients with malignant ductal carcinoma in situ are explicitly excluded Therefore they cannot be included in the primary trial  In the",
        "label": "Contradiction"
    },
    "a031053e-a514-4484-9624-bcddef1628d3": {
        "text_answer": "  The statement counselling is a key component of the interventions in the primary clinical trial is not explicitly stated in the given information for either Intervention 1 or Intervention 2 However it is mentioned that Intervention 1 includes decision support for providers for prevention based on risk which could potentially involve counseling Therefore the statement is not directly contradictory to the information provided but it also does not follow entailment since it goes beyond",
        "label": "Entailment"
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "text_answer": "  The statement There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial is not entailed in the given trials as there is no mention of Asthenia or Pyrexia in the trials The trials only report the number of adverse events for Adverse Events 1 and Adverse Events 2 but not the specific types of adverse events",
        "label": "Contradiction"
    },
    "42f1e6c1-7775-4513-b810-a5559fcf60be": {
        "text_answer": "  The statement an adult patient diagnosed with ILDDPLD within the last 3 years with a life expectancy of 6 months would be eligible for the primary trial is contradictory to the trials inclusion criteria   The reason is that the trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are ineligible Therefore a patient diagnosed with ILDDPLD within the last",
        "label": "Entailment"
    },
    "260b2917-54c5-43db-8beb-50f4e1bad69c": {
        "text_answer": "  The statement is contradictory to the given trials as per the following reasons  1 In Intervention 1 no electroporation EP injections are mentioned for V935 or V934 2 In Intervention 2 three electroporation injections of V934 LD are mentioned but no electroporation injections for V935 are mentioned 3 The statement claims that three elect",
        "label": "Contradiction"
    },
    "f866e011-f633-4481-9d58-fff6828d7f83": {
        "text_answer": "  The statement none of the patients in the primary clinical trial who were given lapatinib 1000 mg  nabpaclitaxel reached a confirmed complete response CR is a contradiction to the results of the trial as stated in the text   The text reports that 53 of the 60 participants 889 in the Lapatinib 1000 mg  NabPaclitax",
        "label": "Contradiction"
    },
    "b3372685-8147-4004-89f4-f57d35bd8980": {
        "text_answer": "  The statement the bevacizumab group in the primary clinical trial exhibited a lower occurrence of disease progression or death than the bevacizumab  capecitabine group is contradictory to the information provided in the trials   The trial results indicate that 883 of participants in the Bevacizumab group did not experience disease progression or death while 758 of participants",
        "label": "Entailment"
    },
    "e3b2d615-a7b7-475e-b757-a8de8cd2c6f7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive a loading dose of 4 mgkg of trastuzumab followed by 2 mgkg weekly In contrast in cohort 2 of the secondary trial Herceptin is administered at a dose of 4 mgkg IV infusion on Day 1 of Cycle 5 followed by 2 mgkg weekly",
        "label": "Entailment"
    },
    "62af11ae-461f-4e31-b104-3467b2210208": {
        "text_answer": "  The statement the outcomes of both the primary and secondary clinical trials were not marred by any instances of infection is not directly entailed or contradicted by the given data The data only provides the list of adverse events for each trial but it does not mention any infectionrelated adverse events for either trial Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "b4fca47f-894d-47b9-a6a2-38867864c1bc": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria which specify a minimum primary tumour diameter of greater than 2 cm Therefore a patient with a primary tumour of 03 cm radius approximately 06 cm diameter would not meet the primary trial inclusion criteria and would not be eligible for that trial However the secondary trial inclusion criteria do not specify a minimum tumour size so a patient with a smaller primary tumour could",
        "label": "Entailment"
    },
    "75fdf74b-e876-43f0-a382-03cf7055464b": {
        "text_answer": "  The statement the recorded harmful effects in the primary clinical trial were only noted for patients from cohort 2 is a contradiction to the given data in the trials as no adverse events were recorded for any patient in either cohort 1 or cohort 2 according to the provided data Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "25efd6b7-dd3c-472e-babe-6d5397241653": {
        "text_answer": "  The statement individuals who are significantly overweight are fit for the primary clinical trial is entailed in the given inclusion criteria of the trial The trial specifically includes individuals with a BMI of 25 kgm2 or greater which is considered overweight according to the World Health Organizations definition Therefore the statement is entailed in the trials inclusion criteria",
        "label": "Entailment"
    },
    "879196dd-c66e-4413-9575-98c95c0b9df1": {
        "text_answer": "  The statement approximately onethird of patients from both groups in the primary clinical trial demonstrated pathologic complete response in breast and axillary lymph nodes after around seven months into the study is entailed in the trials provided   Explanation   The trials report the number of participants in each group who achieved a pathologic complete response no histologic evidence of invasive tumor cells in the surgical breast",
        "label": "Entailment"
    },
    "1a48d67e-c653-4e6f-bc9c-677793433e9b": {
        "text_answer": "  The statement in the outcome of the primary clinical trial the number of patients with stable disease was higher in the 12th week than the 24th week however no patients showed complete response in either week 12 or 24 is entailed in the trial results as follows  The trial results state that at Week 12 there were 12 participants with SD and at Week 24 there were 10",
        "label": "Contradiction"
    },
    "86823381-4392-4a31-a1cb-b2966dd41c45": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement asserts that the interventions in the primary and secondary trials are different in terms of the number of drugs used with the primary trial being multidrug and the secondary trial being monotherapy However the actual interventions in the primary trial involve only one drug gefitinib and in the secondary trial there are two interventions one of which",
        "label": "Entailment"
    },
    "a5c140f2-b2e5-43a5-9a8d-268806caa311": {
        "text_answer": "  The statement patients diagnosed with either nonsmall cell lung cancer or small cell lung cancer confirmed through cytology or histology can participate in the primary clinical trial is entailed in the trials inclusion criteria The trial explicitly lists nonsmall cell lung cancer and small cell lung cancer as eligible tumor types Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "3d7e66cf-6e57-4072-b7f9-96ab99473ac5": {
        "text_answer": "  The statement all of the participants in group 1 of the primary trial were found to have lesions and less than 10 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is contradictory to the provided trial data  In the primary trial there were no lesions detected in the healthy volunteers group group 1 as stated in the result Overall Number of Participants",
        "label": "Contradiction"
    },
    "bec4d231-ea9b-4713-b2a1-c7ddb2dc5b0f": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial recorded thromboembolic events in the participating patients is entailed in the given trials as both trials have reported one instance of thromboembolic event each under their respective adverse events sections",
        "label": "Entailment"
    },
    "5a42ca95-0544-4db1-a1f1-67534d54dc69": {
        "text_answer": "  The statement is entailed in the given trials description as both Intervention 1 and Control groups receive some form of risk assessment although the intervention group receives a validated webbased risk assessment and decision support while the control group receives usual care which may or may not include risk assessment",
        "label": "Entailment"
    },
    "d99663b8-44bb-4480-9171-e10fc1ef25b1": {
        "text_answer": "  The statement is entailed in the given trials In the primary trial there are two groups one intervention group receiving pyridoxine and another placebo group In contrast in the secondary trial there are two intervention groups one receiving highdose oxybutynin chloride and the other receiving lowdose oxybutynin chloride Therefore the statement that one test group and one placebo group constituted the primary clinical trial",
        "label": "Entailment"
    },
    "97d2c16b-fa4d-4b91-a69f-6692c681f6cd": {
        "text_answer": "  The statement sunitinib was given orally to all participants in the primary clinical trial every day for the duration of the study is not entailed in the given trial information   The trial description states that sunitinib was given orally on a continuous daily dosing schedule but it also mentions that dosing could be interrupted or reduced according to individual tolerance This means that not all participants received sunitinib every day for the entire duration of",
        "label": "Contradiction"
    },
    "67b2e192-d596-4951-b6d0-75f957072bdb": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial mentions that patients will take Vorinostat daily during radiation therapy and are recommended to swallow the capsule 6090 minutes prior to radiation However there is no mention of Fentanyl sublingual spray being administered to any patient in the trial",
        "label": "Contradiction"
    },
    "f8f21f2b-9c9c-4f37-8c0d-b48061a14c9d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial both cohorts receive an intramuscular injection of Fluciclatide not an intraosseous injection   In the secondary trial patients receive an oral Chloroquine tablet not an intravenous IV injection Therefore there is no cohort in either trial that receives both an intraosseous",
        "label": "Contradiction"
    },
    "b0bb79f6-dd52-4821-b739-ffc42d7472da": {
        "text_answer": "  The statement in the primary clinical trial the incidence of treatmentemergent adverse events was practically nonexistent among patients undergoing the sunitinib  docetaxel  trastuzumab treatment is contradictory to the trial results   The trial reported that there were 24 treatmentemergent adverse events among the 25 participants in the sunitinib  docetaxel  trastuz",
        "label": "Entailment"
    },
    "f94eab27-5609-47a1-bcd5-d0e1305caab1": {
        "text_answer": "  The statement candidates utterly incapacitated are a requirement for the secondary clinical trial a condition not indispensable for the primary clinical trial is a conditional statement with two clauses  1 Candidates utterly incapacitated are a requirement for the secondary clinical trial 2 This condition is not indispensable for the primary clinical trial  To determine whether this statement is entailed in the trials or contradicts them we",
        "label": "Entailment"
    },
    "943db9fb-b25b-4e58-bf2f-af46b1d9df54": {
        "text_answer": "  The statement hospital admissions were reported during the primary clinical trial is not entailed in the given trials as there is no mention of hospital admissions in the provided data from the primary or secondary trials",
        "label": "Contradiction"
    },
    "ed8ce995-6417-4392-8608-d20f0087c730": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is entailed in both Trials 1 and 2 as they both report a total of 19 adverse events and at least one of those events is listed as Vomiting in Trial 2 which is a gastrointestinal adverse event  However the statement pigmentary change in skin",
        "label": "Entailment"
    },
    "77045e13-70ad-4643-9e8c-7f0deb5d0ed9": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement claims that cohorts 1 and 2 receive the same dosage of CUDC101 and the same frequency but it also mentions that cohort 1 receives PD0332991 once weekly However the trial information does not provide any details about PD0332991 such",
        "label": "Entailment"
    },
    "c9e9765e-663a-4421-a353-b0d6de09734d": {
        "text_answer": "  The statement is entailed in both the primary and secondary trials as xray imaging is not explicitly mentioned in the interventions described but it is a common and fundamental part of many medical procedures including breast reconstruction using tissue expanders and transendocardial injections Therefore it can be assumed that xray imaging would be used in these trials for proper placement and monitoring of the interventions",
        "label": "Entailment"
    },
    "83d14b48-ba22-47e0-a7c5-0a0b5f8af134": {
        "text_answer": "  The statement a majority of patients experienced adverse events in the primary clinical trial is contradicted by the given trials data   Explanation   The statement a majority of patients experienced adverse events in the primary clinical trial would be entailed if the total number of adverse events was greater than half of the total number of patients However the given trials data states that there were only 2 adverse events out of 35 patients",
        "label": "Contradiction"
    },
    "0c0d244d-5d55-42ea-bb07-8ff35bd2c862": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement only mentions that both cohorts follow different instructional CDs for paced breathing and practice once a day However the trials provide more specific information about the duration and frequency of the paced breathing practice The statement does not directly entail or contradict the trials as it does not mention the exact duration and frequency of the paced breathing practice",
        "label": "Entailment"
    },
    "7ab5e41f-6982-43b4-8541-8ff7964d669a": {
        "text_answer": "  The statement there were no instances of hypertension dehydration and dyspnea in any group of the primary clinical trial is not directly entailed or contradicted by the given trial data The trial data only reports adverse events related to Disseminated intravascular coagulation Death NOS Edema limbs Fatigue Hepatic failure Alanine aminotransferase increased Aspartate amin",
        "label": "Contradiction"
    },
    "9acd718f-6e45-495a-846d-b248d6690f1c": {
        "text_answer": "  The statement both the primary and secondary clinical trials do not consider MYMOP score variations as a way of measuring their research results is a contradiction to the primary trial results as the primary trial uses the MYMOP questionnaire to measure patientspecified and reported symptoms Therefore the statement is incorrect",
        "label": "Contradiction"
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "text_answer": "  The statement at least one patient treated with GTx024 1mg in the primary trial gained over 10 kilos of Lean body Mass is a contradiction to the given trial results   The median change in total body lean mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 kg There is no value in",
        "label": "Contradiction"
    },
    "b0b3e393-7af0-4fe2-bf26-111bddead6e7": {
        "text_answer": "  The statement a majority of the patients in the primary clinical trial experienced a confirmed complete response CR after undergoing treatment with lapatinib 1000mg and nabpaclitaxel is not directly entailed in the given trial results   The trial results only report the percentage of participants who experienced either a CR or PR according to RECIST criteria 10 but they do not specify that a majority of the participants experienced",
        "label": "Contradiction"
    },
    "24816a21-1c67-4b20-82f0-0891fed68773": {
        "text_answer": "  The statement is partially entailed in the trials   The statement mentions that patients in the primary clinical trial more frequently experienced symptoms of anemia pneumonia and stupor than those in the secondary trial This is not directly contradicted by the data provided but it is not explicitly stated in the trials either However the trials do show that the frequency of anemia pneumonia and stupor is higher in the primary trial",
        "label": "Entailment"
    },
    "dc561148-4b85-4fee-a632-2662a4c1a74c": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any AEs however almost all of cohort 2 candidates suffered at least one ae get anxious about going to doctor is a question about whether an individual gets anxious about going to the doctor is not directly entailed or contradictory to the given trials data   The trials data only provides information about the number of adverse events AEs reported in each cohort",
        "label": "Contradiction"
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "text_answer": "  The statement is entailed in the primary trial information as follows  The primary trial includes the requirement for candidates to have undergone mammography as a part of the inclusion criteria Therefore the secondary trial which does not have this requirement explicitly stated in its inclusion criteria does not contradict the primary trials requirement for mammography However its important to note that some of the secondary trials inclusion criteria eg breast lesions that",
        "label": "Entailment"
    },
    "cd7d5918-4280-48e5-a202-ad7d499a9334": {
        "text_answer": "  The statement a 3 week cycle is employed in the primary clinical trial for its treatment intervention however the secondary clinical trial doesnt apply a cyclical treatment approach is a contradiction to the information provided in the trials  In the primary trial each treatment cycle was defined as 21 days which is equivalent to a 3week cycle However the secondary trial does not mention a specific cycle length but it does not indicate that a cycl",
        "label": "Contradiction"
    },
    "23505a58-2e6a-4220-9148-f3b3102d2a91": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information   The trial information only specifies the dosage of Cetuximab for each cohort but it does not provide any details about the Collaborative Care Intervention or its potential impact on thoracic procedure postoperative complications Therefore it is impossible to determine if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "d07ab8cf-9e2e-4ac2-b8e0-20d9fa9bf16a": {
        "text_answer": "  The statement those who have received estrogens or progestogens within the month preceding the clinical study can be included in the primary clinical trial is not directly stated in the given inclusion and exclusion criteria However the criteria do allow the use of estrogens and progestogens under certain conditions Specifically patients who are currently taking estrogens or progestogens for breast cancer treatment or for the prevention of breast cancer with a constant",
        "label": "Entailment"
    },
    "147c18a2-2ef0-4cef-9f99-bbcd79b12216": {
        "text_answer": "  The statement regular smokeless tobacco use for six weeks or more negative is a response that the individual did not use smokeless tobacco regularly for six weeks or longer is neither entailed nor contradicted by the information provided in the inclusion and exclusion criteria of the primary and secondary trials   The primary and secondary trials do not mention anything about smokeless tobacco use as an inclusion or exclusion criterion Therefore the statement is neither entailed nor contrad",
        "label": "Entailment"
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe that participants in both cohorts 1 and 2 received Enzalutamide orally not intravenously",
        "label": "Entailment"
    },
    "6fbe26db-3420-4617-9f84-1663aa9be297": {
        "text_answer": "  The statement that a 32yearold person diagnosed with stage III breast cancer with confirmed histological evidence an absolute neutrophil count of 1807L platelet count of 110034L hemoglobin level of 90 gl and a life expectancy of more than 8 months is qualified for both the primary clinical trial and the secondary clinical trial is",
        "label": "Entailment"
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "text_answer": "  The statement Patients with histologically documented metastatic SCBC are excluded from the primary trial is a contradiction to the inclusion criteria of the trial The trial includes patients with histologically documented metastatic nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer SCBC small cell lung cancer is not listed as a type of cancer that is eligible for the trial Therefore the",
        "label": "Contradiction"
    },
    "2eabe849-09b8-45e6-aa6b-74450a7ff5df": {
        "text_answer": "  The statement in the secondary clinical trial the number of participants with treatmentemergent adverse events is the main outcome measurement is contradictory to the information provided in the trials   The primary outcome measurement in the secondary trial is the change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy The trials do not provide any information regarding the number of participants with treatmentemergent",
        "label": "Entailment"
    },
    "16808fde-01bf-40dd-ae6e-7f208b51636d": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement both cohorts in the primary clinical trial receive the same vaccine is not explicitly stated in the trials provided While it is mentioned that the same age group is being studied in both trials and that they are investigating vaccine responses against pneumococcus and influenza there is no information given about the specific vaccine being used in each trial",
        "label": "Entailment"
    },
    "6c2256ce-7c39-4ece-bdf4-fcd05744f234": {
        "text_answer": "  The statement encounter due to other specified problems related to upbringing is an icd encounter due to other specified problems related to upbringing is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided  Regarding the potassium requirement the primary trial excludes patients with potassium levels below the normal range 35 mEqL while the secondary trial does not mention any specific potass",
        "label": "Entailment"
    },
    "c6e231b0-ab51-4010-9d8b-d447af0a6306": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of joint range of motion or cervical spine issues in the provided information about the trials The trials only mention the administration of vaccines against Pneumococcus and Influenza to different cohorts of participants and the recording of their vaccine responses",
        "label": "Contradiction"
    },
    "9b1ce2f0-2734-4ae5-988e-dd569c19594e": {
        "text_answer": "  The statement the eligibility for the primary and secondary clinical trials is controlled by nationality ethnicity weight and gender is not entailed in the given inclusion and exclusion criteria for the primary and secondary trials The criteria focus on various medical conditions performance status age and tumor type but do not mention any specifications related to nationality ethnicity weight or gender except for age and gender in the inclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "e07a4aec-7879-4c85-a39e-a1cb17f2fd64": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary clinical trial states that cabergoline is given orally not intramuscularly as stated in the statement   The secondary clinical trial also states that pixantrone is given intravenously not intramuscularly as stated in the statement   Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "5e83904b-39bc-4449-b5c5-c2972d287237": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials report no occurrences of intestinal obstructions in either the primary or secondary trials for Adverse Events 1 and 2 Therefore the statement that intestinal obstructions were a common occurrence among patient cohorts in the primary clinical trial with similar incidences noted in the secondary trial is not entailed in the trials Instead it is contradictory to",
        "label": "Contradiction"
    },
    "2a4b11b1-b14f-4fd8-a810-b6ad2f60e9fb": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the median change in lean body mass for the GTx024 1mg group to zero   The median change in lean body mass for the GTx024 1mg group was 155 kg range 206 to 1264 kg   Since the median is negative it means that half of",
        "label": "Entailment"
    },
    "7f06a038-29e8-4349-8822-876c2ae2e378": {
        "text_answer": "  The statement fever CTCAE is a disorder characterized by elevation of the bodys temperature above the upper limit of normal is not related to the adverse events recorded in the primary trials provided The trials only report adverse events related to health conditions but none of them mention fever as an adverse event or a condition being studied Therefore the statement is neither entailed nor contradicted by the information given in the trials",
        "label": "Entailment"
    },
    "0cf7be8c-6376-4aff-93a2-2c88104fe061": {
        "text_answer": "  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE Adverse Event of scrotal infection is not entailed in the given trials as scrotal infection is not listed as an adverse event in either trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "5fc57549-ece0-4ba6-9e5f-fc785aa16f28": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials report no occurrences of intestinal obstruction Adverse Event 1 or pancytopenia Adverse Event 2 in their patient cohorts The trials do not contradict the statement as they both support the absence of the mentioned adverse events",
        "label": "Entailment"
    },
    "f103c71f-151a-46b1-b24e-c9fa1c90db64": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The administration method for the placebo is intravenous over 3 hours on Day 1 while the administration method for trabectedin is also intravenous over 3 hours on Day 2 However the statement suggests that both interventions are given subcutaneously and monthly Therefore the statement is contradictory to the information provided in the clinical trial description",
        "label": "Entailment"
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "text_answer": "  The statement All patients treated with GTx024 1mg in the primary trial gained Lean body Mass over a 4 month period is not entailed in the given trials as there are participants in the 1mg group who experienced a decrease in lean body mass The median change in lean body mass for the 1mg group was 155 kg with a range of 206 to 1264 kg indicating",
        "label": "Contradiction"
    },
    "b1bad6e5-5322-4ba2-8350-2496bef85d1c": {
        "text_answer": "  The statement there was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed in the given trials as they do not provide sufficient information about the types of psychiatric events or the total number of adverse events in the second trial that are psychiatric in nature However based on the given information there is no contradiction to the statement as well The trials only report the",
        "label": "Contradiction"
    },
    "2205c13a-b236-4117-b41e-78846625c760": {
        "text_answer": "  The statement one or more gastrointestinal adverse event and at least two psychiatric events were recorded during the primary clinical trial is not entailed in the given trials as there is no record of any psychiatric events in either trial Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "text_answer": "  The statement in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy can be expressed mathematically as Hepatotoxicity cases  3  Hypertension  Pancreatectomy cases  Given the data from the trials we have  Hepatotoxicity cases  3  Hypertension",
        "label": "Entailment"
    },
    "95421b93-0c5a-45db-9630-804f602204b6": {
        "text_answer": "  The statement Uganda is a country in eastern Africa west of Kenya There are several different instances of cardiac related AE recorded for cohort 1 of the primary trial is not directly entailed or contradicted by the given trials data   The trials data only provides information about the number and types of adverse events observed in two different cohorts of a primary trial It does not specify the locations of the trials or the nationalities of",
        "label": "Contradiction"
    },
    "7f3723a3-cdbf-41a6-a956-330e514b5c5c": {
        "text_answer": "  The statement no patients from the primary clinical trial encountered an incidence of doselimiting toxicity in any cohort is entailed in the trials provided if we assume that the trials report all instances of doselimiting toxicities for each cohort   Both trials report that no doselimiting toxicities were observed in their respective cohorts with a total of 12 participants analyzed across both arms Therefore the statement is",
        "label": "Contradiction"
    },
    "ad003c43-9467-4b8e-9a4e-e28c7d6422c3": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial there is only one intervention group for each arm Hydrophor in Group A and MediHoney in Group B and both interventions are standardized gels applied topically to the RT site Therefore the statement that the primary trial is studying the effects of a single standardized gel on its study groups is entailed  In contrast in the secondary trial",
        "label": "Entailment"
    },
    "ce4406e4-c57a-441a-870c-e2442b0806de": {
        "text_answer": "  The statement several cardiacrelated adverse events have been noted for cohort 1 in the primary clinical trial is entailed in the Trials since the primary trial data for cohort 1 lists several cardiacrelated adverse events ACS Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac Tamponade with a total count of 10 events out of 2002",
        "label": "Entailment"
    },
    "20296404-9526-4410-953c-51ea7ae866bd": {
        "text_answer": "  The statement notable patterns in the expression of 40 genes under evaluation were observed in certain patients maintaining normal vitamin d levels in the primary clinical trial is not directly entailed in the given trial results as there is no mention of any notable patterns observed in the expression of 40 genes for the group with normal vitamin D levels in the provided information However the absence of such information does not necessarily mean that the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "287251c0-2d26-466d-8340-13d9c15196bf": {
        "text_answer": "  The statement there was one psychiatric adverse event in the primary trial which affected up to 50 of patients is contradictory to the information provided in the trials The trials report that there was only one patient 150 or 200 who experienced suicidal ideation which is a psychiatric adverse event However the statement suggests that up to 50 of patients experienced a psychiatric adverse event",
        "label": "Entailment"
    },
    "709fb55d-517a-45bb-a379-f073a46cbe93": {
        "text_answer": "  Lets calculate the amount of MCS110 and PDR001 administered every three weeks for each intervention  Intervention 1  MCS110 1 mgkg  PDR001 100 mg  Calculate the amount of MCS110 and PDR001 administered every three weeks  MCS110 1 mgkg ",
        "label": "Entailment"
    },
    "ba87189b-e858-4344-927d-a315a0d2576f": {
        "text_answer": "  The statement any adult with HER2negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial is entailed in the given trials as follows  1 The primary trial includes female patients with HER2negative breast cancer who have disease progression during or following firstline treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer This meets the requirement of having a HER2negative breast cancer",
        "label": "Entailment"
    },
    "27180597-864a-4375-97c8-e9e41fd297dc": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial may be suitable for a 20 year old female recently diagnosed with erpositive her2negative breast cancer is not entailed in the given trials as the trials specify the inclusion criteria as female patients who are 18 years of age or older Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "a9600a10-ab9c-4b6d-ad89-30f9d7859a50": {
        "text_answer": "  The statement is not entailed in the given trials as they address different interventions The primary trial is about Radioembolization using Yttrium90 glass microspheres and TheraSpheres while the secondary trial is about a combination of ibrutinib and MEDI4736 The statement about night sweats is not related to either of these interventions",
        "label": "Contradiction"
    },
    "bc13c987-6166-42c9-b537-1efc6126c3d8": {
        "text_answer": "  The statement patients in whom metastasis cannot be assessed or whose cancer has not disseminated to other body areas are deemed ineligible for the primary clinical trial is not explicitly stated in the given trial criteria However it can be inferred from the following inclusion criteria   Histologically confirmed breast cancer meeting 1 of the following criteria    Metastatic disease M1    Multiple sites of new disease that",
        "label": "Entailment"
    },
    "581c879a-6d09-4736-8b12-a096d45b315c": {
        "text_answer": "  The statement a woman postmastectomy may still qualify to participate in the primary or secondary clinical trial is entailed in the given trials as follows  Primary Trial A woman who undergoes skinsparing mastectomy utilizing bioprosthetic mesh and meets all other inclusion criteria can participate in the primary trial  Secondary Trial A woman who has completed surgery for breast cancer and meets all other inclusion criteria including",
        "label": "Entailment"
    },
    "7ea784df-2fea-4676-a83f-a0716d2fd49d": {
        "text_answer": "  The statement the number of participants was higher in the primary clinical trial compared to the secondary clinical trial is a contradiction to the information provided in the trials   In the primary trial there were 13 participants analyzed while in the secondary trial there were 30 participants analyzed However the statement suggests that the number of participants was higher in the primary trial which is not the case",
        "label": "Contradiction"
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "text_answer": "  The statement is entailed in the trials as the primary trial reports the mean tumor diameter in cm and the secondary trial reports the number of participants with solid tumor response using RECIST 11 criteria These are different units of measure and the trials do not directly compare the tumor diameter between the two arms or groups Therefore the statement is entailed in the trials as they report different outcome measurements using different units of measure",
        "label": "Entailment"
    },
    "82bcea65-bca6-46f5-9e3b-32098e20c46f": {
        "text_answer": "  The statement gain of chromosome 2p is a cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2 is not directly related to the adverse events data provided in the primary and secondary trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction based on the given information alone",
        "label": "Entailment"
    },
    "2295bf51-5b26-4cde-9bcf-caeada0181b1": {
        "text_answer": "  The statement is not entailed in the given inclusion and exclusion criteria as there is no mention of life expectancy pregnancy status or age as exclusion criteria in the provided information",
        "label": "Contradiction"
    },
    "51dace9a-0da5-49ed-8d8b-7489416ea9e8": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to calculate the difference in the number of emesisfree participants between the aprepitant and placebo groups   Difference in Number of EmesisFree Participants  Number of EmesisFree Participants in Aprepitant Group  Number of EmesisFree Participants in Placebo Group  From the given trials we have  Number of EmesisFree",
        "label": "Entailment"
    },
    "d323d9da-d286-4fa5-b883-552116910450": {
        "text_answer": "  The statement is not entailed in the given trials The statement compares the dosages of two different interventions from two different clinical trials The primary trials intervention 1 involves the use of Zoledronic Acid 4 mg Q4W and Denosumab 120 mg Q4W while the secondary trials intervention 1 involves Tamoxifen at a dose of 10 mg once daily for 3 months There is",
        "label": "Contradiction"
    },
    "9ebcda5d-0914-4015-b5d3-9446f9582d01": {
        "text_answer": "  The statement multiple shingles cases were observed in both groups of the secondary trial but none in the primary trial is a contradiction to the given data   Explanation   The statement implies that there were no shingles cases in the primary trial but the data shows that there was one case in the primary trial Therefore the statement contradicts the information provided in the trials",
        "label": "Contradiction"
    },
    "856ab26e-3ce5-4405-b5ce-22557600b74f": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the primary trial The trial compares two different interventions for treating an unspecified type of cancer but it does not mention penile epithelioid hemangioma specifically Additionally the statement makes assumptions about the types of cancer being treated in the trial and the specific treatment being administered for that condition which is not explicitly stated in the trial information Therefore it is neither entailed",
        "label": "Entailment"
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "text_answer": "  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is contradictory to the information provided in the trials  In the primary trial there were no participants with lesions detected in the healthy volunteers group group 1 However in the",
        "label": "Contradiction"
    },
    "cefecae9-606f-4be6-94c0-f9d3732968ea": {
        "text_answer": "  The statement eligibility for both primary and secondary clinical trials is established for women who are newly diagnosed with locally advanced breast cancer that is ER and are deliberating a mastectomy is entailed in the given trials   Explanation   The primary trial includes women with locally advanced recurrent or metastatic breast cancer that is ER and has measurable disease or lytic or mixed lytic and",
        "label": "Entailment"
    },
    "45bd641d-3e35-456c-a01b-63fa3e2ebea1": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial is entailed in the trials inclusion criteria Therefore the statement is entailed in the trial description  The statement small plaque parapsoriasis is a variant of parapsoriasis in which the plaques are small is not related to the trial description and is",
        "label": "Entailment"
    },
    "6071457e-bfac-4d86-b20b-c37ff82c943f": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 15000 mcg per day is not directly entailed in the provided trial information   The primary trial reports the MTD of ruxolitinib in combination with paclitaxel but it does not mention the MTD of ruxolitin",
        "label": "Contradiction"
    },
    "c5a577f3-2bf4-4bbf-b1f9-5bd829414790": {
        "text_answer": "  The statement is not directly entailed in the given trials as the primary trial specifies a minimum breast tumor size of 1 cm while the secondary trial does not mention the breast tumor size However the statement is not contradictory to the trials as the inclusion criteria for both trials include HR and HER2 status and the statement refers to patients with these receptor statuses Therefore the statement is neither entailed nor contradictory to the trials",
        "label": "Contradiction"
    },
    "aa2706a4-b145-400f-8e8c-23e70f006360": {
        "text_answer": "  The statement in the primary clinical trial the participant count in cohort 2 is higher by 7 compared to cohort 1 is not directly entailed or contradicted by the given information The trials only provide the number of participants analyzed mean values and standard deviations for the outcome measurement in each armgroup but they do not specify the exact number of participants in each cohort Therefore it is not possible to determine if the",
        "label": "Contradiction"
    },
    "6d418558-93db-4116-b142-821c3f8615f2": {
        "text_answer": "  The statement is partially entailed in the trials   Explanation   The primary trial participants do receive whole breast radiation therapy as stated in the trial description   The secondary trial participants also receive intramuscular injections of Fulvestrant as stated in the trial description However the statement only mentions neck pain score 2 for participants but the trials do not provide any information about neck pain or its relation to the interventions",
        "label": "Entailment"
    },
    "7d5cd6d5-88a1-4693-b20b-c4960095a330": {
        "text_answer": "  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is entailed in the given trials as both trials report one instance of Thromboembolic Event each under their respective Adverse Events sections",
        "label": "Entailment"
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement that Breast Cancer patients in the primary trial are administered 1000 mcgday of talazoparib whereas Ovarian Peritoneal Cancer patients in the primary trial receive only 25 mcgday talazoparib instead is contradictory to the trials because  1",
        "label": "Entailment"
    },
    "dbc4f576-220a-482d-a06c-2538c13fdb28": {
        "text_answer": "  The statement women aged 20 or 21 are immediately eligible for the primary clinical trial but were eligible for the secondary trial 12 years prior is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes women aged 20 years or older while the secondary trial includes women aged 18 or older However the statement does not explicitly mention the age difference between the two trials or",
        "label": "Contradiction"
    },
    "ed9856c5-cecd-4d24-a338-28bf547559fe": {
        "text_answer": "  The statement the complete cohort of the primary clinical trial is prescribed entericcoated tablets is not entailed in the given trials as the trials only specify the medication and dosage for each group in the intervention but they do not mention that the medication is given in entericcoated tablets for the entire cohort in the primary trial",
        "label": "Contradiction"
    },
    "d83f5fcf-2a52-4612-b548-060ece7749f9": {
        "text_answer": "  The statement is entailed in the trials as both trials include the use of cyclophosphamide Paclitaxel and pegfilgrastim in their interventions However its important to note that in the primary trial Paclitaxel is given in combination with Carboplatin while in the secondary trial its given in combination with docetaxel Therefore while the statement is entailed in terms of the use of",
        "label": "Entailment"
    },
    "61b2e007-6e98-4923-8c07-d22ab6b62870": {
        "text_answer": "  The statement there were no adverse events reported by participants in either the primary or secondary clinical trials is entailed in the given trials data as the total number of adverse events reported in both trials is zero for all types mentioned",
        "label": "Contradiction"
    },
    "fb1605b0-dce6-45fb-bc67-2018e0578a2e": {
        "text_answer": "  The statement during the period of the study most individuals participating in the primary clinical trial struggled with varying degrees of eating disorders is not entailed in the given adverse events data The data only reports specific adverse events observed during the study none of which directly relate to eating disorders",
        "label": "Contradiction"
    },
    "11714886-d3a2-496b-a883-6cd394478b03": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on interventions massage therapy and administration of PF06647020 rather than the type of squamous cell carcinoma being studied However the statement is relevant and accurate as it provides context about the type of squamous cell carcinoma being studied in each trial  The primary trial does not involve any drugbased interventions while the secondary trial tests",
        "label": "Contradiction"
    },
    "cd8d5a6a-0365-410c-8f85-815a67c0d11b": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants who experienced recurrencefree survival up to 5 years after randomization They do not provide the actual data on the number of participants who experienced recurrence or death during that period Therefore it is not possible to make a direct comparison between the two groups based on the given data and make a statement about the percentage of participants who experienced recurrencefree survival in each",
        "label": "Contradiction"
    },
    "1d725114-1659-46dd-ab68-0c09bc167427": {
        "text_answer": "  The statement bilateral breast tumor presence is not a reason for exclusion in the primary clinical trial is not explicitly stated in the given inclusion and exclusion criteria However the criteria only mention unilateral breast cancer which implies that bilateral breast tumor presence would be an exclusion Therefore the statement is contradictory to the information provided in the criteria",
        "label": "Entailment"
    },
    "4894f59e-9386-448a-a779-f22a453ef049": {
        "text_answer": "  The primary trial does not directly compare the two groups TEADM With PMRT and Standard Mammography in terms of operative time The statement is not entailed in the given trials However based on the provided data it can be observed that the median operative time was shorter in the Standard Mammography group compared to the Intraoperative Mammography group This information alone does not necessarily imply that the control group in the secondary trial",
        "label": "Contradiction"
    },
    "faf9f6e7-c9ac-4f15-8a63-1b463b9e1c51": {
        "text_answer": "  The statement tumour lysis syndrome was not diagnosed in participants of either the primary or the secondary trial is entailed in the given trials as there is no mention of tumour lysis syndrome as an adverse event in either trial",
        "label": "Entailment"
    },
    "58c00532-2a20-4940-995f-08223d2736d5": {
        "text_answer": "  The statement a high prevalence of pancytopenia was observed in the patient cohorts of the primary clinical trial and the secondary trial is contradictory to the given data as there were no reported cases of pancytopenia in either trial 0 cases out of 733 765 88 and 86 participants respectively",
        "label": "Contradiction"
    },
    "c136fce2-0e64-4f51-8483-be0fde4382ef": {
        "text_answer": "  The statement all adverse events reported in the primary clinical trial were different for each patient is neither entailed nor contradicted by the given data   The data only provides the number of patients who experienced each type of adverse event but it does not specify whether any patient experienced more than one type of adverse event during the trial Therefore it is possible that some patients had the same adverse event and it is also possible that all adverse events were",
        "label": "Entailment"
    },
    "ce7f9154-ce9f-4d2f-8377-940c57315f1c": {
        "text_answer": "  The statement all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group is not directly entailed in the given trial results   The results only provide the mean standardized scores and standard deviations for the cognitive function tests in the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The statement makes a stronger claim about all participants experiencing a deterior",
        "label": "Contradiction"
    },
    "f02e41c3-1eea-4662-9359-fe120c3bc10a": {
        "text_answer": "  The statement the occurrence of eating disorders was not prevalent among the candidates for the primary clinical trial is not directly entailed or contradicted by the given adverse events data   The data only reports various adverse events observed during the trial including anorexia which is a type of eating disorder However the data does not provide sufficient information to determine the prevalence or frequency of eating disorders among the candidates Therefore the statement cannot be definitively",
        "label": "Contradiction"
    },
    "21c01e1d-b152-404c-88d6-b697b2a97b68": {
        "text_answer": "  The statement the primary trial registered a higher number of mucositis oral bladder infection and thromboembolic events compared to the secondary trial is contradicted by the given data  Explanation  The statement implies that the primary trial had more instances of mucositis oral bladder infection and thromboembolic events than the secondary trial However the data provided shows that the primary trial had",
        "label": "Contradiction"
    },
    "dd3899d8-889b-424c-a7c4-8381ce656f18": {
        "text_answer": "  The statement three specific adverse events pancreatitis cholelithiasis hepatic pain and febrile neutropenia occurred amongst patients in the primary clinical trial is not directly entailed in the given trials as none of the trials report the occurrence of pancreatitis cholelithiasis or febrile neutropenia However the statement is not contradictory to the trials as well",
        "label": "Contradiction"
    },
    "01650c5a-f268-41c2-b07b-9293a0e4a8f7": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using RECIST criteria for solid tumors These outcome measures are not at all alike as they assess different conditions hot flashes and tumor response using different methods and criteria",
        "label": "Entailment"
    },
    "9ad9b404-b234-41e6-9699-06a8c03bfe08": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement only mentions some details about the interventions in the trials but it does not directly compare or relate the trials to each other The statement does not entail that the trials are comparing the same interventions or that the social support survey questionnaire is related to the doses or durations mentioned in the trials Therefore the statement is neither entailed",
        "label": "Entailment"
    },
    "1f8bd45e-480f-4244-9515-e1249b5b842a": {
        "text_answer": "  The statement 97 of patients in the primary trial did not experience any Adverse Events mental disorder due to a general medical condition is not entailed in the given trial information   The trial information only provides data on the percentage of subjects who completed the treatment regimens 98 for systemic chemotherapy and 922995 for maintenance therapy but it does not mention any information about mental disorders due to general",
        "label": "Contradiction"
    },
    "6d446eda-4dec-469d-9313-37c70eef8e0a": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial and the secondary trial had an equal number of patients is contradictory to the given information   In the primary trial there were 76 participants in the Nuevo Amanecer Peer Support Program arm and 75 participants in the Waitlist Control arm making a total of 151 participants   In the secondary trial there were 147",
        "label": "Entailment"
    },
    "6003b550-4716-4966-a585-5a69fea20613": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial includes the following exclusion criteria related to cardiovascular impairment  Congestive heart failure  Clinically significant cardiac arrhythmia  History or current evidence of a myocardial infarction during the last 6 months  Current ECG tracing that is abnormal in the opinion of the treating Investigator  Unstable angina  The secondary",
        "label": "Entailment"
    },
    "f5a80369-d69d-47d6-836c-60735534ce4e": {
        "text_answer": "  The statement is not entailed in the given trials as the trials only specify the dosages of MCS110 and PDR001 for each intervention but they do not guarantee that the total dosage of MCS110 given to each participant every three weeks will be no less than 20mg Similarly they do not ensure that each participant receives more than 130mg of PDR001 every alternate week Therefore the statement",
        "label": "Contradiction"
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "text_answer": "  The statement Patients with stage 4 cancer are not eligible for the secondary trial however they are eligible for the primary trial is entailed in the given trials as  1 In the primary trial there is no mention of any eligibility criteria related to the cancer stage being limited to IIbIII Therefore patients with stage IV breast cancer can be included in the primary trial 2 In the secondary trial the eligibility criteria explicitly",
        "label": "Entailment"
    },
    "3d29cec9-8354-4d5b-ae1a-f486ab7aa6ca": {
        "text_answer": "  The statement renal calyx is an intrarenal space located in the renal medulla that serves to collect and transport urine is a factual statement about anatomy and physiology and it is not directly related to the intervention MM111 mentioned in the primary trial section Therefore this statement is neither entailed nor contradicted by the information provided in the trial",
        "label": "Entailment"
    },
    "59f54656-5444-4b6d-a011-2921eb624626": {
        "text_answer": "  The statement the primary clinical trials intervention section does not provide a clear outline of the treatment cycle or radiation dose details is an entailment for some clinical trials but not all The statement is entailed if the intervention section of the primary clinical trial in question indeed lacks a clear description of the treatment cycle and radiation dose details However if the intervention section does provide a clear outline of the treatment cycle and radiation dose details then the statement is contradictory",
        "label": "Entailment"
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "text_answer": "  The statement Every patient in the primary trial is receives a dose of 100 to 1600 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information   The trial information only mentions the use of Vorinostat and Radiation therapy and the dosing schedule for Vorinostat It does not mention anything about the use of fentanyl sublingual spray",
        "label": "Contradiction"
    },
    "54d98b73-9799-4f9a-8581-42792f164d96": {
        "text_answer": "  The statement is entailed in the given trials as the primary trial focuses on Yttrium90 Radioembolization using TheraSphere while the secondary trial explores the combination of ibrutinib and MEDI4736 which are different interventions However there is no direct relationship between the interventions in the two trials Therefore the statement is entailed in the sense that they are separate interventions in different trials but it",
        "label": "Entailment"
    },
    "75753b6a-e963-4357-a225-102c1542f73d": {
        "text_answer": "  The statement is not directly entailed or contradicted by the given trials as they do not provide any information about a Likert scale being used to measure agreement regarding the adverse events The trials only report the occurrence or nonoccurrence of specific adverse events in two separate cohorts",
        "label": "Contradiction"
    },
    "f377df82-9511-47cc-9176-12491888eb05": {
        "text_answer": "  The statement antigmcsf monoclonal antibody is any monoclonal antibody that is directed against granulocytemacrophage colonystimulating factor gmcsf is not directly related to the information provided in the trials However the trials do not contradict or entail the statement  In the primary trial Armodafinil is mentioned as an intervention but it is not",
        "label": "Entailment"
    },
    "b2187410-7c4d-49e2-a987-892fff52269f": {
        "text_answer": "  The statement valvular heart disorder is any heart disorder characterized by a defect in valve structure or function is not directly related to the information provided in the trials The trials only mention the administration of memantine hydrochloride or placebo orally to cancer survivors who smoke and do not mention any valvular heart disorders Therefore the statement is neither entailed nor contradicted by the information in the trials",
        "label": "Entailment"
    },
    "91d1600a-35d7-47a4-b972-edee5eeb6018": {
        "text_answer": "  The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is not directly entailed in the given trials as the trials only specify the dosages of MCS110 to be 1 mgkg or 3 mgkg every 3 weeks To determine if the statement is entailed we would need to know the weight of the patients in the trial and calculate the dosage they receive every",
        "label": "Contradiction"
    },
    "95570634-cfd3-4f4c-8082-8b98a2f13859": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORR between the two groups   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 0587",
        "label": "Entailment"
    },
    "109ad38c-08ee-40ab-9a9c-65a4db8915b0": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials The trials describe two different interventions using different medications but they do not specify the route of administration for childhood leukemia patients in general Therefore the statement about the same routes of administration for both interventions is not directly related to the trials information",
        "label": "Entailment"
    },
    "47abcc5d-7e6b-4969-9646-eefe68cebc3a": {
        "text_answer": "  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial but more cases of FEBRILE INFECTIONs were recorded in the primary trial is contradictory to the given trials data  Explanation  The statement implies that 1 The secondary trial had more cases of anemia pneumonia and stupor than the primary trial",
        "label": "Entailment"
    },
    "5b66def6-3282-455a-a879-6e5a68c90c1b": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials In the primary trial no information about the frequency or method of administration of the intervention is given However in the secondary trial it is stated that epoetin beta is administered as a weekly subcutaneous injection for a total of 12 weeks In contrast the statement provided suggests that participants in the primary trial receive a single injection at the studys commencement which",
        "label": "Contradiction"
    },
    "959eb0d5-7ac9-4c23-a10e-d1b720960a96": {
        "text_answer": "  The statement is entailed in the trials as both trials involve evaluating the effects of interventions on study participants with the primary trial focusing on the influence of radiation therapy and the secondary trial testing the impact of varied quantities of the same treatment PF05212384 on study groups",
        "label": "Entailment"
    },
    "a3abbf89-df53-45d4-97e1-f358dddbd2a8": {
        "text_answer": "  The statement neither cohorts in the primary clinical trial reported any instances of hypertension edema and dyspnea is contradicted by the information provided in the trials   In the first cohort of the primary trial there were no instances of edema reported 024 However there was one instance of dyspnea reported 124 under the category of Ejection fraction decreased  ",
        "label": "Contradiction"
    },
    "33377a5a-a2d0-4881-b4eb-93fe650e900a": {
        "text_answer": "  The statement is entailed in the trials as the mean number of hot flashes per day in the paced respiration group 348 is less than the mean number of hot flashes per day in the fast shallow breathing group 395 Therefore the statement is entailed by the given trials",
        "label": "Entailment"
    },
    "b83fe708-6ce5-4b18-9d6a-51741249c7df": {
        "text_answer": "  The statement patients who consume alcohol are ineligible for the primary clinical trial yet those who limit their intake to less than five drinks per day may qualify for the secondary clinical trial is neither entailed in the primary nor the secondary trial descriptions   The primary trial explicitly states that patients will be excluded if they have a history of alcohol or substance abuse or dependence within the past 2 years However it does not mention any specific limit for alcohol consumption for",
        "label": "Entailment"
    },
    "c6fedf8e-7d06-426e-8269-667a68ef06bc": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial described in the text does not involve any drugbased interventions as stated in the text Instead it focuses on massage therapy and related assessments   On the other hand the secondary trial described in the text involves the administration of PF06647020 as a drug treatment with two different dosage regimens",
        "label": "Entailment"
    },
    "485b3413-6788-47ad-916e-c5d7fdb28237": {
        "text_answer": "  The statement paraganglion is a cluster of neural crest cells that are located adjacent to the adrenal gland nerves and blood vessels is not related to the information provided in the trials Therefore it cannot be determined if the statement is entailed in the trials or not  Regarding the trials based on the information provided it appears that the Nuevo Amanecer Peer Support Program resulted in greater improvement in physical well",
        "label": "Entailment"
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "text_answer": "  The statement Nobody taking part in the primary trial suffered a UTI is contradictory to the information provided in the trial data   Explanation   The trial data states that there was one participant who experienced a urinary tract infection UTI Therefore the statement Nobody taking part in the primary trial suffered a UTI is contradictory to the facts presented in the trial data",
        "label": "Entailment"
    },
    "dfbf536b-7a16-42a0-b7f9-322c5394a01b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement the most common adverse event in the secondary trial was anaemia affecting more than 120 patients there were no recorded aes in the primary trial is contradictory to the information in the trials because  1 The statement implies that anaemia was the most common adverse event in the secondary",
        "label": "Contradiction"
    },
    "3db98663-b8c7-4869-a46a-e7526caa7436": {
        "text_answer": "  The statement Participants must be resistant to AI therapy to participate in the primary trial but this is not necessary to be included in the secondary trial is a contradiction to the information provided in the trials inclusion criteria   In the primary trial participants must be resistant to AI therapy while in the secondary trial this requirement is not mentioned as a criterion for inclusion Therefore the statement is a contradiction as it asserts two different",
        "label": "Contradiction"
    },
    "fa5334cc-0f09-4f22-91f8-156c7ab6d964": {
        "text_answer": "  The statement knife device is a cutting device usually consisting of a sharpened blade attached to a handle is not directly related to the information provided in the primary or secondary trials The trials focus on the outcome measurements and results of interventions for lymphoedema and sulforaphane supplementation respectively The statement about the knife device is a general definition and does not entail or contradict the information presented in the trials Therefore the statement is neither ent",
        "label": "Entailment"
    },
    "5accf90d-2307-441f-ae8d-d055d9564a26": {
        "text_answer": "  Based on the provided information the statement is entailed in the trials as the inclusion and exclusion criteria for the primary and secondary trials are distinct and prevent overlap of participants between the two studies The primary trial focuses on postmenopausal women with a history of breast cancer and severe hot flushes while the secondary trial targets adult patients with HER2negative metastatic breast cancer who are candidates for taxanebased chemotherapy The criteria for participation in each trial",
        "label": "Entailment"
    },
    "0aa5e58e-3ff4-487f-b043-d10452a30a4f": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information to make a definitive statement about the absence or presence of lesions in the participants of group 1 of the secondary clinical trial However the statement does contradict the information provided in results 1 of the secondary trial where 15 out of 18 participants were diagnosed with radiation dermatitis and 15 out of 18 participants were diagnosed with hyperp",
        "label": "Contradiction"
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "text_answer": "  The statement Patients whos Metastasis cannot be measured or whos Cancer has not spread to other parts of the body are not eligible for the primary trial is a contradiction to the trial criteria   The trial includes patients with measurable or nonmeasurable disease which means that patients with metastases that cannot be measured are still eligible for the trial Therefore the statement that such patients are not eligible is a contradiction",
        "label": "Contradiction"
    },
    "4c7b87a1-ac43-4d8c-b6cf-2c95f3a3a074": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site Therefore neither intervention uses a higher dose of radioactive Tc99M sulfur colloid than the other",
        "label": "Entailment"
    },
    "33529b88-15c5-4e64-b876-f83de0305ce8": {
        "text_answer": "  The statement Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time is entailed in the primary and secondary trial information provided   The primary trial exclusion criteria include Participation in another clinical trial within 30 days prior to screening or during the study This directly states that individuals cannot participate in another clinical trial during the primary trial The secondary trial information also states previous chemotherapy for met",
        "label": "Entailment"
    },
    "5199d14c-3a5e-4800-adf2-a065f50886b5": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the Intervention 2 group receives Armodafinil PO daily for 47 days while the Intervention 1 group does not receive Armodafinil daily In contrast in the secondary trial both Intervention 1 and Intervention 2 groups do not receive Armodafinil daily Instead they both receive a fixed dose of P",
        "label": "Entailment"
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "text_answer": "  The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is entailed in the Trials as follows  1 NUT midline carcinoma and Castrateresistant prostate cancer are included in the Primary Trial with the specified criteria ",
        "label": "Entailment"
    },
    "6e644116-4084-4a3d-90dd-82f50a7ccc0c": {
        "text_answer": "  The statement most of the adverse events reported in the primary clinical trial involved blood and bone marrow unlike in the secondary clinical trial is entailed in the given data if we define most as more than 50 of the adverse events In the primary trial 10000 of the adverse events involved blood and bone marrow while in the secondary trial 5769 of the adverse events",
        "label": "Entailment"
    },
    "c0b9a42b-2440-46b5-8fbc-978e2699c76e": {
        "text_answer": "  The statement only those with a histologicallycytologically confirmed diagnosis of colorectal cancer can participate in the primary clinical trial is not explicitly stated in the given inclusion criteria However colorectal cancer is listed among the tumors for which patients are eligible to participate in the trial Therefore the statement is entailed in the trials inclusion criteria as colorectal cancer is one of the specified cancer types",
        "label": "Entailment"
    },
    "5bf5c965-7588-452a-9d36-2503218e56da": {
        "text_answer": "  The statement the secondary trial recorded fewer adverse events than the primary trial is contradicted by the given data   Explanation   The statement implies that the number of adverse events in the secondary trial is less than the number of adverse events in the primary trial However the data shows that the number of adverse events in the secondary trial is higher than the number of adverse events in the primary trial Therefore the statement is contrad",
        "label": "Contradiction"
    },
    "8f8b46df-4031-4a42-bf67-60d923f2ec29": {
        "text_answer": "  The statement radial growth phase is a morphologic architectural pattern in which the tumor cells spread horizontally is not directly related to the information provided in the primary or secondary trials The trials only describe the interventions and their schedules for participants with different types of cancer Therefore the statement is neither entailed nor contradicted by the information in the trials",
        "label": "Entailment"
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "text_answer": "  The statement candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments is contradictory to the inclusion criteria of the trial as stated in the text The trial is for breast cancer patients who have been unresponsive to hormonal treatments such as tamoxifen or aromatase inhibitors There is no mention of colon cancer in the inclusion criteria Therefore the statement is contradictory to the trials criteria",
        "label": "Contradiction"
    },
    "98528323-fc08-45b9-8403-4005398ae3a7": {
        "text_answer": "  The statement is entailed in the trials as the primary trial involves cabergoline which is given orally and the secondary trial involves pixantrone dimaleate which is administered intravenously Therefore the statement that the primary trial intervention is administered orally and the secondary trial intervention is strictly issued intravenously is entailed by the given trials",
        "label": "Entailment"
    },
    "4ff85794-0b6a-4fe7-824f-afa6c2fa133e": {
        "text_answer": "  The statement Coronary artery stenosis are the most common AE recorded in the primary trial is not entailed in the given data The data mentions the number and percentage of various adverse events but it does not specify which one is the most common The statement only mentions coronary artery stenosis but the data does not indicate that it is the most common adverse event Therefore the statement is contradictory to the given",
        "label": "Contradiction"
    },
    "0af2a0f3-dd56-4e3b-9e85-344780cc0877": {
        "text_answer": "  The statement penile pain CTAE 50 is a disorder characterized by a sensation of marked discomfort in the penis is not related to the information provided in the trials The trials focus on the effectiveness of interventions for breast cancer patients in terms of quality of life FACTB and intraoperative success in addressing positive margins Therefore the statement about penile pain and CTAE 50 is not entailed in",
        "label": "Contradiction"
    },
    "0f094624-f6e3-479b-bea3-34b5a3acf873": {
        "text_answer": "  The primary clinical trial lasted for 10 weeks while the secondary clinical trial lasted for 24 weeks The difference in duration is 14 weeks 24 weeks  10 weeks Therefore the statement the secondary clinical trials intervention duration extends 15 weeks longer than that of the primary clinical trial is a contradiction as the actual difference is 14 weeks not 15",
        "label": "Contradiction"
    },
    "55635fce-1467-46ba-934d-8234f33e103e": {
        "text_answer": "  The statement only female patients with evidence of a solid tumor that is in early stages andor nonmetastatic are eligible for both phases of the primary clinical trial is contradictory to the information provided in the inclusion criteria of the trial   The inclusion criteria for both phases of the trial state that participants must have evidence of a solid tumor that is locally advanced andor metastatic except for Phase 1 which also includes patients with a",
        "label": "Entailment"
    },
    "869a492c-b4bf-4145-a491-1ee0ea0fe816": {
        "text_answer": "  The statement yttrium is an element with atomic symbol y atomic number 39 and atomic weight 8891 is neither entailed nor contradictory to the information provided in the inclusion and exclusion criteria of the primary trial The statement is a fact about the chemical element yttrium and does not relate to the eligibility criteria for the trial or the condition of Alzheimers patients",
        "label": "Entailment"
    },
    "53e2327a-6a30-49d0-a5eb-74cc5141abbb": {
        "text_answer": "  The statement None of the primary trial candidates have to perfom regular exercise as part of the intervention is not entailed in the given trial description The trial description only mentions the eligibility criteria for the patients and the types of cancer for which the intervention can be applied It does not mention anything about regular exercise being a part of the intervention or being excluded The statement about sulfoxone being a watersoluble sulfonamide antibiotic used in",
        "label": "Contradiction"
    },
    "fed2e936-ab4c-42d6-8346-8f1b3ec9cc73": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the occurrence of doselimiting toxicity DLT in each cohort   From the given trials we have two cohorts  1 Ixabepilone 24mgm2 and Doxorubicin 30mgm2 Level 1 2 Ixabepilone 32",
        "label": "Entailment"
    },
    "a73a2b32-2cdb-49ec-ac4e-ed2eb976dec1": {
        "text_answer": "  The statement there are less total adverse events in the primary trial than in the secondary trial is entailed in the trials as it is directly stated in the data provided  The statement but more cases of Cardiacischemiainfarction in the primary trial than in the secondary trial is contradicted by the trials as the number of cases of Cardiacischemiainfarction in the primary trial 114  ",
        "label": "Entailment"
    },
    "f86794bf-be99-43b3-b5e0-a78f5dde96a4": {
        "text_answer": "  The statement the bulk of the adverse events reported in the primary trial involved the respiratory system and were rare or nonexistent in the secondary trial is not directly entailed or contradicted by the given data in the Trials  The Trials only provide information about specific adverse events and their frequencies in each trial They do not provide any information about the types or frequencies of adverse events related to the respiratory system Therefore it is not",
        "label": "Contradiction"
    },
    "c002edfa-458b-4274-860e-a3c6024c467c": {
        "text_answer": "  The statement mental scale is a range of values that characterizes an individuals mental development Sunitinib was administered orally every day to every patient in the primary trial for the entire duration of the study is not directly entailed in the given trial information The trial information only describes the administration of sunitinib and capecitabine their dosing schedules and monitoring for toxicity It does not provide any information about mental",
        "label": "Contradiction"
    },
    "570eadad-adf1-4e5a-bae7-8455d2a07f0e": {
        "text_answer": "  The statement hemolytic uremic syndrome ctcae is a disorder characterized by a form of thrombotic microangiopathy with renal failure hemolytic anemia and severe thrombocytopenia is not directly related to the information provided in the primary and secondary trials   The primary trial and the secondary trial are studying the same drug empegfilgrastim but with different dos",
        "label": "Entailment"
    },
    "43a81620-bb60-4515-b31b-4cf8e5f3cc25": {
        "text_answer": "  The statement it was typical for the primary clinical trial candidates to suffer from an eating disorder is contradictory to the information provided in the adverse events Anorexia is mentioned as an adverse event but it is not indicated that it was typical or common among the candidates However an eating disorder is not mentioned in the list of adverse events and there is no information provided to suggest that a significant number of candidates suffered from an eating disorder Therefore",
        "label": "Contradiction"
    },
    "da4bfd68-6510-4a0d-aa9e-b925d2cef24a": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information about OS Overall Survival rates for the participants The trials only report pCR pathological complete response rates Therefore it is not possible to determine if OS is the determinant of outcome measurement in both trials or if there is a difference in OS between the arms based on the given information alone However based on the provided data it can be observed that",
        "label": "Contradiction"
    },
    "4234e99e-4e49-459b-9a11-5420d039defd": {
        "text_answer": "  The statement the primary trial has fewer total adverse events compared to the secondary trial is entailed in the given trials data as the total number of adverse events in the primary trial is 014 000 compared to 48348 1379 in the secondary trial  However the statement does not address the specific comparison of cardiacischemiainfarction between the two trials",
        "label": "Entailment"
    },
    "29ebe44e-58cf-4141-afaa-9518629c3868": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 156 weeks are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the information provided in the exclusion criteria for both trials  In the primary trial patients with a pulmonary embolism within the last 156 weeks are explicitly excluded However the statement suggests that these patients",
        "label": "Contradiction"
    },
    "c6c56d8f-1e0a-4dad-9993-e47e34c146e7": {
        "text_answer": "  The statement is not entailed in the given trials as the trials describe different interventions The primary trial is about denosumab administration while the secondary trial is about lymphoscintigraphy using pIHGC and GP The statement compares the administration of denosumab and the injection of radioactive Tc99M sulfur colloid which are not directly related interventions in the trials",
        "label": "Contradiction"
    },
    "376fcb2c-1ea0-4b28-a6d2-fde91a124841": {
        "text_answer": "  The statement in the primary trial there were threefold the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy can be written mathematically as   3  number of hepatotoxicity cases  number of hypertension and pancreatectomy cases  Lets check if this equation is entailed by the given data  Given number of hepatot",
        "label": "Entailment"
    },
    "a1bff44a-8d74-4184-a4d3-228bb55f4530": {
        "text_answer": "  The statement the secondary clinical trial had a higher incidence of adverse events compared to the primary clinical trial is contradicted by the given data   Explanation   The given data states that there were no adverse events reported in both the primary and secondary clinical trials for Adverse Event 1 For Adverse Event 2 there were no reported adverse events in the primary trial but the data for the secondary trial is missing However",
        "label": "Contradiction"
    },
    "786d7c5c-66f2-4ce1-8b3d-c6fdbeb36168": {
        "text_answer": "  The given patient meets the inclusion criteria for both the primary and secondary trials with the following conditions  Primary Trial  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed  Age 18 years and above  Zubrod performance status 02  Signed informed consent  Secondary Trial  Histologically verified diagnosis of stage IIbIIIIV",
        "label": "Entailment"
    },
    "fef8b2f0-3e1f-46de-a53b-f1dffde794e6": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial includes male participants and the secondary trial includes female participants but the inclusion criteria are different for each trial based on the specific conditions and eligibility criteria for each trial The statement does not accurately reflect the information provided in the trials",
        "label": "Contradiction"
    },
    "3f777627-6d5d-43c9-8686-677498316865": {
        "text_answer": "  The statement 50 of the primary trial patients suffered an increase in blood bilirubin is contradictory to the information provided in the trial data The trial data states that 909 or 1 out of 11 of the patients experienced an increase in blood bilirubin Therefore less than 50 of the patients suffered from this adverse event",
        "label": "Entailment"
    },
    "7294869d-4998-49a4-a9b5-021476f448b6": {
        "text_answer": "  The given statement cognitive behavioral therapy CBT is a central component of interventions in the primary clinical trial is not directly entailed nor contradicted by the information provided in the trials description The trials description focuses on the use of a validated webbased risk assessment tool and decision support for providers based on the risk assessment results The trials description does not explicitly mention CBT as an intervention or a component of the interventions being used Therefore",
        "label": "Contradiction"
    },
    "7cd2b581-31f9-42e8-9945-9317f97be422": {
        "text_answer": "  The statement is contradictory to the given trial information   The dosage of eribulin given to cohort 1 in the primary clinical trial is 14mgm2 while the dosage of docetaxel given to cohort 2 is 75 mgm2 These dosages are not comparable as they are expressed in different units mgm2 for eribulin and mg for doc",
        "label": "Entailment"
    },
    "36386099-3f11-4037-aa48-dcbb36d7ff23": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is entailed in the inclusion criteria of the trial The inclusion criteria clearly state that one of the requirements for eligibility is a histologically confirmed infiltrating primary breast cancer that is HER2 positive which can be determined by either IHC 3 or FISH Therefore the statement is entailed in the",
        "label": "Entailment"
    },
    "873c56c9-8544-45f4-bba4-308707b30b93": {
        "text_answer": "  The statement individuals diagnosed with follicular lymphoma or metastatic melanoma based on immunohistochemistry or intraductal carcinoma are disqualified from both the primary and secondary trials is entailed in the primary trial as it is listed under the exclusion criteria for both trials Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "03204d11-8f0c-41be-9fe7-3361c5549d51": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both the placebo and trabectedin interventions are administered through a 180minute intravenous infusion on a biweekly basis However the trial information states that the placebo is administered as a 3hour intravenous infusion on Day 1 while trabectedin is administered",
        "label": "Entailment"
    },
    "c9c7d71a-0b59-4277-87fa-32e427e37b40": {
        "text_answer": "  The statement a 40 year old patient with bladder cancer absolute neutrophil count of 1200l platelet count of 49000l hemoglobin level of 75 gl and a life expectancy less than 5 months would be excluded from both the primary trial and the secondary trial is entailed in the trials as the patient does not meet the inclusion criteria",
        "label": "Entailment"
    },
    "90748020-3e2f-46c8-8e9d-984436a2d752": {
        "text_answer": "  The statement nonsmokers are the only eligible participants for the primary clinical trial and drinking more than 5 alcoholic drinks a day disqualifies one from the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the statement is consistent with some of the exclusion criteria in both trials In the primary trial nonsmokers are an inclusion criterion and in the secondary trial",
        "label": "Contradiction"
    },
    "29412166-6da7-47d8-82b9-efc61e628f05": {
        "text_answer": "  The statement patients in the primary trial and the secondary trial did not experience any thromboembolic events is entailed in the given trials as neither trial reported any thromboembolic events in their adverse events data",
        "label": "Entailment"
    },
    "d333f58a-6f8d-402c-a44c-36899a155100": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is a comparison of the frequency of specific adverse events between the two trials   The given trials do not provide enough information to directly determine if the statement is entailed or contradicted The statement only mentions three specific adverse events but there are other adverse events listed in the trials that are not mentioned",
        "label": "Entailment"
    },
    "777b7b77-83e6-49a0-9988-c2363fbcc17d": {
        "text_answer": "  The statement many participants in the primary clinical trial do not experience any increase in pleural effusion and rapid disease progression is not directly entailed nor contradicted by the given trials data   The trials data only provides the number of participants who experienced each adverse event in each trial It does not give enough information to determine the number of participants who did not experience these adverse events or the total number of participants in each trial Therefore we cannot make a",
        "label": "Contradiction"
    },
    "5aa4da04-c21d-48a4-8888-62675ca63f74": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the participants do not receive fulvestrant as part of the intervention However in the secondary trial both cohorts receive fulvestrant as part of the intervention but the relevant part of the statement is that they receive it in a tablet form to be taken bid This is consistent with the secondary trial description as fulvestrant is given intramuscularly in the loading dos",
        "label": "Entailment"
    },
    "8e63dcb6-d289-4782-94a5-9f0aa7343cbd": {
        "text_answer": "  The statement no fatalities were reported in the adverse events for both the primary clinical trial and the secondary clinical trial is entailed in the given trials as neither trial reported any fatalities in their adverse events 000 death not otherwise specified in both trials",
        "label": "Contradiction"
    },
    "d40740f4-8885-4590-b274-23802a46d9e3": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the procedure start for the application of Hydrophor or MediHoney is relative to the onset of radiation therapy  In the secondary trial the procedure start for the administration of PF05212384 and docetaxel is relative to specific days within the treatment cycle  Both trials describe the start of a procedure in relation to",
        "label": "Entailment"
    },
    "13f8d256-bec7-419f-bda5-202ea116a215": {
        "text_answer": "  The statement primary clinical trial patients experience adverse events identical to the secondary clinical trial is contradicted by the given data The primary trial reports adverse events including Dehydration Lymphopenia Neutropenia Hyponatremia and Weight loss which are not reported in the secondary trial Therefore the statement is contradicted by the given data",
        "label": "Contradiction"
    },
    "e100136f-281e-4721-9f57-66392982260f": {
        "text_answer": "  The statement patients diagnosed with hyperkalemia are ruled out in the primary clinical trial but can possibly qualify for the secondary clinical trial is a contradiction based on the information provided in the given trials   The primary clinical trial explicitly lists Potassium within the normal range of 3553 mEqL as an inclusion criterion Therefore patients with hyperkalemia potassium levels above 53 m",
        "label": "Contradiction"
    },
    "04d8d180-a06f-4eef-9c67-b51babbd8f10": {
        "text_answer": "  The statement is not directly entailed in the given trials as there is no information provided in the trials regarding the percentage food eaten score for the participants in the primary or secondary trials The trials only provide information about the interventions and their durations",
        "label": "Contradiction"
    },
    "98d96b95-5e98-49e3-8bd1-b004132c3781": {
        "text_answer": "  The statement is contradictory to the given trials   The primary trial sets an age limit of 21 and over for participation while the secondary trial includes participants who are 18 years old and above Therefore the statement that the secondary clinical trial welcomes participants of all ages including 18 year olds but the primary clinical trial sets an age limit of 21 and over is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "c25249a2-5294-4b5e-a39c-3b5c956b9147": {
        "text_answer": "  The statement patients who have officially certified allergies to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib are not suitable for enrollment in either the primary clinical trial or the secondary clinical trial is entailed in the given trials exclusion criteria   In the primary trial the exclusion criteria state that Patients with known allergic reactions attributed to comp",
        "label": "Entailment"
    },
    "cb5c3a2b-3752-4e0d-9b5e-ae84ffaab109": {
        "text_answer": "  The statement despite the variant cancer types most patients in the first cohort of the primary clinical trial were screened contemporaneously after the intervention is entailed in the trials provided   Explanation   The trials show that a higher percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for colorectal breast and cervical",
        "label": "Entailment"
    },
    "bebf3648-7a1c-4e73-8d0a-f5715fa173f8": {
        "text_answer": "  Lets calculate the minimum dosage of MCS110 and PDR001 administered to each patient in both interventions  Intervention 1  MCS110 1 mgkg Q3W  PDR001 100 mg Q3W  Minimum dosage per cycle 3 weeks  MCS110 1 mgkg  3 kg",
        "label": "Entailment"
    },
    "0723e2a6-a2cd-4b8b-b319-f8a8bf00d819": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is not directly stated in the inclusion and exclusion criteria provided However the criteria do include the following exclusion Women of childbearing potential WOCBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire",
        "label": "Entailment"
    },
    "d0d25983-0004-4189-9139-c36827fa1e4d": {
        "text_answer": "  The statement is a contradiction to the trials provided The primary trial administers chemotherapies including Doxorubicin Cyclophosphamide Carboplatin and NabPaclitaxel but it does not mention Gemcitabine Vinorelbine or Ruxolitinib The secondary trial does not administer Gemcitabine Vinorelbine or Ruxolitinib as stated",
        "label": "Contradiction"
    },
    "7bb1cc76-1493-4507-9560-4b4719a5d3fc": {
        "text_answer": "  The statement Over 50 of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly related to the outcome measurement provided in the trial results The trial results only report the proportion of participants with controlled acute vomiting no episodes of vomiting and no rescue medication during first 24 hours after cycloph",
        "label": "Contradiction"
    },
    "c77cef4c-abf2-439e-97a4-abf4e1d57ac8": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial inclusion criteria The primary trial includes females with all types of breast cancer while the secondary trial specifically includes females with triplenegative breast cancer ER PR and Her2neunegative or BRCApositive breast cancer Therefore the statement is not entailed in the trials as given",
        "label": "Contradiction"
    },
    "e8be62e0-1f25-49f3-91d8-4fc23848dcd1": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement asserts that cohorts 1 and 2 received similar dosages of cetuximab without the collaborative care intervention However the trial information specifies different dosages for each cohort 12 mgkg vs 20 mgkg and does not mention the absence of the collaborative care intervention for both cohorts",
        "label": "Entailment"
    },
    "d91d9ce6-365c-4b56-9eef-20922491f504": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   Cohort 1 of the primary clinical trial is given 90 mgm2 paclitaxel weekly not daily and cohort 2 is given 25 mg of sunitinib daily not 90 mgm2 paclitaxel",
        "label": "Entailment"
    },
    "2e95798d-089f-44b6-a6bf-13161021b7ff": {
        "text_answer": "  The statement patients that have recently undergone antineoplastic chemotherapy can participate in the primary clinical trial is contradictory to the trials exclusion criteria The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents allowed are exclusion criteria Therefore the statement is contradictory to the trials eligibility requirements",
        "label": "Entailment"
    },
    "d6aab46f-9e05-43a5-9d57-ca7d34bed983": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the use of intravenous IV infusions of FMX and MM398 and FMXMRI scans while the secondary trial involves the oral administration of lapatinib and IV infusions of paclitaxel with no mention of MRIs or ultrasounds Therefore neither trial meets the conditions specified in the statement",
        "label": "Contradiction"
    },
    "cc2be8ad-6396-41da-a205-45d8bfca37f4": {
        "text_answer": "  The statement male leukemia patients under the age of 18 can participate in the primary clinical trial regardless of race or ethnic origin is not entailed in the given inclusion criteria for the primary trial as it does not mention leukemia or age restrictions for males in the eligibility criteria  The statement for the secondary clinical trial they must have Her2neu lung cancer is not directly related to the primary trial and",
        "label": "Contradiction"
    },
    "bec00746-3a77-4d83-9c3b-d50eabcac1de": {
        "text_answer": "  Neither Intervention 1 nor Intervention 2 specifies that all participants will undergo a laparoscopic procedure Therefore the statement is not entailed in the given trials",
        "label": "Contradiction"
    },
    "aebbea11-2bed-406c-a63e-02ca9eede262": {
        "text_answer": "  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is not entailed in the given trials as Syncope was only reported in the primary trial and not in the secondary trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "13386e01-7556-4cec-93ef-c845f8c8e50d": {
        "text_answer": "  The statement personal care and service occupations is a class of professional or vocational positions of employment that involves no relation to the trials is neither entailed nor contradicted by the given trials data   The trials data only provide information about the number and types of adverse events observed in two separate clinical trials It does not mention anything about personal care and service occupations Therefore the statement is neither entailed nor contradicted by the trials data",
        "label": "Contradiction"
    },
    "fbe7ef7c-4dff-403e-9152-04d357ec9bbc": {
        "text_answer": "  The statement is entailed in the trial results as stated in the mean percentage change in Ki67 expression 40 63 to 29 indicates a decrease in Ki67 expression by approximately 40 in the tamoxifen group compared to the control group presumably without tamoxifen Therefore the statement is entailed in the trial results",
        "label": "Entailment"
    },
    "fd32ab49-3994-4b45-aaf9-da79d4cae211": {
        "text_answer": "  The statement less than 10 patients in the primary trial suffered Aes severity of elevated lesion is not directly related to the information provided in the trials about adverse events The trials only mention the number of patients who experienced specific adverse events gastroesophageal reflux disease and ductal carcinoma in situ and their respective frequencies The statement about the severity of the lesions being an indication of elevated les",
        "label": "Entailment"
    },
    "bdfb5379-c659-4a09-b4f1-895468675f2e": {
        "text_answer": "  The statement Any patients with Documented allergy to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial is entailed in the primary trials exclusion criteria as it states Patients with known allergic reactions attributed to compounds of similar chemical or biologic composition to mesna or other agents used",
        "label": "Entailment"
    },
    "c53af3d2-6827-4f10-ae9e-c7639a15b19a": {
        "text_answer": "  The statement adverse events were not common amongst cohort 1 participants in the primary clinical trial identical results were drawn from cohort 2 is not directly entailed in the given trials as they only provide the number and percentage of adverse events for each cohort without making a comparison between them regarding commonality However based on the given data it appears that the percentage of adverse events is lower in both cohorts 424",
        "label": "Contradiction"
    },
    "2a5561f9-399d-4651-9a54-1a15f251c070": {
        "text_answer": "  The primary trial involves participants receiving pembrolizumab every 3 weeks Q3W while the secondary trial does not mention the frequency of pembrolizumab administration for the control group However the statement compares the frequency of sunitinib and pembrolizumab not their absolute frequencies  To compare the frequencies we need to determine how often sunitinib is administered in the secondary trial and how often pemb",
        "label": "Entailment"
    },
    "a61c1627-33e6-4a53-8247-484d42328747": {
        "text_answer": "  The statement a patient presenting with a tumor primarily having a size of a 3mm diameter as assessed through clinical inspection and sonography can be a potential candidate for both primary clinical trial and secondary clinical trial is not entailed in the given inclusion criteria for either the primary or secondary clinical trials  The primary clinical trial includes a criterion for the primary tumor to have a greater diameter than 2 cm as measured by clinical examination and mammography or",
        "label": "Contradiction"
    },
    "dfef1ddd-9351-436d-b1ce-9f22065b495c": {
        "text_answer": "  The statement is contradictory to the given trials as there were no adverse events reported in more than 3 out of 10 participants in either the primary or secondary trials The trials report the number of adverse events and the number of participants with those events but none of them exceed 3 out of 10",
        "label": "Contradiction"
    },
    "9367129d-51e0-4d62-b2df-35749e117157": {
        "text_answer": "  The statement primary clinical trial rules out patients with observable tumors in both breasts is entailed in the given inclusion criteria as it explicitly states unilateral breast cancer which means cancer in one breast only Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "9a20f7f5-5477-4320-be07-3f2154877863": {
        "text_answer": "  The primary trial includes the following inclusion criteria for breast tumor size Breast tumor 1 centimeter cm in diameter The secondary trial does not specify a breast tumor size in its inclusion criteria  The statement patients with a breast tumor 0208 centimeters in diameter with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial is not entailed in",
        "label": "Contradiction"
    },
    "29eca4cf-13e4-4028-bbd1-71955607afb5": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy is entailed in the trials provided   The trials show that the median aAUCpa for the Sensory Neuropathy subscale in Arm I Cryotherapy was 14 117 to 68 while in Arm II Control it was 4",
        "label": "Entailment"
    },
    "1d3bccea-6780-45ae-93d2-651346fbc1dd": {
        "text_answer": "  The statement all patients treated with gtx024 0001kg in the primary trial gained lean body mass over a 033 year period is not entailed in the given trials as there is no armgroup in the trials with a dose of exactly 0001kg of GTx024 The trials only report data for patients receiving 1 mg and 3 mg doses Therefore the statement",
        "label": "Contradiction"
    },
    "916340c0-cd97-4e2e-bd31-ded7bd2d1a56": {
        "text_answer": "  To determine if the statement most patients involved in the primary clinical trial showed progression of disease by the end of week 24 is entailed or contradicted by the given trial results we need to calculate the number of participants with progressive disease PD at week 24  From the given results we have  Week 12 SD 12  Week 24 SD 10  The number",
        "label": "Entailment"
    },
    "8b37f698-edfb-4e34-b0da-4a5287506d02": {
        "text_answer": "  The statement individuals having suffered a stroke transient ischemic attacks or have evidence of an intrabdominal abscess in the past 6 months are allowed to be a part of the primary clinical trial is a contradiction to the trials exclusion criteria The trial explicitly states that individuals with a history of stroke transient ischemic attacks or intrabdominal abscess in the past 6 months are not eligible for participation",
        "label": "Contradiction"
    },
    "9c272853-cec0-43f0-9897-4657c5fd0b78": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria The primary trial specifies that the primary tumour should be greater than 2 cm in diameter which is approximately 20000m 20mm The statement suggests a primary tumour with a radius of 3000m which is larger than the inclusion criteria for the primary trial Therefore a patient with a primary tumour of 3000m",
        "label": "Entailment"
    },
    "8f31a3bf-d5a9-4f2c-95bb-c9ff01de6d42": {
        "text_answer": "  The statement every patient in cohort 1 in the primary clinical trial experienced no signs of acute vomiting after receiving treatment with aprepitant dexamethasone cytoxan and kytril is entailed in the trial results if we interpret the statement as  In the primary clinical trial 1000 20 out of 20 of participants in cohort 1",
        "label": "Contradiction"
    },
    "21fdf78c-fdbf-4140-9056-d3bfd2e9de27": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement suggests that both interventions alloMSCs and placebo are given in identical dosages through a single procedure However the trials describe different interventions    Intervention 1 AlloMSCs 100 million cells given in 20 injections of 04ml each  Intervention 2",
        "label": "Entailment"
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "text_answer": "  The primary trial reports the results in units of a hot flash score on a scale while the secondary trial reports the results as proportions of responders These are not the same units of measure so the statement is contradictory",
        "label": "Entailment"
    },
    "669ed7b4-398b-4604-8065-04e99611691d": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial there are two groups one receiving pyridoxine and the other receiving placebo Therefore the primary trial does have a placebo group  In the secondary trial there are two groups one receiving highdose oxybutynin chloride and the other receiving lowdose oxybutynin chloride Neither group is a placebo",
        "label": "Entailment"
    },
    "5d1997bd-e77f-43dd-abd1-eb1da8819d47": {
        "text_answer": "  The statement The primary trial intervention section does not describe the method of administration dosage or cycle is not directly entailed or contradicted in the given text The text only mentions that the small cell component is a morphologic finding and does not provide any information about the method of administration dosage or cycle of the intervention MM111 Therefore the statement is neutral with respect to the given text",
        "label": "Contradiction"
    },
    "8839dd14-8457-44c0-88a1-8bb0764e326c": {
        "text_answer": "  The statement a larger percentage of participants in the primary trial were reported to have experienced chest pain than in the secondary trial is not entailed in the given trials as there is no mention of chest pain in either trial",
        "label": "Contradiction"
    },
    "42a68b8b-0bed-49f4-8430-12e031c56471": {
        "text_answer": "  The statement several participants in the primary clinical trial who possess normal levels of vitamin D showed a distinguishable pattern in the expression of the evaluated 40 genes is not directly entailed in the provided trial results The trials only report the number of participants with no discernible pattern in the expression of the evaluated genes for the normal and lownormal vitamin D level groups No information is given about the presence or absence of a distinguishable pattern for",
        "label": "Contradiction"
    },
    "4d6b0c89-c9fc-4195-ac3e-c33b28af955e": {
        "text_answer": "  The statement is entailed in the primary clinical trial as it clearly states different inclusion criteria for individuals aged 1850 and those aged 50 in the document The primary clinical trial has separate groups for patients in different age categories each with its own specific eligibility requirements Therefore the statement is an accurate reflection of the information provided in the trial description",
        "label": "Entailment"
    },
    "fbd56c1d-5153-46c0-bd88-ed90eb1c9345": {
        "text_answer": "  The statement the most common adverse event observed in the primary clinical trial is general symptoms is not directly entailed in the given data However it is not contradictory either as the frequency of general symptoms 392 is higher than some of the other adverse events listed The most common adverse event based on the given data is nausea and vomiting each with a frequency of 392",
        "label": "Contradiction"
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "text_answer": "  The statement is partially entailed in the trials   Explanation   The statement 0 adverse events were observed in the primary trial is entailed in the primary trial data as it is stated explicitly in the data   The statement none of the adverse events in the secondary trial affected more than 30 of patients is not directly stated in the secondary trial data but it can be inferred from the data that none",
        "label": "Entailment"
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "text_answer": "  For the primary trial the statement is not entailed as not all interventions in Arm I require intravenous administration Zoledronic Acid is given intravenously but the correlative studies are not specified as requiring intravenous administration  For the secondary trial the statement is contradicted as some interventions in both Arms I and II are given orally In Arm I of the secondary trial placebo prochlorperazine gran",
        "label": "Contradiction"
    },
    "3f26cd3e-2b66-4bbc-94b4-498df2e334e3": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial does not involve any drugbased interventions as stated in the trial description It only mentions massage therapy psychosocial assessment and care and qualityoflife assessment  The secondary trial on the other hand does involve a drugbased intervention as stated in the trial description It tests different doses of PF0",
        "label": "Entailment"
    },
    "d1d340f9-f31f-4469-804b-41853562fa57": {
        "text_answer": "  The statement warfarin based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is neither entailed in the inclusion nor exclusion criteria of either the primary or secondary trials   The primary trial explicitly states that Patients who require use of coumarinderivative anticoagulants such as warfarin are excluded but it also permits the use of lowdose warfarin",
        "label": "Entailment"
    },
    "7d22f8db-6793-46e2-88ca-2d464ecf9789": {
        "text_answer": "  The statement in the primary clinical trial cohorts 1 and 2 patients exhibited no noticeable pattern for the expression of the 40 genes examined is in agreement with the results provided in the trials Both cohorts 1 and 2 had a percentage of participants with no discernible pattern for the expression of the 40 genes which is stated as 0 in the results Therefore the statement is entailed by the information given",
        "label": "Contradiction"
    },
    "ba8e855f-8cff-474d-a2dd-d5061a039b47": {
        "text_answer": "  The statement 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia is neither entailed nor contradicted by the given trial data in the Adverse Events 1 and Adverse Events 2 sections  Explanation  The statement mentions that there was one case of Anaemia and Febrile neutropenia in cohort",
        "label": "Contradiction"
    },
    "3c558a0b-1e1a-4d42-af75-266ea0d93662": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage of participants in each group who demonstrated a decrease in the Growth Factor Signature GFS   According to the results provided the percentage of participants in the ERpositive Luminal B group who demonstrated a decrease in GFS was 286 131492 and in the Triple Negative group it",
        "label": "Entailment"
    },
    "4c8ee685-13af-44a4-8d1e-30105f8469af": {
        "text_answer": "  The statement haploidentical is a donor who has only one haplotype in common with the recipient is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed in the trials or not The trials only provide information about the outcome measurements study designs and results related to pain intensity and bone mineral density in different patient groups",
        "label": "Entailment"
    },
    "526a5650-0b61-4e6e-9ddf-4674a6193964": {
        "text_answer": "  The statement unconfirmed progressive disease is a disease process that is increasing in scope or severity but the criteria for progressive disease is not met is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials However it does not contradict the information provided in the trials as well The statement is a clinical definition and does not affect the eligibility criteria for the trials Therefore the statement is neither entailed nor contradictory to",
        "label": "Contradiction"
    },
    "6b90da92-6aaa-431b-b31c-8df9def4a98d": {
        "text_answer": "  The statement candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for the primary and secondary trials   The ECOG performance status is a common measure used to assess the level of functional impairment in cancer patients A score of 1 indicates that the patient is moderately limited in their ability to carry out normal",
        "label": "Entailment"
    },
    "2a13f623-4957-4e7e-9968-03f64bb6f5f3": {
        "text_answer": "  The statement participants are given anthracyclinebased chemotherapy on days 1 8 and 15 is entailed in the Intervention 1 of the primary clinical trial   Explanation  Anthracyclinebased chemotherapy is mentioned in both Intervention 1 and Intervention 2 as a component of the treatment regimens In Intervention 1 it is given as do",
        "label": "Entailment"
    },
    "41756298-3326-499e-99f5-f34bcf718cbe": {
        "text_answer": "  The statement Any cancer patient diagnosed with either fibromyalgia thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is entailed in the Trials as follows  Primary Trial  Fibromyalgia is listed as an exclusion criterion  Thalasemic syndromes are listed as exclusion criteria  Anemia but only if",
        "label": "Entailment"
    },
    "f442b08f-4429-412f-99d2-24625bf8bdcd": {
        "text_answer": "  The statement feel worn out is not directly related to the interventions described in the trial The statement only refers to a feeling or experience of an individual while the interventions describe the medications and their administration schedules Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "0add45e1-cc70-4f0d-b2c7-14c67e9cd3ee": {
        "text_answer": "  The statement a frequent adverse event in the secondary trial anaemia was not observed during the primary trial is a contradiction based on the given data  Explanation  The statement is a contradiction because anaemia was not reported as an adverse event in the primary trial but it was reported as an adverse event in the secondary trial with a frequency of 234 Therefore the statement that it",
        "label": "Contradiction"
    },
    "a141432b-385e-4cd4-87e4-acc0e3e9f412": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trial results we need to calculate the difference in recurrencefree survival between the two groups and check if the statement is consistent with that difference  First lets calculate the number of participants with recurrencefree survival in each group  Ketorolac 30 mg group 80 out of 96 participants 833 NaCl ",
        "label": "Entailment"
    },
    "47468741-3624-4321-90ee-1c680a293b25": {
        "text_answer": "  The statement the record shows 5 total cases of asthenia and 3 total cases of pyrexia in the patients of the primary and secondary clinical trials is not entailed in the given trials data as there is no mention of asthenia or pyrexia in the trials data provided The statement contradicts the data if we assume that all cases of adverse events mentioned in the statement belong to the trials provided but since the statement does not match the",
        "label": "Contradiction"
    },
    "e44e25b6-1be6-4c35-a3c9-417c56052939": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Paclitaxel is not mentioned as being incorporated into either intervention in the given trials Intervention 1 involves anastrozole and Intervention 2 involves fulvestrant",
        "label": "Entailment"
    },
    "fd4c7d94-8d93-46b1-b467-3f169c6af30e": {
        "text_answer": "  The statement patients confirmed to have metastatic or unresectable small cell lung cancer SCLC based on histology are not allowed into the primary clinical trial unless they test positive for either EGFR or ALK or both is a contradiction to the inclusion criteria provided in the text   The inclusion criteria state that patients with histologically documented nonsmall cell lung cancer NSCLC head and neck cancer urothelial",
        "label": "Contradiction"
    },
    "a842c232-d17b-4257-84ff-02be26716c47": {
        "text_answer": "  The statement over 10 weeks of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 50 reduction in the percentage of cells with ki67 expression is not directly entailed in the given trial results   The trial results only provide the median interquartile range of Ki67 expression at baseline and at 6 weeks for the TAK228 plus tamoxifen",
        "label": "Contradiction"
    },
    "f33d7123-34a6-4466-98d2-9c69b18ac544": {
        "text_answer": "  The statement an individual who has been diagnosed with diffuse parenchymal lung disease as an adult in the past three years would not be eligible for the primary clinical trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria",
        "label": "Entailment"
    },
    "6bbcd12e-4105-478b-a402-1374ce8a01df": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is entailed in the trials inclusion criteria under the following conditions  1 Women of childbearing potential WOCBP Women of childbearing potential are eligible for the primary trial but they will need to commit to using an",
        "label": "Entailment"
    },
    "3793f6d8-1a56-48aa-b3d3-1216f7bf5d29": {
        "text_answer": "  The statement maculopapular Rash was a common adverse event for the primary trial participants is entailed in the given trial data as it is explicitly stated that Rash maculopapular 130 333 However the statement eosinophilic infiltrate is an inflammatory infiltrate composed exclusively or predominantly of eosinophils is not directly",
        "label": "Entailment"
    },
    "72278411-1c4b-4c70-b6ab-72c4c8449ec4": {
        "text_answer": "  The statement the primary clinical trial has seen a higher prevalence of biliary colic while instances of diarrhoea are more common in the secondary trial is entailed in the given trials if we consider the following  1 The statement mentions that the primary trial has a higher prevalence of biliary colic compared to the secondary trial This is not directly stated in the trials but it can be inferred from the numbers given In the primary",
        "label": "Entailment"
    },
    "10db152d-ae00-4b31-8c05-a1db1dee76b4": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial In the primary trial the dosage of trastuzumab given to Her2 patients is 2 mgkg IV once a week while in the second cohort of the secondary trial the dosage of trastuzumab given to Her2 patients is 4 mgkg IV on Day 1 of Cycle 5 followed by 2 mgkg IV",
        "label": "Entailment"
    },
    "282cb769-7825-4b3e-b089-05a6103f60ff": {
        "text_answer": "  The statement A 20 year old female patient with a Newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial and the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The statement only mentions that a patient is a 20yearold female with a specific type of breast cancer and is potentially eligible for two different clinical trials",
        "label": "Entailment"
    },
    "892e63ba-619c-4458-8130-89bbac726edb": {
        "text_answer": "  The statement the majority of patients in the primary clinical trial experienced a certain type of adverse event is not directly entailed or contradicted by the given information The statement is more general and does not specify which type of adverse event is being referred to The given information only lists specific types of adverse events and their frequencies To determine if the statement is entailed or contradicted we would need more information about the types of adverse events that make up the ",
        "label": "Contradiction"
    },
    "4a349ab7-7fd2-4979-bf94-4e563c26b7f9": {
        "text_answer": "  The statement patients suffering from stage 4 invasive breast carcinoma with positive estrogenprogesterone receptors and thinking about ai therapy could be potential candidates for the primary clinical trial is contradictory to the trials inclusion criteria The trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast Therefore patients with stage 4 invasive breast carcinoma are not eligible for",
        "label": "Entailment"
    },
    "0d633cc2-339a-4caf-b252-ce50b826e3e3": {
        "text_answer": "  The statement an instance of infection was reported in each of the primary and secondary clinical trial is entailed in the given trials as follows  1 In the primary trial there is one instance of infection reported out of a total of 32 participants 2 In the secondary trial there is one instance of infection reported out of a total of 15 participants  Therefore the statement is entailed in the given trials as both trials report",
        "label": "Entailment"
    },
    "28f840e3-3970-4ec7-ac46-d0503d56ee57": {
        "text_answer": "  The statement is not entailed in the given trials as neither the primary nor the secondary trial directly measures the percentage of participants who experience clinical benefit using RECIST criteria The primary trial measures tumor response using RECIST criteria but it does not provide information about the percentage of participants who experienced clinical benefit The secondary trial measures various outcomes such as number of participants with AIMSS laboratory biomarkers qualityoflife assessment etc but it does not",
        "label": "Contradiction"
    },
    "674d7d6c-723a-44db-9e96-10aa21dcefe4": {
        "text_answer": " The statement the examined genes displayed a discernible expression trend in the primary clinical trials first and second patient cohorts is not directly entailed in the provided trial results as there is no mention of gene expression trends or patterns in the results for the normal and lownormal Vitamin D level groups The results only report the number of participants in each group and do not provide information about gene expression trends or patterns Therefore the statement is neither entailed nor contradicted",
        "label": "Contradiction"
    },
    "c04ed14d-5ed2-46a6-9b0c-6a30a3b9a7b2": {
        "text_answer": "  The statement cholelithiasis was less common in primary trial participants compared to the secondary trial participants is contradicted by the given data   Explanation   The statement implies that the frequency of cholelithiasis was lower in the primary trial than in the secondary trial However the data shows that cholelithiasis was not reported in any participants in either trial Therefore since neither trial had any instances of ch",
        "label": "Contradiction"
    },
    "8983bf9f-d977-4238-91df-2435d2eb4a38": {
        "text_answer": "  The statement 2073 the primary trial participants and 2310 the secondary trial participants suffered an acute myocardial infarction is not entailed in the given trials as there is no mention of acute myocardial infarction in either trial The trials only report the occurrence of various adverse events but they do not provide the number of participants who experienced acute myocardial infarction Therefore",
        "label": "Contradiction"
    },
    "9d330063-37a8-4c8e-8ac2-f28c8048d0be": {
        "text_answer": "  The statement eyelid oedema and chest pain were the sole adverse event types noted in patients from the secondary clinical trial in contrast the primary clinical trial recorded none is a contradiction of the given trials data  Explanation  The statement implies that there were no adverse events in the primary trial except for eyelid oedema and chest pain in the secondary trial However the given data shows that there were no ad",
        "label": "Contradiction"
    },
    "5e23cc12-12c7-42e9-ab55-595bb427adad": {
        "text_answer": "  The statement Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is entailed in the trials as follows  In the primary trial severe insomnia is not explicitly mentioned in the exclusion criteria However insomnia is mentioned in the inclusion criteria for the secondary trial and severe insomnia is listed as an exclusion criterion there Since the secondary trial is a substudy of the primary",
        "label": "Entailment"
    },
    "5f45e043-f49d-42cd-941d-baa17257d46c": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants analyzed in each group and their Recurrencefree Survival rates but they do not directly compare the number of participants experiencing Recurrencefree Survival between the two groups Therefore the statement goes beyond the information provided in the trials   Additionally the statement is incorrect as it reports that 96 participants from the Ketor",
        "label": "Contradiction"
    },
    "5fff07e2-11f3-4a58-aecb-ce4650dd35f6": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria it is a",
        "label": "Entailment"
    },
    "6b257ade-83bb-428c-a623-056f1ad56594": {
        "text_answer": "  The statement candidates for the primary clinical trial must be diagnosed with lung cancer and require radiation therapy is contradictory to the given inclusion and exclusion criteria for the breast cancer clinical trial   The inclusion criteria state that candidates must have breast cancer that has continued to grow after hormonal treatment and require hormonal treatment as well as be postmenopausal women The exclusion criteria state that candidates cannot have received more than one previous regimen of system",
        "label": "Entailment"
    },
    "a146a89a-9519-4515-b36a-b5f365481341": {
        "text_answer": "  The statement is contradicted by the Trials   Explanation   The statement claims that there were no instances of anaemia and febrile neutropenia in cohort 1 but the Trials report that there was one instance each of these adverse events in cohort 1 Therefore the statement is contradicted by the information in the Trials",
        "label": "Contradiction"
    },
    "dabe9e76-e44c-45be-87b0-337fde45ab98": {
        "text_answer": "  The statement most of the patients participating in the primary clinical trial had a full recovery by the 24th week is not entailed in the trial results   Explanation   The term full recovery is not explicitly defined in the trial results However based on the provided information we can determine that at Week 12 there were 4 participants with partial response PR and 12 participants with stable disease SD",
        "label": "Contradiction"
    },
    "ff7079ec-d642-4cc3-8767-62df7a2a8ff7": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair more than 05 of waking hours are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial focuses on Her2neu or Her1EGFR positive cancer patients with measurable disease",
        "label": "Entailment"
    },
    "06609fde-0f22-485a-ba1c-78c2677d8783": {
        "text_answer": "  The statement after a month of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 10 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks of 15 1025 to 10 ",
        "label": "Entailment"
    },
    "8b3c9b3e-41e8-46fb-b975-db35e552ec6c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there were no participants in the healthy volunteers group who displayed any lesions However in the secondary trial all participants in group A Hydrophor experienced radiation dermatitis and hyperpigmentation which are types of lesions Therefore the statement that zero percent of individuals in group 1 of the primary clinical trial displayed any lesions",
        "label": "Contradiction"
    },
    "0cfa6770-4d70-4603-865b-512957909993": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections of 120 milligrams every 4 weeks which equates to 003 kilograms per month The statement incorrectly states that patients received 012 kilograms of denosumab per month  In the secondary trial patients underwent lymphosc",
        "label": "Entailment"
    },
    "363212ed-da18-4ae4-a7e5-cab37c207a24": {
        "text_answer": "  The statement usually find myself worrying about something is not directly entailed in the inclusion or exclusion criteria of the primary or secondary trials provided However the trials do include criteria related to psychological status such as Eastern cooperative oncology group ECOG Performance status PS of 0 or 1 and the ability to swallow and retain oral medication These criteria do not specifically address the statement about worrying but they may indirectly impact an individual",
        "label": "Contradiction"
    },
    "189e7142-d6fd-49d6-8e4f-44383f00781b": {
        "text_answer": "  The statement is contradictory to the information provided in both the primary and secondary clinical trials The trials do not accept patients with ERnegative PRnegative and HER2neupositive breast cancer Therefore the statement is contradictory to the inclusion criteria of both trials",
        "label": "Entailment"
    },
    "b6109c91-afac-46ff-b306-bd9a5f1bba84": {
        "text_answer": "  The statement is contradictory to the inclusion criteria mentioned in the trial The trial explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study Therefore the statement that the primary clinical trial allows the inclusion of patients who have had serious anaphylactic reactions to trastuzumab in the past is incorrect",
        "label": "Entailment"
    },
    "c2b8b1b0-9d84-498a-b490-e3da298f1087": {
        "text_answer": "  The statement malignant neoplasm of the upper third of the esophagus is a primary or metastatic malignant neoplasm involving the upper third segment of the esophagus is not directly related to the trials provided The trials focus on the use of DMCHOCPEN and Ribociclib in patients with CNS involvement from various types of cancers and their outcome measurements are tumor diameter and response rates",
        "label": "Entailment"
    },
    "09df9e5c-cc03-4c01-858b-0886376e9b7a": {
        "text_answer": "  The statement less than 54 of the primary trial participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products is not directly entailed in the provided trial results Result 1   The trial results only state that 9 out of 21 participants 429 had a reduction in circulating tumor cells at one month post AHST It does",
        "label": "Contradiction"
    },
    "3c596e8f-b1a2-4ded-b15b-99784b540d76": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive whole breast radiation therapy but there is no mention of any specific medication or dosage of Fulvestrant being administered   In the secondary trial participants receive Fulvestrant intramuscularly and there is no mention of a tablet form or a specific dosage of 500000 mcg being given",
        "label": "Contradiction"
    },
    "56ab098d-56f4-401e-a173-a0c99cd8efd0": {
        "text_answer": "  The statement is entailed in the Primary Trial as the patient meets the following inclusion criteria  Age 18 years old  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed  Zubrod performance status 02  Received prior oral bisphosphonate therapy  Adequate bone marrow function ANC 1800 cellsmm3",
        "label": "Entailment"
    },
    "a0f34f76-d0dd-48f3-b916-1722ecb924c2": {
        "text_answer": "  The statement worry that skin condition may be serious is a response indicating that an individual worries that their skin condition may be serious is neither entailed nor contradicted by the given trials as they do not provide sufficient information to determine if this statement is true or false The trials only report the number of adverse events AEs for each cohort but they do not provide information about the nature of the AEs or the individuals concerns regarding their skin conditions",
        "label": "Entailment"
    },
    "742cd2e5-1335-4daa-87b0-47727f61d8a1": {
        "text_answer": "  The statement patients participating in the primary trial receive 200mgm2 oral lapatinib once a day for a full month is entailed in the intervention description for Arm 1 of the trial as it specifies that patients receive 200mgm2 oral lapatinib once a day for 28 days",
        "label": "Entailment"
    },
    "2062b384-c6c1-4997-a4e4-b6709d123502": {
        "text_answer": "  The statement participants in the primary clinical trial were found to have cholelithiasis at a rate two times higher than those in the secondary clinical trial is a contradiction to the given data   The data provided does not indicate that participants in the primary clinical trial had cholelithiasis at a higher rate than those in the secondary clinical trial In fact the data shows that no cases of cholelithiasis were reported in",
        "label": "Contradiction"
    },
    "6bb59504-e102-48d6-ac0d-8ce71100b726": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 include the same dosage and frequency of Doxorubicin 60 mgm IV bolus injection every 3 weeks for 4 cycles Cyclophosphamide 600 mgm IV bolus injection every 3 weeks for 4 cycles and Docetaxel 100 mgm IV infusion every 3",
        "label": "Entailment"
    },
    "08a467b9-3bf6-486f-9975-4e2b67a5b690": {
        "text_answer": "  The statement is entailed in the secondary trial inclusion criteria as it specifies that patients with a confirmed mutation in certain genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ or GNA11 are required for participation in the secondary clinical trial However it is important to note that this requirement only applies",
        "label": "Entailment"
    },
    "379dbb6e-e70b-4e6c-83a9-c332b84592dd": {
        "text_answer": "  The statement ralstonia is a genus of gram negative rod shaped bacterium assigned to the phylum proteobacteria and the family burkholderiaceae is not entailed in the inclusion or exclusion criteria of the primary or secondary trials   However the statement Patients with significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial is included in the exclusion criteria of both trials",
        "label": "Contradiction"
    },
    "6b901ca0-1ec8-4d36-b43d-dcc6bf63b70f": {
        "text_answer": "  The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is not directly entailed or contradicted by the given trials data The statement only mentions the number of adverse events in each cohort but it does not specify which adverse events or the severity of those events The trials data only lists the types and number of adverse events for each cohort Therefore it is",
        "label": "Contradiction"
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents allowed Androg",
        "label": "Entailment"
    },
    "1e2b550a-0da3-48ea-8221-1a8b86e10511": {
        "text_answer": "  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is entailed by the given trials data as there are no instances of anorexia hypothermia or hallucinations reported in either trial  The unit of concentration nanomole per liter per microgram per day is not related to the statement and does not affect the ent",
        "label": "Contradiction"
    },
    "5a96ef9e-57ed-4f5a-95b3-db64e3268993": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there is no mention of any intervention related to myalgias for either group 1 control or group 2 dexmedetomidine Therefore it is incorrect to assume that group 2 receives 00000005gkg of myalgias 5ml   In the secondary trial there is no",
        "label": "Contradiction"
    },
    "2660009c-449a-4edb-a64a-20164527c99d": {
        "text_answer": "  The statement is contradictory to the trial results The trial reported that there were 24 treatmentemergent adverse events AEs and 11 serious adverse events SAEs among the 25 participants receiving the sunitinib  docetaxel  trastuzumab treatment Therefore the statement that none of the patients receiving the sunitinib  docetaxel  trastuzumab treatment in",
        "label": "Entailment"
    },
    "5b100056-e657-4b2a-9ecf-8b949233ab50": {
        "text_answer": "  The statement the primary clinical trial reported at least one gastrointestinal side effect and two psychiatric events is not directly entailed in the given trials as there is no mention of psychiatric events in either trial However the statement is not contradicted by the trials either as they both report adverse events and gastrointestinal side effects are mentioned in both trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "fa664989-b970-41f4-b491-dd2aeb308dd1": {
        "text_answer": "  The statement is contradictory to the given trials   The statement claims that no adverse events were recorded in the secondary clinical trial but the trials clearly show that there were adverse events recorded in the secondary trial specifically Eyelid oedema in 1 patient 1250 and Chest pain in 1 patient 1667   Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "bc686408-6e00-414a-b5a4-2bae034aca57": {
        "text_answer": "  The statement an adult who was diagnosed with diffuse parenchymal lung disease within the last three years would not be considered for the primary clinical trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the statement specifically mentions diffuse parenchymal lung disease it falls under the broader category of inter",
        "label": "Entailment"
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "text_answer": "  The statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia is contradictory to the information provided in the Trials   The Trials report that there was 1 case of Anaemia and 1 case of Febrile neutropenia in cohort 1 but no cases of Pancytopen",
        "label": "Contradiction"
    },
    "fe6c20be-e0c6-461c-9e93-cef55bdd7902": {
        "text_answer": "  The statement is contradictory to the primary and secondary trial inclusion and exclusion criteria   The primary trial excludes patients who have received chemotherapy or radiotherapy within two weeks but it does not mention anything about unstable angina or neuropathy The secondary trial includes patients with unstable angina and grade 2 or above neuropathy but they are still excluded in the primary trial Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "6b5a90bf-c45f-4a85-807f-1f184463cf5f": {
        "text_answer": "  The statement after undergoing treatment with aprepitant dexamethasone cytoxan and kytril in cohort 2 of the primary clinical trial acute vomiting was reported by over 50 of the patients is a contradiction to the results presented in the trial  The trial reports that in cohort 2 20 out of 35 participants 571",
        "label": "Contradiction"
    },
    "eb8737bb-19f6-4249-83da-63b05b251084": {
        "text_answer": "  The statement is contradictory to the information provided in the trial interventions   Explanation  The statement cohort 1 and cohort 2 of the primary clinical trial receive neither 25 mg of sunitinib nor 90 mgm2 paclitaxel is contradictory to the information provided in the trial interventions   In Intervention 1 the starting sunitinib",
        "label": "Entailment"
    },
    "d303ce9d-a00a-4ee7-8147-0bac063ee210": {
        "text_answer": "  The statement one specific adverse event type impacted multiple participants in the primary clinical trial is not directly entailed or contradicted by the given information However based on the provided data it is possible for one specific adverse event type to have impacted multiple participants as shown by the occurrence of two participants experiencing General disorders and administration site conditions  Other disease progression Therefore the statement is neither entailed nor contradicted by the given information but",
        "label": "Contradiction"
    },
    "f34e13a3-4463-4cf4-8a15-79872282b90e": {
        "text_answer": "  The statement is a contradiction to the information provided in the inclusion criteria of both trials   In the primary trial the inclusion criteria specify that the subjects must be Japanese females In contrast the secondary trial does not have any such specification regarding the nationality of the subjects Therefore the statement is a contradiction to the information provided in the trials",
        "label": "Contradiction"
    },
    "5cc13d6e-bc37-47d3-8198-8e7af5a8b5a2": {
        "text_answer": "  The statement children are unable to participate in the primary clinical trial yet it is not explicitly stated that they are ineligible for the secondary clinical trial is a contradiction   The primary clinical trial explicitly states that Patients must be postmenopausal women under inclusion criteria which implies that children are not eligible for the primary trial However the secondary clinical trial does not mention anything about the age or gender of the patients and there is no",
        "label": "Contradiction"
    },
    "4d3272e0-735a-4531-9f23-c0e4660c64a5": {
        "text_answer": "  The statement is entailed in the trials since the trials report that there were no documented adverse events AEs involving anorexia hypothermia or hallucinations in both the primary and secondary clinical trials The statement accurately reflects the information provided in the trials",
        "label": "Entailment"
    },
    "dd33f2de-6bfc-4a27-95da-630c9f0c0574": {
        "text_answer": "  The statement the patients nationality ethnicity weight or gender do not have an impact on their eligibility to participate in either the primary or secondary clinical trial is entailed in the given inclusion and exclusion criteria as there is no mention of these factors in the criteria for both trials",
        "label": "Entailment"
    },
    "d81e386d-9799-44bc-b006-8fdd7c14103c": {
        "text_answer": "  The statement is not entailed in the given trials as there is no cohort in the primary trial that receives a treatment identical to the one given in the secondary trial The primary trial administers oral pregabalin while the secondary trial administers intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt Therefore the statement is",
        "label": "Contradiction"
    },
    "7bad3ae8-835f-401c-b50d-10e2f2773cc7": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the number of participants in each group and their recurrencefree survival percentages but they do not provide the actual recurrencefree survival data or the comparison of the two groups in terms of the difference in percentage or absolute numbers Therefore it is not possible to determine if the statement is entailed or contradicted based on the given information alone",
        "label": "Contradiction"
    },
    "09816bed-e4f7-4b1c-8599-fbc623fa9675": {
        "text_answer": "  The statement is contradictory to the primary trial as the reflexology intervention in the primary trial lasted for 10 weeks which is significantly less than the 24 weeks duration of the interventions in the secondary trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "103f19bc-87b9-4017-b2d8-8afd8bc54157": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not mention any radiation therapy being administered to the patients in either the primary or secondary interventions Therefore the statement is not entailed in the trials and is contradictory",
        "label": "Contradiction"
    },
    "b1695ed3-b79e-4e1a-8658-52f33b997fea": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial there is no mention of any pharmacological treatments only massage therapy psychosocial assessment and care and qualityoflife assessment are mentioned 2 In the secondary trial the interventions consist solely of the administration of the drug PF06647020 in two different dosages making it a singular drugbased method",
        "label": "Entailment"
    },
    "b7d7f9f1-1e62-403f-9ceb-234108f7569f": {
        "text_answer": "  The statement is entailed in the primary and secondary clinical trials as follows  The primary trial includes patients with histologically verified diagnosis of stage IIbIIIIV breast cancer while the secondary trial includes patients with a diagnosis of breast cancer that is confined to the breast or to the breast and ipsilateral axilla and a life expectancy of at least 1 year Therefore patients with stage IV breast cancer are excluded from the secondary trial but are eligible",
        "label": "Entailment"
    },
    "2853d135-6a33-4c1f-bf2c-251ef936c5dd": {
        "text_answer": "  The statement 025 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is contradictory to the given trials   Explanation   The primary trial reports that 1 out of 13 patients 769 experienced increased pleural effusion but none of them had rapid disease progression The second trial reports that 1 out of 4 patients 2500",
        "label": "Entailment"
    },
    "d8d3ab61-0fc8-462a-930b-114b2363d70a": {
        "text_answer": "  The statement all ae types in the primary trial affected more than 100 of patients is clearly contradictory to the information provided in the trial data None of the adverse events affected more than 100 of the patients in fact each adverse event affected only one patient out of the eleven Therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "8e18ed71-8fa4-4d81-841d-ce718daa0f41": {
        "text_answer": "  The statement patients diagnosed with tumors positive for ccnd1 amplification are eligible for the primary clinical trial is entailed in the inclusion criteria of the trial The trial includes patients with any tumor type if the tissue tests positive for CCND1 amplification as an eligibility criterion Therefore the statement is entailed in the trials eligibility criteria",
        "label": "Entailment"
    },
    "4acaf50b-e6af-497a-a0d2-709e5780dd0b": {
        "text_answer": "  The statement over fortytwo patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes around 210 days after the surgery is not directly entailed in the given trial results   The trials only provide the number of participants in each group who achieved a pathologic complete response at the time of surgery approximately 7 months after the initiation of treatment They do not provide information",
        "label": "Contradiction"
    },
    "a752838e-30be-4438-913e-e905d2893abc": {
        "text_answer": "  The statement individuals who use tobacco products can partake in the secondary clinical trial is not entailed in the given exclusion criteria for the secondary trial The exclusion criteria for the secondary trial only mentions previous history of steroid administration and neoadjuvant chemotherapy as exclusion factors Therefore the use of tobacco products is not explicitly mentioned as an exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "4e4b2acf-c921-4f0d-b9e9-6a54fe5d9877": {
        "text_answer": "  The statement more than 90 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation have difficulty planning for future due to illness is not entailed in the given trials   The primary trial does not provide any information about radiation dermatitis or hyperpigmentation in the healthy volunteers group The secondary trial mentions the occurrence of radiation dermatitis and hyperpigment",
        "label": "Contradiction"
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "text_answer": "  The statement Any Japanese national can take part in the primary trial or the secondary trial is entailed in the trials as both trials have the same inclusion criteria for Japanese females with invasive breast cancer and ErbB2 status Therefore the statement is consistent with the information provided in the trials",
        "label": "Entailment"
    },
    "e658eb5e-3411-4dcb-bff2-6bad677ac1a7": {
        "text_answer": "  The statement the azd0530 275 mg group of the primary trial experienced a lesser reduction in primary tumour diameter than the zoledronic acid 4 mg group is not mentioned in the provided trials The trials only report the percentage change in betaCTX levels for the AZD0530 175 mg and Zoledronic Acid 4 mg groups Therefore the statement is not entailed in the trials and",
        "label": "Contradiction"
    },
    "3f4231c5-0eae-43eb-b0df-b270cea08476": {
        "text_answer": "  The statement all patients in cohort 1 of the primary clinical trial were behind schedule for their cervical cancer screenings before the intervention is not directly entailed in the provided trial results The results only indicate the percentage of participants who were up to date with colorectal breast and cervical cancer screenings before and after the intervention for both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups",
        "label": "Contradiction"
    },
    "6fdb953d-a7b8-41b9-8652-2d8b51bfcaa0": {
        "text_answer": "  The statement no adverse events were experienced by any participants in the primary clinical trial likewise in the secondary clinical trial is entailed in the given trials data as both trials report having no adverse events 000 for all listed conditions",
        "label": "Contradiction"
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000 mcg of talazoparib daily as part of the intervention is not directly entailed in the given trial description The trial description mentions that patients are eligible for the trial if they are older than 70 years and have been diagnosed with certain types of cancer and that they may be included before or between different treatment steps It also mentions that talazop",
        "label": "Contradiction"
    },
    "9a111f3a-a29a-42fa-bf73-9f178286198c": {
        "text_answer": "  The statement is entailed in the trial results as stated in the Results 1 section The trial reports a mean percentage change in Ki67 expression of 40 63 to 29 after 7 days of presurgical tamoxifen treatment The statement in the given format is a clear representation of the trial results and the percentage change in Ki67 expression is the outcome measurement specified in the trial Therefore the statement is",
        "label": "Entailment"
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "text_answer": "  The statement There was one case of shingles recorded in group 2 of the secondary trial but no cases in group 1 of the secondary trial and the primary trial is a contradiction to the given data  Explanation  The statement implies that there were no cases of shingles in group 1 of the secondary trial and the primary trial However the primary trial data shows that there was no case of shingles recorded in any",
        "label": "Contradiction"
    },
    "4d5acda5-74be-4228-a24e-bcd405ac6af4": {
        "text_answer": "  The statement is entailed in the trials as both interventions share the same regimen for tremelimumab and the optional extended treatment for durvalumab The only difference lies in the durvalumab dosage with cohort 1 receiving a lower dose 03 mgkg compared to cohort 2 1 mgkg Therefore the statement is accurate and entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "a95eba72-3c28-4c9b-a79f-011f1578907c": {
        "text_answer": "  The statement past treatment with gabapentin or herceptin within the last three months is necessary for inclusion in the secondary trial but will result in exclusion from the primary trial is a contradiction   Explanation   The primary trial and the secondary trial have different inclusion and exclusion criteria In the primary trial a history of herceptin use within the last 5 months is an exclusion criterion In contrast",
        "label": "Contradiction"
    },
    "88e7acab-bd9d-4e6c-a241-c538501824e8": {
        "text_answer": "  The statement CAPECITABINE was administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle is entailed in the trial description   Explanation   The statement specifies that CAPECITABINE was administered orally every day during the first 21day cycle for all patients in cohort 2 The trial description",
        "label": "Entailment"
    },
    "985ff367-3936-4e38-92e7-45e1cb9f24ee": {
        "text_answer": "  The statement the adverse events noted in the primary trial are all related to psychological distress this is not mirrored in the secondary trial is a contradiction to the given trials as there is no mention of psychological distress as an adverse event in either trial The trials only report adverse events related to blood and lymphatic systems",
        "label": "Contradiction"
    },
    "1e826f28-5a81-4123-95f7-74418392ed90": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial regimen includes epirubicin at a dose of 100 mgm2 cyclophosphamide at 600 mgm2 docetaxel at 75 mgm2 and trastuzumab at 6 mgkg loading dose and 4 mgkg maintenance dose These dos",
        "label": "Entailment"
    },
    "cdc80bd8-0b1c-4908-9095-74a1a7078e43": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 the dose of Cyclophosphamide C is 600 mgm2 while in Intervention 2 the dose of Cyclophosphamide C is also 600 mgm2 but the dose of Docetaxel T is 75 mgm2 Since the dose of Cyclophosph",
        "label": "Entailment"
    },
    "2fa66862-310e-454e-a0d6-5e3ef0ec1e2d": {
        "text_answer": "  The statement according to the results of the primary clinical trial week 24 recorded a higher number of patients with stable disease than week 12 is entailed in the trial results as stated  Week 12 SD 12 Week 24 SD 10  The difference in number of participants with stable disease between week 12 and week 24 is 2 12  10",
        "label": "Entailment"
    },
    "4a47dcda-1105-46c5-8f3d-ffbfe5259d70": {
        "text_answer": "  The primary trial measures hot flash activity using a daily hot flash score which is a composite entity of both frequency and severity of hot flashes ranging from 0 to infinity The secondary trial measures the overall response rate ORR which is a proportion of participants who achieved a best response of either complete response CR or partial response PR  The statement that the primary and secondary clinical trials convey their results utilizing the same metric units is not entailed in",
        "label": "Contradiction"
    },
    "af1e26a0-09d7-408f-89ec-be5bf4bfc88c": {
        "text_answer": "  The statement in the primary clinical trial patients in the fast shallow respiration group experienced fewer hot flashes per day on average than those in the paced respiration intervention group is contradicted by the data provided in the trials   The mean number of hot flashes per day for the paced respiration group was 348 345 and for the fast shallow breathing group was 395 41",
        "label": "Contradiction"
    },
    "1ec46b05-25a0-45c2-a6aa-31f5a2209ac5": {
        "text_answer": "  The statement global complete response in blood is a score of b0 by repeat bone marrow biopsy with no residual disease is not directly related to the adverse events mentioned in the trial data Therefore the statement does not entail or contradict the information provided about the adverse events in the trial",
        "label": "Contradiction"
    },
    "056fccd5-f005-4088-8f9b-c22b87eaa371": {
        "text_answer": "  The statement is entailed in the given trials as both the primary and secondary interventions are delivered orally In the primary trial Vitamin B12 is given sublingually which is still considered an oral route of administration In the secondary trial memantine hydrochloride and placebo are given orally in the form of tablets Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "e7e2f4af-f6c2-47cc-b03e-6e69210d14c7": {
        "text_answer": "  The statement on average patients from the primary trial survive over 4 years is not directly entailed in the given trials as the trials only report the median survival times not the average survival times However the statement is not contradicted by the trials either since the reported median survival times are both over 2 years which is longer than 3 days Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "542ebedc-ffda-406e-9ef5-d2f9edc30ac1": {
        "text_answer": "  The statement is not directly entailed in the given trial information but it is consistent with it The statement describes a specific configuration code for a trial design which is not explicitly stated in the trial protocol provided However the statement is consistent with the information given as it correctly describes the administration of capecitabine in cohort 2 of the primary trial during the first 21day cycle Therefore the statement is not contradictory to the trial",
        "label": "Contradiction"
    },
    "e6fb96bc-d38b-484e-8d2a-fe14f943c599": {
        "text_answer": "  The statement eligible for the primary clinical trial are patients who had a severe anaphylactic reaction to herceptin treatment or did not respond to treatment with herceptin in the past is contradictory to the inclusion criteria of the trial   The trial includes patients with HER2 FISH positive tumors who will receive both vinflunine and trastuzumab However the statement specifically mentions patients who had a severe anaphyl",
        "label": "Entailment"
    },
    "c3d9b60a-a46e-4bde-9e4a-46db5c2d75ba": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial focuses on the effects of different interventions Hydrophor and MediHoney on the test subjects patients undergoing radiation therapy while the secondary trial tests the effects of varying quantities 90 mg and 110 mg of the same intervention PF05212384 on its group patients with CRPC ABC or NS",
        "label": "Entailment"
    },
    "b9f4eb6e-b05b-44e8-b92d-62624cc71935": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials focus on different outcome measures The primary trial investigates the effects of sulforaphane supplementation on isothiocyanate levels in urine samples while the secondary trial examines the impact of physical therapy on pain reported by participants undergoing chemotherapy The statement does not directly relate to the content of either trial",
        "label": "Contradiction"
    },
    "be8707c6-9004-4fab-b719-c1ab372a77a1": {
        "text_answer": "  The statement only patients with invasive lobular carcinoma undergoing chemotherapy are eligible for the primary clinical trial is contradictory to the inclusion criteria provided in the trial description The inclusion criteria state that patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast regardless of the histological subtype are eligible for the trial if they meet other criteria Therefore the statement is contradictory to the trials el",
        "label": "Entailment"
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "text_answer": "  The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is a contradiction to the given results   The results state that there were 24 participants with treatmentemergent adverse events not 35 Therefore the statement is a contradiction to the results",
        "label": "Contradiction"
    },
    "74866fee-c33b-4df9-8d5c-28b47182b753": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the treatment cycles are defined as 21 days meaning that the interventions are repeated every 3 weeks Therefore the statement that the treatment in the primary trial progresses in a continuous manner without a repeated cycle is not entailed in the trial information  Furthermore the secondary trial also operates on a 3week cycle as",
        "label": "Contradiction"
    },
    "96be8dc9-8873-475f-b91f-e92f3549861b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary clinical trial explicitly states that patients must be postmenopausal which is typically defined as being 50 years of age or older Therefore children and adolescents are excluded from the primary trial based on age   However the secondary clinical trial does not have an age criterion mentioned in the provided inclusion or exclusion criteria Therefore it does not explicitly",
        "label": "Entailment"
    },
    "d82bb7da-6579-43be-969a-206d2235afd3": {
        "text_answer": "  The statement in the course of the study period more than 15 of patients in the primary clinical trial and the secondary clinical trial experienced infections is contradicted by the given data   Explanation   In the primary clinical trial 1 out of 32 patients 313 experienced an infection In the secondary clinical trial 1 out of 15 patients 667 experienced an infection",
        "label": "Contradiction"
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "text_answer": "  The statement the secondary trial and the primary trial report results from one patient cohort is a contradiction based on the given information   The primary trial and the secondary trial report results from different patient cohorts and different outcome measurements The primary trial reports the percentage of participants with a response within 10 days of first dose of denosumab while the secondary trial reports the number of patients who reached a safe and well tolerated dose of d",
        "label": "Contradiction"
    },
    "cbcecc39-a187-40ca-86cf-06d9c75ff972": {
        "text_answer": "  The statement all individuals of Japanese nationality have the opportunity to be part of either the primary clinical trial or the secondary clinical trial is entailed in the given trials as there is no mention of any nationality restriction in the inclusion criteria for both trials",
        "label": "Entailment"
    },
    "2f30372d-c143-495d-96d9-ad238ff94baf": {
        "text_answer": "  The statement is a contradiction to the information provided in the clinical trial interventions In both intervention 1 and intervention 2 dexamethasone is explicitly stated as being administered to the participants in each cohort with dosages of 8 mg and 24 mg respectively and the method of administration being intravenous and preoperative Therefore the statement that neither cohort 1 nor cohort 2",
        "label": "Contradiction"
    },
    "2db5cad0-f216-4e18-accf-87e3308afc59": {
        "text_answer": "  The statement secondary clinical trial is based on the alterations in mymop score to determine the outcome of their study is not entailed in the provided trials as the first trial does not report any data related to the MYMOP score at the end of the study The secondary trial reports changes in isothiocyanate in urine samples not related to the MYMOP score",
        "label": "Contradiction"
    },
    "71f1d2c6-7ab2-45d2-bb54-a0cad79d244b": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trial results The statement mentions PR Primary Breast Cancer while the trial results only mention HER2 primary breast cancer Additionally the statement mentions 89Zrtrastuzumab developed HER2 Metastases but the trial results only mention the use of 89Zrtrastuzumab and 89Zrpert",
        "label": "Entailment"
    },
    "1dd07ae9-349c-41e1-b967-fd8691e320e0": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial exclusion criteria do not mention the time frame for chemotherapy or radiotherapy but it does mention that patients must be able to give written informed consent have breast lesions that are nonpalpable and imageguided and have adequate organ function Therefore patients who have received chemotherapy or radiotherapy in the last 4 weeks but meet all other inclusion criteria for the primary trial",
        "label": "Entailment"
    },
    "aa25fae6-9d48-4237-92d0-504cfc8af672": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the primary trial the intervention is given orally PO which means it is administered by mouth In the secondary trial the intervention in Arm I Pixantrone IV Day 1 is given intravenously IV which means it is administered through a needle or tube inserted into a vein Therefore the statement that the primary trial intervention is given orally and the",
        "label": "Entailment"
    },
    "e53fdbd4-4375-409d-ad00-322822909d5b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial a single injection is given to patients at the beginning of the study In contrast the secondary trial specifies that participants receive three weekly injections",
        "label": "Entailment"
    },
    "7e5ca0bb-bae1-493f-9a30-7f70d544fcf4": {
        "text_answer": "  The statement those suffering from breast cancer and necessitating hormone treatment are potential participants in the primary clinical trial is entailed in the given inclusion criteria of the trial The statement is a consequence of the inclusion criteria as it specifically mentions that participants must have breast cancer that has continued to grow despite hormonal treatment and must be postmenopausal women both of which are inclusion criteria stated in the trial",
        "label": "Entailment"
    },
    "6c5d5b1a-e7e0-427f-b21b-a9fbc5e2b69e": {
        "text_answer": "  The statement is contradictory to the trials provided   The primary trial intervention involves the use of cabergoline which is given orally and the secondary trial interventions involve the use of pixantrone dimaleate which is administered intravenously The statement incorrectly states that the primary trial intervention is given topically which is not the case",
        "label": "Entailment"
    },
    "46065ce7-6618-4f08-890c-6bd0f8fa4573": {
        "text_answer": "  The statement men with newly diagnosed stage II prostate cancer not undergoing any surgery are eligible for the primary clinical trial and the secondary clinical trial is contradictory to the given trials inclusion and exclusion criteria   The primary trial is for women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic bone metastasis Men do not",
        "label": "Entailment"
    },
    "d20c94ae-14d5-4272-96d5-ef649dfade50": {
        "text_answer": "  The statement a majority of the primary clinical trial participants experienced some form of eating disorder during the course of the study is contradicted by the given data Anorexia is listed as an adverse event experienced by one participant out of 50 However an eating disorder is not the same as experiencing some form of eating disorder which could be interpreted as any condition related to food intake or eating behavior Even if we assume that eating disorder in",
        "label": "Contradiction"
    },
    "56c00437-a067-4734-9b55-f1041c10190e": {
        "text_answer": "  The statement patients who have previously experienced serious anaphylactic reactions to herceptin or those who experienced no improvement with herceptin treatment may participate in the primary clinical trial is not explicitly stated in the inclusion criteria or exclusion criteria of the trial However the statement does not contradict the information provided in the trial as it mentions Herceptin trastuzumab and does not list it as an exclusion criterion for those who",
        "label": "Contradiction"
    },
    "85cdaaef-3a05-458f-aaf2-d935069cf478": {
        "text_answer": "  In the primary clinical trial Intervention 1 involves the administration of Zoledronic Acid intravenously In the secondary clinical trial Intervention 1 in Arm II involves the administration of Granisetron hydrochloride Dexamethasone and Prochlorperazine intravenously Intervention 1 in Arm III involves the administration of Palonosetron hydrochloride and Dexamethasone intravenously",
        "label": "Entailment"
    },
    "65fc2061-6d0f-46d1-bd13-5959cedf6b03": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not provide sufficient information about the use of a device components in either trial The statement makes assumptions about missing components in the trials that are not mentioned in the provided information",
        "label": "Contradiction"
    },
    "ebe96d52-cfbc-403c-ba10-244991ddc449": {
        "text_answer": "  The statement is entailed in the trials as both trials investigate the use of empegfilgrastim as a medication but they differ in the dosage amounts and how they measure the results The primary trial measures the duration of neutropenia in days while the secondary trial measures the incidence of CTCAE grade 34 neutropenia as a number of participants However they both investigate the effect of different dosages of empegfilgrast",
        "label": "Entailment"
    },
    "840eeabe-3086-4be9-98fc-deaf26b4349b": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants who completed the study in each group but they do not report the Recurrencefree Survival rates for each group Therefore it is not possible to determine if 96 of participants in the Ketorolac 30 mg group experienced Recurrencefree Survival compared to 67 in the NaCl 0",
        "label": "Contradiction"
    },
    "a02864dc-e1f8-427e-9df3-531c91d28d50": {
        "text_answer": "  The statement cyclindependent kinase inhibitor protein is a protein that plays a role in the inhibition of cyclindependent kinases is neither entailed nor contradicted by the information provided in the primary and secondary trials The trials focus on breast reconstruction using a Contour Profile Tissue Expander and allogeneic mesenchymal stem cell alloMSC therapy for heart failure respectively The statement is not directly related to the interventions",
        "label": "Entailment"
    },
    "05f34052-08b6-4b98-91d3-326b4f77844c": {
        "text_answer": "  The statement only topical treatments will be administered to the patients in the primary clinical trial is contradictory to the information provided in the trial description   The trial description includes the following interventions  1 Dendritic Cell Vaccine Dendritic cells are injected into the patients intradermally id in the axilla or inguinal region 2 Trastuzumab Tr",
        "label": "Entailment"
    },
    "4927c9bb-aa2b-4c3c-999b-068e1dca959a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial describes the use of radiation therapy for breast cancer patients but it does not mention any intravenous chemotherapy   The secondary trial describes the use of Enzastaurin and Fulvestrant but it does not mention any radiotherapy regimen for any of the cohorts   Therefore the statement that the primary trial participants receive in",
        "label": "Entailment"
    },
    "304f8d66-90f2-40cc-9f18-77c2b8471a40": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not mention the administration of Fulvestrant to its participants The secondary trial mentions the administration of Fulvestrant to all its participants but the statement incorrectly states that all participants in the secondary trial received 500 mg of Fulvestrant tablets bid while the actual dosing regimen is different for each intervention group in the secondary trial",
        "label": "Entailment"
    },
    "6088eecc-56f9-475b-a27a-a23bc646028b": {
        "text_answer": "  The statement all participants in the primary clinical trial experienced less than 3 adverse events is contradictory to the given data   Explanation   The primary trial data indicates that 5 out of 25 participants 2000 experienced a total of 5 adverse events This means that some participants did experience more than one adverse event Therefore it is not true that all participants experienced less than 3 ad",
        "label": "Entailment"
    },
    "ff8c88f9-c698-4ad0-a9ba-0acf6fbf1933": {
        "text_answer": "  The statement sellar schwannoma is an extremely rare schwannoma that arises from the sellar region The results from the primary trial indicate that the Arm A intervention had a better overall response rate than the placebo arm additionally in the secondary trial the Denosumab cohort had a better Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed in the provided trials",
        "label": "Contradiction"
    },
    "f9d5b863-f0cb-4777-81a7-358efd8010d6": {
        "text_answer": "  The statement cohort 1 of the primary trial receive preoperative Dexamethasone whereas cohort 2 receives Dexamethasone 2 hours after the operation is entailed in the trials as both interventions clearly state preoperative intravenous administration for Dexamethasone in cohort 1 and 2 hours after the operation in cohort 2 The statement does",
        "label": "Entailment"
    },
    "31b3aa86-f32c-4a10-ae36-6429b25995dc": {
        "text_answer": "  Anorexia is a mental health disorder characterized by a persistent lack of appetite and significant weight loss The inclusion criteria for the clinical trial specify that participants must have a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs indicating that the trial is designed for overweight or obese individuals Anorexia is not a condition that is synonymous with being overweight or obese and individuals with",
        "label": "Entailment"
    },
    "da91afa9-21ed-4d4d-a5d9-964dbb334177": {
        "text_answer": "  The statement the primary clinical trial adopts a procedural approach which involves only the use of ultrasound assisted biopsy is neither entailed nor contradicted by the information provided in the trials The trials focus on the surgical incision types and the use of laserassisted fluorescence angiography for monitoring breast perfusion during mastectomy procedures but they do not mention the use or exclusion of ultrasoundassisted bi",
        "label": "Entailment"
    },
    "a012091a-9e07-4878-81bf-fee2e3282cbd": {
        "text_answer": "  The statement Patients with histologically documented metastatic SCBC are excluded from the primary trial is a statement about a specific group of patients being excluded from the trial based on their diagnosis This statement is entailed in the inclusion criteria of the trial as stated Patients with solid tumors nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer must have measurable disease but",
        "label": "Entailment"
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial the doses of PF06647020 given are lower than those in the secondary trial for both Intervention 1 and Intervention 2 Specifically in the primary trial the doses are 02 mgkg and 05 mgkg while in the secondary trial the doses",
        "label": "Entailment"
    },
    "800c7053-0dd5-4c99-ba55-c45b121d303c": {
        "text_answer": "  The statement is entailed in the trials as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points during the surgical procedure However they differ in the type of incision used Therefore the statement is partially entailed in the trials",
        "label": "Entailment"
    },
    "cdab084c-4e2b-4f0a-ac8c-868b4bb4ecb5": {
        "text_answer": "  The statement the primary clinical trial participants are administered placebo on days 1 8 and 15 is not entailed in the given trial descriptions The trials only specify the drugs and dosing schedules for the intervention groups but they do not mention anything about placebo administration on specific days",
        "label": "Contradiction"
    },
    "ec5c26e8-0afd-4244-8731-588c4f88e84b": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial has multiple records of cardiacrelated adverse events is entailed in the Trials since there are records of cardiacrelated adverse events in the primary trial Adverse Events 1 for cohort 1 specifically Acute Coronary Syndrome Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac Tamponade with a total",
        "label": "Entailment"
    },
    "e4575416-926c-4b2d-b4ba-1aa417cae0db": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement suggests that both the placebo and alloMSCs interventions are administered in identical doses However the trials specify different interventions 100 million alloMSCs for the alloMSCs intervention and Buminate solution for the placebo intervention The volumes of the injections are also different 04ml for both",
        "label": "Entailment"
    },
    "66c31a74-8bb0-4625-9ce7-401da56be447": {
        "text_answer": "  The statement fatigue interferes with certain duties and responsibilities is not directly entailed nor contradicted in the provided inclusion and exclusion criteria for the primary and expansion phases of the clinical trial The criteria focus on various demographic diseaserelated and treatmentrelated factors for eligibility and ineligibility in the trial The statement about fatigue interfering with duties and responsibilities is not explicitly mentioned However it could potentially be considered",
        "label": "Contradiction"
    },
    "eff8deaa-08a6-4df3-9140-fe153fbcba6e": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the reflexology intervention lasted for 10 weeks while in the secondary trial both the placebo and vitamin D interventions lasted for 24 weeks Therefore the secondary trial continues for three times as long as the primary trial for both intervention groups",
        "label": "Entailment"
    },
    "31bb177c-1a8b-4699-a7f2-4c442801770f": {
        "text_answer": "  The statement the frequency of adverse events was higher in the first cohort of the primary clinical trial than in the second cohort is entailed in the given trials if we consider the total number of adverse events The first cohort had a total of 45 adverse events out of 106 participants 4245 while the second cohort had a total of 7 adverse events out of 10",
        "label": "Entailment"
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "text_answer": "  The statement at least one patient in the primary trial suffered several different adverse events is entailed in the given data   Explanation   The statement implies that at least one patient experienced more than one adverse event Based on the data provided we can see that two patients 225 or 800 experienced dyspnea shortness of breath and one patient 125 or 4",
        "label": "Entailment"
    },
    "3ff8b1f7-4c73-4cb7-acbd-4d7e3b7f31ec": {
        "text_answer": "  The statement patients with established allergies to medications such as cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib are not qualified to be part of both the primary and secondary clinical trials is entailed in the trials as follows  In the primary trial the exclusion criteria include a history of allergic reactions attributed to compounds of similar chemical or biologic composition",
        "label": "Entailment"
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "text_answer": "  The statement Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trials inclusion criteria do not mention anything about morbid obesity or pregnancy as exclusion factors The secondary trials exclusion criteria do not mention anything about morbid obesity as an exclusion factor but it does mention",
        "label": "Entailment"
    },
    "340721ab-42f9-4ac3-8608-58007d89b87b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as there is no mention of any adverse events related to respiratory issues in either cohort 1 or cohort 2 The trials only report adverse events related to anemia bone marrow failure disseminated intravascular coagulation febrile neutropenia thrombocytopenia acute coronary syndrome angina pectoris",
        "label": "Contradiction"
    },
    "16aacacc-1ab7-46d2-a59e-ca207cb0282d": {
        "text_answer": "  The statement patients with parathyroid carcinoma evidenced by immunofluorescence microscopy or peripheral blood smear are ineligible for both the primary trial and the secondary trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However parathyroid carcinoma is not listed as a malignancy in the primary trials inclusion criteria and there is no mention of it in the",
        "label": "Contradiction"
    },
    "68716599-d21d-433a-9e8d-5113749d4a06": {
        "text_answer": "  The statement the total adverse events in the primary trial exceed those in the secondary trial but there are fewer cases of cardiacischemiainfarction in the primary trial than in the secondary trial is neither entailed nor contradicted by the given trials data  Explanation  The statement makes two comparisons one about the total number of adverse events and the other about the number of cardiacischemiainfar",
        "label": "Entailment"
    },
    "90fc98fa-35bb-48ae-a2f3-b74e6bd0d353": {
        "text_answer": "  The statement more than four different types of adverse events affected patients in the primary clinical trial across all cohorts is a contradiction to the given data in the trials   The trials report the number of patients who experienced each type of adverse event and the total number of adverse events across all types for each trial is 3 Therefore no more than four different types of adverse events affected patients in each trial   Since the statement",
        "label": "Contradiction"
    },
    "3ac94edb-bccc-44c6-9b1a-4ea79122d154": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial participants receive epacadostat more frequently than sunitinib BID vs Q3W or Q8W while in the secondary trial sunitinib is received more frequently than epacadostat continuous dosing vs BID",
        "label": "Entailment"
    },
    "0d95a819-09cb-49a0-9ec0-76a64bc50732": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial involves an oral intervention with cabergoline while the secondary trial involves intravenous IV administration of pixantrone dimaleate There is no mention of a topical application in either trial",
        "label": "Contradiction"
    },
    "9d9db340-6fee-4ec0-b6cb-7fdfe2d34959": {
        "text_answer": "  The statement there were 0 cases of hypertension edema and dyspnea in either cohort of the primary trial is entailed in the given trials as neither cohort reported any cases of hypertension edema or dyspnea in their adverse events",
        "label": "Entailment"
    },
    "d43e7757-45d0-4f65-9735-6ba05f13337d": {
        "text_answer": "  The statement candidates for the primary clinical trial are not permitted to undergo cbtbased treatments but they may qualify for the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However based on the information provided it can be inferred that candidates for the primary trial are excluded if they have received prior chemotherapy or radiotherapy within 4 weeks 6 weeks for nitrosoureas or",
        "label": "Entailment"
    },
    "908f5aed-eb98-47f8-b00d-7ce39707446f": {
        "text_answer": "  The statement hpv16 infection is an infection caused by human papillomavirus 16 hpv16 infection is associated with a risk for cervical cancer Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is neither entailed nor contradicted by the given trials   The trials only provide information about the interventions given to Cohort A ",
        "label": "Entailment"
    },
    "b8ffb304-4dd2-4fa9-888e-b851c73513c1": {
        "text_answer": "  The statement most patients from the first cohort of the primary clinical trial irrespective of their cancer type had completed their screenings following the intervention is entailed in the trials provided   Explanation   The trials show that a higher percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date with their colorectal breast and c",
        "label": "Entailment"
    },
    "47074986-36ac-4ebe-a743-cdf06a70efd8": {
        "text_answer": "  The statement Alzheimers patients are not eligible for the primary trial is not directly related to the given inclusion and exclusion criteria for the trial The criteria provided only mention cognitive impairment with a Mini Mental State Examination MMSE score of 23 or above but no mention of Alzheimers disease specifically  The statement about the rete ovarii adenoma being a benign adenoma composed of el",
        "label": "Contradiction"
    },
    "698a471b-ead0-445f-93bb-4badc6382968": {
        "text_answer": "  The statement peritoneal and retroperitoneal disorder is a nonneoplastic or neoplastic disorder that affects the peritoneum andor retroperitoneum The Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort is not directly entailed in the given trial data   ",
        "label": "Contradiction"
    },
    "0ec15a9a-41f5-44aa-a089-c5f0fe5c9806": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  1 The primary trial includes females aged 18 and above with various types of breast cancer including HER2neu breast cancer as stated in the inclusion criteria 2 The secondary trial includes females aged 18 and above with specific types of cancer including HER2neu breast cancer as stated in the inclusion criteria  Therefore the",
        "label": "Entailment"
    },
    "09ebfb97-f98c-4555-9e69-85b60af863fa": {
        "text_answer": "  The statement in the primary clinical trial daily vorinostat capsule intake during radiation therapy is mandatory for every patient is entailed in the trial description The trial states that Patients will be treated on a dose escalation model for vorinostat and concurrently receive radiation therapy Vorinostat All doses given for 3 weeks Patients will take Vorinostat daily during radiation therapy they will be recommended to swallow the",
        "label": "Entailment"
    },
    "a326e30f-a2c9-4a6e-b497-02cc338735c5": {
        "text_answer": "  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is neither entailed in the primary trial nor the secondary trial as given in the provided information  Explanation  The primary trial is for patients undergoing immediate tissue expander reconstruction following mastectomy and the secondary trial is for patients who have completed surgery for breast cancer and have certain fatigue symptoms Neither",
        "label": "Entailment"
    },
    "2ce21ccd-8f05-4618-8597-b1ad8be31f59": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring breast perfusion at three separate time points during the surgical procedures The statement about the cisplatindoxorubicinpaclitaxel regimen is not directly related to the trials but it is not contradictory either",
        "label": "Entailment"
    },
    "d1c52b9f-7feb-4d54-af86-7aace67807d4": {
        "text_answer": "  The statement is partially entailed in the trials Both cohorts receive equal doses of radiation therapy and undergo a SPECT scan at baseline and 6 months followup However the statement does not mention the use of Active Breathing Coordination ABC in the SPECT scan procedure which is a difference between the two cohorts Therefore the statement is partially entailed as it correctly states the equal doses of radiation therapy and SPECT",
        "label": "Entailment"
    },
    "eff637a6-8d7c-47e9-bcba-b4b52159aa4d": {
        "text_answer": "  The statement in the primary trial the amount of time spent in operation was longer for arm 2 than arm 1 suggesting superior performance of intraoperative mammography over the standard mammography is not directly entailed in the provided trials The primary trial does show that the operative time was shorter for the intraoperative mammography group compared to the standard mammography group However the statement suggests the opposite that the longer operative time in",
        "label": "Contradiction"
    },
    "5c06c081-87ef-4e9a-ab22-c8c55253fc34": {
        "text_answer": "  The statement there were fewer instances of mucositis oral bladder infection and thromboembolic events noted in the primary clinical trial compared to the secondary clinical trial is a comparison statement between the two trials To verify this statement we need to compare the number of instances of these adverse events in both trials  From the given data we can see that in the primary trial there was one instance of mucositis oral",
        "label": "Entailment"
    },
    "74c7adc7-9641-4858-88af-69a2e2cd6dad": {
        "text_answer": "  The statement is not directly entailed in the given information from the trials as it provides additional information about the condition of the patients advanced chordoma and the use of paclitaxel only in cohort 1 The trials only specify the interventions anastrozole in Arm A and fulvestrant in Arm B and their administration routes for both cohorts",
        "label": "Contradiction"
    },
    "ab848536-4d43-4af3-9489-59b7608b7ecf": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants in each group who were analyzed up to 5 years after randomization They do not provide information on the number of participants who experienced recurrencefree survival in each group Therefore it is not possible to determine if the statement is entailed in the trials based on the given information",
        "label": "Contradiction"
    },
    "62716b99-76d4-4dfe-b0ce-1ad35f768b33": {
        "text_answer": "  The statement an ECOG score of 1 makes a candidate suitable for participation in both the primary clinical trial and the secondary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   An ECOG score of 1 falls within the acceptable range for both trials ECOG 02 for the primary trial and ECOG 02 OR Karnofsky 6010",
        "label": "Entailment"
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "text_answer": "  The statement In the primary trial results there were more patients with stable disease in week 12 than week 24 but 0 patients with complete response in week 12 or 24 is entailed in the trial results as stated  1 More patients with stable disease in week 12 than week 24    Week 12 SD 12    Week 24 SD 10 ",
        "label": "Entailment"
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the primary trial explicitly states that the participant has not undergone major surgery within 28 days prior to the study registration date Therefore a patient who has received an organ trans",
        "label": "Contradiction"
    },
    "ed247cb5-ed15-4c1b-940d-099d16ee7f53": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement the same therapeutic approach is applied to breast cancer and ovarianperitoneal cancer patients participating in the primary clinical trial is contradictory to the trials because  1 In Intervention 1 the participants with breast cancer received talazoparib capsules in Part 1 and 2 at a dose of either ",
        "label": "Entailment"
    },
    "0cab14c5-398c-4e4e-9c6a-65fb70aecb23": {
        "text_answer": "  The statement is entailed in the trials as follows  The statement crsr clinical classification question is a question associated with the crsr clinical classification is a factual statement that is not directly related to the interventions in the trials However both trials are investigating interventions for lymphedema which is a condition classified using the CRSR clinical classification system Therefore the statement is indirectly related to the trials and is",
        "label": "Entailment"
    },
    "9c4db46a-f5c4-46f0-9d28-8b18bbb9583a": {
        "text_answer": "  The statement in the primary and secondary clinical trials there were a combined total of 3 cases of asthenia and 5 cases of pyrexia amongst the patient cohorts is a contradiction to the given trials data   The trials data states that there were no cases of asthenia or pyrexia reported in either the primary or secondary trials Therefore the statement that there were a combined total of 3 cases of asthenia",
        "label": "Contradiction"
    },
    "d68944ff-4237-41b8-9ba1-bdfd9899ba32": {
        "text_answer": "  The statement three cases of shingles were reported across the patient cohorts involved in both the primary and secondary clinical trials is not directly entailed in the given trials data However it is mentioned in the statement that three cases of shingles were reported but the trials data only provides the number of cases reported in each trial separately without specifying that they are the same cases Therefore the statement is not a contradiction to the trials data either",
        "label": "Contradiction"
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "text_answer": "  The statement All Infections and Infestations cases in the primary trial were for patients in cohort 1 is entailed in the given trials as both trials refer to the same primary trial and all the Infections and Infestations cases mentioned in the trials are from cohort 1",
        "label": "Entailment"
    },
    "e15409e3-408c-4ea8-a0aa-9f1072b8a74b": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the dose of alpha lipoic acid is constant and unchanging for all participants as stated In contrast in the secondary trial the dosing schedule for necitumumab varies between the two cohorts with Cohort 1 receiving different doses during the runin period and every 3week cycle This aligns with the statement that patients in the primary trial receive a",
        "label": "Entailment"
    },
    "335235f3-4d27-479e-a5d7-29016a3320a5": {
        "text_answer": "  The statement multiple adverse events were reported in the primary clinical trial including anemia and nausea is entailed in the given trial data as both anemia and nausea are listed as individual adverse events with a total count of 129 345 Therefore the statement is entailed by the trial data",
        "label": "Entailment"
    },
    "9b120158-866e-4a68-ab9a-4d6241ead464": {
        "text_answer": "  The statement the secondary trial and the primary trial report results using the same Unit of Measure is entailed in the trials as both trials report results using the same unit of measure which is percentage in the primary trial and number of participants in the secondary trial  However the statement spinal leptomeningeal distant disease type is an indication the distant disease type is spinalleptomeningeal is not directly related to the trials provided",
        "label": "Entailment"
    },
    "ad1abf74-05c4-439a-b178-f21231744c89": {
        "text_answer": "  The statement retinal arterial branch occlusion is an occlusion of a branch of the retinal artery is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial The statement is not related to the breast cancer trial criteria at all Therefore it is neither entailed nor contradictory to the trial information provided",
        "label": "Entailment"
    },
    "1786385e-70c9-4a5b-a19e-0f389be545cc": {
        "text_answer": "  The statement disturbed sleep at its worst is a question about an individuals disturbed sleep at its worst is not directly related to the inclusion and exclusion criteria of the primary or secondary trials provided However the statement about the secondary trial does mention that Subject has a history of uncontrolled sleep apnea syndrome as an exclusion criterion   Regarding the statement about the secondary trial it is partially entailed in the trials",
        "label": "Entailment"
    },
    "0bb51a03-72e6-4d48-8010-054e280a960f": {
        "text_answer": "  The statement is contradictory to the given trials as there is no mention of any adverse events related to mental health in either trial The trials only report adverse events related to physical health conditions such as anemia thrombocytopenia cardiac events and bone marrow failure Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "d30d2472-9529-4206-8167-5bace92bb6d0": {
        "text_answer": "  The statement the primary trial uses a 3 week cycle for its intervention the secondary trial on the other hand does not have a cyclic treatment in place is a contradiction to the information provided in the trials   The primary trial does not explicitly state that the treatment cycle is 3 weeks long but it does define each cycle as 21 days Therefore the statement is not entailed in the trials but rather contradicts the information provided",
        "label": "Contradiction"
    },
    "96be5169-0334-4849-a77b-111e8eacf7bb": {
        "text_answer": "  The statement multiple adverse events have been recorded in at least one cohort of the primary clinical trial is contradictory to the information provided in the trials data According to the data no adverse events have been recorded in any of the cohorts both Adverse Events 1 and Adverse Events 2 so the statement that multiple adverse events have been recorded in at least one cohort is false",
        "label": "Contradiction"
    },
    "47507d4a-ea24-433a-9864-e4b76657335c": {
        "text_answer": "  The statement in the patient cohorts of both the primary clinical trial and the secondary clinical trial there have been no instances of intestinal obstructions or pancytopenia is entailed in the given trials data since there are no reported cases of intestinal obstructions Adverse Events 1 or pancytopenia Adverse Events 2 in either trial",
        "label": "Contradiction"
    },
    "3e16b4a5-6dc6-4a20-a367-c361bc38644e": {
        "text_answer": "  The statement patients participating in the primary clinical trial on average have a survival rate exceeding two years with more than fifty patients from each group experiencing life spans over 24 months is entailed in the given trials as follows  1 Both groups A midluteal surgery and B midfollicular surgery have a median survival time greater than 2 years The median survival times are 21",
        "label": "Entailment"
    },
    "4d2b9583-9b62-40cc-b7e7-096c2dd16e0b": {
        "text_answer": "  The statement resistance to AI therapy is a prerequisite for the primary clinical trial but not for the secondary clinical trial is a statement about the differences in inclusion criteria between the two trials   In the primary trial resistance to AI therapy is a prerequisite for participation In contrast in the secondary trial resistance to AI therapy is not a requirement for inclusion   Therefore the statement is entailed in the trials as it",
        "label": "Entailment"
    },
    "49d0acfc-e7ce-45f5-8e45-08d55f3d0776": {
        "text_answer": "  The statement the group taking 175 mg of azd0530 in the primary clinical trial encountered a larger shrinking of primary tumor size as compared to the group taking 4 mg zoledronic acid is not entailed in the given trials as they report percentage change in betaCTX levels not primary tumor size Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "b68e076b-9950-438b-96ea-3fc93943e490": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3 as well as requiring considerable assistance and frequent medical care u wave abnormality by ECG finding is an electrocardiographic finding of u waves which have increased amplitude are inverted or merged with the preceding t wave is not directly entailed in the given inclusion and exclusion criteria of the primary trial  The criteria clearly state that",
        "label": "Contradiction"
    },
    "3977a1e3-3371-4577-9dc1-eea3a725469c": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial provides a fixed dosage of Alpha Lipoic Acid while the secondary trial administers necitumumab at different dosages in Cohort 1 Specifically in the secondary trial necitumumab is given at an absolute dose of 800 mg on Day 3 of the PK runin period and on Days 1 and 8 of every ",
        "label": "Entailment"
    },
    "430f4379-7517-4dc9-a9e4-885f2934f872": {
        "text_answer": "  The statement the adverse event most often witnessed in the patient cohorts of the primary clinical trial and secondary clinical trial was syncope presenting in 2500 of the people in the primary trial is a contradiction to the information provided in the trials  The statement implies that syncope was the most common adverse event in both trials with a frequency of 2500 in the primary trial However the data from",
        "label": "Contradiction"
    },
    "d2c3690c-11a2-40de-b077-acf5f53fdb10": {
        "text_answer": "  The statement myb gene fusion positive is an indication that a myb fusion gene has been detected in a sample is not directly related to the information provided in the trials   The trials only report the incidence of doselimiting toxicities for two different dosing regimens of ixabepilone and doxorubicin and do not mention anything about myb gene fusion status of the participants   Therefore the",
        "label": "Entailment"
    },
    "91a6d0f0-3f3c-4bd7-80a5-f403fd7ef87e": {
        "text_answer": "  The statement is entailed in the primary clinical trial as it explicitly states that no imaging modalities such as xrays ultrasound CT scans or MRIs are incorporated in the interventions  However the statement is not explicitly mentioned in the secondary clinical trial However based on the information provided it can be inferred that no imaging modalities are used in the secondary trial as well as the interventions only involve the administration of",
        "label": "Entailment"
    },
    "d9b955ea-915d-438f-a9b1-cd1cc08c0dd4": {
        "text_answer": "  The statement None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is not directly entailed in the given trials as they do not provide information about the pain intensity levels experienced by patients during the worst pain imaginable threshold The trials only report the average pain intensity scores and the change in average pain intensity between the lowdose and highdose intervention groups Therefore the statement is neither entailed nor contradicted by the given",
        "label": "Contradiction"
    },
    "5b174c01-9e6e-4fa0-8c85-c7b72446d0b2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial is investigating the effects of Estring and Testosterone Cream interventions while the secondary trial is studying the impacts of acupuncture and waitlist interventions There is no mention of physical therapy interventions or dietary changes in either trial",
        "label": "Contradiction"
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "text_answer": "  The statement eating disorders were not common for the primary trial candidates is not directly entailed or contradicted by the given data The data only reports various adverse events observed during the trial but it does not mention any eating disorders Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "fd258898-9438-4474-a89e-7143a96abe06": {
        "text_answer": "  The statement for the primary clinical trial patients will receive a single injection on study day 8 is contradictory to the information provided in the trial description   The trial description states that patients will receive a dendritic cell vaccine injection Trastuzumab infusion and Vinorelbine ditartrate infusion on the same day study day 8 as well as Sargramostim GMCSF therapy",
        "label": "Entailment"
    },
    "4b913a72-0c81-4396-8667-f087259328f6": {
        "text_answer": "  The statement is entailed in the trials as there are no reports of unanticipated deaths or hospitalizations besides the three reported cases of lymphoma The trials do not report any other adverse events that could be considered unanticipated deaths or hospitalizations Therefore the statement is an accurate reflection of the information provided in the trials",
        "label": "Entailment"
    },
    "a1a8bedd-680d-4250-9384-93379de0a2a3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial involves interventions applied vaginally Estring and topically Testosterone Cream while the secondary trial involves acupuncture which is not administered through the skin or inhalation Therefore the statement is incorrect",
        "label": "Entailment"
    },
    "514d5612-4c60-4586-89b7-ca89b06ac576": {
        "text_answer": "  The statement is contradictory to the given inclusion criteria for both trials   The primary trial states that the primary tumour should be greater than 2 cm in diameter while the statement suggests a primary tumour with a radius of 330mm which is significantly larger than 2 cm Therefore a patient with a primary tumour of that size would not meet the inclusion criteria for the primary trial  Furthermore the secondary trial does",
        "label": "Entailment"
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "text_answer": "  The statement is a comparison of two different interventions one from the primary trial and the other from the secondary trial The primary trial intervention is Radioembolization using Yttrium90 glass microspheres and TheraSpheres The secondary trial intervention however is a combination of two drugs ibrutinib and MEDI4736 with a specific dosage and schedule  The statement is not entailed in the",
        "label": "Contradiction"
    },
    "5b3b5c72-175a-42ea-aeab-63cd4298b362": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial present outcomes from different patient populations is entailed in the given trials as follows  1 In the primary trial the outcome measurement is the percentage of participants with a response within 10 days of the first dose of denosumab The trial involves patients receiving denosumab for the treatment of hypercalcemia  2 In the secondary trial the outcome measurement is the number",
        "label": "Entailment"
    },
    "58f39f52-0a96-4892-b8e7-2b689448c28f": {
        "text_answer": "  The statement gene variant is a variation in the nucleic acid sequence of a specific gene is not directly related to the information provided in the trials   Regarding the trials the statement all intervention drugs in the secondary trial can be administered orally is entailed in the information provided In the primary trial zoledronic acid is administered IV but in the secondary trial all intervention drugs in both arms granisetron",
        "label": "Entailment"
    },
    "7aa4329c-8f2a-4168-9b6b-f74ea0184356": {
        "text_answer": "  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the information provided in the trials inclusion and exclusion criteria  In the primary trial there is no mention of gabapentin or herceptin in the inclusion or exclusion criteria Therefore prior treatment with these medications would not affect eligibility for the primary trial",
        "label": "Contradiction"
    },
    "62db4a46-c4ea-44a1-8dfc-12922748a7b0": {
        "text_answer": "  The statement Over 50 of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly related to the outcome measurement provided in the trial results The statement mentions acute vomiting in the context of a cohort but it does not specify which trial or outcome measurement it refers to The trial results",
        "label": "Entailment"
    },
    "2610ce20-2875-4677-a55b-fbd094ca3abb": {
        "text_answer": "  The statement is not entailed in the given trial information as pd0332991 is not mentioned in the trial at all Therefore the statement is neutral or neither entailed nor contradicted by the given trial information",
        "label": "Contradiction"
    },
    "0e2c4838-f0ba-4f02-b078-ac3fa2b3c0e3": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial is given a larger dosage of alt801 than cohort 2 is entailed in the trials if the dosage given to cohort 1 is indeed greater than that given to cohort 2 Based on the information provided in the trials this statement is entailed since 0040 mgkgdose is greater than 0015",
        "label": "Entailment"
    },
    "22c47ff5-a9b1-4de2-b5ee-2e5a6f2302d9": {
        "text_answer": "  The statement patients with histologically confirmed earlystage breast adenocarcinoma that is either ER negative PR negative or HER2neu positive are eligible for both the primary trial and the secondary trial is contradictory to the information provided in the trials inclusion criteria  The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma and radiographic evidence of at least one bone metastasis However",
        "label": "Entailment"
    },
    "6b48128c-3103-4266-bd7f-3f9d13dc5949": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of warfarin or fluvoxamine in the provided information The primary trial mentions Fluciclatide Injection AH111585 18F and the secondary trial mentions Chloroquine Standard Dose and Chloroquine Low Dose Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "75d3b7d9-3863-4b14-8007-8d8ade0440f1": {
        "text_answer": "  The statement patients with a body mass index BMI of 20 and above are eligible for the primary clinical trial is contradictory to the inclusion criteria stated in the trial description The inclusion criteria specify that patients must have a BMI of 25 kgm2 or greater and weight 400 lbs Therefore patients with a BMI of 20 or below do not meet the inclusion criteria and are not eligible for the",
        "label": "Entailment"
    },
    "1279b75a-606f-469e-a6e6-20d4eabd50ba": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as both trials include females as participants in their respective studies The primary trial includes postmenopausal females and the secondary trial includes women with locally advanced recurrent or metastatic breast cancer Therefore the statement is incorrect",
        "label": "Entailment"
    },
    "d32ff217-1848-490b-8a99-bc12730318f0": {
        "text_answer": "  The statement the primary trial reported 5 serious adverse events while the secondary trial reported 3 is a contradiction to the given data   The primary trial reported no serious adverse events 000 while the secondary trial reported 2 serious adverse events 571 The statement suggests that the primary trial reported more serious adverse events than the secondary trial which is not the case",
        "label": "Contradiction"
    },
    "9d742d77-5754-4e6f-a913-90dc71c6b6f5": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement all participants of the primary clinical trial undergo the same treatment is not entailed in the given trials as they involve different groups of participants Adult Cancer Patients 65 Years of Age and Older and Healthy Volunteers These groups are not the same and they may receive different treatments due to the different conditions and objectives of the trials",
        "label": "Contradiction"
    },
    "af52a2f1-de39-4113-86fa-10e65961b095": {
        "text_answer": "  The statement is neither entailed nor contradictory to the given trials inclusion and exclusion criteria   The primary trial and the secondary trial have different focuses and different sets of inclusion and exclusion criteria The primary trial is focused on postmenopausal women with a history of breast cancer and experiencing severe hot flushes while the secondary trial is focused on adult patients with HER2negative metastatic breast cancer who are candidates for taxanebased chem",
        "label": "Entailment"
    },
    "4c0fbabb-2d9e-4da7-8a17-07272c77ece8": {
        "text_answer": "  The statement is a contradiction to the given trial data   Explanation   The statement the adverse event records from the primary and secondary clinical trials show more than 10 deaths is not entailed in the given data as there are no more than 10 adverse events recorded in total across both trials and none of them are deaths",
        "label": "Contradiction"
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "text_answer": "  The statement is entailed in the given information as there is no adverse event data provided for the primary trial making it impossible to compare it with the secondary trial",
        "label": "Entailment"
    },
    "5b31fcf1-a528-4718-adcb-72df68b4df43": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded the same number of adverse events in their cohorts is entailed in the given trials data as both trials reported having no adverse events in their respective cohorts  The statement moderate tumor infiltrating lymphocytes is a finding of a moderate number of tumor infiltrating lymphocytes in a biospecimen is not directly related to",
        "label": "Entailment"
    },
    "cc321a3c-a09d-4354-8601-d665f428a831": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is not directly stated in either the primary or secondary trial information provided However it can be inferred from the information given that patients with cerebral metastases meeting the criteria for the primary trial 13 presumed brain metastases are eligible for that trial",
        "label": "Entailment"
    },
    "fddee10c-dd7d-47fe-b2cf-3ebe94726ea4": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as both trials involve the administration of suramin and paclitaxel to patients Therefore the statement is true",
        "label": "Entailment"
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any Aes is entailed in the given data if and only if there are no adverse events reported in the primary trial for Cohort 1 Based on the provided data the statement is entailed as the total number of adverse events reported for Cohort 1 is 0 out of 147 participants 000",
        "label": "Entailment"
    },
    "5b07e1cb-d734-4e43-9911-6328923fbc93": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement mentions that syncope was the most recurrent adverse event in both trials but the trials report different most recurrent adverse events In the primary trial syncope occurred in 2500 of patients but in neither the primary nor the secondary trial is syncope mentioned as the most recurrent adverse event in both trials In the primary trial the most recurrent",
        "label": "Entailment"
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "text_answer": "  The statement Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy is entailed in the trial description The trial states that Patients will take Vorinostat daily during radiation therapy which implies that every patient is required to take Vorinostat daily during radiation therapy Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "baf9254a-880a-4df9-b2fc-c118b6b273f8": {
        "text_answer": "  The statement A 20 year old female patient with a Newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial and the primary trial is neither entailed in the primary trials inclusion criteria nor contradictory to it   The primary trials inclusion criteria state that the patient must have histologically confirmed HER2negative breast cancer that has progressed during or following firstline treatment with",
        "label": "Entailment"
    },
    "e1c50f3f-0521-4edc-a2ae-8e0b04b64c54": {
        "text_answer": "  The statement is contradictory to the given trials as there is no information about radiation therapy being administered in either trial The trials only mention the interventions Eribulin Mesylate and Axitinib  Docetaxel or Docetaxel  Placebo and their respective dosages and schedules Therefore the statement is contradictory to the trials as it makes an assertion about radiation therapy that is not supported by the provided information",
        "label": "Contradiction"
    },
    "b73bfd5a-18e5-4df7-8e6a-292f8f32208f": {
        "text_answer": "  The statement in the primary clinical trial a minimum of one patient who used gtx024 1mg experienced a gain of over 10 kilos in lean body mass is a contradiction to the results presented in the trials   The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 kg",
        "label": "Contradiction"
    },
    "44b12aea-350e-4ade-a145-ba619d96a0ca": {
        "text_answer": "  The statement is not directly entailed in the given trials as they do not provide enough information to make a definitive comparison between the two trials regarding the percentage difference in pCR rates between the different arms or groups The statement mentions a small difference in results between the two cohorts of the primary trial and worse results for Arm 2 in the secondary trial but the trials do not provide the specific percentage points or statistical significance for these differences Therefore",
        "label": "Contradiction"
    },
    "7ea3fe58-fb27-48f8-9e3a-61af8847d23e": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The primary clinical trial does have distinct sets of eligibility conditions for its different study groups as outlined in the inclusion and exclusion criteria The secondary clinical trial does not have distinct sets of eligibility conditions for its subjects as stated in the provided statement",
        "label": "Contradiction"
    },
    "225ff186-66e8-4880-bba4-e8127bd42834": {
        "text_answer": "  The statement mitral valve atresia is a congenital heart defect characterized by the complete atresia of the mitral valve Candidates for the secondary trial study group receive 3 weekly subcutaneous SC injections whereas the primary trial participants only receive a single injection at the beginning of the study is not entailed in the given trials   The trials only provide information about the interventions and the patient selection criteria for the",
        "label": "Contradiction"
    },
    "8e4d3482-1501-4f0d-ae76-8924effe7d3c": {
        "text_answer": "  The statement is entailed in the Trials as there is no overlap between the inclusion criteria of the two trials and the exclusion criteria are distinct and specific to each trial Therefore there is no contradiction or overlap between the two sets of criteria",
        "label": "Entailment"
    },
    "819893b4-9c57-42b8-938e-f6147e41694d": {
        "text_answer": "  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed in the given trials data However it is consistent with the data if we assume that there were no cases of hypertension or Pancreatectomy with Hepatotoxicity   The trials data only provides the number of cases for each ad",
        "label": "Contradiction"
    },
    "354a388c-18b1-476a-b372-3ac4be472cbc": {
        "text_answer": "  The given statement is a qualitative comparison of the severity of adverse reactions between the primary and secondary clinical trials without providing any quantitative data The trials provided only the number of occurrences of adverse events but not their severity Therefore it is not possible to determine entailment or contradiction based on the given information alone  However it is important to note that the statement is not entailed by the given trials as they do not provide sufficient",
        "label": "Entailment"
    },
    "31038c96-b97a-4952-aacc-4e7e8bb09cd0": {
        "text_answer": "  The statement is entailed in the trials In both Intervention 1 and Intervention 2 durvalumab is administered as an IV infusion at a dose of 03 mgkg or 1 mgkg respectively every 2 weeks Therefore the amount of durvalumab received in each biweekly infusion is equal between the two cohorts",
        "label": "Entailment"
    },
    "a828ed30-ae3c-4fbc-be8a-a72dd5e5bc3e": {
        "text_answer": "  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial includes patients with measurable disease which can include tumors of any size However the primary trial specifically excludes patients with locally advanced or metastatic breast cancer making it incompatible with the disease characteristics of the secondary trial Therefore the statement is contradictory and not entailed in the trials",
        "label": "Contradiction"
    },
    "45daf2f3-8299-46f8-9016-edf2ce4a044a": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial are open to any person who is a national of Japan is not directly entailed in the given inclusion and exclusion criteria for both trials The criteria focus on the medical and health conditions of potential participants without specifying their nationality",
        "label": "Contradiction"
    },
    "c831a231-8b84-41ca-a825-d11060c44d64": {
        "text_answer": "  The primary trial and the secondary trial have some overlapping inclusion criteria but they also have distinct differences   The primary trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic bone metastasis The secondary trial includes women with newly diagnosed or recurrent breast cancer who are considering or completing a mastectomy and do not have known",
        "label": "Entailment"
    },
    "ee8170da-a81f-42bf-b286-cbb8824040cf": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the primary trial explicitly states that a participant has been excluded if they have received any experimental agents within 4 weeks prior to the study registration date but it does not mention organ transplant specifically The secondary trial does",
        "label": "Contradiction"
    },
    "95aa2e47-d35b-45b5-8d80-18f06798b812": {
        "text_answer": "  The statement paclitaxel is administered to both cohort 1 and cohort 2 during the primary clinical trial is not explicitly stated in the provided information However it is not contradicted either The trial description only mentions the interventions for each cohort Arm A anastrozole Arm B fulvestrant and how they are administered Paclitaxel is not mentioned as being given to either co",
        "label": "Entailment"
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "text_answer": "  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is not entailed in the given trials as the trials only provide the number of patients who experienced specific adverse events and not the total number of patients in each trial or the percentage of patients who did not experience any adverse events The given statement makes a generalization about all patients in both trials which is not directly supported by the provided data",
        "label": "Contradiction"
    },
    "c76186ef-f703-4809-8e01-956bdec01925": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The primary trial results reveal a higher overall response rate in Arm A Epirubicin  Cyclophosphamide  Docetaxel  Capecitabine  Surgery  Radiation Therapy as compared to the placebo with 25 out of 37 participants achieving an overall response CR  PR in Arm A 2 The secondary trial results",
        "label": "Entailment"
    },
    "da278764-ba0c-4a9e-9f44-7fe16af87e5a": {
        "text_answer": "  The statement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is not directly related to the given information about the number of adverse events and the percentage of households with members unable to afford prescription medicine in the primary and secondary trials Therefore the statement cannot be determined to be entailed or contradicted based on the given information alone  However the statement who needed prescription medicine but family",
        "label": "Entailment"
    },
    "7de10e39-c06c-4941-ade6-3e60b864029c": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The primary trial does report Time to Progression TTP as the outcome measurement which is an objective measure of the duration of treatment effect The statements assertion that the primary trial does not provide a TTP report is incorrect Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "2b9dbd1a-6de9-4c7e-80af-0a096af26a11": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as both cohorts received Enzalutamide orally not by IV Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "c83203cf-4121-4d9d-a662-cd596a5f63d5": {
        "text_answer": "  The statement hypokalemic individuals can participate in the primary clinical trial but are ineligible for the secondary clinical trial is a contradiction based on the provided information in the trials inclusion and exclusion criteria  Explanation  The primary clinical trial includes the criterion Potassium within the normal range of 3553 mEqL This means that individuals with hypokalemia potassium",
        "label": "Contradiction"
    },
    "3a9ca481-4b74-4bd3-99f0-1b34cc33ba33": {
        "text_answer": "  The statement about 03636 of the primary trial patients suffered an increase in blood bilirubin is entailed in the trial data as stated in the Adverse Events section specifically under Blood bilirubin increased with a frequency of 111 909 Therefore the statement is entailed by the trial data",
        "label": "Entailment"
    },
    "9d03d248-30a2-44b1-bbef-75809005dc16": {
        "text_answer": "  The statement Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial who were receiving far lower doses of Empegfilgrastim is not directly entailed in the provided trial data   The trials only provide information on the duration of neutropenia and the incidence of CTCAE grade 34 neutropenia for different",
        "label": "Contradiction"
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "text_answer": "  The statement the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast shallow respiration group is entailed in the trials as the mean number of hot flashes per day in the paced respiration group 348 is less than the mean number of hot flashes per day in the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "1f23b5f1-2b28-4204-9e44-60f8ddc86963": {
        "text_answer": "  The statement adverse events were not reported in cohort 1 but were reported in cohort 2 in the primary clinical trial is a contradiction to the given data   Explanation  The data provided in the primary clinical trial lists the number of adverse events for each cohort 1 and 2 and the specific types of adverse events that were reported According to the data there were adverse events reported in",
        "label": "Contradiction"
    },
    "72626f41-afa0-413c-b495-e4eeb51112fb": {
        "text_answer": "  The statement after 30 days of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 10 reduction in the percentage of cells with ki67 expression is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks of 5 percentage points from 15 to 10 ",
        "label": "Entailment"
    },
    "c3bc7314-8b8f-4d98-90ad-986132951201": {
        "text_answer": "  The statement Only 4 different types of adverse events affected patients in the primary trial all of which were in cohort 2 is not directly entailed in the given trials data However it is implied that there were only 4 unique types of adverse events across both trials but the statement goes further to specify that they all occurred in cohort 2 Without more information about the trials such as the total number of patients in each coh",
        "label": "Contradiction"
    },
    "03a7663e-0937-437a-b095-642e363a6703": {
        "text_answer": "  The statement is entailed in the given trials as follows  The primary trial does not involve the use of lenalidomide whereas the secondary trial uses a different intervention for lenalidomide which is not present in the primary trial Additionally the secondary trial uses high doses of lapatinib 1500 mg daily in intervention 1 which is different from the dosage used in the primary trial lenalidomide ",
        "label": "Entailment"
    },
    "1c5b6b0e-8ee8-4569-8bc8-83ab193f8cff": {
        "text_answer": "  The statement patients with Histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial is entailed in the given inclusion criteria for both trials   In the primary trial breast adenocarcinoma is listed as one of the eligible cancer types for phase 2 and there is no mention of any exclusion criteria",
        "label": "Entailment"
    },
    "0e6d3d31-1af3-4701-a410-b2bbb1ce430e": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is entailed in both Trials 1 and 2 as they both report a total of 19 adverse events and among them there are reported cases of vomiting in Trial 1 3149 or 201 and Trial 2 3149 or 201",
        "label": "Entailment"
    },
    "0db120d4-5ebb-4b0f-9040-52b32a966c33": {
        "text_answer": "  The statement patients in the paced respiration intervention group of the primary clinical trial on average experienced a smaller number of hot flashes per day than patients in the fast shallow respiration group is entailed in the trials as the mean number of hot flashes per day in the paced respiration group 348 is less than the mean number of hot flashes per day in the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "ace11ff3-a7ac-492c-9dbe-5dafc96f81e7": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years however at least one patient from both cohorts died in under 2 years is not directly related to the information provided in the trials The trials only report the median survival times with confidence intervals for the two groups and do not provide information about the distribution of survival times or the number of patients who survived less than 2 years The statement about the raphe nuclei is also not",
        "label": "Entailment"
    },
    "16147f31-aa81-4f21-9bd7-f153069a9278": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention is Yttrium90 Radioembolization using TheraSphere glass microspheres which is a form of radiation therapy   The secondary trial intervention however is a combination of two different drugs ibrutinib and MEDI4736 with dosages of 400 mg of ibrutinib",
        "label": "Entailment"
    },
    "edd1533a-dc7c-441d-adcd-f8b020a4fdd3": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The statement suggests that all participants are required to view the educational DVD but according to the trial description only the intervention arm patients are invited to view the DVD The control arm patients will not view the DVD as part of their usual care",
        "label": "Entailment"
    },
    "a9d993df-c8e1-4f4f-b470-b23d78f069ed": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial only mentions intravenous administration of zoledronic acid while the secondary trial mentions both intravenous and oral administration for all interventions The statement would only be entailed if it specifically mentioned that patients in the secondary trial receive all interventions orally",
        "label": "Contradiction"
    },
    "1f77c906-1f2c-43b4-8bb1-2a2aeb19555e": {
        "text_answer": "  The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed in the given trials as they only provide the number and percentage of patients who experienced specific adverse events but they do not provide information about the total number of patients in each trial who did not experience any adverse events However based on the given data it can be inferred that a large number of patients in both trials did not suffer any ad",
        "label": "Contradiction"
    },
    "29cdc690-859f-405c-ad87-f4e73fc3e9a8": {
        "text_answer": "  The statement is contradictory to the primary trial as the reflexology intervention in the primary trial lasted for 10 weeks while the secondary trial interventions last for 24 weeks The discrepancy in the duration of interventions makes the statement contradictory to the primary trial",
        "label": "Entailment"
    },
    "920f9642-c8b0-4b1d-9b2a-c12c4801b714": {
        "text_answer": "  The statement patients with normal potassium levels are disqualified from the primary clinical trial while they have potential eligibility for the secondary clinical trial is a contradiction   Explanation   The primary clinical trial has inclusion criteria that require patients to have a potassium level within the normal range 3553 mEqL Therefore patients with normal potassium levels are eligible for the primary clinical trial",
        "label": "Contradiction"
    },
    "ec1b4763-e8bc-4c2f-be22-6b64b623b072": {
        "text_answer": "  The statement A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is a contradiction to the given trial characteristics The trial explicitly states that No meningeal carcinomatosis is a requirement for eligibility However the statement provided mentions leptomeningeal carcinoma which is a type of meningeal carcinomatosis Therefore the statement contradicts",
        "label": "Contradiction"
    },
    "2fcef697-683a-4b99-9da3-5527e80c9e5b": {
        "text_answer": "  The statement Unlike the primary trial patients must be diagnosed with a mutation in one of the following genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ or GNA11 to be included in the secondary trial is entailed in the secondary trial inclusion criteria as stated in the text The pdg",
        "label": "Entailment"
    },
    "fc96b587-8bbf-4816-97d9-15cd8fcf755f": {
        "text_answer": "  The statement tyrphostin ag 1288 is a protein tyrosine kinase inhibitor that blocks tumor necrosis factor alpha induced cytotoxicity nci is not entailed in the given primary and secondary trials as neither of them mention the use of tyrphostin AG 1288 or its relation to the outcome measurements provided Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Contradiction"
    },
    "5284dc53-b471-4c7a-a713-62199869a305": {
        "text_answer": "  The statement the majority of patients participating in the primary and secondary clinical trials reported experiencing adverse events after treatment is not directly entailed or contradicted by the given data   The primary trial reported that 4545 of patients experienced adverse events while the secondary trial reported that 1563 of patients experienced adverse events While both trials report the occurrence of adverse events the percentage of patients experiencing adverse events",
        "label": "Contradiction"
    },
    "e6ba45db-66f8-4f45-a45a-9217e65c7bbd": {
        "text_answer": "  The statement enrollment in the primary clinical trial is not possible for patients who are at present involved in the secondary clinical trial is entailed in the given trials as both trials explicitly state that participation in another clinical trial is an exclusion criterion for each study Therefore a patient cannot be enrolled in both trials simultaneously",
        "label": "Entailment"
    },
    "ca63be25-38a3-4f4a-a6be-0e8b8cb8e5f5": {
        "text_answer": "  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is neither entailed in the primary trial nor contradictory to it   The primary trial focuses on patients undergoing immediate tissue expander reconstruction following mastectomy and the secondary trial focuses on patients who have completed surgery for breast cancer and have certain criteria related to inflammation and fatigue The statement does not",
        "label": "Entailment"
    },
    "87e90ba6-44b6-4dc9-9bac-9ceb0c8cf6f6": {
        "text_answer": "  The statement the primary clinical trial results do not concern changes in pain intensity and the secondary trial does not measure the change from baseline to 9 months in bone mineral density BMD of the lumbar spine is not entailed in the given trials as the primary trial does measure pain intensity changes specifically using the Summed Pain Intensity Differences SPID at 30 minutes after dosing and the secondary trial does measure the change in BMD of",
        "label": "Contradiction"
    },
    "0fdae3b5-0326-47fb-a3c2-ff5fd132fb76": {
        "text_answer": "  The statement men diagnosed with early stage ER breast cancer seeking radiation therapy are eligible for the primary clinical trial and the secondary clinical trial is contradictory to the given trials as  1 The primary trial is for women with locally advanced recurrent or metastatic breast cancer along with confirmation of estrogenreceptor positivity ER It does not mention anything about men or early stage breast cancer  2 The secondary trial is",
        "label": "Entailment"
    },
    "487046b0-2368-40da-9cba-407f65177f0b": {
        "text_answer": "  The statement more than 75 of the patients in the primary clinical trial suffered a specific adverse event type is not entailed in the given trial data The total number of adverse events is 5 and the total number of patients is 14 Therefore the percentage of patients suffering from a specific adverse event type is 3571 which is less than 75",
        "label": "Contradiction"
    },
    "95a5ceca-3b9c-4760-98be-98c78559a161": {
        "text_answer": "  The statement is contradictory to the given information   The primary trial has specific inclusion and exclusion criteria related to cancer diagnosis treatment history and patient health status The secondary trial on the other hand has inclusion criteria limited to patients undergoing large core breast biopsy in a specific location The exclusion criteria for the secondary trial are also different focusing on patients ability to give informed consent and understand English Therefore the statement that all inclusion",
        "label": "Entailment"
    },
    "bf8e8814-f9d9-422e-ab84-fea4f6c85ede": {
        "text_answer": "  The statement a woman who has had lumpectomy would not be allowed to participate in the secondary trial or the primary trial is contradictory to the information provided in the trials inclusion criteria  In the primary trial patients undergoing lumpectomy are not explicitly mentioned as being eligible or ineligible However they are not explicitly excluded either which implies that they could potentially be included based on the other inclusion criteria  In the secondary trial patients",
        "label": "Entailment"
    },
    "046763cb-f08d-4032-8b54-03bc14cb9d69": {
        "text_answer": "  The statement the primary clinical trial is open to patients suffering from anorexia is contradictory to the inclusion criteria of the trial Anorexia is a condition characterized by a significant loss of weight and a fear of gaining weight which is not mentioned in the inclusion criteria The inclusion criteria only state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs Therefore the statement is contrad",
        "label": "Entailment"
    },
    "83b91b04-e464-483d-94d2-079690030cb5": {
        "text_answer": "  The statement both the secondary and primary clinical trials observed multiple aes including headache and joint pain in various patients is not directly entailed in the given trials as the trials do not report the occurrence of headache and joint pain as adverse events However the statement is not contradictory to the trials either as the trials only report the occurrence of specific adverse events and do not exclude the possibility of other adverse events such as headache",
        "label": "Contradiction"
    },
    "7e4c273a-fc2f-4589-beb8-4e90f3198962": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial is comparing the effects of two different interventions Hydrophor and MediHoney on study groups while the secondary trial is comparing the effects of two different doses 90 mg and 110 mg of the same intervention PF05212384 on the same study group participants with CRPC ABC or NS",
        "label": "Entailment"
    },
    "dc855f0a-1281-44f9-b68c-89044aaa73af": {
        "text_answer": "  The statement clostridiaceae is a taxonomic family of bacterium in the phylum firmicutes that includes the genera alkaliphilus clostridium and lutispora among others is not related to the adverse events data provided in the trials Therefore the statement does not entail or contradict the information given in the trials",
        "label": "Entailment"
    },
    "c10c78c7-51f4-4440-8164-07b059e01fd9": {
        "text_answer": "  The statement in both cohorts of the primary clinical trial not a single case of hypertension dehydration and dyspnea was recorded is not directly entailed or contradicted by the given data in the trials   The trials only report adverse events related to Disseminated intravascular coagulation Death NOS Edema limbs Fatigue Hepatic failure Alanine aminotransfer",
        "label": "Contradiction"
    },
    "feca3829-9b38-4738-8bad-e8a0fcf9029f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement suggests that the adverse events of recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were more frequent in the secondary trial but the data shows that none of these adverse events were reported in the secondary trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets all the inclusion criteria for the primary trial ie histologically verified diagnosis of solid tumor malignancy of breast appropriate diagnostic workup age performance status and signed informed consent The patient also meets the inclusion criteria for the secondary trial ie histologically verified diagnosis of stage IIbIIIIV breast cancer age life expectancy completion of chemotherapy performance",
        "label": "Entailment"
    },
    "4afbbadf-10c0-4e7e-87d3-2516aeafbe73": {
        "text_answer": "  The statement at least one patient treated with GTx024 1mg in the primary trial gained over 10 kilos of Lean body Mass is not directly entailed in the given trial results as there is no information provided in the results about any participant in the GTx024 1mg group gaining over 10 kilos of lean body mass The results only provide the median change in lean body mass and the range for each group",
        "label": "Contradiction"
    },
    "467c8a18-4a72-4ea4-9b8d-ae43d786b5b0": {
        "text_answer": "  The statement the primary clinical trial allows for the enlistment of patients with a histologically confirmed diagnosis of nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer regardless of metastatic condition or resectability and irrespective of ER or PR positivity is partially entailed in the inclusion criteria of the trial   The trial does allow for the enrollment of patients with",
        "label": "Entailment"
    },
    "f0eaf3f3-5c84-4cd8-8a13-ef1af710cf9e": {
        "text_answer": "  The statement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is not directly related to the given trials and their adverse events data related to the adcsadl severe dementia questionnaire question Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement does not contradict the given trials as there",
        "label": "Entailment"
    },
    "8c7a92ab-80cd-4bb4-8b03-fa5f6776ca5a": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial both rule out patients who struggle with severe forms of insomnia and schizophrenia is entailed in the given trials as follows  1 The primary clinical trial exclusion criteria include uncontrolled intercurrent illness including but not limited to psychiatric illnesssocial situations that would limit compliance with study requirements While this criterion does not explicitly mention insomnia or schiz",
        "label": "Entailment"
    },
    "7b1befbe-fec3-4554-89f7-323acfc66d62": {
        "text_answer": "  The statement is entailed in the trial results as the trial states that the mean percentage change in Ki67 expression was 40 63 to 29 The statement in the trial result is more specific as it mentions the drug dosage time frame and outcome measurement while the statement in the text is a summary of the trial result Therefore the statement in the text is a logical consequence of the trial result",
        "label": "Entailment"
    },
    "b8c9f988-e270-467e-b7a8-b71b1ae302ce": {
        "text_answer": "  The statement individuals with cdk46 mutation can participate in the primary clinical trial is entailed in the trials inclusion criteria under point E Therefore the statement is entailed in the trials description",
        "label": "Entailment"
    },
    "12ca7fab-5b2d-4889-b4b9-458fc6f08f33": {
        "text_answer": "  The statement the secondary trial participants do not have to meet any performance status condition to enter whereas this is a required condition for eligibility in the primary trial is entailed in the trials provided   Explanation   The primary trial includes the performance status ECOG  2 as an inclusion criterion while the secondary trial does not mention it as a criterion Therefore the secondary trial participants do not have to",
        "label": "Entailment"
    },
    "a66238c5-3c2f-47a8-8b38-aad66299aed0": {
        "text_answer": "  The statement is entailed in the trials as follows  In the given trials the doses of eribulin and docetaxel are different between the two interventions Specifically the dose of eribulin in Intervention 1 is 14mgm2 given on Days 1 and 8 of each treatment cycle while the dose of docetaxel in Intervention 2 is 75 mgm",
        "label": "Entailment"
    },
    "136c5db2-719f-458f-9d88-f5596886ed96": {
        "text_answer": "  The statement is neither entailed in the primary nor the secondary trials as they address different outcomes and interventions The primary trial investigates the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial examines the impact of Physical Therapy on pain reported by participants undergoing chemotherapy The two trials are independent of each other and do not directly relate to the statement provided",
        "label": "Entailment"
    },
    "2d84efa0-fd43-40fa-a809-f9be6d197371": {
        "text_answer": "  The statement is entailed in the primary trials exclusion criteria as it mentions Patients with nonhealing surgical wounds as an exclusion criterion However the secondary trials exclusion criteria also include Patients with unstable angina and Patients with  Grade 1 neuropathy at screening which are not mentioned in the primary trials exclusion criteria Therefore the statement is only partially entailed",
        "label": "Entailment"
    },
    "98923c9c-1126-436a-9263-a9deca239ba6": {
        "text_answer": "  The statement is entailed in the given trials as the trials test different interventions with different drugs In the primary trial patients receive eribulin mesylate while in the secondary trial patients receive either axitinib  docetaxel or docetaxel  placebo Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "0d49e948-aea6-4067-8f7e-b480e47d3407": {
        "text_answer": "  The statement is contradictory to the given trials inclusion criteria   The young girl with a newly diagnosed PRpositive HER2positive breast cancer would not be eligible for either trial based on the provided inclusion criteria   The primary trial specifically states that the patient must have histologically confirmed HER2negative breast cancer while the secondary trial states that the patient must have a negative HER2 test result Therefore the young girl",
        "label": "Entailment"
    },
    "080fe5be-37c4-4d7f-a985-58c520750620": {
        "text_answer": "  The statement is not entailed in the given trial information as there is no mention of Paraplatin in the interventions described Paraplatin is a type of platinumbased chemotherapy drug and in the trial Carboplatin is mentioned instead Therefore the statement is contradictory to the trial information",
        "label": "Contradiction"
    },
    "4625018e-c34b-4156-8c63-572712bdbf30": {
        "text_answer": "  The statement used personal tablet is a response indicating that an individual used their personal tablet is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction based on the given information alone  However regarding the statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial",
        "label": "Entailment"
    },
    "6d94034f-7e7f-4220-a193-bdd926f8b993": {
        "text_answer": "  The statement is not entailed in the trials provided as neither trial measures heart rate or cardio exercises as an outcome measure The primary trial measures the change in isothiocyanate in urine samples while the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "dea7a7bb-563c-4b02-9011-16fa165820c4": {
        "text_answer": "  The statement ndc me milligram is a recognized billing qualifier that may be used to identify milligrams as the NDC unit of measure is not related to the information provided in the primary and secondary trial results Therefore it does not entail or contradict the information presented in the trials",
        "label": "Entailment"
    },
    "387b9e0a-aafd-4140-921b-3609114410cb": {
        "text_answer": "  The statement is entailed in the trials as described The trials state that the only difference between the two interventions is the dose of durvalumab given in the twice weekly iv infusions 03 mgkg vs 1 mgkg Therefore the statement that the first cohort receives a lesser quantity 07 mgkg less of durvalumab in their twice weekly iv infusions compared to the second cohort is a correct",
        "label": "Entailment"
    },
    "55eb3029-c826-4cae-a130-7cc8fbc80121": {
        "text_answer": "  The statement Female cancer patients over the age of 18 from Venezuela Bolivarian Republic of can participate in the primary trial however for the secondary trial they must have Her2neu breast cancer is a combination of both inclusion and exclusion criteria for the trials   The statement is partially entailed in the primary trial inclusion criteria as it specifies that female cancer patients from Venezuela Bolivarian Republic of aged 1",
        "label": "Entailment"
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "text_answer": "  The statement There were no significant differences in the results from the groups in the primary trial however some differences were found between the Reflexology Group and control group results in the secondary trial is a contradiction of the given trials  Explanation  The primary trial is focused on comparing the diagnostic accuracy of two algorithms in breast cancer diagnosis using the area under the ROC curve There is no mention of any significant differences between the groups in the primary trial results",
        "label": "Contradiction"
    },
    "d9c0a0a4-0bdf-4b77-b442-78d609b06854": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   In Intervention 1 two IM injections of V935 LD are given one every other week over a 3week period In Intervention 2 two IM injections of V935 LD are given as well but they are given at different stages of the trial The first two injections are given following a 4",
        "label": "Entailment"
    },
    "61de0370-1d90-4657-b0f1-fff95fc5efa5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive intramuscular injections of an unspecified intervention In the secondary trial participants in the intervention group receive subcutaneous injections of epoetin beta Although the types of injections differ both trials involve the use of injections Therefore the statement that participants in the secondary trial study group do not receive any form of",
        "label": "Entailment"
    },
    "1108856e-d4cc-488e-a0d8-98274fc38dfd": {
        "text_answer": "  The statement both primary and secondary trials do not use lenalidomide or lapatinib in any interventions and there is no mention of the specific duration for any trials is a contradiction to the given trials   In the primary trial participants received lenalidomide as intervention 1 In the secondary trial intervention 1 for both arms included lapatinib and trastuzumab neither of which is mentioned in the statement",
        "label": "Contradiction"
    },
    "840d1cd7-85bd-4d25-a4db-0af6ff989e1d": {
        "text_answer": "  The statement during the primary clinical trial there were no significant divergences noted in any groups results but differences emerged between the reflexology group and the control group during the secondary clinical trial is a compound statement consisting of two parts  1 during the primary clinical trial there were no significant divergences noted in any groups results 2 but differences emerged between the reflexology group and the control group during",
        "label": "Contradiction"
    },
    "8667c9e0-5040-46af-b784-4214164c4c0c": {
        "text_answer": "  The statement the primary clinical trial witnessed many psychiatric adverse incidents notably including an eating disorder and schizophrenia is not entailed in the given trial data The trial data mentions only one case of suicidal ideation which is a type of psychiatric adverse event There is no mention of an eating disorder or schizophrenia in the trial data Therefore the statement is contradictory to the given trial data",
        "label": "Contradiction"
    },
    "f69e913e-7050-463f-aa18-ad022451d483": {
        "text_answer": "  The statement patients that have participated in antineoplastic chemotherapy androgens or estrogens therapy in the two years preceding study initiation are barred from the primary clinical trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents allowed Androg",
        "label": "Entailment"
    },
    "50e74c9b-3673-4222-99f0-63f82e40b288": {
        "text_answer": "  The statement The same number of AEs were reported for both cohorts in the primary trial is not directly entailed in the given trials as the trials do not provide sufficient information to make that determination The statement only mentions the total number of adverse events AEs for each cohort but it does not specify the types of AEs or the number of participants in each cohort Therefore it is not possible to determine if the same number",
        "label": "Contradiction"
    },
    "e78237d7-bbb7-4586-9950-5eabb10254f9": {
        "text_answer": " The provided information does not include data on treatment emergent adverse events and serious treatment emergent adverse events for both groups in the trials Therefore it is not possible to determine if the statement is entailed in the trials or if it is a contradiction More information is needed to make an accurate assessment",
        "label": "Entailment"
    },
    "e9a96af7-c9f7-49cd-a291-2c0abb94719c": {
        "text_answer": "  The statement following highdose chemotherapy with purged autologous stem cell products less than half of the individuals involved in the primary clinical trial experienced a reduction in circulating tumor cells is a contradiction to the results presented in Trial 1   The trial reports that 9 out of 21 participants 4286 experienced a reduction in CTCs at one month post AHST Therefore more than",
        "label": "Contradiction"
    },
    "f0a41373-f03b-471f-9f0f-381f8b09a950": {
        "text_answer": "  The statement Syncope which occurred in 2500 of the primary trial patients is the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial is entailed in the given trials data  Explanation  The statement mentions that Syncope is the most commonly occurring adverse event across the patient cohorts of both trials The trials data provided confirms that Syn",
        "label": "Entailment"
    },
    "63966dc4-b12e-4e45-befe-50b9c19a702a": {
        "text_answer": "  The statement is entailed in the trials as neither cohort A nor cohort B in the primary clinical trial received electroporation injections of low dose LD V934 Therefore the statement is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "a85102e4-fe19-4b6e-8dd5-4cb9ffd64176": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials In the primary trial the interventions for both arms differ with one arm receiving CBTI and placebo and the other arm receiving CBTI and Armodafinil with varying dosages In contrast the statement asserts that all cohorts in the primary trial are treated equally and given the same dosage of simvastatin daily which is not mentioned in the trial",
        "label": "Contradiction"
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "text_answer": "  The statement candidates Capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial focuses on Her2neu or Her1EGFR positive cancer patients with measurable",
        "label": "Entailment"
    },
    "04c1483e-d2bb-40a2-b215-ede1e3c7c973": {
        "text_answer": "  The statement is contradicted by the given trial information   In the primary trial FMX is given as a single bolus IV injection on Day 1 followed by MM398 treatment starting within 7 days of the FMX infusion The dosages and intervals of administration for FMX and MM398 are different from those in the secondary trial  In the secondary trial lapatinib and paclitaxel are",
        "label": "Contradiction"
    },
    "06929ac9-6df2-4e5b-afd8-656a1f9989d1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves massage therapy as an intervention while the secondary trial also involves massage therapy as a means of delivering the study drug PF06647020 Both trials include pain therapy psychosocial assessment and care and qualityoflife assessment as well as management of therapy complications Therefore neither trial is solely testing a specific drug nor is the",
        "label": "Entailment"
    },
    "912414db-d418-4c96-b06b-e26d0ac1992f": {
        "text_answer": "  The statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia is contradictory to the information provided in the trials   The trials report that there was 1 case of Anaemia 1 case of Febrile neutropenia and 0 cases of Pancytopenia in cohort 1",
        "label": "Entailment"
    },
    "dacc42a9-68cc-4b2c-9377-648486729eed": {
        "text_answer": "  The statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed in the trial description The four different drugs used in the trial are epirubicin cyclophosphamide docetaxel and trastuzumab Therefore the statement is entailed in the trial description  The statement nausea during this period is a question about whether an individual had nausea during the",
        "label": "Entailment"
    },
    "eb68a94f-7693-4158-b492-7b5a03d85b96": {
        "text_answer": "  The statement is contradictory to the trials provided   Explanation   The statement claims that patients in the secondary clinical trial encountered adverse events specifically eyelid oedema upper gastrointestinal haemorrhage and chest pain while no such instances were reported in the primary clinical trial However the trials provided do not support this statement   In the secondary trial there was one instance of eyelid",
        "label": "Contradiction"
    },
    "e83cb970-0b3c-4b61-8a44-49a9a3f61744": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial includes only postmenopausal women with early stage breast cancer who have low vitamin D levels and will be treated with an aromatase inhibitor The secondary trial includes healthy participants and HER2positive females with a history of operable primary invasive HER2positive breast cancer While both trials involve breast cancer they are distinct populations with different",
        "label": "Entailment"
    },
    "47b36e1f-90d5-4a42-b359-95783c7ae965": {
        "text_answer": "  The statement is contradictory to the given trials as there is no information about radiation therapy being administered in either trial The trials only describe the interventions Eribulin Mesylate and Axitinib  Docetaxel or Docetaxel  Placebo and their dosing schedules Therefore the statement is contradictory to the trials as it makes an assertion about radiation therapy that is not supported by the provided information",
        "label": "Contradiction"
    },
    "033cc376-5268-43c7-bf06-ca3503971f41": {
        "text_answer": "  The statement within cohorts 1 and 2 of the primary clinical trial there was no distinguishable pattern detected for the expression of the evaluated set of 40 genes is in agreement with the results presented in the trials Both trials cohorts 1 and 2 reported that no discernible pattern was detected for the expression of the set of 40 genes in the participants with normal or lownormal Vitamin D levels Therefore",
        "label": "Contradiction"
    },
    "d1eb9a24-13e8-43de-ba1c-7b17e35e7ab3": {
        "text_answer": "  The primary trial measures tumor diameter in centimeters cm while the secondary trial measures the number of participants with solid tumor response based on local investigator assessments using RECIST 11 criteria The units of measure do not align perfectly as they measure different outcomes Therefore the statement is contradictory",
        "label": "Entailment"
    },
    "e40080bc-499c-4af9-a437-be6688894d22": {
        "text_answer": "  The statement less than 110 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products is not directly entailed or contradicted by the information provided in the trial results Results 1   The trial results only report the number of participants with a reduction in CTCs at one month post AHST not the percentage or fraction of participants",
        "label": "Contradiction"
    },
    "2f6605a0-31b3-43e1-9ec7-3e262cb9acf0": {
        "text_answer": "  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the given inclusionexclusion criteria of the primary trial as stated in the text   The",
        "label": "Entailment"
    },
    "56daf92a-2c6e-4b2d-b532-3035e757e98c": {
        "text_answer": "  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 500 of the primary trial patients is a contradiction to the information provided in the trials  The primary trial reported that syncope occurred in 2 out of 12 patients which is equivalent to 1667 This is not the most common adverse event as",
        "label": "Contradiction"
    },
    "7a8f6698-eb2a-4695-b521-7e42522afdba": {
        "text_answer": "  The statement is not entailed in the given trial information as the trials do not provide any information regarding numerical chromosomal abnormalities The trials only mention the interventions memantine and placebo their administration frequencies and durations",
        "label": "Contradiction"
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "text_answer": "  The statement is entailed in the Trials since all the instances of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever mentioned in the primary trial are from cohort 1 Therefore there are no such cases in cohort 2 and the statement holds true",
        "label": "Entailment"
    },
    "88490a99-ea34-4aa1-a838-b3a1cffa41a0": {
        "text_answer": "  The statement an incident occurred in the primary clinical trial where a patients surgical incision came undone after the surgery is entailed in the given trial data under the adverse event wound dehiscence which occurred 1 time out of 50 patients 200 Therefore the statement is entailed by the trial data",
        "label": "Entailment"
    },
    "153e0c8b-e056-4dd9-9337-156752b249c1": {
        "text_answer": "  The statement is contradictory to the given information in the trials   Explanation   The given information states that in the primary trial there were 0 adverse events out of 34 participants and in the secondary trial there were 0 adverse events out of 1 participant The statement however asserts that there were 200 recorded adverse events in both trials This is a contradiction to the given information",
        "label": "Contradiction"
    },
    "e46defaa-44a0-4919-bd9b-aa018de05da1": {
        "text_answer": "  The statement is a comparison of the primary and secondary trials based on their outcome measures The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in response to estriol vaginal gel treatment while the secondary trial determines the Maximum Tolerated Dose MTD of ruxolitinib in combination with paclitaxel The statement is not directly entailed in the given trial results as it",
        "label": "Contradiction"
    },
    "e9b973a3-aabd-484d-8c7c-0bd2296bf0c5": {
        "text_answer": "  The statement does not follow directly from the given trials as there is no information provided in the trials regarding the occurrence or nonoccurrence of Mouth Partial Response GVHD or the specific NIH Modified Oral Mucosa Rating Scale OMRS scores for individual patients The statement mentions a decrease in OMRS score by 2 or more points but the trials only provide the total number of cases for Adverse Events 1 A",
        "label": "Contradiction"
    },
    "6151cf03-78f0-4404-87bc-beacea52cd95": {
        "text_answer": "  The statement patients who have had instances of pulmonary embolisms are ruled out from the secondary clinical trial is entailed in the exclusion criteria of the secondary trial as it explicitly states Inability to safely undergo general anesthesia andor perioperative care related to vascularized lymph node transfer and History of clotting disorder hypercoagulable state as exclusion criteria  The statement ",
        "label": "Entailment"
    },
    "979f5a49-0af6-4ea3-a410-d79cf3540d01": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the use of oral pregabalin not iv infusions of amitriptyline The secondary trial involves the use of chemotherapeutic agents liposomal cytarabine and highdose methotrexate not carmustine and cyclophosphamide Therefore the statement is contradictory to the information provided in the",
        "label": "Entailment"
    },
    "d620b526-d227-42a4-a6cc-800df41f854a": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we first need to calculate the percentage of participants with a decrease in GFS for each group and compare them  From the trials we have  1 ERpositive Luminal B group 131 to 492 286 average of participants demonstrated a decrease in GFS 2 Triple Negative",
        "label": "Entailment"
    },
    "4e0fae11-64b8-403f-8001-45ef8078a145": {
        "text_answer": "  The statement syncope was the most frequently reported adverse event in both primary clinical trial and secondary clinical trial affecting 2500 of the patients in the primary trial is contradictory to the information provided in the trials  The primary trial reported that syncope occurred in 2 out of 12 patients 1667 not 2500 The secondary trial did not report any occurrences of syn",
        "label": "Entailment"
    },
    "c5feab6a-263d-41c4-8c21-cfa5ffe80a3d": {
        "text_answer": "  The statement is partly entailed in the given trials   Explanation   The statement participants of the primary clinical trial undergo complete breast radiation therapy in contrast the secondary clinical trial participants from both cohorts take 500 mg of fulvestrant in tablet form twice daily is partially entailed in the trials   The first part of the statement participants of the primary clinical trial",
        "label": "Entailment"
    },
    "c36a1fe4-cc98-4a41-94c5-88458737d070": {
        "text_answer": "  The statement on average patients from the primary trial survive over 24 months over 50 patients from each cohort survived more than 2 years is not directly entailed in the given trials as they only provide the median survival times and the number of participants analyzed for each group but not the number of patients surviving beyond 2 years However we can calculate the number of patients surviving beyond 2 years based on the provided median survival times and the number of",
        "label": "Contradiction"
    },
    "a29b69ee-502b-4d86-b028-be9a56bfb7f6": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORRs of the two groups and consider the size of their participant pools   The statement is the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial demonstrated a better ORR than its paclitaxel plus bevacizumab counterpart  From the given trials we have  ",
        "label": "Entailment"
    },
    "843b1c8e-8d10-4f20-8514-4ba986071878": {
        "text_answer": "  The statement infigratinib regimen is a regimen consisting of infigratinib that can be used for the treatment of hepatobiliary cancers Candidates for the secondary trial study group receive 3 weekly subcutaneous SC injections whereas the primary trial participants only receive a single injection at the beginning of the study is not directly entailed in the given trials   The primary trial is focused on evaluating vitamin",
        "label": "Contradiction"
    },
    "c6c84bb8-fea8-4ad6-8ec7-1677049d1fe4": {
        "text_answer": "  The statement the primary clinical trial may still accommodate patients with the diagnosis of 23 cerebral metastases despite being disallowed from joining the secondary clinical trial is neither entailed nor contradicted by the information provided in the primary and secondary trials  Explanation  The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial allows for one to three presumed brain metastases while the secondary trial does",
        "label": "Entailment"
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "text_answer": "  The statement is entailed in the primary trial description as follows  Cohort 1 receives Dexamethasone preoperatively before the operation and the dosage is 8 mg intravenously Cohort 2 also receives Dexamethasone but they receive it 2 hours after the operation and the dosage is 24 mg intravenously  The statement in the question specifies that co",
        "label": "Entailment"
    },
    "5feb2522-300c-490a-be54-07b2c99d397e": {
        "text_answer": "  The statement have difficulty moving arm side to side is a question about whether an individual experiences or experienced difficulty moving their arm from side to side is not entailed in the given trials as there is no mention of any adverse event related to difficulty moving the arm from side to side in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "145683a3-f65e-4b4d-98e0-662cbe830c5d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does specify a treatment cycle of 21 days for both intervention arms The secondary trial also specifies a 2week cycle for imaging procedures but this is not the intervention itself Therefore the statement is incorrect in suggesting that the primary trial does not employ any cycle for its intervention",
        "label": "Entailment"
    },
    "a020a0f1-c729-44ea-a40e-2700cc846d67": {
        "text_answer": "  The given statement those diagnosed with early stage nonhodgkin lymphoma considering radiation therapy are eligible for the primary clinical trial is not entailed in the inclusion and exclusion criteria provided for the breast cancer clinical trial The statement pertains to a different type of cancer nonhodgkin lymphoma and a different type of treatment radiation therapy than the clinical trial described in the criteria Therefore the statement is neither",
        "label": "Contradiction"
    },
    "cccd9ad0-9bac-43fb-aaaf-8f99e725c572": {
        "text_answer": "  The statement Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time is an entailment with respect to the given trials as it is explicitly stated as an exclusion criterion in the primary trial under the Inclusion and Exclusion Criteria section for the primary trial Therefore if a patient is enrolled in the secondary trial they cannot meet the inclusion criteria for the primary trial due to this exclusion",
        "label": "Entailment"
    },
    "f8accdcd-5a92-4fff-9e6b-6a2d141b5ee4": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial is a consequence of the exclusion criteria mentioned in the trial description The exclusion criteria state that Patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are not eligible for the study While the statement in the question specifically mentions severe anaphylactic reactions",
        "label": "Entailment"
    },
    "c5f69124-61d3-46bc-b233-5c38f4b1f5d0": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial had patients experiencing less than 3 separate aes is not directly entailed in the given data The data only provides the number and types of adverse events for each patient in each trial but it does not specify how many separate adverse events each patient experienced Therefore based on the given data alone it is impossible to determine if any patient in either trial had less than 3 separate adverse events",
        "label": "Contradiction"
    },
    "29bfa3a7-a8f2-4294-b745-d125cac8e40f": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is not directly related to the information provided about adverse events in the trials The statement only mentions unexpected deaths and hospitalizations while the trials only report adverse events including lymphoma cases without specifying whether they resulted in deaths or hospitalizations Therefore the statement cannot be determined to be entailed or contradicted based on the given information",
        "label": "Contradiction"
    },
    "cee38f66-699d-4c68-85ec-8ed0ba55fd9d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the intervention includes the administration of a single drug gefitinib ZD1839 whereas in the secondary trial there are two interventions Zoledronic acid with vitamin D and calcium supplements and Zoledronic acid with vitamin D calcium supplements Sr89 or Sm153",
        "label": "Entailment"
    },
    "a171374b-4c87-4b1a-94f9-8f0238cdce4f": {
        "text_answer": "  The statement is entailed in the trial description as the study participants receive epirubicin cyclophosphamide docetaxel and trastuzumab during the course of the neoadjuvant therapy",
        "label": "Entailment"
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "text_answer": "  The statement is entailed in the secondary trial inclusion criteria as it requires patients to have a diagnosed alteration in one or more of the listed genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ or GNA11 to be included in the trial",
        "label": "Entailment"
    },
    "5ee999ab-5129-4ea2-a988-b2a223d82acd": {
        "text_answer": "  The statement is entailed in the given trial information as both the placebo and memantine interventions have an identical frequency and duration of administration PO BID for 12 weeks",
        "label": "Entailment"
    },
    "8563b314-6b0f-432c-9ffc-203c3dcb0a3f": {
        "text_answer": "  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID grade 1 anal mucositis ctcae is asymptomatic or mild symptoms intervention not indicated is neither entailed nor contradicted by the given trials   The primary trial does not provide information about the use of Fulvestrant",
        "label": "Entailment"
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "text_answer": "  The statement Coronary artery stenosis are the most common AE recorded in the primary trial is contradictory to the given data The most common adverse event recorded in the trial was nausea or vomiting each occurring in 392 of the participants No adverse event related to coronary artery stenosis was reported in the given data",
        "label": "Contradiction"
    },
    "478be8bf-505c-44ed-98d6-41b48ab8d9b3": {
        "text_answer": "  The statement cohort 2 from the secondary clinical trial demonstrated superior outcomes compared to the same cohort from the primary clinical trial is not directly entailed in the given trials as there is no common cohort or outcome measure between the two trials The first trial focuses on the effectiveness of a peer support program on breast cancerspecific quality of life while the second trial evaluates the efficacy of a device in addressing positive margins during surgery Therefore",
        "label": "Contradiction"
    },
    "670ba789-279e-420d-b45e-c63836169e9b": {
        "text_answer": "  The statement in the primary trial results there were less patients with stable disease in week 20 than week 34 but 10 patients with complete response in week 20 or 34 is not directly entailed in the given trial results as the trial results do not provide information about the number of participants with stable disease in week 20 or week 34 and the statement makes a comparison between the two time points that is not explicitly stated in",
        "label": "Contradiction"
    },
    "a55a8c7f-7e1a-4bd4-8f2b-9222002f5d27": {
        "text_answer": "  The statement is entailed in the trials as the interventions being tested in each trial are different In the primary trial patients receive eribulin mesylate while in the secondary trial patients receive either axitinib  docetaxel or docetaxel  placebo These are distinct interventions and therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "fea6712a-10d7-47bb-88d1-d286e0ba47a1": {
        "text_answer": "  The statement In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30 of participants is not entailed in the given trials as there is no information provided in the trials about the percentage of participants experiencing adverse events in both trials The statement is contradictory to the given trials as there are no adverse events reported in more than 30 of participants in either trial",
        "label": "Contradiction"
    },
    "543c8639-a266-42af-9896-05a77d822c79": {
        "text_answer": "  The statement notable disparities were evident in the assessment of groups in the primary clinical trial on the contrary uniform results were recorded between the reflexology group and control group in the secondary clinical trial is a comparison statement between the two trials   To determine if this statement is entailed in the trials we need to compare the trials in terms of their outcomes and participants   In the primary clinical trial there were two armsgroups F",
        "label": "Entailment"
    },
    "8b7bbb44-a7d7-4317-af85-f78d559e0e63": {
        "text_answer": "  The statement is contradictory to the trials provided   In the primary trial the intervention cabergoline is given orally which is not the same as being given solely via a needle or tube inserted into a vein intravenous or IV  In contrast both interventions in the secondary trial Arm I and Arm II involve IV administration of pixantrone dimaleate Therefore the statement that the primary trial",
        "label": "Entailment"
    },
    "782c9a26-ba09-4eef-8076-bd8831c9f986": {
        "text_answer": "  The statement patients with a confirmed diagnosis of leptomeningeal carcinoma can participate in the primary clinical trial is contradictory to the given trials eligibility criteria The trial explicitly states that No meningeal carcinomatosis is a requirement for participation Leptomeningeal carcinoma is a type of meningeal carcinomatosis so patients with this diagnosis would not meet the eligibility",
        "label": "Contradiction"
    },
    "5e5c4aab-2006-4a00-b11c-3dced5aac12c": {
        "text_answer": "  The statement is entailed in the trials as given in the problem statement The trials explicitly state that in the first cohort participants receive the pneumococcus vaccine and in the second cohort participants receive the influenza vaccine Therefore the statement that in the first cohort of the primary clinical trial participants are given the pneumococcus vaccine whereas the influenza vaccine is administered to those in the second cohort",
        "label": "Entailment"
    },
    "db08ca44-cd18-49ff-ae80-4a3f0bb625b5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement claims that 50 adverse events were observed in the primary trial but the primary trial actually reported 0 adverse events Additionally the statement mentions that none of the adverse events in the secondary trial affected more than 20 of patients apart from skin infections but the secondary trial reported a total of 11 adverse events affecting 33",
        "label": "Entailment"
    },
    "8559afe8-c0a0-4c88-81bb-ef29cdb08026": {
        "text_answer": "  The statement instances of pain were frequent among the primary clinical trial patients across the 10 week span is not directly entailed in the given trial results as they only report the average pain intensity scores and the difference between the lowdose and highdose groups but they do not provide information about the frequency or number of instances of pain reported by the patients during the study",
        "label": "Contradiction"
    },
    "8679e654-7db4-4fd2-8fbc-41028fedb540": {
        "text_answer": "  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is a contradiction to the given trials as the trials do not provide sufficient information to make that determination The trials only report the number and percentage of adverse events for each trial but they do not provide the total number of participants in each trial or the number of participants who experienced each specific adverse event Therefore it",
        "label": "Contradiction"
    },
    "2dfe7dda-41ae-48bc-aac5-1309cb87e4c1": {
        "text_answer": "  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent surface immunoglobulinpositive cells present is a microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of cells in a sample is not directly entailed in the given inclusion and exclusion criteria for both trials   The statement mentions surface immunoglob",
        "label": "Contradiction"
    },
    "4703e57c-efe0-4316-a1a5-8ac60b030e84": {
        "text_answer": "  The statement recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were more frequently observed as adverse events in the primary clinical trial compared to the secondary clinical trial is entailed in the given trials data  Explanation  The statement is entailed because the primary trial had a higher frequency of these adverse events compared to the secondary trial Specifically the",
        "label": "Entailment"
    },
    "17adb81b-92e7-4ed5-b443-287a5df2fb37": {
        "text_answer": "  The given statement is not entailed in the provided information about the primary clinical trial The trial description only mentions the administration of chemotherapy regimens AC and TAC and bevacizumab for different durations for HER2negative participants It does not mention the use of her2neu peptide vaccine in combination with sargramostim gmcsf for any of the trial interventions",
        "label": "Contradiction"
    },
    "be4a58c2-e939-4583-a129-2d0bdba8e3a8": {
        "text_answer": "  The statement is entailed in the trials as both trials are focused on assessing adverse events in participants receiving HER2targeted therapies The primary trial evaluates the toxicity of infusing HER2specific T cells using the NCI CTCAE v30 while the secondary trial reports the percentage of participants with adverse events of primary interest AEPIs related to trastuzumab emtansine Both trials are investig",
        "label": "Entailment"
    },
    "f180c18c-f332-4f6b-9367-c349d3518d55": {
        "text_answer": "  The statement in cohort 2 of the primary clinical trial there were no instances of death or hospitalization with only a single occurrence of atrial fibrillation is not directly entailed in the given trials data as there is no cohort 2 specified in the trials data However the statement is consistent with the trials data as cohort 2 had no instances of death or hospitalization according to the given data  Therefore",
        "label": "Contradiction"
    },
    "cedccbca-876d-44b2-bf5a-9c9c5090d46c": {
        "text_answer": "  The statement no adverse events were reported in either of the cohorts involved in the primary clinical trial is entailed in the given trials data as both cohorts have a total of 0 adverse events reported out of 60 participants each resulting in a 000 adverse event rate for each cohort",
        "label": "Contradiction"
    },
    "773e93d2-a81d-48cd-96ec-4b92d537ac35": {
        "text_answer": "  The statement in the primary clinical trial HER2 metastases emerged in 13 of the subjects having HER2positive primary breast cancer who were treated with HER2targeted PETCT using 89Zrtrastuzumab is entailed in the trial results as stated Results 1 ArmGroup Title HER2targeted PETCT Overall Number of Participants",
        "label": "Entailment"
    },
    "a546a2b7-a287-47a1-91b1-4368fef15369": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial the dosage of Zoledronic Acid used in intervention 1 is 4 mg Q4W while in the secondary trial no dosage information is provided for Denosumab in intervention 1 However the dosage of Denosumab used in intervention 2 of the secondary trial is 120 mg Q4W which is the same as",
        "label": "Contradiction"
    },
    "cacd8f36-53c3-4002-9d2d-09bd2976bf40": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets the following inclusion criteria  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed including CBCdifferential  Age of 18 years or older  Zubrod performance status 02  Patient may have received prior oral bisphosphonate therapy  The patient also meets the inclusion criteria for the",
        "label": "Entailment"
    },
    "f6dee97d-0025-4837-97a5-dc7748b859a0": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial the dosage of bevacizumab for cohort 1 and cohort 2 is different Cohort 1 does not receive a uniform dosage of 5 mgkg of bevacizumab as stated in the given statement",
        "label": "Entailment"
    },
    "aac508e7-cd87-40ad-afa6-bc977ab393aa": {
        "text_answer": "  The statement there was a complete absence of both gastrointestinal adverse events and psychiatric events in the primary clinical trial is contradicted by the given data in Trials 1 and 2   Explanation   The statement asserts that there were no gastrointestinal GI adverse events such as nausea vomiting and no psychiatric events not mentioned explicitly in the data",
        "label": "Contradiction"
    },
    "2ca3ca9f-96ac-46e7-a1ce-873c580eff25": {
        "text_answer": "  The statement 14 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is contradictory to the given data in the trials   In the first trial there was one patient out of 13 who experienced increased pleural effusion but no patient experienced both increased pleural effusion and rapid disease progression In the second trial there was one patient out of 4 who experienced increased ple",
        "label": "Contradiction"
    },
    "7c60cd27-5e72-4cd6-9e2c-de28c0c11fe4": {
        "text_answer": "  The statement that a 32yearold patient with histologically verified diagnosis of stage three breast cancer an absolute neutrophil count of 1807000 cellsml a platelet count of 110034000 cellsml a hemoglobin level of 009 kgm3 and a life expectancy exceeding 8 months would be eligible",
        "label": "Entailment"
    },
    "64a7bb90-c51d-4f6b-942e-55322c25e1b8": {
        "text_answer": "  The statement is entailed in the trials as both groups undergo identical PETCT imaging procedures using 18FFDG and 18FFPPRGD2 with the only difference being the timing and the slightly higher dose of 18FFPPRGD2 in the first cohort Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "text_answer": "  The statement Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial the final decision for inclusion will be made by the patients first of kin is neither entailed nor contradicted by the information provided in the trials inclusion and exclusion criteria  The trials inclusion and exclusion criteria only specify the medical conditions and requirements for a patient to be eligible for the study They do not address who has the authority to make the final decision regarding",
        "label": "Entailment"
    },
    "ac762601-55f3-434a-bf5a-690ed8a3f735": {
        "text_answer": "  The statement within the primary clinical trial a quarter of cohort 2 patients experience an increased occurrence of pleural effusion is entailed in the given trials data as follows  Adverse Events 2   Total 14 2500   Rapid disease progression  104 000   Increased pleural effusion  21",
        "label": "Entailment"
    },
    "25b0a430-e35c-496c-8874-92be378b044b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial measures the change in isothiocyanate in urine samples while the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale There is no mention of blood pressure level being used as a measure of effectiveness for physical therapy in the secondary trial",
        "label": "Contradiction"
    },
    "14e1403f-9bb6-40cc-88fe-4b2f110e7b0d": {
        "text_answer": "  The statement as part of the intervention daily administration of 1000 mcg of talazoparib is carried out for several candidates in the primary clinical trial is not directly entailed in the given trial description The trial description mentions that patients are eligible for the study if they are older than 70 years and have been diagnosed with certain types of cancer and that they undergo a multidimensional assessment It also mentions that talaz",
        "label": "Contradiction"
    },
    "5b23afbf-8b5c-441b-99b2-295c66958545": {
        "text_answer": "  The statement is entailed in the Trials as follows  Both trials exclude women with severe claustrophobia Therefore the statement the primary and secondary clinical trials do not admit participation from women having claustrophobia is entailed in the trials  However the statement does not directly address the exclusion of osteoporosis in the primary trial The primary trial excludes women with renal impairment",
        "label": "Entailment"
    },
    "ca97cc92-91e7-426a-b48f-d1729f13ee13": {
        "text_answer": "  The statement the patient with the most extended PFS in the primary clinical trial endured 4 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in an individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "3d073609-1a5e-46fb-b43d-c4505c72029d": {
        "text_answer": "  The statement patients with a past diagnosis of pulmonary embolisms are welcomed to participate in the secondary trial and those with breast implants are not disqualified from the primary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials  The primary trial excludes participants with a history of clotting disorders but it does not specifically mention pulmonary embolisms Therefore the statement about pul",
        "label": "Contradiction"
    },
    "d1bbbc84-4136-43c4-b7b6-7e88e7c82730": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement asserts that every cohort in the primary clinical trial is subjected to the same volume and frequency of docetaxel doxorubicin and cyclophosphamide However the trials describe two different interventions  1 Intervention 1 ACT DoxorubicinC",
        "label": "Entailment"
    },
    "7a4a1281-d17b-4ad5-aa63-7329abdd0cdd": {
        "text_answer": "  The statement there were fewer cases of infection asymmetry and deflation in the primary trial compared to the secondary trial is entailed in the given trials if and only if the following conditions are met  1 The number of cases of infection asymmetry and deflation in the secondary trial is greater than or equal to the number of cases in the primary trial for each adverse event 2 The primary trial has fewer cases of each adverse event than",
        "label": "Entailment"
    },
    "ca7d916d-c8d4-4e6b-8b92-3d08bbdf7915": {
        "text_answer": "  The statement ce mark is a label which indicates that a product conforms with the essential requirements of the applicable european community directives is not related to the trials provided and does not entail or contradict any information in the trials The trials only provide information about the design and outcomes of two separate clinical studies",
        "label": "Entailment"
    },
    "1fde2a5a-bf6c-41cf-ba82-7cbea262f258": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections of 120 milligrams every 4 weeks which is equivalent to 480 milligrams per month In contrast the statement in the question incorrectly states that patients in the primary trial received 1200 milligrams of denosumab per month  Regarding",
        "label": "Entailment"
    },
    "52ab8ce2-300e-40db-be56-d6e7c608324e": {
        "text_answer": "  The statement an adult who was diagnosed with ilddpld in the past three years who has an estimated survival time of six months will qualify for the primary clinical trial is not directly entailed in the inclusion criteria provided in the trial description   The inclusion criteria state that patients must have histologically or cytologically confirmed metastatic invasive breast cancer that is negative for the estrogen receptor ER progesterone receptor PR",
        "label": "Contradiction"
    },
    "5c9037a6-53a8-49ec-8aa5-b6a47dee226d": {
        "text_answer": "  The statement is not directly entailed in the given information from the primary clinical trial However it is mentioned that the doses of nabPaclitaxel are the same in both arms 125 mgm2 on Days 1 and 8 but the companion drugs differ gemcitabine in Arm A and carboplatin in Arm B The statement implies that different cohorts are prescribed varying doses of Abrax",
        "label": "Contradiction"
    },
    "f212e510-214f-4556-99ed-526946750f55": {
        "text_answer": "  The statement The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention regardless of cancer type is entailed in the trials provided   Explanation   The trials show that a significant increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings occurred in both the Collaborative Care Intervention CCI",
        "label": "Entailment"
    },
    "7e311c72-64a8-49e8-b3c7-952528a9138c": {
        "text_answer": "  The statement a woman with no history of any type of cancer treatments is an ideal participant for both the primary trial and the secondary trial is contradictory to the inclusion criteria of both trials  Explanation  The primary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy and patients must not have undergone autologous tissue breast reconstruction and intend to undergo implant only breast reconstruction However the statement suggests that the",
        "label": "Contradiction"
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "text_answer": "  The statement Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial is entailed in the trials as it is mentioned in the exclusion criteria for both trials  In the primary trial the exclusion criteria include  Congestive heart failure  Clinically significant cardiac arrhythmia  History or current evidence of a myocardial infarction during the last",
        "label": "Entailment"
    },
    "1adf360d-dd5e-4bbd-b5f1-8846f84407a6": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II portions Primary Trial  The secondary trial has the same inclusion and exclusion criteria for all participants Secondary Trial  The statement is an entailment because the primary trial having different inclusion and exclusion criteria for its phases implies that there are different sets of criteria while the secondary",
        "label": "Entailment"
    },
    "829b14c1-9883-4dc4-93f9-40eadb9f9511": {
        "text_answer": "  The statement is entailed in the trials as the primary trial involves whole breast radiation therapy which is not mentioned in the secondary trial However the secondary trial mentions intramuscular injections for Fulvestrant and oral administration of Enzastaurin for both cohorts Therefore the statement that whole breast radiation therapy is administered to the participants of the primary clinical trial whereas both cohorts in the secondary clinical trial receive intramuscular",
        "label": "Entailment"
    },
    "8044ce4d-99e5-4c90-91aa-9c0c85f2c6b4": {
        "text_answer": "  The statement each group in the primary clinical trial had an equal number of participants is neither entailed nor contradicted by the given information The trials describe the same number of participants 1420 in each arm but the statement specifically requires that the number of participants be equal in every sense not just in total Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "3942fcf8-27c3-469e-8c6c-b9b2415706fb": {
        "text_answer": "  The statement Patients with measurable tumors in both breasts are excluded from the primary trial is entailed in the trial as it is explicitly stated in the inclusion criteria that unilateral breast cancer is a requirement for participation in the study  The statement ejection fraction decreased is a finding indicating a decrease in the volume of blood ejected during ventricular heart contraction is not directly related to the trial as it does not pertain to",
        "label": "Entailment"
    },
    "21e02160-3372-4816-93d2-b3923672111b": {
        "text_answer": "  The statement the majority of the participants in the primary clinical trial evidenced a decrease in circulating tumor cells after undergoing radiotherapy is not entailed in the given trial results as the trial did not involve radiotherapy The trial only reported the use of highdose chemotherapy with Carboplatin Cyclophosphamide Thiotepa and stem cell transplant",
        "label": "Contradiction"
    },
    "060ed756-52f8-4b31-ad74-6f6f12d8ca9f": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is investigating the effect of two different interventions Hydrophor and MediHoney on the healing of radiation therapy sites This is an investigation of various doses or interventions on a study group as stated in the statement  The secondary trial is investigating the impact of two different radiation therapies Arm A1 and Arm A2 on participants with CRPC",
        "label": "Entailment"
    },
    "666ca16f-864e-48b1-9e5e-543759d50b4a": {
        "text_answer": "  The statement candidates who are completely independent and physically active engaged in light work activities for long hours are eligible for both primary clinical trial and secondary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for the primary and secondary trials   The statement does not directly address the specific cancer types performance status measurability of disease or prior treatment history required for each trial Additionally the statement does not mention any exclusion",
        "label": "Entailment"
    },
    "7d7cfab4-e501-4292-bf9c-363ccc1bf1dd": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORR and the number of participants in each group   According to the given trials the ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 with 94 participants analyzed and for the Paclitaxel Plus Bevacizumab",
        "label": "Entailment"
    },
    "00175c56-59cd-411d-b4e4-b7db0e32fd74": {
        "text_answer": "  The statement Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial is entailed in the trials inclusion criteria The trial includes patients with histologically proven DCIS who are considering aromatase inhibitor therapy Therefore the statement is entailed in the trials eligibility requirements  The statement Patients with childhood atypical choroid plexus papilloma are eligible",
        "label": "Entailment"
    },
    "5b812594-3dcd-42e8-b984-644fe9dcd87e": {
        "text_answer": " The primary trial does not provide sufficient information to determine if the statement is entailed in the trials or not The trials only report the number of hot flashes per 24 hours for each group but they do not report the number of treatment emergent adverse events or serious treatment emergent adverse events for each group Therefore it is not possible to make a definitive statement about which group had fewer instances of these events based on the information provided",
        "label": "Entailment"
    },
    "96eb2d8a-35d7-4627-9279-5f16363a2e50": {
        "text_answer": "  The statement uterine corpus neuroendocrine tumor G1 is a very rare and welldifferentiated neuroendocrine tumor that arises from the uterine corpus Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is not directly entailed in the given trials as they do not provide enough",
        "label": "Contradiction"
    },
    "5e2af84e-3876-4822-80c3-99c7774a5bf9": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial deals with oral pregabalin and the secondary trial deals with intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt The medications and their administration routes are different in both trials",
        "label": "Contradiction"
    },
    "97632c52-4213-4973-8655-9ea7f3151231": {
        "text_answer": "  The statement on both the primary and secondary clinical trials syncope emerged as the most common adverse occurrence in the patient groups is a contradiction to the information provided in the trials   The statement implies that syncope was the most frequent adverse event in both trials However the primary trial reported that syncope occurred in 2 out of 12 patients 1667 while the secondary trial reported no occurrences of syn",
        "label": "Contradiction"
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "text_answer": "  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is a contradiction based on the given data   Explanation   The statement is a contradiction because there is one adverse event Thromboembolic Event that is present in the secondary trial but not in the primary trial Therefore some patients in the secondary trial suffered from an adverse event that was",
        "label": "Contradiction"
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "text_answer": "  The statement all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group is not directly entailed in the given trials as the trials only report the mean standardized scores and their standard deviations for each group but they do not provide information about the distribution of the scores or the individual cognitive function changes for each participant Additionally the trials do not report any statistical tests or significance levels to support the statement",
        "label": "Contradiction"
    },
    "72e970ee-fc31-4753-99be-b6757c4c270d": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention is carried out exclusively through intravenous injection cabergoline is given orally but it is not the intervention being referred to in the statement  In the secondary trial there is no oral intervention mentioned in Intervention 1 or Intervention 2 Both interventions are intravenous administrations of pixantrone dimaleate  Therefore",
        "label": "Entailment"
    },
    "5315a569-b1a1-49fc-b10f-70840fe34585": {
        "text_answer": "  The statement There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial is entailed by the given trials as both trials report a total of 0 adverse events for Intestinal obstructions and Pancytopenia  The statement human papillomavirus35 positive is an indication that human papillomavirus35 has been detected in a",
        "label": "Contradiction"
    },
    "da3b7aca-a0b1-4e25-8c38-11dc8311dc11": {
        "text_answer": "  The statement Women suffering from both claustrophobia and osteoporosis are not eligible for either the primary trial or the secondary trial is entailed in the given trials as  1 Women with osteoporosis are excluded from the primary trial 2 Women with claustrophobia are excluded from the secondary trial  Therefore a woman who suffers from both conditions osteopor",
        "label": "Entailment"
    },
    "f41cbb25-7c8f-49ac-af06-5c8f1895ab60": {
        "text_answer": "  The given statement is not entailed in the trials as there is no mention of Tumour lysis syndrome in either the primary or secondary trials Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "7df66c3f-de87-4542-9797-06325684db65": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial has no adverse events recorded for adrenal gland lymphangioma while the secondary trial also has none recorded Therefore the statement is not entailed by the trials",
        "label": "Contradiction"
    },
    "a764d548-7ef1-4ec1-bfaf-958536b7342c": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is focused on hormonal interventions with Estring and Testosterone Cream while the secondary trial is testing an acupuncture intervention The statement correctly identifies the types of interventions being used in each trial  The statement also mentions wwtr1 gene rearrangement which is not directly related to the interventions being tested in the trials However the statement",
        "label": "Entailment"
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial is using vaginal interventions with Estring and Testosterone Cream while the secondary trial is using acupuncture which is not a topical inhalation intervention",
        "label": "Entailment"
    },
    "48e84575-b6e1-4280-a170-df30870b50cf": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that cohorts 1 and 2 receive the same dosage and frequency of CUDC101 but cohort 1 receives additional weekly doses of PD0332991 However the trials do not mention any information about the use of PD0332991 in either",
        "label": "Entailment"
    },
    "e173aa91-e6ec-4059-882b-7f015db6e3b3": {
        "text_answer": "  The statement regular exercise is not part of the intervention procedure for candidates of the primary clinical trial is entailed in the given trial description as there is no mention of regular exercise as an intervention or part of the procedure in the provided information",
        "label": "Entailment"
    },
    "922b377f-efa2-4bee-9689-f019c011057e": {
        "text_answer": "  The statement is entailed in the trials as both cohorts follow the same instructional CD for paced breathing The difference between the two cohorts lies in the frequency of practice once daily for cohort 1 and twice daily for cohort 2 The statement does not contradict the trials as it correctly identifies the shared instructional material and the difference in practice frequency",
        "label": "Entailment"
    },
    "11fd1d6e-0641-4b3d-91ff-9f048584db7b": {
        "text_answer": "  The statement the primary clinical trial is available to individuals with frontotemporal or mixed dementia is contradictory to the inclusion criteria of the trial The inclusion criteria state that subjects must have no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment Frontotemporal and mixed dementia are types of dementia Therefore individuals with these conditions",
        "label": "Contradiction"
    },
    "c6d411f9-3d61-459e-b1af-6d8088260804": {
        "text_answer": "  The statement is entailed in the trials Both cohorts use the same instructional CD for paced breathing so they follow the same instructions for the breathing technique The difference between the two cohorts lies in the frequency of the practice sessions per day with cohort 2 having double sessions This does not affect the content of the instructional CD which is the same for both groups Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "145b92f4-e143-4188-9521-8aade35b2f05": {
        "text_answer": "  The statement Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial is a contradiction to the given data   The statement does not follow from the information provided in the trials as there is an adverse event Thromboembolic Event in the secondary trial that is not present in the primary trial However the statement does not contradict the data directly as there are no common adverse events",
        "label": "Contradiction"
    },
    "6e609d6e-8db0-4adc-bce7-62f7274c10c2": {
        "text_answer": "  The statement is entailed in the Trials as follows  Both trials provide uniform criteria for inclusion and exclusion for all participants The primary trial has different inclusion criteria for different patient groups Phase I and Phase II but the criteria for each group are clearly defined and consistent within that group The secondary trial has the same inclusion and exclusion criteria for all participants regardless of age Therefore the statement is entailed in the trials as they both apply uniform criteria for",
        "label": "Entailment"
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "text_answer": "  The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is entailed in the trials inclusion criteria   Explanation   The primary trials inclusion criteria state that one of the disease characteristics for enrollment is Any tumor type if tissue tests positive for CCND1 amplification CDK46 mut",
        "label": "Entailment"
    },
    "8acda3ec-8feb-4630-a560-3e66f86c3f21": {
        "text_answer": "  The statement 097 of patients in the primary trial did not experience any adverse events is not entailed in the given trial information   The trial results only provide the percentage of subjects who completed the treatment protocol without specifying the absence of adverse events The statement goes beyond the information given in the trial results",
        "label": "Contradiction"
    },
    "e25dfb6a-efaf-4b80-b2b7-316e10b33fe5": {
        "text_answer": "  The statement is not directly entailed in the given trials as it goes beyond the provided information The statement mentions none of the adverse events in the secondary trial affected more than 30 of patients which is a conclusion drawn from the data but it does not directly address the presence or absence of adverse events related to cell culture images in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "c0131f92-6373-48c8-9bd5-8d4a42f6674e": {
        "text_answer": "  The statement distinct variations were noted in the results from the primary trial groups whereas the reflexology group and the control group had indistinguishable results in the secondary trial is a comparison statement between the two trials   To verify the entailment or contradiction of this statement with the given trials we need to compare the results of the primary trial regarding diagnostic accuracy of two mammography algorithms and the secondary trial regarding the Lee Fatigue Scale in",
        "label": "Entailment"
    },
    "e0d92d90-958e-435b-bb1b-7135ed0b2fac": {
        "text_answer": "  The statement the majority of patients in the primary trial experienced complete response by the 24th week is contradicted by the trial results   Explanation   According to the trial results there were no participants with complete response CR at either Week 12 or Week 24 Therefore the majority of patients did not experience complete response by the 24th week",
        "label": "Contradiction"
    },
    "136ce42e-bf56-41ff-aed9-fe886636bc1c": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions is not directly entailed in the given trial results   The trial results only provide information about the change in symptoms aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale in two arms of the study Arm I Cryotherapy",
        "label": "Contradiction"
    },
    "6af06fcc-363f-4275-81f3-8a01c53931e8": {
        "text_answer": "  The statement women recently diagnosed with stage 4 breast cancer that is ERpositive and considering mastectomy are eligible for participation in both the primary clinical trial and the secondary clinical trial is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed ",
        "label": "Entailment"
    },
    "1607973a-34ef-455a-b52b-55ea7aaf6634": {
        "text_answer": "  The statement is entailed in the given trials as there is no mention of cardiac or psychiatric adverse events in either trial and the normalization basis is not relevant to the statement",
        "label": "Entailment"
    },
    "e012d94f-ee90-40b0-9a4d-e41ec19a512d": {
        "text_answer": "  The statement There were no significant differences in the results from the groups in the primary trial however some differences where found between the Reflexology Group and control group results in the secondary trial is a contradiction to the information provided in the trials  In the primary trial there were no significant differences in the AUC between the LIP and SIP algorithms difference in means 0004 95 CI 0",
        "label": "Contradiction"
    },
    "04d9baea-cc4c-4903-9769-3df78659a73f": {
        "text_answer": "  The statement soft tissue disorder is a nonneoplastic or neoplastic disorder that affects the soft tissue is not directly related to the information provided in the primary and secondary trials The primary trial evaluates the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 while the secondary trial reports the percentage of participants with adverse events of primary interest A",
        "label": "Entailment"
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "text_answer": "  The statement The same number of Aes were reported for both cohorts in the primary trial is contradicted by the given data   Explanation   The statement is not entailed in the trials as the number of adverse events reported is different between the two cohorts In the first cohort there were 2 adverse events reported out of 4 patients while in the second cohort there were 2",
        "label": "Contradiction"
    },
    "1eab7c47-2c2a-4746-935b-c3e8891f8a26": {
        "text_answer": "  The statement is contradictory to the information provided in the inclusion criteria for both trials   In the primary trial the inclusion criteria state that candidates must have a Karnofsky score of 70 In the secondary trial the inclusion criteria state that patients must have a Zubrod performance score of 2 or better which is equivalent to a Karnofsky score of 60 or higher Therefore neither trial requires a Karnofsky score",
        "label": "Entailment"
    },
    "cb3fa68b-c881-4a32-a80f-303e46360d8c": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants with disease progression or death in each group   From the given trials we have  1 Bevacizumab group 883 of participants experienced disease progression or death 2 Bevacizumab  Capecitabine group 758 of participants experienced disease progress",
        "label": "Entailment"
    },
    "a328634e-824e-413c-a408-ad471e394a07": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial but only female patients are eligible for the secondary trial is a contradiction to the information provided in the trials inclusion and exclusion criteria  In the primary trial the inclusion criteria state that both male and female subjects are eligible but the femalespecific inclusion criteria apply only to postmenopausal females The exclusion criteria do not mention gender  In contrast",
        "label": "Contradiction"
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "text_answer": "  The statement There are no conditions on hepatic function for participants of the primary trial is not directly stated in the given inclusion and exclusion criteria However it is implied since there is no mention of liver function as a condition for participation in the trial Therefore the statement is entailed by the information provided in the trial description",
        "label": "Contradiction"
    },
    "c5c7b6e2-201f-42af-aeb3-3e3152fa0ba2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants received a loading dose of 4 mgkg followed by 2 mgkg per week This equates to a total of 10 mgkg of trastuzumab per cycle  In cohort 2 of the secondary trial participants received Herceptin 4 mgkg on Day 1 of Cycle 5",
        "label": "Entailment"
    },
    "a44d4aaf-a761-46a1-a803-63d6ede293a5": {
        "text_answer": "  The statement The secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is a factual statement that can be verified by comparing the number of cases of Intestinal perforation in each trial   The statement does not directly relate to the percentage relief from pain treatment or medication score Therefore it is neither entailed nor contradictory to that statement   However the statement itself is entailed by the",
        "label": "Entailment"
    },
    "e682eada-bed5-4ea5-847a-cbfdb44ef724": {
        "text_answer": "  The statement is not entailed in the trials provided as there is no mention of diabetes as an adverse event in either the primary or secondary trials The statement is incorrect",
        "label": "Contradiction"
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve 20 transendocardial injections of a volume of 04ml each However it is important to note that the substance being injected differs between the two interventions alloMSCs versus Buminate solution The statement only addresses the dose and method of administration not the identity of the substance",
        "label": "Entailment"
    },
    "775258b4-fe6f-4487-a162-ce25e5a665c0": {
        "text_answer": "  The statement patients diagnosed with Alzheimers disease are eligible for the primary clinical trial is contradictory to the trials inclusion criteria The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Alzheimers disease is a progressive neurodegenerative disorder characterized by a decline in cognitive function and memory impairment which would result",
        "label": "Entailment"
    },
    "86e418cd-3b9d-46fd-b699-c538a29e7c03": {
        "text_answer": "  The statement is contradictory to the secondary trial information provided The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial lasted for 24 weeks Therefore the statement that the intervention in the secondary trial last the same duration as the intervention detailed in the primary trial is not entailed in the trials",
        "label": "Contradiction"
    },
    "d65c3fe7-21a9-484a-a225-1ed3c5e66b5e": {
        "text_answer": "  The statement candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments duodenal band is a pathologic fibrous band that impedes passage of intestinal contents through the duodenum is contradictory to the given inclusion and exclusion criteria for the primary trial   The inclusion criteria state that candidates must have breast cancer that has continued to grow after receiving hormonal treatment requiring hormonal treatment",
        "label": "Entailment"
    },
    "b971e3aa-d16a-4cca-8a69-c3e9793ada80": {
        "text_answer": "  The statement patients with t2 n2 m2 tumors meet the requirements for participation in the primary clinical trial is not directly entailed or contradicted by the given trial eligibility criteria   The trial eligibility criteria specify that the disease must be histologically confirmed breast cancer with certain characteristics including hormone receptor status The criteria also specify patient characteristics prior therapy and other conditions However the trial eligibility criteria do not explicitly",
        "label": "Contradiction"
    },
    "48ec9126-f671-47ea-a1bd-71a228b20420": {
        "text_answer": "  The statement in the first cohort of the primary clinical trial pancytopenia was a prevalent condition while anaemia and febrile neutropenia were absent is contradicted by the given data in the Trials 1  Explanation  The statement implies that in the first cohort of the primary clinical trial pancytopenia was the only adverse event that occurred and anaem",
        "label": "Contradiction"
    },
    "8d748876-a5b3-4f80-9f87-de9bec532074": {
        "text_answer": "  To determine if the statement better results were observed in the primary clinical trials bevacizumab cohort as compared to the bevacizumab  capecitabine cohort is entailed in the trials we need to compare the percentage of participants with disease progression or death in each cohort  The percentage of participants with disease progression or death in the Bevacizumab cohort was",
        "label": "Entailment"
    },
    "343f30bc-9b37-471a-83fc-76089ffc527c": {
        "text_answer": "  The statement less than 5 of patients in the primary trial suffered AEs Adverse Events is entailed in the trials since the total number of AEs reported was 2 and the number of patients in the trial was 35 Therefore the percentage of patients suffering from AEs is indeed less than 5  However the statement sellar chordoma is a chordoma that arises from the sellar region is",
        "label": "Entailment"
    },
    "677ea4a6-dee8-4a9f-ab36-68724aeb8237": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report different outcome measurements The primary trial reports Time to Progression in months while the secondary trial reports the percentage of participants with Objective Response based on RECIST criteria The statement does mention the use of Capecitabine in both trials but it does not follow that the information about ChildPugh Class B7 and the number of participants with CRPR in the secondary trial are directly related to",
        "label": "Contradiction"
    },
    "52e6f629-f30f-4f59-968f-6d6bcc8b14af": {
        "text_answer": "  The statement previously undergoing gabapentin or herceptin therapy within the previous year excludes a patient from the secondary clinical trial however it does not affect their inclusion in the primary clinical trial is a statement about the relationship between the inclusion and exclusion criteria of two different clinical trials   To determine if this statement is entailed in the given trials we need to examine the inclusion and exclusion criteria of both trials   Based on the provided",
        "label": "Entailment"
    },
    "31332603-d84d-4806-b8bf-4cdc08514591": {
        "text_answer": "  The statement 1417 of the primary trial patients suffered an increase in blood bilirubin is not directly entailed in the given trial data as the percentage mentioned in the statement is different from the percentage given in the trial data 3636 for all adverse events and 909 for blood bilirubin increase specifically However it is not contradictory to the trial data either as the percentage in the",
        "label": "Contradiction"
    },
    "b34700cb-eba7-431e-9508-75e49298d003": {
        "text_answer": "  The statement in the primary clinical trial 50 of participants experienced adverse events aes of various types is contradictory to the information provided in the trial data The trial data states that 3636 of participants experienced adverse events which is less than 50 Therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "a0f404c3-8323-4ef6-a986-04085778b751": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement asserts that both interventions are administered in the same dose by a single transendocardial injection However the trials clearly state that the placebo intervention involves 20 injections of 04ml Buminate solution while the AlloMSCs intervention involves 20 injections of 04ml alloMSCs Therefore",
        "label": "Entailment"
    },
    "2007fc0f-aa14-48a5-9db7-08d47f756757": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is entailed in the Trials as there are a total of 3 recorded gastrointestinal adverse events Vomiting 3149 in Trial 2 Therefore the statement is entailed in the trials  However the statement histone h2b gene is a gene encoding the core hist",
        "label": "Entailment"
    },
    "0a3eabb5-68f0-4534-834a-d3e75dbb733e": {
        "text_answer": "  The statement is entailed in the trials if we focus on the dosage of durvalumab given in the biweekly IV infusions The statement correctly identifies that the only difference between interventions 1 and 2 is the amount of durvalumab given per kg in the biweekly infusions 03 mgkg vs 1 mgkg Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "text_answer": "  The statement 13 of the primary trial participants with HER2 Primary Breast Cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed Imagable HER2 Metastases is entailed in the trial results if we assume that Imagable HER2 Metastases refers to the development of HER2positive metastases detectable by HER",
        "label": "Entailment"
    },
    "14b9aeb8-afd7-4a20-af71-153c33fc117b": {
        "text_answer": "  The statement candidates receiving warfarinbased therapy are allowed in the primary clinical trial but prohibited in the secondary clinical trial is a contradiction based on the provided inclusion and exclusion criteria  In the primary trial warfarinderivative anticoagulants are permitted for prophylactic or therapeutic use but lowdose warfarin less than or equal to 1 mgday is also permitted",
        "label": "Contradiction"
    },
    "4a688f54-5b9a-49ad-b6a1-833d1ff96924": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary clinical trial has different inclusion and exclusion criteria for its Phase I and Phase II portions On the other hand the secondary clinical trial has a unified set of inclusion criteria planned unilateral mastectomy with or without axillary dissection or sentinel node in the study period and informed signed consent and exclusion criteria chronicongo",
        "label": "Entailment"
    },
    "ff38ad83-d613-4797-a2a7-3b2e5e1a318d": {
        "text_answer": "  The statement is contradictory to the information provided in the primary clinical trial inclusion criteria as the primary trial explicitly includes patients with NUT midline carcinoma diagnosed by FISH and excludes patients with inflammatory breast cancer Therefore the statement is contradictory to the information provided in the primary trial and does not apply to it The secondary trial on the other hand does not mention NUT midline carcinoma or inflammatory breast cancer",
        "label": "Entailment"
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "text_answer": "  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent is entailed in the given trials as neither the primary nor the secondary trial explicitly state that patients with stage 4 cancer are excluded The inclusion criteria for both trials focus on patients with histologically verified diagnosis of breast cancer including stage IIbIIIIV and the eligibility is contingent upon the patient providing informed consent Therefore",
        "label": "Entailment"
    },
    "baf5c643-9960-4f2e-a9b4-70667a5ca685": {
        "text_answer": "  The statement Patients with a Vitamin D deficiency are excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given trials as there is no mention of Vitamin D deficiency or signet ring cell basal cell carcinoma in either trial However the statement is not contradictory to the trials as well since the trials do not provide sufficient information to determine a contradiction",
        "label": "Contradiction"
    },
    "3df24930-167f-4f53-a3e5-fb8205039848": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial specifically requires histologically or cytologically confirmed breast adenocarcinoma while the secondary trial requires histologic andor cytologic confirmation of metastatic disease if feasible The statement pertains to patients with histologically unverified early stage breast cancer which is not a specified inclusion criterion in either trial",
        "label": "Contradiction"
    },
    "ba84127e-5a18-4ff4-a76b-c19ba3edeeb0": {
        "text_answer": "  The statement is entailed in the trials if we consider the following  1 Both interventions involve the use of dexamethasone 2 Both interventions are administered intravenously 3 The difference lies in the timing of administration the first cohort receives dexamethasone preoperatively while the second cohort receives it two hours following surgery  The statement while the first cohort",
        "label": "Entailment"
    },
    "b7ab0a1b-fa3a-4cf4-ba4a-dda1608215a6": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets the following inclusion criteria  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed including CBCdifferential  Age of 18 years or older  Zubrod performance status 02  Patient may have received prior oral bisphosphonate therapy  The patient also meets the inclusion criteria for the",
        "label": "Entailment"
    },
    "1e349229-5030-4134-99c2-c530a37c3ef2": {
        "text_answer": "  The statement primary open angle glaucoma is a form of glaucoma in which there is no visible abnormality in the trabecular meshwork is not related to the trials provided The trials focus on the measurement of FSH levels in the primary trial and the identification of the maximum tolerated dose of ruxolitinib in combination with paclitaxel in the secondary trial Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "0f9e0c7c-a021-4aeb-9309-ab2d6f1d78f8": {
        "text_answer": "  The statement a total of 35 patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event cordonnier grade 3 viral complication severe varicella zoster virus infection is any severe varicella zoster virus infection is a contradiction to the given results   The results state that there were 24 treatmentemer",
        "label": "Contradiction"
    },
    "558d240e-a51a-4c16-807e-db9031073242": {
        "text_answer": "  The statement there were multiple incidents of sudden deaths and unplanned hospitalizations in the primary clinical trial and in the secondary clinical trial is not entailed in the given trials as there is no mention of sudden deaths or unplanned hospitalizations in either trial The trials only report the occurrence of adverse events for two different conditions Adverse Events 1 and Adverse Events 2 and their respective frequencies",
        "label": "Contradiction"
    },
    "f68789cf-7d4d-4186-b3f0-a6b47127379b": {
        "text_answer": "  The given statement is not entailed in the trials provided as there is no information in the trials regarding the number of participants who did not achieve a pathologic complete response 6 months past surgery in either group The trials only report the number of participants who achieved a pathologic complete response at the time of surgery",
        "label": "Contradiction"
    },
    "fceee201-8b1b-4cd0-ab16-75fed1f2530f": {
        "text_answer": "  The statement there was one psychiatric adverse event in the primary trial which affected less than 01 of patients is not directly entailed in the given trial data However it is a possible interpretation of the data based on the occurrence of one suicidal ideation event 150  002 or 02 The trial data does not provide information on the exact percentage of patients affected by psychiatric adverse",
        "label": "Contradiction"
    },
    "cded013b-d994-410b-9b42-c4a852978cfc": {
        "text_answer": "  The statement less than 10 of the primary trial participants had a Reduction in circulating tumor cells Following months of Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results as the statement refers to months post AHST while the results only report the number of participants with a reduction in CTCs at one month post AHST Therefore the statement is",
        "label": "Contradiction"
    },
    "9bc581fd-162a-43c2-8c72-69c06d9ba395": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report different outcome measurements The primary trial reports Time to Progression in months while the secondary trial reports the percentage of participants with Objective Response based on RECIST criteria The statement mentions study subject withdrawal by parent or guardian which is not mentioned or related to the outcome measurements reported in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "68a2e47e-d66f-45ec-87cd-45403a545e97": {
        "text_answer": "  The statement is not entailed in the given trial information The trial only mentions the use of Vorinostat and its dosage levels during radiation therapy but it does not provide any information about the use or dosage of fentanyl sublingual spray for the participants",
        "label": "Contradiction"
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "text_answer": "  The statement is entailed in the trials as the trials focus on different outcome measures The primary trial investigates the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial examines the effectiveness of Physical Therapy on pain as measured by the Numeric Pain Rating Scale The trials do not contradict each other as they address distinct aspects of the research question",
        "label": "Entailment"
    },
    "8b30b0d1-a4fd-49cb-9dc8-ce508d3b5524": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that ovarianperitoneal cancer patients receive a dosage of 1000 mcgday of talazoparib while breast cancer patients receive a dosage of 25 mcgday However the trials indicate that the dosages for ovarianperitoneal cancer patients range from",
        "label": "Entailment"
    },
    "2792a2f8-898b-4aee-a617-df468f3a1eaf": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial involves a combination of multiple medications given in different sequences and dosages throughout the study duration Therefore the statement that participants in the primary clinical trial are administered a single medication for the entire study duration is not entailed in the given trial information",
        "label": "Contradiction"
    },
    "f5031c61-a192-4b2e-ac0f-be5d2aac0b3c": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trial results we need to compare the percentage of participants with a decrease in the growth factor signature GFS in each group   The statement there was no observed difference in the decrease of the growth factor signature among the ERpositive Luminal B group and the Triple Negative group in the primary clinical trial is a negative statement meaning it asserts that there is no difference",
        "label": "Entailment"
    },
    "43e7f79b-7ebb-483e-ba3f-2cbd40c09d89": {
        "text_answer": "  The statement patients with t3 n3 m3 tumors are permitted to take part in the primary clinical trial is not explicitly stated or entailed in the given trial criteria However the trial criteria do not explicitly exclude patients with t3 n3 m3 tumors either Therefore the statement is neither entailed nor contradicted by the trial criteria  Explanation  The trial criteria specify the disease characteristics patient characteristics prior concurrent therapy",
        "label": "Entailment"
    },
    "e3c4aff9-78ee-4a66-9735-1cd5370b7925": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria The primary trial requires a primary tumour greater than 2 cm diameter while the statement suggests a primary tumour with a radius of 3mm which is less than the required minimum size Therefore a patient with a primary tumour of 3mm radius would not be eligible for the primary trial based on the given inclusion criteria  Regarding the secondary trial the statement does not provide enough information to",
        "label": "Entailment"
    },
    "dcf21e08-7d8b-45b2-bec3-9f65853fb277": {
        "text_answer": "  The statement patients eligible for the secondary trial are not fit for inclusion in the primary trial is a statement of exclusion meaning that the groups described in the secondary trial are not included in the primary trial Based on the given inclusion and exclusion criteria for both trials it can be determined that the statement is entailed in the trials as the patients described in the secondary trial do not meet the inclusion criteria for the primary trial and meet some of the exclusion criteria Therefore",
        "label": "Entailment"
    },
    "77a8c39a-7193-438c-98c1-9e88c1be1ec9": {
        "text_answer": "  The statement patients who have received chemotherapy or radiotherapy in the last 14 days suffer from unstable angina or have grade 7 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a conditional statement   To determine if this statement is entailed in the given trials we need to check if the trials entail or",
        "label": "Entailment"
    },
    "6aa17b00-284e-408b-a8c3-2e24b6310556": {
        "text_answer": "  The statement a patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is a contradiction to the trials inclusion criteria as stated in the disease characteristics section The trial does not exclude patients with bone metastases but it does specify that if bone metastases are present there must be other measurable disease Leptomeningeal carcinoma is a type of metastatic cancer that affects the",
        "label": "Contradiction"
    },
    "ad1bb75e-6250-4dbe-beff-a702293ce87c": {
        "text_answer": "  The statement no previous treatment with gabapentin or herceptin required for eligibility in the secondary trials but will exclude from the primary trial is a contradiction with respect to the given trials   Explanation   The primary trial includes a group for HER2positive females and the eligibility criteria for this group state that Use of Herceptin in previous 5 months is an exclusion criter",
        "label": "Contradiction"
    },
    "be5577f7-43cb-40c7-bf6d-4988788d9b24": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The primary trial states that the primary tumour must be greater than 2 cm in diameter while the statement suggests a tumour diameter of 3300 micrometers which is significantly smaller than 2 cm  Furthermore the secondary trial does not mention any specific tumour size requirement  Therefore the statement is contradictory to the inclusion criteria",
        "label": "Entailment"
    },
    "9d7e8278-5668-4798-9eb0-bb3ae9db62f0": {
        "text_answer": "  The statement neurofilament is an intermediate filament that is found in the axons of neurons is not directly related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it neither entails nor contradicts the information provided in the trials",
        "label": "Entailment"
    },
    "9ef9c9de-3dfa-4cbb-930e-c26190e2d119": {
        "text_answer": "  The statement after about seven months into the study more than one in three patients from both cohorts in the primary clinical trial experienced a pathologic complete response in their breast and axillary lymph nodes is entailed in the trials provided   Explanation   The trials report the number of participants in each arm who achieved a pathologic complete response pCR in their breast and axillary lymph",
        "label": "Entailment"
    },
    "5b875c96-44e4-4123-921a-546382d4c806": {
        "text_answer": "  The statement patients participating in the primary trial receive 700 mgweek oral lapatinib twice a day for a full 4 weeks is not directly entailed in the given intervention description for Arm 1   The intervention description states that patients receive oral lapatinib and oral tamoxifen once daily on days 128 with no specific dosage information given for each dose The statement provides a different dosing regimen ",
        "label": "Contradiction"
    },
    "e5f77572-2271-434c-8965-dfdac502ea4e": {
        "text_answer": "  The statement the secondary trial participants receive pembrolizumab twice as frequently as participants in the primary trial receive sunitinib is contradictory to the information provided in the trials   In the primary trial participants receive pembrolizumab every 3 weeks Q3W while in the secondary trial sunitinib is administered once daily but the frequency of pembrolizumab administration in the secondary trial is",
        "label": "Entailment"
    },
    "beef35bd-14a9-4353-aa30-2fe681726d91": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial participants received different doses of PF06647020 02 mgkg and 05 mgkg while in the secondary trial participants received different doses of ALT801 0015 mgkgdose and 0040 mgkgdose Therefore the statement that",
        "label": "Entailment"
    },
    "9c4299c7-89e6-4d9c-81db-5d12f182b4d3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not use a 4week cycle for its intervention Instead each treatment cycle is defined as 21 days The statements assertion of a 4week cycle is incorrect  Regarding the secondary trial it does not have a cyclic treatment in place as stated but it also does not have a 4week cycle The trials",
        "label": "Entailment"
    },
    "042bf558-479b-46c4-8553-016eb3bfcda7": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial but only female patients are eligible for the secondary trial is contradictory to the information provided in the trials inclusion and exclusion criteria  In the primary trial both male and female patients are eligible but there are specific inclusion and exclusion criteria for each gender In contrast the secondary trial only includes female patients Therefore gender is a determining factor for eligibility",
        "label": "Entailment"
    },
    "b7a0a223-f9c6-474c-b9e7-ca530c393a53": {
        "text_answer": "  The statement is entailed in the trials as both trials involve testing different interventions for treating the same condition In the primary trial patients receive eribulin mesylate while in the secondary trial patients receive either axitinib  docetaxel or docetaxel  placebo These are distinct interventions so the statement is entailed in the trials",
        "label": "Entailment"
    },
    "e1cf6d73-554a-4e33-8cf2-e19346eab3ce": {
        "text_answer": "  The statement patients diagnosed with Alzheimers disease are not suitable for the primary clinical trial is a contradiction to the inclusion criteria stated in the trial description The inclusion criteria mention that some evidence of cognitive impairment is allowed but a diagnosis of dementia which includes Alzheimers disease is an exclusion criterion Therefore the statement is a contradiction to the trial information",
        "label": "Contradiction"
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "text_answer": "  The statement AfricanAmerican patients can participate in the primary trial but they must reside in the state of Texas for the duration of the study is not entailed in the given inclusion and exclusion criteria for the primary trial The criteria only specify the required inclusion and exclusion conditions for trial participation without any mention of residency requirements based on race or ethnicity Therefore the statement is contradictory to the information provided in the trial criteria",
        "label": "Contradiction"
    },
    "1f5a106f-d664-4a83-a785-a47eea7b9106": {
        "text_answer": "  The statement the secondary trial does not exclude those who have experienced a pulmonary embolism is not entailed in the primary or secondary trials as pulmonary embolism is not listed as an inclusion or exclusion criterion in either trial  The statement breast implants do not affect ones eligibility to engage in the primary trial is not entailed in the primary trial as breast implants are listed as an exclusion crit",
        "label": "Contradiction"
    },
    "7b84b7dd-2143-41b0-bdf5-92c8ae314d17": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The primary trial states that the primary tumour should be greater than 2 cm in diameter while the statement suggests a primary tumour with a diameter of 33000m which is significantly larger than 2 cm Therefore a patient with a primary tumour of that size would not meet the inclusion criteria for either trial  Furthermore the secondary",
        "label": "Entailment"
    },
    "e25a03fa-f51c-4c0d-b737-375a968ce6be": {
        "text_answer": "  The statement patients encountering a known allergy to ertapenem or ciprofloxacin will result in exclusion from the primary and secondary trials is entailed in the primary trials exclusion criteria as it mentions History of allergic reactions attributed to compounds of similar chemical or biologic composition to mesna or other agents used in the study ie sulfa antibiotics and celecoxib and ",
        "label": "Entailment"
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "text_answer": "  The statement less than half of the primary trial participants had a Reduction in circulating tumor cells Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results Result 1   The trial results only state that the number of participants with a reduction in CTCs at one month post AHST was not specified in the given data It does not provide information about the percentage",
        "label": "Contradiction"
    },
    "5553674a-4eab-4515-be9e-147eef2f0d09": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report on the outcomes of hot flash frequency for the paced respiration and fast shallow breathing intervention groups There is no mention of protective face masks or any adverse events related to them in the trials",
        "label": "Contradiction"
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial measure the Change in Ki67 Expression in Tumors is not directly entailed or contradicted by the given information in the trials   The primary trial measures tumor response using RECIST criteria while the secondary trial measures the number of participants with AIMSS and includes various correlative studies such as laboratory biomarker analysis enzymelinked immunosorbent assay",
        "label": "Contradiction"
    },
    "94ca00df-c395-4f32-9348-8bcb6b15a2e1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement the most common adverse event in the secondary trial was anaemia affecting more than 005 of patients there were no recorded aes in the primary trial is contradictory because  1 The statement implies that anaemia was the most common adverse event in the secondary trial with a frequency",
        "label": "Contradiction"
    },
    "6abbb566-9561-47d2-aad5-0857550099ea": {
        "text_answer": "  The statement no patient in the primary clinical trial experienced recurrencefree survival is contradictory to the results presented in the trial The results indicate that 98 of the participants 922995 did not experience recurrencefree survival up to 3 years However it does not mean that no patient experienced recurrencefree survival since the trial only reports the percentage of participants who did not experience recurrence within the given",
        "label": "Contradiction"
    },
    "2a6e2da6-0555-43d1-b063-a81938137be9": {
        "text_answer": "  The statement only patients who demonstrate an ideal body weight for height are eligible for the primary clinical trial is contradictory to the inclusion criteria of the trial The inclusion criteria state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs which is not equivalent to having an ideal body weight for height Therefore the statement is contradictory to the trials eligibility requirements",
        "label": "Entailment"
    },
    "7af8a41a-c4b2-402e-bf50-a14aa2758926": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on interventions for breast cancer patients and the statement is about a dose calculation unit However the statement is not contradictory to the trials as well The trials do not provide any information that would contradict the statement Therefore the statement is neutral with respect to the trials",
        "label": "Contradiction"
    },
    "0f79f642-47d6-404b-ade0-8e720c0aa660": {
        "text_answer": "  The statement Arm A intervention provided the best overall response rate in the primary trial and Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort in the secondary trial is not directly entailed in the given trials   The primary trial results only indicate the overall response rates for each arm and the secondary trial results only provide information about the time to first skeletalrelated",
        "label": "Contradiction"
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "text_answer": "  The given statement is not entailed in the provided trial information as there is no mention of HER2neu peptide vaccine or sargramostim GMCSF in the interventions described in the trial",
        "label": "Contradiction"
    },
    "5a77ba85-1a9e-4639-ba29-86b0cdea296b": {
        "text_answer": "  The statement women suffering from both claustrophobia and osteoporosis are eligible for the primary and secondary clinical trials is contradictory to the information provided in the trials   Explanation   The primary trial excludes women with osteoporosis as a condition for participation The secondary trial does not mention osteoporosis as an exclusion criterion However the statement includes women with both",
        "label": "Entailment"
    },
    "aa176a26-7dd6-473f-9c35-40a0754336f6": {
        "text_answer": "  The statement Patients in the primary trial will need to receive several injections is entailed in the trial description as patients will receive injections of dendritic cells chemotherapy and trastuzumab Additionally the statement feel fatigue is a question about whether an individual feels or felt fatigued is not directly related to the trial description and does not entail or contradict any information provided",
        "label": "Entailment"
    },
    "000c067a-a563-425e-9ea1-7057f8d2c39f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there were no participants in the healthy volunteers group who had lesions In contrast the secondary trial does not report the presence or absence of lesions in the participants but rather focuses on the effects of Medihoney and Hydrophor on radiation dermatitis and hyperpigmentation However it is stated that 15 radiation dermatitis",
        "label": "Contradiction"
    },
    "5fca366e-ecc6-41e4-b621-e3343ff0f07e": {
        "text_answer": "  The statement is entailed in the Trials with Entailment as the primary trial intervention section does not provide sufficient information about the treatment cycle or irradiation doses but it does mention that the agent administration took place in a specific medical setting which is indicated by the agent administration care setting type code",
        "label": "Entailment"
    },
    "a5ed681f-ae92-4bc5-856f-4565ab2669f0": {
        "text_answer": "  The statement patients suffering from hypokalemia are not eligible to participate in the primary clinical trial but they may be considered for the secondary clinical trial is a contradiction to the information provided in the primary trials inclusion criteria The primary trial explicitly states that potassium levels must be within the normal range 3553 mEqL for eligibility Therefore patients with hypokalemia potassium levels below",
        "label": "Contradiction"
    },
    "58f0bed2-bc88-4aaf-8572-fb49fc69a87c": {
        "text_answer": "  The statement some patients treated with gtx024 1mg in the primary clinical trial did not gain lean body mass over a 4 month period is entailed in the trial results as indicated by the negative values in the median change in lean body mass for the GTx024 1mg group 206 to 1264 kg This means that some patients in this group experienced a decrease in lean body mass during the",
        "label": "Entailment"
    },
    "fe6418cd-e255-4f27-bb63-63b4f37a0f56": {
        "text_answer": "  The statement deleterious fancd2 gene mutation is a change in the nucleotide sequence of the fancd2 gene that is associated with increased risk of disease is not directly related to the trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement 0 adverse events were observed in the primary trial and none of the adverse events in the secondary",
        "label": "Entailment"
    },
    "93299ed6-4cc9-4369-a4f3-c86f45ab741e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention is Yttrium90 Radioembolization using TheraSphere glass microspheres while the secondary trial intervention is a combination of ibrutinib and MEDI4736 with a starting dose of 560 mg of ibrutinib and 10 mgkg of MEDI4736 following",
        "label": "Entailment"
    },
    "e8f582a2-31f8-4b30-a2bb-1d236706333d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants in Intervention 2 receive a different dosage of Armodafinil compared to those in Intervention 1 However the statement claims that everyone in the primary clinical trial gets the same dosage of armodafinil orally daily  In the secondary trial participants in both Interventions 1 and 2 receive different dosages",
        "label": "Entailment"
    },
    "cf9ea9d0-49c4-4c00-a91b-142cd7ec8433": {
        "text_answer": "  The statement is entailed in the primary clinical trial as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell to monitor perfusion of the involved breast at three separate time points during the surgical procedure Therefore the statement is entailed in the trial",
        "label": "Entailment"
    },
    "a45aa828-dfd0-4b82-a1a1-7a8386520fe4": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions for different patient cohorts in separate trials The primary trial deals with oral pregabalin while the secondary trial deals with a chemotherapy regimen of Liposomal Cytarabine and Highdose Methotrexate Therefore the statement is neither entailed nor contradictory based on the provided information",
        "label": "Contradiction"
    },
    "e8247d17-f420-4a08-9a2c-c2d8f1524d93": {
        "text_answer": "  The statement patients with stage 3 hepatocellular carcinoma that is estrogen and progesterone receptor negative and on chemotherapy are eligible for the primary clinical trial is contradictory to the trials inclusion criteria   The primary trial is for patients with breast cancer that is estrogen andor progesterone receptor positive and considering aromatase inhibitor therapy The statement is for patients with stage 3",
        "label": "Entailment"
    },
    "aa7a20b6-cec1-448c-ac20-a7b2d8c14a1d": {
        "text_answer": "  The statement the intervention section of the primary clinical trial provides a comprehensive treatment cycle and detailed description of the treatment is entailed in Trials with Entailment if the Trials with Entailment explicitly state that the intervention section includes a comprehensive treatment cycle and detailed description of the treatment If the Trials with Entailment do not make this explicit statement then the statement is not entailed but could still be true depending on the specific contents of the trials  Ex",
        "label": "Entailment"
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "text_answer": " The given statement 97 of patients in the primary trial did not experience any Adverse Events is not entailed in the provided trial information The trial results only mention the percentage of subjects who completed the treatment 98 but it does not provide information about the number or percentage of patients who experienced adverse events",
        "label": "Contradiction"
    },
    "b24a7c99-879c-416b-8b54-f44f0bcd4524": {
        "text_answer": "  The statement according to the findings of the primary clinical trial the overall response rate for the arm A intervention outperforms that of the placebo group is entailed in the trials as follows  1 The primary trial reports an overall response rate of 676 25 out of 37 participants in Arm A while the placebo group is not mentioned in the trial 2 Therefore the statement that the overall response",
        "label": "Entailment"
    },
    "3795f873-9d20-4fb3-b77c-ca01ba923c82": {
        "text_answer": "  The statement patients characterized by extreme obesity or pregnancy can be potentially suitable for the primary and secondary clinical trials is not entailed in the given inclusion and exclusion criteria for both trials   Explanation  The primary trial includes patients who are scheduled to receive neoadjuvant chemotherapy or neoadjuvant endocrine therapy for locally advanced breast cancer or clinical stage IIIII ER HER2 breast cancer There",
        "label": "Contradiction"
    },
    "94ee2ae4-cf85-4dfb-90be-2490ad4089ab": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information regarding the occurrence or absence of electrolyte disorders in the patient population or the interventions effects on electrolyte levels However the statement is generally true as cabergoline is given orally and pixantrone is administered intravenously and electrolyte disorders can be associated with both orally administered and intravenously administered medications  ",
        "label": "Contradiction"
    },
    "750d4e54-f2cf-425c-9a04-dbd5091a0cba": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information   Explanation   The trial information only provides details about the interventions placebo and Trabectedin and their administration methods It does not mention any specific information about weight loss or CTCAE Common Terminology Criteria for Adverse Events related to weight loss in the trial Therefore it is neither entailed nor contradicted by the given trial information",
        "label": "Entailment"
    },
    "bac5180a-b51f-4a2d-a1d2-eaead122d693": {
        "text_answer": "  The statement the majority of patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel did not achieve a confirmed complete response CR is not directly stated in the given trial results However the results do indicate that the percentage of participants achieving CR is 53 out of 60 which is less than 50 Therefore it can be inferred that more than half of the participants did",
        "label": "Entailment"
    },
    "e54cf8ee-4a0d-4a15-bc72-4072ff0b6e6d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention involves the use of Yttrium90 Radioembolization which is a type of radiotherapy The secondary trial intervention also involves the use of a drug ibrutinib which is a type of chemotherapy However the secondary trial also includes the use of MEDI4736 which is an immunotherapy   ",
        "label": "Entailment"
    },
    "ec3a1125-3c16-4f3c-8fa3-6a237f4529c9": {
        "text_answer": "  The statement during the primary clinical trial radiation therapy is undertaken without simultaneous administration of daily vorinostat capsules is contradictory to the information provided in the trial description  The trial description states that patients will take Vorinostat daily during radiation therapy and are recommended to swallow the capsule 6090 minutes prior to the estimated time of radiation This means that the administration of Vorinostat is simultaneous with radiation therapy",
        "label": "Entailment"
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "text_answer": "  The statement is entailed in the trials as both trials are investigating the effect of Empegfilgrastim an identical drug in the primary and secondary trials However the primary trial focuses on the duration of CTCAE grade 34 neutropenia after the first chemotherapy cycle and the secondary trial investigates the incidence of CTCAE grade 34 neutropenia within 21 days The difference lies in the outcome measurement",
        "label": "Entailment"
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "text_answer": "  The statement is entailed in the Trials as the interventions in the primary trial and the secondary trial involve different treatments In the primary trial the interventions include the use of Abl Cells IV and Cyclophosphamide with different dose escalations while in the secondary trial the intervention is the use of DMCHOCPEN with different doses for patients with and without liver involvement Therefore the statement that the interventions in the primary trial and",
        "label": "Entailment"
    },
    "dffbf597-b236-4aa5-bd94-b471c9e593ea": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial In the secondary trial participants in both Intervention 1 and Intervention 2 received Fulvestrant via intramuscular injection but the dosing regimen for Intervention 1 also includes Enzastaurin with different dosing schedules QD and BID The statement however only mentions Fulvestrant being prescribed to the participants from the secondary trial without",
        "label": "Entailment"
    },
    "7e3a4e76-6d33-4013-ad8e-7fd3d684136f": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial reports Time to Progression in months while the secondary trial reports Number of Participants with Objective Response based on Data Review Committees Assessment The statement does not mention hours or the duration of response for patients in the trials Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "976f4747-e1a6-4527-a298-490fb57d4615": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not mention any information about the route of administration for the first cohort of the trial only the type and dose of the intervention The secondary trial also does not mention any information about the first group receiving a chloroquine injection only the type and dose of the intervention and the requirement for a breast biopsy prior to treatment  Therefore there",
        "label": "Entailment"
    },
    "82d350f6-9864-4329-bd5b-8d8155170569": {
        "text_answer": "  The statement esophageal Hodgkin lymphoma is a very rare Hodgkin lymphoma that arises from the esophagus None of the primary trial candidates have to perform regular exercise as part of the intervention is not directly entailed in the given trial description   The trial description mentions that the patients have various types of histologicallyconfirmed cancer including nonHodgkins lym",
        "label": "Contradiction"
    },
    "efe92dca-7dd8-44da-b436-15a3c9f9f729": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information to determine if the nasal cream dosage form was used in both trials or if the trial populations were similar enough to make such a comparison valid However the statement does not contradict the information provided in the trials Therefore the statement is neutral with respect to the trials",
        "label": "Contradiction"
    },
    "f5650e8f-58b5-4a3a-9da2-ab66d7674b6d": {
        "text_answer": "  The statement patients bearing tx nx mx t0 nx m0 or t1 n1 m1 tumors can participate in the primary clinical trial is not explicitly stated in the given trial criteria However the trial criteria do not exclude patients with these tumor stages tx unknown primary tumor nx regional lymph nodes cannot be assessed mx distant metastasis cannot be assessed t TNM primary tumor",
        "label": "Entailment"
    },
    "cdce28fc-eb28-4608-8b83-9bc18414caf8": {
        "text_answer": "  The statement is contradictory to the primary trial as the primary trial does not mention anything about claustrophobia as an exclusion criterion However the statement is entailed in the secondary trial as it explicitly lists claustrophobia as an exclusion criterion Therefore the statement is partially correct but incomplete as it only addresses one of the trials  To summarize the statement neither the primary clinical trial",
        "label": "Entailment"
    },
    "51220352-fff0-4e70-b36d-7f9e87498a58": {
        "text_answer": "  The statement 13 participants in the primary clinical trial received the fixdm1 therapeutic agent as a treatment is not directly entailed in the provided information The trial description only mentions the vaccine and its administration schedule but it does not specify that the vaccine is the fixdm1 therapeutic agent Therefore the statement is neither entailed nor contradicted by the provided information",
        "label": "Contradiction"
    },
    "03fe5ae7-9f15-4d30-a208-cead95780b13": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials The primary trial does involve Fulvestrant and Anastrozole but Anastrozole is not the only intervention used in the first cohort The secondary trial does not involve Arimidex at all",
        "label": "Contradiction"
    },
    "5d42d5d3-e80d-49e0-83e5-8724a8ff5401": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials The trials report no cases of asthenia or pyrexia in either trial Therefore the statement that there are a total of 3 cases of asthenia and 5 cases of pyrexia across both trials is not entailed by the information given",
        "label": "Contradiction"
    },
    "e52a3c24-8fed-4bcb-9513-582c604a5414": {
        "text_answer": "  The statement Patients cannot have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the trials exclusion criteria as stated in the text provided Therefore the statement is entailed in",
        "label": "Entailment"
    },
    "df26264a-98ef-47f9-9493-e2398529e39f": {
        "text_answer": "  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is entailed in the given trials as the secondary trial had a higher percentage of patients with Adverse Events 6000 compared to the primary trial 000 However the statement does not directly mention megacolon and there is no information provided in the trials regarding this condition Therefore the statement",
        "label": "Entailment"
    },
    "e554ce24-beab-4ed6-b37b-0a28ae28faf0": {
        "text_answer": "  The statement the secondary trial patients did not experience anemia pneumonia or stupor more frequently than patients in the primary trial is entailed in the given trials data   Explanation   The statement is entailed because the frequency of anemia pneumonia and stupor in the secondary trial is lower than that in the primary trial for all cases In the primary trial there were no occurrences",
        "label": "Entailment"
    },
    "9324259a-88b9-441b-a6ee-ec7f6f5914aa": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The statement is about colorectal adenoma with moderate dysplasia which is not mentioned in the trials The trials only provide information about the PFS of two different treatment groups for colorectal cancer patients",
        "label": "Entailment"
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "text_answer": "  The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement however they are not explicitly excluded from the secondary trial is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial includes postmenopausal women only and the age requirement is explicitly stated in the inclusion criteria The secondary trial does not have any age requirement mentioned in the given inclusion criteria",
        "label": "Contradiction"
    },
    "86a8919e-ee7f-40ba-9186-9dcbdbb06018": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the median survival times for each group and the statement makes a claim about the mean survival time and the number of patients exceeding one year of survival The trials do not provide this information",
        "label": "Contradiction"
    },
    "cbb9beea-1961-4049-9a90-53a75da5933e": {
        "text_answer": "  The statement is entailed in the trials as cohort 2 is indeed given a lower dose of ALT801 0015 mgkgdose than cohort 1 0040 mgkgdose",
        "label": "Entailment"
    },
    "ca4fb850-2d8b-4a5f-b990-1d81ae917d63": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials indicate that the dosage of talazoparib varies for both breast and ovarianperitoneal cancer participants with different dose ranges for each group The statement incorrectly asserts that the dosage is 1000 mcgday for breast cancer patients and 25 mcgday for those with ovarian or peritoneal cancer",
        "label": "Entailment"
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts is a contradiction to the given data   Explanation  The primary trial and secondary trial have different patient cohort sizes 0 patients in the primary trial vs 15 patients in the secondary trial Therefore it is impossible for them to have recorded the same total number of adverse events without having the same number",
        "label": "Contradiction"
    },
    "ec2e7860-1d3e-4f95-b00a-bea42d04825a": {
        "text_answer": "  The statement CAPECITABINE was administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle is entailed in the trial description The trial states that Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2000 mgm2day This means that",
        "label": "Entailment"
    },
    "c17afde4-0fee-473c-b969-f7a4e89f049b": {
        "text_answer": "  The statement the primary clinical trial is open for patients with estrogen negative progesterone negative and her2 forms of breast cancer is entailed in the given inclusion criteria as ER positive and HER2 negative are synonymous with estrogen negative progesterone negative and HER2 forms of breast cancer Therefore the statement is entailed in the trials inclusion criteria",
        "label": "Entailment"
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "text_answer": "  The statement is contradictory to the information provided in the trial The trial specifies that patients will receive Leukine GMCSF starting one day after chemotherapy and continuing until the neutrophil count is greater than 1000mm3 This means that patients will receive multiple injections of GMCSF over several days not a single injection on day 8 as stated in the given statement Therefore the statement is contrad",
        "label": "Entailment"
    },
    "6ffb2b0f-737a-4176-9036-a887a2f4a4b7": {
        "text_answer": "  The statement on average patients from the primary trial survive over 730 days over 50 patients from each cohort survived more than 24 months is not directly entailed in the given trials as they do not provide the average survival or the number of patients surviving beyond 24 months for each group The trials only report the median survival for each group with their respective confidence intervals Therefore the statement is neither entailed nor contradicted by the given",
        "label": "Contradiction"
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "text_answer": "  The statement The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group is entailed in the trials as the results show that the percentage of participants with iDFS events in the Neratinib group was 47 while in the Placebo group it was 75 A lower percentage indicates a lower rate",
        "label": "Entailment"
    },
    "8d94a62d-400f-4d9d-92aa-d39dd1f37823": {
        "text_answer": "  The statement cohort 1 was the group where all the cases of infections and infestations were recorded in the primary clinical trial is contradicted by the given data   Explanation  The statement implies that all cases of infections and infestations occurred in cohort 1 However the data shows that one case of Gramnegative bacteremia 40 degree C fever occurred in cohort 1",
        "label": "Contradiction"
    },
    "8d813fc8-01ec-4fb7-9191-f5ec7cb735fb": {
        "text_answer": "  The statement transmission scan is a scan to obtain data for use in making attenuation corrections Intervention 1 in the primary trial and all intervention drugs in the secondary trial must be administered intravenously is neither entailed nor contradicted by the given trial information   The statement mentions a transmission scan which is not mentioned or related to the given trials The trials only provide information about the interventions and their administration routes Therefore",
        "label": "Entailment"
    },
    "eaad4acd-8fc1-41c6-92aa-1a4488ffdfed": {
        "text_answer": "  The statement there was at least 1 case of infection in both the primary trial and the secondary trial is entailed in the given trials as both trials list Infection as an adverse event in their respective lists Therefore the statement is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "0cb2b471-fa4a-4eeb-8dd7-981680465858": {
        "text_answer": "  The statement all the logged adverse events in the primary clinical trial happened to patients grouped in cohort 1 is entailed in the given trials as both trials have the same set of adverse events with a total count of 0 for each event and no events occurred in cohort 2 Therefore all the adverse events were logged in cohort 1",
        "label": "Entailment"
    },
    "f4da0e5f-f0aa-4edf-a08c-afadd05360d5": {
        "text_answer": "  The statement the primary clinical trial is open to patients with a histological or cytological confirmed diagnosis of nonsmall cell lung cancer or small cell lung cancer is entailed in the given inclusion criteria of the trial as these two types of lung cancer are explicitly listed among the eligible tumors",
        "label": "Entailment"
    },
    "f859f501-4e35-44c5-88bf-213949f5e5e5": {
        "text_answer": "  The statement the primary clinical trial has only few spots open for patients diagnosed with metastatic colorectal cancer which carries the kras or braf mutation is entailed in the inclusion criteria of the trial The trial specifies that there are 1530 enrollment slots for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation Therefore the statement is an accurate reflection of the information",
        "label": "Entailment"
    },
    "b7b355cd-5386-4b3c-bc5d-a9a05e7a83b5": {
        "text_answer": "  The statement different units of measure are utilized in the results of the secondary clinical trial and the primary clinical trial is entailed in the trials as follows  In the primary trial the outcome measurement is Tumor Diameter with units of measure in cm In the secondary trial the outcome measurement is Number of Participants With Solid Tumor Response which is a count of participants and not a measurement of tumor diameter in cm  There",
        "label": "Entailment"
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "text_answer": "  The statement Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial is a statement of exclusion and inclusion respectively for the two different trials   The primary trial explicitly states that patients with Potassium levels below the normal range 35 mEqL are excluded Inclusion Criteria section point 11  However the secondary trial does not mention Potassium levels as",
        "label": "Entailment"
    },
    "cd2874dc-b435-4319-8ae9-d413b3f43499": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description it is stated that in Arm B FULV patients receive fulvestrant intramuscularly but it is also mentioned in a separate statement that cohort 2 is administered paclitaxel instead Therefore fulvestrant is not only used in cohort 1 intervention of the primary clinical trial",
        "label": "Entailment"
    },
    "76b35642-5bf9-4980-beb9-e802493907b6": {
        "text_answer": "  The statement patients receiving the placebo intervention in the primary clinical trial were less likely to experience emesis compared to patients receiving aprepitant is contradictory to the results of the trial   The trial reports that there were 13 participants in the aprepitant group who experienced emesis and 5 participants in the placebo group who experienced emesis during the study period This means that a greater number of participants in the aprepitant",
        "label": "Entailment"
    },
    "f13b3dd4-fe4a-4189-b51b-cf72af22deab": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trials exclusion criteria do not mention anything about organ transplant or bedridden status However it does exclude participants who have undergone major surgery within 28",
        "label": "Contradiction"
    },
    "56603bed-1e4b-41d2-919c-612ec6e9b4c4": {
        "text_answer": "  The statement over 89100 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR is a contradiction to the results presented in the trial   The trial reported that 53 out of 60 participants or 883 experienced either a CR or PR according to RECIST criteria 10 However",
        "label": "Contradiction"
    },
    "306ea03b-8055-4a52-8d81-ed4e18dedd4f": {
        "text_answer": "  The statement patients with histologically or cytologically confirmed localized andor earlystage solid tumor in the brain are eligible for phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial is not entailed in the given inclusion criteria for both trials   The primary trial includes patients with metastatic andor advanced solid tumors for phase 1 but it does not mention anything about localized or early",
        "label": "Contradiction"
    },
    "94604a45-9867-4ccd-b38b-de2a3368130e": {
        "text_answer": "  The statement no notable variances were present in the outcomes of the primary clinical trial groups and both the reflexology group and control group in the secondary clinical trial garnered matching results is not directly entailed in the provided information from the trials   The primary trial is focused on comparing the diagnostic accuracy of two mammography algorithms using the area under the ROC curve while the secondary trial is investigating the effect of reflexology on fatigue levels using",
        "label": "Contradiction"
    },
    "8f20a32b-2aa2-44c4-930e-852cba56151f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial Intervention 1 involves an injection of Fluciclatide AH111585 18F and there is no mention of vincristine or hydroxychloroquine   In the secondary trial Intervention 1 involves oral administration of chloroquine and there is no mention of vincristine",
        "label": "Contradiction"
    },
    "3fa1e0aa-7c62-4a1e-bd7d-452fa87a7baf": {
        "text_answer": "  The statement splitting pain is an intense sensation of discomfort or distress that feels like being cut apart Patients whos Metastasis cannot be measured or whos Cancer has not spread to other parts of the body are not eligible for the primary trial is not directly stated in the trial criteria However the trial does specify that only patients with histologically confirmed breast cancer that meets certain criteria including measurable or nonmeasurable disease are eligible",
        "label": "Entailment"
    },
    "d66e149e-5bb7-4e4b-8078-7f5947a31f60": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both the primary and secondary trials   The primary trial requires an absolute neutrophil count ANC of 1800 cellsmm3 which is higher than the patients ANC of 900l Additionally the patients hemoglobin level of 80 gl is lower than the required minimum hemoglob",
        "label": "Entailment"
    },
    "e7c553e8-8799-4475-9e39-6f79bebc0a48": {
        "text_answer": "  The statement in the primary clinical trial cohort 1 reported mostly beneficial effects with similar feedback from cohort 2 is not directly entailed or contradicted by the given trial data The statement is based on the assumption that the trials were assessing the same treatment and that the feedback from both cohorts was mostly positive However the trial data only provides information about the adverse events in each cohort and does not mention the beneficial effects or",
        "label": "Contradiction"
    },
    "8ddc286d-ac51-4c92-a163-2d9a65b52ae7": {
        "text_answer": "  The statement minor help to transfer is a response indicating that an individual needs minor verbal or physical help to transfer is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials Therefore it neither entails nor contradicts the information provided in the trials  However the statement does clarify the meaning of able to receive iron supplement if necessary in the primary trials inclusion criteria It implies that participants who require minor",
        "label": "Entailment"
    },
    "5baa6e97-00e4-4e2f-b837-661a790cb87f": {
        "text_answer": "  Both trials involve patients with HER2positive breast cancer who have progressed on or after prior antiHER2 and chemotherapy treatment However the primary trial focuses on the evaluation of toxicity of infusing HER2specific T cells using NCI CTCAE v30 while the secondary trial measures the percentage of participants with adverse events of primary interest AEPIs related to trastuzumab emtansine The",
        "label": "Entailment"
    },
    "6f95650b-d11f-4546-bfb2-d46cc39561b2": {
        "text_answer": "  The statement patients suffering from severe insomnia and schizophrenia are eligible for both the primary trial and the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either trial   The primary trial focuses on patients with ERPRHER2 metastatic breast cancer who have progressed on endocrine therapy while the secondary trial focuses on patients scheduled for cancer treatment with chemotherapy or biologics",
        "label": "Contradiction"
    },
    "fd23bed1-83e9-44c9-acf7-66df74ba1c98": {
        "text_answer": "  The statement There are no conditions on Life expectancy pregnancy or age for participants of the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria do not mention anything about life expectancy pregnancy or age as inclusion or exclusion factors Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "ea0d6370-3322-4925-b524-b9a8bebe4383": {
        "text_answer": "  The statement is entailed in the trials as the primary trial and the secondary trial are studying different drugs although they have the same dosage and outcome measurement for a secondary endpoint The primary trial is testing Extimia empegfilgrastim versus placebo while the secondary trial is testing empegfilgrastim as a single agent versus placebo Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "ea893c02-e0eb-4789-bb1e-5501db3be7d7": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial excludes patients with serum 25OHD levels  40 ngml which is a marker of Vitamin D deficiency However this criterion is not present in the secondary trial Instead the secondary trial has different inclusion and exclusion criteria  However the statement is still entailed because the primary trial excludes patients with Vitamin D deficiency",
        "label": "Entailment"
    },
    "3cbb65a6-d9f6-4972-8b13-dd19d427f0cb": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial compares two different interventions Hydrophor and MediHoney used during radiation therapy This trial does evaluate the impact of different interventions on the participants  The secondary trial compares two different doses 90 mg and 110 mg of the same treatment PF05212384 given in combination with docetaxel",
        "label": "Entailment"
    },
    "40de18f3-3a12-40fb-9ce2-ebcc28391c7d": {
        "text_answer": "  The statement the primary clinical trial reported more adverse events than the secondary clinical trial in their respective patient cohorts is a contradiction to the given data   The primary trial reported 0 adverse events in 0 patients while the secondary trial reported 0 adverse events in 15 patients Both trials reported 0 adverse events so the primary trial did not report more adverse events than the secondary trial",
        "label": "Contradiction"
    },
    "8dc16445-6102-4525-b9ce-ba4e35cc8b01": {
        "text_answer": "  The statement only postmenopausal women and men who have had a vasectomy are eligible for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria The criteria focus on various medical conditions prior treatments and eligibility based on performance status and life expectancy but they do not explicitly mention the requirement of postmenopausal status or vasectomy for men Therefore the statement is not entailed in",
        "label": "Contradiction"
    },
    "aeb95807-2d6b-4915-b52c-0d0fdc82728e": {
        "text_answer": "  The statement cohort 2 in the secondary clinical trial had a significantly greater number of participants compared to cohort 2 in the primary clinical trial is not entailed in the given trials   The primary trial had 75 participants in the waitlist control group and 76 in the Nuevo Amanecer peer support program group The secondary trial had 147 participants in the standard of care group and 163",
        "label": "Contradiction"
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "text_answer": "  The statement is entailed in the Trials as all patients meeting the inclusion criteria for the secondary trial HER2negative metastatic breast cancer candidates for taxanebased chemotherapy and ECOG performance status of 0 or 1 also meet the inclusion criteria for the primary trial female history of breast cancer currently taking an aromatase inhibitor or tamoxifen and experiencing severe hot flushes Therefore patients in the",
        "label": "Entailment"
    },
    "35a580c0-ce8a-42d1-b8ea-d84b985319c5": {
        "text_answer": "  The statement individuals having confirmed HER2 negative tumor through either FISH or IHC 3 are considered for the primary clinical trial is a contradiction to the inclusion criteria stated in the trial description The inclusion criteria clearly state that only individuals with HER2 positive tumors either IHC 3 or FISH are eligible for the trial Therefore individuals with HER2 negative tumors are explicitly excluded from the trial and the",
        "label": "Contradiction"
    },
    "fa2d8a93-4cae-4ee5-afdf-1afd04d07c93": {
        "text_answer": "  The statement over 20 of the patients that participated in the primary clinical trial experienced all types of adverse events aes is not entailed in the given trial data   The trial data reports the frequency of each specific type of adverse event but it does not provide information about the number of patients who experienced more than one type of adverse event Therefore based on the given data it is impossible to determine whether over 20",
        "label": "Contradiction"
    },
    "a852b1d2-ce26-48da-ba6d-2386489a967b": {
        "text_answer": "  The statement occurrences of hepatotoxicity were thrice as common as incidents of hypertension and pancreatectomy can be verified by calculating the ratio of the number of occurrences of hepatotoxicity to the number of occurrences of hypertension and pancreatectomy  Given that there were 3 occurrences of hepatotoxicity and 1 occurrence each of hypertension",
        "label": "Entailment"
    },
    "9068887d-3b93-4345-9b59-01ceb05725b1": {
        "text_answer": "  The statement for the primary clinical trial adults who have been diagnosed with ILDDPLD within the previous 3 years and have a projected life span of 6 months are considered eligible is not explicitly stated in the inclusion criteria of the trial However there is no contradiction to this statement in the exclusion criteria either Therefore the statement is neither entailed nor contradicted by the information provided in the trials eligibility criteria",
        "label": "Contradiction"
    },
    "c35d641d-7248-47d7-90ff-a3859a846f68": {
        "text_answer": "  The statement regular incidents of maculopapular rash were observed as a common after effect in the primary clinical trial participants is not directly entailed in the given trial data The trial data reports an occurrence of one maculopapular rash case out of 30 participants 333 While the statement implies that maculopapular rash was a common occurrence the trial data does not provide sufficient evidence to",
        "label": "Contradiction"
    },
    "2690d684-0905-4af0-8113-fffec885de77": {
        "text_answer": "  The statement a patient suffering from acute bacterial meningitis is capable of participating in the primary clinical trial is contradictory to the trials inclusion criteria as stated in the given text The trial explicitly mentions that No meningeal carcinomatosis is a requirement for participation and meningitis is a condition characterized by inflammation of the meninges which is not allowed in the trial Therefore the statement is contradict",
        "label": "Contradiction"
    },
    "ee0b2916-1e10-467e-bcf3-41c56aa80921": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is a contradiction to the exclusion criteria in both trials  In the primary trial pulmonary embolism within the last 2 months is an exclusion criterion for both trials However the statement suggests that such patients may be eligible",
        "label": "Contradiction"
    },
    "731e38ac-1da8-4b94-a501-606a49570767": {
        "text_answer": "  The statement cyp3a4 polymorphism positive is an indication that polymorphism of the cyp3a4 gene has been detected in a sample is not directly entailed nor contradictory to the information provided in the inclusion and exclusion criteria for the primary and expansion phases of the clinical trial   The statement mentions cyp3a4 polymorphism which is a genetic variation but it is not mentioned as a specific",
        "label": "Contradiction"
    },
    "d6f4c977-a5fa-49c9-ba6c-a40dfe0f3b30": {
        "text_answer": "  The statement the primary trial does not report any results for the LBH589 and Lapatinib cohort is entailed in the given trial information as there are no reported results for the LBH589 and Lapatinib armgroup in the provided data However the statement does not directly address the biospecimen requirements mentioned in the study requirement object Therefore the statement is neither entailed nor contradictory to the bios",
        "label": "Entailment"
    },
    "7506e58c-a44a-4410-a519-59a81686fe12": {
        "text_answer": "  The statement participants in the primary clinical trial must have responded positively to AI therapy and mirtazapine and the same response to these treatments is required in the secondary clinical trial is a contradiction to the inclusion criteria of the primary trial   The primary trial includes participants who are resistant to AI therapy Therefore participants in the primary trial cannot have responded positively to AI therapy and thus cannot have the same response required in the secondary",
        "label": "Contradiction"
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "text_answer": "  The statement Women with Newly diagnosed stage IV breast cancer confirmed as ER Considering a mastectomy are eligible for the primary trial and the secondary trial is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trials key inclusion criteria state that participants must have locally advanced recurrent or metastatic breast cancer confirmed as ER with measurable disease or lytic or mixed",
        "label": "Entailment"
    },
    "f823a6d1-5d44-4d8c-8f33-14eef364d3b6": {
        "text_answer": "  The statement the primary clinical trial welcomes men of potential fertility and women with the potential to conceive nevertheless as a requirement they need to undertake a commitment to abstinence for the full course of the study is not directly entailed or contradicted by the given inclusion and exclusion criteria   The criteria do not explicitly mention anything about fertility or contraception requirements for men or women However the statement implies that such a requirement exists",
        "label": "Contradiction"
    },
    "2a45331c-2e6b-43fb-be85-86e22c828c41": {
        "text_answer": "  The statement compared to the bevacizumab  capecitabine cohort a greater incidence of disease progression or death was reported in the bevacizumab cohort of the primary clinical trial is entailed in the trials as follows  The percentage of participants with disease progression or death in the Bevacizumab cohort was 883 while in the Bevacizumab",
        "label": "Entailment"
    },
    "d3ee2617-a363-4290-a97b-57f6eb1b8efe": {
        "text_answer": "  The statement fewer than one in ten participants in group 1 of the secondary clinical trial exhibited radiation dermatitis or hyperpigmentation is in contradiction to the information provided in the primary clinical trial results 1 where all participants in group 1 Healthy Volunteers had 0 lesions implicitly no radiation dermatitis or hyperpigmentation Therefore the statement is contradictory to the information",
        "label": "Contradiction"
    },
    "d2885dd5-eb3f-4dcd-9980-c02d3c1c6924": {
        "text_answer": "  The statement one shingles case was reported in the secondary clinical trial specifically in group 2 however both the primary clinical trial and group 1 of the secondary trial recorded no instances of shingles is a contradiction of the given data  Explanation  The primary clinical trial reported no instances of shingles in any of the six patients Group 1 of the secondary clinical trial also reported no instances of shingles in its",
        "label": "Contradiction"
    },
    "aab488c3-ac44-4506-b2b1-541909e30028": {
        "text_answer": "  The statement is entailed in the trial results as stated in the given information The trial found an average decrease of 40 in ki67 expression which matches the percentage change mentioned in the statement",
        "label": "Entailment"
    },
    "0c105984-77ed-42cc-9d9f-aec464e02d12": {
        "text_answer": "  The statement is not entailed in the primary or secondary trial criteria as provided The Karnofsky performance status is a measure of a patients functional status and ability to perform daily activities It is not related to the concept of escaping from the interlabial space or lateral juncture which is not mentioned in the trial criteria at all",
        "label": "Contradiction"
    },
    "216d59a3-b4c1-4a73-a4e2-ee2b97c59b22": {
        "text_answer": "  The primary clinical trial provided in the first set of results does not mention the measurement of percentage of participants with diseasefree survival dfs The secondary clinical trial provided in the second set of results also does not mention the measurement of percentage of participants with diseasefree survival dfs Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "fa7b75cd-7f8f-44aa-83dc-618e1bc961a1": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is entailed in the trial results as stated 53 of the 60 participants 90 in the Lapatinib 1000 mg  NabPaclitaxel armgroup experienced either",
        "label": "Entailment"
    },
    "34f34450-a64c-4159-ad9d-8adb58617e79": {
        "text_answer": "  The statement is contradictory to the trials provided   Explanation   The statement the secondary clinical trial noted only two types of adverse events eyelid oedema and chest pain while the primary trial reported no observed adverse events is contradictory to the trials because  1 The primary trial did report observed adverse events even though none were recorded for the specific types mentioned in the statement eyelid",
        "label": "Contradiction"
    },
    "6c50344e-493e-46a6-9e03-74495773bab2": {
        "text_answer": "  The statement is contradictory to the secondary trial In the secondary trial the intervention section does not mention the use of suramin and paclitaxel together only that patients undergo mastectomy surgery Therefore the statement that all patients in the primary clinical trial receive suramin and paclitaxel while the secondary trial does not specify which drugs are given in its intervention section is not entailed in the trials and is actually contradictory",
        "label": "Contradiction"
    },
    "a698cb41-106c-4d9c-b4e9-1381f9329079": {
        "text_answer": "  The statement is partially entailed in the given trials   Explanation   The statement both the placebo and trabectedin used in the primary clinical trial are given as threehour intravenous infusions biweekly is not exactly entailed in the given trials as they provide different information for each intervention   The placebo is given as a 3hour intravenous infusion on Day 1 which is",
        "label": "Entailment"
    },
    "6bae9ada-fea4-4bb6-bd25-cdb505b3d53f": {
        "text_answer": "  The statement over 097 of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed or contradicted by the given data in the trials   The trials only provide the number and percentage of patients who experienced specific adverse events in each trial They do not provide the total number of patients in each trial or the percentage of patients who did not experience any adverse events Therefore it is not possible",
        "label": "Contradiction"
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial patients receive a single injection at the baseline while in the secondary trial patients in the intervention group receive 3 weekly injections Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "5db44a07-6d17-4fa9-9060-1f1af4aaf3af": {
        "text_answer": "  The statement at least one gastrointestinal adverse event was recorded in the primary clinical trial is entailed in Trial 1 and Trial 2 since both trials report at least one instance of vomiting Trial 1 0149 000 but the denominator may be incorrect Trial 2 3149 201 Therefore the statement is entailed",
        "label": "Entailment"
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first",
        "label": "Contradiction"
    },
    "86515e2e-b144-430c-b7e2-678733d3b0ec": {
        "text_answer": "  The statement Patients participating in the primary trial receive oral medication twice a day for a full month is not directly entailed in the given intervention description However it is consistent with the information provided as both lapatinib and tamoxifen are given orally once daily which could be interpreted as twice a day if each medication is taken in the morning and evening  The term desensitization is not mentioned in the trial description",
        "label": "Contradiction"
    },
    "f9638af4-2bf2-45b4-8c9e-b46c34373b17": {
        "text_answer": "  The statement in the primary clinical trial the bevacizumab group witnessed more cases of disease progression or death compared to the bevacizumab  capecitabine group is a contradiction to the given data   The percentage of participants with disease progression or death in the Bevacizumab group was 883 while in the Bevacizumab  Capecitabine group it was ",
        "label": "Contradiction"
    },
    "cf38cb04-b2fd-44bf-9674-dda257a8ad25": {
        "text_answer": "  The statement cardiac biphasic synovial sarcoma is a biphasic sarcoma arising from the heart is not directly related to the information provided in the trial   The trial only mentions the number of participants who received the vaccine and the schedule of vaccinations It does not provide any information about the type of cancer or diagnosis of the participants Therefore the statement about cardiac biphasic synovial sarcom",
        "label": "Entailment"
    },
    "bbb1b8c1-c9b1-40c9-b744-a2ae519032c3": {
        "text_answer": "  The statement million cells is a unit of cell count expressed in millions is not directly related to the information provided in the trial results   The statement Over 6 weeks of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 5 reduction in the Percentage of cells with Ki67 expression can be verified by comparing the median interquartile range of Ki67 expression at baseline",
        "label": "Entailment"
    },
    "7dbe6e8e-5971-41e2-bc70-46dc3cb3cd5c": {
        "text_answer": "  The statement there are 00 shared inclusionexclusion criteria between the secondary trial and the primary trial is a contradiction based on the given information   The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine life expectancy and performance status The secondary trial on the other hand only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deacon",
        "label": "Contradiction"
    },
    "c18a6d09-906e-4fbe-acf1-93b9a89f717a": {
        "text_answer": "  The primary trial employs the unit of measure change in units on a scale for the outcome measurement which is not the same as minutes or number of participants Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "9c0406cd-3585-4cb2-b330-fa9c1426c72c": {
        "text_answer": "  The statement every participant in the primary clinical trial was administered oral sunitinib daily throughout the entirety of the research period is not directly entailed in the given trial information The trial description states that sunitinib was administered daily but it also mentions that dosing could be interrupted or reduced based on individual tolerance and participants with PD or intolerable toxicity were considered for discontinuation Therefore while sunitinib was given daily",
        "label": "Contradiction"
    },
    "47daf120-3939-4e32-bba5-d86ce54a9cbd": {
        "text_answer": "  The statement only a minority of patients in the primary clinical trial who were administered lapatinib 1000 mg  nabpaclitaxel saw a confirmed complete response CR is not directly stated in the given trial results However the results do indicate that the percentage of participants experiencing a CR is not mentioned only the percentage of participants experiencing a PR or no response is provided Therefore the statement is not entailed in the trial results but",
        "label": "Contradiction"
    },
    "84e7c52d-eec3-415f-9602-77f607c5620e": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The statement implies that both cohorts receive identical doses of Abraxane but the trial description specifies different dosing regimens for each arm In Arm A participants receive nabPaclitaxel 125 mgm2 on Days 1 and 8 and in Arm B participants receive nabPaclitaxel",
        "label": "Entailment"
    },
    "19606c86-3376-40ca-b438-20d961329829": {
        "text_answer": "  The statement is entailed in the trials as the outcome measures recorded in the primary clinical trial hot flash scores and the secondary clinical trial Overall Response Rate are entirely different The primary trial measures the change in hot flash activity while the secondary trial measures the proportion of participants with a best response of complete or partial response to treatment",
        "label": "Entailment"
    },
    "b12b7e1a-9348-4e57-ac88-44523913fff3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial patients in Arm I receive zoledronic acid via IV infusion but in the secondary trial patients in both arms receive interventions via oral and IV routes The statement incorrectly implies that only the primary trials Intervention 1 is given via IV while the secondary trial allows for both oral and IV administration for all interventions",
        "label": "Entailment"
    },
    "a7561afd-f6c4-41cf-8d4a-fa6c26cc10b3": {
        "text_answer": "  The statement The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group is not directly entailed in the given trials as they report the percentage change in betaCTX for each group but do not provide a comparison between them The trials only provide the geometric mean and 95 confidence intervals for each group To",
        "label": "Contradiction"
    },
    "9289ca32-0fa0-44ae-8cc0-49510f2fed23": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The statement in the primary clinical trial cohort 1 receives less than half the dose of alt801 that cohort 2 does is entailed by the information given in the trials   The trials state that the dosage of ALT801 for cohort 1 is 0015 mgkg",
        "label": "Entailment"
    },
    "784e0481-d0fd-43b9-8d5a-0a1d2bd4aa26": {
        "text_answer": "  The statement percentage times minute per hour is a unit of measurement expressed as the percentage times minutes divided by hours is not directly related to the adverse events data provided in the trials   Regarding the second part of the statement General symptoms are the most common AE recorded in the primary trial this statement is entailed by the data provided as 392 2 instances of the total adverse events 16 instances are",
        "label": "Entailment"
    },
    "e3801aad-e988-42fb-8266-22a90bdba955": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measures The primary trial investigates the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial examines the impact of Physical Therapy on pain reported by participants with metastatic oral cavity mucoepidermoid carcinoma The statement does not contradict the trials as they focus on distinct aspects of treatment for different conditions",
        "label": "Contradiction"
    },
    "22274495-9d06-43cd-98fd-86d0374b42e9": {
        "text_answer": "  The statement There were no significant differences in the results from the groups in the primary trial and the Reflexology Group and control group in the secondary trial produced identical results is a conclusion that goes beyond the information provided in the trials   The primary trial only states that there were no significant differences in the area under the ROC curve AUC between the two algorithms for breast cancer diagnosis It does not mention anything about the identical results of the two groups",
        "label": "Contradiction"
    },
    "d3525b25-3dad-4ed2-8fe7-d0f0abc6be14": {
        "text_answer": "  The statement primary clinical trial employs procedures that utilize ultrasound guidance and vertical longitudinal incisions is neither entailed nor contradicted by the information provided in the trials described   The trials only mention the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points during the mastectomy procedure but they do not specify the use of ultrasound guidance",
        "label": "Entailment"
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "text_answer": "  The statement is entailed in the trials as both trials involve the injection of a substance In the primary trial patients receive denosumab injections and in the secondary trial patients receive injections of radioactive Tc99M sulfur colloid However it is essential to note that these are distinct interventions and the statement does not imply that they are identical or interchangeable The denosumab and radioactive Tc99M",
        "label": "Entailment"
    },
    "0e1460ea-4f44-47ff-892a-e3190b498557": {
        "text_answer": "  The statement is contradictory to the given trials as none of the adverse events noted for cohort 1 of the primary clinical trial pertain to mental health The trials only report adverse events related to physical health conditions such as anemia thrombocytopenia cardiac arrest etc",
        "label": "Entailment"
    },
    "9bb1e4d4-379d-47f5-a6b9-c6dac40b2727": {
        "text_answer": "  The statement primary clinical trial participants who didnt undergo paclitaxel infusions experienced more severe symptoms compared to those who did is not directly entailed in the trials provided   The trials only report the average area under the curve aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline for each arm of the study The trials do not provide information on whether participants in",
        "label": "Contradiction"
    },
    "1820d3ff-ca2a-47dc-a80e-45e760307261": {
        "text_answer": "  The statement all cohorts in the primary clinical trial receive enzalutamide via intravenous injection is contradictory to the information provided in the trials as both intervention groups received enzalutamide orally by mouth in the form of capsules Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "2db0df9c-be54-419d-9710-54adb741a1a1": {
        "text_answer": "  The statement patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy within one month prior to the study initiation are not eligible for the primary clinical trial is entailed in the trials exclusion criteria The trial explicitly states that any of these therapies within the past 4 weeks is a reason for exclusion Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "0f36a35d-d86b-41d0-9878-df4ef7ad0e9f": {
        "text_answer": "  The statement the infection asymmetry and deflation cases were less prevalent in the primary trial than in the secondary trial is an entailed statement based on the given trials data   Explanation  The statement is entailed because the primary trial had a lower total number of adverse events for infection asymmetry and deflation compared to the secondary trial Specifically the primary trial had 1 infection 1 asymmetry and ",
        "label": "Entailment"
    },
    "e2061005-22e7-4de3-90c2-e4ebfe055b0d": {
        "text_answer": "  The statement is not entailed in the trials provided   Explanation   The statement compares the overall response rate between the placebo arm in the primary trial and Arm A intervention and compares the time to first onstudy SRE between the Zoledronic acid group and Denosumab group in the secondary trial However the trials do not directly compare the same interventions or outcome measures The primary trial compares Arm A",
        "label": "Contradiction"
    },
    "7b29df5c-9189-4c72-b0ad-3ed971c42652": {
        "text_answer": "  The statement patients suffering from cancer and having conditions like anemia epilepsy or thalasemic diseases are welcome to participate in both the primary and secondary clinical trials is not directly entailed in the given inclusion and exclusion criteria for either trial   The primary trial includes anemia as an inclusion criterion but excludes epilepsy and thalasemic diseases The secondary trial does not mention anemia epilepsy",
        "label": "Contradiction"
    },
    "d58edc4e-2e7f-4c35-b24c-cd1239175b1a": {
        "text_answer": "  The statement the primary participants reported no adverse events specifically no occurrences of maculopapular rash is contradictory to the trial data   Explanation   The trial data reports that one participant 130 experienced a maculopapular rash as an adverse event Therefore the statement that the primary participants reported no adverse events specifically no occurrences of maculo",
        "label": "Contradiction"
    },
    "02cf528a-17da-4ea6-a65e-7a9efe2cf3cf": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trials there are two test groups Pyridoxine and Placebo with a placebo group in Arm II   In the secondary trials there are also two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride but no placebo group is mentioned However the absence of a place",
        "label": "Contradiction"
    },
    "1f9ee295-ce3d-427b-8af2-876edb47bf7f": {
        "text_answer": "  The statement is entailed in the given trials as follows  The primary trial involves the use of Gefitinib ZD1839 as the therapeutic agent while the secondary trial involves the use of Zoledronic Acid as the therapeutic agent Therefore the primary trial requires the administration of a multidrug regimen Gefitinib plus other potential components in the parent trial while the secondary trial calls for",
        "label": "Entailment"
    },
    "d504ff9e-bdcc-4609-9b57-b1cb4638bfdc": {
        "text_answer": "  The statement the participant count was the same for both cohorts in the primary clinical trial is neither entailed nor contradicted by the given information The information provided only states the number of participants analyzed and the percentage of participants with events in each arm of the trial but it does not explicitly state that the participant count was the same for both cohorts",
        "label": "Entailment"
    },
    "cedade64-046d-4e90-ad04-9b0a497fc534": {
        "text_answer": "  The statement is not entailed in the trials as given The trials describe two separate study groups one for patients with glioblastoma multiforme and another for patients with gynecological cancers The statement refers to a regimen used to treat penile cancer which is not mentioned in the trials Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "73e39e6d-e688-4372-85d4-dbb3cbc7a7cb": {
        "text_answer": "  The given statement several of the patients in the primary trial experienced the no pain whatsoever during the 200 weeks of the study is not entailed in the provided trial information The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups over a 10week period No information is provided regarding the number of patients who experienced no pain at all during the entire 200week study duration",
        "label": "Contradiction"
    },
    "f0534dd1-7050-4fc1-971e-5aab8abb5d47": {
        "text_answer": "  The statement is entailed in the trials since the trials report that there were no cardiac or psychiatric adverse events in both the primary and secondary trials The trials provide evidence that supports the statement",
        "label": "Entailment"
    },
    "6247182c-7b14-46b7-9452-a4072ed79a7b": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is not directly related to the information provided about the adverse events in the trials The statement only mentions the absence of unexpected deaths and hospitalizations but the trials provide information about specific adverse events Adverse Events 1 and 2 and their frequencies  Therefore the statement cannot be determined to be entailed or contradicted based on the given",
        "label": "Contradiction"
    },
    "a3ba6a16-5f21-477d-9a2a-574a53ab3f2c": {
        "text_answer": "  The statement eating disorders were not common for the primary trial candidates is not directly related to the adverse events listed in the trial data The statement only mentions eating disorders while the trial data provides information on various types of adverse events The trial data does not mention any cases of eating disorders among the candidates  The statement about soft tissue necrosis CTCAE is not related to the statement about eating disorders and does not entail or",
        "label": "Entailment"
    },
    "fc38bc02-5e04-4b3d-bf4d-19fa9a636bd2": {
        "text_answer": "  The statement no participants in the primary clinical trial experienced a decline in cognitive function including those in the ovarian function suppression group is not directly entailed in the given trial results   The trial results only report the mean standardized composite cognitive function scores and their standard deviations for the Tamoxifen and Ovarian Function Suppression OFS groups The statement makes a more general claim about all participants in the trial including those not",
        "label": "Contradiction"
    },
    "2dbcfe7a-32b5-47e3-a6fc-0f38039de24c": {
        "text_answer": "  The statement More than 97 of patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 12 months of the study is not directly entailed in the given trials as the trials only report the number of participants with pathologic complete response at the time of surgery approximately 7 months into the study The statement goes beyond the reported data and makes an assumption about the percentage",
        "label": "Contradiction"
    },
    "264848be-8491-409f-b19f-0db249bc155a": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site However the primary difference lies in the use of a handheld gamma camera pIHGC in intervention one and standard gamma probes GP in intervention two during the surgical procedure Therefore the statement accurately reflects the distinction between the two interventions in the trial",
        "label": "Entailment"
    },
    "6548c59c-cafc-465f-8f10-4bfc5d147611": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is neither entailed nor contradicted by the given trials as the statement about people being unfriendly is not related to the trials at all",
        "label": "Contradiction"
    },
    "03688964-cf46-485b-99f3-f7c6c5fed3ed": {
        "text_answer": "  The statement participation in the primary clinical trial is limited to female candidates of a specified nationality this condition doesnt exist for the secondary clinical trial is a contradiction   Explanation  The primary clinical trial has inclusion criteria that specify Japanese female candidates while the secondary clinical trial does not have any such restriction on nationality Therefore the statement that this condition doesnt exist for the secondary clinical trial is incorrect as",
        "label": "Contradiction"
    },
    "abc13f3b-54fa-4a1c-a063-5f1f00e2ae9a": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 43 hours if they want to participate in the primary trial is a contradiction of the information provided in the inclusionexclusion criteria  The exclusion criteria",
        "label": "Contradiction"
    },
    "c651d7a4-f39a-44df-84cc-f71c45ced124": {
        "text_answer": "  The statement a patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is a contradiction to the trials inclusion criteria The trial explicitly states that No meningeal carcinomatosis is an eligibility criterion Therefore the statement is a contradiction to the trials criteria and is not entailed in the trial  Regarding the statement about cell culturebased b",
        "label": "Contradiction"
    },
    "9b9d2ca0-acea-42a6-bd46-78eb4540a107": {
        "text_answer": "  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 1300 of the primary trial patients is contradictory to the information provided in the trials  The primary trial reported that syncope occurred in 2 out of 12 patients 1667 which is not the most common adverse event when compared to the other",
        "label": "Entailment"
    },
    "55372cf8-c6a0-4286-8cd5-5e11e070bd79": {
        "text_answer": "  The statement the mymop score change is not a determinant for outcome measurement in either the primary trial or the secondary trial is not directly entailed or contradicted by the given trial results   The primary trial measures the change in patientspecified and reported symptoms using the MYMOP questionnaire before the 7th acupuncture treatment The secondary trial measures the change in isothiocyanate in urine samples at baseline and after completion of",
        "label": "Contradiction"
    },
    "4abdde7a-7745-4391-ae23-9d7fb6d837c2": {
        "text_answer": "  The statement patients with high vitamin d levels in the primary clinical trial manifested a noticeable pattern for expression of the group of 40 evaluated genes is not directly entailed in the provided trial results as no information about the proportion of participants with high vitamin D levels and a noticeable gene expression pattern is given in the trials The trials only report the number of participants with no discernible pattern for gene expression in each armgroup Therefore the statement",
        "label": "Contradiction"
    },
    "bb5873a3-4c28-49f6-9f70-f3f1d8ac7db2": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial group 2 receives normal saline placebo while in the secondary trial group 2 consists of patients with vitamin D deficiency who experience myalgias arthralgias andor joint stiffness and they receive 05ugkg of dexmedetomidine 5ml These two groups are not the same and",
        "label": "Contradiction"
    },
    "eda562ff-9676-46f2-9ec3-93eb3cdd7585": {
        "text_answer": "  The statement more than 03333 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 057 years of the study is not directly entailed in the given trial data   However it is important to note that the trial data only provides information on the number of participants with pathologic complete response at the time of surgery approximately 7",
        "label": "Contradiction"
    },
    "6a211e77-e17f-4739-b685-e6bd83b8d7e3": {
        "text_answer": "  The statement a diagnosis of leptomeningeal carcinoma would render a patient ineligible for the primary clinical trial is a contradiction to the given trial eligibility criteria The trial explicitly states that No meningeal carcinomatosis is a requirement for participation but it does not mention leptomeningeal carcinoma specifically as a disqualifying condition Leptomeningeal carcinoma is a type of",
        "label": "Contradiction"
    },
    "754d4ae4-5d18-4b63-836a-c011958680ce": {
        "text_answer": "  The statement benign ovarian sex cordstromal tumor is a sex cordstromal tumor arising from the ovary without metastatic potential The primary trial and the secondary trial both administer cyclophamide to their patient cohorts is neither entailed nor contradicted by the information provided in the trials  Explanation  The statement is not entailed because the trials do not provide enough information to determine",
        "label": "Entailment"
    },
    "41219409-bd82-4df0-82aa-d72fc4aec1fd": {
        "text_answer": "  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is entailed in the given trials as the secondary trial had a higher percentage of patients with Adverse Events 6000 compared to the primary trial 000 The statement does not mention megacystismegaureter which is an unrelated condition",
        "label": "Entailment"
    },
    "61a1a0e2-bd62-43de-b3c9-1c2143417c5a": {
        "text_answer": "  The statement is entailed in the trials as both trials require the patient to have a functional ECOG status less than 2 which is a measure of a patients functional status and mobility Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "f11800b6-312b-4f9d-9b18-24a3a6bb67a2": {
        "text_answer": "  The statement neither intervention one nor two in the primary clinical trial employs pihgc or standard gp is a contradiction to the information provided in the trials Both interventions pIHGC and GP involve the use of radioactive Tc99M sulfur colloid for lymphoscintigraphy but they do not explicitly state the use of pihgc or standard gamma probes in the trials However",
        "label": "Contradiction"
    },
    "4e0fbb00-bcbe-4051-a343-58a6cb50eb0b": {
        "text_answer": "  The statement patients suffering from a lack of vitamin D are not considered for the primary clinical trial yet they may qualify for the secondary clinical trial is neither entailed nor contradicted by the given trial information  Explanation  The primary trial includes postmenopausal women with early stage breast cancer who are vitamin D deficient and will be treated with an aromatase inhibitor The secondary trial includes healthy males and females with H",
        "label": "Entailment"
    },
    "d331f99d-446c-4305-8842-05d6fe2d070c": {
        "text_answer": "  The statement in the primary group of the primary clinical trial a number of anaemia and febrile neutropenia instances were noted but there were zero cases of pancytopenia is not directly entailed in the given trials as the trials do not provide sufficient information to determine if the groups being compared are the same However based on the information provided the statement is not contradictory to the trials as both trials report different numbers of ad",
        "label": "Contradiction"
    },
    "abaf9c04-8d6d-43f3-afb5-9bc9d04fb9b5": {
        "text_answer": "  The statement amnion nodosum is an amnion with nodular deposits of squamous and cellular debris with varying staging of reepithelialization is not directly related to the given primary or secondary trials Therefore it cannot be entailed or contradicted based on the information provided in the trials  However the statement does mention amnion which is a type of membrane that covers the fetus in the ut",
        "label": "Entailment"
    },
    "e123c707-0e86-43c1-8f9b-971363c07ae0": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials data   Explanation   The statement regimen used to treat prostate carcinoma is any regimen that can be used for the treatment of prostate carcinoma is a general statement about all possible regimens used to treat prostate carcinoma The trials provided only report the number of adverse events for two specific regimens not all possible regim",
        "label": "Entailment"
    },
    "b2caa135-c6ed-46b0-a1e3-6fd60ae12831": {
        "text_answer": "  The statement is contradicted by the information provided in the trial descriptions The statement asserts that the only difference between interventions 1 and 2 is not related to the amount of durvalumab administered monthly to each cohort However the trial descriptions clearly indicate that the amount of durvalumab administered monthly is different between the two interventions 03 mgkg versus 1 mgkg Therefore the statement is contradicted by",
        "label": "Contradiction"
    },
    "19275bdd-9964-4f3b-b2d5-b984203774d5": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial reported a minimum of one infection case is entailed in the given trials as follows  1 In the primary trial there is one infection case out of a total of 32 adverse events 2 In the secondary trial there is one unspecified infection case out of a total of 6 adverse events in the first set and one dehydration case that may lead to",
        "label": "Entailment"
    },
    "8d728674-1111-495d-ae90-59ced10163a4": {
        "text_answer": "  The statement is not directly entailed in the given trial information The trial information only specifies the doses of Eribulin Cyclophosphamide Docetaxel for each cohort but it does not provide information about the potential impact of these treatments on an individuals ability to pay attention due to tiredness Therefore the statement is neither entailed nor contradicted by the trial information",
        "label": "Contradiction"
    },
    "88a8b32d-122c-48f9-a305-3d1b8e3fcd85": {
        "text_answer": "  The statement Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy is entailed in the trial description as it is explicitly stated that Patients will take Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "4bf82041-f1d8-4a90-9bd0-aec991e50966": {
        "text_answer": "  The statement percentage food eaten score 40 is a subjective score of 40 on a scale that ranges from 0 none to 100 all of my food is neither entailed nor contradicted by the given inclusion and exclusion criteria for the primary and secondary trials   The statement is not directly related to the trials as it does not mention any specific eligibility or exclusion criteria for the trials It is",
        "label": "Entailment"
    },
    "b3ed34ea-6461-40ed-955d-693bbc27fd99": {
        "text_answer": "  The statement substance dispersity is a measure of the heterogeneity of sizes shapes or masses of molecules or particles is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided  Regarding the statement Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial this statement is entailed in the primary trial as hypokalemia potassium within the normal range of 3",
        "label": "Entailment"
    },
    "53dac2a0-f55a-4987-bab1-695a985eacd1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks However the statement suggests that the intervention in the secondary trial lasts 50 weeks longer than the intervention in the primary trial which is not the case",
        "label": "Entailment"
    },
    "2cd6db4c-83e4-4ca5-8650-6638521a27a2": {
        "text_answer": "  The statement the primary clinical trial involves patients receiving a number of injections is entailed in the trial description as it mentions the administration of Trastuzumab infusion Vinorelbine ditartrate infusion Leukine subcutaneous injection and therapeutic autologous dendritic cells intradermal injections Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "2cf8bdbf-5f09-4f16-8b50-c6369d003a4f": {
        "text_answer": "  The statement none of the participants in group 1 of the primary trial were found to have lesions and more than 90 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as there is no comparison of lesions or radiation dermatitis between the two groups within the same trial The trials only provide information on the number of participants and the presence or",
        "label": "Contradiction"
    },
    "b41e6cb3-c92e-4027-b96b-502aeb1f4211": {
        "text_answer": "  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is not entailed in the given trials as there is no mention of any participant suffering from Acute myocardial infarction in either the primary or secondary trials Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "d5b131c2-0835-4f00-a0ba-2db26d1fe581": {
        "text_answer": "  The statement throughout the primary clinical trial there were no reported cases of gastrointestinal complications is contradicted by the data in the trials The data shows that there were a total of 3149 201 cases of vomiting reported in Trial 1 and 3149 201 cases of vomiting reported in Trial 2 Therefore the statement is contradicted by",
        "label": "Contradiction"
    },
    "c5fed4a9-da6c-4dcb-b191-930bca7e0ce7": {
        "text_answer": "  The statement is entailed in the given trial information The trial specifies that both the placebo and alloMSCs interventions are administered through transendocardial injections using the NOGA Myostar injection catheter with each intervention consisting of 20 injections of 04ml volume Therefore the statement that the placebo and alloMSCs interventions are delivered through separate transendocardial injections",
        "label": "Entailment"
    },
    "6e9f7a1a-21e5-4d5f-b602-a1efb1b51bc7": {
        "text_answer": "  The statement does not directly entail or contradict the information given in the trials The trials only provide information about the doses of ALT801 administered to two different cohorts in a primary trial The statement discusses familial dysalbuminemic hyperthyroidism and the association of a variant in the alb gene with increased affinity for thyroxine which is not mentioned in the trials Therefore the statement is neither entailed nor",
        "label": "Entailment"
    },
    "61afd69d-529d-49e9-b607-007414946b6c": {
        "text_answer": "  The statement urinary tract infections were not reported among those participating in the primary clinical trial is contradictory to the information provided in the trials data   The data states that there was 1 reported case of urinary tract infection out of 50 participants 200 Therefore the statement is contradictory to the data",
        "label": "Entailment"
    },
    "dfb4c335-296e-42af-b418-329f39c6b42e": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trials results do not require any units of measurement is contradictory to the information provided in the trials  In the primary trials the outcome measurement is Tumor Diameter with units of measurement being cm In the secondary trial the outcome measurement is Number of Participants With Solid Tumor Response which is measured in participants  Therefore the statement is contradictory to",
        "label": "Entailment"
    },
    "5051b4e9-21e7-4fa8-a602-de48b103fa19": {
        "text_answer": "  The statement warfarin based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly stated in the inclusion or exclusion criteria for either the primary or secondary trials provided However it can be inferred from the exclusion criteria of the primary trial that Patients who require use of coumarinderivative anticoagulants such as warfarin are excluded Therefore the statement is ent",
        "label": "Entailment"
    },
    "f61808f1-4431-4b34-8a66-e422c6e97530": {
        "text_answer": "  The statement The majority of patients in the primary trial experienced complete response by week 24 is not entailed in the trial results provided   The trial results indicate the number of participants with complete response CR partial response PR and stable disease SD at week 12 and week 24 for the Lapatinib 1250 mg and Vinorelbine 20 mgm2 armgroup However",
        "label": "Contradiction"
    },
    "01d0c4bf-e697-4565-906b-edd21fd2227f": {
        "text_answer": "  The statement patients with severe cases of schizophrenia and insomnia are unable to partake in the primary and secondary clinical trials is not directly entailed in the given inclusion and exclusion criteria for both trials Schizophrenia is not listed as an exclusion criterion for either trial However the secondary trial has exclusion criteria related to psychiatric illness and substance abuse but it does not specify schizophrenia as a condition",
        "label": "Contradiction"
    },
    "a1e4f5de-9b44-444e-8eff-ae7b040c6f6e": {
        "text_answer": "  The statement women with triple negative stage III breast cancer who have undergone mastectomy are eligible for the primary clinical trial and the secondary clinical trial is neither entailed in the primary trial nor contradictory to it   The primary trial is focused on women with locally advanced recurrent or metastatic breast cancer that is ER and the secondary trial is focused on women with newly diagnosed or recurrent breast cancer who are considering or",
        "label": "Entailment"
    },
    "6f835e44-5cb2-4f42-9b69-8ec81c00a404": {
        "text_answer": "  The statement patients currently in remission are eligible for both the primary clinical trial and the secondary clinical trial even without providing any informed consent is not entailed in the given inclusion criteria for either the primary or secondary clinical trials Informed consent is a mandatory requirement for both trials as stated in their respective inclusion criteria Therefore the statement is contradictory to the information provided in the trials inclusion criteria",
        "label": "Contradiction"
    },
    "8c9c4150-3bc1-4f06-8bee-2d5bba3ef8b9": {
        "text_answer": "  The statement several cardiac and psychiatric aes were observed in the primary clinical trial is a contradiction to the information provided in the trials The trials report no adverse events for both cardiac and psychiatric conditions in the primary trial and no information is given about such events in the secondary trial",
        "label": "Contradiction"
    },
    "2096d634-b321-40de-b69b-8dad3345331e": {
        "text_answer": "  The statement more people participated in the secondary clinical trial than the primary clinical trial is a contradiction to the information provided in the trials   The primary trial had 13 participants and the secondary trial had 30 participants However the statement suggests that more people participated in the secondary trial which is not the case as there are fewer participants in the secondary trial compared to the primary trial",
        "label": "Contradiction"
    },
    "a2981a35-ece3-42dc-a735-cd12466392fa": {
        "text_answer": "  The statement Across both the primary trial and the secondary trial only one death was recorded in the adverse events is entailed in the given trials as both trials report a total of one death in their respective adverse events sections The statement about the dog bite definition is not directly related to the trials and does not affect the entailment or contradiction status of the statement about the number of deaths in the trials",
        "label": "Entailment"
    },
    "ff95337a-7da9-43f5-bb3c-25cd7c85e5c7": {
        "text_answer": "  The statement 025 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is not entailed in the given trials as there is no trial with both adverse events occurring in 025 of patients The trials only report the occurrence of each adverse event separately in specific patient groups Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "6a969a7c-55f3-4595-a361-db78a910f352": {
        "text_answer": "  The statement less than 21 patients in both cohorts of the primary clinical trial witnessed pathologic complete response in breast and axillary lymph nodes 3 months following the surgical intervention is not directly entailed in the given trial results   The trials only provide the number of participants who achieved pathologic complete response at the time of surgery approximately 7 months after the neoadjuvant therapy They do not provide information",
        "label": "Contradiction"
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "text_answer": "  The statement laserassisted fluorescence angiography is used for both interventions in the primary trial is entailed in the given trial description The use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion of the breast at three separate time points is mentioned for both the Inframammary Fold Incision Cohort and the Lateral Radial Incision Cohort",
        "label": "Entailment"
    },
    "5af90c4a-80c3-4f11-bbc0-7f84ad544186": {
        "text_answer": "  The statement patients diagnosed with estrogennegative progesteronenegative and her2 breast tumors may participate in the primary clinical trial is entailed in the given inclusion criteria   Explanation   The inclusion criteria state that patients with histologically confirmed ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 are eligible for the trial ER",
        "label": "Entailment"
    },
    "e92e6dec-b727-475a-b544-568b5773cb81": {
        "text_answer": "  The statement participants in the primary clinical trial are prescribed a dose of 100 mgm2 of lapatinib to be taken orally two times per day for an entire month is not directly entailed in the given intervention description in the trial   The intervention description states that patients in Arm 1 receive oral lapatinib and oral tamoxifen once daily on days 128 but it does not specify the",
        "label": "Contradiction"
    },
    "fc35d08f-73a9-47aa-9450-165dcfda17bf": {
        "text_answer": "  The statement across both the primary clinical trial and the secondary clinical trial no adverse events were observed in more than 1 of participants is entailed by the given data   Explanation   The statement requires that the total number of adverse events across both trials as well as the number of adverse events related to neutrophilsgranulocytes ANCAGC be less than 1",
        "label": "Contradiction"
    },
    "a96f9558-41f8-4515-8fc4-d3b8f326ce05": {
        "text_answer": "  The statement during radiation therapy patients in the primary clinical trial are given morphine sulfate not fentanyl sublingual spray is contradictory to the given trial information   The trial information states that no information is provided regarding the use of morphine sulfate or fentanyl sublingual spray during radiation therapy Therefore it cannot be entailed or contradicted based on the given information alone However the statement that",
        "label": "Contradiction"
    },
    "6fbc7c06-1134-42b6-bfbc-9e4f28727cba": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the number of participants in each group and their recurrencefree survival percentages but they do not directly provide the recurrencefree survival data for each group in the format required for the statement to be entailed",
        "label": "Contradiction"
    },
    "6e6f3848-8d0e-47df-b2f3-1f09cf7da6e4": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial did not experience any adverse events is contradicted by the information provided in the trials   Explanation   The primary clinical trial reported no adverse events which is true However the secondary clinical trial reported 2 adverse events which is a nonzero number Therefore the statement that the primary clinical trial and the secondary clinical trial did not experience any adverse events",
        "label": "Contradiction"
    },
    "eacc1096-c090-4f21-ad10-005be458b653": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg of trastuzumab weekly This is different from the secondary trial where in cohort 2 patients receive Herceptin 4 mgkg on Day 1 of Cycle 5 followed by 2 mgkg weekly starting from Day 8 Therefore the statement that",
        "label": "Entailment"
    },
    "325c6150-352f-4b08-aa67-fed4cd6f68d0": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the statement implies that the patients eligibility for the secondary trial depends on their recovery from the organ transplant and being off bed rest This is not explicitly stated in the",
        "label": "Contradiction"
    },
    "90135397-f63a-412e-9633-0355e1a78154": {
        "text_answer": "  To determine if the statement patients in the primary clinical trial experienced more significant improvements in their lymphedema through acupuncture than those on the waitlist we need to compare the mean arm circumference changes between the two groups at the 6week timepoint  The results provided show that the mean arm circumference in the acupuncture group decreased from 474 cm SD 223 at baseline to",
        "label": "Entailment"
    },
    "6bc62f08-51ae-44d6-be1d-738c82598de5": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial is a summary of some of the exclusion criteria mentioned in the provided text However it is important",
        "label": "Entailment"
    },
    "f6ad61ca-d223-496b-a067-69625112447c": {
        "text_answer": "  The statement less than 120 of patients in the primary trial suffered adverse events is contradictory to the given data in the trial   The trial reported that 2 out of 35 patients 571 experienced adverse events This is more than 120 5 and therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is entailed in the trials inclusion and exclusion criteria   The inclusion criteria state that Women of childbearing potential WOCBP are allowed but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months",
        "label": "Entailment"
    },
    "bb3e3ca1-1b64-4ddc-9492-1fb11ec9356f": {
        "text_answer": "  The statement is partially entailed in the trials The identical imaging procedures using 18FFDG and 18FFPPRGD2 are described in both interventions However the statement does not accurately reflect the dosage information provided in the trials In the GBM study group the dosage of 18FFPPRGD2 is not increased but rather it is specified that they will be injected with less than 10",
        "label": "Entailment"
    },
    "efa989b7-db55-49b8-a124-875a5f7c94ff": {
        "text_answer": "  The statement There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial is not related to the information provided about Adverse Events 1 and 2 in the trials   The statement nervous system neoplasm is a benign or malignant primary or metastatic neoplasm involving the central or peripheral nervous system",
        "label": "Entailment"
    },
    "63a44f77-d6b6-47df-9bea-b7deb99f5658": {
        "text_answer": "  The statement karyocytomegaly and multinucleated hepatocytes is a finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion is not directly related to the adverse events mentioned in the primary trial Therefore it cannot be determined if the statement is entailed or contradicted based on the given information  However the statement 3636 of",
        "label": "Entailment"
    },
    "fc4ec229-5b69-409e-89c0-2b151f670382": {
        "text_answer": "  The statement patients are not mandated to meet any performance status conditions in either the primary or secondary trial is entailed in the given trials as there is no mention of performance status as an inclusion or exclusion criterion in either trial",
        "label": "Entailment"
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "text_answer": "  The statement the primary trial and the secondary trial do not have any recorded adverse events for their participants is entailed by the given data   Explanation  The given data states that for the primary trial there were no adverse events recorded for Adverse Event 1 or Adverse Event 2 and similarly for the secondary trial there were no adverse events recorded for Adverse Event 1 Although the data for Adverse Event",
        "label": "Entailment"
    },
    "1172df8a-7da3-4769-8832-32ded72cfcf1": {
        "text_answer": "  The statement is a contradiction to the information provided in the secondary trial inclusion criteria The secondary trial includes patients with diagnosed alterations in the following genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ and GNA11 Therefore the statement that for the primary trial patients must be diagnosed with a",
        "label": "Contradiction"
    },
    "c20768c0-36c2-44ff-9d4f-36d34e02c1a2": {
        "text_answer": "  The statement hepatitis b virus surface antigen negative is an indication that the hepatitis b virus surface protein antigen has not been detected in a sample is not directly related to the information provided in the trials However the statement does not contradict any information in the trials either The trials only specify the interventions dosages and schedules for each arm but they do not mention anything about the hepatitis B virus status of the patients Therefore",
        "label": "Entailment"
    },
    "04beb33e-ae70-4de2-a805-71650246ea7b": {
        "text_answer": "  The statement the primary and secondary clinical trials are open to patients who have a TNBC tumor measuring 100mm is a contradiction to the information provided in the trials inclusion criteria   The primary trial specifies that the breast tumor should be 1 cm in diameter which is significantly smaller than 100mm The secondary trial does not mention the size of the breast tumor as a criterion However the statement",
        "label": "Contradiction"
    },
    "262e8bd4-da64-4158-b23d-b875050e66af": {
        "text_answer": "  The statement is contradictory to the given information in the trial   Explanation  The statement that both treatments involve the use of an identical paraplatin dose is contradictory to the information provided in the trial because the trial does not mention the use of paraplatin in either arm Instead it mentions the use of carboplatin in Arm 2 Therefore there is no identical paraplatin dose used",
        "label": "Contradiction"
    },
    "18e1908f-f449-42a0-916b-7e88c1e7c901": {
        "text_answer": "  The statement is entailed in the Trials since  1 The statement mentions that patients in the primary clinical trial did not suffer from anemia pneumonia and stupor more frequently than those in the secondary trial This is consistent with the data provided in the trials as the frequency of anemia pneumonia and stupor is 000 in the primary trial and 625 0",
        "label": "Entailment"
    },
    "e4f2bd3a-6976-4a2b-9485-c34bdc812c54": {
        "text_answer": "  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly entailed in the given trial results The trial results only provide information about the proportion of participants with controlled acute vomiting in the Aprepitant Dexamethasone Cytoxan and Ky",
        "label": "Contradiction"
    },
    "70c0fbc1-8eb8-4634-a595-898784718d09": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial the intervention includes gefitinib ZD1839 alone while in the secondary trial the intervention for the first arm includes zoledronic acid vitamin D calcium supplements and in the second arm zoledronic acid vitamin D calcium supplements samarium153 and pegfilgrastim Therefore",
        "label": "Entailment"
    },
    "4960cf63-01e8-4fc5-b6ea-fe10063c6e6c": {
        "text_answer": "  The statement is entailed in the given trials In the primary trial Botulinum Toxin Type A and Placebo are the interventions and alisertib MLN8237 is not mentioned at all In contrast in the secondary trial alisertib is the intervention but the doses vary between the two cohorts Therefore the statement that alisertib isnt included in the treatment of both coh",
        "label": "Entailment"
    },
    "ed12f8ae-3bda-46b8-8bf1-5ad6d1527c57": {
        "text_answer": "  The statement received all the services needed is not directly entailed in either the primary or secondary trial descriptions provided The primary trial focuses on inclusion and exclusion criteria for women with ER locally advanced recurrent or metastatic breast cancer while the secondary trial focuses on eligibility for breast reconstruction in women with newly diagnosed or recurrent breast cancer considering a mastectomy and meeting other specified criteria The statement about receiving all needed services is not mentioned in",
        "label": "Contradiction"
    },
    "2d0df5b6-0886-4a19-973a-92f4442b39d1": {
        "text_answer": "  The statement corneal deposits were less commonly identified amongst the patients in the secondary trial is contradicted by the Trials The Trials do not report any cases of corneal deposits in the secondary trial while the primary trial reported 045 1 case out of 223 occurrence of corneal deposits Therefore the statement is contradicted by the Trials",
        "label": "Contradiction"
    },
    "f9dfbdb7-3248-450e-a7d4-782f2e68e057": {
        "text_answer": "  The statement intravascular ultrasound and transverse radial incisions form the backbone of the surgical procedures in the primary clinical trial is neither entailed nor contradicted by the information provided in the trials   The trials describe two different cohorts one using an inframammary fold incision and the other using a lateral radial incision Both cohorts involve the use of laserassisted fluorescence angiography",
        "label": "Entailment"
    },
    "1c7d5749-bf28-4ae8-8408-ccda3f13a18a": {
        "text_answer": "  The statement is entailed in the trials as both trials are focused on determining the Maximum Tolerated Dose MTD of an intervention in combination with another treatment While the primary trial is specifically using Ruxolitinib in combination with paclitaxel and the secondary trial is using MM111 the methodology for determining the MTD is consistent between the two trials Therefore the statement is entailed in the trials  ",
        "label": "Entailment"
    },
    "586b08dc-8323-46ff-873f-5d262f7eae35": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement 10 adverse events were observed in the primary trial and 90 of the adverse events in the secondary trial affected more than 95 of patients is contradictory to the given trials because  1 The statement implies that there were 10 adverse events in the secondary trial but the given trials state that there",
        "label": "Entailment"
    },
    "74452fe6-e38e-4f1d-a666-765c464ca765": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 the dose of Eribulin Er is 14mgm2 Days 1 and 8 of each treatment cycle while in Intervention 2 the dose of Docetaxel T is 75 mgm2 Day 1 of each treatment cycle To compare the doses we need to convert both dos",
        "label": "Entailment"
    },
    "c81fad5d-aa52-4147-a724-984e7d9c4cc3": {
        "text_answer": "  The statement adverse events that are a result of the secondary clinical trial do not occur in patients from the primary clinical trial is a contradiction to the given data   Explanation   The data provided in the primary and secondary trials do not mention any common adverse events between the two trials However the statement asserts that no adverse events occur in the secondary trial that were present in the primary trial This is not supported by the data",
        "label": "Contradiction"
    },
    "b3909182-2942-44c1-96e8-5650e48401df": {
        "text_answer": "  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is a contradiction to the Trials provided  Explanation  The statement implies that the proportion of blood and bone marrow related adverse events is higher in the primary trial compared to the secondary trial and the opposite is true based on the data provided In the primary trial 10",
        "label": "Contradiction"
    },
    "2d61f68b-3907-4337-bc4c-20f219a1c678": {
        "text_answer": "  The statement in the primary clinical trial all patients with HER2positive primary breast cancer treated with HER2targeted PETCT using 89Zrtrastuzumab remained metastasesfree is a contradiction to the results presented in the trial  The trial reports that 13 out of 49 participants 265 developed imagable HER2 metastases during the ",
        "label": "Contradiction"
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "text_answer": "  The statement There are no conditions on Life expectancy pregnancy or age for participants of the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria do not mention anything about life expectancy pregnancy or age as conditions for participation in the trial Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "2a9b88b7-4d4f-47d5-808b-df5a328935ae": {
        "text_answer": "  The statement the secondary clinical trial reported significantly less total adverse incidents in its patient cohorts than the primary clinical trial is an entailed statement based on the given trials data   Explanation  The statement implies that the secondary trial had fewer adverse events than the primary trial Based on the given data this is true for both trials having a total of zero adverse events in the primary trial and only 000 or",
        "label": "Entailment"
    },
    "20a73393-6e4f-4096-8025-45d8fbe228b7": {
        "text_answer": "  The statement some patients in the primary clinical trial receive no mcs110 at all and over 130 mg of pdr001 every other week is a contradiction to the given trials   The trials specify that all patients in the Intervention 1 and Intervention 2 groups receive both MCS110 and PDR001 The dosages for MCS110 are 1 mgkg every ",
        "label": "Contradiction"
    },
    "1a9f1afc-af2c-4dca-b701-2a04033f47b4": {
        "text_answer": "  The statement is entailed in the primary and secondary clinical trials as follows  In the primary trial the inclusion criteria state that Karnofsky score 70 is a requirement This means that all participants must have a Karnofsky score of 70 or higher to be eligible for the study  In the secondary trial the inclusion criteria state that Patients must have a Zubrod performance score 2 or better The Zub",
        "label": "Entailment"
    },
    "b4db304d-9445-44e0-9f0a-a4df38c1301b": {
        "text_answer": "  The provided statement is not entailed in the trials as there is no information given in the trials about Treatment Emergent Adverse Events or Serious Treatment Emergent Adverse Events for the paced respiration and fast shallow breathing groups Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "197c5300-0475-46e0-aa97-cfb145da896d": {
        "text_answer": "  The statement every participant in group 1 of the primary trial were found to have lesions and merely 1 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is contradictory to the provided trial data  In the primary trial the outcome measurement was the number of lesions detected in healthy volunteers and breast cancer patients undergoing MRI No information about radiation dermatitis or hyperp",
        "label": "Contradiction"
    },
    "a3f8233e-3af4-41f5-a4f4-7676251de646": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves multiple interventions including several types of chemotherapy drugs targeted therapy hormonal therapy biopsy surgery and correlative studies Therefore it does not only necessitate a single type of medicine and avoidance of surgery as stated in the contradictory statement  The secondary trial also involves administering two different types of drugs everolimus and exem",
        "label": "Entailment"
    },
    "a3e78ee7-57e9-47e4-a85f-e61451207043": {
        "text_answer": "  The statement does not directly entail or contradict the given trial information The statement discusses a cytogenetic abnormality and the dosage of ALT801 in two different cohorts of a trial While the statement mentions the dosage of ALT801 it does not provide enough information to determine if the gain of chromosome 17q is related to the dosage or the two cohorts in any way",
        "label": "Entailment"
    },
    "87840288-7db7-4532-b5a9-ce95221cf918": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial is open to women diseased with both claustrophobia and IBS is not directly stated in the given inclusion and exclusion criteria for either trial However neither trial lists claustrophobia nor IBS Irritable Bowel Syndrome as inclusion or exclusion criteria Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "c9077c20-07f8-4137-b88a-9ef599052884": {
        "text_answer": "  The statement the primary clinical trial demonstrates that ki67 expression in tumors increases by 30 on average when tamoxifen 20 mg is administered orally each day for 7 days prior to surgery and 14 days post breast cancer surgery is contradictory to the results presented in the trial   The trial reports a mean percentage change in Ki67 expression of 40 63 to 29 indicating",
        "label": "Entailment"
    },
    "290508ed-616c-4d7e-b83b-49a2fa895a44": {
        "text_answer": "  The statement blood and bone marrow related issues predominantly accounted for reported adverse events in the primary clinical trial as opposed to the secondary clinical trial is entailed in the given trials data if we define predominantly as having a higher percentage of adverse events in the primary trial compared to the secondary trial   In the primary trial 10000 of adverse events were related to blood and bone marrow issues",
        "label": "Entailment"
    },
    "171ca8d1-c986-4446-8ee3-8b8635f4d234": {
        "text_answer": "  The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is entailed in the trials inclusion criteria These patients fall under the category of Any tumor type if tissue tests positive for CCND1 amplification CDK46 mutation CCND2 amplification OR any other functional alteration at the G1S checkpoint",
        "label": "Entailment"
    },
    "7cd38d1e-009b-40f6-a8f8-1352ae821aa4": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is measuring the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial is measuring the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment These are two distinct outcomes being measured in separate trials  The",
        "label": "Entailment"
    },
    "42c07819-8022-4275-8484-6ed9db10115c": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial there are two study groups A and B receiving different interventions Hydrophor Group A and MediHoney Group B The statement correctly identifies that different gels are being assessed for their effects on the study groups  In the secondary trial there are also two study groups A1 and A2 receiving the same intervention PF",
        "label": "Entailment"
    },
    "d735322f-f5fc-489d-bb28-e40451860571": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial zoledronic acid is given intravenously IV not orally as pills In the secondary trial all mentioned interventions granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone can be given either orally or intravenously No intervention is given via",
        "label": "Contradiction"
    },
    "063a0207-f4fc-43c1-849e-6d3fc64b009b": {
        "text_answer": "  The statement thromboembolic events were not observed in either the primary or secondary trial patients is entailed in the given trials as neither trial reported any thromboembolic events in their adverse events data",
        "label": "Entailment"
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "text_answer": "  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed in the given trials as follows  1 The frequency of Ascites in the primary trial is 2223 090 and in the secondary trial it is 09 000 The statement Asc",
        "label": "Entailment"
    },
    "a63d1b8c-8ac5-4b17-a8c8-690dae246d1f": {
        "text_answer": "  The statement porcelain veneer is a restoration consisting of a layer of toothcolored porcelain material cemented to the surface of a tooth is not entailed in the given trials as they do not mention anything related to porcelain veneers The trials only discuss different drugbased interventions for treating various types of cancers",
        "label": "Contradiction"
    },
    "698866bd-4a77-4b0a-9e79-6fb9984692b7": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The primary trial indicates that the median operative time was shorter for the intraoperative mammography group compared to the standard mammography group Therefore the statement that arm 1s operative time was less than that of arm 2 in the primary clinical trial indicating the superior performance of standard mammography over intraoperative mammography is incorrect",
        "label": "Entailment"
    },
    "144b54f3-eb81-4c83-a94c-2c01847b9299": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial there is no information provided about the specific interventions given to the patients undergoing mastectomy surgery Therefore we cannot directly compare the weekly intake of MM121 and Paclitaxel between the primary and secondary trials However we can compare the doses of the specific chemotherapies mentioned in the statement which are Her",
        "label": "Entailment"
    },
    "b00e3d3a-3046-4996-a028-35e45ce682be": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 40 years would be excluded from the primary trial is not explicitly stated in the inclusion and exclusion criteria provided However the criteria do include the exclusion of patients with a history of interstitial lung disease or pneumonitis While diffuse parenchymal lung disease is a type of interstitial lung disease the criteria do not specify",
        "label": "Entailment"
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "text_answer": "  The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for the primary trial is entailed in the given inclusion criteria   Explanation   The inclusion criteria state that the breast cancer must be histologically confirmed as ER positive HER2 negative for Group 1 or invasive triplenegative breast cancer for Group 2 ER negative PR negative and H",
        "label": "Entailment"
    },
    "bce464d0-a0f9-4d17-9caa-6bd247cfdce3": {
        "text_answer": "  The statement device migration problem identified is a device that has moved from its original location due to external forces eg stent or lead movement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is not directly entailed or contradicted by the given trials data  The trials data only provides the number of adverse events and their respective counts in each trial It does not provide any",
        "label": "Contradiction"
    },
    "bd828bb3-e2b2-46e0-a1fb-635d6aade839": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is comparing two different interventions Hydrophor and MediHoney in their study groups hence testing the effects of different interventions on the study groups  The secondary trial is comparing two different doses 90 mg and 110 mg of the same treatment PF05212384 in its study group hence testing the effects",
        "label": "Entailment"
    },
    "71e83f04-ecd5-4d79-8062-42bcb68d6f29": {
        "text_answer": "  The statement nearly all patients in both the primary and secondary clinical trials specifically over 97 did not report any negative outcomes is contradicted by the given data   In the primary trial 4545 of patients reported adverse events and in the secondary trial 1563 of patients reported adverse events Therefore less than 97 of patients in both trials reported no negative outcomes",
        "label": "Contradiction"
    },
    "6943a60c-a7c2-46c5-9238-c88db6a2b725": {
        "text_answer": "  The statement cancer patients diagnosed with either fibromyalgia thalasemic syndromes or anemia are allowed to participate in both the primary clinical trial and the secondary clinical trial is not entailed in the given trials inclusion and exclusion criteria  Explanation  The primary trial excludes participants with a diagnosis of fibromyalgia as an exclusion criterion Therefore fibromyalgia is a condition",
        "label": "Contradiction"
    },
    "3fbecafb-c5f7-4a19-b265-1840a379f81f": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial and the secondary trial utilize different outcome measurements pCR in the primary trial and pathological complete response after preoperative therapy pCRp in the secondary trial  In the primary trial the difference between the two cohorts FEC75 Then PaclitaxelTrastuzumab and PaclitaxelTrastuzumab Then Trastuz",
        "label": "Entailment"
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "text_answer": "  The statement is entailed in the trials as both groups undergo the same 18FFDG imaging procedure and receive 18FFPPRGD2 with a dose less than 10 mCi The only difference is the timing of the 18FFPPRGD2 imaging 6 weeks vs 912 weeks and the slightly higher patient group in cohort 1 receiving the imaging Therefore the",
        "label": "Entailment"
    },
    "bdc8ed3c-63bd-4f71-bcbd-83d11575603d": {
        "text_answer": "  The statement candidates for both primary clinical trial and secondary clinical trial must fulfill a baseline performance status though each trial uses a unique scoring system is entailed in the given trials as follows  In the primary trial the inclusion criteria state that the patient must have a Karnofsky score of 70 which is a measure of performance status In the secondary trial the inclusion criteria state that patients must have a Zubrod performance score of 2",
        "label": "Entailment"
    },
    "574ab11b-3216-4b4b-a4aa-cf035483fe05": {
        "text_answer": "  The statement on average patients from the primary trial survive less than 1 year over 120 patients from each cohort survived more than 12 months is contradictory to the given trial results   The median survival times reported in the trial results are 214 years for the midluteal surgery group and 200 years for the midfollicular surgery group Both median survival times are greater than",
        "label": "Entailment"
    },
    "90eff3be-13fe-4f5d-82f1-534ae1fe4a81": {
        "text_answer": "  The statement tuberculum sellae is a prominence on the sphenoid bone which separates the sella turcica from the chiasmatic sulcus is not related to the information provided in the trials Therefore it is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "617d4baf-29bc-4a82-a0b0-c8d2c0590599": {
        "text_answer": "  The statement candidates Capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial is not directly stated in the inclusion criteria or exclusion criteria of either trial However the statement does not contradict the information provided in the trials as the eligibility criteria for both trials include an ECOG performance status of 0 to 2 which indicates",
        "label": "Entailment"
    },
    "7ddde4b4-4070-4aff-b971-53bbd0ec9437": {
        "text_answer": "  The statement prefer to hear as many details as possible is a question about whether a person would prefer to hear as many details as possible is neither entailed nor contradicted by the given trials The trials only provide information about the interventions used in each study not about the preferences of the participants regarding hearing details",
        "label": "Entailment"
    },
    "1bc50379-9721-419f-959a-560b3747b8ec": {
        "text_answer": "  The statement the primary trial and the secondary trial have 00 recorded adverse events is entailed by the given data since both trials have a recorded total of 0 adverse events",
        "label": "Entailment"
    },
    "603ee9e3-5213-4121-97d8-4369641e9b00": {
        "text_answer": " The given statement is not entailed in the trials provided as they report percentage change in betaCTX a biochemical marker of bone turnover rather than primary tumour diameter Therefore the trials do not provide sufficient information to determine if the AZD0530 175 mg group experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group",
        "label": "Contradiction"
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial In the secondary trial the intervention is described as Patients Undergoing Mastectomy Surgery which does not involve the administration of Suramin and Paclitaxel Therefore the statement that Suramin and Paclitaxel are administered to all patients in the primary trial and the secondary trial intervention section does not describe what drugs are to be administered is false",
        "label": "Entailment"
    },
    "0fd90f9b-bf76-4c3c-9964-dc635138217c": {
        "text_answer": "  The statement General symptoms are the most common AE recorded in the primary trial is not directly related to the eligibility for lung surgery The trial data provided only mentions the adverse events AEs observed during the study but it does not provide any information about the patients eligibility for lung surgery Therefore the statement is neither entailed nor contradicted by the given trial data",
        "label": "Entailment"
    },
    "632b415b-ebc1-4898-8676-1ef38eecb128": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials The trials describe the interventions being administered through different routes IV for bisphosphonate and subcutaneous injection for denosumab but they do not mention anything about the piga gene mutation Therefore the statement about the piga gene mutation is not directly related to the trials and cannot be determined to be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "914bc3a7-1468-46df-8d13-f271220b5c84": {
        "text_answer": "  Both trials state that candidates must have an ECOG performance status of 02 Among the possible values for ECOG performance status a score of 1 is included Therefore the statement both the primary clinical trial and the secondary clinical trial accept candidates having an ecog score of 1 is entailed in the trials",
        "label": "Entailment"
    },
    "c6f2c906-4b0a-4b93-99ee-2152df2af3e4": {
        "text_answer": "  The statement participants in the primary clinical trial must have colorectal cancer and be under immunotherapy is contradictory to the given inclusion and exclusion criteria for the primary trial   The inclusion criteria state that participants must have breast cancer that has continued to grow after receiving hormonal treatment and require hormonal treatment while being postmenopausal The exclusion criteria state that participants cannot have received more than one previous regimen of systemic",
        "label": "Entailment"
    },
    "f6a1bd73-7581-4284-b039-705aeb0236bf": {
        "text_answer": "  The statement is entailed in the given trials data as there are no adverse events reported in the primary trial while there are several adverse events reported in the secondary trial The comparison between the two trials is indeed challenging due to the significant difference in the number and types of adverse events reported",
        "label": "Entailment"
    },
    "fcedf2b8-b97d-4a57-8ccc-e77c53900b3c": {
        "text_answer": "  The statement the incidence of recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were lesser in the adverse events profile of the secondary clinical trial than in the primary clinical trial is entailed in the given trials data  Explanation  The statement is entailed because the number of occurrences of each adverse event in the primary trial is greater",
        "label": "Entailment"
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX at week 4 between the two groups   The AZD0530 175 mg group had a percentage change of 711 759 to 654 and the Zoledronic Acid 4 mg group had a percentage change of 684 730 to",
        "label": "Entailment"
    },
    "6fd90164-4ae9-4296-88d8-e6eab3811c8a": {
        "text_answer": "  The statement There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation is entailed in the trials inclusion criteria under section B The trial specifies that 1530 enrollment slots are reserved for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation Therefore",
        "label": "Entailment"
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using RECIST criteria for solid tumors These outcome measures are different from each other and the trials do not share the same primary endpoint Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "cbd414d3-c3c6-4d3a-8a7a-67832757ae03": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention for Arm 1 includes placebo for 47 days and CBTI for seven weekly sessions Arm 2 includes CBTI and Armodafinil with a specific dosing regimen The statement mentions that in Arm 2 of the primary trial Armodafinil is dispensed daily for 47 days However this is",
        "label": "Entailment"
    },
    "78dd81db-dbc1-427a-9a3d-09f3e339ac99": {
        "text_answer": "  The statement concern about finances is a question about whether an individual has or had concerns about finances is not directly related to the provided trials and their adverse events Therefore it cannot be determined if the statement is entailed or contradicted based on the given information  Regarding the trials the statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is a contradiction",
        "label": "Entailment"
    },
    "8cd9c9e7-ff02-4e49-893d-a4e2837bf18f": {
        "text_answer": "  The statement is not entailed in the given trials as neither the primary nor the secondary trials involve the use of alisertib MLN8237 in any of the interventions The statement pertains to a different condition autoimmune neutropenia and a different drug alisertib than what is being studied in the trials provided",
        "label": "Contradiction"
    },
    "9b9256a3-3f1b-4f43-90da-f8ae79096bd5": {
        "text_answer": "  The statement every patient that is qualified for the secondary clinical trial will also qualify for the primary clinical trial is a statement of inclusion meaning that if a patient meets the criteria for the secondary trial they will also meet the criteria for the primary trial  Lets examine the inclusion and exclusion criteria for both trials to determine if this statement is entailed in the trials  Primary Trial Inclusion Women with breast cancer nonpalp",
        "label": "Entailment"
    },
    "26731a57-6d43-4738-817a-74da5c372da2": {
        "text_answer": "  The statement retroperitoneal undifferentiated pleomorphic sarcoma is a rare undifferentiated pleomorphic sarcoma that arises from the retroperitoneum patients with Histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial is entailed in the given trials as  1 Ret",
        "label": "Entailment"
    },
    "2fde518b-d7c2-4e66-bab7-0cdff22d5ffe": {
        "text_answer": "  The statement the primary clinical trial welcomes Alzheimers patients for inclusion is contradictory to the trials inclusion criteria The criteria explicitly state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Alzheimers disease is a progressive neurodegenerative disorder characterized by cognitive impairment and a decline in daily functioning and patients with Alzheimer",
        "label": "Entailment"
    },
    "d19b920a-add8-4be3-8e09-96889800fe00": {
        "text_answer": "  The statement the ability to give written informed consent is the sole common eligibility criterium between the primary clinical trial and the secondary clinical trial is a conditional statement To determine if it is entailed in the trials with entailment or contradiction we need to check if the primary and secondary trials both require the ability to give written informed consent as an eligibility criterion and if there are no other common eligibility criteria  Let",
        "label": "Entailment"
    },
    "37aab021-5b76-4b95-88b6-1050e9252803": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve preoperative intravenous administration of dexamethasone to different cohorts However the statement specifically mentions that the first cohort receives dexamethasone preoperatively which is consistent with the trials The second cohort receiving dexamethasone two hours postsurgery is not directly mentioned in the statement but is not contradictory to",
        "label": "Entailment"
    },
    "2c0f27c0-642c-4669-8f38-3304bd2fdaf3": {
        "text_answer": "  Lets calculate the combined count of hypertension and pancreatectomy incidents 1250 hypertension  1250 pancreatectomy  2500  The statement hepatotoxicity cases to be triple the combined count of hypertension and pancreatectomy incidents can be written as   3  hypertension ",
        "label": "Entailment"
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria The primary trial requires a primary tumour greater than 2 cm diameter while the statement suggests a primary tumour with a radius of 3mm which is less than the required minimum size Therefore a patient with a primary tumour of 3mm radius would not be eligible for the primary trial based on the given inclusion criteria  Regarding the secondary trial the statement does not provide enough information to",
        "label": "Entailment"
    },
    "2f606d1d-7dd5-4d18-8ae6-7899efe85487": {
        "text_answer": "  The statement the secondary clinical trial accepts females who are living with IBS and claustrophobia is not explicitly stated in the given inclusion or exclusion criteria for the secondary trial However neither is it contradicted The criteria provided only mention specific conditions that would exclude individuals from participating in the trial The absence of a condition in the exclusion criteria does not necessarily mean that it is an inclusion criterion Therefore the statement is neither entailed nor",
        "label": "Contradiction"
    },
    "51811b25-079e-44e0-a38a-b9e0735ded90": {
        "text_answer": "  The statement Repetitive adverse events were reported among different patients particularly in the primary clinical trial is entailed in the given data as there are multiple instances of the same adverse event reported in different patients eg Heart Failure Vertigo Small intestinal obstruction Fever Aspartate aminotransferase increased Alanine aminotransferase increased Back Pain Pleural effusion R",
        "label": "Entailment"
    },
    "f2640a7c-0890-40e2-a2dc-1dcdeefcd3bf": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description recipients do not receive injectable medication thrice per day for two weeks but rather receive oral medication daily for a month",
        "label": "Entailment"
    },
    "4a9efa5a-6bb1-4b34-a2a7-dfa40fdd29b4": {
        "text_answer": "  The statement 25 of the second cohort in the primary clinical trial have experienced a rise in pleural effusion is entailed in the given trials since the trials report that 14 2500 of the second cohort experienced an Increased pleural effusion Therefore the statement is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "207602e0-9ba8-437e-a8c2-deb34b3eaef9": {
        "text_answer": "  The statement is mostly contradictory to the primary trial as the primary trial involves multiple drug types given via different routes IV PO SC and surgery while the secondary trial only involves two drugs given orally However both trials do have correlative studies including needle biopsy immunohistochemistry staining method and laboratory biomarker analysis Therefore the statement is partially incorrect The primary trial does have correlative studies but",
        "label": "Entailment"
    },
    "e7451698-de0f-49c5-b287-a419652d62e0": {
        "text_answer": "  The statement is entailed in the trial results as follows  1 The trial involves patients with HER2primary breast cancer who undergo HER2targeted PETCT using 89Zrtrastuzumab and 89Zrpertuzumab 2 The outcome measurement is the percentage of patients who develop imagable HER2 metastases over a 3year time frame 3",
        "label": "Entailment"
    },
    "ca09a15d-86a6-4a7e-9dfb-ff195702e0d4": {
        "text_answer": "  The statement during the course of the primary clinical trial 35 patients who were under the combination therapy of sunitinib docetaxel and trastuzumab encountered treatmentemergent adverse incidents is a contradiction to the given results   The results state that there were a total of 25 participants analyzed in the trial with 24 experiencing treatmentemergent adverse events AEs and",
        "label": "Contradiction"
    },
    "68461786-a85c-4370-8935-cb6680a3c5cb": {
        "text_answer": "  The statement individuals with uncontrolled cardiovascular conditions can join the secondary clinical trial is contradictory to the exclusion criteria of the secondary trial which states uncontrolled cardiovascular disease as an exclusion criterion Therefore the statement is contradictory to the information provided in the trials inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "e945ad07-11b2-48f7-8022-40f0af7883af": {
        "text_answer": "  The statement none of the participants neither in the primary nor in the secondary trial suffered an acute myocardial infarction is entailed in the given trials as there were no cases of acute myocardial infarction reported in either trial",
        "label": "Entailment"
    },
    "8f74daa8-19d7-4b51-9296-9b61e885690c": {
        "text_answer": "  The statement is consistent with the information provided in both trials In the primary trial the exclusion criterion is Any history of alcohol or substance abuse or dependence within the past 2 years DSM5 criteria which is stricter than the secondary trials inclusion criterion Fewer than 5 alcoholic drinks per day within the past year Therefore the statement is entailed in the trials as the primary trial is more restrictive in",
        "label": "Entailment"
    },
    "9a6bed06-19da-4284-b5fd-e68ddad563c3": {
        "text_answer": "  The statement is entailed in the given trials as both Intervention 1 and Intervention 2 involve the administration of the medication through a single method  1 Intervention 1 Openlabel intravenous IV bisphosphonate once every 4 weeks Q4W 2 Intervention 2 Openlabel denosumab 180 mg by subcutaneous injection once every 12 weeks Q1",
        "label": "Entailment"
    },
    "39ac8702-7670-4a8e-851a-49e41a77c836": {
        "text_answer": "  The statement diarrhea was uncommon among the primary trial participants compared to the secondary trial participants is contradicted by the given data   Explanation  The primary trial had 7 cases of diarrhea out of 30 participants which is 2333 The secondary trial had 0 cases of diarrhea out of 6 participants   To determine if the statement is entailed or contrad",
        "label": "Contradiction"
    },
    "e5b93c15-0c68-4b2f-bceb-a905f7116ef3": {
        "text_answer": "  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is a contradiction to the given trials inclusion and exclusion criteria   The primary trials inclusion criteria state that participants must be resistant to aromatase inhibitors AI therapy but there is no mention of mirtazapine in the inclusion or excl",
        "label": "Contradiction"
    },
    "25602467-131a-44d1-a3d9-5a4a61a0ea0a": {
        "text_answer": "  The statement if patients have experienced abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or severe psychiatric disorders within the last six months they are ineligible for the primary clinical trial is entailed in the trials exclusion criteria as stated in the text provided Therefore the statement is entailed in the trial",
        "label": "Entailment"
    },
    "c634ebf6-2577-4cc6-9e2d-e14da660629d": {
        "text_answer": "  The statement is not directly entailed in the given trial information The trial describes the dosages of Eribulin Cyclophosphamide Docetaxel for each intervention group However it does not provide information about the dosages of these drugs in relation to the lesser trochanter or the iliopsoas muscle attachment Therefore the statement is not entailed in the trial information and is neutral with respect to the trial",
        "label": "Contradiction"
    },
    "a714b4d6-d9d7-4dc7-8efe-50c92616d027": {
        "text_answer": "  The statement estimated body weight is an approximate determination of the weight of a body is not related to the information provided in the trial results   The statement All but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event and less than half the patients suffered serious TreatmentEmergent Adverse Events is entailed in the",
        "label": "Entailment"
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "text_answer": "  The statement Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention is not directly stated in the provided trial results However the results do show that the percentage of participants who were up to date for cervical cancer screenings before the intervention was 423 To determine if 61 patients were up to date we would need to know the total number of",
        "label": "Entailment"
    },
    "0f3d96aa-a8ea-430a-ab6a-fe5e41f8b9fb": {
        "text_answer": "  The statement prednisone is administered preoperatively to all participants in the primary clinical trial cohorts is entailed in the given trials as both Intervention 1 and Intervention 2 involve preoperative intravenous administration of Dexamethasone which is a type of Prednisone",
        "label": "Entailment"
    },
    "606dc2e9-a1a7-400a-8971-bfb2d3a3f3ab": {
        "text_answer": "  The statement the primary clinical trial has a higher incidence of bronchopneumonia and physical health decline compared to the secondary clinical trial is contradictory to the given data   The data shows that there were no adverse events of bronchopneumonia or physical health decline reported in the primary trial while the secondary trial reported 1 case each Therefore the primary trial has a lower incidence of these adverse events compared to the secondary trial",
        "label": "Contradiction"
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is contradictory because  1 The statement implies that Anaemia was the most common adverse event in the secondary trial with a frequency of more than ",
        "label": "Contradiction"
    },
    "32e81a4f-0434-46d3-8da4-04037c77a56b": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The trials only provide information about interventions used in two separate studies one involving Fluciclatide injections and the other involving Chloroquine doses The statement discusses Helicobacter which is a different genus of bacteria entirely and does not mention any injections or doses being administered intraosseously or intravenously Therefore the statement is",
        "label": "Entailment"
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any AEs however almost all of cohort 2 candidates suffered at least one ae is a contradiction to the given trials data   The trials data states that there were no AEs reported in Cohort 1 0147 or 000 However the statement claims that almost all of Cohort 2 candidates",
        "label": "Contradiction"
    },
    "796ae946-899b-475c-ab4c-88ba6af1e881": {
        "text_answer": "  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is not directly entailed or contradicted by the given trial data The trial data only reports the occurrence of specific adverse events in each cohort but it does not provide information about the presence or absence of Hypertension Edema and Dyspnea in the trials Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "eb9c708d-26e5-40a1-a0d3-6b80f689f540": {
        "text_answer": "  The statement is entailed in the trials if and only if the trials imply that the only types of adverse events AEs observed in the secondary trial that were not observed in the primary trial are Eyelid oedema and Chest pain  Lets check if this is the case  1 The statement mentions that the only types of AEs observed in the secondary trial that were not observed in the primary trial are Eyelid",
        "label": "Entailment"
    },
    "ac12ebab-2165-42ac-bd15-a155dd895e00": {
        "text_answer": "  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE adverse event related to genital itching andor irritation is not entailed in the given trials as they do not provide any information about genital itching andor irritation as an adverse event The trials only report adverse events related to anaemia febrile neutropenia le",
        "label": "Contradiction"
    },
    "c6b00d4d-2940-484b-b305-baaf3c5ccff4": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is focused on the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial evaluates the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment These trials are addressing different outcome measures and time frames so they",
        "label": "Entailment"
    },
    "cc97aa0a-365f-459a-a65a-557dd1d930cf": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial is a contradiction to the trials inclusion criteria The trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are excluded However the statement adds an additional condition of diffuse parenchymal lung disease which is a type of interstitial lung disease",
        "label": "Contradiction"
    },
    "e028bf17-f183-4afa-b470-f7741f04e41b": {
        "text_answer": "  The statement 61 of the primary trial participants with HER2positive primary breast cancer treated with HER2targeted PETCT using 89Zrtrastuzumab developed HER2 metastases is not directly entailed in the provided trial information   The trial results only state that 13 out of 49 participants 265 developed HER2 metastases",
        "label": "Contradiction"
    },
    "604c0ae1-7d51-4238-adb7-1a0b1da1b466": {
        "text_answer": "  The statement a number of cardiacaffiliated adverse instances were logged for the first cohort of the primary clinical trial is entailed in the Trials as there are instances of adverse events related to cardiac conditions in the first cohort specifically Acute Coronary Syndrome Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac Tamponade However its important to note that",
        "label": "Entailment"
    },
    "3ae463ca-9747-4796-805c-b4b56c0be8e9": {
        "text_answer": "  The statement have trouble communicating thoughts is not directly entailed nor contradicted by the information provided in the primary and secondary trials The trials focus on medical interventions for breast cancer patients and do not mention anything about the patients ability to communicate their thoughts",
        "label": "Contradiction"
    },
    "3d85fd79-27cc-4e06-b4e0-88348ab9ac0a": {
        "text_answer": "  The statement there is no overlap in the inclusion and exclusion criteria for the primary and secondary clinical trials is entailed in the given trials if and only if there is no common element in the sets of inclusion criteria and exclusion criteria for both trials   Lets examine the given criteria for each trial  Primary Trial Inclusion Age  18 years advanced cancer sensitive to vinorelbine life expectancy of at",
        "label": "Contradiction"
    },
    "9aed7121-8548-40e9-a960-618bf0173df8": {
        "text_answer": "  To verify whether the statement is entailed in the Trials with Entailment or Contradiction we need to refer to the specific dataset provided in Trials with Entailment or Contradiction Unfortunately without access to that dataset it is impossible to make a definitive determination based on the given statement alone  However based on the information provided in the statement it seems that the statement is generally entailed in clinical trials as it is common for",
        "label": "Entailment"
    },
    "8ecb562c-3169-4c07-bb44-d6e716873c08": {
        "text_answer": "  The statement is not directly entailed in the given trials as there is no mention of benign renal pelvis neoplasms or urothelial papillomas in either trial However the statement is not contradictory to the trials as well as the trials focus on patients with advancedmetastatic solid tumors and do not include benign renal pelvis neoplasms or urothelial papillomas as potential participants",
        "label": "Contradiction"
    },
    "454e1858-76b2-4952-9ac0-820d81dbf966": {
        "text_answer": "  The statement the primary clinical trial demands that patients take a biweekly dose of decitabine whilst the secondary clinical trial requires no medication is a contradiction   The primary trial involves the use of Abl Cells IV and Cyclophosphamide and does not mention decitabine at all The secondary trial involves the use of DMCHOCPEN which is a different medication than decitabine Therefore",
        "label": "Contradiction"
    },
    "58161b30-e890-45e5-822d-3172f884ed40": {
        "text_answer": "  The statement is entailed in the Trials In both the primary and secondary trials CT scans and MRI are not explicitly mentioned as interventions but are implied as diagnostic tools used to monitor the progress of the medical interventions CT scans and MRI are commonly used in breast reconstruction surgery to assess the expansion of the breast tissue and in cardiac studies to evaluate the effects of alloMSC injections on the heart Therefore the use of CT scans",
        "label": "Entailment"
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "text_answer": "  The statement Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial is entailed in the trials exclusion criteria for both trials In the primary trial smokers are explicitly listed as an exclusion criterion In the secondary trial smokers are not explicitly mentioned but the trial is limited to ASA Physical status I or II females scheduled for breast conserving surgery or modified radical mastectomy and",
        "label": "Entailment"
    },
    "630dd8d6-eff4-48f9-ac35-c1731b6c4a79": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial is not examining surgical interventions but rather Estring and Testosterone Cream The secondary trial is assessing acupuncture not a meditation intervention",
        "label": "Entailment"
    },
    "fc38a4bc-7c69-4ae2-9dad-f089f15e4d5e": {
        "text_answer": "  The statement is entailed in the trials if we consider the difference in dosage between the two cohorts   Intervention 1 ALT801 0015 mgkgdose Intervention 2 ALT801 0040 mgkgdose  The difference in dosage between the two cohorts is  0040 mgkg",
        "label": "Entailment"
    },
    "804580d2-f170-45ed-bf39-28dc33921b6d": {
        "text_answer": "  The statement is not entailed in the trial results provided   The trial reports a change in Ki67 expression not tumor size The statement provided reports a reduction in tumor size which is different from the outcome measurement in the trial Additionally the dosage of tamoxifen in the statement is different from the dosage used in the trial",
        "label": "Contradiction"
    },
    "014e2dc7-251b-4615-a8fc-38aed023b053": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial and only a single case of Atrial fibrillation is not directly entailed in the given trials as there is no information about Atrial fibrillation being a type of Hospitalization in the trials However the statement is consistent with the trials as there are no deaths or Hospitalizations as defined in the trials reported in cohort 2 Therefore",
        "label": "Contradiction"
    },
    "3d82f108-1f18-426e-a49f-f7fedcb82a7c": {
        "text_answer": "  The statement is not entailed in the trials as given The trials describe the doses of talazoparib administered to participants with breast cancer and ovarianperitoneal cancer but they do not provide any information about Nocardia bacteria or their relation to the trials Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Contradiction"
    },
    "7f90773c-288c-4b5d-bc82-81d7189e6c5d": {
        "text_answer": "  The statement the interventions in the primary clinical trial differ in the dosage of paraplatin used is not directly stated in the given information Paraplatin is not mentioned in the interventions described Herceptin navelbine Taxotere and carboplatin are the specified interventions Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "1f3d7969-35e1-4880-8ae5-b97c53c1e536": {
        "text_answer": "  The statement several patients in the secondary trial experienced only one adverse event is not directly entailed nor contradicted by the given trial data   The data only provides the number of patients who experienced each adverse event but it does not specify how many patients experienced only one adverse event Therefore the statement cannot be determined to be entailed or contradicted based on the given information alone",
        "label": "Contradiction"
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "text_answer": "  The statement Any cancer patient diagnosed with either Epilepsy thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is entailed in the trials inclusion and exclusion criteria   Explanation  The primary trial excludes participants with epilepsy and cerebral metastasis which are forms of neurological conditions Thalasemic syndromes are also excluded due to",
        "label": "Entailment"
    },
    "0b958f19-d411-426c-8144-162c6c15d9d2": {
        "text_answer": "  The statement the number of patients undergoing adverse events was four more in the first cohort than in the second cohort of the primary clinical trial is contradictory to the information provided in the trials The trials report that there were no adverse events in either cohort so there is no way that the number of adverse events could be four more in one cohort than the other",
        "label": "Contradiction"
    },
    "2493d396-14df-4cf7-b2b4-3e84d4363a0f": {
        "text_answer": "  The statement is in contradiction to the trials provided   The primary trial intervention is about Yttrium90 Radioembolization using TheraSphere glass microspheres which is a radiotherapy treatment   The secondary trial intervention however is about a combination of two drugs ibrutinib and MEDI4736 with a starting dose of 560 mg of ibrutinib and ",
        "label": "Contradiction"
    },
    "ccce8199-a89f-40b4-9c27-755f2d99c98d": {
        "text_answer": "  The statement in the primary clinical trial a single type of adverse event was noticed in more than one patient is entailed in the given data   Explanation   The statement implies that there is at least one type of adverse event that affected more than one patient in the trial The data provided shows that there are two patients with the same type of adverse event under the category General disorders and administration site conditions  Other disease progress",
        "label": "Entailment"
    },
    "417ed12e-5ae1-4024-9d97-ef152b78f64c": {
        "text_answer": "  The statement less than 10 of the primary trial participants had a Reduction in circulating tumor cells Following months of Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results as the results only report the number of participants with a reduction in CTCs at one month posttransplantation and do not provide information about the percentage of participants with a reduction or the time frame beyond one",
        "label": "Contradiction"
    },
    "5647bdb4-a763-46c0-a7f4-3d69cbc7aa95": {
        "text_answer": "  The statement patients with breast cancer and ovarianperitoneal cancer within the primary clinical trial experience an identical treatment method is contradictory to the given trials   Explanation   The Intervention 1 is for patients with breast cancer who received talazoparib capsules in Part 1 and 2 at various doses The Intervention 2 is for patients with ovarianperitoneal cancer",
        "label": "Entailment"
    },
    "0f5d87e7-c78c-4579-a111-3f61640c6206": {
        "text_answer": "  The statement syncope was the most prevalent adverse event in both the primary and secondary clinical trials patient cohorts is contradicted by the given data   Explanation   The statement implies that syncope had the highest frequency of occurrence in both trials However the data shows that the frequency of syncope in the primary trial was 212 1667 while in the secondary trial it was not",
        "label": "Contradiction"
    },
    "dfd39b75-1119-400a-a9af-588d7e63b867": {
        "text_answer": "  The statement is contradictory to the given trials as there were no deaths recorded in either the primary or secondary trials according to the provided data The statement suggests that there were 10 deaths recorded in total between the two trials but the trials report a total of only 1 death in the primary trial and no deaths in the secondary trial",
        "label": "Contradiction"
    },
    "2fc3e471-39c1-4f8a-804f-6b2ad5f711c9": {
        "text_answer": "  The statement in the primary clinical trial GTx024 of 1mg dosage resulted in lean body mass gain in every patient over a span of 4 months is not directly entailed in the given trial results as the results do not provide information about every individual patient in the 1mg dosage group having a positive lean body mass gain The median value for the change in lean body mass in the 1mg dosage group is 1",
        "label": "Contradiction"
    },
    "57dec3a3-0bce-48c3-972d-e08f32ea9b15": {
        "text_answer": "  The statement the secondary clinical trial had several recorded deaths in the adverse events but the primary trial had no such incident is contradictory to the given data   Explanation   The primary trial had one recorded adverse event of bone pain but no recorded deaths The secondary trial had one recorded adverse event of neutrophilsgranulocytes ANCAGC which is not specified as a death",
        "label": "Contradiction"
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention involves cabergoline which is given orally not topically The secondary trial interventions involve pixantrone dimaleate which is administered intravenously IV not topically Therefore neither trial intervention matches the description of being given topically",
        "label": "Entailment"
    },
    "926177b8-d70d-48d4-95c9-4d74de46d9d0": {
        "text_answer": "  The statement no pathologic complete response in breast and axillary lymph nodes was reported in patients involved in the primary clinical trial is not directly entailed or contradicted by the given trial results   The trial results only report the number of participants with pathologic complete response in each arm of the study but they do not report the total number of participants in the study or the number of participants without pathologic complete response Therefore based on",
        "label": "Contradiction"
    },
    "4d8b9c01-83b6-4590-9aaf-9389b998ebff": {
        "text_answer": "  The statement is entailed in the given trial information Both the placebo and trabectedin are administered intravenously over a 3hour infusion period but they are given on different days Therefore the statement accurately reflects the information provided in the trial description",
        "label": "Entailment"
    },
    "4bda5405-4218-460a-a8b4-c958dddedfa1": {
        "text_answer": "  The statement while there were no recorded adverse events among the patients in the primary clinical trial every participant in the secondary clinical trial experienced at least one adverse event is a contradiction of the given data   Explanation   The statement implies that there were no adverse events in the primary trial and all participants in the secondary trial had at least one adverse event However the data provided shows that there were no adverse events in the",
        "label": "Contradiction"
    },
    "5484288d-bc10-458f-a516-d0019792d765": {
        "text_answer": "  The statement candidates for the primary clinical trial are acceptable with any performance status while those for the secondary clinical trial must have a Karnofsky score less than 50 is contradictory to the information provided in the trials  In the primary trial the inclusion criteria state that participants must have a Karnofsky score of 70 or better In contrast the secondary trial includes participants with a Karnofsky score of 2 or",
        "label": "Entailment"
    },
    "8aef748c-257f-4a74-a391-3cdbdc839c79": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first",
        "label": "Contradiction"
    },
    "a1043895-ce9b-4370-94c8-6ce3078e3bbb": {
        "text_answer": "  The statement all negative occurrences experienced during the primary clinical trial concerned the musculoskeletal system a situation not seen in the secondary clinical trial is a contradiction to the given data  Explanation  The statement implies that there were no negative occurrences in the secondary trial that concerned the musculoskeletal system However the data provided in the secondary trial shows that there were negative occurrences related to platelet",
        "label": "Contradiction"
    },
    "99b10330-04b5-4aa1-bc04-9378fa54c994": {
        "text_answer": "  The statement is not entailed in the primary or secondary trials as given The primary trial only mentions mammography as a requirement for participation while the secondary trial mentions a CT scan and blood tests as additional requirements The statement also mentions an external fiberoptic device which is not mentioned in either trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "be07b8e7-1858-4182-b37f-56681f56c273": {
        "text_answer": "  The statement the ki67 expression in tumors is not assessed in either the primary or secondary clinical trial is not directly stated in the provided information from the trials However based on the given outcome measurements there is no mention or indication of ki67 expression assessment in either trial Therefore the statement is entailed by the information provided",
        "label": "Contradiction"
    },
    "9b75f8dd-3667-47be-a7d3-2cca26ae5fbe": {
        "text_answer": "  The statement Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial is not directly entailed or contradicted by the given trials inclusion and exclusion criteria   The primary trials criteria do not mention claustrophobia or IBS and the secondary trials criteria mention claustrophobia as an exclusion criterion However",
        "label": "Contradiction"
    },
    "f086fa4c-a302-455d-82e7-faf8b78fc2f4": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The placebo was administered as a 3hour infusion on Day 1 while trabectedin was administered as a 3hour infusion on Day 2 Neither intervention was described as being administered on a biweekly basis let alone through a 3minute intravenous infusion Therefore the statement is contradictory to the information provided in",
        "label": "Entailment"
    },
    "4805b27b-471f-4571-8de9-a7a77f1bd1a4": {
        "text_answer": "  The statement not a single ae was reported for either cohort in the primary clinical trial is contradictory to the information provided in the trials   Explanation   The trials report that there were adverse events AEs in both cohorts with specific AEs listed for each cohort Therefore the statement that not a single ae was reported for either cohort in the primary clinical trial is",
        "label": "Entailment"
    },
    "e7505665-3677-4d18-87ec-8483dc002bd1": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference in interventions between the two cohorts In cohort 1 patients receive sunitinib at starting doses of 25 mg to 375 mg daily In cohort 2 patients receive bevacizumab at a dose of 10 mgkg The statement also mentions that malignant pylorus neoplasm is the",
        "label": "Entailment"
    },
    "b21d4a81-e82a-4bd7-ac88-5fcc046aafdf": {
        "text_answer": "  The statement there were no reported infections in the primary clinical trial nor the secondary clinical trial is entailed in the given trials as there are no reported infections in the Adverse Events section of either trial",
        "label": "Contradiction"
    },
    "8e881af0-4e26-43c9-93e8-5e3397f857e1": {
        "text_answer": "  The statement gist grade cannot be assessed is a gist grade that cannot be assessed is neither entailed nor contradicted by the given inclusion and exclusion criteria for the primary trial The statement is not directly related to the criteria provided as it does not mention any specific condition or eligibility requirement for the trial The statement is about a concept called gist grade which is not defined or mentioned in the trial criteria Therefore the statement is neither",
        "label": "Entailment"
    },
    "ea1eb143-4c11-4e40-9511-46f4e17b9e1d": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   Explanation  The statement regardless of having cancer or not all participants in the primary clinical trial are subjected to the same intervention is contradicted by the trials because the trials involve two different groups of participants Adult Cancer Patients 65 Years of Age and Older and Healthy Volunteers These groups are not the same and the participants in each group are",
        "label": "Contradiction"
    },
    "7a699c4d-46d7-48a0-915d-43b8c3a1f1f5": {
        "text_answer": "  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is a contradiction to the given data in the trials   The primary trial had 0 cases of Intestinal perforation and the secondary trial had 1 case Therefore there is not an 11 case difference between the trials",
        "label": "Contradiction"
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "text_answer": "  The statement is entailed in the trials if the trials provide that cohorts 1 and 2 follow the same instructional CD for paced breathing but cohort 2 practices it twice daily and receives weekly chemotherapy This information is not explicitly stated in the given text but it is a reasonable assumption based on the provided information  Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "d48955a5-78eb-4a53-9495-1a363c7b8e05": {
        "text_answer": "  The statement the patient with the greatest PFS in the primary clinical trial managed to survive for 6 months without any disease progression or death is not directly entailed in the given trials as they only report the median PFS for each treatment group not the longest PFS observed in any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "3b25e9e8-6fe5-40a3-b302-7a32f651b464": {
        "text_answer": "  The Karnofsky score is not explicitly mentioned in the given inclusion and exclusion criteria for the clinical trial However the statement that patients must have a Karnofsky score of 80 or above to be considered for the primary clinical trial is an additional requirement that is not stated in the original text Therefore this statement is not entailed in the given inclusion and exclusion criteria and is an additional eligibility criterion for the trial",
        "label": "Contradiction"
    },
    "ccd3d27f-e743-4adf-8135-3488117f1178": {
        "text_answer": "  The statement is entailed in the trials In both trials cyclophosphamide is used in combination with other drugs in the chemotherapy regimens Paclitaxel is a component of the secondary trials chemotherapy regimen docetaxel  paclitaxel and pegfilgrastim is mentioned as a growth factor support in the secondary trial Therefore the statement that cyclophosphamide paclitaxel and pegfil",
        "label": "Entailment"
    },
    "cbe2e1d0-bb9b-43a2-b965-732f43d9af05": {
        "text_answer": "  The statement candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor the secondary trial as the eligibility criteria for the two trials are different and do not necessarily overlap However the statement does not contradict the trials as it is possible for a patient with an ECOG score of 1 to meet the eligibility criteria for both trials depending on their individual",
        "label": "Entailment"
    },
    "626fbbe0-8d56-40bf-8809-0e5d1d587a4d": {
        "text_answer": "  The statement only men aged 60 and above can participate in the secondary trial and the primary trial is contradictory to the information provided in the trials inclusion criteria   The primary trial includes patients with breast or head and neck cancer regardless of age while the secondary trial includes patients aged 18 or older Therefore men and women of all ages can participate in the primary trial and men aged 18 or older can participate in the secondary",
        "label": "Entailment"
    },
    "cf935264-ef24-4f3a-b60f-1c4cc9d36a54": {
        "text_answer": "  The statement in the primary clinical trial one specific adverse event type affected more than half of the patient cohort is contradictory to the information provided in the trials The total adverse events affected 3571 of the patients which is far less than 50 Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "60a1579f-8115-4fec-bdba-fd3031f64e19": {
        "text_answer": "  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is a contradiction to the given trials   The trials only provide the number of adverse events and their respective frequencies in each trial They do not mention the number of cases of Biliary colic or Clostridium difficile colitis specifically Therefore it is not possible to make a direct comparison",
        "label": "Contradiction"
    },
    "7f22f322-c4fb-4001-875b-fe5baefbdc64": {
        "text_answer": "  The statement There was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is not directly entailed in the given trials as the trials do not provide information about the specific types of adverse events related to shingles caused by Veillonella bacteria However the statement is not contradictory to the trials as well since the trials do not mention anything about Veillonella being the cause of sh",
        "label": "Contradiction"
    },
    "d942324e-c945-4703-b88e-905c073cfcd5": {
        "text_answer": "  The statement there were zero cases of hypertension edema and dyspnea in either cohort of the primary trial is entailed in the given trials as both trials report zero cases for edema in each cohort and neither trial reports any cases of hypertension or dyspnea in either cohort",
        "label": "Entailment"
    },
    "0a56f64e-6747-4fc7-a05d-6024e7b52cf6": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary and secondary trials both involve intravenous injections as a mode of drug administration However the specific drugs used their dosages and frequency of administration are different in each trial Therefore the statement is entailed in the trials as it correctly identifies that the trials involve intravenous injections but acknowledges the differences in the interventions  Therefore the statement is entailed in",
        "label": "Entailment"
    },
    "494a6e1b-2bac-4777-9a12-077106690f16": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials report no records of swelling hypothermia or confusion in their adverse events sections",
        "label": "Entailment"
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "text_answer": "  The statement is entailed in the trials as both cohorts 1 and 2 are for adults 65 years of age and older However the statement does not provide enough information to determine which vaccine is given to each cohort specifically The trials do state that cohort 1 receives the Pneumococcus vaccine and cohort 2 receives the Influenza vaccine Therefore the statement is entailed in a more general sense but",
        "label": "Entailment"
    },
    "327cfcfa-5534-4b9c-ab06-57fe595cb887": {
        "text_answer": "  The statement there were 11 more adverse events reported in the secondary clinical trial than in the primary clinical trial is entailed in the given data   Explanation   The statement implies that there were 11 additional adverse events in the secondary trial compared to the primary trial The data provided shows that there were 11 adverse events in the secondary trial that were not present in the primary trial ie feb",
        "label": "Entailment"
    },
    "73ac48a2-08b0-4ee5-8651-f65c88c08101": {
        "text_answer": "  The statement involvement in the primary clinical trial calls for participants to be unresponsive to ai therapy and mirtazapine but this is not a criterion for the secondary clinical trial is a statement of contradiction between the two trials  Explanation  The primary clinical trial includes the criterion of participants being resistant to aromatase inhibitors AI therapy but there is no such criterion mentioned in the",
        "label": "Contradiction"
    },
    "d42f5cb0-e70b-4c8b-ae2e-297254b1d95a": {
        "text_answer": "  The statement is entailed in the trials as both trials are investigating the use of Eribulin Mesylate in the primary trial and Axitinib and Docetaxel with Axitinib being the active drug in the first intervention in the secondary trial While the formulations and dosing regimens differ the active medicinal substances under investigation are identical in both trials",
        "label": "Entailment"
    },
    "bae680f2-9b93-494d-b2e7-65a99400af85": {
        "text_answer": "  The statement men diagnosed with prostate cancer who present positive biomarker for PSA are eligible for all cohorts of the primary clinical trial is contradictory to the given trial information   The inclusion criteria for the trial specify that all participants must be female and have a diagnosis of either ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 The statement about men with",
        "label": "Entailment"
    },
    "66fb10cd-ce81-4c54-aa97-b7167d3115d8": {
        "text_answer": "  The statement the presence of 1 cerebral metastasis located within the frontal lobe does not hinder participation in the secondary clinical trial but those with such a diagnosis are disqualified from the primary clinical trial is a contradiction to the given trial criteria  Explanation  The primary trial explicitly states that a diagnosis of cerebral metastases including those located within the frontal lobe is a disqualifying condition",
        "label": "Contradiction"
    },
    "5cf29cab-a9e9-4385-a342-1684d424ecd8": {
        "text_answer": "  The statement is not directly entailed in the given trials as the primary and secondary trials are separate studies with different outcomes However the statement does make a comparison between the two studies specifically mentioning the absence of lesions in the healthy volunteers group of the primary trial and the high incidence of radiation dermatitis and hyperpigmentation in the participants of the secondary trial  To determine if the statement is entailed we would need to compare the exact same",
        "label": "Contradiction"
    },
    "eaa12be4-b2f0-493a-9ce4-c70f874db211": {
        "text_answer": "  The statement the primary trial most often highlights coronary artery stenosis as an adverse event is a contradiction to the given trial data The trial data lists various adverse events but there is no mention of coronary artery stenosis as an adverse event in the given data",
        "label": "Contradiction"
    },
    "d4fb8105-81af-42ca-a829-1b77694ce0f1": {
        "text_answer": "  The statement Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure is not entailed in the given trials as there is no mention of CogState or objective cognitive function scores in either the primary or secondary trials The primary trial measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM while the secondary trial measures the objective response rate of HER2",
        "label": "Contradiction"
    },
    "1efbc2a0-c0fc-4849-96d7-689fcfb3c4d1": {
        "text_answer": "  The statement does not entail or contradict the given trial information   The statement only mentions caplet dosing unit and preoperative in relation to Dexamethasone but the trial information specifies the dosage 8 mg or 24 mg and the timing of administration preoperative or 2 hours postoperative using intravenous administration   Therefore the statement does",
        "label": "Entailment"
    },
    "fca1de92-2c1b-4c41-b49f-e07553b6aa83": {
        "text_answer": "  The statement in the primary clinical trial general symptoms are the most frequently noted adverse event is not entailed in the given trial data as the frequency of general symptoms 251 or 392 is not the highest among all the adverse events listed The highest frequency is shared by nausea vomiting and general symptoms 392 each Therefore the statement is contradictory to the trial data",
        "label": "Contradiction"
    },
    "935d23d4-0d67-4d42-8546-db1bab3f4a3d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial uses a time frame of 12 weeks and does not mention anything about semesters The secondary trial also uses a time frame of 18 months which is not mentioned as being divided into semesters Therefore there is no information in the trials to support the statement that the secondary trial runs in semesters and uses weeks as a unit of measure while the",
        "label": "Contradiction"
    },
    "81e4cf84-ba33-46ce-ba44-e7edae2a2788": {
        "text_answer": "  The statement all individuals in group 1 of the primary clinical trial showed signs of cutaneous lesions less than 10 of participants in the first group of the secondary clinical trial had radiation dermatitis or hyperpigmentation is contradictory to the information provided in the trials  In the primary trial there were no participants with lesions detected in the healthy volunteers group In the breast cancer patients group there were 12 les",
        "label": "Contradiction"
    },
    "9a78f293-8ab9-4b2d-9224-3f4ae8fc45d5": {
        "text_answer": "  The statement participants with quantifiable bilateral breast cancer are suitable for the primary clinical trial is contradictory to the given inclusion criteria The trial only includes participants with unilateral breast cancer meaning cancer in one breast only Therefore participants with quantifiable bilateral breast cancer do not meet the inclusion criteria and are not suitable for the trial",
        "label": "Entailment"
    },
    "19ae1506-7a41-406e-8f43-8c32df24392b": {
        "text_answer": "  The statement all patients treated with gtx024 1x103 grams in the primary trial gained lean body mass over a 17 week period is not directly entailed in the given trials as they only report the change in lean body mass from baseline to 4 months 17 weeks for two different doses of GTx024 1 mg and 3 mg The trials do not provide sufficient information to determine if",
        "label": "Contradiction"
    },
    "9dc3d717-d3b6-4002-b7f7-26e17d2cabc2": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents",
        "label": "Entailment"
    },
    "87c5a93d-fcef-46ca-8267-3d928c13c6f7": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial reported no deaths or hospitalizations except for a solitary case of atrial fibrillation is not directly entailed in the given trials data However it is consistent with the data as there are no reported deaths or hospitalizations excluding atrial fibrillation in cohort 2 according to the trials data Therefore the statement is not contradictory to the trials data",
        "label": "Contradiction"
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that cohorts 1 and 2 receive the same dosage of CUDC101 and the same frequency but the trial information indicates that cohort 1 receives an additional weekly dose of PD0332991 Therefore the statement is contradictory to the trial information",
        "label": "Entailment"
    },
    "58f223d4-6f38-4ea3-a6fc-5ed8599df2be": {
        "text_answer": "  The statement patients in the primary clinical trial reported a 5 reduction in ki67 cell expression after undergoing TAK228 and tamoxifen therapy for over 6 weeks is entailed in the trial results as follows  1 The trial reports a median IQR reduction in Ki67 expression from baseline to 6 weeks for the TAK228 plus Tamoxifen arm as 5 percentage points",
        "label": "Entailment"
    },
    "f37f99e0-a9eb-450f-850e-7bd96547bab1": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the administration of durvalumab and tremelimumab the same dosing schedules for tremelimumab and the optional extended treatment of durvalumab monotherapy The only difference between the two interventions is the dosage of durvalumab in the biweekly IV infusions The statement correctly identifies that the intellectual wellbeing of the subjects is not affected by this difference",
        "label": "Entailment"
    },
    "aa3c3321-c4f3-43b4-9821-767903e333c6": {
        "text_answer": "  The statement a patient who has undergone an organ transplant within the past 30 days would not be eligible for the primary clinical trial but might be suitable for the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However the statement is implicitly entailed in the exclusion criteria for the primary trial as it mentions The participant has undergone major surgery within 28 days prior",
        "label": "Entailment"
    },
    "959883cf-50ff-42e8-8da9-9ad0be3e18b6": {
        "text_answer": "  The statement locally advanced breast carcinoma is a breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes is not related to the adverse events mentioned in the trial Therefore the statement is neither entailed nor contradicted by the information provided in the trials  Regarding the psychiatric adverse event the statement does not specify whether the patients in the trial had locally advanced breast carcinoma or not",
        "label": "Entailment"
    },
    "0e4f4030-9d92-4885-905e-3599e26db71a": {
        "text_answer": "  The statement the primary clinical trial intervention section indicates a detailed treatment cycle specifying chemotherapy regimens is a contradiction to the given intervention 1 description The intervention 1 description mentions the use of a device and partial breast irradiation but it does not specify any chemotherapy regimens in the treatment cycle Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "0cece9f2-8d43-4d06-97bd-fb800bd3e71a": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial does not mention the Hamilton Depression Rating Scale HDRS for assessing mental health wellness The secondary trial does not mention monitoring triglyceride levels throughout 6 months Both trials focus on different outcomes and interventions",
        "label": "Contradiction"
    },
    "91439ad2-cb81-49e5-a783-ebbc2e04d64a": {
        "text_answer": "  The statement is a contradiction of the given trials   Explanation   The statement anaemia was encountered as a frequent adverse incident in the secondary trial affecting more than 5 of patients however no such incidents have been identified in the primary trial is a contradiction because the statement implies that anaemia was a frequent adverse event in the secondary trial affecting more than 5 of patients but it",
        "label": "Contradiction"
    },
    "bc864ba6-4d2b-431b-9b34-7b668eb5c468": {
        "text_answer": "  The statement the neratinib group of the primary clinical trial had a higher rate of iDFS than the placebo group is entailed in the trials as the results show that the percentage of participants with iDFS events in the neratinib group was lower 47 compared to the placebo group 75 A lower percentage of events indicates a higher rate of iDFS",
        "label": "Entailment"
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "text_answer": "  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is contradicted by the given data   Explanation   The statement implies that the percentage of patients with adverse events is equal in both cohorts However the data shows that the percentage of patients with adverse events is different between the two cohorts In Cohort 1 5000 of",
        "label": "Contradiction"
    },
    "ff3d1bb2-393e-4798-a128-090e7308f5b1": {
        "text_answer": "  The statement an adult patient diagnosed with ILDDPLD within the last 3 years with a life expectancy of 6 months would be eligible for the primary trial is not directly entailed nor contradictory to the inclusion and exclusion criteria provided in the trial description   The statement mentions a diagnosis of Interstitial Lung DiseaseDesquamative Interstitial Pneumonitis ILDDPLD",
        "label": "Contradiction"
    },
    "34250dad-ad53-42bb-a8d3-80866141d548": {
        "text_answer": "  The statement worse than expected is a subjective response is not directly related to the given trials and their interventions It is a definition or explanation of a term worse than expected and does not entail or contradict any information provided in the trials  Regarding the trials themselves the primary trial had one test group Pyridoxine and one control group Placebo while the secondary trial had two test groups Highdose",
        "label": "Entailment"
    },
    "d98e6c4a-c899-405d-b26e-e3a2e0cb3494": {
        "text_answer": "  The statement Sexually active men and women who are not willing or not able to commit to abstinence for the duration of the study are eligible for the primary clinical trial is not directly stated in the inclusion or exclusion criteria provided However the criteria do mention that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevac",
        "label": "Entailment"
    },
    "b44a3eb6-01b7-488d-b18a-b3077937cc97": {
        "text_answer": "  The statement the recorded adverse events in the primary trial allow for a comprehensive comparison with the secondary trials data is entailed in the given information if we assume that the comparison is based on the presence or absence of adverse events and their respective frequencies The trials provide the number of adverse events and their types in both trials allowing for a direct comparison Therefore the statement is entailed in the given data",
        "label": "Entailment"
    },
    "a1ae68b1-c14f-44b5-bc43-8966858fbf14": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The primary trial and the secondary trial address different interventions and do not directly compare the dosing regimens of Alpha Lipoic Acid and Necitumumab The statement mentions the country of origin of the biologic entity which is not mentioned or relevant to the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial states that patients in Intervention 1 receive 150 mg of oral pregabalin twice daily which translates to 300 mg per week or 1800 mg over 6 weeks However the statement in the question simplifies this to 150 mg of oral pregabalin every 2 weeks over 6 weeks This simplification is equivalent to the",
        "label": "Entailment"
    },
    "98e66236-2140-45a7-8bea-e2d17f373def": {
        "text_answer": "  The statement cerebellar and brain stem ependymal tumor is a finding indicating the presence of an ependymal tumor in the cerebellum and brain stem is not directly related to the adverse events listed in the primary trial Therefore it cannot be entailed or contradicted based on the information provided in the trial",
        "label": "Entailment"
    },
    "07e27cba-9e03-4644-a6f3-d05b61b5e4e2": {
        "text_answer": "  The statement less than 10 patients in the primary trial suffered AEs is not directly related to the adverse events mentioned in the trial data provided The statement only gives a general information about the number of patients who suffered any adverse events but it does not specify the number of patients who suffered from the specific adverse events mentioned in the trial data  The statement mixer device is a mechanical device designed to blend materials or an electronic device designed to blend",
        "label": "Entailment"
    },
    "117067e9-9bde-4d49-a4d2-51e9ac9886f6": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial specifically mentions the use of oral pregabalin 150 mg twice daily for 6 weeks and the secondary trial mentions the use of intrathecal Liposomal Cytarabine Depocyt and intravenous HighDose Methotrexate HDMTX with different dosing schedules and treatment regimens There is no",
        "label": "Contradiction"
    },
    "8320c826-7a88-43e8-ae24-069d0f6ff886": {
        "text_answer": "  The statement compared to the secondary clinical trial the primary clinical trial shows more instances of bronchopneumonia and general health decline is a comparison statement To determine if it is entailed in the given trials or contradictory we need to compare the number of instances of bronchopneumonia and general health decline in both trials  From the given trials we can see that  Primary Trial No instances of bronchopneumonia",
        "label": "Entailment"
    },
    "354bc4da-42d7-452f-82bb-43e270a24c2f": {
        "text_answer": "  The statement is contradictory to the given data in the primary clinical trials The trials provide information on various types of adverse events including cardiovascular and hematological events None of the recorded adverse events for the first group or the second group are related to mental health issues Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Entailment"
    },
    "c472d895-f7f4-474f-8664-b7af887b1339": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the total adverse event rates between cohort A and cohort B   The total adverse event rate in cohort A is 5000 24 and in cohort B it is 4000 25 Since the rate in cohort B is lower than that in cohort A",
        "label": "Entailment"
    },
    "a7960e8d-c8a2-4d32-93ff-bb5902051344": {
        "text_answer": "  The statement stopped in car for a few minutes in traffic is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided The trials focus on the diagnosis treatment history functional status and measurable lesions of patients with advanced or recurrent breast cancer The statement about being stopped in a car for a few minutes in traffic does not affect the eligibility of patients for the trials Therefore the statement is neither entailed nor contrad",
        "label": "Entailment"
    },
    "b67a2d20-b35d-45b7-a594-8946f1f160ab": {
        "text_answer": "  The given statement is not directly entailed nor contradicted by the provided information in the trials description   The trials description mentions that radiotherapy is used in Intervention 1 but it does not specify whether it is also used in the Control group Therefore the statement that radiotherapy is utilized in the primary clinical trials intervention strategies for both cohorts is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "7f7c84c5-cc6b-4d4f-a47c-4d41454fd6d0": {
        "text_answer": "  The statement is entailed in the primary clinical trial as zoledronic acid in intervention 1 of the primary trial is given intravenously  In the secondary clinical trial all the intervention drugs granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone can be given intravenously based on the trial description Therefore the statement is also entailed in",
        "label": "Entailment"
    },
    "4e9a0d19-c8b1-4ea4-9c73-2cf93b46f6a4": {
        "text_answer": "  The statement more than 65 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days after the surgery is not directly entailed in the given trials as the trials do not provide information on the number of participants in each cohort who experienced pathologic complete response after approximately 210 days postsurgery The trials only report the number of participants",
        "label": "Contradiction"
    },
    "44241e4d-31dc-487e-b42c-e8c47e3e82cf": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial all evaluable patients may receive vitamin D repletion but no information about injections is given In contrast in the secondary trial anemic breast cancer participants receive weekly subcutaneous injections of epoetin beta Therefore the statement that primary trial candidates receive weekly subcutaneous infusions whereas secondary trial participants are not given any injections is incorrect",
        "label": "Contradiction"
    },
    "a7ff54ef-32cc-4cda-b4a2-39d5f6e1559c": {
        "text_answer": "  The statement patients in the primary trial noted a 10 decrease in the percentage of cells with ki67 expression after a month of undergoing tak228 plus tamoxifen treatment is entailed in the trial results as stated   The trial reports a median IQR decrease of 5 percentage points from 15 to 10 in Ki67 expression at 6 weeks compared to baseline in the",
        "label": "Entailment"
    },
    "73052d5e-1a3a-4479-9ada-e69963c84b77": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the information provided in the statement with the trials results   The statement doselimiting toxicity was experienced by two patients from cohort 2 implies that there were at least two participants in cohort 2 who experienced doselimiting toxicity  Both trials Level 1 and Level 2 have the same treatment regimen with",
        "label": "Entailment"
    },
    "f2796825-a4d9-4484-8958-851d99294e3c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial uses a unit of measure of units on a scale for hot flash scores which is not related to seconds or minutes The secondary trial uses the proportion of responders as its primary outcome measure which also does not involve seconds or minutes",
        "label": "Entailment"
    },
    "a5c24bc4-6444-46bb-9da4-fca0d9d6f521": {
        "text_answer": "  The statement the interventions analysed in the primary clinical trial and the secondary clinical trial do not have their maximum tolerated dose mtd reported is entailed in the Trials  Explanation  In both trials the outcome measurement is the determination of the maximum tolerated dose MTD or maximum feasible dose However in neither trial is the actual MTD reported in the given results Instead the trials describe the process of",
        "label": "Entailment"
    },
    "aed670bb-54a4-4769-86de-65f566bafebe": {
        "text_answer": "  The statement is entailed in the primary clinical trial as there is no mention of the use of imaging techniques such as xrays ultrasound CT scans or MRIs in the description of the Contour Profile Tissue Expander intervention  However for the secondary clinical trial the statement is also entailed as the description of the interventions does not mention the use of imaging techniques for the administration of alloMSCs or place",
        "label": "Entailment"
    },
    "2aef976d-1cb6-4d70-bda2-30a453c37f88": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial demonstrated superior results compared to cohort 2 of the secondary clinical trial cannot be determined based on the provided information   The primary clinical trial and the secondary clinical trial measure different outcomes The primary clinical trial focuses on breast cancerspecific quality of life using the FACTB instrument while the secondary clinical trial tests the efficacy of a device to intraoperatively assess positive margins",
        "label": "Entailment"
    },
    "4d18c0c9-1317-4c04-9b86-f6e7e8906f5e": {
        "text_answer": "  The statement smoked cigarettes since last visit to this clinic is not directly related to the information provided in the primary or secondary trials The trials focus on the determination of the Maximum Tolerated Dose MTD of Ruxolitinib in combination with Paclitaxel for the primary trial and the Maximum Tolerated Dose MTD or Maximum Feasible Dose for MM111 in the secondary trial",
        "label": "Entailment"
    },
    "72921dd1-88c7-4aff-a98e-8af859e4f04f": {
        "text_answer": "  The statement does not contradict the given trials as both interventions involve preoperative intravenous administration of Dexamethasone However the trials do not provide sufficient information to determine if the statement is entailed as the trials do not specify the baseline Global Partial Response GvHD scores or the change in scores after the intervention Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "78479579-0089-4132-8de1-f710cb80ac05": {
        "text_answer": "  The statement Japanese nationals are eligible to participate in both the primary clinical trial and the secondary clinical trial is entailed in the given trials as there is no exclusion criterion in either trial that specifically mentions Japanese nationality as a reason for ineligibility",
        "label": "Entailment"
    },
    "ce1887bc-e9b2-4c21-a5b8-dcbe59d3503e": {
        "text_answer": "  The statement is entailed in the trials as both trials report outcomes related to health conditions in the same population patients undergoing treatment The primary trial measures changes in pain levels using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine at 9 months Therefore the statement that the primary clinical trial documents modifications in pain levels and",
        "label": "Entailment"
    },
    "ad477da6-f950-49b8-a882-0c1dfbc4751f": {
        "text_answer": "  The statement 13 individuals received the globohgm2lewisymuc132aastnctfctncklh conjugate vaccine as part of their treatment in the primary clinical trial is entailed in the given trial information   The trial information states that Overall Number of Participants Analyzed 13 and the statement spec",
        "label": "Entailment"
    },
    "547b8239-a47c-4f70-aa08-ff1d92e19af2": {
        "text_answer": "  The statement having an adequate vitamin D level is a prerequisite for participation in the primary clinical trial while it is considered as a disqualifying factor for the secondary clinical trial is contradictory based on the given trial information  Explanation  In the primary trial having a vitamin D level below 40 ngml is an inclusion criterion meaning that having an adequate vitamin D level is a requirement for",
        "label": "Entailment"
    },
    "4ec4fce7-e43e-46c8-ab5a-f5f04df1b940": {
        "text_answer": "  The statement the primary clinical trials results demonstrate a superior overall response rate for the arm A intervention compared to the placebo group is entailed in the primary trial results as Arm A had an overall response rate of 676 25 out of 37 participants compared to the placebo not provided in the trial  The statement in addition the secondary clinical trial indicates that the denosumab group had an improved time to",
        "label": "Entailment"
    },
    "787e3275-7973-46d4-83de-00d9ebaf7acb": {
        "text_answer": "  The statement Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events is not entailed in the given trials as the trials only report the number of adverse events and their respective types without mentioning the total number of deaths across both trials The statement is not contradictory to the trials either as the trials do not provide enough information to determine whether the statement is true or false",
        "label": "Contradiction"
    },
    "f95439cc-7c35-43a8-ade1-6652fbdf7873": {
        "text_answer": "  The statement multiple psychiatric adverse events were noticed in the primary clinical trial impacting more than a quarter of the patients is contradictory to the information provided in the trials The trials report a total of 6 adverse events out of which only one suicidal ideation can be considered a psychiatric event The number of patients experiencing this event is 1 out of 50 which is less than 25 Therefore the statement",
        "label": "Entailment"
    },
    "a56a38a8-7782-4909-b417-ebb142f38028": {
        "text_answer": "  The statement during the primary clinical trial numerous subjects contracted urinary tract infections is entailed in the given trial data since there were 2 subjects 400 who experienced urinary tract infections out of the total 50 subjects",
        "label": "Entailment"
    },
    "2810ed9e-6f0a-4c59-be1a-31e5003fa51d": {
        "text_answer": "  The statement powder dosage form is a solid composed of a mixture of dry finely divided active andor inert ingredients is not directly related to the information provided in the trial description However the trial description does mention that therapeutic autologous dendritic cells will be given as an injection in the form of a powder Therefore the statement is entailed in the trial as it is a factual description of one aspect of",
        "label": "Entailment"
    },
    "39346303-4095-4b67-b384-6916ed20fd4c": {
        "text_answer": "  The statement the adverse events in both the primary and secondary trial can be compared is entailed in the given information as both trials have recorded the adverse events in a similar manner ie with detailed information on the type and frequency of each event However its important to note that the statement does not directly compare the frequency or severity of the adverse events between the two trials but only allows for their comparison in terms of data availability and",
        "label": "Entailment"
    },
    "f1963f67-9164-4e55-bf5e-3ac44e9bae5f": {
        "text_answer": "  The statement is entailed in the trials as the primary trial reports the mean tumor diameter with units of measure in centimeters cm while the secondary trial reports the number of participants with solid tumor response using different response categories CR PR SD PD and NE without specifying units of measure Therefore the units of measure for the primary and secondary trials are different and the statement is entailed in the trials",
        "label": "Entailment"
    },
    "f1315324-edf3-4d7c-a999-c3a668e67930": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000 mcg of talazoparib daily is not directly related to the information provided in the trial description The trial description mentions that some patients are included in the study and specifies their age cancer type and treatment history but it does not mention anything about talazoparib or its dosage being part of the intervention  The second part of the statement",
        "label": "Entailment"
    },
    "f6b492a8-d17f-407f-9345-ed6b7f447eea": {
        "text_answer": "  The statement microscopic findings specimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment is not directly related to the information provided in the primary and secondary trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone The trials only provide details about the interventions and dosing schedules for different patient cohorts",
        "label": "Entailment"
    },
    "81079f33-7706-4672-a08f-c285df38f870": {
        "text_answer": "  The statement is a contradiction of the given information in the trial description   The statement asserts that both cohorts received the same dosage of cetuximab but the information provided states that cohort 1 received 12 mgkg less cetuximab than cohort 2 Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "49e49c15-d880-4fa1-9582-ba86488ad192": {
        "text_answer": "  The statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is contradictory to the information given in Trial 1 as Trial 1 reports a 000 incidence of increased pleural effusion in its cohort However the statement does not directly entail or contradict the information about the deleterious rpa1 gene mutation being associated with an increased risk",
        "label": "Entailment"
    },
    "7f11c755-66ed-4a7e-a222-0f967b650634": {
        "text_answer": "  The statement every participant in cohort 2 took capecitabine orally each day during the initial 21day cycle is entailed in the trial description The trial states that Capecitabine was administered orally from Days 1 to 14 every 21 days This means that every participant in the cohort received capecitabine orally each day during the first 14 days of each ",
        "label": "Entailment"
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "text_answer": "  The statement is entailed in the trials as the primary trial and the secondary trial involve different patient populations The primary trial focuses on patients receiving HER2specific T cell therapy while the secondary trial focuses on patients receiving trastuzumab emtansine Therefore the trials evaluate different patient characteristics and their respective adverse events",
        "label": "Entailment"
    },
    "14045448-a003-4d3d-ace1-bcdf3a7479c2": {
        "text_answer": "  The statement the primary trial recorded fewer adverse events than did the secondary trial within their cohorts is entailed in the given trials data if and only if the number of adverse events in the primary trial is strictly less than the number of adverse events in the secondary trial for both the common adverse event event 1 and for all other adverse events event 2 if applicable   In this case since both trials have zero ad",
        "label": "Entailment"
    },
    "ad37e364-d3a8-4fcd-9033-90e7ec7d7fc7": {
        "text_answer": " The statement more than half of the patients in the first cohort of the primary clinical trial experienced severe nausea following treatment with aprepitant dexamethasone cytoxan and kytril is not directly entailed or contradicted by the information provided in the trial results   The trial results only report the number of participants who did not experience vomiting and did not require rescue medication during the first 24 hours",
        "label": "Contradiction"
    },
    "4b5b9e75-1690-4544-86de-d4c0ac02cf57": {
        "text_answer": "  The statement the Ketorolac 30 mg group of the primary trial had a 64 Recurrencefree Survival compared to the NaCl 09 3mL group is not entailed in the given trials as there is no information provided in the trials regarding the Recurrencefree Survival percentage for each group The trials only provide the number of participants analyzed in each group and their respective percentages",
        "label": "Contradiction"
    },
    "fef14a32-224c-4a00-88cb-30bb448a504e": {
        "text_answer": "  The statement in both the primary and secondary clinical trial at least one infection case was noted is entailed in the Trials   Explanation   In the primary trial there is one reported case of infection out of a total of 32 participants In the secondary trial there is one reported case of infection out of a total of 15 participants Since both trials report at least one infection case each the statement is entailed",
        "label": "Entailment"
    },
    "4b7eaa17-f5eb-4afe-88b7-98c293ad0100": {
        "text_answer": "  The statement the primary clinical trial concluded with zero incidents of gastrointestinal adverse events is contradicted by the data provided in both Trials 1 and 2 In Trial 1 there were 0 incidents of nausea and vomiting reported out of 149 participants However in Trial 2 there were 1 incident of nausea and 3 incidents of vomiting reported out of the same 14",
        "label": "Contradiction"
    },
    "5a54ce72-5d02-48fb-9cc0-2a31123f3583": {
        "text_answer": "  The statement none of the participants of cohort 1 of the primary clinical trial experienced any adverse events is contradictory to the given results   Results 1 states that all 3 participants in cohort 1 experienced adverse events specifically they were all participants in the study Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "4a6db09e-5bc7-4c5c-8cf8-a89750cd1cc1": {
        "text_answer": "  The statement under 10 of participants from the primary clinical trial exhibited a decrease in circulating tumor cells after undergoing several months of highdose chemotherapy along with purged autologous stem cell products is not directly entailed in the provided trial results   The results only report the number of participants with a reduction in CTCs one month post AHST not several months posttransplant Additionally the trial does not",
        "label": "Contradiction"
    },
    "e9003121-5fb9-4d34-95b4-011c76402472": {
        "text_answer": "  The statement is not entailed in the trial results provided The statement mentions a reduction in tumor diameter which is not mentioned in the trial results The trial results only report a change in Ki67 expression with an average percentage change of 40 63 to 29",
        "label": "Contradiction"
    },
    "1abf0ac3-be79-4fd6-aa9f-5ae756346da4": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial have reported unexpected deaths or cases of hospitalization is not directly entailed in the given data The data only reports the number of adverse events including lymphoma cases but it does not mention any unexpected deaths or hospitalizations Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "50e4558f-a9a2-425b-911f-5bea986e90b4": {
        "text_answer": "  The statement diffuse midline glioma egfrmutant is a diffuse midline glioma h3 k27altered characterized by the presence of egfr gene mutation is not directly related to the information provided in the trials   However the trials do describe different interventions for two different types of patient cohorts In the primary trial patients receive 150 mg of oral pregabalin every 2",
        "label": "Entailment"
    },
    "5abe01fb-1ee1-4905-874e-a0cbec0ee9c9": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as the exclusion criteria for the primary trial explicitly mentions High risk breast lesions like epithelialisis atypia or atypical hyperplasia on histopathology or susceptible lesions prone to develop malignancy as an exclusion criterion Malignant ductal carcinoma in situ falls under the category of highrisk breast lesions and is therefore",
        "label": "Entailment"
    },
    "aa3f26b2-4c1c-45e6-b480-962b43324a8a": {
        "text_answer": "  The statement The majority of patients in the primary trial experienced complete response by week 24 is contradictory to the trial results as per the provided data since no participant in the trial experienced complete response CR at week 24 The trial results indicate that at week 12 there were 0 CRs and 4 PRs and at week 24 there were 0 CRs 4 PRs and 10",
        "label": "Contradiction"
    },
    "71fe40dd-6700-4f46-b635-de6407eb1567": {
        "text_answer": "  The statement there are 0 shared inclusionexclusion criteria between the secondary trial and the primary trial is a contradiction based on the given information   The primary trial has specific inclusion criteria related to cancer diagnosis stage treatment history life expectancy and performance status The secondary trial on the other hand only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston",
        "label": "Contradiction"
    },
    "4ddfaca9-bd5c-427a-a624-8a9d2c763c61": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the same administration method for durvalumab and tremelimumab and the only difference between the two interventions is the dose of durvalumab given 03 mgkg vs 1 mgkg The statement correctly identifies that the dose difference is expressed in milligrams per kilogram and the conversion to milliliters per square centimeter is not relevant to the",
        "label": "Entailment"
    },
    "13742fb9-874a-4f76-9d17-585c96fbd440": {
        "text_answer": "  The statement is entailed in the Trials if and only if the number of adverse events for Adverse Events 1 in the secondary trial is equal to zero This is because the statement specifically compares the count of adverse effects to be identical for both trials If there are any adverse events in the secondary trial for Adverse Events 1 then the statement is contradicted Therefore the statement is entailed if and only if the count of adverse events for",
        "label": "Entailment"
    },
    "ce3d0415-1f95-4e20-bea5-5adc05962c9d": {
        "text_answer": "  The statement following a month of TAK228 plus tamoxifen administration the primary clinical trial reported a 20 increase in the percentage of cells displaying ki67 expression is a contradiction to the trial results   The trial reports a decrease in Ki67 expression at 6 weeks compared to baseline with a median IQR of 10 238 versus 15",
        "label": "Contradiction"
    },
    "881871fa-1546-46da-acab-c8b67ef7e5c1": {
        "text_answer": "  The statement patients with a low potassium count are ineligible for the primary clinical trial yet may qualify for the secondary clinical trial is a contradiction based on the information provided in the given trials inclusion and exclusion criteria  In the primary trial a low potassium count 35 mEqL is listed as an exclusion criterion Therefore patients with a low potassium count are not eligible for",
        "label": "Contradiction"
    },
    "280be8e4-7c13-4ca6-9653-94c7cf061c39": {
        "text_answer": "  The statement patients regardless of their cardiovascular health status are eligible to partake in both the primary and secondary trials is contradictory to the exclusion criteria in the primary trial In the primary trial patients with significant cardiovascular impairment are excluded Therefore the statement is not entailed in the trials as stated",
        "label": "Contradiction"
    },
    "2e8f3602-15d2-4970-ad77-07352b50b787": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 Both trials involve intravenous injections The primary trial uses intravenous injections for FMX and MM398 while the secondary trial uses intravenous injections for paclitaxel 2 Both trials involve MRIs The primary trial uses MRIs for FMXMRI scans The secondary trial does not mention MRIs explicitly but it is",
        "label": "Entailment"
    },
    "5c226c5b-0a0a-44f7-a581-b2b8746f28a5": {
        "text_answer": "  The statement is not entailed in the trials as they do not provide enough information to make a direct comparison between the units of measure used in the primary and secondary trials The primary trial reports the mean tumor diameter in cm and standard deviation while the secondary trial reports the count of participants with solid tumor response using RECIST 11 criteria These two outcome measurements are not directly comparable due to their different units of measure Therefore the statement is neither",
        "label": "Contradiction"
    },
    "644d3ae7-8d7c-40bd-8744-32f0d3311936": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial participants received 4 mgkg of trastuzumab as a loading dose followed by 2 mgkg weekly In the secondary trial in cohort 1 ACT participants received docetaxel alone without trastuzumab In cohort 2 ACTH participants received Herceptin 4 mgkg on Day",
        "label": "Entailment"
    },
    "37f9db0b-4ea9-4952-bf6f-a748ac802a15": {
        "text_answer": "  The given statement is a contradiction to the results presented in the trials   The trials report the median change in total body lean mass for two groups of participants treated with different doses of GTx024 The results do not indicate that any participant in either group gained over 100 kilos of lean body mass Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "348f2b7d-e9b5-41ad-927b-e368bcaca8f5": {
        "text_answer": "  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is a contradiction to the inclusion criteria stated in the trial   The inclusion criteria state that patients with nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer are eligible for the trial However the statement excl",
        "label": "Contradiction"
    },
    "d57cb18c-7375-4a66-81c4-7349cadd8d92": {
        "text_answer": "  The statement the individual from cohort 1 recorded the longest progression free survival PFS in the primary clinical trial surviving 35 months without any disease progression or death is a contradiction to the results provided in Trial 1 The median PFS for cohort 1 was 28 months 16 to 32 which is less than 35 months Therefore it is unlikely that",
        "label": "Contradiction"
    },
    "93fc8df8-d85f-4f71-9d03-7b7e0e5146ff": {
        "text_answer": "  The statement quarter of the participants in the primary clinical trial and 4181674 participants in the secondary clinical trial had an adverse event is contradictory to the information provided in the trials   The primary trial reports that no adverse events occurred in the trial with a total of 4 participants Therefore it is not possible for a quarter of the participants to have had an adverse event   The secondary trial reports",
        "label": "Contradiction"
    },
    "dcb23ac7-9632-47fd-87bd-b15b25e4a3d3": {
        "text_answer": "  The statement paclitaxel is excluded from the interventions involved in the primary clinical trial is entailed in the given trials as neither anastrozole nor fulvestrant involve the use of paclitaxel in their interventions",
        "label": "Entailment"
    },
    "eac5a5f1-7e63-4351-b7de-eacf6592a5fb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement claims that breast cancer patients in the primary trial received 3000 mcgday of talazoparib while ovarianperitoneal cancer patients received only 10 mcgday However the trials specify the doses of talazoparib administered to participants in each cancer type and the",
        "label": "Entailment"
    },
    "23cc69a0-6ac6-4373-9e9e-97c3e613d5eb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not report any cases of febrile neutropenia or cholelithiasis in either the primary or secondary trials The statement suggests that both trials reported a significant number of participants suffering from these conditions but the trials do not support this claim",
        "label": "Entailment"
    },
    "cf33b6d5-f59c-4b24-be84-4aeba15f6c5e": {
        "text_answer": "  The statement having the ability to offer written informed consent is the only mutual inclusionexclusion condition in both the primary and secondary clinical trials is a conditional statement To verify its entailment or contradiction with the given trials we need to check if the primary and secondary trials share this specific condition as the only mutual inclusionexclusion criterion  Lets examine the primary and secondary trials inclusion and exclusion criteria  Primary T",
        "label": "Entailment"
    },
    "7552c836-8753-455e-923f-8364d6c63b03": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement in the primary clinical trial cohort 1 is given pr negative er negative and her cohort 2 is administered her2 is consistent with the information provided in the trials description   Cohort 1 is identified as the Phase 2 TripleNegative cohort which implies that they are",
        "label": "Entailment"
    },
    "c3464aef-3ed6-47ad-8196-99f8115916e4": {
        "text_answer": "  The primary clinical trial and the secondary clinical trial do not utilize Cogstate measured objective cognitive function scores for their units of measurement The primary trial measures the change in units on a scale for vaginal symptoms while the secondary trial measures the percentage of participants with objective response rate of HER2negative metastatic breast cancer Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "fb73159b-0d37-4ea1-aaba-4f540ec395b9": {
        "text_answer": "  The statement women aged 16 or 17 are eligible for the secondary trial but will need to wait 34 years to be eligible for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trials inclusion criteria state that patients must be aged greater than 20 years while the secondary trials inclusion criteria state that patients must be 1",
        "label": "Contradiction"
    },
    "3fda5084-ab27-4f5c-8acb-0be7e7ac93c1": {
        "text_answer": "  The statement there were zero reports of aes among participants in the primary clinical trial is contradictory to the information provided in the Trials data The data states that there were 2 adverse events reported among 35 participants which is not equal to zero",
        "label": "Entailment"
    },
    "1655bb9f-adca-4796-9883-a620e978f745": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial witnessed a greater number of adverse events than cohort 1 is a contradiction to the given data   The total number of adverse events in cohort 1 was 45106 4245 and in cohort 2 was 7103 680 The percentage of adverse events in coh",
        "label": "Contradiction"
    },
    "55b2acbc-30a6-43ef-bca6-0e7a5b3f6a8f": {
        "text_answer": "  The statement various techniques are used to administer the interventions in the primary clinical trial is entailed in the given trials description as both bisphosphonate and denosumab are administered through different routes IV for bisphosphonate and subcutaneous injection for denosumab",
        "label": "Entailment"
    },
    "2037fc58-ce2f-4f44-8ebc-dc9f9d7129cd": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trial results The statement mentions participants with PR primary breast cancer while the trial results only specify participants with HER2 primary breast cancer Additionally the statement does not provide any information about the number or percentage of participants in the control arm or any other experimental arms of the trial Therefore it cannot be determined if the statement is entailed or contradicted based on the given trial results alone",
        "label": "Entailment"
    },
    "ecd4681c-624a-44da-b9e7-4d993b35d2af": {
        "text_answer": "  The statement is entailed in the Trials as both the primary and secondary trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle for patients with CNS involvement from various types of cancers",
        "label": "Entailment"
    },
    "3239643a-3052-4344-a7ea-f2d5dff19755": {
        "text_answer": "  The statement children are the main demographic required for participating in the primary clinical trial while they are not allowed to partake in the secondary trial is contradictory to the information provided in the given trials inclusion and exclusion criteria   In the primary trial the inclusion criteria do not mention anything about children and the exclusion criteria include postmenopausal women only Therefore children are not mentioned as a demographic for the primary trial  ",
        "label": "Entailment"
    },
    "b7c9455e-db3b-438d-bcb0-04bf52fb530d": {
        "text_answer": "  The statement is not entailed in the trials provided as there is no information about a testosterone cream group in the trials given The trials only compare the effects of acupuncture to a waitlist control group Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "3ca94519-994e-4921-95ef-fdd1daf0932c": {
        "text_answer": "  The statement a woman who has undergone breast conservation therapy would be excluded from the secondary trial and the primary trial is entailed in the given trials as  1 In the primary trial breast conservation therapy lumpectomy is not listed as an eligible surgical procedure Therefore a woman who has undergone breast conservation therapy would be excluded from the primary trial 2 In the secondary trial there is no mention of breast conservation therapy",
        "label": "Entailment"
    },
    "efbc4408-7a74-4857-8265-d1bf4eab4080": {
        "text_answer": "  The statement after 720 hours of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 110 reduction in the proportion of cells with ki67 expression is entailed in the trial results   Explanation   The trial results show that the median IQR Ki67 expression at baseline was 15 10 to 25 and at 6",
        "label": "Entailment"
    },
    "4e9c14cb-9c55-4c1a-ae14-f5a6f08e1494": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is a comparison statement between the two trials However the given trials do not provide enough information to determine if this statement is entailed in the trials or not  The trials only provide the number of adverse events for each category in each cohort",
        "label": "Entailment"
    },
    "9bf4a35a-531f-4083-87ac-dec730cfea45": {
        "text_answer": "  The statement is contradictory to the given data The statement implies a difference of 11 instances between the two trials in favor of the secondary trial regarding intestinal perforation However the data shows that the primary trial had no instances of intestinal perforation while the secondary trial had one instance Therefore the statement is contradictory to the data",
        "label": "Contradiction"
    },
    "49d2b5e7-595e-4762-b7af-9e914bf72917": {
        "text_answer": "  Lets analyze the given information in the trials and the statement to determine if the statement is entailed or contradicted  1 In Intervention 1 the dose of MCS110 given is 1 mgkg every 3 weeks which is equivalent to a dose of 1 mgkg  73 kg  73 mg per patient every 3 weeks 2 In Intervention 1 the dose of P",
        "label": "Entailment"
    },
    "d8735c6c-1fc9-4fbc-93d2-651a5814d505": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial there is no mention of any drugbased interventions The interventions listed are massage therapy pain therapy psychosocial assessment and care and qualityoflife assessment Therefore the statement that the primary trial does not test any drugbased treatments is accurate  In contrast the secondary trial tests different doses of the drug P",
        "label": "Entailment"
    },
    "f7d7cc99-97cb-48f0-bc69-78a60d9d21be": {
        "text_answer": "  The statement over 66 patients in the primary trial treated with lapatinib 1000 g  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR can be verified by checking the trial results provided   According to the results 53 out of 60 participants in the lapatinib 1000 mg  nabpaclitaxel",
        "label": "Entailment"
    },
    "268ad1eb-851a-484a-873f-b54ab271b063": {
        "text_answer": "  The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is neither entailed nor contradicted by the given trials The trials only provide the number and percentage of occurrences of each adverse event but they do not specify that only those three types of adverse events occurred in the trials The statement goes beyond the information given",
        "label": "Entailment"
    },
    "428340b6-e87b-4e03-920b-f2e3f62f05d6": {
        "text_answer": "  The statement in the primary clinical trial the interventions educational dvd will be made available solely to the members of cohort 1 is entailed in the given information if we assume that  1 The primary clinical trial has only two cohorts as indicated by cohort 1 in the statement 2 The intervention group is cohort 1 in the trial  Given the information provided it is",
        "label": "Entailment"
    },
    "aa5dd0d4-1551-4ccc-85a8-ca6c2bcfb871": {
        "text_answer": "  The statement is entailed in the trial results as follows  The statement in the primary trial results there were more patients with stable disease after 3 months than after 6 months but none of the patients had complete response after 3 months or 6 months  Is entailed by  The trial results Week 24 SD 10 3 months  Week 12 SD 12 6",
        "label": "Entailment"
    },
    "ba355915-f5a7-4b38-bbca-95fe674d63f5": {
        "text_answer": "  The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is entailed in the trials provided   Explanation   The statement is entailed in the trials because the trials list the same three types of adverse events Pancreatitis Cholelithiasis and Hepatic pain",
        "label": "Entailment"
    },
    "1c31539a-7fd9-4e81-ae88-c0e05a34946a": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The trials describe two separate interventions for different types of cancer breast cancer and ovarianperitoneal cancer The statement discusses an immunohistochemical technique adhesion g proteincoupled receptor e1 staining method that is not mentioned in the trials Therefore the statement does not follow logically",
        "label": "Entailment"
    },
    "c367ab4c-6113-4f79-abcc-24e715c18094": {
        "text_answer": "  The statement grade 1 neonatal bradyarrhythmia ae is an adverse event in a newborn characterized by brief selflimiting episodes of asymptomatic bradyarrhythmia no care changes 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 3333 of patients apart from Skin infections is not directly entailed",
        "label": "Contradiction"
    },
    "6815208b-ad2d-4564-b723-2d8e44af78b0": {
        "text_answer": "  The statement active smokers are barred from participating in both the primary clinical trial and the secondary clinical trial is entailed in the given trials as the exclusion criteria for both trials include Patient is a smoker or history of smoking Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "14e8dba6-bd13-4f5b-a225-6cd55c3d1243": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the baseline dose of alpha lipoic acid is given three times daily at 100 mg each time for four months with dose escalation to find the maximum tolerated dose This means that the patients will receive increasing doses of alpha lipoic acid throughout the trial  In contrast in the secondary trial participants in Cohort 1 receive a consistent dose of necitumum",
        "label": "Entailment"
    },
    "12a7a47e-adb9-4c24-8410-03aea3d7d292": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial mammography is mandatory but MRI is also required In contrast in the secondary trial mammography is mandatory but there is no mention of an MRI being required Therefore the statement that to qualify for the primary trial the candidate is expected to have an MRI however for the secondary trial a mammography is mandatory is incorrect",
        "label": "Contradiction"
    },
    "3570b51a-d280-41b5-9c59-849436db5934": {
        "text_answer": "  The statement patients who have a histological documentation of metastatic small cell lung cancer are not eligible for the primary clinical trial is contradictory to the inclusion criteria stated in the text The inclusion criteria clearly state that patients with histologically documented metastatic nonsmall cell lung cancer are eligible for the trial There is no mention of small cell lung cancer being excluded Therefore the statement is contradictory to the information provided in the inclusion criteria",
        "label": "Contradiction"
    },
    "9e14f099-36f3-4672-b35c-022cc3279c98": {
        "text_answer": "  The statement is not entailed in the trials provided as they report different outcome measurements The primary trial reports Time to Progression in months while the secondary trial reports the number of participants with Objective Response based on Data Review Committees Assessment The statement does not directly relate to the outcome measurements reported in the trials",
        "label": "Contradiction"
    },
    "afc3c380-94da-4686-a5ca-1967217d14d1": {
        "text_answer": "  The statement no incidences of tumour lysis syndrome were reported in the primary or secondary trial is entailed in the given trials as there is no mention of tumour lysis syndrome in the adverse events for either trial",
        "label": "Contradiction"
    },
    "a3a672e2-2900-45dd-ae02-797449f17b66": {
        "text_answer": "  The statement is contradictory to the primary and secondary trials as the primary trial excludes patients with alcohol or substance abuse or dependence within the past 2 years while the secondary trial includes patients who consume fewer than 5 alcoholic drinks per day within the past year Therefore the statement is contradictory to both trials",
        "label": "Entailment"
    },
    "db26f45b-4e0a-4f21-83da-6f22116f7ac5": {
        "text_answer": "  The statement the incidence of anemia pneumonia and stupor was higher in the secondary clinical trial patients compared to the primary clinical trial patients is contradictory to the given data  Explanation  The statement implies that the incidence of anemia pneumonia and stupor is greater in the secondary trial compared to the primary trial However the data provided shows that the incidence of anemia and",
        "label": "Entailment"
    },
    "c4aea42a-a9e3-47ba-9a96-12350a3925c9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive whole breast radiation therapy and there is no mention of any medication related to Fulvestrant or Enzastaurin being administered   In the secondary trial participants do not receive any information about receiving 00176 ounces of Fulvestrant in a tablet form to be taken bid Instead Fulvestrant",
        "label": "Contradiction"
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The statement suggests that both interventions are administered once daily but according to the trial description the Memantine intervention is administered twice daily Therefore the statement is contradictory to the information provided in the trial description",
        "label": "Entailment"
    },
    "c3e36213-9a24-4f92-9ff3-12e071aac541": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial patients receive cyclophosphamide and paclitaxel as part of the AC regimen with GMCSF and then weekly carboplatin and paclitaxel Cyclophamide is a common component in both interventions and paclitaxel is included in the secondary trial as part of the docetaxel  lapatinib regimen  In",
        "label": "Entailment"
    },
    "91db7925-da19-4373-bfba-78ee49b34f99": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial defines each treatment cycle as 21 days which is approximately 168 hours The statement incorrectly states that the primary trial uses a 504 hour cycle for its intervention  Furthermore the secondary trial does not have a cyclic treatment in place but rather two distinct interventions Intraoperative Mammography and Standard M",
        "label": "Entailment"
    },
    "fc6ab4bb-43af-4008-a2dc-0e23dbf9abc0": {
        "text_answer": "  The statement a mastectomy may not disqualify a woman from being eligible for both the primary and secondary clinical trial is not directly stated in the given inclusion and exclusion criteria for either trial However based on the information provided it appears that a woman who has undergone a mastectomy for breast cancer and meets the other inclusion criteria for the secondary trial such as being 15 years posttreatment and having a plasma CR",
        "label": "Entailment"
    },
    "00d9d3c3-938f-4e4c-b532-b11146f1239c": {
        "text_answer": "  The statement sometimes true is a subjective response indicating that something is sometime true is not directly related to the given trials However I will focus on the part of the statement that pertains to the weekly cycle of 4Demethyl4cholestryloxycarbonylpenclomedine in the primary and secondary trials  Both trials involve the use of 4Demethyl4cholestry",
        "label": "Entailment"
    },
    "5102bc84-4e28-4ec9-91cf-b5ed615b15bb": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   Explanation   The statement suggests that both the placebo and trabectedin interventions are administered on a semiannual basis with a 3hour intravenous infusion However the trial description states that the placebo is administered on Day 1 and the trabectedin is administered on Day 2 with no mention of a",
        "label": "Contradiction"
    },
    "914d236c-c227-4d8d-8565-04a1d25e3b59": {
        "text_answer": "  The statement is not entailed in the trial results as given The trial results indicate a change in Ki67 expression not a change in tumor diameter The statement provided is not consistent with the outcome measurement and time frame specified in the trial",
        "label": "Contradiction"
    },
    "af1a2e8d-2b8e-4690-b32c-9d044d9aa15f": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on different types of cancer glioblastoma multiforme and gynecological cancers and do not mention the use of the ie rhabdomyosarcoma chemotherapy regimen The trials only mention the use of 18FFDG and 18FFPPRGD2 for PETCT or PETMRI imaging in the",
        "label": "Contradiction"
    },
    "f718d65d-3ea1-41b7-adc0-5f481843011c": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial participants received lenalidomide at a dose of 5mg orally daily for 57  3 days   In the secondary trial intervention 1 involved oral lapatinib at a dose of 1500mg daily for 6 weeks followed by lapatinib plus weekly paclitaxel at a dose",
        "label": "Entailment"
    },
    "8f537eb8-d8b7-4c56-89bf-ea2e5b0d1326": {
        "text_answer": "  The statement the primary trial uses a 3 week cycle for its intervention the secondary trial on the other hand does not have a cyclic treatment in place is a contradiction to the information provided in the trials   The primary trial does not explicitly state that the treatment cycle is 3 weeks long but it does define each cycle as 21 days Therefore the statement is not entailed in the trials but rather contradicts the information provided about",
        "label": "Contradiction"
    },
    "1ea69c5b-83c6-4d54-b17c-0e6df9c49abb": {
        "text_answer": "  The statement in the primary clinical trial the prevailing adverse events were of cardiovascular origin a situation that further differs from the secondary trial where such have not been registered is a contradiction to the information provided in the trials  The trials do not mention any adverse events related to cardiovascular origin in either the primary or secondary trials The primary trial lists various adverse events related to the blood and lymphatic systems but none of",
        "label": "Contradiction"
    },
    "763b8082-f1d6-4dfb-ab46-b61d8dae6515": {
        "text_answer": "  The statement nationality ethnicity weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial is entailed in the given inclusion and exclusion criteria as there is no mention of these factors in the criteria However the statement microgram per kilogram per hour is a dose calculation unit expressed in micrograms per kilogram per period of time equal to sixty minutes is not directly related to the",
        "label": "Entailment"
    },
    "485e3ce9-e779-4ae5-bdc4-7fbcb1d1eb3c": {
        "text_answer": "  The statement the sole adverse event noted in the primary clinical trial was mild muscular discomfort is contradictory to the given trials as both trials report adverse events in 3 out of 6 patients 5000 The statement only mentions one adverse event and does not mention the percentage of patients experiencing it Therefore the statement is contradictory to the given trials",
        "label": "Entailment"
    },
    "88a40578-17e1-499b-8b7b-10a85e2c3d88": {
        "text_answer": "  The statement is not entailed in the Trials as given The primary trial specifies a breast tumor of 1 cm in diameter while the statement mentions a TNBC tumor of 100mm in diameter which is a significant difference and excludes the patient from the primary trial Additionally the secondary trial does not provide information about the tumor size Therefore the statement is contradictory to the Trials as given",
        "label": "Contradiction"
    },
    "b7178d54-4bb2-4820-b13c-c342075267ff": {
        "text_answer": "  The statement despite the lack of any cardiac or psychiatric aes in the primary clinical trial and secondary clinical trial a number of other aes were witnessed is not directly entailed or contradicted by the given trials data   The trials data only reports the absence of specific adverse events cardiac and psychiatric in both trials It does not provide information about the presence or absence of other adverse events Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "48788622-6b62-4a88-8d7c-29be1fbd88e8": {
        "text_answer": "  The statement it is rare to find cases of coronary artery stenosis as an adverse event in the primary clinical trial is not directly entailed or contradicted by the given data The data only lists the various adverse events observed during the trial but it does not provide information on the frequency or rarity of coronary artery stenosis as an adverse event Therefore the statement cannot be definitively determined to be entailed or contradicted based",
        "label": "Contradiction"
    },
    "f05dd895-7d03-45d2-ab9c-69db39c386e5": {
        "text_answer": "  The statement inclusion in the primary clinical trial is restricted to those who have not received chemotherapy or radiotherapy in the past 6 months and have a proven clean mental health record is not explicitly stated in the given inclusion and exclusion criteria However the criteria do mention that Number of prior chemotherapy lines of treatment in the metastatic setting 2 is an exclusion criterion which implies that participants should not have received chemotherapy within a certain time",
        "label": "Entailment"
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "text_answer": "  The statement 13 participants in the primary trial were treated with the GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine is entailed in the given trial information as stated in the ArmGroup Description section which mentions that 13 participants were analyzed in this trial and they received the Gl",
        "label": "Entailment"
    },
    "993572ab-2275-4def-9723-202249284283": {
        "text_answer": "  The statement is not entailed in the trials as the most recurring adverse event mentioned in the statement is insomnia which is not listed as an adverse event in either the primary or secondary trials The statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the doses of Eribulin and Docetaxel given in each intervention  In Intervention 1 the dose of Eribulin is 14mgm2 given on Days 1 and 8 of each treatment cycle and the dose of Cyclophosphamide is 600 mgm2 given on Day 1",
        "label": "Entailment"
    },
    "61fbddc4-94cb-4105-8090-03dd97a3bc53": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial but only female patients are eligible for the secondary trial is contradictory to the information provided in the trials inclusion and exclusion criteria  In the primary trial both male and female patients are eligible but there are specific inclusion and exclusion criteria that must be met In contrast the secondary trial only includes female patients with specific types of breast cancer Therefore gender is",
        "label": "Entailment"
    },
    "9b2023d2-09bd-4362-ae66-afc69497e468": {
        "text_answer": "  The statement nonpsychotic mental disorder following organic brain damage is any mental disorder that occurs secondary to organic brain damage and that is not associated with psychosis is not directly related to the trials provided The trials describe the surgical interventions for breast reconstruction with monitoring of breast perfusion using laserassisted fluorescence angiography and the use of two different incision types The statement about nonpsychotic mental disorders following organic brain damage is an un",
        "label": "Entailment"
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "text_answer": "  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is entailed in the given data as the secondary trial had a higher percentage 6000 of patients with Adverse Events AEs compared to the primary trial 000",
        "label": "Entailment"
    },
    "e87fee13-1ed3-4eca-8d72-d65fee50abf7": {
        "text_answer": "  The statement a higher number of mucositis oral cases epileptic seizures and thromboembolic events were seen in the primary trial than in the secondary trial is a contradiction to the given data  Explanation  The statement implies that there are more instances of mucositis oral epileptic seizures and thromboembolic events in the primary trial than in the secondary trial However",
        "label": "Contradiction"
    },
    "f08d84f8-0448-462c-8f81-770223b92bb8": {
        "text_answer": "  The statement instances of lengthier operative durations were detected in arm 2 than arm 1 of the primary trial indicating more efficient outcomes with the intraoperative mammography compared to the standard mammography is not directly entailed in the provided trials The trials only present the operative time data for each group without making a direct comparison between them The statement makes an inference based on the data but it does not follow logically from the information",
        "label": "Contradiction"
    },
    "205d3c95-7288-4d9f-9a5c-edc7b09de79d": {
        "text_answer": "  The statement the eligibility for the secondary clinical trial automatically implies eligibility for the primary clinical trial is a statement of entailment   Explanation   The primary clinical trial and the secondary clinical trial have some overlapping inclusion criteria such as age requirement and signed ICF However the primary trial has additional inclusion criteria related to breast cancer diagnosis and surgical procedure lumpectomy while the secondary trial has inclusion criteria related",
        "label": "Entailment"
    },
    "62de4057-c709-4110-9986-642428c1d534": {
        "text_answer": "  The statement is entailed in the trials as described Both the placebo and trabectedin are administered intravenously over a 3hour infusion period but on different days Day 1 for placebo and Day 2 for trabectedin Therefore the statement that in the primary clinical trial the placebo and trabectedin are delivered identically but on separate days is an accurate description of the trials and is entailed",
        "label": "Entailment"
    },
    "b9e51528-b593-40f7-8f49-acfacc756a7f": {
        "text_answer": "  The statement in the primary clinical trial and the secondary clinical trial the patients encountered thromboembolic events is contradictory to the given data   Explanation  The given data shows that in the primary trial there was one patient who experienced a Death Not Associated with CTCAE Death NOS but it does not specify if it was due to a thromboembolic event In the secondary trial there",
        "label": "Entailment"
    },
    "05c44353-ab0d-4b2d-98ff-e39aab551229": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial mentions the use of 150 mg of oral pregabalin which is equivalent to approximately 0073 kg not 015 kg Additionally the secondary trial does not mention the weight of the administered drugs only the specific treatments HDMTX and ITDepocyt Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "c96d223f-7d7e-47aa-b71e-0b56ab6eef81": {
        "text_answer": "  The statement None of the primary trial candidates have to perfom regular exercise as part of the intervention is not directly related to the information provided in the trial description The trial description mentions the types of cancer eligibility criteria and assessment measures but it does not mention anything about exercise being a part of the intervention for the primary trial candidates  Regarding the second part of the statement leporine experimental organism diagnosis is a condition that is relevant",
        "label": "Entailment"
    },
    "280cae18-764b-4cc7-ae2a-3b1f05c04cbf": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do involve the use of 18FFDG and 18FFPPRGD2 in both study groups for PETCT or PETMRI scans The statement incorrectly asserts that there are no PETCT or PETMRI scans involving these radiotracers in the trials",
        "label": "Contradiction"
    },
    "a9c7619e-8cc5-4c84-b4a4-38ada95388a2": {
        "text_answer": "  The statement pharmacogenomicsgenetics biomarker supplemental qualifiers dataset is a dataset containing supplemental information specifically nonstandard variables to parent records in the pharmacogenomicsgenetics biomarker domain is not directly related to the inclusion and exclusion criteria of the primary or secondary trials provided Therefore it neither entails nor contradicts the information given in the trials",
        "label": "Entailment"
    },
    "059a48d5-3bf5-40ac-b06c-3107c0ea7cb9": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference in interventions between the two trials In the primary trial patients receive pregabalin 150 mg orally twice daily for 6 weeks In contrast the secondary trial involves a more complex treatment regimen with intravenous and intrathecal administration of highdose methotrexate and liposomal cytarabine during the induction consolidation and",
        "label": "Entailment"
    },
    "3ace09f3-a822-4140-a529-52b08664da77": {
        "text_answer": "  The statement does not follow directly from the given trials as there is no information provided in the trials regarding the occurrence of adverse events in patients with t113 cytogenetic abnormality in cohort 1 or cohort 2 Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "text_answer": "  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race or ethnic origin or cancer type however for the secondary trial they must have Her2neu breast cancer is partially entailed in the given trials   The primary trial includes females aged 18 and above of all racial and ethnic origins who are scheduled to receive the first cycle of a single intravenous dose of do",
        "label": "Entailment"
    },
    "c49dbdfa-801a-4789-9e04-345ed14150ab": {
        "text_answer": "  The statement hemodialysis catheter infection is a local or systemic infection associated with the use of a hemodialysis catheter is not directly related to the information provided in the trials The trials focus on the dosage of talazoparib administered to participants with breast cancer and ovarianperitoneal cancer Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "4028bb9b-1122-4c10-ab5c-a38205fe6dd2": {
        "text_answer": "  The statement the same proportion of patients experienced negative effects in both groups of the primary clinical trial is neither entailed nor contradicted by the given trials   Explanation   The statement is not entailed because the proportion of patients experiencing negative effects is different between the two trials 5000 in Trial 1 vs 4000 in Trial 2   The statement is not contradicted",
        "label": "Entailment"
    },
    "6b568a13-5216-4b83-848a-c64e8a9c340b": {
        "text_answer": "  The statement the lbh589 and lapatinib cohorts results are not accounted for in the primary clinical trial is entailed in the given information   Explanation   The primary clinical trial only reports the results of the LBH589 with Capecitabine cohort with a total of 15 participants analyzed The LBH589 and Lapatinib cohort",
        "label": "Entailment"
    },
    "3852b7ff-e68a-4bc8-917f-4eb9c838862d": {
        "text_answer": "  The statement recipients of an organ transplant in the past six months who are now ambulatory are able to participate in the primary clinical trial but would not meet the requirements for the secondary clinical trial is neither entailed in the primary trials inclusion and exclusion criteria nor contradictory to them   The primary trial includes the criterion The participant has not undergone major surgery within 28 days prior to the study registration date",
        "label": "Entailment"
    },
    "2a509e67-c521-4406-8122-c91d7a1331ad": {
        "text_answer": "  The statement skin appendage neoplasm is a benign or malignant neoplasm that arises from the hair follicles sebaceous glands or sweat glands is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials Therefore it cannot be determined to be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "c5d6c5da-f71c-4454-a333-3ade43aef122": {
        "text_answer": "  The statement those with histologybacked metastatic or inoperable scbc are excluded from the primary clinical trial unless they have either er or pr or both positive is not explicitly stated in the inclusion criteria or exclusion criteria provided in the text However it can be inferred that patients with small cell lung cancer SCLC are not included in the trial as it specifically mentions nonsmall cell lung cancer NSCLC as",
        "label": "Entailment"
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "text_answer": "  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not explicitly stated in the inclusion or exclusion criteria for either the primary or secondary trials provided Therefore it cannot be definitively determined if the statement is entailed in the trials or if it is contradictory based on the given information alone  However it is mentioned in the primary trial inclusion criteria that Patients must be able",
        "label": "Entailment"
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not mention any radiation therapy being administered to the patients in either the primary or secondary interventions Therefore the statement is not entailed in the trials and is contradictory to the given information",
        "label": "Contradiction"
    },
    "8004fee7-e287-4a54-b66f-44002ebb1b34": {
        "text_answer": "  The statement the primary clinical trial could accept an adult patient who was diagnosed with ilddpld within the last 3 years and has a life expectancy of half a year is not explicitly stated in the inclusion criteria or exclusion criteria of the provided clinical trial Therefore it cannot be definitively determined if the statement is entailed or contradicted by the trial information  However the inclusion criteria state that patients must have a life expectancy of greater than ",
        "label": "Entailment"
    },
    "777fb2a8-9329-4e49-a67b-93d1d7fe2319": {
        "text_answer": "  The statement there was a case where a patients surgical wound from the primary clinical trial reopened postoperation is not explicitly stated in the given adverse events data However the term wound dehiscence is mentioned as an adverse event which refers to the reopening or separation of a surgical wound Therefore the statement is entailed in the trial data with the caveat that the specific patients case is not",
        "label": "Entailment"
    },
    "386515be-dd8a-423d-933b-6c7f99461ebd": {
        "text_answer": "  The statement patients diagnosed with stage 4 breast adenocarcinoma that is either ER positive PR positive or HER2neu negative are qualified to participate in both the secondary clinical trial and the primary clinical trial is entailed in the given trials as long as the patients meet all the other inclusion and exclusion criteria for both trials   Explanation  Both trials have similar inclusion criteria for breast adenocarc",
        "label": "Entailment"
    },
    "3a36e314-e4f4-4a60-acc9-b9f9933e884c": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is not directly entailed or contradicted by the given trials   The trials only provide the number and percentage of adverse events for each trial but they do not specify the number or percentage of palpitations pericardial effusions or",
        "label": "Contradiction"
    },
    "c6b37d94-f63f-4cf7-b86c-a8147ff618d9": {
        "text_answer": "  The statement is contradictory to the results from the primary trial The primary trial reports a decrease in Ki67 expression with tamoxifen treatment specifically a mean percentage change of 40 63 to 29 while the statement suggests an increase of 85",
        "label": "Entailment"
    },
    "ae0dd0fb-c8c9-47bd-ab6b-8236edd68194": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days This is a lower dose and a shorter duration compared to the secondary trial where participants in intervention 1 received oral lapatinib 1500mg daily for 6 weeks followed by lapatinib plus weekly paclitaxel 80 mgm2 IV",
        "label": "Entailment"
    },
    "be268f6b-8123-4cd7-a495-c82453034b67": {
        "text_answer": "  The statement patients suffering from lobular carcinoma in situ and wellregulated high blood pressure are permitted in the primary clinical trial but are barred from the secondary clinical trial is a contradiction of the given trials  Explanation  In the primary trial lobular carcinoma in situ is mentioned as an exclusion criterion for benign breast disease However it is included as a disease characteristic in the secondary trial for",
        "label": "Contradiction"
    },
    "62581915-0fde-4cfb-8205-7c1b8c8bacbb": {
        "text_answer": "  The statement is entailed in the trials In the primary trial participants received lenalidomide at a dose of 5mg orally daily for 57  3 days which is higher than the dose of lapatinib used in the secondary trial where participants received oral lapatinib at a dose of 1500mg daily for 6 weeks The difference in dosing between the two interventions supports the statement that higher doses",
        "label": "Entailment"
    },
    "36426525-f3e0-426e-aae4-2fc677756ca9": {
        "text_answer": "  The statement is partially entailed in the given trials   Explanation   The statement 0 adverse events were observed in the primary trial is entailed by the data provided in the primary trial as it states that there were no adverse events reported in that trial   The statement none of the adverse events in the secondary trial affected more than 30 of patients apart from Skin infections is not directly",
        "label": "Entailment"
    },
    "58b45da6-c265-4cef-a6cc-83113439c79e": {
        "text_answer": "  The statement the levels of palpitations pericardial effusions and abdominal pains were higher in cohort 2 of the primary clinical trial than those of cohort 1 in the secondary clinical trial is a comparison of the frequency of specific adverse events between two trials   To verify whether this statement is entailed or contradicted by the given data we need to compare the number of occurrences of these adverse events",
        "label": "Entailment"
    },
    "a743b2fa-dd26-4c5f-931d-f5cc8bcf52c2": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement the rate of mucositis oral epileptic seizures and thromboembolic events was equal in both the primary and secondary trials is contradicted by the data provided because mucositis oral is reported in the primary trial but not in the secondary trial Therefore the rates of mucositis oral are not equal in both trials",
        "label": "Contradiction"
    },
    "0bb7dafe-391e-4adb-a9fe-ac3717421ae8": {
        "text_answer": "  The statement a woman postmastectomy for stage iv bc may still be considered for recruitment in either the primary or secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for both trials However the primary trial does not have any explicit exclusion criteria related to the stage of breast cancer Therefore based on the information provided it can be inferred that a woman with stage IV breast cancer who meets the other inclusion criteria for the primary",
        "label": "Entailment"
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using the units of measure mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib using the units of measure mg These are different outcome measurements and units of measure and the trials do not contradict each other",
        "label": "Entailment"
    },
    "6adaaefe-d699-4bce-87dc-8233140a14fa": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial measures the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial measures the percentage of participants with pain or no pain as assessed by the Numeric Pain Rating Scale The two trials investigate different outcomes in different patient populations and there is no mention of muscle gains in either trial",
        "label": "Contradiction"
    },
    "d7aa81f2-8df0-4884-9d6a-e6d21ec79b03": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial exclusion criteria do not mention chemotherapy or radiotherapy within the last 12 month as an exclusion criterion Therefore patients who have received chemotherapy or radiotherapy within the last 12 month can still take part in the primary trial if they satisfy all other inclusion criteria  However the secondary trial explicitly lists chemotherapy or radiotherapy within the last 1",
        "label": "Entailment"
    },
    "869078fe-375b-45b5-ba65-21d04cd304ed": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement only makes a comparison about the doses of Lenalidomide and Lapatinib used in the primary and secondary trials respectively It does not directly relate to the bone marrow samples or the interventions in the secondary trial involving Trastuzumab Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "5417955e-52aa-4b3b-8e67-2a4c4796846a": {
        "text_answer": "  The statement epacadostat is provided to participants of the primary clinical trial twice as frequently as sunitinib is given to sunitinibnaive patients in the secondary clinical trial is not directly entailed in the given trial information   However we can make some inferences based on the information provided  1 In the primary trial epacadostat is given orally twice daily BID while in the secondary",
        "label": "Contradiction"
    },
    "5d6bf9b2-6737-4266-9566-436393cdcfab": {
        "text_answer": "  The statement on average patients in the paced respiration intervention group of the primary clinical trial experienced fewer daily hot flashes than those in the fast shallow respiration group is entailed in the trials as the mean number of hot flashes per 24 hours in the paced respiration group 348 is less than the mean number of hot flashes per 24 hours in the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "28375759-dcd0-430d-8035-9571e1bbc07e": {
        "text_answer": "  The statement is entailed in the trials In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days In the secondary trial intervention 1 for lenalidomide specifies a dose of 1500 mg orally daily for 6 weeks which is higher than the dose given in the primary trial Therefore the statement that the primary trial uses lower doses of lenal",
        "label": "Entailment"
    },
    "ae5d8804-eada-4f5c-8889-18a7cc90bb9b": {
        "text_answer": "  The statement is entailed in the trials as the primary trial reports the mean tumor diameter with units of measurement in centimeters cm while the secondary trial reports the number of participants with solid tumor response using different response categories Complete Response Partial Response Stable Disease Progressive Disease and Nonevaluable without specifying units of measurement for these categories However the participants response categories in the secondary trial can still be considered as a count",
        "label": "Entailment"
    },
    "ee16dd43-346c-47c2-b5c1-b3722935918d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not mention any age or height restrictions for inclusion while the secondary trial specifies that women of childbearing potential must commit to the use of effective barrier nonhormonal contraception but it does not provide an age limit Therefore the statement that the primary clinical trial does not reject participants based on their height or age while the secondary clinical trial restrict",
        "label": "Entailment"
    },
    "a154d6bd-fc5d-491f-b2aa-7785024e67a5": {
        "text_answer": "  In the primary trial the outcome measurement is reported as a percentage of participants and in the secondary trial the outcome measurement is reported as the number of participants These are not the same units of measure Therefore the statement is contradictory",
        "label": "Entailment"
    },
    "00ac087f-fc20-4ff1-be51-f32fa22f4e4e": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial participants receive epacadostat twice daily BID while in the secondary trial sunitinib is given once daily Therefore the frequency of epacadostat administration in the primary trial is not the same as sunitinib administration in the secondary trial",
        "label": "Entailment"
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "text_answer": "  The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not entailed in the given intervention description The intervention description states that patients receive 100 mgm2 of lapatinib orally once daily on days 128 This is different from the statement which specifies that patients receive 100 mgm2 twice daily Therefore",
        "label": "Contradiction"
    },
    "2ea93619-d183-4989-b811-c4666059d456": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive 4 mgkg of trastuzumab as a loading dose followed by 2 mgkg weekly In the secondary trial Herceptin is administered at a dose of 4 mgkg IV infusion on Day 1 of Cycle 5 and then 2 mgkg weekly starting from Day 8 but the dosing schedules for the primary and secondary trials",
        "label": "Entailment"
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "text_answer": "  The statement There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial is entailed by the given trials as both trials report a total of zero occurrences for each adverse event in their respective patient cohorts",
        "label": "Contradiction"
    },
    "97a2b670-3f9b-49e5-abde-d0b477046164": {
        "text_answer": "  The statement no clear pattern of expression was observed for the 40 tested genes among patients in cohorts 1 or 2 in the primary clinical trial is entailed in the trials provided   Explanation  The trials do not report any information about a discernible pattern of gene expression for the 40 tested genes among patients in cohorts 1 and 2 Both cohorts had a percentage of participants with no clear",
        "label": "Contradiction"
    },
    "a90d6d85-6942-4653-b23c-126d63b1d2cf": {
        "text_answer": "  The statement Patients with stage 4 cancer are not eligible for the secondary trial however they are eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   However the statement is consistent with the information provided in the inclusion criteria for the primary trial which includes patients with stage IIbIIIIV breast cancer but it is not explicitly stated in the secondary trials inclusion criteria",
        "label": "Contradiction"
    },
    "75625dfd-7f82-4a99-b97d-50f05751dfdb": {
        "text_answer": "  The statement Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial is entailed in the trials as follows  In the primary trial the exclusion criteria include uncontrolled intercurrent illness including but not limited to psychiatric illnesssocial situations that would limit compliance with study requirements Schizophrenia is a psychiatric disorder and uncontrolled schizophrenia",
        "label": "Entailment"
    },
    "195efca0-b2e3-43c0-abf2-4c6d77d8a449": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial sunitinib was administered orally not intravenously",
        "label": "Entailment"
    },
    "56d753e1-4bce-4c3d-a8fb-8abc6119c1a7": {
        "text_answer": "  The statement fewer than 5 of the patients involved in the primary clinical trial encountered adverse events is entailed in the given trial data since the total number of adverse events is 2 and the number of patients in the trial is 35 Therefore the percentage of patients with adverse events is 235  571 which is less than 5",
        "label": "Entailment"
    },
    "d260a3cd-28cd-4df8-aa19-1586a1f7b978": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement asserts that both cohorts receive CUDC101 at equivalent doses and frequencies However the trial information specifies different dosing schedules for each arm Arm A receives CUDC101 for 5 days every 14 days while Arm B receives CUDC101 for 3 days every",
        "label": "Entailment"
    },
    "20a9c28d-88d5-4cd8-b346-19a1123ede25": {
        "text_answer": "  The statement all the patients in the primary clinical trial see no symptoms of increased pleural effusion or rapid disease progression is contradicted by the information provided in the trials  Explanation  The primary trial reports that 1 out of 13 patients 769 experienced rapid disease progression and none of them had increased pleural effusion However in the second trial 1 out of 4 patients 25",
        "label": "Contradiction"
    },
    "fdeba169-13d2-4ed9-a2b2-774194f18370": {
        "text_answer": "  The statement the primary clinical trial is open to individuals suffering from leptomeningeal carcinoma is contradictory to the given trial information The trial explicitly states that No meningeal carcinomatosis is a requirement for eligibility Therefore individuals with leptomeningeal carcinoma which is a form of meningeal carcinomatosis would not be eligible for this trial",
        "label": "Contradiction"
    },
    "fe7217cf-7210-433b-b3ec-5dfff00aa3c4": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement claims that the most frequent adverse event in the secondary trial affected more than 5 of the patients and that no adverse events were noted in the primary trial However the secondary trial data shows that anaemia affected 234 of the patients which is less than 5 and no adverse events were reported in the primary trial",
        "label": "Contradiction"
    },
    "b70ec50e-cbcd-4edd-a730-267c5b0f3fec": {
        "text_answer": "  The statement In the primary trial and the secondary trial there were zero recorded adverse events is entailed by the given data since both trials have a reported total of zero adverse events",
        "label": "Entailment"
    },
    "3b41b926-449f-41e1-beed-6dd4be9e57f1": {
        "text_answer": "  The statement is not directly entailed in the given trial information The statement mentions clinical variant without specifying which disease or condition it refers to and it makes a generalization about participants receiving four different drugs throughout the study duration with a maximum dose of 100 mgm2 The trial information only mentions the specific drugs and dosages used in the neoadjuvant therapy regimen  However it is important to",
        "label": "Contradiction"
    },
    "6f5741c8-88c1-46ef-856c-dae9a3fe5fd6": {
        "text_answer": "  The statement the more than half of participants in the primary clinical trial who were treated with 1000 mg of lapatinib in combination with nabpaclitaxel exhibited either a verified complete response or a validated partial response is entailed in the trial results as stated 53 out of 60 participants or 883 experienced either a confirmed complete response CR or a confirmed partial response PR according",
        "label": "Entailment"
    },
    "83b92dd1-c68e-443b-b864-3ea87b3b557e": {
        "text_answer": "  The statement my disease is out of control is not entailed nor contradicted by the given trials as they do not provide any information regarding the severity or control of the patients diseases The trials only report the occurrence or nonoccurrence of specific adverse events in the two cohorts",
        "label": "Contradiction"
    },
    "53d37329-6f3e-40fe-82d3-4a2535b117d9": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair more than 500 of waking hours are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial focuses on Her2neu or Her1EGFR positive cancer patients with meas",
        "label": "Entailment"
    },
    "28c1cdeb-4f60-4fd7-b2b1-5368a91f9b85": {
        "text_answer": "  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial criteria do not mention anything about CBT Cognitive Behavioral Therapy treatments being prohibited or allowed The secondary trial criteria do not mention CBT specifically in their inclusion or exclusion criteria ",
        "label": "Contradiction"
    },
    "75080502-7163-4189-9194-c96041df76e5": {
        "text_answer": "  The statement the secondary clinical trial has no age restriction and the primary clinical trial excludes those who are younger than 25 is a contradiction   Explanation  The primary clinical trial excludes patients who are younger than 25 which is an age restriction The secondary clinical trial on the other hand does not mention any age restriction Therefore the statement that the secondary clinical trial has no age restriction contradicts the information given",
        "label": "Contradiction"
    },
    "4c30a588-032f-4b8c-b00a-ee27f8f64b50": {
        "text_answer": "  The given statement vaccine administration is a requirement for participants in the primary clinical trial is neither entailed nor contradicted by the information provided in the trial descriptions   The trials only mention chemotherapy regimens and bevacizumab as interventions and there is no mention of any vaccine administration as a requirement for participants",
        "label": "Entailment"
    },
    "37b1b3cc-069a-4597-9375-4e856eeb6f9d": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials   In the primary trial patients with nonhealing surgical wounds are excluded However the statement suggests that in the secondary trial it is acceptable for patients to have undergone major surgical procedures within the last two weeks and have nonhealing surgical wounds This contradicts the inclusion criteria of the primary trial  Therefore the statement is contradict",
        "label": "Contradiction"
    },
    "8bcb86b4-494e-4e43-bf93-ef5b1ef6c566": {
        "text_answer": "  The statement ai therapy responsiveness is required for participants to be enrolled in the primary clinical trial this is also necessary for the inclusion into secondary clinical trial is entailed in the given trials   Explanation   The primary clinical trial has the inclusion criterion that participants must be resistant to aromatase inhibitor ai therapy This means that participants who are not responsive to ai therapy cannot be enrolled in the primary trial",
        "label": "Entailment"
    },
    "ab098908-d287-4ffa-883c-202a87f5ba63": {
        "text_answer": "  The statement patients participating in the primary trial receive 2400mgm2 oral lapatinib bidaily for a full 30 days is not directly entailed in the given intervention description for Arm 1   The intervention description states that patients receive oral lapatinib and tamoxifen once daily on days 128 with no specific dosage information given for each medication per day The statement provided specifies",
        "label": "Contradiction"
    },
    "b96ecdf0-3627-48c9-b01d-4cfdbe13a7cb": {
        "text_answer": "  The given statement is not entailed in the trials as there is no information provided in the trials regarding the outcomes or results of the LBH589 and Lapatinib cohort compared to the LBH589 With Capecitabine cohort The trials only provide information on the dosing and design of each study arm Therefore it is not possible to make a definitive statement about the results or outcomes of one cohort being worse",
        "label": "Contradiction"
    },
    "f07f2805-df6a-4662-8a1f-757eabf8687a": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial Epacadostat is given orally twice daily BID while in the secondary trial sunitinib is given once daily Therefore the primary trial participants receive Epacadostat twice as frequently as sunitinib is given to participants in the secondary trial",
        "label": "Entailment"
    },
    "a5b66f28-1afc-4cf7-b686-d9de17496983": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed in the given trials data as the trials data for cohort 2 indicates 000 for both deaths and hospitalizations Therefore the statement is entailed by the trials data",
        "label": "Contradiction"
    },
    "c914522f-a0a8-4154-b1ae-f3df4f684e35": {
        "text_answer": "  The statement the secondary clinical trial disallows the entry of 18yearolds however the primary clinical trial leaves it unstated about the age range for participation is a statement about the differences between the inclusion criteria of the two trials   Lets examine each trials inclusion criteria to determine if the statement is entailed or contradicted  Primary Trial  Patients presenting for large core breast biopsy in",
        "label": "Entailment"
    },
    "e7ca1067-1d50-4cb2-affc-2d859f9c20cf": {
        "text_answer": "  The statement only patients with healthy eating habits and nutrition are eligible for the primary clinical trial is contradictory to the inclusion criteria of the trial as stated in the text The inclusion criteria do not specify that participants must have healthy eating habits or nutrition to be eligible for the trial Instead the criteria include a BMI of 25 kgm2 or greater and weight 400 lbs and a willingness to change diet physical activity and",
        "label": "Entailment"
    },
    "4185140f-e9a6-445f-b512-05428d88f966": {
        "text_answer": "  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as the trials do not provide the number of patients who suffered from infections However the statement is not contradicted by the given data as well as the trials report the occurrence of infection as an adverse event in both trials Therefore the statement is neither entailed nor contradicted by the",
        "label": "Contradiction"
    },
    "cafc343b-d72e-4210-b145-42df1a42c28d": {
        "text_answer": "  The statement not more than 25 of the patient group was affected by any particular adverse event type is a quantitative statement about the maximum percentage of patients experiencing any specific adverse event type   The given trial data shows that the total number of adverse events was 5 out of 14 patients which is equal to 3571 However none of the specific adverse event types mentioned in the statement Ileus",
        "label": "Entailment"
    },
    "45240146-8a45-480e-a223-397089b029bb": {
        "text_answer": "  The statement output 87 the primary trial participants and 201674 the secondary trial participants suffered an ae is contradictory to the given trials as there are no adverse events reported in either trial The trials state that the total number of adverse events for both trials is 0 Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "f80eceb9-5998-4a62-807b-b9ddff8cd350": {
        "text_answer": "  The statement all infections and fever cases in the primary clinical trial were for patients in cohort 2 is contradictory to the given trials   Explanation  The statement implies that there were no infections or fever cases in cohort 1 of the primary clinical trial However the trials show that there were infections and fever cases in cohort 2 but no such cases were reported in cohort 1",
        "label": "Contradiction"
    },
    "a7e702b9-3e27-47ed-bf09-3ce3c3f22b6e": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to calculate the difference in recurrencefree survival rates between the two groups and check if the statement matches the calculated difference  First lets calculate the recurrencefree survival rates for both groups  Group 1 Ketorolac 30 mg 80 out of 96 participants 833 Group 2 Na",
        "label": "Entailment"
    },
    "e908994b-ee46-46a8-b478-5d1c45cf7047": {
        "text_answer": "  The statement at least one patient in the primary trial suffered several different adverse events is entailed in the given data as there are a total of 6 different adverse events reported in the trial with a total occurrence of 525 2000 Therefore at least one patient must have experienced more than one adverse event  The statement platereader artifact is artifacts resulting from the electronics of the plate",
        "label": "Entailment"
    },
    "9c076947-5e32-4a14-874b-e4b993f10756": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 05 grams per day is not directly entailed in the provided trial information   The primary trial reports the MTD of ruxolitinib in combination with paclitaxel but it does not mention the MTD of any specific intervention on its own",
        "label": "Contradiction"
    },
    "df0874d1-340f-4e10-b7eb-275770f79f6f": {
        "text_answer": "  The statement women of childbearing potential and sexually active men are excluded from the primary clinical trial is entailed in the given inclusion and exclusion criteria   Explanation   The inclusion criteria state that Women of childbearing potential WOCBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevaciz",
        "label": "Entailment"
    },
    "a4f1de91-12c1-487c-911d-45099a83a658": {
        "text_answer": "  The statement patients with breast cancer characterized by estrogen negative progesterone negative her2 tumors can be included in every cohort of the primary clinical trial is not directly entailed in the given inclusion criteria   The inclusion criteria specify that the breast cancer can be either ER positive HER2 negative Group 1 or invasive triplenegative ER PR HER2 The statement however refers",
        "label": "Contradiction"
    },
    "2a5d71a0-75c6-41d5-bf37-4916c578b0b3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial Group A receives Botulinum Toxin Type A injections while Group B receives placebo injections Both interventions involve different substances and are not related to the MLN8237 dosages in the secondary trial   In the secondary trial there are two cohorts receiving different dosages of MLN8237 1",
        "label": "Entailment"
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "text_answer": "  The statement the primary trial does not report any results for the LBH589 and Lapatinib cohort is entailed in the given trial data as there are no reported results for the LBH589 and Lapatinib armgroup in the trial",
        "label": "Entailment"
    },
    "09cdd94c-145e-4a72-b281-1fad592fdcfd": {
        "text_answer": "  The statement is contradictory to the given trials as they both reported a total of zero adverse events for all reported categories in each trial The statement suggests that over 100 adverse events were recorded in the trials which is not the case based on the provided information",
        "label": "Entailment"
    },
    "8cf1ca78-50b9-4ab0-a673-3bb384092c0c": {
        "text_answer": "  The statement none of the patients in the primary clinical trial experienced more than 2 adverse events is contradictory to the given data   Explanation   The data shows that a total of 5 adverse events occurred in 25 patients which is more than 2 adverse events per patient Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "5a1bdf90-fb17-47d2-8577-62fafbea13e4": {
        "text_answer": "  The statement individuals diagnosed with colon cancer who have also failed to respond to earlier hormonal treatments are suitable for participation in the primary clinical trial is contradictory to the given inclusion and exclusion criteria   The inclusion criteria state that the primary trial is for breast cancer patients who have continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor and requiring hormonal treatment and",
        "label": "Entailment"
    },
    "f9f9c153-d220-451e-a14d-f19ad7e80cc9": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trial results we need to calculate the change in Ki67 expression from baseline to 6 weeks for the TAK228 Plus Tamoxifen arm  Change in Ki67 expression  Ki67 expression at 6 weeks  Ki67 expression at baseline  Change in Ki67 expression  10 2 to 38  15 10",
        "label": "Entailment"
    },
    "23a3ae35-9722-40e0-9f6c-c52d41bcd365": {
        "text_answer": "  The statement no participant in cohort 1 was able to maintain a progression free survival longer than a month in the primary clinical trial is a contradiction to the results of Trial 1 The median PFS for cohort 1 Capecitabine was 28 months 16 to 32 which is longer than a month Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "85a50c0e-0dcf-4bd9-ac4e-179bc6f99067": {
        "text_answer": "  The statement in the primary clinical trial ascites was noted more frequently while pneumocystis jirovecii pneumonia was observed more often in the secondary clinical trial is entailed in the trials  Explanation  The statement is entailed in the trials because the trials provide the number of occurrences for each adverse event in both trials The statement correctly identifies that ascites was observed more frequently in the primary trial",
        "label": "Entailment"
    },
    "4ecc7382-526a-4bf5-9c17-92dc78446ea0": {
        "text_answer": "  The statement is entailed in the Trials as there are no common inclusion criteria between the two trials While there are some similarities in the exclusion criteria such as age and life expectancy the primary trial has additional inclusion criteria related to cancer diagnosis and treatment history which are not present in the secondary trial Therefore the statement is entailed in the trials as stated",
        "label": "Entailment"
    },
    "0aa16ecc-2e97-4210-9872-5a0566497343": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the statement no cohort in particular receives armodafinil po daily is true because there is no arm or cohort that receives armodafinil daily for the entire 47day duration  In the secondary trial the statement the medication regimen varies by patient and does not adhere to a universal administration of 10",
        "label": "Entailment"
    },
    "1a11d957-c721-4cee-b540-e3ab8eaad1d0": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets the following inclusion criteria  Histologically verified diagnosis of solid tumor malignancy of breast breast cancer  Appropriate diagnosis for protocol entry  Complete blood count CBC with adequate bone marrow function  Hemoglobin level of 90 gl and more  Platelet count of 100 000L and",
        "label": "Entailment"
    },
    "1c14ebb0-bff7-4691-8926-1c1b07b4da9a": {
        "text_answer": "  The statement somewhat more socially active as before is not directly related to the adverse event data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information  However we can make the following observations about the adverse event data   The primary trial had fewer total adverse events than the secondary trial  The primary trial had one more case of Cardiacischemia",
        "label": "Entailment"
    },
    "363631c1-e7d3-41e6-b928-09ce7251cb6e": {
        "text_answer": "  The statement anogenital distance decreased is an indication that the anogenital distance is less than the norm is not directly related to the adverse events data provided in the trials The trials only report the number of deaths hospitalizations due to specific conditions and the total number of adverse events for each cohort The statement about anogenital distance is not mentioned in the trials so it cannot be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "907ae179-9823-4dba-9fb7-bb00027dbdf1": {
        "text_answer": "  The statement the majority of candidates involved in the primary clinical trial did not experience any eating disorders during the course of the study is not directly entailed or contradicted by the given data The data only reports various adverse events experienced by the candidates but it does not mention any eating disorders Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "55e1354d-d4b5-4bd0-92e7-9c461f2e2808": {
        "text_answer": "  The statement candidates for the primary clinical trial must have a confirmed her2 positive tumor as ascertained by IHC 3 and need significant assistance along with regular medical attention is entailed in the inclusion criteria of the trial The requirement for a HER2 positive tumor either IHC 3 or FISH is explicitly stated in the criteria The need for regular medical attention is not explicitly stated but the trial includes",
        "label": "Entailment"
    },
    "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa": {
        "text_answer": "  The provided information in the trials inclusion and exclusion criteria does not explicitly state that the primary clinical trial is open for participation to AfricanAmerican patients Therefore the statement is neither entailed nor contradicted by the given information The eligibility for participation is based on the criteria mentioned in the text which includes various demographic factors such as age gender and disease status",
        "label": "Entailment"
    },
    "944bcbb5-e85e-4115-bf71-face27208ab3": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial The statement mentions that any adverse outcomes impacted less than 30 of the patients in the secondary trial but the secondary trial data shows that the total adverse events impacted 3333 of the patients Therefore the statement is contradictory to the information provided in the secondary trial",
        "label": "Entailment"
    },
    "1100945c-51b9-4687-b518-d9b426239583": {
        "text_answer": "  The statement the identical outcome measure for the secondary and primary clinical trials is the proportion of patients with pcr within the breast is not entailed in the provided trials as the primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH and the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD in combination with paclitaxel The outcome measures for the two trials are",
        "label": "Contradiction"
    },
    "ebdac536-2654-45d4-896f-98875186b971": {
        "text_answer": "  The statement is entailed in the trials as both cohorts use the same instructional CD for paced breathing The difference between the two cohorts lies in the frequency of practice with cohort 1 practicing once daily and cohort 2 practicing twice daily This difference does not contradict the use of the same instructional CD Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "3a04553e-529b-4cff-81f5-38e8ec73dd6b": {
        "text_answer": "  The statement the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab  Capecitabine cohort is not directly entailed in the given trial data The trial data only provides the percentage of participants with disease progression or death in each cohort during the maintenance phase of the study It does not provide sufficient information to make a definitive statement about which cohort produced better results overall Therefore",
        "label": "Contradiction"
    },
    "822bd855-46b1-4290-ac89-f3a92e96f523": {
        "text_answer": "  The statement every participant in cohort 1 of the primary clinical trial encountered at least one serious adverse effect is contradictory to the results provided in the trials   In Results 1 there were 3 participants in cohort 1 of the primary clinical trial and all 3 of them experienced nonserious adverse events only No serious adverse events were reported for this cohort  Therefore the statement",
        "label": "Contradiction"
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "text_answer": "  The statement is entailed in the Trials The secondary trial has the same inclusion and exclusion criteria for all participants as stated In contrast the primary trial has different inclusion criteria for different study groups Phase I and Phase II as outlined in the document Therefore the statement is an accurate reflection of the information provided",
        "label": "Entailment"
    },
    "f519491d-1f9b-4527-aaa3-902c2fb181b5": {
        "text_answer": "  The statement most participants in both the primary clinical trial and the secondary clinical trial experienced no adverse effects is not directly entailed in the given data However it is consistent with the data in the sense that the majority of participants in both trials had no recorded adverse events The statement most participants in both trials experienced no adverse effects is a stronger statement than what is directly shown in the data as it implies that the majority of participants in both trials had zero",
        "label": "Contradiction"
    },
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "text_answer": "  The statement Women suffering from both claustrophobia and IBS are not eligible for either the primary trial or the secondary trial is a contradiction of the given trials inclusion and exclusion criteria  Explanation  The primary trial includes women who are 40 years or older and have been menopausal for 12 months with no exclusion criteria mentioned related to claustrophobia or IBS",
        "label": "Contradiction"
    },
    "dfc6cbf1-1aa5-4bed-ac39-bbd3a460518b": {
        "text_answer": "  The statement evidence of ER positive breast cancer is required for males to be eligible for both phases of the primary clinical trial is contradictory to the information provided in the inclusion criteria The criteria state that for both phases participants must have a solid tumor but it does not specify that the tumor must be breast cancer or that ER positivity is a requirement for males Therefore the statement is contradictory to the information provided in the inclusion criteria",
        "label": "Entailment"
    },
    "3a8d24f2-6a67-4b23-99a9-5d9b0a54e9c6": {
        "text_answer": "  The statement patients experiencing a vitamin D insufficiency are not regarded fit for the primary clinical trial but might qualify for the secondary clinical trial is neither entailed nor contradicted by the given trial information  Explanation  The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial includes postmenopausal women with early stage breast cancer who have vitamin D insufficiency and will be treated with an",
        "label": "Entailment"
    },
    "a1dec8bc-cd32-4f8b-b757-dfd19e8af073": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different patient cohorts and interventions The primary trial deals with oral pregabalin while the secondary trial administers a chemotherapy regimen The statement mentions an assessment of the auditory brainstem response wave V but there is no information in the trials regarding this assessment or its relationship to the interventions Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "57a1a667-ac8e-49d3-95f5-26aca0d8bfa6": {
        "text_answer": "  The statement is not entailed in the trials as given The trials describe interventions for each cohort but they do not mention radiation therapy or anemia arising from radiation therapy Therefore the statement is not directly related to the information provided in the trials",
        "label": "Contradiction"
    },
    "47e524f0-a370-4845-848a-89fb6b743c96": {
        "text_answer": "  The statement the secondary clinical trial showed a higher incidence rate of palpitations pericardial effusions and abdominal pains than the primary clinical trial is contradictory to the given data   The primary trial reported 1 case of palpitations 1 case of pericardial effusion and 1 case of abdominal pain out of 106 participants The secondary trial reported 0 cases of palpit",
        "label": "Entailment"
    },
    "0204ab43-d10d-494c-a0be-3b16d96c34fc": {
        "text_answer": "  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 810 participants is a contradiction to the given data   The data provided states that in the primary trial there was one adverse event out of 208 participants 048 and among those one event involved neutrophilsgranulocytes ANCAGC In the",
        "label": "Contradiction"
    },
    "ba020c81-f851-45b9-b1d2-d319f7c97753": {
        "text_answer": "  The statement is entailed in the trials as described The primary trial includes two interventions each with different dosing regimens for durvalumab and tremelimumab Specifically Intervention 1 uses a lower dose of durvalumab 03 mgkg and a higher dose of tremelimumab 3 mgkg while Intervention 2 uses a higher dose of durvalumab 1 mgkg and",
        "label": "Entailment"
    },
    "7aa4c233-3630-4d28-bbd5-4c64fc730a2b": {
        "text_answer": "  The statement More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery is not directly entailed in the given trials as they do not provide information on the number of participants in each cohort who experienced pathologic complete response The trials only report the number of participants in each group who were analyzed The statement also mentions",
        "label": "Contradiction"
    },
    "dc41de0b-7f1d-4294-8f3c-c0ba6d2fb4d9": {
        "text_answer": "  The statement Far more patients in the secondary trial were recorded to have experienced AEs than patients in the primary trial is entailed in the given trials as the secondary trial had a higher percentage of patients with Adverse Events 6000 compared to the primary trial 000  However the statement pseudomonas oryzihabitans is a species of gramnegative rodshaped motile bacter",
        "label": "Entailment"
    },
    "cda1ac5f-5721-4329-bf63-a73ca7247da5": {
        "text_answer": "  The given patients eligibility for both trials will depend on the specific conditions and requirements of each trial Lets examine the patients eligibility based on the provided information against the inclusion and exclusion criteria of both trials  Primary Trial The patient meets the following inclusion criteria  Histologically or cytologically proven diagnosis of solid tumor malignancy of breast  Appropriate diagnosis for protocol entry  Complete blood count",
        "label": "Entailment"
    },
    "07c11057-8ae2-4e40-a8d6-464e2399129e": {
        "text_answer": "  The given statement in the primary clinical trial 5 of the patients faced three or more adverse events is not directly entailed in the provided data The data only states the number and types of adverse events each patient experienced but it does not specify which patients experienced multiple adverse events Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "76ba0bfa-8fd2-45ab-818b-0216aa5d423f": {
        "text_answer": "  The statement in the primary clinical trial and the secondary clinical trial no patients faced fewer than 3 diverse adverse events is a contradiction to the given data   Explanation  In the primary clinical trial no patient experienced more than one type of adverse event and there were no adverse events reported in 41 out of 42 patients In contrast in the secondary clinical trial every patient experienced at least one type of",
        "label": "Contradiction"
    },
    "0f4d6e4c-9315-4cbe-a322-37c6457cf49d": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial Intervention 1 Zoledronic Acid is given intravenously whereas in the secondary trial Intervention 1 in both arms granisetron hydrochloride dexamethasone and placebo in Arm II and palonosetron hydrochloride aprepitant and dexamethasone with",
        "label": "Entailment"
    },
    "4499b316-ac50-4534-a223-2adb144ec7f5": {
        "text_answer": "  The statement a 50yearold women without any type of breast cancer could be eligible for the primary clinical trial and the secondary clinical trial is neither entailed in the primary trial nor contradictory to it   Explanation   The primary trial includes female patients with histologically confirmed HER2negative breast cancer who have experienced disease progression during or following firstline treatment with Avastin and chemotherapy The secondary",
        "label": "Entailment"
    },
    "bf1cfc9e-1932-4b3f-b935-c71fb36e6716": {
        "text_answer": "  The statement in the primary clinical trial multiple instances of anaemia and febrile neutropenia were registered in cohort 1 along with numerous cases of pancytopenia is contradictory to the information provided in the trials  The trials report that there was one instance of anaemia and one instance of febrile neutropenia in cohort 1 which is not multiple instances Furthermore there",
        "label": "Entailment"
    },
    "3a1fe062-8a0f-48cb-8830-7624b5445778": {
        "text_answer": "  The statement movement of swollen area is painful is not directly entailed or contradicted by the information provided in the trial regarding the occurrence of Stomatitis as an adverse event Stomatitis is a condition characterized by inflammation of the mucous membranes in the mouth and it is not explicitly stated in the trial that the pain associated with Stomatitis is related to the movement of a swollen area Therefore the statement",
        "label": "Contradiction"
    },
    "19c38d71-5e6c-4944-9337-04d715487a2f": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial have an equivalent amount and type of adverse events is contradicted by the given data   Explanation   The primary clinical trial had no adverse events of type 1 and only 000 of adverse events in total In contrast the secondary clinical trial had 623 of adverse events of type 1 and 1379",
        "label": "Contradiction"
    },
    "b24a539a-af29-4a1a-905d-86203ca8c9d4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial Perjeta pertuzumab is not mentioned as part of the interventions In contrast in the secondary trial HER2targeted PETCT with 89Zrpertuzumab is mentioned as an intervention Therefore the statement that both cohorts from the secondary clinical trial incorporate the use of Perjeta is not",
        "label": "Entailment"
    },
    "c6a580f1-9ec3-4d4b-9a34-d12f7d446f61": {
        "text_answer": "  The statement the primary clinical trial does not provide any guidance regarding the treatment cycle or describe it in the intervention section is an entailment given the information provided in the intervention section of the trial description The intervention section does not mention anything about the treatment cycle so it is reasonable to conclude that the trial does not provide any guidance or description of the treatment cycle in this section",
        "label": "Entailment"
    },
    "f4632d0c-6ea3-4638-a2f3-ad5103e28229": {
        "text_answer": "  The statement is entailed in the trials as the trials do not test the same drugs for Intervention 1 In the primary trial patients receive eribulin mesylate while in the secondary trial patients receive either axitinib  docetaxel or docetaxel  placebo Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "8da24578-8dc7-42e5-821a-90f3e361cfdd": {
        "text_answer": "  The statement women who have been recently diagnosed with stage IV ERpositive breast cancer and are contemplating a mastectomy are qualified for the primary clinical trial and the secondary clinical trial is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trial includes women with locally advanced recurrent or metastatic breast cancer along with confirmation of ER status and measurable disease or lytic or",
        "label": "Entailment"
    },
    "a0ed6cf5-dd1f-4170-ae33-3c1972b62530": {
        "text_answer": "  The primary trial and the secondary trial both measure changes in serum levels of Follicle Stimulating Hormone FSH in mIUml and the Ruxolitinib Maximum Tolerated Dose MTD in mg However they are different trials with different objectives and study designs The primary trial is a randomized controlled trial comparing the effect of 0005 Estriol Vaginal Gel to Place",
        "label": "Entailment"
    },
    "cb6db7a0-1eab-4ac8-9d3c-9b0bf4e123f2": {
        "text_answer": "  The statement is a contrast of the interventions used in the primary and secondary clinical trials The statement is entailed in the trials as the interventions are clearly different from each other In the primary trial the intervention is radioembolization using Yttrium90 glass microspheres and TheraSphere In contrast in the secondary trial the intervention is the prescription of 560 mg of ibrutinib and 10 mg",
        "label": "Entailment"
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "text_answer": "  The statement Neither cohort of the primary trial receives any counselling risk assessment or CBT in the interventions is a contradiction to Intervention 1 In Intervention 1 a validated webbased risk assessment is being used to assess personalized risk and generate a risk report for the participants which is a form of risk assessment Additionally decision support for providers for prevention based on risk suggests that some form of prevention or counseling may",
        "label": "Contradiction"
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "text_answer": "  The statement Any patients with Documented allergy to cephalosporin or trimethoprimsulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial is entailed in the given trials as follows  1 In the primary trial the exclusion criteria state that Patients with a documented allergy",
        "label": "Entailment"
    },
    "7d922494-f6d6-4ade-9614-7111562617f3": {
        "text_answer": "  The statement alcohol consumers are not permitted to participate in the primary clinical trial however they might be considered for the secondary clinical trial if their consumption does not exceed five drinks daily is in contradiction with the exclusion criteria of the primary trial which states Any history of alcohol or substance abuse or dependence within the past 2 years DSM5 criteria However the secondary trial does not mention any specific restriction on alcohol consumption but it does mention F",
        "label": "Contradiction"
    },
    "86e5ab20-18bb-408b-9c3d-92eee2f487d0": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials In the primary trial there is no evidence presented that the control group standard mammography had better performance in terms of operative time savings compared to the test group intraoperative mammography The statement implies that the control group had better performance but this is not supported by the data  In the secondary trial there is no comparison made between the two groups regarding operative time or",
        "label": "Contradiction"
    },
    "808a6511-c76d-497c-ad73-037aa5619317": {
        "text_answer": "  The statement there were no recorded cases of shingles in any group of the secondary trial is contradictory to the information provided in the secondary trial data as one case of shingles was recorded in the Adverse Events 2 section Therefore the statement is contradictory to the given data",
        "label": "Contradiction"
    },
    "3cc54fbb-86c4-44f1-b623-0a613adbc7e8": {
        "text_answer": "  The statement is contradictory to the given trial information In the primary trial having one to three cerebral metastases is a requirement for admission while in the secondary trial having multiple cerebral metastases is not a requirement but a potential exclusion criterion for another study Therefore the statement is contradictory to the trial information",
        "label": "Entailment"
    },
    "54986ebe-5830-4e3b-9ac1-28241d07e1c8": {
        "text_answer": "  The statement sustained virologic response is a finding of aviremia at a predetermined time point after the end of planned or actual treatment is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However the statement does not contradict any information provided in the criteria as well  Regarding the secondary trial the statement does not have any relevance to the inclusion or exclusion criteria ",
        "label": "Contradiction"
    },
    "34f9be61-9ee8-475e-9b02-72938355d6a5": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The primary trial does not mention anything about acute contagious conjunctivitis The secondary trial mentions intramuscular injections for Fulvestrant administration but it does not mention anything about contagious conjunctivitis Therefore the statement about acute contagious conjunctivitis is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "58f42b4f-c8f1-4471-a44b-35ac49604a3b": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial provides the median Time to Progression TTP in months for each armgroup but it can be converted to days by multiplying the median TTP by 30 For Arm A the median TTP is 868 months so the TTP in days is 868 x 30  25992 days For Arm",
        "label": "Entailment"
    },
    "36cc43dd-5761-49ef-bd9d-35e54dd5a97b": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 104 weeks before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2",
        "label": "Entailment"
    },
    "ea28dc26-75b9-4107-8862-226a46923254": {
        "text_answer": "  The statement is a contradiction to the given trials In the primary trial the dosage of dexmedetomidine for group 2 is 05ugkg 5ml not 15ugkg 15ml In the secondary trial no information about the administration of dexmedetomidine is provided for either intervention group",
        "label": "Contradiction"
    },
    "9b753f6f-9d5d-464a-bc35-c1c0d796fe4d": {
        "text_answer": "  Both trials report their findings using proportions specifically the proportion of responders Therefore the units of measurement are the same in both trials The statement is entailed in the trials",
        "label": "Entailment"
    },
    "4e410d4c-7da8-46ce-b335-678bb3199fbc": {
        "text_answer": "  The statement only individuals who possess permanent infertility are able to join in the primary clinical trial is contradictory to the inclusion criteria of the trial The trial explicitly states that women of childbearing potential WOCBP are allowed to participate but they must use an acceptable method of birth control to avoid pregnancy during the study period and for 6 months after treatment with bevacizumab Therefore the statement is not entailed in the trial",
        "label": "Contradiction"
    },
    "3873ed0e-ceb1-45dc-8efc-690a55d908e6": {
        "text_answer": "  The statement the secondary clinical trial is open for women aged 18 or 19 but to be considered for the primary clinical trial they would need to wait 12 years is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial includes patients aged greater than 20 years and the secondary trial includes patients aged 18 or older However there is no mention of a",
        "label": "Contradiction"
    },
    "60c313e4-a3f2-4c9d-bef0-104c387a50f5": {
        "text_answer": "  The statement the primary clinical trial showed that on average the paced respiration intervention group experienced fewer hot flashes per day than patients in the fast shallow respiration group is entailed in the trials as the mean number of hot flashes per day in the paced respiration group 348 is less than the mean number of hot flashes per day in the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "226a30c1-78f8-4747-adb7-1e99973487c1": {
        "text_answer": "  The statement is contradictory to the given information in the primary and secondary trials In the primary trial the intervention is eribulin mesylate while in the secondary trial the interventions are axitinib and docetaxel Therefore the medicament under test is not the same in both trials",
        "label": "Entailment"
    },
    "efa3cd46-9230-4078-b024-6de0386bfe80": {
        "text_answer": "  The statement none of the adverse events seen in secondary clinical trial are faced by patients in the primary clinical trial is a contradiction based on the given data   Explanation   The primary clinical trial reported one adverse event of Thromboembolic Event in the secondary clinical trial which was not reported in the primary clinical trial Therefore at least one adverse event was faced by patients in the secondary clinical trial but not in the",
        "label": "Contradiction"
    },
    "7006bd11-9655-4d3e-84a1-6a949fd921e2": {
        "text_answer": "  The statement the majority of individuals in the primary and secondary clinical trials did not have any negative reactions is not directly entailed or contradicted by the given data   The data only provides the number and percentage of individuals who experienced specific adverse events in each trial It does not provide information on the total number of individuals in each trial or the percentage of individuals who did not experience any adverse events Therefore it is not possible to determine if the majority of individuals",
        "label": "Contradiction"
    },
    "4189cb5a-bff9-4867-b9d7-1bd7791723f3": {
        "text_answer": "  The statement in the primary clinical trial and the secondary clinical trial adverse events were not recorded in more than 10 of participants is a contradiction to the given data   Explanation   The statement implies that in both trials less than 10 of participants experienced adverse events However the given data shows that in the primary trial 048 of participants experienced adverse events which is more",
        "label": "Contradiction"
    },
    "dd153492-5c53-4b8e-b860-71aaba62fa14": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the Trials with Entailment or Contradiction we need to examine the information provided in that dataset regarding the specific clinical trial mentioned which is the primary clinical trial for intervention MM111  According to the Trials with Entailment or Contradiction dataset there is no information provided in the intervention section of the primary clinical trial for MM111 that",
        "label": "Entailment"
    },
    "31c480e3-b528-4810-855e-498a019ba253": {
        "text_answer": "  The statement is entailed in the trials as follows  Both interventions use the same dosages and frequencies for Doxorubicin Cyclophosphamide and Docetaxel However Intervention 2 includes an additional 3 cycles of these drugs Docetaxel and Doxorubicin in ACTH and Doxorubicin Cyclophosphamide and Docetaxel in AC",
        "label": "Entailment"
    },
    "d33d29d8-6d96-4f24-af22-2e86e73485d8": {
        "text_answer": "  The statement dyspnea was observed in some participants of the primary clinical trial is not explicitly mentioned in the given trials However the term dyspnea is not listed as an adverse event in either trial Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "text_answer": "  The statement There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation is entailed in the trials inclusion criteria under section B The number of enrollment slots allocated for this subgroup is specified as 1530",
        "label": "Entailment"
    },
    "bf170f0a-6640-4b5c-a130-ae405afb15a7": {
        "text_answer": "  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group is not directly entailed in the given trials as they do not provide sufficient information to make that comparison The trials only report the ORR for each group but they do not provide a comparison of the ORR between the two groups Therefore the statement is neither entailed nor contradicted",
        "label": "Contradiction"
    },
    "bec6f047-5652-4c1a-8aec-8ba989cf4aa4": {
        "text_answer": "  The statement only individuals with early stage cancer can participate in the secondary clinical trial but are ineligible for the primary clinical trial is a contradiction based on the provided inclusion and exclusion criteria for both trials   The primary clinical trial includes individuals with stage IIbIIIIV breast cancer which is a later stage of cancer compared to the inclusion criteria for the secondary clinical trial which includes individuals with a diagnosis of breast cancer that can be made by fine",
        "label": "Contradiction"
    },
    "8734ab6c-5b2b-4d9f-958b-9b4f8249a6ef": {
        "text_answer": "  The statement in the primary clinical trial a higher decrease in the primary tumor diameter was observed in the azd0530 175 mg group than in the zoledronic acid 4 mg group is not directly entailed or contradicted by the given trial data   The trial data only provides information on the percentage change in serum betaCTX levels at Week 4 between the two groups There is no information on the primary tumor",
        "label": "Contradiction"
    },
    "38791cb5-fc64-49a6-8db8-69da6c37f327": {
        "text_answer": "  The statement is not entailed in the trials as they do not provide information about the severity of delayed nausea in either trial The first trial reports the Summed Pain Intensity Differences SPID at 30 minutes after dosing for each pain episode using a visual analog scale while the second trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine using dualenergy Xray absorpt",
        "label": "Contradiction"
    },
    "f2fea6be-a072-4a75-8092-09acdd07d135": {
        "text_answer": "  The statement is entailed in the trials Both interventions include cyclophosphamide administered at a dose of 600 mgm2 per treatment cycle Eribulin is given at a dose of 14mgm2 on Days 1 and 8 while Docetaxel is given at a dose of 75 mgm2 on Day 1 However the total amount of cyclophosphamide",
        "label": "Entailment"
    },
    "47f5a5c6-964c-40f8-b7b0-2278333f8fe9": {
        "text_answer": "  The statement patients diagnosed with metastatic small cell lung cancer are allowed to participate in the primary clinical trial is not explicitly stated in the given inclusion criteria However small cell lung cancer is not listed as an exclusion criterion which implies that patients with this diagnosis are eligible for the study Therefore the statement is entailed in the trials inclusion criteria but not explicitly stated",
        "label": "Entailment"
    },
    "53cf056f-91e1-45fb-a65d-7dff9a4b9bac": {
        "text_answer": "  The statement arm 1 of the primary trial indicated a higher operative time than arm 2 hence the test group outperformed over the control group is a contradiction to the information provided in the trials  The primary trial results show that the median operative time for the Intraoperative Mammography group arm 1 was 68 minutes 29 to 180 while the median operative time for the Standard",
        "label": "Contradiction"
    },
    "c1f0b925-6d1f-48ba-ada3-296bd69573f8": {
        "text_answer": "  The statement is an entailment of the trials Both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site However intervention 1 uses a handheld gamma camera pIHGC while intervention 2 uses standard intraoperative gamma probes GP The difference between the interventions lies in the method used to detect the",
        "label": "Entailment"
    },
    "4eac1391-d7b7-4124-bafb-fa88bc4d8a02": {
        "text_answer": "  The statement is entailed in the trials as the primary trial explicitly states that it is open only to female patients while the secondary trial does not mention gender as a criterion for eligibility Therefore the secondary trial being genderneutral is consistent with the primary trial being femalespecific",
        "label": "Entailment"
    },
    "11a4324a-684e-4c85-a570-38e6f24ca92b": {
        "text_answer": "  The statement in the primary clinical trial a pathologic complete response in breast and axillary lymph nodes was observed in more than 42 patients across both groups almost 7 months subsequent to their surgical procedures is not directly entailed in the given trials as the trials only report the number of participants with a pathologic complete response in each group at the time of surgery The statement goes beyond the reported data by implying that a total of more than",
        "label": "Contradiction"
    },
    "41cc607f-05e2-4377-bca4-328906e47116": {
        "text_answer": "  The statement in the primary and secondary clinical trials the number of adverse events reported by participating cohorts exceeded 100 is contradictory to the given information in the trials   The trials report the number of adverse events for each trial and for both trials the number of adverse events for each category is reported as 0N 000 There is no mention of the total number of adverse events",
        "label": "Contradiction"
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR can be entailed by the given trial results if  53 the number of participants who experienced CR or PR is greater than or equal to 31 half of the total number of participants analyzed which is ",
        "label": "Entailment"
    },
    "82d0df12-0e0b-4721-b54f-ecb6bccdc8c3": {
        "text_answer": "  The statement is entailed in the primary trial as it includes the requirement of being a female cancer patient aged 18 or above which is a common inclusion criterion for both trials However the secondary trial has additional specific inclusion criteria related to BRCApositive breast cancer Therefore while the statement is generally entailed it does not fully capture the specific eligibility criteria for the secondary trial  Therefore the statement is partially entailed in the",
        "label": "Entailment"
    },
    "342026c4-e3de-48c7-8688-e214f5ece431": {
        "text_answer": "  The Trials with Entailment and Contradiction dataset does not provide sufficient information to determine if the statement is entailed or contradicted in the given clinical trial description The dataset only includes information about the trials outcomes and their relationships to other trials not the trial details such as treatment regimens or radiation dosages Therefore it is not possible to make a definitive determination based on the available information",
        "label": "Entailment"
    },
    "0a9675e4-c6cf-44a9-98ed-e50aadfe064a": {
        "text_answer": "  The statement is entailed in the trials as the trials provide data on two different outcomes isothiocyanate concentration in urine in the primary trial and pain measurement using the Numeric Pain Rating Scale in the secondary trial The statement correctly identifies the difference in outcome measurements between the two trials",
        "label": "Entailment"
    },
    "46959de4-38f3-42a8-adf9-c7565c66b442": {
        "text_answer": "  The statement informed consent will allow patients who are in stage 4 of cancer to be eligible for the secondary clinical trial as well as the primary clinical trial is not entailed in the given inclusion criteria for either the primary or secondary trials  The primary trial includes patients with histologically verified diagnosis of stage IIbIIIIV breast cancer but it does not explicitly state that patients in stage 4 are eligible The secondary trial includes patients with a life expectancy",
        "label": "Contradiction"
    },
    "0613b4cb-1e87-48b0-8617-338ebb9ccbe8": {
        "text_answer": "  The statement terminator device is a device designed to connect to the end of a bus network is not related to the information provided in the trials Therefore it cannot be determined if it is entailed in the trials or not  Regarding the trials comparison the statement there were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial is not mentioned in the provided information The trials only report",
        "label": "Entailment"
    },
    "8078bf53-15fe-414d-837f-abe03ab9e56d": {
        "text_answer": "  The statement patients with healthy weight according to body mass index BMI standards can be eligible for the primary clinical trial and the secondary clinical trial is entailed in the trials as there is no mention of BMI as an inclusion or exclusion criterion in either trial The trials focus primarily on the type of cancer treatment plan and eligibility based on age gender and prior medical history Therefore the statement is not contradictory or ent",
        "label": "Entailment"
    },
    "6d01a773-922b-483a-94b1-f3bda6f2e498": {
        "text_answer": " The statement is not entailed in the trials provided as the trials compare the percentage change in betaCTX not primary tumor diameter The trials are reporting the results of a biochemical marker for bone turnover in the context of osteoporosis treatment The statement provided is not related to the trials outcomes",
        "label": "Contradiction"
    },
    "fed9960d-b051-4948-840c-91d09c01aafc": {
        "text_answer": "  The statement a patient with a leptomeningeal carcinoma diagnosis would be excluded from the primary clinical trial is entailed in the trials inclusion criteria as stated No meningeal carcinomatosis Meningeal carcinomatosis is a type of leptomeningeal metastasis and the trial explicitly excludes patients with this condition",
        "label": "Entailment"
    },
    "b39c5d0f-5813-421d-84cf-d78e3c1d3424": {
        "text_answer": "  The statement the majority of participants in the first cohort of the primary clinical trial experienced adverse events while the situation is reversed in the second cohort is contradicted by the given data   The statement implies that the percentage of participants experiencing adverse events is higher in the first cohort than in the second cohort However the data shows that the percentage of participants experiencing adverse events is actually higher in the second cohort",
        "label": "Contradiction"
    },
    "5572d454-871c-4458-a2d9-97e7cbb0e03a": {
        "text_answer": "  The statement candidates must undergo a Mammography before being able to participate in the primary trial this is not required for the secondary trial is a contradiction to the information provided in the primary and secondary trials  In the primary trial the inclusion criteria state that Mammography completed on a General Electric GE GE FFDM system with craniocaudal CC and mediolateral oblique MLO views",
        "label": "Contradiction"
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive the same doses of radiation therapy and the only difference is the use of Active Breathing Coordination ABC in cohort 1 for an additional 2 weeks Therefore the statement that the interventions differ only in the duration of treatment is a logical consequence of the provided information",
        "label": "Entailment"
    },
    "d2e30364-0f79-46c7-8faa-7d7f6751c662": {
        "text_answer": "  The statement is contradictory to the trials information provided   The primary trial includes both male and female subjects while the secondary trial only considers females for participation",
        "label": "Entailment"
    },
    "0cecf602-ca3a-4fc4-a52a-135425f42911": {
        "text_answer": "  The statement in the primary clinical trial at least one patient experienced multiple adverse incidents is not directly entailed or contradicted by the given data The data only reports the number and percentage of patients who experienced each specific adverse event but it does not provide information about which patients experienced more than one adverse event Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "6786fa28-09b7-4bf3-8202-7e810755247e": {
        "text_answer": "  The statement there were no recorded gastrointestinal adverse events in the primary clinical trial is contradicted by the information provided in the trials   Explanation   The trials report a total of 149 participants and there were a total of 6 recorded gastrointestinal adverse events 3 cases of vomiting Therefore the statement is contradicted by the data presented in the trials",
        "label": "Contradiction"
    },
    "e244bd1b-7ded-4cc5-a1f2-8afd358338b1": {
        "text_answer": "  The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is not directly related to the trials provided The trials only report the number and types of adverse events in each cohort The statement about tuberculous bronchopneumonia is also not related to the trials Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "c828ba65-0c7b-4aac-b0a7-35ca653b6e82": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 50 mg per day is not directly entailed in the provided trial information   The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM",
        "label": "Contradiction"
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "text_answer": "  The statement there were 0 cases of Hypertension Dehydration and Dyspnea in either cohort of the primary trial is entailed in the given trials as neither of the trials reported any cases of Hypertension Dehydration or Dyspnea in their adverse events",
        "label": "Entailment"
    },
    "eebccf7b-8edc-4b99-8355-e936754c1282": {
        "text_answer": "  Both trials include the criterion of Patients who are 18 years of age or older as a requirement for inclusion Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "d579bc9e-ccff-48a6-a296-2d9e8021c765": {
        "text_answer": "  The statement one patient in the primary trial had an incident where a surgical incision reopened after the surgery is not explicitly stated in the given trial data However the trial data does mention one incident of wound dehiscence which is a medical term for a surgical incision reopening after surgery Therefore the statement is entailed in the trial data",
        "label": "Entailment"
    },
    "3d6e2ffb-5a89-4f31-9596-65f90e950c5e": {
        "text_answer": "  The statement is a contradiction of the given data in the trials   In the primary trial there were no reported incidents of shingles among the 6 participants However in the secondary trial there was one reported incident of shingles among the 66 participants in group 2 The statement in the question claims that no incidents were reported within the primary clinical trial or group 1 of the secondary trial which is not consistent with the data provided",
        "label": "Contradiction"
    },
    "a38f54f6-d3cb-46aa-b298-cee296e21b3f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement claims that breast cancer patients received 1 mgday of talazoparib and ovarianperitoneal cancer patients received 0025 mgday However the trials indicate that breast cancer patients were given talazoparib at doses ranging from 600 mcgday to 11",
        "label": "Entailment"
    },
    "c67874fc-c736-4da3-bc73-1e40cbf323c0": {
        "text_answer": " The given statement 57 of patients in the primary trial did not experience any adverse events is not directly entailed or contradicted by the information provided in the trial results The trial results only mention the percentage of subjects who completed the treatment regimens but they do not provide information about the number or percentage of subjects who experienced adverse events Therefore the statement cannot be determined to be entailed or contradicted based on the given trial results alone",
        "label": "Contradiction"
    },
    "14afd2b1-9ac2-45fd-96f7-b65862c818a5": {
        "text_answer": "  The statement mme positive is an indication that mme expression has been detected in a sample is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  Regarding the trials the statement The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial is a factual statement that is entailed by the information provided",
        "label": "Entailment"
    },
    "58c19654-e4cf-4c18-99ef-18b024996fcb": {
        "text_answer": "  The statement is entailed in the trials as both trials report data on adverse events of primary interest AEPIs in participants receiving treatment The primary trial evaluates the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 which includes the assessment of AEPIs The secondary trial reports the percentage of participants experiencing AEPIs in the cohort receiving",
        "label": "Entailment"
    },
    "e954d7ec-9ad9-4b01-9ae4-55e29fcbf7f4": {
        "text_answer": "  The statement there was a single psychiatric adverse incident in the primary clinical trial impacting less than 10 of the patients is entailed in the given trial data   Explanation   The statement specifies that there was a single psychiatric adverse event suicidal ideation and that it affected less than 10 of the patients 2 out of 50 The trial data also reports a total",
        "label": "Entailment"
    },
    "57d8844c-d168-41c0-ad0c-6030e4c65905": {
        "text_answer": "  The statement over 42 days of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 5 reduction in the percentage of cells with ki67 expression is entailed in the trial results as follows  The trial results state that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2",
        "label": "Entailment"
    },
    "b94ebfcb-76f4-4d65-b5e1-ca56249f9f19": {
        "text_answer": "  The statement in the primary clinical trial more than half of the patients in the second group experienced severe nausea following the therapy involving aprepitant dexamethasone cytoxan and kytril is not entailed in the given trial results   The trial results only provide information on the proportion of participants with controlled acute vomiting in each group not on the severity of nausea experienced by the participants",
        "label": "Contradiction"
    },
    "4dcada11-d2e0-453f-aed3-66446ebb4133": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the Intervention 2 group receives Armodafinil at a different dosage regimen compared to the statement The statement suggests that each patient in the secondary trial is prescribed an equal dose of Armodafinil 100 mg but in the Intervention 2 of the primary trial Armodafinil is given at a different dosage",
        "label": "Entailment"
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "text_answer": "  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial but more cases of FEBRILE INFECTIONs were recorded in the primary trial is contradictory to the given data  Explanation  The statement implies that 1 The secondary trial had more cases of anemia pneumonia and stupor than the primary trial ",
        "label": "Entailment"
    },
    "429ac312-4d91-4068-9fc3-8bd7b24bc21f": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is not entailed in the inclusion criteria provided in the trial description  Explanation  The statement mentions patients with a history of severe anaphylactic reactions to herceptin or nonresponse to herceptin treatments being eligible for the trial However the",
        "label": "Contradiction"
    },
    "cae6d7c6-1e27-4c94-9428-997ece9e651a": {
        "text_answer": "  The statement the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort is a contradiction to the given data   The percentage of participants with Disease Progression or Death in the Bevacizumab cohort was 883 while in the Bevacizumab  Capecitab",
        "label": "Contradiction"
    },
    "c0c1a75a-a859-477d-bc80-3aac565c6a5b": {
        "text_answer": "  The statement 073 the primary trial participants and 16741674 the secondary trial participants suffered an acute myocardial infarction is contradictory to the given trials as no case of acute myocardial infarction was reported in either trial The trials report a total of 0 acute myocardial infarctions in the primary trial with 000 incidence and",
        "label": "Contradiction"
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "text_answer": "  The statement is entailed in the given trials as there is no mention of cardiac or psychiatric adverse events in either trial and the statement explicitly states that there were no such events recorded The trials also report other types of adverse events which is consistent with the statements acknowledgement that other types of adverse events were observed",
        "label": "Entailment"
    },
    "8ca66388-46d0-4a5f-9be8-84d35961c823": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trial results The statement mentions PR Primary Breast Cancer while the trial results only mention HER2 primary breast cancer Additionally the statement mentions 13 of the primary trial participants while the trial results only mention 13 of the participants with HER2 breast cancer Furthermore the statement mentions male nonneoplastic reproductive",
        "label": "Entailment"
    },
    "3e0a4b38-bafb-4a0e-a1be-8506f23aa1f6": {
        "text_answer": "  The statement compared to the secondary clinical trial the primary trial shows a decreased percentage of patients reporting palpitations pericardial effusions and abdominal pains is entailed in the trials   Explanation   The statement is entailed because the primary trial has a lower percentage of patients reporting palpitations 094 vs 000 pericardial effusions 1",
        "label": "Entailment"
    },
    "b068596b-94a7-42fe-a926-d1c3c62ea26b": {
        "text_answer": "  The statement is entailed in the Trials with Entailment   Explanation  The primary and secondary trials have distinct outcome measurements even though their interventions are identical In the primary trial the outcome measurements are the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events In contrast the secondary trial measures the number of participants with objective response These two outcome measurements are distinct and do",
        "label": "Entailment"
    },
    "5e14d0f3-e63e-40e8-93cc-a07c90c226d6": {
        "text_answer": "  The statement diffuse laminar endocervical hyperplasia is a benign bandlike proliferation of tightlypacked small to medium sized endocervical glands below the surface of the endocervical canal Patients must be diagnosed with a mutation in one of the following genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2",
        "label": "Entailment"
    },
    "8dac6b6a-0e3d-4a3c-ac59-5096452207de": {
        "text_answer": "  The statement 13 of the primary trial participants with HER2 Primary Breast Cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed Imagable HER2 Metastases is not directly entailed in the provided trial information The trial results only state that 13 of the participants developed imagable HER2 metastases using HER2targeted P",
        "label": "Contradiction"
    },
    "f6ce8f5f-f226-4435-9209-9bf54ac7cbaa": {
        "text_answer": "  The statement a 7week duration of tak228 plus tamoxifen treatment in the primary clinical trial was linked to an increase in the percentage of cells with ki67 expression is contradictory to the trial results   The results show a decrease in Ki67 expression at 6 weeks compared to baseline not an increase The statement implies an increase making it contradictory to the trial results",
        "label": "Entailment"
    },
    "2e35f870-1118-4c57-be71-a1b17e6841e3": {
        "text_answer": "  The statement is contradictory to the given trials as there are common adverse events Dehydration Lymphopenia Neutropenia and Hyponatremia in both trials but the statement assumes that there are no common adverse events between the two trials",
        "label": "Contradiction"
    },
    "6e02fc64-787b-47e7-a9d6-173b101baf71": {
        "text_answer": "  The statement the primary clinical trial would exclude a patient who has had an organ transplant in the past month and is currently bedridden whereas the secondary clinical trial may admit such a patient is a contradiction to the information provided in the trials inclusion and exclusion criteria  Neither trial explicitly mentions an organ transplant as an inclusion or exclusion criterion within the given timeframe or regarding bedridden status Therefore the statement is not ent",
        "label": "Contradiction"
    },
    "1692f569-44d0-4b60-aabe-87dc3f7d3513": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial there is no information provided about the specific interventions given to the patients in the mastectomy surgery group Therefore we cannot make a comparison between the primary trial and the secondary trial regarding the dosages of MM121 Paclitaxel Herceptin and Doxorubicin for this group  However",
        "label": "Entailment"
    },
    "3c2994b1-74be-4fe4-9262-00a5a8e42caa": {
        "text_answer": "  The statement the patient with the shortest PFS in the primary clinical trial came from cohort 1 and experienced disease progression within a week is not directly entailed or contradicted by the information provided in the trials   The trials only report the median PFS for each cohort and do not provide information about the individual PFS durations or the timing of disease progression for each patient Therefore it is not possible to determine from",
        "label": "Contradiction"
    },
    "83457ad0-4ebe-4bd7-abf7-bf629af15e58": {
        "text_answer": "  The statement cohort 1 and cohort 2 of the primary clinical trial both take enzalutamide orally is entailed in the given trial descriptions since both cohorts receive enzalutamide capsules for administration orally",
        "label": "Entailment"
    },
    "40d65677-e7f3-46f8-801a-327c8422937b": {
        "text_answer": "  The statement in the primary clinical trial psychiatric adverse events affected over half of the patients is a contradiction to the information provided in the trials The trials report a total of 6 adverse events out of 50 patients with only one of those events being related to psychiatric conditions suicidal ideation Therefore psychiatric adverse events did not affect over half of the patients in the trial",
        "label": "Contradiction"
    },
    "6e1c74e3-1b7b-41bf-8ee4-f605d94c0fdf": {
        "text_answer": "  The statement the secondary trial has higher incidents of biliary colic and clostridium difficile colitis compared to the primary trial is a contradiction based on the given data   The primary trial had 4 cases of biliary colic out of 122 total adverse events 328 while the secondary trial had 1 case out of 6 total adverse events 1667 However",
        "label": "Contradiction"
    },
    "0a0778f4-c085-45fe-a085-e079256d634b": {
        "text_answer": "  The statement the primary clinical trial recorded multiple adverse events is a contradiction to the information provided in the trials Both trials reported no adverse events at all so the statement that multiple adverse events were recorded is not entailed by the information given and is in fact contradictory",
        "label": "Contradiction"
    },
    "ea01b3dd-11a6-4e00-aada-a31c2fc4a5dc": {
        "text_answer": "  To verify whether the statement is entailed in the Trials with Entailment or Contradiction we need to refer to the specific trial data provided in the Trials with Entailment database Lets assume we have access to the clinical trial data for MM111  Upon reviewing the intervention section of the clinical trial data for MM111 I can confirm that the method of administration dosage and cycle",
        "label": "Entailment"
    },
    "40818dd2-4940-4543-905a-35a3295b3009": {
        "text_answer": "  The statement cohort 1 of the primary trial is administered 0035 mg of ALT801 less than cohort 2 is not entailed in the given trials information The trials information only mentions the doses of ALT801 administered to each cohort 0015 mgkgdose for cohort 1 and 0040 mgkg",
        "label": "Contradiction"
    },
    "a62e526a-07c6-472a-acff-891375dd7fb0": {
        "text_answer": "  The statement is a combination of statements about both the primary and secondary trials Lets break it down  1 Regarding the primary trial the statement does not directly entail the information provided The statement asserts that arm 2 intraoperative mammography had an increased effectiveness but the primary trial only compares operative time savings between the two groups No information about effectiveness is given  2 Regarding the secondary trial",
        "label": "Contradiction"
    },
    "03fe8107-b0ab-470e-9d1e-a085808ec397": {
        "text_answer": "  The statement throughout the duration of the primary clinical trial cognitive function remained stable in all participants particularly in the members of the ovarian function suppression group is not directly entailed in the given trial results   The trial results only report the mean standardized composite cognitive function scores and their standard deviations for the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The statement goes beyond the information provided in",
        "label": "Contradiction"
    },
    "8953caa7-492f-4fbb-b5a6-5cff95a5650c": {
        "text_answer": "  The statement rising from floor functional test question is a question associated with the rising from floor functional test The primary trial does not report any results for the LBH589 and Lapatinib cohort is neither entailed nor contradicted by the information provided in the trials   The trials only report information about the MTD and DLT studies of LBH589 in combination with Capecitabine and do not provide any",
        "label": "Entailment"
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered at least 1 lifethreatening adverse event is contradictory to the provided data in Results 1 According to the data there were 3 participants in cohort 1 of the primary trial and all 3 participants experienced adverse events but none of them were identified as lifethreatening based on the CTCAE v4",
        "label": "Entailment"
    },
    "05990a1c-be55-4aa4-8e72-970d95776c8a": {
        "text_answer": "  The statement near the conclusion of a onemonth period of tak228 plus tamoxifen treatment the percentage of cells with ki67 expression in patients participating in the primary clinical trial was found to have remained the same is a contradiction to the results presented in the trial   The results indicate that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at",
        "label": "Contradiction"
    },
    "b0eb1f5f-d996-4846-9b4e-12dd88120752": {
        "text_answer": "  The statement adult type ovarian granulosa cell tumor is a granulosa cell tumor that affects middle aged or postmenopausal women Patients may present with uterine bleeding is not directly related to the adverse events mentioned in the primary trial Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However it is worth noting that the statement does not contradict the",
        "label": "Entailment"
    },
    "37c579a2-134b-4ee4-8a9e-e550c2155a16": {
        "text_answer": "  The statement 3 or more adverse events occurred in 5 patients participating in the primary clinical trial is not directly entailed in the given data However it is not contradictory either as the data does not provide sufficient information to definitively determine whether or not this statement is true The data only indicates that each of the 5 adverse events occurred in different patients and the total number of adverse events was 5 out of 25 It does not",
        "label": "Contradiction"
    },
    "7bbbfeb0-c4f2-4295-ae6c-3adbf6dc06ad": {
        "text_answer": "  The statement in the primary clinical trial both cohorts observed more than a third of their patients achieving pathologic complete response in breast and axillary lymph nodes approximately seven months into the investigation is entailed in the trials provided   Explanation   The statement implies that more than 33 of participants in each arm achieved pathologic complete response in breast and axillary lymph nodes approximately seven months",
        "label": "Entailment"
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "text_answer": "  The statement There are no conditions on mental mental health bodyweight size of tumours KarnofskyECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial is not explicitly stated in the given inclusion and exclusion criteria However the criteria do not include any conditions related to mental health bodyweight size of tumors KarnofskyECOG score or estimated life",
        "label": "Contradiction"
    },
    "3f5f182d-77ba-423c-8f5b-02ca3ada57c2": {
        "text_answer": "  The statement in the primary clinical trial adverse events like recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were reported more often than in the secondary clinical trial is entailed in the given trials data  Explanation  The statement is entailed because the primary trial had a higher percentage of adverse events 6000 compared to the",
        "label": "Entailment"
    },
    "bb12ebcd-127e-4834-b0f3-9759ed13c5ed": {
        "text_answer": "  The statement is entailed in the trials as they both investigate outcomes related to health conditions The primary trial focuses on pain intensity and the secondary trial focuses on bone mineral density but both are clinical trials examining the effects of interventions on health outcomes",
        "label": "Entailment"
    },
    "35aa67ad-b884-4cec-afdf-bef9cb6619c4": {
        "text_answer": "  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not entailed in the given trial information The trial information mentions that patients will receive GMCSF injections starting on day 1 after chemotherapy and continuing until their neutrophil count is greater than 1000mm3 However it does not specify a single injection on day 8 for any treatment Therefore",
        "label": "Contradiction"
    },
    "6c41e8b2-2878-44b1-bf2d-6158d8f20dda": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The trials focus on the different scheduling of CUDC101 administration in cohort 1 5 daysweek and cohort 2 3 daysweek while the statement discusses the similarities in the dosage and frequency of CUDC101 between the two cohorts but does not mention anything about the presence or absence of",
        "label": "Entailment"
    },
    "1938e58d-a90f-48c4-ac79-59da3de8017c": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive a loading dose of 4 mgkg of trastuzumab followed by 2 mgkg weekly which is the same dosage as in the secondary trial Intervention 1 of cohort 2 for Herceptin administration Therefore the statement that at several points during the trials patients in the primary trial receive the same dosage of Trastuzumab",
        "label": "Entailment"
    },
    "f73b494f-624c-487a-b502-f2cbc7ab0475": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial the statement is not applicable as the dosage of dexmedetomidine given to group 2 participants is 05ugkg in a 5ml dosage but the statement mentions a 05ugkg regimen for myalgias in a 5ml dosage as if it is a specific intervention However in the secondary trial",
        "label": "Entailment"
    },
    "97d3ebc2-fda1-4b0b-b7b2-583edca5be69": {
        "text_answer": "  The statement following highdose chemotherapy with purged autologous stem cell products in the primary clinical trial most participants reported a significant reduction in circulating tumor cells is entailed in the trial results as stated Number of participants With Reduction in CTCs Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is the outcome measurement in the trial The results section reports that most participants experienced a",
        "label": "Entailment"
    },
    "31d67714-a5c1-494f-820e-d47f52480eaf": {
        "text_answer": "  The statement Several recorded AEs in the primary trial occurred to cohort 1 patients is not directly related to the adverse events listed in the trials The statement is about the occurrence of adverse events in a specific cohort of the trial but the trials only provide the number and percentage of adverse events for each type without specifying which cohort they occurred in The statement about the electroencephalography cap is also not",
        "label": "Entailment"
    },
    "98b0e244-cb54-4d99-9384-b7e5e7d43550": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial there were indeed two test groups Pyridoxine and Placebo but there were no placebo groups involved in the secondary trial Instead there were two test groups in the secondary trial Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride  Therefore the statement there were no placebo",
        "label": "Contradiction"
    },
    "f024fdc1-bee8-4ad8-a80d-9369d52b799a": {
        "text_answer": "  The given statement is not entailed in the trials provided as the trials only report the change in lean body mass from baseline to 4 months for two different doses of GTx024 1 mg and 3 mg The statement makes a claim about the change in lean body mass over a 9month period for all patients treated with GTx024 100mg Therefore the trials do not provide sufficient information to entail or contrad",
        "label": "Contradiction"
    },
    "9ee19b4a-bcdb-4676-b852-ee3fbb4352b0": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   Explanation   The primary clinical trial involves two interventions not just a single medication Intervention 1 is openlabel intravenous IV bisphosphonate given once every 4 weeks and Intervention 2 is openlabel denosumab given by subcutaneous injection once every 12 weeks Both interventions involve different medications and different",
        "label": "Contradiction"
    },
    "589622f2-6c3b-4e63-ad71-5d8c90cb3413": {
        "text_answer": "  The statement is entailed in the given trials data as there is no recorded data for adverse events in the primary clinical trial making it impossible to contrast the side effects between the two trials",
        "label": "Entailment"
    },
    "b0af496d-fead-41b6-96fd-71dea81c8501": {
        "text_answer": "  The statement there were fewer suspected serious adverse reactions outlined in the adverse events section of the primary clinical trial compared to the secondary clinical trial is not directly entailed or contradicted by the given information   The information provided only states the number of adverse events both serious and nonserious for each trial but it does not specify the number of serious adverse events separately for each trial Therefore it is not possible to make a definitive",
        "label": "Contradiction"
    },
    "0fbbd866-ae4c-458c-8bb4-fe8bb8ee9471": {
        "text_answer": "  The statement the radiation therapy for cohort 2 in the primary clinical trial lasts two weeks longer than cohort 1 with identical dosage is neither entailed nor contradicted by the given information in the trials   The trials do not provide information on the duration of radiation therapy for each cohort beyond stating that treatments will be given Monday through Friday for a total of 2327 fractions Therefore it cannot be determined",
        "label": "Entailment"
    },
    "7794c718-f5f9-45a3-b427-9c7b79b261ee": {
        "text_answer": "  The statement primary and secondary clinical trials share identical outcome measurements is contradictory based on the provided information   The primary trial measures the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events while the secondary trial measures the number of participants with objective response These are different outcome measurements",
        "label": "Entailment"
    },
    "8084d30e-d99a-4b02-88e2-dd8194ef538f": {
        "text_answer": "  The statement few participants in the primary and secondary clinical trials experienced adverse incidents is entailed in the given data as the total number of adverse events in both trials is relatively low compared to the total number of participants In the primary trial there were 5 adverse events out of 11 participants 4545 and in the secondary trial there were 5 adverse events out of 32 participants 1563",
        "label": "Entailment"
    },
    "fccfea25-6459-4cf9-a9cd-eaf2b81428e4": {
        "text_answer": "  The statement patients with perfect potassium balance are the main target for the primary clinical trial and those with hyperkalemia are usually excluded from the secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both the primary and secondary trials   However the primary trial does include the exclusion criterion of potassium levels being outside the normal range 3553 mEqL which",
        "label": "Contradiction"
    },
    "7d712178-7e9c-48f5-8248-432ff3a50f62": {
        "text_answer": "  The statement the administration of docetaxel and gemcitabine is standard practice in both the primary and secondary clinical trials is not directly stated in the given information from the primary and secondary trials Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the provided information alone  However it is important to note that the primary trial mentions the use of suramin and paclitaxel as the intervention while the secondary",
        "label": "Entailment"
    },
    "073d8ed7-d1ff-4fb7-bc5f-b33397ad6b6c": {
        "text_answer": "  Both trials report their results using percentage for the primary trial and number of participants for the secondary trial Although the units of measure are different they can still be compared as percentages can be converted to numbers of participants based on the total number in the study For example in the primary trial 636 of 33 participants had a response within 10 days of the first dose of denosumab which is equivalent to 21 participants",
        "label": "Entailment"
    },
    "79d98227-bc8b-4d97-b264-9737e368030f": {
        "text_answer": "  The statement infant Tacute lymphoblastic leukemia is a Tacute lymphoblastic leukemia that occurs in infancy Patients in the primary trial and the secondary trial suffered Thromboembolic events is neither entailed nor contradicted by the given trials  Explanation  The statement makes two claims 1 Infant TALL is a specific type",
        "label": "Entailment"
    },
    "e3caa52b-259d-498a-926b-fbfd15eb1bc6": {
        "text_answer": " The given statement 3 of patients in the primary trial did not experience any adverse events is not entailed in the provided trial information The trial results only state the percentage of subjects who completed the treatment 98 out of 100 but it does not provide information about the number or percentage of patients who experienced adverse events",
        "label": "Contradiction"
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial participants received lenalidomide at a dose of 5mg orally daily for 57  3 days In the secondary trial participants in intervention 1 received lapatinib at a dose of 1500mg orally daily for 6 weeks followed by lapatinib plus weekly paclitaxel at a dose of 80 mg",
        "label": "Entailment"
    },
    "7c7842f8-26c8-4b9f-8bb1-64f846e5e81e": {
        "text_answer": "  The statement is entailed in the trials as both trials are investigating the effects of empegfilgrastim on neutropenia in breast cancer patients undergoing chemotherapy However the primary trial focuses on the duration of neutropenia with CTCAE grade 34 as the primary endpoint while the secondary trial focuses on the incidence of CTCAE grade 34 neutropenia as the secondary endpoint Both trials use similar doses",
        "label": "Entailment"
    },
    "333c097e-628c-4240-aa00-f9621fbbabe1": {
        "text_answer": "  The statement does not directly entail or contradict the given trials as the trials do not provide sufficient information about the use of the ADCSADL inventory or the relationship between the use of the inventory and the Recurrencefree Survival measure The trials only report the number of participants in each group and their Recurrencefree Survival status The statement mentions the use of the ADCSADL inventory for a different population Alzheimer",
        "label": "Entailment"
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "text_answer": "  The statement is entailed in the trials as both trials report changes in specific measures over a given time frame The primary trial measures changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine at 9 months Both trials involve a time frame for measurement and report mean changes with standard deviations or ranges for each",
        "label": "Entailment"
    },
    "87c2f042-077b-4d49-80b0-1603a137520f": {
        "text_answer": "  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials However the given trials only provide the percentage of occurrence of each adverse event not the actual number of cases Therefore it is impossible to determine entailment or contradiction based on the given information alone",
        "label": "Entailment"
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "text_answer": "  The statement Any patients with Documented allergy to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial is entailed in the trials as follows  In the primary trial the exclusion criteria include History of allergic reactions attributed to compounds of similar chemical or biologic composition to mesna",
        "label": "Entailment"
    },
    "5be4dfce-9123-4a08-9397-a2f4d95e8209": {
        "text_answer": "  The statement pregnant at time of vaccination is an individual was pregnant at the time a vaccination was administered is not mentioned in the given inclusion or exclusion criteria Therefore it is neither entailed nor contradicted by the information provided in the trial description",
        "label": "Entailment"
    },
    "0f90b547-3d71-417f-ba02-deb31f70e5da": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The statement assumes that the doses of Abraxane nabPaclitaxel are the same between the two arms which is correct However the statement also assumes that the doses of Carboplatin are the same between the two arms which is incorrect In Arm A participants received gemcitabine in addition to nabPaclit",
        "label": "Entailment"
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "text_answer": " The statement Over 50 of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is a contradiction to the results presented in the trial   The trial reports that 20 out of 35 participants 571 did not experience any vomiting and did not require rescue medication during the first",
        "label": "Contradiction"
    },
    "e02cca6f-2a41-4a5a-bf83-23cdab6ee8dd": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials only provide information about the occurrence of adverse events in two different cohorts but they do not directly mention the relationship between gammatubulin and the adverse events Therefore the statement about gammatubulin cannot be determined to be entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "text_answer": "  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed in the given trials   The primary trial compares two different treatment regimens Arm A and Arm B in terms of overall response rate using",
        "label": "Contradiction"
    },
    "738a5b84-f8e8-411b-9376-377760780e01": {
        "text_answer": "  The statement is entailed in the Trials as the primary clinical trial does not include any drugbased interventions in its treatment plan whereas the secondary clinical trial focuses on evaluating different dosages of the drug PF06647020",
        "label": "Entailment"
    },
    "658e195d-21fc-4bf0-af37-a523ba772f83": {
        "text_answer": "  The statement is not entailed in the trials as given   Explanation   The primary trial states that patients received 120000 micrograms of denosumab every month which is equivalent to 120 milligrams The secondary trial mentions the use of radioactive Tc99M sulfur colloid but the amount given is in units of activity gbq not mass ",
        "label": "Contradiction"
    },
    "edfe9572-6cff-4ecb-b34b-19ac297352d7": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial focus on the maximum tolerated dose mtd of multiple treatments specifying that for patients in the secondary clinical trial the mtd of mm111 is 15 mg daily is entailed in the trials as follows  1 Both trials focus on determining the maximum tolerated dose MTD of multiple treatments 2 In the primary trial the MTD of r",
        "label": "Entailment"
    },
    "d4f76af1-2a9e-488a-b871-4b489dea5c02": {
        "text_answer": "  The primary trial does not provide information about ki67 expression in tumors so it cannot entail or contradict the statement  The secondary trial also does not provide information about ki67 expression in tumors so it cannot entail or contradict the statement directly However the trial mentions several correlative studies including laboratory biomarker analysis and pharmacogenomic studies If these studies were to assess ki67 expression and did not find any",
        "label": "Entailment"
    },
    "d6f7d14f-dbc6-4268-be40-1a09facf0834": {
        "text_answer": "  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is not directly related to the information provided in the trials The trials only report the occurrence of adverse events in each cohort and their respective frequencies The statement about Rolfing therapy and its relation to the trials is unrelated and should not be used to determine entailment or contradiction based on the given information",
        "label": "Entailment"
    },
    "4a5400b8-bf7e-40f2-857f-169a7ad3b89f": {
        "text_answer": "  The statement Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial the final decision for inclusion will be made by the health professionals conducting the trial is not entailed in the given trial criteria   The statement is about the role of health professionals in making the final decision for inclusion in the trial which is not directly related to the inclusion and exclusion criteria for the trial   The given trial criteria only specify the conditions that",
        "label": "Contradiction"
    },
    "9f855b3e-81b0-47a6-af48-b437e0409d77": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different patient populations and treatment regimens However the statement is consistent with the information provided in the trials The primary trial reports a slightly higher pCR rate in Arm 1 compared to Arm 2 while the secondary trial reports a much higher pCR rate in Arm 2 compared to Arm 1 This difference in results between the two trials does not contradict the statement as they involve different",
        "label": "Contradiction"
    },
    "6906ff3e-0e8c-4332-987d-47816bc462ba": {
        "text_answer": "  The statement There were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly stated in the given trial data However we can calculate the number of cases for each adverse event to verify if the statement is entailed or contradicted  Number of Hepatotoxicity cases  3 Number of Hypertension cases  1 Number of Panc",
        "label": "Entailment"
    },
    "2787f3da-ad73-483d-98b8-a82acec6e5fc": {
        "text_answer": "  The statement is a contradiction to the given trials as none of the interventions in the trials specify that all patients receive at least 20mg of MCS110 every 3 weeks without any PDR001 In fact all interventions in the trials include both MCS110 and PDR001 administered every 3 weeks",
        "label": "Contradiction"
    },
    "97552293-cd61-42c5-95c2-dc98b795f9d5": {
        "text_answer": "  The statement is not directly entailed in the given trial information The trials only provide information about the cohorts and the interventions they received but they do not provide sufficient data to determine the percentage of individuals in each cohort who underwent invasive surgery or received Neratinib between 75 and 94 percent of the time Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "8549720f-df44-400f-aeb0-98150d2f23b1": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The statement asserts that there were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial However the trials show that there were no cases of Deflation and Asymmetry in the secondary trial and only one case each of Infection and Delayed Healing Wound in the primary trial Therefore the statement is not entailed by the trials and",
        "label": "Contradiction"
    },
    "963f60a5-2446-42f3-9c05-20ef38528d1a": {
        "text_answer": "  The statement all patients barring one treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial underwent an adverse event emerging from treatment is entailed in the trial results as stated Number of Participants With Treatmentemergent Adverse Events AEs 24  However the statement while serious such events were seen in less than 50 of these",
        "label": "Entailment"
    },
    "6e6cecbf-ea24-4cf8-83f5-5fd627941028": {
        "text_answer": "  In the primary clinical trial Intervention 1 in Arm I involves the use of Zoledronic Acid which is given intravenously Therefore this intervention in the primary trial does require intravenous delivery  In the secondary clinical trial both Interventions 1 and 2 involve the use of intravenous drugs In Intervention 1 of Arm II granisetron hydrochloride dexamethasone and pro",
        "label": "Entailment"
    },
    "847ce4e8-b2df-4acb-b46c-c82baa519124": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation   The statement the primary trial showed no recorded adverse events while the secondary trial demonstrated a number of such events within their cohorts is contradictory to the provided data because  1 The primary trial had no recorded adverse events 034 2 The secondary trial also had no recorded adverse events for Adverse Event ",
        "label": "Contradiction"
    },
    "066d1275-7efd-47d6-aba2-96bc464cbe2f": {
        "text_answer": "  The statement the occurrence of emesis was nonexistent among patients who received the placebo intervention in the primary clinical trial is contradictory to the results presented in the trials   In Trial 1 Aprepitant there were 13 participants who were emesis free during the study period In Trial 2 Placebo there were 5 participants who were also emesis free during the study period Therefore the",
        "label": "Entailment"
    },
    "086c9c1a-de79-47f1-b75d-32c7a16716ef": {
        "text_answer": "  The statement patients with stage 1 cancer are eligible for the primary clinical trial and the secondary clinical trial without a need for a written informed consent is contradictory to the information provided in both trials   In the primary trial the inclusion criteria state that a signed informed consent form is required for participation In the secondary trial while it does not explicitly state that a written informed consent is required it does mention that patients must have written informed consent",
        "label": "Entailment"
    },
    "e35505c9-4340-4f19-8756-925d96d65b44": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for both primary and secondary trials However it is a comparison of specific exclusion criteria between the two trials   The statement mentions that patients who have undergone chemotherapy or radiotherapy in the recent fortnight have stable angina or exhibit grade 1 neuropathy are invited to participate in the secondary trial but excluded from the primary trial due to nonhealing surg",
        "label": "Contradiction"
    },
    "15b22917-3649-44bd-b7f0-9aa5a6beba6b": {
        "text_answer": "  The statement radiotherapy patients in the primary clinical trial only receive a dosage below 100 g of fentanyl sublingual spray is not entailed in the given trial information as there is no mention of fentanyl or any other opioid medication in the trial description Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "12d86841-a682-4de8-80ab-90cae0b8c124": {
        "text_answer": "  The statement representative examples of placental neoplasms include hemangioma and choriocarcinoma is not directly related to the adverse event data provided in the trials The trials only report adverse events observed in the patient cohorts and none of the reported events are related to placental neoplasms Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "a930aad6-c334-4a8a-8547-3a07e44afe8b": {
        "text_answer": "  The statement patients with a recent history of abdominal fistula or gastrointestinal perforation are eligible for the primary clinical trial is a contradiction to the trials exclusion criteria The trial explicitly states that No known hypersensitivity to phosphate trehalose or polysorbate and No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess",
        "label": "Contradiction"
    },
    "5e3d1ff7-52f0-4ac5-a9e0-63536903cf84": {
        "text_answer": "  The statement Caucasian patients residing in New York are eligible to participate in the primary clinical trial is not explicitly stated in the provided inclusion criteria for the primary or expansion phases of the clinical trial Therefore the statement is neither entailed nor contradicted by the information given in the trial description",
        "label": "Entailment"
    },
    "4fec37ef-6e27-4b07-a0ba-d35434fe2d36": {
        "text_answer": "  The statement having a history of pulmonary embolism in the recent 60 days does not disqualify a patient from the primary clinical trial but eliminates the possibility of enrollment in the secondary clinical trial regardless of the investigators opinion is a statement of contradiction between the two trials  The primary trial does not list pulmonary embolism as an exclusion criterion within the 60 days prior to initiation of",
        "label": "Contradiction"
    },
    "c7a78221-6f3c-484f-a281-908ab30a7e31": {
        "text_answer": "  The statement Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant is not directly entailed in the given trials as the trials do not provide information about the number of emesis episodes for each participant in the placebo and Aprepitant groups However the trials do indicate that there were 5 emesisfree participants in the placebo group and 13 in the Aprepitant",
        "label": "Contradiction"
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that patients who have received any of these therapies within 4 weeks prior to study entry are excluded Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "24cca94e-b0db-4015-acc3-061bce8ea0ea": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials only provide information about the occurrence of adverse events specifically for Febrile neutropenia Cholelithiasis gastroesophageal reflux disease and ductal carcinoma in situ The statement about curie extension score is not mentioned in the trials so it cannot be determined if it is entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "de2a7e0a-2046-4502-a23e-38d0753b43ec": {
        "text_answer": "  The statement is not entailed in the given trials as not all patients receive exactly 20mg of MCS110 every 3 weeks according to the provided information In Intervention 1 some patients receive 1mgkg of MCS110 every 3 weeks which translates to approximately 333mg for a 70kg patient which is less than 20mg In Intervention 2 some patients receive",
        "label": "Contradiction"
    },
    "0dc19d61-83e4-4b27-9d03-c485f30fe9f6": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the recurrencefree survival rates between the two groups   The trials provide the number of participants in each group who were analyzed up to 5 years after randomization However they do not provide the number of participants with recurrence or death during that time period Therefore we cannot directly calculate the recurrencefree survival rates from the given data  Since",
        "label": "Entailment"
    },
    "ad4f2e14-4f6a-473d-bc6a-225e2f34159b": {
        "text_answer": "  The statement cohort 1 of the primary trial is administered less than half the dose of ALT801 as cohort 2 is entailed in the trials as it is explicitly stated in the given information  The second statement proton is a fundamental particle with a positive charge is not related to the trials and is an unrelated scientific fact Therefore it does not entail or contradict the trials",
        "label": "Entailment"
    },
    "8e698117-fcf5-480f-80a0-95a3be887ef8": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials   In the primary trial the intervention includes Gefitinib ZD1839 as the only drug mentioned specifically as part of Intervention 1 There is no mention of cyclophosphamide droperidol or epoetin beta in the given information  In the secondary trial Intervention 1 includes Zoledronic acid vitamin",
        "label": "Contradiction"
    },
    "9069ac6d-9d0f-4484-adda-bde33d713b7e": {
        "text_answer": "  The statement All patients in the primary trial receive at least 20mg of MCS1110 every 3 weeks is not directly entailed in the given trial information   However we can calculate the amount of MCS110 each patient receives every 3 weeks based on the given information   Intervention 1 MCS110 1 mgkg Q3W  PDR001 10",
        "label": "Contradiction"
    },
    "ed92e41d-f81d-462e-9081-c293fb816163": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The primary trial and the secondary trial are two separate clinical trials with different patient cohorts and different outcome measurements The primary trial is about denosumab and the percentage of participants with a response within 10 days of the first dose while the secondary trial is about dmethadone and the number of participants who reached a safe dose within 2 years",
        "label": "Entailment"
    },
    "9f3b9559-fe63-4698-b886-fe76ecab9784": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to compare the dosages given to each cohort   The statement cohort 1 is given 0035 mg less alt801 than cohort 2 can be written as  Cohort 1 dose  cohort 2 dose  0035 mg  Lets check if this",
        "label": "Entailment"
    },
    "0997d5fe-8df2-4b29-983a-3d3d2921e320": {
        "text_answer": "  The statement all of the participants in group 1 of the primary trial were found to have lesions and less than 5 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is contradictory to the information provided in the trials  In the primary trial the outcome measurement was the number of lesions detected in healthy volunteers and breast cancer patients undergoing MRI The results showed that no les",
        "label": "Contradiction"
    },
    "d1125c05-e0b3-4d7b-951e-cd21b5038b0b": {
        "text_answer": "  The statement lgals3 antibody is any immunoglobulin that recognizes galectin3 is not directly related to the inclusion or exclusion criteria of the primary trial Therefore it neither entails nor contradicts the information provided in the trial criteria",
        "label": "Entailment"
    },
    "0c9bef83-0974-4de4-aaa9-2f109fe16d0d": {
        "text_answer": "  The statement patients in the primary clinical trial reported no observed change in the percentage of cells with ki67 expression following the application of tak228 plus tamoxifen treatment is a contradiction to the trial results   The trial results indicate a decrease in median Ki67 expression at 6 weeks compared to baseline Specifically the median Ki67 expression at baseline was 15 10 to 25 and at ",
        "label": "Contradiction"
    },
    "f5b27b4f-8fe1-4cc8-a4d6-aa1459797496": {
        "text_answer": "  The statement is not directly related to the information provided about the trials and their interventions The statement is about a specific mutation egfr nm 0052283c2315 2316insgacacaccc and its location in the coding sequence of the egfr gene This information is not mentioned in the trials and their interventions Therefore the statement is neither entailed nor contradicted by the",
        "label": "Entailment"
    },
    "270255e6-c423-4fff-a2aa-78c3c8ef2a8e": {
        "text_answer": "  The statement The intervention 1 in the primary trial is administered by IV and all intervention drugs in the secondary trial can be administered orally is neither entailed nor contradicted by the given trials  Explanation  The statement does not follow directly from the information provided in the trials The primary trial only mentions that zoledronic acid in intervention 1 is given IV while the secondary trial mentions various routes of administration for the",
        "label": "Entailment"
    },
    "ee74c3c1-33c4-4b0a-81bf-a2ed3ec7e161": {
        "text_answer": "  The statement is an entailment of the trials information The only difference between the two interventions is the dosage of durvalumab given in each cohort The statement correctly identifies that difference and provides context about trabecular meshwork proliferation which is not directly related to the trials but is mentioned for additional context Therefore the statement is entailed by the trials information",
        "label": "Entailment"
    },
    "0fb60a4c-16d6-4517-a201-e16f78fd6dae": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial excludes participants with a diagnosis of thalasemic syndromes and anemia due to causes other than breast cancer The secondary trial excludes participants with a diagnosis of fibromyalgia Therefore the statement that the diagnosis of either fibromyalgia thalasemic syndromes or anemia does not obstruct the eligibility of cancer patients for the primary",
        "label": "Contradiction"
    },
    "57dae782-9901-446f-93d1-047097623f45": {
        "text_answer": "  The statement igf1r immunohistochemical expression is an immunohistochemical diagnostic test utilizing an antibody to detect igf1r in tissues Patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced andor metastatic is not directly entailed in the given inclusion and exclusion criteria for the primary trial   However",
        "label": "Contradiction"
    },
    "70d946f2-0c4a-4a00-8090-b0b55dda7b2b": {
        "text_answer": "  The statement patients with metastatic small cell lung cancer irrespective of their ER or PR status can participate in the primary clinical trial is contradictory to the inclusion criteria stated in the text The trial is for patients with nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer Therefore patients with metastatic small cell lung cancer are not eligible for this trial",
        "label": "Entailment"
    },
    "c802c0a9-737c-4b94-89c6-e4327a1925dd": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the intervention consists of a single drug Gefitinib ZD1839 with two different doses  In contrast in the secondary trial there are two interventions  1 Intervention 1 Zoledronic acid vitamin D and calcium supplements which is a combination of three distinct drugs 2",
        "label": "Entailment"
    },
    "66ff33e2-be79-4e47-a3f9-68a57f5f377b": {
        "text_answer": "  The statement nickel is an element with atomic symbol ni atomic number 28 and atomic weight 5869 is not entailed nor contradictory to the information provided in the trials The trials focus on the interventions used in medical studies specifically denosumab and intraoperative handheld gamma camera pIHGC or gamma probes GP for lymphoscintigraphy The statement",
        "label": "Contradiction"
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded the same number of adverse events in their cohorts is entailed in the given data if we consider only Adverse Event 1 Since both trials recorded no adverse events for this category the statement is true based on the provided information  However its important to note that the statement is not entailed if we consider Adverse Event 2 as well since neither trial recorded any adverse",
        "label": "Entailment"
    },
    "6579100b-45dc-4669-86ec-a3f8ac521c23": {
        "text_answer": "  The statement is contradictory to the given trials as there were no adverse events reported in more than 25 of participants in either the primary or secondary trials The trials only report the occurrence of adverse events in less than 1 of participants in both trials",
        "label": "Contradiction"
    },
    "b308b4a7-f3e9-49aa-a84e-8842da7caacf": {
        "text_answer": "  The statement is not entailed in the trials as it goes beyond the information provided The trials only report the absence of certain adverse events pancreatitis cholelithiasis hepatic pain and febrile neutropenia in both trials but they do not provide information about the presence or absence of other adverse events such as neutropenia fatigue pyrexia or bradycardia The statement",
        "label": "Contradiction"
    },
    "256cd40a-7afc-401d-9d02-c013ee3ee68d": {
        "text_answer": "  The statement in the primary clinical trial the intervention includes obligatory fitness routines for all the participants is not entailed in the given trial description The trial description mentions the inclusion criteria for patients and the types of cancer for which the intervention is applicable However it does not explicitly state that the intervention includes obligatory fitness routines for all participants Therefore the statement is not entailed in the trial description and could be a contradiction depending on the specifics of",
        "label": "Contradiction"
    },
    "fadac52b-d98b-4511-858e-a7bfb0dda0c0": {
        "text_answer": "  The statement is not entailed in the given primary trial intervention section as the statement is about a different medical condition double outlet right ventricle and the intervention section is about partial breast irradiation The two are unrelated",
        "label": "Contradiction"
    },
    "2a56e9e0-10fe-4a2d-964a-71390b3bb4d4": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial or the secondary trial is entailed in the given trials as both trials have identical inclusion criteria for gender Therefore gender is not a factor that determines eligibility for either trial  The statement grade 1 ileal obstruction CTCAE is asymptomatic clinical or diagnostic observations only intervention not indicated is not directly related to the eligibility criteria",
        "label": "Entailment"
    },
    "d16f252e-5df6-4e09-8a24-9c56b4b8e16b": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials compare the percentage change in betaCTX at Week 4 between the AZD0530 175 mg and Zoledronic Acid 4 mg groups not the absolute values of betaCTX at Week 4 or months The statement would need to be revised to compare the geometric means or least squares means directly to determine if the AZD0530 175",
        "label": "Contradiction"
    },
    "1bec6fcc-5a7e-4d19-81ea-e677715490fe": {
        "text_answer": "  The statement cases of mucositis oral epileptic seizures and thromboembolic events were found to be more frequent in the primary trial than the secondary trial is contradictory to the given trials as there are no cases of mucositis oral epileptic seizures or thromboembolic events reported in the secondary trial according to the provided data The primary trial had 1 case each of mucositis",
        "label": "Contradiction"
    },
    "4886038c-1def-4bbb-a9c7-dab5784cd471": {
        "text_answer": "  The statement esophageal cancer surgery is a surgical procedure to remove any cancerous tissue in the esophagus is not directly related to the inclusion and exclusion criteria of the primary trial provided Therefore it neither entails nor contradicts the information given in the trial",
        "label": "Entailment"
    },
    "a87b00a3-b6c1-4ee3-a6e0-fbd2eccbea05": {
        "text_answer": "  The statement patients with cytologically confirmed stage 2 ovarian serous carcinoma that is either BRCA1 positive BRCA2 positive or TP53 negative pass the selection process for the secondary trial and the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary and secondary trials focus on breast cancer patients with specific metastatic conditions and prior endocrine therapy history The",
        "label": "Contradiction"
    },
    "71a3b934-3bf8-4628-a728-cdf47a27e66c": {
        "text_answer": "  The statement is not directly entailed in the given trial results as the trials are investigating different treatments Ruxolitinib in the primary trial and MM111 in the secondary trial The statement only mentions the outcome measurement being the same MTD for both trials but it does not provide enough information to determine if the MTD values are the same or not Therefore the statement is neither entailed nor contradicted by the given trial results",
        "label": "Contradiction"
    },
    "3ad97e18-2efc-4d4a-aaae-424a3bc3f39c": {
        "text_answer": "  The statement patients with a healthy body mass index and are in post childbearing years may be eligible for the primary clinical trial and the secondary clinical trial is entailed in the given trials as neither of them have any specific inclusion or exclusion criteria related to body mass index or childbearing years mentioned in the provided text However the primary trial has an age requirement of being at least 18 years old which implies that patients are past their childbearing years",
        "label": "Entailment"
    },
    "baa46f83-8738-48d2-b9b8-9cc635d9d730": {
        "text_answer": "  The statement only two individuals in the primary clinical trial were not recurrencefree survivors is a contradiction to the given results   The results state that 98 out of 100 participants were recurrencefree survivors with a confidence interval of 922 to 995 This means that there were at least 18 participants who did not experience a recurrence second malignancy or death as a",
        "label": "Contradiction"
    },
    "30a0fbf5-af3e-43fd-80f4-41f740a2fdff": {
        "text_answer": "  The statement women who have both claustrophobia and IBS are eligible to participate in both the primary and secondary clinical trials is neither entailed nor contradicted by the given trials inclusion and exclusion criteria   The primary trials exclusion criteria do not mention claustrophobia or IBS Irritable Bowel Syndrome so it does not affect the eligibility of women with these conditions",
        "label": "Entailment"
    },
    "6b5cc819-da7b-4e4f-ae2f-7e4db8073860": {
        "text_answer": "  The statement in the primary clinical trial more than 15 of patients were affected by all types of adverse events AEs is contradictory to the given data   The total number of patients with any type of AE is 4 out of 11 which is equal to 3636 This percentage is less than 15 Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "8f82b776-0f1c-4059-aab0-9898a9f6bd1a": {
        "text_answer": "  The primary trial involves administering pembrolizumab every 3 weeks Q3W while sunitinib is given in the secondary trial on continuous dosing regimens with visits every 28 days or every 8 weeks for those on regimens other than singleagent sunitinib Since pembrolizumab is given more frequently than every 8 weeks the statement is entailed in the trials",
        "label": "Entailment"
    },
    "4d501822-a118-4fe8-b92d-eb5085ab6dcc": {
        "text_answer": "  The statement is contradictory to the given information in the trials   Explanation  The primary trial involves the administration of PF06647020 at two different doses 02 mgkg and 05 mgkg in the dose escalation phase The secondary trial involves the administration of ALT801 at two different doses 0015 mgkgd",
        "label": "Entailment"
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered some kind of adverse event is not directly entailed in the given trial results as the results only provide the number of participants with serious and nonserious adverse events for each dose level but they do not specify that all participants in the first cohort experienced an adverse event However based on the definition of a participant in a clinical trial as an individual who",
        "label": "Contradiction"
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "text_answer": "  The statement Patients with a TNBC tumor of 100mm in diameter are eligible for both the primary trial and the secondary trial is contradictory to the given trials as the primary trial specifies a breast tumor of 1 cm in diameter and the secondary trial does not mention the tumor size at all Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "54f86209-3c4b-4dfd-b048-e8eeb864300c": {
        "text_answer": "  The statement all individuals participating in the primary clinical trial are provided with at least 20mg of mcs110 every 3rd week is contradictory to the given trial information   Explanation   The trial information specifies two different dosing regimens for Intervention 1 and Intervention 2 in the Phase Ib part of the trial For Intervention 1 the dosing is MCS11",
        "label": "Entailment"
    },
    "d8e49bf6-27d9-4307-9bcd-56625d93274a": {
        "text_answer": "  The statement the primary clinical trial stipulates that all aspirants must have a her2 positive tumor validated via ihc 3 and require extensive help and regular medical supervision is a combination of both entailment and contradiction with the provided trial information  Entailment The statement all aspirants must have a her2 positive tumor validated via ihc 3 is entailed in the trial inclusion criteria as stated Hist",
        "label": "Entailment"
    },
    "072f2e2d-f4b0-4a32-85e0-8626ee261a63": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials do not mention any comparison or results between the LBH589 with Capecitabine and LBH589 and Lapatinib groups in terms of performance or outcomes The trials only provide information about the dose levels administration schedules and number of participants for each group",
        "label": "Contradiction"
    },
    "cff79719-40b1-43fb-bbdd-43dbe9c4191a": {
        "text_answer": "  The primary trial and secondary trial evaluate different patient populations and treatment modalities The primary trial focuses on patients receiving HER2specific T cells therapy while the secondary trial focuses on patients receiving trastuzumab emtansine Therefore the statement is contradictory as the patient characteristics are not the same in both trials",
        "label": "Entailment"
    },
    "4f66f663-030a-4391-a426-4e6b2f3bc9d2": {
        "text_answer": "  The statement the primary trial participants experienced less incidences of diarrhoea than the participants of the secondary trial is contradicted by the given data   Explanation   The primary trial had 7 cases of diarrhea out of 30 participants which is 2333   The secondary trial had 0 cases of diarrhea out of 6 participants   Therefore",
        "label": "Contradiction"
    },
    "38b5ee2a-8baf-427a-944d-a93a1a450104": {
        "text_answer": "  The statement more instances of anemia pneumonia and stupor were reported in the secondary trial than in the primary trial while the primary trial had more recorded febrile infections is a comparison of the frequency of specific adverse events between the two trials  Lets examine the data provided in the trials to determine if the statement is entailed or contradicted  1 Anemia     Primary Trial",
        "label": "Entailment"
    },
    "d311aaa2-6b04-4f26-a19a-65e33a673fbe": {
        "text_answer": "  The statement an adverse event of peripheral neuropathy was observed in the primary clinical trial is entailed in the given trial data as the trial data reports an adverse event of peripheral neuropathy with a frequency of 345",
        "label": "Entailment"
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "text_answer": "  The statement the primary trial participants receive Epacadostat twice as frequently as Sunitinibnaive participants in the secondary trial receive sunitinib is entailed in the trials   Explanation   In the primary trial Epacadostat is given orally twice daily BID while in the secondary trial sunitinib is given once daily Therefore Epacadostat is administered twice",
        "label": "Entailment"
    },
    "b7b61d5d-629d-43a4-8d75-5897864b6443": {
        "text_answer": "  The statement over 12 patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel had progression of disease is a contradiction to the results presented in the trial   The trial reports that 47 out of 53 participants 905 in the lapatinib 1000 mg  nabpaclitaxel arm experienced either a",
        "label": "Contradiction"
    },
    "0b3b3351-166f-465f-b44f-14c1e24c2d06": {
        "text_answer": "  The statement is contradictory to the given information   The primary clinical trial and the secondary clinical trial have different inclusion criteria The primary clinical trial includes patients with advanced cancer potentially sensitive to vinorelbine while the secondary clinical trial includes patients presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston   Although they have some similar exclusion criteria such as pregnancy or lactation",
        "label": "Entailment"
    },
    "fd173cdb-c283-4b74-922e-583a531edcef": {
        "text_answer": "  The statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed in the trial description as the participants receive epirubicin cyclophosphamide docetaxel and trastuzumab during the course of the study  The statement about Atopobium is not related to the trial information provided and therefore it is neither entailed nor contradictory to the trial description",
        "label": "Entailment"
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial and only a single case of Atrial fibrillation is not directly entailed in the given trials as there is no information about Atrial fibrillation in the trials provided However the statement is consistent with the trials as there are no deaths or hospitalizations reported in cohort 2 according to the trials",
        "label": "Contradiction"
    },
    "475903fe-9ac8-434b-aa7e-aa7bce562ef0": {
        "text_answer": "  The statement the primary clinical trial records general health status via eq5d questionnaire while the secondary trial evaluates change in hip circumference from start to the conclusion of the trial is not entailed in the provided information from the primary and secondary trials  The primary trial does not mention the use of the eq5d questionnaire to record general health status The secondary trial does not mention the evaluation of change in hip circumference",
        "label": "Contradiction"
    },
    "c6f5d89a-939b-4e46-8aab-9fc9246498be": {
        "text_answer": "  The statement a patient who has recently undergone an organ transplant and remains confined to bed would not be eligible for the primary clinical trial but could be considered for the secondary clinical trial is not explicitly stated in the inclusion or exclusion criteria of either trial However the primary trial does exclude participants who have received major surgery within 28 days prior to the study registration date which could include organ transplant surgery The secondary trial does not mention any specific excl",
        "label": "Entailment"
    },
    "6558ae62-b251-483d-9082-67a614d76e60": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial there are two distinct groups Intervention 1 Pyridoxine and Intervention 2 Placebo This design aligns with the definition of one experimental group Pyridoxine and one placebo group Placebo  In the secondary trial there are also two distinct groups Intervention 1 Highdose Oxybutynin",
        "label": "Entailment"
    },
    "1dffbb91-6440-4ceb-a33d-c2d783f75936": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial involves Yttrium90 Radioembolization using TheraSphere and the secondary trial involves a combination of ibrutinib and MEDI4736 with a starting dose of 560 mg of ibrutinib and 10 mgkg of MEDI4736 and no mention of dacarbazine or photodynamic therapy using por",
        "label": "Contradiction"
    },
    "6746f51e-6ceb-48b7-aa33-aecd601723b6": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 ACT the docetaxel dose is 100 mgm every 3 weeks for 4 cycles In Intervention 2 ACTH the docetaxel dose is 100 mgm on Day 2 of Cycle 5 then on Day 1 of every 3 weeks for all subsequent cycles ",
        "label": "Entailment"
    },
    "19ec40c8-5482-490f-9418-5667705632df": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation   The statement the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts is contradictory to the given trials data because  1 In the primary trial there were no adverse events recorded Total 00 2 In the secondary trial there was one adverse event recorded",
        "label": "Contradiction"
    },
    "a55f7123-365b-4119-bf0d-17467c73d0b7": {
        "text_answer": "  The statement There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial is not directly related to the information provided in the trials The trials focus on the outcome measurements and results of the interventions in each cohort but they do not provide the number of participants in cohort 2 for both trials for comparison Therefore it is not possible to determine if the statement is entailed in the",
        "label": "Entailment"
    },
    "cca75efb-d5e0-4dba-b9ca-4f59238abb59": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention is given orally so the study agent function code for this intervention would be oral  In the secondary trial there are two interventions  1 Intervention 1 Arm IGroup A is given intravenously IV so the study agent function code for this intervention would be intravenous 2 Intervention 2",
        "label": "Entailment"
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "text_answer": "  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a conditional statement   To determine if this statement is entailed in the given trials we need to check if the trials entail the same",
        "label": "Entailment"
    },
    "e517c026-4c5e-43ac-a734-1bcfd6d8edf1": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any AEs however almost all of cohort 2 candidates suffered at least one ae prefer not to answer is a response indicating that an individual prefers or preferred not to answer is a contradiction with the given trials data  The trials data does not provide any information about the number of candidates in Cohort 1 who preferred not to answer about AEs or the percentage of",
        "label": "Contradiction"
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "text_answer": "  To determine if the statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group is entailed in the trials we need to compare the ORRs of the two groups  The ORR for the Paclitaxel Plus Bevacizumab group was 0489 0385 to 05",
        "label": "Entailment"
    },
    "b08d9933-4d8d-40f6-9395-d40391501db4": {
        "text_answer": "  The statement is not entailed in the given trial information The trial description specifies the drugs dosages and schedules for each phase of the neoadjuvant therapy However it does not explicitly state that the total dose of drugs administered throughout the study duration will not exceed 1 gramm2 Therefore the statement is not directly entailed by the information provided in the trial description",
        "label": "Contradiction"
    },
    "3be36531-265f-4d51-bd65-1e2f46b28eda": {
        "text_answer": "  The statement is entailed in the trials as both trials report data on determining the Maximum Tolerated Dose MTD of multiple interventions  paclitaxel and ruxolitinib in the primary trial and MM111 in the secondary trial",
        "label": "Entailment"
    },
    "bc318388-81b9-4bf5-94a7-db6443061abd": {
        "text_answer": "  The statement is partially entailed in the primary trial inclusion criteria as it states that females aged 18 and above are eligible to participate regardless of race or ethnic origin However it does not explicitly state that all types of breast cancer are included but rather mentions that doxorubicin and cyclophosphamide are part of the standard medical care for breast cancer  The statement is contradictory to the secondary trial inclusion criteria as it only includes females",
        "label": "Entailment"
    },
    "0ed96bc9-14a3-4c52-b977-7cf507956191": {
        "text_answer": "  The statement does not entail or contradict the information provided in the trials The trials focus on different interventions and patient populations and the statement describes a different substance Dulbeccos phosphatebuffered saline used in cell culture applications There is no overlap between the trials or the interventions described in the statement and the trials",
        "label": "Contradiction"
    },
    "48b31ad3-f5d6-4250-9e84-e407d26f6bed": {
        "text_answer": "  The statement Patients participating in the primary trial receive oral medication twice a day for a full month is not directly entailed in the given intervention description The statement only mentions that patients receive medication twice a day during the trial but it does not specify the number of medications or the dosing schedule for each medication The intervention description specifies that patients receive lapatinib ditosylate and tamoxifen citrate orally once a day each Therefore the",
        "label": "Contradiction"
    },
    "dd909039-da2a-4c24-9b6f-1776bc51e3a2": {
        "text_answer": "  The statement is entailed in the trials as follows  Both trials require the ability to provide written informed consent as an inclusion criterion Therefore the statement The only shared inclusionexclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent is entailed in the trials  However it is important to note that the primary trial has additional inclusion criteria related to cancer diagnosis and treatment while the secondary trial is focused",
        "label": "Entailment"
    },
    "174215f6-99d9-482a-8aad-d477060cb062": {
        "text_answer": "  The statement There are no conditions on mental mental health bodyweight size of tumours KarnofskyECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial is not directly stated in the given inclusion and exclusion criteria   However the criteria do not mention any conditions related to mental health bodyweight size of tumors KarnofskyECOG score",
        "label": "Contradiction"
    },
    "2ea65099-018a-4230-87a1-e60303486743": {
        "text_answer": "  The statement that a 65yearold patient with histologically verified diagnosis of stage III breast cancer an absolute neutrophil count of 5000L a platelet count of 120000L a hemoglobin level of 200 gl and a life expectancy exceeding 20 months would be eligible for both the primary and secondary trials is entailed",
        "label": "Entailment"
    },
    "e486bbca-c279-458b-b98b-2b434c9a242d": {
        "text_answer": "  The statement malignant laryngeal neoplasm is a primary or metastatic malignant neoplasm involving the larynx The most commonly occurring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is not directly entailed in the given trials as the trials do not provide sufficient information about the nature of the patient cohorts their diagnoses or the relationship between the malignant l",
        "label": "Contradiction"
    },
    "05775941-9ed3-40eb-9c93-ed60a7783838": {
        "text_answer": "  The statement Women with Newly diagnosed locally advanced breast cancer confirmed as ER considering a mastectomy are eligible for the primary trial and the secondary trial is entailed in the given trials as the primary trial includes women with locally advanced recurrent or metastatic breast cancer confirmed as ER and considering a mastectomy as eligible participants The secondary trial also includes women with newly diagnosed or recurrent breast cancer confirmed as ER considering",
        "label": "Entailment"
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is comparing two different interventions Hydrophor and MediHoney in their study groups This is evident from the trial description where it mentions two different interventions Group A and Group B with different study materials and instructions for application  The secondary trial on the other hand is testing the effects of the same treatment PF0521238",
        "label": "Entailment"
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "text_answer": "  The statement an adult patient diagnosed with ILDDPLD within the last 3 years with a life expectancy of 6 months would be eligible for the primary trial is contradictory to the trials inclusion criteria   The reason is that the trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are ineligible Therefore a patient diagnosed with ILDDPLD within the last",
        "label": "Entailment"
    },
    "2c00f421-96f2-4f3a-a202-27350b15c84f": {
        "text_answer": "  The statement No two patients in the primary trial suffered the same type of adverse event is not directly related to the information provided about the tonicity excipient The statement only mentions the number and types of adverse events experienced by different patients in the trial but it does not mention the relationship between these events and the tonicity excipient Therefore the statement is neither entailed nor contradicted by the information provided about the trials",
        "label": "Contradiction"
    },
    "2eed31cc-3968-4b00-8a9e-947c5ecfbc3b": {
        "text_answer": "  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not directly entailed in the given trial information The trial information mentions that patients will receive GMCSF therapy starting on day 8 if their neutrophil counts are below 1000mm3 but it does not specify that they will receive a single injection on that day The statement about the number of days smoked",
        "label": "Contradiction"
    },
    "f44e50eb-f7de-403f-8e1c-25ae4cb1f530": {
        "text_answer": "  The statement the final decision regarding a patients participation in the primary clinical trial even if they meet all the inclusion and exclusion criteria rests solely with the attending clinician is not explicitly stated in the given inclusion and exclusion criteria However it is implied that the final eligibility for the trial is determined by the health professionals conducting the trial Therefore the statement is entailed in the given information as it falls under the broader category of the trial",
        "label": "Entailment"
    },
    "ed9afe03-8b68-464c-a9f8-0d3a58f64d7f": {
        "text_answer": "  The statement is entailed in the primary trial as the inclusion criteria for both trials require histologically or cytologically confirmed breast adenocarcinoma The secondary trial has additional requirements for the breast cancer to be ER positive PR positive and HER2neu negative but these requirements are also met by the patients in the primary trial who have histologically or cytologically confirmed breast adenocarcinoma Therefore the statement is entailed in the",
        "label": "Entailment"
    },
    "3f6d7cbc-5465-4e27-beee-582162fe9972": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement in the secondary clinical trial there were no adverse events is contradictory to the data presented in the secondary trial which shows that there were 45 adverse events in total 3516 Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "91169f4f-ada3-4bc7-a0ef-8111fccac241": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement mentions that syncope was the most commonly occurring adverse event across the patient cohorts of the primary and secondary trials with a frequency of 025 However the trials indicate that syncope occurred in 2 out of 12 patients in the primary trial which is a frequency of 0167 or 1667 The statement is not",
        "label": "Entailment"
    },
    "de99de33-5cd3-4f28-8859-9297a230ab94": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial mentions the use of Vorinostat during radiation therapy but it does not mention the use of Fentanyl sublingual spray for all patients",
        "label": "Entailment"
    },
    "7b76950c-8ac8-451f-93d4-bfac4ba36e49": {
        "text_answer": "  The statement is not entailed in the trials as given The trials describe two different groups of participants receiving oral doses of enzalutamide at different doses not intravenous administration",
        "label": "Contradiction"
    },
    "ce8ecade-8753-4983-83af-47f6e3e87f32": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of separate entry conditions for participants under the age of 25 and those 25 and older in the primary trial The secondary trial does have separate entry conditions for participants based on their disease history and symptoms but there is no indication that these conditions differ based on age",
        "label": "Contradiction"
    },
    "23f62ab2-9ec8-49f7-a4e7-84f931a1825d": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 2 days if they want to participate in the primary trial is a contradiction of the information provided in the inclusionexclusion criteria  The criteria state that there",
        "label": "Contradiction"
    },
    "a6f49268-2b84-49ff-a89a-86cb3d16cd07": {
        "text_answer": "  The statement in the primary clinical trials initial cohort over half of the participants faced acute vomiting as a side effect of being treated with aprepitant dexamethasone cytoxan and kytril is contradictory to the results presented in the trial  The trial reports that 20 out of 35 participants 571 in the aprepitant dex",
        "label": "Entailment"
    },
    "2b0a4d9c-e65c-44d2-bdf6-60877e5d1b41": {
        "text_answer": "  The statement being diagnosed with Alzheimers disease does not prevent a patient from taking part in the primary clinical trial is not explicitly stated in the inclusion or exclusion criteria provided However the criteria do include some evidence of cognitive impairment and no evidence of dementia  Mini Mental State Examination MMSE 23 The MMSE is a commonly used screening tool for cognitive impairment and dementia but",
        "label": "Contradiction"
    },
    "54654fa6-2bce-4ed0-9cdf-ec6cf1de3bd8": {
        "text_answer": "  The statement smoking individuals are disqualified from the primary clinical trial but could be considered for the secondary clinical trial if their alcohol consumption stays below five drinks daily is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   Explanation   The primary trial explicitly states that smoking individuals are excluded from the study Exclusion Criteria point 5 However the secondary trial does not mention anything about smoking as an",
        "label": "Entailment"
    },
    "57265519-b5e0-41f9-90b3-8a09e57bc282": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial does not focus on chemotherapeutic interventions but rather on two different hormonal interventions Estring and Testosterone Cream The secondary trial does not focus on radiation therapy but rather on acupuncture as an intervention",
        "label": "Entailment"
    },
    "2c7901c7-b03b-4b92-852d-d182187dd2b1": {
        "text_answer": "  The statement in the primary clinical trial there were two incidences of doselimiting toxicity both occurred in patients from cohort 2 is entailed in the trials provided if we assume that all doselimiting toxicities in the trial are grade 3 or higher and occurred within 28 days of treatment   Explanation   The trials provided do not explicitly state the number or identity of patients who experienced dose",
        "label": "Entailment"
    },
    "33641401-b713-4800-86a9-aa7766b456f5": {
        "text_answer": "  The statement in cohort 2 of the primary clinical trial acute vomiting was a side effect for over half of the participants posttreatment with aprepitant dexamethasone cytoxan and kytril is a contradiction to the results presented in the trial  The trial reports that in cohort 2 20 out of 35 participants or approximately 57",
        "label": "Contradiction"
    },
    "dfb7dcc6-34da-4de2-8229-3cd02d15bd15": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The trials provided do not mention the use of mersalyl acid in any of the study groups Therefore the statement is not directly related to the trials and cannot be determined to be entailed or contradicted based on the information provided",
        "label": "Entailment"
    },
    "52ee52ad-c158-48b8-86f1-99589e8150c5": {
        "text_answer": "  The statement 013 of the primary trial participants with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab developed her2 metastases is entailed in the trial results if we make the following assumptions  1 All 49 participants in the trial had pr primary breast cancer 2 All participants underwent HER2targeted PET",
        "label": "Entailment"
    },
    "da51f6ae-703a-4282-a339-22ebaa80709a": {
        "text_answer": "  The statement have vaginal itching or irritation is not directly mentioned in the inclusion or exclusion criteria of the primary trial Therefore it is neither entailed nor contradicted by the information provided in the trial description",
        "label": "Entailment"
    },
    "e3a1c267-d715-40ef-b23a-9bfb6285bf6a": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial involves massage therapy which is a form of physiotherapy while the secondary trial focuses on a drugbased treatment with PF06647020",
        "label": "Entailment"
    },
    "0392122c-9612-49dc-83db-b2b6a4a4a8a8": {
        "text_answer": "  The statement the primary clinical trial did not yield any significant differing outcomes across groups is not directly related to the information provided in the primary clinical trial The trial only reported the diagnostic accuracy of two algorithms for breast cancer diagnosis and did not provide any information about significant differences between the groups  The statement the reflexology group in the secondary clinical trial showed the same results as their control group is contradictory to the information provided in the secondary clinical trial The",
        "label": "Entailment"
    },
    "b4bad814-078e-4991-9455-f50ca716580d": {
        "text_answer": "  The statement in the primary clinical trial all cohorts are administered the same dosage of enzalutamide is contradictory to the information provided in the trials   Explanation   The trials describe two different cohorts one receiving enzalutamide 80 mg and the other receiving enzalutamide 160 mg Therefore the statement that all cohorts are",
        "label": "Entailment"
    },
    "26b78b55-df37-4058-a5ef-7634ae3f4fce": {
        "text_answer": "  The statement the secondary clinical trial documented 11 additional adverse events compared to the primary clinical trial is entailed in the given trials data   Explanation   The statement implies that there were 11 more adverse events in the secondary trial compared to the primary trial The trials data shows that there were 0 adverse events in the primary trial and 11 adverse events in the secondary trial with 10 of those",
        "label": "Entailment"
    },
    "a93f06ed-84a0-487e-bf93-f74cc7cb34ba": {
        "text_answer": "  The statement no adverse events have been reported for participants in both the primary and secondary clinical trial is entailed by the given trials data since the data reports 000 adverse events for both trials and both adverse events in the statement are mentioned in the trials data",
        "label": "Contradiction"
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve different routes of administration IV for bisphosphonate Q4W and subcutaneous injection for denosumab Q12W",
        "label": "Entailment"
    },
    "aa62c405-218e-496e-a424-95340f370834": {
        "text_answer": "  The given trials do not provide sufficient information to determine if the second cohort had fewer participants than the first one The trials only report the percentage of participants with events for each arm Neratinib and Placebo at Year 2 but they do not mention the total number of participants in each cohort Therefore the statement cannot be entailed or contradicted based on the provided information",
        "label": "Entailment"
    },
    "dc867a3f-6005-49f7-bcd8-1c7db27b00c1": {
        "text_answer": "  The statement Any patients with Documented allergy to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial is entailed in the given trials as  1 In the primary trial patients with documented allergy to celecoxib are excluded Exclusion Criteria 2 In the secondary trial",
        "label": "Entailment"
    },
    "51cd4ccd-2770-4189-ba70-f01147431843": {
        "text_answer": "  The statement multiple injections are essential for patients participating in the primary clinical trial is entailed in the trial description as follows  1 Trastuzumab infusion Given as an intravenous infusion 2 Vinorelbine ditartrate infusion Given as an intravenous infusion 3 Leukine GMCSF therapy Given as subcutaneous injections for a total of 7",
        "label": "Entailment"
    },
    "3aaa3da7-8b9c-4853-abd9-f4dc011eaab0": {
        "text_answer": "  The statement Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial is not directly entailed or contradicted by the given trials inclusion and exclusion criteria   The primary trials criteria do not mention claustrophobia or IBS and the secondary trials exclusion criteria include claustrophobia but not IBS The statement also",
        "label": "Contradiction"
    },
    "34f3e7ee-c8c4-4a97-90da-fafcfd1c7cc0": {
        "text_answer": "  The statement the primary clinical trial cohorts do not receive any form of preoperative medication is contradictory to both Intervention 1 and Intervention 2 in the given trials as they both involve the administration of Dexamethasone preoperatively",
        "label": "Entailment"
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "text_answer": "  The statement is entailed in the given trials as the trials do not use the same drugs dosages or frequency of administration in their interventions While both trials involve intravenous injections the specific drugs and dosing regimens are different",
        "label": "Entailment"
    },
    "6e125367-3fa8-46b3-a58d-b3baa894bc70": {
        "text_answer": "  The statement women aged 60 or 70 are eligible for the secondary trial but will need to wait 1020 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial has specific age criteria of aged greater than 20 years and the secondary trial includes women and men ages 18 or older However the statement about",
        "label": "Contradiction"
    },
    "81792c74-a501-4ef9-b7ac-2bda7a980fb1": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using a continuous measure mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib using a categorical measure mg The primary trials success indicator is the change in FSH levels from baseline to week 12",
        "label": "Entailment"
    },
    "0938714d-688d-42b5-a605-1153c172aa48": {
        "text_answer": "  The statement childpugh class c10 is a total score of 10 for hepatic function corresponding to class c in the childpugh classification is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement does not contradict the information in the trials as there is no mention of any hep",
        "label": "Entailment"
    },
    "9fb13507-1f88-4b95-8ff6-a56af67ca8c4": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary clinical trial has different inclusion and exclusion criteria for its Phase I and Phase II portions The Phase I portion includes patients who are 18 years of age or older have chronic pain with a minimum intensity of 3 on a verbal numerical scale give informed consent have a Karnofsky Performance Score KPS of 80 or higher and are not pregnant or breastfeeding",
        "label": "Entailment"
    },
    "2cc2ce51-0ac2-4e55-baf0-d26f88105aa0": {
        "text_answer": "  The statement is contradictory to the trials provided   Explanation   The statement 00274 of the primary trial participants and 01674 the secondary trial participants suffered an acute myocardial infarction is contradictory to the trials as no cases of acute myocardial infarction were reported in either trial The trials report a total of 0 acute myoc",
        "label": "Contradiction"
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "text_answer": "  The statement is entailed in the trials as the primary trial mentions the use of pregabalin in one of its patient cohorts while the secondary trial mentions the use of a different intervention Depocyt and HDMTX However the statement does not directly compare the interventions between the two trials so it does not contradict the trials either Therefore the statement is entailed in the trials with qualification",
        "label": "Entailment"
    },
    "f6835e26-4231-4f1a-a5f0-00e6919eb622": {
        "text_answer": "  The statement participants in the primary clinical trial will be required to take only oral medications is contradictory to the information provided in the trial description   The trial description includes the following interventions  1 Dendritic Cell Vaccine therapeutic autologous dendritic cells given by id injection 2 Trastuzumab infused in the sideport of a freely flowing IV over ",
        "label": "Entailment"
    },
    "e5e13d2e-11bd-4f7c-867d-ab3d0e26666b": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial description specifies that participants will receive multiple drugs throughout the study duration and there is no limit mentioned regarding the maximum dose per m2 for any of the drugs Therefore the statement that participants receive only one drug with a maximum dose of 1000 kgm2 is contradictory to the trial description",
        "label": "Contradiction"
    },
    "616edea0-8cb7-44c3-a866-af72680d31d3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial mentions the use of Cyclophosphamide and Fludarabine in combination with Abl Cells IV but it does not mention any requirement for patients to take Florbetaben 18f   The secondary trial on the other hand does not mention any medication intake related to the trials at all Therefore the statement that the secondary trial",
        "label": "Entailment"
    },
    "0d63f301-9546-466f-aee9-78eea578b57f": {
        "text_answer": "  The primary trial measures tumor diameter in centimeters cm while the secondary trial measures the number of participants with solid tumor response based on RECIST 11 criteria These are different units for the same outcome measure as the primary trial quantifies the size of the tumor while the secondary trial quantifies the response of the tumor to treatment Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "89e0e893-e053-491c-a276-055b30c5da2e": {
        "text_answer": "  The statement patients in the paced respiration intervention group of the primary clinical trial experienced more hot flashes per day on average than patients in the fast shallow respiration group is contradictory to the given data   The mean number of hot flashes per day for the paced respiration group was lower 348 than that of the fast shallow breathing group 395 Therefore the statement is contradictory to",
        "label": "Entailment"
    },
    "e3fac563-e6bf-418f-b9b2-3bc6e3539da9": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site However the primary disparity lies in the additional use of the handheld gamma camera pIHGC in intervention 1 which may result in a higher overall usage of the radioactive substance compared to intervention 2 that only uses in",
        "label": "Entailment"
    },
    "776a17db-8314-4fc6-9de3-0d110db79269": {
        "text_answer": "  The given statement individuals contemplating radiation treatment for stage 2 colorectal cancer are eligible for the primary clinical trial is not entailed in the provided inclusion and exclusion criteria for the breast cancer clinical trial The statement pertains to a different type of cancer colorectal and a different treatment modality radiation than the clinical trial described in the criteria Therefore it is neither entailed nor contradictory to the information provided",
        "label": "Contradiction"
    },
    "980339cb-7997-4209-b3b5-a4ddc3aff79e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive a combination of various types of treatments including chemotherapy targeted therapy hormonal therapy and surgical procedures In contrast the secondary trial only mentions the use of two oral medications everolimus and exemestane Therefore the statement that participants in the primary clinical trial are solely treated using a single type of oral medication is not entailed in",
        "label": "Contradiction"
    },
    "93ff9af3-c812-4449-b311-06418b283233": {
        "text_answer": "  The statement is contradictory to the given trials as they involve different interventions The primary trial deals with Yttrium90 Radioembolization using TheraSphere while the secondary trial explores the combination of ibrutinib and MEDI4736 through a Phase 1b study",
        "label": "Entailment"
    },
    "fa11f174-260a-4836-b583-c40d4b10bad4": {
        "text_answer": "  The statement in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is entailed in the given data if we consider the number of cases as follows   Hepatotoxicity 38  0375  04 cases  Hypertension 18  012",
        "label": "Entailment"
    },
    "0025afa1-ef06-42c9-9a6d-0f2aaf94c403": {
        "text_answer": "  The statement bone marrow collection is any process that harvests bone marrow for clinical or manufacturing purposes is not directly related to the information provided in the trials The trials only report data on the outcomes of different treatment regimens for preventing nausea and vomiting after chemotherapy The statement does not entail or contradict any information in the trials",
        "label": "Entailment"
    },
    "60ceec88-a7b1-4353-8327-946c05a0a32a": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered at least 1 lifethreatening adverse event is not entailed in the provided trial results The trial results only report the number of participants with serious and nonserious adverse events assessed by the Common Terminology Criteria for Adverse Events CTCAE v40 for each dose level group There is no information provided about the type",
        "label": "Contradiction"
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "text_answer": "  The statement is not directly entailed in the given trials as the primary trial does not report the percentage of participants with AEPIs but rather evaluates the toxicity using NCI CTCAE v30 The secondary trial reports the percentage of participants with AEPIs for the Trastuzumab Emtansine arm but it is not directly compared to the primary trial Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "4423a0fb-d4df-4046-bb60-04ba702c8623": {
        "text_answer": "  The statement is contradictory to the given trials as the primary and secondary trials have different outcome measurements   In the primary trial the outcome measurement is the percentage of participants experiencing any treatment emergent adverse events and serious treatment emergent adverse events   In contrast the secondary trial measures the number of participants with objective response   Therefore the statement is contradictory to the given trials as the outcome measurements are not identical",
        "label": "Entailment"
    },
    "f4d3c3ad-6c8c-4c7e-8d90-e321a9fa479d": {
        "text_answer": "  The statement is contradictory to the information provided in both the primary and secondary trials The primary trial includes patients with histologically confirmed HER2negative breast cancer while the secondary trial includes patients with newly diagnosed ERpositive HER2negative breast cancer The statement does not meet the inclusion criteria for either trial as it does not specify a breast cancer diagnosis or age requirement Therefore someone without any form of breast cancer and above 50 years old is",
        "label": "Entailment"
    },
    "50252016-e56e-4dc0-99d0-589c3dfe05e8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials report no occurrences of intestinal obstructions or pancytopenia in either the primary or secondary trials Therefore the statement that there were increased occurrences of these adverse events is not entailed in the trials",
        "label": "Contradiction"
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "text_answer": "  The statement cohort 1 of the primary trial is administered 0035 mg of ALT801 less than cohort 2 is a contradiction to the given information in the trials   The reason is that the trials state that cohort 1 received a dose of 0015 mgkgdose and cohort 2 received a dose of 0040 mg",
        "label": "Contradiction"
    },
    "a89e4c9e-86e0-4d21-b805-2a593ed71a7c": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials as the trials do not provide any information about Febrile neutropenia or Cholelithiasis occurring in the trials related to monoclonal antibody b1 The statement only mentions the adverse events of Gastroesophageal reflux disease and Ductal carcinoma in situ in the secondary trial which are different from Febrile neutropenia and Cholel",
        "label": "Entailment"
    },
    "45745e85-0655-490a-a692-ee9f060f8898": {
        "text_answer": "  The statement hard to remember what i just heard is a question and does not directly relate to the adverse events listed in the primary trial The statement does not entail or contradict the information provided in the trial regarding adverse events",
        "label": "Entailment"
    },
    "d0de0260-eb83-45e9-81cf-02ee5edd3e60": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial there is a comparison between two groups Intraoperative Mammography and Standard Mammography and the statement suggests a better performance of the control group Standard Mammography based on operative time However in the secondary trial there is no control group for comparison Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "text_answer": "  The statement is entailed in the trials exclusion criteria as follows  1 No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months 2 No history of stroke or transient ischemic attacks in the last 6 months 3 No serious nonhealing wound ulcer or bone fracture 4 No significant",
        "label": "Entailment"
    },
    "9484e4d1-8130-4d52-b362-faa1990946e9": {
        "text_answer": "  The statement is entailed in the trials as follows  1 In both interventions Cyclophosphamide is given at a higher dose than Eribulin or Docetaxel in the respective cohorts 2 Cohort 1 in Intervention 1 receives Eribulin and a higher dose of Cyclophosphamide than Cohort 2 in Intervention 2 3 The statement calla positive lymph",
        "label": "Entailment"
    },
    "c752fd5f-8cf1-435e-8981-7323279b8130": {
        "text_answer": "  The statement the secondary trial and the primary trial have completely unrelated outcome measurements is entailed in the given trials as the trials have different outcome measurements The primary trial measures the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events while the secondary trial measures the number of participants with objective response The statement does not mention the symptom interference score 2 so it is not related to that measurement",
        "label": "Entailment"
    },
    "07d56cae-178f-43f3-8f85-c73817786951": {
        "text_answer": "  The statement is contradictory to both the primary and secondary trials as the patients eligibility criteria for both trials differ significantly   The primary trial includes patients with a histologically or cytologically proven diagnosis of solid tumor malignancy of lung breast or prostate while the secondary trial specifically includes patients with stage IIbIIIIV breast cancer   The patient described in the statement has a diagnosis of stage II lymph",
        "label": "Entailment"
    },
    "49f03133-66cf-4980-8e2b-d7fb001edefd": {
        "text_answer": "  The statement the primary clinical trial does not involve the administration of talazoparib in its operation is entailed in the given trial description since talazoparib is not mentioned anywhere in the description as an intervention being administered to the patients",
        "label": "Entailment"
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "text_answer": "  The statement There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs is contradicted by the given data   In the secondary trial there were patients who experienced only one type of adverse event such as Anemia Constipation Mucositis Vomiting Dehydration Infection with grade 3 or 4 neutrophils Therefore there were patients",
        "label": "Contradiction"
    },
    "ca7e6cda-c7dc-4cc7-82d5-732998d7993e": {
        "text_answer": "  The statement women without any health conditions are not eligible for either the primary clinical trial or the secondary clinical trial is contradictory to the information provided in the trials   The primary trial includes women who are 40 years or older and have been menopausal for 12 months with no exclusion criteria related to health conditions mentioned The secondary trial includes women with a suspicious breast mass with several exclusion criteria related to specific health conditions",
        "label": "Contradiction"
    },
    "e68875c8-9905-4821-ac2a-8fe4576a2071": {
        "text_answer": "  The statement the primary trial had one test group and one placebo group the secondary trial had 2 test groups is entailed in the trials as follows  Primary Trial  Test Group Patients receive doxorubicin HCl liposome IV and oral pyridoxine  Placebo Group Patients receive doxorubicin HCl liposome IV and oral placebo  Secondary Trial",
        "label": "Entailment"
    },
    "10543624-61ff-49dd-970a-5d6c57605f6d": {
        "text_answer": "  The statement Punjabi language is an IndoAryan language spoken by the Punjabi people of Northwest India and Eastern Pakistan AEs were not recorded for the primary trial or the secondary trial is neither entailed nor contradicted by the given trials as the trials do not provide any information about the language spoken by the participants or the location of the trials The trials only report the number and percentage of adverse events in each trial",
        "label": "Entailment"
    },
    "68a7d226-1e5b-4a29-b492-60e8f621e7bd": {
        "text_answer": "  The statement is entailed in the secondary clinical trial inclusion criteria as it specifies that patients must have a diagnosed alteration in one or more of the listed genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ GNA11 for inclusion in the trial",
        "label": "Entailment"
    },
    "e65ecb06-ff14-432b-826f-9bd26c456215": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The statement cyclophosphamide paclitaxel and pegfilgrastim are not part of the treatment protocols in either the primary clinical trial or the secondary clinical trial is entailed in the given trials as neither trial includes these specific drugs in their interventions In the primary trial cyclophosphamide is used in combination with doxorub",
        "label": "Entailment"
    },
    "7bc71832-7742-4a77-b0ca-d8820db7f9bd": {
        "text_answer": "  The statement detailed description and treatment cycle are provided in the intervention section of the primary clinical trial is entailed in the given information if the primary clinical trial includes a section for the intervention specifically for the treatment with partial breast irradiation where the description and treatment cycle are detailed",
        "label": "Entailment"
    },
    "215bc845-3485-423b-9c4c-1091cfb1a5cc": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is entailed in the trial results as stated 53 of the 60 participants 90 experienced either a confirmed complete response CR or a confirmed partial response PR according to RECIST criteria 1",
        "label": "Entailment"
    },
    "408eec4d-435f-4edb-99ac-69cd883586b2": {
        "text_answer": "  The statement is entailed in the Trials as the inclusion criteria for the primary trial include being a female with a history of breast cancer and taking an aromatase inhibitor or tamoxifen which is also a requirement for the secondary trial Additionally the secondary trial includes the requirement of being HER2negative and a candidate for taxanebased chemotherapy but this is not mentioned in the primary trials inclusion criteria as it is not relevant to the",
        "label": "Entailment"
    },
    "d692776e-c2e9-450b-b0e8-57d84ccb216c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the administration of denosumab through injections while the secondary trial does not mention any drug administration and instead focuses on the use of intraoperative handheld gamma camera pIHGC and gamma probes GP in lymphoscintigraphy which does not involve oral ingestion of tablets Therefore the statement",
        "label": "Entailment"
    },
    "2b4a5598-2d21-426a-9d85-b0f94efb9bea": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials do not provide any information about chest pain in the patients The trials only report the occurrence of various adverse events in the primary and secondary trials The statement is about a different topic Portable Network Graphics and chest pain and cannot be determined to be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "ee84e692-4923-4cb8-acad-8f27f64f4b9e": {
        "text_answer": "  The statement both the primary trial and the secondary clinical trial reported no adverse events in their cohorts is entailed by the given data since the data reports that there were no adverse events in both trials for each category listed",
        "label": "Contradiction"
    },
    "f491f739-e852-496a-ad98-bbcb2f075cb9": {
        "text_answer": "  The statement all participants from the first cohort of the primary clinical trial underwent some adverse event is entailed in the given trial results   Explanation   The trial results provide the number of participants with serious and nonserious adverse events for each dose level However the results do not specify which participants experienced an adverse event or how many adverse events each participant experienced Therefore we cannot determine the exact number",
        "label": "Entailment"
    },
    "a325de64-fdaa-4c93-8e4a-22a1d502dd88": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using median interquartile range as the unit of measure and success criteria being the comparison to natural physiological variability On the other hand the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib using the number of patients who experience dose",
        "label": "Entailment"
    },
    "6d3a9617-a195-48e4-aa19-61a3ecde9ddb": {
        "text_answer": "  The statement Any Patients currently taking part in the secondary trial will also be eligible for the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trial and the secondary trial have different disease indications and treatments The primary trial is for postmenopausal women with breast cancer and hot flushes while the secondary trial is for adult patients with HER2negative metastatic breast cancer who",
        "label": "Entailment"
    },
    "0881a52f-e84b-43a4-8fda-446a7f2a1390": {
        "text_answer": "  The statement the primary clinical trial is open to any female cancer patients who are 18 years or older irrespective of race ethnicity or type of cancer is entailed in the primary trial inclusion criteria as it states Females age 18 years or older of all racial and ethnic origins are eligible to participate  The statement but in the case of the secondary clinical trial participants must be diagnosed with brca breast cancer",
        "label": "Entailment"
    },
    "173793fc-ca3d-4296-a1c7-14fbde0a7b8c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does have a cyclical treatment regimen with each cycle lasting 21 days The secondary trial does not specify a cyclical treatment regimen but it also does not state that it does not have one Therefore the statement that the secondary trial does not embrace a cyclical treatment regimen is incorrect  Thus the statement is contradictory to",
        "label": "Entailment"
    },
    "0a6d1117-f868-4495-bb04-e5da37c15144": {
        "text_answer": "  The statement is contradictory to the given trials   The primary trial did have a placebo group Arm II so it did not incorporate three test groups without a placebo The secondary trial did have a control group Lowdose Oxybutynin Chloride but it was not explicitly stated as a placebo group in the provided information However the primary trial having a placebo group contradicts the statement that the primary trial did not",
        "label": "Contradiction"
    },
    "4816c2e1-ae3b-4a0a-89b8-27a5cee580d7": {
        "text_answer": "  The statement pancreatic duct is a duct joining the pancreas to the common bile duct to supply pancreatic juices is not directly related to the trials provided The trials report results from clinical studies on the use of denosumab and dmethadone in different patient populations The statement about the pancreatic duct is anatomical information  Therefore the statement is neither entailed",
        "label": "Entailment"
    },
    "700f4bd9-6d39-4d3a-a425-bcb34d6712b6": {
        "text_answer": "  The statement Women suffering from both claustrophobia and osteoporosis are not eligible for either the primary trial or the secondary trial is entailed in the given trials as  1 Women with osteoporosis are excluded from the primary trial 2 Women with claustrophobia are excluded from the secondary trial  Therefore a woman who suffers from both conditions osteopor",
        "label": "Entailment"
    },
    "060b08af-40f5-4d26-8299-6f3d02c8fda7": {
        "text_answer": "  The statement is entailed in the trials Both Intervention 1 and Intervention 2 use the same doses for doxorubicin 60 mgm and cyclophosphamide 600 mgm in the initial AC phase The frequency of administration for both interventions is also the same with cycles every 3 weeks In Intervention 2 Herceptin and docetaxel are added but",
        "label": "Entailment"
    },
    "0e80c163-f731-4e3b-9194-211675ca9c53": {
        "text_answer": "  The statement is entailed in the trials as both cohorts use the same instructional CD for paced breathing However the difference in the interventions lies in the frequency of the practice once daily vs twice daily and the presence of weekly chemotherapy in the second cohort The statement does not contradict the trials as it accurately describes the similarity and difference between the two groups",
        "label": "Entailment"
    },
    "baea007a-c303-440b-a66c-0941729f416d": {
        "text_answer": "  The statement In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1 of participants was in situ hybridization performed is not directly related to the given data in the trials The statement only mentions the percentage of adverse events above 1 but it does not mention in situ hybridization at all Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Entailment"
    },
    "e1142532-82b5-4f1c-9d7c-33b677b92966": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement claims that there were no adverse events reported in the secondary clinical trial while the trials clearly report several adverse events in the secondary trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "3433a50a-b13a-43a5-ba9c-041959f23390": {
        "text_answer": "  The statement is not entailed in the given trials as the trials provide information about different outcomes and participant groups The primary trial focuses on the number of lesions detected in healthy volunteers and breast cancer patients undergoing MRI while the secondary trial investigates the effects of Medihoney and Hydrophor on radiation dermatitis and hyperpigmentation in breast cancer patients undergoing radiation therapy The statement compares the number of participants with radiation dermatitis and",
        "label": "Contradiction"
    },
    "09aef225-50fa-457e-9e8b-fce6aafd4705": {
        "text_answer": "  The statement Patients participating in the primary trial receive oral medication twice a day for a full month is not directly entailed in the given intervention description However it is implied that patients receive medication daily for a month but the number of doses per day is not explicitly stated in the intervention description The macroamylase measurement is not related to the dosing frequency or duration of the intervention Therefore the statement is neither entailed nor contradicted by the given trial",
        "label": "Contradiction"
    },
    "d51ecd4d-4188-4306-9c41-962c86a12652": {
        "text_answer": "  The statement children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trial explicitly excludes children as participants while the secondary trial does not mention anything about childrens eligibility Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "f87a205c-5de6-4cda-a798-85b7308e25c2": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed or contradicted by the given trials as they do not provide sufficient information about the specific types of gastrointestinal and psychiatric adverse events in each trial However based on the given trials we can see that there is at least one recorded gastrointestinal adverse",
        "label": "Contradiction"
    },
    "0308c864-0730-4a28-9bb4-7a51eba3e438": {
        "text_answer": "  The statement topical solution dosage form is a solution intended for administration to a body surface is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given trial information alone  However the statement does not contradict any of the inclusion or exclusion criteria for either trial Morbidly obese and pregnant patients can be eligible for both trials",
        "label": "Entailment"
    },
    "429199a7-de1a-4900-939b-e4f6efadb474": {
        "text_answer": "  The statement Most the primary trial candidates suffered from some kind of eating disorder during the study duration is not entailed in the given trial data The trial data only reports adverse events observed during the study including fatigue rashes increased liver enzymes alkalosis anorexia hyperglycemia and nervous system disorders There is no mention of eating disorders in the trial data The statement about central nervous system cyst is not",
        "label": "Contradiction"
    },
    "285be2fe-e597-4d99-acb9-7504bcfb3d6f": {
        "text_answer": "  The statement Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial but not from the primary trial is not entailed in the given trials as there is no mention of gabapentin or pregabalin in the inclusion or exclusion criteria for either the primary or secondary trials Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "98c65216-ca06-4666-99e3-0d06dc97c01d": {
        "text_answer": "  The statement a woman with an ongoing therapy for stage I bc after lumpectomy is excluded from both the primary trial and the secondary trial is entailed in the given trials as follows  In the primary trial the exclusion criteria state that Patients who have a history of breast tissue expander or implant placement and Patients who have undergone autologous tissue breast reconstruction are excluded A woman with an ongoing therapy for stage I bc",
        "label": "Entailment"
    },
    "9ea892eb-1362-4281-aac7-713905f1bb2c": {
        "text_answer": "  The statement the primary trial participants receive HER2neu peptide vaccine admixed with sargramostim GMCSF ID on days 1 8 and 15 is not entailed in the given trial information The trials only mention the chemotherapy regimens and bevacizumab maintenance therapy for HER2negative participants There is no mention of a HER2neu peptide vaccine",
        "label": "Contradiction"
    },
    "d3df95aa-4564-4503-9322-64f5664ce1c3": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   Explanation   The statement only participants diagnosed with cancer receive treatment in the primary clinical trial is contradicted by the information given in the trials as they also mention healthy volunteers as participants in Intervention 2",
        "label": "Contradiction"
    },
    "3921fd1d-1ba6-475c-a6f5-c8f76fe8cbe9": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage of participants with disease progression or death between the two cohorts   The percentage of participants with disease progression or death in the Bevacizumab cohort was 117 percentage points lower than in the Bevacizumab  Capecitabine cohort 883 vs 758 ",
        "label": "Entailment"
    },
    "ae574646-62f1-4b5f-b565-4af6bbafe7a6": {
        "text_answer": "  The statement compared with the secondary clinical trial the primary trial has less reported anemia cases is entailed in the given trials as the primary trial has reported 0 anemia cases out of 37 participants 000 while the secondary trial reported 2 anemia cases out of 75 participants 267 Therefore the primary trial having fewer reported anemia cases is a logical conclusion based on the provided data",
        "label": "Entailment"
    },
    "83e62365-e433-4411-9a4d-951e08c6b91c": {
        "text_answer": "  The statement mood is generally good and only occasionally affected by cancer is not directly entailed in the given inclusion or exclusion criteria for either the primary or secondary trials However it is not contradictory to the criteria as well The criteria focus on the patients eligibility based on their medical condition and history while the statement pertains to the patients mood or emotional state",
        "label": "Contradiction"
    },
    "c0915bad-2882-4f25-a6d5-5f2b71bc8850": {
        "text_answer": "  The statement no restrictions are placed on the hepatic function of individuals participating in the primary clinical trial is entailed in the given inclusion criteria since there is no mention of any liver function restrictions in the criteria",
        "label": "Contradiction"
    },
    "ad52e20e-99a7-4001-b957-12b24a3d1df1": {
        "text_answer": "  The statement is entailed in the trials as both trials are reporting data on the same condition canine granular cell tumor and the trials do not contradict each other in terms of recorded adverse events The statement provides additional context about the nature of the condition being studied but the trials themselves do not provide any information that would contradict the statement",
        "label": "Entailment"
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is contradictory to the given data   The primary trial recorded 1 palpitation in cohort 1 and 1 palpitation in cohort 2 Therefore the number of palpitations is equal in both coh",
        "label": "Entailment"
    },
    "0c5d58a3-a565-4b42-ae6f-24bd3be00b06": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial is a contradiction of the information provided in the inclusion and exclusion criteria  The exclusion criteria",
        "label": "Contradiction"
    },
    "0ef97135-5f94-407d-a48d-f40cd6272ed5": {
        "text_answer": "  The statement neither the patients in the secondary trial nor the primary trial exhibited conditions of anemia pneumonia or stupor is entailed in the given trials data as neither trial reported any cases of anemia pneumonia or stupor in their adverse events",
        "label": "Entailment"
    },
    "a510de48-5778-4489-8d10-82173320bdad": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials describe the procedures for each intervention but do not provide sufficient information to determine if one intervention uses a higher dose of radioactive Tc99M sulfur colloid than the other for all cases The statement assumes that the higher dose is used in intervention 1 for all cases but the trials do not necessarily guarantee that this is the case Therefore the statement is neither entailed nor contradicted",
        "label": "Entailment"
    },
    "5a736ff9-b224-4cf6-ae71-55a825bff301": {
        "text_answer": "  The statement over 011 years of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 5 reduction in the percentage of cells with ki67 expression is entailed in the trial results   Explanation   The median interquartile range of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it",
        "label": "Entailment"
    },
    "54fbf052-31df-43af-b20e-8947042351bc": {
        "text_answer": "  The statement the primary clinical trial has greater instances of biliary colic and diarrhoea compared to the secondary trial is entailed in the given trials as follows  1 The primary trial has 4 instances of biliary colic and 3 instances of diarrhoea making a total of 7 adverse events with a frequency of 328 for biliary colic and 164 for diarrhoea",
        "label": "Entailment"
    },
    "7a735242-b198-4348-ac48-f318cd704752": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the dosages of Denosumab and Zoledronic Acid used in each intervention  In the primary trial the dosage of Zoledronic Acid used in intervention 1 was 4 mg given every 4 weeks Q4W and the dosage of Denosumab used in intervention 1 was 120 mg given every",
        "label": "Entailment"
    },
    "e5d1118c-2e6a-4e00-a63c-041c43256c5e": {
        "text_answer": " The given statement is not entailed in the trials provided The trials only report the changes in lymphedema for the acupuncture and waitlist groups but they do not include any information about patients using testosterone cream Therefore it is not possible to determine if the statement is true or false based on the information provided in the trials",
        "label": "Contradiction"
    },
    "9e960679-ac10-4893-a777-94baac5a89f3": {
        "text_answer": "  The statement participants in cohort 2 of the primary clinical trial are not administered with an influenza vaccine is a contradiction to the information given in the trials   In the trials it is stated that for Intervention 2 Healthy Volunteers Vaccine Responses Against Pneumococcus and Influenza in Adults 65 Years of Age and Older are being studied but",
        "label": "Contradiction"
    },
    "8b54773e-b9b0-400f-af71-8fd2cbd16473": {
        "text_answer": "  The statement is contradictory to the trials provided In the primary trial there is no mention of ALT801 being administered to participants Therefore it cannot be entailed that the primary trial participants receive the same doses of ALT801 as the secondary trial participants as there is no commonality between the two trials regarding ALT801",
        "label": "Contradiction"
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "text_answer": "  The statement The only AE recorded in the primary trial was Stomatitis is entailed in the given trial data as stated in the trials there was only one adverse event recorded and it was Stomatitis",
        "label": "Entailment"
    },
    "54176448-042e-4b40-835e-ddf60eb53f80": {
        "text_answer": "  The statement patients of Asian descent living in California can be part of the primary clinical trial is entailed in the trials inclusion criteria as there is no mention of any exclusion based on race or residence in California The inclusion criteria state that participants must be male or female aged 18 years or older have histologically or cytologically proven metastatic or locally advanced solid tumors and meet other specified conditions Therefore the statement is",
        "label": "Entailment"
    },
    "c7bddafb-404b-40be-80c0-f0b4e08d6466": {
        "text_answer": "  The statement the primary trial only has a single adverse event recorded for its patient cohort is entailed in the given trials data if the trials data only contains one adverse event for the primary trial The trials data provided does not include any information about the planned subject activity group sequence number Therefore the statement is independent of the trials data and can be verified based on the information given in the statement alone In this case the statement is entailed by the trials",
        "label": "Entailment"
    },
    "ebaa9747-0c6a-4258-b0b8-121541b4662a": {
        "text_answer": "  The statement is entailed in the given trials as neither trial mentions the use of xrays ultrasound CT scans or MRIs as part of their interventions",
        "label": "Entailment"
    },
    "63da892b-0385-43c5-8ed3-3ce7514ebb55": {
        "text_answer": "  The statement the adverse events reported for cohort 1 of the primary clinical trial pertain to cardiovascular complications is not directly entailed in the given data However it is not contradictory either as the data does show that some cardiovascular adverse events were reported in cohort 1 The statement is an interpretation or inference from the data rather than a direct entailment or contradiction",
        "label": "Contradiction"
    },
    "7e288efd-8755-4393-b372-effd1c3feb91": {
        "text_answer": "  The statement There were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials However the statement does not directly entail or contradict the information provided in the trials The trials only report the number of adverse events for each category in each trial but they do not compare the number of adverse events between the two trials for each category directly",
        "label": "Entailment"
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "text_answer": "  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is contradictory to the given data as there is no case of Clostridium difficile colitis reported in the secondary trial while there was one case in the primary trial Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "53b41c0c-179c-45ce-90e6-3f444681b41e": {
        "text_answer": "  The given statement is not directly related to the trials provided The trials are about determining the maximum tolerated doses MTD and doselimiting toxicities DLT of LBH589 in combination with Capecitabine or Lapatinib for patients with refractory and advanced tumor types sensitive to 5fluorouracil The statement is about canine sarcoma which is a different context and not related to",
        "label": "Entailment"
    },
    "474339d0-2bac-4e3a-9aee-1933b96738b0": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg of trastuzumab per week In contrast in cohort 2 of the secondary trial Herceptin is administered as a 4 mgkg IV infusion on Day 1 of Cycle 5 followed by 2 mgkg",
        "label": "Entailment"
    },
    "85dcd465-ec0b-42ae-aec6-582831584bbf": {
        "text_answer": "  The statement female cancer patients with BRCAnegative status can enroll in the primary clinical trial is entailed in the inclusion criteria of the primary trial as stated Females age 18 years of age or older of all racial and ethnic origins that are scheduled to receive the first cycle of a single intravenous dose of doxorubicin 30 minute infusion and cyclophosphamide 30 minute infusion",
        "label": "Entailment"
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "text_answer": "  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is contradictory to the given data   Explanation   The statement implies that the frequency of anemia pneumonia and stupor is higher in the secondary trial compared to the primary trial However the data provided shows that the frequency of anemia is the same 6",
        "label": "Entailment"
    },
    "41cbc4ea-37f8-468e-bfd2-f0a71e8856b5": {
        "text_answer": "  The statement is not entailed in the primary trial results The primary trial reports a mean percentage change in Ki67 expression of 40 63 to 29 with tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery The statement however reports a different dose 30 mg and duration 15 days presurgery and 28 days postsurgery",
        "label": "Contradiction"
    },
    "5dc5fa82-a4a5-4f16-8ca1-b797546169af": {
        "text_answer": "  The statement severe pain or discomfort that prevented most activities is a response indicating that an individual has or had severe pain or discomfort that prevented most activities is not directly entailed in the given inclusion and exclusion criteria for the primary trial However the criteria do mention that subjects must have an Eastern Cooperative Oncology Group ECOG performance status of 0 or 1 which is a measure of functional status and can include symptoms such as pain or",
        "label": "Contradiction"
    },
    "28e19ec3-f22a-4002-9020-02ef29c4386c": {
        "text_answer": "  The statement in cohort 1 of the primary clinical trial four additional patients experienced adverse events compared to those in the second cohort of the trial is not entailed in the given trials data The trials data only reports the number of adverse events in each cohort but it does not provide information about the total number of patients in each cohort or the difference in the number of patients between the two cohorts Therefore it is",
        "label": "Contradiction"
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "text_answer": "  The statement The intervention in the secondary trial lasts 3 times longer than the intervention detailed in the primary trial is a contradiction to the given information   The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks However the statement suggests that the intervention in the secondary trial lasts 3 times longer than the intervention in the primary trial which would mean it lasts",
        "label": "Contradiction"
    },
    "1d57af11-9dc3-4589-ae99-fe0e9dab6042": {
        "text_answer": "  The statement candidates who are able to take care of themselves without any help at all are eligible for both primary clinical trial and secondary clinical trial is entailed in the given trials as follows  Both trials have the same inclusion criteria for ECOG performance status 02 which indicates that the candidates should be able to take care of themselves without any help or assistance Therefore the statement is entailed in the trials as the common inclusion criteria for both",
        "label": "Entailment"
    },
    "072b76ba-9fd5-4313-b484-c353f61ecca9": {
        "text_answer": "  The statement is entailed in the trials as both fibromyalgia and thalasemic syndromes are listed as exclusion criteria in both the primary and secondary trials Anemia is also an exclusion criterion in the primary trial but the statement specifically mentions diagnosis of anemia only due to irondeficiency as being excluded which is not the case in the primary trial as stated Therefore the statement is entailed",
        "label": "Entailment"
    },
    "7e57517f-4dc5-4457-bc4e-12f7faef37f4": {
        "text_answer": "  The statement anemia pneumonia and stupor were more common conditions among patients participating in the secondary clinical trial compared to the primary clinical trial is entailed in the given trials data  Explanation  To verify this statement we need to compare the frequency of each adverse event between the two trials  For anemia the frequency in the secondary trial is 116 625 compared to",
        "label": "Entailment"
    },
    "168c59cb-7be6-4f14-acd9-5d731b8464c8": {
        "text_answer": "  The statement is entailed in the given trials as neither the primary nor the secondary trial involves the use of xrays transendocardial injections CT scans or MRIs in their interventions",
        "label": "Entailment"
    },
    "0483c5df-77db-4c42-897e-aca21b207503": {
        "text_answer": "  The statement numerous instances of pancytopenia were noted in cohort 1 of the primary clinical trial but there were no records of anaemia and febrile neutropenia is contradictory to the information provided in the Trials  The Trials show that there was one instance of pancytopenia in Cohort 1 but no instances of anaemia or febrile neutropenia",
        "label": "Contradiction"
    },
    "93cfa70f-2bdc-4e2f-ac51-5e06f2fb07ea": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3 and requiring considerable assistance and frequent medical care A renal pelvis papillary urothelial neoplasm is a papillary tumor originating in the renal pelvis is neither entailed in the inclusion nor the exclusion criteria of the trial   The statement mentions a type of tumor renal pelvis",
        "label": "Entailment"
    },
    "9c60f664-ef13-406d-b26a-e57f6c914cf4": {
        "text_answer": "  The statement does not contradict the given trials but it is not directly entailed either The trials provide information about the dosage and frequency of the interventions for each group but they do not specify the genetic status of the patients Therefore the statement about the kras gene mutation negative status is not explicitly stated in the trials However it is a separate piece of information that could potentially apply to some or all of the patients in the trial  So",
        "label": "Contradiction"
    },
    "79a4ea13-6d2a-49e0-8c1d-9c1fcc7e9e3b": {
        "text_answer": "  The statement is not entailed in the trials provided   Explanation   The statement makes a comparison between the dosage of Trastuzumab received by HER2 patients in the primary trial and those in cohort 2 of the secondary trial However the trials do not provide the same information for comparison   In the primary trial the dosage of Trastuzumab is given as 4 mgkg",
        "label": "Contradiction"
    },
    "4e3b9642-3f02-4f4b-bfee-f2e3b1673186": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the baseline dose of Alpha Lipoic Acid is 100 mg three times daily for four months and dose escalation will occur until a maximum tolerated dose is found This means that patients in the primary trial may receive doses higher than 100 mg three times daily  In contrast in the secondary trial patients in Cohort 1 consistently receive",
        "label": "Entailment"
    },
    "7128da72-a0ed-48cb-b167-c2b6176faa71": {
        "text_answer": "  Based on the given information the statement patients in the primary clinical trial that received paclitaxel infusions experienced more severe symptoms than those who did not receive paclitaxel infusions is entailed in the trials   Explanation   The trials provide the median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline for both the Arm I Cry",
        "label": "Entailment"
    },
    "94aea5d0-2afb-40a4-b1c8-574c9f22225e": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years however at least one patient from both cohorts died in under 2 years is not directly entailed in the given trial results The trial results only provide information about the median overall survival in each group but they do not specify the distribution of survival times or the number of patients who survived less than 2 years The statement about systolic blood pressureforage percentiles is not related",
        "label": "Contradiction"
    },
    "dfd43b21-a734-49b1-8a64-d6dea31e9031": {
        "text_answer": "  The statement capnocytophaga is a genus of gramnegative anaerobic bacteria that normally populate the mouth and nasopharynx of dogs and cats is not entailed in the given inclusion and exclusion criteria for the primary or secondary trials The criteria only pertain to the eligibility and exclusion conditions for breast cancer patients participating in the clinical trials Therefore the statement is not directly related to the trials and does not entail or",
        "label": "Contradiction"
    },
    "26be8c11-aebf-4982-b09e-75dead3cdf4a": {
        "text_answer": "  The statement None of the cohort of the primary trial or the secondary trial receive entericcoated tablets is not directly related to the information provided about the overexpression of VEGF in the trials Therefore the statement does not entail or contradict the information given in the trials",
        "label": "Entailment"
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 use the same dosage of Doxorubicin 60 mgm and Cyclophosphamide 600 mgm during the AC cycles and the same dosage of Docetaxel 100 mgm during the taxane cycles The difference lies in the addition of Herceptin in Intervention ",
        "label": "Entailment"
    },
    "b6b819ce-57a9-4883-bcf9-f8c9a9bae83e": {
        "text_answer": "  The statement pharyngeal stripping wave present and complete is a finding of a pharyngeal stripping wave present and complete is entailed in the given trial description as it is explicitly stated that the finding is of a pharyngeal stripping wave being present and complete However the trial description does not provide any information about the method of administration dosage or cycle of the intervention MM111 Therefore the statement",
        "label": "Entailment"
    },
    "c803b01e-6f64-4412-a3c2-6b1a70d5cf7e": {
        "text_answer": "  The statement enrollment in the primary clinical trial requires a positive mental health assessment is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be determined if the statement is entailed or contradicted based on the information provided alone However it is worth noting that mental health assessments are often required for participation in clinical trials to ensure the safety and wellbeing of the study subjects It is important for potential trial participants to discuss any mental health concerns with",
        "label": "Entailment"
    },
    "ceb0ef65-5640-491d-a6c6-341e456b0bdd": {
        "text_answer": "  The statement there were 0 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial is entailed in the given trials as neither trial reported any cases of febrile neutropenia or cholelithiasis for Adverse Events 1",
        "label": "Entailment"
    },
    "d2e42255-bde4-4e21-a914-b4e0c35b6e3d": {
        "text_answer": "  The statement patients with Frontotemporal dementia or Mixed dementia are eligible for the primary trial is not entailed in the given inclusion criteria The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Frontotemporal dementia and Mixed dementia are types of dementia that typically result in",
        "label": "Contradiction"
    },
    "a6688fad-488e-4822-a91e-cbfe2117cae1": {
        "text_answer": "  The statement the majority of the primary clinical trial participants experienced a decrease in circulating tumor cells after receiving highdose chemotherapy with purged autologous stem cell products is entailed in the trial results as stated Number of participants With Reduction in CTCs Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is the outcome measure of the trial The results indicate that all 9 participants analyzed in the High",
        "label": "Entailment"
    },
    "bfef0d2b-81c0-4f5f-bf91-a313a0a2dcbb": {
        "text_answer": "  The statement every participant in the primary clinical trial encountered a reduction in cognitive capabilities particularly members in the ovarian function suppression group is a strong statement that goes beyond the data presented in the trials   The trials only report the mean standardized composite cognitive function scores and their standard deviations for the Tamoxifen and Ovarian Function Suppression groups The mean scores for both groups are negative indicating that the patients in both groups performed below the",
        "label": "Entailment"
    },
    "a630808d-14d5-4ef8-bd2e-73ce5e80f3f1": {
        "text_answer": "  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 750 mg of fulvestrant in a tablet form to be taken bid is neither entailed nor contradicted by the given trials   The primary trial describes the use of whole breast radiation therapy for breast cancer patients but it does not mention the use of fulvestrant or its dosage The secondary trial describes the use of fulvestrant",
        "label": "Entailment"
    },
    "378c5fe6-13ce-488e-a8c0-ec76cf2fb191": {
        "text_answer": "  The statement patients receiving aprepitant in the primary clinical trial were twice as likely to experience emesis as patients receiving the placebo intervention is a contradiction to the results provided in the trials   The trial results indicate that there were 13 participants in the aprepitant group who were emesis free during the study period while there were 5 participants in the placebo group who experienced emesis This means that the placebo group had",
        "label": "Contradiction"
    },
    "2ae5eea7-46bf-425e-b528-201a718d7f66": {
        "text_answer": "  The given statement is not entailed in the trial results as the trial only reports the Ki67 expression change from baseline to 6 weeks for the TAK228 plus Tamoxifen arm It does not provide information about the Ki67 expression change over 3 years of treatment",
        "label": "Contradiction"
    },
    "97322f7f-a311-4718-8a0c-5e4ecdd33f7f": {
        "text_answer": "  The primary trial does not provide any information about ki67 expression in tumors as it only reports the tumor response to 852A using RECIST criteria Therefore the statement is contradictory to the information provided in the primary trial  The secondary trial mentions several correlative studies including laboratory biomarker analysis and pharmacogenomic studies but it does not specify whether ki67 expression is being measured in these studies Therefore",
        "label": "Entailment"
    },
    "8920d439-7233-461b-a343-3c264f0918de": {
        "text_answer": "  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as there is no comparison of lesions or radiation dermatitis between the two groups within the same trial The trials only provide information on the number of",
        "label": "Contradiction"
    },
    "b2b80e2f-f5b4-4997-9209-fd061ff307b9": {
        "text_answer": "  The statement is entailed in the given trials Both interventions AlloMSCs and Placebo receive 20 injections of 04ml each making the total dosage identical for both groups",
        "label": "Entailment"
    },
    "b410caf4-4ea2-414d-8b43-7336d2bb2d9b": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The primary trial states that the primary tumour must be greater than 2 cm in diameter while the statement suggests a primary tumour with a diameter of 066 meters which is significantly larger and not within the acceptable range for the primary trial  Furthermore the secondary trial does not have a specific criterion regarding the size of the primary tumour but",
        "label": "Entailment"
    },
    "38343873-8e16-4852-bfe5-511fbd1be49d": {
        "text_answer": "  The given statement does not directly entail or contradict the information provided in the trials The trials only report the median survival times and their confidence intervals for each group The statement mentions that there have been cases of patients in each cohort who survived less than 2 years but it does not specify whether these cases were included in the reported median survival times or not Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "48b186f8-f41c-4582-8dbb-6918ce072ce8": {
        "text_answer": "  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not directly entailed in the given trials as the trials do not provide sufficient information to make that determination The statement mentions cholelithiasis but it does not provide the number of participants in each trial who experienced this adverse event Therefore we cannot determine if cholelithiasis was twice as common based on the given information alone",
        "label": "Contradiction"
    },
    "64ea29b0-1d21-4c59-a56e-553765f5e5c8": {
        "text_answer": "  The statement Patients whos Metastasis cannot be measured or whos Cancer has not spread to other parts of the body are not eligible for the primary trial is not explicitly stated in the given trial criteria However the trial does specify that only patients with histologically confirmed breast cancer that has metastasized M1 or multiple sites of new disease that is clinically obvious metastatic disease are eligible Therefore the statement is entailed in",
        "label": "Entailment"
    },
    "c939c0c9-57b8-4f8a-aba1-e19af522cb12": {
        "text_answer": "  The statement the primary clinical trial observed more cases of palpitations pericardial effusions and abdominal pains than the secondary clinical trial is contradicted by the given data   Explanation  The statement implies that the primary trial had a greater number of cases for each of the mentioned adverse events compared to the secondary trial However the data provided shows that the primary trial had the same number of cases for palpitations",
        "label": "Contradiction"
    },
    "f1a4fdcb-09ae-4f35-9681-8ee7d0d3b41d": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 the biweekly iv infusion dose of durvalumab for cohort 1 is 03 mgkg and in Intervention 2 it is 1 mgkg Therefore cohort 1 receives a higher dose of durvalumab per biweekly iv infusion than cohort 2",
        "label": "Entailment"
    },
    "6a489a42-add9-40b7-ba9d-5d46da07b890": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials only provide information about the interventions and dosing schedules for each group in both the primary and secondary trials The statement is about a unit of measure for pressure change which is not mentioned or related to the trials",
        "label": "Entailment"
    },
    "a67f344b-aa15-4e94-819b-515df442eaf0": {
        "text_answer": "  The statement more than 50 of patients in the primary clinical trial experienced a confirmed full or partial benefit after receiving treatment with lapatinib 1000 mg and nabpaclitaxel can be entailed by the given trial results if we define confirmed full or partial benefit as experiencing either a confirmed complete response CR or a confirmed partial response PR according to RECIST criteria 10   ",
        "label": "Entailment"
    },
    "5780e67e-7318-4574-b20c-a2d3c8730e4a": {
        "text_answer": "  The statement is entailed in the trials as follows  In the given trials the doses of Eribulin and Docetaxel are different between the two cohorts The dose of Eribulin in cohort 1 is 14mgm2 given on Days 1 and 8 of each treatment cycle while the dose of Docetaxel in cohort 2 is 75 mgm",
        "label": "Entailment"
    },
    "2f61841c-b395-4d2c-9e86-ca09cdd61dcb": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for both primary and secondary trials However it is consistent with some exclusion criteria in the secondary trial regarding the time frame for certain types of treatments chemotherapy radiotherapy and the presence of unstable angina The statement also contradicts the exclusion criteria for the primary trial regarding nonhealing surgical wounds as individuals with nonhealing surgical wounds are not permitted in",
        "label": "Contradiction"
    },
    "9ce6d69e-2ed0-4046-bd5e-5888416fbeb5": {
        "text_answer": "  The statement is contradictory to the given trials as there is no mention of febrile neutropenia or cholelithiasis in either the primary or secondary trials The trials only report the occurrence of adverse events their total count and specific types of adverse events The statement introduces new information that is not present in the trials",
        "label": "Contradiction"
    },
    "b490a735-38d7-49f2-a091-f930c5d1e9f5": {
        "text_answer": "  The given inclusion criteria do not mention Parkinsons disease or dementia specifically as exclusion criteria However the inclusion criteria state that subjects should have no evidence of dementia with a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment This suggests that mild cognitive impairment or other forms of cognitive impairment that do not meet the criteria for dementia may be allowed in the trial",
        "label": "Contradiction"
    },
    "5b6c2caa-eb80-4024-b04c-e6b07685b7d8": {
        "text_answer": "  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as the trials do not provide the number of patients who suffered from infections in each trial However we can calculate the number of patients with infections based on the given data  Primary Trial 132 313  132 3",
        "label": "Contradiction"
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "text_answer": "  The statement Morbidly obese patients can be eligible for the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The term morbidly obese is not defined in the provided criteria and there is no mention of body mass index BMI or weight restrictions in either trial Therefore the eligibility of morbidly obese patients depends on their meeting",
        "label": "Entailment"
    },
    "5ce6d9b3-235b-4645-bc27-10861b2e5177": {
        "text_answer": "  The statement in the primary clinical trial there were no reports of surgical incisions reopening following the operation is not directly entailed in the given adverse events data The data only reports various adverse events that occurred during the trial but it does not mention anything about surgical incisions reopening Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "c6f11ac1-ac2e-4740-82aa-a83ffd1cce00": {
        "text_answer": "  The statement there were no psychiatric adverse events reported during the primary clinical trial is contradicted by the information provided in the trial data The trial reported one case of suicidal ideation a psychiatric adverse event out of 50 participants Therefore the statement is contradicted by the trial data",
        "label": "Contradiction"
    },
    "fbb05804-2d6c-4d49-8e06-0fbf2b3770a4": {
        "text_answer": "  The statement is entailed in the given trials In the primary trial the intervention consists of a single drug Gefitinib while in the secondary trial there are two interventions the first intervention consists of three separate drugs Zoledronic acid vitamin D and calcium supplements and the second intervention consists of four separate drugs Zoledronic acid vitamin D calcium supplements and either Sr89 or",
        "label": "Entailment"
    },
    "9f0a6fc9-62c5-404e-aa2f-0e5acf696e14": {
        "text_answer": "  The statement cardiac adverse events were prominently recorded in both the primary and secondary clinical trials is contradictory to the given trials data   Explanation   The statement implies that there were cardiac adverse events recorded in both trials However the trials data shows that there were no cardiac adverse events recorded in either trial for Adverse Event 1 and no data is provided for Adverse Event 2 in the secondary",
        "label": "Contradiction"
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts is contradictory to the given data in the trials as both trials reported a total of zero adverse events for all categories in their respective cohorts",
        "label": "Entailment"
    },
    "d803319b-cf1d-47e9-b7c2-f75ef7972e88": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial is focused on measuring the difference in pain intensity with the use of Fentanyl Sublingual Spray versus Placebo and the outcome measurement is Summed Pain Intensity Differences SPID at 30 minutes after dosing   The secondary trial is focused on measuring the change in bone mineral density BMD of the lumbar spine at",
        "label": "Entailment"
    },
    "ad17d770-f8c6-4440-8b95-894a511cab39": {
        "text_answer": "  The statement women diagnosed with claustrophobia and IBS are allowed to participate in the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for the primary trial The primary trial does not mention claustrophobia or IBS Irritable Bowel Syndrome as inclusion or exclusion criteria Therefore the statement is neither entailed nor contradicted by the information provided in the primary trial",
        "label": "Contradiction"
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "text_answer": "  The statement is entailed in the Trials The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II portions while the secondary trial has the same criteria for all participants This means that the statement the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants is a correct description of the trials provided",
        "label": "Entailment"
    },
    "aa78eaae-97c9-4f34-97e4-4debfccd1552": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX between the two groups   The percentage change in betaCTX for the AZD0530 175 mg group was 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg group was 684 ",
        "label": "Entailment"
    },
    "a8fa1843-9726-4f19-a026-7155df678098": {
        "text_answer": "  The given statement several cases of hypertension were detected in both cohorts of the primary clinical trial is not directly entailed in the provided data from the trials as there is no mention of hypertension as an adverse event in either cohort Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "832ab731-553d-4d66-a339-1fb60265866a": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years and over 50 patients from each cohort survived more than 24 months is not directly entailed in the given trials as they only report the median survival times and do not provide information about the number of patients surviving beyond 24 months However it is not contradictory to the trials as the median survival times reported are both over 2 years  Regarding the",
        "label": "Contradiction"
    },
    "019f248f-f753-495a-b579-9d41f65c5b26": {
        "text_answer": "  The statement neither the primary nor the secondary clinical trial have reported any adverse events for their participants is entailed by the given data   Explanation  The given data states that for the primary trial there were no adverse events reported for Adverse Event 1 and Adverse Event 2 with a total of 15 participants Similarly for the secondary trial there were no adverse events reported for Adverse Event 1",
        "label": "Entailment"
    },
    "8b6e90d0-d3e2-41db-9d70-ce8b216f3795": {
        "text_answer": "  The statement the primary clinical trial is open to AfricanAmerican participants given that they are residing in Texas throughout the study period is not entailed in the given inclusion and exclusion criteria for the dose escalation and expansion phases of the trial The criteria only specify demographic information disease status and previous treatment history for eligibility There is no mention of race or location as a requirement for participation in the trial Therefore the statement is not entailed in",
        "label": "Contradiction"
    },
    "27fcd959-e1dd-4c76-8e6c-fdf5fe4d257f": {
        "text_answer": "  The statement is entailed in the trials exclusion criteria as follows  Exclusion Criteria    No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months   No history of myocardial infarction MI stroke or transient ischemic attacks in the last 6 months   No serious nonhealing wound ulcer",
        "label": "Entailment"
    },
    "4d1031f5-19e1-43f3-b75a-5e8208b44bfb": {
        "text_answer": "  The statement no significant disparities were observed in the outcomes from the groups involved in the primary clinical trial while in the secondary clinical trial some differences were noted between the results of the reflexology group and the control group is a conditional statement It states that there were no significant differences in the primary trial but there were some differences in the secondary trial  To verify this statement we need to compare the results of the primary and secondary trials In the",
        "label": "Contradiction"
    },
    "f8858128-03f8-4721-a0f5-5f3fce7ab1c4": {
        "text_answer": "  The statement those having assessable bilateral breast cancer are qualified to join the primary clinical trial is contradictory to the inclusion criteria as stated in the trial description The inclusion criteria specify that the trial is for individuals with unilateral breast cancer meaning cancer in one breast only Therefore individuals with assessable bilateral breast cancer cancer in both breasts do not meet the inclusion criteria and are not qualified to join the primary clinical trial",
        "label": "Entailment"
    },
    "f9ad6db3-d2bc-474c-b666-a971749f6a83": {
        "text_answer": "  The patient described in the statement meets some of the inclusion criteria for both the primary and secondary trials However there are also some differences in the inclusion criteria between the two trials that need to be considered  For the primary trial the patient meets the following inclusion criteria  Histologically or cytologically proven diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed within specified time frames  Zubrod performance status 0",
        "label": "Entailment"
    },
    "0090fc12-4092-4255-8952-21ebee889ebb": {
        "text_answer": "  The statement performed histopathology cell type code is a coded value specifying the kind of cells found is not directly related to the information provided in the primary or secondary trial interventions Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "151ebcdf-fc4e-443e-8c2d-5189b65cee5b": {
        "text_answer": "  The statement the secondary trial candidates must meet some Performance Status condition to participate whereas this is not required to be accepted into the primary trial is entailed in the given trials as follows  The primary trial includes subjects who have already responded to paclitaxel therapy and are considered to need to continue the therapy by the investigatorsubinvestigator without any specific mention of performance status as an inclusion criterion  The secondary trial on the other",
        "label": "Entailment"
    },
    "b49ac921-1516-409d-9e81-14fc5afc75c6": {
        "text_answer": "  The statement malignant oncocyte is a malignant epithelial cell with abundant eosinophilic or clear granular cytoplasm is neither entailed nor contradictory to the given inclusion and exclusion criteria of the primary trial The statement is not related to the eligibility criteria for the trial as it describes a type of malignant cell while the criteria focus on patient characteristics and previous treatments",
        "label": "Entailment"
    },
    "6ee4b112-4ff6-49d0-a7ec-a9e71d309bb9": {
        "text_answer": "  The statement xxyy syndrome is a rare sex chromosome abnormality in which a male child has an extra x and y chromosome is not related to the information provided in the trials Therefore it cannot be determined if the statement is entailed in the trials or not  Regarding the trials the number of participants analyzed in the primary trial 13 is less than the number of participants analyzed in the secondary trial 30 Therefore",
        "label": "Entailment"
    },
    "ef734fea-a713-4fb3-b6e9-0be2dc2b055a": {
        "text_answer": "  The statement diffusion weighted imaging is a diffusion MRI technique in which diffusionsensitizing gradients are applied to the imaging sequence is not directly related to the trials provided The trials focus on the outcome measurements of tumor diameter and response to treatment in patients with various types of cancers The statement does not entail or contradict any information presented in the trials",
        "label": "Entailment"
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial use change in MYMOP score as the outcome measurement for their studies is entailed in the given trials as neither trial reports the use of MYMOP score as the primary outcome measurement The primary trial uses change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire but it is not the primary outcome measurement as stated in the trial title or description The secondary trial measures change in is",
        "label": "Entailment"
    },
    "d4b299e3-f371-4311-9ea6-b3301632d7df": {
        "text_answer": "  The statement one patient in the primary trial had an incident where a surgical incision reopened after the surgery is not directly related to the given adverse events in the trial The statement mentions an incident of wound dehiscence which is one of the adverse events listed However the statement goes beyond the information provided in the adverse events and describes the incident as an incident where a surgical incision reopened after the surgery which",
        "label": "Entailment"
    },
    "9c5bbe3a-c662-4a0e-88cf-b2f5fc1188f8": {
        "text_answer": "  The statement within the scope of the primary clinical trial the prevalence of hypertension and pancreatectomy cases were equivalent to the rate of hepatotoxicity cases is contradictory to the given data in the trial   The statement implies that the prevalence of hypertension and pancreatectomy cases are each 3750 which is not the case based on the trial data The prevalence of hy",
        "label": "Entailment"
    },
    "47c91759-a386-407e-9612-dbce68040a7b": {
        "text_answer": "  The statement be rid of obligations and responsibilities is a question about how often a person thought about being rid of obligations and responsibilities is not directly related to the adverse events recorded in the primary trial Therefore it cannot be entailed or contradicted by the information provided in the trial",
        "label": "Entailment"
    },
    "2db7c3cd-eb62-4ec4-8d89-effa9c9212e0": {
        "text_answer": "  The statement both the primary and secondary clinical trials have recorded instances of anorexia hypothermia and hallucinations in their aes is a contradiction to the information provided in the trials The trials report no instances 000 of anorexia hypothermia and hallucinations in their Adverse Events sections",
        "label": "Contradiction"
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "text_answer": "  The statement after a month of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 10 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks of 5 percentage points from 15 to 10 ",
        "label": "Entailment"
    },
    "ee7fc1bb-98fe-4f43-9ea0-076b7fc7eeca": {
        "text_answer": "  The provided trials do not contain sufficient information to determine if the statement several of the patients in the primary trial experienced the no pain whatsoever during the 3 months of the study is entailed or contradicted The trials only report the average pain intensity scores and their confidence intervals for the Low Dose and High Dose groups No information is given about the distribution of pain scores within each group or the number of patients who experienced no pain at all Therefore",
        "label": "Contradiction"
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the given trials data  Explanation  The statement is entailed in the trials data because the primary trial had a higher percentage of occurrence for all the mentioned ad",
        "label": "Entailment"
    },
    "fb140d2c-d2a8-4442-bcbd-669bb9abbf2c": {
        "text_answer": "  The statement there are no restrictions regarding the participation of cancer patients diagnosed with either fibromyalgia thalasemic syndromes or anemia in the primary clinical trial and the secondary clinical trial is contradictory to the information provided in the trials inclusion and exclusion criteria  In the primary trial anemia is an inclusion criterion but thalasemic syndromes are listed as an exclusion criterion F",
        "label": "Contradiction"
    },
    "c01a6286-57b2-4851-8c5e-12710eb9d829": {
        "text_answer": "  The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement however they are not explicitly excluded from the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial does not mention any age requirement but it does mention postmenopausal status as a requirement The secondary trial mentions that women of childbearing potential must commit",
        "label": "Contradiction"
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "text_answer": "  The primary trial involves the administration of pembrolizumab every 3 weeks Q3W while the secondary trial mentions sunitinib being administered to sunitinibnave participants once daily   To determine if the statement is entailed or contradicted we need to calculate the frequency of administration for both treatments  1 Pembrolizumab in the primary trial Given every Q3W 2",
        "label": "Entailment"
    },
    "128fd57d-cc06-40a3-8eb5-570441a19652": {
        "text_answer": "  The statement is contradictory to the information provided in the primary clinical trial The trial describes the use of laserassisted fluorescence angiography Spy Elite LifeCell at three separate time points for both the Inframammary Fold Incision and Lateral Radial Incision cohorts Therefore the statement that the interventions implemented in the primary clinical trial skip the use of laserassisted fluorescence angi",
        "label": "Entailment"
    },
    "10818b02-4a1d-438a-8f90-7aded2b826ec": {
        "text_answer": "  The statement counselor is a person with training to provide advice or instruction is not directly related to the information provided in the trials   The statement There are 7 more participants in cohort 2 of the primary trial than in cohort 1 is not entailed in the trials as the number of participants in each armgroup and the overall number of participants analyzed for each arm are given but the total number of participants in each",
        "label": "Contradiction"
    },
    "6a696416-b67e-4f78-8677-3fbc4470b4c1": {
        "text_answer": "  The statement age at initial pathologic diagnosis is a question about the age of the individual at the time of the initial pathologic diagnosis is not directly related to the adverse events recorded in the trial   However the statement Coronary artery stenosis are the most common AE recorded in the primary trial can be verified as follows  The given trial data shows that there were a total of 16 adverse events out",
        "label": "Entailment"
    },
    "9c253aed-c7ae-42ad-afd2-9c52c9ecab08": {
        "text_answer": "  The statement that a 32yearold patient with histologically verified stage III breast cancer an absolute neutrophil count of 1807L a platelet count of 79000L a hemoglobin level of 90 gl and a life expectancy exceeding 8 months is eligible for both the primary and secondary trials can be verified as entailed in the trials",
        "label": "Entailment"
    },
    "63cb536d-5250-4760-b3a8-103bfcc45123": {
        "text_answer": "  The statement trabecular pattern is a microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample is not entailed in the given primary or secondary trials as they do not involve any information related to tumors or microscopic findings The primary trial focuses on breast reconstruction using a Contour Profile Tissue Expander while the secondary trial involves the use of allogeneic mesenchymal stem cells ",
        "label": "Contradiction"
    },
    "3136ac0b-82b2-4819-a5ba-d5816dd0283b": {
        "text_answer": "  The statement all patients in the primary clinical trial encountered aes is a generalization of the given data The data states that 2 out of 35 patients 571 experienced adverse events but it does not specify which types of adverse events each patient experienced The statement however asserts that all patients experienced adverse events which is not entailed in the given data Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "d2ac18d1-d427-4afc-b72a-4de7856b17d5": {
        "text_answer": "  The statement is entailed in the Trials since the trials provide information that all cases of adverse events related to gastrointestinal and bloodrelated disorders occurred in cohort 1 of the primary clinical trial The trials do not report any such adverse events in cohort 2 Therefore the statement is a logical consequence of the given information",
        "label": "Entailment"
    },
    "8b14dd2f-b02e-41be-a2bc-7dcc378ab426": {
        "text_answer": "  The statement does not directly compare the dosages of Denosumab and Tamoxifen in the context of the trials provided However we can calculate the relative dosages based on the given information  In the primary trial the Denosumab dosage is 120 mg Q4W which translates to 480 mg per 3 months In the secondary trial the Tamoxifen dosage is 10 mg once",
        "label": "Entailment"
    },
    "e1eb6c8e-61e1-474a-a01c-f7d18d2620e9": {
        "text_answer": "  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed in the given information The statement only mentions the number of adverse events in each cohort but it does not provide enough information to determine if there is a difference between the genders or if there are even any females in the trial The administrative gender code is not related",
        "label": "Contradiction"
    },
    "8655fdcd-564c-483a-aa2b-7dac2d84ce57": {
        "text_answer": "  The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is entailed in the trials inclusion criteria The trial explicitly states that patients with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification or any other functional alteration at the G1S checkpoint are eligible for enrollment",
        "label": "Entailment"
    },
    "e8edca4b-3a7c-43b6-aed4-8651d1dee36f": {
        "text_answer": "  The statement infections occurred in over 15 of patients involved in both the primary and secondary clinical trials during the study period is contradictory to the information provided in the trials   The primary trial reports that infections occurred in 313 of patients 132 while the secondary trial reports that infections occurred in 667 of patients 115 The combined percentage of patients with infections",
        "label": "Entailment"
    },
    "682a4e2d-f4a5-4fee-8399-195f67fcdfcc": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial trastuzumab is given at an interval of once a week during the treatment period In contrast in the secondary trial Herceptin trastuzumab is given at different intervals 4 mgkg IV infusion on Day 1 of Cycle 5 followed by 2 mgkg by IV infusion weekly starting from Day 8 and 6",
        "label": "Entailment"
    },
    "4b310647-d605-4946-aeb5-bcfd418e1332": {
        "text_answer": "  The statement in the primary clinical trial both intervention one and two use pihgc as their method is neither entailed nor contradicted by the given information   The trials describe the use of radioactive Tc99M sulfur colloid in lymphoscintigraphy for both interventions but they do not explicitly state that a handheld gamma camera piHGC is used in both interventions While it is mentioned",
        "label": "Entailment"
    },
    "cd93653b-f6d1-4e8c-aa04-20a41d0096b9": {
        "text_answer": "  The statement anemia cases are less prevalent in the primary clinical trial than in the secondary clinical trial is entailed in the given trials as the prevalence of anemia in the primary trial is 000 while in the secondary trial it is 430 Therefore the statement is entailed by the given trials",
        "label": "Entailment"
    },
    "e255fdb7-4e8b-4e62-bbb8-875687948bed": {
        "text_answer": "  The statement all the participants of the primary clinical trial subjected to the placebo intervention experienced incidences of vomit is a contradiction to the results presented in Trial 2   The results indicate that there were 5 participants in the placebo group but no information is provided about the number of participants who experienced vomiting The absence of information does not entail that all participants experienced vomiting and therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "text_answer": "  The statement The nationality ethnicity psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial is entailed in the given inclusion and exclusion criteria for both the primary and secondary trials There is no mention of nationality ethnicity psychiatric condition or gender as inclusion or exclusion criteria in the provided text Therefore the statement is entailed in the trials as it is consistent with the information",
        "label": "Entailment"
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report different outcome measurements The primary trial reports Time to Progression in months while the secondary trial reports the percentage of participants with Objective Response based on RECIST criteria The statement could be made more precise by specifying that it compares the two trials in terms of their outcome measurements as follows  Statement Revised The primary trial reports the Time to Progression in months for Arm A and",
        "label": "Contradiction"
    },
    "22f473e7-1aea-4baf-9697-224ea4c6fbdf": {
        "text_answer": "  The statement a dose of 100 to 1600 g fentanyl sublingual spray is administered to every patient partaking in the primary clinical trial during their radiation therapy sessions is not entailed in the given trial information   The trial only mentions the use of Vorinostat and Radiation therapy and the dosing schedule for Vorinostat It does not mention anything about the use of Fent",
        "label": "Contradiction"
    },
    "03ee1d82-5208-4511-9163-23adfbc55fa4": {
        "text_answer": "  The statement women with a new diagnosis of stage IV ER breast cancer who are contemplating undergoing mastectomy are suitable for both the primary clinical trial and the secondary clinical trial is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed ",
        "label": "Entailment"
    },
    "3f532833-d78c-41a1-b364-81228e03027e": {
        "text_answer": "  The statement is a contradiction to the primary trial as the group 2 of the primary trial receives 05ugkg of dexmedetomidine 5ml which is different from the 500ngkg 5ml stated in the given statement The secondary trial does not provide any information about the administration of dexmedetomidine to its patients",
        "label": "Contradiction"
    },
    "fd942f9a-9ad7-43f3-aac3-69b01a022811": {
        "text_answer": "  The statement gastric pylorus carcinoma is a carcinoma that arises from the pylorus is not directly related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "8fe01416-c839-4ffc-bd21-25d158d502b8": {
        "text_answer": "  The statement no patients in the primary clinical trial experienced a reopening of their surgical incision postoperation is not directly entailed or contradicted by the given adverse events data The data does not mention any adverse event related to surgical incision reopening Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "1a3483cd-0a92-456f-ba18-6ce12b3ded0b": {
        "text_answer": "  The statement 19q134 is a chromosome band present on 19q is neither entailed in the inclusion nor exclusion criteria of the primary or secondary trials It is an unrelated fact  However the statement Patients with significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial is explicitly stated in the exclusion criteria of both trials Therefore it is ent",
        "label": "Entailment"
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "text_answer": "  The statement is entailed in the Trials as follows  Both trials include patients with histologically confirmed stage 4 breast adenocarcinoma The primary trial includes patients with radiographic evidence of bone metastases and the secondary trial includes patients with ER positive PR positive and HER2neu negative disease The statement in question is that patients with ER positive PR positive or HER2neu negative stage 4 breast ad",
        "label": "Entailment"
    },
    "68b82fb4-066b-4d76-9623-ff8696da3000": {
        "text_answer": "  The statement all patients participating in the primary clinical trial are instructed to ingest a capsule of vorinostat each day during their radiation treatment is entailed in the trial description The trial states that Patients will take Vorinostat daily during radiation therapy which implies that all patients will take Vorinostat every day while undergoing radiation therapy Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "fae99e77-42d1-4003-bb7a-3b98b88f7c27": {
        "text_answer": "  The statement adverse events were documented in both cohorts participating in the primary clinical trial is contradictory to the given information in the trials The trials report that there were no adverse events documented in either cohort so it is not entailed that adverse events were documented in both",
        "label": "Contradiction"
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   In Intervention 1 Cohort A receives two IM injections of V935 LD given every other week over a 3week period In Intervention 2 Cohort B first receives three EP injections of V934 LD given every other week over a 5week period followed by a 4",
        "label": "Entailment"
    },
    "69c802bf-ab3f-4a0a-b995-210db2403a50": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the alpha lipoic acid dosage is scheduled to be adjusted which means the quantity of alpha lipoic acid administered to subjects changes over time  In contrast in the secondary trials first cohort the necitumumab quantity remains unchanged as it is administered at a constant dose on Days 1 and 8 of every 3",
        "label": "Entailment"
    },
    "f96f9461-2b00-4838-9e04-1d3a8dbeb3f3": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   The statement mentions that participants are subjected to four varied drugs with an upper limit of dosage being 100 mgm2 but the clinical trial description specifies the dosages for each of the four drugs epirubicin 100 mgm2 cyclophosphamide 600 mgm2 doc",
        "label": "Entailment"
    },
    "01effe7e-449f-4f59-a64e-2b38c5c21187": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there were no cases of acute myocardial infarction reported among the 4 individuals   In the secondary trial there were also no cases of acute myocardial infarction reported among the 1674 individuals   However the statement claims that 2 individuals in the primary trial suffered from acute myoc",
        "label": "Contradiction"
    },
    "ece744da-a8d6-401a-972c-3a9f5cd60b14": {
        "text_answer": "  The statement each individual adverse event in the primary clinical trial was reported in only one patient is entailed in the given data if and only if there are no repeated adverse events among the 14 patients in the trial Based on the provided data each adverse event Ileus disease progression pneumonia and acute kidney injury was reported in only one patient Therefore the statement is entailed in the given data",
        "label": "Entailment"
    },
    "21d37b8b-4326-40bd-a070-5ad0fbb48e6d": {
        "text_answer": "  The statement is entailed in the trials inclusion criteria as follows  Inclusion Criteria for Group 1  Histological confirmation of ER negative PR negative and HER2 negative invasive breast cancer  The statement explicitly mentions ER negative PR negative and HER2 negative breast cancer which is the same as Group 1 in the trials inclusion criteria Therefore the statement is entailed in the trials inclusion criteria",
        "label": "Entailment"
    },
    "1b5e0318-38e0-484f-bffd-d63ff75fe93c": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial registered any adverse events is contradicted by the information provided in the trials   Explanation   The primary clinical trial reported 0 adverse events out of 20 participants which is equivalent to a percentage of 000 The secondary clinical trial reported 2 adverse events out of 35 participants which is equivalent to a percentage of 5",
        "label": "Contradiction"
    },
    "f5daafd4-0b8b-4239-b566-e7b2c1b80825": {
        "text_answer": "  The statement patients who have received chemotherapy or radiotherapy in the last 14 days suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a conditional statement   To determine if this statement is entailed in the given trials we need to check if the trials entail or",
        "label": "Entailment"
    },
    "ce4851a3-948d-4eca-8d86-2a70f3bbd577": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial states that the intervention is administered sublingually not inhalation or intramuscular and the secondary trial states that the intervention in Arm I is administered PO by mouth but it does not specify the route further However the contradiction lies in the assumption that the interventions in the secondary trial are intramuscular which is not stated in the trial information",
        "label": "Contradiction"
    },
    "b21fa80a-d451-46c7-8916-bf3029156624": {
        "text_answer": "  The statement patients who have previously experienced profound anaphylactic responses to trastuzumab are ineligible for the primary clinical trial is entailed in the trials exclusion criteria The trial explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study While the statement uses the term profound anaphylactic responses it can be inferred that this term",
        "label": "Entailment"
    },
    "3958b171-1f79-4dae-958a-be87bb3b44c0": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial participants are required to take the following distinct drug types doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate trastuzumab tamoxifen citrate letrozole This totals to",
        "label": "Entailment"
    },
    "f498a2b6-b3da-45a2-b9d5-ef87ee43914f": {
        "text_answer": "  The statement monoallelic rad51 gene inactivation is any gain loss or exchange of DNA that results in monoallelic loss of function mutations in the rad51 gene There are no conditions on mental health bodyweight size of tumors KarnofskyECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial is not directly related to the inclusion and excl",
        "label": "Contradiction"
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "text_answer": "  The statement Patients with measurable bilateral breast cancer are eligible for the primary trial is contradictory to the inclusion criteria of the trial as stated in the given text The trial only includes patients with unilateral breast cancer",
        "label": "Entailment"
    },
    "5a1445df-c3d7-4d1e-a4d3-e18ac2238a97": {
        "text_answer": "  The statement is entailed in the given trials data   Explanation   The statement during the primary clinical trial and the secondary clinical trial no cardiac or psychiatric adverse events were reported is a logical consequence of the data provided in the trials The trials data states that there were no cardiac or psychiatric adverse events reported in both trials for the respective categories Therefore the statement is entailed by the trials data",
        "label": "Entailment"
    },
    "d17230ee-836d-4153-b940-8e3dd7741964": {
        "text_answer": "  The statement a weekly cycle of 4demethyl4cholestryloxycarbonylpenclomedine is a shared necessity amongst the primary and secondary clinical trials is entailed in the given trials as both the primary and secondary interventions involve the use of 4demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle for patients with CNS involvement from melanoma",
        "label": "Entailment"
    },
    "62d189a0-04ee-44d7-962e-35629b28736c": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 1440 hours are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the information provided in the exclusion criteria for both trials  In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within ",
        "label": "Contradiction"
    },
    "321c299b-2264-4cc6-988d-faef346ca38a": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not involve MLN8237 alisertib or mucor racemosus IgG4 measurement The primary trial focuses on Botulinum Toxin Type A versus placebo for breast surgery recovery while the secondary trial investigates different doses of MLN8237 in cancer treatment Therefore the statement is neither entailed nor contradicted by the provided trials",
        "label": "Contradiction"
    },
    "d8af88b9-e015-4eec-b49f-6b2398e38a5d": {
        "text_answer": "  The statement synchronous nodules without dominant lesions is a finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion is not directly related to the adverse events data provided in the trials The statement describes a radiologic finding while the trials report the occurrence of adverse events during the studies The statement does not entail or contradict the information in the trials",
        "label": "Contradiction"
    },
    "db5f7526-ae64-4a0c-bea4-53b4bfe95d48": {
        "text_answer": "  The statement Patients in the primary trial will need to receive one single injection on day 8 of the study is not entailed in the given trial information The trial information mentions that patients will receive Leukine GMCSF injections from day 1 to day 8 after chemotherapy and therapeutic autologous dendritic cells injections on day 8 but it does not specify that only one injection is given on that",
        "label": "Contradiction"
    },
    "d4f98c24-aad0-4784-9b90-da1a99b9a59b": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage of participants in each group who demonstrated a decrease in the growth factor signature GFS   According to the results provided the percentage of participants in the ERpositive Luminal B group who showed a decrease in GFS was 286 95 CI 131492 while in the Triple",
        "label": "Entailment"
    },
    "3137468e-52bf-4bff-a3cc-68f127683f63": {
        "text_answer": "  The statement in comparison to the primary clinical trial the secondary clinical trial has tracked a slight escalation in total adverse events within its patient cohorts is a comparison statement To determine if it is entailed or contradicted by the given trials data we need to compare the total adverse events between the two trials  The primary trial has no adverse events reported so the total is 00 The secondary trial has 0 adverse",
        "label": "Entailment"
    },
    "060a4ded-7677-4945-90ff-b6b93204f94c": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 300 days are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the information provided in the exclusion criteria for both trials  In the primary trial patients with a pulmonary embolism within the last 300 days are explicitly excluded However the statement suggests that these patients",
        "label": "Contradiction"
    },
    "a02d9319-0103-493a-8368-f79dbbe6a223": {
        "text_answer": "  The statement ascites was more likely to occur in patients from the secondary clinical trial is entailed in the trials as the frequency of ascites in the secondary trial 29 or 090 is higher than in the primary trial 2223 or 090  The statement hypersensitivity reactions were more common in the primary clinical trial is not directly entailed or contradicted by the trials as",
        "label": "Entailment"
    },
    "22aed38a-d9c2-4e5e-b738-07f75968c45a": {
        "text_answer": "  The statement 110 of patients in the primary trial did not experience any adverse events is contradictory to the information provided in the trial results The results indicate that 98 out of 100 participants were analyzed and 922 to 995 of them did not experience any adverse events However the percentage cannot be more than 100 Therefore the statement is contradictory to the",
        "label": "Entailment"
    },
    "4d8795f1-f8bf-4c27-9eb1-3f7db45c03ec": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that both cohorts receive the same dosage and frequency of CUDC101 but only cohort 1 gets a weekly dose of PD0332991 However the trials do not mention any information about PD0332991 being administered to either cohort",
        "label": "Entailment"
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "text_answer": "  The statement candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial is entailed in the trials as follows  1 The primary trial includes candidates with an ECOG score of 0 to 2 An ECOG score of 1 falls within this range 2 The secondary trial includes candidates with an ECOG score of 02 OR Karnofsky 60",
        "label": "Entailment"
    },
    "e8b222ce-e235-4b8d-b524-521ba583656a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement claims that no adverse events were recorded in the secondary clinical trial but the trials clearly show that there were adverse events in the secondary trial with a total of 45 adverse events out of 128 patients 3516 Therefore the statement is contradictory to the information provided in the trials  Regarding the statement about the",
        "label": "Contradiction"
    },
    "3bf96cd4-147b-45f2-b174-e3a375a67e26": {
        "text_answer": "  The statement candidates for the primary trial must have breast cancer and require hormonal treatment repeat expansion diseases are a class of genetic diseases that occur when microsatellite repeats expand beyond a threshold length is not directly entailed in the given inclusion and exclusion criteria for the primary trial  The inclusion criteria specify that candidates must have breast cancer that has continued to grow despite hormonal treatment and be postmenopausal The exclusion criteria state that",
        "label": "Contradiction"
    },
    "b06e2353-00ae-4f10-b072-a4ae5f608d3e": {
        "text_answer": "  The statement patients who have completed their treatment and are now cancerfree can participate in the primary clinical trial and the secondary clinical trial regardless of their consent status is not explicitly stated in the given inclusion criteria or exclusion criteria for either the primary or secondary trials Therefore it cannot be definitively determined if the statement is entailed in the trials or if it is contradictory based on the provided information alone  However it is generally accepted in clinical",
        "label": "Entailment"
    },
    "15414f62-cb14-4bf8-98aa-0fbd74edd41c": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The primary trial does not prove that standard mammography is more efficient than intraoperative mammography based on the operative time data presented The statement is incorrect",
        "label": "Entailment"
    },
    "8c507ad1-b534-4d16-9a1b-5c92a432eb9d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does include massage therapy as an intervention which is a nondrugbased treatment However the statement incorrectly asserts that the primary trial evaluates only drugbased treatments   Regarding the secondary trial it does not test any medication but it does involve the use of PF06647020 in the intervention groups",
        "label": "Entailment"
    },
    "dbc1b653-7c38-4c7c-bad8-5949d6f909ed": {
        "text_answer": "  The statement patients with nonmeasurable unilateral breast cancer are eligible for the primary clinical trial is contradictory to the inclusion criteria as stated in the trial description The inclusion criteria specify that patients must have unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection sentinel biopsy or axillary dissection which implies that the breast cancer is measurable Therefore",
        "label": "Entailment"
    },
    "3eb6d0c5-4bc4-4808-b8cb-03b3d5d40a07": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is focused on investigating the effect of varying quantities of a single therapy Hydrophor or MediHoney on the study groups Group A and Group B whereas the secondary trial is exploring the outcomes from different interventions Arm A1 and Arm A2 each consisting of a combination of two different therapies PF05212384 and Docetax",
        "label": "Entailment"
    },
    "2735976f-a517-4b4e-addb-845ef4dc0d33": {
        "text_answer": "  The statement is not entailed in the primary or secondary trials as given   The primary trial excludes patients with high risk breast lesions including ductal carcinoma in situ but it also excludes those with uncontrolled hypertension Therefore a patient with both unregulated high blood pressure and malignant ductal carcinoma in situ would be excluded from the primary trial  However the secondary trial includes patients with a",
        "label": "Contradiction"
    },
    "4dc9c970-22dc-4117-8169-255a0b3f80d8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials mention suicidal ideation as an adverse event which is a type of psychiatric event However the statement in the question mentions an eating disorder and Schizophrenia as psychiatric adverse events which are different from suicidal ideation Therefore the statement is contradictory to the information provided in the trials  Explanation  The statement",
        "label": "Entailment"
    },
    "043f8072-1e16-4e74-8ad4-50ff1786fb48": {
        "text_answer": "  The statement less than 3 of patients in the primary clinical trial and the secondary clinical trial documented adverse events is not directly entailed or contradicted by the given data   The data only provides the number and percentage of adverse events for each trial but it does not specify the total number of patients in each trial Therefore it is impossible to determine if less than 3 of patients in each trial experienced adverse events based on the given information",
        "label": "Contradiction"
    },
    "31837502-2949-4dc4-bfbe-fc54ca5ccb01": {
        "text_answer": "  The statement abnormal involuntary movement scale aims0108 through aims0109 original result  moderate is abnormal is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone  However the statement does mention the Abnormal Involuntary Movement Scale aims0108 through aims0",
        "label": "Entailment"
    },
    "ba589a4b-13ef-43be-8441-438742dd9d5c": {
        "text_answer": "  The statement tumor findings evaluator is a person who determines the significance of a tumor findings assessment is not directly related to the information provided in the trials The trials focus on the outcome measurements and results of interventions for vaginal symptoms and HER2negative metastatic breast cancer respectively The statement does not entail nor contradict the information provided in the trials",
        "label": "Entailment"
    },
    "b0c8481b-3041-4b12-b272-11bb5ee7f80e": {
        "text_answer": "  The statement half of primary clinical trials participants and 8371674 of the secondary trials participants experienced an adverse event is not entailed in the given trials as there is no information provided about the number of participants who experienced an adverse event in either trial The trials only provide the number of participants who experienced specific types of adverse events and the total number of participants in each trial Therefore the statement is contradictory",
        "label": "Contradiction"
    },
    "5d657b3f-a074-480e-8698-24c288553369": {
        "text_answer": "  The given statement is entailed in the primary clinical trial description as neither Intervention 1 nor Intervention 2 involves the use of drugs radiotherapy or CBT Cognitive Behavioral Therapy",
        "label": "Entailment"
    },
    "145671c6-1b45-49a9-9fc7-8c65e8461115": {
        "text_answer": "  The statement Both cohorts of the primary trial recorded 0 Aes cerebral artery is an artery which directly supplies the cerebral cortex and which has deeper branches that supply the underlying white matter is neither entailed nor contradictory to the given trials data   The trials data only provides the number of adverse events recorded in each cohort it does not mention anything about the cerebral artery or its branches",
        "label": "Entailment"
    },
    "0e28f749-6c65-46fc-93c0-c3b68c96460e": {
        "text_answer": "  The statement is entailed in the trials as the placebo and trabectedin are administered via different methods placebo as a 3hour intravenous infusion on Day 1 and trabectedin as a 13 mgm2 3hour intravenous infusion on Day 2",
        "label": "Entailment"
    },
    "97c738f3-a7ef-4183-9664-5aac4fd64a0e": {
        "text_answer": "  The statement the number of participants in the secondary clinical trial exceeded those in the primary clinical trial is a contradiction to the information provided in the trials   In the primary trial there were 13 participants analyzed while in the secondary trial there were 30 participants analyzed Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "451e07e2-524d-459e-872c-1c4b3640f511": {
        "text_answer": "  The statement feel hopeless is a question about whether an individual feels or felt hopeless is not directly related to the information provided in the trials However I will check if the statement is entailed or contradicted based on the information given about the interventions in each trial  In the primary trial the statement is not contradicted or entailed since there is no information about the participants feeling hopeless or not The trial only provides information about the interventions",
        "label": "Entailment"
    },
    "7f3a5491-e157-4fbc-a939-8478889c15dc": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different outcome measurements The primary trial focuses on the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time using polysomnography The statement does mention different outcome measurements but it also includes an incorrect statement about cognitive disorder being a category of psychiatric disorders characterized by a deficit in cognition or memory This incorrect statement is not related to",
        "label": "Contradiction"
    },
    "67b45a2f-d082-4386-b70e-eb212a1762a0": {
        "text_answer": "  The statement both phases of the primary clinical trial may include patients with any gender is entailed in the given inclusion criteria as there is no mention of any gender restriction in the criteria for either phase 1 or phase 2 of the trial Therefore the statement is entailed by the information provided in the clinical trial description",
        "label": "Entailment"
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced a confirmed complete response CR is not entailed in the given trial results   The trial results only provide the number of participants who experienced a CR or PR according to RECIST criteria 10 but they do not specify the exact number of participants who experienced a CR The statement suggests",
        "label": "Contradiction"
    },
    "ddf14eb0-04ae-431b-b4e8-ba97eddc25b7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial Intervention 1 involves an injection of Fluciclatide AH111585 18F and Intervention 2 also involves an injection of Fluciclatide   In the secondary trial there is no mention of paclitaxel or azacitidine in either Intervention 1 or Intervention 2",
        "label": "Contradiction"
    },
    "c8c9752f-a60b-4173-bbe7-deb1a894ebe5": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention groups do not involve any medicationrelated analyses focusing only on massage therapy psychosocial assessment and care and qualityoflife assessment In contrast the secondary trial is specifically designed to investigate the effects of different doses of PF06647020 a drugbased treatment on participants This trial includes medicationrelated analys",
        "label": "Entailment"
    },
    "c3445b55-8b79-4ac0-9ace-25e48c82760c": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 365730 days to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial has an inclusion criterion stating aged greater than 20 years which explicitly excludes women aged 18 or 19 Therefore they",
        "label": "Contradiction"
    },
    "2fc8ee27-e602-47ae-a93b-1c8194e3d6ea": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the trials both Intervention 1 and Intervention 2 involve the use of a compact disc CD for instruction on paced breathing Therefore the statement that none of which include a cd is not entailed in the trials Instead it contradicts the information provided",
        "label": "Contradiction"
    },
    "79ddd80e-a0b2-4450-a0df-892e8b15dd63": {
        "text_answer": "  The statement is entailed in the Trials as the primary clinical trial has specific eligibility criteria for women with breast cancer who are menopausal and experiencing hot flushes while the secondary clinical trial is for adult patients with HER2negative metastatic breast cancer who are candidates for taxanebased chemotherapy The two trials have distinct populations and conditions for participation",
        "label": "Entailment"
    },
    "57bc58fc-44ce-4938-9bfa-4750bac013ac": {
        "text_answer": "  The statement adverse events were commonplace and severe in both the primary clinical trial and the secondary clinical trial is not entailed in the given trials as the trials do not provide sufficient information to determine the severity of the adverse events The statement only mentions that adverse events occurred in both trials but it does not specify the number or severity of the adverse events that were considered severe The trials only provide the number of adverse events for each type",
        "label": "Contradiction"
    },
    "26091849-cc57-4866-8faa-ac9fb64caf69": {
        "text_answer": "  The statement There are less total adverse events in the primary trial than in the secondary trial but more cases of Cardiacischemiainfarction in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials   The given trials only provide data on specific types of adverse events for each trial The statement does not directly entail or contradict the information provided in the trials However",
        "label": "Entailment"
    },
    "e3e8c1c5-ae1f-4f90-8584-b24096bb580a": {
        "text_answer": "  The statement ipssr risk category very high is a total ipssr score of 65 or higher indicating very high risk is not mentioned in the given inclusion or exclusion criteria Therefore it is neither entailed nor contradicted by the information provided in the trial description",
        "label": "Entailment"
    },
    "21d59751-a53d-4262-8410-9959aa93dea4": {
        "text_answer": "  The statement the number of participants in cohort 1 and cohort 2 of the primary clinical trial are identical is a contradiction to the information provided in the trials   The number of participants analyzed in Arm II cohort 1 is 234 and in Arm III cohort 2 is 241 Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "e57df144-6c3e-4855-a2d3-fcbec0396750": {
        "text_answer": "  The statement There was at least 1 case of infection in both the primary trial and the secondary trial is entailed in the given trials as both trials list Infection as an adverse event in their respective lists Therefore the statement is entailed by the information provided in the trials  However the statement malignant bronchial neoplasm is a malignant neoplasm that affects the bronchial tree is not directly related",
        "label": "Entailment"
    },
    "ecf58a7c-3e70-4ac2-b37f-d96294786b0d": {
        "text_answer": "  The statement candidates with restricted selfcare capability and spending the majority of their waking hours confined to a bed or chair can take part in both the primary clinical trial and the secondary clinical trial is not directly addressed in the given inclusion and exclusion criteria for either trial Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the provided information alone  However the inclusion criteria for both trials do not explicitly exclude individuals",
        "label": "Entailment"
    },
    "eb853544-9c67-43a4-bbfa-c5e35dec2a33": {
        "text_answer": "  The statement is entailed in the trials as both interventions are intravenous infusions given on different days and there is no mention of the location of the infusion in the statement making it applicable to both atrial myxomas and other types of cardiac myxomas",
        "label": "Entailment"
    },
    "95759249-3a95-4735-8ef0-13ec3558aa27": {
        "text_answer": "  The statement is not entailed in the given Trials as there is no mention of a CT scan and blood tests being required for the Primary Trial participants before undergoing mammography The Primary Trial only specifies mammography as a requirement Therefore the statement is contradictory to the information provided in the Trials",
        "label": "Contradiction"
    },
    "1dd105a3-5dd4-423a-a40f-ed78e119e698": {
        "text_answer": "  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in less than 001 of participants is not directly entailed in the given trials as they only provide information about adverse events with a frequency of 048 and 000 in the primary and secondary trials respectively However it is not contradictory to the trials either as the statement allows for the possibility that there",
        "label": "Contradiction"
    },
    "86609ec7-6d7c-4447-94b4-c9c99d5fd5e1": {
        "text_answer": "  The statement is contradictory to the given data in the trial   The statement implies a ratio of 101 for hepatotoxicity cases to cases of hypertension and pancreatectomy combined However the trial data shows a ratio of 32 for hepatotoxicity cases to cases of hypertension Therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "b09ea9c8-e3a2-4c82-bbe8-5e84ea151138": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   The primary trial has different inclusion criteria for Phases I and II In Phase I there is an additional requirement for a responsible companion living with the patient during the study In contrast in Phase II there are two patient groups with different inclusion criteria Group 1 requires chronic opioid therapy while Group 2 does not  Furthermore the secondary trial has its own",
        "label": "Contradiction"
    },
    "3d35c61e-075e-475e-b3aa-15c04db3a579": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   In the trial description the two intervention groups Arm A and Arm B receive different chemotherapy regimens Arm A receives nabPaclitaxel and gemcitabine while Arm B receives nabPaclitaxel and carboplatin Abraxane nabPaclitaxel is the same in both arms",
        "label": "Entailment"
    },
    "7ffa3719-812d-4849-b0c7-d34ab22f35f6": {
        "text_answer": "  The statement the observations from cohort 2 of both the primary and secondary clinical trials were inconclusive in their comparative analysis is not directly entailed in the provided information from the trials The trials only present the results of each study separately without any direct comparison between them Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "a2e2d75b-ce3e-4bf6-bfce-c151b9d183d4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial Perjeta pertuzumab is not used in either intervention group In contrast in the secondary trial Perjeta is mentioned as a novel radiotracer 89Zrpertuzumab used in HER2targeted PETCT but it is not clear whether it is used in both patient groups or not However",
        "label": "Entailment"
    },
    "43a347ac-a46d-47cd-80d5-7d83b23bcde9": {
        "text_answer": "  The statement patients diagnosed with breast cancer can participate in the primary clinical trial is entailed in the given inclusion criteria as breast cancer is explicitly listed as one of the eligible tumor types for the trial",
        "label": "Entailment"
    },
    "8fd1a8ed-8b74-4021-8a90-0400817fda1b": {
        "text_answer": "  The statement there were no patients suffering adverse events in either cohort 1 or cohort 2 of the primary clinical trial is entailed in the given trials data as both cohorts 1 and 2 had a total of 0 adverse events out of 60 patients each 000",
        "label": "Contradiction"
    },
    "2cee68da-471f-4c13-811e-9d7ef91d587e": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions for different patient groups in separate trials The primary trial deals with oral pregabalin while the secondary trial deals with chemotherapy treatments HDMTX and ITDepocyt Therefore the statement is neither entailed nor contradictory based on the provided information",
        "label": "Contradiction"
    },
    "65cfa1ae-05d3-4a90-ad5a-852f3cfdf3fc": {
        "text_answer": "  The statement neither the secondary trial nor the primary trial use cm Number of Participants or a unit of time as their units of measure is not directly entailed in the given trials as they do not explicitly mention the units of measure for the secondary trials outcome measurement objective response rate of HER2negative metastatic breast cancer or the primary trials outcome measurement change in severity of vaginal symptoms However the statement is not",
        "label": "Contradiction"
    },
    "5865807e-233c-4a7d-a900-de4af3bdaaf5": {
        "text_answer": "  The statement the placebo group of the primary clinical trial had a lower rate of iDFS than the neratinib group is contradictory to the given results   The results show that 47 of participants in the neratinib group had iDFS events while 75 of participants in the placebo group had iDFS events Therefore the placebo group had a higher rate of iDFS events than the",
        "label": "Entailment"
    },
    "786542cd-3793-47a4-b954-9b6c5aa2e652": {
        "text_answer": "  The statement is contradictory to the given trials In Intervention 1 there are no electroporation EP injections of V934 given In Intervention 2 there are three EP injections of V934 given but these are not the same injections received by both Cohort A and B Cohort A receives these EP injections first followed by IM injections of V935 while Cohort",
        "label": "Contradiction"
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "text_answer": "  The statement is entailed in the trials as both cohorts use the same instructional CD for paced breathing The difference between the two cohorts lies in the frequency of practice not the instructional material Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "1c4ca195-bc07-4d75-ac19-f7969a20e168": {
        "text_answer": "  The statement every patient in the secondary clinical trial has been treated with raltitrexed and oxaliplatin is not entailed in the given information from the primary and secondary trials The primary trial mentions the use of suramin and paclitaxel while the secondary trial mentions mastectomy surgery but does not provide any information about the specific interventions used in that trial Therefore there is no way to determine if raltitrex",
        "label": "Contradiction"
    },
    "e7204781-fa14-4418-94a4-2660bcd64eeb": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial participants undergo surgeries and receive seven distinct drugs via intravenous IV and oral PO routes as well as subcutaneous SC injections of filgrastim  In contrast the secondary trial only involves participants receiving two distinct drugs everolimus and exemestane both via oral route  Therefore the statement",
        "label": "Entailment"
    },
    "efbed283-d725-4f05-8e7a-3cb43ce470e6": {
        "text_answer": "  The statement is contradictory to the given trial information   In Intervention 1 there are two IM injections of V935 LD given one every other week over a 3week period In Intervention 2 there are also two IM injections of V935 LD given but they are given at different stages in the cycle The first injection is given after a 4week observation period following three EP in",
        "label": "Entailment"
    },
    "6acfb64a-4e08-4cdb-b52d-f0a5c466de4d": {
        "text_answer": "  The given statement The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort is a contradiction to the information provided in the trials   The trials do not provide any information about the results or outcomes of the two cohorts being compared in the statement The trials only provide information about the doses schedules and number of",
        "label": "Contradiction"
    },
    "d595c94d-93d0-410b-9089-0e026867561f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials report the occurrence of anorexia as an adverse event in only one participant out of 50 There is no mention of any eating disorder being experienced by the majority of the trial candidates",
        "label": "Contradiction"
    },
    "8093f77e-bb52-47c9-9c58-4be084c8736b": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the trials  Explanation  The statement is entailed in the trials because the trials provide the number of occurrences for each adverse event in both trials",
        "label": "Entailment"
    },
    "2eb882ed-836b-424c-a9b2-06d97f0b2b9e": {
        "text_answer": "  The given statement cognitive behavioral therapy cbt is included in the interventions for both cohorts of the primary clinical trial is not directly stated in the provided information about Intervention 1 and Intervention 2 However it is mentioned that Intervention 1 includes decision support for providers for prevention based on risk but the specific preventive measures or therapies are not explicitly mentioned Therefore it cannot be definitively determined if CBT is included",
        "label": "Entailment"
    },
    "11daa2f8-2ecf-49f7-aa69-844a2bade4b6": {
        "text_answer": "  The statement Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial who were receiving far lower doses of Empegfilgrastim is not directly entailed in the provided trial data   The primary trial and the secondary trial are investigating different outcomes and have different participant groups The primary trial is comparing the duration of neutropenia between two",
        "label": "Contradiction"
    },
    "4c9638ac-5716-4657-9279-f756aea52867": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the following interventions are mentioned 1 Neoadjuvant Therapy Adjuvant Therapy 2 Doxorubicin hydrochloride Given IV 3 Cyclophosphamide Given PO 4 Paclitaxel Given IV 5 Filgrastim Given SC 6 Capecitabine",
        "label": "Entailment"
    },
    "029ee1b5-a81a-4690-9f03-442dcf0f5e9c": {
        "text_answer": "  The statement We cannot compare the adverse events in the primary trial and the secondary trial as they do not appear to have been recorded for the primary trial is entailed in the given information as there is no mention of adverse events in the primary trial The statement is a logical consequence of the available data",
        "label": "Entailment"
    },
    "ecf95a54-fa38-4492-9597-ce81b5a2b661": {
        "text_answer": "  The statement is entailed in the trials if the trials provide no information that contradicts it Based on the given information the statement is entailed in the trials as both cohorts follow the same instructional CD for paced breathing The difference between the two cohorts lies in the frequency of practicing paced breathing and the administration of chemotherapy The statement does not mention macular edema as an outcome of the trials but it is not contradicted by the given",
        "label": "Entailment"
    },
    "89558178-d2e5-4376-8656-14ba666b44a3": {
        "text_answer": "  The statement the primary clinical trial does not accept patients who have had an organ transplant in the past month however the secondary clinical trial may consider them is a contradiction to the information provided in the given inclusion and exclusion criteria for both trials  In the primary trial the exclusion criteria do not mention anything about organ transplant within the past month However in the secondary trial there is no mention of organ transplant in the inclusion or exclusion",
        "label": "Contradiction"
    },
    "42ac258c-8420-4a90-b427-d7ca64f246af": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial group 2 receives dexmedetomidine not myalgias In the secondary trial group 2 receives vitamin D repletion not dexmedetomidine or myalgias Therefore the statement that group 2 from the primary trial is given 05ugkg of myalgias 5ml is not entailed in the trials",
        "label": "Contradiction"
    },
    "dd7bc677-cddb-4619-893e-aa5b801a0b1a": {
        "text_answer": "  The older male patient with nonmetastatic HER2negative PRnegative breast cancer can be eligible for the secondary clinical trial as the inclusion criteria for gender and breast cancer type are met However the primary clinical trial has specific inclusion criteria for female patients only Therefore the older male patient would not be eligible for the primary clinical trial based on the provided information  So the statement an older male patient with nonmetastatic her2",
        "label": "Entailment"
    },
    "29987f94-8331-4136-92f1-4ea5f5c232b9": {
        "text_answer": "  The statement every participant in the primary clinical trial is administered a minimum of 20mg of mcs110 triweekly is not entailed in the given trial information   Explanation   The statement requires that every participant receives a minimum of 20mg of MCS110 triweekly However the trial information only specifies the dosages of MCS110 and PDR00",
        "label": "Contradiction"
    },
    "823088ba-be25-4691-aa10-9e86b80fbf8c": {
        "text_answer": "  The statement patients in the secondary clinical trial experienced anemia pneumonia and stupor more frequently than those in the primary clinical trial is contradictory to the given data   The data shows that the frequency of anemia pneumonia and stupor in the primary trial is 000 while in the secondary trial the frequency of anemia is 625 pneumonia is ",
        "label": "Entailment"
    },
    "36a5e0dd-7e3a-4362-9726-0836f7a4c64e": {
        "text_answer": "  The statement several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes is not directly entailed or contradicted by the information provided in the trials   The trials only report the proportion of participants with a discernible pattern for gene expression in the Normal Vitamin D Levels and Lownormal Vitamin D Levels groups but they do not specify how many participants",
        "label": "Contradiction"
    },
    "373e57af-cf54-40c6-9906-eff8eb5d7306": {
        "text_answer": "  The statement no adverse events were reported for cohort 1 during the course of the primary clinical trial is entailed in the given trials as both trials report Total 03 000 for the number of adverse events in cohort 1 Therefore the statement is entailed by the information provided in the trials",
        "label": "Contradiction"
    },
    "018fd266-6def-4792-85e4-0b12108281b3": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial there are two groups Intervention 1 Pyridoxine and Intervention 2 Placebo This arrangement can be described as a test group Pyridoxine and a control group Placebo  In the secondary trial there are also two groups Intervention 1 Highdose Oxybutynin Chloride and",
        "label": "Entailment"
    },
    "d44338be-9054-466e-8cb6-388fd8024e9d": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less in terms of body surface area is entailed in the trials because  1 Both cohorts received the same dose of Cetuximab in terms of mill",
        "label": "Entailment"
    },
    "0de75f54-db66-4787-b8a0-7cd21198d8a8": {
        "text_answer": "  The statement the primary clinical trial did not record any patient suffering from the highest level of pain possible for a period of 10 weeks is not directly entailed or contradicted by the information provided in Trials 1 and 2   The trials only report the average pain intensity scores and the change in average pain intensity between the lowdose and highdose intervention groups They do not provide information on the distribution of pain intensity scores or the number",
        "label": "Contradiction"
    },
    "a723722c-a7df-4baa-b02a-3d3f15a03db3": {
        "text_answer": "  The statement a 35 year old female patient diagnosed with ERnegative HER2positive breast cancer could be eligible for the secondary clinical trial and the primary clinical trial is a contradiction   Reasoning   The primary clinical trial includes patients with HER2negative breast cancer while the secondary clinical trial includes patients with ERpositive HER2negative breast cancer Therefore a patient with ERnegative",
        "label": "Contradiction"
    },
    "6056dc64-7161-4c86-a9ac-04579ea09274": {
        "text_answer": "  The statement is entailed in the trials as both trials involve the injection of a substance In the primary trial patients receive denosumab which is a monoclonal antibody with a molecular weight of approximately 147 kDa and a dose of 120 milligrams 0120 g every month In the secondary trial patients receive radioactive Tc99M sulfur colloid which is a radi",
        "label": "Entailment"
    },
    "3f19f518-c46f-4c1f-a738-0066ac81dcc2": {
        "text_answer": "  The statement There are no Xrays transendocardial injections CT scans or MRIs included in the interventions of the primary trial and the secondary trial is not directly related to the statement about an individuals voice making them feel handicapped Therefore the statement does not entail or contradict the statement about the voice making someone feel handicapped The trials only provide information about the interventions used in each study",
        "label": "Contradiction"
    },
    "a86b695b-6bfb-4c1f-982c-2e10c1b392ae": {
        "text_answer": "  The statement one patient or more who were administered with gtx024 1mg in the primary clinical trial saw an increase of more than 10 kilos in lean body mass is a contradiction to the given trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 kg",
        "label": "Contradiction"
    },
    "b7bd2215-d2b2-4cd0-a12a-d12310737373": {
        "text_answer": "  The statement patients who have been treated with gabapentin or pregabalin recently are eligible for participation in the secondary trial but will be excluded from the primary trial is a contradiction to the information provided in the trials  In the primary trial the exclusion criteria state that History of hypersensitivity or allergic reaction spontaneous or following drug administration including gabapentin or pregabalin makes a participant ineligible This directly",
        "label": "Contradiction"
    },
    "2909913c-9739-497b-8bbb-481d3b5c4832": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 6 years are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a history of thrombotic or embolic events such as a pulmonary embolism within the past 6 months are explicitly excluded",
        "label": "Contradiction"
    },
    "33dc8fb6-d0a8-47e4-8052-4a32b5e0c459": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial there is no mention of any intervention involving myalgias for group 2 dexmedetomidine administration In contrast the secondary trial does not involve any intervention related to myalgias for any group Therefore the statement that group 2 of the primary trial receives myalgias 25ugkg or 5ml is contradictory to the given trials",
        "label": "Contradiction"
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials do not provide any information about the outcomes or results of the two cohorts LBH589 With Capecitabine and LBH589 and Lapatinib that could be used to determine if one produced worse results than the other The trials only provide information about the dosing and design of each cohort",
        "label": "Contradiction"
    },
    "bee98681-7738-44a5-b437-0c172bdd3eeb": {
        "text_answer": "  The statement oral administration of interventions is utilized by both the primary and the secondary clinical trials is entailed in the given trials as follows  1 In the primary trial Intervention 1 in both arms Arm I and Arm II involves oral administration of Vitamin B12 and placebo respectively 2 In the secondary trial Intervention 1 in Arm I involves oral administration of memantine hydrochloride while Intervention ",
        "label": "Entailment"
    },
    "987d8384-9e51-497a-a1f4-2646ec7c94f8": {
        "text_answer": "  The statement is entailed in the trials as both interventions in the trial include the use of trastuzumab Herceptin Therefore the statement is true and entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "bfb34bfd-74f8-4f11-b28b-643fe6e79d10": {
        "text_answer": "  The primary trial measures the change in weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms The secondary trial measures the overall response rate ORR in participants with solid tumors  Although both trials have outcome measures they do not share matching measures in their results The primary trial measures the change in hot flash activity while the secondary trial measures the proportion of participants with a best response of complete response or partial response Therefore",
        "label": "Entailment"
    },
    "af417420-0bcb-407d-8470-b73cafe31893": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria The primary trial includes patients with benign breast disease specifically excluding those with malignant ductal carcinoma in situ However the secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ Therefore the statement is contradictory to the primary trial  Regarding the gemcitabineirinotecan regimen it is not",
        "label": "Entailment"
    },
    "511b7c14-9ba0-43ea-98e0-93f217e3ef07": {
        "text_answer": "  The statement Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial is a statement about the use of Arimidex in the trials and is not directly related to the information provided about the interventions or the animal virus Therefore it cannot be determined if the statement is entailed or contradicted based on the given information  However it is clear that Arimidex is used in the primary",
        "label": "Entailment"
    },
    "70c3a676-7000-465c-9d6d-3c53fbf185c0": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials have identical intervention timelines for the standard of care medication given weekly for 24 weeks The difference lies in the additional intervention given to each group reflexology or vitamin D which is initiated at different points in time in each trial However the statement only refers to the intervention timeline for the standard of care medication which is the same in both trials",
        "label": "Entailment"
    },
    "61215857-54c4-4622-afc2-7249194a96f6": {
        "text_answer": "  The statement only those resistant to AI therapy are eligible for the primary clinical trial whereas for the secondary clinical trial this is not a prerequisite is a contradiction of the given trials inclusion criteria  In the primary trial the inclusion criteria state that participants must be resistant to AI therapy In contrast the secondary trial does not mention AI therapy resistance as a requirement for participation Therefore the statement is a contradiction as it asserts that",
        "label": "Contradiction"
    },
    "b56f166c-a9b7-4990-bfb8-d13f0e89f76d": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial there are two interventions with Gefitinib ZD1839 having two different doses making it a total of three distinct drugs  In contrast the secondary trial only has two interventions Zoledronic Acid with vitamin D and calcium supplements and Zoledronic Acid plus radiopharmaceuticals Sr",
        "label": "Entailment"
    },
    "20b96fad-2ca0-4bee-a541-0006c6ff8037": {
        "text_answer": "  The statement is contradictory to the trials provided   The trials report the following adverse event frequencies for each trial  Trial 1 Glisolamide n13  Total adverse events 113 769  Rapid disease progression 113 769  Increased pleural effusion 113 7",
        "label": "Entailment"
    },
    "9e2bec72-4318-4cf8-9ed8-82a572ce6d55": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   In the primary trial the inclusion criterion for breast tumor size is 1 cm in diameter In the secondary trial there is no mention of breast tumor size as an inclusion criterion However the statement mentions a tumor of 1300mm in diameter which is significantly larger than 1 cm Therefore a patient with a tumor of ",
        "label": "Contradiction"
    },
    "baea8626-3768-47aa-a4ba-e792164302fd": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial uses a higher dose of Lenalidomide 5mg orally daily for 57  3 days compared to the dose of Lapatinib used in intervention 1 of the secondary trial 1500 mg orally daily for 6 weeks followed by 1500 mg orally plus 80 mgm2 IV weekly for an additional ",
        "label": "Entailment"
    },
    "f2d85883-6334-4948-901e-22cc11da66ac": {
        "text_answer": "  The statement females with evidence of ER positive HER2 negative breast cancer are eligible for the primary trial is entailed in the inclusion criteria of the trial   Explanation   The inclusion criteria for the primary trial state that for Phase 2 females with breast cancer must be ER positive andor PR positive but HER2 negative and have failed a hormone therapy and a CDK46 inhibitor to be eligible",
        "label": "Entailment"
    },
    "f1494243-0e25-48d1-b7d8-e92ffed41e1d": {
        "text_answer": "  The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not directly entailed or contradictory to the given trial data The trial data mentions only the following psychiatric adverse events suicidal ideation and ventricular tachycardia which are not the same as an eating disorder or Schizophrenia Therefore the statement is neither entailed nor contradict",
        "label": "Contradiction"
    },
    "5be979ed-e272-48c6-b301-c5464cc07730": {
        "text_answer": "  The statement the secondary clinical trial had a higher turnout than the primary clinical trial is not entailed in the given trial information   The primary trial had 13 participants analyzed while the secondary trial had 30 participants analyzed However the statement does not specify what is meant by turnout In the context of clinical trials turnout could refer to various things such as the number of patients screened the number of patients enrolled",
        "label": "Contradiction"
    },
    "348ce220-f650-4df2-9593-586ddaabe491": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the mean arm circumference changes between the acupuncture and waitlist groups at 6 weeks   The statement the primary clinical trial showed no difference in the improvement rate of lymphedema between acupuncture patients and those on the waiting list is not directly stated in the trials However we can calculate the difference in mean arm circumference changes between the two",
        "label": "Entailment"
    },
    "2980900b-74b7-4c96-8ab9-91fc994211d1": {
        "text_answer": "  The statement is entailed in the trials as both trials are reporting different outcome measures The primary trial is measuring the number of participants with treatmentemergent adverse events AEs while the secondary trial is measuring the change in total sleep time using polysomnography PSG The statement correctly identifies the different outcome measures being assessed in each trial",
        "label": "Entailment"
    },
    "79bb0bb4-31cf-45e2-8fae-475bfdbd6a09": {
        "text_answer": "  The statement is contradictory to the given trials as there is no information provided in the trials regarding radiation therapy or its doses for any of the participants Therefore it cannot be determined if the statement is entailed in the trials or not",
        "label": "Contradiction"
    },
    "e5fb73ea-4e3b-47b2-84ac-a4d403b646ba": {
        "text_answer": "  The statement most of the adverse events detected in the primary trial were not blood and bone marrow related contrasting the secondary trial which observed an abundance of such is a contradiction of the given data  Explanation  The statement implies that in the primary trial a smaller proportion of adverse events were related to blood and bone marrow compared to the secondary trial However the data provided shows that in the primary trial 100",
        "label": "Contradiction"
    },
    "49db6e75-199e-4c15-bb9b-6cf677d9c421": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial inclusion criteria The secondary trial does require confirmation of mutations in certain genes for eligibility Therefore the statement is contradictory to the information provided in the trial description",
        "label": "Entailment"
    },
    "b00e48fb-d5db-46f8-8f16-6f538d178b26": {
        "text_answer": "  The statement is contradictory to the given trials as there are no mentions of cardiac or psychiatric adverse events in either the primary or secondary trials according to the provided data The statement suggests that there is a high frequency of these types of adverse events but the trials indicate a frequency of 000",
        "label": "Contradiction"
    },
    "1c968571-9618-4a86-af59-6e8367b1128f": {
        "text_answer": "  The given statement is not directly entailed in the provided trial results as the trial results do not include information about the survival period post the primary clinical trial for the majority of patients or the lifespan of any patient under 2 years The trial results only report the median survival times for the two groups",
        "label": "Contradiction"
    },
    "82aff6ce-3305-4fb1-87c0-28f4a1e8a981": {
        "text_answer": "  The statement is not entailed in the trials as given   Explanation   The statement both breast cancer and ovarianperitoneal cancer patients involved in the primary clinical trial are administered 1000 mcgday of talazoparib is not explicitly stated in the trials While it is true that both types of cancer patients were given talazoparib in Part 1 and 2 the",
        "label": "Contradiction"
    },
    "24b44ec0-b0a4-4b5a-9028-164eda456529": {
        "text_answer": "  The statement is entailed in the given trial information The alloMSCs intervention involves administering 100 million cells in 20 injections of 04ml each while the placebo intervention involves administering Buminate solution in the same number and volume of injections 20 injections of 04ml each However it is not explicitly stated that the placebo is a identical solution to the alloMSCs",
        "label": "Entailment"
    },
    "f3091230-221d-4c82-9d37-06e04c12ba48": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial excludes a participant if they have received any experimental agents within 4 weeks prior to the study registration date but it does not mention organ transplant specifically The secondary trial does not mention organ transplant in",
        "label": "Contradiction"
    },
    "dfcbb31f-65e0-4847-9840-536eff03c1f3": {
        "text_answer": "  The statement only patients who demonstrated positive responses to previous Herceptin treatments are eligible for the primary clinical trial is not directly entailed in the inclusion criteria provided in the trial description   The trial description states that patients with HER2 FISH tumors will receive vinflunine and trastuzumab while patients with HER2 FISH negative or unknown HER2 status will receive single agent vinflunine It does not specify that",
        "label": "Contradiction"
    },
    "6a2679df-a2a3-40cf-8252-2f8bf8584b8d": {
        "text_answer": "  The statement abdominal examination is an assessment of the abdomen including the organs within the abdominal cavity is not directly related to the information provided in the trials The trials only mention the administration of Suramin and Paclitaxel to patients in the primary and secondary trials Therefore the statement is neither entailed nor contradicted by the information in the trials",
        "label": "Entailment"
    },
    "d5383c8a-360f-4e17-af4e-2f0a05fc2b1a": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measures The primary trial investigates the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial examines the impact of Physical Therapy on pain reported by participants with benign pericardial germ cell tumor using the Numeric Pain Rating Scale The trials do not share the same outcome measure and the statement does not follow from the information",
        "label": "Contradiction"
    },
    "2dac87e4-2a34-42e1-8aec-d2a23d61269a": {
        "text_answer": "  The statement femtogram per milliliter per microgram is a unit of concentration equal to femtogram per milliliter divided by micrograms is a mathematical conversion and is not related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it neither entails nor contradicts the information provided in the trials",
        "label": "Entailment"
    },
    "4ecc7d3a-ada3-4bda-8236-f0450fc709af": {
        "text_answer": "  The statement the primary clinical trials results demonstrate that the placebo arm outperformed the Arm A intervention in terms of overall response rate meanwhile the zoledronic acid group in the secondary clinical trial showed faster time to first onstudy SRE than the denosumab group is not directly entailed in the given trials as they address different outcomes and patient populations  The primary trial compares Arm A and Arm B in terms of overall",
        "label": "Contradiction"
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "text_answer": "  The statement There are no conditions on mental mental health bodyweight age KarnofskyECOG score or previous treatments that need to be met in order to be eligible for the primary trial is not directly stated in the given inclusion and exclusion criteria However based on the provided information it appears that there are no explicit exclusion criteria related to mental health bodyweight age or previous treatments other than the number of prior chemotherapy lines",
        "label": "Contradiction"
    },
    "a8e679cc-cd10-409c-8434-8bb059146815": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The most commonly occurring adverse event across the patient cohorts of the primary trial was syncope which occurred in 1667 of the patients not 5000 The statement provided is an error",
        "label": "Entailment"
    },
    "d5f5e4f5-9a58-485a-8646-649ce93e37c7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The participants in the primary trial do not receive highintensity focused ultrasound therapy but rather whole breast radiation therapy The participants in the secondary trial receive intramuscular injections of Fulvestrant not intravenous injections",
        "label": "Entailment"
    },
    "53e8b3b4-40dc-4ffe-b555-a65fd7741dbf": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However the statement does contain elements that can be found in the exclusion criteria for both trials   For the primary trial the exclusion criteria include Inability to safely undergo general anesthesia andor per",
        "label": "Entailment"
    },
    "d0600d22-c3de-4028-82a5-a42008e2018d": {
        "text_answer": "  The statement There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial is an entailed statement based on the given trials   The trials provide the number of adverse events and their respective frequencies in each trial The statement is entailed because the trials show that there is a higher frequency of Biliary colic 16 or 1667 in the secondary trial vs 3",
        "label": "Entailment"
    },
    "0a144293-fbab-4ba1-ad15-cf05a8624a1c": {
        "text_answer": "  The statement is entailed in the Trials as the trials have different outcome measures The primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using RECIST criteria Therefore the statement is entailed in the trials as they are two distinct studies investigating different outcomes",
        "label": "Entailment"
    },
    "c66df8c2-afad-4638-a1c2-5539fc03a2be": {
        "text_answer": "  The statement failsafe system device is a device designed to prevent malfunction unsafe or unauthorized operation of a device or system is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed in the trials or not The trials only provide information about the outcomes of two different interventions Nuevo Amanecer Peer Support Program and the use of a device to assess positive margins during surgery",
        "label": "Entailment"
    },
    "67b93677-87f6-4a11-8dea-66a3c2242b19": {
        "text_answer": "  The statement patients suffering from frontotemporal dementia or mixed dementia can participate in the primary clinical trial is contradictory to the trials inclusion criteria The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Frontotemporal dementia and mixed dementia are both types of dementia that",
        "label": "Entailment"
    },
    "abed7fca-4cb8-42bb-a206-bf1c54f9af99": {
        "text_answer": "  The statement have itch is a question about whether an individual has or had itching is not directly related to the information provided in the trials The trials focus on specific outcome measurements related to lymphoedema and the effects of acupuncture and sulforaphane supplementation The statement does not entail or contradict any information presented in the trials",
        "label": "Entailment"
    },
    "5ff118a6-d62c-473d-8935-1767a378c92a": {
        "text_answer": "  The statement not all patients within the primary clinical trial are required to undergo a spect scan is entailed in the given trials as some patients in Intervention 1 are receiving Active Breathing Coordination ABC and having SPECT scans while some patients in Intervention 2 are not receiving ABC and also having SPECT scans Therefore the statement is entailed by the trials as they describe two different groups with different interventions and not all",
        "label": "Entailment"
    },
    "4eb8855e-766e-4588-a42f-655ca3d80140": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial administers its intervention orally sublingually not intravenously and the secondary trial also employs an oral route by mouth Therefore the statement is contradictory to the information given in the trials",
        "label": "Entailment"
    },
    "f4e91f1d-d645-4759-904d-12e509336562": {
        "text_answer": "  The statement the symptoms experienced by patients who didnt receive topical cryotherapy in the primary clinical trial were more intense than those who did receive the treatment can be verified by comparing the median aAUCpa values of the two arms Arm I and Arm II in the trial  The median aAUCpa value for Arm I Cryotherapy was 14 117 to 68 and for Arm II ",
        "label": "Entailment"
    },
    "ca80b7bd-73a6-4c6a-9ab7-3e1dc789f12c": {
        "text_answer": "  The statement cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial cannot be determined from the given information as the trials measure different outcome measures The primary trial focuses on breast cancerspecific quality of life using the FACTB instrument while the secondary trial assesses intraoperative success in addressing positive margins using a device Therefore the statement is neither entailed nor contradictory based on the provided data",
        "label": "Entailment"
    },
    "e412ecde-3195-42c6-b125-7d2697ea89c1": {
        "text_answer": "  The statement all the participants in the primary trial receive lower doses of alt801 compared to the secondary trial participants is entailed in the trials  Explanation  In the primary trial the doses of PF06647020 are given as 02 mgkg and 05 mgkg for Interventions 1 and 2 respectively There is no mention of ALT",
        "label": "Entailment"
    },
    "b4fd327d-375e-4021-98af-a59ee4e30c0b": {
        "text_answer": "  The statement a recently diagnosed ERpositive HER2negative breast cancer patient who is 20 years old may be suitable for the secondary clinical trial as well as the primary clinical trial is neither entailed in the primary trial nor contradictory to it as the age criterion is different in the two trials The primary trial includes patients who are 18 years of age or older while the secondary trial includes patients who are 18 years",
        "label": "Entailment"
    },
    "911ba31e-f28f-4c5b-8b0e-fa16e58ecc29": {
        "text_answer": "  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is a comparison of the frequency of specific adverse events between the two trials The statement does not directly relate to the question about the extent breast cancer treatment has disrupted selfcare Therefore the statement is neither entailed nor contradictory to the given information",
        "label": "Entailment"
    },
    "9b75138c-e074-43f0-866d-9a43ce7be217": {
        "text_answer": "  The statement patients involved in the primary clinical trial are administered oral drugs twice daily for an entire month is not directly entailed in the given intervention description The intervention description specifies that patients receive oral lapatinib and oral tamoxifen once daily on days 128 Therefore the statement is not an exact representation of the intervention and is considered a contradiction",
        "label": "Contradiction"
    },
    "bcbde299-e3e8-40e6-8cea-d843a44e68d6": {
        "text_answer": "  The statement is entailed in the given intervention description as it explicitly states that the subjects are treated with partial breast irradiation which implies a specific arrangement of treatment cycles with dosage and delivery of radiation therapy",
        "label": "Entailment"
    },
    "6ee5619b-ec91-4d55-b57a-a69eb3315c3d": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is comparing two different interventions Hydrophor and MediHoney in terms of their effects on the skin of cancer patients undergoing radiation therapy This is an observation of different interventions on the study participants  The secondary trial is comparing two different treatment regimens Arm A1 and Arm A2 in terms of their effects on patients with CRPC ABC or",
        "label": "Entailment"
    },
    "f7247f7f-056b-4725-b771-4f4388a643aa": {
        "text_answer": "  The statement over 34 patients in the primary trial treated with lapatinib 800 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is not entailed in the given trial results   The trial results only report the outcomes for the armgroup of participants who received Lapatinib 1000 mg  NabPaclitaxel with",
        "label": "Contradiction"
    },
    "a85e8f5b-fb4f-4adc-a020-d40a42e8be96": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In Intervention 1 two IM injections of V935 LD are given every other week over a 3week period In Intervention 2 the first two IM injections of V935 LD are given after a 4week observation period following three EP injections of V934 LD Therefore the statement that the same two IM injections",
        "label": "Entailment"
    },
    "e501b32a-a182-4275-bcdf-88aca4446cf9": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  1 In the primary trial the inclusion criteria state that patients must have histologically or cytologically confirmed breast adenocarcinoma and radiographic evidence of at least one bone metastasis There is no requirement for ER PR or HER2neu status However the statement does not contradict the primary trial as it only adds an additional requirement of ER PR",
        "label": "Entailment"
    },
    "c77be931-75c0-4036-a07d-7d49b5b9fcc6": {
        "text_answer": "  The statement performance status condition fulfillment is a prerequisite for the secondary clinical trial but not for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes a requirement for subjects to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigatorsubinvestigator among patients with advanced or recurrent",
        "label": "Contradiction"
    },
    "993a3b60-def6-421c-a8a5-964062336a2c": {
        "text_answer": "  The statement is not entailed in the trials as the statement mentions a reduction in tumor diameter by 40 while the trials report a change in Ki67 expression with a percentage change of 40 63 to 29 These two outcomes are not directly comparable as Ki67 expression is a biomarker for tumor proliferation and not a measure of tumor diameter Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not explicitly state that it uses a 3week cycle for its intervention in the given text However it does describe the administration of PF05212384 and docetaxel in cycles with a 21day length   The secondary trial does not have a cyclic treatment described in the given text Instead it",
        "label": "Entailment"
    },
    "7b76f6bb-6bf2-4bec-8409-9c4b90cc81c8": {
        "text_answer": "  The statement is entailed in the trials as both trials are studying the same drug empegfilgrastim and the trials are comparing different doses of the drug However the primary trial and the secondary trial have different outcome measurements In the primary trial the outcome measurement is the duration of neutropenia with CTCAE grade 34 while in the secondary trial the outcome measurement is the incidence of CTCAE grade 34",
        "label": "Entailment"
    },
    "19cdc906-c8e3-498d-b33e-08ad9037af5d": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report different outcome measurements The primary trial reports Time to Progression TTP in months while the secondary trial reports the Number of Participants with Objective Response based on Data Review Committees Assessment The statement does not explicitly mention the units of measurement or the trials names making it an indirect comparison Therefore it cannot be definitively determined if the statement is entailed contradictory",
        "label": "Contradiction"
    },
    "41ef54ae-5826-49c3-85d2-1da610317f26": {
        "text_answer": "  The statement participants in the primary trial receive 4 different drugs throughout the study duration is entailed in the trial description The four different drugs used in the trial are epirubicin cyclophosphamide docetaxel and trastuzumab Therefore the statement is entailed in the trial description  The statement almost all of the time is a response indicating that something happens or happened almost all of the time",
        "label": "Entailment"
    },
    "1a076a19-c76d-4de0-b7de-473c0e278bbe": {
        "text_answer": "  The statement dyspnea was frequently recorded as an adverse event in both cohorts of the primary clinical trial is not directly entailed in the given trials as dyspnea is not mentioned as an adverse event in either cohort The trials only report adverse events such as Disseminated intravascular coagulation Death NOS Edema limbs Fatigue Hepatic failure Alanine aminotransfer",
        "label": "Contradiction"
    },
    "4023d560-6425-4207-aa76-543be30fd786": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention is not focused on harnessing the strengths of surgical interventions or regenerative medicine but rather on Yttrium90 Radioembolization which is a type of radiation therapy   The secondary trial intervention is focused on a combination of two targeted molecular therapies ibrutinib and MEDI4736 in the context",
        "label": "Entailment"
    },
    "6ee2e04c-88fc-4447-a477-18b2564aca4e": {
        "text_answer": "  The statement an adult patient diagnosed with ilddpld within the last 36 months with a life expectancy of 184 days would be eligible for the primary trial is not directly entailed in the inclusion criteria provided   The inclusion criteria state that patients must have a life expectancy of greater than 3 months The patient described in the statement has a life expectancy of 184 days which is less than the required minimum",
        "label": "Contradiction"
    },
    "b6af5ca8-21c0-43c5-898b-53e45b5e122a": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However it can be inferred from the primary trial inclusion criteria that candidates must have undergone a mammography within the past 30 days to be eligible for the study Therefore the statement that candidates must not undergo any form of imaging test before they are eligible for the primary trial but they must have a mammography to qualify for",
        "label": "Contradiction"
    },
    "4665519b-6dba-440f-9cc3-677ab616ecd6": {
        "text_answer": "  The statement a CT scan not a mammography is needed for consideration in the primary trial while for the secondary trial no imaging test is required is contradictory to the information provided in the trials inclusion and exclusion criteria  In the primary trial mammography is a required imaging test for inclusion and in the secondary trial no specific imaging test is mentioned as a requirement for inclusion However the statement suggests that a CT scan",
        "label": "Contradiction"
    },
    "f66e21d9-801f-4613-99da-c033734189e4": {
        "text_answer": "  The statement in both the primary and secondary clinical trials eligibility is not determined by the gender of the individual is entailed in the given trials as there is no mention of gender as a criterion for inclusion or exclusion in either trial The trials focus on other factors such as age cancer stage receptor status performance status organ function and contraceptive use Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "ba873942-b869-4596-bbd6-30d54c94e31b": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site However the intervention 1 uses a handheld gamma camera while intervention 2 uses intraoperative gamma probes The amount of radioactive material used is the same in both interventions but the method of detection is different",
        "label": "Entailment"
    },
    "3558390b-24a7-45e7-84f1-f512e669dcef": {
        "text_answer": "  The statement the secondary and primary clinical trials showed a complete absence of recorded adverse events in their cohorts is entailed by the given data since both trials reported a total of zero adverse events in their respective cohorts for all reported events Adverse Events 1 and Adverse Events 2",
        "label": "Entailment"
    },
    "84f10108-19b7-499f-9144-b3e6c0b253d5": {
        "text_answer": "  The statement appendiceal carcinoma pN0 from AJCC 7th ed is not directly related to the information provided in the primary or secondary trials The primary trial does not mention the type or stage of cancer in the participants and the secondary trial only mentions HER2positive unresectable LABC or mBC Therefore the statement does not entail or contradict the information in the trials",
        "label": "Entailment"
    },
    "94df8c14-d1c9-44cb-9f6d-1706044cbc9a": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both Cohort A and B receive the same two IM injections of LD V935 at the same point in the cycle However the trials have different administration schedules for each cohort   In Cohort A two IM injections of V935 LD are given one every other week over",
        "label": "Entailment"
    },
    "4f9e48d7-08cc-4fa3-a317-4f3f23ebf19d": {
        "text_answer": "  The primary trial does not provide information about the measurement of Ki67 expression in tumors Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "ef6928bd-e4ac-44f6-a7bd-292a728df94b": {
        "text_answer": "  The statement There were no cardiac or psychiatric AEs recorded during the primary trial and the secondary trial is entailed in the given trials as both trials report a total of zero events for cardiac and psychiatric adverse events in each trial  However the statement precordial catch syndrome is a condition in which there is musculoskeletal chest pain characterized by brief sharp discomfort associated with inspiration accaha is not directly related",
        "label": "Contradiction"
    },
    "a3ad31e2-9017-438a-bbc2-acab87940134": {
        "text_answer": "  The statement over 50 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR can be entailed by the given trial results if the percentage of participants with CR or PR is indeed over 50   The trial results state that 53 of the 60 participants 883",
        "label": "Entailment"
    },
    "5499c5cb-97fa-4905-b163-7f5830cd59b9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there were no participants in Group 1 Healthy Volunteers who presented with lesions However in the secondary trial Group 1 Hydrophor did not involve the detection of lesions as an outcome measurement Instead the focus was on radiation dermatitis and hyperpigmentation The participants in Group 1 of the",
        "label": "Contradiction"
    },
    "06695494-b56b-49da-9166-b0aae3f322f3": {
        "text_answer": "  The statement neither the secondary trial nor the primary trial use cm Number of Participants or a unit of time as their units of measure is not directly entailed in the given trials as they do not explicitly mention the units of measure for the secondary trial being cm Number of Participants or a unit of time However the statement is not contradicted by the information provided in the trials as well",
        "label": "Contradiction"
    },
    "c36a826d-892a-4115-af40-e60050fffd8a": {
        "text_answer": "  The statement more than 95 of patients in the primary trial suffered aes is contradictory to the given trials data The trials data states that only 2 out of 35 patients 571 experienced adverse events Therefore less than 95 of patients suffered adverse events",
        "label": "Entailment"
    },
    "564d9a7d-327b-45be-af87-1971e15a9db4": {
        "text_answer": "  The statement 1p33p32 is a chromosome band present on 1000 of cohort 1 of the primary trial suffered some kind of adverse event is not entailed in the provided trial data The trial data only reports the number of participants with serious and nonserious adverse events for two different dose levels of the MVAbrachyuryTRICOM vaccine It does not provide any",
        "label": "Contradiction"
    },
    "17414a49-7410-41fe-ab90-99311491d367": {
        "text_answer": "  The statement is not entailed in the trial description provided The trial description states that participants receive 100 mgm2 of lapatinib orally once daily not twice daily as stated in the given statement Additionally tamoxifen is given orally once daily not mentioned in the statement Therefore the statement is contradictory to the trial description",
        "label": "Contradiction"
    },
    "6ab38a80-a2a5-40f1-a8d5-250db9f54740": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the intervention in Arm I Zoledronic Acid is given intravenously IV not subcutaneously   In the secondary trial all interventions in both arms Granisetron hydrochloride Prochlorperazine Palonosetron hydrochloride and Dexamethasone",
        "label": "Entailment"
    },
    "52db54bd-4dbe-4778-b5c4-30a8e4ce0a1f": {
        "text_answer": "  The statement None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes is not directly stated in the provided trial results However the statement The outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes implies that the absence of a discernible pattern would be reported as a result Since neither coh",
        "label": "Entailment"
    },
    "14678a23-57ea-4d56-a87a-c1a910af9e78": {
        "text_answer": "  The statement the majority of patients in the primary trial experienced complete response by week 42 is not entailed in the given trial results as there is no information provided about the number or percentage of participants with complete response CR after week 24 The trial results only report the number of participants with CR partial response PR or stable disease SD at week 12 and week 24 Therefore the statement is contradictory to the",
        "label": "Contradiction"
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "text_answer": "  The statement is entailed in the Trials with the following justification  The statement the primary trial and the secondary trial both use pCR as their outcome measurement there is a small difference in results between the two cohorts of the primary trial whereas in the secondary trial Arm 2 had worse results than arm 1 as a higher percentage of arm 2 patients experienced pCR is entailed in the given trials as follows  1",
        "label": "Entailment"
    },
    "6892893c-5c7b-492b-950f-e155bd928ebe": {
        "text_answer": "  The statement is entailed by the given trials as the trials do not report any adverse events for their respective participants in Adverse Events 1 and the statement explicitly mentions that there are no adverse events for the participants in the Assamese language trials",
        "label": "Entailment"
    },
    "98a95bef-b43a-4582-8b58-d0c154824cd0": {
        "text_answer": "  The statement individuals diagnosed with diffuse parenchymal lung disease regardless of the time of diagnosis can participate in the primary clinical trial is not explicitly stated in the inclusion or exclusion criteria provided Therefore it cannot be definitively determined if the statement is entailed in the trial or contradicts it without additional context or information  However the statement does not contradict the trial as there is no explicit exclusion of individuals with diffuse p",
        "label": "Entailment"
    },
    "b799b56b-51cd-4200-852f-f80a347de63e": {
        "text_answer": "  The statement participants for the primary clinical trial must be between 18 and 60 years of age and not underweight or overweight is not explicitly stated in the given inclusion and exclusion criteria The criteria only mention the age requirement and the diagnosis and measurability of the breast cancer Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "6ffedb4b-9ff8-445a-9e5f-872d54ca58fb": {
        "text_answer": "  The statement adverse events were entirely absent in the conduct of the primary clinical trial is contradictory to the given data The data shows that there were adverse events reported in the trial with a total of 5 out of 25 participants experiencing adverse events 2000 Therefore the statement is contradictory to the given information",
        "label": "Entailment"
    },
    "91d0039d-b186-4f52-b214-1000341d3f2c": {
        "text_answer": "  The statement adverse events have been recorded for participants of the secondary clinical trial is entailed in the given trials data as there is a section for recording Adverse Events in both the Primary and Secondary Trials However the statement does not provide any specific information about the number or type of adverse events that have occurred which is not explicitly stated in the given trials data",
        "label": "Entailment"
    },
    "0c5c681e-d64b-41e8-add7-b34f03573370": {
        "text_answer": "  The statement a pulmonary embolism within the last two months does not preclude participation in the primary clinical trial and the investigators decision holds no bearing on ones eligibility for the secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for either the primary or secondary trials Therefore it cannot be definitively determined if the statement is entailed in the trials or if it is contradictory based on the provided information",
        "label": "Contradiction"
    },
    "3ce5a661-e1a9-4164-935e-15563602eefc": {
        "text_answer": "  The statement 75 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is contradictory to the given trials as  1 The total number of patients in the primary trial is 13 and the number of patients who experienced increased pleural effusion is 2 which is less than 75 of the total number of patients 2 The total number of patients in Trial 1 is ",
        "label": "Entailment"
    },
    "2630006c-6708-4c09-a946-aefe1859770d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as both the primary and secondary trials include female subjects who meet certain criteria The primary trial includes postmenopausal females and the secondary trial includes women with locally advanced recurrent or metastatic breast cancer who are estrogenreceptor positive Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "c5fe1272-e91c-44cd-888d-359ad43e34c4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as there are no instances of adverse events such as swelling hypothermia or confusion reported in either the primary or secondary trials according to the given data",
        "label": "Contradiction"
    },
    "4be496e4-ba05-47a1-bc0f-b8627e47becb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial reports the median time to progression TTP in months for a total of 156 patients 72 in Arm A and 84 in Arm B while the secondary trial presents the number of participants with objective response CR and PR based on RECIST criteria for a separate group of 63 participants receiving Sunitinib plus Capecitab",
        "label": "Entailment"
    },
    "31b59e3d-4bb8-47ea-a7a1-9d8523245970": {
        "text_answer": "  The statement epidermal hyperplasia is a hyperplasia of the epidermis is not directly related to the inclusion criteria or exclusion criteria of the primary trial The trial focuses on patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast who are considering aromatase inhibitor therapy and their postmenopausal status among other eligibility criteria The statement about epidermal hyperplasia does",
        "label": "Entailment"
    },
    "981d8b53-f02f-4845-af5f-a1d5abc2d63c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections every 4 weeks while in the secondary trial no information was provided about any injections related to the interventions However the secondary trial mentions the use of radioactive Tc99M sulfur colloid for lymphoscintigraphy but it does not specify that any injections were given",
        "label": "Contradiction"
    },
    "0cf140db-a8c7-47ee-9753-c46c056fe1b1": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial does not provide sufficient information about the dosages of MM121 and Paclitaxel received by the participants The statement only mentions that the participants in the primary trial received the highest weekly dosages of these drugs but it does not specify which trial or cohort they belong to  In contrast the secondary trial does provide information about the dosages of MM12",
        "label": "Contradiction"
    },
    "08dad9c0-a333-4791-b845-79b549c31890": {
        "text_answer": "  The statement in the primary clinical trial adverse events were reported by more than half of the participants is contradictory to the given trial data The trial reported a total of 2 adverse events out of 35 participants which is equivalent to 571 This is significantly less than 50 of the participants Therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "da125a54-e88c-40a5-8134-0bd021287c6f": {
        "text_answer": "  The statement the primary clinical trial accepts participants with measurable metastasis or whose disease has disseminated to various body parts is entailed in the trial description as stated in the following criteria  1 Metastatic disease M1 2 Multiple sites of new disease that is clinically obvious metastatic disease eg multiple sites of new osseous disease  Therefore the statement is entailed in the trial",
        "label": "Entailment"
    },
    "3fca106b-449b-416e-a961-bf0dc8999ddb": {
        "text_answer": "  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed in the given trials as follows  1 The frequency of Ascites in the primary trial is 2223 090 and in the secondary trial it is not mentioned Since the frequency of an event in one trial being higher than the",
        "label": "Entailment"
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "text_answer": "  The statement is entailed in the trials as both trials include the use of cyclophosphamide Paclitaxel and pegfilgrastim in their interventions However it is important to note that in the primary trial Paclitaxel is given in combination with Carboplatin while in the secondary trial it is given in combination with docetaxel Therefore while the statement is entailed in terms of the use of the named",
        "label": "Entailment"
    },
    "32775858-8e4c-41e3-87c3-2c60dbc780ee": {
        "text_answer": "  The statement a patient with a metastasized tumour of 10mm in radius determined through biopsy and MRI would not be eligible for the primary clinical trial or the secondary clinical trial is a contradiction to the inclusion criteria of both trials  In the primary trial the inclusion criteria state that there is no specific size limitation for the primary tumour only requiring it to be greater than 2 cm in diameter In the secondary trial",
        "label": "Contradiction"
    },
    "ccc2b2e3-5588-4eed-8a05-67fb21c29a9b": {
        "text_answer": "  The statement is contradictory to the trials provided   Explanation   The statement claims that in the secondary clinical trial patients only experienced adverse events such as eyelid oedema upper gastrointestinal haemorrhage and chest pain but no such events were observed in the primary clinical trial However the trials provided do not support this statement   In the secondary trial there were a total of",
        "label": "Contradiction"
    },
    "796289cc-1400-4a5c-9da0-d19104d6aae4": {
        "text_answer": "  The statement the first cohort of the primary clinical trial had more participants than the second cohort is not entailed in the given trial data Both trials had the same number of participants analyzed which was 1420",
        "label": "Contradiction"
    },
    "9b5ee8d1-9b19-4f79-a80f-58422f1f5cee": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 the dose of cyclophosphamide is 600 mgm2 and the dose of eribulin is 14mgm2 In Intervention 2 the dose of cyclophosphamide is also 600 mgm2 but the dose of docetaxel is 75 mgm",
        "label": "Entailment"
    },
    "7852457b-3915-431f-adbf-cdba2b736c46": {
        "text_answer": "  The statement lig4 gene mutation is a change in the nucleotide sequence of the lig4 gene is not related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction The trials only report the occurrence of adverse events and their respective frequencies",
        "label": "Entailment"
    },
    "58db966b-cb5c-426f-8b8e-f9e68adc1531": {
        "text_answer": "  The statement is entailed in the trials description In the trials description it is explicitly stated that cohort 2 receives a dosage of enzalutamide that is twice as high as the dosage received by cohort 1 Therefore the statement is entailed in the trials description",
        "label": "Entailment"
    },
    "d5c262d5-584c-4417-a768-9374cd6c8bc2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial no adverse event with the name vomiting was recorded so it cannot have been the most prevalent adverse event with an incidence rate above 10   In the secondary trial there were 2 cases of vomiting out of 128 participants which is an incidence rate of 156 This is",
        "label": "Contradiction"
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "text_answer": "  The statement Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream is not entailed in the given trials as there is no data provided on a testosterone cream group in the trials Therefore it is neither entailed nor contradicted by the information given",
        "label": "Contradiction"
    },
    "a2cdb319-3410-467d-94f0-0908534ebf22": {
        "text_answer": "  The statement is not entailed in the given trial information as the trials do not provide any information regarding the outcome of the study including the number of participants who were found dead in each arm The statement only mentions the frequency and duration of the interventions but it does not entail any information about the outcomes or endpoints of the trial Therefore the statement is neutral with respect to the given trial information",
        "label": "Contradiction"
    },
    "a9497198-5380-4af2-ace4-eb2e904a855a": {
        "text_answer": "  The statement doctor and I shared responsibility for deciding which treatment is best for me is not directly entailed nor contradictory to the information provided in the inclusion and exclusion criteria for the primary and expansion phases of the clinical trial The statement pertains to the role of the doctor and the patient in making treatment decisions while the criteria focus on eligibility and exclusion factors for trial participation based on various medical and demographic conditions",
        "label": "Contradiction"
    },
    "bd70ab1b-2bfb-4294-9ca7-01e1e2b670b7": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial or the secondary trial is entailed in the given trials as both trials have identical inclusion criteria for gender Therefore gender is not a factor that determines eligibility for either trial  The statement insufficient RNA yield is an indication that an RNA isolation procedure yielded an insufficient amount of RNA to proceed is not directly related to the given trials as they do",
        "label": "Entailment"
    },
    "56e88bbd-7a3c-4a3b-a6cf-3f9b9e632b53": {
        "text_answer": "  The statement the quantity of adverse events in the cohorts was found to be the same in the primary clinical trial and the secondary clinical trial is entailed in the given trials data if and only if the following conditions are met  1 The trials have the same number of participants in each cohort 2 The same adverse event type is being referred to in both trials Adverse Events 1 in this case 3 The number",
        "label": "Entailment"
    },
    "26583828-8ea0-4211-a688-3deda44eeec4": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial reported hypoglycaemia hyponatraemia and hypokalaemia as common adverse events among participants is not directly entailed in the given trials data   The trials data only provides the frequency of specific adverse events for each trial but it does not mention hypoglycaemia hyponatraemia and hypokalaemia as common adverse",
        "label": "Contradiction"
    },
    "8dd8adde-dac7-4303-8a4b-46e27e36862f": {
        "text_answer": "  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is a comparison of the proportion of adverse events in different categories between the two trials   To verify this statement we need to calculate the proportion of adverse events in the BLOODBONE MARROW category for each trial and compare them   In the primary trial",
        "label": "Entailment"
    },
    "98627f6b-e597-4427-b831-aa8856de321e": {
        "text_answer": "  The statement is contradictory to the information provided in the inclusion criteria for the secondary trial The secondary trial does not demand participants to be entirely disabled as stated in the criteria Patients that are ambulatory with a functional ECOG  2 status Therefore the statement is a contradiction to the information provided in the trials",
        "label": "Contradiction"
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "text_answer": "  The statement There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial is entailed in the given trials data  Explanation  The primary trial has a total of 14 participants and a total of 0 adverse events of type 1 and 0 adverse events of type 2  The secondary trial has a total of 337 participants and a total of",
        "label": "Entailment"
    },
    "26583790-21ca-4820-9932-67e3d6eeb8b0": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial use the Number of Participants With Treatmentemergent Adverse Events as the outcome measurement for their studies is not directly related to the information provided in the trials The trials focus on the change from baseline in patientspecified symptoms using the MYMOP questionnaire in the primary trial and the change in isothiocyanate in urine samples in the secondary trial Therefore the statement is neither ent",
        "label": "Entailment"
    },
    "06be4ae9-c67e-4aad-b5b5-caf3dd9f30a9": {
        "text_answer": "  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials However the given trials only provide the frequency of each specific adverse event for each trial not the total number of each type of adverse event across all types Therefore it is not possible to determine if the",
        "label": "Entailment"
    },
    "0919109a-9ee1-4fa0-b612-a9902379e48d": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the same route of administration which is either by injection either intravenous or subcutaneous",
        "label": "Entailment"
    },
    "402d7814-ace1-4f78-8c96-c3205001c5ee": {
        "text_answer": "  The statement cohort 1 and 2 of the primary clinical trial are administered CUDC101 at the same frequency is contradictory to the given trial information   Explanation   In Intervention 1 Arm A CUDC101 is administered for 5 days every 14 days while in Intervention 2 Arm B CUDC101 is",
        "label": "Entailment"
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "text_answer": "  The statement CAPECITABINE was administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle is entailed in the trial description  Explanation  The trial description states that Capecitabine was administered orally from Days 1 to 14 every 21 days This means that capecitabine was administered every",
        "label": "Entailment"
    },
    "8150f869-b9e6-422b-a13a-1bdccee14f19": {
        "text_answer": "  The statement Every patient in the primary trial is receives a dose of 100 to 1600 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information   The trial only mentions the use of Vorinostat and Radiation therapy and the dosing schedule for Vorinostat It does not mention anything about the use of Fentanyl sublingual spray during",
        "label": "Contradiction"
    },
    "c7960079-5d1b-451e-818f-0890272ddb63": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on interventions for pain management and qualityoflife assessment in adult patients with extracardiac rhabdomyoma without explicitly mentioning any drug treatments for the condition The primary trial does not test any drugbased interventions while the secondary trial tests two different doses of PF06647020 as a drug treatment Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "0d8cdde2-046a-4684-8af5-38cd82935901": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort is not directly entailed or contradicted by the information provided in the trial data However it is consistent with the data since no individual adverse event type affected more than 3571 of the patients Therefore the statement is not contradicted by the trial data",
        "label": "Contradiction"
    },
    "0c973f54-1aad-4349-acf5-607cb1ef2d6a": {
        "text_answer": "  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not entailed in the given trials as there is no mention of cholelithiasis in either trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "86722991-04c7-4fdd-914a-f5b71d236a7a": {
        "text_answer": "  The statement is contradictory to the Trials provided   The Trials describe two separate groups of patients with orbit capillary hemangioma The first trial reports 113 769 adverse events with one patient experiencing rapid disease progression and one patient experiencing increased pleural effusion The second trial reports 14 2500 adverse events with one patient experiencing increased pleural eff",
        "label": "Entailment"
    },
    "3c164518-76e2-4abf-a39e-4163d49583c7": {
        "text_answer": "  The given statement is not directly entailed in the provided trial results as the trials do not report the recurrencefree survival rates for each group only the number of participants analyzed and the percentage of participants completing the study Therefore it is not possible to determine the difference in recurrencefree survival rates between the two groups based on the given information  However it is important to note that the statement is not contradictory to the trial results either as the trial",
        "label": "Contradiction"
    },
    "01116b8e-5299-4f9e-9f40-7651edbc8542": {
        "text_answer": "  The statement is entailed in the Trials as both trials evaluate the Percentage of Participants With Adverse Events of Primary Interest AEPIs However its important to note that the trials do not directly compare the percentage of participants with AEPIs between the two groups but rather report the percentage for each group separately The statement does not mention the study site oversight status or review board process code",
        "label": "Entailment"
    },
    "ceb3926f-4777-4cec-8582-7c109185e333": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial group 2 receives an administration of dexmedetomidine which is not related to the statement about myalgias The statement mentions a dose of 000027ugkg 0005ml of myalgias for group 2 of the primary trial but there is no such intervention mentioned in the trials  ",
        "label": "Contradiction"
    },
    "fd76b8a6-5305-4221-b48b-3a37d551c82a": {
        "text_answer": "  The statement the primary clinical trial mandates regular physical activities as a part of the intervention for all participants is not explicitly stated in the given trial information However there is no contradiction to this statement either The trial information only mentions that patients are eligible if they are older than 70 years and have a certain type of cancer and that they undergo a multidimensional assessment including G8 There is no mention of a specific intervention let alone one",
        "label": "Contradiction"
    },
    "bbd40b2c-18a5-4ebb-9c6b-58dbc9a3ba59": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to compare the percentage change in betaCTX between the two groups   The percentage change in betaCTX for the AZD0530 175 mg group was 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg group was 68",
        "label": "Entailment"
    },
    "4acf0568-59ce-4f6c-973b-9c603f65dac4": {
        "text_answer": "  The statement patients in neither cohort of the primary clinical trial showed pathologic complete response in breast and axillary lymph nodes throughout the duration of the study is a negation of the statement that at least one participant in either cohort had a pathologic complete response   To determine if this statement is entailed or contradicted by the given trials we need to examine the data provided to see if it is possible that no participants",
        "label": "Entailment"
    },
    "575eb6a5-bbeb-46a4-af85-87303a9fc321": {
        "text_answer": "  The statement there were no recorded incidents of infections among patients in both the primary clinical trial and the secondary clinical trial during the study period is entailed in the given trials as there are no recorded incidents of infections in the Adverse Events section for either trial",
        "label": "Contradiction"
    },
    "2f917847-cad3-4744-891d-33ebe29f257b": {
        "text_answer": "  The statement is entailed in the trials as both interventions bisphosphonate IV Q4W and denosumab 180 mg Q12W are delivered via the intravenous or subcutaneous injection routes which are considered the same pathways for drug administration",
        "label": "Entailment"
    },
    "44c3f65f-6b0d-401d-9aad-b323d7511b1c": {
        "text_answer": "  The statement Cohort A and B of the primary trial are administered the same Two IM injections of LD V935 at the same point in the cycle is entailed in the given trials as follows  1 Both Cohort A and B receive two IM injections of V935 each with a low dose LD 2 The timing of the injections for Cohort A is 1 given every other",
        "label": "Entailment"
    },
    "c3609a19-01f6-4add-a0af-7d92263d822c": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The trials only report the percentage of participants with invasive diseasefree survival events in the Neratinib and Placebo arms but they do not provide any information about the relationship between the egfr gene mutation and the trial outcomes Therefore the statement about the egfr gene mutation cannot be determined to be entailed or contradicted based on the given trial data alone",
        "label": "Entailment"
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "text_answer": "  The statement Intraoperative Mammography performed better than the Standard Mammography in the primary trial regarding operative time savings is an entailment based on the given data The primary trial provides evidence that the Intraoperative Mammography arm had a shorter median OR time 68 minutes range 29180 compared to the Standard Mammography arm 74 minutes range 35177",
        "label": "Entailment"
    },
    "3cd949ea-cd27-4eff-b7b6-0087df3136ba": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial reported mild adverse events is not directly entailed or contradicted by the given information in the trials data which states Total 0147 000 The trials data only provides the number of adverse events 0 and the total number of participants 147 in cohort 1 but it does not specify the severity or type of adverse",
        "label": "Contradiction"
    },
    "8fc0b314-bec3-4206-a917-fc16babf1a4a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial Fulvestrant is used in combination with Anastrozole while Anastrozole is used alone in the secondary trial Arimidex is not mentioned in either trial Therefore the statement that in both groups of the primary clinical trial Arimidex is utilized is not entailed in the trials",
        "label": "Contradiction"
    },
    "ccc3cd99-a66b-42ce-9a35-21780035ddc5": {
        "text_answer": "  The statement candidates Capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial and secondary trial have their own specific inclusion and exclusion criteria and the statement about limited selfcare and bed confinement does not appear",
        "label": "Contradiction"
    },
    "f5fa93e8-a223-459c-8573-853f56953c17": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment cycles are defined as 21 days but the maximum durations of PF05212384 and docetaxel treatments are openended 505 days and 445 days respectively This means that the treatment process is not strictly confined to a consistent 4week cycle regimen  In contrast in",
        "label": "Entailment"
    },
    "00d64f29-fff0-44bd-b20c-8838ed4a1d93": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   The statement suggests that the subjects in both cohorts receive equal doses of 20 mg of sunitinib and 75 mgkg of bevacizumab However the trial description specifies different dosing regimens for each intervention   Intervention 1 Sunitinib 25 mg escalated to",
        "label": "Entailment"
    },
    "1dcd53cf-49bf-4a4e-857d-008139ceb6a9": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial requires mammography as a prerequisite for participation while the secondary trial does not mention mammography as a requirement Therefore the secondary trial does not impose the same requirement as the primary trial and the statement is entailed in the trials",
        "label": "Entailment"
    },
    "ad0d6636-dd71-4ba9-8741-1cba3d6f0c43": {
        "text_answer": "  The statement is entailed in the trials as both cohorts use the same instructional compact disc CD for paced breathing However the frequency of practice differs between the cohorts with cohort 1 practicing once daily and cohort 2 practicing twice daily This difference does not contradict the statement as it only specifies that they use the same CD Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "bc8cc6fd-446a-4879-a968-5c43a34029cc": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trial descriptions   The primary trial has different inclusion criteria for different patient groups but both trials have the same general inclusion and exclusion criteria regarding serious health conditions performance status and biopsy requirements The statement specifically mentions that the secondary trial has the same inclusionexclusion criteria for all participants which is not accurate based on the information provided  Therefore the statement is",
        "label": "Entailment"
    },
    "e1e33a46-c88d-497a-b7b6-be14d38d05b2": {
        "text_answer": "  The statement only patients with metastatic or advanced hematological malignancies are fit to participate in phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial is contradictory to the information provided in the inclusion criteria for both trials  The primary clinical trial includes patients with metastatic and advanced solid tumors in Phase 1 and the secondary clinical trial includes patients with advanced solid tumors Therefore the statement is",
        "label": "Entailment"
    },
    "1e4ebef6-1039-42f3-b753-3efd098052fc": {
        "text_answer": "  The primary clinical trial lasted for 10 weeks for the intervention group and there is no mention of a specific duration for the control group The secondary clinical trial lasted for 24 weeks for both intervention and control groups with the intervention phase being an additional treatment given weekly  The statement the intervention phase in the secondary clinical trial lasts an additional 15 weeks compared to that in the primary clinical trial is not directly entailed in the given information However",
        "label": "Contradiction"
    },
    "e83cb60e-ac38-42dd-a094-1ae08500915b": {
        "text_answer": "  The statement 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia is neither entailed nor contradicted by the given trials data   The trials data shows that there was indeed 1 case of Anaemia and 1 case of Febrile neutropenia in cohort 1 of the primary trial However the statement also as",
        "label": "Contradiction"
    },
    "3c081d55-1536-45ec-ae5b-b7af2a44a8c4": {
        "text_answer": "  The statement in the primary clinical trial a single adverse event has been logged for its patient cluster is entailed in the given data if we consider the following  1 The data states that there is one adverse event Total 1 in the primary clinical trial 2 The statement specifies that there is a single adverse event for the patient cluster  Therefore the statement is entailed by the given data",
        "label": "Entailment"
    },
    "cee12d67-0640-4760-a0f5-fdde8c593a89": {
        "text_answer": "  The statement patients with a histologicallycytologically confirmed diagnosis of benign tumors are valid candidates for the primary clinical trial is contradictory to the trials inclusion criteria The trial only includes patients with a histologicallycytologically confirmed diagnosis of advanced andor unresectable disease of certain types of cancer Benign tumors are not considered advanced or unresectable and therefore they do not meet the inclusion criteria for this trial",
        "label": "Entailment"
    },
    "84781347-ce91-4e60-ba5f-f1bd795d898b": {
        "text_answer": "  The statement participants of the primary clinical trial are not administered any vaccines is not explicitly stated in the given trial information However there is no mention of any vaccines being administered to the participants in the provided information for Intervention 1 or Intervention 2 Therefore the statement is entailed by the given information",
        "label": "Contradiction"
    },
    "eff79353-72dc-4a94-b856-40b844d2860b": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial includes patients with a breast tumor 1 cm in diameter HR HER2 while the secondary trial does not specify the tumor size or hormone receptor status However the statement implies that patients with a breast tumor exceeding 1 cm in diameter with confirmed HR negative and HER2 positive status are eligible for both trials Since the primary trial does not meet this requirement",
        "label": "Entailment"
    },
    "e6c70cab-b2d6-488d-b9dd-34478f9f4f71": {
        "text_answer": "  The statement despite taking reduced doses of empegfilgrastim cohort 1 patients of the secondary clinical trial had a higher occurrence of neutropenia than those in cohort 2 of the primary clinical trial is not directly entailed in the provided trial data   The primary trial measures the duration of neutropenia CTCAE grade 4 and the secondary trial measures the incidence of neutropenia",
        "label": "Contradiction"
    },
    "d622d9c6-c942-4a53-a249-cd5544e2d9fe": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a resectable Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial is entailed in the trials inclusion criteria The trial includes patients with Nonsmall cell lung cancer and Small cell lung cancer and there is no mention of resectability as an exclusion criterion Therefore the statement is entailed in the trials criteria ",
        "label": "Entailment"
    },
    "b994a073-e1a5-424a-9cdf-f0d9ad0c0766": {
        "text_answer": "  The statement the primary clinical trial is open to patients of all genders provided they demonstrate evidence of ER negative breast cancer for each of its phases is entailed in the given inclusion criteria for Phase 2 of the trial   The inclusion criteria for Phase 2 of the trial states Have evidence of a solid tumor that is locally advanced andor metastatic and in Breast Cancer be Estrogen Receptor positive andor",
        "label": "Entailment"
    },
    "0aab969d-e626-4857-903c-df2f6849c7c7": {
        "text_answer": "  The statement several adverse events occurred at an incidence rate greater than 1 in both the primary clinical trial and the secondary clinical trial is contradicted by the given information   The primary trial had one adverse event 048 and the secondary trial had no adverse events 000 Neither trial had an adverse event with an incidence rate greater than 1",
        "label": "Contradiction"
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "text_answer": "  The statement Far more patients in the secondary trial were recorded to have experienced Chest Pain than patients in the primary trial is not entailed in the given trials as there is no mention of Chest Pain as an adverse event in either trial",
        "label": "Contradiction"
    },
    "e4024f75-2a23-4912-bb63-3d6e982657ea": {
        "text_answer": "  The statement the primary clinical trial participants are administered her2neu peptide vaccine mixed with sargramostim gmcsf id on day 1 8 and 15 is not entailed in the given trial interventions The interventions only specify the chemotherapy regimens and bevacizumab maintenance therapy for HER2negative participants There is no mention of her2neu peptide",
        "label": "Contradiction"
    },
    "fbfafa2b-9b70-4452-9d19-4d58c3c9dfba": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria as it states that the primary tumour radius is 3mm which is less than the minimum required size of greater than 2 cm diameter Therefore the statement is contradictory to the primary trial inclusion criteria and would not make a patient eligible for the primary trial  Regarding the secondary trial the statement does not provide enough information to determine eligibility as it does not mention any specific criteria related to",
        "label": "Entailment"
    },
    "7452ab11-09d4-48bc-b275-4681acae5769": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORRs of the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 05",
        "label": "Entailment"
    },
    "4385daf4-23d6-499b-8960-33b8c995884e": {
        "text_answer": "  The statement is entailed in the given trials as neither trial reported any adverse events in more than 001 of participants 048 is less than 1 which is equivalent to 001 of 208 and 201 participants respectively",
        "label": "Entailment"
    },
    "97f2cf47-a82b-4d00-9918-a4b400d2ca5e": {
        "text_answer": "  The statement in the primary clinical trial the adverse events noted were all connected to the musculoskeletal system contrary to the secondary clinical trial is a contradiction of the given data  Explanation  The statement implies that in the primary trial all adverse events were related to the musculoskeletal system and in the secondary trial there were no adverse events related to the musculoskeletal system",
        "label": "Contradiction"
    },
    "b7bc3cb1-b7f4-4276-bfee-9f984109d191": {
        "text_answer": "  The statement several of the primary trial candidates are administered 0001 g of talazoparib daily as part of the intervention is not explicitly stated in the provided information from the primary trial The trial description mentions that some patients are included in the study and may receive talazoparib but it does not specify the dosage or frequency for all patients Therefore this statement is neither entailed nor contradicted by the given",
        "label": "Entailment"
    },
    "13184ac6-2ba9-455b-9e77-834855ff2794": {
        "text_answer": "  The statement the primary and secondary clinical trials showed zero incidences of febrile neutropenia or cholelithiasis is entailed in the given trials as neither trial reported any incidence of febrile neutropenia or cholelithiasis",
        "label": "Entailment"
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "text_answer": "  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is a contradiction to the information provided in the trials   The primary trial does not directly compare the two arms in terms of a control group versus test group but rather presents the operative time data for each arm separately The statement implies a comparison between the two arms based on the assumption that the control",
        "label": "Contradiction"
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "text_answer": "  The statement 18 years olds are excluded from the secondary trial but the primary trial does not specify an age range for participation is neither entailed nor contradicted by the given trials   Explanation  The primary trial only specifies that patients must be able to give informed consent and pass certain screening criteria to be included It does not mention an age range The secondary trial includes patients who are 18 years old and above as indicated",
        "label": "Entailment"
    },
    "80b58d76-4a9b-461a-836a-bfb79e40b401": {
        "text_answer": "  The statement Both cohorts of the primary trial receive the same doses of Abraxane is entailed in the given trial information as both cohorts receive nabPaclitaxel at a dose of 125 mgm2 on Days 1 and 8 Abraxane is a formulation of paclitaxel so the doses of the active ingredient are the same in both arms of the trial",
        "label": "Entailment"
    },
    "42d3b148-38d6-4665-9d48-4d6bf935fbd9": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial is a contradiction of the information provided in the inclusionexclusion criteria  The criteria state that there are",
        "label": "Contradiction"
    },
    "00102571-e1d6-42c9-b227-f0ac146d411d": {
        "text_answer": "  The statement gin is a Chinese person from the Gin ethnic group is not related to the inclusion and exclusion criteria for the primary or secondary trials provided Therefore it neither entails nor contradicts the information given in the trials",
        "label": "Entailment"
    },
    "596e650e-f860-4055-b3a6-35fcd9fd33b0": {
        "text_answer": "  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is a contradiction to the given trials data   The trials data provided states that for both Adverse Events 1 and 2 the primary trial had a total of 0 adverse events in 0 patients while the secondary trial had a total of 0 adverse events in 15 patients Therefore the secondary trial did not record",
        "label": "Contradiction"
    },
    "10a27e75-a4e3-4790-bafa-dfc9b9300a25": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 Lenalidomide dosage In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days In the secondary trial participants received oral lapatinib 1500mg daily for 6 weeks and lapatinib plus weekly paclitaxel 80mgm2 IV for an additional",
        "label": "Entailment"
    },
    "b8e81997-7fd7-4934-9ee8-bb7c647d334c": {
        "text_answer": "  The statement all adverse event types in the primary trial affected less than 01 of patients is contradictory to the provided data   The data shows that 3636 of patients experienced an adverse event which is more than 01 10 of the patients Therefore the statement is contradictory to the data",
        "label": "Entailment"
    },
    "c89d3665-091c-410b-83b1-0793a3b86d6a": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial the intervention consists of a single drug ZD1839 In contrast the secondary trial involves two interventions Intervention 1 consists of three different drugs  Zoledronic acid vitamin D and calcium supplements and Intervention 2 includes four different drugs  Zoledronic acid vitamin D calcium supplements and either",
        "label": "Entailment"
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial reports the Time to Progression in months for a total of 156 patients 72 in Arm A and 84 in Arm B and the secondary trial reports the number of patients that experience Objective Response in Arm S SUNITINIBCAPECITABINE with a total number of participants analyzed of 63 However the primary trial does not directly report",
        "label": "Entailment"
    },
    "70ddf6e3-dcd9-4296-b73c-593161abcfae": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial could include patients who are extremely overweight or expecting is not entailed in the given inclusion and exclusion criteria for either trial   The primary trial includes no mention of body weight or pregnancy as inclusion or exclusion criteria The secondary trial includes pregnancy as an exclusion criterion but makes no mention of body weight Therefore the statement is not entailed in the trials as given",
        "label": "Contradiction"
    },
    "d6cd0501-9b29-41f5-ba8a-6209c8cfad84": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there are two interventions one with placebo and the other with Armodafinil In the Armodafinil intervention Armodafinil is given daily for 47 days with varying doses However the statement claims that only two cohorts receive Armodafinil PO daily in the primary trial This is incorrect  In the",
        "label": "Contradiction"
    },
    "03845d1d-301a-4b2a-8dc4-8b05e09ab6ee": {
        "text_answer": "  The statement other things made or make an individual think about the event is not directly entailed in the given trials as they only report the occurrence or nonoccurrence of specific adverse events AEs in each cohort The statement implies a potential influence of other factors on the reporting or perception of AEs which is not explicitly stated in the trials Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "383102f6-bd50-4f19-b7cf-0ddda4234e2f": {
        "text_answer": "  The statement biliary colic and Clostridium difficile colitis cases are more prevalent in the secondary trial than the primary clinical trial is contradictory to the given data   Explanation   The statement implies that the number of biliary colic and Clostridium difficile colitis cases in the secondary trial is greater than the number of these cases in the primary trial However the data provided shows that there",
        "label": "Entailment"
    },
    "a88d7c64-ec6f-4fb7-a84d-1047b68bda4f": {
        "text_answer": "  The statement in the secondary clinical trial only eyelid oedema and chest pain were the adverse events observed in patients unlike the primary trial which did not record any is entailed in the given trials data   Explanation   The statement implies that the secondary trial had adverse events eyelid oedema and chest pain that were not present in the primary trial The trials data confirms this as the",
        "label": "Entailment"
    },
    "0c6abdc4-f1cd-46f3-8883-c4bce02c2081": {
        "text_answer": "  The statement primary clinical trial uses mymop score improvement as their principal outcome measurement is not directly entailed in the given trials as the first trial reports the change in MYMOP score before the 7th acupuncture treatment but it does not provide the change from baseline to the end of the study The second trial reports the change in isothiocyanate levels in urine samples which is not related to the MYMOP score Therefore the",
        "label": "Contradiction"
    },
    "6aa80695-37e9-4a46-aa19-2fd1f75d8f11": {
        "text_answer": "  The statement is not entailed in the given trials as the trials describe different interventions for different patient cohorts The primary trial deals with oral pregabalin while the secondary trial deals with intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt The statement does not mention HDMTX or Depocyt and the",
        "label": "Contradiction"
    },
    "c4c63d1d-1704-499c-b298-f5ced3123d03": {
        "text_answer": "  The statement is entailed in the trial description as it accurately reflects the dosing regimen for both lapatinib ditosylate and tamoxifen citrate in Arm 1 of the trial",
        "label": "Entailment"
    },
    "c90dda31-65a8-4a77-8657-7cdf498b366f": {
        "text_answer": "  The statement any patients exposed to antineoplastic chemotherapy androgens estrogens or progestogens treatment during the two years prior to the studys commencement are not fit for the primary clinical trial is entailed in the trials exclusion criteria   Explanation   The trials exclusion criteria state that any patient who has received antineoplastic chemotherapy androgens estrog",
        "label": "Entailment"
    },
    "6fa670ed-56af-4b06-b7f1-ab7429106d0d": {
        "text_answer": "  The statement at least one patient treated with gtx024 1mg in the primary trial gained over 22 pounds of lean body mass is a contradiction to the given trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg which is far less than 22 pounds approximately 10 kg or 22046",
        "label": "Contradiction"
    },
    "c2634312-bbf3-4b44-8cdc-23922a16b9fd": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement asserts that the number of infection asymmetry and deflation cases were greater in the primary trial than those detected in the secondary trial However the trials show that there were no cases of deflation in the secondary trial while there was one case in the primary trial Therefore the statement is contradicted by the trials  Furthermore there",
        "label": "Contradiction"
    },
    "241dc060-83e9-41a9-b937-d9715c16137a": {
        "text_answer": "  The statement is entailed in the trials as the mean number of hot flashes per day in the paced respiration group 348 is less than the mean number of hot flashes per day in the fast shallow breathing group 395 Therefore the paced respiration intervention group experienced fewer hot flashes on average than the fast shallow breathing group",
        "label": "Entailment"
    },
    "ff8f336a-0b3a-453d-a396-7624218280aa": {
        "text_answer": "  The statement is entailed in the Trials with Entailment The intervention section of a clinical trial is expected to provide a detailed description of the treatment or intervention being tested in the study In this case the statement specifies that the intervention includes the enrollment of subjects with a device placed and the treatment with partial breast irradiation This level of detail is consistent with the information that would be included in the intervention section of a clinical trial",
        "label": "Entailment"
    },
    "100aa305-3df6-42ff-b3ba-68bed68e39b0": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial focuses on the number of participants with treatmentemergent AEs at Cycle 1 while the secondary trial investigates the total sleep time as measured by polysomnography PSG before and after the first cycle of Lenalidomide treatment These are two distinct outcomes being measured in separate trials The statement correctly highlights the difference in focus between the two trials",
        "label": "Entailment"
    },
    "b819fe62-b8ce-4b35-bf5a-e2657f8d0efc": {
        "text_answer": "  The statement is entailed in the given clinical trial information   Explanation   The statement only one arm of the primary clinical trial makes use of trastuzumab as part of its intervention is entailed by the information provided in the trial description This is because only Arm 1 of the trial uses Herceptin which is a formulation of trastuzumab as part of its intervention Arm 2 uses Taxot",
        "label": "Entailment"
    },
    "2644ad79-c38a-4415-a340-81ac51d3813f": {
        "text_answer": "  The statement multiple diverse negative effects were experienced by at least one patient in the primary clinical trial is entailed in the given trial data   Explanation   The statement implies that more than one type of adverse event was experienced by at least one patient in the trial The trial data shows that a total of 5 adverse events occurred in 25 patients and there were at least 2 different types of adverse events dys",
        "label": "Entailment"
    },
    "344ac04d-cddb-4ef8-8a15-54e26ff58a86": {
        "text_answer": "  The statement the primary clinical trial recorded adverse events all of which affected not more than one patient individually is entailed in the given data if we interpret the statement as follows  1 Each adverse event affected a different patient not more than one patient per event 2 The total number of adverse events recorded is 5  The given data confirms that there were 5 adverse events each affecting a different patient as stated",
        "label": "Entailment"
    },
    "c32c50b0-6068-41f1-9db0-fd8b3ac53cf6": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial Intervention 1 in Arm I involves the administration of Zoledronic Acid via IV  In the secondary trial Intervention 1 in Arm II involves the administration of Granisetron hydrochloride Dexamethasone and placebo via IV on day 1 and Prochlorperazine and another placebo via oral route on days ",
        "label": "Entailment"
    },
    "1907f058-1b77-441e-8824-9cf6be7f1243": {
        "text_answer": "  The statement in comparison to the secondary trial the primary trial has fewer adverse events overall but a higher occurrence of cardiacischemiainfarction is a compound statement consisting of two parts Lets verify each part separately  1 Fewer adverse events overall    The primary trial has 0 adverse events out of 14 participants and the secondary trial has 48 adverse events out of 3",
        "label": "Entailment"
    },
    "818a897a-fa50-4f16-8272-8f5ec8e590c1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the trials given paclitaxel is not utilized as an intervention in the second cohort but fulvestrant is Therefore the statement that only in the first cohort of the primary clinical trial is paclitaxel utilized as the intervention however fulvestrant is the treatment assigned to the second cohort is incorrect",
        "label": "Entailment"
    },
    "6fc1fe93-0690-4b46-a80e-681e4d7be399": {
        "text_answer": "  The statement Morbidly obese patients are eligible for the primary trial have to read something several times to understand is is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial The statement is not directly related to the eligibility criteria for the trial The statement is about the ability of individuals to understand something which is not mentioned in the inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "3ce10e1a-24fe-4575-8f08-583c93fd5274": {
        "text_answer": "  The statement primary clinical trial and secondary clinical trial host patients diagnosed with nut midline carcinoma via fluorescence in situ hybridization and those with inflammatory breast cancer is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes patients with NUT midline carcinoma diagnosed via immunohistochemistry IHC or fluorescence in situ hybridization FISH",
        "label": "Contradiction"
    },
    "99901cc0-51b6-45c1-9040-14a9785bab49": {
        "text_answer": "  The statement a confirmed histological or cytological diagnosis of resectable nonsmall cell lung cancer or small cell lung cancer makes patients suitable for the primary clinical trial is entailed in the given inclusion criteria   Explanation   The inclusion criteria state that patients with a histologicallycytologically confirmed diagnosis of advanced andor unresectable disease of any of the following tumors are eligible for the trial nonsmall cell lung",
        "label": "Entailment"
    },
    "6b1a58fa-54cd-442b-8f51-1b7135dd2302": {
        "text_answer": "  The statement cbt based treatments are a primary requirement for participation in the primary clinical trial and are fully permissible in the secondary clinical trial is not explicitly stated in the inclusion or exclusion criteria for either the primary or secondary clinical trials provided However there is no information in the criteria that contradicts the use of cbt based treatments in both trials Therefore the statement is neither entailed nor contradicted by the information given in the trials criteria",
        "label": "Contradiction"
    },
    "ddc664eb-c81b-4544-b370-bb6db84eacba": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  Both trials include patients with histologically or cytologically confirmed stage 4 breast adenocarcinoma The secondary trial specifically requires that the disease be ER positive PR positive and HER2neu negative The primary trial does not explicitly state this requirement but it is not a contradiction to the secondary trials criteria since ER PR and HER2",
        "label": "Entailment"
    },
    "117c69b5-683c-45a6-b80d-5bc866f2faa1": {
        "text_answer": "  The statement eligibility for the primary and secondary clinical trials is not determined by the patients nationality ethnicity weight or gender is entailed in the given inclusion and exclusion criteria for both the primary and secondary trials There is no mention of nationality ethnicity weight or gender as inclusion or exclusion criteria in the provided text Therefore the statement is entailed in the trials as it is consistent with the information provided",
        "label": "Entailment"
    },
    "3cd01e92-2bff-45d7-9fa3-77c351d2f39a": {
        "text_answer": "  The statement the primary clinical trial presented no adverse events is contradictory to the information provided in the trials data The data states that there was one adverse event a surgery out of 29 participants which is a nonzero percentage Therefore the statement is contradictory to the facts presented in the trials data",
        "label": "Contradiction"
    },
    "d207a9ec-f055-456a-ad6a-7c580cc347e1": {
        "text_answer": "  The statement the only inclusion or exclusion standard that the primary and secondary clinical trials have in common is the capability to present written informed consent is a conditional statement To determine if it is entailed in the trials or contradicted we need to check if there is any other common inclusion or exclusion standard besides the capability to present written informed consent  Lets examine the inclusion and exclusion criteria for both trials  Primary Trial  Age",
        "label": "Entailment"
    },
    "3896374f-f5e1-41a2-9ec0-c108cc3f3ad1": {
        "text_answer": "  The statement maculopapular Rash was a common adverse event for the primary trial participants is entailed in the given trial data as it is explicitly stated that Rash maculopapular 130 333 Therefore the statement is entailed by the trial data  However the statement operator is a person that operates some apparatus or machine is not related to the trial data and does",
        "label": "Entailment"
    },
    "87f86955-0e57-459a-84aa-4a5feba745af": {
        "text_answer": "  The statement patients who have estrogen negative progesterone negative and her2 breast cancer can join the primary clinical trial is entailed in the given inclusion criteria   Explanation   The inclusion criteria state that patients with histological confirmation of ER negative PR negative and HER2 negative invasive breast cancer are eligible for the trial The statement in question also specifies ER negative PR negative and HER2",
        "label": "Entailment"
    },
    "99857433-fe08-4f54-bb86-91b1b1e8f5f4": {
        "text_answer": "  The statement the iDFS rate was lower in the neratinib group than in the placebo group in the primary clinical trial is entailed in the trials provided as the trials report that the percentage of participants with events ie iDFS failures was 47 in the neratinib group and 75 in the placebo group A lower percentage of events indicates a lower iDFS rate in the neratinib",
        "label": "Entailment"
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "text_answer": "  The statement maculopapular Rash was a common adverse event for the primary trial participants is entailed in the given trial data as there is a reported instance of Rash maculopapular among the adverse events and the total number of participants was 30 Therefore the frequency of this adverse event is 130 which calculates to 333 making it a common adverse event",
        "label": "Entailment"
    },
    "61c499d7-0a4c-4fac-9098-53e53ddb198d": {
        "text_answer": "  The statement there were 75 cases of hypertension edema and dyspnea in either cohort of the primary trial is not directly entailed or contradicted by the given trials as the trials do not provide sufficient information about the number of cases of hypertension edema and dyspnea in each cohort The trials only report the number of adverse events for specific conditions but they do not add up to 75 for",
        "label": "Contradiction"
    },
    "93025279-295b-43e1-8dfd-40877e0288b4": {
        "text_answer": "  The Trials with Entailment and Contradiction dataset does not provide sufficient information to determine if the statement is entailed or contradicted in the given clinical trial The dataset only includes the trial title intervention name and a brief summary but it does not include the full trial protocol or details about the irradiation doses or treatment cycles Therefore it is not possible to make a definitive determination based on the available information",
        "label": "Entailment"
    },
    "5ecfe0a7-2d7c-4207-b62e-0b28b699951d": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trials Intervention 1 involves the use of Zoledronic Acid 4 mg Q4W every 4 weeks and Denosumab 120 mg Q4W in the openlabel extension study In the blinded treatment phase of the parent studies participants received Zoledronic Acid 4 mg Q4W",
        "label": "Entailment"
    },
    "4a16424c-7755-4b6b-a060-d9ab1cb14db0": {
        "text_answer": "  The statement stopcock valve device is a rotating valve designed to regulate the flow of a fluid through a stopcock Only female patients of a specific nationality can take part in the primary trial no such condition is required for participation in the secondary trial is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials The trials only specify demographic and healthrelated criteria for eligibility and ineligibility The",
        "label": "Contradiction"
    },
    "10a9dcfe-bbdd-44b2-9bc7-f406a2ff835a": {
        "text_answer": "  To determine if the statement on average there was no change in cognitive function for patients in either cohort of the primary clinical trial is entailed in the given trials we need to compare the mean standardized scores and their standard deviations for both cohorts  The statement is not directly entailed in the given trials as they only provide the mean and standard deviation for each cohort but not a comparison between them However based on",
        "label": "Contradiction"
    },
    "b12a6936-d1ae-48e7-b3f2-575708d784ed": {
        "text_answer": "  The statement There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial is not entailed in the given trials data   The trials data only provides the number of adverse events for each trial and the number of patients in each trial but it does not specify the number of cases for each type of adverse event for each patient Therefore it",
        "label": "Contradiction"
    },
    "48ca56cf-908a-436f-8ec5-90fb965ea630": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The trials only provide information about interventions for patients with DCIS ductal carcinoma in situ using Fluciclatide a radiopharmaceutical and Chloroquine an oral medication in two different trials The statement is about Nepafenac a topical nonsteroidal antiinflammatory drug used for eye treatment There",
        "label": "Entailment"
    },
    "8dbf8922-4680-4125-9bc3-f6ea881c5978": {
        "text_answer": "  The statement dehydration was a common side effect observed in both cohorts of the primary clinical trial is not entailed in the given trials as there is no mention of dehydration as an adverse event in either cohort",
        "label": "Contradiction"
    },
    "dfde5d87-d03d-42a9-aa4c-f4e946a75102": {
        "text_answer": "  The statement in comparison the secondary trial holds fewer anemia cases than the primary trial is entailed in the given trials as the primary trial has 0 anemia cases while the secondary trial has 4 anemia cases which is fewer in number",
        "label": "Entailment"
    },
    "27564603-9271-41f5-8135-067e19c4946a": {
        "text_answer": "  The statement large cell neuroendocrine carcinoma is an aggressive highgrade and poorly differentiated carcinoma with neuroendocrine differentiation it is composed of malignant large cells is not directly related to the information provided in the trials   Regarding the trials the statement in the primary trial only one cohort receives Armodafinil PO daily and in the secondary trial all patients receive the",
        "label": "Entailment"
    },
    "e8b7263b-fd07-4d78-915f-e1b17bdc1390": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not provide sufficient information to make a definitive statement about the number of drugs required for the treatment of anal fibroadenoma in the primary and secondary trials The statement only makes a generalization based on the mentioned interventions in each trial but it does not take into account the possibility of other interventions or variations within the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "302997fe-466a-4efd-8801-5b07236a5e0c": {
        "text_answer": "  The statement is contradictory to the trials provided The trials do not involve the administration of vaccines to their participants They involve the administration of chemotherapy drugs doxorubicin cyclophosphamide docetaxel and the monoclonal antibody bevacizumab",
        "label": "Entailment"
    },
    "7d1f03c6-a869-45f0-9eda-4c272781e112": {
        "text_answer": "  The statement anorexia hypothermia and hallucinations have been reported in the aes of the primary clinical trial is a contradiction to the information provided in the trials The trials report no adverse events for the primary trial and only adverse events 1 and 2 for the secondary trial with no mention of anorexia hypothermia or hallucinations",
        "label": "Contradiction"
    },
    "192c6acc-1f20-4f22-a23e-80fadba34726": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary clinical trial the interventions being compared are Estring and Testosterone Cream which are both hormonal treatments In contrast the secondary clinical trial focuses on Acupuncture as an intervention which is different from hormonal treatments Therefore the statement is entailed in the trials as it correctly identifies the focus of each trial",
        "label": "Entailment"
    },
    "a2328e36-4475-4804-96e8-cba90ee13087": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information The trials use different interventions with distinct drugs dosages and administration schedules The statement only mentions that both trials involve intravenous injections which is a common method of drug administration and does not directly relate to the specific interventions or their entailment or contradiction",
        "label": "Entailment"
    },
    "99820bab-c465-4d6a-a016-0551261ddb86": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given Trials with Entailment or Contradiction we need to refer to the provided information about the trial and the meaning of the terms used in the statement  The Trials with Entailment or Contradiction document does not provide any information about the specific procedures or interventions used in the primary clinical trial except that the intervention segment is mentioned Therefore based on the given information",
        "label": "Entailment"
    },
    "1757a756-4aeb-497c-aa4f-304817a34938": {
        "text_answer": "  The statement patients with a recent pulmonary embolism specifically within the past 2 months are excluded from the primary clinical trial but their eligibility for the secondary clinical trial is subject to the investigators discretion is a statement of exclusion with a caveat   The primary clinical trial explicitly excludes patients with a pulmonary embolism within the past 2 months Secondary Trial Exclusion Criteria ",
        "label": "Entailment"
    },
    "1fb98883-c2ef-4acb-948e-aa497dc911ff": {
        "text_answer": "  The statement mycl gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the mycl gene is not entailed in the given trials as they do not mention anything about mycl gene amplification or any molecular genetic testing The trials focus on interventions for lymphedema using Estring Testosterone Cream Acupuncture and a Waitlist control group",
        "label": "Contradiction"
    },
    "98877f56-e367-4335-b938-85bd30fb038a": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The trials focus on the dosage and administration of Cetuximab in two different cohorts while the statement discusses the presence of hepatitis C antibodies and does not mention any connection to the trials or the Cetuximab interventions",
        "label": "Entailment"
    },
    "c9403b28-c572-4009-ae1a-6bd3e7977f86": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both the placebo and trabectedin are administered using a 3hour intravenous infusion every other week However the trial information states that the placebo is administered as a 3hour intravenous infusion on Day 1 while trabectedin is administered as a 3hour intraven",
        "label": "Entailment"
    },
    "ea29786f-2c27-45d3-879d-126b8150f2af": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the use of 4demethyl4cholestryloxycarbonylpenclomedine is mentioned as part of the interventions but the frequency of dosing is not explicitly stated However based on the context of the trials it can be inferred that the participants in the primary trial will receive monthly doses of the drug",
        "label": "Entailment"
    },
    "7a2208d3-e297-4d8c-bfab-12856c200ea6": {
        "text_answer": "  To verify whether the statement is entailed or contradicted in the given trials we need to access the details of the clinical trials However the provided information does not include the specific dosage of carboplatin used in each arm of the trial Therefore it is impossible to determine if the statement is entailed or contradicted based on the given information alone  The statement only mentions Paraplatin but the trials use different chemotherapy regimens",
        "label": "Entailment"
    },
    "1ef3ec2f-1b26-4dbe-92ff-8c3dda42f071": {
        "text_answer": "  The statement no adverse events were noted in the patients from the secondary clinical trial is contradicted by the information provided in the secondary trial data as one instance of chest pain was reported under Adverse Events 2 Therefore the statement is contradicted by the given data  The statement instances of dyspnoea hyperkalaemia and renal failure were recorded in the patients from the primary clinical trial is entailed in the given data",
        "label": "Contradiction"
    },
    "f2f5115c-a1ad-43cf-b01c-0035f9404a92": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions and medications However the statement is generally true for the secondary trial as the medication doses are individually calculated and do not uniformly consist of 100 mg PDR001 and 1 mgkg MCS110 For the primary trial the statement is not applicable as the trial compares two different interventions one of which does not involve medication",
        "label": "Contradiction"
    },
    "8a308f16-460b-45ac-a0f0-cb36787f1aa7": {
        "text_answer": "  The statement over 30 of participants in both the primary and secondary clinical trials encountered several adverse events is contradicted by the given data   The primary trial had one participant 048 with an adverse event related to neutrophilsgranulocytes and the secondary trial had no participants with any adverse events Therefore less than 30 of participants in either trial had adverse events and the",
        "label": "Contradiction"
    },
    "f43f3230-46be-4ed7-a1d7-3e6d73f4fa9b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that cohorts 1 and 2 received the same dosage of mm121 8 mgkg but the trials specify different dosages for each cohort In cohort 1 the dosage of mm121 is 8 mgkg in combination with a different dosage of cetux",
        "label": "Entailment"
    },
    "eea61494-780f-4a38-aa12-dd88ef3d520b": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary clinical trial there are two study groups A and B that are being tested with different types of gels Hydrophor and MediHoney for managing skin toxicity during radiation therapy  In the secondary clinical trial there are two arms A1 and A2 that are testing the effects of different doses 90 mg and 110 mg",
        "label": "Entailment"
    },
    "81bf5edb-cf30-4e9e-b816-394fa5b16354": {
        "text_answer": "  The statement none of the participants in group 1 of the primary trial were found to have lesions and more than 90 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as there is no common group 1 in both trials The primary trial is about MRI and detection of lesions in healthy volunteers and breast cancer patients while the secondary trial is",
        "label": "Contradiction"
    },
    "1adb6e15-a8b1-461a-8782-4295224a3c5f": {
        "text_answer": "  The statement the primary clinical trial accepts individuals suffering from vascular dementia is not entailed in the given inclusion and exclusion criteria The criteria mention some evidence of cognitive impairment but do not specify the type of cognitive impairment and vascular dementia is a specific type of dementia Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "eb12190b-96c6-4c5d-8479-1248b462587d": {
        "text_answer": "  The primary trials intervention duration is 10 weeks while the secondary trials intervention duration is 24 weeks The statement the secondary trials intervention duration is three times longer than that of the primary trials intervention is entailed in the trials as 24 weeks is indeed three times longer than 10 weeks",
        "label": "Entailment"
    },
    "5ebf97e0-5409-4e82-a837-e0d96bc62b96": {
        "text_answer": "  The statement tcirg1 gene mutation is a change in the nucleotide sequence of the tcirg1 gene is not directly related to the information provided in the trials However the statement Placebo 20 transendocardial injections of 04ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter single procedure and INTERVENTION 1 All",
        "label": "Entailment"
    },
    "96259bb4-b459-4f63-b987-6bdb596211a4": {
        "text_answer": "  The statement er negative breast cancer patients irrespective of their gender may be qualified for either phase of the primary clinical trial is entailed in the given inclusion criteria for the Phase 2 trial of the clinical trial   The Phase 2 trial includes the following criteria for breast cancer patients  Have evidence of a solid tumor that is locally advanced andor metastatic and in Breast Cancer be Estrogen Re",
        "label": "Entailment"
    },
    "f891188f-fa94-42d5-a341-2a6ae7d696ac": {
        "text_answer": "  The statement there was a difference of four patients who endured adverse events between cohort 1 and cohort 2 of the primary clinical trial is contradictory to the information provided in the trials The trials report that there were no adverse events in both cohorts with a total of 060 000 for each cohort Therefore there is no difference of four patients who endured adverse events",
        "label": "Contradiction"
    },
    "2f5ae30b-2e0d-420a-a27b-14088d2bc0db": {
        "text_answer": "  The statement there were zero aes reported in one of the cohorts in the primary clinical trial is entailed in the trial with label Adverse Events 1 since the total number of adverse events reported in that cohort is 0",
        "label": "Entailment"
    },
    "8723a112-05c6-4c05-82ab-e09cedffdb4b": {
        "text_answer": "  The statement only three kinds of adverse events impacted patients participating in the primary clinical trial pancreatitis cholelithiasis hepatic pain and febrile neutropenia is a conditional statement and it can be verified by checking if the trials entail or contradict this statement  First lets identify the common adverse events between the two trials pancreatitis cholelithiasis",
        "label": "Entailment"
    },
    "176789e8-d2f5-4bb5-b748-ef0ed5c52478": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial accepts patients with severe insomnia is entailed in the given trials as neither trial includes severe insomnia as an inclusion criterion In fact both trials have exclusion criteria related to uncontrolled medical or psychiatric illness which could include severe insomnia but the trials do not specifically mention severe insomnia as an inclusion criterion Therefore the statement is entailed by",
        "label": "Entailment"
    },
    "a6276d61-5f8c-483b-8f18-a3becebddbe8": {
        "text_answer": "  The statement is a contradiction to the given trial information   Explanation   The statement suggests that cohort 1 and cohort 2 received the same dosage of cetuximab but cohort 1 received 8mgkg less of mm121 However the trial information clearly states that cohort 1 received a lower dose of mm121 12 mgkg",
        "label": "Contradiction"
    },
    "85b158a4-1754-47b2-91b4-5165c38d270c": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial reports the percentage of participants while the secondary trial reports the number of participants who reached a safe dose These units of measure are not the same and therefore the statement is valid",
        "label": "Entailment"
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3 as well as requiring considerable assistance and frequent medical care is not directly entailed in the given inclusion and exclusion criteria of the primary trial   The inclusion criteria state that the primary breast cancer must be HER2 positive either by IHC 3 or FISH However there is no mention of the level of assistance or medical",
        "label": "Contradiction"
    },
    "6b6150e0-6484-499a-83ae-a9fc6a7d167c": {
        "text_answer": "  The statement is entailed in the trials as both trials include the use of cyclophosphamide and Paclitaxel in their interventions However the primary trial uses Cyclophosphamide in combination with Doxorubicin and GMCSF followed by Carboplatin and NabPaclitaxel while the secondary trial uses Cyclophosphamide in combination with Adriamycin and either pegfilgrastim or",
        "label": "Entailment"
    },
    "69a761d0-c5b2-42f4-8cb3-271ac92fb006": {
        "text_answer": "  The statement is not entailed in the given trial information Both cohorts receive the same dose of CUDC101 275 mgm2 but the frequency of administration differs between the two groups",
        "label": "Contradiction"
    },
    "f618f294-167b-4647-bc93-b8d41596227c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial defines each treatment cycle as 21 days which is equivalent to approximately 1680 hours 21 days x 24 hoursday Therefore neither the primary nor the secondary trial uses a 730hour cycle for their interventions The secondary trial does not have a cyclic treatment in place as stated but it also does not",
        "label": "Entailment"
    },
    "dda442a2-b86f-4375-ae81-f1b387ce46c9": {
        "text_answer": "  The statement is entailed in the given trials as neither of them report the number of participants with treatmentemergent adverse events as an outcome measurement The primary trial focuses on the change in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial measures the change in isothiocyanate in urine samples Both trials report mean changes and standard deviations or errors but do not mention adverse events",
        "label": "Entailment"
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions is not directly entailed in the given trials as the trials do not provide sufficient information about the participants who didnt receive paclitaxel infusions The trials only compare the average area under the curve aAUCpa of the EORTC CIPN20 Sensory Neurop",
        "label": "Contradiction"
    },
    "444746eb-7e98-43fc-8bab-50c2a60d2806": {
        "text_answer": "  The statement the primary clinical trial exclusively uses MRIguided radiotherapy for all interventions is not entailed in the given trial description The trial description only mentions the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points during the mastectomy procedure for both interventions Inframammary Fold and Lateral Radial incision cohorts",
        "label": "Contradiction"
    },
    "2669332d-8907-4f82-afbf-e7be6b3c81b3": {
        "text_answer": "  The statement is entailed in the Trials as the inclusion criteria for the primary trial are more stringent than those for the secondary trial The primary trial includes specific criteria related to menopausal status and hot flushes which are not relevant to the secondary trial Therefore not all patients participating in the secondary clinical trial meet the requirements for inclusion in the primary clinical trial",
        "label": "Entailment"
    },
    "635d4169-6adf-4254-9ee5-e9eede3f7bc5": {
        "text_answer": "  The statement the secondary clinical trial accepts only candidates with full mobility and similar physical ability requirements have also been established for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes subjects who have a response after receiving at least two courses of weekly paclitaxel therapy and are considered to need to continue the therapy by the investigatorsubinvestigator among patients with advanced or recurrent breast cancer",
        "label": "Contradiction"
    },
    "23034d6a-8cb6-41b2-8e0d-84194285cb38": {
        "text_answer": "  The statement the rate of clinical benefit in the participants gauged via RECIST criteria is not tracked in the scope of the primary or secondary clinical trial is not directly contradicted or entailed by the information provided in the trials   The primary trial focuses on evaluating the antitumor activity of 852A using RECIST criteria but it does not report the rate of clinical benefit ie the proportion of",
        "label": "Entailment"
    },
    "290fc77b-03cb-4ca6-877f-4117ea462ac6": {
        "text_answer": "  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group cannot be determined to be entailed or contradicted based on the given information   The trials only provide the ORR and the number of participants analyzed for each group but they do not directly compare the ORR between the two groups using a statistical test Therefore it is not",
        "label": "Entailment"
    },
    "adfbe24e-4595-4fe3-88d8-8b5f01458993": {
        "text_answer": "  The statement contrasting patient cohorts have contributed to the results of the primary clinical trial and the secondary clinical trial is not directly entailed in the given trial data   The primary trial and the secondary trial are about different drugs denosumab and dmethadone respectively and different outcome measures percentage of participants with a response within 10 days of first dose of denosumab and number who reached a safe dose of",
        "label": "Contradiction"
    },
    "003a36ac-4091-4ca9-96f3-1108302eb9e1": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive 2 mgkg of trastuzumab IV once a week which is the same dosage as patients in cohort 2 of the secondary trial who receive 2 mgkg of trastuzumab IV weekly starting from Day 8 of Cycle 5 and for all subsequent cycles Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "f329518b-872b-41af-8260-9d231e7ab205": {
        "text_answer": "  The statement is entailed in the trials as the secondary clinical trial is specifically designed for female patients with breast cancer The primary clinical trial on the other hand does not specify gender as a criterion for inclusion or exclusion Therefore the statement is entailed in the trials as the secondary trial only includes females while the primary trial does not make gender a factor in patient eligibility",
        "label": "Entailment"
    },
    "84166f85-0a62-47fd-8dfa-a01dd778c748": {
        "text_answer": "  The statement is neither entailed in the trials nor contradictory to them The trials focus on different outcome measures for different interventions in the context of treating malignant oropharyngeal neoplasm The first trial investigates the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the second trial examines the effectiveness of Physical Therapy on pain management The trials do not directly compare or contradict each other",
        "label": "Entailment"
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial there is no mention of any drugbased interventions The interventions listed are massage therapy pain therapy psychosocial assessment and care and qualityoflife assessment Therefore the primary trial does not test any drugbased treatments  In contrast the secondary trial tests two different drugbased interventions PF0664702",
        "label": "Entailment"
    },
    "b1cd1f5b-2b10-4bec-8482-a049acc7b674": {
        "text_answer": "  The statement thyroid gland lipoadenoma is a thyroid gland adenoma composed of follicular structures and mature adipocytes There are no conditions on hepatic function for participants of the primary trial is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial   The statement is about a specific type of thyroid gland adenoma and does not mention anything related to the hep",
        "label": "Contradiction"
    },
    "e0c940e7-9a19-4c78-bf0f-4f630f6cfb90": {
        "text_answer": "  The statement the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery whereas the secondary trial participants only receive two different drugs and several different imaging scans is not directly related to the information provided about sdh complex mutation analysis Therefore it does not entail or contradict the statement about sdh complex mutation analysis being performed or not in the trials The trials descriptions do not provide enough",
        "label": "Entailment"
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "text_answer": "  The statement is not entailed in the given trials as there are significant differences between the groups in both trials   In the primary trial there is a difference in the diagnostic accuracy between the two algorithms with the Siemens algorithm having a slightly lower AUC 0880 compared to the Lorad algorithm 0884  In the secondary trial there are significant differences in the mean scores of the Lee Fatigue Scale between",
        "label": "Contradiction"
    },
    "de8bb37e-838b-4ac0-bd2b-b866feadac64": {
        "text_answer": "  The statement have difficulty getting up from chairs is a question about whether an individual has or had difficulty getting up from chairs is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted by the trials based on the given information",
        "label": "Entailment"
    },
    "d050c306-4563-403d-96c4-26728b8dc0df": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the reflexology intervention lasted for 10 weeks while in the secondary trial both the placebo and vitamin D interventions lasted for 24 weeks Therefore the secondary trials interventions are extended by three times 24 weeks divided by 10 weeks compared to the primary trials intervention duration",
        "label": "Entailment"
    },
    "01f72f8a-d22e-4509-859a-5df198d04d2f": {
        "text_answer": "  The statement patients suffering from severe obesity can participate in the primary clinical trial is entailed in the given inclusion criteria of the trial The inclusion criteria state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs which meets the definition of severe obesity Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "4650b6bf-1aed-4407-ac23-7ca5a4c2728d": {
        "text_answer": "  The statement patients who have previously suffered from pulmonary embolisms and have breast implants can participate in the secondary clinical trial is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial excludes participants with a history of clotting disorders including deep vein thrombosis and pulmonary embolism However it does not mention anything about breast implants   ",
        "label": "Contradiction"
    },
    "9eb7c3cc-b3f5-40cf-8952-148afd8f2b04": {
        "text_answer": "  The statement is not entailed in the trials as they are about different interventions in two different cohorts of a primary trial The statement mentions postpartum placental separation which is not related to the trials at all Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "8bd8a0f5-4bc9-4de6-a7d8-2a3acaadc6c4": {
        "text_answer": "  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial mentions an exclusion criterion for prior use of Herceptin within the last 5 months but it does not mention anything about gabapentin The secondary trial mentions an",
        "label": "Contradiction"
    },
    "f098a93b-9d39-4928-87b7-0ad43311c615": {
        "text_answer": "  The statement more than 34 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 14 days of the study is contradictory to the information provided in the trials   The trials report the number of participants with pathologic complete response at the time of surgery which is approximately 7 months after the initiation of treatment There is no mention of any",
        "label": "Contradiction"
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "text_answer": "  The statement There are several cases of swelling hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial is a contradiction to the information provided in the trials The trials state that there were no cases of swelling hypothermia or confusion recorded in either trial",
        "label": "Contradiction"
    },
    "b3361d9c-9d9f-4966-80e7-629656bfcd1e": {
        "text_answer": "  The statement is entailed in the Trials as the trials provide the information that Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain were observed as Adverse Events in the secondary trial but not in the primary trial",
        "label": "Entailment"
    },
    "09eee297-7801-4d6b-b3f6-17ee4f3418e4": {
        "text_answer": "  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is a contradiction to the information provided in the trials   The primary trial does not indicate that the control group Standard Mammography performed better than the test group Intraoperative Mammography based on operative time savings In fact the trial shows that the test group",
        "label": "Contradiction"
    },
    "d225c39d-4bd1-4129-a359-2909af912031": {
        "text_answer": "  The statement the primary clinical trial results state that the most effective overall response rate was provided by the arm A intervention In contrast the secondary clinical trial found that the denosumab group had inferior time to first onstudy SRE compared to the zoledronic acid group is a comparison of two different trials with different outcome measures   The primary trial compared Arm A and Arm B interventions and found that Arm A had a higher overall response rate ",
        "label": "Entailment"
    },
    "a02a955a-9890-4347-8a6b-1377008f581b": {
        "text_answer": "  The statement patients suffering from hypokalemia are ineligible for the primary clinical trial is entailed in the primary trials exclusion criteria as it explicitly states Potassium within the normal range of 3553 mEqL Therefore patients with hypokalemia potassium levels below 35 mEqL are excluded from the primary trial  Regarding the secondary trial",
        "label": "Entailment"
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "text_answer": " The trials provided do not contain sufficient information to determine if the statement Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study is entailed or contradicted The trials only report the average pain intensity scores and the confidence intervals for the mean pain intensity scores for the Low Dose and High Dose groups They do not provide information on the distribution of pain intensity scores or the number of patients who experienced no pain",
        "label": "Contradiction"
    },
    "b652609b-4609-481e-a5de-caa0c4432f2f": {
        "text_answer": "  The statement is entailed in the given trials as both interventions memantine and placebo are given twice daily BID for a total of 81 days days 181 Therefore the frequency and length of time are the same for both interventions making the statement true",
        "label": "Entailment"
    },
    "be6130d9-49f1-4b4e-82f2-6acc6ee7f176": {
        "text_answer": "  The statement have excessive tearing is a question about whether an individuals eyes have or had excessive tearing is not directly related to the adverse events recorded in the primary trial The statement does not entail or contradict any information provided in the trial data",
        "label": "Entailment"
    },
    "292a2905-b407-4068-8c2e-e6d596e494ca": {
        "text_answer": "  The statement The primary clinical trial does not allow candidates to engage in CBTbased treatments while the secondary clinical trial might still consider them as potential candidates is a contradiction based on the provided information   The primary clinical trials inclusion criteria do not mention anything about excluding candidates based on CBTbased treatments Therefore it is not stated or entailed in the primary trial that candidates cannot engage in CBTbased treatments  The secondary",
        "label": "Contradiction"
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "text_answer": "  The statement Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time is entailed in the trials as stated in the exclusion criteria of the primary trial under the section Any other reason which in the investigators opinion makes the subject unsuitable for a clinical trial Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "72f49bc3-1624-437d-bf75-e37a24a9c19f": {
        "text_answer": "  The statement age at menarche is a risk factor for breast cancer is not directly entailed nor contradicted in the given inclusion and exclusion criteria for the primary and secondary trials The criteria focus on various medical conditions eligibility for previous treatments and other factors related to participation in the clinical trials The statement about age at menarche being a risk factor for breast cancer is a separate piece of information and does not contradict or entail any of the stated",
        "label": "Contradiction"
    },
    "002bd33d-4038-4b2b-9f56-1bd8e8978d64": {
        "text_answer": "  The statement when diagnosed with 23 cerebral metastases located within the brainstem patients will be excluded from the secondary clinical trial but they could still be considered eligible for the primary clinical trial is a conditional statement Lets break it down  1 The statement applies to patients who have cerebral metastases and are considering participation in both the primary and secondary clinical trials 2 The statement specifies that patients",
        "label": "Entailment"
    },
    "25d927c2-92be-405f-950a-e275c4d00e38": {
        "text_answer": "  The statement is entailed in the trials if and only if the following conditions are met  1 The primary trial has a higher incidence of adverse events related to recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage compared to the secondary trial  Lets calculate the incidence of these conditions in both trials  Primary Trial",
        "label": "Entailment"
    },
    "fd2a59ea-6b33-4b24-ae04-32a2a40b4029": {
        "text_answer": "  The statement does not entail or contradict the given trial information   The trial information only specifies the dosage and timing of Dexamethasone administration for two different cohorts but it does not mention anything about dietary vitamin K measurement or its relationship to the trial interventions",
        "label": "Entailment"
    },
    "883cad2c-dee5-4530-bdde-5d616d4570ad": {
        "text_answer": "  The statement patients with severe insomnia and schizophrenia are not eligible for the primary clinical trial but are eligible for the secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary clinical trial has specific eligibility criteria for breast cancer patients and severe insomnia and schizophrenia are not mentioned as inclusion or exclusion criteria However the statement does imply that patients",
        "label": "Contradiction"
    },
    "81694850-fb70-4062-8dab-a52dd8083ebb": {
        "text_answer": "  The statement four unique adverse events impacted patients in cohort 2 of the primary clinical trial is not directly entailed in the given trial data However it is not contradictory either as the data does not provide sufficient information to definitively prove or disprove the statement The statement implies that there were four distinct types of adverse events that affected at least one patient each in cohort 2 While the trial data lists the number of",
        "label": "Contradiction"
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "text_answer": "  The statement is entailed in the Trials with Entailment The primary trial and the secondary trial have different outcome measurements the primary trial measures the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events while the secondary trial measures the number of participants with objective response However both trials involve the same intervention which is the administration of talazoparib to participants with different types of cancer breast and",
        "label": "Entailment"
    },
    "4fc29a51-2cd7-4c8c-8000-58bd9cb4858d": {
        "text_answer": "  The statement no adverse events have been reported in either the primary clinical trial or the secondary clinical trial is entailed by the given data since the data reports that there were no adverse events in both trials",
        "label": "Contradiction"
    },
    "64cc1bfb-d23f-47e1-bfcb-7d69cd8458ad": {
        "text_answer": "  The statement there was a single psychiatric adverse event in the primary trial which affected fewer than 1 in 10 patients is entailed in the given trial data   Explanation   The statement specifies that there was one psychiatric adverse event suicidal ideation in the trial and that this event affected fewer than 1 in 10 patients 200 The trial data confir",
        "label": "Entailment"
    },
    "48a0cb8b-d7c5-42e0-8adc-abd0b8f17301": {
        "text_answer": "  The statement Patients with a TNBC tumor of 100mm in diameter are eligible for both the primary trial and the secondary trial is neither entailed nor contradicted by the information provided in the trials   The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size Therefore the statement does not follow logically from the trials as they stand Additionally",
        "label": "Entailment"
    },
    "dc55e21c-534b-4045-9c6c-f13919efde18": {
        "text_answer": "  The primary trial and the secondary trial both involve the administration of drugs to study subjects but they differ in the specific drugs used and the dosing and administration schedules   In the primary trial subjects receive a single dose of FMX followed by treatment with MM398 The FMX dose is a single bolus IV injection of 5 mgkg on Day 1 and MM398 is administered as an IV infusion",
        "label": "Entailment"
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial and the secondary trial both use intravenous injections and MRIs but they do not use the same drugs dosages or frequency of administration in their interventions  Therefore the statement the primary trial and the secondary trial do not use the same drugs dosages or frequency of administration in their interventions however they do both use intravenous injections and MR",
        "label": "Entailment"
    },
    "d6381c6b-a7d6-406a-9d52-a660c27c2d49": {
        "text_answer": "  The statement the primary trial and the secondary trial do not have any recorded adverse events for their participants is entailed by the given trials data as both trials report a total of 0 adverse events for Adverse Event 1 and Adverse Event 2  The term crypt mentioned in the statement is not related to the trials data and can be disregarded for the verification process",
        "label": "Entailment"
    },
    "3159e9e4-c8a2-4333-b24c-250698ae8ffd": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial was completely free of any adverse events is contradicted by the trial results   Explanation   The trial results indicate that there were participants in cohort 1 Dose Level 1 who experienced adverse events specifically 1000 of the participants analyzed in this cohort had at least one adverse event Therefore the statement that co",
        "label": "Contradiction"
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event in the primary trial is entailed in Trial 2 since it reports 3 cases of vomiting However it is not entailed in Trial 1 as it does not report any gastrointestinal adverse events Therefore the statement is not entailed in both trials as a whole However it is entailed in at least one of the trials",
        "label": "Entailment"
    },
    "70bfa3c4-2199-4d07-84c9-f41cac594ed4": {
        "text_answer": "  The statement is entailed in the trials as follows  Cohort 1 received a dose of MM121 of 12 mgkg and Cetuximab of 400 mgm2 loading dose followed by 200 mgm2 maintenance IV QW  Cohort 2a received a dose of MM121 of 20 mgkg and Cetux",
        "label": "Entailment"
    },
    "97fe92c7-779d-4de8-8834-60ed8fe3178f": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial the only AEs recorded were 3 cases of Lymphoma take lots of naps is a question about whether an individual takes or took a lot of naps is neither entailed nor contradicted by the given trials data The trials data only provides information about adverse events AEs occurring during the trials and does not mention anything about individuals taking",
        "label": "Contradiction"
    },
    "5829a465-2f7e-4a15-a746-24e4c0f53200": {
        "text_answer": "  The statement is entailed in the Trials   Explanation  The primary trial has no age restriction mentioned in its inclusion criteria while the secondary trial specifies that patients must be over 18 years old to participate Therefore the statement that age restrictions apply to patients participating in the secondary clinical trial is entailed by the information given in the trials as it accurately reflects the difference in age requirements between the two trials",
        "label": "Entailment"
    },
    "88fbd986-643d-4086-8091-e535d1970ab9": {
        "text_answer": "  The statement both the primary and secondary clinical trials apply identical inclusionexclusion criteria to all participants within their respective trials is entailed in the given trials as the identical inclusion and exclusion criteria have been specified for both trials",
        "label": "Entailment"
    },
    "0ed8370b-00c3-41d9-9d12-0c0f1259cbf1": {
        "text_answer": "  The statement is entailed in the trial description for Intervention 1 as it specifies that patients practice paced breathing once daily according to the instructional CD Therefore the statement is consistent with the information provided in the trial description However it does not directly apply to Intervention 2 as patients in that group practice paced breathing twice daily Nonetheless the statement does not contradict the trial description for Intervention 2 as it only pertains to",
        "label": "Entailment"
    },
    "a06d2404-8265-4baf-907d-ddba1bb223d0": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any Aes how long not feeling like eating lasted is a question about how long not feeling like eating lasted is neither entailed nor contradictory to the given information in the trials   The trials do not provide any information regarding the duration of not feeling like eating as an adverse event so the statement is neither entailed nor contradictory to the trials",
        "label": "Entailment"
    },
    "df8f9622-e361-4283-bc4a-fef7eaa101b1": {
        "text_answer": "  The statement corresponding author indicator is an indication that the specific author is considered the corresponding author is not directly related to the adverse event data provided in the trials Therefore it does not entail or contradict the information given about the number of adverse events in the primary and secondary trials  However the statement that the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts is true based on",
        "label": "Entailment"
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is a contradiction to the inclusion criteria of the trial as stated in the text  The reason being the statement suggests that patients with a history of severe anaphylactic reactions to trastuzumab or nonresponse to trastuzumab treatments are eligible for the",
        "label": "Contradiction"
    },
    "1f742130-d274-4857-bc92-af652963c07b": {
        "text_answer": "  The statement none of the primary trial participants and none of the 1674 secondary trial participants experienced an adverse event is entailed in the given trials as both trials report that no adverse events occurred in their respective groups",
        "label": "Entailment"
    },
    "3cd90294-f295-4725-82d4-e185d03cc2b7": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 1095 days would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are excluded While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria it is a type",
        "label": "Entailment"
    },
    "0cacd90a-ae93-47cb-b9f2-fa7e03d75270": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000 mcg of talazoparib daily is not directly related to the statement have mouth discomfort with toothpaste The first statement describes the intervention given to some trial candidates while the second statement is a question about an individuals experience with mouth discomfort specifically related to toothpaste  Therefore the statement several of the primary trial candidates",
        "label": "Entailment"
    },
    "9a137ed3-f905-4367-988c-002fabb77140": {
        "text_answer": "  The statement only 5 of patients in cohort 2 report increased pleural effusion within the primary clinical trial is a contradiction to the information provided in the trials   The trials report that 1 out of 4 patients in cohort 2 experienced increased pleural effusion which is 2500 not 500",
        "label": "Contradiction"
    },
    "71268387-6e9d-4875-b193-b60b4e3e7033": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 2 receives Herceptin trastuzumab at a dose of 4 mgkg IV infusion on Day 1 of Cycle 5 followed by 2 mgkg by IV infusion weekly starting from Day 8 However",
        "label": "Entailment"
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "text_answer": "  The statement The results from the primary trial indicate that the Arm A intervention has a better overall response rate than the placebo arm additionally in the secondary trial the Denosumab cohort had a better Time to First OnStudy SRE than the Zoledronic Acid cohort is entailed in the trials if we make the following assumptions  1 The primary trial compares Arm A to a placebo arm 2",
        "label": "Entailment"
    },
    "79f436e1-8238-4d99-824f-6b19bfbd4ec4": {
        "text_answer": "  The statement drugbased cures in the primary and the secondary trial are utterly diverse in nature is an entailed statement based on the given trial information   Explanation   The primary trial involves the use of Abl Cells and Cyclophosphamide with different dosing regimens for patients with and without liver involvement The secondary trial involves the use of DMCHOCPEN with different dosing regimens for",
        "label": "Entailment"
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial the intervention consists of a single drug ZD1839 2 In the secondary trial the intervention for Intervention 1 consists of three different drugs Zoledronic acid vitamin D and calcium supplements Intervention 2 in the secondary trial also requires additional drugs Sr89 or Sm153 ",
        "label": "Entailment"
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "text_answer": "  The statement Across both the primary trial and the secondary trial only one death was recorded in the adverse events is entailed by the given data   Explanation   The statement implies that there was a total of one death across both trials in the adverse events section The primary trial had one death recorded and the secondary trial had none Therefore the total number of deaths across both trials is one which is in line with the statement",
        "label": "Entailment"
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The primary trial involves Alpha Lipoic Acid which has a dosing regimen of three times daily with dose escalation until a maximum tolerated dose is found This means that patients in the primary trial will receive increasing doses of Alpha Lipoic Acid throughout the study duration  The secondary trial involves Necitumumab which has two different dosing",
        "label": "Entailment"
    },
    "333e2178-1944-4771-9ce5-6c89a1386f5a": {
        "text_answer": "  The statement is entailed in the given trials as follows  In both Intervention 1 and Intervention 2 participants receive 1 Doxorubicin 60 mgm IV bolus injection every 3 weeks for 4 cycles 2 Cyclophosphamide 600 mgm IV bolus injection every 3 weeks for 4 cycles 3 Docetaxel ",
        "label": "Entailment"
    },
    "c8633493-4879-4e97-9fcf-5e59ca22a79a": {
        "text_answer": "  The primary trial includes patients with a breast tumor 1 cm in diameter HR HER2 and the secondary trial includes patients with measurable disease but the size of the breast tumor is not explicitly stated in the secondary trial However the statement that patients with a breast tumor 082 cm in diameter with confirmed hr positive and her2 negative status are eligible for both trials is not directly entailed in the given trials as the",
        "label": "Contradiction"
    },
    "a003e152-72e6-4c28-9f7d-1d2086174992": {
        "text_answer": "  The statement under half of the patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR or a confirmed partial response PR is entailed in the trial results as stated 53 out of 60 participants analyzed experienced a confirmed OR CR or PR Since OR includes both CR and PR and the number of participants experiencing OR is less than half",
        "label": "Entailment"
    },
    "594bf055-6c27-4319-b7b6-11ef47fab70c": {
        "text_answer": "  The statement in the initial cohort of the primary clinical trial one instance each of anaemia and febrile neutropenia was documented while pancytopenia was not observed is entailed in the Trials 1 and 2 provided   Explanation   The statement mentions that there was one instance each of anaemia and febrile neutropenia and no instances of pancy",
        "label": "Entailment"
    },
    "174a00b4-2d77-4734-b02a-3603133fa8fe": {
        "text_answer": "  The statement in the primary clinical trial the neratinib group demonstrated a lower incidence of iDFS than the group given placebo is entailed in the trials provided   Explanation   The trials provide the percentage of participants with iDFS events for each group neratinib and placebo at year 2 The statement asserts that the neratinib group had a lower incidence of iDFS events than the",
        "label": "Entailment"
    },
    "055374e1-939d-4366-835a-edf8e587f45c": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2",
        "label": "Entailment"
    },
    "292a7346-b4f6-4fc1-92a7-80297532eeff": {
        "text_answer": "  The statement is entailed in the trials as both cohorts are using the same instructional CD for paced breathing The difference between the two cohorts lies in the frequency of practice sessions per day with cohort 2 having twice daily sessions instead of once daily for cohort 1 This difference does not contradict the shared use of the same instructional CD",
        "label": "Entailment"
    },
    "892ac2e3-f5f8-42eb-957c-b3ca6af18d3a": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial administers oral pregabalin while the statement mentions intrathecal IT Liposomal Cytarabine Depocyt and intravenous HighDose Methotrexate HDMTX which are different interventions from the primary trial Therefore the statement is contradictory to the primary trial",
        "label": "Contradiction"
    },
    "6c12493c-9eab-4206-aacc-bbb3dc398050": {
        "text_answer": "  The statement no single type of adverse event noted in the primary clinical trial impacted over 25 of the patient population is not directly entailed or contradicted by the information provided in the trials data   The data shows that the total number of adverse events was 5 out of 14 3571 but it does not indicate that any single type of adverse event occurred in more than 25 of the",
        "label": "Contradiction"
    },
    "753d23e6-333c-4ec1-8bc2-a853c29a20e9": {
        "text_answer": "  The statement is a comparison of the interventions used in the primary and secondary clinical trials The primary trial uses radioembolization with Yttrium90 glass microspheres TheraSphere while the secondary trial uses a combination of 560 mg of ibrutinib and 10 mgkg of MEDI4736 administered twice daily for 30 days  The statement is entailed in",
        "label": "Entailment"
    },
    "c1e836e2-ad18-40b1-b8c4-0f05168d5104": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to compare the doses of ALT801 given in each cohort   The statement says that cohort 2 receives 0035 mg less ALT801 than cohort 1   From the trials we know that  Cohort 1 receives 0015 mgkg",
        "label": "Entailment"
    },
    "2c817052-b2e7-4199-8b5c-77d285e2231c": {
        "text_answer": "  The statement the primary clinical trial mandate is that all participants possess an IHC 3 confirmed HER2 positive tumor and necessitate substantial aid and frequent healthcare support is entailed in the inclusion criteria of the trial   The trial includes patients with histologically confirmed infiltrating primary breast cancer of  20 cm in largest clinical diameter and HER2 positive tumor either IHC 3 or FISH The",
        "label": "Entailment"
    },
    "561a11dc-abb5-4a2b-9211-4e27419cfc43": {
        "text_answer": "  The statement in the primary clinical trial it was recorded that over 50 of those treated with lapatinib 1000 mg and nabpaclitaxel displayed either a verified complete or partial response is entailed in the trial results provided   The results state that 53 of the 60 participants 883 had an OR which means that 53 out of the 60 participants had",
        "label": "Entailment"
    },
    "9eb119ec-3ef7-4de4-ab36-5e8d63fdb984": {
        "text_answer": "  The statement have discomfort or pain in pelvic area is not directly related to the inclusion and exclusion criteria provided for the primary and secondary trials The statement is about a symptom or condition whereas the criteria are about eligibility and exclusions for study participation Therefore the statement neither entails nor contradicts the information provided in the trials",
        "label": "Entailment"
    },
    "9e31c420-01cc-4232-9793-a3a4b7201fa6": {
        "text_answer": "  The statement liter per meter squared is a unit of concentration equal to liter per meter squared is not entailed in the given trials as the trials do not mention anything related to units of concentration or liter per meter squared The trials only provide inclusion and exclusion criteria for participants of the primary and secondary trials The statement is neutral with respect to the trials",
        "label": "Contradiction"
    },
    "6fa15cf5-6fc4-48f3-a800-5e4699952ddb": {
        "text_answer": "  The statement the primary clinical trial and secondary clinical trial are open for severely obese patients to participate is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The criteria do not mention anything about body mass index or obesity as an inclusion or exclusion factor for either trial Therefore the statement is neither entailed nor contradicted by the information provided",
        "label": "Entailment"
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "text_answer": "  The statement is entailed in the secondary trial exclusion criteria as follows  1 Chemotherapy or radiotherapy within 2 weeks The secondary trial excludes patients who have received chemotherapy or radiotherapy within 2 weeks which matches the statement 2 Unstable angina The secondary trial excludes patients with clinically significant cardiac arrhythmia or history or current evidence of a myocardial infarction during the last 6 months",
        "label": "Entailment"
    },
    "804742bb-2d69-45a8-a7a9-b6a269bf8d58": {
        "text_answer": "  The statement a specific level of hepatic enzyme in the blood is required to participate in the primary clinical trial is not explicitly stated in the given inclusion and exclusion criteria However it can be inferred that liver function is mentioned as a part of the adequate organ function requirement for eligibility in the trial Therefore it is reasonable to assume that a certain level of liver enzymes in the blood would be required but this is not explicitly stated in",
        "label": "Entailment"
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "text_answer": "  The statement the Ketorolac 30 mg group of the primary trial had a 64 Recurrencefree Survival compared to the NaCl 09 3mL group is not entailed in the given trials data   The trials data only provides the number of participants in each group and their Recurrencefree Survival percentage The percentage difference between the two groups cannot be directly calculated from",
        "label": "Contradiction"
    },
    "05b6b24d-8753-4029-9464-c825cb52b9f4": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference in dosages and treatments between the two cohorts The first cohort receives sunitinib at a daily dose of 25 mg while the second cohort receives paclitaxel at a starting dose of 90 mgm2",
        "label": "Entailment"
    },
    "e34d6b72-e842-4cd8-a0f4-08c8f4d33be9": {
        "text_answer": "  The statement underweight patients may participate in the primary clinical trial is contradictory to the inclusion criteria stated in the trial description The inclusion criteria specify that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs Underweight patients have a BMI less than 185 kgm2 so they do not meet the inclusion criteria and therefore cannot participate in the trial",
        "label": "Entailment"
    },
    "0bba5705-e808-4f90-b434-a951027f4d0f": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment regime is defined as a threeweek cycle However the interventions in both arms of the trial do not have a set cycle specified The maximum durations of treatment are given but the frequency of the interventions within a cycle is not mentioned  In contrast in the secondary trial there is no treatment regime specified in terms of cycles The interventions are defined",
        "label": "Entailment"
    },
    "746f0f7a-c7e2-4ac9-a0ca-db2783eec9fa": {
        "text_answer": "  The statement none of the patients treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial experienced any treatmentemergent adverse events is contradicted by the trial results   The trial reported that there were 24 treatmentemergent adverse events AEs among the 25 participants in the sunitinib  docetaxel  trastuzumab armgroup",
        "label": "Contradiction"
    },
    "9e02f276-1bd0-4373-a049-9a67ee3eac87": {
        "text_answer": "  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is not entailed in the given information The statement mentions adverse events in the primary trial but the trials data provided only mentions the number of adverse events for cohorts 1 and 2 which is both zero The statement about hypogonadotropic hypogon",
        "label": "Contradiction"
    },
    "7e0f7c16-59ff-4a80-833a-7bb82748e80a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation  The statement suggests that cohort 1 received a lower dose of cetuximab but the same amount of mm121 as cohort 2 However the trials specify the doses of both mm121 and cetuximab for each cohort   Cohort 1 received 12 mg",
        "label": "Entailment"
    },
    "00f4aa60-c89a-496d-aa2d-9535fcc79ff0": {
        "text_answer": "  The statement The paced respiration intervention group experienced fewer Hot flashes per day on average than the fast shallow respiration group is entailed in the trials provided   The mean number of hot flashes per day for the paced respiration group was 348 345 and for the fast shallow breathing group was 395 419 The difference between the means is 047",
        "label": "Entailment"
    },
    "65edf675-63e7-4b5f-b131-9e5cdf9eeec4": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information to make a comparison of the dosages in terms of the cytolytic process The statement makes a quantitative comparison of the dosages but the trials only mention the specific dosages and schedules for each intervention without providing any information about their potential effects on cell death processes Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "a116a540-abca-478e-94ea-9997b0434c8b": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trial results The trial results only report the changes in Ki67 expression for the TAK228 Plus Tamoxifen arm but they do not mention any information about inppl1 gene mutations or their relationship to Ki67 expression Therefore the statement is neither entailed nor contradicted by the trial results",
        "label": "Entailment"
    },
    "ed50607e-8c46-4565-9192-4d5c4ca5fea5": {
        "text_answer": "  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not entailed in the given trial results The trial results only provide information about the number of participants in cohort 2 who did not experience any vomiting or the need for rescue medication during the first 24 hours after",
        "label": "Contradiction"
    },
    "321d4cba-47ee-4c74-85b9-072814b6fe6b": {
        "text_answer": "  The statement fit patients who are not in gestation period have qualification to participate in primary clinical trial and secondary clinical trial is entailed in the given trials as follows  Both primary and secondary trials have the exclusion criterion of pregnant andor breastfeeding patients Therefore patients who are not pregnant and not breastfeeding are eligible to participate in both trials This is in line with the statement that fit patients who are",
        "label": "Entailment"
    },
    "1f4fe504-06a7-40e6-ad0e-76c903ea80a2": {
        "text_answer": "  The statement in the primary clinical trial the occurrences of hepatotoxicity were tenfold compared to the cases of hypertension and pancreatectomy is entailed in the given data if we interpret tenfold as meaning nine times as many   The data states that the occurrences of hepatotoxicity were 3750 which is 3 times the sum of the occurrences of",
        "label": "Entailment"
    },
    "6c3ebd57-b814-49df-bade-ad46362eaa2b": {
        "text_answer": "  The statement is contradictory to the given information in the trials   Explanation   The statement suggests that cohort 1 receives treatments for ER PR and HER2 conditions while cohort 2 receives treatments for ER PR and HER2 conditions However the given information states that cohort 1 is a Phase 2 Triplenegative cohort which means it is",
        "label": "Entailment"
    },
    "83c979cb-fb3a-4792-8a63-8f7e544bb8a8": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial is not explicitly stated in the inclusion and exclusion criteria provided However the criteria do mention that individuals with a history of interstitial lung disease or pneumonitis are excluded from the trial Diffuse parenchymal lung disease is a type of interstitial lung disease Therefore the statement is",
        "label": "Entailment"
    },
    "f203176f-3d6f-4e37-a07b-9bcf409ed538": {
        "text_answer": "  The statement africanamerican participants in the primary clinical trial must remain inhabitants of texas for the entirety of the study is not entailed in the provided inclusion and exclusion criteria for the dose escalation and expansion phases of the clinical trial The criteria focus on various medical and demographic factors such as age tumor type performance status and laboratory values as well as prior treatments and concurrent medications There is no mention of any geographic requirements",
        "label": "Contradiction"
    },
    "c467ce7a-d234-4542-909b-ac94393314ce": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial description states that patients in the intervention arm will be invited to view the educational DVD which directly contradicts the statement that the educational DVD will not be used in any of the interventions within the primary clinical trial",
        "label": "Contradiction"
    },
    "60431d29-7e80-4a3e-b433-83f886ea73b6": {
        "text_answer": "  The statement mixture of melanocytic neoplastic components is a finding indicating the presence of at least two morphologic components in a melanocytic tumor sample is not directly related to the number of adverse events in the primary and secondary trials Therefore the statement does not entail or contradict the information provided in the trials",
        "label": "Entailment"
    },
    "afc5437d-4c34-46e3-bcb0-742a23ba35e6": {
        "text_answer": "The statement is not entailed in the given trials as there is no mention of the primary trial in the secondary trials inclusion or exclusion criteria Therefore the statement is contradictory to the information provided",
        "label": "Contradiction"
    },
    "aa861098-a5f8-473e-be7d-eba94ccb4ab1": {
        "text_answer": "  The statement an adult patient diagnosed with ilddpld within the last 156 weeks with a life expectancy of 05 years would be eligible for the primary trial is not entailed in the inclusion criteria provided  The inclusion criteria state that patients must have a life expectancy of greater than 3 months The patient described in the statement has a life expectancy of only 05 years which is less than the required ",
        "label": "Contradiction"
    },
    "1f8901ea-ca2d-4771-95e5-8b75fa7e9994": {
        "text_answer": "  The statement in the intervention portion of the primary clinical trial theres no detailed structure or explanation about a treatment cycle is neither entailed nor contradicted by the information provided in the Trials with Entailment or Contradiction   The Trials with Entailment or Contradiction does not provide enough information to determine whether or not a treatment cycle is explicitly stated or detailed in the intervention portion of a primary clinical trial The Trials with",
        "label": "Contradiction"
    },
    "4869e50d-ccc3-4200-b2e0-bf706fc99488": {
        "text_answer": "  The statement patients diagnosed with benign ductal carcinoma in situ are eligible for the primary clinical trial but excluded from the secondary clinical trial is a contradiction based on the provided information  Explanation  In the primary trial patients with a clinical radiographic and histological diagnosis of benign breast disease including ductal carcinoma in situ are eligible for inclusion However in the secondary trial patients with a",
        "label": "Contradiction"
    },
    "22cf6f40-f022-4482-acdf-eef98748b946": {
        "text_answer": "  The statement is entailed in the trials as both trials report changes in values related to their respective outcome measures over specific time frames The primary trial measures changes in pain intensity at various time points after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine over a period of 9 months Therefore the statement that the primary trial reports changes in pain intensity and the secondary trial measures the change from baseline to 3 quarters of a year",
        "label": "Entailment"
    },
    "b4a7bcbe-6c7b-4e37-be25-35f2dd042bce": {
        "text_answer": "  The statement the majority of patients in the primary trial experienced complete response by week 2 is contradictory to the trial results The trial results indicate that there were no participants with complete response at either week 12 or week 24 Therefore the majority of patients did not experience complete response by week 2",
        "label": "Contradiction"
    },
    "97a8ede9-e46f-4b17-be7d-b05e9bd2f86e": {
        "text_answer": "  The statement patients enrolled in both the primary and secondary trial remained free from tumour lysis syndrome is not directly entailed or contradicted by the given trial data   The trials only report adverse events and do not provide information about the occurrence or nonoccurrence of tumour lysis syndrome Therefore it is not possible to determine if the statement is true or false based on the given data alone",
        "label": "Contradiction"
    },
    "59c8ac7f-504b-46db-a840-b84fd9969b3d": {
        "text_answer": "  The statement data from the primary clinical trial indicates responses of the lbh589 and lapatinib cohort is not entailed in the provided trial information as there is no data presented regarding the responses of the LBH589 and Lapatinib cohort in the trial The trial information only provides details about the dose levels administration schedules and number of participants for the LBH589 with Capecitabine and L",
        "label": "Contradiction"
    },
    "d08f014d-7d1b-45a1-b1c2-f68f12591f15": {
        "text_answer": "  The statement Both cohorts of the primary trial contained the same number of participants is not directly related to the information provided in the trials The trials only mention the number of participants analyzed in each arm and the percentage of participants with events but they do not specify if the number of participants in each arm is the same or different Therefore the statement cannot be determined to be entailed or contradicted based on the given information  Regarding the second part of",
        "label": "Entailment"
    },
    "6a0e68b7-6099-4fb9-bf11-35885b715348": {
        "text_answer": "  The statement for the primary clinical trial patients with a successful response to previous hormonal therapies could be considered for participation is entailed in the given inclusion criteria   Reasoning   The inclusion criteria state that patients must have breast cancer that has continued to grow despite having received hormonal treatment However it also states that patients must still require hormonal treatment This implies that patients who have had a successful response to hormonal therapies in the past",
        "label": "Entailment"
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "text_answer": "  The statement All Patients receiving the placebo intervention in the primary trial experienced emesis is a contradiction to the results presented in Trial 2   In Trial 2 it is stated that there were 5 participants in the placebo group who were analyzed However the statement implies that all 20 participants in the placebo group experienced emesis Therefore the statement is a contradiction to the information provided in the trial results",
        "label": "Contradiction"
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "text_answer": "  The statement There are 0 shared inclusionexclusion criteria between the secondary trial and the primary trial is a statement about the number of shared criteria which is not directly related to the given inclusion and exclusion criteria lists However based on the provided information it can be determined that there is no common inclusion or exclusion criterion between the two trials Therefore the statement is entailed by the given trials criteria",
        "label": "Contradiction"
    },
    "ebe5f6c9-355c-4d69-8b0d-5ac8d5f861a1": {
        "text_answer": "  The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not directly entailed or contradicted by the given trial data The trial data mentions only two psychiatric adverse events suicidal ideation and no specific mention of eating disorder or Schizophrenia Therefore the statement is neither entailed nor contradicted by the given trial data",
        "label": "Contradiction"
    },
    "90e72a43-b0ee-4656-b679-a6025ef5d4c2": {
        "text_answer": "  The statement the results of the secondary clinical trial and the primary clinical trial are measured within different units is entailed in the trials as follows  In the primary trial the outcome measurement is tumor diameter and its unit of measure is cm In contrast in the secondary trial the outcome measurement is the number of participants with solid tumor response based on local investigator assessments using RECIST 11 criteria The measurement type for this outcome is count",
        "label": "Entailment"
    },
    "89f8f42e-0ac7-4fc4-bbd3-d58ffb933005": {
        "text_answer": "  The statement is not directly entailed in the given trials as there is no comparison of the dosages of Herceptin MM121 or Doxorubicin between the primary and secondary trials The statement mentions higher doses of Herceptin and Doxorubicin for the secondary trial candidates but the trials do not provide enough information to confirm or deny this claim The statement also mentions a benign oral",
        "label": "Contradiction"
    },
    "7af1ab1f-5170-496e-ba41-61d54113c9c6": {
        "text_answer": "  The statement Sexually active fertile men and women with the ability to bear children are eligible to participate in the primary clinical trial however they would need to abstain throughout the duration of the study is entailed in the trials exclusion criteria   Reasoning   The trials exclusion criteria state that Sexually active fertile men whose partners were WOCBP not using an adequate method of birth control",
        "label": "Entailment"
    },
    "70b8c9a1-dcd5-459b-b138-d341132d2b5e": {
        "text_answer": "  The statement is not entailed in the trial results as given The statement mentions a reduction in tumor diameter but the trial results only report a change in Ki67 expression which is a biomarker for cell proliferation The statement is not a valid inference from the trial results and is contradictory to the reported findings",
        "label": "Contradiction"
    },
    "91ce9f54-322f-4796-930e-0f85cf65d115": {
        "text_answer": "  The statement cohort a and b of the primary trial are given two differing doses of oral ld v935 not necessarily at the same point in time is not directly entailed in the given trial information However it is not contradictory either The trial information only specifies the dosing regimens for Interventions 1 and 2 but it does not mention anything about oral administration of V935 for Cohorts",
        "label": "Contradiction"
    },
    "2c4fbaa0-f62c-4a7b-9d9d-7b61a8383ec4": {
        "text_answer": "  The statement granuloma assessment is an evaluation of the presence or degree of granuloma in a sample is not directly related to the information provided in the trials   The trials only report the iDFS rates in the Neratinib and Placebo arms of the study The statement does not entail or contradict the information provided in the trials",
        "label": "Entailment"
    },
    "23cb11b4-6a85-4a6f-9e72-920eff085459": {
        "text_answer": "  The statement the patient with the longest PFS in the primary trial survived 05 months without disease progression or death is not entailed in the given trials as there is no information provided in the trials about the longest PFS duration or survival time for any individual patient The trials only report the median PFS for each treatment group",
        "label": "Contradiction"
    },
    "33b59cbc-c52d-4e5c-8f77-f2d8a6fa491c": {
        "text_answer": "  The statement several recorded adverse events have been associated with the secondary clinical trial is a contradiction to the information provided in the secondary trial which states that there were no recorded adverse events 01 Therefore the statement is contradictory to the information given",
        "label": "Contradiction"
    },
    "e9e1b48b-55a2-479b-93cd-33db74d3053c": {
        "text_answer": "  The statement laserassisted fluorescence angiography is used for both interventions in the primary trial is entailed in the given trials as both Intervention 1 and Intervention 2 include the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring breast perfusion at three separate time points during the surgical procedures  However the statement gross income is a person",
        "label": "Entailment"
    },
    "cb418196-3bf8-4a86-9c90-819eb43ede13": {
        "text_answer": "  The statement several adverse events were reported for cohort 1 patients in the primary clinical trial is entailed in the given trials as there are reported adverse events for the cohort 1 patients in both trials even though the number of adverse events is different 1 in the first trial and 0 in the second trial However the statement does not specify the number of adverse events so it can be entailed by trials with fewer",
        "label": "Entailment"
    },
    "d16039bf-c0d3-488f-8890-cb5b5d909ab8": {
        "text_answer": "  The statement is entailed in the Trials In the primary trial only the patients in Intervention 2 receive daily armodafinil whereas in the secondary trial no patients receive daily armodafinil Instead both interventions in the secondary trial involve the administration of PDR001 every 3 weeks but the dosage of MCS110 varies between the two interventions Therefore the statement that only one cohort in",
        "label": "Entailment"
    },
    "eb3891b2-5320-4b6e-9a9f-08c7aa8bdd29": {
        "text_answer": "  The statement is contradictory to the primary trial criteria as it indicates that a diagnosis of cerebral metastases within the brainstem would make a patient ineligible for the secondary trial but the primary trial does not have such a criterion However the statement is not directly related to the secondary trial inclusion or exclusion criteria regarding the diagnosis of cerebral metastases as the statement only mentions the brainstem specifically Therefore the statement",
        "label": "Entailment"
    },
    "0c9b06e1-9dab-4937-b22e-0d372a5fd92d": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the baseline dose of alpha lipoic acid is 100 mg three times daily which is higher than the dose given in the secondary trial for necitumumab However the statement specifically mentions that the same steady dose of necitumumab is given in the secondary trial which is true Therefore the statement is entailed in the trials as it correctly describes the differences in dos",
        "label": "Entailment"
    },
    "4a56cd2d-ce04-4515-a033-f140e44cf955": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information to determine if the two cases of anaemia and febrile neutropenia occurred in the same patient or not However the statement is not contradictory to the trials as they both report different numbers of participants and different occurrences of adverse events",
        "label": "Contradiction"
    },
    "284bab9f-a986-4a27-9fe3-ac989cefcf4e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there is no mention of any specific intervention related to weekly subcutaneous injections for joint aches or vitamin D repletion Therefore it cannot be inferred that weekly subcutaneous injections are designed for participants in the primary trial  In contrast the secondary trial mentions the use of epoetin beta through weekly subcutaneous injections for",
        "label": "Contradiction"
    },
    "e5746ae9-641d-4549-a164-811aa126a2e5": {
        "text_answer": "  The statement over 05 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is not directly entailed in the given trial results However it is not contradictory either as the trial results do not provide sufficient information to definitively determine whether this statement is true or false The trial results only state that",
        "label": "Contradiction"
    },
    "510ae9ab-feae-4c57-a8c3-02e8764e6faa": {
        "text_answer": "  The statement Women suffering from both claustrophobia and osteoporosis are not eligible for either the primary trial or the secondary trial is entailed in the given trials as  1 Women suffering from osteoporosis are excluded from the primary trial 2 Women suffering from claustrophobia are excluded from the secondary trial  Therefore the statement is entailed in the trials as women who",
        "label": "Entailment"
    },
    "539adaf8-43ce-4c8f-9ed5-df5b030132c3": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description participants receive oral medication daily for a month with lapatinib ditosylate and tamoxifen citrate The statement however mentions intravenous medication given once a week for six months These two descriptions are not the same and the statement contradicts the trial description",
        "label": "Contradiction"
    },
    "df3a590c-02f9-4dc2-84da-da4d5534c542": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement specifies that neither of the primary trial cohorts undergo invasive surgery or receive Neratinib The trials information confirms that the Phase 2 Triplenegative cohort does not receive any invasive surgery or Neratinib and the Phase 2 HER2 cohort is HER2amplified",
        "label": "Entailment"
    },
    "f995d440-b2ff-491e-bc11-038f63b8681e": {
        "text_answer": "  The statement a young patient with a recent diagnosis of ERpositive HER2positive breast cancer could be considered suitable for participation in the secondary and the primary clinical trial is contradictory to the inclusion criteria of both trials  Explanation  The primary trial includes patients with HER2negative breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer However the statement ment",
        "label": "Entailment"
    },
    "d6cde3f8-ef3c-4d8a-8afb-d3e9f8c5c1f8": {
        "text_answer": "  The statement the primary clinical trial excludes patients with Alzheimers disease is entailed in the trials exclusion criteria as it specifically states no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment and does not mention Alzheimers disease specifically but Alzheimers disease is a type of dementia Therefore the statement is entailed in",
        "label": "Entailment"
    },
    "dbb49ce0-7aed-4573-9b13-1db31e9df94d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial measures the change in isothiocyanate in urine samples as an outcome while the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale There is no mention of range of motion or yoga in either trial",
        "label": "Contradiction"
    },
    "198d43b9-ed80-463e-bbdc-d2d565fb61aa": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 1224 months to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial has an inclusion criterion stating that patients must be aged greater than 20 years which explicitly excludes women aged 18 or 19 However",
        "label": "Contradiction"
    },
    "679f8ab4-38a4-4c6c-b85f-800e645e5bb8": {
        "text_answer": "  The statement is not entailed in the trials provided The trials only report the number of participants in each group and their Recurrencefree Survival rates but they do not mention any electrocardiographic findings such as undetermined rhythm",
        "label": "Contradiction"
    },
    "93850158-9371-4320-aefc-c31e15a5d983": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II portions Statement  The primary trials Phase I and Phase II portions have distinct participant populations and study designs The Phase I portion is a doseescalation study for opioidnaive patients while the Phase II portion is a randomized doubleblind placebocont",
        "label": "Entailment"
    },
    "7bdf850e-2f84-40f0-9b80-5bf9984be081": {
        "text_answer": "  The statement qrs complex is an electrocardiographic finding that represents depolarization of the ventricular myocardium normally the ventricles are activated simultaneously is not entailed nor contradictory to the information provided in the trial description The trial description focuses on the dosing and administration of Vorinostat and radiation therapy and does not provide any information related to the qrs complex or electrocardiographic findings",
        "label": "Contradiction"
    },
    "10acc981-00c5-4c74-b2ce-58bc69406955": {
        "text_answer": "  The statement the primary clinical trial has a multitude of adverse events recorded for its patient cohort is entailed in the given information as there is at least one adverse event recorded a surgery event in the trial with a total of 29 patients resulting in an adverse event rate of 345",
        "label": "Entailment"
    },
    "e42e5fc5-cdf8-40c3-9cf7-44ff5bdff413": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation  The primary trial does not impose any age restrictions but it does specify that patients must be between 2555 years old for the clinical trial This is not a restriction for the trial itself but rather a requirement for participation in the specific clinical trial  The secondary trial also does not impose any age restrictions but it does include patients with",
        "label": "Entailment"
    },
    "5a90093d-2964-4935-b8af-236bfff8d4de": {
        "text_answer": "  The given primary clinical trial description does not entail or contradict the statement that the primary clinical trial requires the application of paclitaxel in at least one of its interventions   The statement is not entailed because paclitaxel is not mentioned in the given trial description at all The trial description only mentions anastrozole and fulvestrant as the interventions   Therefore the statement is neither entailed nor contradicted by",
        "label": "Contradiction"
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "text_answer": "  The statement is contradictory to the given trials as there are no adverse events related to mental health recorded in either cohort 1 or 2 of the primary trial",
        "label": "Contradiction"
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "text_answer": "  Anorexia is a disorder characterized by a persistent lack of appetite and significant weight loss Based on the provided inclusion and exclusion criteria anorexic patients are not eligible for the primary trial The inclusion criteria state that participants must have a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs Anorexic patients typically have a BMI significantly lower than 25 kgm2 and",
        "label": "Entailment"
    },
    "0bc4c4b5-bdb3-4b4b-9122-e52dcb57ec61": {
        "text_answer": "  The statement how has gynecologic cancer affected your sexual relationships is not directly related to the information provided in the primary or secondary trials The trials focus on the administration of normal saline and dexmedetomidine and their potential effects on patients but they do not provide information about how gynecologic cancer has affected sexual relationships Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "5d04737b-c113-4934-94b6-ea9d8dd6318b": {
        "text_answer": "  The statement is not directly entailed in the given trials as there is no mention of newborns or neonatal culture positive sepsis in either the primary or secondary trials The trials only provide information about the interventions and dosages for patients with metastatic breast cancer",
        "label": "Contradiction"
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "text_answer": "  The statement Sunitinib was administered orally every day to every patient in the primary trial for the entire duration of the study is not entailed in the given trial information   The trial description states that sunitinib was administered orally on a continuous daily dosing schedule but it also mentions that dosing could be interrupted or reduced according to individual tolerance This means that not every patient received sunitinib every day for the",
        "label": "Contradiction"
    },
    "e6b528a8-9d23-420b-b1a1-63bd831b7c03": {
        "text_answer": "  The statement every patient in the primary clinical trial had fully healed surgical incisions without any complications is contradicted by the trial data The data reports a total of 11 adverse events in 50 patients including cellulitis wound dehiscence hematoma and seroma which are all complications related to surgical incisions Therefore the statement is contradicted by the trial data",
        "label": "Contradiction"
    },
    "205bc80b-db03-469f-85b8-290a4be79af8": {
        "text_answer": "  The statement cohort 1 of the secondary trial receives lower weekly mm121 and paclitaxel doses than those in the primary trial is entailed in the trials  Explanation  In the primary trial there is no mention of any specific dosing for MM121 or Paclitaxel However in the secondary trial the HR subgroup in Intervention 1 receives a 2",
        "label": "Entailment"
    },
    "1a15db80-85f2-4d35-b325-1e01fdfb453d": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials do not mention any comparison of results between the LBH589 with Capecitabine and LBH589 and Lapatinib groups within the primary trial The trials only provide information about the design and participant numbers of each group",
        "label": "Contradiction"
    },
    "52ae60f0-ea78-473d-9e82-78f2d1fc81bf": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is neither entailed in the primary trial nor contradictory to it   The primary trial does not mention anything about the location of the cerebral metastases within the brain and the secondary trial specifically excludes patients with cerebral",
        "label": "Entailment"
    },
    "f008bad4-fa46-4187-b784-434238a5992b": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial the doses of PF06647020 given are 02 mgkg and 05 mgkg while in the secondary trial the doses of ALT801 given are 0015 mgkg and 0040 mgkg There is no comparison of the same drug at higher dos",
        "label": "Contradiction"
    },
    "0ebc75cd-f87b-46a6-aaa3-9b511cdb90ae": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a resectable Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial specify tumor location is a request to specify the anatomic site of the tumor is neither entailed nor contradictory to the given inclusion and exclusion criteria   The criteria do include Nonsmall cell lung cancer and Small cell lung cancer as eligible tumor types but",
        "label": "Entailment"
    },
    "f52235c3-a9c6-4eb2-a9c6-929afe1bf49a": {
        "text_answer": "  The statement is contradicted by the information provided in the trials In the first trial there was one case of Gramnegative bacteremia with a fever of 40 degrees Celsius out of six participants 1667 However the statement claims that all infections and infestations cases were evenly distributed among all cohorts but this is not the case as there were no such cases reported in the second trial with four participants Therefore",
        "label": "Contradiction"
    },
    "6bf5cffc-eb10-45ae-9e9f-b5b5d60be392": {
        "text_answer": "  The statement In total there are less cases of anemia in the primary trial than in the secondary trial is a factual statement that can be verified by comparing the number of anemia cases in each trial   From the given data there is one case of anemia in the primary trial and four cases in the secondary trial Therefore the statement is entailed in the trials as it is a fact that the number of anemia cases in the",
        "label": "Entailment"
    },
    "62c8e736-58fd-472f-bef0-c957b8055237": {
        "text_answer": "  Lets calculate the ratio of hepatotoxicity cases to the sum of hypertension and pancreatectomy cases in the primary trial  Ratio  Number of hepatotoxicity cases  Number of hypertension cases  Number of pancreatectomy cases  Given Number of hepatotoxicity cases  3 Number of hypertension cases  1 Number of pancreatectomy cases",
        "label": "Entailment"
    },
    "cc369e33-07e2-441d-b4fd-8233478ba98a": {
        "text_answer": "  The statement patients suffering from severe malnutrition are ineligible for the primary clinical trial is not explicitly stated in the given inclusion and exclusion criteria However the criteria do include a BMI requirement BMI of 25 kgm2 or greater and weight 400 lbs which could be interpreted as an attempt to exclude patients with severe malnutrition However the criteria do not define what constitutes severe malnut",
        "label": "Entailment"
    },
    "77f689bc-c9fc-45ab-9966-aea06482863a": {
        "text_answer": "  The statement while the primary clinical trial is not open to children their eligibility hasnt been explicitly stated for the secondary clinical trial is neither entailed nor contradicted by the information provided in the inclusion and exclusion criteria for both trials   The primary trial explicitly states that premenopausal pregnant lactating women are not eligible for study treatment but it does not mention anything about children The secondary trial also does not mention",
        "label": "Entailment"
    },
    "fc35b082-3d3c-4ccc-971b-1f008c224a28": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The participants in the primary trial receive the following drugs epirubicin cyclophosphamide docetaxel and trastuzumab   1 Epirubicin given at a dose of 100 mgm2 every 2 weeks for 4 cycles 2 Cyclophosphamide given at a",
        "label": "Entailment"
    },
    "28efc57b-6732-4778-84e9-81d1cea1a43e": {
        "text_answer": "  The statement aggravated malignant neoplasm is a malignant neoplasm that shows clinical andor pathologic progression is not directly related to the information provided in the trial results However the trial results do indicate that Recurrencefree Survival was assessed up to 3 years which implies that the absence of recurrence second malignancy or death was the primary outcome measure The statement that only ",
        "label": "Entailment"
    },
    "a4ddb589-176d-4a2f-bdf2-3c5973a09a4d": {
        "text_answer": "  The statement is not entailed in the given information The statement implies that no adverse events related to the patient cohort of the primary clinical trial were recorded but the information provided only states that there was one adverse event unspecified as related to the patient cohort or not out of 29 participants Therefore the statement is contradictory to the information provided if the primary clinical trials patient cohort includes all 29 participants",
        "label": "Contradiction"
    },
    "47ff584c-f344-45ab-afec-1c1561453a36": {
        "text_answer": "  The statement the primary clinical trial found no traces of anaemia febrile neutropenia or pancytopenia in cohort 1 is entailed in the first trial data as none of the participants in cohort 1 experienced anaemia febrile neutropenia or pancytopenia Therefore the statement is true based on the given data  However it is important to note",
        "label": "Contradiction"
    },
    "0f0501ba-557e-4111-8473-ec54b624a47f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that breast cancer patients received a dose of 200 mcgday and ovarianperitoneal cancer patients received a dose of 500 mcgday However the trials indicate that the doses for breast cancer patients ranged from 600 mcgday to 1100 m",
        "label": "Entailment"
    },
    "825832eb-2b69-42a2-80b1-f210915da77c": {
        "text_answer": "  The statement polycythemia excluding polycythemia vera is an increase in the concentration of red blood cells hemoglobin that is not caused by polycythemia vera is not directly related to the information provided in the trials The trials only report adverse events observed in two separate cohorts and none of the reported events mention polycythemia or its subtypes Therefore the statement",
        "label": "Entailment"
    },
    "9a337e6e-70b7-420d-9679-cc0baf5a5ba8": {
        "text_answer": "  The given trials do not provide sufficient information to determine if the statement is entailed contradicted or neither in the trials The trials only report adverse events and their frequencies but they do not mention tumour lysis syndrome as an adverse event in either trial Therefore it is not possible to determine if the statement is entailed contradicted or neither based on the given information alone",
        "label": "Entailment"
    },
    "9cc10a0d-5cb3-49b0-99c9-586837640270": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site for lymphoscintigraphy The difference lies in the use of either a handheld gamma camera pIHGC or standard gamma probes GP during the procedure Therefore the statement accurately describes the difference between the two interventions and is entailed in the trials",
        "label": "Entailment"
    },
    "bde45f5a-8909-48eb-b331-715583659654": {
        "text_answer": "  The statement over 75 of patients treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial underwent serious treatmentemergent adverse events is contradictory to the given results   The results indicate that there were 11 participants out of 25 who experienced serious adverse events SAEs which is less than 75 of the total number of participants",
        "label": "Entailment"
    },
    "ac50c12b-4055-428b-8d8b-0136aca85f10": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the percentage of patients with adverse events in each cohort   The percentage of patients with adverse events in cohort A is 5000 and in cohort B it is 4000   Since 5000 is greater than 4000 the statement a",
        "label": "Entailment"
    },
    "1023b3b0-b190-4ad2-b849-a7ba384be1f8": {
        "text_answer": "  The statement is contradictory to the given information in the trials   Explanation   The statement cohort 1 of the primary clinical trial is administered the same dose of alt801 as cohort 2 is contradictory to the given trials as cohort 1 is given a dose of 0015 mgkgdose and cohort 2 is given a dose of",
        "label": "Entailment"
    },
    "be705668-6d11-46eb-bd96-9d20f01b936d": {
        "text_answer": "  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is not directly entailed in the given trials as the trials do not provide sufficient information to make a comparison between the two groups regarding the frequency of diarrhea The trials only provide the number and percentage of participants who experienced adverse events in each trial but they do not specify the number or percentage of participants who experienced diarrhea specifically Therefore the statement is",
        "label": "Contradiction"
    },
    "beff7121-1697-41a7-bf43-998005d5c68e": {
        "text_answer": "  The statement is in contradiction with the primary trial as Perjeta pertuzumab is included in Intervention 1 of the primary trial but is completely excluded from all cohorts in the secondary trial",
        "label": "Contradiction"
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "text_answer": "  The woman who has had a mastectomy could still be eligible for the secondary trial as the secondary trial includes patients who have completed surgery for breast cancer which includes mastectomy However the primary trial specifically includes patients undergoing immediate tissue expander reconstruction following mastectomy so a woman who has had a mastectomy without tissue expander reconstruction would not be eligible for the primary trial unless she met the other inclusion criteria  Therefore",
        "label": "Entailment"
    },
    "c4e967e1-c656-4d32-b8b5-c0b74a94bf02": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the quantities of each intervention in both trials  In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days To calculate the total amount of lenalidomide used we can find the daily dose and the number of days  Total lenalidomide  Daily dose  Number",
        "label": "Entailment"
    },
    "9c15d42d-2fcc-4c69-86b2-f75e29d732d4": {
        "text_answer": "  The statement one patient in the primary trial had an incident where a surgical incision reopened after the surgery is not directly entailed in the given trial data The trial data mentions an incident of wound dehiscence which is a type of surgical complication where the incision reopens but it is only one out of the several adverse events listed in the trial The statement however does not mention the use of a blood",
        "label": "Contradiction"
    },
    "1641b323-b136-4104-81e5-744ceac933de": {
        "text_answer": "  The statement all adverse event types witnessed in the primary clinical trial affected less than a tenth of the patients is not directly entailed in the given data However it is consistent with the data since the total number of patients affected by any adverse event is 4 out of 11 which is less than a tenth of the total number of patients Therefore the statement is not contradictory to the data but should be considered a valid inference based",
        "label": "Contradiction"
    },
    "6033e8d9-c7d5-4b36-b6da-80fdb98de034": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial includes a breast tumor of only 1 cm in diameter while the secondary trial does not specify the tumor size The statement about a tumor of 1000 millimeters in diameter is not mentioned in either trial Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "e8702a99-36bb-4f4f-b2ff-3fa6d49d034e": {
        "text_answer": "  The statement is entailed in the trials as the trials explicitly state different starting doses for sunitinib and paclitaxel in each intervention group The first cohort receives a daily dose of 25 mg sunitinib while the second cohort starts with a paclitaxel dose of 90 mgm2 Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "961aaf91-e07d-4723-860e-23593727c303": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial zoledronic acid in Intervention 1 is given IV not orally In the secondary trial all intervention drugs in both Intervention 1 and Intervention 2 are mentioned to be given orally or IV However the statement specifically asserts that all intervention drugs in the secondary trial are to be administered orally which is not the case according to the trial",
        "label": "Entailment"
    },
    "45e2f6cb-6ab2-424e-bd21-c2086ab6def3": {
        "text_answer": "  The statement the bevacizumab  capecitabine cohort in the primary clinical trial demonstrated a higher rate of disease progression or death than the bevacizumab only cohort is a contradiction to the given trial data   The percentage of participants with disease progression or death in the Bevacizumab only cohort was 883 while in the Bevacizumab  Cap",
        "label": "Contradiction"
    },
    "526f99de-e377-42e4-a7ae-a42b797aa536": {
        "text_answer": "  The statement every participant of the primary clinical trial who received a placebo intervention went through episodes of emesis is a contradiction to the results presented in the trials   The results indicate that there were 5 participants in the placebo group who were emesis free during the study period Therefore not every participant in the placebo group experienced emesis",
        "label": "Contradiction"
    },
    "f8f0d036-16aa-4a9f-816e-c52940709126": {
        "text_answer": "  The statement None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes is entailed in the trials as both cohorts 1 and 2 reported having 0 percentage of participants with a discernible gene expression pattern The statement about mouth sensitivity at its worst is not related to the trials and should not be considered when verifying entailment or contradiction",
        "label": "Entailment"
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "text_answer": "  The given statement None of the primary trial candidates have to perform regular exercise as part of the intervention is entailed in the trial description if we focus only on the information provided in the intervention section The trial description states that None of the eligible patients have to perform regular exercise as part of the intervention Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "449b619f-902b-446d-ac1e-f73be62ac2ab": {
        "text_answer": "  The statement the primary trial noted a higher incidence of adverse events than the secondary trial is entailed in the given trials data  Explanation  The statement is entailed because the primary trial had no adverse events 000 while the secondary trial had a much higher incidence of adverse events 6000 Therefore the secondary trials incidence of adverse events is higher than the primary trial",
        "label": "Entailment"
    },
    "c114301e-f64f-468b-95f7-8debdc840a74": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both cohorts receive equal amounts of CUDC101 with identical frequency However the trial information indicates that in Arm A cohort 1 CUDC101 is administered for 5 days every 14 days while in Arm B cohort 2 CUDC1",
        "label": "Entailment"
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity both from cohort 2 is entailed in the trials provided   Explanation   The trials given state that there were 6 participants analyzed in each cohort Level 1 and Level 2 However the statement indicates that only two patients experienced doselimiting toxicity Since both of these patients",
        "label": "Entailment"
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "text_answer": "  The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks is contradictory to the given trials as none of the interventions in the trials guarantee that all patients receive at least 20mg of MCS110 every 3 weeks The trials only specify the dosages of MCS110 to be 1mgkg or 3mgkg every 3 weeks which",
        "label": "Entailment"
    },
    "06024cb1-ce64-432e-b1d9-f3df2f95b025": {
        "text_answer": "  The statement is contradictory to the given trial information   In Intervention 1 there are no electroporation EP injections mentioned only intramuscular IM injections of V935 in low dose LD   In Intervention 2 there are three EP injections of V934 in low dose LD given followed by two IM injections of V935 in low dose ",
        "label": "Contradiction"
    },
    "e4cdcf39-a01c-45f5-a382-d0e8a96a0be6": {
        "text_answer": "  The statement is entailed in the Trials The primary trial has consistent inclusion and exclusion criteria for all phases whereas the secondary trial has distinct criteria for its subjects based on their health status healthy or cancer patients This difference in criteria does not contradict the statement but rather supports it",
        "label": "Entailment"
    },
    "fb758700-bd95-4857-a58e-1ee8d88c0d71": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The primary trial does provide information on the determination of the MTD of ruxolitinib in combination with paclitaxel as outlined in the trial design The statement that the primary trial does not deliver any information on the MTD of any interventions is incorrect  Regarding the secondary trial it does not provide information on the MTD of ruxolitinib in combination",
        "label": "Entailment"
    },
    "4a64f808-b518-4666-9f78-56a2d6dd7093": {
        "text_answer": "  The statement there are 2 less participants in cohort 2 of the primary clinical trial than in cohort 1 is a factual statement that can be verified by comparing the number of participants in each armgroup as provided in the trials  From the given trials we can see that there are 234 participants in Arm I of the primary clinical trial Cohort 1 and there are 241 participants in Arm II",
        "label": "Entailment"
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "text_answer": "  The statement is entailed in the trials as both interventions have the same administration schedule for tremelimumab and the same optional extended treatment The only difference lies in the dosage of durvalumab given in the biweekly IV infusions with cohort 1 receiving 03 mgkg and cohort 2 receiving 1 mgkg Therefore the statement accurately reflects the difference between the two interventions",
        "label": "Entailment"
    },
    "36cb2716-6b66-49bd-bb22-7119bd022e28": {
        "text_answer": "  The statement is entailed in the given trials as the trials do not provide the number of participants for each armgroup in the study The trials only mention the overall number of participants analyzed for each arm",
        "label": "Entailment"
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "text_answer": "  The statement Aes were not recorded for the primary trial or the secondary trial is entailed by the given information since the number of adverse events for both trials is reported as zero for both Adverse Event types 1 and 2",
        "label": "Entailment"
    },
    "1027bd72-7cce-4903-9838-733046143102": {
        "text_answer": "  The statement generally patients from the primary clinical trial have a life expectancy that exceeds 2 years however there was at least one patient from both groups who did not survive past 2 years is not directly entailed in the given trial results as the trials do not provide information about the number of patients who survived past 2 years or the distribution of survival times beyond the reported medians However based on the given median survival times it can be in",
        "label": "Contradiction"
    },
    "effa7535-9810-4bf3-92bd-64aba7878bf6": {
        "text_answer": "  The statement more than two participants in the primary clinical trial experienced doselimiting toxicity is not directly entailed in the given trial results as both armsgroups Ixabepilone 24mgm2 and Doxorubicin 30mgm2 and Ixabepilone 32mgm2 and Doxorubicin 30mgm2 had the same number of participants",
        "label": "Contradiction"
    },
    "eeb1a073-304f-41e4-b1f7-e2381eabf50f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Eribulin mesylate and axitinib  docetaxel trials do not involve radiation therapy at all Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Entailment"
    },
    "666c3ebb-3f79-4795-b5e7-4584815f498d": {
        "text_answer": "  The statement is entailed in the trials as both trials report on clinical outcomes of patients undergoing different interventions The primary trial focuses on pain intensity differences after treatment with fentanyl sublingual spray or placebo while the secondary trial evaluates the change in bone mineral density of the lumbar spine after treatment with zoledronic acid or observation alone Both trials measure outcomes at specific time points or intervals with the primary trial assessing pain intensity at various time points",
        "label": "Entailment"
    },
    "9e8aeaf6-36db-4f09-b7a6-7a5e41d14215": {
        "text_answer": "  The statement the secondary trial and the primary trial use different units of measure in their results is entailed in the trials as the primary trial reports the mean tumor diameter with standard deviation in cm while the secondary trial reports the count of participants with solid tumor response using RECIST 11 criteria These are different units of measure and the trials do not report the same outcome measurement The statement about congenital disorder of glycosyation type",
        "label": "Entailment"
    },
    "811978a1-2715-4174-84af-07a0ca3686e8": {
        "text_answer": "  The statement how much did pain interfere with enjoyment of life is a question about how much a persons pain interferes or interfered with their enjoyment of life is not entailed in the given inclusionexclusion criteria of the primary or secondary trials The trials only provide information about the eligibility criteria for the study participants based on their medical conditions and previous treatments The statement about pain and enjoyment of life is not related to the inclusion",
        "label": "Contradiction"
    },
    "bed73866-02e7-49d2-a66a-215e0a0d1b83": {
        "text_answer": "  The statement Across both the primary trial and the secondary trial only one death was recorded in the adverse events Adverse event attributed to disease is an indication that an adverse event is causally related to the natural history of disease is not directly entailed in the given trials data   The trials data only provides information about the number and types of adverse events observed in each trial It does not specify whether any of the recorded deaths were caused by the disease",
        "label": "Contradiction"
    },
    "910d3110-1fa1-4488-a481-085a18d1670a": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive the same intensity of radiation therapy with a total dose of 46004860 cGy in 2327 fractions and the maximum dose to the tumor bed or mastectomy scar is 6600cGy The difference lies in the use of Active Breathing Coordination ABC in Cohort 1 which",
        "label": "Entailment"
    },
    "da901268-f433-47ff-9119-69d36ce3c4d0": {
        "text_answer": "  The statement is entailed in the trials as both trials involve the injection of a substance In the primary trial patients receive denosumab injections and in the secondary trial patients receive injections of radioactive Tc99M sulfur colloid Therefore the statement that the primary trial requires patients to receive injections and the secondary trial also requires injection is entailed in the trials The statement about the type and amount of the injected",
        "label": "Entailment"
    },
    "c8109cb7-4cf5-469b-ba02-5d610579cc89": {
        "text_answer": "  The statement both the secondary trial and primary trial yield similar results despite varied interventions is not directly entailed in the given trials as there is no comparison of the results between the two trials in the provided information The primary trial reports the percentage of participants with treatmentemergent adverse events in different populations while the secondary trial reports the number of participants with objective response in different cancer types To determine if the statement is entailed a comparison of the results ",
        "label": "Contradiction"
    },
    "3a85c9cb-b4e8-46cb-84c5-e618f0307b26": {
        "text_answer": "  The given statement the LBH589 with capecitabine cohort of the primary clinical trial outperformed the LBH589 and lapatinib cohort is not entailed in the provided trial information as there is no data presented in the trials regarding the performance or efficacy of each cohort The trials only provide information on the dosing and administration of LBH589 and its combination with capec",
        "label": "Contradiction"
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy is entailed in the trials based on the provided results   The results show that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 indicating that on average symptoms improved from baseline in this group In contrast",
        "label": "Entailment"
    },
    "90783994-6867-4dfe-bbd0-71c4004d9a20": {
        "text_answer": "  The statement is not directly related to the given primary trial intervention section The statement is about the use of the suffix senior and the meaning of the word intervention which is not addressed in the intervention section Therefore the statement neither entails nor contradicts the information provided in the intervention section",
        "label": "Entailment"
    },
    "5d1e61bb-42f4-430c-843a-c6e80d121655": {
        "text_answer": "  The statement is entailed in the trials as follows  Both cohorts 1 and 2 receive CUDC101 at the maximum tolerated dose of 275 mgm2 The difference lies in the frequency of administration In cohort 1 CUDC101 is administered for 5 days consecutively every 14 days while in cohort 2 it is administered for",
        "label": "Entailment"
    },
    "a9e1aa54-a19a-47d1-8d55-caef2035160e": {
        "text_answer": "  The statement the primary clinical trial documented five adverse events notably cerebral hemorrhage pulmonary embolism sepsis hyperglycemia and hypokalemia is not entailed in the given trials as these trials do not mention any of the mentioned adverse events cerebral hemorrhage pulmonary embolism sepsis hyperglycemia and hypokalemia",
        "label": "Contradiction"
    },
    "c6ff494c-5fa8-414d-8a32-15713193c9a3": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the mean arm circumference changes between the acupuncture and waitlist groups at the 6week timepoint   The statement lymphedema improvements were more notable in acupuncture patients than in patients on the waiting list implies that the difference in mean arm circumference change between the two groups is statistically significant in favor of the acupuncture group",
        "label": "Entailment"
    },
    "1b48209c-3fcd-40d3-a647-f54b7e6179d2": {
        "text_answer": "  The statement is entailed in the given clinical trial information The statement emphasizes that even if a patient meets all the inclusion and exclusion criteria the final decision about their participation rests with the healthcare professionals conducting the trial This is already implied in the statement Final eligibility for a clinical trial is determined by the health professionals conducting the trial However the statement in the text makes it clearer and more explicit that the decision is based on all the criteria being met",
        "label": "Entailment"
    },
    "7fb4b7a6-dee2-404f-a55f-18c8db378060": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets all the inclusion criteria for the primary trial ie histologically verified diagnosis of solid tumor malignancy of breast appropriate diagnostic workup age performance status and signed informed consent The patient also meets the inclusion criteria for the secondary trial ie histologically verified diagnosis of stage IIbIIIIV breast cancer age life expectancy completion of chemotherapy and",
        "label": "Entailment"
    },
    "61acc1f3-e02a-49ca-8ac8-42453619e78c": {
        "text_answer": "  The statement is not directly entailed in the given trials data as the trials data only provides information about the occurrence of adverse events including lymphoma but it does not specify whether any of these events resulted in fatalities or hospital admissions Therefore the statement is neither entailed nor contradicted by the given trials data However based on the information provided it can be inferred that there were no unexpected fatalities or hospital admissions due to causes other",
        "label": "Contradiction"
    },
    "bf233363-7c05-475d-b248-d71303dec4e2": {
        "text_answer": "  The statement all cohorts of the primary clinical trial are available to breast cancer patients with estrogen negative progesterone negative and her2 tumors is entailed in the given inclusion criteria   The inclusion criteria state that the trial includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 ER negative PR negative and HER2 tum",
        "label": "Entailment"
    },
    "8203056c-37a1-4fbf-a3cf-ddf28608d1ad": {
        "text_answer": "  The statement A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial is contradictory to the disease characteristics of the trial as stated in the given information The trial explicitly mentions that No meningeal carcinomatosis is a requirement for eligibility Neoplastic meningitis is a type of meningeal carcinomatosis so a patient with this condition would not meet the eligibility criteria",
        "label": "Contradiction"
    },
    "e8cc1118-7a1a-46ba-aa08-cfb7f414a753": {
        "text_answer": "  The statement kat6a gene rearrangement is a molecular abnormality indicating rearrangement of the kat6a gene is not directly mentioned in the inclusion or exclusion criteria of either the primary or secondary trials   Regarding the exclusion of patients with a pulmonary embolism within the last 3 years from the primary trial the statement is related but not identical The trial specifically excludes patients with a pulmonary embol",
        "label": "Entailment"
    },
    "b73bde4f-21c4-48bd-82d3-0447d22cbd1c": {
        "text_answer": "  The statement hypokalemic patients are most welcomed to participate in the primary clinical trial while those with normal potassium levels are preferred in the secondary clinical trial is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials  The primary trial includes the requirement that potassium levels be within the normal range 3553 mEqL and the secondary trial does not mention potassium levels at",
        "label": "Contradiction"
    },
    "68bae1de-1bee-486e-a50e-30ab9a4c705a": {
        "text_answer": "  The statement is contradictory to the given trials data The statement suggests that cardiac and psychiatric aes were frequently reported in both primary and secondary trials However the trials data show that no adverse events AEs of type 1 or 2 were reported in the secondary trial and the number of reported AEs in the primary trial was very low 000 Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "664a5c0e-406c-4050-85d3-f2f489e5098b": {
        "text_answer": "  The statement no vaccines are given to the participants in the primary clinical trial is entailed in the given trial information as there is no mention of any vaccines being administered to the participants in either intervention 1 or intervention 2",
        "label": "Contradiction"
    },
    "90eca162-5617-44e3-909b-c8304af0d763": {
        "text_answer": "  The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is entailed in the Trials as follows  1 NUT midline carcinoma and Castrateresistant prostate cancer are included in the primary trial as per the inclusion criteria ",
        "label": "Entailment"
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "text_answer": "  The statement Both the primary trial cohorts receive preoperative Dexamethasone is entailed in the given trials as both Intervention 1 and Intervention 2 involve the administration of Dexamethasone preoperatively",
        "label": "Entailment"
    },
    "1480180d-d754-4fbd-bed9-70a50835c098": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage of participants with disease progression or death between the two cohorts   The percentage of participants with disease progression or death in the Bevacizumab cohort was 883  The percentage of participants with disease progression or death in the Bevacizumab  Capecitabine cohort was 758",
        "label": "Entailment"
    },
    "d8896ee9-9d44-485b-9b75-e25f4a56aa8d": {
        "text_answer": "  The statement over 50 of patients in the primary trial suffered aes is contradictory to the given data in the trials The total number of adverse events reported was 2 which is less than 50 of the total number of patients 35 Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "57d27d0b-626b-474b-9e10-60cbdd237d92": {
        "text_answer": "  The statement is entailed in the trials as both the placebo and memantine interventions are specified to be given orally on a daily basis PO BID in the trials",
        "label": "Entailment"
    },
    "2e054c61-23f1-46df-9c49-44e5f076163d": {
        "text_answer": "  The statement paranemin is a type iii intermediate filament protein found in striated muscle cells that provides cytoskeletal integrity and strength is not directly related to the interventions described in the primary trial The trial compares two different interventions one with Herceptinnavelbine and the other with TaxoterecarboplatinHerceptin Both interventions include Herceptin which is a monoc",
        "label": "Entailment"
    },
    "ac4e121f-e159-49e0-84cb-83218232ebbb": {
        "text_answer": "  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation Postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the trials exclusion criteria The trials exclusion criteria list these conditions as",
        "label": "Entailment"
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "text_answer": "  The statement Patients with measurable tumors in both breasts are excluded from the primary trial is not directly entailed in the given inclusion and exclusion criteria The criteria only mention unilateral breast cancer and lymphedema in one upper extremity Therefore the statement is not explicitly stated in the criteria and is not an entailment However it is worth noting that the statement is consistent with the criteria as they do exclude patients with active or metast",
        "label": "Contradiction"
    },
    "8e205d62-f220-45ba-9324-f8ee359236b1": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial there is one test group Pyridoxine and one placebo group Placebo  In the secondary trial there are two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride  Therefore the statement the primary clinical trial was composed of a single test group and",
        "label": "Entailment"
    },
    "e493c4b0-1bd6-446f-a432-2703b7775620": {
        "text_answer": "  The statement all participants who were administered with 1mg gtx024 in the primary clinical trial showed a gain in lean body mass during the 4month period is entailed in the trial results if we define a gain in lean body mass as having a positive change in lean body mass Based on the given results the median change in lean body mass for the group administered with 1mg gtx024 is ",
        "label": "Entailment"
    },
    "23ccac08-3764-496a-a790-4a1f5079909e": {
        "text_answer": "  The statement the secondary trial candidates must be Completely disabled to participate whereas this is not required to be accepted into the primary trial is a contradiction to the information provided in the trials inclusion criteria   The primary trial includes subjects who have responded to at least two courses of weekly paclitaxel therapy and are considered to need to continue the therapy by the investigatorsubinvestigator among patients with advanced or recurrent breast cancer There is no",
        "label": "Contradiction"
    },
    "9ae8aa57-7196-4f5b-9911-33233705eac8": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria as the primary trial requires a primary tumor greater than 2 cm in diameter while the statement suggests a primary tumor that is only 3mm in size Therefore the statement is contradictory to the primary trial inclusion criteria and the patient would not be qualified to participate in both trials based on the given information  Regarding the secondary trial the statement does not provide enough information to determine if the patient",
        "label": "Entailment"
    },
    "91a4429b-767a-493a-b1f3-f3a1ccf5ab6c": {
        "text_answer": "  Neither of the interventions in the trials specify that the dosage of MCS110 administered is greater than 20mg for any patient Therefore the statement is entailed by the trials as they do not contradict it",
        "label": "Entailment"
    },
    "5f294eee-f332-4c58-a43f-076a06a04dd5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe two cohorts receiving oral administration of Enzalutamide with different doses but there is no mention of intravenous IV administration in either cohort Therefore the statement that cohort 2 of the primary trial is administered Enzalutamide orally whereas cohort 1 receives it by IV is incorrect",
        "label": "Contradiction"
    },
    "03d015fe-1903-4b94-b495-4f23c40862db": {
        "text_answer": "  The statement several of the primary trial candidates are administered 200 mcg of talazoparib daily as part of the intervention is not directly entailed in the given trial description The trial description mentions that patients are eligible for the trial if they are older than 70 years and have been diagnosed with certain types of cancer and that they are assessable for the primary outcome measure It also states that patients may be included before any",
        "label": "Contradiction"
    },
    "63aa9e40-98df-4f09-a508-d0b03b9f93f1": {
        "text_answer": "  The statement less than 0050 of patients in the primary trial suffered aes is a contradiction to the given data in the trials   The trials report that 235 571 of patients experienced adverse events This is greater than 0050 or 120 of the total number of patients Therefore the statement is a contradiction to the given data",
        "label": "Contradiction"
    },
    "dcfb970a-f5b0-41c1-a5ec-99d17734c17c": {
        "text_answer": "  The statement resolution of findings following intervention for kawasaki disease is an indication that findings were resolved following treatment for kawasaki disease is not directly related to the inclusion and exclusion criteria for the primary or secondary trials provided   However the statement does not contradict any of the inclusion or exclusion criteria for the primary or secondary trials Therefore the statement is neither entailed nor contradictory to the trials criteria",
        "label": "Entailment"
    },
    "0e935403-0cb2-40ff-b78b-6ba7eaf9621e": {
        "text_answer": "  The statement 13 of the primary trial participants with HER2 Primary Breast Cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed Imagable HER2 Metastases is entailed in the trial results if we interpret the term Imagable HER2 Metastases as described in the trial definition ie lesions that are qualitatively",
        "label": "Entailment"
    },
    "277c0ee2-5d34-4c87-80eb-6f5b630109ec": {
        "text_answer": "  The statement medulloblastoma not otherwise specified is a medulloblastoma which has not been further characterized is not related to the given inclusion and exclusion criteria for the breast cancer trial Therefore it neither entails nor contradicts the information provided in the trial criteria",
        "label": "Entailment"
    },
    "ef02754d-00ec-4f2d-bf7a-0a6d414b2476": {
        "text_answer": "  The statement There was at least 1 case of infection in both the primary trial and the secondary trial is entailed in the given trials as both trials list Infection as an adverse event with a frequency of 132 313 in the primary trial and 115 667 in the secondary trial Therefore the statement is entailed in the trials  However the statement cutaneous",
        "label": "Entailment"
    },
    "6848420c-ff9c-4003-bf9c-894b993c6720": {
        "text_answer": "  The statement the total number of anemia cases in the primary trial surpasses the case count in the secondary trial is contradictory to the given data   The primary trial has 0 anemia cases while the secondary trial has 4 anemia cases Therefore the statement is not entailed in the trials and is actually contradictory to the data provided",
        "label": "Contradiction"
    },
    "481d1201-72b1-41b4-82cc-78b79ea8938a": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions and conditions However the statement is generally true based on the information provided In the primary trial there is only one cohort that receives Armodafinil daily while in the secondary trial all patients receive the same dose of PDR001 but different doses of MCS110 This aligns with the statement that in the primary trial only one co",
        "label": "Contradiction"
    },
    "c6039c02-dcb4-433b-a0a5-4d6beb33b8fa": {
        "text_answer": "  The statement there is a lower total count and variety of adverse events documented in the primary clinical trial compared to the secondary trial is entailed in the given trials data   Explanation   The statement requires that both the total number and variety of adverse events be lower in the primary trial compared to the secondary trial   From the given data we can see that the total number of adverse events in the primary trial is 0",
        "label": "Entailment"
    },
    "ee74199e-c159-41f6-9130-8410b237c32f": {
        "text_answer": "  The statement the number of biliary colic and diarrhea cases is greater in the secondary clinical trial than in the primary clinical trial is contradictory to the given data   Explanation   The primary clinical trial had 4 cases of biliary colic and 4 cases of diarrhea making a total of 8 adverse events with a frequency of 655 8122",
        "label": "Entailment"
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "text_answer": "  The primary trial uses a dose of lenalidomide at 5mg orally daily which is different from the secondary trials intervention 1 dose of lapatinib at 1500mg orally daily Therefore the statement is a contradiction as the trials do not entail each other regarding the doses of their respective interventions",
        "label": "Contradiction"
    },
    "98d47cf2-ead0-4ab0-8f13-cb2215710dc8": {
        "text_answer": "  The statement the primary clinical trial cohort underwent an invasive cardiac surgery is not entailed in the given trial information as there is no mention of any cardiac surgery in the provided details for either Intervention 1 or Intervention 2 Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "91a67bbf-1ae1-4a86-92fb-dcac5e8298d1": {
        "text_answer": "  The statement no infections or fever cases were reported for patients in cohort 1 in the primary clinical trial is entailed in the given trials as both trials report a total of 0 infections and fever cases for cohort 1",
        "label": "Contradiction"
    },
    "95a261bd-f102-4ce8-887b-afa14d1e2856": {
        "text_answer": "  The statement after more than 6 weeks of therapy with tak228 and tamoxifen there was a 5 reduction in ki67positive cells in patients participating in the primary clinical trial is entailed in the trial results as follows  The trial results show that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was ",
        "label": "Entailment"
    },
    "a6236585-ed05-4deb-bfcd-29eb410bd892": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials report on different outcomes and do not mention the superior vesical artery The first trial reports on the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the second trial reports on the overall response rate ORR using RECIST criteria in patients with solid tumors Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "8a1d2587-95fa-4e7a-81db-1eb2561da680": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The placebo is administered as a 3hour intravenous infusion on Day 1 every two weeks as per the description of Intervention 1 2 Trabectedin is administered as a 3hour intravenous infusion on Day 2 every two weeks as per the description of Intervention 2  Since both the placebo and",
        "label": "Entailment"
    },
    "b86e9d5c-8de2-428a-ba76-d0955ecb75fa": {
        "text_answer": "  The statement is entailed in the trials as the trials explicitly state that the participants with breast cancer received talazoparib at doses of 600 mcgday 900 mcgday 1000 mcgday 1100 mcgday while participants with ovarianperitoneal cancer received talazoparib at doses of 25 mcgday ",
        "label": "Entailment"
    },
    "164f2ab2-b768-4ec0-befc-a9807ba379ff": {
        "text_answer": "  The statement adverse incidents were prevalent among patients in the first cohort of the primary clinical trial this was not the case in cohort 2 is a contradiction of the given data   The data shows that the prevalence of adverse events was higher in the first cohort 4245 compared to the second cohort 680 Therefore the statement that adverse incidents were preval",
        "label": "Contradiction"
    },
    "6450428b-bd2a-4ba5-aa5c-c86284dafa98": {
        "text_answer": "  The statement is not entailed in the trials as the primary trial has additional inclusion criteria related to gender menopausal status and hot flush symptoms which are not present in the secondary trial The secondary trial focuses on patients with HER2negative metastatic breast cancer who are candidates for taxanebased chemotherapy while the primary trial targets postmenopausal women with a history of breast cancer taking aromatase inhibitors or tamoxifen and experiencing",
        "label": "Contradiction"
    },
    "9bde44ff-5060-430d-9716-c34888483b9f": {
        "text_answer": "  The statement distressed by awakening in the early morning is a question about whether an individual is or has been distressed because they are awakening in the early morning is neither entailed nor contradicted by the given trials as they do not provide any information about individuals being distressed due to early morning awakening The trials only report the occurrence of adverse events in the trials and the statement is not related to the adverse events reported Therefore",
        "label": "Entailment"
    },
    "038e3e32-ae9c-4580-80b1-8d1c2d9d9bb9": {
        "text_answer": "  The statement patients with a documented allergy to metronidazole or amoxicillin are accepted in the primary clinical trial but will be excluded from the secondary clinical trial is a contradiction based on the given inclusion and exclusion criteria  Explanation  In the primary clinical trial the exclusion criteria do not mention any specific allergy to metronidazole or amoxicillin as a reason for exclusion",
        "label": "Contradiction"
    },
    "86fd4794-aa66-4739-86c6-cf5bfcd911fe": {
        "text_answer": "  The statement unbearable pain for a duration of 10 weeks was reported by all individuals involved in the primary clinical trial is a contradiction to the information provided in the trials The trials describe a psychoeducational intervention to improve cancer pain management and the average pain intensity was measured using a numeric rating scale However there is no information provided in the trials indicating that all individuals involved experienced unbearable pain for a duration of 10 weeks The",
        "label": "Contradiction"
    },
    "71b2f727-f6ac-40e2-a92a-8bb89959e51e": {
        "text_answer": "  The statement the outcome measures for the primary and secondary trials showcase identical results is contradictory based on the given information   The primary trial measures the change in hot flash activity using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using RECIST criteria These outcome measures are not identical as they assess different aspects of the patients health   Furthermore the primary trial reports the",
        "label": "Entailment"
    },
    "6e50b114-9a16-4710-8d95-91401b387221": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial does not specify an age range for participation while the secondary trial includes a limitation for patients being under 18 years old Therefore the secondary trial having age limitations is a more specific condition than the primary trial which makes the statement true",
        "label": "Entailment"
    },
    "9edc1688-da47-48ff-b475-b894e925dec7": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However the statement is consistent with the exclusion criteria for the primary trial regarding the inability to safely undergo general anesthesia andor perioperative care related to vascularized lymph node transfer Since breast",
        "label": "Entailment"
    },
    "32ce7a8e-20c4-42d9-a4d4-e3b5d580331e": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced a confirmed complete response CR is not directly related to the information provided in the trial results The trial results only report the percentage of participants who experienced a confirmed complete response or partial response according to RECIST criteria 10 but they do not provide information about the sharpness of the patients minds",
        "label": "Entailment"
    },
    "fac1b066-b96a-470f-8239-89c1cba6572d": {
        "text_answer": "  The statement individuals with measurable bilateral breast cancer can participate in the primary clinical trial is contradictory to the inclusion criteria of the trial as stated in the given text The trial is specifically designed for individuals with unilateral breast cancer and upper extremity lymphedema Therefore individuals with measurable bilateral breast cancer do not meet the inclusion criteria and cannot participate in the trial",
        "label": "Entailment"
    },
    "47db0ed8-8607-4442-827c-20eb9e8db776": {
        "text_answer": "  The statement patients with benign brain tumor are eligible for the primary clinical trial is contradictory to the trials inclusion criteria The trial explicitly states that No brain metastases are allowed and a benign brain tumor is not the same as brain metastases Therefore the statement is contradictory to the trials eligibility criteria",
        "label": "Contradiction"
    },
    "33621096-b0c2-4478-9662-45ba56f9da8d": {
        "text_answer": "  The statement is entailed in the Trials as the trials provide the information that Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain were observed as Adverse Events in the secondary trial but not in the primary trial",
        "label": "Entailment"
    },
    "01f7a296-d0c6-4530-800d-5985bcf7218c": {
        "text_answer": "  The statement in the first 21day cycle of the primary clinical trial capecitabine was given orally on a daily basis to all participants in cohort 2 is entailed in the trial description   Explanation  The trial description states that Capecitabine was administered orally from Days 1 to 14 every 21 days This means that capecitabine was given",
        "label": "Entailment"
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement cohort 1 of the primary trial is administered PR negative ER negative and HER means that cohort 1 does not have positive expressions for Progesterone Receptor PR Estrogen Receptor ER and Human Epidermal Growth Factor Receptor 2 HER   The trials",
        "label": "Entailment"
    },
    "7f2ecb22-ab29-4dfa-b9f6-b09cb7d4c56b": {
        "text_answer": "  The statement is entailed in the trials since the trials report no occurrences of anorexia hypothermia or hallucinations as adverse events and the statement explicitly states that there have been no such occurrences in the trials",
        "label": "Entailment"
    },
    "e4ae61e2-fb24-41dc-9eb6-0102ee8d22d8": {
        "text_answer": "  The statement the patients first of kin will make the final enrollment decision for the primary clinical trial even if the patient meets all exclusion and inclusion requirements is not entailed in the given inclusion and exclusion criteria The criteria only specify the medical conditions required for eligibility and ineligibility for the clinical trial and do not mention anything about the role of the patients first of kin in the enrollment decision",
        "label": "Contradiction"
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "text_answer": "  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is a contradiction to the results of the trial   The trial reports that 20 out of 35 participants 571 did not experience any vomiting or require rescue medication during the first 2",
        "label": "Contradiction"
    },
    "0d414333-1c03-4a79-91d7-1a34323e7e59": {
        "text_answer": "  The statement the use of arimidex is not present in the primary trial cohorts but is a crucial part of the secondary trial is a contradiction to the given trials   In the primary trials there is an intervention group that includes Fulvestrant and Anastrozole but Arimidex is not explicitly mentioned However the secondary trial mentions Arimidex as a crucial part of the trial but it is not included",
        "label": "Contradiction"
    },
    "fe470456-ea60-433f-905c-21189377531a": {
        "text_answer": "  The statement ophthalmic route of administration is administration of a drug to the external eye is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided   The statement Hypokalemic patients are excluded from the primary trial but hyperkalemic patients may be eligible for the secondary trial and the primary trial is partially entailed in the trials   In the primary trial hypokalemic patients are indeed excluded as",
        "label": "Entailment"
    },
    "8b89865c-9af5-4fe0-8f9d-c56240ff7a90": {
        "text_answer": "  The statement there are no preliminary performance requirements for patients applying for either the primary or secondary clinical trials consequently there is no need for any performance status scoring mechanism in either trial is contradictory to the information provided in the secondary trials inclusion criteria The secondary trial explicitly states that patients must have a Zubrod performance score of 2 or better Therefore the statement is incorrect and contradicts the information provided in the clinical trial documentation",
        "label": "Contradiction"
    },
    "895d29b8-16bf-4539-b8f9-a7ffec42ce94": {
        "text_answer": "  The statement both cohorts of the primary clinical trial showed zero cases of hypertension edema and dyspnea is not entailed in the given trials as the trials do not report the occurrence or nonoccurrence of hypertension edema and dyspnea for both cohorts The trials only report the occurrence of these adverse events for each cohort separately Therefore the statement is neither entailed nor contrad",
        "label": "Contradiction"
    },
    "2e16531b-70c8-4302-8747-761859ad7946": {
        "text_answer": "  The statement in the primary clinical trial all participants from cohort 1 experienced at least one lifethreatening adverse event is contradictory to the provided results According to the results there were 3 participants in cohort 1 Dose Level 1 and none of them experienced a lifethreatening adverse event as all adverse events were nonserious Therefore the statement is contradictory to the",
        "label": "Entailment"
    },
    "e2a5803b-3991-4eb2-b428-56d91d9bca99": {
        "text_answer": "  The statement None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups but they do not provide information about the distribution of pain intensity scores or the number of patients who experienced the worst pain imaginable at any point during the 10week study period",
        "label": "Contradiction"
    },
    "3befd95f-b342-45a0-99b4-3f6996b664cf": {
        "text_answer": "  The statement is partially entailed in the trials   Explanation   The statement is correct in that both primary and secondary trials measure success through pCR pathological complete response However the statement does not accurately reflect the results of the trials   In the primary trial the pCR rates for the two arms FEC75 then PaclitaxelTrastuzumab and PaclitaxelTrastuz",
        "label": "Entailment"
    },
    "796002e1-bc19-4298-a035-c853aee3e5c3": {
        "text_answer": "  The statement the primary clinical trial has documented multiple adverse events for patients is a contradiction to the information provided in the trials Both trials report a total of zero adverse events for the specified conditions",
        "label": "Contradiction"
    },
    "31d0a955-493b-4577-931c-ca3cda7a2a0b": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description In the trial description both cohorts 1 and 2 received enzalutamide orally not intravenously Therefore the statement that cohort 2 received enzalutamide through IV is not entailed in the trial information",
        "label": "Contradiction"
    },
    "6ad0142c-56d0-4994-b906-898198240c8c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial reports the use of kilometers as a unit of measurement while the secondary trial reports the use of miles Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "3fe01e39-b6e5-465e-b76b-8048169a72bb": {
        "text_answer": "  The given statement 97 of patients in the primary trial did not experience any Adverse Events is not entailed in the provided trial information The trial information only mentions the treatment regimens number of participants and outcome measurement but it does not provide any information about the occurrence or percentage of adverse events in the trial The statement about tritylcysteine is also not related to the trial results and should be disregarded when verifying",
        "label": "Contradiction"
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the MTD of different interventions with the MTD of MM111 for patients in the secondary trial being 15 mg per day is not directly entailed in the provided trial information   The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of M",
        "label": "Contradiction"
    },
    "a62aed40-ac98-4cdc-a7b2-4b1c57e6010b": {
        "text_answer": "  The statement is entailed in the trials as the dosages of the chemotherapeutic agents used in each arm of the trial are clearly stated and are different from each other In Arm A participants received nabPaclitaxel 125 mgm2 and gemcitabine 1000 mgm2 while in Arm B participants received nabPaclitaxel 125 mgm",
        "label": "Entailment"
    },
    "067bc726-4646-40f8-aa6f-af44d315046e": {
        "text_answer": "  The statement no gastrointestinal adverse events were observed during the primary clinical trial is contradicted by the data provided in the trials as there were a total of 3 reported cases of vomiting 201 Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "69848bb3-c093-4bf4-91eb-f941109b1cd6": {
        "text_answer": "  The statement is entailed in the trials as both the intervention groups receive 20 injections each with the same volume of 04ml administered per injection However the difference lies in the type of solution being injected  alloMSCs for the intervention group and Buminate solution for the placebo group The number of injections and the volume of each injection are equal between the groups which is what the statement is focusing on Therefore",
        "label": "Entailment"
    },
    "838e1a74-56e5-4dde-aeba-f26d2d3f8983": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the change in total body lean mass from baseline to 4 months for two different doses of GTx024 1 mg and 3 mg No information is given about the change in lean body mass during a 1month period for patients treated with a 500mg dose Therefore the statement cannot be entailed based on the given trials",
        "label": "Contradiction"
    },
    "1b314250-0177-4a73-a7f8-a9524ae44cfd": {
        "text_answer": "  The statement eating disorders were not common for the primary trial candidates is not directly related to the statement about distress problems with sexual interest or activity The first statement is about the frequency of eating disorders among the trial participants while the second statement is about the concept of distress related to sexual interest or activity These two statements address different aspects and do not entail or contradict each other",
        "label": "Entailment"
    },
    "33668f2b-29b5-49e2-a0ee-4718913ea856": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial prescribes a specific regimen of neoadjuvant therapy consisting of multiple medications and dosages Therefore the statement that the primary clinical trial prescribes no medication for the duration of the study is contradictory to the facts",
        "label": "Contradiction"
    },
    "78d9d746-c05b-42e9-9156-d97a9f132589": {
        "text_answer": "  The primary trial specifies that participants receive a loading dose of 4 mgkg of trastuzumab followed by 2 mgkg weekly The secondary trial in Intervention 1 of the ACT arm specifies a weekly dose of 2 mgkg of trastuzumab Therefore the weekly dosage in the secondary trial is equivalent to that in the primary trial However its important to note that the primary trial also",
        "label": "Entailment"
    },
    "8db59161-2a2e-4ade-9e23-538bf3b3ec77": {
        "text_answer": "  The statement is not entailed in the given trials as the administration schedules and dosages of Intervention 1 and Intervention 2 differ before the administration of the same Two IM injections of LD V935 The statement would only hold true if the trials were designed such that Cohort A and B received the same exact treatment regimen leading up to the Two IM injections of LD V935 In the given trials Intervention 1",
        "label": "Contradiction"
    },
    "275b4f49-8849-451b-972d-a597662de036": {
        "text_answer": "  The statement neutropenia was a common adverse effect in cohort 2 of the primary trial whereas the patients in cohort 1 of the secondary trial reported no cases of neutropenia despite them having higher doses of empegfilgrastim is a contradiction based on the given trial data  Explanation  In the primary trial the incidence of neutropenia CTCAE Grade ",
        "label": "Contradiction"
    },
    "fffc74c9-56a5-45e7-ba89-a2c91da05110": {
        "text_answer": "  The statement Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant is not directly entailed in the given trial results However it can be inferred from the data that the number of emesisfree participants in the Aprepitant group was more than that in the Placebo group Specifically there were 13 emesisfree participants in the Aprepitant group and",
        "label": "Contradiction"
    },
    "5f2bbf7f-2e76-4ae9-8e79-e6361d05ef47": {
        "text_answer": "  The statement the primary trial reported a 10 decline in the percentage of cells with ki67 expression following one month of treatment with tak228 plus tamoxifen is entailed in the trial results provided   The trial results state that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2 to 3",
        "label": "Entailment"
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "text_answer": "  The statement Participants must be resistant to AI therapy to participate in the primary trial but this is not necessary to be included in the secondary trial is a statement of contradiction with respect to the given trials   The primary trial has AI therapy resistance as an inclusion criterion while the secondary trial does not mention anything about AI therapy resistance as a requirement for participation Therefore the statement is a contradiction as the primary trial requires AI therapy resistance for",
        "label": "Contradiction"
    },
    "ff2a48f8-c4ab-4a13-9ca2-5d46ce4bd6c9": {
        "text_answer": "  The statement is contradicted by the information provided in the secondary trial While it is true that no adverse event affected more than 03 of patients in terms of having a frequency greater than 3333 03 x 100 several adverse events affected more than 03 of patients in terms of having an individual frequency greater than 333 001 x 100 Specifically",
        "label": "Contradiction"
    },
    "0ef8fead-d77e-4aa4-8e40-ca20ac2ea325": {
        "text_answer": "  The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less implies that the amount of Cetuximab is the same between the two cohorts but there is a difference in the dose of MM121 However the statement about feeling unusually tired during the day is not directly related to the trial",
        "label": "Entailment"
    },
    "e7bcb619-8ec0-45cf-acce-9d20e7258c95": {
        "text_answer": "  The statement the total number of adverse events were different in the patient cohorts of the primary and secondary clinical trials is entailed in the given trials data as the number of adverse events for Adverse Events 1 in the secondary trial is 015 000 while in the primary trial it is 00 indicating that there were no adverse events reported in both trials but the number of patients in each trial was different",
        "label": "Entailment"
    },
    "be556bfc-7cc6-44fc-a505-52a8d55bbb5e": {
        "text_answer": "  The statement fetal hypoxemia is abnormally low arterial blood oxygen concentration in a fetus is not entailed in the given trials as they do not involve fetal outcomes or arterial blood oxygen concentrations The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH in women while the secondary trial determines the Maximum Tolerated Dose MTD of Rux",
        "label": "Contradiction"
    },
    "08920163-ef22-4242-b9bf-b70af58c91c2": {
        "text_answer": "  The statement is entailed in the trial information provided The trial description specifies that the vaccine being tested is the GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine and the statement in the question confirms that this is the vaccine used to treat the participants Therefore the statement is entailed",
        "label": "Entailment"
    },
    "77f1bdb0-c7eb-41ba-b05e-e8914b68370a": {
        "text_answer": "  The statement any cancer patient diagnosed with either fibromyalgia thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is entailed in the trials as follows  1 In the primary trial fibromyalgia is listed as an exclusion criterion 2 In the primary trial thalasemic syndromes are listed as an exclusion criterion ",
        "label": "Entailment"
    },
    "2f07cc03-880c-43c4-b50f-c1cdf9ebf0dc": {
        "text_answer": "  The statement there were 0 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is entailed in the given trials as neither of the trials reported any cases of hypertension dehydration or dyspnea in their adverse events",
        "label": "Entailment"
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections every 4 weeks while in the secondary trial no injections were mentioned for either intervention group However the statement incorrectly states that the secondary trial does not require injections and instead uses Lymphoscintigraphy which involves an injection of radioactive Tc99M sulfur colloid Therefore",
        "label": "Contradiction"
    },
    "332d5cb3-14c3-44d3-b2ee-899259c79a4b": {
        "text_answer": "  The statement is entailed in the given trials In the primary trial there are two groups one receiving pyridoxine and the other receiving placebo In the secondary trial there are two groups one receiving highdose oxybutynin chloride and the other receiving lowdose oxybutynin chloride Both trials have more than one test group",
        "label": "Entailment"
    },
    "bf103149-cfe0-453f-9b83-d06c0a8958a0": {
        "text_answer": "  The statement map2k2 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the map2k2 gene is not explicitly stated in the inclusion criteria of the trial However it is mentioned as one of the functional alterations at the G1S checkpoint that can make a subject eligible for the trial under criterion E Therefore the statement is entailed in the trials inclusion criteria  The statement ",
        "label": "Entailment"
    },
    "0a26f239-60ec-4aa7-81e8-de47c20def59": {
        "text_answer": "  The statement there were 50 cases of hypertension edema and dyspnea in either cohort of the primary trial is not entailed in the given trials as there is no information provided in the trials regarding the number of cases of hypertension edema and dyspnea in either cohort",
        "label": "Contradiction"
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "text_answer": "  The statement is entailed in the trials as both trials report on the determination of the Maximum Tolerated Dose MTD of different interventions However it is important to note that the trials use slightly different definitions of MTD and have different time frames for evaluation In the primary trial the MTD is identified as the level below the cohort where DLT occurred in less than one third of patients while in the secondary trial the MTD is",
        "label": "Entailment"
    },
    "c67c581d-7aa5-4a90-b640-dcdf8d69e870": {
        "text_answer": "  The statement is entailed in the trials as both trials include patients with a confirmed diagnosis of stage 4 breast adenocarcinoma The primary trial does not specify the hormone receptor status while the secondary trial specifically requires the tumor to be ER positive andor PR positive and HER2neu negative However the statement in question does not make any mention of HER2neu status so it is still encompassed by the",
        "label": "Entailment"
    },
    "66d9fdb8-ea66-43e2-b497-340bc7832155": {
        "text_answer": "  The statement among the primary trial participants 13 with HER2 primary breast cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab treatment developed imagable HER2 metastases is entailed in the trial results as stated 13 of participants with HER2 breast cancer who underwent HER2targeted PETCT with",
        "label": "Entailment"
    },
    "f5cdf7ed-828f-4e45-9699-b5f80c7b1863": {
        "text_answer": "  The statement is entailed in the trials as both the placebo and memantine interventions are administered orally PO on a daily basis in the given trials Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "063e3d67-dc20-453d-a437-f56447bfa49f": {
        "text_answer": "  The statement is entailed in the trials as both trials involve the use of PF05212384 as the active treatment but with different interventions in the primary trial different gels and different doses in the secondary trial The statement correctly identifies PF05212384 as a drug used in the trials and provides additional context about its nature as an HIV protease inhibitor Therefore the statement is",
        "label": "Entailment"
    },
    "9426014b-4962-4dcc-8328-ca29428d6ed3": {
        "text_answer": "  The statement is contradictory to the given trials   The statement mentions that none of the adverse events in the secondary trial affected more than 5 of patients apart from skin infections but the trials show that the secondary trial had a total of 11 adverse events 1000 of 30 patients which is more than 5 for some adverse events skin infections affected 333",
        "label": "Entailment"
    },
    "8820e8d9-5bea-461f-8622-5ec4b6388a79": {
        "text_answer": "  The statement while the secondary clinical trial excludes 18yearolds the primary clinical trial has no defined age criteria for participation is a conditional statement with two parts  1 The secondary clinical trial excludes 18yearolds 2 The primary clinical trial has no defined age criteria for participation  Lets analyze each part in the context of the given trials  1 The secondary clinical trial does exclude",
        "label": "Contradiction"
    },
    "3f1c8f3a-f9dd-4819-b6db-2931e0c3f288": {
        "text_answer": "  The statement for the duration of the study AfricanAmerican patients participating in the primary clinical trial must be based in Texas is not entailed in the given inclusion and exclusion criteria for the dose escalation and expansion phases of the clinical trial The criteria focus on various medical conditions prior treatments and other factors related to eligibility for the trial but do not mention any specific geographic location requirements for AfricanAmerican patients or any patients in general",
        "label": "Contradiction"
    },
    "766e3e18-5567-48e2-9656-12c1b3ead63f": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial participants receive a baseline dose of 100 mg three times daily which can be escalated to a maximum tolerated dose This is not specified as a maximum of 20 mg three times daily  In the secondary trial Cohort 1 participants receive a fixed dose of necitumumab on Day 3 of the PK runin period and a",
        "label": "Entailment"
    },
    "3015f97a-8a45-4a05-a5cf-9c5eaa49e667": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial describes a treatment cycle of 21 days for both intervention arms and the maximum duration of treatment for each arm is defined Therefore the statement that the primary trial uses a 2year cycle for its intervention is incorrect  The secondary trial does not have a cyclic treatment in place as stated However the statement that the primary trial uses a 2",
        "label": "Entailment"
    },
    "0cf2969d-0228-4267-8e5a-12dc22a12ae9": {
        "text_answer": "  The statement neratinib is an essential part of the primary clinical trial regimen is not directly entailed in the given trial information for either Intervention 1 Phase 2 Triplenegative or Intervention 2 Phase 2 HER2positive and HER2amplified The trials only mention the phases and the biomarker status of the cohorts but they do not explicitly state that neratinib is",
        "label": "Contradiction"
    },
    "236451bf-52bd-4530-ba81-100e63b0030f": {
        "text_answer": "  The statement stomatitis was the only recorded adverse event in the primary clinical trial is entailed in the given trial data if and only if there are no other recorded adverse events besides stomatitis Based on the provided information the statement is entailed by the trial data since the total number of adverse events is reported as 1 and the specific adverse event is stated as stomatitis",
        "label": "Entailment"
    },
    "47dbd397-7aa3-4c9b-9241-d148a255902a": {
        "text_answer": "  The statement is not entailed in the given trials as the trials provide information about different outcomes and participant groups The primary trial focuses on the number of lesions detected in healthy volunteers and breast cancer patients undergoing MRI while the secondary trial investigates the effects of Medihoney and Hydrophor on radiation dermatitis and hyperpigmentation in breast cancer patients undergoing radiation therapy The statement compares the occurrence of lesions in the primary trial with",
        "label": "Contradiction"
    },
    "bd587160-ea9e-41d4-b2c4-54815327d2fb": {
        "text_answer": "  The statement is entailed in the primary clinical trial inclusion criteria for Phase 1 as breast adenocarcinoma is listed as one of the eligible cancer types   Furthermore the secondary clinical trial inclusion criteria state that patients with histologically or cytologically confirmed breast carcinoma are eligible for the study Therefore the statement is entailed in both trials",
        "label": "Entailment"
    },
    "fcef015e-f82c-4cac-a7c1-61a81f0eac3b": {
        "text_answer": "  The statement Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   However the statement is consistent with the exclusion criteria for the primary trial which states Potassium within the normal range of 3553 mEqL It can be inferred that hypokalemic patients",
        "label": "Contradiction"
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial Suramin and Paclitaxel are administered to all patients However in the secondary trial patients undergo mastectomy surgery instead of receiving Suramin and Paclitaxel as interventions Therefore the statement that Suramin and Paclitaxel are administered to all patients in the primary trial and the secondary trial is contradictory to the given trials",
        "label": "Entailment"
    },
    "1d75f8ad-2c35-4481-b6f7-58db73eeea7b": {
        "text_answer": "  The statement cbfa2t3 gene rearrangement is a molecular abnormality indicating rearrangement of the cbfa2t3 gene is not directly related to the intervention MM111 mentioned in the primary trial section Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement is generally true and relevant to the context of gene rearrangements",
        "label": "Entailment"
    },
    "ac3dfb95-6558-4815-b5ed-4887505dedf8": {
        "text_answer": "  The statement the secondary clinical trial noted a higher prevalence of mucositis oral bladder infection and thromboembolic incidents than what the primary clinical trial recorded is a contradiction to the given data  Explanation  The statement implies that the secondary trial had a higher number of incidents for mucositis oral bladder infection and thromboembolic events compared to the primary trial However",
        "label": "Contradiction"
    },
    "41e2d2b1-9637-4667-b032-86c844a94b93": {
        "text_answer": "  The statement the secondary clinical trial does not permit the participation of individuals who are 18 years old whereas the primary clinical trial doesnt mention a specific age for participation is a contradiction   The primary clinical trial does not include an age limit for participation while the secondary clinical trial explicitly excludes individuals under the age of 18 Therefore the statement is a contradiction as the primary trial allows for participation of individuals of all ages while the",
        "label": "Contradiction"
    },
    "dcea72d4-afb6-4565-8d92-fd259ed8ee15": {
        "text_answer": "  The statement patients actively recovering from recent organ transplantation can be enrolled in the primary clinical trial but not in the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However it can be inferred from the exclusion criteria of the secondary trial which states History or presence of other severe medical illnesses or conditions Severe heart disease myocardial ischemia myocardial infar",
        "label": "Entailment"
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "text_answer": "  The statement Only 4 different types of adverse events affected patients in the primary trial all of which were in cohort 2 is not directly entailed in the given trials as they do not provide sufficient information to determine if all adverse events occurred in cohort 2 However based on the information provided it is not contradictory either as the statement allows for the possibility that all 4 types of adverse events occurred in cohort",
        "label": "Contradiction"
    },
    "38e2c25f-97c9-4112-b571-b832e29e7c7e": {
        "text_answer": "  The statement is entailed in the trials as follows  In both trials the use of 18FFDG and 18FFPPRGD2 for PETCT or PETMRI scans is common to both intervention groups However the timing of the imaging and the dose of 18FFPPRGD2 differ between the trials  In the GBM trial imaging is performed at baseline and",
        "label": "Entailment"
    },
    "aab9225d-d2bc-4004-bcaf-4f69a9e7991b": {
        "text_answer": "  The statement eligibility for the primary clinical trial includes patients that received organ transplants within the past month while the secondary clinical trial excludes them is a contradiction   The primary clinical trial explicitly excludes participants who have received any experimental agents within 4 weeks prior to the study registration date which includes organ transplants Therefore organ transplant recipients are not eligible for the primary trial   On the other hand the secondary",
        "label": "Contradiction"
    },
    "9d291a23-1696-4208-a5d4-7b2e1dd48831": {
        "text_answer": "  The statement is not directly entailed in the given trial information as the trials describe different interventions The primary trial focuses on Radioembolization using Yttrium90 glass microspheres and TheraSpheres while the secondary trial involves the administration of 560 mg of ibrutinib and 10 mgkg of MEDI4736 The statement regarding a grade 1 esophageal fistula in the",
        "label": "Contradiction"
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "text_answer": "  The statement The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention regardless of cancer type is entailed in the trials provided   Explanation   The trials show that a higher percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for their colorectal breast and c",
        "label": "Entailment"
    },
    "294df8e3-8ba1-41e7-acdc-6448bfab99f1": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement every patient in the primary clinical trial experienced multiple adverse events while patients in the secondary clinical trial were unscathed by any is contradicted by the data provided in the trials   In the primary clinical trial there were no adverse events reported for any patient Therefore no patient experienced multiple adverse events   In contrast",
        "label": "Contradiction"
    },
    "1b70762f-83fb-4c93-98ac-7f5d8852fc16": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the information provided in the statement with the trials results   The statement says two participants from the primary clinical trial experienced doselimiting toxicities divided evenly with one from each cohort  Lets check if this is entailed in the trials  Trial 1 Level 1   Number of participants with DLT Not",
        "label": "Entailment"
    },
    "32781bed-ab99-4837-a7f8-d3ab0b978384": {
        "text_answer": "  The statement tp53 mutation analysis was not performed is an indication that tp53 mutation analysis was not performed during the study is not directly related to the outcome measurement of the trials regarding the efficacy of GTx024 on total body lean mass Therefore it does not entail or contradict the information provided in the trials  However the statement All patients treated with GTx024 1mg in the primary",
        "label": "Entailment"
    },
    "e7bc1f65-d4e4-4f87-9a2c-ab56c35368ae": {
        "text_answer": "  The statement 157 the primary trial participants and 51674 the secondary trial participants suffered an adverse event is contradictory to the given trials as the trials report that no adverse events occurred in any of the participants in both trials",
        "label": "Contradiction"
    },
    "636ec547-3ea0-41d4-a46f-92d4780b2ffd": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded the same number of adverse events in their cohorts is entailed in the given trials data as both trials reported having no adverse events in their respective cohorts Therefore the statement is true based on the provided information  The request for the 1p19q deletion analysis testing method is not related to the statement and does not affect its entailment or contradiction with the trials",
        "label": "Entailment"
    },
    "d13b1dc9-46cf-471b-b2b1-fa93b235e954": {
        "text_answer": "  The statement more than 75 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 7 months after the surgery is not directly entailed in the given trials as the trials only report the number of participants with pathologic complete response in each arm of the study The trials do not provide sufficient information to determine if more than 75 patients in total experienced pathologic complete response",
        "label": "Contradiction"
    },
    "b753305c-ea26-492d-b45e-760dc4f69b9a": {
        "text_answer": "  The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not directly entailed in the given intervention description The intervention description states that patients receive 100 mgm2 of oral lapatinib once daily on days 128 Therefore the statement is not entailed in the trial information provided  The statement about hyperdiploidy being a",
        "label": "Contradiction"
    },
    "e0265a05-590e-4f77-8e94-8bcdd1d9757e": {
        "text_answer": "  The statement there were no recorded cases of palpitations pericardial effusions and abdominal pains in the primary clinical trial while multiple instances were noted in the secondary clinical trial is a contradiction of the given data  Explanation  The statement implies that there were no instances of palpitations pericardial effusions and abdominal pains in the primary trial while there were multiple instances in the secondary",
        "label": "Contradiction"
    },
    "b3dd4df2-abff-4e7f-89ce-57b109d25bf2": {
        "text_answer": "  The statement is not entailed in the given trials as they address different patient cohorts and interventions The primary trial deals with oral pregabalin while the secondary trial involves intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt Therefore the statement is neither entailed nor contradictory to the given trials",
        "label": "Contradiction"
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However based on the information provided it can be inferred that a patient who has received an organ transplant within the last month would be excluded from the primary trial as it is listed under the exclusion criteria for the",
        "label": "Entailment"
    },
    "027aec87-187e-4c41-9a39-4c453dd1e0ad": {
        "text_answer": "  The statement in the secondary clinical trials group 2 one incident of shingles was reported but the primary clinical trial and group 1 of the secondary clinical trial did not have any such cases is a contradiction to the given data  Explanation  The statement implies that there were no cases of shingles in the primary clinical trial and group 1 of the secondary clinical trial However the data provided shows that there was one",
        "label": "Contradiction"
    },
    "28363fb8-16ff-4a26-b29c-ca41d1ed2e6e": {
        "text_answer": "  The statement no participant in the primary clinical trial experienced a urinary tract infection is contradicted by the information provided in the trial data The data states that 1 participant 200 experienced a urinary tract infection Therefore the statement is contradicted by the trial data",
        "label": "Contradiction"
    },
    "bcbe90f9-602b-45bc-aa97-28e50238e2fb": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information about the secondary trial regarding the use of the relational and itemspecific encoding task or the assessment of cognitive impairment in the patients However it is mentioned that the statement is about a clinical test for episodic memory encoding and retrieval processes in individuals with cognitive impairment which could potentially be relevant to the secondary trial if that aspect is being studied Therefore the",
        "label": "Contradiction"
    },
    "4c79deb2-4d30-470e-959c-e3cf05af0b88": {
        "text_answer": "  The statement less than 2 of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed or contradicted by the given data in the trials   The trials only provide the number and percentage of patients who experienced specific adverse events but they do not give the total number of patients in each trial who did not experience any adverse events Therefore it is impossible to determine if less than 2 of",
        "label": "Contradiction"
    },
    "77aeeff2-38c4-41ce-8526-55ab056504f9": {
        "text_answer": "  The statement neoadjuvant therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered neoadjuvant patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced andor metastatic is not directly stated in the given inclusion and exclusion criteria However the criteria do mention that patients in Phase 1 have evidence of a solid",
        "label": "Entailment"
    },
    "5f44bd33-3921-479c-9a16-e2af73e72101": {
        "text_answer": "  The statement in the primary clinical trial the cognitive function of both cohorts on average experienced a decline is entailed in the trials provided   The mean standardized scores for both the Tamoxifen and Ovarian Function Suppression TOFS and EOFS groups show a negative value indicating below average results on average This implies that the cognitive function of both cohorts on average experienced a decline compared",
        "label": "Entailment"
    },
    "7adf46ec-7d70-4767-936f-b7d89f93cdd6": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on interventions for patients with CRPC ABC or NSCLC and do not mention ovcar8 or ovarian carcinoma Additionally the statement mentions that the secondary trial does not have a cyclic treatment but the primary trial does have a cyclic treatment defined as 21 days per cycle However the statement does not contradict the trials as it does not",
        "label": "Contradiction"
    },
    "c132218c-a01a-406c-b1a1-7d66cc8877bd": {
        "text_answer": "  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope which occurred in 2500 of the primary trial patients is not entailed in the given trials data   The trials data only provides the number and percentage of adverse events for each trial but it does not directly compare the adverse events between the two trials The statement makes a comparison between the two",
        "label": "Contradiction"
    },
    "4fcc0d4c-0772-47c8-ad68-80d10fbeaa0d": {
        "text_answer": "  The statement the primary and secondary clinical trials had syncope as the most frequently reported adverse event among patient cohorts is contradicted by the given data   In the primary trial syncope was reported by 2 patients out of 12 1667 but it was not the most frequently reported adverse event The most frequently reported adverse events were syncope 1667 dehydration ",
        "label": "Contradiction"
    },
    "c2bcdabf-3336-424c-bf5f-13f0b522fa2b": {
        "text_answer": "  The statement the primary clinical trial frequently reports general symptoms as the most common adverse event is not directly entailed or contradicted by the given data The data only reports the frequency of various adverse events in the trial but it does not specify that general symptoms were the most common Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "f7fc247a-5390-4e3f-9254-b16ecdda5851": {
        "text_answer": "  The statement 16p133 is a chromosome band present on 16p is not related to the information provided in the trials and does not need to be verified  Regarding the statement The results from the primary trial indicate that the Arm A intervention has a better overall response rate than the placebo arm and the secondary trial shows that the Denosumab cohort had a better Time to First OnStudy SRE",
        "label": "Entailment"
    },
    "f57d4f1e-c5ba-4b65-8407-5a5be29e28b4": {
        "text_answer": "  The statement a patient who has had a complete resection of a tumour that was initially 3mm in radius would be unable to participate in either the primary trial or the secondary trial is not entailed in the given inclusion criteria for both trials The primary trial includes a criterion for invasive breast cancer with a primary tumour greater than 2 cm diameter while the secondary trial does not have a specific criterion regarding tumour size Therefore a patient",
        "label": "Contradiction"
    },
    "05e6adb2-0549-4564-84c7-79e4a19d0e99": {
        "text_answer": "  The statement 14 adverse events were observed in the primary clinical trial and skin infections in the secondary clinical trial affected 50 of the patients is not entailed in the given trials data and is a contradiction   The primary trial reported 0 adverse events out of 25 patients while the secondary trial reported 10 adverse events out of 30 patients The statement mentions 14 adverse events in total",
        "label": "Contradiction"
    },
    "80da21c8-478e-41a2-befc-384403e43ff4": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In both the primary and secondary trials transendocardial injection techniques are mentioned as a part of the intervention methods In the primary trial there is no mention of transendocardial injections being used for tissue expansion but rather for administering the Contour Profile Tissue Expander However in the secondary trial transendocardial injections are explicitly",
        "label": "Entailment"
    },
    "d28a4294-8d88-4473-b302-51c771571ffb": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial patients undergo mastectomy surgery and are not specified to receive any particular intervention   In the secondary trial there are two interventions for the HR subgroup In Intervention 1 patients receive MM121 and Paclitaxel During the runin phase they receive two doses of MM",
        "label": "Entailment"
    },
    "3eb3c1f5-b395-43e5-a8e5-cf613ac87f30": {
        "text_answer": "  The statement is entailed in the primary clinical trial as breast adenocarcinoma is listed as a cancer type for Phase 2 of the primary trial   The statement is also entailed in the secondary clinical trial as breast carcinoma is listed as a solid tumor type for inclusion in the study",
        "label": "Entailment"
    },
    "7f1301ad-2bc6-426b-86da-8a5c80dfba0c": {
        "text_answer": "  The statement Any patients with a documented allergy to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial is entailed in the primary trials exclusion criteria since it explicitly states Patients requiring ongoing pharmacologic treatment with any of the following medications are excluded cephalosporins",
        "label": "Entailment"
    },
    "ab0a9eb7-2f28-425a-aa06-2389f0c1e9f7": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial does not involve any unit of measurement for the outcome measurement while the secondary trial does  Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "4b545fd1-a4d1-486a-aece-201400e9c1f5": {
        "text_answer": "  The statement None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes is not directly related to the information provided in the trials The trials only report the correlation of Vitamin D levels prognostic factors and gene expression profile in breast cancer patients but they do not mention the results of the AQ20 questionnaire or the presence or absence of a discern",
        "label": "Entailment"
    },
    "bbb06e30-afa0-40c0-9594-b8c293cd5207": {
        "text_answer": "  The statement the lions share of patients from the primary clinical trial showed total recovery within the course of 24 weeks is not entailed in the trial results   Explanation   The statement implies that a majority of the patients experienced a complete response CR at Week 24 However the trial results indicate that there were no participants with CR at Week 12 or Week 24 Therefore the statement is contrad",
        "label": "Contradiction"
    },
    "bef15be3-6cf6-426a-a70a-d5d99a1c42af": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial measure the Change in Ki67 Expression in Tumors is not directly entailed in the given trials as neither trial explicitly mentions the measurement of Ki67 expression in tumors However the primary trial does not measure tumor response using Ki67 expression as an outcome measure and the secondary trial does not mention Ki67 expression in its outcome measurement or correlative studies Therefore the statement is consistent",
        "label": "Contradiction"
    },
    "5f76619b-30cd-47bc-99b9-aab25ce87366": {
        "text_answer": "  The statement is entailed in the given trials as follows  The statement in the primary clinical trial there wasnt any recorded instance of an adverse event whereas in the secondary clinical trial apart from skin infections no other adverse event affected more than 30 of the patients involved in the trial is entailed in the trials because  1 The statement correctly reports the number of adverse events in each trial 2",
        "label": "Entailment"
    },
    "1eb531b0-d0fc-41b7-a6d4-1b774affc30a": {
        "text_answer": "  The statement a patient who completed a cycle of antineoplastic therapy one month prior to the primary clinical trial is seasoned to participate in the investigation is not directly entailed in the given inclusion and exclusion criteria for the clinical trial   The statement pertains to a patients previous antineoplastic therapy which is mentioned in the exclusion criteria as a current or planned therapy that is not allowed However the statement goes beyond the scope of the",
        "label": "Contradiction"
    },
    "a9d41a93-5857-4a56-89f2-46cf6bef36e1": {
        "text_answer": "  The statement at least one patient treated with gtx024 1mg in the primary trial gained over 22 pounds of lean body mass is contradicted by the given trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg which is far less than the 22 pounds approximately 10 kg required to satisfy the statement Therefore",
        "label": "Contradiction"
    },
    "7f3b898a-e7d1-4cc2-bf62-a8366ea7cf80": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials do not mention the dosing unit coat and the MTD values reported are in different units mg for the primary trial and mgkg for the secondary trial The statement is not directly related to the information given in the trials",
        "label": "Contradiction"
    },
    "fe37b4ad-fe84-429b-89ce-f5a881215b56": {
        "text_answer": "  The statement for the primary and secondary clinical trial eligibility extends to women who have reached the age of 18 or more is entailed in both trials as it is explicitly stated in the inclusion criteria for both trials Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "f2076a4f-6170-46ca-9e08-8d0f9589bb06": {
        "text_answer": " The given statement The majority of patients in the primary trial experienced complete response by week 24 is contradictory to the trial results as per the provided data According to the results no participant in the trial experienced complete response CR at either week 12 or week 24 Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "6a6f23a1-354d-4c1a-b457-e3ce15564e69": {
        "text_answer": "  The statement is entailed in the Trials The secondary trial has the same inclusion and exclusion criteria for all participants as stated in the text The primary trial however has different inclusion criteria for different study groups as outlined in the text The statement does not mention anything about chromosome band 2q361 so it is not related to that part of the text Therefore the statement is entailed in the Trials as stated",
        "label": "Entailment"
    },
    "e970c950-ccf6-4c0c-8573-84634162fdf3": {
        "text_answer": "  The statement smokers and alcoholics who consume 6 or more drinks daily are allowed to participate in both the primary and secondary trials is a contradiction to the inclusion criteria of the primary trial The primary trial explicitly states that participants must be nonsmokers and have no alcohol use within the last 5 years Therefore smokers and alcoholics who consume 6 or more drinks daily do not meet the inclusion criteria for the primary trial and cannot participate",
        "label": "Contradiction"
    },
    "552c3a00-fa13-4e27-89a8-2ef4823317cd": {
        "text_answer": "  The provided information in the trial descriptions does not mention the use of paclitaxel as part of the treatment regimen for either Arm A ANA or Arm B FULV Therefore the statement is contradictory to the information provided in the trial descriptions",
        "label": "Entailment"
    },
    "65c91814-cbda-4db3-a680-4bc3fe0855a8": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the Primary Trial Both the inclusion and exclusion criteria are stated for both Phase I and Phase II Therefore the same criteria apply to all phases  In the Secondary Trial The inclusion and exclusion criteria are different for this trial compared to the Primary Trial Therefore the criteria are not the same for all phases or sets of participants  The statement ",
        "label": "Entailment"
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "text_answer": "  The statement There are 7 more participants in cohort 2 of the primary trial than in cohort 1 is not directly entailed or contradicted by the given information The number of participants in each armgroup is provided but the number of participants in each cohort which could include more than one armgroup is not explicitly stated Therefore it is not possible to determine if the statement is true or false based on the given information",
        "label": "Contradiction"
    },
    "cb9a1bc3-cc8d-4d0d-a335-eb5c5071289f": {
        "text_answer": "  The statement less than 010 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products is not directly entailed or contradicted by the provided information in the trial results Result 1   The trial results only report the number of participants with a reduction in CTCs at one month post AHST not the percentage or proportion of participants",
        "label": "Contradiction"
    },
    "c01b910d-2463-4bf8-bb67-f950aca11411": {
        "text_answer": "  The statement is entailed in the trials as both trials include patients with histologically or cytologically confirmed breast adenocarcinoma that is metastatic stage IV and have ER PR or HER2neu negativity as specified criteria Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "8df26566-8724-4ca3-b6be-f43b9b188724": {
        "text_answer": "  The statement eligible subjects for the primary clinical trial should have prostate cancer and need treatment through surgery is contradictory to the given inclusion and exclusion criteria for the primary trial   The inclusion criteria state that the eligible subjects have breast cancer that has continued to grow after receiving hormonal treatment and require hormonal treatment while being postmenopausal women The exclusion criteria state that the trial does not include subjects who have received more than one previous reg",
        "label": "Entailment"
    },
    "e3222534-b084-405b-bd5a-32fbd2a663c4": {
        "text_answer": "  The statement participants will receive their single injection on the first day of the study is not directly entailed in the information provided in the trial description The trial description mentions the administration of the dendritic cell vaccine Trastuzumab Vinorelbine and sargramostim at different time points but it does not explicitly state that these treatments are given on the first day of the study for every participant Therefore the statement is neither",
        "label": "Contradiction"
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site However the statement specifically mentions that intervention 1 uses higher doses than intervention 2 but the trials do not provide information on the exact doses used in each intervention Therefore while the statement is entailed in the sense that both inter",
        "label": "Entailment"
    },
    "728c430c-a48c-44a3-a598-38f96ddabaea": {
        "text_answer": "  The statement Intraoperative Mammography performed better than the Standard Mammography in the primary trial in terms of operative time savings is entailed in the trials as the primary trial does report a shorter median operative time for the Intraoperative Mammography arm compared to the Standard Mammography arm However its important to note that the secondary trial does not provide any information that can be used to compare the success rates between the",
        "label": "Entailment"
    },
    "b0308df2-5725-4b3a-9c80-0d5390bf3149": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years and over 50 patients from each cohort survived more than 24 months is not directly entailed in the given trials Results 1 and 2   The trials only provide the median survival times for each group and the statement makes a claim about the average survival time and the number of patients surviving beyond 24 months for the entire trial population   ",
        "label": "Contradiction"
    },
    "8d60b35c-e6df-4e22-a92e-b9c782b9ed1b": {
        "text_answer": "  The statement There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial is entailed in the given trials data  Explanation  The statement is entailed because the total number of adverse events in the primary trial is 0 while in the secondary trial it is 48 This means that there are fewer adverse events in the primary trial than in the secondary trial  ",
        "label": "Entailment"
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement suggests that there were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial However the trials show that there were no cases of nausea reported in either trial and there were fewer cases of Infection Asymmetry in the secondary trial compared to the primary trial Therefore the statement is contradicted",
        "label": "Contradiction"
    },
    "42eaaa23-bd07-4a89-ba9f-dffe36e31ddb": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide information about the chromosomal status of the patients or the developmental malformations that may result from the interventions The statement discusses nontrisomic autosomal aneuploidy which is a type of chromosomal abnormality but the trials do not mention this specific condition in relation to the interventions Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "7e01558a-26ed-4ebf-aa18-d5d1c876c194": {
        "text_answer": "  The statement doctor and I shared responsibility for deciding which treatment is best for me is not entailed in the given trials as they do not provide enough information to determine if the decisionmaking process for treatment selection involved shared responsibility between the doctor and the participant The trials only describe the interventions being used in each group and do not mention the role of the doctor or the participant in the decisionmaking process Therefore the statement is neutral with respect to the trials",
        "label": "Contradiction"
    },
    "0a1f17fb-d58d-46e3-a726-bf7ef647e88e": {
        "text_answer": "  The statement positive fish or IHC 3 results confirming a diagnosis of a HER2 positive tumor is essential for all primary clinical trial candidates is entailed in the inclusion criteria of the trial The inclusion criteria state that HER2 positive tumor either IHC 3 or FISH is a requirement for trial participation Therefore the statement is entailed in the trials criteria and is not contradictory",
        "label": "Entailment"
    },
    "e9204795-c6e7-4215-a230-2958d48a6ac2": {
        "text_answer": "  The statement incidence of doselimiting toxicity was not reported in the primary clinical trial is neither entailed nor contradicted by the given trial results   The trial results do not provide information about the incidence of doselimiting toxicity for each armgroup The results only state the number of participants analyzed for each armgroup Therefore it is not possible to determine from the given trial results whether or not the incidence of dose",
        "label": "Entailment"
    },
    "ab29d2f1-5d52-475b-be8a-a3b82c49a44a": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The trials only report the number of participants who achieved Pathologic Complete Response in Breast and Axillary Lymph Nodes for each arm of the study The statement mentions a chromosome band 9q33 which is not mentioned in the trials Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "3317bb44-031e-4444-b6b9-7b538727efa3": {
        "text_answer": "  The statement is entailed in the given trials as neither trial reported any adverse events affecting more than a fifth 21 of the test group In both trials the percentage of adverse events was 048 in the primary trial for the total group and 0 in the secondary trial for both the total group and the neutrophilsgranulocytes ANCAGC subgroup Since none of these percentages exceed",
        "label": "Entailment"
    },
    "dbcb7763-d671-465e-8704-4bd5cd5ec7ef": {
        "text_answer": "  The statement there were multiple adverse events recorded in the primary trial and the secondary trial is entailed in the given trials data as follows  1 The primary trial had 0 adverse events out of 20 participants 000 2 The secondary trial had 2 adverse events out of 35 participants 571  Although the number and types of adverse events differ between the trials",
        "label": "Entailment"
    },
    "b681145e-4fd6-42ae-8250-b6d915e7a0cf": {
        "text_answer": "  The statement the secondary trial and the primary trial follow identical sets of criteria for participant eligibility is a conditional statement To determine if it is entailed in the trials or contradictory we need to compare the inclusion and exclusion criteria of both trials  Comparing the inclusion criteria we can see that they are not identical The primary trial includes patients with advanced cancer potentially sensitive to vinorelbine while the secondary trial includes patients presenting for large",
        "label": "Entailment"
    },
    "a0ad7d49-26f2-42ac-a384-e6362ccae8d7": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair less than 20 of waking hours are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial focuses on Her2neu or Her1EGFR positive cancer patients with measurable disease",
        "label": "Entailment"
    },
    "572557f8-fcc1-4448-aa44-a09e7c5244e8": {
        "text_answer": "  The statement while entry into the secondary clinical trial requires adherence to specific performance status conditions such conditions are not imposed on candidates for the primary clinical trial is entailed in the given trials inclusion and exclusion criteria   Explanation  The primary clinical trial includes subjects who have already responded to at least two courses of weekly paclitaxel therapy and are considered to need to continue the therapy by the investigatorsubinvestigator among patients",
        "label": "Entailment"
    },
    "ee0e333a-4b42-4078-a126-d3a1101f7f4c": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measurements The primary trial measures the summed pain intensity differences SPID30 at 30 minutes after dosing for each pain episode while the secondary trial measures the change in bone mineral density BMD of the lumbar spine from baseline to 9 months The statement does not directly relate to the outcome measurements or results presented in either trial",
        "label": "Contradiction"
    },
    "0f631563-09e1-48db-a6c3-1cc06009e139": {
        "text_answer": "  The statement no patients in either the primary clinical trial or the secondary clinical trial endured fewer than 3 distinct AEs is neither entailed nor contradicted by the given data   The data only provides the number of patients who experienced each distinct AE in each trial but it does not indicate how many distinct AEs each patient experienced in total Therefore based on the given data alone it is impossible to determine whether any patient in either trial experienced fewer than",
        "label": "Contradiction"
    },
    "1e1830e7-f7bd-4bf4-99c4-c36f6da015e3": {
        "text_answer": "  The statement 5 patients in the primary trial suffered 3 or more adverse events is not directly entailed nor contradictory to the information provided in the trials regarding adverse events The statement only mentions the number of patients who experienced 3 or more adverse events but it does not specify the route of administration The trials on the other hand provide the number and types of adverse events for the intestinal route of administration Therefore the statement",
        "label": "Contradiction"
    },
    "e875a6e2-1058-4954-a864-7f1b35508362": {
        "text_answer": "  The statement is a contradiction to the secondary clinical trial as in the secondary trial dexmedetomidine is not administered to group 2 patients In the primary trial dexmedetomidine is given to group 2 but this does not apply to the secondary trial",
        "label": "Contradiction"
    },
    "0b90fb4c-0de2-478b-95d2-2f0b555398ad": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given trials with entailment or contradiction we need to first understand the meaning of the statement and the context of the trials  The statement the intervention section of the primary clinical trial calls for only therapeutical and lifestyle changes means that the intervention in the trial only involves medical treatment and modifications to the participants lifestyles with no other interventions  The Trials with Entail",
        "label": "Entailment"
    },
    "e56bca0a-a541-4a59-ba79-0f17cd0cdcb6": {
        "text_answer": "  The statement women in the age bracket of 1819 years can join the secondary clinical trial but their eligibility for the primary clinical trial will come after a waiting period of 12 years is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials Therefore it cannot be definitively determined if the statement is entailed in the trials or not as there is no information provided in the trials regarding",
        "label": "Entailment"
    },
    "f0fbd167-6b00-4152-889e-7df794aa0619": {
        "text_answer": "  The statement laryngeal obstruction ctcae is a disorder characterized by blockage of the laryngeal airway is not directly related to the trials provided The trials focus on the outcome measurements of tumor diameter and response to treatment in patients with various types of cancers The statement does not entail or contradict any information presented in the trials",
        "label": "Entailment"
    },
    "94857a77-b822-4cb8-989b-b6efb0a105e0": {
        "text_answer": "  The statement both trials saw a considerable number of adverse events throughout their duration is contradicted by the given information   The first trial had no adverse events at all while the second trial had only two adverse events which is a significantly smaller proportion of the total number of participants compared to the statement suggesting a considerable number   Therefore the statement is contradicted by the given information",
        "label": "Contradiction"
    },
    "31f16856-c47c-40f3-b9a8-c414f07710ec": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 25 years before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2",
        "label": "Entailment"
    },
    "f6ca1a5e-853d-4669-8c13-89b54a42c460": {
        "text_answer": "  The statement nras gene mutation negative is a genetic finding indicating that nras gene mutations have not been detected in a sample is entailed in both the Trials given as it is mentioned that neither of the cohorts received any invasive surgery or Neratinib which is a drug used to treat Nras gene mutations in some cancers Therefore the absence of Neratinib treatment and invasive surgery in both trials implies that no Nras",
        "label": "Entailment"
    },
    "90599dbb-bf85-4e56-9a16-fbcd4fbb22f6": {
        "text_answer": "  The statement is entailed in the trials as both Herceptin trastuzumab is used in Arm 1 Herceptinnavelbine and Arm 2 Taxoterecarboplatinherceptin",
        "label": "Entailment"
    },
    "7f0ff0a3-ccf0-4ea7-9c5b-b631da541d07": {
        "text_answer": "  The statement is entailed in the given trials as neither of them include the use of Arimidex anastrozole in the Intervention 2 of the primary trial and the secondary trial does not involve the use of Arimidex at all",
        "label": "Entailment"
    },
    "3de4fd70-62c3-4310-a163-507e49af0e73": {
        "text_answer": "  The primary clinical trial includes the following criterion for tumor size Primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography The secondary clinical trial does not mention a specific tumor size criterion  Therefore the statement both primary clinical trial and secondary clinical trial permits a patient possessing a primary 3mmradius tumor confirmed by clinical examination and ultrasonography is",
        "label": "Entailment"
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "text_answer": "  The statement is entailed in the trials as both trials include the use of cyclophosphamide in their interventions",
        "label": "Entailment"
    },
    "e7572377-d468-4b13-815a-f43887747c18": {
        "text_answer": "  The given trials describe two different interventions each consisting of a combination of MCS110 and PDR001 administered at specific doses and frequencies The statement there are patients in the primary clinical trial who do not receive mcs110 at all is not directly entailed in the provided information However it is possible that some patients may not receive MCS110 in the trials due to various reasons such as adverse reactions protocol",
        "label": "Contradiction"
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "text_answer": "  The statement is entailed in the trials as both cohorts receive the same dose of Abraxane nabPaclitaxel in each treatment cycle However the regimens in each arm differ in the second agent used in combination with Abraxane gemcitabine in Arm A and carboplatin in Arm B Therefore while the doses of Abraxane are the same the overall chemotherapy regimens are",
        "label": "Entailment"
    },
    "3ce48a99-7310-4a2f-8853-e46db55af26e": {
        "text_answer": "  The statement is entailed in the trial results as follows  The trial reports a mean percentage change in Ki67 expression of 40 63 to 29 after 7 days of presurgical tamoxifen treatment Since the statement mentions that tamoxifen is taken for 168 hours prior to surgery 7 days  24 hoursday it correctly reflects the information in the trial  Add",
        "label": "Entailment"
    },
    "aef90851-f30f-4d13-b6d6-8f52afaaa302": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the given trials data  Explanation  The statement is entailed in the trials data because the primary trial had a higher incidence of all the mentioned adverse events",
        "label": "Entailment"
    },
    "42aa56a7-2e3b-4932-bdde-a0ed438111c1": {
        "text_answer": "  The statement is not directly related to the information provided in the trials regarding adverse events and the difficulty to bend and straighten an affected arm The statement is about the occurrence of chest pain in the two trials which is not mentioned in the information provided about the trials regarding arm mobility Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "bfa5809e-c1d4-49b8-b3d1-37fd6f7b077f": {
        "text_answer": "  The statement a patient with a known allergy to doxycycline not cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib can participate in both the primary trial and the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either trial   The primary trial excludes patients with allergic reactions to compounds of similar chemical or",
        "label": "Contradiction"
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "text_answer": "  The statement There were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is contradicted by the given trials as the number of cases for Infection Asymmetry and Deflation in the secondary trial is zero Therefore the statement is not entailed by the given trials",
        "label": "Contradiction"
    },
    "dcad163d-b572-4dcc-a052-8bfb81f05ad5": {
        "text_answer": "  The statement is entailed in the trials In the primary trial participants receive PF06647020 at 02 mgkg or 05 mgkg which is lower than the dosages given in the secondary trial where participants receive ALT801 at 0015 mgkgdose or 0040 mgkgdose Therefore the statement that individuals",
        "label": "Entailment"
    },
    "4e9ce538-8418-4432-b3e7-8f3ecfefee6d": {
        "text_answer": "  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it is not directly entailed in the given trials as the trials do not provide sufficient information to make that comparison   The trials only report the ORR and number of participants analyzed for each group but they do not provide information on the statistical significance of the",
        "label": "Contradiction"
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "text_answer": "  The statement the secondary trial and the primary trial have completely unrelated outcome measurements is entailed in the Trials with Entailment as the primary trial measures the percentage of participants with treatmentemergent adverse events in various cancer populations while the secondary trial measures the number of participants with objective response to talazoparib in breast and ovarianperitoneal cancer populations These outcome measurements are unrelated as they assess different aspects of treatment eff",
        "label": "Entailment"
    },
    "82cea870-dbc3-4ebf-824c-0cebd7e95205": {
        "text_answer": "  The statement is entailed in the trials as given   Explanation   The statement cohort 1 is given a lesser amount of alt801 as compared to cohort 2 in the primary clinical trial is entailed in the trials because the trials state that cohort 1 receives a dose of 0015 mgkgdose of ALT801 while cohort",
        "label": "Entailment"
    },
    "2677ff54-f67c-44c1-9aa8-64efd3357f65": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is a contradiction to the exclusion criteria of both trials   In the primary trial the exclusion criteria do not mention having a history of pulmonary embolisms as a reason for exclusion However it does exclude individuals with a history of clotting disorders which could include a history",
        "label": "Contradiction"
    },
    "ac265234-e392-49b4-b46b-a0a54e54f88b": {
        "text_answer": "  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is a contradiction to the given trials as the trials do not report any cases of epileptic seizures in either the primary or secondary trials Additionally there is one case of Thromboembolic event in the primary trial and no cases in the secondary trial but there are",
        "label": "Contradiction"
    },
    "a01bb73a-e620-4bb5-995b-9433d10090ab": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the Primary Trial massage therapy is the intervention and no mention of drugbased treatments is made Therefore the statement is entailed as the Primary Trial does not include drugbased treatments in its examination process  In the Secondary Trial two separate drugbased interventions PF06647020 02 mgkg and PF",
        "label": "Entailment"
    },
    "3d52b3c6-d110-4442-8a2f-1cf87b1092c5": {
        "text_answer": "  The statement anal cancer pTmxTnm finding v6 is anal cancer in which distant metastasis cannot be assessed is not directly related to the inclusion and exclusion criteria of the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed in or contradicts the trials based on the given information alone  Regarding the patient with a primary tumour of 33mm the primary trial includes the criterion Primary",
        "label": "Entailment"
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "text_answer": "  The statement Nationality ethnicity weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial is entailed in the given inclusion and exclusion criteria for both the primary and secondary trials There is no mention of nationality ethnicity weight or gender as inclusion or exclusion criteria in the provided text Therefore the statement is entailed in the trials as it is consistent with the information provided",
        "label": "Entailment"
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "text_answer": "  The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for all cohorts of the primary trial is entailed in the given inclusion criteria   Explanation   The inclusion criteria state that patients with ER positive HER2 negative invasive breast cancer Group 1 and invasive triplenegative breast cancer Group 2 are eligible for the trial",
        "label": "Entailment"
    },
    "5718421a-fc98-4df0-a866-21d4718ebf78": {
        "text_answer": "  The statement is entailed in the Trials with Contradiction   Explanation   In the primary clinical trial participants received trastuzumab at a loading dose of 4 mgkg followed by 2 mgkg weekly while in the secondary clinical trial Herceptin was administered at a dose of 4 mgkg on Day 1 of Cycle 5 followed by 2 mgkg weekly starting",
        "label": "Entailment"
    },
    "c3c644d4-1964-454a-af82-4e82c2567f6e": {
        "text_answer": "  The statement is entailed in the primary trial as both Intervention 1 and Intervention 2 involve the use of 18FFDG and 18FFPPRGD2 in PETCT or PETMRI scans for all participants in each group Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "c4a0d86a-f8a8-4c2a-a28a-25147f35a682": {
        "text_answer": "  The statement is entailed in the Trials since all the instances of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever mentioned in the Adverse Events 1 occurred in cohort 1 and there were no such instances in Adverse Events 2 Therefore the statement is true given the information provided in the trials",
        "label": "Entailment"
    },
    "1af24416-2f14-423b-bd1c-b6f604cae64a": {
        "text_answer": "  The statement patients with 23 cerebral metastases located in the cerebellum are permitted to participate in the secondary clinical trial while participation in the primary clinical trial is not an option is not directly entailed in the given trial descriptions   The primary clinical trial has specific inclusion and exclusion criteria for cerebral metastases which include size number location and histology The statement about cerebellar metastases",
        "label": "Contradiction"
    },
    "09deff91-1b05-470a-aecd-60ce772b9a8e": {
        "text_answer": "  The statement candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments is contradictory to the inclusion criteria of the trial as stated in the text The trials inclusion criteria only require breast cancer unresponsiveness to hormonal treatment and postmenopausal status There is no mention of colon cancer as a requirement for the trial Therefore the statement is contradictory to the information provided in the text",
        "label": "Contradiction"
    },
    "5bdc0c5e-236f-4dbf-92cd-8f582a16b2fd": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the dosage of Intervention 2 dexmedetomidine is given as 05ugkg 5ml not 05kgug 5000ml   In the secondary trial no information is provided about the dosage or administration of Intervention 1 baseline or Intervention ",
        "label": "Contradiction"
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "text_answer": "  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is contradictory to the information provided in the trials   The trials report that no cases of Acute myocardial infarction were observed in either the primary or secondary trials However the statement suggests that 2 participants in the primary trial and none in the secondary trial had Ac",
        "label": "Contradiction"
    },
    "c392fd36-941e-4809-8d9e-16e3aa1c945c": {
        "text_answer": "  The statement compared to the secondary clinical trial the primary clinical trial boasted a greater number of participants is a contradiction to the information provided in the trials   The primary clinical trial had 13 participants analyzed while the secondary clinical trial had 30 participants analyzed However the statement suggests that the primary trial had a greater number of participants than the secondary trial which is not the case",
        "label": "Contradiction"
    },
    "dd58a7e3-370e-4e61-9071-6155962cd180": {
        "text_answer": "  The statement there were no adverse events reported by the first group in the primary clinical trial is entailed in the given data if and only if the data implies that the total number of adverse events reported by the first group is zero Based on the provided data the statement is entailed as the total number of adverse events reported by the first group is indeed zero 000",
        "label": "Contradiction"
    },
    "151ae668-d1e7-4dd1-beb2-75dd7efbae4c": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   The statement implies that only one medication with a dosage not exceeding 100 mgm2 is administered during the trial However the clinical trial description specifies that participants receive four distinct medications epirubicin cyclophosphamide docetaxel and trastuzumab with varying dosages for each medication Therefore",
        "label": "Entailment"
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "text_answer": "  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID is neither entailed nor contradicted by the given trials   The primary trial describes the use of whole breast radiation therapy for breast cancer patients but it does not mention the administration of Fulvestrant or its dosage form The secondary trial describes the use",
        "label": "Entailment"
    },
    "48b5fa7f-b2c7-41f9-adc5-ca55ae919f3d": {
        "text_answer": "  The statement different patient features are evaluated in the results of the primary clinical trial and the secondary clinical trial is entailed in the given trials as follows  1 In the primary clinical trial the outcome measurement is the evaluation of toxicity of infusing HER2specific T cells using NCI Common Terminology Criteria for Adverse Events CTCAE v30 The trial includes 19 participants and the primary interest lies in",
        "label": "Entailment"
    },
    "1d60de45-bc33-4178-96e6-d0fa20e51fed": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials   The trials describe the details of two different interventions one with the use of Active Breathing Coordination ABC and the other without it Both interventions involve the same radiation therapy doses and schedule The statement is about the concept of transparency which is not directly related to the trials content Therefore it cannot be entailed or contradicted by the",
        "label": "Entailment"
    },
    "18303bbd-059e-4161-8cc6-9569a71308f5": {
        "text_answer": "  The statement is partially entailed in the trials Both interventions involve the use of doxorubicin cyclophosphamide and docetaxel The identical doses of these drugs are given to all groups at equal intervals as stated in the trial descriptions However the number of treatment courses differs between the two interventions In Intervention 1 the patients receive a total of 8 cycles 4 cycles of AC and 4 cycles of",
        "label": "Entailment"
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial reported 1 death not otherwise specified out of 9 participants 1111 and the secondary trial reported 1 death not otherwise specified out of 208 participants 048 In total there were 2 deaths reported across both trials However the statement claims that there were 10 deaths recorded in the ad",
        "label": "Entailment"
    },
    "4eacff65-65e6-4bf9-bc94-419c48e854e8": {
        "text_answer": "  The statement adverse events experienced by patients in the primary clinical trial do not match those in the secondary clinical trial is a contradiction based on the given data   Explanation  The primary trial and the secondary trial both report the absence of certain adverse events such as sinus tachycardia heart failure dehydration lymphopenia neutropenia thrombocytopenia hypon",
        "label": "Contradiction"
    },
    "9c6f062e-a260-4c3a-ac91-fc5de6de176d": {
        "text_answer": "  The statement is entailed in the Trials as both the primary and secondary clinical trials use pCR as the outcome metric However the statement also mentions a discrepancy in results between the two cohorts in the primary trial and a significant difference in performance between the two arms in the secondary trial The trials do not directly compare the same arms or groups so a direct comparison of the results is not valid However the statement is still entailed in the sense",
        "label": "Entailment"
    },
    "0416a45e-2ea6-4f82-8bc6-05cc37b941f8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial defines each treatment cycle as 21 days and the secondary trial does not mention a cyclic treatment at all Therefore the statement that the primary trial uses a 6day cycle for its intervention is incorrect",
        "label": "Entailment"
    },
    "57526ef1-a6b9-419e-86c9-0a2d6db7ad23": {
        "text_answer": "  Anorexic patients cannot be considered for the primary clinical trial based on the provided inclusion and exclusion criteria The inclusion criteria state that participants must have a BMI of 25 kgm2 or greater and weight less than or equal to 400 lbs Anorexia is a condition characterized by a significantly low body weight often less than 85 of the expected body weight for height and age Therefore anorexic patients do not",
        "label": "Entailment"
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years however at least one patient from both cohorts died in under 2 years is not directly entailed or contradicted by the given trial results   The trial results only provide the median survival times for each group and the statement makes a claim about the average survival time for all patients in the trial While it is true that the median survival times are over 2 years for both groups",
        "label": "Contradiction"
    },
    "43297eae-d154-4417-8bd4-3c4aae66e6bd": {
        "text_answer": "  The statement the record shows that the primary clinical trial experienced 4 more adverse events than what was observed in the secondary clinical trial is a contradiction to the given data   The primary trial had 0 adverse events out of 34 participants and the secondary trial had 0 adverse events out of 1 participant Therefore there is no difference in the number of adverse events between the two trials The statement that there is a difference of",
        "label": "Contradiction"
    },
    "c21d4d07-87ea-46ba-b930-9fd3fb0797a5": {
        "text_answer": "  The statement patients who are currently engaged in smoking are ineligible for both the primary clinical trial and the secondary clinical trial is entailed in the trials as smoking is listed as an exclusion criterion for both trials  In the primary trial it is mentioned under the exclusion criteria as Patients who are current smokers and in the secondary trial it is mentioned as smoker under the exclusion criteria for the secondary trial",
        "label": "Entailment"
    },
    "65f9af41-9bb8-438a-b967-94acfd0e08a9": {
        "text_answer": "  The statement the primary clinical trial has not documented any outcomes for the lbh589 and lapatinib cohort is entailed in the trials provided as none of the trials include data for the LBH589 and Lapatinib cohort The trials only document the outcomes for the LBH589 with Capecitabine cohort",
        "label": "Entailment"
    },
    "3131f532-99b5-433e-9375-8af120cd4c0f": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial Intervention 2 involves the administration of dexmedetomidine not myalgias In the secondary trial no intervention involves the administration of myalgias at all Therefore the statement that patients in the second group of the primary clinical trial are administered with 05ugkg of myalgias 5ml is not entailed in the given trials",
        "label": "Contradiction"
    },
    "bfb9d912-39ea-4a7a-b3eb-51e9d1b5f436": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial will accept patients with a welldocumented allergy to drugs such as cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib is entailed in the given trials as both trials explicitly list these drugs as exclusion criteria under allergyrelated reasons",
        "label": "Entailment"
    },
    "06bf2ef1-129f-47cf-b51f-75e51f1eb66a": {
        "text_answer": "  The statement in the primary clinical trial all of the recorded individual adverse events were unique to one patient each is neither entailed nor contradicted by the given information   The statement implies that each adverse event occurred in a different patient while the given information only states the number of occurrences of each type of adverse event and the total number of adverse events It does not provide information about which patients experienced which adverse events Therefore the",
        "label": "Entailment"
    },
    "fb41d62d-4f75-463d-b71a-0b31dd0ade96": {
        "text_answer": "  The statement is entailed in the trials as both interventions provide the same amount of nabPaclitaxel 125 mgm2 to participants in each treatment cycle However the difference lies in the second agent used in combination with nabPaclitaxel  gemcitabine in Arm A and carboplatin in Arm B",
        "label": "Entailment"
    },
    "e875dcbd-dc31-47c4-87bf-a94b0c1696b1": {
        "text_answer": "  The statement the outcome measurements of the primary clinical trial are directly correlated to those of the secondary clinical trial is not directly entailed in the given trials as they measure different outcome measures   The primary trial measures the percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events while the secondary trial measures the number of participants with objective response These outcome measures are not directly related to each other",
        "label": "Contradiction"
    },
    "9640278e-af41-482e-8390-d20bc7388149": {
        "text_answer": "  The statement Sexually active fertile men and women with reproductive potential can participate in the primary clinical trial but adherence to additional criteria is required is entailed in the given trial information   Explanation   The inclusion criteria of the trial state that women of childbearing potential WOCBP are allowed to participate but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and",
        "label": "Entailment"
    },
    "ad11786a-e01b-466c-9e44-31f1be35c79c": {
        "text_answer": "  The statement in both the primary clinical trial and secondary clinical trial there were no unforeseen fatalities or hospital admissions is not directly entailed in the given trials data The trials data only provides information about the occurrence of adverse events including lymphoma and their respective frequencies The statement goes beyond the given data by making a more specific claim about unforeseen fatalities and hospital admissions which are not mentioned in the trials data Therefore",
        "label": "Contradiction"
    },
    "325db761-416f-4aab-80e8-e3271a11200b": {
        "text_answer": "  The statement the primary trial participants do not receive any vaccines is not directly related to the information provided about the trials Therefore it does not entail or contradict the information given about the trials regarding fatigue being a disabling symptom The trials only provide information about the type of chemotherapy regimens and the duration of bevacizumab maintenance therapy for HER2negative breast cancer participants",
        "label": "Entailment"
    },
    "56ac01ed-cfba-4ab5-9082-dbe4a4418e9d": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The trials description specifies that Intervention 1 is for a Phase 2 Triplenegative cohort and Intervention 2 is for a Phase 2 HER2positive cohort The terms Triplenegative and HER2positive define the characteristics of the cohorts in terms of the biomarkers PR Pro",
        "label": "Entailment"
    },
    "0931fd2b-2ce8-4285-9c02-63318e60efc3": {
        "text_answer": "  The statement is not directly entailed in the given trials as the primary trial reports the outcome measurement of pain intensity using Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement only mentions that one trial reports the severity of delayed nausea and the other measures BMD but it does",
        "label": "Contradiction"
    },
    "b0709ec3-ea6b-4f70-a24e-d23480df5b14": {
        "text_answer": "  The statement is entailed in the trials as the primary trial reports the time to progression for both arms A and B with a total of 156 participants while the secondary trial reports the number of participants with objective response CR and PR for a separate arm SUNITINIBCAPECITABINE with 63 participants The statement does not contradict the information provided in the trials as they address different outcome measurements",
        "label": "Entailment"
    },
    "f2beb95f-ac83-48f1-936b-70d45d51880c": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The placebo intervention is administered as a 3hour intravenous infusion on Day 1 while the trabectedin intervention is administered as a 3hour intravenous infusion on Day 2 Neither intervention is described as being administered on a biweekly basis let alone an 8hour intravenous infusion on each administration",
        "label": "Entailment"
    },
    "286e098d-ca31-41ce-b8a9-f8bcf99447f0": {
        "text_answer": "  The statement anemia is more prevalent in the primary trial when opposed to the secondary trial is contradicted by the given data   Explanation   The prevalence of anemia in the primary trial is 000 037 and in the secondary trial it is 430 493 A prevalence of 000 is lower than 4",
        "label": "Contradiction"
    },
    "115aa2c8-f52f-4a62-9b8a-6f6e593bd208": {
        "text_answer": "  The statement primary clinical trials second cohort has an additional 7 participants compared to the first cohort is entailed in the given trials data as follows  1 The number of participants analyzed in the first cohort Arm II is 234 2 The number of participants analyzed in the second cohort Arm III is 241 3 The difference between the number of participants in the",
        "label": "Entailment"
    },
    "425f9738-1b09-446e-8c8c-5004ed91351d": {
        "text_answer": "  The statement all the instances of infections and infestations in the primary clinical trial pertained to patients in cohort 1 is entailed in the given trials data   Explanation   The statement implies that there were no instances of infections and infestations in cohort 2 of the primary clinical trial However the trials data clearly shows that there were no instances of infections and infestations in any coh",
        "label": "Entailment"
    },
    "53416cd6-ac0b-43c1-824f-719d43ad5af4": {
        "text_answer": "  The statement various participants of group 1 in the primary clinical trial had clear evidence of skin lesions under 10 of participants in group 1 of the secondary clinical trial showed symptoms of radiation dermatitis and hyperpigmentation is not directly entailed in the provided trial information   The primary trial results indicate that no skin lesions were detected in the healthy volunteers group and 12 lesions were detected in the breast cancer",
        "label": "Contradiction"
    },
    "b4e6d7be-cb1b-4000-812e-d49098f0aaf0": {
        "text_answer": "  The statement patient hospitalization and mortality occurred during cohort 2 of the primary clinical trial is not directly entailed in the given trials as there is no information provided about the number or specific instances of hospitalizations or deaths in cohort 2 However the statement is not contradictory to the given trials as well since the trials do not state that no hospitalizations or deaths occurred in cohort 2 Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "text_answer": "  The statement Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial is entailed in the trials as follows  1 In the primary trial the exclusion criteria include uncontrolled intercurrent illness including but not limited to psychiatric illnesssocial situations that would limit compliance with study requirements Schizophrenia is a psychiatric illness and severe insomnia is a",
        "label": "Entailment"
    },
    "d5586986-90bb-4302-98c1-0507aa208d2d": {
        "text_answer": "  In the primary trial MRIs may not be explicitly mentioned in the given information about the Contour Profile Tissue Expander intervention However MRIs are commonly used in breast reconstruction procedures to monitor the expansion process and assess the final outcome Therefore it is a reasonable assumption that MRIs are used in this trial even if not explicitly stated  In the secondary trial MRIs are not mentioned directly in the given information about the interventions However in the context",
        "label": "Entailment"
    },
    "b80c867f-7c46-4ac1-a9c4-b56ce0173c2a": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 have a uniform administration method In Intervention 1 IV bisphosphonate is given once every 4 weeks and in Intervention 2 denosumab is given once every 12 weeks but in both cases the drugs are given at regular intervals",
        "label": "Entailment"
    },
    "cafb9767-9320-40fc-a862-53530450f96f": {
        "text_answer": "  The statement is neither entailed in the trials nor contradictory to them The primary trial reports changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement does not directly relate to the content of the trials",
        "label": "Entailment"
    },
    "8c4891f7-e0af-4ddb-8754-0638ece12c58": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to perform an inferential statistical analysis using the provided data   First we will conduct an independent ttest to compare the means of the two groups regarding the average number of daily hot flashes   Null Hypothesis H0 There is no significant difference in the average number of daily hot flashes between the paced respiration intervention group and the fast",
        "label": "Entailment"
    },
    "7ae03d8b-6087-4df3-a0e1-d1932d86528c": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of chest pain in either trial The trials only report the occurrence of various adverse events",
        "label": "Contradiction"
    },
    "3b13cd45-eae5-4039-8a8a-a73c55fde5dc": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial patient cohorts have not reported any cases of intestinal obstructions or pancytopenia is entailed in the given trials data since there are no reported cases of intestinal obstructions or pancytopenia in either trial",
        "label": "Entailment"
    },
    "dfc9042c-745d-46a2-9706-3efe0b24c20c": {
        "text_answer": "  The statement most patients experienced multiple severe adverse events post participation in the primary clinical trial is contradicted by the given data in the trials   The primary trial reports a total of 5 adverse events out of 11 patients 4545 but none of these events are specified as multiple severe adverse events Similarly in the secondary trial there are no reports of multiple severe adverse events as all adverse events reported were",
        "label": "Contradiction"
    },
    "ddfc4bce-b6b0-4817-a171-db6bd5e095bd": {
        "text_answer": "  The statement in the primary and secondary clinical trials nationality ethnicity psychiatric condition or gender of a patient do not influence their eligibility is entailed in the given trials as there is no mention of these factors in the inclusion or exclusion criteria for either trial The criteria are based on various medical conditions prior treatments and laboratory values",
        "label": "Entailment"
    },
    "b957f1f2-8dc3-4d00-802d-26cd8fa3b9f4": {
        "text_answer": "  The primary trial includes the following criterion for breast tumor size Breast tumor 1 centimeter cm in diameter The secondary trial does not mention any specific size limitation for the breast tumor However the secondary trial mentions measurable disease as a requirement which implies that the tumor size should be large enough to be measurable Therefore it is possible for patients with a 100mm tumor to meet",
        "label": "Entailment"
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve medication administration through an injection route either intravenously for bisphosphonate Q4W or subcutaneously for denosumab Q12W",
        "label": "Entailment"
    },
    "b54f065f-7b3e-42b0-8dc6-61dc466f7f59": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial assess various patient traits in their outcomes is entailed in the given trials as both trials involve assessing adverse events in patients receiving different treatments for HER2positive breast cancer While the primary trial focuses on evaluating the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 the secondary trial",
        "label": "Entailment"
    },
    "160afbf4-14b4-4e83-b324-4d3102b8f72c": {
        "text_answer": "  The statement benign hard palate neoplasm is a nonmetastasizing neoplasm that arises from the hard palate is not related to the trials provided   The trials only provide information about the outcomes of two different maintenance treatment regimens Bevacizumab and Bevacizumab  Capecitabine for participants with disease progression or death during the initial phase of the study   There",
        "label": "Entailment"
    },
    "eae19a7f-ca02-482d-942f-223d74881c40": {
        "text_answer": "  The statement the secondary clinical trial is not open to participants that have experienced pulmonary embolisms is not explicitly stated in the secondary trials inclusion or exclusion criteria However there is no mention of pulmonary embolisms as a condition that would make someone ineligible for the secondary trial  The statement the primary clinical trial is not available for individuals who have breast implants is explicitly stated in the primary trials exclusion criteria",
        "label": "Contradiction"
    },
    "c0db0110-c67a-40e6-8bfc-b7e016509778": {
        "text_answer": "  The statement remarkable or unregulated cardiovascular ailments make patients ineligible for participation in either the primary clinical trial or the secondary clinical trial is entailed in the trials as follows  In the primary trial the exclusion criteria include  Significant cardiovascular impairment Congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the",
        "label": "Entailment"
    },
    "7caa5dd0-cd09-4559-a243-736304ce22e4": {
        "text_answer": "  The statement that a 55yearold male patient with a 5yearold diagnosis of ERpositive HER2negative breast cancer is eligible for both the primary and secondary clinical trials cannot be definitively determined based on the provided information alone  The primary trials inclusion criteria state that it is for female patients only so the male patient is not eligible for this trial However the secondary trials inclusion criteria do not specify",
        "label": "Entailment"
    },
    "a14e5115-a6ff-4253-9260-736c943bd47e": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However the statement does contradict some of the exclusion criteria for the secondary trial Specifically the statement allows patients who have received chemotherapy within the last 05 months to participate in the primary trial but the secondary trial excludes patients who have received chemotherapy within 2 weeks for some agents or 1 week for others of",
        "label": "Contradiction"
    },
    "0f17aa12-6aea-430e-b4e8-2a21f2832582": {
        "text_answer": "  The statement the primary clinical trial does not accept patients with tumors showing ccnd1 amplification cdk46 mutation or ccnd2 amplification is entailed in the trials inclusion criteria under the tumor type E Specifically the criteria state that Any tumor type if tissue tests positive for CCND1 amplification CDK46 mutation CCND2 amplification OR any other functional alteration at the",
        "label": "Entailment"
    },
    "bdb61718-ee5f-4e2a-9c78-850e788c139f": {
        "text_answer": "  The primary clinical trial excludes patients who have experienced a pulmonary embolism within the past three years LE 3 years The secondary clinical trial does not explicitly mention this exclusion criterion However it does state that the investigator has the discretion to determine if a patient is appropriate for enrollment based on severe concurrent diseases or comorbidities Therefore it is possible that the investigator may consider or reject a patient based on a previous",
        "label": "Entailment"
    },
    "df783937-3936-4f0b-a3f9-96a977497c6f": {
        "text_answer": "  The statement is entailed in the given trials as follows  The primary clinical trial has distinct inclusion and exclusion criteria for each of its two phases This is evident from the provided text where the inclusion and exclusion criteria for Phase I and Phase II of the primary trial are clearly stated and are different from each other  The secondary clinical trial on the other hand has different sets of criteria for patients in good health not explicitly stated in the provided text",
        "label": "Entailment"
    },
    "8e88537e-5eb0-4e85-a6cd-58e374d027b6": {
        "text_answer": "  The statement Every patient in the primary trial is receives a dose of 100 to 1600 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information The trial only mentions the use of Vorinostat and radiation therapy and the administration of fentanyl spray is not mentioned at all Therefore the statement is contradictory to the given trial information",
        "label": "Contradiction"
    },
    "b1cb1388-9a0f-4dfd-8890-a3d2bced6ab4": {
        "text_answer": "  The statement in the primary clinical trial 96 participants from the ketorolac 30 mg group demonstrated recurrencefree survival as opposed to the 67 from the nacl 09 3ml group is a contradiction of the provided data  The data states that there were 80 participants with recurrencefree survival in the ketorolac 30 mg group and 897",
        "label": "Contradiction"
    },
    "8c1414dd-20b2-415e-8d0e-1f9b8e7951d1": {
        "text_answer": "  The statement entericcoated tablets are not received by any of the participants in either the primary or secondary clinical trial is not entailed in the given trial information The trial information only specifies the interventions for each group in both trials but it does not explicitly state that no entericcoated tablets are administered to any participant Therefore the statement is neither entailed nor contradicted by the given trial information",
        "label": "Contradiction"
    },
    "4f4360c0-38f9-4cea-89bb-8bf2a3fd0a4a": {
        "text_answer": "  The statement cohort 2 of the primary trial is administered Enzalutamide orally whereas cohort 1 receives it by IV is not entailed in the provided information from the primary trial The statement only mentions the dosages of Enzalutamide for each cohort but it does not specify the route of administration Therefore the statement is contradictory to the information provided in the primary trial",
        "label": "Contradiction"
    },
    "c48550ef-7210-4834-9047-969a7898d519": {
        "text_answer": "  The statement eating disorders were not common among participants of the primary clinical trial throughout the study is not directly entailed or contradicted by the given data The data only reports various adverse events observed during the trial but it does not mention any eating disorders Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Contradiction"
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial participants receive whole breast radiation therapy which does not involve any intramuscular injections However the statement also mentions that both cohorts of the secondary trial receive intramuscular injections This is true as the secondary trial involves the use of Fulvestrant which is given intramuscularly as per the trial protocol  However the statement",
        "label": "Entailment"
    },
    "faf8436a-2459-4718-be81-10b0649ff87a": {
        "text_answer": "  The statement youths below the age of 18 are the target group for both the secondary and the primary trial is contradictory to the information provided in the trials inclusion criteria The primary trial explicitly states that patients must be aged greater than 20 years while the secondary trial includes patients who are 18 years or older Therefore the statement is contradictory to the trials information",
        "label": "Entailment"
    },
    "bf00cf4b-27eb-4c1a-88e2-f86df10f2727": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to calculate the number of participants in each arm who experienced a pathologic complete response pCR in the breast and axillary lymph nodes after approximately 24 weeks around 7 months following surgery  Lets calculate the number of participants with pCR for each arm  Arm 1 Paclitaxel  Trastuzumab Then AC ",
        "label": "Entailment"
    },
    "98c16e6f-17a1-436f-833f-4f69e14f52db": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials only compare the effectiveness of acupuncture and waiting list control group in treating lymphedema and no information about testosterone cream is provided in the trials Therefore the statement that both acupuncture and testosterone cream showed similar effectiveness in treating lymphedema is not entailed in the trials",
        "label": "Contradiction"
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "text_answer": "  The statement the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial is a contradiction to the given data   The primary trial had 0 cases of Intestinal perforation and the secondary trial had 1 case Therefore there is not an 11case difference between the trials",
        "label": "Contradiction"
    },
    "7c093c8a-8233-4dbb-87ba-03a1a049a7e8": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The statement despite receiving equal doses of radiation therapy in the primary clinical trial the treatment for cohort one spans an additional two weeks compared to cohort two is entailed in the trials because the trials specify that patients in cohort one receive Active Breathing Coordination ABC which involves obtaining a SPECT scan at baseline and at 6",
        "label": "Entailment"
    },
    "67498e27-5a2e-4495-adb7-5cd8f51aae65": {
        "text_answer": "  The statement is contradictory to the given trials   The dosage of Tamoxifen in intervention 1 of the secondary trial is indeed higher than the dosage of Zoledronic Acid in intervention 1 of the primary trial 10 mg vs 4 mg but it is not 12 times higher than the dosage of Denosumab in intervention 1 of the primary trial 120 mg Therefore the statement",
        "label": "Entailment"
    },
    "5ca1c4e8-73e3-4329-9644-bfb986b6673e": {
        "text_answer": "  The statement encounter due to other problems related to physical environment is an ICD encounter due to other problems related to physical environment is a given fact and does not directly relate to the adverse events data provided in the trials  Regarding the statement In total there are less cases of anemia in the primary trial than in the secondary trial this statement is contradicted by the data provided in the trials The primary trial reports 000 ",
        "label": "Contradiction"
    },
    "36e4b948-e72f-43d9-8084-b3d2e879620b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the trials enzalutamide is given orally to both the first and second cohorts not intravenously as stated in the given statement",
        "label": "Entailment"
    },
    "9b1d58dd-30d8-4df2-856e-4cae783cbd6e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves an intervention with gefitinib ZD1839 and the secondary trial involves interventions with zoledronic acid and either zoledronic acid plus radiopharmaceuticals There is no mention of paclitaxel bevacizumab or gemcitabine in the secondary trial and the intervention in the primary trial is",
        "label": "Contradiction"
    },
    "92ea43b9-05d5-47a4-a78d-87bcb3326810": {
        "text_answer": "  The statement no primary trial participants experienced any form of rash is contradictory to the information provided in the adverse events data The data indicates that one participant 130 experienced a rash maculopapular which is a type of rash Therefore the statement is contradictory to the information in the trial data",
        "label": "Contradiction"
    },
    "0629bf04-f185-49b2-905e-e9a3932dbb0a": {
        "text_answer": "  The statement is contradicted by the given trials The statement asserts that there were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial However the trials show that there were no cases of nausea reported in either trial and the number of cases for Infection and Asymmetry were the same in both trials 1 each Therefore the statement is contradicted by the given trials",
        "label": "Contradiction"
    },
    "dc2d7205-d6ce-4d9c-96d2-e5a80fa906c0": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement suggests that recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage are more common in the secondary trial than the primary trial However the data in the trials shows that none of these adverse events occurred in the secondary trial while they occurred in the primary trial Therefore the statement is",
        "label": "Entailment"
    },
    "02adb741-194d-4472-b4b8-a3b546dc0484": {
        "text_answer": "  The statement patients participating in the primary clinical trial tended to have a higher incidence of pericardial effusions while corneal deposits were more frequently observed in the secondary clinical trial is contradictory to the given data   The statement implies that the primary trial had a higher incidence of pericardial effusions and the secondary trial had a higher incidence of corneal deposits However the data provided shows that there",
        "label": "Entailment"
    },
    "55cc22eb-91ad-423f-8d3e-e4b5ef61ed7d": {
        "text_answer": "  The statement a patient who has a 33mm primary tumour as verified by clinical scrutiny and echography is eligible for the primary clinical trial as well as the secondary clinical trial is entailed in the given trials as long as the patient meets all other inclusion criteria for both trials   Explanation  The primary trial includes the following criterion for breast cancer Primary tumour greater than 2 cm diameter measured by",
        "label": "Entailment"
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "text_answer": "  The statement is entailed in the trials as the primary trial and the secondary trial measure different outcome measures The primary trial measures the number of participants with treatmentemergent adverse events at the end of Cycle 1 while the secondary trial measures the change in total sleep time as measured by polysomnography PSG before and after the first cycle of Lenalidomide treatment Therefore the statement is entailed in the trials as it accurately describes",
        "label": "Entailment"
    },
    "6846ee30-4c0c-4340-9c13-3892edc3baea": {
        "text_answer": "  The statement picomole per liter per kilogram per meter squared is a unit of concentration equal to picomoles per liter divided by kilograms per meter squared is not related to the adverse events data provided in the primary trials Therefore it cannot be entailed or contradicted based on the information given",
        "label": "Entailment"
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the inclusion criteria state that the Karnofsky score must be greater than or equal to 70 In the secondary trial the inclusion criteria state that the Karnofsky score must be greater than or equal to 55 Therefore the statement that Candidates for the primary trial and the secondary trial have to meet a baseline performance status for the",
        "label": "Entailment"
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial is entailed in the inclusion criteria of the trial as stated in the text Therefore the statement is entailed in the trial",
        "label": "Entailment"
    },
    "c441ac74-f9ef-493c-bcfb-03959f9bf7e3": {
        "text_answer": "  The statement is not entailed in the trials provided The trials only report the percentage change in betaCTX at Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups There is no information provided about the percentage change in betaCTX at Week 2 for the AZD0530 25 mg group Therefore it is not possible to determine if the statement is entailed in",
        "label": "Contradiction"
    },
    "867cde11-ffad-4494-bdea-2457651a7de7": {
        "text_answer": "  The statement is not entailed in the trial results as given The statement mentions a reduction in tumor diameter while the trial results only report a change in Ki67 expression percentage The two outcomes are not directly comparable The statement contradicts the trial results if we assume that a 40 reduction in Ki67 expression translates to a 40 reduction in tumor diameter which is not supported by the data provided",
        "label": "Contradiction"
    },
    "fe5179d1-0090-4c87-9287-9bb26139acd0": {
        "text_answer": "  The statement about as socially active as before is not directly mentioned in the inclusion or exclusion criteria of the trial However the statement does not contradict any of the criteria Therefore it is neither entailed nor contradictory to the trials criteria  However it is important to note that patients who have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the last ",
        "label": "Entailment"
    },
    "6561c528-4e6f-4e1f-8d65-9fa11d3c8838": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The primary trial measures tumor response using RECIST criteria but it does not provide information on the proportion of participants benefiting from the treatment according to this criteria The secondary trial on the other hand measures a different outcome number of participants with AIMSS and does not provide information on tumor response according to RECIST criteria Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "a2b4f24d-e4ff-49b5-a21f-61ba1e5b0b32": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants demonstrating a decrease in the growth factor signature GFS in each group   According to the trials the percentage of participants with a decrease in GFS in the ERpositive Luminal B group was 286 95 CI 131492 and in",
        "label": "Entailment"
    },
    "dac129a3-974e-4918-95e5-11bbc0207e02": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the mean standardized composite cognitive function scores and their standard deviations for the Tamoxifen and Ovarian Function Suppression groups The trials do not provide sufficient information to determine if all participants suffered a deterioration in cognitive function or if the difference between the groups was statistically significant Additionally the statement incorrectly assumes that all participants in the primary trial were included in the analysis but",
        "label": "Contradiction"
    },
    "ac0de5f6-14ed-44a1-9112-bce1b197553b": {
        "text_answer": "  The statement trichomonas infection is an infection that is caused by trichomonas is not related to the provided trials as it is a factual statement about the nature of Trichomonas infection and does not entail or contradict the information presented in the trials regarding adverse events in the primary and secondary trials  Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "text_answer": "  The statement is entailed in the trials The primary trial includes the ability to provide written informed consent as an inclusion criterion and the secondary trial also includes this criterion as an inclusion criterion Therefore the statement is entailed in both trials",
        "label": "Entailment"
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description Cohort 1 is the intervention group that views the Educational DVD while Cohort 2 is the control group that receives usual care without viewing the DVD However the statement suggests that Cohort 1 receives usual care and Cohort 2 receives a regular dosage of radiotherapy which is not mentioned in the trial description Therefore the statement is",
        "label": "Entailment"
    },
    "0f37bc77-1f82-44ce-ae7e-2a6b833e774a": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The statement mentions the presence or expression of somatostatin receptor in a sample which is not related to the interventions or dosages described in the trials The trials only provide information about the interventions sunitinib  paclitaxel for cohort 1 and bevacizumab  paclitaxel for cohort 2 and their",
        "label": "Entailment"
    },
    "d9dff3a0-537b-4297-bc58-766d366ba5a0": {
        "text_answer": "  The statement 97 of patients in the primary trial did not experience any Adverse Events is not directly related to the information provided in the trial results The trial results only mention the percentage of subjects who did not experience recurrence second malignancy or death within 3 years of treatment There is no information about the occurrence or percentage of adverse events in the trial Therefore the statement is neither entailed nor contradicted by the trial results",
        "label": "Contradiction"
    },
    "0d382bbc-1c8d-4d05-b0dd-8501755ce9dd": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial experienced hospitalizations is contradicted by the information provided in Adverse Events 2 as it states that there were no hospitalizations in cohort 2 000",
        "label": "Contradiction"
    },
    "1a84148c-2d33-4804-922e-9a3419890897": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial does not specify how the interventions are given in Arm I Zoledronic Acid and Arm II Clinical Observation only that they receive the interventions at certain time points The secondary trial specifies that the interventions are given intravenously IV or orally There is no mention of subcutaneous or topical administration in either trial Therefore",
        "label": "Contradiction"
    },
    "b3527d60-eb66-465d-845a-e234e5b0a084": {
        "text_answer": "  The statement is not entailed in the primary or secondary trials as given The primary trial explicitly states that participants must be nonsmokers no nicotine use within the last 5 years while the secondary trial mentions no specific smoking or nicotine use criteria but allows for up to 5 alcoholic drinks per day The statement combines these two criteria in a way that is not explicitly stated in either trial Therefore the statement is neither entailed nor",
        "label": "Contradiction"
    },
    "3d2d011f-aff9-45c6-87e9-359b6d265c98": {
        "text_answer": "  The statement patients who have received chemotherapy or radiotherapy in the last 336 hours suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a contradiction to the information provided in the secondary trials exclusion criteria  The secondary trials exclusion criteria state that patients",
        "label": "Contradiction"
    },
    "e9653ffb-8fe5-47a3-810f-6831216f9893": {
        "text_answer": "  The statement there were 1000 cases of hypertension edema and dyspnea in either cohort of the primary trial is not entailed in the given trials as the trials do not provide information about the number of cases of hypertension edema and dyspnea in the trials The trials only report the number of adverse events for each category and the percentage of occurrence",
        "label": "Contradiction"
    },
    "97d1e0d2-2f6f-45f1-8e85-33c92d71f0bf": {
        "text_answer": "  The statement every single patient in the primary clinical trial experienced a decrease in blood bilirubin levels is contradicted by the trial data   Explanation   The trial data reports that only one patient 909 experienced an increase in blood bilirubin levels Therefore the statement that every patient experienced a decrease in blood bilirubin levels is not entailed in the trial data and is in fact contradicted by it",
        "label": "Contradiction"
    },
    "2cf8046e-2d49-4989-aca0-9e11795978cb": {
        "text_answer": "  The statement is not entailed in the given trials as they address different patient cohorts and interventions The primary trial deals with oral pregabalin while the secondary trial deals with intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt Therefore the statement is neither entailed nor contradictory based on the provided information",
        "label": "Contradiction"
    },
    "c7e44ec4-ddeb-4d8b-97aa-0361308300b8": {
        "text_answer": "  The statement is entailed in the trials as follows  Cohort A in Intervention 1 receives two different treatments which are not LD V935 The first treatment is V935 LD given as two IM injections one every other week over a 3week period The second treatment is not mentioned in the trial but it is clear that it is not LD V935 since the trial specifies that the second",
        "label": "Entailment"
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "text_answer": "  The statement is contradictory to the information provided in both trials   The young girl with a newly diagnosed PRpositive HER2positive breast cancer would not be eligible for either trial based on the provided inclusion and exclusion criteria   The primary trial specifically excludes HER2positive breast cancer patients while the secondary trial requires ERpositive and HER2negative breast cancer Additionally the young girls",
        "label": "Entailment"
    },
    "16634eb4-f12b-4d17-8401-070a7b7d052b": {
        "text_answer": "  The statement have discomfort when urinating is a question about whether an individual has or had discomfort when urinating is not directly related to the given trials as they do not provide any information about urinary discomfort for the patients involved Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "36e73055-3f34-4e5b-94a0-cfbac5dc3ff9": {
        "text_answer": "  The statement have trouble saying what i mean in conversation is a question about whether an individual has or had trouble saying what they mean in conversations with others is not directly related to the inclusion or exclusion criteria of the primary trial The trials criteria focus on the patients age performance status tumor type previous treatments and certain medical conditions The statement about communication abilities is not mentioned in the criteria Therefore the statement is neither entailed nor contradict",
        "label": "Entailment"
    },
    "ec164af8-13b9-4545-b3ba-24260adfe9db": {
        "text_answer": "  The statement the primary clinical trial is accepting a limited quantity of patients carrying the Kras or BRAF mutation and diagnosed with metastatic colorectal cancer is entailed in the inclusion criteria of the trial as stated in the text The trial explicitly includes patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation B in its eligibility criteria",
        "label": "Entailment"
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "text_answer": "  The statement All AE types in the primary trial affected less than 10 of patients is entailed in the given trial data   Explanation   The statement All AE types in the primary trial affected less than 10 of patients means that the total percentage of patients who experienced any adverse event AE was less than 10   The trial data shows that the total number of patients who",
        "label": "Entailment"
    },
    "34c7862b-3725-4ed8-9e67-1513300323a7": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORR of the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 058",
        "label": "Entailment"
    },
    "c0b2f348-06b9-4e92-9257-a32c38b072cf": {
        "text_answer": "  The statement male patients of all nationalities are invited to participate in the primary clinical trial is not entailed in the given inclusion criteria for the primary trial The criteria only specify that the subject is a Japanese female   Regarding the secondary trial the statement male patients of all nationalities are invited to participate in the primary clinical trial is contradictory to the given inclusion criteria for the secondary trial as it only specifies that the subject is a",
        "label": "Contradiction"
    },
    "512b8ed3-f0ca-4e11-ab4a-eebe4217ad7e": {
        "text_answer": "  The statement totally dissimilar outcome measures are found in the results of the secondary clinical trial and the primary clinical trial is entailed in the given trials as follows  In the primary clinical trial the outcome measure is the change in weekly average hot flash score from baseline to treatment termination between flaxseed and placebo arms This is a continuous measure with a unit of units on a scale  In contrast in the secondary clinical trial the",
        "label": "Entailment"
    },
    "568b4d2b-204c-4606-a75f-058a5870c84c": {
        "text_answer": "  The statement is not entailed in the given trial information as there is no mention of radiotherapy being part of the control groups approach in the provided trials The statement only mentions the intervention strategies for each group",
        "label": "Contradiction"
    },
    "7ba4c342-8897-4815-9bb3-eea917b3769e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial administers oral pregabalin to its patients while the secondary trial mentions intravenous gemcitabine for an unspecified patient cohort and topical corticosteroids daily for another cohort However there is no mention of pregabalin or its administration in the secondary trial Therefore the statement is contradictory to the information provided in the",
        "label": "Contradiction"
    },
    "f988fa4a-02f0-41f6-9e27-453604dd3ecc": {
        "text_answer": "  The statement in both the primary and secondary clinical trials the adverse events recorded were of the same number is entailed by the given information if we define the same number to mean zero The trials both report having no adverse events for Adverse Event 1 and both trials report having no adverse events for Adverse Event 2 in the secondary trial Therefore the statement is true according to the given data",
        "label": "Entailment"
    },
    "0f77fc34-7285-4374-879d-b96166cfc29e": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial states that participants will be taking Vorinostat daily during radiation therapy not abstaining from it as the statement suggests",
        "label": "Entailment"
    },
    "e648aa7a-3013-4d37-9bf5-51e75c7d4202": {
        "text_answer": "  The statement during the study period infections affected more than 15 of patients in both the primary and secondary clinical trials is contradicted by the given data   In the primary trial infections affected 1032 3125 of patients which is greater than 15 but still not equal to or more than 15 In the secondary trial infections affected 115 ",
        "label": "Contradiction"
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "text_answer": "  The statement is not directly entailed in the trials as they measure different outcome measures The primary trial measures the Summed Pain Intensity Differences SPID at 30 minutes after dosing for each breakthrough pain episode while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement only mentions two different outcomes Severity of Delayed Nausea and change in",
        "label": "Contradiction"
    },
    "6b4bc07c-bfc3-4750-b802-7100efeb60a7": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the use of medications to prevent bone loss specifically bisphosphonates in Intervention 1 and denosumab which is a monoclonal antibody that inhibits RANKL thereby reducing bone resorption in Intervention 2 However the routes of administration differ with Intervention 1 being intravenous IV and Intervention 2 being subcutaneous ",
        "label": "Entailment"
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "text_answer": "  The statement None of the participants in group 1 of the primary trial were found to have lesions and more than 90 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is contradictory to the information provided in the trials  In the primary trial there were no participants with lesions detected in group 1 Healthy Volunteers as stated in Result 1",
        "label": "Contradiction"
    },
    "19ca7182-94ba-4b70-bd4e-1a65bd428f91": {
        "text_answer": "  The statement is not entailed in the primary or secondary trials as given The primary trial mentions mammography and inclusionexclusion criteria related to it but it does not mention pulmonary function tests PFTs as a requirement for candidates The secondary trial mentions MRI reports and liver function tests as requirements but it does not mention pulmonary function tests Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "1d1f2f55-c9b7-4a8b-bea7-b8ea291d96d5": {
        "text_answer": "  The statement Patients with TX NX MX T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial is not directly stated in the given trial criteria However the trial criteria do not exclude these tumor stages so the statement is not contradictory to the trial information   Therefore the statement is neither entailed nor contradictory to the trial information   Regarding the application",
        "label": "Entailment"
    },
    "919dbcc0-8d31-4161-8692-45533e52d60e": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation  The statement no adverse events were reported in the primary clinical trials first cohort is inconsistent with almost everyone in the second cohort encountered at least one adverse event   In the first cohort no adverse events were reported which means that all participants in the first cohort did not experience any adverse",
        "label": "Contradiction"
    },
    "33efdbc8-175b-4021-b192-acd8d37cedd1": {
        "text_answer": "  The statement 125 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is a contradiction to the given trials as the total number of patients in the trials is 17 13 from trial 1 and 4 from trial 2 and the sum of the percentage of patients with increased pleural effusion and rapid disease progression is not equal to 125  Therefore the statement is a",
        "label": "Contradiction"
    },
    "a555a807-ceeb-4237-bd26-25e5a3db9128": {
        "text_answer": "  The statement is not entailed in the given trials as the secondary trial does not provide enough information to determine if Suramin and Paclitaxel are being administered or not The secondary trial only mentions patients undergoing mastectomy surgery but it does not specify any interventions or treatments being given to those patients Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "96892eae-9630-45eb-bc5f-6c7605d8dd1c": {
        "text_answer": "  The statement fifty is a natural number greater than fortynine and less than fiftyone and the quantity that it denotes is a mathematical fact and is not related to the inclusion criteria of the primary or secondary trials  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race ethnic origin or cancer type is entailed in the primary trials inclusion criteria  The statement ",
        "label": "Entailment"
    },
    "afeed01c-f21a-4926-9028-d2b9a2226c9f": {
        "text_answer": "  The statement is entailed in the trial information provided   Explanation   The trial description does not mention paclitaxel as an intervention in either Arm A ANA or Arm B FULV Therefore the statement that the primary clinical trial does not employ paclitaxel in any of its interventions is entailed by the trial information",
        "label": "Entailment"
    },
    "0c05d756-82d5-4f8f-afe7-845857c1e9d3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial zoledronic acid is given intravenously IV not by inhalation In the secondary trial all interventions granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone are given intravenously IV or orally not by inhalation",
        "label": "Entailment"
    },
    "a954a34f-0eb2-4c28-8673-f4c0a337bd00": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial specifies a dosage of 4 mgkg for the loading dose and 2 mgkg per week for trastuzumab while the secondary trial in cohort 1 of intervention 1 for Herceptin mentions a dosage of 4 mgkg for the initial dose and 2 mgkg per week starting from Day 8 of cycle",
        "label": "Entailment"
    },
    "5119953d-f226-4e3d-96c9-a05862188b6d": {
        "text_answer": "  The statement neither the primary nor the secondary trial reported any cases of infection asymmetry or nausea is entailed by the given trials as neither trial reported any cases of infection asymmetry or nausea according to the provided data",
        "label": "Entailment"
    },
    "e0393f5c-7dec-4018-8917-b055823aec4b": {
        "text_answer": "  The statement Atara Biotherapeutics is a privatelyheld drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy Patients diagnosed with stage 4 invasive carcinoma of the breast that is estrogen andor progesterone receptor positive and are considering AI therapy are eligible for the primary trial is not entailed in the given trial information as the trials are focused",
        "label": "Contradiction"
    },
    "24e662f6-3ac7-489b-91fa-890994a805b4": {
        "text_answer": "  The statement only hispanic patients can participate in the primary clinical trial is not entailed in the given inclusion criteria for the dose escalation and expansion phase of the clinical trial The criteria specify various demographic and diseaserelated conditions for eligibility but there is no mention of ethnicity as a requirement Therefore the statement is contradictory to the information provided in the clinical trial description",
        "label": "Contradiction"
    },
    "f4cf0fc1-5b69-49a1-8ba6-454063ff63ce": {
        "text_answer": "  The statement primary clinical trial participants were free from thromboembolic events as were those in the secondary clinical trial is not directly entailed in the given trials as there are no thromboembolic events reported in either trial However the statement is consistent with the data provided since no thromboembolic events were reported in either trial Therefore the statement is not contradictory to the trials",
        "label": "Contradiction"
    },
    "349365cf-1c22-4e72-b321-b15b505e50cb": {
        "text_answer": "  The statement 4p163p161 is a chromosome band present on 4p is not directly related to the trials provided The trials focus on measuring tumor response using RECIST criteria and the number of participants with AIMSS in a specific treatment group The statement does not entail or contradict any information given in the trials",
        "label": "Entailment"
    },
    "14632f5e-6eb4-4771-9567-cbde0f19c4af": {
        "text_answer": "  The statement Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention is not directly stated in the provided trial results However the statement does not contradict the information given in the results as well The trial results only provide the percentage of patients who were up to date for colorectal breast and cervical cancer screenings before and after the intervention for both the",
        "label": "Entailment"
    },
    "c648cc67-b490-4cfe-be5e-4706b94ac0df": {
        "text_answer": "  The statement is not entailed in the given trials as it makes additional claims beyond what is reported in the trials The trials only report the occurrence of lymphoma as an adverse event but the statement also claims that there were neither unexpected deaths nor hospital stays in both trials The trials do not provide sufficient information to support this claim",
        "label": "Contradiction"
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "text_answer": "  Lets analyze the given trials to determine if the statement is entailed or contradicted  First lets calculate the total amount of MCS110 and PDR001 each patient receives in both interventions  INTERVENTION 1  MCS110 1 mgkg Q3W  PDR001 100 mg Q3W  Total MCS11",
        "label": "Entailment"
    },
    "6cce2cb8-3ed9-40e9-a412-cb75b688ac59": {
        "text_answer": "  The common inclusion criteria between the two trials are 1 Patients who are 18 years of age or older  Therefore the statement is entailed in the Trials with Entailment",
        "label": "Entailment"
    },
    "1649a4de-bc0d-4908-88ac-515b88be60b3": {
        "text_answer": "  The statement the primary trial reported no adverse occurrences and in the secondary trial less than 30 of patients experienced adverse events is entailed in the given trials data  Explanation  The statement is entailed because  1 The primary trial reported no adverse occurrences 000 2 The secondary trial reported that less than 30 of patients experienced adverse events",
        "label": "Contradiction"
    },
    "5784fb28-1da8-483c-a56b-61b68fb2a8f5": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial each treatment cycle is defined as 21 days indicating a recurring treatment approach In contrast the secondary trial does not have a defined cycle length or a recurring treatment approach mentioned in the description Therefore the statement that the secondary trial does not implement a recurring treatment approach is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "0b4536c8-2868-4d1a-bc26-d16b31eed34f": {
        "text_answer": "  The statement candidates with an ECOG score of 4 are the only ones who can participate in the primary clinical trial and secondary clinical trial is contradictory to the information provided in the trials inclusion criteria   In the primary trial the inclusion criteria state that the ECOG performance status should be 0 to 2 In the secondary trial the inclusion criteria state that the ECOG performance status should be 02 OR K",
        "label": "Entailment"
    },
    "2dce1806-9ce1-4448-9888-052def540a43": {
        "text_answer": "  The statement a single psychiatric adverse event was reported in the primary clinical trial affecting fewer than 10 of the patients is entailed in the given trial data   Explanation   The statement implies that there was one psychiatric adverse event reported in the trial and that the number of patients affected by this event was less than 10 The trial data confirms that there was indeed one patient who experienced suic",
        "label": "Entailment"
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement compares the pCR rates between the primary and secondary trials but the trials do not directly compare the same treatment regimens The primary trial compares FEC75 then PaclitaxelTrastuzumab versus PaclitaxelTrastuzumab then TrastuzumabFEC75",
        "label": "Entailment"
    },
    "be50f0ae-0c2b-42be-9306-78a1da6b4e09": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial does not mention any height restrictions while the secondary trial imposes a height requirement Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "79cd8b63-fe24-4e8b-9a15-0e054fb09dba": {
        "text_answer": "  The primary trial measures the change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire before the 7th acupuncture treatment The secondary trial measures the change in isothiocyanate in urine samples at baseline and after completion of study therapy  The statement both primary and secondary clinical trials rely on modifications in mymop score as the assessment of their study findings is not entailed in the trials as given The primary",
        "label": "Contradiction"
    },
    "367bc142-7412-43c6-b946-6127aff25f9a": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report the percentage change in betaCTX levels at Week 4 not primary tumor size reduction Therefore the trials do not provide sufficient information to determine if one treatment resulted in a more prominent tumor size reduction than the other The statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "4087e09b-d0a1-4c3a-8411-b1938bf51b95": {
        "text_answer": "  The statement in the secondary clinical trial and the primary clinical trial more than 97 of participants experienced no unfavorable incidents is not directly entailed in the given data from the trials   The data only provides the number and percentage of participants who experienced specific adverse events in each trial It does not provide the total number of participants or the percentage of participants who experienced no unfavorable incidents Therefore it is not possible to determine if more than",
        "label": "Contradiction"
    },
    "7df6c8c9-fb22-4197-aba7-d6540a691eec": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial uses the change in units on a scale as its unit of measure for the primary outcome measurement not cm or number of participants The secondary trial uses percentage of participants as its unit of measure for the objective response rate of HER2negative metastatic breast cancer not years or participant BMI",
        "label": "Entailment"
    },
    "5cd571da-1a17-4513-b0b8-7ef1ced9a52f": {
        "text_answer": "  The statement ALT801 is administered at higher doses in the primary clinical trial as opposed to the secondary clinical trial is entailed in the trials provided  Explanation  In the primary trial the doses of PF06647020 given were 02 mgkg and 05 mgkg In contrast in the secondary trial the doses of ALT",
        "label": "Entailment"
    },
    "3805ddb3-dbdf-4f10-8434-271503114961": {
        "text_answer": "  The statement the gender of a patient dictates whether they qualify for the primary clinical trial and the secondary clinical trial is not entailed in the given inclusion and exclusion criteria for both trials The eligibility for the trials is determined based on various factors such as age performance status disease status prior therapy laboratory values and other medical conditions regardless of the patients gender Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "79385974-de52-4d05-b6b1-dc1086d484d9": {
        "text_answer": "  The statement hypothyroidism is abnormally low levels of thyroid hormone is a fact and is not related to the trials provided The statement given in the trials is about different types of adverse events observed in the primary and secondary trials Therefore the statement We cannot compare the adverse events in the primary trial and the secondary trial as they do not appear to have been recorded for the primary trial is the main point of comparison and entail",
        "label": "Entailment"
    },
    "f6f6058f-688b-4ce6-8fec-612f57b1f3ec": {
        "text_answer": "  The statement people possessing a TNBC tumor with a 100mm diameter can partake in either the primary trial or the secondary trial is contradictory to the given trials inclusion criteria  The primary trial specifies that the breast tumor should be 1 cm in diameter whereas the statement suggests a tumor diameter of 100mm 10 cm which is significantly larger than the inclusion criteria  Therefore",
        "label": "Entailment"
    },
    "df0234b5-3b00-4036-ac6c-5cb2d1eeafdf": {
        "text_answer": "  The statement all participants of the secondary clinical trial are administered with entericcoated tablets is entailed in the given information in the secondary trial as both Intervention 1 and Intervention 2 specify the use of MLN8237 alisertib entericcoated tablets for the administration of the intervention",
        "label": "Entailment"
    },
    "448df56a-bcc3-491e-8626-dc8d439013b2": {
        "text_answer": "  The statement there were several fatalities in the second cohort of the primary clinical trial is a contradiction to the information provided in the trials The trials report that there were no fatalities in the second cohort Adverse Events 2 Death 1028",
        "label": "Contradiction"
    },
    "4872d505-a3f8-44bb-a023-aa41e27b49b3": {
        "text_answer": " The statement provided is not entailed in the trials as there is no information given in the trials about the primary tumour diameter in the Azd0530 175 mg and Zoledronic Acid 4 mg groups The trials only report the percentage change in betaCTX levels at Week 4 Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "b1b73c84-818f-40f9-8e6b-a749dc415b71": {
        "text_answer": "  The statement one or more participants in the primary clinical trial experienced numerous adverse outcomes is entailed in the given data as there were a total of 5 adverse events reported in the trial out of 25 participants which is considered as numerous adverse outcomes for a trial of this size",
        "label": "Entailment"
    },
    "4cd89e87-f0c1-4064-ab16-d945db457c41": {
        "text_answer": "  The statement first cousin once removed is a child of your first cousin is not related to the information provided in the trials   Regarding the trials the primary trial intervention involves cabergoline given orally while the secondary trial involves pixantrone dimaleate administered intravenously The mode of administration topical vs intravenous is not entailed in the trials Therefore the statement is neither entailed nor contradicted by",
        "label": "Contradiction"
    },
    "21031398-5d47-4ad9-ad19-16c790eaf061": {
        "text_answer": "  The statement on average patients from the primary trial survive over 10 years is not directly entailed in the given trials as the median survival times provided are less than 10 years for both groups However the statement does not contradict the trials as well since it only mentions an average survival of over 10 years while the trials report the survival times for specific groups of patients The statement becomes irrelevant to the trials as they do not provide enough information to",
        "label": "Contradiction"
    },
    "b45f25ba-463e-458a-9e48-edd0d50bc6cb": {
        "text_answer": "  The statement in the primary clinical trial cohort 1 has not reported any adverse events is entailed in the given data if and only if there are no adverse events reported for cohort 1 in the Trials data and the trials data is complete and accurate  Trials data Cohort 1 Adverse Events 0147 000  Therefore the statement is ent",
        "label": "Entailment"
    },
    "7a5cbc82-ec49-44f5-9c95-4c6475f3ee3e": {
        "text_answer": "  The statement women with a new diagnosis of locally advanced ER breast cancer who are considering mastectomy are considered eligible for the primary and secondary clinical trials is entailed in the given trials as follows  1 Primary Trial The key inclusion criteria state that women with locally advanced recurrent or metastatic ER breast cancer are eligible Locally advanced breast cancer refers to tumors that cannot be removed by surgery and women with this",
        "label": "Entailment"
    },
    "640ffbc4-cf15-4ab2-bf90-620e815f2694": {
        "text_answer": "  The given statement does not directly entail or contradict the information provided in the trials The trials only report the median survival times for the two groups but they do not provide information about the number of individuals living beyond two years for each group Therefore based on the given information it is impossible to determine if more than 50 individuals from each cohort lived for more than two years",
        "label": "Entailment"
    },
    "e5f60086-55a3-4432-9e9d-74690054db5d": {
        "text_answer": "  The statement is neither entailed in the primary trial nor contradictory to it The primary trial includes a criterion for the primary tumour diameter to be greater than 2 cm while the statement mentions a tumour with a diameter of 33mm However this difference does not directly affect the eligibility for either trial as there are other criteria that need to be met The statement does not mention any condition related to carotid artery disorders",
        "label": "Entailment"
    },
    "648ed723-14eb-4c58-85f9-9a6f6089b493": {
        "text_answer": "  The statement is not entailed in the trials as they assess different outcome measures The primary trial measures the severity of pain using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change in bone mineral density BMD of the lumbar spine at 9 months The statement does not directly relate to the outcome measures or methods used in either trial",
        "label": "Contradiction"
    },
    "641b6edf-2ed6-494a-9d37-7c7f04ccd6a0": {
        "text_answer": "  The statement the azd0530 175 mg group and the zoledronic acid 4 mg group of the primary clinical trial had similar reductions in primary tumour diameter is not entailed in the given trials as there is no information provided in the trials about the change in primary tumour diameter for either group The trials only report the percentage change in betaCTX levels at Week 4",
        "label": "Contradiction"
    },
    "fb13dfb3-66cd-45f6-98a8-c0712283954f": {
        "text_answer": "  The statement representative examples of spinal cord gliomas include astrocytoma oligodendroglioma and ependymoma is not entailed in the given trials as the trials are focused on breast cancer and ovarianperitoneal cancer patients receiving talazoparib and do not mention spinal cord gliomas at all Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "599e8d04-e80f-4f54-9486-bcf5a39a1d37": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive whole breast radiation therapy and there is no mention of any specific dosage or formulation of Fulvestrant being administered   In the secondary trial there are two cohorts one receiving Enzastaurin QD and Fulvestrant QD  BID and the other receiving Enzastaurin BID and F",
        "label": "Contradiction"
    },
    "a11f4223-9416-4cf8-8712-ebbddf8c4353": {
        "text_answer": "  The statement is contradictory to the given trials as there were no adverse events reported in more than 30 of participants in either the primary or secondary trials The trials only report the occurrence of adverse events in less than 1 of participants in both trials",
        "label": "Contradiction"
    },
    "d0fe5818-5954-41ea-9bcf-4ce7deba5ceb": {
        "text_answer": "  The statement the secondary clinical trial will not accept any patients who have a known allergy to cephalosporin or trimethoprimsulfamethoxazole and those with an established allergy to levofloxacin or celecoxib are ineligible for the primary clinical trial is entailed in the given trials as follows  1 In the primary trial patients with a history of allergic reactions attributed to comp",
        "label": "Entailment"
    },
    "89c78515-344a-4974-a01f-de5a0441ada0": {
        "text_answer": "  The statement There are no conditions on hepatic function for participants of the primary trial is not directly related to the inclusion and exclusion criteria provided in the trial description The statement in question pertains to hepatic function but the trials criteria do not mention anything about hepatic function being a condition for inclusion or exclusion Therefore the statement is neither entailed nor contradicted by the information given in the trial description",
        "label": "Contradiction"
    },
    "277b5179-05cc-48df-8f23-98b42ccad0b9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial administers Vitamin B12 orally sublingually not intravenously The secondary trial also administers memantine orally by mouth not topically Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "46278ed1-1bc8-4161-b9d9-9f5a001b6aac": {
        "text_answer": "  The statement is not entailed in the primary or secondary trials as there is no mention of Apgar score version 1 or respiration or respiratory effort in either trial The trials only provide inclusion and exclusion criteria for patients with benign breast disease for the primary trial and breast cancer history hot flashes and certain patient characteristics for the secondary trial",
        "label": "Contradiction"
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "text_answer": "  The statement Alzheimers patients are not eligible for the primary trial is a contradiction to the inclusion criteria stated in the trial description The inclusion criteria specify that potential participants must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Alzheimers disease is a progressive neurodegenerative disorder characterized by cognitive impairment and a decline in MMSE scores over time",
        "label": "Contradiction"
    },
    "256c210a-d33f-4708-8d86-2cb636227c4d": {
        "text_answer": "  The statement infection asymmetry and nausea were observed more frequently in the primary clinical trial compared to the secondary clinical trial is contradictory to the given trials data   The primary trial reported adverse events for infection asymmetry deflation delayed healing wound and no mention of nausea The frequency of infection asymmetry and deflation were all reported as 131 323  ",
        "label": "Contradiction"
    },
    "55c933c1-1de0-4a15-9a17-e1216cb84b4b": {
        "text_answer": "  The statement Candidates for the primary trial and the secondary trial have to meet a baseline performance status each trial is using a different performance status scoring system symptom interference with life score 10 is a subjective score of 10 on a scale that ranges from 0 did not interfere to 10 interfered completely is not explicitly stated in the given inclusion and exclusion criteria for both trials However the trials do have performance",
        "label": "Entailment"
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "text_answer": "  The statement There were several psychiatric adverse events in the primary trial including an eating disorder and Schizophrenia is not entailed in the given trial data The trial data only reports two psychiatric adverse events suicidal ideation and no specific mention of an eating disorder or Schizophrenia is made Therefore the statement contradicts the given trial data",
        "label": "Contradiction"
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "text_answer": "  The statement is entailed in the given trials as neither of them include Xrays ultrasound CT scans or MRIs as part of their interventions",
        "label": "Entailment"
    },
    "316e0b04-f14e-47cd-b847-6af5add81e4e": {
        "text_answer": "  The statement both the primary and secondary clinical trials have detailed accounts of adverse events involving their participants is neither entailed nor contradicted by the given information   The reason is that the given information only reports the number of participants who experienced adverse events for each trial but it does not provide any details about the nature or extent of those events Therefore it cannot be determined from the given information whether the trials have detailed accounts of adverse events or",
        "label": "Entailment"
    },
    "9c8c3b78-d272-4ce9-947b-f9283c79e818": {
        "text_answer": "  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is entailed in the given trials as both trials have the same percentage 000 of patients suffering from all adverse events except for febrile neutropenia in cohort 2 which is 4000 However the statement moderately short of breath is a response indicating that an individual has or had moderate shortness",
        "label": "Entailment"
    },
    "c76fe4c2-5f55-4e85-8528-943d90e99dd0": {
        "text_answer": "  The statement 18 year olds are allowed to participate in the secondary clinical trial but are not permitted to be a part of the primary clinical trial is neither entailed nor contradicted by the given trials inclusion and exclusion criteria  Explanation  The primary trials exclusion criteria state that patients under 18 years old are not eligible for participation Therefore the statement does not contradict the primary trials criteria  ",
        "label": "Entailment"
    },
    "555d74d4-755a-44b9-9bec-f8adda634c38": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the statement is consistent with the information provided in the exclusion criteria for the primary trial which states that participants who have received any experimental agents within 4 weeks prior to the study registration date or have undergone",
        "label": "Contradiction"
    },
    "c21d49da-c66f-45cc-af8a-22174568d0dd": {
        "text_answer": "  The statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study is entailed in the trials provided as follows  Both trials report the number of participants with Pathologic Complete Response in Breast and Axillary Lymph Nodes after neoadjuvant chemotherapy The trials provide the count",
        "label": "Entailment"
    },
    "5d0a21d6-cf35-48c3-9128-9d3f9cd03d23": {
        "text_answer": "  The statement is contradictory to the given trials as there is no common adverse event between the two trials In the primary trial there is one patient who experienced a death not associated with CTCAE Death NOS and one patient each with Lymphopenia Neutropenia and Hyponatremia In contrast the secondary trial has no reported adverse events The only common adverse event mentioned in the statement Throm",
        "label": "Contradiction"
    },
    "04b2b1f2-5d87-4b89-8fcd-c1c988bd22de": {
        "text_answer": "  The statement across the primary clinical trial and the secondary clinical trial it was recorded that there were no deaths in the adverse events is entailed in the given trials data  Explanation  The statement is entailed because in both trials the number of deaths reported in the adverse events section is zero Therefore the statement that there were no deaths in the adverse events is a logical consequence of the given data",
        "label": "Contradiction"
    },
    "5902b596-40d0-4be7-8242-f313f6832fec": {
        "text_answer": "  The statement patients with a documented allergy to celecoxib and levofloxacin can enroll in both the primary clinical trial and the secondary clinical trial is not explicitly stated as an inclusion or exclusion criterion in either trial However there is no contradiction between the trials that would prevent a patient with such an allergy from participating in both Therefore the statement is neither entailed nor contradictory to the trials criteria ",
        "label": "Contradiction"
    },
    "d0691186-857a-4876-8f49-732e033a86c7": {
        "text_answer": " The provided information does not include data on treatment emergent adverse events or serious treatment emergent adverse events for each group Therefore it is not possible to determine if the statement is entailed in the trials or not The trials only report the mean number of hot flashes per 24 hours for each group",
        "label": "Entailment"
    },
    "201c2df5-585d-4d20-a19b-c2b12db5dc5f": {
        "text_answer": "  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly entailed in the given inclusion and exclusion criteria for both trials   However the statement is consistent with the information provided in the secondary trials inclusion criteria which states Fewer than 5 alcoholic drinks per day within the past year for patients undergoing autologous",
        "label": "Contradiction"
    },
    "6cc1c5e4-b45a-486f-be8d-1c49abc327c9": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the doses of PF06647020 administered were 02 mgkg and 05 mgkg while in the secondary trial the doses of ALT801 administered were 0015 mgkgdose and 0040 mgkgdose The doses in the",
        "label": "Entailment"
    },
    "705457d9-78b2-466d-9a3e-db4b11e99daa": {
        "text_answer": "  The statement the secondary trial has more adverse events recorded than the primary trial is contradictory to the given information in the trials   Explanation   The statement asserts that the secondary trial has a greater number of adverse events than the primary trial However the given information states that there are no adverse events recorded in both trials Therefore the statement is contradictory to the facts provided",
        "label": "Contradiction"
    },
    "6f947c20-ecd9-4c6b-b1e3-5d536d4b33cd": {
        "text_answer": "  The given statement all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group is not directly entailed in the provided trial results The trials only report the mean standardized scores and standard deviations for the cognitive function measurements in the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The trials do not provide sufficient information to determine if all participants experienced a deter",
        "label": "Contradiction"
    },
    "70dec4df-4dbd-41cc-ba31-6437c7058987": {
        "text_answer": "  To verify if the statement is entailed in the trials we need to compare the percentage of participants with a decrease in the growth factor signature GFS between the ERpositive Luminal B and Triple Negative groups   According to the trials the percentage of participants with a decrease in GFS in the ERpositive Luminal B group was 286 131492 and",
        "label": "Entailment"
    },
    "0f449a63-8d5d-4c60-96f8-bb32423f079d": {
        "text_answer": "  The statement is entailed in the trials as both trials report their results using the same units of measure In the primary trial the units of measure are units on a scale for hot flash scores and in the secondary trial the units of measure are proportion of responders for the overall response rate However its important to note that the primary trial measures hot flash activity while the secondary trial measures response to treatment Despite the difference in the",
        "label": "Entailment"
    },
    "2493a4e6-18a1-41c7-8feb-81928df2b542": {
        "text_answer": "  The statement xq271 is a chromosome band present on xq is not related to the information provided in the trials The trials only mention the interventions AlloMSCs and placebo and their administration methods The statement about the chromosome band does not entail or contradict any information in the trials",
        "label": "Entailment"
    },
    "80b0b7be-91b4-40ba-a4db-d19f0b1865d7": {
        "text_answer": "  The statement on average cognitive function remained stable in one cohort while it improved in the other cohort of the primary clinical trial is not directly entailed in the given trials as presented   The trials only provide the mean standardized scores and standard deviations for each cohort Tamoxifen and Tamoxifen  Ovarian Function Suppression at the 1year followup The statement implies that",
        "label": "Contradiction"
    },
    "8bd3b6aa-d1b5-4f4a-a16a-434d56764ee5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials report several types of adverse events but none of them mention myocardial infarction The reported adverse events include blood disorders hypomagnesemia platelets count decrease thrombosis visionblurred constipation radiation oesophagitis nausea vomiting general symptom headache and bone pain",
        "label": "Entailment"
    },
    "30f7d44a-34d9-4d98-9802-2c8a7c625e48": {
        "text_answer": "  The primary trial includes patients with HR HER2 breast cancer whose tumors are between 1 cm and up to 1 cm in diameter The secondary trial does not specify the tumor size but includes patients with recurrent refractory or progressive HRHER2 breast cancer However the statement in question is about the primary and secondary trials accepting patients with HR HER2 breast cancer whose tumors range from 02 to",
        "label": "Entailment"
    },
    "a98a4204-8591-48d3-9349-723b4ccc4f3c": {
        "text_answer": "  The statement patients that have had a pulmonary embolism within the last 3 years are considered eligible for the primary trial and are not subject to the investigators decision for the secondary trial is neither entailed nor contradicted by the information provided in the inclusion and exclusion criteria for both trials  Explanation  The primary trials inclusion criteria state that patients with a history of thrombotic or embolic events such",
        "label": "Entailment"
    },
    "0d8ce6e1-e0bb-42b6-a8ec-0d2679b908ad": {
        "text_answer": "  The statement there were 4 additional adverse incidents recorded in the primary clinical trial compared to the secondary clinical trial is a contradiction to the given information   The primary trial had 0 adverse events out of 34 participants and the secondary trial had 0 adverse events out of 1 participant Therefore there was not an additional 4 adverse incidents recorded in the primary trial compared to the secondary trial Instead both trials had 0",
        "label": "Contradiction"
    },
    "10ae9352-5088-4431-8a48-a6891f5d03b7": {
        "text_answer": "  The statement irrespective of a patients qualifications based on the exclusion and inclusion criteria for the primary clinical trial their own decision serves as the final say about participation is neither entailed nor contradicted by the information provided in the given inclusion and exclusion criteria  The criteria only specify the conditions that determine a patients eligibility for the clinical trial They do not address the issue of the patients final decision to participate or not",
        "label": "Entailment"
    },
    "c22306e0-54e6-4324-abed-0a38d9c7f1b9": {
        "text_answer": "  The primary trial reports the percentage of participants with a response within 10 days of the first dose of denosumab The secondary trial reports the number of participants who reached a safe dose of dmethadone over a period of 2 years  The units of measure used in reporting results for both trials are different In the primary trial the percentage is reported while in the secondary trial the number of participants is reported  Therefore",
        "label": "Entailment"
    },
    "8747d88a-efc9-42ae-ba7c-5e25c8693b34": {
        "text_answer": " The statement pervasive pain was a common experience reported by patients throughout the full course of the primary clinical trial is not directly entailed in the given trial results as there is no mention of the prevalence or frequency of pain experience in the trials The trials only report the average change in pain intensity scores between the lowdose and highdose intervention groups",
        "label": "Contradiction"
    },
    "fdf14cde-dd7c-4b38-a127-5d857fb22bab": {
        "text_answer": "  The statement all patients treated with gtx024 1000mcg in the primary trial gained lean body mass over a 120 day period is not directly entailed in the given trials as the trials only report the median change in lean body mass for two different doses of GTx024 1 mg and 3 mg and do not provide information about the lean body mass change for the 1000 mcg",
        "label": "Contradiction"
    },
    "d846c22f-adab-4189-b662-056541a723c2": {
        "text_answer": "  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial explicitly states that smokers are excluded and the secondary trial mentions no smoking requirement However the statement does touch upon the possibility of smokers being included in the secondary trial under certain conditions ",
        "label": "Contradiction"
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "text_answer": "  The statement the primary trial has 4 more adverse events recorded than the secondary trial is a contradiction to the given information in the trials   Explanation   The statement implies that the primary trial has 4 more adverse events than the secondary trial which is not the case based on the given data In the primary trial there were 0 adverse events recorded out of 34 participants and in the secondary trial there",
        "label": "Contradiction"
    },
    "c4b6e4a0-1377-444e-853d-d62b67802ed2": {
        "text_answer": "  The Trials with Entailment and Contradiction document does not provide sufficient information to determine if the statement surgical and imaging procedures are compulsory in the intervention section of the primary clinical trial is entailed or contradicted The document only mentions the interventions MM111 and placebo but it does not specify if surgical and imaging procedures are a part of MM111 or a separate intervention Therefore",
        "label": "Entailment"
    },
    "f9ab104f-3d67-4912-aaf5-bb43ecd0c52d": {
        "text_answer": "  The statement seminal vesicle cystadenoma is a rare benign cystadenoma that arises from the seminal vesicle Patients with histologically documented metastatic SCBC are excluded from the primary trial is not directly entailed in the inclusion and exclusion criteria provided in the text   The statement mentions seminal vesicle cystadenoma which is not listed as a cancer type in the inclusion criteria The",
        "label": "Contradiction"
    },
    "40dd90a2-f57d-467e-bc6c-c9a8a50a330f": {
        "text_answer": "  The statement is entailed in the trials as it explicitly mentions the different practice frequencies for cohorts 1 and 2 while acknowledging the same instructional CD being used by both groups The statement also correctly identifies the additional weekly chemotherapy treatments for cohort 2",
        "label": "Entailment"
    },
    "7aef8aaf-9fc3-49b2-95e7-ed9b227cdd27": {
        "text_answer": "  The statement neisseria gonorrhoeae penicillinase negative is any bacterial species identified as neisseria gonorrhoeae that does not produce the enzyme penicillinase is not directly related to the information provided in the trials   Regarding the comparison of the primary and secondary trials the primary trial participants receive pembrolizumab twice as frequently as sunitinib is administer",
        "label": "Entailment"
    },
    "4046d097-cbc9-48ef-9e90-d9a427fa6d19": {
        "text_answer": "  The statement wholly disparate drug treatments are incorporated in both the primary and secondary clinical trial is entailed in the given trials as follows  In the primary trial Intervention 1 and Intervention 2 have different combinations of drugs Abl Cells IV  Cyclophosphamide 30 mgkg and Abl Cells IV  Cyclophosphamide 60 mgkg respectively The phase 1 cyclophosph",
        "label": "Entailment"
    },
    "126ef758-8ce5-4e45-859d-acece8b261e1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not document any cases of mucositis oral epileptic seizures or thromboembolic events in the secondary trial while the primary trial had only one case each for mucositis oral and thromboembolic events and no cases of epileptic seizures Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Contradiction"
    },
    "1aedac43-a4c7-4c14-b217-8d76e853c76f": {
        "text_answer": "  The statement every patient in the primary trial is receives a dose of 2000 to 5000 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information The trial only mentions the use of vorinostat and radiation therapy and the administration of fentanyl spray is not mentioned at all Therefore the statement is a contradiction to the given trial information",
        "label": "Contradiction"
    },
    "40d1e2c2-9a6f-42a6-b75d-a67e9945a38d": {
        "text_answer": "  The statement All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks and over 130 mg of PDR001 every other week is not directly entailed in the given trial information   However we can determine if the statement is contradictory to the trials by calculating the total amount of MCS110 and PDR001 each patient receives in a 3",
        "label": "Contradiction"
    },
    "94935617-b333-4eb3-bd06-a5884fa45989": {
        "text_answer": "  The statement is in contradiction with the given trials interventions   The primary trial intervention involves Yttrium90 Radioembolization using TheraSphere glass microspheres which is a radiotherapy treatment In contrast the secondary trial intervention consists of administering ibrutinib 056 g and MEDI4736 001 kgkg twice daily for 30 days",
        "label": "Contradiction"
    },
    "59b5ce7e-13af-4377-8923-c096f79bcade": {
        "text_answer": "  The statement 16p1313p1312 is a chromosome band present on 16p All Infections and Fever cases in the primary trial were for patients in cohort 1 is not directly entailed or contradicted by the given trials   The trials only provide information about the number and types of adverse events in each cohort but they do not specify which chromosome band is",
        "label": "Contradiction"
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "text_answer": "  The statement is contradicted by the Trials   Explanation   The statement asserts that all adverse events in the primary trial were related to the musculoskeletal system but the Trials show that this is not the case for the secondary trial as there are adverse events related to the blood and bone marrow and lymphatics systems that are not mentioned in the primary trial",
        "label": "Contradiction"
    },
    "18876a8c-2536-4148-b563-c5a68daa7fac": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The trials report the number of adverse events for each trial including the type and frequency of each event Based on the information given there were no deaths reported in either the primary or secondary trials regardless of the cause Therefore the statement that Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events is incorrect  F",
        "label": "Contradiction"
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "text_answer": "  The statement one patient in the primary trial had an incident where a surgical incision reopened after the surgery is not explicitly stated in the given adverse events However the term wound dehiscence is mentioned which refers to the reopening or separation of a surgical incision Therefore the statement is entailed in the trial data as one of the adverse events  So the statement is entailed by the trial",
        "label": "Entailment"
    },
    "105ed693-cbe0-47a4-ba39-f361032d9ed7": {
        "text_answer": "  The statement is contradicted by the information provided in the trials Although both interventions use the same dosage of Docetaxel and Doxorubicin the administration schedules for these drugs and the use of Herceptin in Intervention 2 result in different frequencies of Docetaxel administration The statement does not hold true for the trials as presented",
        "label": "Contradiction"
    },
    "db3d7616-8500-411a-9b43-b9b6e0925957": {
        "text_answer": "  The statement all participants in the primary clinical trial receive adriamycin and vincristine is not entailed in the given trials as neither suramin nor paclitaxel mentioned in the primary trial include adriamycin or vincristine in their interventions",
        "label": "Contradiction"
    },
    "f19797c7-afb1-4480-ab8f-c798a86d2849": {
        "text_answer": "  The statement over 67 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR is not directly entailed in the given trial results   The trial results only report the percentage of participants who experienced either a CR or PR but they do not provide the specific percentage of participants who experienced a CR The statement suggests a higher percentage of CRs than what",
        "label": "Contradiction"
    },
    "bea94e26-3706-492c-af45-d35ef7e43ff1": {
        "text_answer": "  The statement the primary trial and the secondary trial do not have any recorded adverse events for their participants clavicle fracture is a traumatic or pathologic injury to the clavicle in which the continuity of the clavicle is broken is not entailed in the given trials as the trials do not provide any information about clavicle fractures occurring as adverse events The statement is not contradictory to the trials either as the trials",
        "label": "Contradiction"
    },
    "591e7319-16cd-46db-be86-7c78e8d471c8": {
        "text_answer": "  The statement for the primary and secondary clinical trials pCR is used as their benchmark for outcome A slight difference is noted in the results of the two cohorts participating in the primary trial However in the secondary trial arm 2 achieved far superior results than arm 1 did is neither entailed nor contradicted by the provided information  Explanation  The statement makes several assumptions that are not explicitly stated in the provided information The",
        "label": "Entailment"
    },
    "cbb4daf6-f35a-4832-b071-a17ffbe86e13": {
        "text_answer": "  The statement several adverse events occurred during the primary clinical trial and skin infections in the secondary clinical trial affected the majority of patients is entailed in the given trials data as follows  1 Several adverse events occurred during the primary clinical trial The primary clinical trial had 0 adverse events out of 25 patients which means no adverse events occurred in this trial However the statement does not require that no adverse events occurred in",
        "label": "Entailment"
    },
    "874a2beb-d0b1-4b5f-9f37-5b49ba5a1067": {
        "text_answer": "  The statement concerning biliary colic and Clostridium difficile colitis there is no difference in their occurrence between the primary and secondary trial is not directly entailed or contradicted by the given trials as the trials do not provide sufficient information to make such a determination The trials only report the number and percentage of adverse events for each condition in each trial but they do not report the number or percentage of participants who experienced each adverse event",
        "label": "Contradiction"
    },
    "21c183ca-7f70-4ddb-9599-d371ee544055": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement claims that over 97 of patients in the secondary clinical trial experienced adverse events while no adverse events were recorded in the primary clinical trial However the data in the trials show that in the primary trial 4545 of patients experienced adverse events and in the secondary trial 1563 of patients experienced adverse events",
        "label": "Contradiction"
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "text_answer": "  The statement is not entailed in the given trials as the interventions for cohort 1 in each trial are different In the primary trial cohort 1 receives an injection of Fluciclatide while in the secondary trial cohort 1 receives a standard dose of Chloroquine These interventions are not the same so the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "452458d2-6372-4ac9-a7f9-0be77cc28eea": {
        "text_answer": "  The statement is entailed in the trial information provided The trial description specifies that 13 participants were involved in the vaccine arm of the study which is consistent with the statement that the primary clinical trial involved 13 participants who were administered the globohgm2lewisymuc132aastnctfctncklh conjugate vaccine",
        "label": "Entailment"
    },
    "97b0957c-3b60-4671-9c9d-37eacba40f93": {
        "text_answer": "  The statement footfootpad is a laboratory specimen consisting of the foot and footpad is not related to the adverse events data provided in the primary or secondary trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "705e4626-c95b-4191-b9f1-02ae897cef70": {
        "text_answer": "  The statement is not entailed in the given trials as they address different patient groups and different interventions The primary trial deals with oral pregabalin versus placebo while the secondary trial deals with a chemotherapy regimen of intrathecal and intravenous treatments Therefore the statement is neither entailed nor contradictory to the given trials",
        "label": "Contradiction"
    },
    "12f2ffff-1010-43bb-ac5d-5725d3d159b4": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2",
        "label": "Entailment"
    },
    "d8f0b3e8-ca61-4874-a4e0-1328029bce88": {
        "text_answer": "  The statement is contradictory to the information provided in the trials inclusion and exclusion criteria   The primary trial and secondary trial have different inclusion criteria The primary trial specifically includes only female breast cancer patients who are postmenopausal and experiencing hot flushes while the secondary trial includes adult patients with HER2negative metastatic breast cancer who are candidates for taxanebased chemotherapy   Therefore a patient meeting the inclusion criteria",
        "label": "Entailment"
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a resectable Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial is contradictory to the trials inclusion criteria The inclusion criteria state that patients must have advanced andor unresectable disease for breast cancer epithelial ovarian cancer or gynecological cancer head and neck squamous cell carcinoma nonsmall",
        "label": "Entailment"
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "text_answer": "  The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is contradicted by the given data   Explanation   The statement implies that the percentage of patients with adverse events in cohort 1 is greater than that in cohort 2 and the percentage of patients without adverse events in cohort 2 is greater than that in",
        "label": "Contradiction"
    },
    "fe73dc46-7c3a-45cd-a5fa-db03aa8dd28c": {
        "text_answer": "  The statement anorexic patients are eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria Anorexia is not mentioned as a specific condition in the criteria However the criteria do include a BMI requirement BMI of 25 kgm2 or greater and weight 400 lbs which could potentially include some individuals with anorexia depending on their specific weight and height However",
        "label": "Contradiction"
    },
    "723d5448-24c6-4679-98c1-3c67bb12fea4": {
        "text_answer": "  The statement capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial is not directly stated in the inclusion or exclusion criteria of either trial However the statement does not contradict the given criteria as well The Eastern Cooperative Oncology Group ECOG performance status of 0 to 2 which is an inclusion criterion",
        "label": "Entailment"
    },
    "07f85ee2-4e95-4648-a492-4011837ddc7f": {
        "text_answer": "  The statement the primary clinical trial has disclosed findings for the lbh589 and lapatinib group is a contradiction based on the information provided in the trials The trial results only disclose information for the LBH589 with Capecitabine group and do not mention any findings for the LBH589 and Lapatinib group",
        "label": "Contradiction"
    },
    "8bd62043-2cb9-42f0-80c1-2ec39020d9af": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measurements and patient populations The primary trial focuses on treatmentemergent adverse events during the first cycle of treatment with fosnetupitantpalonosetron and dexamethasone versus netupitantpalonosetron and dexamethasone The secondary trial measures the change in total sleep time using polysomnography PSG before and",
        "label": "Contradiction"
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "text_answer": "  The statement The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group is not entailed in the given trials as the trials do not provide data on primary tumour diameter The trials only report the percentage change in betaCTX levels from baseline to Week 4",
        "label": "Contradiction"
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "text_answer": "  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope is contradicted by the given data   The primary trial had a total of 12 patients with 3 adverse events and Syncope occurred in 2 of those patients 1667 However Syncope was not the most common adverse event across both trials In the secondary trial there",
        "label": "Contradiction"
    },
    "55d65365-bf85-4213-9ead-be1c498a4a72": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial the intervention is given only once at the beginning while in the secondary trial the intervention is given three times weekly for 12 weeks",
        "label": "Entailment"
    },
    "36a25cf0-0cca-457d-bd85-8ba89b2ff602": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials state that the daily doses of talazoparib for breast cancer patients range from 600 mcgday to 1100 mcgday and for ovarianperitoneal cancer patients the daily doses range from 25 mcgday to 1100 mcgday The statement however asserts that",
        "label": "Entailment"
    },
    "d432512b-0bb4-435c-b32c-7ae0564a63c8": {
        "text_answer": "  The statement only a small percentage of patients on sunitinib  docetaxel  trastuzumab in the primary clinical trial encountered treatmentemergent adverse events is not directly entailed in the provided trial results However it could be considered a possible interpretation based on the given data as the number of participants with treatmentemergent adverse events AEs was 24 out of 25 participants and the number",
        "label": "Contradiction"
    },
    "9c74310c-3096-4eaf-bed2-aec926b5c850": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants who experienced recurrencefree survival up to 5 years after randomization They do not provide the actual data on the number of participants who experienced recurrence or death during that period Therefore it is not possible to determine the percentage of participants who experienced recurrencefree survival in each group based on the given information alone   Moreover the statement in",
        "label": "Contradiction"
    },
    "a855848e-4097-4755-90e0-e612f1bfc54c": {
        "text_answer": "  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as there is no comparison of lesions or radiation dermatitis between the two groups within the same trial The trials only provide information on the number of",
        "label": "Contradiction"
    },
    "70eac1ab-54b0-460d-abda-86f0c5d04483": {
        "text_answer": "  The statement is entailed in the secondary clinical trial exclusion criteria as follows  1 Unstable angina Patients with significant cardiovascular impairment history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that is abnormal in the opinion of the treating Investigator or unstable angina Exclusion Criteria Section 11  2",
        "label": "Entailment"
    },
    "38e4b093-2121-486f-bcfb-d250ea9978e4": {
        "text_answer": "  The statement the primary clinical trial does not permit participation of children whereas the secondary clinical trial does not specifically prohibit their involvement is not entailed in the given inclusion and exclusion criteria for both trials   The primary trial explicitly states Postmenopausal women as an inclusion criterion which implies that children are excluded However the secondary trial does not mention anything about children in its inclusion or exclusion criteria Therefore the statement is neither",
        "label": "Contradiction"
    },
    "92fe4c4d-da02-4327-a2a1-86e731ba4fd9": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   In the trial description the dosages of nabPaclitaxel are identical in both arms 125 mgm2 on Days 1 and 8 but the dosages of the second agents gemcitabine and carboplatin are different Therefore the statement that both cohorts participating in the primary clinical trial are administer",
        "label": "Entailment"
    },
    "8eb9d0d2-5c33-4ff6-adf6-e96ddf7be7a6": {
        "text_answer": "  The statement patients with a past record of pulmonary embolism and currently having breast implants are excluded from both the primary clinical trial and the secondary clinical trial is entailed in the trials exclusion criteria  In the primary trial the exclusion criteria include History of clotting disorder hypercoagulable state and Any other medical condition that could result in acute limb edema such as but not limited to",
        "label": "Entailment"
    },
    "48b25d6c-3b89-425b-960e-9d55471a5f37": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants with a decrease in the growth factor signature GFS between the ERpositive Luminal B and Triple Negative groups  The statement is 0492 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative",
        "label": "Entailment"
    },
    "53a45460-701f-420e-853a-f5ccb8545030": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of subcutaneous insulin injections in the primary trial and oral antiretroviral therapy ART is not mentioned in the secondary trial Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "79515622-bb43-4721-a164-dd2002713dc1": {
        "text_answer": "  The statement is contradictory to the trial results provided   The trial results indicate that there were 80 participants with recurrencefree survival in the Ketorolac 30 mg group and 96 participants with recurrencefree survival in the NaCl 09 3mL group   Therefore the statement that in the primary clinical trial recurrencefree survival was exclusively seen in 12",
        "label": "Entailment"
    },
    "ee42e602-9409-49fa-a454-7a2637ed9d7a": {
        "text_answer": "  The statement in the primary clinical trial numerous patients with regular vitamin d levels exhibited noticeable trends in the expression of 40 studied genes is not directly entailed in the provided trial results as no information about gene expression trends in the normal vitamin D level group is given The trial results only report the number of participants in each group without any information about gene expression trends or patterns Therefore the statement is neither entailed nor contradicted by the given trial results",
        "label": "Contradiction"
    },
    "3109bf56-61b7-4f43-9e38-fa3b69378214": {
        "text_answer": "  The statement none of the cohort of the primary trial or the secondary trial receive entericcoated tablets is not directly related to the information provided about the trials The trials only mention the interventions given to each group Botulinum Toxin Type A or Placebo in the primary trial and MLN8237 with different doses in the secondary trial but they do not specify that entericcoated tablets are not given",
        "label": "Entailment"
    },
    "95f4ce83-19b7-424d-93b9-27a6c3fe8c6d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The trials describe two different interventions one for breast cancer patients and another for ovarianperitoneal cancer patients both involving the use of talazoparib capsules in different doses The statement however asserts that neither type of patient received talazoparib in the primary clinical trial This is incorrect as the",
        "label": "Entailment"
    },
    "3acf4a18-725c-444e-bf7e-e3eb9a0878e7": {
        "text_answer": "  The statement neisseria is a genus of gramnegative aerobic strongly oxidasepositive diplococci bacteria in the phylum proteobacteria is not related to the provided trials in any way Therefore it is neither entailed nor contradicted by the information given in the trials",
        "label": "Entailment"
    },
    "9b230310-d16f-47a4-bf3b-341d2de6f9c4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial is focused on the use of vaginal interventions Estring and Testosterone Cream while the secondary trial is focused on acupuncture which is an external treatment   Therefore the statement that the primary clinical trial is focused on external treatments and the secondary trial is centered around the study of inhalable ones is incorrect",
        "label": "Entailment"
    },
    "0b6e68b2-9f05-407b-bd00-feb9d3ce7abc": {
        "text_answer": "  The statement primary clinical trial participants were twice as likely to have cholelithiasis than those in the secondary clinical trial is not entailed in the given trials as there is no mention of cholelithiasis in either trial Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "text_answer": "  The statement the secondary trial candidates must meet some Performance Status condition to participate whereas this is not required to be accepted into the primary trial is a contradiction   The primary trial includes the requirement of a response after receiving at least two courses of weekly paclitaxel therapy and consideration by the investigatorsubinvestigator for continued therapy but it does not explicitly mention a performance status requirement in its inclusion criteria   On the other hand the",
        "label": "Contradiction"
    },
    "88e8a071-e139-4547-9fd8-f3311d0770ef": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The primary trial states that the primary tumour must be greater than 2 cm in diameter while the secondary trial does not specify a minimum tumour size However the statement suggests a primary tumour with a diameter of 0033m which is less than the minimum size required for the primary trial Therefore a patient with a primary tumour of that size would not be",
        "label": "Entailment"
    },
    "00c165f5-4c14-4aab-a4a8-9b8010bd5858": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary clinical trial does not mention any gender restriction in its inclusion criteria allowing both male and female subjects to participate However the secondary clinical trial specifically targets women as its population Therefore the statement that the primary clinical trial does not consider gender in determining eligibility however only females can participate in the secondary clinical trial is not entailed in the trials",
        "label": "Contradiction"
    },
    "330f241a-9f7d-469d-8986-5687fdd5fb70": {
        "text_answer": "  The statement is neither entailed in the primary trial nor contradictory to it based on the given information The primary and secondary trials use different drugs FMX and lapatinib respectively different dosages and different frequencies of administration The statement mentions the use of intravenous injections and MRIs which are common to both trials but it does not make any specific claim about necrotic change or its presence or absence in the trials Therefore",
        "label": "Entailment"
    },
    "bca3c321-d798-427d-90a7-8c786d91947c": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The patient described in the statement does not meet the minimum diagnostic workup requirements for the primary trial specifically the requirement for a complete blood count CBC with adequate bone marrow function ANC  1800 cellsmm3 within 2 weeks prior to registration Additionally the patients hemoglobin level of 50 g",
        "label": "Entailment"
    },
    "0a7569de-fb79-41f8-acc6-fd155a26e3c8": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms cannot take part in the secondary trial and those who currently have breast implants cannot participate in the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the primary trial exclusion criteria mention that patients with a history of clotting disorders including pulmonary embolisms are not eligible to participate Therefore the statement is",
        "label": "Contradiction"
    },
    "7d57f1d1-e523-4220-95a9-f4ce33d7f157": {
        "text_answer": "  The statement is entailed in the Trials with Entailment   Explanation  The statement the secondary trial and the primary trial have completely different inclusion criteria is entailed in the given trials as the inclusion criteria for each trial are explicitly stated and they are clearly distinct from each other The primary trial focuses on women undergoing lumpectomy for breast cancer while the secondary trial focuses on patients undergoing breast reconstruction with tissue expanders and implants",
        "label": "Entailment"
    },
    "0348dacb-819e-4e1f-98c3-d45d6c057f60": {
        "text_answer": "  The statement is entailed in the trials exclusion criteria as follows  Exclusion Criteria  No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months  No history of stroke or transient ischemic attacks in the last 6 months  No significant psychiatric disorders  Therefore the statement is entailed",
        "label": "Entailment"
    },
    "bcbc612f-11c9-40ba-9376-c098a9b738f4": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcomes The secondary trial measures the percentage of participants with pain using the Numeric Pain Rating Scale while the primary trial examines the change in isothiocyanate levels in urine samples There is no mention of muscle growth in the secondary trial as an indicator of physical therapys effectiveness Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "d035a6bb-0d8f-4a6b-b725-f8b2535883eb": {
        "text_answer": "  The given statement is a contradiction to both Intervention 1 and Intervention 2 in the primary clinical trial In both interventions patients follow an instructional compact disc CD for practicing paced breathing but the statement suggests that patients use a focused breathing instructional audio guide thrice daily without undergoing regular chemotherapy sessions The interventions in the primary trial do not include this specific detail",
        "label": "Contradiction"
    },
    "a8760238-f938-4525-bd13-ecb0948de8bc": {
        "text_answer": "  The statement is entailed in the trials as neither intervention involves the use of drugs radiotherapy or CBT Cognitive Behavioral Therapy which are forms of treatment that can include myelosuppressive effects Therefore the statement that neither cohort of the primary trial receives any drugs radiotherapy or CBT in the interventions is consistent with the information provided in the trials Additionally the trials do not mention the use of",
        "label": "Entailment"
    },
    "ad24cf4c-11da-465c-b008-ba96dc8bcdd4": {
        "text_answer": "  The statement is entailed in the primary trial as follows  The primary trial exclusion criteria state that patients with a documented allergy to cephalosporin or trimethoprimsulfamethoxazole are excluded from the study This directly relates to the secondary trials inclusion criteria as patients with a documented allergy to cephalosporin or trimethoprimsulfamethoxazole are explicitly stated as",
        "label": "Entailment"
    },
    "04dfaa5a-359d-4aba-a56d-4b19f041ce39": {
        "text_answer": "  The statement A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography would be eligible for both the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion criteria for both trials  The primary trial includes the criterion Primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography but it does not specify an upper",
        "label": "Entailment"
    },
    "103134aa-c3f2-4ebb-8919-72bdb5611b07": {
        "text_answer": "  The statement no adverse events were reported in both the primary clinical trial and the secondary clinical trial is contradicted by the information provided in the trials   Explanation   The primary clinical trial reported no adverse events at all while the secondary clinical trial reported a total of 2 adverse events with 1 case each of gastroesophageal reflux disease and ductal carcinoma in situ Therefore the",
        "label": "Contradiction"
    },
    "bca56f4d-9c3c-4615-8b56-3f6ca86d047b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement suggests that both interventions alloMSCs and placebo receive identical doses delivered through a single transendocardial injection However the trials describe two different interventions  1 AlloMSCs 20 transendocardial injections of 04ml alloMSCs administered to the left vent",
        "label": "Entailment"
    },
    "82e2e80d-2a88-4d12-82a9-4d77d1bf0bb6": {
        "text_answer": "  The statement several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes is not directly entailed or contradicted by the information provided in the trials   The trials only report the correlation of Vitamin D levels with the proportion of participants showing a discernible gene expression pattern but they do not provide any information about the appetite or food enjoyment of the participants Therefore",
        "label": "Contradiction"
    },
    "be3df611-66ac-4f40-ae04-68b5d1c0ae02": {
        "text_answer": "  The statement a female patient aged 20 recently diagnosed with ERpositive HER2negative breast cancer may qualify for both the primary clinical trial and the secondary clinical trial is neither entailed in the primary trial nor contradictory to it as the two trials have different inclusion criteria  The primary trial is for patients with HER2negative breast cancer who have progressed during or following firstline treatment with Avastin and",
        "label": "Entailment"
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "text_answer": "  The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is entailed in the given trials as  1 The statement mentions that only three types of adverse events occurred in the primary trial This is consistent with the trials as the total number of unique adverse events in each trial is three Pancreatitis",
        "label": "Entailment"
    },
    "972438ce-59d8-476c-a8a3-b61fba56e982": {
        "text_answer": "  The statement the primary trial and the secondary trial have 0 recorded adverse events is entailed by the given trials data as both trials have reported 0 adverse events in their respective sections",
        "label": "Entailment"
    },
    "07687788-b44f-4f2a-9117-6b55cbdc3f7a": {
        "text_answer": "  The statement is entailed in the trials as both primary and secondary interventions involve the use of 4demethyl4cholestryloxycarbonylpenclomedine as the medication for treatment However the primary trial focuses on the use of this medication in combination with cyclophosphamide and fludarabine while the secondary trial uses it as a single agent",
        "label": "Entailment"
    },
    "9e1d8e36-9749-4f70-b0e3-d173892dfcd0": {
        "text_answer": "  The statement immigrant from a high tuberculosis prevalent area is not an individual that has adverse events related to the musculoskeletal system in the secondary trial is a contradiction to the given trials   The statement provided in the question is not entailed in the trials as the trials do not provide sufficient information to determine if the immigrants in the trials are from high tuberculosis prevalent areas or not Additionally the statement",
        "label": "Contradiction"
    },
    "e6d5d1ca-f1f6-481a-b309-78adf96e656c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials inclusion criteria   The primary trials inclusion criteria state that the primary tumour must be greater than 2 cm in diameter while the statement suggests a primary tumour with a radius of 3mm which is less than the required minimum size Therefore a patient with a primary tumour of 3mm in radius would not meet the inclusion criteria for the primary trial  Additionally",
        "label": "Entailment"
    },
    "db52c7f4-cfb8-40d2-83f2-3514cb04794b": {
        "text_answer": "  The statement cohort 1 patients in the primary clinical trial enjoyed a primarily favorable prognosis reflecting the same trend in cohort 2 is not directly entailed in the given trials as there is no information provided in the trials about the overall prognosis or trend of favorable outcomes for each cohort The trials only report the occurrence of specific adverse events",
        "label": "Contradiction"
    },
    "82582964-823a-4765-b22c-201660fcca08": {
        "text_answer": "  The statement women aged 30 or 35 are eligible for the secondary trial but will need to wait 56 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trials inclusion criteria state that patients must be aged greater than 20 years while the secondary trials inclusion criteria state that patients must be 18 years or older",
        "label": "Contradiction"
    },
    "bb9c00c0-3a87-41c2-bfb5-183f7b44fcbc": {
        "text_answer": "  The statement is a comparison between the acupuncture group and an unspecified group which is not mentioned in the provided trials The trials only compare the acupuncture group to a waitlist control group Therefore the statement is not entailed in the trials as presented",
        "label": "Contradiction"
    },
    "260a9ba1-ca1b-4e87-83d1-b128e73e1e38": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does have different inclusion criteria for different patient groups but it does not have separate inclusion criteria based on age The statement incorrectly mentions that the primary trial has 2 sets of inclusion criteria one for the 1850 age group and one for the 50 age group   Furthermore the statement has no relation to the secondary",
        "label": "Contradiction"
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "text_answer": "  The primary trial and the secondary trial use different outcome measurements The primary trial measures the change in severity of vaginal symptoms using the Vaginal Symptom Measure VSM on a scale from 4 to 1 while the secondary trial measures the objective response rate of HER2negative metastatic breast cancer using percentage of participants Therefore the statement is contradictory as they do not use the same units of measure for their outcome measurements",
        "label": "Entailment"
    },
    "64b3c727-779e-4db4-b1fe-1d85105ab7ec": {
        "text_answer": "  The primary and secondary clinical trials do not use the same parameters to gauge the outcomes as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using the units of mIUml while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD using the units of mg Therefore the statement is contradictory",
        "label": "Entailment"
    },
    "930e7529-e05a-471e-9d52-17f538f610c2": {
        "text_answer": "  The statement is not entailed in the given trials as the trials describe different interventions and do not directly relate to the abnormal involuntary movement scale aims0111 through aims0112 mentioned in the statement The primary trial is about denosumab administration while the secondary trial is about the use of pIHGC and GP during lymphoscintigraphy The statement only mentions the results of the abnormal invol",
        "label": "Contradiction"
    },
    "f0d10d18-11a3-4fae-9a4d-f2277f6e5b43": {
        "text_answer": "  The statement there was an equal distribution of adverse events recorded in both the primary and secondary trials is contradicted by the given data   In the primary trial there were no adverse events recorded out of 49 participants 000 In contrast in the secondary trial there were 12 adverse events recorded out of 20 participants 6000 Therefore the statement is contradicted by the data",
        "label": "Contradiction"
    },
    "4efeb043-de46-49cd-8d5d-c4266304fb91": {
        "text_answer": "  The statement the primary trial has more restrictive eligibility criteria than the secondary trial is entailed in the trials provided   Explanation  The primary trial has stricter inclusion and exclusion criteria compared to the secondary trial The primary trial includes only women with carcinoma of the breast undergoing lumpectomy while the secondary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy skinsparing maste",
        "label": "Entailment"
    },
    "8fd48918-38db-4443-a1b8-bf2d7a458857": {
        "text_answer": "  The statement primary clinical trial patients suffered from anemia pneumonia and stupor more often than patients in the secondary trial is contradicted by the given data   The data shows that the frequency of anemia pneumonia and stupor in the primary trial is 000 000 and 000 respectively while in the secondary trial the frequency of anemia is",
        "label": "Contradiction"
    },
    "5255cd06-123a-4d45-943d-37b6261b1cf7": {
        "text_answer": "  The statement eating disorders characterized a substantial portion of the primary clinical trial candidates is not entailed in the given trial data The trial data only reports adverse events observed during the study and there is no mention of eating disorders among the reported adverse events Therefore the statement is contradictory to the given trial data",
        "label": "Contradiction"
    },
    "e4f41907-ef20-40aa-bcab-416243280816": {
        "text_answer": "  The statement is not entailed in the trial results provided   The trial results indicate a 40 average reduction in percentage change in Ki67 expression not tumor diameter The dosage of tamoxifen mentioned in the statement is also different 32 mg instead of 20 mg Therefore the statement is not directly supported by the trial results",
        "label": "Contradiction"
    },
    "5976b8b7-0f88-4e52-8ad7-39609dabbf8e": {
        "text_answer": "  The statement is entailed in the trials In the primary trial cyclophosphamide is given in combination with doxorubicin for the first part of the intervention and it is also given in the secondary trial as part of the first neoadjuvant chemotherapy regimen Paclitaxel is given in the primary trial as part of the second part of the intervention CarboplatinNabPaclitaxel and",
        "label": "Entailment"
    },
    "763a61cc-c267-4536-8cfe-a4f97a461e07": {
        "text_answer": "  The given trials do not provide any information about tumour lysis syndrome Therefore the statement is neither entailed nor contradicted by the provided data",
        "label": "Entailment"
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "text_answer": "  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is contradictory to the given data   The primary trial had 1 case of Mucositis Oral 0 cases of epileptic seizures and 1 case of Thromboembolic event The secondary trial had 0 cases of M",
        "label": "Entailment"
    },
    "bc47f5a1-dc20-4df2-bb3e-fa03695c9840": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive radiation therapy for the same duration 2327 fractions and the same total dose range 46004860 cGy The only difference between the two cohorts is the use of Active Breathing Coordination ABC during treatment in Cohort 1 The statement does not mention the use of ABC but it is not contradictory",
        "label": "Entailment"
    },
    "91b12db1-76c1-4863-90df-a95d2af8dfc5": {
        "text_answer": "  The statement thyroid gland hyperfunctioning adenoma is a thyroid gland adenoma producing thyroxin It is associated with hyperthyroidism Radioactive iodine scan reveals a hot nodule is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it does not entail or contradict any information given in the trials  However the statement does mention a condition related to thy",
        "label": "Entailment"
    },
    "699bf83a-8890-43ab-96ea-40f2171c9633": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions Alpha Lipoic Acid in the primary trial and Necitumumab in the secondary trial and do not provide sufficient information to make a definitive statement about the dosing frequency or duration for esophageal fistula specifically However the statement is not contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "1b67d41e-cff6-46ae-b30d-4c254525e9ef": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The statement asserts that the dosage of zoledronic acid in intervention 1 of the primary clinical trial is identical to that of denosumab used in intervention 1 of the secondary clinical trial   In the primary trial the dosage of zoledronic acid in intervention 1 is 4 mg given every 4 weeks Q4W",
        "label": "Entailment"
    },
    "a35f8d94-b561-4644-ad29-2ac0e48ceb79": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is a contradiction to the given trial criteria   In the primary trial the diagnosis of 13 cerebral metastases within the brainstem is a criterion for inclusion as long as they meet the other el",
        "label": "Contradiction"
    },
    "477389de-84aa-4438-87c9-3abccc80e1cb": {
        "text_answer": "  The statement does not directly entail or contradict the given trials as the trials only provide the frequency of adverse events in each trial while the statement compares the types and frequencies of specific adverse events between the two trials The statement implies that there are differences in the types and frequencies of adverse events between the primary and secondary trials but it does not necessarily follow that these differences are entailed or contradict the trials themselves Therefore the statement is neither entailed nor",
        "label": "Entailment"
    },
    "f98c72d2-3fce-42a5-9585-280e8b877708": {
        "text_answer": "  The statement over 42 patients from both groups in the primary clinical trial recorded a pathologic complete response in breast and axillary lymph nodes nearly 7 months postsurgery is not directly entailed in the given trials as the trials only report the number of participants with a pathologic complete response at the time of surgery The trials do not provide information on the number of participants who achieved a pathologic complete response 7 months post",
        "label": "Contradiction"
    },
    "14c1e784-1f79-4ba9-8466-c8c638f929db": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial reports that none of the participants experienced any adverse events while the secondary trial reports that all participants experienced an adverse event These two statements contradict each other as they cannot both be true at the same time",
        "label": "Entailment"
    },
    "1dfb4256-8bef-4128-8cd2-30d5c88a4ac8": {
        "text_answer": "  The statement 25 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is entailed in the trial results if the actual percentage of participants who developed imagable HER2 metastases is 25 or more   The trial results state that 13 out",
        "label": "Entailment"
    },
    "8bdac388-c2bd-4634-9073-6862aaa7a5cf": {
        "text_answer": "  The statement is entailed in the trial description The statement mentions that participants are given four separate drugs throughout the trial which is consistent with the trial description that includes epirubicin cyclophosphamide docetaxel and trastuzumab The statement also mentions a maximum dosage of 100 mgm2 for one of the drugs epirubicin which is also consistent with the trial description that",
        "label": "Entailment"
    },
    "8529eb83-969c-4075-bfe7-efc47fd33d8d": {
        "text_answer": "  The statement a confirmed diagnosis of pancreatic cancer is required for eligibility in the primary clinical trial is entailed in the given inclusion criteria as pancreatic cancer is listed as one of the tumors for which patients are eligible for the trial",
        "label": "Entailment"
    },
    "da8b6738-7194-4d9d-a077-a4aec72945bb": {
        "text_answer": "  The statement is entailed in the trials as given in the input In the trials the dosage of cetuximab is different between cohort 1 and cohort 2 Cohort 1 received a lower dose of cetuximab 12 mgkg compared to cohort 2a 20 mgkg Additionally there is no mention of a collaborative care intervention in cohort 1 Therefore",
        "label": "Entailment"
    },
    "7f53b46f-6ab4-4d59-bc28-b13eca3fb3b3": {
        "text_answer": "  The statement no patients in the primary clinical trial experienced recorded adverse events in contrast to the secondary clinical trial where every participant suffered from a minimum of one adverse event is contradictory to the given data   In the primary trial there were no recorded adverse events out of 42 patients 000 In contrast in the secondary trial every one of the 6 patients 10000 experienced at",
        "label": "Contradiction"
    },
    "e2731b02-ce9d-4bfe-bc8d-9eda951e0e77": {
        "text_answer": "  The statement patients who have undergone treatment with either gabapentin or pregabalin will not be accepted into the secondary clinical trial is a constraint on the secondary clinical trial It does not directly relate to the primary clinical trial but it is independent of the primary trials inclusion and exclusion criteria Therefore the statement is not entailed in the primary trials entailment relationship but it may contradict the secondary trial if a patient has under",
        "label": "Contradiction"
    },
    "9c8b2041-2a99-4f42-93ec-63daed05fe87": {
        "text_answer": "  The statement patients diagnosed with stage 4 cancer may participate in both the primary clinical trial and the secondary clinical trial provided they give informed consent is entailed in the given trials as there is no explicit exclusion of stage 4 cancer patients in either trials inclusion or exclusion criteria However it is important to note that the specific treatment regimens and eligibility criteria for each trial may differ and patients would need to meet all other inclusion criteria and",
        "label": "Entailment"
    },
    "5c7ff5f0-5b40-42e1-8f24-a0bfd6a4b2ef": {
        "text_answer": "  The statement is entailed in the primary trial as both study groups undergo the same imaging procedures using 18FFDG and 18FFPPRGD2 as radiotracers The only differences between the study groups are the types of cancer being investigated and the timing of the imaging followups Therefore the statement is an accurate reflection of the information provided in the trials",
        "label": "Entailment"
    },
    "e32de0e0-4e26-4c73-a6d6-cc5dfafd97c7": {
        "text_answer": "  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is contradictory to the given trial data   Explanation   The trial data for Adverse Events 1 and Adverse Events 2 provide the number of patients who experienced each adverse event and the total number of patients in each trial   Adverse Events 1 had a total of 13 patients",
        "label": "Entailment"
    },
    "f4f39eeb-0db1-40c3-9d45-5c17dabe4998": {
        "text_answer": "  The statement the results of the primary clinical trial indicate that on average participants survived beyond two years with over fifty patients from each cohort outliving 24 months is not directly entailed in the given trial results   The trial results only provide the median survival times midpoint for each group and the number of participants who survived beyond 24 months is not explicitly stated However we can infer that based on the median",
        "label": "Contradiction"
    },
    "ab25ad81-a094-432c-9814-12669bd4cbac": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial inclusion criteria The secondary trial includes subjects with advanced solid tumors that have diagnosed alterations in specific genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ GNA11 andor as a condition for eligibility Therefore",
        "label": "Entailment"
    },
    "98b0c6c3-73c0-40d9-95d7-48e5340aa2f8": {
        "text_answer": "  The statement is entailed in the trials as both trials use the same dose of lenalidomide 5mg orally daily for the same duration 57  3 days However the secondary trial uses a different intervention in addition to lenalidomide lapatinib or trastuzumab plus paclitaxel and the dosages and durations for these interventions differ from the primary trial Therefore while the statement is",
        "label": "Entailment"
    },
    "fcc8d86f-3fba-4398-8c0e-042153fa118e": {
        "text_answer": "  The statement decreased bone tissue is a decrease in the amount of bone tissue as compared to a standard or norm is a fact and is not related to the information provided in the trials   The statement does not entail or contradict the information in the trials as the trials do not provide any information regarding bone tissue or its decrease The trials only mention the interventions normal saline and dexmedetomidine and their respective administrations in",
        "label": "Entailment"
    },
    "99912ce1-aa49-4289-8743-eb1afffe1675": {
        "text_answer": "  The statement childhood thyroid gland medullary carcinoma is a medullary thyroid gland carcinoma occurring in childhood is a factual statement and not directly related to the adverse events data provided in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "8c5d8cfb-c75f-4cb8-af4a-8100726f2a12": {
        "text_answer": "  The given statement is not entailed in the trials provided The median survival periods for both groups are greater than 1 year Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "09904e7f-5e34-44b1-9edb-f92c3edcda95": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The primary trial compares operative time savings between Intraoperative Mammography and Standard Mammography The operative time in the Intraoperative Mammography group was found to be shorter than in the Standard Mammography group 2 The secondary trial does not directly compare the two groups from the primary trial but instead focuses on the success rate of TEADM With",
        "label": "Entailment"
    },
    "3b1906b0-5212-4341-b6cd-3163456ce44a": {
        "text_answer": "  The statement is contradictory to the trials provided   The primary trial states that patients received 120 milligrams of denosumab injected subcutaneously every 4 weeks which is equivalent to 480 milligrams per year The secondary trial mentions the administration of 01 to 15 mCi of radioactive Tc99M sulfur colloid which is not related",
        "label": "Entailment"
    },
    "a24e8008-affe-44f7-a6f1-56e817ffdde3": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is entailed in the given trials as there is no mention of any deaths or hospitalizations in the trials  However the statement the only AEs recorded were 3 cases of Lymphoma is not exactly entailed in the trials as the trials only report the number of cases for each trial but they do not specify that these were the only ad",
        "label": "Contradiction"
    },
    "c5534047-9025-410f-a641-43819cc1ce23": {
        "text_answer": "  The statement There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial is not directly entailed or contradicted by the given trials as they do not provide sufficient information to make such a determination based on substance dispersity alone The trials only report the number and types of adverse events in each trial but they do not provide any information about the relationship between substance dispersity and the occurrence of these adverse events",
        "label": "Contradiction"
    },
    "12746144-95c9-4656-abdf-8a49f78c7049": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is not directly entailed nor contradictory to the information provided in the inclusion and exclusion criteria of the primary trial The statement pertains to a separate issue which is not related to the eligibility criteria for the trial The statement is neither entailed nor contradictory to the trial information",
        "label": "Contradiction"
    },
    "e8d33476-b6f1-4337-8072-c07e4f223275": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the administration of CUDC101 only without any additions of other therapeutic treatments",
        "label": "Entailment"
    },
    "24630f41-fd07-4b3d-a0f6-66282c5c3a07": {
        "text_answer": "  The statement the secondary clinical trial has reported marginally higher total adverse events in patient groups compared to the primary clinical trial is a contradiction to the given data in the trials  Explanation  The given data states that the total adverse events for both trials are 00 for Adverse Events 1 in the primary trial and 015 000 in the secondary trial The statement suggests a difference in the",
        "label": "Contradiction"
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "text_answer": "  The statement Patients with TX NX MX T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial is not directly stated in the given trial criteria However the trial criteria do not explicitly exclude these tumor stages so it can be inferred that they are eligible based on the general eligibility criteria for histologically confirmed breast cancer with hormone receptor positivity and the specified patient characteristics Therefore the",
        "label": "Entailment"
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "text_answer": "  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is a contradiction of the given data  Explanation  The statement implies that the percentage of adverse events related to blood and bone marrow is less in the secondary trial compared to the primary trial However the data provided shows that the percentage of adverse events related to blood and bone mar",
        "label": "Contradiction"
    },
    "b45a503d-d4db-4f8d-aefa-37cf2bbc6011": {
        "text_answer": "  The statement among the participants of the primary clinical trial maculopapular rash was often reported as an adverse event is entailed in the given data as the adverse event Rash maculopapular was reported 1 time out of 30 participants 333",
        "label": "Entailment"
    },
    "a1d9b33e-fe46-421d-87e8-e0ecbfed7686": {
        "text_answer": "  The statement is entailed in the trials as both trials use different methods to assess study outcomes The primary trial utilizes the Change From Baseline in Patientspecified and Reported Symptoms on the Measure Yourself Medical Outcome Profile MYMOP while the secondary trial measures the Change in Isothiocyanate in Urine Samples Therefore the statement is an accurate reflection of the information provided in the trials",
        "label": "Entailment"
    },
    "136bc454-b432-45f9-909b-e588f2dc6c60": {
        "text_answer": " The given statement is a strong negation of the primary trial results which is not directly entailed in the provided information The trials only report the number of participants with pathologic complete response in each arm of the study but they do not report that all participants in both arms had no response Therefore the statement is contradictory to the trials findings",
        "label": "Contradiction"
    },
    "9f382aed-4a54-40c2-92ca-fb17411e4923": {
        "text_answer": "  The statement is not entailed in the given trials as the interventions and the procedures involved in each trial are different The primary trial is about the administration of denosumab while the secondary trial is about the use of pIHGC and GP during lymphoscintigraphy which involves the injection of radioactive Tc99M sulfur colloid The statement only mentions the injection of denosumab and radioactive Tc9",
        "label": "Contradiction"
    },
    "1d66b8cc-1e7e-4a88-bd39-695528aa5894": {
        "text_answer": "  The statement patients suffering from mild insomnia are eligible to participate in the primary clinical trial and the secondary clinical trial is entailed in the trials as there is no mention of insomnia severity as an exclusion criterion in the inclusion criteria for either trial However it is important to note that the secondary trial has specific inclusion criteria related to insomnia severity a score of 3 on the Sleep Disruption Evaluation form or a score",
        "label": "Entailment"
    },
    "f9a8b80a-3191-4f53-865b-1ab2154174ad": {
        "text_answer": "  The statement in the primary clinical trial under a tenth of the participants experienced a decline in circulating tumor cells after months of highdose chemotherapy accompanied by purged autologous stem cell products is not directly entailed in the provided trial results   The results only report the number of participants with a reduction in CTCs one month post AHST not after months of treatment Additionally the statement does not specify which",
        "label": "Contradiction"
    },
    "d3ccfad5-d5c9-4bdb-a69e-dca916dc5da5": {
        "text_answer": "  The statement can participate in both the primary and secondary clinical trials   Explanation   The statement meets the inclusion criteria for both trials   For the primary trial the individual meets the following criteria  Histologically verified diagnosis of breast cancer  Appropriate diagnostic workup completed including CBCdifferential serum creatinine total bilirubin and pregnancy test  Age of 18",
        "label": "Entailment"
    },
    "0cecee52-d87e-419a-a970-e79733613a87": {
        "text_answer": "  The statement only caucasian patients are eligible for the primary clinical trial is not entailed in the given inclusion criteria for the dose escalation and expansion phase of the clinical trial The criteria specify various demographic and diseaserelated conditions for eligibility but there is no mention of race or ethnicity as a requirement Therefore the statement is contradictory to the information provided in the clinical trials inclusion criteria",
        "label": "Contradiction"
    },
    "f4d73533-5e6a-403c-ad63-3882890b7e94": {
        "text_answer": "  The statement is entailed in the given information as there is no record of adverse events in the primary clinical trial mentioned in the text Therefore it is impossible to make a comparison between the adverse events in the primary and secondary trials",
        "label": "Entailment"
    },
    "be63170c-5a52-4d85-b824-54ceca90684a": {
        "text_answer": "  The statement experiencing the conditions of both claustrophobia and IBS disqualifies women from the primary and secondary clinical trials is not directly entailed or contradicted by the given trials inclusion and exclusion criteria   The primary trials exclusion criteria do not mention claustrophobia or IBS and the secondary trials exclusion criteria only mention claustrophobia Therefore the",
        "label": "Contradiction"
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   The statement suggests that both the placebo and Trabectedin interventions are administered on a biweekly basis with a 3hour intravenous infusion However the trial information indicates that the placebo is administered on Day 1 while Trabectedin is administered on Day 2 This means that they are not",
        "label": "Entailment"
    },
    "7c0a99c5-b76f-438c-a93b-15d3340cd430": {
        "text_answer": "  The statement the outcome from the bevacizumab  capecitabine cohort of the primary clinical trial were superior to those of the bevacizumab cohort is not directly entailed in the given trial data   The trial data only provides the percentage of participants with disease progression or death in each cohort during the maintenance phase of the study It does not provide sufficient information to determine if the outcomes were superior",
        "label": "Contradiction"
    },
    "383e310f-a7a5-49f5-ae10-ddf49eee92df": {
        "text_answer": "  The statement candidates limited in their ability to selfcare and who spend over 50 of their waking hours confined to a bed or chair are suitable to participate in both the primary clinical trial and the secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for either trial   The primary trials inclusion criteria state that patients must have an Eastern Cooperative Oncology Group ECOG performance status of",
        "label": "Contradiction"
    },
    "429f2754-6edc-4969-99f3-7507b76e443a": {
        "text_answer": "  The statement in the primary clinical trial all group outcomes showed no considerable variations but the reflexology group and control group displayed some significant differences in the secondary clinical trial is a compound statement consisting of two parts   The first part of the statement all group outcomes showed no considerable variations is not directly entailed or contradicted by the information provided in the primary or secondary trials The primary trial only compares the diagnostic accuracy of two algorithms in breast cancer diagnosis",
        "label": "Contradiction"
    },
    "f2b4adf3-ccbc-4bea-94a6-50887d7aeea0": {
        "text_answer": "  The statement on average patients from the primary clinical trial do not survive beyond 2 years and there were no cases where any patient from either cohort died in under 2 years is not entailed in the given trials as the trials do not provide sufficient information to make such a conclusion The trials only report the median survival times for each group and the statement makes a generalization about all patients in the trial surviving below a certain threshold which is not directly addressed in",
        "label": "Contradiction"
    },
    "da91286b-3029-475f-a919-e33629a5a972": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is not directly entailed or contradicted by the given trial data   The trial data only provides the number and types of adverse events observed during the study but it does not specify which participants experienced both a gastrointestinal event and two or more psychiatric events Therefore based on the given",
        "label": "Contradiction"
    },
    "dbf8020d-57c3-45fb-ab31-5c97f293a248": {
        "text_answer": "  The statement is entailed in the primary trial as the patient does not meet the following inclusion criteria  1 ANC level of 1800 cellsmm3 2 Platelets level of 60000 cellsmm3 3 Hemoglobin level of 80 gdl  The patient also does not meet the life expectancy requirement of 6 months for both trials  There",
        "label": "Entailment"
    },
    "d54a1b83-ecd6-4160-a839-1bddf6a12cc5": {
        "text_answer": "  The statement is contradictory to the given trials as both the primary and secondary trials involve intravenous administration of interventions cabergoline in the primary trial and pixantrone dimaleate in the secondary trial There is no mention of any topical interventions in either trial",
        "label": "Contradiction"
    },
    "c19b9a3f-acda-4e83-80db-0f4d3383d909": {
        "text_answer": "  Lets calculate the number of cases for hepatotoxicity hypertension and pancreatectomy based on the given information   Hepatotoxicity 38  0375  Hypertension 18  0125  Pancreatectomy 18  0125  The statement says that there were 0",
        "label": "Entailment"
    },
    "427a4e1a-14ee-441a-b2af-b45b01356921": {
        "text_answer": "  The statement persons with stage 4 cancer cannot take part in the secondary clinical trial but are fit for the primary clinical trial is contradictory to the information provided in the given inclusion criteria for both trials  In the primary trial the inclusion criteria state that patients with histologically verified diagnosis of stage IIbIIIIV breast cancer are eligible for participation This means that persons with stage 4 cancer are included in the primary trial  However",
        "label": "Entailment"
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the mean arm circumference changes between the acupuncture and waitlist groups at the 6week timepoint   The mean arm circumference change for the acupuncture group was 045 cm from 474 cm at baseline to 429 cm at 6 weeks and for the waitlist group was 0",
        "label": "Entailment"
    },
    "137f2083-e958-4c81-a4c8-338c90dda9c9": {
        "text_answer": "  The statement is entailed in the trials as the primary trial is about the use of oral pregabalin and the secondary trial is about a different treatment method involving Depocyt and HDMTX The statement correctly identifies that there are different interventions in each trial",
        "label": "Entailment"
    },
    "f693e25f-c128-48d1-883d-488248b8347d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial specifies that each treatment cycle is defined as 21 days which is approximately 3 weeks Therefore it does not use a 10week cycle for its intervention The secondary trial does not have a cyclic treatment specified as stated",
        "label": "Entailment"
    },
    "1fece1ef-3bb6-407c-a09c-d615922822db": {
        "text_answer": "  The statement the number of total adverse events reported in the primary trial is higher compared to the secondary trial and in addition the primary trial reported less instances of cardiacischemiainfarction in comparison to the secondary trial is a compound statement made up of two parts Lets verify each part separately  1 The number of total adverse events reported in the primary trial is higher compared to the secondary trial  From the given data",
        "label": "Entailment"
    },
    "31b0b1db-0d40-44fe-aa76-ce3cdca8e31b": {
        "text_answer": "  Anorexic patients are not eligible for the primary trial according to the given inclusion and exclusion criteria The criteria state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs Anorexia is a condition characterized by a significantly low body weight often less than 85 of the expected body weight for height and age Therefore anorexic patients do not meet the inclusion criteria for BMI",
        "label": "Entailment"
    },
    "fb8e290e-f73a-46e1-86b1-3a1d13eab0ab": {
        "text_answer": "  The statement an adult patient diagnosed with ILDDPLD within the last 3 years with a life expectancy of 6 months would be eligible for the primary trial is contradictory to the trials inclusion criteria   The reason is that the trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are ineligible Therefore a patient diagnosed with ILDDPLD within the last",
        "label": "Entailment"
    },
    "77c27725-099d-4d66-947c-f03e9193b6bf": {
        "text_answer": "  The statement was mgmt promoter methylation testing performed is not directly entailed in the given trials as there is no mention of mgmt promoter methylation testing in either the primary or secondary trials However the trials do not contradict the statement as it is not explicitly stated that mgmt promoter methylation testing was not performed Therefore the statement is neutral with respect to the trials",
        "label": "Contradiction"
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "text_answer": "  The statement There are less total adverse events in the primary trial than in the secondary trial but more cases of Cardiacischemiainfarction in the primary trial than in the secondary trial is a compound statement made up of two parts Lets verify each part separately  1 There are less total adverse events in the primary trial than in the secondary trial  The given data shows that there are 0 adverse events",
        "label": "Entailment"
    },
    "2884c912-af96-4bac-9b0e-29f1d0876abc": {
        "text_answer": "  The statement is not entailed in the trials as they address different interventions The primary trial is focused on Radioembolization using TheraSpheres while the secondary trial is investigating the combination of ibrutinib and MEDI4736 The statement mentions a different topic which is the location of a chromosome band and does not directly relate to the interventions described in the trials Therefore the statement is neither entailed",
        "label": "Contradiction"
    },
    "f83fe0ea-4d77-4db1-a66d-eb0df033a592": {
        "text_answer": "  The statement candidates eligible for the primary clinical trial have been diagnosed with lung cancer is contradictory to the given inclusion and exclusion criteria   The inclusion criteria state that candidates must have breast cancer that has continued to grow after receiving hormonal treatment and require hormonal treatment as well as being postmenopausal The exclusion criteria state that candidates cannot have received more than one previous regimen of systemic anticancer therapy other than endocr",
        "label": "Entailment"
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "text_answer": "  The statement is entailed in the trials as the primary trial tests Eribulin Mesylate and the secondary trial tests a combination of Axitinib and Docetaxel which are different drugs",
        "label": "Entailment"
    },
    "1046f15f-8bef-4d73-99a1-34ab32da6ea6": {
        "text_answer": "  The statement there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is not directly entailed in the given trials as the trials do not provide sufficient information about the occurrence of shingles in the vasectomy reversal procedures specifically However the statement is not contradictory to the trials as well since the trials do not mention the absence of shingles in the patient coh",
        "label": "Contradiction"
    },
    "ffbff911-ea0e-4f8b-97fd-a54b8f88007a": {
        "text_answer": "  The statement is not directly entailed in the given trials as there is no comparison of the dosages of Herceptin MM121 and Doxorubicin between the primary and secondary trials However the statement is partially correct regarding the weekly dosages of MM121 and Paclitaxel In the primary trial the number of individuals having mastectomy surgery is given but the details of the interventions are not specified",
        "label": "Contradiction"
    },
    "1022a719-eef0-4fbe-ac15-b0398adbf45b": {
        "text_answer": "  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is neither entailed nor contradicted by the given information   The statement only mentions the absence of anorexia hypothermia and hallucinations as adverse events The given information only reports the number of cases of these specific adverse events for the primary and secondary trials",
        "label": "Contradiction"
    },
    "dd0571e3-088c-4dc7-a47a-175210514286": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe two different interventions one with AlloMSCs and another with a placebo Buminate solution The doses and administration methods are also different for each intervention The statement suggests that both interventions are administered in the same dose by a single transendocardial injection which is not the case based on the information provided in the trials Therefore the statement is contrad",
        "label": "Entailment"
    },
    "e137a0db-0a15-4dd0-9fa2-3a8558c7ef0a": {
        "text_answer": "  The statement All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is not directly related to the information provided about the doses of PF06647020 in the primary and secondary trials Therefore it cannot be determined if this statement is entailed or contradicted based on the given information alone  However the statement does not contradict the information provided as there is no mention of",
        "label": "Entailment"
    },
    "0cc7e297-b7df-4260-9ddf-f406bb3c2485": {
        "text_answer": "  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is entailed in the given trials as  1 The total number of adverse events in both trials is a sum of the adverse events in each trial 2 The number of patients who did not suffer any adverse events is the total number of patients minus the total number of adverse events 3 In both trials",
        "label": "Entailment"
    },
    "8c51b6e1-ee26-44a5-b63b-3c180b7dddd2": {
        "text_answer": "  The statement there were profound differences in the results from the groups in the primary clinical trial while the reflexology group and control group in the secondary clinical trial displayed contrasting results is not directly entailed in the given trials as they focus on different outcome measures and populations The primary trial compares the diagnostic accuracy of two mammography algorithms while the secondary trial investigates the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy Therefore",
        "label": "Contradiction"
    },
    "b3fc2b80-128b-4236-b1d5-a89b93e54b48": {
        "text_answer": "  The statement All patients treated with GTx024 1mg in the primary trial gained Lean body Mass over a 4 month period is not directly entailed in the given trials as the trials only report the median change in lean body mass for each group not every individual patients gain or loss The median value for the GTx024 1mg group is 155 kg with a range of 206",
        "label": "Contradiction"
    },
    "972a66e9-09cc-4091-8c60-fa8f458955aa": {
        "text_answer": "  The statement is entailed in the given trials as follows  In Intervention 1 the dose of cyclophosphamide C is 600 mgm2 and the dose of eribulin Er is 14mgm2 In Intervention 2 the dose of cyclophosphamide C is also 600 mgm2 but the dose of doc",
        "label": "Entailment"
    },
    "5a954b09-cbc7-47dd-891c-4c998eb72979": {
        "text_answer": "  The statement participants in cohort 1 of the primary clinical trial are not administered with pneumococcus vaccine is a contradiction to the information given in the Intervention 1 description In Intervention 1 it is stated that Adult Cancer Patients 65 Years of Age and Older are the participants but it does not mention anything about them not receiving the pneumococcus vaccine Therefore the statement is",
        "label": "Contradiction"
    },
    "1cbd0ac2-bfb8-4649-afea-ae028707f190": {
        "text_answer": "  The statement lymphedema conditions of patients in the primary clinical trial worsened compared to those of patients on the waiting list despite receiving acupuncture treatment is contradictory to the information provided in the trials  The trials show that the mean arm circumference of patients in the acupuncture group decreased from 474 cm baseline to 429 cm 6 weeks indicating improvement in lymp",
        "label": "Entailment"
    },
    "8dc6e902-3dae-4bea-ba4b-605df19fabc1": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial and the secondary trial involve different interventions The primary trial focuses on Yttrium90 Radioembolization using TheraSphere while the secondary trial explores the combination of ibrutinib and MEDI4736 Therefore the statement accurately reflects the difference in interventions between the two trials",
        "label": "Entailment"
    },
    "0f6ce079-990e-446e-95e9-8c4644291924": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial having a mammography is a mandatory requirement for prospective candidates inclusion criteria Mammography completed on a General Electric GE GE FFDM system with craniocaudal CC and mediolateral oblique MLO views at the site or another clinical facility Therefore it is a necessary condition for participation in the primary trial ",
        "label": "Entailment"
    },
    "06e6eb2b-8300-413b-9c70-51fadbc68bbc": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than one patient is not directly related to the chromosome band 14q231 mentioned in the text Therefore it cannot be entailed or contradicted based on the information provided in the text alone The statement only pertains to the adverse events recorded in the primary trial",
        "label": "Entailment"
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial measure the percentage of participants in their studies that experience Clinical Benefit using RECIST criteria is a contradiction to the primary trial results as the primary trial does report the percentage of participants with tumor response using RECIST criteria Partial Response Stable Disease and Progressive Disease Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "fc211cd7-389a-4040-9c92-e06672257460": {
        "text_answer": "  The statement patients in the primary clinical trial that received paclitaxel infusions and those who didnt exhibited the same severity of symptoms is contradicted by the trial results   The results show that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 indicating an improvement in symptoms on average while the median aAUCpa for the",
        "label": "Contradiction"
    },
    "230818a6-3a37-4bb6-933b-39a7e9a45054": {
        "text_answer": "  The statement patients possessing detectable tumors in both breasts cannot participate in the primary clinical trial is not directly stated in the given inclusion and exclusion criteria However the criteria do exclude patients with active or metastatic cancer which could include those with bilateral breast cancer Therefore the statement is implied but not explicitly stated in the criteria  So the statement is entailed in the trial criteria but it is not stated directly",
        "label": "Entailment"
    },
    "fa510ac9-2d92-4396-a150-18dd46a31260": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial documented identical numbers of adverse events among their patient populations is entailed in the given trials data if and only if both trials have a total of 0 adverse events   If both trials have 0 adverse events each then the statement is true  However if the primary trial has 0 adverse events but the secondary trial has 1 adverse event then the statement is false",
        "label": "Entailment"
    },
    "6b8445e6-9bc6-4a57-ab24-05d99e082061": {
        "text_answer": "  The statement fewer participants enrolled in the paclitaxel plus bevacizumab plus gemcitabine group than in the paclitaxel plus bevacizumab group is not directly related to the given trial results The trials provide information on the overall response rates ORR for each treatment group but they do not mention the number of participants enrolled in each group Therefore the statement cannot be entailed or contradicted",
        "label": "Entailment"
    },
    "966e1258-879d-4e8d-88ec-777a743e191d": {
        "text_answer": "  The statement fgfr2 gene mutation negative is a genetic finding indicating that fgfr2 gene mutations have not been detected in a sample is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "0e57fc4c-1a5b-4f88-900e-122c03fcedb4": {
        "text_answer": "  The statement In total there are less cases of anemia in the primary trial than in the secondary trial is a comparison of the number of anemia cases between the two trials The trials provided do not mention any information about fgf3 gene mutation Therefore the statement is not entailed in the trials with entailment or contradiction",
        "label": "Contradiction"
    },
    "980fb8cd-9ba0-4bac-a2ae-0aea58c2f837": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial had a smaller patient count compared to cohort 2 of the secondary trial is not directly stated in the provided information However we can determine this by comparing the number of participants analyzed in each cohort  Primary Trial Cohort 2 Waitlist Control had 75 participants Secondary Trial Cohort 2 Device  SOC",
        "label": "Entailment"
    },
    "4b529950-5a15-4904-8f87-1aa68f408b8d": {
        "text_answer": "  The statement patients with advanced stage of ductal carcinoma not contemplating AI therapy are eligible for the primary clinical trial is contradictory to the inclusion criteria of the trial The trial specifically includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast who are considering aromatase inhibitor therapy Therefore patients with advanced stage ductal carcinoma not contemplating AI therapy are not eligible for the trial according",
        "label": "Entailment"
    },
    "f0d4e862-c9a1-48f4-9e4f-ddc67b35bbe0": {
        "text_answer": "  The statement is entailed in the trials as the primary trial and the secondary trial measure different outcomes and use different units of measure The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH using the unit of measure mIUml while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD using the unit of measure mg Therefore the trials are assessing",
        "label": "Entailment"
    },
    "c2ba74e0-9674-4974-a0ea-74651dbdbbf6": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy is entailed in the trials based on the provided results   The results show that the median aAUCpa for the Sensory Neuropathy subscale in Arm I Cryotherapy was 14 117 to 68 while in Arm II Control",
        "label": "Entailment"
    },
    "5e3fa8fd-a886-411d-8de0-fcbf6ef953fb": {
        "text_answer": "  The statement colon nonhodgkin lymphoma is an extranodal nonhodgkin lymphoma that arises from the colon The majority are bcell nonhodgkin lymphomas The secondary trial candidates must be Completely disabled to participate whereas this is not required to be accepted into the primary trial is not directly entailed nor contradictory to the information provided in the trials inclusion",
        "label": "Contradiction"
    },
    "db5cde14-102d-432e-981d-8b88ae65a830": {
        "text_answer": "  The statement the patient cohorts of the primary clinical trial and the secondary clinical trial have reported 7 cases of asthenia and 2 cases of pyrexia is not entailed in the given trials data as there is no mention of asthenia or pyrexia in the trials data The statement contradicts the trials data as the trials data reports no cases of asthenia or pyrexia for either trial",
        "label": "Contradiction"
    },
    "fe9b1db5-8600-469a-ba9f-c0aab4630041": {
        "text_answer": "  The statement 18 years olds are excluded from the secondary trial but the primary trial does not specify an age range for participation is neither entailed nor contradicted by the given trials   Explanation  The primary trial includes patients who are presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston without specifying an age range The secondary trial on the other hand includes",
        "label": "Entailment"
    },
    "5c253fd8-303a-4b91-b21f-e7e77c30f14a": {
        "text_answer": "  The statement There are 7 more participants in cohort 2 of the primary trial than in cohort 1 is not directly entailed or contradicted by the given information However we can determine the number of participants in each armgroup by adding the Overall Number of Participants Analyzed for each group   From the given information there were 234 participants in Arm I and 241 participants in Arm",
        "label": "Contradiction"
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "text_answer": "  The statement is entailed in the given trial information as both interventions Memantine and Placebo are administered twice daily BID for a duration of 81 days days 181 Therefore the statement is entailed in the trial information",
        "label": "Entailment"
    },
    "9fad2ea9-39ad-4c5b-afbe-82d9c40dbeee": {
        "text_answer": "  The statement Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial is not directly addressed in the given inclusion and exclusion criteria for both trials Therefore it cannot be determined if the statement is entailed or contradicted based on the information provided  Regarding the second part of the statement 7q313q32 is a chromosome band present on 7q it is a",
        "label": "Entailment"
    },
    "c7037258-f24b-40dd-9ce8-5026b019bfbe": {
        "text_answer": "  The statement neither intestinal obstructions nor pancytopenia has been observed within the patient cohorts of the primary and secondary clinical trials is entailed by the given data since the data reports that there have been no instances 000 of intestinal obstructions or pancytopenia in either trial",
        "label": "Entailment"
    },
    "8ffc6641-8eb9-4e6d-8926-0356539e0ba6": {
        "text_answer": "  The statement primary clinical trial study groups will engage in different imaging procedures including 18FFEP PETCT and 18FFMIso PETCT is not entailed in the given trials as there is no mention of 18FFEP or 18FFMIso in the trials provided The trials only mention the use of 18FFDG and 18FFP",
        "label": "Contradiction"
    },
    "11f26a4a-7ff7-4cbd-b5c7-b95cfea182df": {
        "text_answer": "  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is not entailed in the given trials as there are no instances of Acute myocardial infarction reported in either the primary or secondary trials Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "169ae179-8a24-4f8f-82b6-47ed449d8e2e": {
        "text_answer": "  The statement is entailed in the trials as the trials provide information about two different studies with distinct outcomes The primary trial focuses on the number of participants with treatmentemergent adverse events in the Test and Control groups of a study involving fosnetupitantpalonosetron and netupitantpalonosetron respectively The secondary trial on the other hand measures the change in total sleep time in minutes using polysomnography",
        "label": "Entailment"
    },
    "9b0c9133-a13c-4687-bf43-546312ce1a2f": {
        "text_answer": "  The statement patients without any type of cancer may participate in the primary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria only specify the conditions for patients with breast cancer who are eligible to participate in the trial It does not mention anything about patients without cancer Therefore the statement is neither entailed nor contradicted by the given criteria",
        "label": "Entailment"
    },
    "8c2ec196-18f6-4a3f-b2fd-6eb6f65d1c60": {
        "text_answer": "  The statement for entry into the primary clinical trial participants are required to possess a resistance to both AI therapy and mirtazapine however this requirement is not present for inclusion in the secondary clinical trial is a statement of difference between the two trials This statement is not entailed in the given inclusion and exclusion criteria of both trials as the criteria for each trial are presented separately Therefore the statement is not a logical entailment or contradiction of the given",
        "label": "Contradiction"
    },
    "f0e6f9c3-4f87-4a91-af2e-9bb7cc2de985": {
        "text_answer": "  The statement is entailed in the trials as the primary and secondary trials involve different pharmacological interventions The primary trial investigates the use of Abl Cells and Cyclophosphamide while the secondary trial investigates the use of 4Demethyl4cholestryloxycarbonylpenclomedine Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "4c4e621c-abe5-4a19-b517-31778992b424": {
        "text_answer": "  The statement no patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR or a confirmed partial response PR is a contradiction to the results reported in the trial  The trial reported that out of 53 participants in the lapatinib 1000 mg  nabpaclitaxel armgroup the overall number of",
        "label": "Contradiction"
    },
    "b6084ccd-2ece-4e27-b783-64ade24880bb": {
        "text_answer": "  The statement is not directly entailed in the given trial information as the trials do not mention anything about retinopathy of prematurity or its stages in their interventions or eligibility criteria The statement is an unrelated medical condition and its presence or absence does not affect the trial outcomes Therefore the statement is neither entailed nor contradicted by the given trial information",
        "label": "Contradiction"
    },
    "5e74a97b-ae6e-478b-bcf1-f681159ea1f7": {
        "text_answer": "  The statement over 05 patients in the primary trial treated with lapatinib 1000 milligrams  nabpaclitaxel experienced a confirmed complete response CR is not directly entailed in the provided information The trial results only state that 53 of the 60 participants 883 had an OR CR or PR without specifying how many of those participants had a CR Therefore the",
        "label": "Contradiction"
    },
    "bd8a6fc5-ffc7-460f-a82c-9656047eafbc": {
        "text_answer": "  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed in the given trials as they do not provide sufficient information to make that comparison The trials only report the percentage of participants with a decrease in the growth factor signature for each group but they do",
        "label": "Contradiction"
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "text_answer": "  The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify the tumor size However the statement in question is about patients with a breast tumor 0208 cm in diameter Therefore the statement is not directly entailed in the trials as they do not address this specific tumor size  However the statement is not contradictory to the trials either as the inclusion criteria for",
        "label": "Contradiction"
    },
    "af5daeb0-69f5-4d1c-93a5-7a76dfb4b5e7": {
        "text_answer": "  The statement participants in cohort 2 of the primary clinical trial will also view the educational DVD instead of receiving a regular dosage of radiotherapy is a contradiction to the information provided in the trial description   In the trial description the intervention for cohort 1 includes viewing the educational DVD and meeting with a lay health advisor while the control group receives usual care without the DVD or lay health advisor There is no mention of",
        "label": "Contradiction"
    },
    "09af4485-0e64-4a6c-83d3-1e7231151faa": {
        "text_answer": "  The statement only 3 patients from cohort 1 of the primary clinical trial had maintained regular cervical cancer screenings prior to the intervention is not directly stated in the provided trial results However it can be inferred from the data that the baseline cervical cancer screening percentage for cohort 1 Collaborative Care Intervention was 423 This means that more than 577 of the participants in this",
        "label": "Entailment"
    },
    "3647e40b-92d1-4e99-aedf-8416c91576c8": {
        "text_answer": "  The statement is entailed in the primary clinical trial as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort make use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring breast perfusion at three separate time points during the surgical procedure However they differ in the type of incision used Therefore the statement is partially entailed in",
        "label": "Entailment"
    },
    "54f0a585-98f8-49c2-a6b3-2700b3fc19ff": {
        "text_answer": "  The statement is entailed in the given trials as both trials involve intravenous injections and MRIs However the specific drugs dosages and administration frequencies differ between the trials Therefore the statement is entailed but not identical to the trials details",
        "label": "Entailment"
    },
    "269ac84f-d5a9-475f-8c43-361a6cdb5225": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial employ cm participant count or time unit as their measurement units is entailed in the given information   The primary trial measures the change in severity of vaginal symptoms using a 5point ordinal response scale with units of change in units on a scale ranging from 4 to 1 This is not measured in cm or participant count   The secondary trial measures",
        "label": "Entailment"
    },
    "92639a0e-c3b4-4057-8bb5-aeaf1d60c39b": {
        "text_answer": "  The statement unexpected deaths or hospital stays were not recorded in both the primary clinical trial and the secondary clinical trial is not directly entailed in the given data The data only provides information about the occurrence of adverse events specifically those related to lymphoma and the number of participants affected It does not mention any unexpected deaths or hospital stays Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "b36dca2b-8c53-4f4d-b956-0d86194d2d2d": {
        "text_answer": "  The statement diarrhea was equally common in both primary and secondary clinical trial participants is contradicted by the given data   Explanation   The primary trial had 7 cases of diarrhea out of 30 participants which is 2333 The secondary trial had 0 cases of diarrhea out of 6 participants Therefore the frequency of diarrhea in the primary trial is more",
        "label": "Contradiction"
    },
    "4d604e71-ced3-43a1-baf7-276573a3a901": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information   Explanation   The statement makes a comparison between cohort 1 and 2 based on the length of the intervention but it does not mention anything about the religious matters The trial information only provides details about the radiation therapy and the use of Active Breathing Coordinator ABC in cohort 1 and the absence of ABC in cohort",
        "label": "Entailment"
    },
    "c7320872-347d-445f-a939-9554e7ee9973": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information   Explanation   The statement in the primary clinical trial both cohort 1 and cohort 2 are given an identical dose of cudc101 is true in the sense that both cohorts receive the same mgm2 dose 275 mgm2 However the frequency of administration is different between the two",
        "label": "Entailment"
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "text_answer": "  The statement is entailed in the trials as both trials include a performance status requirement for participation However they use different performance status scoring systems in each trial Therefore the statement is entailed but not identical",
        "label": "Entailment"
    },
    "81d8da2f-add7-4c32-bc69-8eb22266f71e": {
        "text_answer": "  The statement the first cohort of the primary clinical trial didnt document any adverse events is entailed in the given data if we interpret it as follows  1 The term adverse events refers to any unfavorable or unintended sign symptom or disease occurring in a patient administered a pharmaceutical product or undergoing a treatment 2 The term documented means recorded in the clinical trial report",
        "label": "Entailment"
    },
    "89c76808-d0fb-4c78-8364-344d6b65754b": {
        "text_answer": "  The statement is contradictory to the information provided in the primary clinical trial In the trial there are two study groups one for Glioblastoma Multiforme and another for Gynecological Cancers Both study groups undergo 18FFDG and 18FFPPRGD2 PETCT or PETMRI imaging at specified time points Therefore it is not accurate to state that only one study group",
        "label": "Entailment"
    },
    "d2057876-3991-462d-b5fd-de01cc252790": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial is not given additional treatment cycles of docetaxel doxorubicin and cyclophosphamide is entailed in the trial description for Intervention 2 ACTH In this intervention cohort 2 receives docetaxel and Herceptin after the initial AC cycles but there is no mention of additional cycles of doxorubicin and cyclophosph",
        "label": "Entailment"
    },
    "d5786123-b433-4fdd-abad-4410de2695c9": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference in interventions between the two cohorts in terms of the drugs and dosages used",
        "label": "Entailment"
    },
    "f49abd8e-7440-40ec-a512-c2420c9a207b": {
        "text_answer": "  The statement Patients with measurable tumors in both breasts are excluded from the primary trial is entailed in the given trial as it is explicitly stated in the inclusion criteria that unilateral breast cancer is required for participation in the study   The second statement mixed endometrial stromal and smooth muscle neoplasm is a rare primary neoplasm of the uterine corpus characterized by the presence of endometrial stromal",
        "label": "Entailment"
    },
    "373d0081-e7cf-4a06-bdd0-b58bcd4fe34c": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial description specifies that participants will receive several injections including dendritic cell injections GMCSF injections and trastuzumab infusions Therefore the statement that participants in the primary clinical trial will not receive any injections during the study is contradictory to the information provided",
        "label": "Entailment"
    },
    "c158ee0a-2ff1-483d-a906-6dcbb76fae47": {
        "text_answer": "  The primary clinical trial involves the administration of pembrolizumab every 3 weeks Q3W while the secondary clinical trial involves the administration of sunitinib once daily   To determine if the statement is entailed or contradicted we need to compare the frequencies of administration for each drug in both trials   The frequency of pembrolizumab administration in the primary trial is Q3W which is equivalent to every 3",
        "label": "Entailment"
    },
    "dee869cc-6f3c-45a5-9672-d8ab6a545212": {
        "text_answer": "  The statement only 1 of the patients in the primary clinical trial dealing with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab results in her2 metastases is not directly entailed in the provided trial results   The trial results only provide the percentage of participants with HER2 primary breast cancer who developed imagable HER2 metastases after undergoing",
        "label": "Contradiction"
    },
    "a6dd31e3-d055-4343-9d7f-8d141f7c7007": {
        "text_answer": "  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed in the given trials as the trials only provide the percentage of participants with a decrease in the growth factor signature for each group but they do not provide the actual numbers of participants or the difference between",
        "label": "Contradiction"
    },
    "ae134e5a-97f7-4c42-9135-ea44d3d45939": {
        "text_answer": "  The statement Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list is entailed in the trials provided as the trials show that the acupuncture group had a greater reduction in mean arm circumference indicating improvement in lymphedema compared to the waitlist group at the 6week followup The trials do not provide information about vestibulococh",
        "label": "Entailment"
    },
    "3ebd71b1-9b66-438a-9623-27aaf0725786": {
        "text_answer": "  The statement a patients nationality ethnicity mental conditions or gender are not factors considered when determining eligibility for the primary and secondary clinical trials is entailed in the given trials as there is no mention of these factors in the inclusion or exclusion criteria provided",
        "label": "Entailment"
    },
    "466321f2-f997-47c7-a166-faeffe581547": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial administers Vitamin B12 sublingually while the secondary trial administers memantine orally not Vitamin B12 Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "aadd13d6-3100-41ef-947f-6b29d3118d67": {
        "text_answer": "  The statement in order to be eligible for the primary clinical trial a participant must have a bodyweight within the range of 50100kgs is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information provided However there is no mention of bodyweight restrictions in the given criteria so it is unlikely that the statement is entailed",
        "label": "Entailment"
    },
    "5a515d1f-131f-4dc9-9179-97f41957904a": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial require patients to be resistant to AI therapy and mirtazapine for participant eligibility is not entailed in the given trials inclusion and exclusion criteria  The primary clinical trial specifically includes participants who are resistant to AI therapy while the secondary clinical trial does not mention anything about AI therapy or mirtazapine in its inclusion or exclusion criteria  Therefore",
        "label": "Contradiction"
    },
    "b3a79047-9f6a-43d4-88e6-8c8a26b3a47f": {
        "text_answer": "  The statement only patients within cohort 1 had cases of infections and infestations in the primary clinical trial is entailed in the given trials data   Explanation  The trials data shows that out of the total 10 patients 6 in cohort 1 and 4 in cohort 2 there were 2 adverse events AEs in cohort 1 all of which were classified",
        "label": "Entailment"
    },
    "d42bd39b-e72e-418b-bd8a-6f1769fde12d": {
        "text_answer": "  The statement to participate in the primary clinical trial a candidate must have a minimum karnofsky score of 60 is an additional inclusion criterion for the trial as stated in the trials exclusion criteria it does not contradict the given information in the inclusion and exclusion criteria Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "36aac65a-5d56-4abd-b278-e9e3de78d480": {
        "text_answer": "  The statement the primary clinical trial involves patients taking oral medicine on a twice daily schedule for the duration of one month is contradictory to the information provided in the trial description   The trial description states that patients receive oral lapatinib and oral tamoxifen once daily on days 128 This means that patients take the oral medications every day for 28 days but they take each medication only once a day not twice Therefore",
        "label": "Entailment"
    },
    "1a1826f4-79d9-4df0-a8d8-fe9c3d75d783": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on the interventions being administered to the patients and do not explicitly mention any correlation between the interventions and the cyld gene mutation However the statement does make an assumption about the duration of the higher dose administration for Alpha Lipoic Acid in the primary trial and the consistent dose of Necitumumab in the secondary trial for patients with cyld gene mutation Without further information",
        "label": "Contradiction"
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "text_answer": "  The statement Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is entailed in the Trials as follows  1 NUT midline carcinoma is an inclusion criterion for the primary trial 2 The statement does not exclude patients with NUT midline carcinoma from the secondary trial ",
        "label": "Entailment"
    },
    "8719ae55-97f1-4d19-8e9c-85c086898291": {
        "text_answer": "  The statement in cohort 1 of the primary clinical trial most participants fell behind in their screening schedules postintervention without being influenced by the type of their cancer is not directly entailed in the provided trial results The results show an increase in the percentage of participants who were up to date with their colorectal breast and cervical cancer screenings after the intervention in both the Collaborative Care Intervention CCI and",
        "label": "Contradiction"
    },
    "0428ab54-eddd-4ee8-a58f-45ec7d7630f7": {
        "text_answer": "  The statement patients in the primary clinical trial who did not receive topical cryotherapy reported symptom improvement compared to those receiving cryotherapy is contradictory to the trial results   The results show that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 indicating that the symptoms have worsened on average compared to baseline In contrast the median aAU",
        "label": "Entailment"
    },
    "a4c5aecb-d375-43b7-bee0-dea9651fb7d6": {
        "text_answer": "  Both trials measure tumor diameter in centimeters cm for the primary outcome measurement Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "7d36e2e7-cf12-4281-8db5-2c30f23b427b": {
        "text_answer": "  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial unless they have nonhealing surgical wounds is contradictory to the exclusion criteria of the secondary trial  The secondary trial explicitly states that patients who have received chemotherapy or radiotherapy",
        "label": "Entailment"
    },
    "cc177dab-2d93-40dd-8b7f-ac1755325605": {
        "text_answer": "  The statement is entailed in the primary trial as the inclusion criteria for the primary trial includes Adults with histologically or cytologically confirmed breast adenocarcinoma radiographic evidence of at least one bone mets Easter Cooperative Oncology Group status of 0 1 or 2 and adequate organ function which is a subset of the inclusion criteria for the secondary trial The secondary trial includes the additional requirement of histologically confirmed breast cancer",
        "label": "Entailment"
    },
    "c7f3e0a2-44e0-4da9-a3ac-665d3e80f111": {
        "text_answer": "  The statement despite similar intervention strategies the primary clinical trial and secondary clinical trial exhibit disparate outcome measurement techniques is entailed in the given trials as follows  1 In the primary clinical trial the outcome measurement is the percentage of participants experiencing any treatment emergent adverse events and serious treatment emergent adverse events 2 In the secondary clinical trial the outcome measurement is the number of participants with objective response  Although both trials involve the",
        "label": "Entailment"
    },
    "51ea9225-4ef8-4bf6-878a-2476cb59b916": {
        "text_answer": "  The statement 77 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is entailed in the trial results as stated 13 of 49 participants 265 developed imagable HER2 metastases on HER2targeted PET",
        "label": "Entailment"
    },
    "d88d1ea7-3d60-4234-896b-2060dee299f7": {
        "text_answer": "  The statement is entailed in the trials Both interventions involve practicing paced breathing for a total of 15 minutes per day but they differ in the frequency of practice per day once vs twice However the statement specifically focuses on the fact that they follow different relaxation audio guides which is true according to the trials one group uses the guide for 15 minutes once daily and the other group uses it for 15 minutes twice daily Therefore",
        "label": "Entailment"
    },
    "920775c5-aa23-4be9-8aa1-241ecef90b51": {
        "text_answer": "  The statement is a contradiction to the primary trial as the group 2 of the primary trial does not receive any dosage of dexmedetomidine while the secondary trials group 2 does receive a dosage of dexmedetomidine 1ugkg which is different from the group 2 in the primary trial",
        "label": "Contradiction"
    },
    "bfeb1617-a5a5-40f7-8f09-f20c40a4cee0": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials only provide information about the doses of PF06647020 and ALT801 administered to participants in each study but they do not mention any familial relationships between the participants Therefore the statement about paternal half siblings does not follow directly from the trials",
        "label": "Entailment"
    },
    "24480821-2a6d-4359-bfb8-348ca85dffbb": {
        "text_answer": "  The statement the primary trial does not report any results for the LBH589 and Lapatinib cohort is entailed in the trials provided as there is no data reported for the LBH589 and Lapatinib armgroup in the given results However the statement does not mention Trovirdine which is not mentioned in the trials at all Therefore the statement is entailed in the trials regarding the absence of results for",
        "label": "Entailment"
    },
    "9313b787-6fe7-4eb7-93cb-13ce8cfe92f0": {
        "text_answer": "  The statement every patient in the primary clinical trial who received 1mg of gtx024 experienced an increase in lean body mass over four months is not entailed in the given trials as there is a negative value in the full range of change in lean body mass for some participants in the 1mg group Therefore it is not guaranteed that every participant in this group experienced an increase in lean body mass The trials only indicate that the median change in lean body",
        "label": "Contradiction"
    },
    "f48fabb1-f814-4f89-acf9-7ff95948b8d9": {
        "text_answer": "  The statement with the exception of one all patients who were treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial experienced adverse events emergent from treatment is entailed in the trial results as stated that there were 24 treatmentemergent adverse events in total among the 25 participants   The statement and serious adverse events were experienced by less than half is also entailed",
        "label": "Entailment"
    },
    "0ef3e1a1-d303-46de-8940-07746737fe87": {
        "text_answer": "  The statement breast cancer patients who have estrogen negative progesterone negative and her2 tumors can participate in all groups of the primary clinical trial is entailed in the given trial criteria   Explanation  The inclusion criteria state that the trial includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 ER negative PR negative",
        "label": "Entailment"
    },
    "3c2830d4-9341-4c0d-8ed3-51eb47d2cd17": {
        "text_answer": "  The statement the frequency of cholelithiasis in both the primary and secondary trials were the same is contradictory to the given data as cholelithiasis was reported in none of the participants in the secondary trial while it was reported in none of the participants in the primary trial Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "e2fcdf94-c0b2-4d75-a40d-2c2ec8200208": {
        "text_answer": "  The statement None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is not directly related to the information provided in the trials The trials only report the average pain intensity scores and the difference between the lowdose and highdose groups but they do not mention if any patient experienced the worst pain imaginable for 10 weeks Therefore the statement cannot be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "e9146895-e9b0-49cb-b05e-9264b682cece": {
        "text_answer": "  The statement adverse events were reported by fewer than 5 of the participants in the primary clinical trial is entailed in the given trials data as the total number of adverse events reported was 2 and the total number of participants was 35 resulting in a percentage of 571 which is less than 5",
        "label": "Entailment"
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "text_answer": "  The statement is entailed in the Trials since neither the primary nor the secondary trials report any cases of Febrile neutropenia or Cholelithiasis",
        "label": "Entailment"
    },
    "a74afb52-7b03-4c41-b57b-7473ef025c18": {
        "text_answer": "  The statement nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer patients identified through fluorescence in situ hybridization are eligible for participation in both the primary clinical trial and the secondary clinical trial is not explicitly stated in the given inclusion criteria for either trial However the primary trial does include nut midline carcinoma and castrateresistant prostate cancer as eligible conditions and there is no",
        "label": "Contradiction"
    },
    "5acf1755-279a-400a-9a2e-c71daaeeab0d": {
        "text_answer": "  The statement play doubles tennis is a question about whether an individual played doubles tennis The primary trial participants receive Epacadostat twice as frequently as Sunitinibnaive participants in the secondary trial receive sunitinib is neither entailed nor contradicted by the given trial information  Explanation  The statement makes a comparison between the frequency of administration of Epacadostat in the primary trial and the frequency of sunit",
        "label": "Entailment"
    },
    "87f63f2e-5648-4b9f-9f25-a5adb80dcb1d": {
        "text_answer": "  The statement is contradicted by the information provided in the secondary trial While no adverse event affected more than 03 of patients individually the total number of adverse events 1030 or 3333 is greater than 0 Therefore the statement that 0 adverse events were observed in the primary trial and none of the adverse events in the secondary trial affected more than 03 of patients is contrad",
        "label": "Contradiction"
    },
    "65ef313d-74d5-4e56-a6c8-6a3768774a55": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve different routes of administration Bisphosphonate is given intravenously IV once every 4 weeks while denosumab is given subcutaneously SC once every 12 weeks Therefore the statement that the interventions are administered through different routes is a logical consequence of the information provided in the trials",
        "label": "Entailment"
    },
    "51a15c75-5a89-48c3-a93d-4f464e915ba2": {
        "text_answer": "  The statement is entailed in the trials provided The trials state that there was one patient 150 who experienced suicidal ideation 150 or 200 of the total which is considered a psychiatric adverse event and affects less than 10 of the patients The coordinating committee is not directly mentioned in the trials but the trials do not contradict the statement that such a committee may exist and be involved",
        "label": "Entailment"
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "text_answer": "  The statement Women suffering from both claustrophobia and osteoporosis are not eligible for either the primary trial or the secondary trial is entailed in the given trials as follows  1 Women with osteoporosis are excluded from the primary trial 2 Women with claustrophobia are excluded from the secondary trial 3 The statement Women suffering from both claustrophob",
        "label": "Entailment"
    },
    "25f963fe-42f5-4294-9489-17d8fd17b4f2": {
        "text_answer": "  The statement is entailed in the primary trials exclusion criteria since it explicitly mentions a documented allergy to levofloxacin as an exclusion criterion However it is not explicitly mentioned in the secondary trials exclusion criteria Therefore the statement is entailed in the primary trial but not necessarily in the secondary trial  Regarding the secondary trial the statement is correct that patients with a confirmed allergy to cephalos",
        "label": "Entailment"
    },
    "caab457d-0650-4010-9d8e-4c8e474070ff": {
        "text_answer": "  The statement several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia is not directly entailed in the given trials as they do not provide sufficient information about the condition of the patients regarding pancytopenia in cohort 1 However the statement is not contradictory to the trials as well since the trials do not mention",
        "label": "Contradiction"
    },
    "e12077dc-2ef2-4276-b755-4664b0a0f0ea": {
        "text_answer": "  In the primary trial both Group A and Group B receive injections which are not entericcoated tablets Therefore the statement is contradictory to the primary trial  In the secondary trial participants receive entericcoated tablets of MLN8237 during the treatment cycles The statement is entailed in the secondary trial  However the statement as a whole is contradictory to the primary trial since it does not",
        "label": "Entailment"
    },
    "5a91060d-576b-405f-a8a6-c74cc3c24c62": {
        "text_answer": "  The statement in the primary clinical trial over 70 of the participants had a decrease in circulating tumor cells despite not receiving any form of chemotherapy is contradictory to the information provided in the trial results   The trial results indicate that the participants received highdose chemotherapy with Carboplatin Cyclophosphamide and Thiotepa prior to the stem cell transplant Therefore it is not accurate to",
        "label": "Entailment"
    },
    "7febdcf0-e8ff-4511-a96b-c160e3dd127e": {
        "text_answer": "  The statement is entailed in the trials as the secondary trial had a higher percentage 6000 of patients experiencing adverse events AEs compared to the primary trial 000 The specific types of AEs mentioned in the secondary trial recurrent malignancy graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were not mentioned in the primary trial",
        "label": "Entailment"
    },
    "42dca69f-0e7b-4945-9123-90e576db8c25": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the use of denosumab which is a monoclonal antibody medication given as an injection every 4 weeks The secondary trial involves the use of pIHGC and GP which both require the administration of radioactive Tc99M sulfur colloid as an injection around the tumor site for lymphoscintigraphy",
        "label": "Entailment"
    },
    "65dbfec2-08fb-4853-9e50-79ec4c97500f": {
        "text_answer": "  The statement a minor recently diagnosed with ilddpld predicted to live for one year is permitted to participate in the primary clinical trial is not entailed in the given inclusion and exclusion criteria The criteria only specify that patients must have a life expectancy of greater than 3 months Therefore the statement is not directly addressed in the provided information and is not an entailment or contradiction",
        "label": "Contradiction"
    },
    "7b71a3ac-e8b3-4e8f-ac95-c3dfe88676d5": {
        "text_answer": "  The statement is contradictory to the given trials   The statement says apart from skin infections no adverse event in the secondary trial affected more than 10 of patients but the secondary trial data shows that several adverse events affected more than 10 of patients including diarrhea 2333 neutrophil count decreased 333 platelet count decreased 1",
        "label": "Contradiction"
    },
    "44b1585a-3a5f-4ff7-a523-04923546b2c0": {
        "text_answer": "  The statement some patients participating in the primary clinical trial receive MCS110 more frequently than every 3 weeks is not directly entailed in the given trial information The trial information only specifies that MCS110 is given every 3 weeks for both interventions However it does not exclude the possibility that some patients may receive additional doses of MCS110 between the scheduled Q3W doses due to reasons such as disease progression or",
        "label": "Contradiction"
    },
    "d21d3871-d8c2-4a0a-b99f-291a721a1a18": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures tumor diameter in cm and the secondary trial measures number of participants with solid tumor response using different criteria such as Complete Response CR Partial Response PR Stable Disease SD Progressive Disease PD and Nonevaluable NE which are all different units of measurement Therefore the statement that the outcome measurements for both trials incorporate distinct units is entailed in the trials",
        "label": "Entailment"
    },
    "a1cf2da3-a2a8-4fa1-9812-5f50a75994ad": {
        "text_answer": "  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is a contradiction to the given data   In the primary trial all adverse events were related to blood and bone marrow while in the secondary trial only 3333 of the adverse events were related to blood and bone marrow Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "1b3e5b01-1b05-4025-9100-2c6e6e7faf20": {
        "text_answer": "  The statement the neratinib group in the primary clinical trial exhibited a lesser idfs rate compared to the placebo group is entailed in the trials as the results show that the percentage of participants with idfs events in the neratinib group 47 was lower than in the placebo group 75",
        "label": "Entailment"
    },
    "efe8b336-1781-4777-a1a0-fe34c59c63ab": {
        "text_answer": "  The statement Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the difference between the two intervention groups but they do not mention the number of patients who experienced no pain at all during the study Therefore the statement is neither entailed nor contradicted by the information provided",
        "label": "Contradiction"
    },
    "0e7c3f86-cbc8-478d-b89c-1f75b53323fe": {
        "text_answer": "  The statement the patient with the longest PFS in the primary trial survived 105 days without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "dc8fb0ce-165a-4d79-afb2-25a85f7c40b6": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials do not report any outcomes or comparisons between the LBH589 and lapatinib group and the LBH589 with capecitabine group The trials only provide information on the dose levels administration schedules and number of participants for each group Therefore it is not possible to determine if one group had better outcomes than the other based on the given information",
        "label": "Contradiction"
    },
    "bb0cf2c6-fbb2-4ca2-9f44-9ae8c5a9f63e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants receive a total of 11 different interventions including 7 different types of drugs some given by IV PO or SC therapeutic conventional surgery and correlative studies   In contrast the secondary trial only mentions the use of two different drugs everolimus and exemestane both given orally There is",
        "label": "Entailment"
    },
    "ed8ee6d6-5a37-4338-af72-e87bb50ec4d9": {
        "text_answer": "  The statement a majority of individuals in the primary clinical trial demonstrated complete response in a span of 24 weeks is contradicted by the trial results   The trial results indicate that at Week 12 there were 0 participants with CR and at Week 24 there were also 0 participants with CR Therefore no participant in the trial demonstrated complete response in a span of 24 weeks The statement is contradicted by the trial results",
        "label": "Contradiction"
    },
    "fbd6b437-ba96-46fd-933f-8299e0efb0e5": {
        "text_answer": "  The statement 13 participants in the primary trial were treated with the GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine is entailed in the trial information provided The trial information states that Overall Number of Participants Analyzed 13 and the participants were treated with the specified",
        "label": "Entailment"
    },
    "1cbc4e95-3407-4aab-bb7d-ba3abd1882f3": {
        "text_answer": "  The statement In the primary trial results there were more patients with stable disease in week 12 than week 24 but 0 patients with complete response in week 12 or 24 is not directly related to the information provided about the number of participants with clinical benefit CB at week 12 and week 24 in the given trial The statement only mentions the number of participants with stable disease but it does not specify whether those participants",
        "label": "Entailment"
    },
    "4f45090f-0954-43a7-9f56-60c5283459bd": {
        "text_answer": "  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is a statement of a difference in inclusion criteria between the two trials   The primary trial and the secondary trial have different inclusion criteria In the primary trial participants must be resistant to AI therapy and mirtazapine while in the secondary trial this requirement is not",
        "label": "Entailment"
    },
    "b20dadde-0f33-42ca-aa3e-c9333cdffe89": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The statement suggests a higher incidence of serious adverse reactions in the primary trial compared to the secondary trial but the trials both report a total of zero serious adverse reactions in each trial Therefore the statement is contradictory to the facts presented",
        "label": "Contradiction"
    },
    "12586895-bb1c-4772-ab01-94163d0393ab": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement the most common adverse event in the secondary trial was anaemia affecting more than 999 of patients there were no recorded aes in the primary trial is contradictory to the trials because  1 The statement claims that anaemia affected more than 999 of patients in the secondary",
        "label": "Contradiction"
    },
    "2758e742-d065-4813-bfd2-881fe16826bd": {
        "text_answer": "  The statement patients with a confirmed histological diagnosis of metastatic or nonresectable small cell lung cancer are not eligible for the primary clinical trial unless their result is positive for ER or PR or both is a contradiction to the inclusion criteria stated in the text   The inclusion criteria state that patients with histologically documented metastatic or unresectable nonsmall cell lung cancer are eligible for the trial There is no mention of small cell",
        "label": "Contradiction"
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "text_answer": "  The statement Hypokalemic patients are excluded from the primary trial but hyperkalemic patients may be eligible for the secondary trial and the primary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trial explicitly excludes patients with potassium levels below the normal range 35 mEqL which aligns with the statement that hypokalemic patients are excluded However the statement",
        "label": "Entailment"
    },
    "a198b3a9-ee15-4f4a-b587-d6ddb86efa73": {
        "text_answer": "  The statement encounter due to exposure to radiation is an ICD encounter due to exposure to radiation is not related to the content of the primary or secondary trials The trials describe interventions using different drugs Abl Cells Cyclophosphamide Fludarabine and DMCHOCPEN and their respective dose escalation schemes for patients with and without liver involvement The statement about ICD encounters is an unrelated medical terminology",
        "label": "Entailment"
    },
    "0f434232-d1a2-4d35-a49c-dd52c8353b9f": {
        "text_answer": "  The statement the majority of patients in the primary trial experienced complete response by month 24 is contradicted by the trial results   Explanation   The trial results indicate that at Week 12 there were no participants with complete response CR and at Week 24 there were also no participants with CR The number of participants with CR at both time points was 0   However the number of participants with",
        "label": "Contradiction"
    },
    "22b968d1-4ffd-4562-aeb0-e1e022212b08": {
        "text_answer": "  The statement Not a single one of the participants in group 1 of the primary trial were found to have lesions and more than 95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed in the given trials   The primary trial does not provide information about the presence or absence of radiation dermatitis or hyperpigmentation in the healthy volunteers",
        "label": "Contradiction"
    },
    "116c9dea-44ba-402e-8948-67ee9bb4f942": {
        "text_answer": "  The statement Both cohorts of the primary trial receive the same doses of Abraxane is entailed in the trial description as both arms receive nabPaclitaxel at the same dose 125 mgm2 However the statement does not directly address the doses of Carboplatin or Abraxane in relation to each other so it cannot be definitively determined if the statement Both co",
        "label": "Entailment"
    },
    "bea08563-704d-4475-9dbd-d7617d1a6a63": {
        "text_answer": "  The statement is entailed in the trials as both trials are studying the same drug empegfilgrastim but with different doses and outcome measurements The primary trial is focused on the duration of neutropenia with CTCAE grade 34 in breast cancer patients while the secondary trial is focused on the incidence of CTCAE grade 34 neutropenia in patients with lymphoma prostate lymphoma is",
        "label": "Entailment"
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "text_answer": "  The statement the primary trial participants do not receive any vaccines is entailed in the given trial descriptions as there is no mention of any vaccines being administered to the participants in either intervention 1 or intervention 2",
        "label": "Entailment"
    },
    "a9aae47f-ecbe-49ea-983b-73c8b6a95506": {
        "text_answer": "  The statement is entailed in the given trials as follows  The statement there were zero adverse instances recorded in the primary clinical trial is directly stated in the primary trial data  The statement while in the secondary clinical trial the number of patients who were affected by any such instances did not exceed 30 is an implication of the secondary trial data The data shows that the total number of adverse events was 10 out of ",
        "label": "Entailment"
    },
    "dcad8706-4bfe-4076-9bd5-babca4f63beb": {
        "text_answer": "  The statement 50 the primary trial participants and 110 the secondary trial participants suffered an adverse event is contradictory to the information provided in the trials   The primary trial had a total of 4 participants and none of them suffered any adverse event Therefore 0 of the primary trial participants suffered an adverse event   The secondary trial had a total of 1674 participants and none",
        "label": "Entailment"
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial has distinct inclusion and exclusion criteria for its Phase I and Phase II portions The Phase I criteria include a requirement for a responsible companion to live with the patient during the study while the Phase II criteria separate patients into two groups based on their use of opioids   On the other hand the secondary trial has separate inclusion and exclusion criteria for healthy",
        "label": "Entailment"
    },
    "d3630897-ec5d-4c22-b2cd-5a8355dfdd88": {
        "text_answer": "  The statement is entailed in the primary and secondary trial criteria Both trials include patients with histologically confirmed stage 4 breast adenocarcinoma that is ER positive PR positive or HER2neu negative Therefore these patients are eligible for both trials",
        "label": "Entailment"
    },
    "9367299b-070b-4902-b857-bca1c45b6fd1": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the Trials with Entailment or Contradiction we need to refer to the specific trial information In this case we are given the name of an intervention MM111 but no information about the Trials with Entailment or Contradiction is provided  Therefore it is not possible to make a definitive determination based on the given information alone We would",
        "label": "Entailment"
    },
    "186e198a-63dc-4ac9-8ae0-7790f32ec792": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients in Intervention 1 receive MM121 at a dose of 20 mgkg weekly and Paclitaxel at a dose of 80 mgkg weekly during the 12week treatment period In contrast in the secondary trial patients in Intervention 1 receive MM121 at a dose of 20 mgkg weekly for ",
        "label": "Entailment"
    },
    "65910ca9-d27b-4350-9213-1cb7aea575a2": {
        "text_answer": "  The statement the primary clinical trial imposes no restrictions based on mental health bodyweight tumour size karnofskyecog score or estimated life expectancy for eligibility is not explicitly stated in the given inclusion and exclusion criteria However the criteria do not mention any restrictions related to mental health bodyweight tumour size karnofskyecog score or estimated life expectancy as exclusion factors Therefore the",
        "label": "Contradiction"
    },
    "50d67398-cd3f-4d6e-afeb-419ae6f64c0d": {
        "text_answer": "  The statement the primary clinical trial is suitable for those with triple positive breast cancer is contradictory to the given trial information The trial is designed for patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 Triple positive breast cancer refers to the presence of ER PR progesterone receptor and HER2 positivity However the trial does not include",
        "label": "Entailment"
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "text_answer": "  The statement is not entailed in the given trials as it contradicts the information provided in the secondary trial regarding the occurrence of adverse events affecting more than 30 of patients diarrhea with a rate of 2333",
        "label": "Contradiction"
    },
    "e74e47e7-4627-4dd9-aedd-cbc5b5cdd669": {
        "text_answer": "  The statement mucositis oral bladder infection and thromboembolic events were seen more often in the secondary clinical trial than they were in the primary clinical trial is contradictory to the given data  Explanation  The statement implies that the frequency of mucositis oral bladder infection and thromboembolic events is higher in the secondary clinical trial compared to the primary clinical trial However",
        "label": "Entailment"
    },
    "b464cd26-7734-455c-85c1-04a4ec324c55": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial is entailed in the trials exclusion criteria Therefore the statement is entailed by the information provided in the trial description",
        "label": "Entailment"
    },
    "22031bc7-9954-4b2b-b905-a5d34e0eea98": {
        "text_answer": "  The statement her2 metastases developed in 13 of the participants with pr primary breast cancer treated using her2targeted petct 89zrtrastuzumab in the primary clinical trial is entailed in the trial results 1 as the trial reports that her2 metastases developed in 13 of the participants in the HER2targeted PETCT arm of",
        "label": "Entailment"
    },
    "3b29fe26-bf01-4e85-aa0e-33e83b1db660": {
        "text_answer": "  The statement is not directly entailed in the primary or secondary trial inclusion or exclusion criteria provided However the statement implies that a patient with a history of pulmonary embolism within the past three years may be eligible for the secondary trial despite being ineligible for the primary trial due to this condition This is not explicitly stated in the trial criteria but it is possible for such a patient to be evaluated on a casebycase basis by the investigator",
        "label": "Contradiction"
    },
    "8183a43e-0284-483d-a22c-08502b0ebc8a": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The statement mentions a specific patient with a longest PFS of 35 months in the Capecitabine cohort but the trials only report the median PFS for each group The trials do not provide enough information to determine if this specific patient was included in the analysis or not Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "f5cb1b5d-53b5-464b-a160-17cd59481705": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial Cohort 1 receives an injection of fluciclatide while in the secondary trial Cohort 1 receives a standard dose of chloroquine which are two different interventions",
        "label": "Entailment"
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "text_answer": "  The statement Paclitaxel is not used in either of the primary trial interventions is entailed in the given trials as neither Anastrozole nor Fulvestrant involve the use of Paclitaxel in their interventions",
        "label": "Entailment"
    },
    "d47eb708-7ca4-4894-bc28-e276e61c0333": {
        "text_answer": "  The statement the primary clinical trial does not involve administering any vaccines to the participants is entailed in the given trial information as there is no mention or indication of any vaccines being administered in either Intervention 1 or Intervention 2",
        "label": "Entailment"
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is a contradiction to the given trial criteria   In the primary trial there is no exclusion for cerebral metastases within the brainstem as long as they meet the other eligibility criteria However in the secondary",
        "label": "Contradiction"
    },
    "70cd062f-8f49-47ac-80c0-d3608a574517": {
        "text_answer": "  The statement the secondary trial and the primary trial have completely unrelated outcome measurements but the same interventions h33a gene mutation is a change in the sequence of the h33a gene is not directly related to the information provided in the trials The trials only provide information about the safety and efficacy outcomes of the interventions SG and talazoparib in different patient populations The statement mentions the h33",
        "label": "Entailment"
    },
    "01593a0d-0547-4ed6-8ad6-6c5ecdbeb74a": {
        "text_answer": "  The statement is contradicted by the information provided in the trials as both Intervention 1 and Intervention 2 use different routes of administration  IV for bisphosphonate Q4W and subcutaneous injection for denosumab Q12W",
        "label": "Contradiction"
    },
    "edb0a92a-08c0-4083-864e-26d845000fa6": {
        "text_answer": "  The statement both phases of the primary clinical trial are only open to male patients who demonstrate evidence of a locally advanced andor metastatic solid tumor is contradictory to the information provided in the inclusion criteria of the trial   The inclusion criteria state that the trial is open to both male and female patients but with specific requirements for female participants regarding contraception The trial is open to male patients who have a locally advanced andor metastatic",
        "label": "Entailment"
    },
    "52c84a93-a09f-47b5-b928-385830350390": {
        "text_answer": "  The statement intragastric balloon procedure is a procedure in which a saline filled balloon is placed in the stomach to assist with weight loss laserassisted fluorescence angiography is used for both interventions in the primary trial is not entailed in the given trials as there is no mention of an intragastric balloon procedure in the trials provided The trials only describe two different surgical interventions for breast reconstruction one using an",
        "label": "Contradiction"
    },
    "32c2dfce-b209-49f3-9f03-5e39b97b18c4": {
        "text_answer": "  The statement patients diagnosed with ductal carcinoma in situ and contemplating AI therapy are suitable for the primary clinical trial is entailed in the trials inclusion criteria The trial includes patients with histologically proven DCIS as a type of breast cancer that is eligible for the study Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "7064d383-b7a5-44a0-a9aa-3fae7b7ded9c": {
        "text_answer": "  The statement dont really enjoy food is a response indicating that an individual does not really enjoy food is not directly related to the trials provided Therefore it cannot be determined if it is entailed in the trials with entailment or contradiction  Regarding the trials the statement that there were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary",
        "label": "Entailment"
    },
    "c958d134-cecd-4212-9043-bc1d5131d555": {
        "text_answer": "  The statement only those having colon cancer and showing no response to past hormonal treatments will be considered for the primary clinical trial is contradictory to the inclusion criteria of the trial as stated in the text The trial includes women with breast cancer who have had hormonal treatment but not colon cancer and have shown continued growth of their cancer Therefore the statement is contradictory to the trials inclusion criteria",
        "label": "Contradiction"
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "text_answer": "  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE is entailed in the given trials as both trials report that no participants suffered from any adverse event",
        "label": "Entailment"
    },
    "54c35538-e933-40b0-bf84-299e0b291ef3": {
        "text_answer": "  The statement infections and fever cases in the primary clinical trial were exclusively observed in patients of the first cohort is entailed in the given trials if we assume that the trials refer to the same clinical trial with two cohorts and the total number of patients in both cohorts is 10 6 in the first cohort and 4 in the second cohort The statement is entailed because all the infections and fever cases mentioned in",
        "label": "Entailment"
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "text_answer": "  The statement the secondary trial and the primary trial use the same outcome measurement is contradictory to the given information   The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH and the change from baseline to Week 12 in serum levels of FSH while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD in combination with paclit",
        "label": "Entailment"
    },
    "cfef163a-3390-4b89-9a6f-7c351262625d": {
        "text_answer": "  The statement patients with deficient vitamin D levels in the primary clinical trial displayed a discernible pattern for expression of the 40 evaluated genes is not directly entailed in the provided trial results as no information about vitamin D deficiency levels or the gene expression profile is given for the analyzed groups in the trials The trials only report the number of participants with no discernible pattern for gene expression in each group Therefore the statement is neither entailed nor",
        "label": "Contradiction"
    },
    "d1e7f535-40de-425b-9478-7d09f3d4cf06": {
        "text_answer": "  The statement people with cytologically or histologically confirmed metastatic andor advanced solid tumor in their breast can participate in phase 1 of the primary clinical trial and are also eligible for every cohort of the secondary clinical trial is entailed in the given trials inclusion criteria   Explanation  The primary clinical trial includes breast adenocarcinoma female patients only as one of the eligible cancer types for phase",
        "label": "Entailment"
    },
    "2cc09c00-1375-4603-a6ee-dd5ceb87733a": {
        "text_answer": "  The statement the primary clinical trial excludes patients with histologically confirmed metastatic small cell lung cancer SCLC is a contradiction to the inclusion criteria provided in the text The trial does include patients with histologically documented metastatic nonsmall cell lung cancer but it does not mention any exclusion for SCLC Therefore the statement is a contradiction to the information given in the text",
        "label": "Contradiction"
    },
    "37b9368c-1aae-4acd-ad7a-ffe4422c9e5d": {
        "text_answer": "  The statement Brucella is a genus of aerobic gramnegative coccobacilli shaped bacteria assigned to the phylum proteobacteria and the family brucellaceae is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "395c6ba7-5123-4d61-a803-be3345d0ab23": {
        "text_answer": "  The statement the primary clinical trial reported a ten times higher number of hepatotoxicity incidences as compared to hypertension and pancreatectomy cases is entailed in the given trial data if we interpret ten times higher as meaning at least three times higher   Heres the reasoning  1 The trial reported 3 hepatotoxicity cases out of 8 total cases which is a rate of ",
        "label": "Entailment"
    },
    "e9972d7c-b9f7-4846-9708-1e1f63e96e83": {
        "text_answer": "  The statement is contradictory to the information provided in the trial descriptions The trials do not specify that every subject in both cohorts receives a standard dose of 15 mg of sunitinib daily In Intervention 1 the starting dose of sunitinib is 25 mg daily which can be escalated to 375 mg daily based on certain conditions In Intervention 2 the information about sunitinib dosing",
        "label": "Entailment"
    },
    "c355603f-22d8-4363-ac79-6e591b4fcfac": {
        "text_answer": "  The statement There were more cases of Infection Asymmetry and Deflation in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials for the specific types mentioned in the statement   The given data in the trials does not directly support this statement as it only provides the number of occurrences for each trial but not a comparison between them Therefore the statement is neither entailed nor contradicted by",
        "label": "Entailment"
    },
    "9bea0473-ca9d-4a63-befe-db1825744484": {
        "text_answer": "  The statement there was no significant difference in the results produced by cohort 2 of the primary and secondary clinical trials cannot be determined based on the provided information   The primary trial and secondary trial are evaluating different outcome measures The primary trial is focused on breast cancerspecific quality of life using the FACTB instrument while the secondary trial is assessing the efficacy of a device in addressing positive margins during surgery Therefore it is",
        "label": "Contradiction"
    },
    "9f81f8a6-84d2-40b3-b8c5-3616f2f638a8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The trials describe the interventions as being administered orally for memantine and placebo by mouth The statement however suggests that the placebo is administered intravenously and memantine is administered orally Therefore the statement contradicts the information provided in the trials",
        "label": "Contradiction"
    },
    "fb1cfb53-fb70-4131-9ed0-00b5f93ecf26": {
        "text_answer": "  The statement a patient in the primary clinical trial suffered from a reopened surgical cut following the procedure is not explicitly stated in the given adverse events However the term wound dehiscence is mentioned in the adverse events which refers to the reopening or breaking down of a surgical wound Therefore the statement is entailed in the trial data as one of the adverse events",
        "label": "Entailment"
    },
    "dfe9c306-0a1f-4940-b9bb-00a238abc818": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria The primary trial specifies that the primary tumour should be greater than 2 cm in diameter which is approximately 20000m 20mm The statement suggests a primary tumour with a radius of 3000m which is larger than the inclusion criteria for the primary trial Therefore a patient with a primary tumour of 3000m",
        "label": "Entailment"
    },
    "bd791a1a-f4e4-43fb-8be0-ad1bced0aa60": {
        "text_answer": "  The statement the primary clinical trial would not admit a patient diagnosed with leptomeningeal carcinoma is a contradiction to the given trial information The trial explicitly states that No meningeal carcinomatosis is a requirement for eligibility However leptomeningeal carcinomatosis is a type of meningeal involvement by cancer Therefore the statement contradicts the trial information",
        "label": "Contradiction"
    },
    "6032e3ab-9d85-4c3b-aeb1-a93f45ba4735": {
        "text_answer": "  The statement there were no cases of shingles reported in neither the patient cohorts of the primary trial nor the secondary trial is entailed in the given trials as there are no instances of shingles reported in both trials",
        "label": "Contradiction"
    },
    "55365a7b-df7e-4586-aeff-3ed268a4979f": {
        "text_answer": "  The statement is entailed in the given trials data   Explanation   The statement in both the primary clinical trial and the secondary clinical trial there were zero recorded serious adverse events is a logical consequence of the data provided in the trials The trials data states that in the primary trial there were zero serious adverse events out of a total of 34 participants and in the secondary trial there were zero serious adverse events out",
        "label": "Entailment"
    },
    "92e676b6-34f9-4b11-bfad-b45cf8942d2a": {
        "text_answer": "  The statement the secondary clinical trial has witnessed an unexpected death and hospitalizations is not entailed in the given trials as there is no information about unexpected deaths or hospitalizations in the trials The trials only provide data on adverse events for two different trials but they do not specify whether any of those events were unexpected or resulted in death or hospitalization Therefore the statement is contradictory to the given trials as they do not support or follow from the information provided",
        "label": "Contradiction"
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "text_answer": "  The statement cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial cannot be determined based on the provided information   The primary trial and the secondary trial measure different outcomes The primary trial measures quality of life using the FACTB instrument while the secondary trial measures intraoperative success in addressing positive margins using the CSR test Therefore it is not possible to make a direct comparison between the",
        "label": "Entailment"
    },
    "9011533a-e400-4b32-96d4-a60ddc58ddbe": {
        "text_answer": "  The statement is not entailed in the given trials as the drug regimen for the secondary trial is not specified in the provided information Therefore it is neither entailed nor contradicted by the trials",
        "label": "Contradiction"
    },
    "43a12cb4-7a50-4e64-b01f-1d1bfb5c4ba9": {
        "text_answer": "  The statement the primary trial had no documented adverse events unlike the secondary one where anaemia was a frequent occurrence is a contradiction of the given trials data   Explanation   The statement implies that there were no adverse events in the primary trial while the secondary trial had anaemia as a frequent occurrence However the data provided shows that there were indeed no adverse events documented in the primary trial ",
        "label": "Contradiction"
    },
    "e96067c7-ab5d-4afc-b70c-f892aef0dce4": {
        "text_answer": "  The statement A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial is contradictory to the disease characteristics of the trial as stated in the given information The trial explicitly mentions that No meningeal carcinomatosis is a requirement for eligibility Neoplastic meningitis is a type of meningeal carcinomatosis which is a condition characterized by the presence of cancer cells in the cere",
        "label": "Contradiction"
    },
    "01982a9a-3299-4be8-8201-0397508b2f88": {
        "text_answer": "  The given statement numerous patients in the primary clinical trial felt no discomfort at all throughout the 10week study is not entailed in the provided trial results as there is no mention of the number or percentage of patients in either group who felt no discomfort at all during the study The trial results only report the average pain intensity scores and the difference between the two intervention groups",
        "label": "Contradiction"
    },
    "1a4794c9-035c-4e78-b2e5-d8104428bdc0": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is neither entailed in the primary trial nor contradictory to it   The primary trial does not mention anything about exclusion based on the number of cerebral metastases The secondary trial specifically excludes patients with 23 cerebral metast",
        "label": "Entailment"
    },
    "4ce3082f-28f9-4e23-8808-dde496f77535": {
        "text_answer": "  The statement adverse events observed during the secondary clinical trial exceeded those in the primary clinical trial is a contradiction to the given data   Explanation   The given data states that there were no adverse events reported in both the primary and secondary clinical trials for Adverse Event 1 For Adverse Event 2 there is no data provided for the secondary clinical trial   Therefore it is not possible to make a",
        "label": "Contradiction"
    },
    "9c7ccf99-0768-4a8a-bde9-bb3cb9b65c67": {
        "text_answer": "  The statement no infections and infestations cases were registered in the primary clinical trial is entailed in the given data from Trial 1 since there were no cases of infections and infestations reported in Trial 1 and the statement is more specific than the information provided in the trials However it is not directly stated in the trials that no infections and infestations cases were reported in Trial 2 but since there were no cases reported",
        "label": "Contradiction"
    },
    "90474244-ea60-4670-b586-8ca32b80af7f": {
        "text_answer": "  The statement all the adverse events reported in the primary clinical trial were experienced by patients in the first cohort is entailed in the given trials as both trials have the same set of adverse events with a total count of 0 or 1 event for each type and all of them have a count of 0 in the first cohort Therefore the statement is true given the information provided in the trials",
        "label": "Entailment"
    },
    "9121985c-34cf-4378-b6ad-3b7a522c9ba5": {
        "text_answer": "  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is not directly entailed in the given trials as the trials do not provide sufficient information to determine if there were Thromboembolic events in both trials for the same patients or different patients However based on the information provided it is known that there was one Thromboembolic event in each trial Therefore the statement is not contradictory to",
        "label": "Contradiction"
    },
    "52d479a4-9cd7-4fb6-b37f-f455c6c81402": {
        "text_answer": "  The statement cohort 1 participants in the primary clinical trial exhibited absolutely no adverse event throughout the duration is entailed in the given trials as both trials report that none of the participants in cohort 1 experienced any adverse event",
        "label": "Contradiction"
    },
    "880b2544-5c9d-4ce7-8d26-1081c7851cb9": {
        "text_answer": "  The statement is entailed in the given trials as there is no mention of any drugrelated assessments in the primary trial while the secondary trial explicitly states the use of the drug PF06647020 and its associated assessments",
        "label": "Entailment"
    },
    "0744abca-2e7d-4e4a-a325-642ba6d16135": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to calculate the number of emesisfree participants in each group and compare them   From the given results we have   Aprepitant group 13 emesisfree participants  Placebo group 5 emesisfree participants  To find the number of participants who experienced emesis we can subtract the number of emesisfree participants from",
        "label": "Entailment"
    },
    "87273b6d-f10d-4638-ab87-bceade2d6510": {
        "text_answer": "  The statement patients with a diagnosis of severe insomnia are not eligible for either the primary or secondary clinical trial is entailed in the trials as follows  In the primary trial severe insomnia is not explicitly mentioned as an exclusion criterion However insomnia is mentioned as a symptom that is not allowed in the secondary trial Since the primary trial does not allow patients with uncontrolled intercurrent illness including psychiatric illness",
        "label": "Entailment"
    },
    "64e22fa4-990b-4196-874a-a5ecf04cf3fb": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different outcome measurements and interventions The primary trial measures the influence of ascorbic acid supplements on isothiocyanate concentration in urine samples while the secondary trial evaluates the effectiveness of physical therapy on pain reported by participants undergoing chemotherapy The statement is an interpretation of the trials focus based on the provided information and is not explicitly stated in the trials themselves",
        "label": "Contradiction"
    },
    "6232508a-0f99-485f-9b84-af5692dac27b": {
        "text_answer": "  The statement after four weeks of treatment with tak228 plus tamoxifen the primary clinical trial observed no changes in the percentage of cells expressing ki67 is a contradiction to the results presented in the trial   The trial reports the Ki67 expression at baseline and at 6 weeks not at 4 weeks The statement implies that there was no change in Ki67 expression after 4 weeks but the trial does not",
        "label": "Contradiction"
    },
    "fd2867fb-a94f-42ce-87a1-aebdcfd015b8": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given Trials with Entailment or Contradiction we need to first understand the context of the trials and the meaning of the terms used in the statement  The Trials with Entailment or Contradiction is a hypothetical construct and does not provide any specific information about the clinical trial involving MM111 Therefore we cannot directly verify the statement using the given",
        "label": "Entailment"
    },
    "413156ec-dbfb-4c78-9518-cbde7d4765da": {
        "text_answer": "  The statement objective cognitive function scores which are evaluated using cogstate are used as units of measure in both the secondary clinical trial and the primary clinical trial is not entailed in the given trials as the trials do not provide any information regarding the use of objective cognitive function scores or the Cogstate tool in measuring the outcomes The trials only report the outcome measurements and results related to vaginal symptoms and HER2negative metastatic breast cancer respectively",
        "label": "Contradiction"
    },
    "4fec2620-4ede-44a4-adc9-54b525e89387": {
        "text_answer": "  The statement is entailed in the trials if and only if there are no adverse events related to cardiology or psychology reported in both the primary and secondary trials Based on the given information the statement is entailed as both trials report no adverse events related to cardiology or psychology",
        "label": "Entailment"
    },
    "75c25f91-4918-40d6-b84d-d5be844b97ef": {
        "text_answer": "  The statement an increased blood bilirubin was recorded in 3636 of the patients who participated in the primary clinical trial is entailed in the given trial data as it is explicitly stated that Blood bilirubin increased in 1 out of 11 patients 909 which is equivalent to 3636 when expressed as a percentage of the total number of patients",
        "label": "Entailment"
    },
    "86a5a47e-a2cb-461e-bcc5-8f71620376b8": {
        "text_answer": "  The statement There were no significant differences in the results from the groups in the primary trial however some differences where found between the Reflexology Group and control group results in the secondary trial is a separate statement from the trials provided and cannot be directly verified as entailed or contradicted based on the information given  The trials describe two separate studies with different outcome measures and participant populations The primary trial compares the diagnostic accuracy of two mammography processing algorithms while the secondary",
        "label": "Contradiction"
    },
    "31ec9b33-fa24-4cd9-9341-c54adaa250cd": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 36 months would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the statement specifically mentions diffuse parenchymal lung disease it falls under the broader category of interst",
        "label": "Entailment"
    },
    "2f6221cf-15f0-4da7-b800-d65f4dd001d7": {
        "text_answer": "  The statement the performance status for candidates is not influential for admission into the primary clinical trial or the secondary clinical trial is contradictory to the information provided in the inclusion criteria for both trials In the primary trial there is a requirement for a Karnofsky score of 70 which is a measure of performance status In the secondary trial there is a requirement for a Zubrod performance score of 2 or better Therefore the statement is contradict",
        "label": "Entailment"
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement There were 0 adverse events in the primary trial and the secondary trial is contradictory to the trials because  1 In the primary trial there were no adverse events reported 020 or 000 2 In the secondary trial there were 2 adverse events reported 23",
        "label": "Contradiction"
    },
    "e547ee04-f454-4ec3-b2fb-9ea04c97bdab": {
        "text_answer": "  The statement numerous adverse events were noted in the primary clinical trial and over half of the patients in the secondary clinical trial were affected by skin infections is a combination of two separate claims Lets verify each claim individually  Claim 1 numerous adverse events were noted in the primary clinical trial  The primary clinical trial had a total of 0 adverse events out of 25 patients which is not considered numerous",
        "label": "Entailment"
    },
    "64839cde-9ad9-4363-9d78-7a2621bc7ec4": {
        "text_answer": "  The statement for the initial 21 days of the primary clinical trial all patients in cohort 2 were given capecitabine orally every day is entailed in the trial description   Explanation  The trial description states that capecitabine was administered orally from Days 1 to 14 every 21 days This means that all patients in the trial received capecitabine for the",
        "label": "Entailment"
    },
    "8bc0e440-faca-4386-8718-e306978edb67": {
        "text_answer": "  The statement minor salivary gland is a small salivary gland located within the aerodigestive tract Patients with NUT midline carcinoma determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The statement is not entailed in the primary trial as the",
        "label": "Entailment"
    },
    "974d4228-3dd6-42ab-b4e6-1b3f8e9ecdc5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials While both cohorts received equal dosages of cetuximab the statement asserts that cohort 1 received an additional collaborative care intervention However there is no mention of such an intervention in the description of cohort 1 in the trials Therefore the statement is contradictory to the information provided",
        "label": "Contradiction"
    },
    "6c31de8a-736c-4741-99d3-fcd0c921e83f": {
        "text_answer": "  The statement compared to the secondary clinical trial the frequency of pericardial effusions was higher in the primary clinical trial whereas corneal deposits were more often noted in the latter is entailed in the Trials if and only if  1 The frequency of pericardial effusions is higher in the primary trial than in the secondary trial 2 The frequency of corneal deposits is higher in the secondary trial than in",
        "label": "Entailment"
    },
    "0a44470c-bf27-4795-aa25-f30a58771625": {
        "text_answer": "  The statement is entailed in the trial results as they directly state that The results show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40 on average The statement in the question is a paraphrased version of the trial results and the nervous system component is not relevant to the trial results so it does not",
        "label": "Entailment"
    },
    "647c8d22-6888-4f04-a70b-0245b68a6fab": {
        "text_answer": "  The statement patients in the final stage of cancer cannot partake in the primary clinical trial but are eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both the primary and secondary trials   The primary trial has specific inclusion and exclusion criteria related to the stage of breast cancer but it does not explicitly state that patients in the final stage cannot participate in the trial Instead it includes specific criteria related to the",
        "label": "Contradiction"
    },
    "07dab01c-f419-4079-bd0d-491740c5ec95": {
        "text_answer": "  The statement several patients in the primary clinical trial experienced identical adverse events is entailed in the given trial data as there are multiple instances of the same adverse event reported for different patients eg Heart Failure Vertigo Small intestinal obstruction etc each occurring in 130 333 of the patients",
        "label": "Entailment"
    },
    "16505ccd-8394-4c6e-8ab2-bbf56583c6be": {
        "text_answer": "  The statement is entailed in the trial information as follows  In Intervention 1 the dose of Cyclophosphamide C is 600 mgm2 while in Intervention 2 the dose of Cyclophosphamide C is also 600 mgm2 However the dose of Eribulin Er in Intervention 1 is 14mgm2",
        "label": "Entailment"
    },
    "9022a69a-98fa-45ab-8a03-3a6e81102d03": {
        "text_answer": "  The statement patients with tumors exhibiting ccnd1 amplification cdk46 mutation or ccnd2 amplification are not eligible for the primary clinical trial is entailed in the trials inclusion criteria   Explanation   The trials inclusion criteria state that patients with tumors that test positive for CCND1 amplification CDK46 mutation CCND2 amplification or any",
        "label": "Entailment"
    },
    "e5e7bbc4-cce7-41e3-b973-ac14fdff5600": {
        "text_answer": "  The statement is contradictory to the given trials as cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide a radiopharmaceutical while cohort 1 of the secondary trial is administered a standard dose of Chloroquine an oral medication and neither trial mentions an intravenous IV administration for Chloroquine",
        "label": "Entailment"
    },
    "66a9e527-8f35-4c41-be7f-ad854d0066f9": {
        "text_answer": "  The statement occurrence date range validation code is a coded value specifying the degree of authoritativeness or certitude of the occurrence date Any Japanese national can take part in the primary trial or the secondary trial is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary and secondary trials The statement is not directly related to the eligibility criteria for the trials",
        "label": "Entailment"
    },
    "8a79949b-06e3-4943-a63d-248e1a432a7b": {
        "text_answer": "  The statement unlimited enrolment is available for the primary clinical trial targeting patients with early stage colorectal cancer without kras or braf mutations is contradictory to the information provided in the inclusion criteria of the trial   The trial specifies a limited number of enrollment slots for patients with metastatic colorectal cancer 1530 but it does not mention anything about unlimited enrolment for patients",
        "label": "Entailment"
    },
    "7758b88c-2f21-4b63-b76d-010298f50aa7": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial is administered a similar dose of enzalutamide as cohort 2 is contradictory to the information provided in the trials   Explanation   Cohort 1 received enzalutamide 80 mg two 40 mg capsules daily while cohort 2 received enzalutamide 16",
        "label": "Entailment"
    },
    "9a749008-f77d-49bf-b529-82d049a8f446": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORRs of the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 05",
        "label": "Entailment"
    },
    "5c2d33e2-9759-4060-9bdd-7ecda4123cda": {
        "text_answer": "  The statement 0 out of 7 the primary trial participants and 0 out of 1674 the secondary trial participants experienced an adverse event is entailed in the given trials data as both trials report no occurrences of adverse events in their respective participant groups",
        "label": "Entailment"
    },
    "03837d34-3ddb-4bfc-a993-b27e2d16f427": {
        "text_answer": "  The statement is neither entailed nor contradicted by the trials provided The primary trial reports the outcome measurement of pain intensity using a visual analog scale while the secondary trial reports the change in bone mineral density using DEXA scan The statement is about a different concept homeopathic dilution unit which is not mentioned or related to the trials",
        "label": "Entailment"
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "text_answer": "  The statement is contradictory to the trials provided The primary trial measures the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine while the secondary trial measures the percentage of participants with pain or no pain as assessed by the Numeric Pain Rating Scale There is no mention of muscle gains in either trial",
        "label": "Contradiction"
    },
    "c5fb4937-5177-47c9-8ce2-1fdec2a17942": {
        "text_answer": "  The statement 57 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is entailed in the trial results if we assume that 13 out of 49 participants mentioned in the statement refers to the number of participants who developed imagable HER2 metastases ",
        "label": "Entailment"
    },
    "72d62a11-d0ff-4e2b-8bb9-22a1858b4914": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial participants receive multiple types of treatments including chemotherapy targeted therapy and hormonal therapy as well as surgical procedures such as needle biopsy and therapeutic conventional surgery   In contrast the secondary trial only involves the administration of two specific drugs everolimus and exemestane without any surgical procedures mentioned   Therefore the statement",
        "label": "Entailment"
    },
    "607586af-260d-46ef-88ce-b8672e4aaa25": {
        "text_answer": "  The statement Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial is not directly entailed or contradicted by the given trials   The trials only provide the number and percentage of adverse events for each trial but they do not compare the frequency or incidence of specific adverse events between the two trials for Japanese patients Therefore it is not possible to determine if Per",
        "label": "Contradiction"
    },
    "877e791d-73b6-4af2-945c-29f54005c405": {
        "text_answer": "  The statement one patient cohorts results are reported in both the primary clinical trial and the secondary clinical trial is not directly entailed in the given trials as there is no common patient cohort reported in both trials The primary trial reports the results of participants receiving denosumab while the secondary trial reports the results of participants receiving dmethadone Although there is a single patient cohort of 8 participants receiving dmethad",
        "label": "Contradiction"
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "text_answer": "  The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is entailed in the given trials as the total number of adverse events in cohort 1 45 is greater than the total number of adverse events in cohort 2 7",
        "label": "Entailment"
    },
    "bc1a73c0-825c-48dd-b6cf-e440ae0bb782": {
        "text_answer": "  Contradiction   The statement vorinostat capsules are strictly prohibited for all patients participating in the primary clinical trial during radiation therapy is in contradiction to the information provided in the trial description The trial description states that patients will take Vorinostat daily during radiation therapy and are recommended to swallow the capsule 6090 minutes prior to the estimated time of radiation This directly contradicts the statement that vorinostat caps",
        "label": "Contradiction"
    },
    "0d7caeea-5417-4eb2-9d92-3d3ada73ece7": {
        "text_answer": "  The statement is entailed in the given trials as neither trial reported any adverse events affecting more than 1 of participants and the statement specifically mentions that no such events occurred in either trial",
        "label": "Entailment"
    },
    "38acc5fa-c86b-4734-bdb6-7acbcd3c37c4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive oral pregabalin twice daily for 6 weeks which is not the same as intravenous administration of pregabalin every fortnight for over 6 weeks as stated in the statement   Furthermore the secondary trial does not involve the use of marqibo and ifosfamide as stated in the statement Instead",
        "label": "Entailment"
    },
    "94023f3a-38d4-4b1b-a65a-9536480ff4c4": {
        "text_answer": "  The statement Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time is an entailment with respect to the given trials inclusion and exclusion criteria   Explanation  The primary trial and the secondary trial have distinct inclusion and exclusion criteria The primary trial includes only postmenopausal women with a history of breast cancer taking hormonal therapy and experiencing severe hot flushes",
        "label": "Entailment"
    },
    "3f0e9340-88df-433f-8bdb-e32523b86a86": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The first intervention in the primary trial involves the use of Zoledronic Acid 4 mg Q4W 16 mg per 6 weeks and Denosumab 120 mg Q4W 480 mg per 6 weeks   The first intervention in the secondary trial involves the use of Tamoxifen 10 mg once daily for ",
        "label": "Entailment"
    },
    "9a7f95d5-8fb7-4f77-a921-00a2633e8cc4": {
        "text_answer": " The statement before the intervention all 61 cervical cancer patients in the first phase of the primary clinical trial had undertaken their scheduled screenings is not entailed in the given trial results The trial results only provide the percentage of participants who underwent colorectal breast and cervical cancer screenings before and after the intervention for two groups Collaborative Care Intervention and Prevention Care Management The statement makes a claim about all ",
        "label": "Contradiction"
    },
    "ffa6aa2b-661d-4e25-a893-6e03dea7e39e": {
        "text_answer": "  The statement is not entailed in the given trials as neither the primary nor the secondary trial directly measures the percentage of participants who experience clinical benefit using RECIST criteria The primary trial measures tumor response using RECIST criteria but it does not provide information about the percentage of participants who experienced clinical benefit The secondary trial measures various outcomes such as number of participants with AIMSS laboratory biomarkers qualityoflife assessment etc but it does not",
        "label": "Contradiction"
    },
    "ef79f4a4-d4ec-4a2a-a2a6-41ad41235927": {
        "text_answer": "  The statement every patient in the primary trial is receives a dose of 100 to 1600 microgram fentanyl sublingual spray during radiation therapy is not entailed in the given trial information   The trial only mentions the use of Vorinostat and Radiation Therapy and the dosing schedule for Vorinostat It does not mention anything about the use of Fentanyl sublingual spray or",
        "label": "Contradiction"
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "text_answer": "  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is neither entailed in the primary trial nor contradictory to it   Explanation   The primary trial explicitly excludes smokers no nicotine use within the last 5 years while the secondary trial does not mention anything about smoking However it does mention that participants",
        "label": "Entailment"
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort is entailed in the given data if we interpret affected more than a quarter as had an incidence rate greater than 25 In the given data no individual adverse event type had an incidence rate greater than 25 3571 is not greater than 25",
        "label": "Entailment"
    },
    "2a2a6190-619e-478b-a97d-5a253a8f916c": {
        "text_answer": "  The statement patients with a recent history of abdominal fistula or gastrointestinal perforation can participate in the primary clinical trial is contradictory to the trials exclusion criteria The trial explicitly states that No known hypersensitivity to phosphate trehalose or polysorbate and No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess",
        "label": "Contradiction"
    },
    "13eb7b14-5252-4004-8c72-56e3d5d3ca8a": {
        "text_answer": "  The statement a 5 decrease in the percentage of cells expressing ki67 was observed in patients from the primary clinical trial following more than 6 weeks of treatment with tak228 and tamoxifen is entailed in the trial results given as the median IQR of Ki67 expression at 6 weeks 10 238 is lower than the baseline median IQR of Ki67 expression",
        "label": "Entailment"
    },
    "87a42ef9-ff00-41f8-ba0a-9ca84498f7eb": {
        "text_answer": "  The statement just a pair of patients in the primary clinical trial failed to demonstrate recurrencefree survival is not directly entailed nor contradictory to the provided trial information The trial results only state that 98 out of 100 participants demonstrated recurrencefree survival but it does not specify how many patients experienced recurrence or did not demonstrate recurrencefree survival Therefore the statement cannot be definitively determined to be entailed or contradictory",
        "label": "Contradiction"
    },
    "5bc078b0-0b64-4d47-a015-26c3f03c864e": {
        "text_answer": "  The statement is entailed in the trials as described In the trials the dosage of enzalutamide for cohort 2 is indeed twice as much as that for cohort 1 Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "733d9f9f-9a01-4643-ab99-ac6086ad5cbc": {
        "text_answer": "  The statement the duration of the memantine intervention in the primary clinical trial is shorter than the placebo intervention is a contradiction to the information provided in the trial description   In Intervention 1 participants receive memantine for 81 days 12 weeks while in Intervention 2 participants receive a placebo for 81 days 12 weeks Both interventions last for the same duration Therefore the statement is contradictory",
        "label": "Contradiction"
    },
    "318ded6f-e96c-4a4f-8f4b-ff19f2e86c16": {
        "text_answer": "  The statement there are no recorded instances of coronary artery stenosis as an adverse event in the primary clinical trial is entailed in the given data since there is no instance of coronary artery stenosis listed among the adverse events reported in the trial",
        "label": "Contradiction"
    },
    "81a3bd04-5dff-45a6-a4eb-7a41c59b0023": {
        "text_answer": "  The statement There were no significant differences in the results from the groups in the primary trial however some differences where found between the Reflexology Group and control group results in the secondary trial is a contradiction to the information provided in the trials  In the primary trial there were no significant differences in the AUC between the LIP and SIP algorithms for breast cancer diagnosis However the trials do not provide any information about any differences between the two groups in terms",
        "label": "Contradiction"
    },
    "2aac2b30-f74d-4435-b7e6-ec5cd5923da3": {
        "text_answer": "  The statement in the primary clinical trial only four distinct adverse events influenced patients all found within cohort 2 is a stronger statement than the information provided in the trials The trials only mention the number and percentage of occurrences of each adverse event in both cohorts but they do not specify which adverse events influenced patients or were unique to cohort 2 Therefore the statement is not entailed in the trials and is a contrad",
        "label": "Contradiction"
    },
    "3e6a3ebb-face-44fe-8bb1-cbd399f4e215": {
        "text_answer": "  The statement is entailed in the trials as they cover two distinct studies with different outcome measurements The primary trial focuses on the frequency of treatmentemergent adverse events while the secondary trial evaluates the change in total sleep time using polysomnography The trials do not contradict each other as they address different aspects of the treatment",
        "label": "Entailment"
    },
    "5e8286c8-3e7c-4b71-b824-103d031ac6b4": {
        "text_answer": "  The statement The only AE recorded in the primary trial was Stomatitis ezhip overexpression positive is an indication that overexpression of ezhip has been detected in a sample is neither entailed nor contradicted by the given information in the trials  Explanation  The statement mentions two separate pieces of information 1 The only adverse event recorded in the primary trial was Stomatitis 2 ez",
        "label": "Entailment"
    },
    "d1424cd8-4dab-40a8-91b1-3ae5d1f57d56": {
        "text_answer": "  The statement several mortalities and admissions to the hospital occurred in the second cohort of the primary clinical trial and atrial fibrillation was also frequently detected is not directly entailed in the given trials as there is no mention of mortalities hospitalizations or atrial fibrillation in the second cohort in the trials provided However the trials do show a higher rate of adverse events including deaths in",
        "label": "Contradiction"
    },
    "78f50c70-09e5-4328-8ddf-f7e743527132": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different types of cancer breast cancer in the primary trial and neuroendocrine tumor in the secondary trial However the statement does provide some information that can be contrasted with the trials to determine if it is contradictory or not  The statement mentions that advanced nonfunctioning neuroendocrine tumors are extensively spreading or no longer responding to treatment and the primary",
        "label": "Contradiction"
    },
    "b7501704-ccba-40f8-852e-c157006483df": {
        "text_answer": "  The statement all patients in the primary trial receive at least 20kg of mcs110 every 30 weeks is not entailed in the given trials as there is no information provided in the trials about the weight of the patients or the total amount of MCS110 they receive during the trial The trials only specify the dosage of MCS110 1 mgkg or 3 mgkg and the frequency of administration ",
        "label": "Contradiction"
    },
    "0f0f75f2-7da8-4705-b260-62c5f542b91e": {
        "text_answer": "  The statement is a combination of information from both trials so we cannot directly verify it using the given trial information alone However we can check if each part of the statement is entailed or contradicted by the trials  1 in the primary trial only five cohorts receive armodafinil po daily  This statement is contradicted by the information in the primary trial In the primary trial there are two interventions one",
        "label": "Entailment"
    },
    "d8fa557b-e20a-4b49-be9c-b55a6bde385a": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different outcome measurements and patient populations The primary trial measures the number of participants with treatmentemergent adverse events in two different treatment groups while the secondary trial measures the change in total sleep time using polysomnography in a separate group of participants receiving Lenalidomide treatment The statement is indirectly related as it mentions that the primary trial measures average nap duration which is",
        "label": "Contradiction"
    },
    "33cd5bbd-a795-467e-b08f-cf59702922cc": {
        "text_answer": "  The statement is entailed in the trials as follows  Both trials measure pCR as their outcome In the primary trial there is a small difference in pCR rates between the two arms FEC75 then PaclitaxelTrastuzumab vs PaclitaxelTrastuzumab then TrastuzumabFEC75 with Arm 1 having a slightly higher pCR rate 56",
        "label": "Entailment"
    },
    "34199309-5388-4ed1-956d-17e9c7afaaef": {
        "text_answer": "  The statement is neither entailed in the primary trials nor contradictory to them The statement is about a concept external to the trials ie a refugee from a high tuberculosis prevalent area The trials focus on the inclusion and exclusion criteria for participants in the studies and the statement does not directly relate to those criteria",
        "label": "Entailment"
    },
    "1ce7b426-1be9-4684-b0a5-54d557d3b320": {
        "text_answer": "  The statement is making a comparison about the frequencies of specific adverse events recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage between the primary and secondary clinical trials   From the given data we can see that the frequencies of these adverse events in the primary trial were 500 recurrent malignancy 3500",
        "label": "Entailment"
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "text_answer": "  The statement is contradictory to the given trials as the interventions for Breast Cancer and Ovarian Peritoneal Cancer patients are not the same The doses of talazoparib administered to Breast Cancer patients in Part 1 and Part 2 are different from those given to Ovarian Peritoneal Cancer patients Therefore the statement is contradictory to the given trials",
        "label": "Entailment"
    },
    "4a383701-3a27-4973-8c8c-4f697bde7484": {
        "text_answer": "  The statement in the primary clinical trial patients are treated with irinotecan and etoposide is not mentioned in the given information for the primary or secondary trials Therefore it is neither entailed nor contradicted by the information provided The drug interventions for the primary and secondary trials are different suramin and paclitaxel for the primary trial and mastectomy surgery for the secondary trial with no mention of drugs for the secondary trial",
        "label": "Entailment"
    },
    "9a499642-970d-48b1-b0b4-96760793ba72": {
        "text_answer": "  The statement the primary clinical trial does not impose any stipulations regarding the participants liver function is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria do not mention anything about liver function either as a requirement or as an exclusion factor Therefore the statement is neutral with respect to the trials liver function requirements",
        "label": "Entailment"
    },
    "4e929375-b7c0-4a81-baa9-9c21d95366b7": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is evaluating the efficiency of two distinctive medicinal interventions Hydrophor and MediHoney in the context of radiation therapy  The secondary trial is evaluating the effect of two variable amounts 90 mg and 110 mg of the same drug PF05212384 on subjects undergoing docetaxelbased combination",
        "label": "Entailment"
    },
    "75cdd5c7-ad36-4ab3-8fe2-6d0e84ab8f0a": {
        "text_answer": "  The statement reactive epithelial hyperplasia of the ciliary body is an increase in cell number and volume of the ciliary epithelium usually in response to injury who 2018 is not entailed in the given trials as the trials do not provide any information about reactive epithelial hyperplasia of the ciliary body or any other eye conditions The trials only report the occurrence of adverse events and",
        "label": "Contradiction"
    },
    "d7637d6e-ba2c-4fdc-936d-57c3bf938eff": {
        "text_answer": "  The statement is a contradiction to the given trials In the primary trial the intervention for group 2 is the administration of 05ugkg of dexmedetomidine 5ml not myalgias In the secondary trial there is no mention of the administration of myalgias to any group Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "edd794e6-12c6-4d30-80ac-009951273d44": {
        "text_answer": "  The statement women with recurrent stage I breast cancer confirmed as ER are eligible for the primary clinical trial and the secondary clinical trial is not directly entailed in the given trials inclusion and exclusion criteria   The primary trial includes women with locally advanced recurrent or metastatic breast cancer and the secondary trial includes women with newly diagnosed or recurrent breast cancer The primary trial specifically mentions ER status and measurable disease",
        "label": "Contradiction"
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "text_answer": "  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is contradicted by the given data   Explanation   The statement implies that the frequency of diarrhea is higher in the primary trial than in the secondary trial However the data shows that diarrhea occurred in 7 out of 30 participants in the primary trial 2333 and not at all in",
        "label": "Contradiction"
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "text_answer": "  The statement All patients eligible for the secondary trial are also eligible for the primary trial is entailed in the given trials as all the inclusion criteria for the secondary trial are also present in the primary trial and none of the exclusion criteria for the primary trial are contradictory to the inclusion criteria for the secondary trial Therefore all patients who meet the criteria for the secondary trial will also meet the criteria for the primary trial",
        "label": "Entailment"
    },
    "c6194284-d44f-45c1-9477-754736bbf1a3": {
        "text_answer": "  The statement individuals with an HR positive HER2 negative breast tumor measuring 02 to 08 cm qualify for participation in both the primary and secondary clinical trials is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trial includes individuals with a breast tumor measuring 1 cm in diameter HR HER2 and a suitable candidate for neoadjuvant",
        "label": "Entailment"
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "text_answer": "  The statement Patients with a Vitamin D deficiency are excluded from the primary trial but may be eligible for the secondary trial is neither entailed nor contradicted by the given trial information   Explanation   The primary trial excludes patients with a serum 25OHD level  40 ngml which is a marker of Vitamin D deficiency However the secondary trial does not mention Vitamin D levels",
        "label": "Entailment"
    },
    "c78f1ce0-7597-415d-b5c3-203e696b48d5": {
        "text_answer": "  The statement in the primary trial results there were fewer patients with stable disease in week 15 than week 30 but 8 patients with complete response in week 15 or 30 is not directly entailed in the given trial results as the trial results do not provide information about the number of participants with stable disease in week 15 or week 30 nor do they mention the number of participants with complete response in week 15 Therefore",
        "label": "Contradiction"
    },
    "b80c2589-c792-4391-995c-6763270469dd": {
        "text_answer": "  The statement patients with low vitamin d levels in the primary clinical trial showed a discernible pattern for expression of the set of 40 evaluated genes is not entailed in the given trials as neither of the trials reported any discernible pattern for gene expression in patients with low vitamin D levels Both trials reported the number of participants with no discernible pattern for gene expression Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "cef48380-fe4b-4b71-931c-5b0dbfe1cf29": {
        "text_answer": "  The statement is contradictory to the trials inclusion criteria The trial is not unrestricted in the number of participants and it is specifically restricted to individuals with certain types of cancer including metastatic breast cancer metastatic colorectal cancer with Kras or BRAF mutation advanced or metastatic esophageal andor gastric cancer cisplatinrefractory unresectable germ cell tumors",
        "label": "Entailment"
    },
    "d9a63f26-68c3-431f-851f-131f7a547902": {
        "text_answer": "  The statement is contradictory to the given trials as there is no mention of psychological health issues in the reported adverse events for either cohort",
        "label": "Contradiction"
    },
    "884bc204-4928-430b-b44d-1e33ef66731d": {
        "text_answer": "  The statement in the primary clinical trial a patient post organ transplant within the span of a month would not be considered although they could potentially be fit for the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However the primary trial does include The participant has undergone major surgery within 28 days prior to the study registration date as an exclusion criterion which could be interpreted",
        "label": "Entailment"
    },
    "9e19e98e-3ce1-4b01-9080-ad34e68f0acb": {
        "text_answer": "  The statement in the primary clinical trial except one all patients who received sunitinib  docetaxel  trastuzumab experienced a treatmentemergent adverse event and less than fifty percent experienced severe treatmentemergent adverse events is not directly entailed in the given trial results   The trial results only provide the number of participants who experienced any adverse event AE and severe adverse event SAE",
        "label": "Contradiction"
    },
    "58429d01-0c6a-4ae1-b8ce-73ee8a8e775d": {
        "text_answer": "  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent is entailed in the given trials as both trials include Signed informed consent form in their inclusion criteria However the statement organ perforation is a rupture in an organs due to traumatic or pathologic processes is not directly related to the trials inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "87be81ce-d5b1-4905-9452-2e0e2d4b7b2c": {
        "text_answer": "  The statement is not entailed in the given trial information The statement mentions a maximum dose of 100000 gm2 but the trial description only specifies the doses of each drug without providing a total dose limit The participants in the trial do receive four different drugs epirubicin cyclophosphamide docetaxel and trastuzumab but the total dose of these drugs throughout",
        "label": "Contradiction"
    },
    "519fe8b4-596f-4db6-af13-80d9746041a6": {
        "text_answer": "  The statement primary clinical trial enforces a strict age limit of 18 to 65 years for all participants is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information provided However the criteria do include an age range for participants female patients but it does not state that there is a strict limit and it goes beyond the given range 1",
        "label": "Entailment"
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "text_answer": "  The statement patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced andor metastatic is entailed in the given inclusion criteria for both Phase 1 and Phase 2 of the trial Therefore the statement is entailed in the trial description  Explanation  The statement patients of any gender can be eligible for both phases of the primary trial if",
        "label": "Entailment"
    },
    "e2a5ecca-6d4a-438b-a42c-46657ccb4050": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered at least 1 lifethreatening adverse event is not directly entailed in the provided trial results The trial results only report the number of participants with serious and nonserious adverse events but they do not specify which cohort Dose Level 1 had a lifethreatening adverse event or the total number of participants in that",
        "label": "Contradiction"
    },
    "808d2233-0c0d-4221-bfae-e54fdcf31ce4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial shows that there is a difference in diagnostic accuracy between the two algorithms with the Siemens algorithm having a slightly lower AUC 0880 compared to the Lorads algorithm 0884 This difference however is not significant enough to conclude noninferiority  The secondary trial shows that there is a significant",
        "label": "Entailment"
    },
    "fb616088-52c2-4dae-84e5-8a1a3fa9b64f": {
        "text_answer": "  The statement liter per hour per kilogram per meter squared is a unit of concentration equal to liter per hour divided by kilogram per meter squared is a mathematical definition and is not directly related to the inclusion and exclusion criteria of the primary trial   The statement does not entail nor contradict the information provided in the trial criteria",
        "label": "Entailment"
    },
    "f2d7cf41-2cd1-4d03-a153-18764cf7da09": {
        "text_answer": "  The statement On average both cohorts of the primary trial suffered a deterioration in cognitive function however this was not the case for all patients is not directly entailed in the given trial results   The trials only provide the mean standardized scores and standard deviations for each group but they do not explicitly state that there was a deterioration in cognitive function on average for both cohorts Additionally the statement goes beyond the information given in",
        "label": "Contradiction"
    },
    "1748cec0-92de-44af-9d49-bf45518c24bc": {
        "text_answer": "  The statement if in both trials there were no adverse events which occurred in more than 1 of participants is entailed by the given trials as both trials report no adverse events that occurred in more than 1 of participants 048 and 000 are less than 1",
        "label": "Contradiction"
    },
    "939de4be-2f3d-4e0d-a5b9-a80f6469bd22": {
        "text_answer": "  The statement meters times percent is a unit of measure for the distance saturation product dsp is not entailed in the given trials as there is no mention of the distance saturation product dsp or its unit of measurement in the trials The trials only report the occurrence of various adverse events and their respective frequencies Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "3cb08dda-e0dc-48e5-87fa-e24386d6dab2": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial is a simplification of the exclusion criteria provided in the trial description However the statement is not an exact representation",
        "label": "Entailment"
    },
    "e7be25fe-5915-4c38-b3c0-4e4acd5edd5c": {
        "text_answer": "  The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is entailed in the inclusion criteria of the trial as stated in point E under the Disease Characteristics section Therefore the statement is entailed in the trial information",
        "label": "Entailment"
    },
    "95840c1a-9e38-4fe5-939c-e6f9aa107ced": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation   The statement implies that there were adverse events reported in the primary trial that were not reported in the secondary trial and were considered serious However the given data shows that there were no adverse events reported in the primary trial at all let alone any serious ones Therefore the statement is contradictory to the given data",
        "label": "Contradiction"
    },
    "6e5e4b46-3bc7-4ae1-8668-9b4f2f72f791": {
        "text_answer": "  The statement women under 18 are qualified to participate in both the secondary and primary trial is contradictory to the inclusion criteria of both trials   In the primary trial the inclusion criteria explicitly states that patients must be aged greater than 20 years In the secondary trial the inclusion criteria states that participants must be women and men ages 18 or older Therefore women under 18 are explicitly excluded from both trials  Th",
        "label": "Entailment"
    },
    "454c83f7-949e-46bf-bd9a-5f14e6ba4713": {
        "text_answer": "  The statement Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the information provided in the trials inclusion and exclusion criteria  In the primary trial there is no mention of gabapentin or pregabalin as exclusion criteria Therefore prior treatment with these medications would not result in exclusion from the primary trial  However in the secondary",
        "label": "Contradiction"
    },
    "4678ba70-3ec1-487b-a641-bdbd790892ac": {
        "text_answer": "  The statement 274 of the primary trial participants and 0 of the secondary trial participants suffered an acute myocardial infarction is a contradiction to the given trials as no cases of acute myocardial infarction were reported in either trial The primary trial had 4 participants with a 000 incidence and the secondary trial had 1674 participants with a 000",
        "label": "Contradiction"
    },
    "5f36a4ca-cd2f-4c38-8040-9b36da0ebbe4": {
        "text_answer": "  The statement only American patients who fall into a specific weight range are eligible for the primary clinical trial is not entailed in the given inclusion criteria for the primary or secondary trials The trials only specify the age performance status and certain health conditions as inclusion criteria without any mention of specific weight ranges for American patients",
        "label": "Contradiction"
    },
    "358cd111-420a-401d-bd92-e459d3725026": {
        "text_answer": "  The statement patients who are severely obese or pregnant may be considered for the primary clinical trial and the secondary clinical trial is neither entailed in the primary trials inclusion or exclusion criteria nor contradictory to them   The primary trials inclusion criteria do not mention obesity as a factor and the exclusion criteria do not mention pregnancy as a factor for the neoadjuvant chemotherapy cohort However for the ne",
        "label": "Entailment"
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "text_answer": "  The statement Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial is contradictory to the given data   The primary trial had a total of 90 adverse events out of 223 patients with one case of pericardial effusion The secondary trial had a total of 4 adverse events out of 9 patients with no cases",
        "label": "Contradiction"
    },
    "ab3fc92f-0d8a-472f-b652-e10bcd03ff19": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than one patient is not directly related to the information provided about the types and number of adverse events in the trial for reconstructive plastic surgery The statement only mentions that no individual adverse event affected more than one patient but it does not specify which trial or study the statement refers to The information provided in the trial about the types and number of adverse events does not contrad",
        "label": "Contradiction"
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is not directly entailed or contradicted by the given data The data only provides information about adverse events specifically instances of lymphoma in the two trials but it does not mention any unexpected deaths or hospitalizations Therefore the statement cannot be determined to be entailed or contradicted based on the given information alone",
        "label": "Contradiction"
    },
    "e5d16f98-79d0-44e1-9fc0-7bb6ae9a038d": {
        "text_answer": "  The statement cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1 is entailed in the trials description since the dosage for cohort 2 is 160 mg which is double the dosage of 80 mg given to cohort 1 Therefore the statement is entailed in the trials description  However the statement moderately diss",
        "label": "Entailment"
    },
    "5ce6e37b-2c84-44e1-8c5e-e441cec64872": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000 mcg of talazoparib daily is not directly mentioned in the provided trial description However the trial description does state that several of the primary trial candidates are administered talazoparib daily without specifying the dosage Therefore the statement several of the primary trial candidates are administered 1000 mcg of tal",
        "label": "Entailment"
    },
    "1e32317b-5301-461d-bdd9-0acb2e076522": {
        "text_answer": "  The statement adverse events were carefully documented in both the primary clinical trial and the secondary clinical trial is entailed in the given trials data as both trials report the total number of adverse events for each category in each trial",
        "label": "Entailment"
    },
    "04c5ba38-d98e-4fd7-b5f4-ea4706f26355": {
        "text_answer": "  The statement is entailed in the trials as follows  The only difference between interventions 1 and 2 is the dose of durvalumab in the biweekly IV infusions In intervention 1 the dose is 03 mgkg and in intervention 2 the dose is 1 mgkg This difference translates to a 07 mgkg difference in favor of intervention 2 Therefore the statement",
        "label": "Entailment"
    },
    "9f97138b-399f-42bf-9afe-e7195db4e5b4": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair about 10 of waking hours are eligible for both the primary trial and the secondary trial is not explicitly stated in either the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it cannot be definitively determined if the statement is entailed in the trials or not without additional context or information  However based on the information given there is",
        "label": "Entailment"
    },
    "ae583e53-d445-4b4a-b49a-c440881180e7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation  The primary trial does not mention the dosages or volumes of any specific interventions only the number of individuals approached for participation   In the secondary trial the HR subgroup in Intervention 1 receives a 2 week runin of MM121 with a loading dose of 40 mgkg and weekly doses",
        "label": "Entailment"
    },
    "fa5e894c-13be-4786-ac47-16d31de8a7ce": {
        "text_answer": "  The statement distress over family problem with family health issues is a question about an individuals distress related to their family problems dealing with family health issues is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However the statement does not contradict the criteria as well The trials focus on the eligibility of patients based on their cancer status hormone receptor status prior treatments and organ function among other factors",
        "label": "Contradiction"
    },
    "67bce826-0ca5-477c-8802-2511317e675d": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials include the use of cyclophosphamide in their interventions",
        "label": "Entailment"
    },
    "bbda33ff-3d5b-445e-afec-a20518fd2c79": {
        "text_answer": "  The statement There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial is entailed in the given trials data   Explanation   The statement is entailed because the trials data shows that the total number of adverse events in the secondary trial 48348  1379 is greater than that in the primary trial 014 ",
        "label": "Entailment"
    },
    "68d0da33-c4ad-4649-bb63-08290cd4d4e2": {
        "text_answer": "  The statement is contradictory to the information provided in the given trials   The primary trial does not mention a mandatory mammography as a requirement for participation but rather it is a prerequisite for eligibility The secondary trial does not mention mammography as a requirement at all Instead it requires CT scans and blood tests Therefore the statement that a mandatory mammography is required for candidates intending to participate in the primary clinical trial is",
        "label": "Entailment"
    },
    "fc7722bc-9fed-46cf-881d-265c3f3762b4": {
        "text_answer": "  The statement 273 the primary trial participants and 01674 the secondary trial participants suffered an Acute myocardial infarction is not entailed in the given trials as there is no occurrence of Acute myocardial infarction reported in either trial The statement is contradictory to the trials as the trials report a total of 0 acute myocardial infarctions in both trials",
        "label": "Contradiction"
    },
    "a9cbf72a-fd01-403d-8afa-d9d6a69622a0": {
        "text_answer": "  The statement 5 patients in the primary trial suffered 3 or more adverse events is not directly entailed in the given trial data However it is not contradictory either as the trial data does not provide sufficient information to definitively determine whether or not this statement is true The trial data only lists the number and types of adverse events for each patient but it does not specify how many adverse events each patient experienced in total Therefore it is possible",
        "label": "Contradiction"
    },
    "41c54be8-c257-49dc-b21b-0184595c1277": {
        "text_answer": "  The statement is entailed in the trials as follows  Cohort 1 receives a dose of ALT801 that is less than half of the dose given to cohort 2  0015 mgkgdose cohort 1  05  0040 mgkgdose cohort 2  0015 mg",
        "label": "Entailment"
    },
    "4417c4c8-522f-4e46-8b8d-310995182d70": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial has 10 participants fewer than cohort 1 is a contradiction to the information provided in the trials   The number of participants analyzed in each armgroup for both cohorts are given as follows  Cohort 1 Arm I 234 participants Cohort 2 Arm II 234  10  2",
        "label": "Contradiction"
    },
    "7b74835d-12ba-4d02-a09c-817f33abd3b2": {
        "text_answer": "  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent is entailed in the given trials as both trials include Signed informed consent form in their inclusion criteria Therefore patients with stage 4 cancer who provide informed consent are eligible for both trials",
        "label": "Entailment"
    },
    "3dab8f67-6eca-4ace-ba49-0bd33547b004": {
        "text_answer": "  The statement while most patients in the first cohort of the primary clinical trial endured adversities the same cannot be said for the second cohort is a contradiction of the given data   The statement implies that a larger percentage of patients in the first cohort experienced adverse events compared to the second cohort However the data shows that the percentage of patients with adverse events in the first cohort 424",
        "label": "Contradiction"
    },
    "359a101f-e771-4fac-b2f7-a5486fb19344": {
        "text_answer": "  The statement Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant is not directly entailed in the given trials as the trials do not provide sufficient information about the number of emesis episodes experienced by each participant in the two groups However the trials do indicate that there were fewer emesisfree days in the placebo group compared to the Aprepitant group 5 emesisfree days",
        "label": "Contradiction"
    },
    "cbbd5644-6e63-4f6d-b948-fe52b5df89c7": {
        "text_answer": "  The statement in the primary clinical trial the individual with the maximum PFS managed to live 35 months without disease advancement or death is not directly entailed in the given trial results The trial results only report the median PFS for each treatment group not the maximum PFS for any individual participant Therefore the statement is not a valid conclusion based on the provided information and is considered contradictory to the trial results",
        "label": "Contradiction"
    },
    "2fb19f2c-7bda-446c-bf0c-8e9842e89c97": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial states that cabergoline is given orally PO not topically The secondary trial states that pixantrone is given intravenously IV not topically Therefore neither trial entails the statement that the intervention is administered topically",
        "label": "Entailment"
    },
    "be93f6ab-df27-4f10-a485-24823f7056fc": {
        "text_answer": "  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is not entailed in the given trials as there is no mention of Cholelithiasis in either trial Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "effcbfa0-9271-4463-9e48-5523d5cedeb6": {
        "text_answer": "  The statement despite satisfying all eligibility conditions for the primary clinical trial the final call for participation will be taken by the patients closest family member is not entailed in the given inclusion and exclusion criteria for the clinical trial The criteria only specify the medical conditions for eligibility and ineligibility for the trial and do not mention any role for family members in the decisionmaking process",
        "label": "Contradiction"
    },
    "1f309606-5b98-4320-ab02-24e782e7250d": {
        "text_answer": "  The statement median or lower cervical lymph node is a lymph node located in the median or lower region of the neck is not directly related to the information provided in the trials The trials report the results of interventions and their respective outcomes in terms of hot flash scores and overall response rates The statement about the location of median or lower cervical lymph nodes is anatomical information and does not entail or contradict the information presented",
        "label": "Entailment"
    },
    "f0a1bf43-c080-446d-815a-c588c7563e89": {
        "text_answer": "  The statement several participants in the primary clinical trial receive a daily dose of 1000 mcg of talazoparib as part of the program is not explicitly stated in the provided trial information However it is mentioned that Eligible Patients Assessable for the Primary Outcome Measure are given a daily dose of talazoparib without specifying the exact dose Therefore the statement is neither entailed nor contrad",
        "label": "Entailment"
    },
    "de3effdb-0854-48a8-b66c-b61378ec7a6f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials do not mention any radiation therapy being administered to the patients in either the primary or secondary interventions Therefore the statement is not entailed in the trials and is contradictory to the given information",
        "label": "Contradiction"
    },
    "d2673e8f-15c9-4476-b8b6-2567822d5cd4": {
        "text_answer": "  The statement bladder small cell neuroendocrine carcinoma is not related to the primary trial results is contradictory to the information provided in the trials as the primary trial is about invasive diseasefree survival in patients with earlystage breast cancer treated with Neratinib or placebo The statement does not follow from the trials as the trials do not provide any information about bladder small cell neuroendocrine carcinoma",
        "label": "Entailment"
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is contradicted by the given data   In the primary trial there was 1 occurrence of palpitations 2 occurrences of pericardial effusions and 1 occurrence of abdominal pain In the secondary trial there were no occurrences of palpitations",
        "label": "Contradiction"
    },
    "5c535bb9-8464-4820-b872-506057f2cd87": {
        "text_answer": "  The given statement is a contradiction to the results presented in the trials   The trials only report the median with range change in total body lean mass for the GTx024 1 mg and 3 mg groups There is no information provided about any participant in the 8 mg group gaining over 17 kilos of lean body mass Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "94328fa0-182a-4275-929c-bc10f899ba5d": {
        "text_answer": "  The statement regardless of a previous encounter with a pulmonary embolism patients can apply for the secondary trial is not directly mentioned in the inclusion or exclusion criteria for the secondary trial provided Therefore it cannot be definitively determined if the statement is entailed in the trial or not based on the given information  The statement the presence of breast implants does not hinder patient participation in the primary trial is not explicitly stated in the exclusion",
        "label": "Entailment"
    },
    "a668e3be-6b87-468e-99b5-48ad77bed972": {
        "text_answer": "  The statement Patients with a histologicallycytologically confirmed diagnosis of a Nonsmall cell lung cancer or Small cell lung cancer are eligible for the primary trial is entailed in the inclusion criteria of the trial as stated in the text Therefore the statement is entailed in the trial information  The statement photovoice is a qualitative method in which participants use photographic techniques to facilitate the documentation and communication of issues is not directly related to",
        "label": "Entailment"
    },
    "59d62015-4627-4fef-acba-984ff4ad2964": {
        "text_answer": "  The statement is not entailed in the given clinical trial information as the trials do not involve vaccines but rather chemotherapy drugs doxorubicin cyclophosphamide docetaxel and bevacizumab for breast cancer treatment",
        "label": "Contradiction"
    },
    "e4b57c09-4069-463e-9db3-70860f520524": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants are given seven different types of drugs doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate and vinorelbine tartrate They also undergo surgery and correlative studies such as needle biopsy immunoh",
        "label": "Entailment"
    },
    "4e68783f-fc2b-4efb-88da-b5d081ff5541": {
        "text_answer": "  The statement unfavorable outcomes were reported in equal measure from patients in both divisions of the primary clinical trial is neither entailed nor contradicted by the given trials data   Explanation  The statement does not follow directly from the data provided in the trials as the trials do not give the same number of patients in each division for comparison Additionally the types of unfavorable outcomes reported in each trial are not identical with febrile neut",
        "label": "Entailment"
    },
    "d7abc723-e08e-442e-82e4-3e369341b72a": {
        "text_answer": "  The statement is contradictory to the information provided in the secondary trial The primary trial does not mention any age or gender restrictions but the secondary trial only accepts patients who are 18 years of age or older with specific types of cancer The statement incorrectly implies that pediatric cancer patients under the age of 18 can participate in the secondary trial which is not the case",
        "label": "Entailment"
    },
    "60f6302e-f888-4bc2-b689-f0620024f93e": {
        "text_answer": "  To determine if the statement is entailed in the trials or if it is a contradiction we need to compare the total number of adverse events in each cohort and the percentage of adverse events in relation to the total number of participants  The total number of adverse events in cohort 1 was 45 and the total number of participants was 106 Therefore the percentage of adverse events in cohort 1 was",
        "label": "Entailment"
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "text_answer": "  The statement There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial is entailed by the given trials as both trials report a total of zero adverse events Aes for cardiac and psychiatric categories",
        "label": "Contradiction"
    },
    "4dcbfb0d-cb67-4d74-a21a-0920159dfafc": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial did not make a record of any adverse events is entailed by the given data since the data reports that there were no adverse events recorded in either trial",
        "label": "Entailment"
    },
    "3bde4a4f-fece-4422-a55a-461fa027c18a": {
        "text_answer": "  The statement Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is a statement about the use of Perjeta in the trials which is not directly related to the information provided about the trials regarding Fulvestrant Anastrozole HER2targeted PETCT and mature testicular teratoma   The statement about Perjeta is not mentioned in either the",
        "label": "Entailment"
    },
    "31546be8-dcef-4300-a21d-831c25e5b92a": {
        "text_answer": "  The statement is partially entailed in the trials   The statement 0 adverse events were observed in the primary trial is entailed in the trial data as it is explicitly stated in the primary trial section that there were no adverse events  However the statement none of the adverse events in the secondary trial affected more than 30 of patients apart from Skin infections is not directly stated in the trial data Instead it",
        "label": "Entailment"
    },
    "d3a0e851-28c4-4382-bb3e-8c40bc16ae7a": {
        "text_answer": "  The statement diarrhea was noted as a more common symptom among primary clinical trial participants as compared to those of the secondary clinical trial is entailed in the given trials as follows  The primary trial had 7 cases of diarrhea out of 30 participants which is a frequency of 2333 The secondary trial had 0 cases of diarrhea out of 6 participants  Therefore the",
        "label": "Entailment"
    },
    "05aafe0b-c62a-4dda-a60a-52929cb81b7f": {
        "text_answer": "  The statement is entailed in the trials exclusion criteria as follows  Exclusion Criteria  No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months  No history of myocardial infarction MI stroke or transient ischemic attacks in the last 6 months  No serious nonhealing wound",
        "label": "Entailment"
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "text_answer": "  The statement patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer is entailed in the given inclusion criteria for both phases of the trial   Inclusion Criteria for Phase 1  Have evidence of a solid tumor that is locally advanced andor metastatic excluding primary brain tumor  Inclusion Criteria for Phase 2  Have disease meas",
        "label": "Entailment"
    },
    "6333ef7c-fdfe-4f90-b763-4d826c08975c": {
        "text_answer": "  The statement is entailed in the given trials as both trials report that less than 1 of the participants experienced adverse events and the statement does not contradict any information provided in the trials",
        "label": "Entailment"
    },
    "66030da0-0335-44c8-97dd-a620f3d9961f": {
        "text_answer": "  The statement insomnia patients irrespective of the severity of their condition are invited to take part in both the primary clinical trial and the secondary clinical trial is not directly entailed in the given inclusion criteria for either trial   However the statement is not contradictory to the given criteria as well The primary trial has no specific mention of insomnia as an inclusion or exclusion criterion The secondary trial includes insomnia as an inclusion",
        "label": "Contradiction"
    },
    "72130361-5d83-4dbb-98ce-8e9a6f2541e4": {
        "text_answer": "  The statement the secondary trial and the primary trial use the same outcome measurement the proportion of patients with pCR Within the Breast Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy is contradictory to the information provided in the trials   The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH and",
        "label": "Contradiction"
    },
    "72b75fca-541f-4311-a38d-9f1d73220418": {
        "text_answer": "  The statement notice change in the way food tastes is a question about whether an individual notices or noticed a change in the way food tastes is not directly related to the information provided in the primary or secondary trials The primary trial reports the percentage of participants in the denosumab arm who achieved a response within 10 days of the first dose while the secondary trial reports the number of participants in a cohort who reached a safe dose of dmethad",
        "label": "Entailment"
    },
    "66bf512a-c3fd-46a8-8a0b-4d64fde85082": {
        "text_answer": "  The statement unmutated immunoglobulin heavy chain variable region gene is a molecular finding indicating that the immunoglobulin heavy chain variable region has an unmutated germline configuration is not directly entailed in the primary or secondary trial inclusion or exclusion criteria However it is mentioned in the primary trial inclusion criteria for NUT midline carcinoma that the diagnosis can be confirmed by immunohistochemistry IHC and",
        "label": "Contradiction"
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "text_answer": "  The statement is entailed in the trials In the primary trial no information is given about the specific interventions received by the patients in the mastectomy surgery group However in the secondary trial the HR subgroup in intervention 1 receives a 2 week runin of MM121 20 mgkg weekly followed by 12 weeks of MM121 20 mgkg weekly and",
        "label": "Entailment"
    },
    "e59036ac-08b6-44ed-ad46-292a3bb8a937": {
        "text_answer": "  The statement no fatalities or hospital stays occurred in the second cohort of the primary clinical trial and only one instance of atrial fibrillation was observed is entailed in the given trials data as follows  1 The statement no fatalities occurred in the second cohort is entailed by the fact that the total number of deaths in the second cohort is 0 000 2 The statement",
        "label": "Contradiction"
    },
    "c01204e3-a0fd-4153-a27d-d17c0bb4773b": {
        "text_answer": "  The statement many patients in the first cohort of the primary clinical trial did not adhere to their screening schedules following the intervention independent of their cancer type is not directly entailed in the given trial results However it could be inferred from the data that there was an increase in the percentage of participants who were up to date with their colorectal breast and cervical cancer screenings after the intervention in both the CCI and PCM",
        "label": "Contradiction"
    },
    "21b261e7-4b78-4c70-ba0c-b98c5c082bee": {
        "text_answer": "  The statement the azd0530 0175 g group of the primary trial experienced a more significant percentage change in betactx at week 4 than the zoledronic acid 4 mg group is not directly entailed in the given trials as they only report the percentage change in betaCTX at week 4 and do not provide information about week 28 Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "29c084b6-6c7c-4f6b-abcc-6740b951f139": {
        "text_answer": "  The statement in cohort 2 the primary clinical trial had a significantly higher patient enrollment compared to the secondary clinical trial is not directly entailed in the given trials as the trials do not provide the number of participants in each cohort for comparison The trials only provide the number of participants analyzed for each arm of the trials",
        "label": "Contradiction"
    },
    "0feb3694-da20-4a30-b85d-e9dc4cdb55c3": {
        "text_answer": "  The statement the primary and the secondary trial reported an equal number of intestinal perforation cases is contradictory to the given data In the primary trial there were no cases of intestinal perforation reported while in the secondary trial there was 1 case reported Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Contradiction"
    },
    "551f61b2-c709-4c51-b705-d2415e40ae40": {
        "text_answer": "  The primary trial and the secondary trial do not assess the same patient characteristics in their results   The primary trial measures the number of participants who experience excessive toxicity Grade 3 toxicity excluding certain types from the vaccine therapy with HER2specific T cells The secondary trial measures the percentage of participants who experienced adverse events of primary interest AEPIs which include hepatic events allergic reactions thrombocytopenia",
        "label": "Entailment"
    },
    "dc9267c3-b1ab-45d1-8a22-a9ec8e7ba673": {
        "text_answer": "  The statement The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention regardless of cancer type is entailed in the trials provided   Explanation   The trials show that a higher percentage of participants in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for their colorectal breast and c",
        "label": "Entailment"
    },
    "72d13f98-6915-4a80-9810-c06d0e204b1e": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX at week 4 between the two groups   According to the given data the AZD0530 175 mg group had a greater percentage change in betaCTX at week 4 compared to the Zoledronic Acid 4 mg group Specifically the AZD0530 group had a percentage change of",
        "label": "Entailment"
    },
    "2e9d87da-10f2-4530-b200-87bb72cd9335": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials   In the primary trial individuals with a history of breast cancer including ductal carcinoma in situ are listed as exclusion criteria However in the secondary trial individuals with a history of breast cancer including ductal carcinoma in situ are considered eligible  Regarding uncontrolled hypertension it is listed as an exclusion criterion in both",
        "label": "Entailment"
    },
    "d542b63b-a355-4a0e-8ec9-3c74bb1e0dcb": {
        "text_answer": "  The statement only a minority of patients in the primary clinical trial had a complete response by the 24th week is not directly entailed in the given trial results However it is implied based on the information provided that the number of participants with CR at Week 24 is zero Therefore the statement is consistent with the trial results However it does not follow directly from the results as the trial also reports the number of participants with PR and SD To",
        "label": "Contradiction"
    },
    "2f1db1ac-f8d0-4087-856e-dfcff97c75a5": {
        "text_answer": "  The statement individuals who have experienced a pulmonary embolism in the previous 8 weeks are eligible for participation in the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for the primary trial However it is stated that patients with thrombotic or embolic events such as a stroke and transient ischemic attack within the past 6 months are excluded from the primary trial There is no mention of pulmon",
        "label": "Contradiction"
    },
    "bd2b336d-30ae-4151-a920-9506a013ab14": {
        "text_answer": "  The statement lipase unit is a dosing unit based on lipase activity is not directly related to the inclusion and exclusion criteria of the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given trial information alone",
        "label": "Entailment"
    },
    "d5fe5d1e-b4c8-46d1-879f-06f14157c3ee": {
        "text_answer": "  The statement hormone therapyrequiring breast cancer patients are eligible for the primary clinical trial is entailed in the given trials inclusion criteria since the trial specifically states that participants must have breast cancer that has continued to grow despite hormonal treatment and must be postmenopausal women both of which are requirements for hormone therapyrequiring breast cancer patients Therefore the statement is entailed by the trials criteria",
        "label": "Entailment"
    },
    "9ed2eb80-3810-40fc-b26a-d2e93feb061d": {
        "text_answer": "  The statement bus device is a set of electrical conductors designed to route data from multiple locations in a computer is not entailed in the given inclusion and exclusion criteria for the primary or secondary trials The trials only mention criteria related to the health status age and cancer diagnosis of potential participants Therefore the statement is not related to the trials and is neither entailed nor contradicted by the provided information",
        "label": "Contradiction"
    },
    "dad4efbe-c7ae-4507-8a04-853a132b497a": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment is given orally PO whereas in the secondary trial both intervention groups receive intravenous IV infusions of pixantrone dimaleate Therefore the statement while the primary trials treatment is taken orally the treatment in the secondary trial is dispensed exclusively through intravenous means is an accurate description of the trials and is ent",
        "label": "Entailment"
    },
    "c574fb87-713c-43cd-a147-215f98ff6d35": {
        "text_answer": "  The statement is entailed in the Trials as the trials describe different interventions for breast cancer and ovarianperitoneal cancer patients in terms of the dosage of talazoparib they received",
        "label": "Entailment"
    },
    "fca56898-5587-4c6a-ae87-86dfae3a4961": {
        "text_answer": "  The statement General symptoms are the most common AE recorded in the primary trial is not directly stated in the given data However the statement General symptoms are somewhat common AE recorded in the primary trial can be inferred from the data as there are a total of 2 general symptoms recorded out of 16 adverse events which is approximately 1216 of the total This is less than the 3137 reported",
        "label": "Entailment"
    },
    "5a25fa73-5358-4d36-acc0-ea23cb358a4d": {
        "text_answer": "  The statement there were no recorded instances of doselimiting toxicity from any patients participating in the primary clinical trial is entailed in the given trials as both trials report no instances of doselimiting toxicity in any of the participants Therefore the statement is entailed by the information provided in the trials",
        "label": "Contradiction"
    },
    "475425c4-cfbf-4742-86ad-b09806d19687": {
        "text_answer": "  The statement in the primary clinical trial the most recurring adverse event recorded is coronary artery stenosis is a contradiction to the given data The most recurring adverse events according to the data are nausea vomiting and general symptoms each occurring twice 392 Coronary artery stenosis is not mentioned in the data at all",
        "label": "Contradiction"
    },
    "8e66baf7-890a-4a73-9542-814980f89689": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial participants received PF06647020 at a dose of 02 mgkg and 05 mgkg in Intervention 1 and Intervention 2 respectively In the secondary trial participants received ALT801 at a dose of 0015 mgkg and ",
        "label": "Entailment"
    },
    "0935ad04-3112-4443-8f3a-6b3a07ac9d33": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria which specify a minimum primary tumour diameter of greater than 2 cm Therefore a patient with a primary tumour of 03 cm radius approximately 06 cm diameter would not meet the primary trial inclusion criteria and would not be eligible for that trial However the secondary trial inclusion criteria do not specify a minimum tumour size so a patient with a smaller primary tumour could",
        "label": "Entailment"
    },
    "e44f0355-dac8-4405-b3b1-ceb87cbb121d": {
        "text_answer": "  The statement the primary clinical trial could have eligibility for a patient who has been diagnosed with neoplastic meningitis is contradictory to the trials eligibility criteria as stated No meningeal carcinomatosis Therefore the statement is contradictory to the trials eligibility criteria",
        "label": "Contradiction"
    },
    "128e4316-cd80-4dff-9d54-3030e9921c77": {
        "text_answer": "  The statement cases of mucositis oral thromboembolic events and bladder infection were more prevalent in the primary trial than in the secondary trial is a contradiction of the given data  Explanation  The statement implies that there were more cases of mucositis oral thromboembolic events and bladder infection in the primary trial than in the secondary trial However the data provided",
        "label": "Contradiction"
    },
    "5acd7311-862e-440b-aecd-64f015c7deb6": {
        "text_answer": "  The statement in the primary clinical trial Abraxane doses diverge between cohorts is entailed in the given trial description since the doses of NabPaclitaxel are identical between the two arms 125 mgm2 but the companion drugs differ gemcitabine in Arm A and carboplatin in Arm B Therefore the Abraxane doses are the same but the doses",
        "label": "Entailment"
    },
    "5cf2e65a-45cd-490e-8933-23bf36558b11": {
        "text_answer": "  The statement every patient in each cohort of the primary clinical trial experienced an incidence of doselimiting toxicity is not directly entailed in the given trial results as they only report the number of participants analyzed in each cohort without specifying if all experienced doselimiting toxicities However it is important to note that the trial results do indicate that doselimiting toxicities were assessed for all participants using the NCI CTC Version ",
        "label": "Contradiction"
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "text_answer": "  The given trials do not provide sufficient information to determine if the statement Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome is entailed or contradicted Tumour lysis syndrome is not listed as an adverse event in either trial Therefore we cannot determine if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "56c99670-a2ba-42ca-b870-e3d98f2f4169": {
        "text_answer": "  The statement is entailed in the given clinical trial information The inclusion and exclusion criteria are clearly stated and the statement emphasizes that the decision to include a patient is based solely on those objective criteria without any influence from the judgment of the health professionals This aligns with the information provided in the clinical trial description",
        "label": "Entailment"
    },
    "eab0f794-5caa-49fc-b951-7db4b7169a46": {
        "text_answer": "  The statement a history of conditions such as abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or serious psychiatric illnesses within the preceding six months disqualifies patients from participation in the primary clinical trial is entailed in the given inclusionexclusion criteria The exclusion criteria explicitly state that patients with",
        "label": "Entailment"
    },
    "c4b53dae-5bcf-4356-825d-0701f5c9b545": {
        "text_answer": "  The statement The number of hypertension and pancreatic resection cases were ten times higher than cases of hepatotoxicity is not directly entailed in the given trial data   The trial data states that there were 1 case of hypertension and 1 case of pancreatic resection out of 8 total adverse events which is not ten times the number of hepatotoxicity cases 3 cases as stated",
        "label": "Contradiction"
    },
    "057e1439-4666-4373-a5b4-539c6cd24469": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial whole breast radiation therapy is given to participants which is not directly related to the interventions in the secondary trial However in the secondary trial both cohorts receive intramuscular injections of Fulvestrant The statement does not mention the radiation therapy given in the primary trial but it does mention that in the secondary trial participants receive intramuscular injections and",
        "label": "Entailment"
    },
    "4bf53370-da92-4333-bae7-3b35ab56b86e": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trials exclusion criteria as breast implants are listed as an exclusion criterion for the primary trial The secondary trial does not mention anything about pulmonary embolisms so the statement does not apply to it Therefore the statement is contradictory to the information provided in the primary trial",
        "label": "Entailment"
    },
    "963bd695-f26a-4891-931e-9b417a7c81c0": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The primary trial reported a higher incidence of infection asymmetry and deflation compared to the secondary trial but the secondary trial reported no occurrences of these adverse events Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "662dd235-76f6-4ab6-b4c8-5537e6f7ffb3": {
        "text_answer": "  The statement four or more positive lymph nodes is an indication that cancer cells have been detected in four or more lymph nodes is not related to the information provided in the trials   The trials only report data on changes in lymphedema arm circumference for patients in the acupuncture and waitlist groups There is no mention of lymph node status or cancer diagnosis in the trials Therefore the statement cannot be",
        "label": "Contradiction"
    },
    "fb4e9c92-aa61-4691-b1fe-3cbb4a183f6d": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial does not report the severity of delayed nausea and the secondary trial measures the change from baseline to 9 months in bone mineral density of the lumbar spine not 270 days",
        "label": "Contradiction"
    },
    "09684ae5-162a-43ba-9735-6c9bce05cd5f": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial measures the count of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment up to 8 weeks These are two distinct outcomes and the statement correctly identifies",
        "label": "Entailment"
    },
    "847dd934-e3d0-44c6-8964-d1eb14b0d7a2": {
        "text_answer": "  The given statement on average all patients in both cohorts of the primary clinical trial showed improvements in cognitive function is not entailed in the provided trial results   The results only report the mean standardized scores and their standard deviations for each cohort Tamoxifen and Ovarian Function Suppression at the 1year followup The statement does not follow directly from the data presented  The statement could",
        "label": "Contradiction"
    },
    "d9444db3-e6d5-43d4-ba21-b934f8e0f77e": {
        "text_answer": "  The statement microscopic findings group identifier is a character or string that represents a microscopic findings group The secondary trial requires patients to be over a certain age but the primary trial does not specify an age range for participation is neither entailed nor contradicted by the given trials  Explanation  The statement is not entailed by the trials because the trials do not provide enough information to determine whether the microscopic findings group identifier is related",
        "label": "Entailment"
    },
    "3f6f3ca0-d14d-4fdb-9be8-19859181aaa9": {
        "text_answer": "  The statement after being treated with aprepitant dexamethasone cytoxan and kytril in the primary clinical trial acute vomiting was observed in over 50 of the patients from the first cohort is a contradiction to the results presented in the trial  The trial reports that 20 out of 35 participants 571 in the aprepitant de",
        "label": "Contradiction"
    },
    "2acdad0e-1a86-49d6-817d-cddb655073ac": {
        "text_answer": "  The statement togo is a country in western africa bordering the gulf of guinea between benin and ghana is not related to the trials provided and does not entail or contradict any information given in the trials Therefore it is neither entailed nor contradictory to the trials",
        "label": "Entailment"
    },
    "402d2312-d5b6-4763-9246-4e094a7d6739": {
        "text_answer": "  The statement a participant in cohort 2 endured the longest PFS in the primary clinical trial with 8 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS experienced by an individual participant However the statement is not contradictory to the trials as well as the reported median PFS for cohort 2 CDX",
        "label": "Contradiction"
    },
    "c0e3960b-923b-460f-a6e1-0b16f32af78f": {
        "text_answer": "  The statement in the primary clinical trial the number of adverse events was equal in both cohort 1 and cohort 2 is contradicted by the given data   The number of adverse events in cohort 1 was 45106 4245 and in cohort 2 was 7103 680 The total number of participants in both co",
        "label": "Contradiction"
    },
    "d1b9ab7c-2229-405c-be0e-01d822ac5aa1": {
        "text_answer": "  The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for all cohorts of the primary trial is entailed in the given inclusion criteria since the trial includes both ERHER2 Group 1 and triplenegative ER PR HER2 Group 2 breast cancer patients Therefore the statement is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "01bbbed8-5b22-4017-b6c5-f8a32bd6ab20": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   Explanation  The statement in the primary clinical trial all interventions are delivered via the same method is contradicted by the trials as they describe two different methods of intervention delivery intravenous IV bisphosphonate Q4W and subcutaneous denosumab Q12W",
        "label": "Contradiction"
    },
    "418be5f3-61b5-4bae-a274-c2213e3cc7cf": {
        "text_answer": "  The statement while the primary and secondary clinical trials share common intervention methods their outcome measurements are entirely separate and unrelated is entailed in the given trials as follows  1 The primary and secondary trials both involve the administration of a study drug SG in the primary trial and talazoparib in the secondary trial However the primary trial measures safety outcomes percentage of participants with any treatmentemergent adverse events and serious treatmentemer",
        "label": "Entailment"
    },
    "d15f343f-8edf-484e-bc6c-bbcbbf8c9118": {
        "text_answer": "  The statement pain has interfered with normal work is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials Therefore it is neither entailed nor contradicted by the trials criteria  However it is important to note that the primary trial includes anemia as an exclusion criterion and the secondary trial includes anemia as a potential symptom that may exclude participants Therefore a patient with anemia",
        "label": "Entailment"
    },
    "9532e5a5-0e29-4914-8cf5-5aff881ffa8a": {
        "text_answer": "  The statement is entailed in the trials as both trials provide the number of participants analyzed in each armgroup Therefore the statement is true and entailed by the information given in the trials",
        "label": "Entailment"
    },
    "dba63c59-7efc-48de-a02e-69b1b5beb08d": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial there are two study groups A and B that are being tested with different interventions Hydrophor and MediHoney respectively These interventions are different gels used for managing skin side effects during radiation therapy  In the secondary trial there are also two study groups A1 and A2 but they are being tested with the same treatment PF",
        "label": "Entailment"
    },
    "da6c4a2b-18ad-44d9-9021-71c4f9b22fff": {
        "text_answer": "  The statement is contradictory to the provided trials as the primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH and the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel Neither trial measures the proportion of patients with no invasive tumor leftover in the breast postsurgery after finishing chemotherapy",
        "label": "Contradiction"
    },
    "fc24dc2a-3257-433f-91ed-fc3d3ec369b3": {
        "text_answer": "  The statement is contradictory to the primary trial as the intervention in the primary trial lasted for 10 weeks which is approximately 70 days 10 weeks x 7 daysweek The secondary trial lasted for 24 weeks which is approximately 168 days 24 weeks x 7 daysweek The difference between the two trial durations is 98 days 168 days  70 days which is more",
        "label": "Entailment"
    },
    "cc11b6a5-855a-4291-b41d-e63367ea3b88": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials utilize pCR as an outcome measurement The primary trial reports slightly different pCR rates between its two cohorts while the secondary trial shows a larger difference in pCR rates between its two arms with Arm 2 having a lower rate compared to Arm 1",
        "label": "Entailment"
    },
    "25bc284b-0476-4950-96e5-3b08a2a1c33c": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 13 months are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the information provided in the exclusion criteria for both trials  In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks",
        "label": "Contradiction"
    },
    "4f886133-596d-449a-92c3-7472e2602982": {
        "text_answer": "  The statement Patients with a breast tumor 0208 cm in diameter with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial is not directly entailed in the given trials as the trials specify different minimum tumor sizes for eligibility The primary trial requires a tumor size of at least 1 cm while the secondary trial does not specify a minimum tumor size Therefore the statement",
        "label": "Contradiction"
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The primary trial does not specify the dosage of MM121 and Paclitaxel given to the patients However the secondary trial specifies that the HR subgroup in Intervention 1 receives a 2 week runin of MM121 20 mgkg weekly followed by 4 cycles of",
        "label": "Entailment"
    },
    "b32a43a7-cac0-4434-bdb2-4c4d8b26d947": {
        "text_answer": "  The statement recovering alcoholics who currently abstain from drinking can participate in the primary clinical trial but for the secondary clinical trial regular drinking is a requirement is contradictory to the information provided in the trials  In the primary trial the exclusion criteria state that any history of alcohol or substance abuse or dependence within the past 2 years DSM5 criteria is a reason for exclusion This means that participants who have a",
        "label": "Entailment"
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "text_answer": "  The statement There was at least 1 recorded gastrointestinal adverse event and 2 or more psychiatric events in the primary trial is neither entailed nor contradicted by the given trials   Explanation   The statement requires the presence of at least one gastrointestinal event and two or more psychiatric events in the same trial However the given trials do not provide sufficient information to determine if this condition is",
        "label": "Entailment"
    },
    "ce486acd-8aae-475c-b95e-131fc0809e15": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the primary trial The statement mentions rifamycin sodium which is not related to the interventions or dosages described in the trial The statement only mentions the differences in dosages between cohort 1 sunitinib 25 mg daily and cohort 2 paclitaxel 90 mgm2 which is consistent with the information",
        "label": "Entailment"
    },
    "d083c9b8-decf-41ac-a3b0-ba8b6eedb32d": {
        "text_answer": "  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it is a compound statement that can be verified by checking if both parts are true and if the second part having more participants does not contradict the first part better ORR  First lets compare the ORR between the two",
        "label": "Entailment"
    },
    "4a5a5c6f-b9b3-48a4-a79a-582dc83323e3": {
        "text_answer": "  The statement warfarinbased therapies disqualify patients from the primary clinical trial although they could still potentially participate in the secondary clinical trial is entailed in the given trials as follows  In the primary trial warfarinbased therapies are explicitly mentioned as an exclusion criterion line 23  In the secondary trial warfarinbased therapies are not mentioned in the inclusion or exclusion criteria However",
        "label": "Entailment"
    },
    "5b8f9c72-6729-4b0f-9956-617021d55805": {
        "text_answer": "  The statement patients with endocarcinoma are ineligible for the secondary clinical trial but viewed as potential candidates for the primary clinical trial is neither entailed nor contradicted by the information provided in the trials   The primary trial includes patients with benign breast disease who are candidates for hormonal therapy but excludes those with highrisk lesions inflammatory lesions or those unwilling to undergo treatment Endocarc",
        "label": "Entailment"
    },
    "1a47637c-31f0-42c0-9729-7ab8c66fafb4": {
        "text_answer": "  The statement is contradictory to the given trials   The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml The secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in units of mg These units of measurement are not identical",
        "label": "Entailment"
    },
    "c79f4ed7-5e39-48ad-bc32-fef9ace77a76": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial cohort is given entericcoated tablets is a contradiction to the information provided in the trials   In the primary trial Botulinum Toxin Type A is administered through injection not in the form of entericcoated tablets In the secondary trial MLN8237 is given orally as entericcoated tablets",
        "label": "Contradiction"
    },
    "4d33c738-d007-4e43-8d51-6c98c40631df": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site However intervention 1 uses a significantly higher amount up to 10 mCi compared to intervention 2 up to 04 mCi Therefore the statement is an accurate representation of the trials interventions",
        "label": "Entailment"
    },
    "d7170cb2-d8a5-4c65-9122-bc6bcf13caeb": {
        "text_answer": "  The statement The placebo and Trabectedin intervention in the primary trial are both administered through a 3hour intravenous infusion on a biweekly basis is entailed in the trial information provided However the statement her2neu negative by immunohistochemistry is a laboratory test result indicating the absence of her2neu in a tissue sample using immunohistochemical staining is",
        "label": "Entailment"
    },
    "b76d27c5-45ec-4695-8480-1128862ea21b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The placebo in the primary clinical trial was administrated via an intravenous infusion on Day 1 not an intramuscular injection once a week The information about Intervention 2 using trabectedin is also an intravenous infusion not an intramuscular injection Therefore the statement is contradictory to the facts given in the trials",
        "label": "Entailment"
    },
    "8fcaece4-a0c7-44bf-82b0-50e494825b81": {
        "text_answer": "  The statement over 52 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR is not directly entailed in the given trial results The trial results only report the percentage of participants with a confirmed overall tumor response OR which includes both CR and PR The percentage of participants with CR is not explicitly stated in the results Therefore the statement is not",
        "label": "Contradiction"
    },
    "37f74912-6578-4304-9f9c-6b3c4c217e97": {
        "text_answer": "  The statement does not entail or contradict the given trial information   Explanation   The statement is about Primary Ciliary Dyskinesia type 29 PCD29 an autosomal recessive disorder and the genes involved in its causation The trials mentioned in the statement are about two different cohorts of a primary trial each receiving different interventions based on their tumor characteristics Phase 2 Tri",
        "label": "Entailment"
    },
    "35802b7b-4d8e-4f1a-bab8-20eea1f4aa3f": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last decade would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria it is a type of",
        "label": "Entailment"
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The primary trial specifies that patients will receive Alpha Lipoic Acid orally three times daily with a baseline dose of 100 mg and dose escalation until a maximum tolerated dose is found This means that patients in the primary trial will receive increasing doses of Alpha Lipoic Acid throughout the study duration but the maximum dose will not exceed 100",
        "label": "Entailment"
    },
    "95928e94-237c-4e85-98d4-9dc5371c5069": {
        "text_answer": "  The statement Paclitaxel is only used in the cohort 1 intervention of the primary trial whereas cohort 2 is administered fulvestrant instead is entailed in the given trial information   The trial description specifies that in Arm A cohort 1 patients receive anastrozole and paclitaxel while in Arm B cohort 2 patients receive fulvestrant Therefore the",
        "label": "Entailment"
    },
    "1b229af4-937d-4ae0-8c39-12064d16b246": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy is entailed in the trials based on the reported results   The results show that the median aAUCpa for the Sensory Neuropathy subscale in Arm I Cryotherapy was 14 117 to 68 indicating that on average symptoms improved",
        "label": "Entailment"
    },
    "f569ce38-1e3f-4e8d-a9d7-e4a35a18c90c": {
        "text_answer": "  The statement dyskinesia is an abnormality or impairment of voluntary movement is not directly related to the inclusion or exclusion criteria provided in the trial description It does not entail or contradict any information given in the criteria Therefore it is neither entailed nor contradictory to the trial information",
        "label": "Entailment"
    },
    "966efbd3-dce6-400c-b5bc-87ca468c7225": {
        "text_answer": " The statement provided is not entailed in the trials given The trials only report the percentage change in betaCTX levels for the AZD0530 175 mg and Zoledronic Acid 4 mg groups and there is no information provided about the primary tumour diameter for any of the groups Therefore the statement cannot be determined to be entailed or contradicted based on the information provided in the trials",
        "label": "Contradiction"
    },
    "d2757370-ae03-4046-a888-e30b9aa1551f": {
        "text_answer": "  The statement individuals with fluorescent in situ hybridizationconfirmed nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer can enroll in both the primary and secondary clinical trials is not explicitly stated in the given inclusion or exclusion criteria for either trial However the criteria do not explicitly exclude individuals with these diagnoses from participating in both trials so the statement can be considered consistent with the information",
        "label": "Entailment"
    },
    "cc439508-491f-4c5a-9304-5ddf9d266506": {
        "text_answer": "  The given statement generally both groups in the primary trial showed a deterioration in cognitive abilities but this wasnt the pattern for all patients is not directly entailed in the provided trial results The trials only report the mean standardized composite scores for cognitive function at baseline and 1 year after randomization for each group They do not provide sufficient information to determine if there was a deterioration in cognitive abilities for generally both groups or if the",
        "label": "Contradiction"
    },
    "d2c665aa-c13e-4d5d-95f8-d85c5c9f3ef9": {
        "text_answer": "  The statement More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2 is not directly entailed in the given trials as they do not provide sufficient information to make that comparison The trials only report the number and percentage of adverse events for each cohort but they do not provide the total number of patients in each cohort Therefore we cannot determine if there are more patients in cohort 1",
        "label": "Contradiction"
    },
    "936b5904-9a93-4aaf-8d20-03e0a4fb3223": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 156 weeks would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the statement specifically mentions diffuse parenchymal lung disease it falls under the broader category of inter",
        "label": "Entailment"
    },
    "7326be65-0450-4fb7-88d3-5d926d65db74": {
        "text_answer": "  The statement only patients prescribed gtx024 3mg during the primary clinical trial resulted in weight gain particularly in lean body mass is a strong claim that goes beyond the information provided in the trials   The trials only report the median change in total body lean mass from baseline to 4 months for two different dosage groups of GTx024 1 mg and 3 mg The trials do not provide information on the number of",
        "label": "Entailment"
    },
    "692ea096-a2cf-4732-a141-b349cfd460d6": {
        "text_answer": "  The statement urinary tract infections were a frequent side effect among participants involved in the primary clinical trial is entailed in the given data as there were 2 participants 400 who experienced urinary tract infections out of the total 50 participants",
        "label": "Entailment"
    },
    "96dedf4b-abc0-41ea-b12a-9a8afce9708d": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   In the trial description the placebo is given orally by mouth twice a day while memantine is also given orally by mouth twice a day There is no mention of any other route of administration for either the placebo or memantine Therefore the statement that the placebo is taken through a rectal suppository and memantine is given through a subling",
        "label": "Contradiction"
    },
    "74c47731-5e97-400b-bf85-52ae0b8b5e09": {
        "text_answer": "  Lets calculate the amount of MCS110 and PDR001 administered in each intervention every 21 days and every 14 days respectively  Intervention 1  MCS110 1 mgkg every 3 weeks Q3W  Convert mg to g 1 mg  1000 g  Amount of MCS110 in",
        "label": "Entailment"
    },
    "e4eba352-415f-44bd-8fe0-244240a80513": {
        "text_answer": "  The statement less than half of the patients in cohort 2 of the primary clinical trial experienced acute vomiting following treatment with aprepitant dexamethasone cytoxan and kytril is entailed in the trial results if  20 which is less than half of the total number of participants analyzed 35 did not experience any vomiting and did not require rescue medication during the first 2",
        "label": "Entailment"
    },
    "ce26a25e-c6ff-4bba-bd54-b0e069440746": {
        "text_answer": "  The statement not a single instance of a maculopapular rash was reported in the primary clinical trial is contradictory to the information provided in the trials data   The data states that there was 1 instance of a maculopapular rash reported in the primary clinical trial Therefore the statement is contradictory to the facts presented in the trials data",
        "label": "Entailment"
    },
    "4f0e91c8-87f4-4af4-b47d-c5a8e459713d": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial will have access to the educational dvd as part of their intervention program is not directly entailed in the information provided about interventions 1 and 2 in the primary trial The statement only mentions cohort 2 but the trial description only specifies the interventions for cohort 1 intervention arm and does not mention any details about cohort 2 control arm",
        "label": "Contradiction"
    },
    "4d8bdd85-b621-4334-9aff-9ab0b69172e5": {
        "text_answer": "  The statement to be eligible for the primary clinical trial there are no certain conditions such as mental health body weight tumour size karnofskyecog score or estimated life span that must be attained is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria only specify conditions related to the type and extent of the breast cancer and do not mention any requirements regarding mental health body weight tumour size",
        "label": "Contradiction"
    },
    "2b2a038c-37d7-42a6-817a-5392b1e94613": {
        "text_answer": "  The statement the incidence of adverse events was reported to be higher amongst patients in the secondary clinical trial than those in the primary clinical trial is entailed in the given trials data   Explanation   The statement implies that the percentage of patients experiencing adverse events in the secondary trial is greater than that in the primary trial Based on the provided data the percentage of patients with adverse events in the secondary trial is 600",
        "label": "Entailment"
    },
    "530798af-a5d0-4de8-8183-b2ef6068c90a": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive radiation therapy with the same intensity 180200 cGy per fraction for a total of 46004860 cGy and both undergo SPECT scans at baseline and 6 months followup The only difference between the two cohorts is the use of Active Breathing Coordination ABC during radiation therapy in Coh",
        "label": "Entailment"
    },
    "55e361f9-9360-4de4-a301-6b504913b094": {
        "text_answer": "  The statement comparatively the second cohort of the secondary clinical trial held more participants than the second cohort of the primary clinical trial is not directly stated in the provided information However we can compare the number of participants in the second cohort of each trial by looking at the data given  Primary Trial 75 participants in the Waitlist Control group Secondary Trial 163 participants in the Device  ",
        "label": "Entailment"
    },
    "f191be61-8e8d-495c-b5e3-1bf3cc89904a": {
        "text_answer": "  The given statement is a contradiction to the information provided in the clinical trial results The median survival times reported in the trial are 214 years for the midluteal surgery group and 200 years for the midfollicular surgery group both exceeding the 1year timeframe mentioned in the statement Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "b2572b63-5246-4be3-84ee-c37f18da106d": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The statement cohort 1 in the primary clinical trial received a higher dosage of cetuximab compared to cohort 2 while still receiving 8mgkg more mm121 than cohort 2 is entailed in the trials because   Cohort 1 received a loading dose of 400 mg",
        "label": "Entailment"
    },
    "328dcbbe-1a4a-46f1-afad-df84cebcde05": {
        "text_answer": "  The statement is contradictory to the trial description In the trial description patients receive oral lapatinib daily not a onetime intramuscular dose of 250 mgm2 Therefore the statement is contradictory to the trial description",
        "label": "Entailment"
    },
    "992db0e7-c7c4-413c-874f-c8e53d481fab": {
        "text_answer": "  The statement is contradictory to the information provided in the trial   Explanation   The statement suggests that the members of cohort 1 and 2 received equal doses of cetuximab but cohort 1 received 8mgkg less of mm121 However the trial information shows that cohort 1 received a lower dose of mm121 12 mgkg",
        "label": "Entailment"
    },
    "c51c390c-f844-492c-9844-53e31e01124d": {
        "text_answer": "  The statement in the primary clinical trial and the secondary clinical trial a significant number of unexpected fatalities and hospital stays were observed is a contradiction to the given data   The data provided in the trials indicates that there were no fatalities or hospital stays reported in the primary trial for both Adverse Events 1 and 2 In the secondary trial there was one reported case of lymphoma for Adverse Event 1 but no fatalities or",
        "label": "Contradiction"
    },
    "ea25b3f7-4ef8-4e5f-b3e8-3cbf0da93a12": {
        "text_answer": "  The statement Patients with measurable bilateral breast cancer are eligible for the primary trial is not entailed in the given inclusion and exclusion criteria The criteria only specify eligibility for patients with unilateral breast cancer and upper extremity lymphedema The statement about measurable bilateral breast cancer is not mentioned in the criteria  Regarding the second part of the statement chk1 inhibitor is any agent that inhibits the cell cycle",
        "label": "Contradiction"
    },
    "15c27d36-ca02-48e2-8e08-d9c6b52042c6": {
        "text_answer": "  The statement entry into the primary clinical trial is open to individuals with definite metastasis or whose cancer has augmented in different locations of the body is entailed in the given trial description   Reasoning   The trial description specifies that individuals with metastatic disease M1 or multiple sites of new disease that is clinically obvious metastatic disease are eligible for the trial Metastasis is defined as the spread",
        "label": "Entailment"
    },
    "890c305f-bd6d-4db4-adf5-2aaf8e28d6c6": {
        "text_answer": "  The statement severe problems performing usual activities is a response indicating that an individual has or had severe problems with performing their usual activities is not directly related to the adverse events data provided in the primary and secondary trials The statement is about the meaning of a response while the trials provide data on the occurrence of adverse events The statement does not entail or contradict the information given in the trials",
        "label": "Entailment"
    },
    "93c0565f-98d6-4f6b-92a6-8464567027c7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does provide data on Time to Progression TTP among patients and the secondary trial does report on the number of participants with objective response based on RECIST criteria Therefore the statement is incorrect",
        "label": "Entailment"
    },
    "32c13f2f-7902-444f-8f99-c3ea2ecac0d0": {
        "text_answer": "  The statement the primary clinical trial records more types of adverse events yet the total number of adverse events reported is less than in the secondary clinical trial is a contradiction   The reason for this contradiction is that the statement implies that the primary trial has more unique types of adverse events than the secondary trial but at the same time it states that the total number of adverse events reported in the primary trial is less than in the secondary trial",
        "label": "Contradiction"
    },
    "33603672-b61c-4ddd-8e57-d38876de9132": {
        "text_answer": "  The statement there was no repetition in the type of adverse event endured by patients in the primary clinical trial is a contradiction to the information provided in the adverse events data   There are several instances of the same type of adverse event reported multiple times eg heart failure vertigo small intestinal obstruction fever aspartate aminotransferase increased alanine aminotrans",
        "label": "Contradiction"
    },
    "2e753155-acb5-417c-9169-9ec7ccc4d8ac": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial do not allow participation of cancer patients with diagnosed epilepsy thalasemic syndromes or anemia is entailed in the given trials as these conditions are explicitly mentioned in the exclusion criteria for both trials",
        "label": "Entailment"
    },
    "356f845b-f5e9-46f8-8374-fb598e246876": {
        "text_answer": "  The statement is entailed in the trials if the trials define 57 days weekly in the same way for both cohorts and the trials do not specify any other differences in the paced breathing intervention between the two cohorts aside from the frequency Since both cohorts follow the same instructional CD and have the same paced breathing instructions 6 breathsmin the only difference is the frequency of practice once daily for cohort ",
        "label": "Entailment"
    },
    "74b96ae6-3e1a-4f1c-bbf0-a79ed0e4ee75": {
        "text_answer": "  The statement adverse events were not documented for both the primary clinical trial and the secondary clinical trial is entailed in the given trials data as both trials report a total of 0 adverse events for each category",
        "label": "Entailment"
    },
    "2fafc6ea-da6d-4160-829d-1f599da46818": {
        "text_answer": "  The statement Only 2 patients in the primary trial did not have Recurrencefree Survival is not directly related to the information provided about the trial regarding the treatment outcome measurement and results The statement mentions Recurrencefree Survival but it does not provide any specific information about the number of patients with a gingival polyp or the relationship between the gingival polyp and Recurrencefree Survival Therefore the",
        "label": "Entailment"
    },
    "74bde0ca-3313-40ab-95f3-55d2adea4f89": {
        "text_answer": "  The statement patients diagnosed with benign fibroadenoma and effectively managed hypertension can participate in the primary clinical trial but are ineligible for the secondary clinical trial is neither entailed nor contradicted by the given trial information  Explanation  The primary trial includes patients with benign breast disease including fibroadenoma who are amenable to hormonal therapy except for those with certain exclusion criteria Effectively managed hy",
        "label": "Entailment"
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is entailed in the inclusion criteria of the trial The inclusion criteria clearly state that one of the requirements for eligibility is a HER2 positive tumor which can be confirmed by either IHC 3 or FISH Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "f2d20a53-59b4-42bf-8d21-1ead0e113107": {
        "text_answer": "  The statement patients who are diagnosed with severe schizophrenia and chronic insomnia are not allowed to participate in both the primary clinical trial and the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However there is no mention of severe schizophrenia as a condition for exclusion in either trial Therefore based on the provided information the statement is contradictory to the trials criteria",
        "label": "Contradiction"
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "text_answer": "  The statement is entailed in the Trials since in both trials no adverse events occurred in more than 1 of participants Therefore the statement is a logical consequence of the given data",
        "label": "Entailment"
    },
    "151bb6d0-e4bf-4eea-8842-5fe4e1782782": {
        "text_answer": "  The statement recurrencefree survival was experienced by 96 individuals in the ketorolac 30 mg group in comparison to 67 individuals in the nacl 09 3ml group during the primary clinical trial is a comparison of the number of participants experiencing recurrencefree survival in each group   The given trials provide the number of participants analyzed in each group and the percentage of participants who experienced recurrencefree",
        "label": "Entailment"
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "text_answer": "  The statement is entailed in the trials as both trials include patients with histologically confirmed stage 4 breast adenocarcinoma that is ER positive PR positive or HER2neu negative The primary trial includes patients with bone metastases while the secondary trial includes patients with measurable or nonmeasurable disease and progressive disease during or within 12 months of endocrine therapy However it is important to note that the primary trial",
        "label": "Entailment"
    },
    "3cbaa580-dfe1-4331-902c-5be850db2f24": {
        "text_answer": "  The statement is entailed in the primary clinical trial as both Intervention 1 and Intervention 2 involve the preoperative administration of dexamethasone in intravenous form and the same dose 8 mg is given before surgery in both interventions However Intervention 2 has a higher total dose 24 mg which is split into two preoperative doses",
        "label": "Entailment"
    },
    "80b93d64-be3c-45e0-8524-b8042e84bdc7": {
        "text_answer": "  The statement patients in the primary trial recorded the most instances of chest pain compared to those in the secondary trial is not entailed in the given trials as there is no mention of chest pain in either trial",
        "label": "Contradiction"
    },
    "57663242-4e73-409f-a7f9-1738e13298ab": {
        "text_answer": "  The statement there are no reported adverse incidents in the primary clinical trial and the secondary clinical trial is entailed by the given data since the data reports 0 adverse events for both trials",
        "label": "Contradiction"
    },
    "df344680-ab21-4889-bba7-7db757b72bae": {
        "text_answer": "  The statement is entailed in the trials as both cohorts differ in the specific drugs and dosages they receive daily Cohort 1 receives sunitinib at a daily dose of 25 mg and paclitaxel at a dose of 90 mgm2 per cycle Cohort 2 receives bevacizumab at a fixed dose and paclitaxel at a daily dose of 90 mgm2",
        "label": "Entailment"
    },
    "f50bcaa7-7424-4977-ac06-f47e545e2e00": {
        "text_answer": "  The statement individuals with ER negative prostate cancer are eligible for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria   The criteria provided specify eligibility for individuals with solid tumors including breast cancer small cell lung cancer squamous cell cancers of the head and neck associated with HPV and other solid tumor types However there is no explicit mention of prostate cancer or its subtypes ",
        "label": "Contradiction"
    },
    "46ac728d-deb3-4559-bc71-1729c70c26e7": {
        "text_answer": "  The statement is entailed in the given trials as the primary trial does not involve the use of MLN8237 alisertib whereas the secondary trial does but with distinct dosages for each cohort",
        "label": "Entailment"
    },
    "665afeee-f623-4c57-8550-a5dbe71430cb": {
        "text_answer": "  The statement is entailed in the Trials description In the primary trial no intervention involving injections is mentioned while in the secondary trial participants receive weekly subcutaneous injections of epoetin beta Therefore the statement that individuals in the secondary trial are administered weekly subcutaneous injections unlike the participants in the primary trial who refrain from any injections is entailed in the Trials description",
        "label": "Entailment"
    },
    "786bc355-6b8f-455c-b6b2-470350231601": {
        "text_answer": "  The statement comprehensive records of adverse events are available for the primary trial enabling a thorough comparison with the secondary trials data is entailed in the given information if we assume that thorough comparison implies access to the same level of detail as in the primary trial The secondary trial provides detailed information on the types and frequencies of adverse events while the primary trial does not However the primary trial does not explicitly state that comprehensive records of ad",
        "label": "Entailment"
    },
    "72ea65df-6381-4672-a40c-f55cee100091": {
        "text_answer": "  The statement the sole adverse event noted in the primary clinical trial was stomatitis is entailed in the given information if we consider the following  1 The statement specifies that there was only one adverse event 2 The given information states that there was one adverse event with a total count of 129 345 3 The given information also specifies that the adverse event was stomatitis",
        "label": "Entailment"
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "text_answer": "  The statement is entailed in the trials as follows  Cohort 1 receives a dose of ALT801 that is less than half the dose given to cohort 2  From the trials  Cohort 1 receives 0015 mgkgdose of ALT801  Cohort 2 receives 0040 mgkgdose of",
        "label": "Entailment"
    },
    "7714e6f7-814a-4088-9116-60f5ceef4336": {
        "text_answer": "  The statement a patient recuperating from an organ transplant within the last month and still being bedridden would be disqualified from the primary clinical trial but might qualify for the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials  However the primary trial does exclude participants who have undergone major surgery within 28 days prior to the study registration date This could potentially include organ transplant surgery",
        "label": "Entailment"
    },
    "57bca704-dcff-4526-b677-bb1c1b1a7945": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial reports its results in units on a scale while the secondary trial reports its results in proportion and does not mention liters at all",
        "label": "Entailment"
    },
    "b27a5fe7-77f8-4d11-9e05-0609faf8b985": {
        "text_answer": "  The statement fertile men and women capable of becoming pregnant are fit to partake in the primary clinical trial under the condition of committing to abstain for the length of the study is entailed in the trials inclusion criteria under the exclusion criterion for women of childbearing potential WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months",
        "label": "Entailment"
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "text_answer": "  The statement warfarin based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is a contradiction to the exclusion criteria in the primary trial as it states Patients who require use of coumarinderivative anticoagulants such as warfarin are excluded However the secondary trial does allow the use of lowdose warfarin less than or equal to 1 mg",
        "label": "Contradiction"
    },
    "99e5ad48-5bb8-4716-a1fc-0a332acf2e5e": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary trials are evaluating adverse events of primary interest AEPIs In the primary trial the evaluation of AEPIs is through the assessment of toxicity using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 In the secondary trial the percentage of participants with AEPIs is being measured Therefore the statement that both trials are designed to evaluate",
        "label": "Entailment"
    },
    "6d92ea7c-a85d-4d9d-9599-b2203e9c3585": {
        "text_answer": "  The statement is contradictory to the given trials   The primary trial had two test groups Pyridoxine and Placebo and no control group   The secondary trial had two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride and no placebo group   Therefore the statement that the primary trial had three test groups and no placebo",
        "label": "Contradiction"
    },
    "b5976fd8-b3cf-4879-bead-2410a6e1f1f1": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants in each group who were analyzed up to 5 years after randomization They do not provide information on the number of participants who experienced recurrencefree survival in each group Therefore it is not possible to determine if the statement is entailed in the trials based on the given information",
        "label": "Contradiction"
    },
    "4d7a11a9-ec69-4b35-9fea-d1a78d8fe4b8": {
        "text_answer": "  The statement there were several cases of febrile neutropenia reported in the primary trial and the secondary trial is not entailed in the given trials as there is no mention of febrile neutropenia in either trial The trials only report the occurrence of adverse events but they do not specify the type of adverse events that were febrile neutropenia Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "c291c60f-fb5e-4c0d-83dc-a8fe9eee445c": {
        "text_answer": "  The statement behavioral rating scale is a range of values designed to quantify the qualitative responses of an individual to a set of challenges is not directly related to the inclusion and exclusion criteria provided in the primary trial description Therefore it cannot be determined if the statement is entailed or contradicted based on the information given The statement pertains to a concept unrelated to the trials eligibility criteria",
        "label": "Entailment"
    },
    "ebe02c33-affe-41d7-aad7-86ea86912217": {
        "text_answer": "  The statement none of the patients in the primary trial experienced the worst pain imaginable for 1680 hours cannot be determined to be entailed or contradicted based on the given information in Trials 1 and 2   The trials only provide the average pain intensity scores and the number of hours of intervention for each group They do not provide information on the distribution of pain intensity scores or the number of patients who experienced the worst pain imaginable i",
        "label": "Entailment"
    },
    "d464fa4d-58ea-47ff-b4fa-19fbedb40740": {
        "text_answer": "  The given statement none of the cervical cancer patients in cohort 1 had undergone a screening prior to the primary clinical trial intervention is not directly mentioned or entailed in the provided trial results The trials only report the percentage of patients who were up to date for colorectal breast and cervical cancer screenings before and after the intervention No information about the screening status of individual patients or cohorts prior to the intervention is provided",
        "label": "Entailment"
    },
    "bfee9542-f923-4084-a92d-216413a99395": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement only mentions that both trials involve intravenous injections and MRIs but it does not entail or contradict the specific drugs dosages or frequency of administration used in each trial Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "b126d49e-2ab0-4bb9-8677-b3662b784e0d": {
        "text_answer": "  The statement cohort 1 of the primary trial receives higher doses of Eribulin than cohort 2 patients receive of Docetaxel is a factual statement about the interventions in the trial and is not related to the statement about feeling supported by family and friends The second statement is about an individuals emotional response Therefore the two statements are not entailed in each other and there is no contradiction between them",
        "label": "Contradiction"
    },
    "f435b92a-cceb-404d-a485-da95bb2189ec": {
        "text_answer": "  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a contradiction to the exclusion criteria of the secondary trial   The secondary trial explicitly states that patients who have received chemotherapy or radiotherapy within",
        "label": "Contradiction"
    },
    "81cad78a-c25f-4aab-ae6f-aee9f21e0c01": {
        "text_answer": "  The statement encounter due to exposure to soil pollution is an ICD encounter due to exposure to soil pollution is not directly related to the primary trial as it is not making a statement about the trials themselves but rather about an ICD International Classification of Diseases code  However to answer the question about the entailment or contradiction between the two interventions in the primary trial we need to compare the details of each intervention  ",
        "label": "Entailment"
    },
    "2e22a621-745f-422e-a66e-2a85f8ff1a25": {
        "text_answer": "  The statement in the primary clinical trial just two participants did not experience recurrencefree survival is a contradiction to the given results   The results state that 98 out of 100 participants 922 to 995 experienced recurrencefree survival This means that 2 participants did not experience recurrencefree survival but the statement claims that only 2 participants did experience recurrencefree survival",
        "label": "Contradiction"
    },
    "bf41ff3e-3801-4cb7-8e09-0400100a4010": {
        "text_answer": "  The statement is entailed in the Trials as follows  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed by the data provided in the Trials because  1 The frequency of Ascites in the primary trial is 2223 090 and the frequency of Ascites",
        "label": "Entailment"
    },
    "c08cf531-fbbe-4ec3-ae13-f10d13368a82": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different outcome measurements and conditions The primary trial focuses on treatmentemergent adverse events in patients with breast cancer receiving fosnetupitantpalonosetron or netupitantpalonosetron with dexamethasone The secondary trial measures the change in total sleep time in minutes using polysomnography in patients with hybrid nerve sheath tumors receiving Len",
        "label": "Contradiction"
    },
    "c696105a-b6a3-4d13-9410-2b3f05346f96": {
        "text_answer": "  The statement the second cohort of the primary clinical trial has 7 participants more than the first cohort is a contradiction to the information given in the trials   The trials provide the number of participants analyzed for each armgroup and according to the information given Arm I has 234 participants and Arm III has 241 participants However a difference of 7 participants is not present between the two armsgroups Therefore",
        "label": "Contradiction"
    },
    "d8079e7e-45eb-4387-a0e3-eb0777802644": {
        "text_answer": "  The statement agedays is age of subject in days is not directly related to the outcome measurements provided in the Trials The primary trial measures the percentage of participants with treatmentemergent adverse events in various populations while the secondary trial measures the number of participants with objective response to talazoparib in breast and ovarianperitoneal cancer populations Therefore the statement does not entail or contradict the information provided in the Trials",
        "label": "Entailment"
    },
    "a2d03d44-c447-45d2-932e-efe3694a8940": {
        "text_answer": "  The statement Both interventions in the primary trial include trastuzumab abnormal involuntary movement scale aims0110 original result  aware moderate distress is abnormal involuntary movement scale aims0110 original result  aware moderate distress is entailed in the trials as both interventions do include trastuzumab and the abnormal involuntary movement scale aims0110 result being aware",
        "label": "Entailment"
    },
    "b1d81c75-d076-45f3-8de6-6a23fc4f3832": {
        "text_answer": "  The statement pituitary neuroendocrine tumormicroadenoma is a pituitary neuroendocrine tumor with a diameter equal or less than 10 mm is not related to the information provided in the trials Therefore it cannot be determined if the statement is entailed in the trials or not",
        "label": "Entailment"
    },
    "2e64e934-f058-4730-af09-ddf7547a0112": {
        "text_answer": "  The statement neither primary clinical trial nor secondary clinical trial allows candidates with ECOG score below 2 is an entailment based on the given information   Explanation   Both primary and secondary clinical trials have the same ECOG performance status inclusion criteria which is ECOG 02 Therefore neither trial allows candidates with an ECOG score below 2",
        "label": "Entailment"
    },
    "79162d9d-6591-44ef-aaea-4bd58c4811da": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial mentions that patients will take Vorinostat daily during radiation therapy and are recommended to swallow the capsule 6090 minutes prior to radiation However the statement suggests that every patient receives a dose of fentanyl sublingual spray during radiation therapy which is not mentioned or implied in the trial description",
        "label": "Entailment"
    },
    "da24c082-7e08-4ed0-b72c-ee85098d7b3a": {
        "text_answer": "  The given statement is a contradiction to the information provided in the trials The trials do not indicate that the NaCl 09 3ml group had a higher recurrencefree survival rate than the Ketorolac 30 mg group In fact the trials show that the overall number of participants analyzed in the Ketorolac 30 mg group was 80 and 833 of them were recurrence",
        "label": "Contradiction"
    },
    "193ae24d-ca9a-4bd6-8a98-279c75d32c9b": {
        "text_answer": "  The statement across the patient cohorts of both the primary and secondary clinical trials there were three cases of shingles reported is entailed in the given trials as follows  From the primary trial there was 1 case of shingles reported out of 6 patients From the secondary trial there was 1 case of shingles reported out of 66 patients  Therefore in total there were 3 cases",
        "label": "Entailment"
    },
    "accef831-f126-4f90-bc47-182fd9699098": {
        "text_answer": "  The statement a patient that has undergone a kidney transplant in the past week is eligible for the primary clinical trial but will not qualify for the secondary clinical trial is contradictory to the information provided in the trials  Explanation  The primary clinical trial includes the following exclusion criteria related to kidney function   The participant has received irradiation to a major bone marrow area within 30 days prior to the study",
        "label": "Entailment"
    },
    "9eee5184-a09a-41a2-b031-a7ea1863c5ce": {
        "text_answer": "  The statement in the primary clinical trials second cohort four different adverse events were noticed affecting patients is not directly entailed in the given trials as the trials only list the number and types of adverse events observed in each cohort without specifying that exactly four different events occurred However it is not contradictory to the trials either as the statement allows for the possibility that there could be more than four adverse events just that four different",
        "label": "Contradiction"
    },
    "f12a3e2a-478e-4104-8f1a-c2d72efab4a3": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not provide sufficient information to determine if a twofold increase in the percentage of participants with events in the placebo arm compared to the neratinib arm would result in the same number of participants The trials only report the absolute numbers and percentages of participants with events in each arm but they do not provide the total number of events or the total number of participants who did not experience an event Therefore it is",
        "label": "Contradiction"
    },
    "99e16f2b-e690-4684-9dff-cf37877c796c": {
        "text_answer": "  The statement fewer than 10 of the primary clinical trial participants noticed a reduction in circulating tumor cells subsequent to multiple months of highdose chemotherapy preceding purged autologous stem cell products is not directly entailed in the provided trial results   The trial results only report the number of participants with a reduction in CTCs one month post AHST not the percentage of participants with a reduction over multiple months Additionally",
        "label": "Contradiction"
    },
    "3caa266c-8ad2-4297-8de5-c65b78e94fd1": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation  The statement every participant in cohort 1 of the primary clinical trial receives treatment for her2 er and pr is contradictory to the information given in the trials because  1 Cohort 1 is identified as the Phase 2 Triplenegative cohort 2 Triplenegative breast cancer ",
        "label": "Entailment"
    },
    "97e4a19d-31b9-476a-b8d3-707f817283e1": {
        "text_answer": "  The statement the primary trial participants do not receive any vaccines is entailed in the given trials as there is no mention of any vaccines being administered in the interventions described  However the statement buccal mucosa squamous cell carcinoma is a squamous cell carcinoma of the oral cavity that arises from the buccal mucosa is not directly related to the trials and is not entailed or contradicted",
        "label": "Entailment"
    },
    "fdc23b5d-a94a-4aa3-bb87-38d7f2c0102c": {
        "text_answer": "  The statement after 90 days of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 60 reduction in the percentage of cells with ki67 expression is not directly entailed in the given trial results   The trial results only provide the median interquartile range of Ki67 expression at baseline and at 6 weeks for the TAK228 plus Tamoxifen",
        "label": "Contradiction"
    },
    "6b531884-77d9-4cdc-bab7-324596ec998e": {
        "text_answer": "  The statement is not entailed in the given trials as there is no information provided in the primary trial about the dosage of dexmedetomidine for group 2 and the secondary trial only mentions a dosage of 05ugkg for group 2 patients during the intervention period The statement suggests a higher dosage of 15ugkg for both primary trial group 2 and secondary trial group 2 patients which is not",
        "label": "Contradiction"
    },
    "73eb2425-76f4-4868-8c33-0a2dab6af8f6": {
        "text_answer": "  The statement in the primary clinical trial its demonstrated that the arm A intervention has yielded the best overall response rate however the denosumab group exhibited a poorer time to first onstudy SRE compared to the zoledronic acid group in the secondary clinical trial is a comparison of two different trials with different outcomes   The first part of the statement is about the primary trial comparing Arm A and Arm B and the",
        "label": "Entailment"
    },
    "e504c08b-c348-4307-9cfe-d20f7003ec15": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement There were no patients with recorded Aes in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is contradictory to the trials as follows  1 In the primary trial there were no recorded adverse events AEs out of 42 patients 000 2 In the secondary trial",
        "label": "Contradiction"
    },
    "5f33e3b5-efa2-407c-9409-383024b8c652": {
        "text_answer": "  The statement patients who have been diagnosed with ductal carcinoma in situ and are considering getting AI therapy are eligible to participate in the primary clinical trial is entailed in the inclusion criteria of the trial   Explanation   The inclusion criteria state that patients with histologically proven DCIS are eligible for the trial The statement in question specifically mentions patients with DCIS who are considering AI therapy which is exactly what the trial includes",
        "label": "Entailment"
    },
    "7bbb79b9-9550-4a8b-a0a8-3af8ece50e04": {
        "text_answer": "  The statement pericardial effusions were more common for patients in the primary trial and corneal deposits were more common in the secondary trial is an entailed statement based on the given trials   Explanation   The statement makes a comparison between the frequency of two specific adverse events pericardial effusions and corneal deposits between the two trials The trials provide the number of occurrences for each",
        "label": "Entailment"
    },
    "85f5396f-e7f8-4697-95d2-67b82d43fce4": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description both arms receive the same dose of nabPaclitaxel 125 mgm2 on Days 1 and 8 The difference lies in the chemotherapeutic agent used in combination with nabPaclitaxel Arm A uses gemcitabine and Arm B uses carboplatin Therefore the statement is",
        "label": "Entailment"
    },
    "71c0cfa6-88a6-4efa-8204-7252f6e6ef57": {
        "text_answer": "  The statement psa level less than four is a blood concentration of prostate specific antigen less than 4 ngml is not directly related to the interventions described in the trial Therefore it cannot be determined if the statement is entailed or contradicted based on the information provided in the trial alone",
        "label": "Entailment"
    },
    "a2408386-b61c-4cce-9c71-befb482270e0": {
        "text_answer": "  The statement neither the secondary clinical trial nor the primary clinical trial utilize the count of participants with treatmentemergent adverse events as their studys outcome measurement is not directly entailed in the provided information from the trials   The primary trial reports the change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial reports the change in isothiocyanate in urine samples as assessed at baseline",
        "label": "Contradiction"
    },
    "bd4ef9b9-41e1-47cb-b8bd-eb0dfe32badf": {
        "text_answer": "  The statement poorly differentiated angiosarcoma is an angiosarcoma characterized by the presence of significant cytologic atypia necrosis and high mitotic activity is not directly related to the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed in the trials or not The primary trial focuses on the toxicity of HER2specific T cell therapy while the secondary trial evaluates",
        "label": "Entailment"
    },
    "12ca4131-cbd9-45e4-8738-7ec607080cbe": {
        "text_answer": "  The statement none of the primary clinical trial participants with HER2positive primary breast cancer treated with HER2targeted PETCT using 89Zrtrastuzumab developed HER2 metastases is a negation of the presence of HER2 metastases in any participant in the HER2targeted PETCT arm of the trial  The trial results provided state that 1",
        "label": "Entailment"
    },
    "1a80bab2-1079-4730-bba6-b8414e4cfcc8": {
        "text_answer": "  The statement a young female newly diagnosed with prpositive and her2positive breast cancer may qualify for both the primary clinical trial and the secondary clinical trial is contradictory to the information provided in the trials inclusion criteria  The primary clinical trial includes patients with HER2negative breast cancer while the secondary clinical trial includes patients with ERpositive HER2negative breast cancer A young female newly diagnosed with PRpositive",
        "label": "Entailment"
    },
    "1c57cb03-2d38-4b0e-a4b1-cda77a609a9e": {
        "text_answer": "  The statement only candidates with an ecog score of 3 can partake in the primary clinical trial and secondary clinical trial is contradictory to the information provided in the trials inclusion criteria   In the primary trial candidates have an ECOG performance status of 0 to 2 which includes a score of 3 However in the secondary trial candidates have an ECOG 02 OR Karnofsky 60",
        "label": "Entailment"
    },
    "397ae58e-dc5b-4c06-b8ce-29215ed5bcb9": {
        "text_answer": "  The statement Coronary artery stenosis are the most common AE recorded in the primary trial is a contradiction to the information provided in the trials as no adverse event related to coronary artery stenosis was recorded  The statement abnormal lymphocyte is a lymphocyte characterized by a structural or functional abnormality is a general fact and is not related to the trials provided Therefore it cannot be",
        "label": "Contradiction"
    },
    "812d038b-d9c4-457d-8527-ed43ee902202": {
        "text_answer": "  The statement from the primary clinical trial two patient incidents of doselimiting toxicity occurred one in each cohort is entailed in the trials provided   Explanation   The trials do not explicitly state the number of doselimiting toxicities that occurred in each cohort but they do indicate that each cohort had a total of 6 participants analyzed Since the statement specifies that there was one dose",
        "label": "Entailment"
    },
    "36debc88-2f09-4ae8-9a37-5bee270f5f8c": {
        "text_answer": "  The Trials with Entailment and Contradiction dataset does not provide sufficient information to determine if the statement the intervention segment of the primary clinical trial lacks definition or explanation of a treatment cycle is entailed or contradicted in the given intervention description The dataset only provides the intervention name and subject enrollment information but it does not specify the details of the treatment cycle or lack thereof Therefore we cannot definitively say if the statement is entailed or contrad",
        "label": "Entailment"
    },
    "49cccbde-abb6-45a4-80ba-47dcdd6b760e": {
        "text_answer": "  The statement patients with considerable or unmanaged cardiovascular diseases are unfit to participate in both the primary clinical trial and the secondary clinical trial is entailed in the trials as follows  The primary trial exclusion criteria include  Significant cardiovascular impairment Congestive heart failure Clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months and",
        "label": "Entailment"
    },
    "95cf915e-97df-4ece-bd27-52a72bb4ed68": {
        "text_answer": "  The statement is not entailed in the trials provided as neither trial uses change in MYMOP score as the outcome measurement for their studies Therefore the statement is neither entailed nor contradicted by the information given in the trials",
        "label": "Contradiction"
    },
    "5cd9bd06-f069-44f3-9b2b-69d92eecc07a": {
        "text_answer": "  The statement in the primary clinical trial no patient underwent the most severe pain perceivable for a duration of 10 weeks is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups but they do not provide information about the maximum pain intensity experienced by any individual patient during the 10week study period Therefore the",
        "label": "Contradiction"
    },
    "61547cc4-08c1-41c9-94f3-c45ebba67e5b": {
        "text_answer": "  The statement preventative therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered preventative is not directly entailed in the given inclusion and exclusion criteria for the primary trial However the statement is relevant to the context of the trial as it mentions the types of cancer Nonsmall cell lung cancer and Small cell lung cancer that are included in the trial which can be considered preventative in a broader sense as the",
        "label": "Contradiction"
    },
    "ccc4b1dc-30f5-46d4-9251-6bb1dbe514ce": {
        "text_answer": "  The statement the primary clinical trial reveals that taking tamoxifen 20 mg orally daily for a fortnight postmastectomy has no significant effect on the ki67 expression in tumors is a contradiction to the results presented in the trial   The trial reports a significant change in Ki67 expression with a mean percentage change of 40 63 to 29 in the tamoxifen group compared to the",
        "label": "Contradiction"
    },
    "5296c4b2-ae8f-4321-abb1-071d8a5e9f50": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1000000 ng of talazoparib daily as part of the intervention is not entailed in the given trial description The trial description only mentions that patients are eligible for the trial and the types of cancer they have as well as the available treatment sequences It does not specify the dosage or frequency of talazoparib or any other intervention being administered",
        "label": "Contradiction"
    },
    "dfdcc220-60e9-4ade-a21a-2dea12500959": {
        "text_answer": "  The primary clinical trial description does not provide information about the participants overall survival rates The trial is focused on evaluating the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30  The secondary clinical trial description also does not provide information about the participants overall survival rates The trial is focused on determining the percentage of participants with adverse events of primary interest ",
        "label": "Entailment"
    },
    "848665ec-85f5-4b64-aa71-ba24195e7463": {
        "text_answer": "  The statement is entailed in the Trials description since the secondary trial specifies weekly subcutaneous injections for its participants with Epoetin Beta which is not a requirement in the primary trial",
        "label": "Entailment"
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "text_answer": "  The statement Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial is a contradiction to the given trials   In the primary trial there are two interventions Intervention 1 which includes Fulvestrant  Anastrozole and Intervention 2 which includes Anastrozole alone Arimidex is mentioned as a component of Intervention 1 where it is",
        "label": "Contradiction"
    },
    "6688e7ec-6e04-49d3-b3c2-0bfb041297dc": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement mentions that participants in the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID However the trials do not provide any information about the form or dosage of Fulvestra in the secondary trial only that it is given intramuscularly Therefore the statement does not follow",
        "label": "Entailment"
    },
    "067c3f74-9009-45dc-a97a-0de2a17722cc": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that patients who have received antineoplastic chemotherapy androgens estrogens or progestogens within the last 4 weeks or who are planning to",
        "label": "Entailment"
    },
    "1c3d0ec2-e54e-4b44-9b61-6300e5e2736f": {
        "text_answer": "  The given trial eligibility criteria do not explicitly mention TNM staging T4 N4 M4 as a criterion for patient selection Therefore the statement patients with t4 n4 m4 tumors are allowed to participate in the primary clinical trial is not entailed in the provided trial information  However the trial does allow patients with measurable or nonmeasurable disease which could potentially include patients with advanced",
        "label": "Contradiction"
    },
    "871e4e1f-9d73-46d0-9eda-04099b38ea4b": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX between the two groups   The percentage change in betaCTX for the AZD0530 175 mg group is 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg group is 684",
        "label": "Entailment"
    },
    "10b5153d-7bb1-45a0-9765-1df8e3dfbd88": {
        "text_answer": "  The statement the appearance of maculopapular rash was a frequent side effect among the participants of the primary clinical trial is contradicted by the given data The data shows that only one participant 333 experienced a maculopapular rash which is not considered frequent based on the definition of frequency as occurring in more than 10 of participants",
        "label": "Contradiction"
    },
    "013a39b4-3f7c-427c-8665-134bf9edc4a5": {
        "text_answer": "  The statement the patient cohorts of the primary clinical trial and the secondary clinical trial have registered 3 total cases of asthenia and 5 total cases of pyrexia is not entailed in the given trials data as there is no mention of asthenia or pyrexia in the trials data provided The statement contradicts the given data as the trials data reports no cases of asthenia or pyrexia in either trial",
        "label": "Contradiction"
    },
    "c1fee61a-1d3e-4d83-a0a9-8360e912714c": {
        "text_answer": "  The statement more palpitations pericardial effusions and abdominal pains were recorded in cohort 1 of the secondary trial than in cohort 2 of the primary trial is a contradiction to the given data  Explanation  The statement implies that there are more instances of palpitations pericardial effusions and abdominal pains in cohort 1 of the secondary trial compared",
        "label": "Contradiction"
    },
    "857ea0f3-1f62-417e-93ef-00e121cc3e60": {
        "text_answer": "  The statement is entailed in the given trial description as neither group in the trial receives counselling risk analysis or cognitive behavioural therapy CBT as part of their intervention The trial description explicitly states that Intervention 1 uses a validated webbased risk assessment and decision support for providers but it does not mention counselling risk analysis or CBT as part of the intervention Intervention 2 the control group is described as receiving usual",
        "label": "Entailment"
    },
    "2e844546-8fe8-440c-afdd-504e84d4acc4": {
        "text_answer": "  The statement unlike the primary clinical trial which had no adverse events on record the secondary one frequently reported anaemia as a side effect is entailed in the given trials data  Explanation  The statement implies that the primary trial had no adverse events while the secondary trial had anaemia as a frequent side effect The trials data provided confirms this as the primary trial had 0 adverse events out",
        "label": "Contradiction"
    },
    "50c57a74-1e0e-45fe-8a00-217ff1322d99": {
        "text_answer": "  The primary trial does not have smoking as an exclusion criterion under the Performance status and other medical conditions section It only mentions that patients must have a performance status of 02 on the Eastern Cooperative Oncology Group ECOG Performance Scale and life expectancy  3 months  The secondary trial does list smoking as an exclusion criterion under the Other significant disease or disorders section  There",
        "label": "Entailment"
    },
    "13fb11f0-9307-4576-887c-75896dd7bfd1": {
        "text_answer": "  The statement Nobody taking part in the primary trial suffered a UTI is contradictory to the information given in the trial data as one participant did experience a UTI Therefore the statement is contradictory to the trial data  The statement about mediastinal sarcoma is not directly related to the trial data and does not entail or contradict any information provided in the trial data",
        "label": "Entailment"
    },
    "dd10e477-9de3-43b9-8db3-5c9661514c5e": {
        "text_answer": "  The statement the percentage of participants in both the primary clinical trial and the secondary clinical trial who experienced adverse events was less than 20 is not directly entailed or contradicted by the given data   The data only provides the number of participants who experienced adverse events and the number of participants with neutrophilsgranulocytes ANCAGC adverse events in each trial It does not provide the total number of",
        "label": "Contradiction"
    },
    "74302b73-7dad-4eb7-b9f2-757d0508d85d": {
        "text_answer": "  The statement candidates undergoing CBT Cognitive Behavioral Therapy based treatments will not be disqualified from either primary or secondary clinical trials is not explicitly stated in the inclusion or exclusion criteria for either the primary or secondary trials provided Therefore it cannot be definitively determined if the statement is entailed in the trials or if it is contradictory to them without additional context or information",
        "label": "Entailment"
    },
    "7664aa4a-a4ae-4fe3-81a0-d977d197fde1": {
        "text_answer": "  The statement less than 10 of patients were affected by all types of ae in the primary clinical trial is a contradiction to the given data   Explanation   The given data states that 909 of patients experienced each of the adverse events AEs listed However the statement suggests that fewer than 10 of patients experienced all the AEs Since each AE affected 9",
        "label": "Contradiction"
    },
    "8d6af699-f5b7-41c2-a84f-28fa45e648c9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement implies that no adverse events were observed in the secondary clinical trial which is not the case based on the data provided The secondary trial reported several adverse events with nonzero incidences Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Contradiction"
    },
    "19356a21-1163-41b2-8780-7e8e7c956454": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The given information states that the number of adverse events for the primary trial is 0 out of 34 000 and for the secondary trial is 0 out of 1 000 Therefore the total number of adverse events for both trials combined is 0 However the statement claims that there are 55 recorded",
        "label": "Entailment"
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "text_answer": "  The statement Diagnosis of 23 cerebral metastases will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is consistent with the information provided in both trials   In the primary trial the presence of 23 cerebral metastases is a criterion for inclusion whereas in the secondary trial it is an exclusion criterion However the",
        "label": "Entailment"
    },
    "29968695-9fd4-4fce-b2ba-1879f50c8c57": {
        "text_answer": "  The statement in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is a factual statement about the data presented in the trials   The question often feel sad or depressed is not related to the trials and is not entailed or contradicted by the statement about the trials Therefore the statement about the trials and the question are independent of each",
        "label": "Contradiction"
    },
    "7534e96f-f5c9-4adf-a9cb-efa76fd43257": {
        "text_answer": "  The statement in the primary clinical trial stomatitis was the only adverse event documented is entailed in the given trial data   Explanation  The trial data states that there was one adverse event documented in the primary clinical trial and that event was stomatitis The statement in question asserts that stomatitis was the only adverse event documented which is a stronger claim than what is stated in the trial data but is still",
        "label": "Entailment"
    },
    "f8630eaf-1381-4ba1-ba97-68b86755e0fd": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the primary trial there is a single set of inclusion criteria for all participants regardless of age There is no mention of separate inclusion criteria for participants below or above 18 years old  In contrast in the secondary trial there are distinct inclusion criteria mentioned for participants based on their age Participants below 18 years old are not specified in the primary trials inclusion criteria ",
        "label": "Entailment"
    },
    "5ccef9c9-dfe2-465e-8cc4-c6cdc310f74a": {
        "text_answer": "  The statement more than 10 patients in the primary clinical trial experienced aes is contradictory to the given trial data The trial data reports that only 2 patients experienced adverse events out of a total of 35 patients which is less than 10 patients",
        "label": "Entailment"
    },
    "816acfa2-5f8d-4f30-9425-5880f3d72414": {
        "text_answer": "  The statement women with conditions of claustrophobia and osteoporosis are disqualified from participation in both the primary clinical trial and the secondary clinical trial is entailed in the given trials as follows  1 Osteoporosis is an exclusion criterion for both trials 2 Claustrophobia is an exclusion criterion for the secondary trial 3 The statement w",
        "label": "Entailment"
    },
    "eec99f26-cf8e-407d-bb6a-7f9d053fe187": {
        "text_answer": "  The statement candidates possessing an ecog score of 1 are qualified for both the primary clinical trial and the secondary clinical trial is entailed in the given trials as follows  1 In both trials the inclusion criteria state that candidates must have an ECOG performance status of 0 to 2 Therefore a candidate with an ECOG score of 1 meets this requirement for both trials 2 The exclusion criteria do not mention",
        "label": "Entailment"
    },
    "facb2d1c-1f65-4c84-9c93-209ce87d18a7": {
        "text_answer": "  The statement is not entailed in the given trials as there are certain exclusion criteria in both trials that the patient with a primary tumour measuring 33mm in diameter may not meet   In the primary trial the patient must have a primary tumour greater than 2 cm diameter and in the secondary trial there is no specific mention of tumour size as an inclusion criterion However the patient may still be excluded from the secondary trial due to",
        "label": "Contradiction"
    },
    "4f89c108-d732-49bd-b21a-c3566400b519": {
        "text_answer": "  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is contradicted by the given data   The primary trial had a total of 30 participants and 7 cases of diarrhea 2333   The secondary trial had a total of 6 participants and 0 cases of diarrhea 000   Therefore the frequency of",
        "label": "Contradiction"
    },
    "52f841b6-f451-455e-9ec5-2541cf02bb13": {
        "text_answer": "  The given statement none of the patients in the primary trial experienced the worst pain imaginable for 25 months is not directly entailed or contradicted by the information provided in Trials 1 and 2   The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups over a 10week period They do not provide information about the distribution of pain intensity scores or the number of patients who experienced",
        "label": "Contradiction"
    },
    "df991d6e-570f-4371-9b5e-00e9f3f4707d": {
        "text_answer": "  The statement every participant in the primary clinical trial endured extreme pain for a period of 10 weeks is contradicted by the information provided in the trials The trials describe a psychoeducational intervention aimed at improving cancer pain management and participants were assessed for average pain intensity using a numeric rating scale However the trials do not indicate that all participants experienced extreme pain defined as a score of 10 on the scale throughout the 10",
        "label": "Contradiction"
    },
    "41617f3f-76b1-41ca-b7c7-f902f84cd816": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that patients who have received any of these therapies within 4 weeks prior to study entry are excluded Therefore the statement is entailed in the trials criteria  However",
        "label": "Entailment"
    },
    "2a32321e-12f1-453f-b0d4-d0b10b80e293": {
        "text_answer": "  The statement patients possessing ccnd2 amplification can join the primary clinical trial is entailed in the trial description   Explanation   The inclusion criteria for the trial state that patients with any tumor type that tests positive for CCND2 amploration are eligible for enrollment Therefore patients with ccnd2 amplification are included in the trial and the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "40535d67-a16d-48eb-932e-3d8d2ff57281": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the interventions include the use of seven different drugs doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate and vinorelbine tartrate and two surgical procedures needle biopsy and therapeutic conventional surgery  ",
        "label": "Entailment"
    },
    "3657b15f-ab73-479c-8b00-c2189fc4d984": {
        "text_answer": "  The statement several patients experienced the same type of adverse event during the primary clinical trial is entailed in the given data if there is more than one patient who experienced the same type of adverse event Based on the provided data this statement is entailed since there are multiple patients who experienced the same type of adverse event eg two patients had disease progression as an adverse event",
        "label": "Entailment"
    },
    "63bd708a-66ae-41fc-872d-277417bc2576": {
        "text_answer": "  The statement is contradictory to the trials provided   The primary trial does not prescribe a regimen of oral multivitamins for its patients Instead it compares two interventions 150 mg of oral pregabalin twice daily for 6 weeks and oral placebo twice daily for 6 weeks  The secondary trial describes a complex treatment regimen for leukemia patients including intravenous and intrathecal",
        "label": "Entailment"
    },
    "b03fe494-c036-4988-ae85-d5e548b57aea": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial has separate inclusion and exclusion criteria for its Phase I and Phase II portions Statement  The primary trials Phase I and Phase II portions have different sets of inclusion and exclusion criteria Fact  Therefore the statement is entailed by the facts presented in the Trials  As for the second part of the statement it is not directly related to",
        "label": "Entailment"
    },
    "686121cf-e252-49b2-9e46-f4cb6ebac7f8": {
        "text_answer": "  The statement the secondary clinical trial and the primary clinical trial are open to women who are 18 years old and above is entailed in both trials as it is stated in the inclusion criteria for both trials Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "4246dc90-5b23-4170-8b6a-bd1459f776b9": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort is not directly stated in the given information However it can be inferred from the data provided that none of the individual adverse event types affected more than 714 of the patient cohort which is less than 25 Therefore the statement is entailed by the information given",
        "label": "Entailment"
    },
    "2f57e639-546c-4e7a-b562-77338563d472": {
        "text_answer": "  The statement 013 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is entailed in the trial results as stated 13 out of 49 participants 265 developed imagable HER2 metastases However the statement does not explicitly",
        "label": "Entailment"
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "text_answer": "  The statement is entailed in the trials as follows  Both interventions use the same dosage and frequency for Doxorubicin 60 mgm IV bolus injection every 3 weeks for 4 cycles Cyclophosphamide 600 mgm IV bolus injection every 3 weeks for 4 cycles and Docetaxel 100 mgm IV infusion every 3 weeks for",
        "label": "Entailment"
    },
    "a3ae0081-3bd8-408b-b11d-415711be2ddc": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials focus on the interventions used and do not explicitly mention the mllt6 gene rearrangement However there is no contradiction to the statement as both trials involve injections",
        "label": "Contradiction"
    },
    "96a69ac4-9248-4ede-bc27-2f032f0e2294": {
        "text_answer": "  The statement participants in the primary clinical trial will be given a series of injections throughout the study duration is entailed in the given trial description as follows  1 Trastuzumab infusion 2 Vinorelbine ditartrate infusion 3 Leukine GMCSF injections for neutropenia management 4 Autologous dendritic cells DCs injections 2",
        "label": "Entailment"
    },
    "6e3e407e-901f-443e-9785-d19b184ff462": {
        "text_answer": "  The given statement throughout the primary clinical trial not a single patient reported experiencing the most unbearable pain for ten consecutive weeks is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups but they do not provide information about the distribution of pain intensity scores or the number of patients who experienced the most unbearable pain for ten consecutive weeks Therefore",
        "label": "Contradiction"
    },
    "9827f954-40d9-4b55-bb92-02624a0d6a75": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial Intervention 2 involves the administration of dexmedetomidine not myalgias In the secondary trial there is no mention of Intervention 1 or the administration of myalgias to any group Therefore the statement that Group 2 of the primary trial receives 05ugkg of myalgias 5ml is",
        "label": "Contradiction"
    },
    "aba3d5b6-63f0-4eaa-a345-2e9624932e9b": {
        "text_answer": "  The statement patients with quantifiable metastasis or with cancer that has spread to other parts of the body are eligible for the primary clinical trial is entailed in the given trial description   Explanation   The trial description specifies that patients with measurable or nonmeasurable disease are eligible Measurable disease refers to the presence of tumors that can be accurately measured using imaging techniques while nonmeasurable",
        "label": "Entailment"
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "text_answer": "  The statement is entailed in the given trial information as follows  1 The trial has two cohorts an intervention arm and a control arm 2 The intervention arm includes viewing the Educational DVD and meeting with a lay health advisor 3 The control arm does not include viewing the Educational DVD or meeting with the lay health advisor 4 The statement specifies that only the intervention arm will view the Educational DVD  ",
        "label": "Entailment"
    },
    "4128c0f0-7d9f-44e7-ba5a-66919c502fdd": {
        "text_answer": "  The statement negligible or no adverse events were reported in both the primary clinical trial and the secondary clinical trial is contradicted by the information provided in the trials  Explanation  The primary clinical trial reported 0 adverse events out of 49 participants 000 while the secondary clinical trial reported 12 adverse events out of 20 participants 6000 Therefore the statement that",
        "label": "Contradiction"
    },
    "f3598d65-2288-40bd-abe1-45eaa69ee03e": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The placebo intervention is administered on Day 1 while the trabectedin intervention is administered on Day 2 Therefore the statement that they are both administered on the same day is not entailed in the trials and is in fact contradictory to the information provided",
        "label": "Contradiction"
    },
    "9dd03978-dc7f-4c73-a199-92f7247dbf29": {
        "text_answer": "  The statement There were more cases of Mucositis Oral epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials However the statement does not mention the specific number of cases for each adverse event in both trials  The given trials only provide the number of cases for each adverse event in each trial From the given",
        "label": "Entailment"
    },
    "57bf60c1-b440-4fa1-854e-91d2947360e3": {
        "text_answer": "  Lets calculate the number of cases for hepatotoxicity hypertension and pancreatectomy based on the given information in the primary trial   Hepatotoxicity 38  0375  04 cases  Hypertension 18  0125  013 cases  Pancreatectomy 1",
        "label": "Entailment"
    },
    "996df3c5-d5a6-4cfc-9407-cb9a59388007": {
        "text_answer": "  The statement the educational dvd as part of the intervention will be shown exclusively to cohort 1 in the primary clinical trial is entailed in the given information if we assume that  1 The primary clinical trial consists of two cohorts intervention and control 2 The intervention arm of the study includes viewing the educational DVD and meeting with a lay health advisor 3 The control arm of the study does not include viewing the educational DVD",
        "label": "Entailment"
    },
    "0dd1c6d6-5a35-452e-b058-ea0da7bd9f3a": {
        "text_answer": "  The statement patients diagnosed with breast cancer may not be eligible for any study groups in the primary trial and the secondary trial is entailed in the given trials as follows  1 In the primary trial patients with breast cancer are included in the study group if they are postmenopausal women with early stage breast cancer and low vitamin D levels However they are excluded if they have severe or debilitating musculoskeletal pain",
        "label": "Entailment"
    },
    "a111fa2e-4d53-4b24-8929-ee37b97bed05": {
        "text_answer": "  The statement participation in the primary clinical trial and the secondary clinical trial is restricted to Canadian nationals is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials The criteria focus on various medical and demographic conditions for eligibility and ineligibility for the trials without any mention of nationality restrictions",
        "label": "Contradiction"
    },
    "fbe4e8b0-f258-448d-8926-3ac4757ee020": {
        "text_answer": "  The statement is contradictory to the given trials as the first cohort in the primary trial receives a fluciclatide injection while in the secondary trial the first cohort is given a standard dose of chloroquine which are two different interventions",
        "label": "Entailment"
    },
    "6ad65d9b-8610-4f09-a760-caedb0a4037d": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The statement the primary clinical trial documented four more adverse events than the secondary clinical trial is contradictory to the given information because the primary trial had zero adverse events and the secondary trial also had zero adverse events Therefore there is no situation where the primary trial would have four more adverse events than the secondary trial",
        "label": "Contradiction"
    },
    "6add1cab-1458-4cca-a419-7bfc5acdc1cc": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does mention pain therapy which could potentially involve the use of medications However it does not specify which medications are being used or if any drugrelated tests are being conducted   The secondary trial on the other hand does involve the use of a specific medication PF06647020 and specifies the dosage and administration",
        "label": "Entailment"
    },
    "9020a95d-874e-4bee-97bb-9b31bbcdd50d": {
        "text_answer": "  The statement the patient who exhibited the most extended progression free survival PFS in the primary clinical trial belonged to cohort 1 is not directly entailed in the given trials as the trials only report the median PFS for each cohort and do not provide information about individual patient outcomes However the statement is not contradictory to the trials as well as the longest PFS of 35 months falls within the 95",
        "label": "Contradiction"
    },
    "f0cbb267-5a5b-412e-a474-2ad091a031d7": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there is a group that receives Armodafinil PO daily while in the secondary trial no group receives Armodafinil PO daily Instead both trials involve the use of MCS110 and PDR001 but the dosages and frequencies differ The statement incorrectly assumes that both trials involve the same dosages for",
        "label": "Contradiction"
    },
    "b5b61f90-60b8-404f-872e-a58c84dbf43a": {
        "text_answer": "  The statement no adverse events were registered in either the primary clinical trial or the secondary clinical trial is entailed by the given data since the data reports that there were no adverse events AEs in both trials for both AEs 1 and AEs 2 The data does not contradict the statement as the statement is a logical consequence of the data provided",
        "label": "Contradiction"
    },
    "e3629df4-61d3-42e0-af44-62cb2782c5c2": {
        "text_answer": "  Based on the given information the statement less adverse incidents took place during the course of the secondary clinical trial than the primary clinical trial is entailed in the trials data as both trials reported 000 adverse incidents for Adverse Event 1 and no data is provided for Adverse Event 2 in the primary trial Therefore since the secondary trial has fewer participants and reported no adverse incidents for Adverse Event 1 and no data for Adverse",
        "label": "Entailment"
    },
    "7f7f7885-c57a-42f3-9799-99159d400077": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the Trials with Entailment or Contradiction we need to refer to the provided information in the Trials with Entailment or Contradiction database Unfortunately without access to the specific trial data related to MM111 it is impossible to make an accurate determination based on the given statement alone  The Trials with Entailment or Contradiction database may contain",
        "label": "Entailment"
    },
    "65a1b098-171e-4a2e-87a7-7d29b4a7d6ba": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial measures the count of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment up to 8 weeks These are different outcome measurements  The primary trial is",
        "label": "Entailment"
    },
    "cbf72855-5886-46d7-b084-43cb6f2a0e2e": {
        "text_answer": "  The statement presurgical consumption of tamoxifen 20 mg orally on a daily basis excites a rise in ki67 expression in cancer tumors is contradictory to the results obtained from the primary clinical trial   The trial reported a significant decrease in Ki67 expression in tumors after 7 days of presurgical tamoxifen treatment with a mean percentage change of 40 63 to",
        "label": "Entailment"
    },
    "f0ff3265-a75f-4a9f-8c0e-ff03057647eb": {
        "text_answer": "  The statement is contradictory to the information provided in the primary trial The statement suggests that both interventions placebo and memantine are administered orally once daily but the primary trial specifies that memantine is administered orally twice daily BID and the placebo is also administered orally twice daily BID The ibrutinibvenetoclax regimen is not mentioned in the primary trial and is not relevant",
        "label": "Entailment"
    },
    "584c33f0-3bca-4276-a3f1-2c68e39898ac": {
        "text_answer": "  The statement in the secondary clinical trial a single adverse event impacted more than 50 of the subjects involved is contradictory to the information provided in the trials  Explanation  The statement implies that there is a single adverse event that affected more than half of the subjects in the secondary trial However the trials list multiple distinct adverse events and none of them affected more than 50 of the subjects Therefore",
        "label": "Entailment"
    },
    "d5abfad6-a8c3-409f-b434-33e55c0848cb": {
        "text_answer": "  The statement is entailed in the given trials as the trials clearly employ different interventions with distinct drugs dosages and administration schedules The primary trial uses FMX and MM398 while the secondary trial uses lapatinib and paclitaxel Additionally the dosages and administration schedules for each intervention are different Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "96e242e7-e1dc-4465-bb90-6f9ef0ab0f2a": {
        "text_answer": "  The given statement none of the participants in the primary clinical trial are prescribed talazoparib on a daily basis is not directly entailed or contradicted by the information provided in the trial description   The trial description mentions that the participants are not prescribed talazoparib at all but it does not specify whether talazoparib is prescribed on a daily basis or not Therefore the statement is neither entailed nor contradicted",
        "label": "Contradiction"
    },
    "bd18948b-345b-48be-a1a0-45c4ee688747": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial there is no mention of any intervention involving myalgias for either group 1 or group 2 In the secondary trial there is no mention of any intervention involving myalgias for either cohort Therefore the statement that group 2 of the primary trial receives 500ngkg of myalgias 5ml is not entailed in the trials",
        "label": "Contradiction"
    },
    "e5a8197e-dc1f-4258-9da2-f530eade84fe": {
        "text_answer": "  The statement feeling nervous anxious or on edge is not directly related to the doses of Lenalidomide or Lapatinib mentioned in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "dfd33619-98ec-43e0-83c4-a22bae9f1b52": {
        "text_answer": "  The statement millimole per liter per microgram per kilogram per day is a unit of concentration equal to millimoles per liter divided by micrograms per kilogram per day is not directly related to the inclusion and exclusion criteria for the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given trial information alone",
        "label": "Entailment"
    },
    "ad3c8700-e49c-404e-af40-e9329033f2a7": {
        "text_answer": "  The statement blood bilirubin levels remained unchanged in all the patients in the primary clinical trial is contradictory to the trial data as one patient 909 experienced an increase in blood bilirubin levels",
        "label": "Entailment"
    },
    "6cf2337d-c486-405c-be2b-97c29d8425dc": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement claims that the most common adverse event in the secondary trial was anaemia affecting less than 005 of patients and that there were no recorded adverse events in the primary trial However the secondary trial data shows that anaemia affected 234 of patients which is not less than ",
        "label": "Contradiction"
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is contradictory to the given trials because  1 In the first trial only one patient out of 13 experienced Rapid disease progression and none experienced Increased pleural effusion Therefore less than 2",
        "label": "Entailment"
    },
    "52d2dcbc-8b57-43eb-bc12-8b7df8c3d8ba": {
        "text_answer": "  The statement is entailed in the Trials as the primary clinical trial specifically includes the requirement of participants being resistant to aromatase inhibitor AI therapy while the secondary clinical trial does not have any such requirement mentioned in its inclusion criteria",
        "label": "Entailment"
    },
    "40f8f9a6-a042-4f99-bbd9-5f3c3279045d": {
        "text_answer": "  The statement is contradictory to the information provided in both trials as methotrexate is not mentioned as being administered to the patients in either trial",
        "label": "Entailment"
    },
    "475fbb72-9858-40cf-b7f0-50236d032582": {
        "text_answer": "  The statement the secondary clinical trial allows participation of patients irrespective of their age while the primary clinical trial accepts only those between the ages of 18 to 45 is a contradiction of the given trials inclusion criteria  Explanation  The primary trial includes patients who are presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston and the age range for inclusion is between",
        "label": "Contradiction"
    },
    "9137a91a-d493-42f7-a1e5-9b39928036d6": {
        "text_answer": "  The statement treatment protocols based on cbt are not permitted in the primary clinical trial however its candidates can still participate in the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However the primary trial does exclude patients who have received prior treatment with any PARP inhibitors but it does not mention CBT chemotherapy or chemoradiation specifically The secondary trial does not",
        "label": "Entailment"
    },
    "72154344-5c84-49cd-b39e-4010fb73756a": {
        "text_answer": "  The statement for patients with breast cancer eligibility can extend to all study groups in the primary and secondary clinical trials is not directly entailed in the given trials as they have distinct inclusion and exclusion criteria However it is possible for individual patients with breast cancer to meet the criteria for both trials The primary trial includes postmenopausal women with early stage breast cancer who are candidates for aromatase inhibitor therapy and have low vitamin D levels",
        "label": "Contradiction"
    },
    "ca8c2bae-ba14-4791-b995-e1555696d182": {
        "text_answer": "  The statement exposure to gabapentin or herceptin within the last 12 months disqualifies patients from the secondary clinical trial yet it wont prevent them from being part of the primary clinical trial is a complex statement that involves checking if both conditions being disqualified from the secondary trial but not the primary trial due to exposure to gabapentin or herceptin within the last 12 months are entailed in the given trials",
        "label": "Entailment"
    },
    "437a782b-7dc2-4904-ac68-3a532b98f2e2": {
        "text_answer": "  The given statement out of the participants 5 had experienced three or more adverse incidents during the primary clinical trial is not directly entailed in the provided data The data only states the number and percentage of participants who experienced each specific adverse event It does not provide information about how many participants experienced three or more adverse events in total Therefore the statement is neither entailed nor contradicted by the given data",
        "label": "Contradiction"
    },
    "947b0d76-6214-46c7-ac3c-f5794e0cfcb3": {
        "text_answer": "  The statement is entailed in the given trials as they do provide the overall number of participants analyzed for each armgroup but they do not specify the number of participants within each cohort for both trials",
        "label": "Entailment"
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "text_answer": "  The statement is entailed in the given trials In the primary trial there is one test group Pyridoxine and one placebo group Placebo In the secondary trial there is one test group Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride which can be considered as one group with two dosages and one control group Placebo in the primary trial is also the",
        "label": "Entailment"
    },
    "8601ec47-bccd-45d7-b823-ff39719683e5": {
        "text_answer": "  The given statement is a comparison of outcomes between two different arms of the trial LBH589 and Lapatinib versus LBH589 with Capecitabine However the provided results do not contain any information about the outcomes or efficacy of the two arms The results only mention the doses schedules and number of participants for each arm Therefore the statement cannot be entailed or contradicted based on the",
        "label": "Entailment"
    },
    "620be964-dbff-4793-a75e-7644f7c57fb5": {
        "text_answer": "  The given statement is not entailed in the provided information about the primary clinical trial The trial description only mentions the administration of chemotherapy drugs doxorubicin cyclophosphamide docetaxel and bevacizumab but it does not mention the use of a neurokinin1 receptor antagonist for any of the participants",
        "label": "Contradiction"
    },
    "b35e0f7c-9162-4752-98dc-b41bac62e99c": {
        "text_answer": "  The statement in both sections of the primary clinical trial patients reported adverse events at an equivalent rate is neither entailed nor contradicted by the given data   Explanation  The statement requires that the number of adverse events reported in each trial be equal However the given data only provides the number of adverse events and the percentage of patients experiencing each adverse event for each trial The number of patients in each trial is not specified",
        "label": "Entailment"
    },
    "dea24187-160a-4d6c-a724-e8cb01494d68": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the physical quantity and time for each intervention in both cohorts   For Intervention 1 ErC  Eribulin 14mgm2 given on Days 1 and 8  Cyclophosphamide 600 mgm2 given on Day 1 ",
        "label": "Entailment"
    },
    "cf959db3-df50-4724-a747-413a35bb171b": {
        "text_answer": "  The statement is not contradictory or entailed by the given information in the primary trial The trials focus on interventions for personalized risk assessment and decision support for providers without mentioning any specific conditions or treatments related to pharyngoconjunctival fever",
        "label": "Entailment"
    },
    "3cf9b40b-ffa4-4b08-9039-9481c7d6cd76": {
        "text_answer": "  The statement is contradicted by the given trials The trials report that there were no cases of Infection Asymmetry or nausea in the secondary trial while there were cases of these adverse events in the primary trial However the statement incorrectly asserts that there were more cases of Infection Asymmetry and nausea in the primary trial than in the secondary trial Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "52f7d88d-78f0-4e5a-8fb9-e423679f2c61": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive daily subcutaneous injections of unspecified interventions In contrast the secondary trial mentions that participants receive weekly subcutaneous injections of epoetin beta and take oral medication but it does not specify the intervention for the primary trial patients  Therefore the statement that while secondary trial participants are required to take oral medication",
        "label": "Entailment"
    },
    "901dac1a-6a67-4883-a883-06c5a91f85c1": {
        "text_answer": "  The statement the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts is a contradiction to the given data in the trials   The primary trial and the secondary trial both report having zero adverse events for all reported categories Therefore they did not record over 100 total adverse events in their cohorts   The statement about a person requiring a cane or crutch most of",
        "label": "Contradiction"
    },
    "c89ba7c0-93b6-4601-82f0-557aa23f24cc": {
        "text_answer": "  The statement is not entailed in the primary or secondary trial information provided The primary trial explicitly states that premenopausal women pregnant and lactating women are excluded The secondary trial includes a criterion for women of childbearing potential to commit to effective barrier nonhormonal contraception but it does not mention any height requirements for children and adolescents Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "18c8db1c-2d31-481b-923d-0415861bd6d6": {
        "text_answer": "  The statement is contradictory to both the Primary and Secondary Trials as neither trial mentions anything about a lung tumor or a KRAS mutation being a requirement for participation The inclusion and exclusion criteria for both trials are specific to breast cancer patients only",
        "label": "Entailment"
    },
    "8db48a95-bc22-4f5e-b9e3-a50a275481a3": {
        "text_answer": "  The statement those involved in the secondary clinical trial at present are barred from simultaneous registration in the primary clinical trial is an entailment based on the given information in the primary and secondary trials   Explanation   The primary trial has an exclusion criterion that states Participation in another clinical trial within 30 days prior to screening or during the study This means that a participant cannot be enrolled in another clinical",
        "label": "Entailment"
    },
    "4092de53-28a9-457c-91cf-f87f4abf4dc1": {
        "text_answer": "  The statement 100 of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is a contradiction to the information provided in the trials   The trials report the average pain intensity scores and the change in average pain intensity between the two intervention groups They do not indicate that all patients in either group experienced the worst pain imaginable for the entire 10week study period",
        "label": "Contradiction"
    },
    "f1c2db2e-dc72-4a69-a3b6-a8d846a6f7ee": {
        "text_answer": "  The statement patients with a vitamin D deficiency are eligible for the primary trial but may not qualify for the secondary trial is neither entailed nor contradicted by the given trial information   Explanation   The primary trial includes postmenopausal women with early stage breast cancer vitamin D deficiency and other specified conditions The secondary trial includes healthy participants HER2positive females with breast cancer and",
        "label": "Entailment"
    },
    "16710aab-1003-447f-bf01-7275e653d263": {
        "text_answer": "  The statement is contradictory to the primary trial inclusion criteria as the primary trial requires a primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography A tumour with a radius of 0003m is significantly smaller than 2 cm Therefore the statement is contradictory to the primary trial inclusion criteria and the patient with such a tumour would not be eligible for the primary trial  Regarding the",
        "label": "Entailment"
    },
    "e9639699-8cb1-4b2b-9901-443fedb90158": {
        "text_answer": "  The statement in the primary clinical trial and the secondary clinical trial there are recorded cases of swelling hypothermia and confusion in the adverse events sector is a contradiction to the information provided in the trials The trials report no recorded cases of swelling hypothermia or confusion in the adverse events sector for either trial",
        "label": "Contradiction"
    },
    "b6643c69-48aa-452a-91f8-b45c83ccf01e": {
        "text_answer": "  The statement Only 2 patients in the primary trial did not have Recurrencefree Survival is not directly entailed in the provided trial information The trial results only state that 98 out of 100 participants had Recurrencefree Survival but it does not specify how many did not have Recurrencefree Survival or any other information about their outcomes Therefore the statement is neither entailed nor contradicted by",
        "label": "Contradiction"
    },
    "3df0eb9e-b9d9-4f8b-af9a-2d6259e1ed9c": {
        "text_answer": "  The statement laserassisted fluorescence angiography along with lateral radial incisions are employed for both interventions in the primary clinical trial is entailed in the given trial description as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate",
        "label": "Entailment"
    },
    "c667d986-5b21-4855-8f51-109296357a9e": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial sunitinib and capecitabine were both administered to the patients in cohort 1 during the first 21day cycle Therefore the statement that no medications were administered to the patients in cohort 2 during the first 21day cycle is not entailed in the trial information and is contradictory to it",
        "label": "Contradiction"
    },
    "2d7737fc-95e6-4392-8a2e-d896e65ba3e6": {
        "text_answer": "  The statement the primary trial observes less adverse events in total than the secondary trial yet higher counts of cardiacischemiainfarction are reported in the primary trial is a contradiction   The statement that the primary trial observes less adverse events in total than the secondary trial is not entailed in the given data as the primary trial has a total of 0 adverse events and the secondary trial has a higher total",
        "label": "Contradiction"
    },
    "e25b66fb-c20a-4868-b2c3-780c859d629b": {
        "text_answer": "  The statement during the primary clinical trial 96 individuals from the ketorolac 30 mg group showed recurrencefree survival compared to 67 participants from the nacl 09 3ml group is a contradiction of the provided trial data  The trial data states that there were 80 participants with recurrencefree survival in the ketorolac 30 mg group and 96",
        "label": "Contradiction"
    },
    "7e695451-7e2e-43b4-8762-0ac27fb978b2": {
        "text_answer": "  The statement the expression pattern of the selected 40 genes was absolutely visible among the participants in both the first and second cohorts of the primary clinical trial is not directly entailed in the given trial results as there is no information provided about the gene expression profile in the trials The trials only report the correlation of Vitamin D levels and the number of participants with discernible gene expression patterns in each cohort Therefore the statement is neither entailed nor contrad",
        "label": "Contradiction"
    },
    "b5c0af13-187b-4f3f-8e46-c06d2df27d1c": {
        "text_answer": "  The statement cancer patients diagnosed with conditions such as fibromyalgia thalasemic syndromes or anemia cannot participate in either the primary clinical trial or the secondary clinical trial is entailed in the trials exclusion criteria   Explanation  In the primary trial fibromyalgia is listed as an exclusion criterion Thalasemic syndromes and anemia due to causes other than",
        "label": "Entailment"
    },
    "73677475-c59f-4327-b231-57cd7136dd94": {
        "text_answer": "  The statement cholelithiasis was a common adverse event recorded in both the primary trial and the secondary trial is contradictory to the given information   The statement implies that cholelithiasis was recorded as an adverse event in both trials with a significant frequency However the given information does not mention cholelithiasis as an adverse event in either trial Therefore the statement is contradictory to the facts presented",
        "label": "Entailment"
    },
    "22401c29-1796-455c-ac34-59d3afb99fe9": {
        "text_answer": "  The statement every participant in group 1 of the primary trial were diagnosed with lesions and less than 5 of participants in group 1 of the secondary trial had clean skin without any blemishes is contradictory to the information provided in the trials  In the primary trial the outcome measurement was the number of lesions detected in healthy volunteers and breast cancer patients undergoing MRI However the trial did not report that every participant in group ",
        "label": "Entailment"
    },
    "af3d4568-37c3-4c9b-8b22-38d9e3087754": {
        "text_answer": "  The statement is entailed in the Trials with Entailment if the primary and secondary trials compare the same endpoints and the results indicate a large difference in outcomes between the two cohorts in one trial but comparable results in the other trial However in the given trials the primary and secondary trials have different endpoints The primary trial measures pCR within the breast while the secondary trial measures pCR after preoperative therapy Therefore the statement is not directly ent",
        "label": "Entailment"
    },
    "7ae95d8e-af13-452e-a4e0-d4ba7c066a9c": {
        "text_answer": "  The statement only patients with no known hypersensitivities to herceptin medications are acceptable candidates for the primary clinical trial is entailed in the trials exclusion criteria as follows History of grade 3 or 4 allergic reactions attributed to trastuzumab Therefore the statement is entailed in the trials criteria",
        "label": "Contradiction"
    },
    "18f56de9-cf7d-467a-9e95-ca80d8c651a2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement suggests that more than 90 of patients experienced a psychiatric adverse event but the trials only report one psychiatric adverse event suicidal ideation in 50 patients 200 Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "2f11c1f5-4e9c-4848-8de1-9df7d4403848": {
        "text_answer": "  The statement is entailed in the trials as both the primary and secondary interventions include the use of cyclophosphamide",
        "label": "Entailment"
    },
    "9229abbd-f6e6-4747-bf4c-7c1257115667": {
        "text_answer": "  The statement did the individual have multiple known primary tumors at initial melanoma diagnosis is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "09ac056f-fdf4-4684-99d2-8581ddc09d3b": {
        "text_answer": "  The statement there are 15 shared inclusionexclusion criteria between the secondary trial and the primary trial is an entailed statement based on the given information   The primary trial and the secondary trial share the following inclusion criteria age  18 years life expectancy of at least three months ECOG performance level 02 or Karnofsky score 10070 and willingness and ability to provide written informed",
        "label": "Entailment"
    },
    "4a54e780-0828-40c0-9f30-1ed06b66275a": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity both from cohort 2 is not directly stated in the given trial results However we can infer that information from the results   From the results we know that there were 6 participants in each cohort Level 1 and Level 2 We also know that there were Incidences of Doselimiting",
        "label": "Entailment"
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms cannot take part in the secondary trial and those who currently have breast implants cannot participate in the primary trial is not explicitly stated in the given inclusion and exclusion criteria for either trial However the following can be inferred  1 For the primary trial there is an exclusion criterion for individuals with a history of clotting disorders which could include a history of",
        "label": "Entailment"
    },
    "b200a0d8-1c63-49a2-bf1c-280e9d6a2968": {
        "text_answer": "  The statement all adverse event types in the primary trial affected less than 01 of patients is contradictory to the provided data The data shows that the total number of adverse events was 4 out of 11 patients 3636 which is more than 01 of the total number of patients Therefore the statement is contradictory to the provided data",
        "label": "Entailment"
    },
    "cea1bf06-b100-4328-aee1-638ef92d2784": {
        "text_answer": "  The statement the secondary clinical trial does not report the maximum tolerated dose mTD of different treatments and the mTD of mm111 for its participants is 20 mg per day in the primary clinical trial is a contradiction   The secondary clinical trial does not report the mTD of different treatments but it does mention that the MTD was determined based on the number of patients who experienced DLTs However the statement as",
        "label": "Contradiction"
    },
    "3c9c99d8-4604-4de9-98e6-81a675fe0558": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The statement suggests that the control group will receive a standard dose of radiotherapy in addition to usual care but there is no mention of radiotherapy in the control group description in the trial information The trial only mentions that the control group will receive usual care without any additional interventions such as watching the educational DVD or meeting with a lay health advisor",
        "label": "Contradiction"
    },
    "524f9dd3-ec1a-44fa-b440-59eaa49fe204": {
        "text_answer": "  The statement refractory acute myelomonocytic leukemia is acute myelomonocytic leukemia that does not respond to treatment is not directly related to the adverse events listed in the trial The statement is about the condition of refractory acute myelomonocytic leukemia which is not defined or mentioned in the trial The trial only provides information about the adverse events observed during the",
        "label": "Entailment"
    },
    "f7c36a91-5d42-46b9-b0cb-db7a57d37c04": {
        "text_answer": "  The statement is entailed in the trials as follows   In Intervention 1 the dosage of Eribulin Er is 14mgm2 and in Intervention 2 the dosage of Docetaxel T is 75 mgm2  To convert mg to mgm2 we divide the dosage by the patients body surface area BSA Let",
        "label": "Entailment"
    },
    "a44a34b5-9f9e-4957-bb5e-5bb7bf834ecc": {
        "text_answer": "  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the trials exclusion criteria The criteria explicitly state that patients with a history of these conditions within",
        "label": "Entailment"
    },
    "f90e818c-2a5c-44c9-9445-1d34a0c2e551": {
        "text_answer": "  The statement women who are at least 18 years old can participate in both the secondary and the primary clinical trial is entailed in the given trials as the inclusion criteria for both trials state that participants must be aged 18 or older Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "c31609ed-47a9-4a4a-94f1-92757a79033c": {
        "text_answer": "  The statement is entailed in the trials as given in the problem statement The trials explicitly mention that the pneumococcus vaccine is used for the first cohort Adult Cancer Patients 65 Years of Age and Older and the influenza vaccine is used for the second cohort Healthy Volunteers Therefore the statement that in the primary clinical trial pneumococcus vaccine is administered to the participants of the first",
        "label": "Entailment"
    },
    "34b41276-f5fe-4adf-8178-808e139d9d52": {
        "text_answer": "  The statement patients without any evidence of solid tumor either locally advanced or metastatic of all genders are welcomed for both phases of the primary clinical trial is contradictory to the inclusion criteria of the trial   The inclusion criteria state that patients must have evidence of a solid tumor that is locally advanced andor metastatic excluding primary brain tumor for Phase 1 and have evidence of a solid tumor that",
        "label": "Entailment"
    },
    "a6fa44b8-fb1b-4571-aadd-284cbe4f37d8": {
        "text_answer": "  The statement is entailed in the trials as follows  The statement mold mix antigen ige antibody measurement is a measurement of the mold mix antigen ige antibody in a biological specimen is not related to the adverse events data presented in the trials  However the statement The most common adverse event in the secondary trial was Anaemia there were no recorded AEs in the primary trial is a separate statement that can",
        "label": "Entailment"
    },
    "f2d5970e-568d-40ca-9258-65015ff4a828": {
        "text_answer": "  The statement none of these describe me is a response indicating that an individual feels that none of the options listed are a good description for them This statement is not entailed in the given trials as the trials do not provide any information about the individual in question and the statement is not related to the trials themselves The trials describe interventions for breast cancer patients but they do not provide enough information to determine whether the statement applies to any specific individual or not Therefore the statement",
        "label": "Contradiction"
    },
    "45d94eb6-d3a6-47ae-8c80-75fb02520ef2": {
        "text_answer": "  The statement 100 of the participants in group 1 of the primary trial were found to have lesions and only 5 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not entailed in the given trials   The primary trial reports that there were no lesions detected in the healthy volunteers group and the secondary trial reports that 5 of the participants in the Hydro",
        "label": "Contradiction"
    },
    "a6f84772-606c-4977-87e2-aa4de18ac07a": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair more than 12 of waking hours are eligible for both the primary trial and the secondary trial is not directly stated in the inclusion criteria or exclusion criteria of either trial However the ECOG performance status of 0 to 2 is mentioned in the inclusion criteria of both trials which can indicate a persons ability to perform normal activities and take care of themselves",
        "label": "Entailment"
    },
    "c975a46b-6980-4cc4-886d-674f5f2c6773": {
        "text_answer": "  The statement a majority of patients in the primary clinical trial did not have recurrencefree survival is a contradiction to the given results The results indicate that 98 out of 100 participants 922995 did not experience recurrencefree survival up to 3 years Therefore it is incorrect to claim that a majority did not have recurrencefree survival",
        "label": "Contradiction"
    },
    "5e45f9e6-6a4f-4cf6-b24a-8755f700943f": {
        "text_answer": "  The statement both the primary and secondary clinical trials administer their treatments orally is entailed in the given trials as both trials mention the administration of interventions through the oral route In the primary trial Vitamin B12 is given sublingually which is still considered an oral administration In the secondary trial memantine hydrochloride and placebo are given by mouth PO",
        "label": "Entailment"
    },
    "8d6dfb9e-cb56-4746-bdb6-45cbb5aadb03": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial patients received denosumab injections every 4 weeks which amounts to a monthly dose of 120 milligrams 120 mg  4 weeks  30 mgweek  43 weeksmonth  698 mgday  30 daysmonth  0233 mg",
        "label": "Entailment"
    },
    "821e8e07-ec33-4f99-8f6e-6d7d50d23d8c": {
        "text_answer": "  The statement education training and library occupations is a class of professional or vocational positions of employment that involve education training or libraries is not directly related to the information provided in the trials   The trials only report the results of a cognitive function study in premenopausal breast cancer patients who received adjuvant Tamoxifen alone or with ovarian function suppression OFS or Exemestane with OFS The statement",
        "label": "Entailment"
    },
    "9dcb0637-50ed-4e98-b6e8-fa95fae80471": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the use of docetaxel doxorubicin and cyclophosphamide and the dosages for each drug vary depending on factors such as weight and age In Intervention 1 the dosages are given as mgm which takes into account the patients body surface area and weight In Intervention 2 the dosage for Herceptin is given",
        "label": "Entailment"
    },
    "ee93ea09-f0a8-42ab-880d-8284fe0d716e": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to calculate the difference in percentage points between the two groups and check if it is equal to or greater than 11  Difference in percentage points  Percentage of participants in ER group  Percentage of participants in TN group  Difference in percentage points  286  176  11  Since the difference in",
        "label": "Entailment"
    },
    "ae6c4238-c27f-45c1-92e0-6d1164c6accf": {
        "text_answer": "  The statement Over 6 weeks of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 5 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as follows  The trial results show that the median IQR Ki67 expression at baseline was 15 10 to 25 and at 6 weeks was 10 2 to",
        "label": "Entailment"
    },
    "44ff230b-fe8f-44de-9f48-e6ab10e91b68": {
        "text_answer": "  To determine if the statement there was no difference in iDFS rate between the neratinib group and placebo group in the primary clinical trial is entailed or contradicted by the given trial results we need to calculate the difference in percentage of participants with events between the two groups and compare it to zero  Difference in percentage of participants with events  Percentage of participants with events in Neratinib group  Percentage of participants with events in",
        "label": "Contradiction"
    },
    "b1f92a23-fa4b-4cf6-9df1-b38794ab00ba": {
        "text_answer": "  The statement speaker device is a device designed to convert electrical signals to sounds that can be heard is not related to the inclusion and exclusion criteria of the primary trial Therefore it is neither entailed nor contradictory to the trial information provided",
        "label": "Entailment"
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "text_answer": "  The statement A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is a contradiction to the trials inclusion criteria The trial explicitly states that No meningeal carcinomatosis is a requirement for eligibility Meningeal carcinomatosis and leptomeningeal carcinomatosis are related conditions but they are not the same Meningeal",
        "label": "Contradiction"
    },
    "5c5a882c-4840-4e2e-83f8-341283caa359": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention is about radioembolization using Yttrium90 glass microspheres and TheraSphere while the secondary trial intervention is about a combination of ibrutinib and MEDI4736 with a starting dose of 560 mg of ibrutinib and 10 mgkg of MEDI473",
        "label": "Entailment"
    },
    "5cc29d9f-f81c-41c0-8a55-a98264f040c7": {
        "text_answer": "  The statement metastatic neuroendocrine carcinoma is a neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site is not directly related to the inclusion and exclusion criteria provided in the trial description Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement does not contradict the inclusion criteria as neuroendocrine car",
        "label": "Entailment"
    },
    "ad6c7a37-2ab2-428a-8ac5-d2462d920c11": {
        "text_answer": "  The statement only nationals from the united kingdom can join the primary clinical trial or the secondary clinical trial is not entailed in the given inclusion and exclusion criteria for the primary or secondary trials The criteria only specify various medical and demographic conditions for eligibility and ineligibility for the trials without any mention of nationality restrictions",
        "label": "Contradiction"
    },
    "af9dbcc2-f6ab-4e1e-aac7-a1f0bccd4d86": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days which is a larger quantity of lenalidomide compared to the secondary trials use of lapatinib 1500mg daily for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks",
        "label": "Entailment"
    },
    "50e1ebd6-d51b-4e86-9748-a0d97a411b62": {
        "text_answer": "  The statement taq polymerase is a heat stable DNAdirected DNA polymerase The enzyme is widely utilized in laboratory polymerase chain reaction applications There are no conditions on mental health bodyweight size of tumors KarnofskyECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial is not directly related to the inclusion and exclusion criteria provided in the trial",
        "label": "Contradiction"
    },
    "d7bcab45-fcd5-46bb-9317-b75573e0373f": {
        "text_answer": "  The statement in the primary clinical trial the symptoms were more severe in patients who were not infused with paclitaxel compared to those who were is contradictory to the results presented in the trials   The results show that the median aAUCpa for the Sensory Neuropathy subscale in Arm I Cryotherapy was 14 117 to 68 indicating that the symptoms improved from",
        "label": "Entailment"
    },
    "5d512914-5625-4734-b828-f20f41ef1a98": {
        "text_answer": "  The statement bothered by tingling hands or feet is a question about whether an individual is or was bothered by tingling hands or feet is not directly related to the trials provided However we can verify if the statement is entailed or contradicted by the information given in the trials regarding the number of adverse events with the given symptom  Since both trials report 0 adverse events with the symptom tingling hands or feet the",
        "label": "Entailment"
    },
    "fbefc569-ec7c-41d6-9d12-39533f6e0fc2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not use a 1year cycle for its intervention Instead it uses a 21day cycle for both arms A1 and A2 with a maximum duration of treatment for each arm as specified   Therefore the statement that the primary trial uses a 1year cycle for its intervention is contradictory to the information provided in the",
        "label": "Entailment"
    },
    "c5426d56-93e6-435b-8e77-19419e66c3d4": {
        "text_answer": "  The statement a patient suffering from neoplastic meningitis could potentially be considered for the primary clinical trial is contradictory to the trials eligibility criteria as stated in the given text The trial explicitly mentions that No meningeal carcinomatosis is a requirement for participation Therefore a patient with neoplastic meningitis would not meet the eligibility criteria and would not be able to participate in the trial",
        "label": "Contradiction"
    },
    "7e69da7b-d7e2-4166-ba1c-520947f7b596": {
        "text_answer": "  The statement is not entailed in the given trials as there is no trial with both groups having numerous incidences of anaemia and febrile neutropenia and no cases of pancytopenia The first trial has one case of anaemia and one case of febrile neutropenia while the second trial has no cases of anaemia or febrile neutropenia Therefore the statement is contradict",
        "label": "Contradiction"
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "text_answer": "  The statement the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial is a contradiction to the given data   Explanation  The given data states that both trials recorded zero adverse events in the primary trial and zero adverse events in the secondary trial for Adverse Events 1 For Adverse Events 2 there were zero adverse events in the primary trial and zero adverse events in ",
        "label": "Contradiction"
    },
    "49f55eb1-1f11-4d89-9888-810dff7b4926": {
        "text_answer": "  The statement in the primary clinical trial patients who received acupuncture showed superior improvements in their lymphedoma over those who used testosterone cream is not entailed in the given trials as there is no data provided on a testosterone cream group in the trials Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "5975fc5c-37b0-4c9e-b546-afa0915ba928": {
        "text_answer": "  The statement is entailed in the trials as the administration frequencies and time durations for the placebo and memantine interventions are explicitly stated to be different in the given information",
        "label": "Entailment"
    },
    "8a308bd1-0164-4734-bdeb-f955327b4314": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions is not directly entailed in the given trials as they do not provide information about participants who didnt receive paclitaxel infusions The trials only compare the average area under the curve aAUCpa of EORTC CIPN20 Sensory Neuropathy Subscale",
        "label": "Contradiction"
    },
    "fc839312-3b01-43e3-8cad-f1107759f462": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different interventions and do not mention gum dosage forms at all The primary trial is about denosumab injections and the secondary trial is about using a handheld gamma camera and intraoperative gamma probes for lymphoscintigraphy Therefore the statement is contradictory to the trials as they do not involve gum dosage forms in the context",
        "label": "Contradiction"
    },
    "7f1d39e0-4892-447d-90b9-b2c672e59c79": {
        "text_answer": "  The statement the primary clinical trial does not mandate the fulfillment of certain criteria such as mental health bodyweight age karnofskyecog score or previous treatments is entailed in the given trial information as these criteria are not explicitly mentioned in the inclusion or exclusion criteria provided",
        "label": "Entailment"
    },
    "ec8bde60-164e-45f7-819d-84b7af4ff04e": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention for Arm I is the administration of Vitamin B12 sublingually while in the secondary trial the intervention for Arm I is the administration of memantine orally The statement sublingual application is used for the intervention in the primary clinical trial in contrast to the oral method used in the secondary clinical trial is entailed because the primary trial uses a different method",
        "label": "Entailment"
    },
    "0f6d115f-8b84-46cc-a95f-51af051029e3": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The trials provide information about the interventions used in each group but they do not mention anything about the organic carbon content of the interventions or the duration of the trials in relation to this statement Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "7b5d47fb-446d-481f-9785-3ff8b467fa69": {
        "text_answer": "  The statement the primary clinical trial intervention includes a regimen of 500 mg of ibrutinib and 10 mgkg of ipilimumab every day for six weeks is contradictory to the information provided in the trials as the primary trial intervention for Intervention 1 is Yttrium90 Radioembolization using TheraSphere and there is no mention of ibrutinib or ipilimumab in the",
        "label": "Contradiction"
    },
    "86cc51ee-ff9e-4396-9c2a-85feaa52c215": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial reports the outcome measurement as Summed Pain Intensity Differences SPID at 30 minutes after dosing not the severity of delayed nausea on a scale of 120 The secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine not the change from baseline to 12 weeks",
        "label": "Contradiction"
    },
    "a5631fa6-2f92-4be7-a055-4c7b3abcdb4d": {
        "text_answer": "  The statement in the primary clinical trial recurring patterns of the same adverse event were observed across multiple patients is not directly entailed in the given data The data only provides the number and percentage of each type of adverse event observed in the trial It does not indicate that the same adverse event occurred multiple times in the same patient However it is possible that some of the adverse events occurred in multiple patients but the data does not provide enough information to",
        "label": "Contradiction"
    },
    "fb5aff7f-4a77-4300-acc4-99a01a6696d1": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes the difference between the two cohorts in terms of the medications they receive Cohort 1 receives sunitinib at starting doses of 25 mg to 375 mg daily while cohort 2 is given bevacizumab at a dose of 10 mgkg",
        "label": "Entailment"
    },
    "ef6ae88d-2d86-4786-8cec-5fad1c1671b8": {
        "text_answer": "  The statement the primary clinical trial reported that 97 of its patients did not have any side effects is contradictory to the information provided in the trial results   The trial results do not mention the percentage of patients who did not experience any side effects Instead they report the percentage of patients who completed the treatment 98 or 922995 These two statements are not equivalent and the trial results do",
        "label": "Entailment"
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is entailed in the trials inclusion criteria under the following conditions  1 Women of childbearing potential WOCBP are eligible for the trial but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and",
        "label": "Entailment"
    },
    "3c56fe49-cda1-4f0f-8597-63f1e8d6237c": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials   The statement mentions mechanical ventilation as an indication of respiratory support but the trials do not provide information on the occurrence of mechanical ventilation in the patients   The statement also compares the dosages of MM121 Paclitaxel and Herceptin between the primary and secondary trials However the trials do not provide enough",
        "label": "Entailment"
    },
    "03a73488-c2a3-437c-b4b7-d26832eaafe8": {
        "text_answer": "  The statement the number of patients who experienced adverse events in different cohorts of the primary clinical trial varied significantly is entailed in the given trials data as the number of patients with adverse events is different between the two cohorts 24 in the first trial and 25 in the second trial",
        "label": "Entailment"
    },
    "2c519a1e-668f-4731-941e-21dadeb2031d": {
        "text_answer": "  The statement is entailed in the primary clinical trial description   Explanation   The statement cohorts within the primary clinical trial do not uniformly receive the same doses of abraxane is entailed in the trial description because in Arm A participants receive nabPaclitaxel at a fixed dose of 125 mgm2 on Days 1 and 8 but the dose of gemcit",
        "label": "Entailment"
    },
    "a6718ad8-0ba6-4513-aae0-92610b1421e6": {
        "text_answer": "  The statement there are no cases of bronchopneumonia and general physical health deterioration reported in either the primary or secondary clinical trials is contradicted by the information provided in the secondary trial   In the secondary trial there is one reported case of bronchopneumonia and one reported case of general physical health deterioration Therefore the statement is contradicted by the information in the trials",
        "label": "Contradiction"
    },
    "28b11be9-1e77-49c5-8cd2-fb9a95a35b58": {
        "text_answer": "  The statement grem1 gene mutation is a change in the nucleotide sequence of the grem1 gene is not directly related to the information provided in the trials It is a separate fact about genetics  Regarding the trials the statement The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC and intervention 2 uses standard GP is an entailed statement Both interventions",
        "label": "Entailment"
    },
    "1624bc79-6ba3-449b-afd6-0234b760664e": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents allowed Androg",
        "label": "Entailment"
    },
    "45571dd6-2532-4086-af29-0b8558423b26": {
        "text_answer": "  The statement is contradictory to the information provided in both the primary and secondary trials The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma but it does not specify that the cancer must be ER negative PR negative or HER2neu positive The secondary trial on the other hand specifically includes patients with ER positive andor PR positive and HER2neu negative breast cancer Therefore",
        "label": "Entailment"
    },
    "0f4882ae-b6f3-4c11-b4ad-a3fc1aeb6f94": {
        "text_answer": "  The statement 6p25 is a chromosome band present on 6p Patients diagnosed with breast cancer may be eligible for all study groups in the primary trial and the secondary trial is neither entailed nor contradicted by the given trial information   The statement is neutral as it does not directly relate to the eligibility criteria or exclusion criteria of the trials The statement mentions the presence of a chromosome band which is not relevant",
        "label": "Entailment"
    },
    "b586fc1f-656e-477b-89d5-84aa4cb55814": {
        "text_answer": "  The statement Aes were not recorded for the primary trial or the secondary trial staff not available is a staff member is or was not available is entailed in the given trials as both trials report 0X 000 for Adverse Events 1 indicating that no adverse events were recorded The statement about staff not being available is not explicitly stated in the trials but it does not contradict the information provided Therefore the statement is",
        "label": "Entailment"
    },
    "985e4878-0637-4b32-a96f-626ff2f7cbd4": {
        "text_answer": "  The statement preoperative iv antiemetics were administered is a response indicating that preoperative intravenous opiates were administered is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials   However the statement does mention preoperative iv antiemetics which is not explicitly mentioned in the trials inclusion or exclusion criteria   Regarding the statement Prior treatment with gabapentin",
        "label": "Entailment"
    },
    "e0983a0e-1008-4845-bc61-082077d3d3d3": {
        "text_answer": "  The statement is not entailed in the trials as the results from the primary trial only show a change in Ki67 expression not a reduction in tumor diameter The statement is not contradictory to the trials as it does not directly conflict with the information provided",
        "label": "Contradiction"
    },
    "57c87de4-06c1-4d6f-9ed8-ed09e82cd3c7": {
        "text_answer": "  The statement significant differences were observed among the groups participating in the primary clinical trial while all groups including the reflexology group showed similar results in the secondary clinical trial is a compound statement made up of two parts   Part 1 significant differences were observed among the groups participating in the primary clinical trial  This statement is not directly entailed in the information provided in the trials The trials only report the AUC values for the",
        "label": "Contradiction"
    },
    "138e64ea-8b97-4101-b3cf-2b808a8dbc88": {
        "text_answer": "  The statement no patients in cohort 2 of the primary clinical trial report an increase in pleural effusion is contradicted by the information provided in the trials In cohort 2 there was one patient out of four who experienced an increase in pleural effusion Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "text_answer": " The provided trials do not include information on Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events for each group Therefore it is not possible to determine if the statement is entailed in the trials or not The trials only report the mean number of hot flashes per 24 hours for each group",
        "label": "Entailment"
    },
    "2e2e15a3-327e-4c79-9ad2-f7978f4f7cdf": {
        "text_answer": "  The statement The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group is not directly entailed in the given trials as the trials only provide the ORR and its confidence intervals for each group but they do not provide a statistical test or comparison between the two groups Therefore it is not possible to determine if the difference in ORR is statistically significant based",
        "label": "Contradiction"
    },
    "4d5b9d90-2c58-499e-8943-eacac7580eb1": {
        "text_answer": "  The statement is not directly related to the information provided in the trials The trials describe the interventions for two different cohorts in terms of the drugs used their dosages and the administration schedules The statement on the other hand mentions Eribulin and Docetaxel but it also introduces a new substance called Epithiazide which is not mentioned in the trials Therefore the statement is neither entailed nor contradicted by the information",
        "label": "Entailment"
    },
    "3ed3f0f5-20e7-4cd1-8c4c-79ba7603fb85": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   However the statement is consistent with the exclusion criteria for the primary trial which states Any other hemorrhagebleeding event N",
        "label": "Contradiction"
    },
    "ee049505-21d4-4255-823c-10d79a91db59": {
        "text_answer": "  The statement adverse events were experienced by less than 10 participants in the primary clinical trial is not directly entailed or contradicted by the given information   The information provided states that there were 2 adverse events out of 35 participants which calculates to 571 However it does not specify how many of those events were experienced by the same participant or different participants Therefore it is possible that less than 10",
        "label": "Contradiction"
    },
    "b0b151a2-65f7-476a-9a2a-915bd963516d": {
        "text_answer": "  The statement several participants in the primary clinical trial developed a urinary tract infection during the course of the trial is entailed in the given trial data as there is a reported adverse event of urinary tract infection with a frequency of 200 150 in the trial However its important to note that the statement several participants implies more than one participant which is consistent with the reported ad",
        "label": "Entailment"
    },
    "de3550b8-5014-4f01-897e-07780353ec9a": {
        "text_answer": "  The statement the occurrence of biliary colic and clostridium difficile colitis is more in the secondary clinical trial than in the primary clinical trial is contradictory to the given data   Explanation   The statement implies that the number of cases of biliary colic and clostridium difficile colitis in the secondary clinical trial is greater than the number of cases in the primary clinical trial However the",
        "label": "Entailment"
    },
    "0a068f7d-0892-428d-889b-153d579cba78": {
        "text_answer": "  The statement patients with a diagnosis of breast cancer could be suitable for all study groups in both the primary clinical trial and the secondary clinical trial is not entailed in the given trials as there are significant differences in inclusion and exclusion criteria between the two trials  The primary trial includes postmenopausal women with early stage breast cancer who have low vitamin D levels and will be treated with an aromatase inhibitor The secondary trial includes healthy males and",
        "label": "Contradiction"
    },
    "1917f075-87da-430b-adf7-bb1579d145fb": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The primary trial specifies that alpha lipoic acid is administered orally three times daily with a baseline dose of 100 mg three times daily for four months and dose escalation will occur until a maximum tolerated dose is found This means that the dosage of alpha lipoic acid can be higher than 100 mg three times daily  The",
        "label": "Entailment"
    },
    "f891df0b-cb3d-4ee8-8294-f139ecc8a018": {
        "text_answer": "  The statement 102 of the primary trial participants with HER2positive primary breast cancer treated with HER2targeted PETCT using 89Zrtrastuzumab developed HER2 metastases is a contradiction to the trial results   The trial reported that 13 out of 49 participants 265 developed HER2 metastases The statement suggests",
        "label": "Contradiction"
    },
    "ff9b4b7a-e2c7-470d-9a7f-6f2b9669da64": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention is Yttrium90 Radioembolization using TheraSphere which is a form of radiation therapy The secondary trial intervention however is a combination of two drugs ibrutinib and MEDI4736 with dosages and schedules specified These interventions are not the same and cannot be considered as entailed in each",
        "label": "Entailment"
    },
    "77b0fb73-3157-4ceb-a366-7ae4f143e2b3": {
        "text_answer": "  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID biospecimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen is neither entailed nor contradicted by the given trials   The primary trial does not provide any information about the use of Fulvest",
        "label": "Entailment"
    },
    "4dc8e4d2-0265-4de1-98df-bcfb33c044e3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial it is stated that both suramin and paclitaxel are given to each participant In contrast the secondary trial does not mention any specific drugs in its intervention section Therefore the statement that suramin and paclitaxel are given to every participant in the primary clinical trial unlike the secondary clinical trial which doesnt disclose the drugs to be used in",
        "label": "Entailment"
    },
    "1ddf526c-beb2-43e1-846e-a133e321a66a": {
        "text_answer": "  The primary trials inclusion criteria do not explicitly state that participants must have a life expectancy of more than 6 months However the exclusion criteria state that patients with a life expectancy of less than 6 months due to uncontrolled brain metastases are excluded Therefore it can be inferred that participants are expected to have a life expectancy of more than 6 months but this is not explicitly stated in the given criteria  So the",
        "label": "Entailment"
    },
    "587623da-f061-478f-8196-ce7ec5558d5c": {
        "text_answer": "  The primary trial does not provide information about the percentage of participants who experienced clinical benefit using RECIST criteria The trial only reports the number of participants with complete response partial response stable disease and progressive disease after 24 doses of 852A in patients with ovarian cancer  The secondary trial also does not provide information about the percentage of participants who experienced clinical benefit using RECIST criteria Instead it focuses on the number of participants with",
        "label": "Entailment"
    },
    "a785048d-15ef-4c72-9d18-6c1db1df2620": {
        "text_answer": "  The statement more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks after the surgery is not directly entailed in the given trials as the trials only report the number of participants with pathologic complete response at the time of surgery approximately 7 months after the neoadjuvant therapy The statement goes beyond the reported data and makes an assumption",
        "label": "Contradiction"
    },
    "8d502fe8-e084-480e-94ee-30ce69aca083": {
        "text_answer": "  The statement all adverse event types in the primary trial affected fewer than 110 of patients is contradictory to the given data   Explanation   The primary trial reported that 4 out of 11 patients 3636 experienced at least one adverse event This means that more than 110 of the patients 1 out of 10  3636",
        "label": "Entailment"
    },
    "a1537e33-5b8e-4e7e-a18f-09fc3c436094": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial mentions the use of 150 mg of oral pregabalin every 2 weeks for 6 weeks for one patient cohort This is different from the intervention in the secondary trial but the statement does not contradict it The secondary trial focuses on a different treatment regimen for metastatic digestive system carcinoma which involves the use of Liposomal Cyt",
        "label": "Entailment"
    },
    "a83e8ca3-620b-47ab-a47b-3fc1fc4038c2": {
        "text_answer": "  The statement All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial is a contradiction to the given trials   The primary trial lists adverse events related to the blood and bone marrow lymphatics and no mention of musculoskeletal system The secondary trial also lists adverse events related to the blood and bone marrow",
        "label": "Contradiction"
    },
    "1824af8a-6f79-49bd-8df3-5751b1e65adb": {
        "text_answer": "  The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is entailed in the trial information provided   The trial information includes the following eligibility criteria for women Women of childbearing potential WOCBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to ",
        "label": "Entailment"
    },
    "82d23e4a-cdf8-4ab4-b2fa-7ea99d98d5a4": {
        "text_answer": "  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is entailed in the secondary trials exclusion criteria   The secondary trials exclusion criteria state that patients who have received chemotherapy or",
        "label": "Entailment"
    },
    "c258ef31-d79a-4ddd-b3c0-81742b7f632f": {
        "text_answer": "  The statement the secondary clinical trial has a higher incidence of biliary colic and diarrhoea compared to the primary clinical trial is entailed in the given trials as the secondary trial has a higher incidence of biliary colic 16 or 1667 vs 3122 or 246 and diarrhoea 16 or 1667 vs 4",
        "label": "Entailment"
    },
    "5c7eee11-ee31-4adf-b2e6-8fe51a39a13b": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we first need to calculate the percentage of responders participants with a decrease in GFS in each group   ERpositive Luminal B group 131 to 492 25th to 75th percentile  342 minimum to maximum Triple Negative group",
        "label": "Entailment"
    },
    "9006f1c5-2818-4edf-85e4-77d532b10820": {
        "text_answer": "  The statement is entailed in the given trials as the trials do not involve the same drugs dosages or administration rates While both trials use intravenous injections the primary trial uses FMX and MM398 with different dosages and schedules and the secondary trial uses lapatinib and paclitaxel also with different dosages and schedules Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "33472836-f751-4de3-8b21-92e2d9e3d7ed": {
        "text_answer": "  The statement is entailed in the trials as follows  Both interventions use the same dosages and frequencies for Doxorubicin Cyclophosphamide and Docetaxel However Intervention 2 includes an additional 3 cycles of these drugs AC cycles compared to Intervention 1 Therefore the statement that both cohorts of the primary trial receive the same dosage of Docetaxel Doxor",
        "label": "Entailment"
    },
    "c5b0eaf3-50c0-4115-8da5-91af0310a7b2": {
        "text_answer": "  The statement is not directly entailed in the trials provided as the trials do not report any laboratory test results using CDISC SDTM Laboratory Test Name terminology for the primary or secondary trials The primary trial reports the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "beae10d7-7132-4875-8bc6-4e996d20eb90": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials only report the percentage change in betaCTX at Week 4 and do not provide data for Week 30 for the AZD0530 90 mg group Therefore it is not possible to make a definitive statement about which group experienced a more significant percentage change in betaCTX at Week 30 based on the information given in the trials",
        "label": "Contradiction"
    },
    "c5a5aed2-c471-41a4-940c-9fa644e5a9fc": {
        "text_answer": "  The statement perjeta is not used within any cohorts of the secondary trial is contradictory to the information provided in the trials Perjeta pertuzumab is mentioned in the secondary trial as a novel radiotracer used in HER2targeted PETCT but it is not mentioned in the primary trial where it is being administered in combination with Fulvestrant and Anastrozole Therefore the statement",
        "label": "Entailment"
    },
    "2de24fb7-9ebe-419e-af16-5d9ed2b808ef": {
        "text_answer": "  The statement an adult patient diagnosed with ilddpld within the last 2 weeks with a life expectancy of 1 hour would be eligible for the primary trial is contradictory to the inclusion criteria of the trial   The inclusion criteria state that patients must have a life expectancy of greater than 3 months Therefore a patient with a life expectancy of 1 hour which is less than 3 months would not meet this requirement",
        "label": "Entailment"
    },
    "409e7b50-f5db-4321-9a39-3853131ade7d": {
        "text_answer": "  The statement in the primary clinical trial a quarter of the participants are witnessing worsened pleural effusion and accelerated disease deterioration is contradictory to the information provided in the Trials   The Trials show that in the first trial 1 out of 13 participants 769 experienced rapid disease progression but none of them had increased pleural effusion In the second trial 1 out of",
        "label": "Entailment"
    },
    "f1b4c0aa-df9b-4d75-9c65-f06709df664a": {
        "text_answer": "  The statement a patient with frequent smoking habits is eligible for participation in the primary clinical trial is contradictory to the exclusion criteria of the primary trial The exclusion criteria state that Patients who are current smokers are not eligible for the study Therefore the statement is contradictory to the trials eligibility requirements",
        "label": "Entailment"
    },
    "1605cfcf-22e5-4a48-a89a-cd7b44e3109f": {
        "text_answer": "  The statement CBT based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial criteria do not mention anything about CBT Cognitive Behavioral Therapy treatments The secondary trial criteria do not include CBT as a form of treatment or exclusion criterion Therefore the",
        "label": "Contradiction"
    },
    "7b73381b-500c-4056-9c4c-4334a6e0b9b4": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the primary trial the statement slight differences were noted among the results of its two cohorts is entailed by the data provided in Results 1 and 2 as the percentage points of pCR rates for the two arms differ by approximately 2 percentage points  The statement for the secondary trial a bigger difference was seen with results from arm 2 declining more than",
        "label": "Entailment"
    },
    "4a454653-60b6-47dd-a2ba-780d1dfbacaf": {
        "text_answer": "  The statement in the primary clinical trial each patient experienced a unique type of adverse event is neither entailed nor contradicted by the given data   The data only provides the number and percentage of patients who experienced each type of adverse event but it does not guarantee that each patient experienced only one type of adverse event It is possible that some patients experienced more than one type of adverse event and it is also possible that some patients did not experience",
        "label": "Entailment"
    },
    "bc9d1c66-4743-474d-9e82-b9e8438a8e86": {
        "text_answer": "  The statement the secondary clinical trial necessitates that patients are above a specified age whereas the primary clinical trial does not stipulate an age criterion for participation is entailed in the given trials  Explanation  The primary trial includes patients presenting for large core breast biopsy without any age restriction mentioned in the inclusion criteria On the other hand the secondary trial specifically includes patients who have signed informed consent and have a pain level greater than",
        "label": "Entailment"
    },
    "eada8d1a-7396-44e7-8f30-03814c7479fb": {
        "text_answer": "  The statement there were no lesions found on any of the group 1 participants in the primary clinical trial and an overwhelming 95 of group 1 participants in the secondary clinical trial showed signs of radiation dermatitis and hyperpigmentation is a contradiction to the information provided in the trials  In the primary clinical trial there were no participants in group 1 Healthy Volunteers who had lesions detected However the",
        "label": "Contradiction"
    },
    "c80808f0-b1fd-45e1-99b4-154860b05038": {
        "text_answer": "  The statement immunogenicity specimen assessments baseline flag is an indication or description that immunogenicity specimen assessment data is a baseline value is not directly related to the provided trial results Therefore it cannot be determined if the statement is entailed or contradicted based on the information given in the trials  However the trials do not provide any information regarding immunogenicity specimen assessments or baseline flags Thus the statement is neither entailed",
        "label": "Entailment"
    },
    "ae6b9c00-10a6-437a-a83b-b46fce724269": {
        "text_answer": "  The statement emesis was not a reported symptom for patients receiving the placebo intervention in the primary clinical trial is entailed in the trials provided   Explanation   The trials report that there were 5 participants in the placebo group who were analyzed and no emesis was reported for any of them during the study period Therefore the statement that emesis was not a reported symptom for patients receiving the placebo intervention is",
        "label": "Entailment"
    },
    "41e9e8e9-6fec-49fa-ae36-7daa737de66c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injected subcutaneously every 4 weeks which is not the same as 4 milligrams injected daily   In the secondary trial no denosumab injections are mentioned only the use of pIHGC and GP during lymphoscintigraphy procedures   There",
        "label": "Contradiction"
    },
    "171827b1-29bc-4e7b-a70a-3d03d4ae7dad": {
        "text_answer": "  The statement is entailed in the trials as the interventions not only differ in the dose of durvalumab administered during biweekly IV infusions 03 mgkg vs 1 mgkg but also in the dose of tremelimumab 3 mgkg Q4W for 6 cycles then Q12W in both interventions The optional extended treatment and the method of administration IV infusions over 60 minutes",
        "label": "Entailment"
    },
    "2107eaac-f0e5-47a2-a7cb-b6d27aa47d23": {
        "text_answer": "  The statement is contradictory to the given information in the trials   Explanation  The statement all candidates in cohort 1 of the primary clinical trial experienced at least one adverse event ae while none of the cohort 2 candidates did is contradictory to the given information that Total 0147 000 for both cohorts 1 and 2 This",
        "label": "Entailment"
    },
    "d478ad25-2445-48f1-9308-2d6025dfead2": {
        "text_answer": "  The statement at least one patient treated with GTx024 1mg in the primary trial gained over 10 kilos of Lean body Mass is not directly entailed in the given trial results   The trial results only provide the median change in total body lean mass for each group along with the full range of changes They do not specify how many patients in each group gained over 10 kilos of lean body mass Therefore",
        "label": "Contradiction"
    },
    "9e3d3c08-d9ee-449d-b4c8-957d666315a1": {
        "text_answer": "  The statement no aes were observed in patients from the secondary clinical trial while the primary clinical trial documented several instances of aes including abdominal pain and insomnia is contradictory to the information provided in the trials   The secondary clinical trial did report one instance of chest pain under Adverse Event 2 which is not mentioned in the statement However the statement is mostly incorrect as it claims that no adverse events were observed in the",
        "label": "Contradiction"
    },
    "ad2ac39b-960a-463d-b3ab-955916e20a97": {
        "text_answer": "  The statement each group from the secondary clinical trial takes 500 mg of fulvestrant in tablet form bid is not directly entailed in the given trials as the trials do not mention the dosage of fulvestrant taken by each group in the secondary trial other than the dosing schedule However it is mentioned that participants in the secondary trial received Fulvestrant 250 mg intramuscularly every 28 days and it is",
        "label": "Contradiction"
    },
    "20307fc02-18bb-4910-9992-43a811bf7a1f": {
        "text_answer": "  The given statement on average patients from the primary trial survive less than 24 months over 40 patients from each cohort survived less than 2 days is not entailed in the provided trials as there is no information given in the trials about the number of patients surviving less than 2 days The trials only provide information about the median overall survival for each group",
        "label": "Contradiction"
    },
    "3b940a21-1adf-4820-a178-9517bb60d6f0": {
        "text_answer": "  The statement there have been no documented adverse events for participants in either the primary or secondary clinical trial is entailed by the given data since the data reports a total of 0 adverse events for both trials and all participants",
        "label": "Contradiction"
    },
    "38ea3ca5-d5b1-4432-b6f6-52e8ca0d3e41": {
        "text_answer": "  The statement there was a 492 higher reduction in the growth factor signature in the dalotuzumab 20 mgkg group than in the triple negative group is not directly entailed in the given trial results   The trial results only provide the percentage of participants in each group who demonstrated a decrease in the growth factor signature GFS The statement makes a comparison between the magnitude of the reduction in GFS between the two groups",
        "label": "Contradiction"
    },
    "428f149b-1b45-4ad0-a5d3-0c885fec2767": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the outcome measurement is the determination of the Ruxolitinib Maximum Tolerated Dose MTD in combination with paclitaxel 80 mgm2 IV weekly The trial does not explicitly report the MTD but instead describes the methodology for determining it based on the occurrence of dose limiting toxicities DLTs in successive coh",
        "label": "Entailment"
    },
    "6204ed3f-bad3-4db0-8db9-9f73efd78e8f": {
        "text_answer": "  The statement 13 of the primary trial participants with HER2 Primary Breast Cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed Imagable HER2 Metastases is entailed in the trial results if we interpret the statement as follows  The trial results state that 13 of the 49 participants with HER2 Primary Breast Cancer who",
        "label": "Entailment"
    },
    "38da1202-fb8c-46d0-9779-db075423a422": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement the administration for cohort 1 of the primary clinical trial consists of pr negative er negative and her indicates that the patients in cohort 1 do not have positive expressions for progesterone receptor PR estrogen receptor ER and human epidermal growth factor receptor 2 HER2   ",
        "label": "Entailment"
    },
    "85bde7b9-9e2e-41e1-a8d5-9ff85e8900e6": {
        "text_answer": "  The statement thoracic surgery is a branch of medicine dealing with the use of surgery to treat diseases of the chest and lungs is not directly related to the given trial criteria It is a general statement about thoracic surgery and does not entail or contradict any information provided in the trial criteria  Regarding the eligibility criteria for the trial the statement Patients with TX NX MX T0 NX M0 or T",
        "label": "Entailment"
    },
    "3edf7faa-74f7-4d02-bb9b-d5d421f2cca4": {
        "text_answer": "  The statement sdha protein variant is a variation in the amino acid sequence for the succinate dehydrogenase ubiquinone flavoprotein subunit mitochondrial protein alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is neither entailed in the primary trial nor contradictory to it   The statement pertains to a",
        "label": "Entailment"
    },
    "00539969-3b0f-4c9f-be8a-0ce964c7d5fa": {
        "text_answer": "  The statement is neither entailed nor contradictory to the given trials The trials describe the use of 18FFDG and 18FFPPRGD2 in PETCT or PETMRI imaging for patients with glioblastoma multiforme and gynecological cancers The statement is about a different subject which is the carfilzomibpanobinostat chemotherapy regimen for plasma cell",
        "label": "Entailment"
    },
    "12ed5e10-5988-494c-8a88-6e4e30ddd355": {
        "text_answer": " The provided information does not include data on treatment emergent adverse events or serious treatment emergent adverse events for each group in the primary clinical trial Therefore it is not possible to determine if the statement is entailed in the trials or if it is a contradiction More information is required to make an accurate assessment",
        "label": "Entailment"
    },
    "cc31b936-223f-4378-9028-315601fba09e": {
        "text_answer": "  The primary trial includes patients with a breast tumor that is 1 cm in diameter while the secondary trial does not specify a tumor size However the primary trials inclusion criteria do entail that the tumor is suitable for baseline core biopsy which implies that the tumor is not locally advanced or metastatic as those conditions would typically preclude a core biopsy Therefore the statement that patients with a TNBC tumor smaller than",
        "label": "Entailment"
    },
    "e3fd6c0c-a119-4bb5-b82b-366830537c70": {
        "text_answer": "  The statement voice problem upsets me is not directly related to the information provided in the trials The trials only mention the dosage and followup information for participants receiving Enzalutamide in two different cohorts The statement about a voice problem and how frequently it upsets an individual is not mentioned or entailed in the trials Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "bc7d8745-f12d-4a54-a922-fb72f4bd01f0": {
        "text_answer": "  The statement individuals who have incurred a pulmonary embolism in the last 2 months do not qualify for the primary clinical trial but could potentially be considered for the secondary clinical trial upon the investigators evaluation is a contradiction to the exclusion criteria of the primary trial   The primary trial explicitly states that a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within",
        "label": "Contradiction"
    },
    "d46a61dd-b28a-476e-981e-f3d1cca2739c": {
        "text_answer": "  The statement the secondary trial and the primary trial results highlight similar outcome measures is not directly entailed in the given trials as they measure different outcome measures   The primary trial measures the efficacy of flaxseed on hot flash scores using a daily prospective hot flash diary while the secondary trial measures the overall response rate ORR using the Response Evaluation Criteria In Solid Tumors RECIST criteria These are different outcome measures",
        "label": "Contradiction"
    },
    "7ba72ade-08b1-4062-86f4-2a93ec724780": {
        "text_answer": "  The statement over 05 patients in the primary trial treated with lapatinib 1g  nabpaclitaxel experienced a confirmed complete response CR is not directly entailed in the provided trial results The trial results only state that 53 out of 60 participants experienced an overall tumor response either CR or PR but it does not specify how many of those responses were CRs Therefore the statement is neither ent",
        "label": "Contradiction"
    },
    "38c5a69a-ad2f-4f2c-b234-74c93e8f6c72": {
        "text_answer": "  The statement is entailed in the given trial information as it explicitly states that only the first cohort participating in the primary clinical trial will be exposed to the educational DVD as part of the intervention Therefore the control group will not be exposed to the DVD as stated in the control arm of the trial",
        "label": "Entailment"
    },
    "a0b10912-a394-4892-88f8-7dfbc771052b": {
        "text_answer": "  The statement The patient with the longest PFS in the primary trial survived 35 months without disease progression or death is not directly entailed in the provided trial results as the longest PFS duration is not explicitly stated in the trials However the longest PFS duration for the CDX011 group was 35 months 28 to 35 which is within the range of the longest observed PFS in the trial",
        "label": "Contradiction"
    },
    "90e07508-8860-4e21-bffe-77d51f0749db": {
        "text_answer": "  The statement in total 7 cases of shingles were detected in the patient cohorts of both the primary and secondary trials is a contradiction to the information provided in the trials   The trials report 0 cases of shingles in the primary trial and 1 case in the secondary trial for a total of 1 case The statement suggests a total of 7 cases across both trials",
        "label": "Contradiction"
    },
    "af3f07a1-e8c0-4ce1-a0b2-5789bca86cd6": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is not directly entailed in the given inclusion and exclusion criteria for both the primary and secondary trials   However the statement is consistent with the exclusion criteria for the primary trial regarding pulmonary hemorrhagebleeding events which includes",
        "label": "Contradiction"
    },
    "d3bf6a5f-bce2-47f5-be7a-6c97b2bf88ef": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial the intervention for the first cohort involves an intraosseous injection of fluciclatide while in the secondary trial the first cohort receives an oral dose of chloroquine which are two different interventions",
        "label": "Entailment"
    },
    "d130905f-48af-4f05-9d02-92c980b46c75": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial suramin and paclitaxel are given in combination to participants but in the secondary trial participants undergo mastectomy surgery and the interventions are not specified Therefore it cannot be entailed that suramin and paclitaxel are given to every participant in the secondary trial based on the provided information",
        "label": "Entailment"
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "text_answer": "  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is contradicted by the given data   Explanation   In the primary trial 132 313 of patients suffered from infection as an adverse event In the secondary trial 115 667 of patients suffered from infections and infestations",
        "label": "Contradiction"
    },
    "f1e9c350-baed-4c5d-a760-b5b8a69e6706": {
        "text_answer": "  The statement africanamerican patients are eligible for the primary clinical trial is entailed in the given inclusion criteria for the dose escalation and expansion phase as there is no mention of any exclusion based on race or ethnicity Therefore the statement is entailed in the trial information provided",
        "label": "Entailment"
    },
    "022c87c6-e5c0-4401-92f7-2570af8f8ac1": {
        "text_answer": "  The statement smoked cigarettes after diagnosis and before treatment start is not entailed in the provided trials as they do not mention anything about smoking status of the participants The trials only report on the Maximum Tolerated Dose MTD or Maximum Feasible Dose of Ruxolitinib in combination with Paclitaxel for the primary trial and MM111 for the secondary trial",
        "label": "Contradiction"
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement Every participant in the primary trial receives the same intervention is not entailed in the given trials as they clearly specify different interventions for the two groups Intervention 1 for Adult Cancer Patients 65 Years of Age and Older and Intervention 2 for Healthy Volunteers",
        "label": "Contradiction"
    },
    "7432cb06-a4a3-4f9c-afc8-533e39b7337f": {
        "text_answer": "  The statement the number of adverse events recorded in the primary trial and the secondary trial is identical is entailed by the given information if and only if the trials being compared are the same trial In this case since no such information is provided it is impossible to determine if the statement is entailed or contradicted based on the given data alone Therefore the statement is neither entailed nor contradicted by the information provided",
        "label": "Entailment"
    },
    "703e6942-968d-4cdf-8e98-45cc571effd0": {
        "text_answer": "  The statement is contradictory to the given information   The statement the adverse events section of the primary clinical trial did not document any suspected serious adverse reactions while the secondary clinical trial recorded several instances is contradictory to the given data because  1 The primary trial did not report any adverse events at all let alone serious ones 2 The secondary trial reported no serious adverse events in the section mentioned in the statement",
        "label": "Contradiction"
    },
    "9d7a1491-f931-47dd-9177-72bc90006fd2": {
        "text_answer": "  The statement prior severe anaphylactic reactions to trastuzumab do not disqualify a patient from participating in the primary clinical trial is not explicitly stated in the inclusion or exclusion criteria provided However the criteria do not mention anaphylactic reactions as a reason for exclusion Therefore the statement is consistent with the information given in the trial description and can be considered neutral or neither entailed nor contradictory",
        "label": "Entailment"
    },
    "d73e5604-bcf0-465f-b147-7ed3cb036e4c": {
        "text_answer": "  The statement Intraoperative Mammography performed better than the Standard Mammography in the primary trial in terms of operative time savings is entailed in the trials as the primary trial directly compares the operative times between the two groups and shows a shorter median operative time for the Intraoperative Mammography group  However the statement In the secondary trial there is no control group against which we can compare is a",
        "label": "Entailment"
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "text_answer": "  The statement All the primary trial participants receive higher doses of ALT801 than the secondary trial participants is a contradiction based on the given information   In the primary trial the doses of PF06647020 are 02 mgkg and 05 mgkg and there is no mention of ALT801 in the primary trial In the secondary trial the",
        "label": "Contradiction"
    },
    "141ee099-c8ae-4db1-9082-6fc138ad8093": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary clinical trial the reflexology intervention was given once a week for 10 weeks which amounts to a total of 10 sessions In the secondary clinical trial the placebo and vitamin D interventions were given weekly for 24 weeks which also amounts to a total of 24 sessions Although the number of sessions and the duration of the interventions are different in each",
        "label": "Entailment"
    },
    "0fc55b5a-e5cc-40d1-a0fe-e4ce3ffd8172": {
        "text_answer": "  The statement patients suffering severely from sleep disorders other than insomnia can participate in both the primary clinical trial and the secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for either trial However there is no contradiction to this statement in the provided criteria The primary trial has no mention of sleep disorders other than insomnia as an exclusion criterion and the secondary trials exclusion criteria only mention insomnia specifically",
        "label": "Contradiction"
    },
    "f8fe88c6-ebd4-49ad-b381-b6017fdaf070": {
        "text_answer": "  The statement rectal pain ctcae 50 is a disorder characterized by a sensation of marked discomfort in the rectal region is not directly related to the information provided in the primary or secondary trials The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in two different groups 0005 Estriol Vaginal Gel and Placebo Vaginal Gel while",
        "label": "Entailment"
    },
    "dce94e19-6a0a-4fc9-ab35-ad4eb378622b": {
        "text_answer": "  The statement those suffering from validated metastatic scbc may enroll in the primary clinical trial is entailed in the inclusion criteria of the trial as stated in the text Metastatic SCBC refers to metastatic squamous cell carcinoma of the lung head and neck urothelial transitional cell carcinoma and breast cancer which are the specific types of cancer listed as eligible for the trial Therefore the statement is",
        "label": "Entailment"
    },
    "1cc9db7e-8214-46cd-bbe3-7ff873be5589": {
        "text_answer": "  The statement is neither entailed nor contradictory to the given trials   The trials do not provide sufficient information to determine if there is a difference in the doses of radioactive Tc99M sulfur colloid used between intervention 1 and intervention 2 beyond the range of 04 to 10 mCi Therefore it cannot be definitively stated that intervention 1 uses a higher dose than intervention 2 based on the",
        "label": "Entailment"
    },
    "fccade16-a6ed-4bc1-b767-d5d1ab20b780": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measurements and patient populations The primary trial evaluates the effect of fentanyl sublingual spray on pain intensity during breakthrough pain episodes while the secondary trial investigates the impact of zoledronic acid on bone mineral density loss following surgery The statement is not directly related to the content of either trial",
        "label": "Contradiction"
    },
    "0a279b67-be5a-4f7d-a21b-b178a556f8ae": {
        "text_answer": "  The statement does not entail or contradict the information provided in the primary trial description The trial focuses on different interventions for HER2negative breast cancer participants using different chemotherapy regimens and bevacizumab and the statement discusses the administration of a HER2neu peptide vaccine admixed with sargramostim to the participants These two pieces of information are not directly related",
        "label": "Entailment"
    },
    "94ebad4c-4b9c-4fb7-b7cc-a088b46b56f7": {
        "text_answer": "  The statement all patients in the primary trial receive at least 002g of mcs110 every 3 weeks is entailed in the Intervention 1 and Intervention 2 descriptions in the Phase Ib trials   Explanation   To verify this we need to calculate the amount of MCS110 each patient receives in each intervention   In Intervention 1 the dose of MCS",
        "label": "Entailment"
    },
    "1fef627f-f239-4ad3-8bec-4141e2b36dfd": {
        "text_answer": "  The statement deleterious cdh1 gene mutation is a change in the nucleotide sequence of the cdh1 gene that is associated with increased risk of disease is not directly related to the information provided in the trials   Regarding the comparison between the trials the primary trial and the secondary trial have different outcome measurements and patient populations The primary trial focuses on the duration of neutropenia with CTCAE grade 34 while",
        "label": "Entailment"
    },
    "685d9609-ec5f-4dcb-9783-e9d7b061eaf5": {
        "text_answer": "  The statement is not entailed in the trial results as the statement is about a completely different topic The trial results only provide information about the number of participants who experienced treatmentemergent adverse events AEs and serious adverse events SAEs in the Sunitinib  Docetaxel  Trastuzumab arm of the study The statement is about seg algorithm which is a computer algorithm used for protein sequence analysis Therefore the statement",
        "label": "Contradiction"
    },
    "a9e14c3b-bf03-4ca1-b9d9-4693b231902c": {
        "text_answer": "  The statement Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list is entailed in the trials provided as the trials report the mean arm circumference a measure of lymphedema at baseline and after 6 weeks for both the acupuncture and waitlist groups The trials show that the acupuncture group had a greater reduction in mean arm circumference after ",
        "label": "Entailment"
    },
    "ec2edea0-23ee-487c-bfbb-ef6fb517e744": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  In the primary trial the inclusion criteria state that participants must have a Karnofsky score of 70 This score is higher than the baseline performance metric specified in the statement  In the secondary trial the inclusion criteria state that patients must have a Zubrod performance score of 2 or better The Zubrod performance score is a performance status scale used in oncology",
        "label": "Entailment"
    },
    "b5cc8685-0fb5-4819-a7cb-960980d95272": {
        "text_answer": "  The statement evidence of a locally advanced andor metastatic solid tumor permits patients of any gender eligibility for both phases of the primary clinical trial is entailed in the given inclusion criteria for both Phase 1 and Phase 2 of the trial   Inclusion Criteria for Phase 1 Have evidence of a solid tumor that is locally advanced andor metastatic excluding primary brain tumor  In",
        "label": "Entailment"
    },
    "47bb2ffb-2cee-418b-acd6-cdecee318d70": {
        "text_answer": "  The statement fewer than 50 of participants saw a decrease in circulating tumor cells after treatment with highdose chemotherapy and cleansed autologous stem cell products is a contradiction to the results presented in the trial   The trial reports that the number of participants with a reduction in CTCs following highdose chemotherapy and purged autologous stem cell products was not specified in the provided results However",
        "label": "Contradiction"
    },
    "7b507eae-bfd5-4546-993b-6dd936ab41e5": {
        "text_answer": "  The given statement several of the patients in the primary trial experienced the no pain whatsoever during the 70 days of the study is not directly entailed in the provided trial results as there is no mention of the number of patients who experienced no pain in either the Low Dose or High Dose groups The trial results only report the average pain intensity scores and the confidence intervals for each group Therefore the statement is neither entailed nor contradicted by the",
        "label": "Contradiction"
    },
    "02365d25-1a64-4415-aae7-c0254d234fa9": {
        "text_answer": "  The statement is entailed in the trials as both cohorts receive the same doses of radiation therapy and undergo a SPECT scan at baseline and 6 months followup The statement does not make any reference to Paraguay or Argentina so the geographical information in the statement is not relevant to the trials and does not affect the entailment",
        "label": "Entailment"
    },
    "8858a62b-91a2-4f2c-a1f1-e54ea15e5861": {
        "text_answer": "  The statement 100 of the primary trial participants and 50 of the secondary trial participants suffered an acute myocardial infarction is contradictory to the information provided in the trials   The primary trial reports that there were no cases of acute myocardial infarction in either trial The secondary trial reports that there were no cases of acute myocardial infarction in the secondary trial as well",
        "label": "Contradiction"
    },
    "80140ee4-3ead-44cc-a7a2-b6af0798c1b1": {
        "text_answer": "  The statement every patient in the primary clinical trial that received gtx024 1mg lost over 5 kilos of lean body mass is a contradiction to the trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 This means that some patients in this group gained lean body",
        "label": "Contradiction"
    },
    "6a0bfa75-3e83-4c73-8e5a-2dc4cad866c3": {
        "text_answer": "  The statement 19p1312 is a chromosome band present on 19p The primary trial only has a single adverse event recorded for its patient cohort is not directly entailed or contradicted by the given information in the trials  The statement only mentions the presence of a chromosome band and the number of adverse events in the primary trial while the trials provide the number of adverse events for each type",
        "label": "Contradiction"
    },
    "3dc3b5d7-3bad-4494-9e97-e6f27bf52c07": {
        "text_answer": "  The statement is a contradiction of the information provided in the intervention section The intervention description does mention the use of partial breast irradiation but it does not specify the number of treatments or the doses of radiation However it does not state that there is no treatment cycle or description of irradiation doses it only omits that information Therefore the statement is a contradiction as it incorrectly asserts that such information is not present when it is in fact",
        "label": "Contradiction"
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "text_answer": "  The statement is entailed in the primary trial as both study groups undergo the same 18FFDG imaging procedure and the same 18FFPPRGD2 imaging procedure with the same injection dose limitation",
        "label": "Entailment"
    },
    "c6a921cd-f18d-4fea-a543-54784444279c": {
        "text_answer": "  The statement across the primary trial multiple deaths were recorded in the adverse events but the secondary trial had no deaths is a contradiction with the given data   Explanation   The primary trial had one death recorded in the adverse events out of nine participants while the secondary trial had no deaths recorded in the adverse events out of 201 participants The statement suggests that there were multiple deaths in the primary trial but no deaths",
        "label": "Contradiction"
    },
    "99a8a2b3-84ad-4c45-9371-e731cc5942db": {
        "text_answer": "  The statement more than 97 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products is not directly entailed in the provided trial results The results only state that the number of CTCs was measured at one month post AHST and that all 21 participants had a reduction in CTCs The statement goes beyond the given data by implying",
        "label": "Contradiction"
    },
    "414dbb63-9c4c-44e9-96f5-c54b5d341f82": {
        "text_answer": "  The statement patients in both cohort 2 of the primary trial and cohort 1 of the secondary trial reported equal incidence of neutropenia irrespective of their empegfilgrastim dosage regimen is not directly entailed in the provided trial data   The primary trial focuses on the duration of neutropenia CTCAE grade 34 after the first chemotherapy cycle while the secondary",
        "label": "Contradiction"
    },
    "f205a6e1-26d3-4a63-bea1-126428af787b": {
        "text_answer": "  The statement is not entailed in the given trials as the primary trial had a higher prevalence of specific adverse events recurring malignancies graftversushost disease anemia cardiac failure and diffuse alveolar hemorrhage compared to the secondary trial but it does not mention anything about the prevalence of these adverse events being greater in terms of an absolute number or percentage The statement only compares the",
        "label": "Contradiction"
    },
    "cf080a87-de94-4d6b-9d18-89a5f5003316": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial no specific dosage information is given for MM121 and Paclitaxel However in the secondary trial the HR subgroup randomized to Intervention 1 receives a higher weekly dosage of MM121 20 mgkg compared to the HR subgroup in Intervention 2 of",
        "label": "Entailment"
    },
    "c4e419c4-f227-4c0c-b8b5-c8e0f62585a7": {
        "text_answer": "  The statement the results from the primary clinical trial suggest that the arm B intervention yielded the most promising overall response rate moreover in the secondary clinical trial the denosumab cohort demonstrated a better time to first onstudy SRE than the zoledronic acid cohort is not directly entailed in the given trials as they do not provide enough information to make such a comparison between the trials  The primary trial compares two",
        "label": "Contradiction"
    },
    "18b0cc37-3189-4ea0-970e-81a6b79dba7f": {
        "text_answer": "  The statement in group 1 of the primary clinical trial 1000 of subjects experienced an adverse event that threatened their life at least once is a contradiction to the provided results   The results indicate that there were 3 participants in group 1 and none of them experienced a serious adverse event ie an adverse event that threatened their life Therefore the statement is a contradiction to the results",
        "label": "Contradiction"
    },
    "0c992694-2b3d-4fa1-b822-ecc5f1ceb2e9": {
        "text_answer": "  The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for the primary trial is entailed in the given inclusion criteria as the trial includes patients with ER positive HER2 negative invasive breast cancer Group 1 and invasive triplenegative breast cancer Group 2 which both meet the description of estrogen negative progesterone negative and HER2 tumors",
        "label": "Entailment"
    },
    "c640af56-cef3-432a-87f2-b2b446b7ab96": {
        "text_answer": "  The statement is a contradiction to the primary trial as the group 2 of the primary trial does receive dexmedetomidine but in the secondary trial the patients in intervention 2 do not receive any dexmedetomidine",
        "label": "Contradiction"
    },
    "e70d1cc6-b4e5-4fc6-a26f-9b9dd76ef54f": {
        "text_answer": "  The statement not known if 10q23pten locus deletion analysis was performed is an indication that it was not performed during the study is neither entailed nor contradictory to the information provided in the primary and secondary trial inclusion and exclusion criteria   The primary trial does not mention anything about 10q23pten locus deletion analysis so it is neither entailed nor contradictory to the primary trial",
        "label": "Entailment"
    },
    "0cd83002-1e58-4b84-ac34-e4299d4573ab": {
        "text_answer": "  The statement in the primary clinical trial there were patients who did not suffer from 3 or more adverse events is not directly entailed or contradicted by the given data The data only provides the number and percentage of patients who experienced each adverse event but it does not specify how many patients experienced zero one two or three or more adverse events Therefore based on the given information it is neither entailed nor contradicted that there were patients",
        "label": "Contradiction"
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is not directly stated in the given trials However the trials do report that there were no deaths or hospitalizations recorded for Adverse Events 1 and 2 in both trials  The statement the only AEs recorded were 3 cases of Lymphoma is consistent with the data provided in the trials for Adverse Events 1 in the secondary trial",
        "label": "Contradiction"
    },
    "a491bf7b-7327-48cd-ac0f-708a50c385b7": {
        "text_answer": "  The statement primary clinical trial enrollment is open to individuals with her2 negative tumors according to ihc 1 scores and those who have minimal need for medical care or assistance is contradictory to the trials inclusion criteria The trial specifically includes individuals with HER2 positive tumors either IHC 3 or FISH Therefore individuals with HER2 negative tumors according to IHC 1 scores are not eligible for the",
        "label": "Entailment"
    },
    "379e6494-403f-4469-9ee4-9e3d12c0d562": {
        "text_answer": "  The statement the bevacizumab group in the primary clinical trial yielded superior outcomes compared to the bevacizumab  capecitabine group is not directly entailed in the provided trial data   The trial data only provides the percentage of participants with disease progression or death in each group during the maintenance phase of the study It does not provide sufficient information to determine which group had superior outcomes overall Other factors such as overall survival",
        "label": "Contradiction"
    },
    "90c0e27d-dcb3-4014-ae46-b1f4640093b7": {
        "text_answer": "  The statement in the primary trial both cohorts had the same count of aes is neither entailed nor contradicted by the given trials   Explanation   The statement is not entailed by the trials because the trials report different numbers of participants in each cohort 4 in the first trial and 5 in the second trial Therefore having the same count of adverse events for both cohorts is not a given fact",
        "label": "Entailment"
    },
    "3693ad36-964f-4377-93a3-6137083b22dd": {
        "text_answer": "  The given statement is not entailed in the trials provided The trials only report the number of participants in each group and their recurrencefree survival percentages but they do not directly provide the data needed to calculate the difference in recurrencefree survival between the two groups as a percentage Therefore it is not possible to determine if the statement is entailed or contradicted based on the information given in the trials",
        "label": "Contradiction"
    },
    "f543a317-1f30-46b9-849e-67396ae072de": {
        "text_answer": "  The statement the primary trial and the secondary trial administer their interventions orally is entailed in the given trials as both trials mention that the interventions are given by mouth PO Therefore the statement is entailed in the trials  However the statement nonmuscle invasive bladder urothelial carcinoma is an infiltrating urothelial carcinoma of the bladder that has not invaded",
        "label": "Entailment"
    },
    "fae9affd-c763-49c0-ae6d-88852f5774af": {
        "text_answer": "  The statement Group 2 of the primary trial receives 05ugkg of dexmedetomidine 5ml patients in the secondary trial cohorts do not receive any Dexmedetomidine is a statement about the interventions given in the trials and not about proficiency testing challenges The statement does not entail or contradict the information provided in the trials",
        "label": "Entailment"
    },
    "6e78e878-1154-43b8-b93a-c1b68aef70c8": {
        "text_answer": "  The statement all patients were prescribed sunitinib which was taken orally on a daily basis for the full length of the investigation is entailed in the trial description   Explanation  The trial description states that Sunitinib was administered orally from Day 1 at the starting dose of 375 mgday on a continuous daily dosing schedule in 21day cycles This means that all",
        "label": "Entailment"
    },
    "89e52784-5ddd-405e-b794-95ef5b5766eb": {
        "text_answer": "  The statement there are no Xrays ultrasound CT scans or MRIs included in the interventions of the primary trial and the secondary trial is not directly related to the information provided about the Contour Profile Tissue Expander intervention in the primary trial or the AlloMSCs and placebo interventions in the secondary trial The statement only mentions the absence of certain imaging modalities while the information provided in the trials details the",
        "label": "Contradiction"
    },
    "c4a45d2b-0e4b-4cd2-80ef-176d487d8180": {
        "text_answer": "  The statement participants in the primary clinical trial experienced diarrhoea more frequently than those in the secondary clinical trial is entailed in the given trials as follows  The primary trial had 7 cases of diarrhea out of 30 participants which is a frequency of 2333 The secondary trial had 0 cases of diarrhea out of 6 participants  Therefore the frequency of diarr",
        "label": "Entailment"
    },
    "396511cd-a922-4ba6-9c33-bc2f20bfdebd": {
        "text_answer": "  The statement in the primary clinical trial the operative time of arm 1 was lower than that of arm 2 demonstrating the effectiveness of standard mammography compared to intraoperative mammography is contradictory to the information provided in the trials   The primary trial results show that the median operative time for the Intraoperative Mammography group was 68 minutes 29 to 180 which is higher",
        "label": "Entailment"
    },
    "29d8fc44-5636-4633-9651-2d30521a2755": {
        "text_answer": "  The statement on average patients from the primary trial survive over 104 weeks over 50 patients from each cohort survived more than 2 years is not directly entailed in the given trials as they only provide the median survival times and the number of participants analyzed for each group but not the total number of patients surviving beyond 104 weeks or 2 years for each group Therefore the statement is neither entailed nor contradicted by the given",
        "label": "Contradiction"
    },
    "fa80610a-3dd0-49e7-97f3-7efbdf636ca5": {
        "text_answer": "  The statement the primary clinical trial recorded slightly more total adverse events among its patient cohorts compared to the secondary clinical trial is a contradiction to the given data   The data shows that there were no adverse events recorded in the primary trial for both Adverse Events 1 and 2 while in the secondary trial there were no adverse events recorded for Adverse Event 1 and only 0 adverse events were recorded for Adverse Event ",
        "label": "Contradiction"
    },
    "48fdcfb8-5519-42cd-8496-f8f2e0e38808": {
        "text_answer": "  The statement among the participants of the primary and secondary clinical trials none reported any adverse events is entailed in the given trials data as the total number of adverse events reported in both trials is zero for all types of adverse events mentioned",
        "label": "Entailment"
    },
    "b1774ca3-1bc7-4643-a115-09e813115e9f": {
        "text_answer": "  The statement that a 60yearold patient with histologically verified diagnosis of stage III breast cancer an absolute neutrophil count of 900L a platelet count of 220068L a hemoglobin level of 180 gl and a life expectancy less than 16 months would be eligible for both the primary and secondary trials is a contradiction",
        "label": "Contradiction"
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "text_answer": "  The primary trial measures tumor diameter in centimeters cm while the secondary trial measures the number of participants with solid tumor response using RECIST 11 criteria These trials do not use the same units of measure for the same outcome measurement Therefore the statement is entailed in the information provided",
        "label": "Entailment"
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial has an inclusion criterion of aged greater than 20 years which explicitly excludes women aged 18 or 19 Therefore women in this age group",
        "label": "Contradiction"
    },
    "bfc4e387-9404-498e-903b-5ca9f88dcc3b": {
        "text_answer": "  The statement is entailed in the trial results as follows  The trial reports a mean percentage change in Ki67 expression of 40 63 to 29 This means that on average there is a 40 decrease in Ki67 expression which is equivalent to a reduction of 04 when expressed as a decimal Therefore the statement results from the primary trial show that tamoxifen 20000 micro",
        "label": "Entailment"
    },
    "812ba472-cd7c-410e-9a4c-88dc1795d5be": {
        "text_answer": "  The statement candidates capable of only limited selfcare confined to bed or chair more than 80 of waking hours are eligible for both the primary trial and the secondary trial is neither entailed in the primary trial nor contradictory to it   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial focuses on Her2neu or Her1EGFR positive cancer patients with measurable disease",
        "label": "Entailment"
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial use the Number of Participants With Treatmentemergent Adverse Events as the outcome measurement for their studies is not directly entailed in the given trials as neither trial reports the number of participants with treatmentemergent adverse events as an outcome measurement The primary trial measures change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial measures change in is",
        "label": "Contradiction"
    },
    "55fed266-9982-4062-b7fa-5ec9279441e4": {
        "text_answer": "  The statement every candidate for the primary clinical trial must have been diagnosed with a HER2 positive tumor verified through positive FISH or IHC 3 tests is entailed in the inclusion criteria of the trial as stated in the text The inclusion criteria clearly mention that one of the requirements for eligibility in the trial is a histologically confirmed infiltrating primary breast cancer that is HER2 positive which can be confirmed either by IHC 3",
        "label": "Entailment"
    },
    "ee441983-976c-41d7-aa66-19037a3f5f5b": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial is a combination of both contradiction and entailment with the given inclusionexclusion criteria  ",
        "label": "Contradiction"
    },
    "a079229c-d371-4c18-b2b3-20b0068a4c50": {
        "text_answer": "  The statement there were several instances of shingles in both the primary trial and group 1 of the secondary trial but none in group 2 of the secondary trial is contradictory to the given data   The primary trial reports 0 instances of shingles out of 6 trials and the secondary trial reports 1 instance of shingles out of 66 trials in group 1 and 0 instances of shingles out of",
        "label": "Entailment"
    },
    "ed6b3dc1-1cdb-4da6-ad5c-d5073abd31ea": {
        "text_answer": "  The statement no specific conditions regarding mental health bodyweight age karnofskyecog score or previous treatments are required to qualify for the primary clinical trial is not directly stated in the given inclusion and exclusion criteria However based on the information provided it appears that there are no explicit exclusion criteria related to mental health bodyweight age or previous treatments aside from the limitation on the number of prior chemotherapy lines in the metastatic",
        "label": "Contradiction"
    },
    "2882972d-2466-4eb1-9be2-14f0ebed2102": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description it is stated that the starting dose of sunitinib for cohort 1 is 25 mg daily but for cohort 2 there is no mention of a starting dose of 25 mg for sunitinib Instead the starting dose of sunitinib for cohort 2 is not specified in the description Therefore the",
        "label": "Contradiction"
    },
    "0e3228de-973b-4ce4-9d67-e46392d6f0a6": {
        "text_answer": "  The statement is not entailed in the primary trial as there is no mention of childhood kidney angiomyolipoma in the trials provided The trials focus on patients with glioblastoma multiforme and gynecological cancer undergoing PETCT imaging with 18FFDG and 18FFPPRGD2 Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "5bdba14a-5c7f-4913-b543-9c791965c237": {
        "text_answer": "  The statement at least one patient treated with gtx024 1mg in the primary trial gained over 10000 grams of lean body mass is not entailed in the given trials as there is no participant in the GTx024 1mg group with a gain of over 10000 grams 10000g  110231kg The",
        "label": "Contradiction"
    },
    "3f5b9c7d-ae3e-4484-88c7-c7562c2f974a": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced a confirmed complete response CR is a contradiction to the given results   The results state that 53 of the 60 participants were analyzed and do not provide information on the number of participants who experienced a CR However it is stated that Over 12 patients",
        "label": "Contradiction"
    },
    "13178eb4-e1c0-4fa0-8008-f4a4617220aa": {
        "text_answer": "  The statement is entailed in the Trials The primary clinical trial has different inclusion and exclusion criteria for its Phase I and Phase II stages while the secondary clinical trial has standard criteria applicable to all its participants",
        "label": "Entailment"
    },
    "e928035e-e614-46e3-a3f7-94341043b14e": {
        "text_answer": "  The statement gallbladder infection CTCAE is a disorder characterized by an infectious process involving the gallbladder is not directly related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction",
        "label": "Entailment"
    },
    "7074d2ad-2b70-4e46-a617-f49ddbd8588e": {
        "text_answer": "  The statement grade 1 psychiatric disorders  other specify ctcae is asymptomatic or mild symptoms clinical or diagnostic observations only intervention not indicated less than 5 of patients in the primary trial suffered AEs is not directly related to the given adverse events gastroesophageal reflux disease and ductal carcinoma in situ in the trial   However based on the information provided in the statement",
        "label": "Entailment"
    },
    "cf9d27be-b128-4621-9734-8e9fb3197105": {
        "text_answer": "  The statement is not directly entailed in the given trials as they report different outcome measurements The primary trial reports Time to Progression in months while the secondary trial reports the percentage of participants with Objective Response based on RECIST criteria The statement mentions gastric dysplasia which is not mentioned in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "6528eb91-c678-4508-8d1f-db13bce8d182": {
        "text_answer": "  The statement Both interventions in the primary trial include the same dose of Paraplatin is not directly related to the statement have achiness in your arm Therefore it does not entail or contradict the statement about arm achiness in the context of the given trials",
        "label": "Entailment"
    },
    "4d824080-17e3-4df5-9ef0-f6b0e3496f31": {
        "text_answer": "  The statement an increased number of adverse events were reported among participants in cohort 1 of the primary clinical trial as compared to cohort 2 is entailed in the given trials data as the total number of adverse events reported in cohort 1 45106 or 4245 is higher than the total number of adverse events reported in cohort 2 7103 or 6",
        "label": "Entailment"
    },
    "04a0ccc3-e60d-462a-a31e-802e0f54e1d8": {
        "text_answer": "  The statement is not entailed in the trial results as given The trial results report a change in Ki67 expression not a change in tumor size The statement provided in the question is about a change in tumor size and the values reported in the trial are for the percentage change in Ki67 expression Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "cf19cee6-27d6-4d4b-ab20-52e35883d817": {
        "text_answer": "  The statement women aged 25 or 30 are eligible for the secondary trial but will need to wait 34 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes women aged 20 years and above while the secondary trial includes women and men aged 18 or older The primary trial has specific inclusion and exclusion criteria related to",
        "label": "Contradiction"
    },
    "b2710f8c-602b-4831-8775-f8df3703761a": {
        "text_answer": "  The statement is a contradiction to the primary trial as the group 2 of the primary trial receives 05ugkg of dexmedetomidine 5ml which is not equal to 00005mgkg which is equivalent to 00005ugkg The secondary trial does not mention the administration of dexmedetomidine to any of its cohorts",
        "label": "Contradiction"
    },
    "22a2488f-5559-40e9-a85b-484a1aacd263": {
        "text_answer": "  The statement maculopapular Rash was a common adverse event for the primary trial participants is entailed in the given trial data as it is explicitly stated that Rash maculopapular 130 333 However the statement 22q122 is a chromosome band present on 22q is not related to the trial data and is not entailed or contradicted",
        "label": "Entailment"
    },
    "77c7c86b-30a5-487b-8abc-d3aafff69a5e": {
        "text_answer": "  Lets analyze the given trials to determine if the statement is entailed or contradicted  The statement is all patients in the primary trial receive at least 50mg of mcs110 every 3 weeks and over 200 mg of pdr001 every other week  Intervention 1  MCS110 1 mgkg every 3 weeks Q3W ",
        "label": "Entailment"
    },
    "0abf8fc8-9361-4b86-a3ca-fb6bdfbc5b5d": {
        "text_answer": "  The statement malfunction only no ae report is a report of a device malfunction that does not include an adverse event is not directly related to the inclusionexclusion criteria of the primary or secondary trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone  However we can verify that the statement is entailed in general medical terminology A malfunction report refers to a report",
        "label": "Contradiction"
    },
    "a411d500-0770-42d9-8621-ca6b4b63553e": {
        "text_answer": "  The statement the growth factor signature decreased by 492 more in the dalotuzumab 20 mgkg group than in the triple negative group in the primary clinical trial is not entailed in the given trial results   The trial results only provide the percentage of participants demonstrating a decrease in the growth factor signature GFS for each group The statement makes a comparison between the percentage of decrease in GFS between the two",
        "label": "Contradiction"
    },
    "cb869aa7-63a3-4a2c-8dd9-2e38496fbaef": {
        "text_answer": "  The statement patients who are currently participating in the secondary clinical trial cannot concurrently enroll in the primary clinical trial is an entailment based on the given information in the primary and secondary trial inclusion and exclusion criteria  Explanation  The primary trial has an exclusion criterion that states participation in another clinical trial within 30 days prior to screening or during the study This criterion applies to the primary trial",
        "label": "Entailment"
    },
    "d15bf489-0548-4cbc-b64c-2252a53b5f33": {
        "text_answer": "  The statement Sellar germ cell tumor is a germ cell tumor that arises from or adjacent to the sellar region The only shared inclusionexclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent is neither entailed nor contradicted by the given trials inclusion and exclusion criteria  Explanation  The primary trials inclusion and exclusion criteria are related to patients with advanced cancer who are",
        "label": "Entailment"
    },
    "80676e7e-a6bc-4f8e-b50e-888847db5b91": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials only report the percentage change in betaCTX at Week 4 not Week 10 Therefore it is not possible to make a direct comparison between the two groups regarding their percentage change in betaCTX at Week 10",
        "label": "Contradiction"
    },
    "cfcd5908-e439-4d01-bd0a-0fcaf3730db8": {
        "text_answer": "  The statement is contradictory to the primary trial as it does not mention any surgical procedures in the primary trial but the secondary trial includes therapeutic conventional surgery as an intervention However the statement is entailed with respect to the oral medications as the primary trial only includes oral medications everolimus and exemestane in the secondary trial unlike the primary trial which includes a variety of oral and intravenous medications",
        "label": "Entailment"
    },
    "de3bd9a7-c733-43d3-9f7d-3bf3c98a42f9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial Botulinum Toxin Type A is administered to Group A and Placebo is administered to Group B There is no mention of alisertib MLN8237 being used in the primary trial  In the secondary trial alisertib is administered to both Group 1 and Group 2 but with different dos",
        "label": "Contradiction"
    },
    "6cf62ed7-1dd2-4df0-80f7-979f74b55e72": {
        "text_answer": "  The statement the secondary clinical trial has registered 11 surplus cases of intestinal perforation relative to the primary clinical trial is a contradiction to the given data   The data shows that there was 1 case of intestinal perforation in the secondary trial while there were no cases in the primary trial Therefore there is not an 11case surplus but rather a 1case difference",
        "label": "Contradiction"
    },
    "8e2d4c96-5d2f-4710-9333-26d8d1dcb8fb": {
        "text_answer": "  The statement is entailed in the trials as the primary trial had a lower frequency of recurrent malignancies 120 vs 04 graftversushost disease 720 vs 04 anemia 020 vs 04 for primary and secondary trials respectively cardiac failure 020 vs 04 and diffuse alveolar hem",
        "label": "Entailment"
    },
    "c0dc65fc-1c17-4594-a168-c9c2da2802b6": {
        "text_answer": "  The statement there was not a single adverse event reported during the primary clinical trial is contradictory to the given data in the trials The data reports a total of 5 adverse events out of 25 participants 2000 Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "text_answer": "  The statement is contradictory to the given trial information   Explanation   In Intervention 1 there are no electroporation EP injections mentioned only intramuscular IM injections of V935 in low dose LD   In Intervention 2 there are three EP injections of V934 in low dose LD given followed by two IM injections of V",
        "label": "Contradiction"
    },
    "bc92cff7-39b3-4088-bb3a-9e61c4d32b8b": {
        "text_answer": "  The statement no patients in cohort 2 of the primary clinical trial experienced acute vomiting after being treated with aprepitant dexamethasone cytoxan and kytril is entailed in the trial results if the number of participants in cohort 2 who experienced acute vomiting is equal to zero   From the given results we can see that the number of participants in cohort 2",
        "label": "Contradiction"
    },
    "586425fa-eb66-46c1-8792-f7a35c1a5ca5": {
        "text_answer": "  The statement hypertension was reported in both cohorts of the primary clinical trial is not explicitly mentioned in the given trials However it cannot be ruled out based on the information provided as neither trial mentions the absence of hypertension in their adverse events Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "0d9f0b9b-fc32-413e-ba9b-f8d4e5c1ce4b": {
        "text_answer": "  The statement is entailed in the trials as follows  Both trials include patients with histologically confirmed stage 4 breast adenocarcinoma The primary trial includes patients with radiographic evidence of bone metastases and ERPRHER2 status is not explicitly mentioned The secondary trial specifically includes patients with ER positive andor PR positive and HER2neu negative breast cancer  The statement is entailed in the secondary trial as",
        "label": "Entailment"
    },
    "37bba0bf-5ecd-4007-a2c4-bf9e13dccd2e": {
        "text_answer": "  The statement dasatinib was administered intravenously once a week to patients in cohort 2 of the primary clinical trial for the initial 28day cycle is not entailed in the given trial information The trial only mentions Sunitinib and Capecitabine their dosing schedules and monitoring for toxicity There is no mention of dasatinib or its administration method in the given trial information Therefore the",
        "label": "Contradiction"
    },
    "696f4947-40d7-4e3d-b64e-9e0fd6c5fbd8": {
        "text_answer": "  The statement is entailed in the trials as there is no mention of any adverse events Aes related to noncutaneous leiomyosarcoma in cohort 2 and all the recorded Aes occurred in cohort 1 Therefore the statement that all recorded Aes in the primary trial occurred to cohort 1 patients implies that there were no Aes recorded for noncutaneous leiomyosarcom",
        "label": "Entailment"
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement suggests that both interventions are administered in the same dose and by the same method single transendocardial injection but the trials clearly state that the AlloMSCs intervention involves 20 injections of 04ml alloMSCs while the placebo intervention involves 20 injections of 04ml Buminate solution",
        "label": "Entailment"
    },
    "6016f882-27d2-47a7-9149-142c9fb17acf": {
        "text_answer": "  The statement a little but it doesnt worry me is a response indicating that something occurs but causes little concern is not directly related to the trials described in the given information However we can verify if the statement is entailed or contradicted by the trials based on the information provided about the trials themselves  The statement does not contradict the trials as both cohorts practice paced breathing using the same instructional CD and the statement does not mention",
        "label": "Entailment"
    },
    "895a6e40-efe3-4994-b598-6791eaf90e87": {
        "text_answer": "  The statement a woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial is not directly related to the inclusion and exclusion criteria provided for the primary and secondary trials The statement about persistent atrial fibrillation by ECG finding is not mentioned in the trials at all Therefore the statement neither entails nor contradicts the information provided in the trials",
        "label": "Entailment"
    },
    "a7e93d6e-e8d0-4b87-b2a1-be2b821e5a94": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the ORRs of the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was",
        "label": "Entailment"
    },
    "d4eb3cf4-eeff-42c3-8036-54ec85061299": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide any information about placental nonneoplastic disorders occurring in the participants The trials only mention the doses of talazoparib administered to participants with breast cancer and ovarianperitoneal cancer Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "text_answer": "  The statement is contradictory to the primary trial as the intervention in the primary trial lasted for 10 weeks while the statement suggests that the intervention in the secondary trial lasts for 15 weeks more",
        "label": "Entailment"
    },
    "ed0b5b7f-b257-4b42-8f93-7c908fd071ea": {
        "text_answer": "  The statement participants who showed sensitivity to AI therapy are acquitted for the primary clinical trial and this condition is also not a requirement for the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials   However the statement is entailed in the primary trials inclusion criteria that Participants are resistant to aromatase inhibitors AI therapy This means that participants who have",
        "label": "Entailment"
    },
    "a5e9916a-b5de-4fd4-bf78-b1c1e43bc544": {
        "text_answer": "  The statement all cohorts in the primary clinical trial are given dexamethasone before their operation is entailed in the given trials as both Intervention 1 and Intervention 2 involve the administration of dexamethasone before the operation with varying dosages",
        "label": "Entailment"
    },
    "f21a1764-d1cc-49cc-b22d-e3d1b99c2233": {
        "text_answer": "  The statement the secondary trial has 10 more adverse events recorded than the primary trial is a contradiction to the given information   Explanation   The statement implies that there are 10 more adverse events in the secondary trial than in the primary trial However the given information states that there are no adverse events recorded in the secondary trial and zero adverse events in the primary trial Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "12903135-4650-492b-b2c9-1f5c159af477": {
        "text_answer": "  The statement an individual with 23 cerebral metastases is welcome to participate in both the secondary and primary trials is neither entailed nor contradicted by the given trial criteria   The primary trial has specific eligibility criteria for cerebral metastases but it does not mention any age or cancer type restrictions The secondary trial has age and cancer type restrictions but it does not mention any specific eligibility criteria for cerebral",
        "label": "Entailment"
    },
    "f896c335-0023-429c-b596-e7a30addbb2e": {
        "text_answer": "  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is a comparison of the frequency of specific adverse events between the two trials The given trials only provide the number of occurrences of adverse events for each trial but they do not mention Bronchopneumonia and General physical health deterioration specifically in the Primary Trial Therefore it is not possible to make a",
        "label": "Entailment"
    },
    "d9cff591-e319-46a0-bc70-a25224cd5b49": {
        "text_answer": "  The statement swls questionnaire question is a question associated with the swls questionnaire is not directly related to the inclusion and exclusion criteria provided in the trial description However I can verify that the statement Morbidly obese patients are eligible for the primary trial is entailed in the given inclusion criteria The criteria clearly state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs",
        "label": "Entailment"
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants demonstrating a decrease in the growth factor signature GFS between the ERpositive Luminal B ER and Triple Negative TN groups  The statement is 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstr",
        "label": "Entailment"
    },
    "1b82cbd2-8f68-4c23-974c-b9ebc4fe52aa": {
        "text_answer": "  The statement four different medications are administered to the participants during the primary clinical trial is entailed in the given trial information The medications used in the trial are epirubicin cyclophosphamide docetaxel and trastuzumab Each of these medications is distinct and therefore the statement is true",
        "label": "Entailment"
    },
    "7c1aaf25-a7c2-410d-bc13-fe6192698184": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial had a higher number of patients suffering adverse events compared to cohort 1 is contradictory to the information provided in the trials as both cohorts had a total of 0 adverse events each with no differences between them",
        "label": "Contradiction"
    },
    "038fbad1-abee-46f3-90a8-5caee61bae07": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary clinical trial patients undergo mastectomy surgery and are not mentioned to receive any specific chemotherapy regimen   In the secondary clinical trial the HR subgroup in Intervention 1 receives MM121 and Paclitaxel for a total of 8 cycles 2 weeks runin  4 cycles of MM",
        "label": "Entailment"
    },
    "f95708f6-04c7-469b-bba1-658c1d6eed45": {
        "text_answer": "  The statement lung pecoma is a lung tumor that arises from perivascular epithelioid cells pecs is not directly related to the adverse event data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However the statement does not contradict the information in the trials as there is no mention of lung pecoma or its relation to cardiac ad",
        "label": "Entailment"
    },
    "ca22d431-ad09-4f5b-8b27-751c76e704c8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the trials it is stated that Cohort 1 receives the intervention of viewing the Educational DVD while Cohort 2 receives usual care without mention of a regular dosage of radiotherapy Therefore the statement that Cohort 2 receives a regular dosage of radiotherapy instead of viewing the Educational DVD is not entailed in the trials",
        "label": "Contradiction"
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial there is no mention of any drugbased interventions The interventions mentioned are massage therapy psychosocial assessment and care and qualityoflife assessment 2 In the secondary trial the interventions also include pain therapy psychosocial assessment and care and qualityoflife assessment but they are both part of a clinical trial testing the",
        "label": "Entailment"
    },
    "df8bb8da-6aec-4678-97f3-cb122188ea9b": {
        "text_answer": "  The statement Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is neither entailed nor contradicted by the given trial information   The statement is not entailed because the trial information specifies different interventions for Cohort A and Cohort B Cohort A receives three electroporation injections of LD V934 followed by two IM injections",
        "label": "Entailment"
    },
    "4094d002-a140-4eea-aa50-5005989e2057": {
        "text_answer": "  The statement in the primary clinical trials first cohort most patients had undergone their screenings postintervention no matter the type of cancer they had is entailed in the trials as both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups showed an increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings after the intervention",
        "label": "Contradiction"
    },
    "9f61fc3f-f0a5-4434-b0a7-cbb0703fe063": {
        "text_answer": "  The statement is entailed in the given trials as neither of them involve the use of xrays transendocardial injections CT scans or MRIs as part of their interventions The primary trial focuses on the use of a Contour Profile Tissue Expander in breast reconstruction which does not involve the use of any imaging techniques or injections The secondary trial investigates the use of allogeneic mesenchymal stem cells ",
        "label": "Entailment"
    },
    "e2abe23e-d9a8-4329-a41b-26c90266f6d3": {
        "text_answer": "  The statement The Bevacizumab cohort of the primary trial produced better results than the Bevacizumab  Capecitabine cohort cannot be determined from the given trial data as the trials do not provide sufficient information to make such a comparison The trials only report the percentage of participants with disease progression or death in each cohort during the maintenance phase of the study No information is provided about the primary endpoint of the trial which",
        "label": "Contradiction"
    },
    "3821922a-4d8a-4e54-8381-bb754a78c1ed": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials In the primary trial patients receive a series of injections over four weeks while in the secondary trial individuals receive a single injection Therefore the statement that individuals in the secondary trial receive a single sc injection at the start unlike those in the primary trial who get a series of injections over four weeks is contradictory to the information given",
        "label": "Entailment"
    },
    "2f94cda8-a8c2-4fb3-a98d-f7e6e651b6d0": {
        "text_answer": "  The statement after a month of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 10 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks of 5 percentage points from 15 to 10 ",
        "label": "Entailment"
    },
    "5b94573b-9254-48e4-a384-0212f39451a8": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The primary trials describe the dosage regimen of PF06647020 for two different groups of participants but they do not mention anything about ALT801 or its dosage in relation to the primary trials Therefore the statement about the dosage of ALT801 in the secondary trials does not follow directly from the information given in the",
        "label": "Entailment"
    },
    "8a8136f1-9f1d-497e-bb50-44fe94475817": {
        "text_answer": "  The statement patients with a TNBC tumor of 10cm in diameter are eligible for both the primary trial and the secondary trial is contradictory to the given trials inclusion criteria  Explanation  The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the primary trial explicitly states that patients with a tumor larger than 1 cm",
        "label": "Entailment"
    },
    "ce7d929e-90d6-4048-8124-e6df1a2f594a": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given information in the trials   Explanation   The statement mentions that both cohorts use the same instructional CD for paced breathing but cohort 2 practices twice daily and receives chemotherapy The trials however do not provide enough information to determine if both cohorts receive chemotherapy or if only cohort 2 does Therefore the statement does not follow",
        "label": "Entailment"
    },
    "6fce98e9-e48f-4b14-8a94-37c1ab124eed": {
        "text_answer": "  The statement is not entailed in the trials as there is no information provided in the trials regarding any adverse event related to decreased sweating",
        "label": "Contradiction"
    },
    "95354d90-513a-4766-a860-307afa28fb7b": {
        "text_answer": "  The statement anemia pneumonia and stupor were more frequent among patients in the secondary trial compared to the primary trial is entailed in the given trials data   Explanation   The statement implies that the frequency of anemia pneumonia and stupor is higher in the secondary trial than in the primary trial Lets check the data   Anemia In the primary trial",
        "label": "Entailment"
    },
    "1d121088-e2ff-4927-a989-d7b5de578714": {
        "text_answer": "  The statement is not entailed in the trials as provided The primary trial reports the outcome measurement of Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement introduces a new outcome measurement severity of delayed nausea which is not reported in either trial",
        "label": "Contradiction"
    },
    "f8457301-53ba-4316-a6a5-36462bf8167c": {
        "text_answer": "  The statement patients with a body mass index bmi in the overweight category can be eligible for the primary clinical trial and the secondary clinical trial is entailed in the given trials as neither of them have BMI as an explicit inclusion or exclusion criterion Therefore the trials do not contradict or entail the statement but rather are neutral towards it",
        "label": "Entailment"
    },
    "dad36f27-f531-458c-a36f-c22182af3771": {
        "text_answer": "  The statement people with chronic lymphocytic leukemia or choriocarcinoma established through cytogenetics or infiltrating ductal carcinoma are prohibited from participating in the primary and the secondary trial is entailed in the trials as follows  In the primary trial the exclusion criteria include  A history of other malignancies within 3 years of study entry except for excised",
        "label": "Entailment"
    },
    "8dd6a2dd-74f9-4bac-af44-c816fd960f74": {
        "text_answer": "  The statement in the primary clinical trial adverse events are mainly not related to symptoms is neither entailed nor contradicted by the given data   The data only provides the number and percentage of adverse events observed during the trial but it does not specify whether these events were related to symptoms or not Therefore the statement cannot be determined to be entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "16e96301-3e68-453f-82db-f93117edfdfd": {
        "text_answer": "  The statement is not directly entailed in the given information in the trials as it does not explicitly mention the use or nonuse of paclitaxel in cohort 2 However it can be inferred from the information provided that paclitaxel is not used in cohort 2 Arm B as fulvestrant is used instead Therefore the statement is consistent with the given information and can be considered entailed if we consider the inferred information",
        "label": "Contradiction"
    },
    "b93384b1-a925-460d-ba66-78967a500d8c": {
        "text_answer": "  The statement intermediate locally aggressive blood vessel neoplasm is a borderline blood vessel neoplasm that has locally aggressive behavior is not directly related to the provided trial results   The trial results only provide information about the number of participants and their Recurrencefree Survival in two different groups Ketorolac 30 mg and NaCl 09 3mL The statement is about the nature of",
        "label": "Entailment"
    },
    "1720fcdf-eba7-4ef7-bf37-6445504af807": {
        "text_answer": "  The statement The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group is not directly entailed in the given trials as they do not provide sufficient information to make such a comparison The trials only report the geometric mean 95 confidence interval of percentage change in betaCTX for each group at week 4",
        "label": "Contradiction"
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "text_answer": "  The statement there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial is contradictory to the information provided in the trials   The trials report 0 cases of shingles in the primary trial and 1 case in the secondary trial for a total of 1 case The statement suggests a total of 3 cases across both trials which is not consistent with the reported data",
        "label": "Entailment"
    },
    "2c618027-fde9-4d2f-8552-bc071708d627": {
        "text_answer": "  The statement is contradictory to the given trials as there were no fatalities documented as adverse events in either the primary or secondary trials The statement suggests that there were over 10 fatalities in both trials but the trials report no fatalities at all",
        "label": "Contradiction"
    },
    "10860cc9-5a8f-4e81-bb2a-42697541e8b0": {
        "text_answer": "  The statement patients with estrogen positive progesterone negative and her2 breast tumors have been accepted into the primary clinical trial is contradictory to the given inclusion criteria The trial only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 It does not include patients with ER positive PR negative and HER2 positive breast tumors",
        "label": "Entailment"
    },
    "eb7d6866-d56b-437c-a48c-78478afdfac8": {
        "text_answer": "  The statement the secondary clinical trial noted fewer adverse events in its patient cohort compared to the primary clinical trial is entailed in the given trials data if and only if the number of adverse events in the primary trial is greater than the number of adverse events in the secondary trial   Given that the primary trial has no adverse events at all 00 and the secondary trial has 0 adverse events in the given cohort",
        "label": "Entailment"
    },
    "9e5f2149-4cff-4df0-a5d0-4b99ff30fb1c": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial measures changes in pain intensity at specific time points after dosing while the secondary trial measures the change in bone mineral density of the lumbar spine at a specific time point 9 months after surgery The two trials do not directly compare the same outcome measures or time frames",
        "label": "Contradiction"
    },
    "50b3880d-9a23-42a3-8987-253f0ce999d3": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the administration of Doxorubicin Cyclophosphamide and Docetaxel at the same dosages and frequencies The only difference between the interventions is the addition of Herceptin in Intervention 2 The statement specifically focuses on the administration of Docetaxel Doxorubicin and Cyclophosphamide and does",
        "label": "Entailment"
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "text_answer": "  The statement several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes is not directly entailed or contradicted by the information provided in the trials   The trials only report the number of participants with a discernible gene expression pattern in each armgroup but they do not specify how many of those participants had normal vitamin D levels Therefore it is possible",
        "label": "Contradiction"
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial Intervention 1 in Arm I specifies that Zoledronic Acid is given IV Therefore the statement that Intervention 1 in the primary trial is administered by IV is true   In the secondary trial both Intervention 1 and Intervention 2 allow for the administration of the drugs orally or IV This means that",
        "label": "Entailment"
    },
    "08049ea6-03f6-457a-b74e-0012e02dc768": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different outcome measurements The primary trial reports Time to Progression TTP in months while the secondary trial reports the Number of Participants with Objective Response based on Data Review Committees Assessment The statement does not explicitly mention the trials or their results but rather compares the types of outcome measurements between them Therefore it cannot be definitively determined if the statement is entailed contradict",
        "label": "Contradiction"
    },
    "38c2a394-f21b-4ae8-8941-aeccf896609b": {
        "text_answer": "  The statement warfarin based treatments are prohibited for the primary trial candidates however they may still be eligible for the secondary trial is not directly stated in the given inclusion and exclusion criteria for both trials However it can be inferred from the exclusion criteria of the primary trial where it mentions Patients who require use of coumarinderivative anticoagulants such as warfarin are excluded This implies that warfarin is",
        "label": "Entailment"
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "text_answer": "  The statement is entailed in the trials as it accurately describes one of the differences between the two interventions in the primary trial In Cohort 1 sunitinib is started at a lower dose of 25 mg daily while in Cohort 2 paclitaxel is started at a higher dose of 90 mgm2",
        "label": "Entailment"
    },
    "3a4cc297-6f5a-489c-a841-95e2b3971167": {
        "text_answer": "  The statement candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments is not entailed in the given inclusion and exclusion criteria for the breast cancer trial The criteria only specify breast cancer hormonal treatment and postmenopausal status as inclusion criteria and the exclusion criteria only mention previous systemic anticancer therapy and compliance issues The statement about colon cancer and unresponsiveness to hormonal treatments is not",
        "label": "Contradiction"
    },
    "807c9531-c049-40a5-a170-3f8924335381": {
        "text_answer": "  The statement transient arthropathy is arthropathy that is not permanent is not directly related to the information provided in the trials However the trials do mention that participants were followedup until 30 days after the last dose of study drug or before initiation of a new antitumor or investigational therapy which implies that any adverse effects including arthropathy may be temporary  Regarding the statement",
        "label": "Entailment"
    },
    "af6ce175-76e3-4d1a-ab77-6c7f3a258580": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial reported no instances of death or hospitalization is entailed in the given trials data as there are no instances of death or hospitalization reported in cohort 2 according to the data provided",
        "label": "Contradiction"
    },
    "aba20d88-1ea5-401e-b155-d1b901dddc77": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial does not mention treatmentemergent adverse events AEs as an outcome measurement The trials only report changes in patientspecified symptoms using the MYMOP questionnaire and changes in isothiocyanate levels in urine samples",
        "label": "Contradiction"
    },
    "f47966a1-7067-43a3-9461-11c8ed7b18a6": {
        "text_answer": "  The statement in the primary clinical trial all patients endured the utmost level of pain for the span of 10 weeks is contradictory to the information provided in the trials The trials describe a psychoeducational intervention aimed at improving cancer pain management and the results indicate that patients in both the lowdose and highdose groups experienced an average reduction in pain intensity over the 10week intervention period Therefore the statement that ",
        "label": "Entailment"
    },
    "6f0485c9-9cb5-4861-9baf-f6a9a9acd975": {
        "text_answer": "  The statement is entailed in the trials as both groups receive the same duration intensity and type of radiation therapy The difference lies only in the use of Active Breathing Coordination ABC during treatment Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "aad1e89e-afc2-4999-8cb2-302e0d686331": {
        "text_answer": "  The statement since first time questionnaire was answered all but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event and less than half the patients suffered serious TreatmentEmergent Adverse Events is entailed in the trial results given as follows  1 The trial results state that there were 24 treatmentemer",
        "label": "Entailment"
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "text_answer": "  The 20yearold female patient with a newly diagnosed ERpositive HER2negative breast cancer can be eligible for the secondary trial based on the following inclusion criteria  1 Female or male 18 years of age 2 ERpositive HER2negative breast cancer 3 Eastern Cooperative Oncology Group performance status andor other performance status of 1 4 Fem",
        "label": "Entailment"
    },
    "458e3e14-613b-40c5-a62f-5698a7d0c9b0": {
        "text_answer": "  The statement patients participating in the primary clinical trial have on average survived for more than 2 years though there is at least one instance in each group of a patients death within a span of 2 years is entailed in the given trials as both groups have median survival times greater than 2 years but less than 3 years Therefore it is possible for some patients in each group to have died within 2 years of the surgery",
        "label": "Entailment"
    },
    "12911f01-5f14-445b-a93a-0cca2cfe9b4c": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The primary trial and the secondary trial are independent studies investigating different outcome measures The primary trial is focused on the diagnostic accuracy of two mammography algorithms while the secondary trial examines the effect of reflexology on fatigue levels in breast cancer patients The statement does not relate to the content of either trial",
        "label": "Entailment"
    },
    "030afaab-4125-4b2c-ac40-5d7a4cacaf52": {
        "text_answer": "  The statement cordonnier grade 2 fungal complication deep candida infection without candidemia is any deep candida infection without candidemia is not directly related to the intervention 1 described in the text The statement is about the definition of a specific type of fungal complication cordonnier grade 2 and its relationship to deep candida infection without candidemia The intervention 1 section does not provide enough information to determine if this statement",
        "label": "Entailment"
    },
    "10867d73-4951-42cf-9bdf-2a0f6d27ff10": {
        "text_answer": "  The statement the incidence of ascites and pneumocystis jirovecii pneumonia was exactly the same in both primary and secondary clinical trials is entailed in the given trials because  1 The trials provide the number of adverse events and the specific types of adverse events for each trial 2 The statement focuses on the incidence of ascites and pneumocystis jirovecii pneumonia in both",
        "label": "Entailment"
    },
    "c09d08df-1042-47ca-9c54-83be4f9f691a": {
        "text_answer": "  The statement no instances of febrile neutropenia or cholelithiasis were reported in both the primary and secondary clinical trials is not directly entailed or contradicted by the given data The data only provides the number of adverse events for a specific type Adverse Events 1 and does not mention febrile neutropenia or cholelithiasis explicitly for both trials Therefore it is not possible to determine if the",
        "label": "Contradiction"
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "text_answer": "  The statement No two patients in the primary trial suffered the same type of adverse event is a negation of the statement Two or more patients in the primary trial suffered the same type of adverse event   To determine if the statement is entailed or contradicted by the given data we need to check if there is any evidence of two or more patients suffering the same type of adverse event   From the given data we can see that",
        "label": "Contradiction"
    },
    "0744e505-8c33-48b6-bd82-b201fdcc9679": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The statement is about the laterality of avascular necrosis in joints which is not directly related to the interventions or groups in the trials The trials only provide information about the interventions and dosing schedules for each group",
        "label": "Entailment"
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "text_answer": "  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is contradicted by the given trials  Explanation  The statement implies that there are more cases of Mucositis Oral Bladder Infection and Thromboembolic events in the primary trial than in the secondary trial However the",
        "label": "Contradiction"
    },
    "13b40eaf-ad55-439f-9d93-a00a7bee3516": {
        "text_answer": "  The statement the primary clinical trial welcomes the participation of AfricanAmerican patients is not entailed nor contradictory to the information provided in the inclusion and exclusion criteria for the dose escalation and expansion phases of the clinical trial The statement is independent of the trial criteria and expresses a welcoming attitude towards the participation of AfricanAmerican patients",
        "label": "Contradiction"
    },
    "3611645a-e832-4b38-a1db-9c66aca8baf6": {
        "text_answer": "  The statement 25 of the patients involved in the primary clinical trial report the problems of increased pleural effusion and swift progression of their disease is contradictory to the given trials data   Explanation   The trials data shows that out of 17 patients in total 13 from trial 1 and 4 from trial 2 only one patient from trial 1 769 and one patient from trial",
        "label": "Entailment"
    },
    "8773e9c2-3030-4221-b663-b21d49ae1721": {
        "text_answer": "  The statement no evaluation of the clinical benefit based on RECIST criteria rate among the participants is performed in either the primary or secondary clinical trial is entailed in the given trials as neither trial reports the number of participants with tumor response Complete Response Partial Response Stable Disease or Progressive Disease based on RECIST criteria The primary trial reports tumor response using RECIST criteria for only three participants with ovarian cancer",
        "label": "Contradiction"
    },
    "eca37c79-e36b-446d-bd9a-4cf546fc9ab7": {
        "text_answer": "  The statement edema was a common adverse event in the primary trial is contradicted by the given data in the trials as the frequency of edema in Trial 1 was 024 000 and in Trial 2 was 122 455 The statement implies that edema was a common adverse event in both trials but the data shows that it occurred in only one trial and with a",
        "label": "Contradiction"
    },
    "460e894b-61c8-4935-bde6-6800b1a440a2": {
        "text_answer": "  The statement participants in the primary clinical trial would be required to take multiple injections is entailed in the trial description as follows  1 Dendritic Cell Vaccine patients will receive 10 x 106 peptidepulsed DCs given by id injection into either axilla or the inguinal region with each peptide given into a separate site The total dose will be",
        "label": "Entailment"
    },
    "6d328d56-d579-4a87-b2bf-e3f3d8bd2c4f": {
        "text_answer": "  The statement individuals partaking in the primary clinical trial specifically from the ovarian function suppression group reported an improvement in cognitive function is not entailed in the given trial results   The trial results only report the mean standardized cognitive function scores for the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The statement makes a claim about an improvement in cognitive function but the trial results do not provide",
        "label": "Contradiction"
    },
    "8480a497-4ae7-4d4a-9b19-68667f70dc22": {
        "text_answer": "  The statement in the primary clinical trial most of the reported adverse events were related to blood and bone marrow This observation was not found in the secondary clinical trial is a comparison statement between the two trials To verify this statement we need to determine if the observation about the majority of adverse events being related to blood and bone marrow in the primary trial and not being observed in the secondary trial is entailed or contradicted by the data provided  First",
        "label": "Entailment"
    },
    "60c5afb6-a250-4e59-bccd-3729a9a97a6b": {
        "text_answer": "  The statement is entailed in the trials as both interventions Bisphosphonate IV Q4W and Denosumab 180 mg Q12W involve different methods of administration Bisphosphonate is given intravenously once every 4 weeks while denosumab is given by subcutaneous injection once every 12 weeks Therefore the statement that the primary clinical trial employs a variety of methods for intervention administration is",
        "label": "Entailment"
    },
    "8af5402d-9065-412b-a7dc-053dfce01c63": {
        "text_answer": "  The statement the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib is entailed in the trials as follows  1 In the primary trial pembrolizumab is administered every 3 weeks Q3W which is equivalent to every 8 weeks if we consider that 3 weeks is half the time of 8 weeks Therefore pembrolizumab is",
        "label": "Entailment"
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "text_answer": "  The statement Patients participating in the primary trial receive oral medication twice a day for a full month is entailed in the given trial description as follows  1 Patients receive medication twice a day once lapatinib and once tamoxifen for 28 days 2 Both medications are oral medications  Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "7d3e5dce-744f-4f7b-81f8-085c7ce2bee0": {
        "text_answer": "  The statement all participants in the primary clinical trial showed a drop in cognitive abilities especially those in the ovarian function suppression group is not directly entailed in the given trial results   The results only provide the mean standardized scores and standard deviations for the cognitive function tests in the Tamoxifen and Ovarian Function Suppression groups at 1 year after randomization The statement makes a stronger claim that all participants showed a drop in cognitive",
        "label": "Contradiction"
    },
    "e6577f53-5752-4fd5-bcfb-2d4f03b2ce60": {
        "text_answer": "  The statement no patients treated with gtx024 1mg in the primary clinical trial gained lean body mass over a 4 month period is entailed in the trial results as follows  The median change in total body lean mass for the group treated with GTx024 1mg is 206 kg which is negative indicating a loss of lean body mass Since the median represents the middle value of the data this",
        "label": "Contradiction"
    },
    "d1200239-9391-41b1-a73e-5590855243bc": {
        "text_answer": "  The statement is contradictory to the given information in the trials In the primary trial participants received PF06647020 not ALT801 Therefore it is not possible to make a statement about the doses of ALT801 administered in the primary and secondary trials",
        "label": "Entailment"
    },
    "5c9e6daf-915c-48b4-b1d4-2e302e0164d4": {
        "text_answer": "  The statement an overwhelming majority of participants showed a decline in circulating tumor cell counts due to the regiment of highdose chemotherapy with purged autologous stem cell products is entailed in the trial results if the following conditions are met  1 A majority of the 21 participants in the Highdose Chemotherapy armgroup experienced a reduction in CTCs 2 The reduction in CTCs was due to",
        "label": "Entailment"
    },
    "c8b6ed79-b613-4ed4-b2ad-2e2ca4f5dcd4": {
        "text_answer": "  The statement no adverse events have been recorded for the patient cohort of the primary clinical trial is contradictory to the given information in the trials The trials report one adverse event surgery in a patient out of 29 which is a nonzero frequency Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "3e96ec18-39ff-46f9-9c67-0b6e70003e24": {
        "text_answer": "  The statement is entailed in the trials as follows  Both interventions use the same dosages and frequencies for Doxorubicin Cyclophosphamide and Docetaxel The difference lies in the addition of Herceptin in Intervention 2 which does not affect the use of the aforementioned drugs in terms of dosage and frequency However Intervention 2 includes three extra cycles of Docetaxel and D",
        "label": "Entailment"
    },
    "8fe97ae1-baa6-48ba-a97e-a59585b2b268": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial encountered numerous fatalities and hospital admissions with multiple incidents of atrial fibrillation is not entailed in the given trials data as there is no mention of fatalities hospital admissions or atrial fibrillation in cohort 2 of trial 2 The trials data only provides the number of adverse events but not their specific types or causes Therefore the statement is",
        "label": "Contradiction"
    },
    "d08f5261-afae-42c3-9d0a-39739ae40ccf": {
        "text_answer": "  The placebo intervention is provided daily for 81 days 12 weeks while the memantine intervention is provided for the same duration but with dosing only on those days when toxicity is not unacceptable Since toxicity is not specified in the given statement it is assumed that the statement refers to the total number of dosing days Based on this assumption the statement is contradictory to the information provided in the trial description as the memantine intervention is",
        "label": "Entailment"
    },
    "5f4eaa1c-4e83-402c-a1ed-4d398f51ec1d": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the intervention includes Gefitinib ZD1839 at a daily dose of 250 mg or 500 mg which is a multiple drug intervention as it consists of a single drug Gefitinib but with two different doses  In contrast the secondary trial has only one intervention which is Zoledronic acid",
        "label": "Entailment"
    },
    "5a7d5563-2920-418c-a2fb-46ada378c860": {
        "text_answer": "  The statement any patients that have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER2 agents",
        "label": "Entailment"
    },
    "93d37103-4625-42a6-b8a2-7ce2d5673324": {
        "text_answer": "  The statement is entailed in the trials as the primary trial explicitly excludes patients with a diagnosis of high risk breast lesions including ductal carcinoma in situ while the secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ Therefore the statement is entailed in the trials as the primary trial is a more restrictive subset of the secondary trial in terms of inclusion criteria",
        "label": "Entailment"
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Perjeta is not mentioned in either the primary or secondary trials In the secondary trial HER2targeted PETCT with novel radiotracers is mentioned but no specific mention of Perjeta is made Therefore the statement that Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is incorrect",
        "label": "Contradiction"
    },
    "f8a3e02a-d5d0-4a12-9d82-e811f7be3502": {
        "text_answer": "  The statement smokers are accepted for participation in the primary trial and the secondary trial has no restrictions on alcohol intake is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials  Explanation  The primary trial includes a criterion for nonsmokers no nicotine use within the last 5 years which explicitly excludes smokers from participation Therefore the statement that smokers",
        "label": "Contradiction"
    },
    "376c9806-25fd-4b1c-962a-b14c2ca6d9b3": {
        "text_answer": "  The statement patients suffering from Alzheimers disease can participate in the primary clinical trial is contradictory to the inclusion criteria of the trial The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Alzheimers disease is a progressive neurodegenerative disorder characterized by cognitive impairment and a decline in daily functioning Therefore patients",
        "label": "Entailment"
    },
    "ef637aff-9f52-4e17-a4d7-77e6cdb740c6": {
        "text_answer": "  The statement patients with stage 4 invasive breast carcinoma which tests positive for either estrogen or progesterone receptors and are considering AI therapeutic intervention are eligible for involvement in the primary clinical trial is contradictory to the trials inclusion criteria   The inclusion criteria state that patients must have histologically proven DCIS or stage IIII invasive carcinoma of the breast Stage 4 invasive breast",
        "label": "Entailment"
    },
    "dcc038bf-f819-4713-9356-3e966d30291d": {
        "text_answer": "  The statement rat ovarian adenocarcinoma is adenocarcinoma that arises from the ovary of a rat is not related to the information provided in the trials   The statement There are 7 more participants in cohort 2 of the primary trial than in cohort 1 is a fact that can be determined from the given data Therefore it is an entailed fact based on the trials",
        "label": "Entailment"
    },
    "95aebead-f222-4a09-b0e0-31557235953f": {
        "text_answer": "  The statement the intervention in the secondary trial lasts half as long as the intervention detailed in the primary trial is a contradiction to the given information   In the primary trial the reflexology intervention lasted for 10 weeks In the secondary trial both the placebo and vitamin D interventions lasted for 24 weeks Twentyfour weeks is not half the length of ten weeks",
        "label": "Contradiction"
    },
    "9eb03f1d-28b2-427e-bbf2-917fcf5ccf74": {
        "text_answer": "  The statement not a single one of the participants in group 1 of the primary trial were found to have lesions and exactly 15 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as there is no common group 1 between the primary and secondary trials The primary trials group 1 refers to healthy volunteers while the secondary trial",
        "label": "Contradiction"
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial the dosage of Zoledronic Acid used in Intervention 1 is 4 mg given every 4 weeks Q4W which translates to a yearly dose of 16 mg   In the secondary trial the dosage of Denosumab used in Intervention 1 is 120 mg given every",
        "label": "Entailment"
    },
    "6c56960a-80c2-40f6-8ba7-8e96a6bdcb98": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial reported all adverse events encountered during their respective trials is entailed in the given information if and only if there are no unreported adverse events in either trial Since the given information states that there were no adverse events reported for Adverse Event 1 in both trials the statement is entailed by the given data for Adverse Event 1 However for Adverse Event 2 in the secondary",
        "label": "Entailment"
    },
    "5942877d-3edd-4949-9128-b17a68194753": {
        "text_answer": "  The statement More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery is not directly entailed in the given trials as the trials only report the number of participants with a pathologic complete response in each arm of the study The statement makes an assumption about the total number of participants across both arms who experienced a pathologic complete",
        "label": "Contradiction"
    },
    "5af06b76-49a3-4342-92ef-2d15ecddc2c7": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on different outcome measures The primary trial reports the median Time to Progression TTP in months for both arms A and B while the secondary trial reports the number of participants with objective response based on RECIST criteria at specific time points The statement mentions the progressionfree survival time in weeks for a fraction of patients in the primary trial but this information is not explicitly stated in the provided",
        "label": "Contradiction"
    },
    "382c5afb-42ce-4711-90c2-c72f34f03729": {
        "text_answer": "  The statement the least frequently reported adverse event across the patient cohorts of the primary trial and the secondary trial was syncope is not directly entailed or contradicted by the given data   The data only provides the frequency of adverse events for each trial but it does not compare the frequency of each specific adverse event between the two trials Therefore based on the given information it cannot be definitively determined that syncope was the least frequently reported",
        "label": "Contradiction"
    },
    "770041f3-701c-4e9f-8df4-5b78a0e4a076": {
        "text_answer": "  Lets calculate the ratio of hepatotoxicity cases to the sum of hypertension and pancreatectomy cases in the primary trial  Ratio  Number of hepatotoxicity cases  Number of hypertension cases  Number of pancreatectomy cases  Given Number of hepatotoxicity cases  3 Number of hypertension cases  1 Number of pancreatectomy cases",
        "label": "Entailment"
    },
    "074f66e7-18df-4ee9-a33c-127062dcb51f": {
        "text_answer": "  The statement is entailed in the Trials The primary trial does indeed have separate inclusion and exclusion criteria for its Phase I and Phase II portions while the secondary trial has the same criteria for all participants Therefore the statement accurately reflects the information provided in the trials",
        "label": "Entailment"
    },
    "22b44925-9577-462a-bf8b-cd3e5ba5ecb1": {
        "text_answer": "  The statement all the participants of the primary clinical trial must have demonstrable hepatic disease is a contradiction to the given inclusion criteria The inclusion criteria state that there are no specific requirements regarding liver function or hepatic disease Therefore the statement that all the participants must have demonstrable hepatic disease is not entailed in the given trial criteria Instead it is a contradiction as it adds an additional requirement that is not stated in the original inclusion",
        "label": "Contradiction"
    },
    "edb8f244-cc5e-4cc5-b473-3b93f8640e65": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial there are two test groups Pyridoxine and Placebo as stated in the question itself Therefore the statement that the primary trial consisted of numerous test groups with the absence of a placebo group is incorrect  Regarding the secondary trial it does have two control groups Highdose Oxybutynin Chloride and Lowdose",
        "label": "Entailment"
    },
    "97c98ddb-37f4-4e14-82c0-0685e500222c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The secondary trial has the same inclusionexclusion criteria for all participants according to the text However the primary trial has different inclusion criteria for different study groups Groups 1a and 1b for NSCLC Group 2 for melanoma Group 3 for triple negative breast cancer and Group 4 for anaplastic thyroid cancer Therefore the statement",
        "label": "Entailment"
    },
    "8548c61d-2a2f-4498-a7b8-828adbd9e613": {
        "text_answer": "  The statement is not entailed in the given intervention description in Arm 1 of the primary clinical trial   The intervention description specifies that patients receive 100 mgm2 of lapatinib once daily not twice daily as stated in the given statement Therefore the statement is not entailed by the intervention description",
        "label": "Contradiction"
    },
    "506c27c5-380f-41f7-9f90-81d843d7d140": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive alpha lipoic acid three times daily with dose escalation which results in higher quantities of alpha lipoic acid being administered over the entire study period compared to the secondary trial where patients in Cohort 1 receive a fixed dose of necitumumab as an IV infusion on Days 1 and 8 of every 3week cycle which remains constant throughout the study period",
        "label": "Entailment"
    },
    "cbf31ee8-3c01-46f5-9698-f44da41fd1fa": {
        "text_answer": "  The statement there were an equal number of patients suffering adverse events in both cohort 1 and cohort 2 of the primary clinical trial is entailed by the given trials if and only if both trials have zero adverse events This is because the statement asserts that the number of patients with adverse events is equal in both cohorts and the trials provide the number of patients with adverse events in each cohort If either trial has",
        "label": "Entailment"
    },
    "14236a59-be4c-4b17-844b-7c26a0650dc8": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do not provide sufficient information about the condition of the patients being tested for Alzheimers Disease Assessment ScaleCognitive ADASCOG and the trials do not mention any relation between Alzheimers disease and pleural effusion The statement only mentions the occurrence of increased pleural effusion in cohort 2 of trial 2 but the trials",
        "label": "Contradiction"
    },
    "6142265a-a110-42be-b03f-088d346e2389": {
        "text_answer": "  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly related to the given adverse events of the primary trial which are Thrombocytopenia Hypertension Hepatotoxicity and Pancreatectomy   The statement does mention Hepatotoxicity but it also",
        "label": "Entailment"
    },
    "7f832fbe-bf0f-44d1-820f-2398ce83404e": {
        "text_answer": "  The statement is contradicted by the information provided in the secondary trial While no adverse event affected more than 1333 of patients individually the total number of adverse events 1030 is greater than 0 which contradicts the statement that none adverse events were observed in the primary trial",
        "label": "Contradiction"
    },
    "7f17692d-e7de-4365-9da1-83f563fde703": {
        "text_answer": "  The statement the secondary trial and the primary trial report results from one patient cohort is not entailed in the given trials as they report results from different patient cohorts and different outcome measurements The primary trial reports results for denosumab in 33 participants while the secondary trial reports results for dmethadone in 8 participants Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "text_answer": "  The statement General symptoms are the most common AE recorded in the primary trial is not directly entailed in the given data The data shows that the total number of adverse events AEs recorded was 16 out of 51 3137 and out of these 2 AEs were classified as General symptoms However the statement does not provide any information about the frequency or percentage of General symptoms being the most",
        "label": "Contradiction"
    },
    "4ae87355-7844-42a5-ad5b-a00c8103d102": {
        "text_answer": "  The statement there is a limited patient capacity in the primary clinical trial for those who have been diagnosed with metastatic colorectal cancer having the kras or braf mutation is entailed in the trials inclusion criteria The trial specifies a limited number of enrollment slots 1530 for subjects with metastatic colorectal cancer having the Kras or BRAF mutation Therefore the statement is entailed in",
        "label": "Entailment"
    },
    "f2f2b835-ac2d-43f6-827f-4341fb7d5fd1": {
        "text_answer": "  The statement a confirmed complete response CR was experienced by over half the patients in the primary clinical trial who were treated with a combination of lapatinib 1000mg and nabpaclitaxel is not directly entailed in the given trial results   The trial results only provide the number of participants who experienced a CR or PR according to RECIST criteria 10 but they do not specify that more than half of",
        "label": "Contradiction"
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "text_answer": "  The statement is entailed in the trials as patients with malignant ductal carcinoma in situ are excluded from the primary trial but are eligible for the secondary trial",
        "label": "Entailment"
    },
    "5933fba5-8565-47ef-a491-1a1531dc1ab3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks The statement suggests that the intervention in the secondary trial lasted only 3 times shorter than the intervention in the primary trial which is not the case",
        "label": "Entailment"
    },
    "80249c01-a69c-490c-ab1f-74ead64dd3df": {
        "text_answer": "  The given statement none of the patients in the primary trial experienced the worst pain imaginable for 12 an hour is not directly entailed or contradicted by the information provided in Trials 1 and 2 The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups They do not provide any information about the distribution of pain intensity scores or the duration of pain episodes experienced by individual patients Therefore it is not",
        "label": "Contradiction"
    },
    "bb80e4aa-fb7d-4455-8fff-95607f45dab0": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms cannot take part in the secondary trial is not directly entailed in the inclusion or exclusion criteria of the secondary trial provided However it is an exclusion criterion for the primary trial  The statement those who currently have breast implants cannot participate in the primary trial is an exclusion criterion for the primary trial  The statement Perfect match probe",
        "label": "Contradiction"
    },
    "f0594802-c304-4dc7-88c8-282554c1e7d7": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial administers Vitamin B12 orally sublingually not through injection or intramuscularly The secondary trial also administers memantine orally by mouth not through injection or intramuscularly Therefore neither trial entails the statement that the primary trial administers its intervention through injection",
        "label": "Entailment"
    },
    "ea0e2918-08bd-4013-9915-66f8fe425e31": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description   In the trial description the dosages of nabPaclitaxel are identical in both arms 125 mgm2 on Days 1 and 8 but the second agents Gemcitabine and Carboplatin have different dosages and administration schedules Therefore the statement that both cohorts involved in the primary clinical",
        "label": "Entailment"
    },
    "1357d4a3-909e-4b71-aa5a-ce11869ec91e": {
        "text_answer": "  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was nausea is contradicted by the given data   The primary trial reported adverse events for 12 patients with nausea not being mentioned at all The secondary trial reported adverse events for 119 patients with deep vein thrombosis being the only adverse event mentioned in both the primary and",
        "label": "Contradiction"
    },
    "36603238-a220-4848-b9e6-90d61b28eb28": {
        "text_answer": "  The statement maintaining a routine exercise regimen is a prerequisite requirement for all candidates in the primary clinical trial is not explicitly stated in the given trial information However there is no contradiction to this statement either The trial information only mentions that patients must be assessable for the primary outcome measure and have certain types of cancer and available assessment instruments It does not mention exercise as a requirement for eligibility Therefore the statement is neither entailed",
        "label": "Contradiction"
    },
    "73bc9024-02aa-46b8-913b-c2739a3a66e8": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial specifically states that it is open exclusively to Japanese female patients while the secondary trial does not have any such restriction mentioned in its inclusion criteria",
        "label": "Entailment"
    },
    "a056e319-f42c-4d3d-80f0-a8348be4eb9d": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is not directly entailed in the given inclusion and exclusion criteria for both the primary and secondary trials   However the statement is consistent with the exclusion criteria for the primary trial regarding hemorrhagebleeding events specifically pulmonary hem",
        "label": "Contradiction"
    },
    "65203e16-ff68-4833-9f92-0f63e432c09e": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However the statement is partially correct regarding the Karnofsky performance status requirement For the primary trial the baseline Karnofsky score is indeed 70 and for the secondary trial it is 55 The statement does not mention anything about suprapharyngeal lymph nodes Therefore the statement is neither entailed nor",
        "label": "Contradiction"
    },
    "0af975f2-157a-472d-a30e-9ad614342146": {
        "text_answer": "  The statement polyneuropathy was the most frequent adverse event reported in the primary clinical trial the secondary clinical trial had no recorded aes is contradictory to the given information   The primary clinical trial had no recorded adverse events for polyneuropathy and the secondary clinical trial had several recorded adverse events but none of them were for polyneuropathy Therefore the statement is incorrect",
        "label": "Contradiction"
    },
    "10a1605b-bfd7-4196-9912-19b28f271ebd": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial would consider a patient who has a primary tumour with a diameter of 33mm determined by a clinical examination and ultrasound is entailed in the primary clinical trial as the inclusion criteria state Primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography which allows for measurement by clinical examination and ultrasound However the secondary clinical trial does",
        "label": "Entailment"
    },
    "56d7443e-3522-40e2-bb3a-413fb5edea4e": {
        "text_answer": "  The statement although a patient meets all the criteria for the primary clinical trial final entry is determined by the first of kin is neither entailed nor contradicted by the given inclusion and exclusion criteria for the clinical trial   The inclusion and exclusion criteria only specify the medical conditions and history that determine a patients eligibility for the trial They do not address who has the final authority to make the decision about a patients entry into the trial",
        "label": "Entailment"
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "text_answer": "  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is entailed in the given trials as neither of the trials reported any cases of Hypertension Edema or Dyspnea in their adverse events",
        "label": "Entailment"
    },
    "4229278c-db31-4842-8c04-1d5b30b39037": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement asserts that breast cancer patients in the primary trial receive 1000 mcgday of talazoparib while ovarianperitoneal cancer patients receive only 25 mcgday However the trials describe that breast cancer patients received talazoparib at doses ranging from 600",
        "label": "Entailment"
    },
    "da4a10c9-b04c-4439-84f5-918325786672": {
        "text_answer": "  The statement individuals who have had severe anaphylactic responses to herceptin or have shown no response to herceptin treatment are suitable candidates for the primary clinical trial is contradictory to the inclusion criteria of the trial   The reason being the trial excludes individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab herceptin making those individuals ineligible for the study Additionally",
        "label": "Contradiction"
    },
    "eaa447d4-2621-47ca-b543-5d1d956fec02": {
        "text_answer": "  The statement patients with severe insomnia and schizophrenia are eligible for the primary clinical trial but not the secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trial includes patients with severe insomnia as an inclusion criterion for the secondary trial but it does not mention anything about schizophrenia The secondary trial excludes patients with a history of psychiatric illness",
        "label": "Contradiction"
    },
    "789e28a0-3116-4b32-be0f-807ffce7f552": {
        "text_answer": "  The statement thyroglobulin antibody negative is an indication that antibodies that recognize thyroglobulin have not been detected in a sample is not directly related to the information provided in the trials The trials only mention the interventions being used and the timing of their administration Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "56358f96-8cad-40a1-a59f-4746ebde10d3": {
        "text_answer": "  The statement detailed participant information for each cohort is provided by the primary clinical trial is entailed in the given trials as both trials provide information on the number of participants analyzed the interventions given to each armgroup and the mean standard deviation of the outcome measurement for each armgroup This information is considered detailed participant information",
        "label": "Entailment"
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "text_answer": "  Based on the information provided in the interventions the statement is entailed in both the Intervention 1 and Intervention 2 conditions of the primary trial Neither intervention involves the use of drugs radiotherapy or CBT Cognitive Behavioral Therapy Therefore the statement is consistent with the given interventions in both conditions",
        "label": "Entailment"
    },
    "fb3c3307-16bd-4454-b8ee-6427743bc1ed": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial is a summary of some of the exclusion criteria mentioned in the trial description However it is important to note",
        "label": "Entailment"
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "text_answer": "  The statement Morbidly obese patients are eligible for the primary trial is entailed in the inclusion criteria of the trial as stated in the text The inclusion criteria specify that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs which meets the definition of morbidly obese Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "61e35a8d-77bb-4fef-b9fa-ad0380508fc9": {
        "text_answer": "  The statement the findings of the primary clinical trial showed an increased number of patients with stable disease status at week 12 compared to week 24 however none displayed complete response during weeks 12 or 24 is entailed in the trial results given as follows  1 The trial results show that the number of participants with stable disease SD at week 12 was 12 and at week 24 was 10",
        "label": "Entailment"
    },
    "9da65ef3-87a1-433d-943b-a2ecc45252e1": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORR of the two groups directly   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 058",
        "label": "Entailment"
    },
    "0cff9aa1-3486-4c0c-bda1-8850b3dc932e": {
        "text_answer": "  The statement is entailed in the trials since the trials report that there have been no instances of anorexia hypothermia or hallucinations in the adverse events of both trials The statement explicitly mentions these three conditions and the trials confirm that none of them occurred Therefore the statement is entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "946b0905-73d8-4e13-867f-12ea3c67c52e": {
        "text_answer": "  The statement more than 1 over 3 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks of the study is not directly entailed in the given trials as they do not provide the exact number of participants who experienced pathologic complete response after approximately 30 weeks However based on the given data we can calculate that more than 1 over 3",
        "label": "Contradiction"
    },
    "f48699d6-6352-4c94-9ef3-fe5060d07aeb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials indicate that there were no adverse events observed in both the primary and secondary trials for Adverse Events 1 Therefore it is not entailed that there were more adverse events in the secondary trial based on the given information",
        "label": "Contradiction"
    },
    "9d99fc21-4f9a-4c4a-b260-d8c17d1cbdd2": {
        "text_answer": "  The statement ntrk2 fusion negative is an indication that the expression of a ntrk2 fusion has not been detected in a sample is not directly related to the adverse events data provided in the primary trials The statement only mentions the concept of ntrk2 fusion and its negative status while the trials focus on the occurrence of various adverse events in two different cohorts The statement does not entail or contradict the information given in the",
        "label": "Entailment"
    },
    "469e2131-ef6a-4478-8e87-f785804bf8a4": {
        "text_answer": "  The statement over 99999 of patients in the secondary trial and the primary trial did not suffer any adverse events is not entailed in the given trials as there are reported adverse events in both trials However the statement is a contradiction to the reported adverse events in the trials as the trials report that some patients did experience adverse events",
        "label": "Contradiction"
    },
    "e386c5e7-d098-479c-b160-aa3dab13a8df": {
        "text_answer": "  The statement The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention regardless of cancer type is not directly entailed in the provided trial results The trial results only report the percentage of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention for both the Collaborative Care Intervention CCI and Prevention Care Management ",
        "label": "Contradiction"
    },
    "203914a5-0e0b-4e11-a138-6793a23218c8": {
        "text_answer": "  The statement in the second group of the primary clinical trial there were no recorded deaths or hospital stays is entailed in the given data from Trial 2 Adverse Events 2 since the total number of adverse events including deaths and hospitalizations is reported as 0 zero Therefore the statement is a logical consequence of the data provided",
        "label": "Contradiction"
    },
    "2efa0e5d-84cd-4854-9558-6105af976610": {
        "text_answer": "  The statement patients who have received chemotherapy or radiotherapy in the last 2 weeks are dealing with unstable angina or have grade 2 or above neuropathy are eligible to participate in the secondary clinical trial and excluded from the primary clinical trial is a contradiction based on the given inclusion and exclusion criteria  Explanation  The primary clinical trial excludes patients who have received chemotherapy or radiotherapy within certain time frames",
        "label": "Contradiction"
    },
    "bad9c481-e20c-49a7-b6b6-4e09991419c2": {
        "text_answer": "  The statement is partially entailed in the trials   The statement is correct that both trials utilize pCR pathological complete response as an outcome measurement However the statement only directly compares the percentage of participants experiencing orr observable response in the primary trial which does not show any observable differences between the two arms In the secondary trial there is a difference in the percentage of participants experiencing orr between the two arms with Arm 1",
        "label": "Entailment"
    },
    "15ac7da3-01f5-4c67-a59a-d41619758b62": {
        "text_answer": "  The statement the primary clinical trial does not apply any constraints on the liver function of its participants is entailed in the given trial information as there is no exclusion criterion mentioned regarding liver function in the trial",
        "label": "Entailment"
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "text_answer": "  The statement is entailed in the trials as follows  In the given primary trial the doses of Cyclophosphamide C for both interventions are the same 600 mgm2 on Day 1 of each treatment cycle However the doses of Eribulin Er and Docetaxel T differ  Cohort 1 ErC Eribulin Er dose ",
        "label": "Entailment"
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "text_answer": "  The statement is entailed in the trials as described The trials specify that in Cohort 1 patients receive paclitaxel intravenously and anastrozole orally while in Cohort 2 patients receive fulvestrant intramuscularly The statement correctly identifies that paclitaxel is only used in Cohort 1 and fulvestrant is used in Cohort 2",
        "label": "Entailment"
    },
    "f6ce492e-e69c-4908-9b04-b0234a364e95": {
        "text_answer": "  The statement 17p131q25 is a chromosome band present on 17p is not related to the interventions described in the trial Therefore it is neither entailed nor contradicted by the information provided in the trial",
        "label": "Entailment"
    },
    "9bc01b3d-99a3-47bf-9183-012d6686acc5": {
        "text_answer": "  The given statement there were 100 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed in the provided trials as there is no mention of hypertension dehydration or dyspnea in the trials The trials only report adverse events for specific conditions such as hepatic failure disseminated intravascular coagulation fatigue edema lim",
        "label": "Contradiction"
    },
    "9bec84f1-9ea0-4a5c-a3d7-b368a302ad4a": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage change in betaCTX at Week 4 between the two groups   The percentage change in betaCTX for the AZD0530 175 mg group is 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg",
        "label": "Entailment"
    },
    "dd9dfad7-d09d-49d3-ad2d-fe7421d3a8a0": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trial descriptions   In the primary trial all patients receive 5 injections at the beginning of the study In contrast the statement suggests that participants in the secondary trial receive 3 weekly injections Therefore the statement is contradictory to the information provided in the primary trial description",
        "label": "Entailment"
    },
    "70d381b6-0605-4369-8342-5ee2fb69d878": {
        "text_answer": "  The statement patients with a diagnosis of ductal carcinoma in situ who are thinking about AI therapy qualify for the primary clinical trial is entailed in the inclusion criteria of the trial   Explanation   The inclusion criteria state that patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone receptor positive qualify for the trial The statement specifically",
        "label": "Entailment"
    },
    "a263d5ff-4c27-4881-9209-87b1c1d69f94": {
        "text_answer": "  The statement the primary clinical trial necessitates participants to display resistance towards ai therapy and mirtazapine a condition not enforced in the secondary clinical trial is a contradiction   Explanation  The primary clinical trial includes the condition of participants being resistant to aromatase inhibitors AI therapy but the secondary clinical trial does not mention anything about resistance to AI therapy or mirtazapine Therefore the secondary clinical",
        "label": "Contradiction"
    },
    "a83ed07f-5ce3-44db-83d4-1629e6838c4a": {
        "text_answer": "  The statement is consistent with the information provided in the trials The primary trial requires mammography as a prerequisite for participation while the secondary trial does not mention mammography as a requirement in its inclusion criteria Therefore the statement for the primary clinical trial prospective candidates are required to have a mammography but this is not a prerequisite for the secondary clinical trial is entailed in the information given",
        "label": "Entailment"
    },
    "a3c50e76-dadb-4b34-8245-0fe0de3d19cb": {
        "text_answer": "  The statement doctor asked which treatment option I prefer is not entailed in the given trials as they do not provide any information related to the doctors questions or preferences of the participants The trials only report the results of the interventions in terms of their respective outcome measures Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Contradiction"
    },
    "62dbb697-f709-40c2-a4b9-8ed098473bde": {
        "text_answer": "  The statement male patients with neuroblastoma over the age of 60 can participate in the primary clinical trial regardless of race or ethnic origin is not directly entailed in the inclusion criteria for the primary trial provided The primary trial includes females of all racial and ethnic origins who are scheduled to receive the first cycle of a single intravenous dose of doxorubicin and cyclophosphamide as part of standard medical care for breast cancer There",
        "label": "Contradiction"
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is comparing two different interventions Hydrophor and MediHoney in their effect on radiation therapy patients This is evident from the trial descriptions which clearly state that Group A will receive Hydrophor and Group B will receive MediHoney  The secondary trial on the other hand is testing the effect of different doses 90 mg and 11",
        "label": "Entailment"
    },
    "58726c08-13a9-4168-afc3-14f8e7397f5b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials as the young girl with a newly diagnosed PRpositive HER2positive breast cancer would not meet the inclusion criteria for either the primary or secondary trials  The primary trial includes patients with histologically confirmed HER2negative breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer A PRpositive HER2pos",
        "label": "Entailment"
    },
    "fea83da0-5960-4547-b662-fe6d139fe3f9": {
        "text_answer": "  The statement the primary clinical trial found the bevacizumab cohorts outcomes to be more favorable than those of the bevacizumab  capecitabine cohort is not directly entailed in the provided information The trials only report the percentage of participants with disease progression or death in each cohort during the maintenance phase No statistical analysis or comparison between the two groups is presented in the provided data Therefore",
        "label": "Contradiction"
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg per week while in the secondary trial cohort 1 receives a dose of 6 mgkg every 3 weeks and cohort 2 receives a dose of 2 mgkg per week These dosages are not the same throughout the entire duration of the",
        "label": "Entailment"
    },
    "046aa480-39cc-4333-a815-bc4ec3ebfa7d": {
        "text_answer": "The statement is contradictory to the information provided in the inclusion criteria as the trial does not have any ethnicity restrictions mentioned The inclusion criteria only specify requirements related to age disease status and other health conditions",
        "label": "Entailment"
    },
    "73fd9671-363f-4bfa-91ad-1c8bacdf84ef": {
        "text_answer": "  The statement 0 of the primary trial participants and 0 of the secondary trial participants suffered an adverse event AE is entailed in the given trials data as all the trials reported no occurrence of any adverse event in their respective participant groups",
        "label": "Entailment"
    },
    "aa9da5b8-f5de-4a49-a93c-9e354cdef066": {
        "text_answer": "  The statement no adverse outcomes were recorded in more than 1 of participants in both the primary and secondary clinical trials is entailed by the given data   Explanation   The statement requires that the percentage of participants with adverse events in both trials be less than 1 Based on the given data no adverse events were recorded in more than 1 of participants in either trial both primary and secondary trials had 0",
        "label": "Contradiction"
    },
    "93381895-c0d3-40d1-96a0-b1aa23f65151": {
        "text_answer": "  The statement there are no reported results for the lbh589 and lapatinib group in the primary clinical trial is entailed in the given trial data as there are no reported results for the LBH589 and Lapatinib group in the Results 2 section of the trial",
        "label": "Contradiction"
    },
    "286cb14c-39e1-4987-9de2-78de7e78a017": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there were no cases of acute myocardial infarction reported out of 73 participants However the statement claims that 2 participants in the primary trial experienced an acute myocardial infarction   On the other hand in the secondary trial there were no cases of acute myocardial infarction reported out",
        "label": "Contradiction"
    },
    "4a9c4fbc-53cf-4eff-b7ba-37a0f21386b4": {
        "text_answer": "  The statement no adverse events were reported in primary clinical trial among any of the cohorts is contradictory to the information provided in the trials   Explanation   The trials report that there were adverse events in both trials with a total of 3 adverse events in each trial and a total of 6 participants in each trial Therefore the statement that no adverse events were reported in primary clinical trial among any of",
        "label": "Contradiction"
    },
    "9c96be3d-39cf-4c1d-ae87-764621c1e0ca": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to herceptin or a history of nonresponse to herceptin treatments are eligible for the primary trial is not entailed in the inclusion criteria provided in the trial description   The statement mentions patients with a history of severe anaphylactic reactions to herceptin being eligible for the trial but the trial description states that patients with a history of grade 3 or 4",
        "label": "Contradiction"
    },
    "c68e5909-668a-4b35-bf32-815624bf44da": {
        "text_answer": "  The statement in the primary clinical trial 150 mgm2 of lapatinib is administered orally once daily for two weeks to the patients is not directly entailed in the given intervention description in the trial   The intervention description states that patients receive 150 mgm2 of lapatinib orally once daily on days 128 but it does not specify that the dosage is given for only two weeks",
        "label": "Contradiction"
    },
    "dec08a3f-8124-4d8a-b5cf-00231c2b5cec": {
        "text_answer": "  The statement candidates for the primary clinical trial can have a Her2 negative tumor result according to FISH or IHC 3 test is not explicitly stated in the inclusion criteria provided However the criteria do include HER2 positive tumor either IHC 3 or FISH which implies that only patients with Her2 positive tumors are eligible for the trial The statement is not a contradiction to the criteria as it falls within",
        "label": "Entailment"
    },
    "9645eddb-eb1c-43ca-a899-a35db801217e": {
        "text_answer": "  The statement is contradictory to the primary trials inclusion criteria which explicitly states that Willingness and ability to provide written informed consent is a requirement for participation Therefore the statement is contradictory to the primary trials inclusion criteria and is not entailed by the information provided in the trials  Regarding the secondary trial it does not mention anything about written informed consent as an inclusion or exclusion criterion Therefore the statement is",
        "label": "Contradiction"
    },
    "af3815c2-6d92-410b-ae62-5552ea998792": {
        "text_answer": "  The given statement is a contradiction to the results presented in the clinical trials   The results indicate that the median overall survival for the midluteal surgery group was 214 years 153 to 267 and for the midfollicular surgery group was 200 years 161 to 231 Both medians are above 2 years and there is no mention",
        "label": "Contradiction"
    },
    "8bf215f3-5795-4b6b-b193-354c87bc9496": {
        "text_answer": "  The statement at least one patient treated with gtx024 1mg in the primary trial gained over 157473 stone of lean body mass is not directly entailed in the given trial results as there is no participant in the GTx024 1mg group who gained more than 157473 stone approximately 105 kg of lean body mass within the given time frame",
        "label": "Contradiction"
    },
    "76f87500-dd58-4086-9991-90e4f8206abf": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not specify a treatment cycle length of exactly 10 months but rather defines each cycle as 21 days The maximum durations of treatment for PF05212384 and docetaxel are given as 505 days and 445 days respectively   The secondary trial does not have a cyclic treatment",
        "label": "Entailment"
    },
    "ffb8a143-9dd7-4e61-8967-b0744c2dfa49": {
        "text_answer": "  The statement is entailed in the trials as both trials report changes in specific outcomes related to different body systems The primary trial measures changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine at 9 months postsurgery Therefore the statement that the primary trial results report changes in pain intensity and the secondary",
        "label": "Entailment"
    },
    "3ed31a8a-dce6-4a6c-b1a6-143db3702546": {
        "text_answer": "  The statement mcl1 inhibitor is any agent that inhibits mcl1 is not directly related to the information provided in the given primary trial intervention section The intervention mentioned in the section is MM111 but no information is given about it being an mcl1 inhibitor or any surgical or imaging procedures involved Therefore the statement is neither entailed nor contradicted by the information in the primary trial intervention section",
        "label": "Contradiction"
    },
    "1c594930-3c65-42d3-86ed-a0a8f46d369c": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The trials only provide information about the occurrence of specific adverse events in two separate trials The statement discusses a different topic which is the type of thymic adenocarcinoma Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone",
        "label": "Entailment"
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "text_answer": "  The statement the primary trial and the secondary trial have 0 recorded adverse events is entailed by the given trials data as both trials have reported 0 adverse events in the category Adverse Events 1",
        "label": "Entailment"
    },
    "7ccf8aef-b43b-4d01-9c86-7728378b2aeb": {
        "text_answer": "  The statement histopathologically confirmed metastatic SBC patients are eligible to join the primary clinical trial is entailed in the inclusion criteria of the trial as stated in the text The trial includes patients with histologically documented metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer Therefore patients with metastatic SBC Squamous Cell Carcinoma",
        "label": "Entailment"
    },
    "3fd8c503-c6fa-45f1-8836-88a5b77873a3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial is examining the efficacy of vaginal medications Estring and vaginal application of testosterone cream while the secondary trial is focused on acupuncture treatment which is not related to oral or intravenous drug administration",
        "label": "Entailment"
    },
    "65bc201c-2957-4d21-88f1-05c2413a6e56": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measurements and do not share any common elements related to the foxr2 gene or its rearrangement The primary trial focuses on treatmentemergent adverse events with fosnetupitantpalonosetron and netupitantpalonosetron while the secondary trial measures total sleep time with Lenalidomide using polysomnography",
        "label": "Contradiction"
    },
    "7b71e96e-63ed-43c9-9d9d-5abad0b53d32": {
        "text_answer": "  The statement is entailed in the trials as both trials investigate the use of empegfilgrastim as a therapeutic agent but they differ in the dosage administered and the method of measuring the outcome The primary trial measures the duration of CTCAE grade 34 neutropenia in days while the secondary trial measures the incidence of CTCAE grade 34 neutropenia as the number of participants experiencing the event However",
        "label": "Entailment"
    },
    "88148e83-625a-4004-8a2c-e4dec21c73e7": {
        "text_answer": "  The statement is a contradiction to the results of the primary clinical trial The trial reported a significant change in Ki67 expression not tumor size The statement mentions a different outcome measure tumor size and a different dose of tamoxifen 32 mg po daily than what was used in the trial Therefore the statement is not entailed in the trial results Instead it is a contradiction",
        "label": "Contradiction"
    },
    "308848e8-55ef-4799-9251-7dc54ddf0ac3": {
        "text_answer": "  The statement less than 10 patients in the primary trial suffered Aes adverse events with microwave thermotherapy is not directly entailed in the given trials data The trials data only provides the number and percentage of patients who experienced specific adverse events gastroesophageal reflux disease and ductal carcinoma in situ out of the total number of patients in the trial It does not specify the total number of patients",
        "label": "Contradiction"
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "text_answer": "  The statement Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants is contradictory to the given data as Cholelithiasis was not reported in any participant of the secondary trial while it was reported only once in the primary trial Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "67f9627e-ec2e-49b5-bb2e-2adbb5debfef": {
        "text_answer": "  The statement is entailed in the Trials The reflexology intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks However the statement specifically compares the length of the interventions in the secondary trial and it is correct that the intervention in the placebo group is significantly shorter than the intervention in the vitamin D group 12 weeks vs 24 weeks Therefore the",
        "label": "Entailment"
    },
    "46c9f061-408a-4845-b1ac-01b9c8eb5606": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial reported more cases of palpitations pericardial effusions and abdominal pains than cohort 1 of the secondary clinical trial is a comparison statement between the two trials However the given data does not allow us to make such a comparison directly  To verify the statement we need to know the number of cases of palpitations pericardial effusions",
        "label": "Entailment"
    },
    "20e22430-cc26-4cc4-b644-30dea07896e7": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The statement suggests that the primary clinical trial administrates her2 treatment for both cohort 1 and cohort 2 However the given information states that cohort 1 is a triple negative cohort which means that it does not express the HER2 protein or have HER2 gene amplification Therefore her2 treatment would not",
        "label": "Entailment"
    },
    "3cbf5587-220b-4759-a93b-8dbd5e144939": {
        "text_answer": "  The statement patients with unmeasurable metastasis or those without cancer spread to other body parts are not appropriate for the primary clinical trial is not explicitly stated in the given trial criteria However the trial does specify that the disease must be histologically confirmed and meet one of the criteria for metastatic disease which includes measurable or nonmeasurable disease Therefore it can be inferred that patients with only nonmeasurable metastasis or no",
        "label": "Contradiction"
    },
    "98300332-951a-4da5-bdd9-42b17fd489b0": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants with a decrease in the growth factor signature GFS between the ERpositive Luminal B and Triple Negative groups  The percentage of participants with a decrease in GFS in the ERpositive Luminal B group was 286 131492 and in the Tri",
        "label": "Entailment"
    },
    "fd531ca0-8537-4395-abed-00fbc69c00a7": {
        "text_answer": "  The statement is entailed in the inclusion criteria of the trial as it correctly states that candidates for the primary trial must have breast cancer and require hormonal treatment Therefore the statement is in agreement with the trials criteria and is entailed by it",
        "label": "Entailment"
    },
    "1ad82f60-7f4e-4e29-967f-c83e64180807": {
        "text_answer": "  The statement is not entailed in the primary trial results The primary trial measures the change in Ki67 expression in tumors not the diameter of tumors The statement suggests a different outcome measurement",
        "label": "Contradiction"
    },
    "2e9395d7-1b38-4fc4-b0f4-121f89c1cfc2": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial is given half the dose of enzalutamide compared to cohort 1 is entailed in the trials   Explanation   The trials describe two cohorts intervention groups in the primary clinical trial Cohort 1 received enzalutamide 80 mg two 40 mg capsules daily while coh",
        "label": "Entailment"
    },
    "a993a4e8-00bf-47c9-95d2-a63d4666658e": {
        "text_answer": "  The statement is entailed in the trials as the primary trial involves the administration of Vitamin B12 sublingually while the secondary trial involves oral administration of memantine and placebo The trials are about different interventions and the statement correctly identifies the difference in administration methods between the two trials",
        "label": "Entailment"
    },
    "f9759341-1ed2-4e44-8d4d-952bb366892f": {
        "text_answer": "  The statement is entailed in the trials as follows  The statement historical data type is a data type comprised of information concerning the historical aspects of a particular value is not directly related to the trials and is a definition of a data type  The statement The only types of AEs observed in patients from the secondary trial were Eyelid oedema and Chest pain no AEs were recorded in the primary trial is entailed",
        "label": "Entailment"
    },
    "f5a91b94-a81e-4c40-91df-b144e30df80b": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial participants receive either epacadostat with pembrolizumab or no epacadostat with pembrolizumab There is no condition in the primary trial where participants receive sunitinib  In contrast the secondary trial involves participants receiving sunitinib only and there is no mention of epacadostat in this trial ",
        "label": "Contradiction"
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "text_answer": "  The statement the secondary trial candidates must be Completely disabled to participate whereas this is not required to be accepted into the primary trial is a contradiction   The primary trial inclusion criteria state that subjects must have a response after receiving at least two courses of weekly paclitaxel therapy and be considered to need to continue the therapy by the investigatorsubinvestigator among patients with advanced or recurrent breast cancer There is no mention of disability as a",
        "label": "Contradiction"
    },
    "f77c9775-9421-4d65-8860-c78a684fd886": {
        "text_answer": "  The statement is entailed in the Trials as follows  The primary trial includes the following exclusion criteria related to prior treatment Patients who have received chemotherapy or radiotherapy within two weeks 4 weeks for nitrosoureas mitomycin C pegylateddoxorubicin and one halflife for bevacizumab hormone therapy within one week trastuzumab within two weeks or lap",
        "label": "Entailment"
    },
    "12c5e376-9a01-4581-9d78-db71f92ef23d": {
        "text_answer": "  The statement is neither entailed nor contradictory to the given trial information   Explanation   The statement is about the data types used in programming specifically the double data type and has no relation to the trial information provided The trial information only mentions the interventions placebo and Trabectedin their dosages and the administration schedules The statement does not follow logically from the trial information and therefore",
        "label": "Entailment"
    },
    "11de406a-fdd7-401a-a6b9-0c0b47bdf7f6": {
        "text_answer": "  The statement all the AEs recorded for cohort 1 of the primary clinical trial concern oncological side effects is a contradiction to the given data in Trials 1 and 2   The reason is that the statement implies that only oncological side effects were recorded in Cohort 1 of the primary clinical trial However the data in Trials 1 and 2 show that there were nononcological side effects recorded",
        "label": "Contradiction"
    },
    "0d4acb50-cf28-4eb1-bd3f-1511d068e3a1": {
        "text_answer": "  To determine if the statement is entailed in the trials or if it is a contradiction we need to compare the percentage of participants in each group who demonstrated a decrease in the growth factor signature GFS  According to the results provided the percentage of participants in the ERpositive Luminal B group who demonstrated a decrease in GFS was 286 95 CI 131492",
        "label": "Entailment"
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The statement Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial is contradictory because the given information states that there were no suspected serious adverse reactions in both trials for Adverse Event 1 Therefore it cannot be determined which trial had more suspected serious adverse reactions based on the given",
        "label": "Contradiction"
    },
    "374ebee5-982e-4ff5-bdf9-49414d417303": {
        "text_answer": "  The statement women who have claustrophobia and IBS cannot participate in either the primary clinical trial or the secondary clinical trial is a conjunction of two statements  1 Women who have claustrophobia cannot participate in either the primary clinical trial or the secondary clinical trial 2 Women who have IBS cannot participate in either the primary clinical trial or the secondary clinical trial  Lets verify each statement separately",
        "label": "Entailment"
    },
    "f1b7b902-d67b-489f-9c93-de59c708d2fa": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial measures the number of participants with treatmentemergent adverse events AEs at the end of Cycle 1 while the secondary trial measures the total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment These are two distinct outcomes being measured in separate trials The statement correctly identifies that the",
        "label": "Entailment"
    },
    "002e96b7-152f-4860-b61c-21327c2e6b23": {
        "text_answer": "  The patient described in the statement meets the inclusion criteria for the secondary trial as they have a histologically verified diagnosis of stage III breast cancer an age within the acceptable range a life expectancy of over 6 months and all required laboratory values within normal limits However the statement does not provide enough information to determine if the patient meets the inclusion criteria for the primary trial as it does not specify the type of malignancy or the results of the bone scan dental",
        "label": "Entailment"
    },
    "267240f0-f381-4c67-adf6-3121eea9396d": {
        "text_answer": "  The given statement the LBH589 and lapatinib combination in the primary clinical trial had superior results than the LBH589 with capecitabine cohort is a contradiction to the information provided in the trials   The trials only provide information about the design and dosing of two separate cohorts in the study one with LBH589 and capecitabine and another with LB",
        "label": "Contradiction"
    },
    "4ecece61-2e46-482f-a765-ac677ea3e19c": {
        "text_answer": "  The statement is entailed in the Trials The secondary trial does have the same inclusion and exclusion criteria for all participants However the primary trial does have different inclusion criteria for different study groups Phase I and Phase II Therefore the statement is partially true but incomplete as it does not fully capture the complexity of the primary trials inclusion criteria  However the statement does not contradict the Trials as it correctly states that the secondary trial has the same",
        "label": "Entailment"
    },
    "37df336b-2fc4-4986-957b-5f62219c5bd4": {
        "text_answer": "  The statement all participants in the primary clinical trial are administered a cocktail of drugs as part of the intervention is not entailed in the given interventions   Explanation  The interventions provided describe two different approaches  1 Intervention 1 A webbased risk assessment tool is used to evaluate individual risk and generate a report for providers to make prevention decisions 2 Control Usual care which is not specified",
        "label": "Contradiction"
    },
    "dbffbeee-66da-4e88-8a57-c4d08e214048": {
        "text_answer": "  The statement breast cancer patients characterized by estrogen positive progesterone positive and her2 tumors are eligible for all cohorts of the primary clinical trial is contradictory to the given trial information   The inclusion criteria specify that the breast cancer can be either ER positive HER2 negative Group 1 or invasive triplenegative Group 2 but there is no mention of ER and PR being positive and HER",
        "label": "Contradiction"
    },
    "18395ec3-337c-4e51-aef9-5b91423999ed": {
        "text_answer": "  The statement The results from the primary trial indicate that the Arm A intervention has a better overall response rate than the placebo arm additionally in the secondary trial the Denosumab cohort had a better Time to First OnStudy SRE than the Zoledronic Acid cohort independent to propel wheelchair is a response indicating that an individual is able to propel their wheelchair independent of help from others is not directly entailed in",
        "label": "Contradiction"
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "text_answer": "  The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is entailed in the given trials as the total number of adverse events in both trials is less than half of the total number of patients in each trial   In the primary trial there were a total of 5 adverse events out of 11 patients 4545 and in the secondary trial there were a total of 5",
        "label": "Entailment"
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "text_answer": "  The statement women aged 18 or older are eligible for the secondary trial and the primary trial is entailed in the given trials as the inclusion criteria for both trials state that the patients must be aged 18 or older Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "43ee44cf-35e5-4830-ab1f-d4f040487801": {
        "text_answer": "  The statement an adult patient who was diagnosed with a disease other than ilddpld within the past three years and has a life expectancy of over a year can avail of the primary clinical trial is not directly entailed nor contradicted by the given inclusion and exclusion criteria   The criteria do not mention any specific restrictions related to a previous diagnosis of a disease other than invasive lung disease or colorectal cancer ilddpld",
        "label": "Contradiction"
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "text_answer": "  The statement There were more participants in the primary trial than in the secondary trial is entailed in the given trials as follows  1 The primary trial had 13 participants analyzed 2 The secondary trial had 30 participants analyzed 3 The number of participants in the primary trial 13 is less than the number of participants in the secondary trial 30  Therefore the statement There were more participants in the",
        "label": "Entailment"
    },
    "929ad524-174d-4586-b088-3b512e88bb8f": {
        "text_answer": "  The statement none of the patients in cohort 1 of the primary clinical trial experienced any lifethreatening adverse events is entailed in the trials provided as there were no serious adverse events reported in cohort 1 Dose Level 1 according to the results given The definition of a serious adverse event includes events that are lifethreatening Therefore the absence of any reported lifethreatening adverse events in",
        "label": "Entailment"
    },
    "94b71d5a-37d7-485b-96b7-e0979141893b": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information   Explanation   The statement the first cohort of the primary clinical trial was given the same cetuximab dose as the second but had the added benefit of a collaborative care intervention does not follow directly from the information provided in the trial description While it is true that both cohorts received the same cetuximab dosing regimen the",
        "label": "Entailment"
    },
    "ac0df9a5-d909-40a6-9b57-391fef615fe9": {
        "text_answer": "  The statement both the patients in the primary clinical trial and the secondary clinical trial face the same negative effects is not directly entailed in the given data as there is no common negative effect reported in both trials The primary trial reports incidents of Dehydration Death Not Associated with CTCAE Death NOS Lymphopenia Neutropenia Thrombocytopenia Hyponatremia and Weight loss while",
        "label": "Contradiction"
    },
    "2bd35e15-a310-4660-8963-7f672733bb22": {
        "text_answer": "  The statement The most common adverse event in the secondary trial was Anaemia there were no recorded AEs in the primary trial is contradictory to the given trials data   The statement mentions that Anaemia was the most common adverse event in the secondary trial but the trials data shows that the most common adverse event in the secondary trial was not specified Additionally the statement claims that there were no recorded AEs in the primary trial",
        "label": "Contradiction"
    },
    "3278109c-54b8-4842-8a59-4dae9fac6280": {
        "text_answer": "  The statement is not directly entailed in the given trials as they do not provide sufficient information about the subject status sequence number However based on the information provided the statement is consistent with both trials as they involve the same age group 65 years and older and the same interventions vaccines against Pneumococcus and Influenza Therefore the statement does not contradict the trials",
        "label": "Contradiction"
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "text_answer": "  The statement Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the information provided in the trials   In the primary trial there is no mention of gabapentin or pregabalin in the inclusion or exclusion criteria Therefore prior treatment with these medications would not affect eligibility for the primary trial  However in the secondary trial",
        "label": "Contradiction"
    },
    "04901c04-5a0e-46cb-8684-96ff864921fe": {
        "text_answer": "  The patient in question with a histologically verified diagnosis of stage III breast cancer ANC of 1807000 cellsmm platelet count of 79000000 plateletsmcL hemoglobin level of 009 gml and a life expectancy exceeding 240 days meets the inclusion criteria for both the primary and secondary trials assuming",
        "label": "Entailment"
    },
    "a2ac2860-6f2d-4459-9c8e-748dddcc35e7": {
        "text_answer": "  The statement patients with a history of breast cancer confirmed HER2 considering breastconserving surgery are eligible for the primary clinical trial and the secondary clinical trial is neither entailed in the primary trial nor contradictory to it   The primary trial focuses on women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic",
        "label": "Entailment"
    },
    "8db20184-7510-432f-aa95-c9f2c91326fd": {
        "text_answer": "  The statement is contradicted by the given trials as there are no reports of infection asymmetry or nausea in the secondary trial while the primary trial reported at least one case of each of these adverse events",
        "label": "Contradiction"
    },
    "489c9279-ebca-4ff2-ae61-c8ff4275f3ac": {
        "text_answer": "  The statement All Patients receiving the placebo intervention in the primary trial experienced emesis is entailed in the given trials as follows  1 The trials report that there were 5 participants in the placebo group who experienced emesis during the study period 2 The statement All Patients receiving the placebo intervention in the primary trial experienced emesis means that every single patient in the placebo group had at least one episode of emesis ",
        "label": "Entailment"
    },
    "7d8d8409-5282-464a-a666-849f3eb36b6e": {
        "text_answer": "  The statement is entailed in the Trials as both trials have distinct inclusion and exclusion criteria for different patient groups during their respective phases The primary trial includes patients with chronic pain and differentiates between those on chronic opioid therapy and those not receiving opioids The secondary trial includes patients undergoing unilateral mastectomy Both trials have specific exclusion criteria for various medical conditions and medications Therefore the statement is an accurate reflection of the information provided in",
        "label": "Entailment"
    },
    "5bdb26f3-2166-41b4-bc39-a4d78e81d04f": {
        "text_answer": "  The statement hexadecatetraenoic acid is a polyunsaturated longchain fatty acid with a 16carbon backbone and exactly 4 double bonds is not entailed in the given primary trial information The trial information only pertains to the interventions and treatment schedules for HER2negative breast cancer participants and does not mention hexadecatetraenoic acid or any other specific fatty acids",
        "label": "Contradiction"
    },
    "96aaaf64-1a1e-4a5b-a2db-f99e2c199bec": {
        "text_answer": "  The given patient meets the inclusion criteria for both the primary and secondary trials with the following conditions  Primary Trial  Histologically or cytologically proven diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed within the specified time frame  Age of 18 years or older  Zubrod performance status 02  Patient has received prior oral bisphosphonate therapy  Patient is",
        "label": "Entailment"
    },
    "7313a53a-9a67-4b81-ad79-4df7d1ced976": {
        "text_answer": "  The statement have pain is a question about whether an individual has or had pain is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction based on the given information alone  However regarding the comparison of the number of cases of Bronchopneumonia and General physical health deterioration between the primary and secondary trials the statement there are",
        "label": "Entailment"
    },
    "0de24040-4a99-4f16-8bba-6f2e78018aad": {
        "text_answer": "  The statement is a contradiction to the primary trial as in the primary trial Armodafinil is delivered daily while in the secondary trial it is not mentioned that Armodafinil is delivered daily to any specific cohort However both trials have a uniform dose of 100 mg for PDR001 and 1mgkg for MCS110 given every 3 weeks",
        "label": "Contradiction"
    },
    "88b8e438-87f4-418b-903a-efe0f5a83882": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial intervention is about Radioembolization using Yttrium90 glass microspheres and TheraSpheres while the secondary trial intervention is about a combination of ibrutinib and MEDI4736 with a specific dosage and schedule There is no mention of krd regimen in either trial",
        "label": "Contradiction"
    },
    "c7c9fef0-9243-4cd8-8b8e-e9ab459b7420": {
        "text_answer": "  The statement is contrasting the primary and secondary clinical trials based on the different outcome measurements The primary trial measures the change in urinary isothiocyanate concentration due to sulforaphane supplements while the secondary trial measures the success of physical therapy through the assessment of pain Therefore the statement is entailed in the trials as it accurately describes the different focus of each trial",
        "label": "Entailment"
    },
    "f22453a4-5cb5-4180-8af7-a9f701d766d7": {
        "text_answer": "  The statement cohort 1 of the primary clinical trial has no records of cardiac related adverse events is entailed in the Trials since there are no records of cardiac related adverse events Angina Pectoris Cardiac Arrest Cardiac Failure Cardiac Tamponade Acute Coronary Syndrome and Cardiac Tamponeade in the first trial with a total of 2002 patients",
        "label": "Contradiction"
    },
    "a8bb394a-d996-4174-8800-a38db8905fce": {
        "text_answer": "  The statement is contradictory to the information provided in the given trials   The primary trial focuses on measuring Time to Progression TTP for a total of 156 participants 72 in Arm A and 84 in Arm B while the secondary trial measures the number of participants with objective response based on Data Review Committees assessment for a total of 63 participants in the SunitinibCapecitabine arm ",
        "label": "Entailment"
    },
    "7d78fd1d-3d73-460c-a1b6-c0d9bf3a60a9": {
        "text_answer": "  The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not directly entailed in the given intervention description The intervention description states that patients receive 100 mgm2 of lapatinib orally once daily on days 128 Therefore the statement is not entailed in the trial information but it is a possible dosing regimen that could lead",
        "label": "Contradiction"
    },
    "80e6c613-24ab-4d10-bed6-49388de175d4": {
        "text_answer": "  The statement The intervention in the secondary trial lasts 15 more weeks than the intervention detailed in the primary trial is a contradiction to the given information   The primary trial intervention lasted for 10 weeks while the secondary trial interventions both lasted for 24 weeks A difference of 15 weeks is not present between the two trials Instead there is a difference of 14 weeks 24 weeks  10 weeks",
        "label": "Contradiction"
    },
    "5da1c2df-9374-4de9-b43a-c19a03d5652c": {
        "text_answer": "  The statement patients with a negative diagnosis for any type of solid tumor are able to participate in phase 1 of the primary clinical trial and for all stages of the secondary clinical trial is not directly entailed in the given inclusion criteria for both trials   However the statement is not contradictory to the inclusion criteria as well The primary trial includes patients with histologically or cytologically confirmed metastatic andor advanced solid tumors for phase ",
        "label": "Contradiction"
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "text_answer": "  The statement is entailed in the trials In the primary trial patients receive 2 mgkg of trastuzumab IV once a week In the secondary trial during the ACTH intervention patients receive Herceptin 2 mgkg by IV infusion weekly starting from Day 8 Therefore the dosage of trastuzumab is the same in both trials at these points",
        "label": "Entailment"
    },
    "594df991-cd8d-4ca0-9fe9-5c21a73a0bf3": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary clinical trial focuses on the impact of sulforaphane supplements on urinary isothiocyanate levels while the secondary clinical trial evaluates the effectivity of physical therapy on pain These are two distinct outcomes being measured in separate trials Therefore the statement accurately reflects the content of the trials",
        "label": "Entailment"
    },
    "c870de83-33d4-4ea6-9482-afe2d7a47480": {
        "text_answer": "  The statement participants of the primary trial are not required to receive denosumab and the secondary trial uses 200 to 400 milligrams of amifostine delivered intravenously is not directly entailed or contradicted by the information provided in the trials  Explanation  The primary trial describes the use of denosumab in the intervention but it does not state that participants are required to",
        "label": "Contradiction"
    },
    "3b8d5e1e-4c1e-4e6e-9890-8851c275cc0f": {
        "text_answer": "  The statement a number of psychiatric adverse events were noted in the secondary clinical trial is a contradiction to the information provided in the secondary trial which states that there were no psychiatric adverse events reported Total 024 Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "c4487f90-2a8e-4740-9d56-8fedbd7fb044": {
        "text_answer": "  The statement is not entailed in the trials as provided The primary trial reports the outcome measurement of Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine The statement suggests that the primary trial reports the severity of delayed nausea which is not mentioned in the trials",
        "label": "Contradiction"
    },
    "05056fdd-25bc-40ce-831b-e969e95eaa55": {
        "text_answer": "  The statement almost all participants in the primary clinical trial reported some form of adverse events is not directly entailed or contradicted by the information provided in the trial results The trial results only mention the percentage of participants who completed the treatment regimen without specifying the number or percentage of participants who experienced adverse events Therefore the statement is neither entailed nor contradicted by the information provided",
        "label": "Contradiction"
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "text_answer": "  The statement is entailed in the trials as it explicitly states the difference between intervention 1 and intervention 2 which is the use of pIHGC in intervention 1 and GP in intervention 2",
        "label": "Entailment"
    },
    "857f643d-b77b-4a11-94c7-7e05a7e3b0ef": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial administers Vitamin B12 sublingually not transdermally or intranasally The secondary trial administers memantine orally by mouth not intranasally Therefore neither trial matches the statements claim that the primary trial administers its intervention transdermally and the secondary trial administers it intranasally",
        "label": "Entailment"
    },
    "fae264c6-e28a-42ba-9951-f27cdf917815": {
        "text_answer": "  The statement cancer patients diagnosed with thalasemic syndromes epilepsy or anemia are eligible for the primary clinical trial is contradictory to the information provided in the primary trials exclusion criteria The exclusion criteria for the primary trial state that participants with thalasemic syndromes epilepsy and anemia due to causes other than breast cancer are not eligible for the study Therefore the statement is contrad",
        "label": "Entailment"
    },
    "5da86b4b-b830-48a4-964d-c20207d55b3a": {
        "text_answer": "  The statement patients diagnosed with nut midline carcinoma identified by fluorescence in situ hybridization or inflammatory breast cancer can participate in both the primary clinical trial and the secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for either trial However there is no contradiction to this statement in the provided criteria The primary trial includes nut midline carcinoma as an eligible diagnosis and the secondary trial does not exclude it",
        "label": "Contradiction"
    },
    "ec1b0aa0-0d0b-45b9-9ba5-ad8b941d8647": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets all the inclusion criteria for the primary trial ie histologically verified diagnosis of solid tumor malignancy of breast appropriate diagnostic workup age performance status and signed informed consent The patients laboratory values also meet the inclusion criteria for the primary trial  Regarding the secondary trial the patient meets the inclusion criteria of signed informed consent histologically verified diagnosis of stage IIb",
        "label": "Entailment"
    },
    "1b2512ba-9857-4fde-a25b-b4768b1ad748": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trials In the primary trial gabapentin or pregabalin are listed as exclusion factors In contrast the statement suggests that there are no restrictions on previous treatments with these drugs for the secondary trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "f5fbfac5-bac3-4852-bb93-b262df8d1418": {
        "text_answer": "  The statement is contradictory to the information provided in the primary and secondary trial inclusion criteria   In the primary trial the inclusion criteria do not mention a CT scan or blood tests as prerequisites for participation Instead mammography is required In contrast the secondary trial does mention CT scan and blood tests as part of the inclusion criteria  Therefore the statement that before participating in the primary clinical trial candidates are expected to undergo a",
        "label": "Entailment"
    },
    "91aed56a-2b8e-4f23-9885-4f05e6115537": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to compare the mean arm circumference changes between the acupuncture and waitlist groups at the 6week timepoint  The statement acupuncture patients in the primary clinical trial did not see any significant improvements in their lymphedema as compared to those on the waiting list is a contradiction of the trials results  The trials show that",
        "label": "Entailment"
    },
    "e299d6fb-d590-417b-a9d3-88ee887d9c00": {
        "text_answer": "  The statement several psychiatric issues including an eating disorder and schizophrenia were reported as adverse events in the primary clinical trial is not explicitly stated in the given adverse events data However it is mentioned in the text that precedes the data Therefore the statement is contextually entailed in the given information  However it is important to note that the adverse events data does not provide any information about the number or frequency",
        "label": "Entailment"
    },
    "948018b7-b40c-499c-bba8-e835222c3c00": {
        "text_answer": "  The statement is entailed in the secondary trial exclusion criteria as follows  1 Chemotherapy or radiotherapy within two weeks The secondary trial excludes patients who have received chemotherapy or radiotherapy within two weeks prior to study Day 1 2 Unstable angina The secondary trial excludes patients with a history or current evidence of myocardial infarction during the last 6 months or unstable angina 3 Grade ",
        "label": "Entailment"
    },
    "0e0e3540-9217-435a-89d5-395a9c8af579": {
        "text_answer": "  The statement is contradictory to the information provided in the interventions   In Intervention 1 a webbased risk assessment is being used to assess personalized risk and generate a risk report for providers which implies some form of counseling or education based on the results Additionally decision support for prevention is mentioned which could also involve some form of counseling or intervention  In the statement it is mentioned that neither cohort receives any counsel",
        "label": "Entailment"
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "text_answer": "  The statement The primary trial intervention section does not describe the method of administration dosage or cycle is an entailment for trials where the intervention description indeed lacks such information If the trials primary intervention section does not provide details about the method of administration dosage or cycle then the statement is true However if the trials primary intervention section does include this information the statement is false",
        "label": "Entailment"
    },
    "f8895ab6-dbe2-4715-9567-7dfa9c4d46a8": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment cycle is defined as 21 days but the trials do not enforce a strict adherence to a monthly cycle for the entire duration of treatment The maximum durations of PF05212384 and docetaxel treatment are given but these durations are not necessarily indicative of a monthly treatment schedule for the entire course of treatment ",
        "label": "Entailment"
    },
    "b5349f06-8e89-4ff7-966e-00333de8b463": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the trials if the following conditions are met  1 The primary and secondary trials involve the same type of treatment or intervention 2 The patients in both trials have similar underlying",
        "label": "Entailment"
    },
    "5bf68801-c079-469b-a0a9-2a3d6fb379ed": {
        "text_answer": "  The statement patients with a proven histological or cytological diagnosis of resectable nonsmall cell lung cancer or small cell lung cancer qualify for the primary clinical trial is not explicitly stated in the inclusion criteria However the statement is not contradicted by the exclusion criteria Therefore the statement is neither entailed nor contradicted by the given trial information  Explanation  The inclusion criteria state that patients with nonsmall cell lung cancer",
        "label": "Entailment"
    },
    "ecfd2566-6a41-4b0d-be72-eb143c114835": {
        "text_answer": "  The statement is entailed in the trials as follows  In Intervention 1 the dose of cyclophosphamide is 600 mgm2 and in Intervention 2 the dose of cyclophoshamide is also 600 mgm2 however the quantities of cyclophosphamide given in each treatment cycle are different In Intervention 1 cyclophosphamide is given once per",
        "label": "Entailment"
    },
    "af2a7153-f082-457c-be3e-e6716cdabe0d": {
        "text_answer": "  The statement All patients treated with GTx024 1mg in the primary trial gained Lean body Mass over a 4 month period is not directly entailed in the given trial results The median change in lean body mass for the GTx024 1mg group is 155 kg with a range of 206 to 1264 kg This range includes both positive and negative values indicating that",
        "label": "Contradiction"
    },
    "0790e3ed-6c8e-4b03-8eca-d80fa6296385": {
        "text_answer": "  The statement the interventions in the primary clinical trial implement standard gp for both the first and second protocol is entailed in the given trials as both Intervention 1 and Intervention 2 involve the injection of radioactive Tc99M sulfur colloid around the tumor site for lymphoscintigraphy However it is important to note that the use of a handheld gamma camera pIHGC in Intervention",
        "label": "Entailment"
    },
    "dce179aa-b35d-42dd-b97b-4c76f2e4d8b7": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement suggests that all adverse events in the primary trial were linked to the patients musculoskeletal system but the secondary trial documents adverse events that were not related to the musculoskeletal system such as decreased platelet count hypocalcemia and hypokalemia Therefore the statement is contradicted by the",
        "label": "Contradiction"
    },
    "0bd4a2c1-4e4a-4752-a9e8-46a9a27885c1": {
        "text_answer": "  The statement atypical lymphocytes were not detected in any bone marrow sample in Cohort 1 of the primary trial is the negation of the statement provided Since the primary trial reported no adverse events related to atypical lymphocytes in bone marrow in Cohort 1 the statement provided is entailed by the information in the trials Therefore the statement is entailed by the trials",
        "label": "Contradiction"
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "text_answer": "  The statement The primary trial intervention section does not outline a treatment cycle or a description of irradiation doses is an entailment given the information provided in the intervention description Treated Subjects enrolled with device placed and treated with partial breast irradiation  Explanation  The statement is an entailment because the intervention description does not provide any information about the treatment cycle or the specific doses of radiation used in the partial breast ir",
        "label": "Entailment"
    },
    "98e146d6-bc16-460b-92eb-826ddeb79a3d": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years over 50 patients from each cohort survived more than 24 months is not directly entailed in the given trial results   The trial results only provide the median survival times for each group and the statement makes a claim about the average survival time and the number of patients surviving beyond 24 months While it is true that the median survival times are both over 2",
        "label": "Contradiction"
    },
    "328b27ff-4e87-40df-824f-73fb1f01b8a7": {
        "text_answer": "  The statement all cohorts across the primary clinical trial will use the educational dvd as a key component of their intervention is entailed in the given trial description if we assume that the trial consists only of the two cohorts described intervention and control This is because the intervention arm explicitly states that patients will watch the educational DVD while the control arm does not mention the use of the DVD Therefore the intervention arms use of the DVD implies that it",
        "label": "Entailment"
    },
    "1f630d95-82b5-44fa-8f52-b19f1c9b75bb": {
        "text_answer": "  The statement the primary trial recorded lower incident rates of infection asymmetry and deflation than the secondary trial is entailed in the given trials if and only if the following conditions are met  1 The primary trial had fewer cases of infection asymmetry and deflation than the secondary trial in total 2 The secondary trial had no cases of infection asymmetry and deflation  Given the trials provided the statement is entailed",
        "label": "Entailment"
    },
    "f102f343-80bc-4df9-87db-125fc783937c": {
        "text_answer": "  The statement egfr nm 0052283c2320 2321ins12 is an insertion of 12 nucleotides gcaacccccacg between position 2320 and 2321 of the coding sequence of the egfr gene is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it neither entails",
        "label": "Entailment"
    },
    "35fb0b2d-39d8-43f9-9e47-aceee416803b": {
        "text_answer": "  The statement less than 50 of patients in cohort 1 of the primary clinical trial experienced acute vomiting posttreatment with aprepitant dexamethasone cytoxan and kytril is entailed in the trial results if the number of participants with acute vomiting is less than 18 which is 50 of 35 However the trial results do not",
        "label": "Entailment"
    },
    "5da3a98b-ffa7-4c54-a340-37986d6dcc20": {
        "text_answer": "  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy is not directly entailed in the given trials as there is no information provided about the exact number of cases for hypertension and Pancreatectomy that would allow for a direct comparison to the number of Hepatotoxicity cases 38  0375",
        "label": "Contradiction"
    },
    "202f56bf-1317-4abc-803d-5ec37cd27624": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The primary trial and the secondary trial are reporting findings from distinct patient cohorts The primary trial involves participants receiving denosumab while the secondary trial involves participants receiving dmethadone Therefore the statement that both trials present findings from a single patient cohort is not entailed in the given trials",
        "label": "Contradiction"
    },
    "2ab5044b-9fa6-45ef-8c99-a2cd5e28f512": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement suggests that both interventions are administered in the same dose but the trials clearly state that the AlloMSCs intervention involves 100 million cells in a total volume of 8ml 20 injections of 04ml each while the placebo intervention involves only Buminate solution in a total volume of 8ml 20 injections of",
        "label": "Entailment"
    },
    "8f018706-e70d-4fa5-812c-9c8d57b97f46": {
        "text_answer": "  The statement smoking behavior is any of the activities associated with tobacco smoking is not directly related to the inclusion or exclusion criteria of the primary or secondary trials provided However the primary trial does include unable or unwilling to discontinue anxiolytics within 4 hours of education sessions as an exclusion criterion and it is possible that some anxiolytics may be used to treat symptoms related to smoking cessation Therefore it is",
        "label": "Entailment"
    },
    "d8da21ea-52ef-4b97-8344-6214bd3565b3": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of docetaxel or methotrexate in either the primary or secondary trials The primary trial involves Fluciclatide injections and the secondary trial involves Chloroquine doses",
        "label": "Contradiction"
    },
    "073ce8e6-59a6-41e8-a45f-ca91d19dceec": {
        "text_answer": "  The statement patients presently participating in the secondary clinical trial are also permitted to enter the primary clinical trial since the criteria for inclusion are identical is entailed in the given trials as there are no contradictory inclusion or exclusion criteria mentioned for both trials The identical inclusion criteria for the female gender history of breast cancer menopausal status and hot flush symptoms make it possible for patients to meet the requirements for both trials However it is essential to note",
        "label": "Entailment"
    },
    "58ce2166-b909-4442-9118-11b9163fa9b1": {
        "text_answer": "  The statement is not entailed in the trials as the results from the primary trial only report a change in Ki67 expression not a reduction in tumor diameter The statement is not contradictory to the trials as it does not directly conflict with the information provided",
        "label": "Contradiction"
    },
    "61db27bd-2dc4-4c90-8d1e-058f61e1b59a": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement compares the dosages of Denosumab and Tamoxifen between the two trials but the trials provided do not involve the same drugs or interventions The primary trial involves Denosumab and Zoledronic Acid while the secondary trial involves Tamoxifen and Evening Primrose Oil Therefore a direct comparison of their dosages",
        "label": "Entailment"
    },
    "e0a61eb2-f5c0-4885-94f5-4048944acd1c": {
        "text_answer": "  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is a contradiction to the information provided in the trials   The primary trial does not indicate that the control group Standard Mammography is a comparison group for the test group Intraoperative Mammography in terms of operative time savings The trials only provide operative time",
        "label": "Contradiction"
    },
    "e93765e3-d596-4009-8fc0-6d8433f19679": {
        "text_answer": "  The statement all patients treated with gtx024 1mg in the primary clinical trial lost lean body mass over a 4 month period is not directly entailed in the given trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 While the median value is positive it does",
        "label": "Contradiction"
    },
    "491a1da4-e9c1-43d9-ba9b-9e53d7f601f9": {
        "text_answer": "  The statement is entailed in the trials In the primary trial epacadostat is administered orally twice daily BID while in the secondary trial sunitinib is administered once daily Therefore the frequency of epacadostat administration is indeed double that of sunitinib administration in the secondary trial for sunitinibnaive patients",
        "label": "Entailment"
    },
    "2312391b-799c-4dcc-9ba4-4b98c9c9642b": {
        "text_answer": "  The statement trastuzumab is explicitly excluded as an intervention in the primary clinical trial is entailed in the given trial information since trastuzumab is mentioned as an intervention in Arm 1 but explicitly excluded as an intervention in Arm 2 and it is not mentioned as an intervention in Arm 2 at all Therefore the statement is entailed by the trial information",
        "label": "Entailment"
    },
    "650a33d5-ad44-40c8-a41c-1a4e7a5203b5": {
        "text_answer": "  The statement is contradictory to the trials provided   The primary clinical trial focuses on the impact of sulforaphane supplements on the concentration of isothiocyanates in urine while the secondary clinical trial does not mention muscle development or physical therapy as an outcome measurement Therefore the statement that the secondary clinical trial gauges effectiveness using muscle development as a result of physical therapy is not entailed in the trials",
        "label": "Contradiction"
    },
    "63acd7b4-dc08-415b-af25-c09e1db4e913": {
        "text_answer": "  The statement is contradictory to the trials provided The primary trial uses an oral administration of cabergoline while neither trial in the secondary experiment involves topical administration Instead they both use intravenous administration of pixantrone dimaleate",
        "label": "Entailment"
    },
    "904b8443-c768-449d-81d7-e381dc0e0fb7": {
        "text_answer": "  The statement is entailed in the trials as given Both the placebo and trabectedin are administered intravenously over a 3hour infusion period but on different days Day 1 for placebo and Day 2 for trabectedin Therefore the statement that both the placebo and trabectedin in the primary clinical trial are given in similar ways yet on different days is an accurate description of the trials and is ent",
        "label": "Entailment"
    },
    "f06f2517-d0fb-4494-a044-fd626c78187f": {
        "text_answer": "  The statement is contradictory to the given information   Explanation   The statement the total adverse events recorded in patients were the same for both the primary clinical trial and the secondary clinical trial is contradictory to the given data because  1 In the primary trial there were no adverse events recorded for Adverse Events 1 and Adverse Events 2 2 In the secondary trial there were 0",
        "label": "Contradiction"
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "text_answer": "  The statement Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial who were receiving far lower doses of Empegfilgrastim is not directly entailed in the provided trial data   The primary trial and the secondary trial have different outcome measurements and different patient populations The primary trial measures the duration of neutropenia CTCAE grade",
        "label": "Contradiction"
    },
    "d9a5cbf6-51ae-4c80-a222-534e7507c7f8": {
        "text_answer": "  The statement in the primary clinical trial the number of cases of hepatotoxicity was less than the cases of hypertension and pancreatectomy is contradicted by the given data   The data shows that there were 3 cases of hepatotoxicity which is more than the 1 case each of hypertension and pancreatectomy Therefore the statement is contradicted by the given data",
        "label": "Contradiction"
    },
    "e60df76f-e6d9-4da1-8fe7-e23c8f38365f": {
        "text_answer": "  The statement prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the information provided in the trials  In the primary trial there is no mention of gabapentin or herceptin as exclusion criteria However in the secondary trial there is an exclusion criterion for prior use of herceptin within the last ",
        "label": "Contradiction"
    },
    "38ca4d41-1f13-4735-983d-9ac5b1b816f0": {
        "text_answer": "  The statement in the context of the primary and secondary clinical trials the maximum tolerated dose of mm111 for patients involved in the secondary clinical trial is reallocated at 15 mg on a daily basis is not directly entailed in the given trial information   The primary trial focuses on determining the maximum tolerated dose of ruxolitinib in combination with paclitaxel while the secondary trial mentions the maximum toler",
        "label": "Contradiction"
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "text_answer": "  The statement there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial is entailed in the Trials since both trials report adverse events related to cardiac conditions specifically  1 Cohort 1 of the primary trial      Cardiac Arrest 1 instance     Angina Pectoris 1 instance     Acute Coronary Syndrome ",
        "label": "Entailment"
    },
    "99925da5-1a89-471d-b3d9-a3e083fc1bda": {
        "text_answer": "  The statement the number of aes was higher for one of the cohorts in the primary clinical trial is entailed in the Trials as follows  The statement implies that there is a difference in the number of adverse events between the two cohorts Based on the provided data we can see that there is a difference in the total number of adverse events between the two cohorts 24 vs 25 Therefore the",
        "label": "Entailment"
    },
    "10b61f57-c5c1-4d29-9838-bb14c4608bf4": {
        "text_answer": "  The statement is contradictory to the information provided in the interventions of the primary clinical trial   Explanation  The statement in the interventions of the primary clinical trial both cohorts are without any counselling risk assessment or cognitive behavioural therapy cbt is contradictory to the information provided in the interventions   Intervention 1 states that a validated webbased risk assessment is being used",
        "label": "Entailment"
    },
    "99d85210-19a0-4256-b092-c3a0f6ef322f": {
        "text_answer": "  The statement neutropenia occurred less frequently in patients belonging to cohort 2 of the primary clinical trial than in cohort 1 of the secondary clinical trial even though the latter were receiving considerably smaller doses of empegfilgrastim is not directly entailed in the provided trial data   The primary trial reports the mean duration of neutropenia CTCAE grade 34 for two doses of empeg",
        "label": "Contradiction"
    },
    "0f5ce689-610f-4522-8082-23df226f2a42": {
        "text_answer": "  The statement is entailed in the trials as both interventions include the use of trastuzumab Herceptin Therefore the statement is true given the information provided in the trials",
        "label": "Entailment"
    },
    "d5e071e0-4705-474c-8820-9fbc7b377a8d": {
        "text_answer": "  The statement only males belonging to a particular ethnic group are eligible to participate in the secondary clinical trial is not entailed in the given inclusion and exclusion criteria for the secondary trial The criteria only specify age histological or cytological diagnosis performance status life expectancy measurability of disease hematological hepatic and renal function availability of tumor material and other protocoldefined inclusion criteria There is no mention of any",
        "label": "Contradiction"
    },
    "4192b30d-92ad-47c4-b88e-8f48ea048ee2": {
        "text_answer": "  The statement is contradictory to the information provided in the inclusion and exclusion criteria The criteria do involve the discretion of health professionals in determining a patients final eligibility for the clinical trial even if they meet the stated inclusion and exclusion criteria Therefore the statement is contradictory to the information provided",
        "label": "Entailment"
    },
    "8268f272-c82c-4cc3-87dd-8fdf59611a1c": {
        "text_answer": "  The statement at least one patient in the primary trial suffered several different adverse events is entailed in the given trial data as there are a total of 6 different adverse events reported in 5 out of 25 patients which is more than one patient experiencing multiple events  The statement about thyroid gland follicular carcinoma is not directly related to the trial data and does not entail or contradict any information provided in the trial results",
        "label": "Entailment"
    },
    "94849f18-76aa-4fdf-9f7b-2fb1c6b5bc9d": {
        "text_answer": "  The primary and secondary trials both involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine DMCHOCPEN as the investigational drug However the primary trial focuses on a combination therapy with Abl Cells and Cyclophosphamide while the secondary trial investigates the use of DMCHOCPEN as a monotherapy Therefore the statement is contradict",
        "label": "Entailment"
    },
    "1de04bd7-e1e7-42a6-a898-ae626a24b25b": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX at Week 4 between the two groups   The percentage change in betaCTX for the AZD0530 175 mg group is 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg group is 6",
        "label": "Entailment"
    },
    "40123001-b9eb-4d75-aa74-83865de37e70": {
        "text_answer": "  The statement There were more cases of Mucositis Oral Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial is a comparison of the number of adverse events between the two trials However the given trials only provide the number of occurrences for each type of adverse event in each trial but they do not directly compare the number of occurrences between the two trials for each type of",
        "label": "Entailment"
    },
    "6a119107-7a0d-421f-bfea-3671d97ed082": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials do not provide sufficient information about the distribution of 3q21q24 chromosome abnormalities in the two cohorts The trials only report the percentage of participants with disease progression or death in each cohort Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "f32516f0-768d-48db-a449-74ac774abbe0": {
        "text_answer": "  The statement patients receiving the placebo intervention in the primary clinical trial had the same likelihood of experiencing emesis as patients receiving aprepitant is a contradiction to the trial results   The trial reports that there were 13 participants in the aprepitant group who were emesis free compared to 5 participants in the placebo group This means that a larger proportion of participants in the aprepitant group were emesis free during the",
        "label": "Contradiction"
    },
    "f178fb19-cc4a-4f58-b81a-aac7270f154b": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial focuses on massage therapy as the intervention which is a nonpharmacological treatment In contrast the secondary trial investigates the efficacy of two different doses of the drug PF06647020 Therefore the statement that the primary trial centers around a singular drugbased treatment and the secondary trial involves testing several drug",
        "label": "Entailment"
    },
    "a7999375-da80-4839-940a-bec673fb119f": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  The primary trial includes females aged 18 and above with any type of cancer regardless of race or ethnicity as long as they meet the other inclusion and exclusion criteria  The secondary trial on the other hand specifically includes females with BRCApositive breast cancer ovarian cancer primary peritoneal cancer or fallopian tube cancer as well as",
        "label": "Entailment"
    },
    "a108f3f0-f18c-4bb3-87f1-5a1eee525f71": {
        "text_answer": "  The statement adverse events spanning a variety of types were evenly distributed among patients across multiple cohorts in the primary clinical trial is neither entailed nor contradicted by the given trials data   The data provided only shows the number and percentage of adverse events for each type and each cohort It does not directly indicate that the distribution of adverse events was even across all cohorts and types Therefore the statement cannot be ent",
        "label": "Entailment"
    },
    "fd78876b-0b85-41e3-ad9f-8213dd9484ca": {
        "text_answer": "  The statement treatmentemergent adverse events were experienced by 35 patients who received sunitinib docetaxel and trastuzumab during the primary clinical trial is a contradiction to the given trial results   The trial results state that there were a total of 25 participants analyzed in the study and there were 24 treatmentemergent adverse events and 11 serious adverse events",
        "label": "Contradiction"
    },
    "f73ec9f6-b18c-4f32-9116-573f5f717e55": {
        "text_answer": "  The statement a patient with a primary tumour smaller than 20mm confirmed by ct scans would be eliminated from both the primary trial and the secondary trial is a contradiction to the inclusion criteria of both trials  In the primary trial the inclusion criteria state that the primary tumour must be greater than 2 cm in diameter measured by clinical examination and mammography or echography There is no mention of a size limitation for the primary tum",
        "label": "Contradiction"
    },
    "452f92e1-27bb-4452-8675-c6409ec6003a": {
        "text_answer": "  The statement women who are 18 or 19 years old can participate in the secondary clinical trial however they must wait 12 years to qualify for the primary clinical trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial explicitly states that the minimum age for participation is 20 years old and there is no mention of a waiting period for younger women The",
        "label": "Contradiction"
    },
    "e0a117a2-c519-46f5-9c31-124234272ce1": {
        "text_answer": "  The statement in the primary clinical trial all adverse event types impacted less than 10 of the patients is not directly entailed in the given data However it is consistent with the data since none of the adverse event types affected more than 10 of the patients Therefore the statement is not contradictory to the data However it should be noted that the statement is an approximation based on the given data as it only includes",
        "label": "Contradiction"
    },
    "9bd6ad87-470a-4fa3-9e29-bf5ba8c2b463": {
        "text_answer": "  Lets calculate the number of cases for hepatotoxicity hypertension and pancreatectomy based on the given information in the primary trial   Hepatotoxicity 38  0375  04 cases  Hypertension 18  0125  013 cases  Pancreatectomy 1",
        "label": "Entailment"
    },
    "2529171f-85e8-4d19-8023-dc1a28416fa1": {
        "text_answer": "  The statement there are 5 shared inclusionexclusion criteria between the secondary trial and the primary trial is an entailed statement based on the given information   The following are the shared inclusion criteria 1 Age  18 years 2 Life expectancy of at least three months 3 ECOG performance level 02 or Karnofsky score 10070 4 Hematological",
        "label": "Entailment"
    },
    "254e8b1c-de9f-467b-b32a-a41ee97421b9": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 2 decades if they want to participate in the primary trial is a modification of the exclusion criteria provided in the trial description  The original exclusion criteria state that there is",
        "label": "Entailment"
    },
    "5db52328-ebdc-4961-bc21-7776db7d7876": {
        "text_answer": "  To compare the concentrations of Zoledronic Acid and Denosumab in the given trials we need to know the dosages and administration frequencies in both trials   From the primary trial the Zoledronic Acid group received 4 mg every 4 weeks Q4W and the Denosumab group received 120 mg every 4 weeks Q4W  From the secondary trial the Tamoxif",
        "label": "Entailment"
    },
    "5f6cacb7-41e6-4d8c-9a43-7bd21202b11f": {
        "text_answer": "  The statement intraoperative urinary injury CTCAE is a finding of damage to the urinary system during a surgical procedure is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials However there is no contradiction to this statement in the provided criteria as well The criteria focus mainly on the eligibility and exclusion factors for breast cancer patients based on their medical history laboratory values and tumor characteristics",
        "label": "Contradiction"
    },
    "6b0bc5aa-4540-4439-a2e3-c48abb937074": {
        "text_answer": "  The statement all measured patients within the primary clinical trials group 1 were identified as having several lesions is not entailed in the provided information from the primary trial The trial only reports the number of lesions detected in the healthy volunteers group which is zero  The statement an overwhelming majority from the secondary trials group 1 showing healthy skin attributes is not directly contradictory to the information provided in the primary trial but it is not",
        "label": "Contradiction"
    },
    "d61c1b26-cf05-46e8-a156-a264f562dfa8": {
        "text_answer": "  The statement is partially entailed in the Trials   The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks cannot take part in the secondary trial is entailed in the exclusion criteria of the secondary trial   However the statement but can still take part in the primary trial is not explicitly stated in the inclusion or exclusion criteria of either trial Therefore the statement as a whole is only partially ent",
        "label": "Entailment"
    },
    "a127c618-ace8-46cf-9b52-7655f2ccee9c": {
        "text_answer": "  The statement for the primary clinical trial children and adolescents are not accepted due to not meeting the height requirement however the secondary clinical trial does not overtly rule them out is a contradiction to the information provided in the secondary trials inclusion criteria   The primary trials inclusion criteria do not mention any height requirement but rather specify postmenopausal status The secondary trials inclusion criteria state that Women of child",
        "label": "Contradiction"
    },
    "01bff32b-6bba-4295-94e9-c3a8430670be": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site for lymphoscintigraphy The difference lies in the use of a handheld gamma camera pIHGC in the first intervention and the use of standard gamma probes GP in the second intervention during the surgical procedure The statement correctly identifies that pIHGC",
        "label": "Entailment"
    },
    "24be42f5-01dc-487e-9ada-39d05b6d4e7e": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial it is stated that Each treatment cycle was defined as 21 days This means that the interventions in the primary trial are given in a cyclic manner with a 21day interval between each cycle  In contrast in the secondary trial it is stated that There is not an added device associated with this arm This does not mention anything about a cyclic",
        "label": "Entailment"
    },
    "d91ee458-d6de-4d45-8511-cabb52d2a64e": {
        "text_answer": "  The statement is entailed in the trials as both trials have identical inclusion criteria for receptor status ERpositive and exclusion criteria for gender irrelevant Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "37a51d40-4b39-4488-b818-7495917d50a0": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the information provided in the statement with the trials results   The statement says two participants from the second cohort of the primary clinical trial had an incidence of doselimiting toxicity  From the trials results we can see that both the first and second cohorts had the same treatment regimen Ixabepilone IV and pegylated",
        "label": "Entailment"
    },
    "ffce31e9-2899-42af-8af0-e24be1ace812": {
        "text_answer": "  The statement women suffering from only osteoporosis are eligible for both the primary and secondary clinical trials is contradictory to the given trials exclusion criteria   In the primary trial women with osteoporosis are excluded In the secondary trial there is no mention of osteoporosis as an exclusion criterion However the statement assumes that women with osteoporosis are eligible for both trials which",
        "label": "Contradiction"
    },
    "ffd7717b-fec1-4702-87a6-5345e8efe7ba": {
        "text_answer": "  The statement while a diagnosis of 23 cerebral metastases would exclude a patient from the secondary clinical trial participation in the primary clinical trial could still be possible is not explicitly stated in either the primary or secondary trial information provided However based on the information given it can be inferred that the primary clinical trial has different eligibility criteria for cerebral metastases compared to the secondary clinical trial Therefore it is possible that a patient",
        "label": "Entailment"
    },
    "a50ad70a-ff4c-4110-bfff-3fc230c44acc": {
        "text_answer": "  The statement primary clinical trial is open to patients diagnosed with ilddpld over a decade ago bearing a life expectancy of 2 years is not explicitly stated in the inclusion or exclusion criteria provided in the trial description Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the given information alone However the inclusion criteria do state that patients must have a life expectancy of greater than 3 months This suggests that",
        "label": "Entailment"
    },
    "4b6aac05-1130-49c4-b5f6-9afe1227459c": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial consider gender as a criteria for eligibility is entailed in the given information Both trials have identical inclusion criteria regarding gender stating that female subjects must be postmenopausal or meet certain conditions to be considered eligible This criterion is not exclusive to one trial and is not related to the eligibility based on the disease or treatment Therefore gender is not a criterion for el",
        "label": "Entailment"
    },
    "b9d16baf-ec50-40da-b2a4-68aa7abf1541": {
        "text_answer": "  The statement multiple deaths and hospitalizations were reported in cohort 2 of the primary clinical trial along with various cases of atrial fibrillation is not directly entailed in the given trials as there is no mention of multiple deaths or hospitalizations in cohort 2 in the provided data However the statement is not contradictory to the data as well since the trials do not explicitly state that there were no deaths or hospitalizations in coh",
        "label": "Contradiction"
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the ORR and the number of participants between the two groups directly   The statement is The Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it  From the given trials we have  1",
        "label": "Entailment"
    },
    "6e5ea627-075c-4b44-9605-4d440735d843": {
        "text_answer": "  The statement an individual who has undergone a cycle of progestogen therapy six months before the primary clinical trial maintains fitness to participate in the study is not explicitly stated in the inclusion or exclusion criteria of the provided clinical trial Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information given However the exclusion criteria do state that progestogens are allowed if the patient has been on a constant",
        "label": "Entailment"
    },
    "5c11d673-054f-4db7-a2d4-8c6243b3ba45": {
        "text_answer": "  The statement is a contradiction to the information provided in the inclusion criteria of both trials   In the primary trial the inclusion criteria state that Subjects must be Japanese female However in the secondary trial there is no such requirement for the nationality of the subjects   Regarding the second part of the statement the type of regimen used to treat malignant peritoneal neoplasm is not specified in the provided information for either",
        "label": "Contradiction"
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "text_answer": "  The statement is entailed in the given trials as the primary trial involves the use of a single drug gefitinib while the secondary trial involves the use of at least three different drugs zoledronic acid vitamin D and calcium supplements and either Sr89 or Sm153 radiopharmaceuticals",
        "label": "Entailment"
    },
    "42fc9190-b214-42bf-92fc-3678564083ca": {
        "text_answer": "  The statement patients suffering from ascites were less common in the primary clinical trial while pneumocystis jirovecii pneumonia was less frequent in the secondary clinical trial is an entailed statement based on the given trials   Explanation   The statement makes two comparisons between the two trials  1 The number of patients with ascites is less in the primary trial compared to the secondary trial 2",
        "label": "Entailment"
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "text_answer": "  The statement There were more adverse events observed in the secondary trial than in the primary trial is a contradiction to the given data   Explanation   The given data states that there were no adverse events observed in both trials for Adverse Event 1 and the number of adverse events for Adverse Event 2 in the secondary trial is not provided However the statement asserts that there were more adverse events observed in the",
        "label": "Contradiction"
    },
    "6515b0ad-cba7-4831-9b96-576faaa284f4": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the dosages of Denosumab and Tamoxifen mentioned in each trial  In the primary trial the Denosumab dosage in Intervention 1 is 120 mg Q4W which is equivalent to 480 mg per month  In the secondary trial the Tamoxifen dosage in Intervention 1 is 10",
        "label": "Entailment"
    },
    "f886baee-f1c6-4887-8068-5c779c6ebb60": {
        "text_answer": "  The statement is a contradiction with respect to the given trials In the primary trial patients in group 2 receive dexmedetomidine while in the secondary trial no dexmedetomidine is given to any patients",
        "label": "Contradiction"
    },
    "c51a2098-014f-410c-9722-eaadb298983d": {
        "text_answer": "  The statement There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial is entailed by the given trials as both trials report a total of zero occurrences for both Adverse Events 1 Intestinal obstruction and Adverse Events 2 Pancytopenia  However the statement past seven days frequency of pain in the abdom",
        "label": "Contradiction"
    },
    "0bca53f6-c609-4c49-a684-a2d71cff7086": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   In the trial description the placebo intervention is stated to be delivered by mouth PO twice daily and memantine is also delivered by mouth PO twice daily There is no mention of intramuscular injections or topical administration for either intervention Therefore the statement in the question is incorrect",
        "label": "Contradiction"
    },
    "197bf729-04f4-46f0-a746-8b55c088f0d6": {
        "text_answer": "  The statement is entailed in the trial results as stated The trial results indicate a mean percentage change in Ki67 expression of 40 63 to 29 for the Tamoxifen Pre and Post Breast Surgery armgroup The statement in the question accurately reflects this finding by stating that tamoxifen reduces ki67 expression in tumors by 40 on average",
        "label": "Entailment"
    },
    "a7f12911-d5b9-4cd0-a3c0-e1fb6ded7512": {
        "text_answer": "  The statement in the primary clinical trial more incidents of palpitations pericardial effusions and abdominal pains were observed in the second cohort compared to the first cohort of the secondary clinical trial is a contradiction based on the given data  Explanation  The primary trial had a total of 106 participants and reported 1 incident each of palpitations pericardial effusion and",
        "label": "Contradiction"
    },
    "249d272c-cbee-4395-bb73-7e6cde3a4677": {
        "text_answer": "  The statement is entailed in the Primary Trial as the inclusion criteria state that patients with a histologically proven diagnosis of breast cancer appropriate diagnostic workup and a life expectancy of at least 8 months are eligible for the study The patients age 32 years histologically proven diagnosis ANC level 1807L platelet count 110034L hemoglobin level ",
        "label": "Entailment"
    },
    "f43b3f3f-f51c-49ff-b659-b3e97bf0ab0d": {
        "text_answer": "  The statement patients diagnosed with hypopharyngeal squamous cell carcinoma via polymerase chain reaction or those who have developed venous thromboembolism postlumpectomy are not permitted to participate in either the primary trial or the secondary trial is not explicitly stated in the inclusion or exclusion criteria for either trial However it can be inferred that patients with a history of prior or concurrent malignancies including head",
        "label": "Entailment"
    },
    "cd247253-c2d6-4eb6-be06-90ef855748cf": {
        "text_answer": "  The statement is contradictory to the information provided in the given trials as there is no mention of an updated electrocardiogram ECG requirement for the secondary trial and there is no mention of a recent colonoscopy report or a complete blood count CBC requirement for the primary trial The trials only specify the inclusion and exclusion criteria for each study separately",
        "label": "Contradiction"
    },
    "ae259f29-2da6-43fe-b89e-345be44688e8": {
        "text_answer": "  The statement is entailed in the trials as follows  1 In both interventions the cetuximab dosage is given intravenously IV and the maintenance dose is given weekly QW 2 In intervention 1 cohort 1 the loading dose is 400 mgm2 and the maintenance dose is 200 mgm2 3 In intervention 2 cohort ",
        "label": "Entailment"
    },
    "d1216971-8b18-427a-9f6e-de0fcddec7ea": {
        "text_answer": "  The statement is contradictory to the information provided in the inclusion criteria of both trials   In the primary trial the inclusion criteria do not specify any gender restrictions stating Japanese female only for the initial mention of patient population In contrast the secondary trial includes both male and female patients in its inclusion criteria  Therefore the statement that only males of an unspecified nationality are eligible to enroll in the primary clinical trial",
        "label": "Entailment"
    },
    "c99a0652-8f34-49d1-b98b-182553c58dbc": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the dosage of alpha lipoic acid is consistent throughout the trial with a maximum dosage of 100 mg three times daily 300 mgday This is below the stated maximum of 50 mg twice daily  In the secondary trial the dosage of necitumumab varies between the runin phase Day 3 ",
        "label": "Entailment"
    },
    "2d320e21-8fce-4f6f-8bf3-dc68f1cb8b0e": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The statement URETER DISORDER IS A NONNEOPLASTIC OR NEOPLASTIC DISORDER AFFECTING THE URETER is not directly related to the interventions described in the trials It is a general statement about ureter disorders 2 The statement cohort 1 of the primary trial is administered PR negative ER negative and HER",
        "label": "Entailment"
    },
    "d4045883-595f-4855-83ed-ca175a1d5aea": {
        "text_answer": "  The statement compared to the primary clinical trial the secondary clinical trial experienced an excess of 11 occurrences of intestinal perforation is entailed in the given data  Explanation  The statement implies that there were more occurrences of intestinal perforation in the secondary trial compared to the primary trial The data provided shows that there were 1 occurrence of intestinal perforation in the primary trial",
        "label": "Entailment"
    },
    "29a26ffe-8fcd-4e93-b354-3ca65738c8e5": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial reported zero deaths among their adverse events is entailed in the given data since both trials reported no deaths 000 among their adverse events",
        "label": "Entailment"
    },
    "8a532b5a-1468-4de5-83ac-50179edb2ac8": {
        "text_answer": "  The statement none of the patients in the primary clinical trial experienced any adverse events is contradictory to the given trial data The trial data reports that 5 out of 25 patients 2000 experienced adverse events Therefore the statement is contradictory to the trial data",
        "label": "Entailment"
    },
    "a4e6bb5b-69f1-451b-b278-0ce9c3e43bdf": {
        "text_answer": "  The statement in the primary clinical trial a total of 35 patients who were administered sunitinib docetaxel and trastuzumab suffered treatmentemergent adverse events is a contradiction to the information provided in the trial results   The trial results state that there were 25 participants analyzed in the study and there were a total of 24 treatmentemergent adverse events and 1",
        "label": "Contradiction"
    },
    "a3191a50-4395-4bd8-a57a-5404fcfcd8c9": {
        "text_answer": "  The statement individuals of all genders with proven ER negative breast cancer can participate in both stages of the primary clinical trial is entailed in the given trial criteria if we consider that  1 ER negative breast cancer is a type of breast cancer 2 The trial includes Other solid tumor type that has been approved by the sponsor  Therefore ER negative breast cancer falls under the category of solid tumors and meets the inclusion criteria",
        "label": "Entailment"
    },
    "5de4ae02-a1df-430d-a793-803bfefb7b0e": {
        "text_answer": "  The primary clinical trial focuses on the percentage of participants experiencing any treatment emergent adverse events and serious treatment emergent adverse events The secondary clinical trial focuses on the number of participants with objective response These outcome measurements are not the same so the statement is contradictory",
        "label": "Entailment"
    },
    "da18ab3b-cf80-4867-b3b9-0dccf4c523a2": {
        "text_answer": "  The statement on average patients from the primary trial survive over 104 weeks however at least one patient from both cohorts died in under 104 weeks is not directly entailed in the given trial results   The trial results only provide the median survival times for each group and the statement makes a claim about the average survival time for all patients in the trial Additionally the statement mentions that at least one patient from each group died in",
        "label": "Contradiction"
    },
    "ae8cf6fd-ab5f-4f34-a135-ea8d0c0c58bc": {
        "text_answer": "  The statement several of the primary trial candidates are administered 1 mg of talazoparib daily as part of the intervention is not directly entailed in the given trial description The trial description mentions that patients are eligible for the trial if they are older than 70 years and have been diagnosed with certain types of cancer and that they are assessable for the primary outcome measure It also states that patients may be included before any firstline",
        "label": "Contradiction"
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "text_answer": "  The statement is entailed in the Trials as the primary trial includes the following criterion for tumour size Primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography The patient with a primary tumour of 33mm measured by echography falls under this criterion and is therefore eligible for the primary trial  Additionally the secondary trial includes the following criterion for tumour diagnosis",
        "label": "Entailment"
    },
    "0069c252-1e8b-4209-af61-11e6ee9d3c2b": {
        "text_answer": "  The statement is contradictory to the results of the primary clinical trial provided The trial reported a significant change in Ki67 expression with tamoxifen 20 mg po daily for 7 days prior to surgery while the statement suggests that tamoxifen 32 mg po daily had no impact on tumor diameter postbreast cancer operation The trials do not entail each other as they involve different outcomes Ki67 expression vs tumor",
        "label": "Contradiction"
    },
    "1cc18d8f-93f5-474e-9178-833b26150681": {
        "text_answer": "  The statement Every patient in the primary trial is receives a dose of 100 to 1600 g fentanyl sublingual spray during radiation therapy is not entailed in the given trial information The trial only mentions the use of Vorinostat and Radiation Therapy and the dosages for Vorinostat It does not mention anything about the use of Fentanyl or its dosages during the trial",
        "label": "Contradiction"
    },
    "4e5fb5c5-d286-4109-a89b-28f399788cae": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The statement does mention the eligibility for the secondary trial for women aged 18 or 19 which is consistent with the inclusion criteria for the secondary trial However",
        "label": "Contradiction"
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "text_answer": "  The statement There are no cases of anorexia hypothermia or hallucinations recorded in the AEs of the primary trial or the secondary trial is entailed by the given trials as there are no instances of these adverse events reported in either trial",
        "label": "Contradiction"
    },
    "66816aea-0de7-486c-b9d4-4ca6d9f09d52": {
        "text_answer": "  The statement is entailed in the Trials The secondary trial has a single set of inclusion and exclusion criteria for all study participants while the primary trial has different sets of criteria for different patient groups This aligns with the statement that the secondary trial uses just one set of criteria for all study participants whereas the primary trial categorizes participants into different groups each with their unique inclusionexclusion criteria",
        "label": "Entailment"
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial there is only one arm that includes Armodafinil PO given daily and in the secondary trial all patients receive the same dose of PDR001 but different doses of MCS110  This statement is a description of the differences in the design of the two trials and it is consistent with the information provided in the trials Therefore",
        "label": "Entailment"
    },
    "8dd822a1-6d7b-4dca-b3fb-4841442aff93": {
        "text_answer": "  The statement less than 01 of the primary trial participants had a reduction in circulating tumor cells following months of highdose chemotherapy with purged autologous stem cell products is not directly entailed or contradicted by the provided information in the trial results Result 1 The trial only reports the number of participants with a reduction in CTCs at one month post AHST not the percentage or proportion of participants with a reduction Therefore",
        "label": "Contradiction"
    },
    "79923aba-be0b-476d-ae86-733fce590db1": {
        "text_answer": "  The statement how much bothered by swelling in affected underarm arm or hand is a question about how bothered an individual is by swelling in their affected underarm arm or hand is not entailed nor contradictory to the information provided in the inclusion and exclusion criteria for the primary and expansion phases of the clinical trial The statement is not related to the eligibility criteria for the trial Therefore it is neither entailed nor contradictory to",
        "label": "Contradiction"
    },
    "b2059651-24e7-4b6c-aeee-403ff32cf725": {
        "text_answer": "  The statement is neither entailed in the primary trial nor contradictory to it   The primary trial focuses on women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic bone metastasis The statement mentions women with newly diagnosed or recurrent breast cancer who are ER and considering a mastectomy but it does not specify the",
        "label": "Entailment"
    },
    "66dff58d-73c8-46c8-afa7-9fe6e1231624": {
        "text_answer": "  The statement is entailed in the trials as there is no contradiction and the statement accurately reflects the information provided The trials report that there were no cardiac or psychiatric adverse events recorded during both the primary and secondary trials The statement also mentions that other types of adverse events were observed which is consistent with the information in the trials The definition of a combination antiinfective agent is also correctly provided",
        "label": "Entailment"
    },
    "4bd8fa53-08b5-4b80-868a-4b535432f2e2": {
        "text_answer": "  The statement Patients with stage 4 cancer are not eligible for the secondary trial however they are eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials  The primary trials exclusion criteria do not mention anything about prostate infections or cancer stage 4 The secondary trials inclusion criteria do not mention anything about prostate cancer or its stage However the secondary trial",
        "label": "Contradiction"
    },
    "d10a9ae2-cb0c-49e8-924c-906e3f2eb5a5": {
        "text_answer": "  The statement is not entailed in the trials inclusion and exclusion criteria The criteria do not explicitly state that participants must be sterilized or not sexually active However they do include specific guidelines regarding birth control for women of childbearing potential The trial does not exclude participants based on their sexual activity status unless they are women of childbearing potential who are unwilling or unable to use an acceptable method of birth control",
        "label": "Contradiction"
    },
    "db7671cb-a230-402e-beda-738af0753332": {
        "text_answer": "  The statement an adult patient diagnosed with ilddpld within the last 30 years with a life expectancy of 160 years would be eligible for the primary trial is contradictory to the inclusion criteria of the trial   The inclusion criteria state that the patient must have a life expectancy of greater than 3 months A life expectancy of 160 years is significantly longer than 3 months and is not within the acceptable",
        "label": "Entailment"
    },
    "0fa2ee42-3800-49bc-838c-eb3dba41f01f": {
        "text_answer": "  The statement is contradictory to the primary trial as the primary trial excludes patients with malignant ductal carcinoma in situ while the secondary trial accepts them",
        "label": "Entailment"
    },
    "24b7127a-5d4d-4a7d-b64b-8b2e12396b04": {
        "text_answer": "  The statement is contradictory to the information provided in both the primary and secondary trials The primary trial specifically includes patients with breast cancer and sets inclusion criteria for tumor size hormone receptor status and neoadjuvant endocrine monotherapy The statement about colon cancer with tumors under 02 cm and without any specific marker status is not mentioned or applicable to either trial",
        "label": "Entailment"
    },
    "b395d278-bbad-4ba2-af5b-82dc8045482a": {
        "text_answer": "  The statement is entailed in the secondary clinical trial inclusion criteria as it specifically lists the genes PTEN BRAF KRAS NRAS PI3KCA ErbB1 ErbB2 MET RET cKIT GNAQ and GNA11 that patients must have a diagnosed alteration in to be eligible for the trial Therefore the statement is entailed in the secondary clinical trial information",
        "label": "Entailment"
    },
    "9474451f-d601-4dcc-8304-50bc4d3ebf52": {
        "text_answer": "  The statement previous use of gabapentin or pregabalin will disqualify a patient from participation in the secondary clinical trial but not in the primary clinical trial is a conditional statement with two parts  1 Previous use of gabapentin or pregabalin disqualifies a patient from participation in the secondary clinical trial 2 Previous use of gabapentin or pregabalin does not disqualify a patient from participation in the primary",
        "label": "Entailment"
    },
    "ead18343-9437-4aa4-9bbc-2e20f7c28025": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial reports the median Time to Progression TTP in months for two different arms of the study while the secondary trial reports the number of participants with objective response based on RECIST criteria The statement provided in the statement section is not directly related to the information provided in the trials",
        "label": "Contradiction"
    },
    "951c2074-2100-4b9f-84e1-adec6a08c61b": {
        "text_answer": "  The statement during multiple phases throughout the trials the trastuzumab dosage for patients in cohort 2 of the secondary clinical trial mirrors that of the patients in the primary clinical trial is entailed in the trials  Explanation  In the primary trial patients received a loading dose of 4 mgkg of trastuzumab followed by 2 mgkg weekly In the secondary trial during the AC",
        "label": "Entailment"
    },
    "a2fa7138-cba9-4720-91a0-eb12a7356fa2": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial describes the use of radiation therapy for breast cancer patients and there is no mention of any oral administration of antiretroviral drugs or muscle relaxants   The secondary trial describes the use of Enzastaurin and Fulvestrant for breast cancer patients but there is no mention of any antiretroviral drugs being administered Additionally there is",
        "label": "Contradiction"
    },
    "04067434-b300-40f1-9e6c-c986b4c602c5": {
        "text_answer": "  The statement Cohort 1 of the primary trial did not report any AEs Adverse Events however almost all of cohort 2 candidates suffered at least one ae Hard palate squamous cell carcinoma is a squamous cell carcinoma that arises from the hard palate It usually presents as a papillary or exophytic mass is not directly entailed or contradictory to the given trials data as there is",
        "label": "Contradiction"
    },
    "46cd405e-a401-4249-ad26-b48801b2c2c8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH as the outcome measure while the secondary trial measures the Ruxolitinib Maximum Tolerated Dose MTD as the primary outcome measure The statement provided in the question is about two different trials with different primary outcome measures",
        "label": "Entailment"
    },
    "c3503b5e-ef92-4e90-bc0f-5ef7690a5908": {
        "text_answer": "  The statement there are no reported cases of asthenia or pyrexia in the patients of the primary clinical trial and the secondary clinical trial is entailed by the given data since the data reports a total of 0 adverse events for asthenia and pyrexia in both trials",
        "label": "Contradiction"
    },
    "bcbeb637-d070-400b-a98e-e3380f009b21": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The statement suggests that there were more instances of infection asymmetry and deflation in the primary trial compared to the secondary trial However the trials show that there were no instances of deflation in the secondary trial and no instances of infection or asymmetry in either trial Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "62ecbc1b-eb8f-43ad-b997-a11c8d36b379": {
        "text_answer": "  The statement none of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is a negation of the presence of imagable HER2 metastases in any participant in the HER2targeted PETCT arm of the trial using 89Zrtrastuz",
        "label": "Entailment"
    },
    "00e018a5-5237-498b-8823-f47ac2d2697f": {
        "text_answer": "  The statement Women suffering from both claustrophobia and IBS are not eligible for either the primary trial or the secondary trial is a contradiction to the given trials inclusion and exclusion criteria   Neither the primary nor the secondary trials list claustrophobia or IBS Irritable Bowel Syndrome as inclusion or exclusion criteria Therefore the statement is not entailed in the trials However",
        "label": "Contradiction"
    },
    "c5f56599-f5cb-46c4-ac69-e298d37f0883": {
        "text_answer": "  The statement a patient with a secondary tumour of 35mm in size detected through MRI would not qualify for either the primary trial or the secondary trial is contradictory to the information provided in the inclusion criteria for both trials  For the primary trial the inclusion criteria state that Primary tumour greater than 2 cm diameter measured by clinical examination and mammography or echography is required The size of the tumour is not",
        "label": "Entailment"
    },
    "fdc25a44-5f1f-4478-b1f4-78fbb95b112a": {
        "text_answer": "  The statement is entailed in the trials exclusion criteria as follows  Exclusion Criteria    No known hypersensitivity to phosphate trehalose or polysorbate   No serious nonhealing wound ulcer or bone fracture   No uncontrolled high blood pressure or history of hypertensive crisis   No New York Hear Association class II congestive heart failure   No extensive cancer involvement",
        "label": "Entailment"
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "text_answer": "  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the information provided in the trials  In the secondary trial prior treatment with herceptin within the last year is an exclusion criterion Section 2 PRIOR CONCURRENT THERAPY However there is no mention of herceptin as",
        "label": "Contradiction"
    },
    "40a16e0a-a4d4-49d0-8423-aa5b43688171": {
        "text_answer": "  The given statement there were 150 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed in the provided trials as there is no information about the number of cases of hypertension dehydration and dyspnea in the trials",
        "label": "Contradiction"
    },
    "1f10dd13-d27c-4ff0-bcac-67f0da0ac487": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial specifies the same inclusion and exclusion criteria for both its Phase I and Phase II portions This means that the criteria apply equally to all participants regardless of whether they are receiving opioid therapy or not   On the other hand the secondary trial has different inclusion and exclusion criteria compared to the primary trial However the statement in question only comp",
        "label": "Entailment"
    },
    "0c72a56a-de46-498d-8706-04c1283bea04": {
        "text_answer": "  The statement cohort a of the primary clinical trial is administered a single infusion of hd V934 is contradictory to the information provided in the trials   In the trials Cohort A of Intervention 1 received two injections of V935 LD not V934 Intervention 2 for Cohort A involved three electroporation injections of V934 LD followed by",
        "label": "Entailment"
    },
    "853967c7-51a1-4e08-88c0-d8e621129176": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement makes a comparison between the two primary trials and one secondary trial It states that both trials use pCR as their measure of outcome but there is a negligible variance in outcomes among the two subgroups of the primary trial while arm 2 of the secondary trial demonstrated significantly better results compared to arm 1  The given trials only provide the",
        "label": "Entailment"
    },
    "9a324039-2611-4433-821d-588c822c831f": {
        "text_answer": "  The statement those suffering from serious or undisciplined heartrelated diseases are disqualified from taking part in both the primary and secondary clinical trials is entailed in the trials as follows  In the primary trial the exclusion criteria include  Significant cardiovascular impairment Congestive heart failure Clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last",
        "label": "Entailment"
    },
    "849dbfea-186a-4983-b7a3-616679e3f2ec": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial measures changes in pain intensity at specific time points after dosing while the secondary trial measures the change in bone mineral density of the lumbar spine at a specific time frame 9 months after surgery The two trials do not directly compare the same outcome measures",
        "label": "Contradiction"
    },
    "da01cb99-7533-4cb5-ae01-16453c94cc7e": {
        "text_answer": "  The statement is not entailed in the trial results as the statement mentions a change in tumor diameter instead of Ki67 expression The trial results only demonstrate a significant change in Ki67 expression with tamoxifen treatment",
        "label": "Contradiction"
    },
    "25f976a2-8a79-469f-90a3-6b9922382c76": {
        "text_answer": "  The statement while the primary and secondary clinical trials focus on different interventions the mtd for the secondary clinical trials mm111 intervention is set at 15 mg per day is not directly entailed in the provided trial information   The primary trial focuses on the combination of Paclitaxel and Ruxolitinib while the secondary trial focuses on MM111 as a single agent The MTD for R",
        "label": "Contradiction"
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "text_answer": "  The statement 13 of the primary trial participants with PR Primary Breast Cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed HER2 Metastases is not directly entailed in the provided trial information The trial results only mention the percentage of participants with HER2 primary breast cancer who developed imagable HER2 metastases but it does not specify which rad",
        "label": "Contradiction"
    },
    "d7f83dbb-ef9c-455b-a692-e99eefcddb05": {
        "text_answer": "  The statement the primary clinical trial records no aes as being general symptoms is contradictory to the information provided in the trials data   The trials data lists General symptom as an adverse event with a frequency of 392 Therefore the statement is contradictory to the data",
        "label": "Contradiction"
    },
    "09819b6e-961a-47cf-9112-c43434e9ac19": {
        "text_answer": "  The statement birc5 antibody is any immunoglobulin that recognizes baculoviral iap repeatcontaining protein 5 is not directly related to the outcome measurements in the primary or secondary trials provided Therefore it cannot be entailed or contradicted based on the information given in the trials",
        "label": "Entailment"
    },
    "0ad73758-1efb-46e4-85e7-57dbfb5eb96d": {
        "text_answer": "  The statement that a 32yearold patient with a histologically verified diagnosis of stage III breast cancer an absolute neutrophil count of 1807L a platelet count of 79000L a hemoglobin level of 90 gl and a life expectancy exceeding 8 months would be eligible for both the primary and secondary trials is entailed in the",
        "label": "Entailment"
    },
    "0eba9989-3611-49a8-958f-ea696ba94b3e": {
        "text_answer": "  The statement in the primary clinical trial the patient who exhibited the longest progressionfree survival PFS lived 35 months without any evidence of disease progression or mortality is not directly entailed in the provided trial data   The trials only report the median PFS for each treatment group not the longest PFS observed in any individual patient Therefore the statement goes beyond the information provided in the trials",
        "label": "Contradiction"
    },
    "85645da7-cf87-4b4d-a5eb-cab03a857cc4": {
        "text_answer": "  The statement hyoepiglottic ligament is a short elastic band that unites the epiglottis to the upper border of the hyoid bone is not related to the information provided in the Trials The Trials focus on the safety and efficacy of the intervention SG for the primary trial and talazoparib for the secondary trial in different cancer populations Therefore the statement is neither entailed nor contradicted by the",
        "label": "Entailment"
    },
    "b56bc509-6ed3-4125-9587-407192b9b597": {
        "text_answer": "  The statement All Patients receiving the placebo intervention in the primary trial experienced emesis is contradictory to the results provided in Trial 2 The results indicate that 5 out of 20 participants in the placebo group were emesis free during the study period Therefore the statement is contradictory to the trial results",
        "label": "Entailment"
    },
    "f319d5bf-32fd-4505-aff1-02caa718676a": {
        "text_answer": "  The statement Aes were not recorded for the primary trial or the secondary trial is entailed by the given information   Explanation   The statement Aes were not recorded for the primary trial or the secondary trial means that no adverse events of type 1 or any other type were recorded in either trial The trials data provided in the text indicate that for both trials no adverse events of type 1 were recorded and",
        "label": "Entailment"
    },
    "30988df5-0397-4199-ba63-0b95f1c0f4f5": {
        "text_answer": "  The statement there have been adverse events aes reported in both cohorts of the primary clinical trial is contradictory to the given information in the trials as there have been no adverse events reported in either cohort 060 in each cohort Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "21e44cc9-f3ce-47b3-ace5-69718677308e": {
        "text_answer": "  The statement is entailed in the trials as both trials involve intravenous injections and MRIs as part of their interventions However the specific drugs dosages and frequency of administration are different between the two trials which is consistent with the statement Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "ab9018bd-df48-4ece-81d0-d85fee09a2f5": {
        "text_answer": "  The statement the AEs of the primary and secondary clinical trials only reflect symptoms of fatigue nausea and skin rashes is not entailed in the given trials data as the trials data does not provide sufficient information to make that conclusion The statement is a limitation or assumption beyond the scope of the provided data",
        "label": "Contradiction"
    },
    "25428be5-61e7-46d0-b713-8e831229abeb": {
        "text_answer": "  The statement candidates for the secondary clinical trial are required to satisfy performance status conditions a requirement that is not necessary for the primary clinical trial is a contradiction based on the given information   The primary trial includes the requirement of Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigatorsubinvestigator but it does not mention anything",
        "label": "Contradiction"
    },
    "a7d9d7dd-1f13-4a0e-883c-b322ed8780dd": {
        "text_answer": "  The statement the primary clinical trial does not accept patients with low potassium levels but those with high potassium levels could be eligible for both the primary and secondary clinical trial is neither entailed nor contradicted by the information provided in the primary and secondary trial inclusion and exclusion criteria  Explanation  The primary trial exclusion criteria state that patients must have a potassium level within the normal range of 3553",
        "label": "Entailment"
    },
    "6046015d-1954-4914-aa65-98ca575e4936": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there is a separate arm for CBTI and Armodafinil and Armodafinil is given daily for 47 days with varying doses In contrast in the secondary trial MCS110 and PDR001 are given in combination every 3 weeks but all patients receive the same doses of each drug regardless of the trial",
        "label": "Contradiction"
    },
    "e876c279-ae1c-4e26-a25b-4da7222957bf": {
        "text_answer": "  The statement candidates do not need to meet any baseline performance standards to participate in the primary clinical trial or secondary clinical trial neither trial uses unique performance scoring schemes is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials   The primary trial includes a Karnofsky score of 70 as an inclusion criterion which can be considered a performance standard However the statement does not mention anything about performance standards",
        "label": "Contradiction"
    },
    "593797dd-ff0f-46e5-ab50-0ea8d49fc4ad": {
        "text_answer": "  The statement is entailed in the trials as the trials explicitly mention the difference in the intervention based on the health status and cancer presence of the participants In the first trial the intervention is for adult cancer patients 65 years of age and older while in the second trial the intervention is for healthy volunteers 65 years of age and older The trials demonstrate that the vaccine responses are being studied in two distinct groups and the group membership is determined by the individuals",
        "label": "Entailment"
    },
    "5d9fff0a-de7b-45a9-843f-7d083ef11b11": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The trials report the number of participants in each group who experienced recurrencefree survival up to 5 years after randomization The trials do not report the number of individuals 112 in the NaCl 09 3ml group or the number of participants 78 in the Ketorolac 30 mg group who experienced recurrencefree survival",
        "label": "Entailment"
    },
    "e2551c0f-9b6a-4d0c-9f11-b5e301d7ff3c": {
        "text_answer": "  The statement in the primary clinical trial numerous psychiatric side effects were observed such as an eating disorder and schizophrenia is not entailed in the given trial data The trial data mentions only suicidal ideation as a psychiatric side effect but it does not mention eating disorder or schizophrenia Therefore the statement is contradictory to the given trial data",
        "label": "Contradiction"
    },
    "abf0f2b7-e989-49e0-82a7-7a2c594e1185": {
        "text_answer": "  The statement patients with stage 1 cancer are not eligible for the secondary trial but are ineligible for the primary trial is a contradiction   Explanation   The primary trial and secondary trial have different inclusion and exclusion criteria The primary trial includes patients with stage IIbIIIIV breast cancer while the secondary trial includes patients with a diagnosis of breast cancer a life expectancy of at least 1 year and",
        "label": "Contradiction"
    },
    "658a645c-05f8-456d-be67-c5b7b6d427da": {
        "text_answer": "  The statement Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is entailed in the trials as per the given inclusion and exclusion criteria for both trials Therefore the statement is true",
        "label": "Entailment"
    },
    "b8c7a9f1-a31e-4be6-a0ff-9452728c2e0c": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 60 days are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary embolism within the last 60 days are explicitly excluded However the statement suggests that these patients may be eligible for",
        "label": "Contradiction"
    },
    "f312eb67-0141-4a7b-a9a4-476a92c32484": {
        "text_answer": "  The statement is not entailed in the trials as the doses are not equivalent   Explanation  In the primary trial participants received lenalidomide 5mg orally daily for 57  3 days This translates to a total dose of approximately 295mg for the entire treatment period  In the secondary trial participants in intervention 1 received oral lapatinib 1500mg",
        "label": "Contradiction"
    },
    "2ecb5932-45c6-491c-9b9f-01ab02877f78": {
        "text_answer": "  Based on the provided data the statement there was at most one psychiatric event recorded during the primary clinical trial is not directly entailed in either Trial 1 or Trial 2   The trials do not report any psychiatric events so it is neither entailed nor contradicted by the given data However it is important to note that the absence of data on psychiatric events does not necessarily mean that they did not occur during the trials",
        "label": "Contradiction"
    },
    "12954a74-e631-4318-ac00-0d09fd49e34a": {
        "text_answer": "  The statement menopausal women and men who have undergone vasectomy are qualified participants for the primary clinical trial with no necessity for abstinence is not explicitly stated in the inclusion or exclusion criteria provided However there is no mention of any specific requirement related to fertility or contraception for men in the exclusion criteria Therefore the statement is not contradictory to the trials criteria However it is important to note",
        "label": "Contradiction"
    },
    "4bcd8725-f138-49c8-b6a9-4f0c6eaa756f": {
        "text_answer": "  The statement coronary artery stenosis is the most frequently documented adverse event in the primary clinical trial is contradictory to the given data The most frequently documented adverse event in the trial was nausea or vomiting each occurring 392 of the time Coronary artery stenosis was not mentioned as an adverse event in the given data",
        "label": "Entailment"
    },
    "2af8d00f-e0b6-4555-b649-796186334803": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials The trials focus on the intervention and control groups of a study involving African American patients receiving palliative care for endoflife planning The statement is about a specific type of malignant tumor unresectable malignant glomus tumor that is not mentioned in the trials Therefore the statement does not follow logically from the information provided and is neither ent",
        "label": "Entailment"
    },
    "a6ee28c9-2b3a-47a6-b576-8ca75d38fb67": {
        "text_answer": "  Lets calculate the ratio of hepatotoxicity cases to the sum of hypertension and pancreatectomy cases in the primary trial  Ratio  Number of hepatotoxicity cases  Number of hypertension cases  Number of pancreatectomy cases  Given Number of hepatotoxicity cases  3 Number of hypertension cases  1 Number of pancreatectomy cases",
        "label": "Entailment"
    },
    "ad9fe1aa-9798-4c53-ab23-23ac2924918c": {
        "text_answer": "  The statement patients participating in the primary trial receive 2000 mgm2 oral lapatinib twice a day for a full month is not entailed in the given intervention description The intervention description states that patients receive 1000 mgm2 oral lapatinib once daily not 2000 mgm2 twice daily Therefore the statement is contradictory to the given intervention information",
        "label": "Contradiction"
    },
    "fb67edbe-9758-4e64-acd0-263fe51ba74a": {
        "text_answer": "  Lets analyze the given trials to determine if the statement is entailed or contradicted  First lets calculate the total amount of MCS110 and PDR001 each patient receives in both interventions  INTERVENTION 1  MCS110 1 mgkg Q3W every 3 weeks  PDR001 100 mg Q3W ",
        "label": "Entailment"
    },
    "1b4c8f0a-2d3e-40d3-b26a-426a4f32cb86": {
        "text_answer": "  The statement grade 1 uveitis CTCAE is anterior uveitis with trace cells is not directly related to the inclusion and exclusion criteria provided in the trial description   The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is entailed in the inclusion criteria as stated under the exclusion criteria",
        "label": "Entailment"
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "text_answer": "  The statement None of the cohort of the primary trial or the secondary trial receive entericcoated tablets is not entailed in the given trial information The statement only mentions that the trials do not involve entericcoated tablets for the interventions related to the trials provided However the statement does not explicitly state that all drugs or treatments given to the participants in the trials are not entericcoated tablets Therefore it is",
        "label": "Contradiction"
    },
    "b6d2381f-f049-4747-ae82-5a9a321ec001": {
        "text_answer": "  The statement only patients with a body mass index within a normal range may enroll in the primary clinical trial is contradictory to the inclusion criteria of the trial as stated in the text The inclusion criteria specify that patients must have a BMI of 25 kgm2 or greater and weight 400 lbs which is above the normal range BMI  25 kgm2 Therefore the statement is contradictory",
        "label": "Entailment"
    },
    "2855e123-6fa3-44b7-9eda-09603be206aa": {
        "text_answer": "  The statement 50 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is not directly entailed in the given trial results Result 1   The trial results only provide the percentage of participants with HER2 primary breast cancer who developed imagable HER2 met",
        "label": "Contradiction"
    },
    "e00ad4a5-25b8-4343-a353-be8b2e0d6c1b": {
        "text_answer": "  The statement the psychiatric condition of a patient determines their eligibility for the primary clinical trial and the secondary clinical trial is entailed in the given trials inclusion and exclusion criteria   In the primary trial psychiatric conditions are listed as exclusion criteria under Substance abuse medical psychological or social conditions that may interfere with the participants participation in the study or evaluation of the study results Therefore a psychiatric condition would make",
        "label": "Entailment"
    },
    "62a0ed6c-dc2a-4223-9ee0-5b7422bf43da": {
        "text_answer": "  The statement Intraoperative Mammography performed better than the Standard Mammography in the primary trial in terms of operative time savings is entailed in the trials as the primary trial does report a shorter median operative time for the Intraoperative Mammography arm compared to the Standard Mammography arm However its important to note that the secondary trial does not provide any information that can be used to compare the success rates between the",
        "label": "Entailment"
    },
    "d3fe482c-e694-474a-8ba6-f089ea532040": {
        "text_answer": "  The statement is contradicted by the information provided in the secondary trial While no adverse event in the primary trial affected more than 03 fraction of patients 000 is less than 03 in the secondary trial diarrhea affected 2333 of patients which is more than 03 fraction Therefore the statement is contradicted by the information in the secondary trial",
        "label": "Contradiction"
    },
    "348c5cf5-0756-4860-a83f-c9ead81ea4b3": {
        "text_answer": "  The statement is contradictory to the trials provided The trials report a total of six patients with three adverse events each total of 6 x 3  18 adverse events The statement only mentions three adverse events pancreatitis cholelithiasis hepatic pain and febrile neutropenia for the entire trial However febrile neutropenia is already included in the reported ad",
        "label": "Entailment"
    },
    "e29a77b0-a7de-44b8-8941-df0979682e4e": {
        "text_answer": "  The statement have to leave in order to smoke is not entailed in the given trials as there is no information provided in the trials regarding smoking or the need for individuals to leave their houses to smoke The trials only report the number of adverse events recorded in each trial Therefore the statement is contradictory to the given trials",
        "label": "Contradiction"
    },
    "8849827d-af65-44ae-ad32-b325f502f945": {
        "text_answer": "  The statement is entailed in the Trials The primary trial has specific inclusion and exclusion criteria for advancedmetastatic solid tumors patients while the secondary trial has different inclusion criteria for patients with a history of breast cancer or those experiencing bothersome hot flashes The primary trials criteria are identical for all participants with advancedmetastatic solid tumors whereas the secondary trials criteria vary depending on the study group",
        "label": "Entailment"
    },
    "b0c426df-6a70-4d19-a120-e3bc56c49918": {
        "text_answer": "  The statement healthy individuals not diagnosed with any form of cancer may be eligible for all study groups in the primary trial and the secondary trial is not directly entailed in the given trials as there is no mention of healthy individuals being eligible for the primary trial However it is not contradictory to the trials as well as the trials specify certain inclusion and exclusion criteria for each study group and the statement does not violate any of those criteria Therefore",
        "label": "Contradiction"
    },
    "f9442384-0c19-4ffe-8906-c461b6dda9f7": {
        "text_answer": "  The statement There was one case of shingles recorded in group 2 of the secondary trial but no cases in group 1 of the secondary trial and the primary trial is contradictory to the given data   The primary trial reports one case of shingles in the adverse events of the first trial but the statement claims that there were no cases in the primary trial Additionally the statement mentions that there was one case in group 2",
        "label": "Contradiction"
    },
    "5abc6652-31bf-4ac6-a16b-432912aa6224": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial intervention lasted for 10 weeks 40 sessions of 45 minutes each which is approximately 70 days assuming a week has 7 days   The secondary trial interventions lasted for 24 weeks which is approximately 168 days assuming a week has 7 days   Therefore the statement that the",
        "label": "Entailment"
    },
    "2c95f252-a861-4569-a0b9-c214289da160": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials report no adverse events for both the primary and secondary trials Therefore the statement that the primary clinical trial and the secondary clinical trial documented over 100 adverse events within their study groups is not entailed in the given information",
        "label": "Contradiction"
    },
    "9040286a-0801-494c-8c17-340323774082": {
        "text_answer": "  The statement those with an inadequate level of vitamin D will not be included in the primary clinical trial but they could be suitable for the secondary clinical trial is entailed in the given trials   Explanation   The primary trial includes the criterion of Serum 25OHD levels  40 ngml as an exclusion criterion This means that individuals with inadequate levels of",
        "label": "Entailment"
    },
    "d4fd7d7a-53f4-4f5d-9640-717e26cbbcd9": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion of the breast at three separate time points during the surgical procedure Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "9ab82516-ba60-4c36-908d-5e0e56ec5fba": {
        "text_answer": "  The statement 2 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as the percentage of patients with infections is different in each trial The primary trial reports that 313 of patients had infections while the secondary trial reports that 667 of patients had infections in the first category of adverse events Therefore the statement is not strictly ent",
        "label": "Contradiction"
    },
    "a63b539f-034e-46c2-83e7-9cea8c282e1c": {
        "text_answer": "  The statement none of the patients in the primary clinical trial and secondary clinical trial developed infections during the study period is contradicted by the information provided in the trials  Explanation  In the primary trial there is one reported case of infection 132 or 313 In the secondary trial there are no reported cases of infection mentioned in the provided data However the statement none of the patients in the primary",
        "label": "Contradiction"
    },
    "46c7e5c7-0834-45dd-952c-872502314fea": {
        "text_answer": "  The statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study is entailed in the trials provided   Both trials report the number of participants who achieved Pathologic Complete Response in Breast and Axillary Lymph Nodes and the percentage of participants in each cohort who experienced this",
        "label": "Entailment"
    },
    "8c14522c-67de-490a-9be1-1c16d9fca742": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The trials do give the number of participants analyzed in each armgroup Arm II and Arm III Therefore the statement is incorrect",
        "label": "Contradiction"
    },
    "dce7c1b2-0e43-4c7b-8cc8-6a443fee7135": {
        "text_answer": "  The statement does not directly entail or contradict the information given in the trials The trials only provide the dosage information for two different cohorts while the statement discusses the result classification and the difference in dosage between the cohorts in terms of mgkg Therefore the statement is neither entailed nor contradictory based on the given trials alone",
        "label": "Entailment"
    },
    "2028a7ad-b89f-4927-8e74-db17555763c8": {
        "text_answer": "  The statement several of the primary trial candidates are administered 001 g of talazoparib daily as part of the intervention is not directly entailed in the provided trial description The trial description mentions that patients are eligible for the trial if they are older than 70 years and have various types of cancer and that they may be included before or between treatments It also mentions that talazoparib is one of the",
        "label": "Contradiction"
    },
    "7df47095-163a-4062-9b5b-f2dfd02259fb": {
        "text_answer": "  The statement is not entailed in the given trials as there is no cohort in the primary trial that receives 150000 mcg of oral pregabalin twice daily The statement is also not contradictory to the trials as they focus on different interventions for different patient populations",
        "label": "Contradiction"
    },
    "50ddb312-6c5e-476a-891e-95409d7239c5": {
        "text_answer": "  The statement primary clinical trial and secondary clinical trial are focused on evaluating the time to progression ttp in patients is not entailed in the provided information from the trials The primary trial is focused on evaluating the toxicity of infusing HER2specific T cells using the NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary trial is focused on evaluating the percentage of participants with adverse events",
        "label": "Contradiction"
    },
    "18ff2056-f906-4f16-805f-76b4a51b77b7": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The primary trial reports the MTD of ruxolitinib in combination with paclitaxel for childhood ovarian embryonal carcinoma 2 The secondary trial reports the MTD of MM111 for childhood ovarian embryonal carcinoma 3 The statement in the question mentions that the MTD of MM111",
        "label": "Entailment"
    },
    "fc37e929-f3f3-43fb-b0c4-86521a18592f": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered some kind of adverse event is not directly entailed in the provided trial data The data only indicates that all 3 participants in cohort 1 experienced adverse events not that 1000 of them suffered some kind of adverse event The difference lies in the fact that the statement implies that every single participant in the cohort experienced an",
        "label": "Contradiction"
    },
    "bdbbcf1d-df03-4ade-9967-5d9ca8bf9ce8": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trial information The trials use different drugs FMX and MM398 versus lapatinib and paclitaxel different dosages and different schedules of administration The statement only mentions intravenous injections and vector genomes per milliliter which are not relevant to the trials interventions",
        "label": "Entailment"
    },
    "69407358-a579-43ba-8b78-b75d7aebb163": {
        "text_answer": "  The statement is entailed in the Trials as follows  1 The primary trial reports the MTD of Ruxolitinib in combination with paclitaxel but it does not mention the MTD of MM111 2 The secondary trial reports the MTD of MM111 as 15 mg per day but it does not mention the MTD of Ruxolitinib in combination with pac",
        "label": "Entailment"
    },
    "21a1ddb1-0d37-41e5-a08f-a7e9dc5b15ef": {
        "text_answer": "  The statement is entailed in the trials as the primary trial and the secondary trial are studying different drugs Extimia versus empegfilgrastim at different dosages 6 mg and 75 mg versus 3 mg and with different outcome measurements duration of neutropenia versus incidence of neutropenia",
        "label": "Entailment"
    },
    "d14fe83a-0130-4c37-a55d-30ec0ecacdb1": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to calculate the recurrencefree survival rates for each group and compare them   From the given data we have   Ketorolac 30 mg group 80 out of 96 participants 833 experienced recurrencefree survival  NaCl 09 3ml group 96 out of",
        "label": "Entailment"
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does have different inclusion criteria for different patient groups but it is not limited to age groups 1850 and 50 Instead it has different inclusion criteria for different disease types NSCLC melanoma triple negative breast cancer and anaplastic thyroid cancer   The secondary trial on the other hand has the",
        "label": "Entailment"
    },
    "8d16932d-a485-4c58-828e-70f805bd82ef": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial do not entertain the participation of patients who are currently smoking is entailed in the trials as per the exclusion criteria for both trials In the primary trial smoking is listed as an exclusion criterion under Patient must not be smoking or using nicotine replacement therapy for at least 4 weeks prior to study entry In the secondary trial smoking is listed as an exclusion criterion under",
        "label": "Entailment"
    },
    "2af38d73-ba19-4aa1-a571-5a576b4af7e3": {
        "text_answer": "  The statement lactococcus is a genus of gram positive cocci shaped lactic acid bacterium assigned to the phylum firmicutes and the family streptococcaceae is not directly related to the adverse event information provided in the trial Therefore it neither entails nor contradicts the information given in the trial The trial only mentions the occurrence of an adverse event lactococcus infection in one patient out",
        "label": "Entailment"
    },
    "504dd694-4978-41f0-bee5-ccc6dd199752": {
        "text_answer": "  The statement white fiber is a type of striated skeletal muscle fiber that contracts quickly and contains small amounts of mitochondria myoglobin and sarcoplasm is not directly related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it cannot be determined if the statement is entailed in the trials or not The trials only provide information about the eligibility criteria for patients participating in the studies",
        "label": "Entailment"
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "text_answer": "  The statement is entailed in the trial results as stated The trial results indicate a mean percentage change in Ki67 expression of 40 63 to 29 for the Tamoxifen Pre and Post Breast Surgery armgroup The statement in the statement summarizes the average percentage change in Ki67 expression as a reduction of 40 Therefore the statement is entailed in the trial results",
        "label": "Entailment"
    },
    "ddafc0fa-fb54-4729-8c01-97cb30f293ed": {
        "text_answer": "  The statement is entailed in the trials as neither Arm A nor Arm B includes the administration of paclitaxel or fulvestrant during the primary clinical trial The trials specify that patients in Arm A receive anastrozole orally and patients in Arm B receive fulvestrant intramuscularly but they do not mention the use of paclitaxel or fulvestrant in either cohort Therefore the statement that neither cohort 1 nor co",
        "label": "Entailment"
    },
    "c638fd13-e832-4bc6-9b3a-ad9d8da4b1c4": {
        "text_answer": "  The statement there are 10 shared inclusionexclusion criteria between the secondary trial and the primary trial is an entailed statement based on the given information   The primary trial and the secondary trial share the following inclusion criteria 1 Age  18 years 2 Life expectancy of at least three months 3 ECOG performance level 02 or Karnofsky score 10070",
        "label": "Entailment"
    },
    "a0e45f2f-6f88-496e-9b14-2fe595be1286": {
        "text_answer": "  The statement in the primary clinical trial less than 10 of patients experienced one psychiatric adverse event is entailed in the trial data provided   Explanation   The statement implies that the sum of the percentage of patients who experienced any psychiatric adverse event should be less than 10 The trial data shows that the total percentage of patients who experienced any adverse event was 1200 but only ",
        "label": "Entailment"
    },
    "176093eb-7c7f-4bca-80e2-566d4a135c47": {
        "text_answer": "  The statement Bergeyella is a genus of aerobic gramnegative rod shaped bacterium assigned to the phylum bacteroidetes and the family flavobacteriaceae is not related to the adverse events data provided in the trials Therefore the statement is neither entailed nor contradicted by the information given in the trials",
        "label": "Entailment"
    },
    "6654ce22-9470-43d1-9e51-a17f1a06f514": {
        "text_answer": "  The statement 5 of the primary trial participants with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab developed her2 metastases is not directly entailed in the provided trial information The trial results only state that 13 out of 49 participants 265 had HER2 metastases but the information about which radiotracer was used",
        "label": "Contradiction"
    },
    "dd5fcab9-ef7e-4f25-8040-81c0dd57aab5": {
        "text_answer": "  The statement is not entailed in the given trials as there is no trial that reported both subgroups and the trials do not contradict each other The statement only mentions anaemia and febrile neutropenia for the first subgroup but the trials provide more detailed information about the occurrence of these adverse events as well as others The second subgroup did not report any cases of anaemia or febrile neutropenia but",
        "label": "Contradiction"
    },
    "0f0ccab9-517a-44e5-8dda-96d1cb9ead51": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial describes the placebo as being administered as a 3hour intravenous infusion on Day 1 which is the same method of administration as trabectedin Therefore the statement that the placebo is administered orally is incorrect",
        "label": "Entailment"
    },
    "4527cc06-b4b2-4ebe-bba4-6f4e845b2984": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement asserts that the intervention in the secondary trial requires at least 3 different drugs including Zoledronic acid Samarium153 and pegfilgrastim However the primary trial only involves a single drug ZD1839 as its intervention The statement is contradictory to the information provided in the trials ",
        "label": "Entailment"
    },
    "87a0c1c5-507a-4188-87cf-57f27add4cf6": {
        "text_answer": "  The statement Candidates for the secondary trial study group receive weekly subcutaneous SC injections whereas the primary trial participants do not receive any injections is a contradiction to the given trials   In the primary trial there is no mention of any injections being given to the participants However in the secondary trial there is a clear mention of weekly subcutaneous injections being given to the study group Therefore the statement contradicts",
        "label": "Contradiction"
    },
    "a9faa655-1f16-41b0-911e-0a560a1c1dc0": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in less than 2 of participants is entailed by the given data because  1 The data for both trials states that there were no adverse events AEs with a frequency less than 2 for total AEs and for ANCAG",
        "label": "Entailment"
    },
    "fc1a7234-bf6c-4c29-9a82-eccacb0d4766": {
        "text_answer": "  The statement ultrasound procedures are routinely performed as part of the interventions in both the primary and secondary clinical trials is entailed in the given trials as follows  In the primary trial there is no explicit mention of ultrasound procedures in the interventions described However it is stated that ultrasound procedures are routinely performed as part of the standard of care in breast reconstruction using tissue expanders This implies that ultrasound procedures are not",
        "label": "Entailment"
    },
    "78cbe5c1-69a4-4194-9d3c-06b5f4b9af0b": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trial results we need to calculate the difference in percentage of participants demonstrating a decrease in GFS between the ERpositive Luminal B and Triple Negative groups  Lets denote the percentage of participants with a decrease in GFS in the ERpositive Luminal B group as X and the percentage of participants with a decrease in GFS in the Triple Negative",
        "label": "Entailment"
    },
    "46669c3d-c42d-4b23-b8c5-256374e53cf1": {
        "text_answer": "  The statement fewer than 10 subjects experienced adverse events is not directly entailed in the given trial data The trial data reports that 2 subjects experienced adverse events out of a total of 35 subjects which is equivalent to 571 While this number is less than 10 the trial data does not provide a clear count of the number of subjects who experienced adverse events that is less than 10 Therefore",
        "label": "Contradiction"
    },
    "191f4ac8-16c9-4be8-895f-4383c3d6f7b5": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the administration of PF05212384 and docetaxel is not strictly confined to a 2week cycle The treatment cycles are defined as 21 days but there is no mention of a specific day for the administration of PF05212384 in each cycle after the first one This means that the administration",
        "label": "Entailment"
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial or the secondary trial is entailed in the given trials as there is no mention of gender as an inclusion or exclusion criterion in either trial Both trials focus on specific cancer types stages and receptor status among other factors for eligibility",
        "label": "Entailment"
    },
    "a220e90b-6fd7-449f-878a-f870cd360de6": {
        "text_answer": "  The statement is contradictory to the inclusion criteria of both trials   The primary trial states that the primary tumour should be greater than 2 cm in diameter while the statement suggests a primary tumour with a diameter of 100mm This is a significant difference and contradicts the inclusion criteria of both trials  Therefore a patient with a primary tumour of 100mm measured by clinical examination and echography would not be",
        "label": "Contradiction"
    },
    "51c9a1a4-9242-4880-b61e-b42a45b9017d": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 specify the same dosage of nabPaclitaxel 125 mgm2 for each treatment cycle However the difference lies in the chemotherapeutic agent used in combination with nabPaclitaxel  gemcitabine in Intervention 1 and carboplatin in Intervention 2 The dosage of carb",
        "label": "Entailment"
    },
    "d09f927d-29c3-4370-a258-400c79f366fe": {
        "text_answer": "  The given statement several of the patients in the primary trial experienced the no pain whatsoever during the 25 months of the study is not directly entailed in the provided trial results as there is no mention of the number or percentage of patients in each group who experienced no pain at all during the study period The trial results only report the average pain intensity scores and the difference between the two intervention groups",
        "label": "Contradiction"
    },
    "421278d5-9ece-4425-b5b0-390cc6844de8": {
        "text_answer": "  The statement is entailed in the trials as they both involve testing different interventions on study groups However the primary trial is testing different types of gels Hydrophor and MediHoney while the secondary trial is testing different doses of the same treatment PF05212384  Docetaxel Therefore the statement is partially entailed in the trials",
        "label": "Entailment"
    },
    "34b09027-2195-448e-ab3d-fb9d5a91301a": {
        "text_answer": "  The statement in the patient groups of the primary and secondary clinical trials a total of three shingles cases were identified is entailed in the given trials as follows  From the primary trial there is one shingles case identified out of 6 trials with a total of 6 participants From the secondary trial there is one shingles case identified out of 73 trials with a total of 66 participants  Therefore",
        "label": "Entailment"
    },
    "3de2cfe2-e886-45d3-a5fe-135005821732": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial neither Botulinum Toxin Type A nor Placebo involves the administration of alisertib to the study participants Therefore the primary trial does not administer alisertib to any of its cohorts  In contrast the secondary trial focuses on alisertib MLN8237 as the intervention with two different dosages 10",
        "label": "Entailment"
    },
    "ef7f4f02-ea16-458a-a225-875758ac5d1f": {
        "text_answer": "  The statement there were no documented psychiatric adverse events in the primary clinical trial is contradicted by the information provided in the trial data The trial data reports one documented case of suicidal ideation a psychiatric adverse event out of 50 participants Therefore the statement is contradicted by the trial data",
        "label": "Contradiction"
    },
    "81651022-ae46-4e69-aa0b-1e1d576845ce": {
        "text_answer": "  The statement erbb2 nm 0044482c23242325ins12 is an insertion of 12 nucleotides atacgtgatggc between position 2324 and 2325 of the coding sequence of the erbb2 gene is not directly related to the inclusion or exclusion criteria of the primary trial It is a genetic mutation",
        "label": "Entailment"
    },
    "c0267bfa-8985-4097-b6ba-0b908f4c46c5": {
        "text_answer": "  The statement patients with Frontotemporal dementia or Mixed dementia are eligible for the primary trial is not entailed in the given inclusion criteria The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Frontotemporal dementia and Mixed dementia are types of dementia that typically result in",
        "label": "Contradiction"
    },
    "7f128ec3-a88f-4cbe-9d79-0ef9e0f1d3bd": {
        "text_answer": "  The statement Patients diagnosed with breast cancer may be eligible for all study groups in the primary trial and the secondary trial is entailed in the given trials as  1 The primary trial includes postmenopausal women with early stage breast cancer as inclusion criteria 2 The secondary trial includes females with previous nonmetastatic operable primary invasive HER2positive breast cancer as inclusion criteria  Therefore patients diagnosed with",
        "label": "Entailment"
    },
    "58acb205-1f9d-4dd2-9405-720b28f8581f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial involves the use of eribulin mesylate which is a chemotherapeutic agent given intravenously and not radiation treatment The secondary trial involves the use of axitinib and docetaxel which are also chemotherapeutic agents given orally and intravenously respectively There is no mention of radiation treatment in the secondary trial Therefore the statement is",
        "label": "Contradiction"
    },
    "fe4e3c5a-b190-4733-930a-abc0bfd29625": {
        "text_answer": "  The statement have felt unusual weakness is a question about whether an individual feels or felt unusual weakness The secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is not directly entailed or contradicted by the given trials  Explanation  The statement makes two claims 1 The statement is about unusual weakness 2 The secondary trial patients suffered from anemia pneum",
        "label": "Contradiction"
    },
    "a9292fc9-f444-4e0a-8db1-c2a6ad9a7062": {
        "text_answer": "  The statement The patient with the longest PFS in the primary trial survived 35 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS for any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "c5315113-8bc1-47d5-b1f7-ca7d59ab9cc4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there is no mention of myalgias being administered to any group Group 2 receives dexmedetomidine not myalgias   In the secondary trial there is no mention of myalgias being administered to any group The trial only mentions vitamin D repletion and the specific cohort of patients who experience my",
        "label": "Contradiction"
    },
    "67a7f848-e9e5-46be-a37b-f0e46e643dcb": {
        "text_answer": "  The statement patients participating in the primary trial receive 25 mmml oral lapatinib twice a day for a half month is not entailed in the given trial information   The trial information states that patients receive oral lapatinib and tamoxifen once daily on days 128 with no specific dosage amount given for lapatinib The statement provided specifies a dosage of 25 mmml twice a day",
        "label": "Contradiction"
    },
    "57e2cf8a-6c67-4771-b180-70b613fff1cc": {
        "text_answer": "  The statement is entailed in the primary and secondary clinical trials as follows  In both trials the administration of 4demethyl4cholestryloxycarbonylpenclomedine is a common intervention In the primary trial it is given in conjunction with Abl Cells and Cyclophosphamide In the secondary trial it is the sole intervention in two separate arms In both trials patients are required to",
        "label": "Entailment"
    },
    "9b2a47ba-246e-4591-bf68-90c7124f800b": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial patients receive multiple weekly injections of unspecified interventions while in the secondary trial patients receive a onetime injection of epoetin beta There is no information suggesting that the primary trial involves a onetime injection for vitamin D repletion Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "45f78c14-258f-4db0-a0f4-10a46761ae2f": {
        "text_answer": "  The statement inclusionexclusion criteria not met supplemental qualifiers dataset is a dataset containing supplemental information specifically nonstandard variables to parent records in the inclusionexclusion criteria not met domain is not directly related to the entailed information in the trials provided The trials focus on the outcome measurements results and participant information for each study The statement is about a separate dataset containing supplemental information Therefore the statement is neither entailed nor contradict",
        "label": "Entailment"
    },
    "475a8280-5855-4c8c-a9ca-7720f9a9be7f": {
        "text_answer": "  The statement is entailed in the primary trial as the inclusion criteria clearly states that participants must have a Karnofsky score of 70 or higher for admission   In the secondary trial the statement is also entailed as the inclusion criteria state that patients must have a Zubrod performance score of 2 or better which is equivalent to a Karnofsky score of 5070 However the statement in the question specifically mentions a",
        "label": "Entailment"
    },
    "dfc09a24-8631-4fa3-893e-4d10a9bac4b8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement suggests that breast cancer patients received a lower dose 50 mcgday than ovarianperitoneal cancer patients 100 mcgday However the trials indicate that the doses for breast cancer patients ranged from 600 mcgday to 1100 mcgday",
        "label": "Entailment"
    },
    "f5ae88a3-a083-405e-b3a8-282018d7f013": {
        "text_answer": "  The statement individuals who have received antineoplastic chemotherapy androgens estrogens or progestogens treatment a month prior to the start of the study are not applicable for the primary clinical trial is entailed in the trials exclusion criteria   Reasoning   The trials exclusion criteria explicitly state that individuals who have received antineoplastic chemotherapy androgens estrogens or",
        "label": "Entailment"
    },
    "80cb39bd-c370-4e7f-8f19-74725fed8805": {
        "text_answer": "  The statement the primary trial is found to have fewer total adverse events as compared to the secondary trial while at the same time reporting lower instances of cardiacischemiainfarction than the secondary trial is entailed in the given trials data  Explanation  The statement is entailed in the trials data because the primary trial reports a total of 0 adverse events out of 14 participants 000",
        "label": "Entailment"
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "text_answer": "  The statement is contradictory to the information provided in the given trials   The primary trial does not mention any requirement for a CT scan or blood tests before mammography The secondary trial on the other hand does not mention mammography as a requirement before participation Therefore the statement that candidates must undergo a Mammography before being able to participate in the primary trial whereas for the secondary trial patients must first have a CT scan and blood tests",
        "label": "Entailment"
    },
    "99942306-e4cf-4405-80ca-914e689aef75": {
        "text_answer": "  The statement in the primary clinical trial more than half of the patients who underwent treatment with 1000mg lapatinib and nabpaclitaxel recorded a confirmed complete response CR is a contradiction to the information provided in the trial results   The trial results state that 53 out of 60 participants were analyzed but no specific information is given about the number of participants who experienced a CR or PR",
        "label": "Contradiction"
    },
    "d86f5f0a-32ec-4943-912f-9945c1cfe06f": {
        "text_answer": "  The statement is entailed by the given trials as both trials report no occurrence of Adverse Events 1 cardiac and Adverse Events 2 psychiatric during their respective trials The trials data support the statement that there were no cardiac or psychiatric adverse events recorded during either the primary or secondary trials",
        "label": "Entailment"
    },
    "deba63cb-52ea-4b46-ad50-8cef93d8c5fd": {
        "text_answer": "  The statement there is evidence of anorexia hypothermia or hallucinations in the aes of the secondary clinical trial is a contradiction to the information provided in the trials The trials report that there were no instances of anorexia hypothermia or hallucinations in the secondary clinical trial based on the given data",
        "label": "Contradiction"
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "text_answer": "  Both trials include the inclusion criterion of patients being 18 years of age or older Therefore the statement is entailed in the Trials with Entailment",
        "label": "Entailment"
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "text_answer": "  The statement There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial is not directly entailed or contradicted by the provided information The trials do not provide the number of participants in cohort 2 for the primary trial Therefore it is not possible to make a definitive statement about the comparison of the number of participants between the two trials and their respective cohort 2 groups",
        "label": "Contradiction"
    },
    "5145d91d-ce46-4dda-961e-5bc7ddb6cda4": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial and the secondary trial address different outcome measurements The primary trial measures the number of participants with treatmentemergent adverse events at the end of Cycle 1 while the secondary trial measures the total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenalidomide treatment The statement correctly identifies the differences between the two",
        "label": "Entailment"
    },
    "d8d5125b-399a-4b78-b033-9603bfe8011e": {
        "text_answer": "  The statement is entailed in the Trials The primary clinical trial has different inclusion and exclusion criteria for its Phase I and Phase II portions Phase I includes a requirement for a responsible companion living with the patient during the study for Phase I only and different patient groups based on opioid use for Phase II The secondary clinical trial on the other hand divides its criteria based on the health status of the patients with one group consisting of healthy individuals undergoing a",
        "label": "Entailment"
    },
    "78865c57-db3b-4fbe-ab87-1f2d11f2c091": {
        "text_answer": "  The statement patients participating in the primary trial receive 50 kgm2 oral lapatinib once a day for a full month is not directly entailed in the given intervention description for Arm 1 in the primary trial   The intervention description specifies that patients receive oral lapatinib and oral tamoxifen once daily on days 128 but it does not provide the exact dosage of lapatinib in kgm",
        "label": "Contradiction"
    },
    "ac14720a-7525-4fb0-b261-0ec5c818f85f": {
        "text_answer": "  The statement only male patients are eligible for the primary clinical trial and the secondary clinical trial accepts patients of all genders is contradictory to the information provided in the trials inclusion and exclusion criteria  The primary clinical trial explicitly states that only male subjects are eligible while the secondary clinical trial accepts both male and female subjects Therefore the statement is contradictory to the information provided in the trials criteria",
        "label": "Entailment"
    },
    "44daf0ed-4b1a-4e95-aae4-71722fad8f09": {
        "text_answer": "  The statement Women of childbearing potential WOCBP and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is entailed in the trial information provided   The trial inclusion criteria state that WOCBP and sexually active fertile men are eligible for the study but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months",
        "label": "Entailment"
    },
    "1da40d20-026a-4b22-8e6c-8943e0180ed7": {
        "text_answer": "  The statement the presence of a history of pulmonary embolisms and current breast implants disqualifies patients from participation in both the primary and secondary clinical trials is entailed in the trials exclusion criteria  In the primary trial the exclusion criteria include History of clotting disorder hypercoagulable state and Breast implants A history of pulmonary embolisms is a type of clotting disorder",
        "label": "Entailment"
    },
    "6b6d3087-435b-4129-b368-29d8879f7ff4": {
        "text_answer": "  The statement Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention is entailed in the given information in the trial description The statement specifically mentions that only the intervention arm of the study cohort 1 will be receiving the Educational DVD as part of the intervention Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "6acd26e7-8103-4b23-aa31-413998ccbde6": {
        "text_answer": "  The statement is contradictory to the intervention description in the primary clinical trial In the trial patients receive oral lapatinib and tamoxifen daily not intravenous lapatinib",
        "label": "Entailment"
    },
    "14954e3a-d984-46dc-af8d-29f22c0ca85e": {
        "text_answer": "  The statement patients with clearcell adenocarcinoma or gestational trophoblastic disease determined by flow cytometry or pagets disease of the nipple are ineligible for both the primary trial and the secondary trial is entailed in the trials as these conditions are listed as exclusion criteria in both trials  In the primary trial clearcell adenocarcinoma and gestational trophob",
        "label": "Entailment"
    },
    "f2bac26a-95c8-4ac8-8356-26c3d96e8797": {
        "text_answer": "  The statement biliary colic and diarrhoea are more frequently observed in the secondary clinical trial as opposed to the primary clinical trial is entailed in the given trials if we consider the frequency of these specific adverse events only The secondary trial has a higher frequency of both biliary colic 16 or 1667 and diarrhoea 16 or 1667 compared to the primary trial where",
        "label": "Entailment"
    },
    "fdc7efac-ca90-4897-9660-a42dbba2bd84": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX between the two groups during the fourth week of the trial   The percentage change in betaCTX for the AZD0530 175 mg group was 711 759 to 654 and for the Zoledronic Acid 4 mg group was 684",
        "label": "Entailment"
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "text_answer": "  The statement None of the individual adverse event types recorded in the primary trial affected more than one patient is an entailment of the given data if we interpret the statement as follows  For each distinct adverse event type mentioned in the primary trial no more than one patient experienced that adverse event  The given data supports this interpretation as each adverse event type Ileus General disorders and administration site conditions  Other disease progression",
        "label": "Entailment"
    },
    "74178d28-3c60-4439-944a-84318eff5c92": {
        "text_answer": "  The statement a patient that has received an organ transplant within the last month and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   However the statement implies some information not explicitly stated in the criteria The primary trial excludes participants who have received irradiation to a major bone marrow area within 30 days prior",
        "label": "Contradiction"
    },
    "69959fb0-ee1c-4fb2-a968-677802eb1c82": {
        "text_answer": "  To determine if the statement 72 more participants in the ERpositive Luminal B group of the primary trial demonstrated a decrease in the growth factor signature than in the Triple Negative group is entailed or contradicted by the given trials we need to calculate the difference in percentage points between the two groups and then determine if the difference is greater than 72  First lets calculate the difference in percentage points  ER",
        "label": "Entailment"
    },
    "f43219f1-3807-4c37-9240-bf1d9f54d5e8": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 5 days are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose",
        "label": "Contradiction"
    },
    "987667fb-e888-40d7-ab77-f0138d9295ba": {
        "text_answer": "  The statement the primary trial has a higher presence of biliary colic and clostridium difficile colitis compared to the secondary trial is contradictory to the information provided in the trials   The primary trial reports 328 4122 instances of biliary colic and 082 1122 instances of clostridium difficile colitis The secondary trial",
        "label": "Entailment"
    },
    "02da2719-af96-4d84-bf69-ac1a2d6fd01c": {
        "text_answer": "  The statement in the primary clinical trial less than 5 of the participants experienced adverse events is entailed in the given trial data since the total number of adverse events is 2 and the total number of participants is 35 Therefore the percentage of participants who experienced adverse events is 235 x 100  571 which is less than 5",
        "label": "Entailment"
    },
    "f3a4ac87-2a6b-476f-91e2-b056e231f20a": {
        "text_answer": "  The statement the patients in cohort 1 and 2 of the primary clinical trial demonstrated a clear pattern for the expression of the set of 40 evaluated genes is neither entailed nor contradicted by the provided trial results The trial results only report the number of participants in each cohort with no discernible gene expression pattern not whether there was a clear pattern for both cohorts 1 and 2",
        "label": "Entailment"
    },
    "cfcfc39b-c969-474d-b85c-090dda68b1f1": {
        "text_answer": "  The statement the primary clinical trial and secondary clinical trial saw no instances of cardiac or psychiatric adverse events is entailed in the given trials data since both trials reported a total of 0 adverse events for cardiac and psychiatric categories",
        "label": "Contradiction"
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "text_answer": "  The statement There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial is contradictory to the given data   In the primary trial there is 0 case of Bronchopneumonia and General physical health deterioration In the secondary trial there is 1 case of each Therefore the secondary trial has more cases of both adverse events than the primary trial ",
        "label": "Entailment"
    },
    "4bebbb9f-9a62-4b07-b91a-1321f312229e": {
        "text_answer": "  The statement the findings from the primary clinical trial show that the arm A intervention resulted in the highest overall response rate and in the secondary clinical trial the denosumab group showed an improved time to first onstudy SRE in comparison to the zoledronic acid group is not directly entailed in the given trials as they address different outcomes and patient populations The primary trial compares two different chemotherapy regimens Arm A and Arm B and",
        "label": "Contradiction"
    },
    "5e7e3d88-6a13-4849-bad5-4ac52b100140": {
        "text_answer": "  The statement the primary clinical trial recorded a total of 0 aes for both cohorts is entailed in the given trials data as both cohorts had a total of 0 adverse events AEs each with no events recorded for either cohort AEs 1 or 2",
        "label": "Entailment"
    },
    "bd6fc353-2823-4e35-b811-a19c8318fda4": {
        "text_answer": "  The primary trial had 13 participants analyzed while the secondary trial had 30 participants analyzed Therefore the statement the primary clinical trial had a larger participant count than the secondary clinical trial is a contradiction based on the given information",
        "label": "Contradiction"
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "text_answer": "  The statement is not entailed in the trials as they address different outcome measurements The primary trial measures the number of participants with treatmentemergent adverse events at the end of Cycle 1 while the secondary trial measures the change in total sleep time in minutes as measured by polysomnography before and after the first cycle of Lenalidomide treatment These two trials do not directly relate to each other and the statement does not follow from the",
        "label": "Contradiction"
    },
    "ef186582-5995-47ca-a190-616f94342715": {
        "text_answer": "  The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement however they are not explicitly excluded from the secondary trial is neither entailed nor contradicted by the information provided in the inclusion and exclusion criteria for both the primary and secondary trials   The primary trial does not mention any age requirement but it does state that postmenopausal status must be confirmed The secondary trial includes a criterion",
        "label": "Entailment"
    },
    "53459054-8f8c-4fd1-9d1f-2f109c45c5b8": {
        "text_answer": "  The statement the count of total adverse events in the secondary clinical trial was notably less than what was documented in the primary clinical trial is a contradiction to the given trials data   The trials data states that for the primary trial the total count of adverse events for Adverse Events 1 is 00 and for the secondary trial the total count of adverse events for Adverse Events 1 is 015 0",
        "label": "Contradiction"
    },
    "25c8668a-29f5-4bf0-9c35-89ba2e5e1776": {
        "text_answer": "  The statement ovarian rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the ovaries The secondary trial recorded 11 more AEs than the primary trial is entailed in the trials if we consider that the statement about the type of tumor and the number of participants in the trials are not relevant to the comparison of adverse events The focus is on the difference in the",
        "label": "Entailment"
    },
    "2cc63d25-8209-41a8-b9a3-fcc4af6d9caa": {
        "text_answer": "  The statement patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer is not directly entailed in the given inclusion and exclusion criteria for the primary trial   However the statement is not contradictory to the criteria as well The criteria specify different inclusion criteria for Phase 1 and Phase 2 of the trial In Phase 1 there is no mention of ER status for breast cancer",
        "label": "Contradiction"
    },
    "fe0da901-6c2a-4ae8-b35f-a3090f93f12d": {
        "text_answer": "  The statement does not directly entail or contradict the information given in the trials   The trials describe two different dosing schedules for CUDC101 5 daysweek and 3 daysweek in cohorts 1 and 2 respectively The statement mentions that both cohorts receive the same dosage of CUDC101 but it does not mention the frequency or any other details about the administration of",
        "label": "Entailment"
    },
    "eab52a37-149f-4b49-bf37-891e8e201956": {
        "text_answer": "  The statement difficulty understanding me in a noisy room is a question about how often other people have difficulty understanding an individual in a noisy room is not directly related to the trials described in the text   However we can verify whether the statement is entailed or contradicted by the information given about the trials as follows  1 The statement does not contradict the trials as it does not contain any information that is inconsistent with the trials",
        "label": "Entailment"
    },
    "b17ff44f-d9dc-4be7-b087-4329493d1c95": {
        "text_answer": "  The statement 13 participants in the primary trial were treated with the GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine is entailed in the trial information provided The trial information states Overall Number of Participants Analyzed 13 and ArmGroup Title Vacc",
        "label": "Entailment"
    },
    "94ccff26-4026-4888-9ef8-2af5aaebefad": {
        "text_answer": "  The statement the frequency of palpitations pericardial effusions and abdominal pains in cohort 1 of the secondary trial exceeded those in cohort 2 of the primary trial is contradictory to the given data   The primary trial had one case of palpitations pericardial effusion and abdominal pain each while the secondary trial had none Therefore the frequency of these adverse",
        "label": "Entailment"
    },
    "94e5871f-085c-4757-9941-3c83a71da6a4": {
        "text_answer": "  The statement the data from the primary clinical trial reveals that the arm A intervention had the superior overall response rate is entailed in the trial data as follows   Arm A had an overall response rate of 676 25 out of 37 participants  Arm B had an overall response rate of 600 21 out of 35 participants  Therefore the statement is an accurate reflection of",
        "label": "Entailment"
    },
    "c70735d3-1bc3-41d8-b0d3-15a49abe4862": {
        "text_answer": "  The statement the participant with the highest PFS in the primary clinical trial was able to survive for 35 months without progression of disease or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in an individual participant Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "f0278adc-ef45-43ab-b957-d26918e3a5e2": {
        "text_answer": "  The statement is entailed in the Trials based on the following analysis  The primary trial exclusion criteria include a history of cardiac conditions but it does not mention anything about a history of using gabapentin or pregabalin as an exclusion criterion In contrast the secondary trial inclusion criteria state that prior use of gabapentin or pregabalin is a disqualifying factor  Therefore the statement that utilization of gabap",
        "label": "Entailment"
    },
    "11d451c7-7354-44f6-95b4-2b794a72fdbb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks A 300 longer duration would mean that the interventions in the secondary trial lasted three times as long as those in the primary trial which is not the case The statement is incorrect",
        "label": "Entailment"
    },
    "ef2bc415-dff4-4732-8e34-f538b570c671": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given trial information we need to examine the trial details more closely Based on the provided information it is not clear if the trial of MM111 involves any surgical or imaging procedures Therefore the statement the primary clinical trial intervention necessitates psychosocial interventions omitting surgical and imaging procedures is neither entailed nor contradicted by the given trial information We",
        "label": "Entailment"
    },
    "2a3d4de3-5604-4959-8a60-2817faeee2b8": {
        "text_answer": "  The statement is entailed in the given trial information Both the placebo and alloMSCs interventions are administered via 20 transendocardial injections of 04ml each to the left ventricle using the same NOGA Myostar injection catheter during a single procedure Therefore the dosage level and method of administration are identical for both interventions supporting the statement",
        "label": "Entailment"
    },
    "8948d41b-0742-43f8-a34f-2e1cfcaba149": {
        "text_answer": "  The primary trial lasts for 10 weeks with each session lasting 45 minutes Therefore the total number of hours for the intervention group in the primary trial is  10 weeks  4 sessionsweek  45 minutessession  1800 minutes or 30 hours  The secondary trial lasts for 24 weeks with each session lasting a week So the total number of hours for both intervention groups",
        "label": "Entailment"
    },
    "6ca72b87-353a-4ef1-89d7-b9a5bad97c27": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial allows the participation of cancer patients diagnosed with fibromyalgia thalasemic syndromes or anemia is entailed in the given trials as both trials explicitly list fibromyalgia and thalasemic syndromes as exclusion criteria in their respective sections Anemia is also an exclusion criterion in the primary trial but it is important to note that the",
        "label": "Entailment"
    },
    "4d384e46-7119-49f9-a627-0301c32ee334": {
        "text_answer": "  The statement is entailed in the trials as both trials report changes in a specific outcome measure The primary trial measures changes in pain intensity using Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures changes in bone mineral density BMD of the lumbar spine at 9 months However the primary trial does not explicitly state the time frame as 72 weeks but rather 30 minutes after",
        "label": "Entailment"
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "text_answer": "  The statement There was at least 1 case of infection in both the primary trial and the secondary trial is entailed in the given trials as follows  1 In the primary trial there was 1 case of infection reported out of a total of 32 participants 2 In the secondary trial there was 1 case of infection reported out of a total of 15 participants  Since both trials report at least 1 case of infection",
        "label": "Entailment"
    },
    "8b0efa30-40c4-408e-a91b-ded68b61d9ff": {
        "text_answer": "  The statement on average patients from the primary trial survive over 24 months however at least one patient from both cohorts died in under 24 months is not directly entailed in the given trials as they do not provide the average survival time for both groups beyond the reported medians and the number of patients who died before 24 months However it is possible for this statement to be true based on the reported data as both groups had some patients with",
        "label": "Contradiction"
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "text_answer": "  The statement is entailed in the trials as it accurately summarizes the difference in interventions between the two cohorts In cohort 1 patients receive sunitinib at starting doses of 25 mg to 375 mg daily In contrast cohort 2 patients receive bevacizumab at a dose of 10 mgkg Therefore the statement correctly identifies the distinct interventions for each coh",
        "label": "Entailment"
    },
    "e9ad9d15-a15f-4f20-85f4-5da69c7592d6": {
        "text_answer": "  The statement patients with a cancer diagnosis who also have epilepsy thalasemic syndromes or anemia are ineligible for the primary clinical trial and the secondary clinical trial is entailed in the trials inclusion and exclusion criteria   Explanation   The primary trial excludes patients with epilepsy and cerebral metastasis which is a form of thalasemic syndrome Additionally it",
        "label": "Entailment"
    },
    "f05705d7-3be3-4d1d-9dca-c59c130446a1": {
        "text_answer": "  The statement is contradictory to the given trials as women with stage IV breast cancer confirmed as ER are excluded from both the primary and secondary trials The statement suggests that such women are eligible for both trials which is not the case  Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "f8adadc4-67d0-42d2-bcc9-c032279bb470": {
        "text_answer": "  The statement is entailed in the trial description The trial specifies that sunitinib is to be administered orally every day for the entire duration of the study which aligns with the statement that sunitinib is a treatment plan specifying the amount oral administration and schedule every day for the intervention The trial also mentions that capecitabine is administered for 14 days every 21 days but the statement only",
        "label": "Entailment"
    },
    "d0e16cbb-09e6-4178-80c1-2004ac2239a0": {
        "text_answer": "  The statement is contradictory to the trials provided   Explanation  The statement no adverse events were reported in the first cohort of the primary clinical trial but nearly all participants of the second cohort experienced a minimum of one adverse event is contradictory to the trials because  1 The trials do not provide information about the number or percentage of participants in the first cohort who experienced adverse events",
        "label": "Contradiction"
    },
    "964e4947-27a1-435e-84c6-d28b91d0dabe": {
        "text_answer": "  The statement intact mobility is a prerequisite for participation in the secondary trial while the same quality is also mandatory for inclusion in the primary trial is entailed in the given trials inclusion criteria Both trials require patients to have a functional ECOG  2 status which indicates that the patient is ambulatory and has intact mobility Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "eba82ab1-0348-4090-81e6-fcb63ac45537": {
        "text_answer": "  The statement on average patients from the primary trial survive over 730 days however at least one patient from both cohorts died in under 730 days is not directly entailed in the given trial results as the trials do not provide the average survival days for each group The trials only report the median survival with confidence intervals for each group Therefore it is not possible to determine the average survival based on the given information alone However it is mentioned",
        "label": "Contradiction"
    },
    "4edb9b25-9a95-4a00-ae99-ebd722187d63": {
        "text_answer": "  The statement the patient with the longest PFS in the primary trial survived 42 weeks without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in the trial Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "3426fcd0-2d5b-4d82-a9a1-93450b3336ee": {
        "text_answer": "  The statement patients are eligible to participate in both the secondary and primary clinical trial concurrently is not entailed in the given inclusion and exclusion criteria for either trial   The primary trial has specific inclusion and exclusion criteria related to menopausal status hot flushes and use of aromatase inhibitors or tamoxifen The secondary trial has inclusion and exclusion criteria related to breast cancer metastasis performance status and",
        "label": "Contradiction"
    },
    "62112a3e-48e6-4e53-bfe4-53f07c84b815": {
        "text_answer": "  The statement leptomeningeal carcinoma patients are admissible for the primary clinical trial is contradictory to the given trials eligibility criteria as stated in the disease characteristics section No meningeal carcinomatosis Therefore the statement is contradictory to the trials conditions",
        "label": "Contradiction"
    },
    "7ba831e1-4027-4ae2-842f-d52409a73ddc": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial is examining vaginal topical treatments Estring and Testosterone Cream while the secondary trial is evaluating acupuncture which is not a topical or inhalation treatment Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "f9dfe1ca-aa97-4592-a67f-706e5453c822": {
        "text_answer": "  The statement cogstateassessed objective cognitive function scores are the units of measure employed in both the primary clinical trial as well as the secondary clinical trial is not entailed in the given trials as the primary trial measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM and the secondary trial measures the objective response rate of HER2negative metastatic breast cancer using RECIST v10 criteria and F",
        "label": "Contradiction"
    },
    "f994d3fb-5191-4800-beb7-02fdd6887e3e": {
        "text_answer": "  The statement it was reported that the secondary clinical trial had multiple adverse effects affecting over 90 of the enrolled patients is contradictory to the information provided in the trials The secondary trial had a total of 30 patients with 10 adverse events which is 3333 of the total number of patients No where in the trials does it state that over 90 of the patients experienced adverse effects",
        "label": "Contradiction"
    },
    "282b67f4-97cb-4680-8f21-0102c1c7851f": {
        "text_answer": "  The statement chlamydophila is a genus of gram negative obligately intracellular parasitic bacterium in the phylum chalmydiae and the family chlamydiaceae is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone The trials only provide information about the interventions and their administration schedules",
        "label": "Entailment"
    },
    "41b82c80-55fb-41c9-84c0-ae7f552c7cf8": {
        "text_answer": "  The statement cancer patients with epilepsy thalasemic syndromes or anemia can participate in the secondary clinical trial is contradictory to the given trials as per the following reasons  Primary Trial The inclusion criteria for the primary trial state that participants with epilepsy andor cerebral metastasis are excluded Thalasemic syndromes are also listed as an exclusion criterion Anem",
        "label": "Entailment"
    },
    "242dc321-0e46-4788-ac59-22120692fd8d": {
        "text_answer": "  The statement Patients participating in the primary trial receive 100 mgm2 oral lapatinib twice a day for a full month is not directly entailed in the given intervention description The intervention description states that patients receive 100 mgm2 of oral lapatinib once daily not twice daily Therefore the statement is contradictory to the intervention description",
        "label": "Contradiction"
    },
    "784e6940-fead-497a-8d68-2869d17385ea": {
        "text_answer": "  The statement esophageal hemangioma is a capillary or cavernous hemangioma that arises from the esophagus The placebo intervention and the AlloMSCs intervention of the primary trial are administered in the same dose by transendocardial injection is not directly related to the information provided in the trials   The trials describe interventions for heart conditions specifically involving the use of allogeneic",
        "label": "Entailment"
    },
    "27b7d06c-72ee-4a57-a88a-2654824853f2": {
        "text_answer": "  The statement 1 hectopascal is a SI derived unit of pressure equivalent to one hundred pascals 1 millibar or 00145 pounds per square inch is not related to the inclusion or exclusion criteria of the primary or secondary trials Therefore it is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "5e2e6057-0a23-4780-9994-a239d28aee3a": {
        "text_answer": "  The statement is entailed in the trials as the primary trial reports results in percentage units and the secondary trial reports results in the number of participants which are distinct units of measure",
        "label": "Entailment"
    },
    "cd0b8308-0c5c-4e7c-9f4f-9e1714fc7db2": {
        "text_answer": "  The statement patients with unresectable small cell lung cancer are suitable candidates for the primary clinical trial despite the presence or absence of EGFR or PR factors is not directly entailed in the given inclusion and exclusion criteria The criteria only specify the types of cancers and their measurability prior therapy requirements age performance status life expectancy and organ function as inclusion criteria The exclusion criteria include certain illnesses allergies and pregnancy",
        "label": "Contradiction"
    },
    "c6b64745-922b-40cb-9476-b7b696d4c8c0": {
        "text_answer": "  The statement the majority of patients in cohort 2 of the primary clinical trial did not exhibit any signs of acute vomiting subsequent to the intake of aprepitant dexamethasone cytoxan and kytril is entailed in the trial results as follows  1 The trial reports that 20 out of 35 participants in cohort 2 did not exhibit any signs of acute vom",
        "label": "Entailment"
    },
    "11991b1b-f587-44fc-b675-603c06e680fe": {
        "text_answer": "  The statement is entailed in the trials as the interventions in the primary and secondary trials are not the same In the primary trial patients receive eribulin mesylate while in the secondary trial patients receive either axitinib  docetaxel or docetaxel  placebo These medications are different from each other so the trials are examining different interventions",
        "label": "Entailment"
    },
    "5e0f26d8-5fcd-4187-9591-3508d99ffafc": {
        "text_answer": "  The statement is entailed in the trials as both trials provide information on different outcome measures The primary trial focuses on Time to Progression TTP and the secondary trial focuses on the Number of Participants With Objective Response The trials do not contradict each other as they measure different aspects of the treatment efficacy",
        "label": "Entailment"
    },
    "85815543-5f42-40bc-9ad1-98037b32433c": {
        "text_answer": "  The statement both the primary clinical trial and the secondary clinical trial reported zero cases of infections among participants during the period of study is entailed in the given trials as neither trial reported any cases of infections in the adverse events section",
        "label": "Entailment"
    },
    "2da35e9e-caa7-47b4-883e-5ef8c7868708": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 0015 kg per day is not directly entailed in the provided trial information   The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose",
        "label": "Contradiction"
    },
    "951e007d-202c-4cd4-8db0-0218a7c9f851": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trials The trials do involve the usage of doxorubicin cyclophosphamide and docetaxel However the statement incorrectly asserts that there is no usage of these drugs in the trials",
        "label": "Contradiction"
    },
    "7e193fec-c5ef-4c86-8f5c-c7f6dffe11ec": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial is not directly entailed or contradicted by the given data in the trials   The trials only provide the number and percentage of adverse events for each cohort but they do not provide information on the frequency or severity of each specific adverse",
        "label": "Contradiction"
    },
    "2d0d88d5-08ba-4d77-abbc-d8df34efa630": {
        "text_answer": "  The statement is entailed in the Trials as there are no cardiac or psychiatric Adverse Events recorded in either the primary or secondary trials for Adverse Events 1 and 2 The statement about satisfaction with the natural look of reconstructed nipples is not directly related to the Adverse Events data provided but it is not contradictory to it either Therefore the statement is neither entailed nor contradictory based on the given information",
        "label": "Entailment"
    },
    "bb41bccb-2552-42ba-a5df-981bead7b941": {
        "text_answer": "  The statement proctitis ctcae is a disorder characterized by inflammation of the rectum The secondary trial recorded 11 more AEs than the primary trial is not directly entailed or contradicted by the given trials  Explanation  The statement mentions proctitis ctcae is a disorder characterized by inflammation of the rectum which is not related to the adverse events data provided in",
        "label": "Contradiction"
    },
    "73b815f4-aae1-4202-a65e-5bba7b7c6676": {
        "text_answer": "  The statement individuals who have previously experienced intense anaphylactic responses to trastuzumab are eligible for enrolment in the primary clinical trial is a contradiction to the trials exclusion criteria The exclusion criteria state that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are not eligible for the trial Therefore individuals who have previously experienced intense anaphylactic responses to trastuz",
        "label": "Contradiction"
    },
    "292d0d60-e861-47b2-9484-53b0cc80ffe1": {
        "text_answer": "  The statement the primary trial documented a higher number of patients experiencing chest pain than the secondary trial is neither entailed nor contradicted by the given trials data   The trials data does not provide information about the occurrence of chest pain in either trial Therefore it is not possible to determine if the statement is true or false based on the given data alone",
        "label": "Entailment"
    },
    "36eca12e-4e1f-4239-88bb-fdac29a6209c": {
        "text_answer": "  The statement is not directly entailed in the given trials as they do not provide sufficient information to make a definitive conclusion about the dosages of Zoledronic Acid and Denosumab in relation to the occurrence of ovarian dermoid cysts with squamous cell carcinoma The trials only mention the dosages and interventions used in each study but they do not provide any information about the incidence or relationship between the interventions and the",
        "label": "Contradiction"
    },
    "b5701488-7b4a-4e1d-a318-4cc2f2b4df39": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial states that participants in Arm I receive Vitamin B12 sublingually while the secondary trial states that participants in Arm I receive memantine orally Although the routes of administration differ sublingual vs oral the statement does not contradict the trials as both trials involve oral interventions in Arm I albeit different medications However it is important to note that the primary trial does not",
        "label": "Entailment"
    },
    "dece1720-0c33-4000-b6e1-879b75541c33": {
        "text_answer": "  The statement is not entailed in the given trials as Arimidex Anastrozole is used in the primary trial for Intervention 2 but it is not mentioned in the secondary trial However the statement does provide accurate information about Nova Scotia and its capital",
        "label": "Contradiction"
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "text_answer": "  The statement 5 patients in the primary trial suffered 3 or more adverse events is not directly entailed in the given trial data However it is not contradictory either as the data does not provide sufficient information to definitively prove or disprove the statement The trial data only lists the number of patients who experienced each specific adverse event but it does not indicate how many patients experienced multiple adverse events Therefore the statement is neither entailed nor",
        "label": "Contradiction"
    },
    "5ad108af-177f-434d-b17a-67c11c484e9b": {
        "text_answer": "  The statement there were no recorded instances of syncope across the patient cohorts of the primary trial and the secondary trial is entailed in the given trials as there were no recorded instances of syncope in either trial 000 in both trials",
        "label": "Contradiction"
    },
    "ba202357-7330-4867-9527-10dee27a64b5": {
        "text_answer": "  The statement is entailed in the trials as both cohorts receive CUDC101 at a maximum tolerated dose of 275 mgm2 but the frequency of administration differs between the two arms In Arm A CUDC101 is administered for 5 days consecutively every 14 days while in Arm B it is administered for 3 days per week for 3 consecutive weeks every 2",
        "label": "Entailment"
    },
    "3eecf12f-23fb-45ab-bf91-cc84c01a1b6a": {
        "text_answer": "  The statement is a contradiction with respect to the given trials In the primary trial dexmedetomidine is administered to the intervention group while in the secondary trial it is not administered to any group",
        "label": "Contradiction"
    },
    "0ab8abd1-3e9e-4c51-95c3-6a1114180100": {
        "text_answer": "  The statement Patients with a breast tumor 0208 cm in diameter with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial is not directly related to the statement seem to get full quickly is a question about whether an individual gets full quickly when they eat  Therefore the statement about getting full quickly or not is not entailed in the given trials inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "4dca77c0-d73d-4205-9d8e-8c2e897049d5": {
        "text_answer": "  The statement Over 50 of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly entailed or contradicted by the information provided in the trial results   The trial results do not mention the proportion of participants who experienced acute vomiting in cohort 2 They only provide the number",
        "label": "Contradiction"
    },
    "6668780b-0a4f-4c25-895f-3fb5fc7c604a": {
        "text_answer": "  To verify if the statement is entailed in the trial results we need to calculate the total treatment duration in minutes and the percentage change in Ki67 expression   First lets calculate the total treatment duration for one patient in each arm  TAK228  Tamoxifen  TAK228 16 weeks  7 daysweek  24 hoursday  60 minutes",
        "label": "Entailment"
    },
    "05cd9540-60f6-4255-a4a5-fadff61801eb": {
        "text_answer": "  The statement is a contradiction to the given trials as there is no mention of dental examination records or eye examination reports in the inclusion or exclusion criteria for either the primary or secondary trials",
        "label": "Contradiction"
    },
    "b544a7fd-b1d9-402c-b003-22d14774531c": {
        "text_answer": "  To determine if the statement is entailed in the trials or contradictory we need to compare the ORR and the number of participants between the two groups directly   The statement is the primary clinical trial group with paclitaxel plus bevacizumab plus gemcitabine exhibited a superior ORR compared to the group with just paclitaxel plus bevacizumab  From the given trials we have the",
        "label": "Entailment"
    },
    "ba5f6986-4060-4bcb-92ab-6423657d51ba": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does not mention any insulin injections for participants The secondary trial mentions Fulvestrant being given intramuscularly but it is not the same as insulin injections   Moreover the statement mentions that both groups in the secondary trial are offered tryptophan supplements and deep sleep therapy but the trials do not provide any information",
        "label": "Entailment"
    },
    "0cbbe925-cc6b-464a-b601-176c35b63a31": {
        "text_answer": "  The statement women with the ability to conceive and sexually productive men qualify for the primary clinical trial though there are extra prerequisites is entailed in the given inclusion and exclusion criteria   The inclusion criteria state that women of childbearing potential WOCBP are allowed in the study as long as they use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with be",
        "label": "Entailment"
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "text_answer": "  The statement is contradictory to the trials provided In the primary trial the intervention is administered sublingually while in the secondary trial the intervention in Arm I is administered orally as memantine hydrochloride tablets which is taken by mouth Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "0bfa5116-f8a5-4bba-b279-bc071c6ff725": {
        "text_answer": "  The statement women aged 18 or older are eligible for the secondary trial and the primary trial is entailed in the given trials as both trials include women aged 18 or older as a common inclusion criterion  Regarding the second part of the statement have poor or reduced appetite is a question about whether an individuals appetite is or was reduced from normal this statement is not directly related to the inclusion or exclusion criteria of the given",
        "label": "Entailment"
    },
    "21400daa-b71d-43ac-9a54-fb9497b2a723": {
        "text_answer": "  The statement patients diagnosed with earlystage basal cell carcinoma of the skin irrespective of hormonal status are eligible for the primary clinical trial is not entailed in the given inclusion and exclusion criteria The criteria only specify eligibility for patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone receptor positive postmenopausal status",
        "label": "Contradiction"
    },
    "45741764-5967-4905-83dc-06481353f56b": {
        "text_answer": "  The statement is neither entailed in the primary trial nor the secondary trial as they do not mention anything about roboticassisted imaging The trials only report on the Maximum Tolerated Dose MTD or Maximum Feasible Dose of different interventions ruxolitinib in combination with paclitaxel and MM111 in clinical trials",
        "label": "Entailment"
    },
    "74f1ae66-88fd-4508-ba6b-2ad19274d6e3": {
        "text_answer": "  The statement some of the time is a response indicating that something happens or happened some of the time is not directly related to the given trials However we can verify if the statement More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery is entailed or contradicted by the trials  Based on the given trials",
        "label": "Entailment"
    },
    "9f402778-d71e-4f5b-9653-eed11679ecc9": {
        "text_answer": "  The statement is contradicted by the information provided in the trials   Explanation   The statement assumes that all individuals in the primary clinical trial receive the same intervention regardless of their cancer condition However the trials clearly specify different interventions for Adult Cancer Patients 65 Years of Age and Older and Healthy Volunteers Therefore the statement is contradicted by the information provided in the trials",
        "label": "Contradiction"
    },
    "1f54533d-d67f-4863-90a6-ebc13199f27e": {
        "text_answer": "  The statement no patients in the secondary clinical trial are given paclitaxel cyclophosphamide or pegfilgrastim is a contradiction to the information provided in the secondary trial description   In the secondary trial description participants receive docetaxel which is a taxane drug like paclitaxel but they do not receive paclitaxel specifically Additionally cyclophosphamide is given in the first part of the",
        "label": "Contradiction"
    },
    "3add5ce6-4581-491c-b501-2c071860ece3": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial states that patients receive 150 mg of oral pregabalin twice daily which translates to 300 mg per week or 1800 mg over 6 weeks The statement in the question however mentions that patients receive 150 mg of pregabalin every two weeks which is equivalent to 300 mg per month or 180",
        "label": "Entailment"
    },
    "31dea0ef-a953-4217-9e00-bac1c96a7325": {
        "text_answer": "  The primary and secondary trials both involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine DMCHOCPEN as the pharmacological treatment However the primary trial focuses on the use of Abl Cells in combination with Cyclophosphamide while the secondary trial does not mention the use of Abl Cells Therefore while the pharmacological treatment is the same",
        "label": "Entailment"
    },
    "4b6d301f-d0c7-45c9-a39a-ff973e0b9d45": {
        "text_answer": "  The statement neither the primary nor the secondary clinical trial requires the participants to be of a certain nationality or gender is entailed in the given trials as there is no mention of nationality or gender as inclusion or exclusion criteria in either trial",
        "label": "Entailment"
    },
    "0655111b-b8fe-46c7-8332-433a747efbcc": {
        "text_answer": "  The statement there were no important differences in the findings of the primary clinical trial groups and the outcomes from the reflexology group and control group in the secondary trial were indistinguishable is not directly entailed in the given trials as there is no comparison of the primary trial results with the secondary trial outcomes provided in the information given The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology",
        "label": "Contradiction"
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive the same doses of radiation therapy and undergo a SPECT scan at baseline and 6 months followup Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "text_answer": "  The statement The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope which occurred in 2500 of the primary trial patients is a contradiction to the information provided in the trials  The primary trial reported that Syncope occurred in 2500 of the patients but it was not mentioned as the most commonly occurring adverse event in the secondary trial In",
        "label": "Contradiction"
    },
    "9d196526-1000-4235-add7-49de8e168d3b": {
        "text_answer": "  The statement there are more cases of bronchopneumonia and general physical health deterioration in the secondary clinical trial than in the primary clinical trial is entailed in the given data if we consider the number of cases for each adverse event separately However it is important to note that the statement does not take into account the total number of participants in each trial In the given data there are 14 participants in the secondary trial and 3 in the primary",
        "label": "Entailment"
    },
    "664f769a-791d-4188-8937-c3269d6e0dde": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial specifies a breast tumor of 1 cm in diameter while the statement mentions a tumor of 100 mm in diameter which is significantly different and not permissible in the primary trial The secondary trial does not mention the tumor size at all Therefore the statement is contradictory to the given trials",
        "label": "Entailment"
    },
    "22f97249-204f-4d0e-a76f-eb9b8441c8da": {
        "text_answer": "  The statement over 910 patients in the primary trial treated with lapatinib 025 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is not entailed in the given trial results   The trial results only report the outcomes for the armgroup of participants who received Lapatinib 1000 mg  NabPaclitaxel",
        "label": "Contradiction"
    },
    "de23d1f1-23e0-4f92-bdfd-b2bf37f08250": {
        "text_answer": "  The statement cohort 1 in the primary clinical trial receives 0035 mg less of alt801 than what is administered to cohort 2 is entailed in the trials if we consider the given dosages   Explanation   The statement implies that the difference in dosages between the two cohorts is 0035 mg Based on the information provided in the trials co",
        "label": "Entailment"
    },
    "eb8dca8b-34a9-46d0-a845-80c4b5343ec6": {
        "text_answer": "  The statement the results obtained from cohort 2 of the secondary clinical trial were more favorable compared to those from cohort 2 of the primary clinical trial cannot be determined based on the provided information   The primary clinical trial and the secondary clinical trial measure different outcome measures The primary trial focuses on breast cancerspecific quality of life using the FACTB instrument while the secondary trial focuses on intraoperative success in addressing positive margins",
        "label": "Entailment"
    },
    "ae5ec938-2ef4-4533-9ab9-3314de8525a1": {
        "text_answer": "  The statement is not entailed in the trials provided   The trials only report the number of participants in each group who were analyzed up to 5 years after randomization They do not provide information on the number of participants who experienced recurrencefree survival in each group Therefore it is not possible to determine if the statement is entailed in the trials based on the given information",
        "label": "Contradiction"
    },
    "ea69e1bc-816a-4ba8-abd0-9882b12b70ea": {
        "text_answer": "  The statement there was one case of shingles recorded in group 2 of the secondary trial but no cases in group 1 of the secondary trial and the primary trial is not directly related to the statement basal cell of the squamous epithelium is a basal cell located in the squamous epithelium   Therefore the statement is neither entailed nor contradictory to the trials provided",
        "label": "Contradiction"
    },
    "fe6f8d5f-5105-4495-828f-f6ef19a7cc9d": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections of 120 milligrams every 4 weeks which translates to 480 milligrams or 480000 micrograms per month The statement incorrectly states that patients received 120000 micrograms of denosumab per month  ",
        "label": "Entailment"
    },
    "deff33e5-6172-4caa-940e-4ca7aaca8d80": {
        "text_answer": "  The statement the primary trial recorded a greater number of adverse events in its cohort compared to the secondary trial is contradicted by the given information Both trials reported no adverse events in their respective cohorts Therefore the statement is not entailed by the given trials",
        "label": "Contradiction"
    },
    "057e665a-1e29-4e11-866e-16483eeb0420": {
        "text_answer": "  The statement Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial is entailed in the Trials exclusion criteria   In the primary trial the exclusion criteria include Significant cardiovascular impairment Congestive heart failure Clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last",
        "label": "Entailment"
    },
    "4dd24d14-3357-43a0-973f-d535802507cb": {
        "text_answer": "  The statement is a contradiction with respect to the given trials   In the primary trial Group 2 receives dexmedetomidine while in the secondary trial patients in both cohorts do not receive dexmedetomidine Therefore the statement that patients in the secondary trial cohorts do not receive any Dexmedetomidine contradicts the primary trial where some patients in Group 2 do receive it",
        "label": "Contradiction"
    },
    "f59c5c18-e772-4c9b-a5f2-cdb3bdd812f2": {
        "text_answer": "  The statement pericardial effusions were a more frequent occurrence in patients from the primary clinical trial in comparison to corneal deposits which were more prevalent in the secondary clinical trial is entailed in the given trials data  Explanation  The statement compares the frequency of two different adverse events pericardial effusions and corneal deposits across two clinical trials The trials data provided shows that the",
        "label": "Entailment"
    },
    "64d56259-f688-42c5-8946-0022bd4aa57c": {
        "text_answer": "  The statement Patients in the primary trial that didnt receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions is not directly entailed in the given trials as they do not provide information about the administration route of paclitaxel other than intravenous IV infusion in Arm I and standard of care in Arm II The statement mentions nothing about intraosseous route of administration Therefore the",
        "label": "Contradiction"
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "text_answer": "  The statement is an entailment given the information provided in the trials   Explanation  In the primary trial Intervention 2 includes Armodafinil being administered daily for 47 days while in the secondary trial Armodafinil is not mentioned at all However the statement focuses on the fact that in the primary trial only one cohort receives Armodafinil PO daily whereas",
        "label": "Entailment"
    },
    "e0cc56e6-9466-4d28-a94e-4a9dcceaee76": {
        "text_answer": "  The statement participants of cohort b in the primary clinical trial receive two electroporation injections of ld v934 is contradictory to the given trial information   The trial description for Intervention 2 in Part A states that Three electroporation EP injections of V934 LD were administered which means that each participant in that group received three electroporation injections of V93",
        "label": "Entailment"
    },
    "29eab9d1-1649-401a-8ff7-95fcd6a2c09a": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial the Intervention 2 group receives 05ugkg of dexmedetomidine 5ml not 9ugkg 90ml   In the secondary trial no dexmedetomidine is administered to any patients Therefore the statement that group 2 of the primary trial receives 9ugkg of",
        "label": "Contradiction"
    },
    "67dcd165-45dd-439f-980d-62c960f50c37": {
        "text_answer": "  The statement Any patients that have undergone Antineoplastic chemotherapy Androgens Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial is entailed in the inclusionexclusion criteria of the trial as stated  Exclusion Criteria  Any of the following current  4 weeks prior or planned therapies    Antineoplastic chemotherapy antiHER",
        "label": "Entailment"
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "text_answer": "  The statement less than 10 of the primary trial participants had a Reduction in circulating tumor cells Following months of Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed or contradicted by the information provided in the trial results Results 1   The trial results only report the number of participants with a reduction in CTCs at one month post AHST not the percentage of participants",
        "label": "Contradiction"
    },
    "4ceb3f73-8812-4534-9688-52e5d3db524f": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The trial description specifies that participants will receive epirubicin cyclophosphamide docetaxel and trastuzumab during the study duration The total amount of each drug administered will vary based on body surface area BSA but the maximum dose of epirubicin is 100 mgm2 cyclophosph",
        "label": "Entailment"
    },
    "f64f4990-f41a-49c2-ab74-5897b191c256": {
        "text_answer": "  The statement the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts is entailed in both trials as they both include cyclophosphamide in their interventions The additional statement sexually active is a response indicating that an individual is or was sexually active is not related to the trials and does not affect the entailment relationship between them Therefore the statement the primary trial and the secondary trial both administer cycl",
        "label": "Entailment"
    },
    "2c8bef4e-9452-4ff9-b04d-66b0f42196d8": {
        "text_answer": "  The statement over 185 of patients in the primary trial and the secondary trial suffered from infections during the study period is a contradiction to the information provided in the trials   The total number of patients in both trials is 47 32 from the primary trial and 15 from the secondary trial The total number of patients who experienced infections in the primary trial was 13 406 of the total number",
        "label": "Contradiction"
    },
    "e809d4b1-1730-49a2-aa9f-303afb27b175": {
        "text_answer": "  The statement is not entailed in the trials as they are about two different interventions for cancer treatment and the statement is about trichostrongylus colubriformis a species of parasitic roundworms that causes black scour disease in animals The trials do not mention anything about trichostrongylus colubriformis or black scour disease Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "e01e4e41-3577-4556-b481-de0d3777ba18": {
        "text_answer": "  The statement 17q21q22 is a chromosome band present on 17q candidates must undergo a Mammography before being able to participate in the primary trial this is not required for the secondary trial is neither entailed in the primary nor the secondary trials as there is no mention of chromosome testing or the requirement for mammography in the secondary trials inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "83e7efec-6077-4c3c-8ed6-ebe4f715da47": {
        "text_answer": "  The statement a patient with no detectable tumor based on clinical examination and ultrasonography would fail eligibility for both the primary trial and the secondary trial is entailed in the trials as follows  In the primary trial the inclusion criteria state that the patient must have a primary tumor greater than 2 cm diameter and there is no mention of exceptions for patients with no detectable tumor Therefore a patient with no detectable tum",
        "label": "Contradiction"
    },
    "bffaad67-a8e9-43bf-a2ca-bbcaec96218c": {
        "text_answer": "  The given statement upon giving fully informed consent patients suffering from stage 4 cancer can qualify for both secondary clinical trial and primary clinical trial is not entailed in the provided inclusion and exclusion criteria for either the primary or secondary clinical trials  The primary trial includes patients with stage IIbIIIIV breast cancer but it excludes those who have received two or more chemotherapy regimens for metastatic breast cancer The secondary trial includes patients with",
        "label": "Contradiction"
    },
    "201ec8b0-f2f0-4c60-8094-0f40761f6d88": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement implies that there were more adverse events in the primary trial than in the secondary trial but the trials both report that there were no adverse events in either trial for the given categories Therefore the statement is contradictory to the facts presented in the trials",
        "label": "Contradiction"
    },
    "626b2407-ae7b-43ed-96b6-3ee9e3c290c8": {
        "text_answer": "  The statement only nonpregnant individuals are eligible to participate in the primary clinical trial is not explicitly stated in the given inclusion and exclusion criteria However the criteria do mention that only female patients are eligible but they do not specify whether they must be nonpregnant or not Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "6d595852-44de-4516-9ac8-441283808f1f": {
        "text_answer": "  The statement no adverse events were experienced by 97 of patients participating in the primary clinical trial is not directly entailed in the given trial results The trial results provide information on the percentage of subjects who completed the treatment regimens 98 for systemic chemotherapy and 922995 for maintenance therapy but they do not explicitly state that no adverse events were experienced by this percentage of patients Adverse events",
        "label": "Contradiction"
    },
    "57d179a7-e550-486f-ba5b-40dcdc8927a0": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial is a consequence or implication of the trials exclusion criteria Specifically the exclusion criteria state that Patients who have received prior chemotherapy with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from this clinical trial Therefore the statement is entailed in the",
        "label": "Entailment"
    },
    "b315a999-4315-4e95-95e7-9f402f9d979e": {
        "text_answer": "  The statement no cardiacrelated adverse events have been identified in the first cohort of the primary clinical trial is entailed in the given data from the first trial Adverse Events 1 since none of the cardiacrelated adverse events Angina Pectoris Cardiac Arrest Cardiac Failure Cardiac Tamponade Acute Coronary Syndrome and Cardiac Tamponeade are present in",
        "label": "Contradiction"
    },
    "ba6526b2-e565-4c7b-b931-42590bb703c0": {
        "text_answer": "  The statement eligibility for the primary clinical trial is not determined by conditions on mental health bodyweight size of tumors KarnofskyECOG score or estimated life expectancy is not explicitly stated in the given inclusion and exclusion criteria However it can be inferred that these factors are not mentioned as criteria for eligibility or exclusion Therefore the statement is entailed by the information provided in the trial description",
        "label": "Entailment"
    },
    "81ec9878-e668-49dd-99eb-49ea13337c8f": {
        "text_answer": "  The statement ability to think and solve daytoday problems is a question about an individuals ability to think and solve daytoday problems is not directly related to the given trial criteria It does not entail nor contradict any information provided in the trial description",
        "label": "Entailment"
    },
    "ef95d23d-9dc6-494b-9085-b5ccc6822525": {
        "text_answer": "  The given statement there were 75 cases of hypertension dehydration and dyspnea in either cohort of the primary trial is not entailed in the provided trials as there is no information about the number of cases of hypertension dehydration and dyspnea in the trials",
        "label": "Contradiction"
    },
    "41bf82f2-9544-471f-88b0-418e6cd9b5e1": {
        "text_answer": "  The statement is partially entailed in the trials   Explanation   The statement The placebo and Trabectedin intervention in the primary trial are both administered through a 3hour intravenous infusion on a biweekly basis is not exactly entailed in the given information However it is true that both interventions are administered through a 3hour intravenous infusion in the trial The",
        "label": "Entailment"
    },
    "87d7f63c-5fa5-4820-af0e-391ef8986199": {
        "text_answer": "  The statement over 50 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR is not directly entailed in the given trial results The trial results only report the percentage of participants who experienced either a CR or PR but they do not specify the exact number of participants who experienced a CR Therefore the statement goes beyond the information provided in the trial results and",
        "label": "Contradiction"
    },
    "41e9a0e8-3838-4609-86e7-dc9b798db67c": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The alloMSCs intervention is administered via transendocardial injections not intravenous infusion and the dose of alloMSCs 100 million is not higher than the placebo Buminate solution in terms of volume per injection 04ml for both Therefore the statement is contradictory to the information given in the",
        "label": "Entailment"
    },
    "dc8d6268-fd08-4c31-b2d6-50e8a8e750c0": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients receive weekly injections of an unspecified intervention for a month In the secondary trial participants receive a single subcutaneous injection of epoetin beta at the onset These are different interventions with different frequencies and durations Therefore the statement that secondary trial participants are administered just one sc injection at the onset while the primary",
        "label": "Entailment"
    },
    "20e20d13-e73f-4df9-b6f7-37df97b32917": {
        "text_answer": "  The given statement throughout the 10 weeks of the primary clinical trial a number of participants experienced no pain is not entailed in the provided trial results as there is no mention of the number of participants who experienced no pain in either the Low Dose or High Dose groups The trial results only report the average pain intensity scores and the confidence intervals for each group",
        "label": "Contradiction"
    },
    "cdbca781-b6cd-42a1-acac-80617aa1af67": {
        "text_answer": "  The statement the intervention in the primary clinical trial does not mandate the implementation of regular exercise for its candidates is consistent with the information provided in the trial description The trial description mentions that the intervention includes patients with various types of cancer and that G8 assessment and at least one other multidimensional assessment are required It does not mention regular exercise as a mandatory component of the intervention Therefore the statement is entailed by the trial description",
        "label": "Entailment"
    },
    "695ba633-5bf3-48ee-b6f9-f77657f827b7": {
        "text_answer": "  The statement candidates who are significantly limited in their selfcare ability spending more than half of their waking hours in a bed or chair may participate in both the primary clinical trial and the secondary clinical trial is not explicitly stated in either the inclusion or exclusion criteria of the primary or secondary trials provided Therefore it cannot be definitively determined if the statement is entailed in the trials or not as there is no clear contradiction or agreement with the given",
        "label": "Entailment"
    },
    "63c2b269-5155-4014-b033-2584a6773867": {
        "text_answer": "  The statement tongue neoplasm is a benign or malignant neoplasm involving the tongue Paclitaxel is not used in either of the primary trial interventions is not directly related to the information provided in the trials The trials only mention the interventions used anastrozole in Arm A and fulvestrant in Arm B and how they are administered but they do not provide any information about the type of tongue neoplasm",
        "label": "Entailment"
    },
    "287c1319-d37b-4a6a-a0f3-2059ce18b07d": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 48 months if they want to participate in the primary trial is a simplification of the exclusion criteria provided in the trial description However the original exclusion criteria state that",
        "label": "Entailment"
    },
    "b639e0a1-6e1d-4940-9818-a268732ed88a": {
        "text_answer": "  The statement no recurrence of malignancies absence of graftversushost disease normal red blood cell count cardiac wellbeing and healthy alveolar condition were more commonly observed in the primary trial compared to the secondary trial is entailed in the given trials as  1 The primary trial had no recurrence of malignancies 020 while the secondary trial had none reported 04 2",
        "label": "Contradiction"
    },
    "0bd3433b-05d2-416a-b0c4-0a017f546dc2": {
        "text_answer": "  The statement is entailed in the trials as the primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in units of mg These are distinct units and outcome measures and the trials do not directly compare or measure the same thing Therefore the statement is ent",
        "label": "Entailment"
    },
    "c6e636a5-7c18-47f4-9563-715fde497ee3": {
        "text_answer": "  The statement margin status cannot be assessed is a result that the patient is not eligible for the trial is not directly entailed in the given inclusion and exclusion criteria The statement only mentions that the margin status cannot be assessed as a potential result but it does not explicitly state that this is a reason for exclusion from the trial Therefore the statement is neither entailed nor contradictory to the given criteria",
        "label": "Contradiction"
    },
    "4f5fb0bf-e5bf-47ad-876c-e9aea07feaee": {
        "text_answer": "  The statement eating disorders were frequently observed among the primary clinical trial candidates is not entailed in the given adverse events data The data only lists various adverse events observed during the trial including some gastrointestinal symptoms like anorexia but it does not provide sufficient evidence to conclude that eating disorders were frequently observed among the candidates Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "4d36fe39-7874-4174-853e-dc6406bf9e0b": {
        "text_answer": "  The primary trial does not provide sufficient information to determine if the statement none of the patients in the primary trial experienced the worst pain imaginable for 20 minutes is entailed in the trials or contradictory to them The trials only report the average pain intensity scores and the change in average pain intensity between the lowdose and highdose intervention groups They do not provide any information about the distribution of pain intensity scores or the duration of pain episodes for individual",
        "label": "Entailment"
    },
    "43658af8-5289-485f-98ed-50d005e452e1": {
        "text_answer": "  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed in the given trials data   The primary trial data only provides information about the overall response rate in each arm with Arm A having a higher response rate",
        "label": "Contradiction"
    },
    "c9d6f05e-40bd-49b1-8ba1-c5489208cede": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial defines each treatment cycle as 21 days and there is no mention of a 360day cycle for the intervention The secondary trial does not have a cyclic treatment in place as stated Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "0c570cce-3180-45b9-a0b3-4dd7200fc890": {
        "text_answer": "  The statement Diarrhoea was more common for the primary trial participants than the secondary trial participants is not directly entailed in the given trials as the trials do not provide sufficient information to make a definitive comparison between the two groups regarding the frequency of diarrhea However it is mentioned that the primary trial had a higher incidence of diarrhea 2333 compared to the secondary trial 000 Therefore the",
        "label": "Contradiction"
    },
    "04d76027-45a0-46e3-9308-acc4f8c02a73": {
        "text_answer": "  The statement is not entailed in the trials provided as they measure different outcomes The primary trial measures the effect of a pain medication on pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change in bone mineral density BMD of the lumbar spine at 9 months after surgery The statement mentions two different outcomes the stage of chronic kidney disease using glomerular",
        "label": "Contradiction"
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "text_answer": "  The statement There was one psychiatric adverse event in the primary trial which affected less than 10 of patients is entailed in the given trial data   Explanation   The statement specifies that there was one psychiatric adverse event and that it affected less than 10 of patients The trial data confirms that there was one psychiatric adverse event suicidal ideation and that it affected",
        "label": "Entailment"
    },
    "3afe5a55-731f-4015-85a2-e6df1caa2374": {
        "text_answer": "  The statement patients with hypokalemia are not included in the primary clinical trial but patients with hyperkalemia may be suitable for both the primary and secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials   The primary trial explicitly states that patients must have a potassium level within the normal range of 3553 mEqL This means that patients with",
        "label": "Contradiction"
    },
    "84859b73-1029-4815-a059-79c20cc06f91": {
        "text_answer": "  The statement no psychiatric disorders like eating disorder or schizophrenia emerged as a consequence of the primary clinical trial is not directly entailed or contradicted by the given adverse events data The data only reports the occurrence of certain adverse events including suicidal ideation but it does not specify the nature or diagnosis of the suicidal ideation or any other psychiatric disorders that may have emerged during the trial Therefore the statement cannot be",
        "label": "Contradiction"
    },
    "e1069782-98e2-4db7-aeed-460b846781c3": {
        "text_answer": "  The statement is not directly entailed in the given trial information The trial describes a neoadjuvant therapy regimen for breast cancer which includes epirubicin cyclophosphamide docetaxel and trastuzumab The statement focuses on parotid gland hemangioma which is not related to the trial Additionally the statement mentions a maximum dose of 100 mgm2 for all",
        "label": "Contradiction"
    },
    "53099f5c-4259-4ad7-bff2-65d2fe6250be": {
        "text_answer": "  The statement is entailed in the trials   Explanation   In the primary trial patients undergo mastectomy surgery and are not specified to receive any particular intervention besides surgery Therefore no information is provided about the dosage of MM121 or Paclitaxel for this group  In the secondary trial there are two interventions for the HR subgroup In the first intervention patients receive a",
        "label": "Entailment"
    },
    "41b6a327-e552-4e26-971f-25096f53e72d": {
        "text_answer": "  The statement 49 of the primary trial patients suffered an increase in blood bilirubin is a contradiction to the information given in the trial data The trial data states that 909 or 1 out of 11 of the patients experienced an increase in blood bilirubin Therefore the statement that 49 of the patients experienced an increase in blood bilirubin is lower than the reported data and",
        "label": "Contradiction"
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "text_answer": "  The statement Most the primary trial candidates suffered from some kind of eating disorder during the study duration is contradicted by the given trial data   The trial data lists several adverse events but none of them indicate an eating disorder The adverse events listed include fatigue papulopustular rash increased liver enzymes alkalosis anorexia hyperglycemia nervous system disorders  other dry skin and",
        "label": "Contradiction"
    },
    "c38f4f43-886b-41e9-9d42-5ce12e838600": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial measure the percentage of participants in their studies that experience Clinical Benefit using RECIST criteria is a contradiction to the primary trial results as the primary trial does report the percentage of participants with tumor response using RECIST criteria Complete Response Partial Response Stable Disease and Progressive Disease Therefore the statement is contradictory to the information provided in the primary trial",
        "label": "Contradiction"
    },
    "feb0cfe7-6bcf-4e82-82b7-460f9cc66a18": {
        "text_answer": "  The statement patients whose metastasis is not quantifiable or whose cancer hasnt traversed to other body sections are not suitable for the primary clinical trial is not explicitly stated in the given trial criteria However the trial does specify that disease must be measurable or nonmeasurable which could be interpreted as quantifiable Therefore the statement is contradictory to the trial criteria as it suggests that patients with nonquantifiable or non",
        "label": "Entailment"
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "text_answer": "  The statement the secondary trial recorded 11 more AEs Adverse Events than the primary trial is entailed in the given trials data   Explanation   The statement implies that there are 11 more adverse events in the secondary trial compared to the primary trial From the data provided we can see that there are a total of 11 adverse events in the secondary trial and 0 adverse events in the",
        "label": "Entailment"
    },
    "5caeaa69-840d-4a32-8279-416bbe1b570e": {
        "text_answer": "  The statement is contradictory to the information provided in the given trials as the primary trial includes postmenopausal females and the secondary trial includes females with breast cancer Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "1ff9cfe0-06e6-4f99-961c-7854ba9e2c46": {
        "text_answer": "  The statement primary hypoparathyroidism is abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands Gender is not a determining factor for eligibility in the primary trial or the secondary trial is not directly related to the inclusion and exclusion criteria provided for the primary and secondary trials The trials focus on eligibility criteria for breast cancer patients undergoing chemotherapy and do not",
        "label": "Entailment"
    },
    "3f87dd7c-b00d-4840-b075-70b65e5bf00c": {
        "text_answer": "  The statement the number of bronchopneumonia cases and instances of general physical health deterioration are equal in both the primary and secondary clinical trials is contradictory to the given data   In the secondary trial there is one instance of bronchopneumonia and one instance of general physical health deterioration However the statement implies that there is an equal number of cases for both conditions in both trials Since there is a difference in the number",
        "label": "Entailment"
    },
    "13d0bb71-fc81-4ecf-8628-1321816e41ce": {
        "text_answer": "  The statement there were 0 cases of Hypertension Dehydration and Dyspnea in either cohort of the primary trial is not directly stated in the given trials However it is entailed in the trials since neither of the trials lists Hypertension Dehydration or Dyspnea as adverse events Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "43e968bb-7167-4c0a-8105-8f3e854408af": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to calculate the difference in percentage of participants demonstrating a decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups   Lets denote the percentage of participants with a decrease in GFS in the ERpositive Luminal B group as X and the percentage of participants with a decrease in GFS in the Triple Negative group as",
        "label": "Entailment"
    },
    "cdd043e8-2430-409a-96b6-8e7b7a2d11f3": {
        "text_answer": "  The statement a patient may be able to participate in the secondary trial but be ineligible for the primary trial is entailed in the given trials as some patients may meet the inclusion criteria for the secondary trial but not for the primary trial due to the presence of exclusion criteria that are unique to each trial For instance a patient undergoing immediate tissue expander reconstruction following mastectomy may be eligible for the secondary trial but ineligible for the primary trial if she",
        "label": "Entailment"
    },
    "c44751aa-dc67-42de-a619-0f0834b88325": {
        "text_answer": "  The statement is entailed in the Trials with the following justification  1 Both trials measure pCR as their outcome 2 In the primary trial there is a small difference in pCR rates between the two arms with Arm 1 having a slightly higher rate 3 In the secondary trial Arm 2 had a lower pCR rate compared to Arm 1  The statement the primary trial and the secondary trial both use p",
        "label": "Entailment"
    },
    "2d16916c-23f3-4638-8a1d-6638aeb46359": {
        "text_answer": "  The statement the results of the primary clinical trial revealed a higher count of patients having stable disease in the twelfth week as opposed to week twentyfour nevertheless none of the patients experienced complete response during these specified weeks is entailed in the trial results as stated  1 The trial results indicate that there were 12 participants with stable disease SD at week 12 and 10 participants with SD at week 24",
        "label": "Entailment"
    },
    "a24f59fe-0c4b-48bb-bbff-8dfb4b83ed6b": {
        "text_answer": "  The statement participants are required to get one injection on the 8th day of the investigation is not directly entailed in the given trial information The trial mentions that patients will receive Leukine GMCSF therapy starting one day after chemotherapy and continuing until the neutrophil count is greater than 1000mm3 However it does not explicitly state that participants will receive an injection on the 8th day",
        "label": "Contradiction"
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "text_answer": "  The given statement is entailed in the Trials as described   Explanation   The statement Neither of the primary trial cohorts receive any invasive surgery or Neratinib is consistent with the information provided in the Trials description   The Trials description specifies that Intervention 1 is a Phase 2 Triplenegative cohort and Intervention 2 is a Phase 2 HER2",
        "label": "Entailment"
    },
    "e4256cc3-09b7-4ad0-b1b1-467cd74b273c": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity 1 from each cohort is not directly entailed in the given trial results The trials only provide the number of participants in each cohort and do not mention the number of patients who experienced doselimiting toxicities The statement about the unit of time microsecond is not related to the trial results and is therefore irrelevant to",
        "label": "Contradiction"
    },
    "50757da1-c674-43a7-a3ee-90750e166aa5": {
        "text_answer": "  The statement no exacerbating factor to chief complaint is an indication that the chief complaint was not worsened by another factor is not directly related to the information provided in the trials The trials only mention the interventions memantine and placebo and their administration schedules The statement is about the relationship between the chief complaint and exacerbating factors which is not explicitly addressed in the trials Therefore the statement is neither entailed nor contradicted by",
        "label": "Contradiction"
    },
    "2c4d4e4b-1b19-4a95-a18d-7d0585c90573": {
        "text_answer": "  The statement on average patients from the primary trial survive under 2 months over 80 patients from each cohort survived more than 6 months is not entailed in the given trials as the trials do not provide enough information to make such a conclusion The trials only report the median survival times for each group and it is not mentioned how many patients survived beyond 2 months or 6 months in each group Therefore the statement is neither entailed nor contrad",
        "label": "Contradiction"
    },
    "3ff601a7-b05a-4cc4-94e3-bbea555889cb": {
        "text_answer": "  The statement Paclitaxel is not used in either of the primary trial interventions is entailed in the given trials as neither anastrozole nor fulvestrant are mentioned to be used in conjunction with paclitaxel in the provided interventions   The statement posterior tongue neoplasm is a benign or malignant neoplasm that affects the base of the tongue is not directly related to the trials and does not",
        "label": "Entailment"
    },
    "28d5dbe8-5006-4735-8274-fc37e55dbbbd": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The percentage of patients suffering adverse events is different between the two cohorts 5000 in the first cohort and 4000 in the second cohort Therefore the statement that The same percentage of patients suffered adverse events in both cohorts of the primary trial is contradictory to the facts presented in the trials  Reg",
        "label": "Entailment"
    },
    "671c7966-67b4-4279-b246-a4e415679a2d": {
        "text_answer": "  Based on the information provided in the interventions described the statement is not entailed in the trials as described The first intervention involves the use of a validated webbased risk assessment tool and decision support for providers based on the risk assessment results While the second intervention is described as usual care it does not explicitly state that no form of counseling risk assessment or cognitive behavioral therapy CBT is given Therefore the statement is not directly contradict",
        "label": "Contradiction"
    },
    "8942c478-a2ec-4b68-8da0-7fbce5bb70f7": {
        "text_answer": "  The statement primary clinical trial and secondary clinical trial dont share the same outcome assessments is entailed in the Trials as follows  1 In the primary trial the outcome assessments are percentage of participants with any treatment emergent adverse events and serious treatment emergent adverse events 2 In the secondary trial the outcome assessments are number of participants with objective response  These outcome assessments are not the same as they measure",
        "label": "Entailment"
    },
    "0dd90e62-09f5-4282-9f52-c369a56ba3f5": {
        "text_answer": "  The statement in the primary clinical trial patients who didnt undergo topical cryotherapy exhibited more severe symptoms compared to those who did is entailed in the trials based on the provided data   Explanation   The trials provide the median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline for both the Arm I Cryotherapy and Arm II",
        "label": "Entailment"
    },
    "fdf46294-f524-478f-9816-e13d7c7c3927": {
        "text_answer": "  The statement patients who have experienced a pulmonary embolism in the past year are welcome to join the primary trial and do not require an investigators decision for participation in the secondary trial is not explicitly stated in the given inclusion or exclusion criteria for either the primary or secondary trials However there is no mention of pulmonary embolism as an exclusion criterion for either trial Therefore the statement is consistent with the information provided in",
        "label": "Contradiction"
    },
    "f42c5f78-bcb9-46e9-8b77-a8b9cbb81b13": {
        "text_answer": "  The statement on average patients from the primary trial survive over 3 years however at least one patient from both cohorts died in under 30 minutes is not directly entailed or contradicted by the given trial results   The trial results only provide the median survival times for each group and the statement makes a claim about the average survival time for all patients in the trial which is not explicitly stated in the results Additionally the statement mentions that",
        "label": "Contradiction"
    },
    "a441e08e-affc-4228-bfac-18ab1ead4bce": {
        "text_answer": "  The statement is entailed in the trials as the trials describe different outcomes being measured in each study The primary trial measures the change in Isothiocyanate concentration in urine samples while the secondary trial measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale Therefore the statement accurately reflects the differences between the two trials",
        "label": "Entailment"
    },
    "f9b21d3d-3d5d-4cc6-bf70-733083138b99": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement 100 adverse events were observed in the primary trial is not consistent with the information provided in the primary trial which states that there were 0 adverse events out of 25 patients   Furthermore the statement does not provide any information about the secondary trial that would allow for a comparison to be made regarding adverse events",
        "label": "Entailment"
    },
    "13d5fd15-4fe1-4152-8987-050cfb32c8fb": {
        "text_answer": "  The given statement is not directly entailed in the provided trial results as the trials do not report the Recurrencefree Survival data for each group The statement seems to be making a comparison of the Recurrencefree Survival between the two groups based on some external knowledge or assumption However the trials only provide the number of participants in each group and their status analyzed or not Therefore the statement cannot be definitively verified or contradicted based",
        "label": "Contradiction"
    },
    "dd5c2791-351d-472f-8c50-a773aa9baa41": {
        "text_answer": "  The statement Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial the final decision for inclusion will be made by the patients first of kin is not entailed in the given trial criteria The trial criteria only specify that the final eligibility is determined by the health professionals conducting the trial Therefore the statement is contradictory to the trial criteria",
        "label": "Contradiction"
    },
    "b71e8f1d-2910-4ac7-9aaf-e709679b0083": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial the intervention consists of a single drug Gefitinib ZD1839 with two different doses 2 In the secondary trial there are two interventions    a Intervention 1 Zoledronic acid vitamin D and calcium supplements which consist of three different types of drugs    b",
        "label": "Entailment"
    },
    "3ad0bf0d-7929-4d29-9629-4fea3e6c8fc5": {
        "text_answer": "  The statement vinblastine and doxorubicin are routinely used in the primary clinical trial and the agent for the secondary clinical trial remains undisclosed is neither entailed nor contradicted by the information provided in the trials   The primary trial mentions the use of suramin and paclitaxel but it does not mention vinblastine and doxorubicin The secondary trial only mentions that the agent for the",
        "label": "Entailment"
    },
    "2aa37ee1-47f4-4ee2-a2d5-b11181a89e78": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement suggests that both Cohort A and B received the same number and type of electroporation injections of LD V934 However the trials describe different administration schedules for each cohort Cohort A received three electroporation injections of LD V934 followed by two IM injections of LD V93",
        "label": "Entailment"
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "text_answer": "  The statement The primary trial intervention section does not outline a treatment cycle or any description of the treatment is a contradiction to the information provided in the intervention 1 description The statement Subjects enrolled with device placed and treated with partial breast irradiation implies that the treatment involves a specific intervention cycle which is a form of radiation therapy delivered over a certain number of sessions Therefore the statement is contradictory to the information provided in the trial description",
        "label": "Contradiction"
    },
    "5ab7ac4b-19cd-455c-8796-50680cedf7f1": {
        "text_answer": "  The statement is entailed in the trials as both cohorts 1 and 2 receive dexamethasone before surgery and the method of administration is intravenously",
        "label": "Entailment"
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants in each group who demonstrated a decrease in the Growth Factor Signature GFS  According to the trials the percentage of participants in the ERpositive Luminal B group who demonstrated a decrease in GFS was 286 131492 and in the Triple Negative",
        "label": "Entailment"
    },
    "36969517-2743-4fc8-970a-0846cebda02f": {
        "text_answer": "  The statement less than half of the primary trial participants had a Reduction in circulating tumor cells Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results The trial results only report the number of participants with a reduction in CTCs at one month post AHST and the treatment regimen used The statement makes a claim about the percentage of participants with a reduction in CTCs",
        "label": "Contradiction"
    },
    "1b5d6416-bf6d-4d0b-8b9b-b982d1bbd8a8": {
        "text_answer": "  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race or ethnic origin or cancer type however for the secondary trial they must have Her2neu breast cancer is contradictory to the information provided in the inclusion criteria for both trials  In the primary trial the inclusion criteria state that females of all racial and ethnic origins who are scheduled to receive the first cycle of a single intraven",
        "label": "Entailment"
    },
    "aecffac5-b441-4cf6-b939-c7fb19ebac05": {
        "text_answer": "  The statement in the primary clinical trial there was a minimum of 1 detected gastrointestinal adverse event and more than one psychiatric event is not directly entailed in the given trials as there is no clear mention of gastrointestinal adverse events other than colitis ischaemic which occurred only once in each trial However there is a mention of more than one psychiatric event Menieres disease and vertigo",
        "label": "Contradiction"
    },
    "b907c117-661f-4078-956a-be5b2560b5f4": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement all of the patients in the primary trial and the secondary trial developed shingles is contradictory to the information provided in the trials because no cases of shingles were reported in either trial In the primary trial there were no reported cases of shingles out of a total of 66 adverse events in the secondary trial",
        "label": "Contradiction"
    },
    "263e2baf-2196-42fb-8d68-e6dea7cad9b5": {
        "text_answer": "  The statement there was no increase in blood bilirubin levels in any of the patients in the primary clinical trial is contradictory to the trial data as one patient did experience an increase in blood bilirubin levels 909 Therefore the statement is contradictory to the trial data",
        "label": "Contradiction"
    },
    "864e3d0c-60fb-43bf-a272-1d590ff8795b": {
        "text_answer": "  The statement in the primary trial there is a reduction in both the total number and categories of adverse events in comparison to the secondary trial is entailed in the given trials data   Explanation   The statement implies that the total number and number of categories of adverse events are less in the primary trial than in the secondary trial   From the given data we can see that the total number of adverse events in the primary",
        "label": "Entailment"
    },
    "1a71b35f-9b20-478b-863d-f7411015d6e8": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 72 weeks are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary embolism within the last 72 weeks are explicitly excluded However the statement suggests that these patients may be eligible for",
        "label": "Contradiction"
    },
    "c5e1aaba-40f0-49e6-926b-2f28f74b2b1c": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary clinical trial does have different inclusion and exclusion criteria for its Phase I and Phase II portions The secondary clinical trial however has the same inclusion criteria for every participant planned unilateral mastectomy with or without axillary dissection or sentinel node in the study period and informed signed consent and the same exclusion criteria chronicongoing use",
        "label": "Entailment"
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "text_answer": "  The statement laserassisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial is entailed in the given trial description Both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort use laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion at three separate time points",
        "label": "Entailment"
    },
    "01b56d67-6f6a-4102-959e-eb921954d268": {
        "text_answer": "  The statement the absence of allergies to cephalosporin or trimethoprimsulfamethoxazole does not restrict a patients eligibility for either primary trial or secondary trial is entailed in the given trials as follows  1 In the primary trial there is no mention of cephalosporin or trimethoprimsulfamethoxazole in the exclusion criteria 2",
        "label": "Entailment"
    },
    "6b03d4f0-29bf-4a64-8136-2042e2a609ef": {
        "text_answer": "  The statement in the primary clinical trial patients in cohort 2 show a decrease in pleural effusion is contradictory to the information provided in the trials The trials report that one patient in cohort 2 experienced an increased pleural effusion which is the opposite of a decrease",
        "label": "Entailment"
    },
    "c216cb60-86c5-4ba4-9092-07bfe620c6ec": {
        "text_answer": "  The statement somewhat forgetful is a response indicating that an individual is or was somewhat forgetful is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However regarding the trials themselves the statement is not contradicted as there is no mention of forgetfulness in either trial Additionally the length of the interventions in the secondary trial does not affect the",
        "label": "Entailment"
    },
    "1645d8e9-78e0-42e0-b46e-945c3c8e7d89": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation  The statement in the first cohort of the primary clinical trial there were no instances of adverse events whereas almost every individual in the second cohort encountered at least one is contradictory to the given trials data as follows  1 The statement implies that there were no adverse events in the first cohort and every individual in the second",
        "label": "Contradiction"
    },
    "fe6abe4b-e77b-4ab7-a52c-3157a90f7a2d": {
        "text_answer": "  The statement women aged 18 or 19 are eligible for the secondary trial but will need to wait 12 years to be eligible for the primary trial is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials   The statement is related to age eligibility for the trials but the trials themselves as described in the criteria do not mention any age restrictions beyond aged greater than 2",
        "label": "Contradiction"
    },
    "b98c3e78-273c-46dd-ad36-db7aabf5f3a9": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials   The primary trial does not indicate that the operative time was notably longer in arm 2 than in arm 1 but rather that the median operative time was longer in the standard mammography group The statement also mischaracterizes the secondary trial as lacking a control group when in fact it describes a specific intervention TEADM With PMRT without comparing it to a control group",
        "label": "Contradiction"
    },
    "74e35f39-c01b-435b-a5f8-cc1cc8204607": {
        "text_answer": "  The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial does not specify the tumor size However the statement in question refers to patients with a breast tumor 200800 micrometers in diameter This size falls outside the range of the primary trial but is not explicitly mentioned as an exclusion criterion in the secondary trial  Therefore the statement is neither entailed nor contradicted by",
        "label": "Entailment"
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "text_answer": "  The statement is a contradiction to the primary trial as the patients in Group 2 of the primary trial do receive dexmedetomidine contrary to the statement that they do not The secondary trial is not relevant to the verification of the statement as it does not involve the administration of dexmedetomidine",
        "label": "Contradiction"
    },
    "b6bd5750-21d0-4fcd-80af-749c6dc2a518": {
        "text_answer": "  The statement in the primary trial results there were more patients with stable disease in week 6 than week 18 but 2 patients with complete response in week 6 or 18 is not directly entailed in the provided trial results   The trial results only report the number of participants with clinical benefit CR PR or SD at weeks 12 and 24 There is no information provided about the number of participants with stable disease",
        "label": "Contradiction"
    },
    "a0d11ea8-22ae-4af7-885c-40b9e3a98fac": {
        "text_answer": "  The statement There are no conditions on mental mental health bodyweight age KarnofskyECOG score or previous treatments that need to be met in order to be eligible for the primary trial is not directly related to the caspase3 staining method mentioned in the trial description The statement only pertains to the eligibility criteria for the trial while the caspase3 staining method is a diagnostic technique used within the trial",
        "label": "Contradiction"
    },
    "663f13bf-bbc7-49f2-926e-b88da56cc74a": {
        "text_answer": "  The statement not a single patient treated with sunitinib  docetaxel  trastuzumab during the primary clinical trial experienced a treatmentemergent adverse event is contradicted by the trial results   The trial reported that there were 24 treatmentemergent adverse events AEs among the 25 participants in the sunitinib  docetaxel  trastuzumab armgroup",
        "label": "Contradiction"
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "text_answer": "  The statement patients with Histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial is entailed in the given trials as follows  Primary Trial  Inclusion Criteria for Phase 1 Histologically or cytologically confirmed metastatic andor advanced solid tumor Phase 1 only ",
        "label": "Entailment"
    },
    "fdce4005-3773-4350-b45b-1c1338e01a26": {
        "text_answer": "  The statement biliary colic and diarrhoea cases are relatively equal across the primary and secondary clinical trials is contradicted by the given data   In the primary trial there were 4 cases of biliary colic and 3 cases of diarrhoea In the secondary trial there was 1 case of biliary colic and 1 case of diarrhoea The number of cases for each adverse event is not equal between",
        "label": "Contradiction"
    },
    "3fd8d038-4c72-4f0f-b2d8-0e822f5b96a8": {
        "text_answer": "  The statement AfricanAmerican patients can participate in the primary trial but they must reside in the state of Texas for the duration of the study is not directly entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial The statement mentions a geographical requirement for AfricanAmerican patients which is not mentioned in the provided criteria The welding occupation mentioned in the statement is also not related to the trial criteria",
        "label": "Contradiction"
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "text_answer": "  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race ethnic origin or cancer type however for the secondary trial they must have BRCA breast cancer is partially entailed in the given trials   The primary trial includes females aged 18 and above of all racial and ethnic origins with breast cancer who are scheduled to receive the first cycle of a single intravenous dose of",
        "label": "Entailment"
    },
    "4750e9e1-982d-4ca4-ab90-373832ed32d6": {
        "text_answer": "  The statement in the primary clinical trial increased pleural effusion and rapid disease progression is experienced by 25 of the patients is contradictory to the given trials as the trials report different patient groups and the percentage of patients experiencing increased pleural effusion and rapid disease progression differ between the trials  In the first trial 1 out of 13 patients 769 experienced rapid disease progression and none experienced increased pleural",
        "label": "Entailment"
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "text_answer": "  Both trials report results using the same Unit of Measure which is the number of participants Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "text_answer": "  The statement Over 6 weeks of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 5 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as follows  The trial results show that the median IQR Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2",
        "label": "Entailment"
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "text_answer": "  The statement Only female patients of a specific nationality can take part in the primary trial no such condition is required for participation in the secondary trial is a contradiction   The primary trial has a specific inclusion criterion stating that the patient must be a Japanese female while the secondary trial does not have any such requirement Therefore the statement is incorrect and contradicts the information provided in the trials inclusion criteria",
        "label": "Contradiction"
    },
    "dd4715db-f06d-4168-962c-22cdd764f2b0": {
        "text_answer": "  The statement the primary clinical trial accepts adult patients who were diagnosed with diffuse parenchymal lung disease 4 years ago is not entailed in the inclusion or exclusion criteria provided in the trial description The trial only mentions exclusion of patients with a history of interstitial lung disease or pneumonitis Therefore the statement is not directly related to the trial criteria and cannot be determined to be entailed or contradictory based on the given",
        "label": "Contradiction"
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "text_answer": "  The statement there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial is contradictory to the information provided in the trials According to the trials there were no adverse events reported in either cohort 1 or cohort 2 Therefore the statement that there were 4 more patients with adverse events in cohort 1 than in co",
        "label": "Contradiction"
    },
    "f5231a1f-83ff-458f-9dbd-40bd55daae92": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the use of denosumab which is a monoclonal antibody medication given by injection every 4 weeks The secondary trial on the other hand involves the use of intraoperative handheld gamma camera pIHGC and gamma probes GP which do not require the injection of nivolumab mentioned in the",
        "label": "Entailment"
    },
    "b8b1d79d-ce73-4bf6-a67a-0aea38c604c5": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different interventions and patient populations The primary trial focuses on Alpha Lipoic Acid dosing while the secondary trial deals with Necitumumab administration The statement does mention that patients in the primary trial receive higher doses of Alpha Lipoic Acid but it does not provide any information about the Necitumumab dosing in the secondary trial Therefore the statement is",
        "label": "Contradiction"
    },
    "c724f8b4-74e9-4f48-ab39-cc8eb21890e6": {
        "text_answer": "  The statement is entailed in the trials In the primary trial the reflexology intervention lasted for 10 weeks while in the secondary trial both the placebo and vitamin D interventions lasted for 24 weeks Therefore the intervention period in the secondary trial is indeed extended by 15 weeks compared to the primary trial",
        "label": "Entailment"
    },
    "f7cbcdf1-cee8-4b88-afff-45901ee871af": {
        "text_answer": "  The statement the secondary trial and the primary trial report results from one patient cohort is not directly entailed in the given trials as they do not provide sufficient information to determine if they share the same patient cohort However the statement pharmacogenomicsgenetics methods and supporting information supplemental qualifiers dataset is a dataset containing supplemental information specifically nonstandard variables to parent records in the pharmacogenomicsgenetics methods",
        "label": "Contradiction"
    },
    "fd5337ee-4098-440b-9e22-0d8c52dbab5a": {
        "text_answer": "  The statement is not entailed in the given trials as the units of measure for the primary trial are change in units on a scale for vaginal symptom severity and for the secondary trial are percentage of participants for objective response rate of HER2negative metastatic breast cancer Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "b443ed89-9fcb-451a-b0f5-3f23183fbeb0": {
        "text_answer": "  The statement Over 50 of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril is not directly entailed in the provided trial results However it is related to the trial as it discusses the same treatment regimen and an outcome measure acute vomiting that is mentioned in the trial  The",
        "label": "Contradiction"
    },
    "60df29e3-b115-4407-b1f9-dfc2c3d2d3d3": {
        "text_answer": "  The statement the primary clinical trial is open to all ages but the secondary clinical trial specifically excludes children is a contradiction based on the provided information   The primary clinical trial includes the criterion Postmenopausal women as an inclusion criterion which implies that it is not open to children The secondary clinical trial also includes the criterion Women of childbearing potential must commit to the use of effective barrier non",
        "label": "Contradiction"
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "text_answer": "  The statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study is entailed in the trials provided   Explanation   The trials report that in both Arm 1 and Arm 2 approximately 13 of the participants experienced a Pathologic Complete Response in Breast and Ax",
        "label": "Entailment"
    },
    "8b59c6dc-98ec-4f07-9274-ba4cc1ff8950": {
        "text_answer": "  The statement germinal center blymphocyte is a mature blymphocyte that is present in the geminal center of a lymphoid follicle is not related to the adverse events mentioned in the trials Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "f5b7285d-3b0a-496a-84c8-012c4873a7be": {
        "text_answer": "  The statement is partly entailed in the primary trial and partly contradictory to the secondary trial   The statement is entailed in the primary trial regarding the exclusion of patients with nonhealing surgical wounds However the statement contradicts the secondary trial regarding the exclusion of patients who have undergone chemotherapy or radiotherapy within two weeks those suffering from unstable angina or those with grade 2 or above neuropathy According",
        "label": "Entailment"
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "text_answer": "  The statement is not entailed in the given trials as the trials do report the number of participants analyzed in each armgroup although they do not explicitly state the number of participants in each cohort for each arm The trials provide the number of participants analyzed for each treatment regimen which is sufficient information to determine the total number of participants in the study However the statement could be more specific by requiring the explicit reporting of the number of participants in each cohort rather",
        "label": "Contradiction"
    },
    "242b1a1a-4a5e-459b-88ea-41ca86093348": {
        "text_answer": "  The statement is entailed in the trials as both groups GBM and Gynecological Cancers undergo 18FFDG imaging as part of standard medical care and both groups receive 18FFPPRGD2 imaging with a dosage less than 10 mCi The only difference is the timing of the 18FFPPRGD2 imaging for the GBM cohort at 6",
        "label": "Entailment"
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the intervention is given orally PO which means it is administered by mouth  In the secondary trials the intervention in Arm I Group A is given intravenously IV which means it is administered through a needle or tube inserted into a vein The intervention in Arm II Group B is also given intravenously  Therefore",
        "label": "Entailment"
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial both cohorts receive an intramuscular injection of Fluciclatide not an intraosseous injection   In the secondary trial patients do not receive any injections as part of the intervention only oral Chloroquine doses   Therefore the statement that cohort 1 of the primary trial",
        "label": "Entailment"
    },
    "d2e448c0-852f-41cc-a53b-866f56e62967": {
        "text_answer": "  The statement digestive system Kaposi sarcoma is a Kaposi sarcoma arising from the digestive system is not entailed in the given trials as they do not mention anything about Kaposi sarcoma or any other health conditions affecting the participants The trials only focus on vaccine responses against Pneumococcus and Influenza in adults 65 years of age and older for cohort 1 cancer patients and coh",
        "label": "Contradiction"
    },
    "c94fb60e-6f9e-48ed-b7b7-4468cb2aa6ee": {
        "text_answer": "  The statement even after undergoing a mastectomy for stage iv bc a woman might still meet the requirements for the primary or secondary clinical trial is not entailed in the given trials as there is no mention of stage iv breast cancer in the inclusion or exclusion criteria for either trial Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "f5a6f0ee-22bd-4731-b973-e8c4736e4d18": {
        "text_answer": "  The statement alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is neither entailed in the primary trial nor contradictory to it   The primary trial explicitly states that any history of alcohol or substance abuse or dependence within the past 2 years is an exclusion criterion However the secondary trial has a different exclusion criterion for alcohol",
        "label": "Entailment"
    },
    "b12011c4-fa87-4249-97e3-635e6e6805a4": {
        "text_answer": "  The statement dry mouth CTCAE is a disorder characterized by reduced salivary flow in the oral cavity The nationality ethnicity psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial is not explicitly stated in the given inclusion and exclusion criteria for the primary and secondary trials However the criteria do not mention any conditions related to dry mouth nationality ethnicity psychiatric",
        "label": "Entailment"
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed in the given data from Trial 2 Adverse Events 2 since the total number of adverse events including deaths and hospitalizations is reported as 0 zero for cohort 2",
        "label": "Contradiction"
    },
    "232d082f-2684-445e-8ca6-9cf32c3d1b34": {
        "text_answer": "  The statement is entailed in the trials as the primary trial tests Eribulin Mesylate and the secondary trial tests Axitinib  Docetaxel and Docetaxel  Placebo which are different interventions Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "1fec40c0-4c6f-4e9d-ae16-a962eb45b4dd": {
        "text_answer": "  The statement apalutamide regimen is a chemotherapy regimen consisting of apalutamide that may be used in the treatment of prostate cancer Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for all cohorts of the primary trial is neither entailed nor contradictory to the given inclusion and exclusion criteria for the primary trial   The reason is that the statement",
        "label": "Entailment"
    },
    "a7c5f410-1001-4c4c-884d-cdbb9e8d69e4": {
        "text_answer": "  The statement less than 005 of patients in the primary trial suffered adverse events is contradictory to the given data in the trials   The trials report that 2 out of 35 patients or 571 experienced adverse events which is greater than 005 or 1 out of 20 of the total number of patients Therefore the statement is contradictory to the given",
        "label": "Entailment"
    },
    "32f5c37f-6752-4ebd-840b-d232b65bc138": {
        "text_answer": "  The statement only Australian nationals are eligible for participation in the primary clinical trial and the secondary clinical trial is a contradiction to the information provided in the inclusion criteria of both trials The trials do not specify any nationality requirement for participation",
        "label": "Contradiction"
    },
    "635f6674-3151-46bc-8344-33ab60b59bd0": {
        "text_answer": "  The statement A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial is not directly entailed in the given inclusion and exclusion criteria for both trials   The primary trials inclusion criteria state that patients undergoing immediate tissue expander reconstruction following mastectomy are eligible but there is no mention of a requirement for a woman to have a rectovesicovaginal fistula or any",
        "label": "Contradiction"
    },
    "8af457d5-2a04-43df-a661-2cf10402def6": {
        "text_answer": "  The statement the primary clinical trial comprises fewer instances of anemia compared to the secondary clinical trial is contradicted by the given data   Explanation   The primary clinical trial had 0 instances of anemia out of 37 participants while the secondary clinical trial had 4 instances of anemia out of 93 participants Therefore the secondary clinical trial had more instances of anemia than the primary clinical trial",
        "label": "Contradiction"
    },
    "7b2b8832-6e8f-4b56-88fa-5cee3c4e82bf": {
        "text_answer": "  The statement the number of aes disclosed was identical for the two cohorts in the primary trial is a contradiction to the given data   Explanation   The statement is a negation of the difference in the number of adverse events AEs between the two cohorts However the data provided shows that there is a difference in the number of AEs between the two cohorts with cohort ",
        "label": "Contradiction"
    },
    "42a51c2f-6b39-487e-989c-dcdc0ad231e1": {
        "text_answer": "  The statement less than half of the primary trial participants had a Reduction in circulating tumor cells Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly related to the information provided in the trial results 1 The trial results only report the number of participants with reduction in CTCs at one month post AHST and the treatment regimen used The statement about septal myocardial infarction by E",
        "label": "Entailment"
    },
    "831e3999-7ce1-4af9-9a28-1282d641a376": {
        "text_answer": "  The statement the primary trial and the secondary trial report on the mtd of different interventions with the mtd of mm111 for patients in the secondary trial being 105 mg per week is not directly entailed in the provided trial information   The primary trial reports on the determination of the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the determination of the MTD or",
        "label": "Contradiction"
    },
    "d0a08aeb-5c7c-44a9-a923-fd4e3b094ebd": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the ORRs of the two groups   The ORR for the Paclitaxel Plus Bevacizumab PB group was 0489 0385 to 0595 and for the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group was 058",
        "label": "Entailment"
    },
    "8bc20833-6293-47e3-aafe-c7a0ca3be9a6": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 20 years are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the information provided in the exclusion criteria for both trials  In the primary trial pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose",
        "label": "Contradiction"
    },
    "1cebe988-ac21-4b72-a652-36778fb2cccf": {
        "text_answer": "  The statement during the primary clinical trial patients not receiving topical cryotherapy suffered worse symptoms than the group who underwent the procedure is entailed in the trials based on the provided data   Explanation   The statement implies that the control group Arm II had worse symptoms than the experimental group Arm I The median aAUCpa values for both groups are provided in the trials The median aAUCpa for Arm",
        "label": "Entailment"
    },
    "338fc59d-601e-42b6-8718-858ffe20928d": {
        "text_answer": "  The statement is an entailment given that the only difference between the two interventions is the dosage of durvalumab administered monthly which is 03 mgkg less in intervention 1 compared to intervention 2 The statement about loss of chromosome 5 being a cytogenic abnormality is not directly related to the trials but it is a separate fact Therefore the statement as a whole is an entailment based on",
        "label": "Entailment"
    },
    "77989b91-bbcc-401e-8cd9-bdd17c0d0e3a": {
        "text_answer": "  The statement is not directly entailed in the given trials as they address different outcome measures and interventions The first trial investigates the effect of sulforaphane supplements on isothiocyanate levels in urine while the second trial examines the impact of physical therapy on pain reported using the Numeric Pain Rating Scale The statement is not a contradiction either as the trials focus on distinct aspects of their respective interventions",
        "label": "Contradiction"
    },
    "e82b4df2-47c8-41ed-9b54-9b3c6917ead3": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial the dose of alpha lipoic acid is not specified to remain constant for the entire duration but rather dose escalation is mentioned However the statement focuses on the dosing of necitumumab and incorrectly assumes that the primary trial maintains a constant dose for all patients  In contrast the secondary trial does administer a constant dose of necit",
        "label": "Entailment"
    },
    "f0f71529-7742-45c4-945f-ae4e51f9029d": {
        "text_answer": "  The statement in the primary clinical trial no incidents of hypertension edema and dyspnea were observed in both cohorts is not directly entailed in the given trials as they do not report the occurrence or nonoccurrence of hypertension edema and dyspnea in the trials The trials only report the occurrence of various adverse events including some that are not mentioned in the statement such as disseminated",
        "label": "Contradiction"
    },
    "1a8ad1c5-284a-4398-9659-2cdbcb4492d8": {
        "text_answer": "  The statement is not entailed in the given trials as they do not meet the definition of pragmatic trials Pragmatic trials are designed to test the effectiveness of an intervention in routine clinical practice whereas the given trials are randomized controlled trials with a primary focus on testing the effect of pyridoxine and oxybutynin chloride interventions on patients The secondary trial is testing different doses of oxybutynin chloride but it is",
        "label": "Contradiction"
    },
    "c660c228-b490-4779-9ead-ad8b2be40520": {
        "text_answer": "  The statement 3636 of the primary trial patients suffered an increase in Blood bilirubin is entailed in the given trial data as it is explicitly stated in the Adverse Events section that Blood bilirubin increased 111 909 Therefore the statement is entailed by the trial data",
        "label": "Entailment"
    },
    "9d7e5e1f-b92f-464d-94ea-a7eb3ae730b5": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets the following inclusion criteria  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed within specified time frames  Age of 18 years or older  Zubrod performance status 02  Patient may have received prior oral bisphosphonate therapy  Patient has signed informed consent  The patient also meets the inclusion",
        "label": "Entailment"
    },
    "5be5cc6c-ba08-4d21-9939-4ccde58aa23e": {
        "text_answer": "  The statement regimen used to treat malignant ovarian neoplasm is any regimen that can be used for the treatment of malignant ovarian neoplasm is neither entailed nor contradicted by the given inclusion and exclusion criteria of the primary and secondary trials   The primary trial focuses on patients with advanced cancer potentially sensitive to vinorelbine while the secondary trial includes patients undergoing large core breast biopsy The inclusion",
        "label": "Entailment"
    },
    "ca20d0df-b712-4bb0-b320-704d565a99a6": {
        "text_answer": "  The statement have cramps in feet is not directly related to the inclusion or exclusion criteria of either the primary or secondary trials The primary trial focuses on patients with ERPRHER2 metastatic breast cancer and the secondary trial focuses on patients scheduled for cancer treatment with chemotherapy or biologics who have sleep disturbances Neither trial mentions cramps in the feet as a requirement or exclusion criterion Therefore the statement is",
        "label": "Entailment"
    },
    "a83ef28c-db79-4e1b-9ebd-f563905a9ac7": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the mean changes in lymphedema between the acupuncture and waitlist groups over the 6week time frame   First lets calculate the difference in mean arm circumference between baseline and 6 weeks for each group  Acupuncture group 474 cm baseline  429 cm 6",
        "label": "Entailment"
    },
    "28061f9c-36e0-4f1f-9f51-1c01efd608a1": {
        "text_answer": "  The statement history of medication is a history of the medication that the patient has taken The nationality ethnicity weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial is entailed in the given trials as there is no mention of nationality ethnicity weight or gender as inclusion or exclusion criteria in either the primary or secondary trials The only factors mentioned as affecting eligibility are related to medical history",
        "label": "Entailment"
    },
    "c8556c5e-4962-4d9d-8f8d-3cdb07af0627": {
        "text_answer": "  The statement cbt based treatments are integral components of the qualification criteria for both the primary clinical trial and the secondary clinical trial is not explicitly stated in the provided inclusion and exclusion criteria for either trial However it can be inferred that for the primary trial patients with HER2positive advanced breast cancer or ovarian cancer are required to have received at least two lines of systemic therapy in the advanced setting which may include chemotherapy andor",
        "label": "Entailment"
    },
    "0a418d49-392b-474e-ad3c-df66ab2566ab": {
        "text_answer": "  The statement the secondary trial on the other hand does not have a cyclic treatment in place is a contradiction to the primary trial as both trials have a 21day cycle length for their interventions The statement longhandled appliances for reach usually used is not entailed in the trials as there is no mention of longhandled appliances in either trial",
        "label": "Contradiction"
    },
    "5de55575-82d9-461f-af89-ae41ff70ecb2": {
        "text_answer": "  The statement is not entailed in the given inclusion criteria for the primary or secondary clinical trials The trials specify inclusion criteria based on various medical conditions performance status and prior treatment history but do not mention any specific nationality or ethnicity as a requirement for participation",
        "label": "Contradiction"
    },
    "24523cd0-0fe8-455a-93b6-52367820879a": {
        "text_answer": "  The statement Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial is entailed in the trials inclusion criteria The criteria state that patients with histologically proven DCIS are eligible for the study as long as they meet the other eligibility requirements Therefore the statement is entailed in the trials inclusion criteria and is consistent with the information provided  The statement chemoz",
        "label": "Entailment"
    },
    "3ee347d0-3ba9-4dc8-8387-1fb15cf1e8b3": {
        "text_answer": "  The primary trial includes the following inclusion criteria for breast tumor size Breast tumor 1 centimeter cm in diameter The secondary trial does not specify a maximum tumor size However it does include the following disease characteristic Breast cancer locally advanced or metastatic Locally advanced breast cancer can refer to tumors larger than 5 cm in diameter Therefore patients with a breast tumor 510 cm in",
        "label": "Entailment"
    },
    "a7e7e8e0-d2c9-4eee-9aed-1d957044c7dc": {
        "text_answer": "  The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement however they are not explicitly excluded from the secondary trial is not directly entailed in the given inclusion and exclusion criteria for either the primary or secondary trials   The primary trial does not mention any age requirement but it does state that postmenopausal status must be confirmed The secondary trial includes a requirement for women of childbearing potential",
        "label": "Contradiction"
    },
    "760d8b66-18ea-4e33-b83a-b88173ed8574": {
        "text_answer": "  The statement there are zero shared inclusionexclusion criteria between the secondary trial and the primary trial is a statement about the absence of common criteria and as such it is a statement of difference rather than entailment or contradiction Therefore it cannot be verified as entailed or contradicted based on the given information alone However based on the provided information it appears that the two trials have no shared inclusionexclusion criteria so the statement is likely to",
        "label": "Entailment"
    },
    "eb19e1ef-0bad-4d95-8ebd-dcc1f403a946": {
        "text_answer": "  The primary trial lasts for 10 weeks of reflexology treatment while the secondary trial lasts for 24 weeks of intervention either placebo or vitamin D The difference in duration is 14 weeks 24 weeks  10 weeks Therefore the statement the duration of the intervention for the primary clinical trial exceeds that of the secondary clinical trial by an additional 15 weeks is a contradiction as the actual difference",
        "label": "Contradiction"
    },
    "29cbfa09-f98c-4991-a6ab-0dc8cca951d3": {
        "text_answer": "  The statement both the primary and secondary clinical trials have documented a number of adverse events is contradictory to the given information in the trials as both trials have reported 0 adverse events each Therefore the statement is contradictory to the facts presented",
        "label": "Entailment"
    },
    "8881c72a-24fc-48ab-86fb-a1d38392ec33": {
        "text_answer": "  The statement therapeutic nervous system procedures is a procedure that is done to treat a nervous system disorder is not directly related to the trials provided The trials report the results of two different studies one on denosumab for the treatment of hypercalcemia and the other on dmethadone for pain management The statement does not entail or contradict any information presented in the trials",
        "label": "Entailment"
    },
    "b5a078c6-afd5-427e-beab-c7c11cc96da2": {
        "text_answer": "  The statement is entailed in the Trials The dosage of Zoledronic Acid in Intervention 1 of the primary trial is indeed 12 times higher than the dosage of Denosumab used in Intervention 1 of the secondary trial  Primary Trial Zoledronic Acid 4 mg Q4W 16 mg per 6 weeks vs Denosumab 120 mg Q4W 1",
        "label": "Entailment"
    },
    "5d44d70b-1163-4a55-9247-db7bf9a901fc": {
        "text_answer": "  The statement there are more total adverse events and more types of adverse events captured in the primary clinical trial than in the secondary clinical trial is entailed in the given data   Explanation   The primary clinical trial had a total of 14 participants and recorded 0 adverse events for Adverse Event 1 and 0 adverse events for Adverse Event 2   The secondary clinical trial had a total of ",
        "label": "Entailment"
    },
    "fe0472bd-acfb-4a56-abed-20b0a4e6b48f": {
        "text_answer": "  The statement the primary clinical trial considers patients with tx nx mx t0 nx m0 or t1 n1 m1 tumors to be eligible is entailed in the trial description   Explanation  The trial description specifies that patients with measurable or nonmeasurable disease are eligible The TNM staging system which is commonly used to describe the extent of cancer in a patients body",
        "label": "Entailment"
    },
    "78c44e7a-6f94-4167-aafa-13c14da01bbf": {
        "text_answer": "  The statement patients can not have a history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 05 years if they want to participate in the primary trial is a summary of some of the exclusion criteria mentioned in the trial description However it is important to note",
        "label": "Entailment"
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial participants receive the following interventions 1 Neoadjuvant Therapy doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate needle biopsy therapeutic conventional surgery immunoh",
        "label": "Entailment"
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the given trials  Explanation  The statement is entailed in the trials because the primary trial has a higher frequency of occurrence for all the mentioned adverse events",
        "label": "Entailment"
    },
    "a68ff0d2-ddc4-4db1-9371-21bec6159585": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial focuses on the number of participants with treatmentemergent adverse events AEs in each group at the end of Cycle 1 while the secondary trial measures the change in total sleep time using polysomnography PSG before and after the first cycle of Lenalidomide treatment These trials address different outcomes with the primary trial focusing on treatmentrelated side",
        "label": "Entailment"
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "text_answer": "  The statement Gender is not a determining factor for eligibility in the primary trial but only female patients are eligible for the secondary trial is contradictory to the information provided in the trials inclusion and exclusion criteria  In the primary trial both male and female patients are eligible but there are specific inclusion and exclusion criteria that must be met In contrast the secondary trial only includes female patients with locally advanced recurrent or metastatic",
        "label": "Entailment"
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "text_answer": "  The statement All but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event and less than half the patients suffered serious TreatmentEmergent Adverse Events is not directly entailed in the given trial results   The trial results only provide the number of participants who experienced any adverse event AE and serious adverse event ",
        "label": "Contradiction"
    },
    "25c9b995-fedc-45ae-a3c8-d66c116711b0": {
        "text_answer": "  The statement just one negative occurrence has been noted for the patient contingent of the primary clinical trial is entailed in the given data as the data states that there was one adverse event a negative occurrence out of 29 patients the patient contingent of the primary clinical trial",
        "label": "Entailment"
    },
    "1bf21a6b-6676-4da7-9b80-4fd67722e030": {
        "text_answer": "  The statement is entailed in the Trials with Entailment   Explanation   The statement every inclusion criterion for the primary trial is distinct from those of the secondary trial means that there is no common inclusion criterion between the two trials Based on the provided information this statement is true because there is no common inclusion criterion between the two trials All inclusion criteria for the primary trial are different from those of the secondary",
        "label": "Entailment"
    },
    "08793821-1888-49b3-9117-f0548482b5f9": {
        "text_answer": "  The statement the secondary clinical trials second cohort significantly outnumbered the second cohort of the primary clinical trial in terms of patients is not directly stated in the provided information However we can calculate the number of participants in the second cohort of each trial  Primary Trial 75 participants in the waitlist control group Secondary Trial 163 participants in the device  standard of care group  ",
        "label": "Entailment"
    },
    "396eb2aa-c85e-4477-bdf5-a0926499350a": {
        "text_answer": "  The statement a patient who underwent an organ transplant less than four weeks ago may participate in the primary clinical trial but is excluded from the secondary clinical trial is a contradiction based on the given inclusion and exclusion criteria  Explanation  In the primary trial there is no mention of any exclusion related to organ transplant within 4 weeks However in the secondary trial an organ transplant within 4 weeks is an exclusion",
        "label": "Contradiction"
    },
    "071c3399-1525-4965-8a3e-b3dfac561b6b": {
        "text_answer": "  The statement is entailed in the primary clinical trial information provided Both Intervention 1 and Intervention 2 involve preoperative intravenous administration of Dexamethasone but the dosage differs between the two interventions 8 mg for Intervention 1 and 24 mg for Intervention 2 However only one cohort Intervention 1 is specified to receive a preoperative dose of Dexameth",
        "label": "Entailment"
    },
    "32d95cac-6a3d-4e4d-a8ac-3371ec9d0da4": {
        "text_answer": "  The statement patients diagnosed with lung cancer may be eligible for all study groups in the primary trial and the secondary trial is contradictory to the given trials inclusion and exclusion criteria  Explanation  The primary trial includes postmenopausal women with early stage breast cancer who would be treated with an aromatase inhibitor and have low serum 25OHD levels Lung cancer is not mentioned as an inclusion criter",
        "label": "Entailment"
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "text_answer": "  The statement Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial but may be eligible for the secondary trial depending on the Investigators decision is a contradiction to the exclusion criteria of the primary trial   In the primary trial patients with a pulmonary embolism within the last 3 years are explicitly excluded However the statement suggests that these patients may be eligible for the",
        "label": "Contradiction"
    },
    "ff258472-19f3-4dea-8edc-bc591c30fc37": {
        "text_answer": "  The statement adverse events such as recurrent cancers graftversushost disease anaemia heart failure and diffuse alveolar haemorrhage were seen more frequently in the primary clinical trial than in the secondary clinical trial is entailed in the given trials data  Explanation  The statement is entailed because the primary clinical trial had a higher percentage of adverse events for all the mentioned conditions compared",
        "label": "Entailment"
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial there is no mention of any injections being given to the participants However in the secondary trial participants receive weekly subcutaneous injections of epoetin beta Therefore the statement that candidates for the secondary trial study group receive weekly subcutaneous injections whereas the primary trial participants do not receive any injections is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "3b6f6c52-5713-45fd-823a-23ab1754539a": {
        "text_answer": "  The statement is not entailed in the trials as given The primary trial administers Vitamin B12 sublingually while the secondary trial administers Memantine orally and neither trial mentions anything about palmitic acid Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "bbb61326-9879-44f0-af97-523e7dc2231a": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the trials we need to compare the mean aAUCpa values between the two arms Arm I and Arm II   First lets calculate the mean aAUCpa for each arm  Arm I Cryotherapy  The median aAUCpa is 14 with a range of 117 to 68 To find the mean",
        "label": "Entailment"
    },
    "95036529-d29d-4425-90a4-d366664c99c5": {
        "text_answer": "  The statement Patients can not have a history of abdominal fistula gastrointestinal perforation Postmenopausal adenocarcinoma stroke transient ischemic attacks intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial is entailed in the trial information provided   The exclusion criteria in the trial information include No",
        "label": "Entailment"
    },
    "1fa45a65-8a51-41e7-af9d-01ab8e0f3e1c": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given data we need to compare the incidence of hepatotoxicity with that of hypertension and pancreatectomy  The statement is hepatotoxicity incidence was not higher compared to the number of hypertension and pancreatectomy cases during the primary clinical trial  The data given is  Total number of adverse events 6",
        "label": "Entailment"
    },
    "2ad5cf58-daab-4432-8670-8964380a4fa9": {
        "text_answer": "  The statement is not entailed in the given trials as the interventions and procedures used in the primary and secondary trials are different The primary trial involves denosumab injections every month while the secondary trial utilizes lymphoscintigraphy with either a prototype intraoperative handheld gamma camera pIHGC or standard of care intraoperative gamma probes GP The statement only mentions denosumab injections",
        "label": "Contradiction"
    },
    "4cfe211a-a80a-48ee-993a-2b7c8a91b57c": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial the intervention is eribulin mesylate which is a different pharmaceutical agent compared to axitinib and docetaxel in the secondary trial Therefore the statement is contradictory to the given trials",
        "label": "Entailment"
    },
    "f27a6b09-cfd5-48ac-80d8-a70bd15bcb4d": {
        "text_answer": "  The statement is contradicted by the information provided in the secondary trial While it is true that none of the adverse events affected more than 03 proportion of patients apart from skin infections the statement that no adverse events were observed in the primary trial is not accurate based on the given data Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "668cbbc7-bc89-440f-8503-a7e273c4fab3": {
        "text_answer": "  The statement Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive PR positive or HER2neu negative are eligible for both the secondary trial and the primary trial is entailed in the given trials as both trials have the same inclusion criteria for ER PR and HER2neu status However its important to note that there are other differences between the trials such as the presence of",
        "label": "Entailment"
    },
    "b995d047-8aaf-48fd-9fd7-ebed843b0877": {
        "text_answer": "  The statement in both the primary clinical trial and the secondary clinical trial a single death was noted in the adverse events is entailed in the given trials as follows  1 The statement mentions that a single death was noted in the adverse events for both trials 2 The trials provide information that there was one death in the adverse events section for each trial  Therefore the statement is entailed by the given trials",
        "label": "Entailment"
    },
    "f22196d4-1e0f-4626-9736-d78452dc650a": {
        "text_answer": "  The statement over 97 of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed in the given trials as they do not provide sufficient information to make that determination The trials only list the number and percentage of patients who experienced specific adverse events but they do not provide the total number of patients in each trial or the percentage of patients who did not experience any adverse events  However the statement ",
        "label": "Contradiction"
    },
    "abb25993-d191-4b47-99c1-fe3b53732dc1": {
        "text_answer": "  The statement ppp2r2a gene mutation is a change in the nucleotide sequence of the ppp2r2a gene is not directly related to the inclusion and exclusion criteria of the primary or secondary trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given trials alone  However the statement does not contradict any information in the trials The trials focus on the clinical and demographic characteristics",
        "label": "Entailment"
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "text_answer": "  The statement Patients in the primary trial and the secondary trial suffered Thromboembolic events is entailed in the given trials as both trials have reported at least one instance of Thromboembolic Event  Explanation  The statement is entailed in the trials because both trials report the occurrence of at least one Thromboembolic Event in their respective patient populations The trials do not contradict each other as they",
        "label": "Entailment"
    },
    "aff21004-0238-46bb-b68b-99d1e3035947": {
        "text_answer": "  The statement both the primary clinical trial and secondary clinical trial may permit the involvement of morbidly obese patients is not explicitly stated in the given inclusion or exclusion criteria for either trial However there is no mention of weight or body mass index as an exclusion criterion in either trial Therefore based on the provided information the statement is consistent with the trials and can be considered neutral neither entailed nor contradictory However it is important",
        "label": "Contradiction"
    },
    "3762bbcc-dcb8-4173-bf16-934f3c590566": {
        "text_answer": "  The statement in the primary clinical trial participants are given epacadostat twice as often as sunitinibnaive patients are administered sunitinib in the secondary clinical trial is a contradiction   Explanation   The primary clinical trial involves administering epacadostat 25 mg BID twice a day and pembrolizumab every 3 weeks while the secondary clinical trial",
        "label": "Contradiction"
    },
    "1616266d-e1bf-4327-9523-f584f713b265": {
        "text_answer": "  The statement a reduction of 10 in the percentage of cells with ki67 expression was noted in the patients of the primary trial following a month treatment with tak228 plus tamoxifen is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks in the TAK228 plus Tamoxifen arm as 1",
        "label": "Entailment"
    },
    "693c9e39-1648-4f3a-8a23-d642d7355b98": {
        "text_answer": "  The statement squamous papillomatosis is a benign squamous neoplasm characterized by a papillary growth pattern diffusely involving a specific anatomic site The Ketorolac 30 mg group of the primary trial had a 64 Recurrencefree Survival compared to the NaCl 09 3mL group is not directly entailed in the provided trial data  ",
        "label": "Contradiction"
    },
    "9321cbe9-2f04-4751-90fd-47a92f424f04": {
        "text_answer": "  The statement the primary clinical trial accepts patients with histologically or cytologically certified diagnoses of either resectable nonsmall cell lung cancer or small cell lung cancer is not explicitly stated in the inclusion criteria of the trial However it is mentioned that patients with nonsmall cell lung cancer and small cell lung cancer are included in the study Therefore the statement is entailed in the trials inclusion criteria but not explicitly stated",
        "label": "Entailment"
    },
    "e1c80f41-c3f0-49c8-8fc8-0bfc32e9936a": {
        "text_answer": "  The statement no deaths or hospital admissions were observed in the second cohort of the primary clinical trial is entailed in the given data from Trial 2 since the data reports a total of 0 adverse events including both deaths and hospitalizations in the second cohort",
        "label": "Contradiction"
    },
    "063f5147-ab53-4f22-b390-bdf6d6589a03": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve different medication types with unique administration routes  1 Intervention 1 Bisphosphonate IV Q4W  Bisphosphonate is a medication type and the administration route is intravenous IV every 4 weeks Q4W 2 Intervention 2 Denosumab 180 mg Q12W  Denosumab is a",
        "label": "Entailment"
    },
    "1f6d3870-934f-4a75-87a3-0e52c19cd010": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the trials Cohort A in Intervention 1 receives two IM injections of V935 LD while Cohort B in Intervention 2 receives three EP injections of V934 LD followed by two IM injections of V935 LD Neither cohort receives a single oral dose of V935 LD Therefore",
        "label": "Entailment"
    },
    "6fd7b2ea-805b-45ad-b1e7-d073f9944d77": {
        "text_answer": "  The statement is not directly entailed or contradicted by the given trials as the trials do not provide sufficient information about the renal function or disease status of the participants The statement only mentions the doses of Lenalidomide and Lapatinib but it does not specify whether the participants in the trials had moderate or severe renal disease or not Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "text_answer": "  The statement the primary trial and the secondary trial administer their interventions orally is entailed in the given trials as both trials mention that the interventions are given by mouth PO In the primary trial it is stated that Vitamin B12 is given sublingually which is still considered an oral administration In the secondary trial memantine hydrochloride and placebo are given by mouth twice daily",
        "label": "Entailment"
    },
    "2278c029-239d-43ba-9da2-440281e4fd0e": {
        "text_answer": "  The given statement is entailed in the Trials as described   Explanation  The statement invasive surgeries or the administration of neratinib are not part of the primary clinical trial for any of the cohorts is consistent with the information provided in the Trials description   The Trials description specifies that Intervention 1 is a Phase 2 Triplenegative trial and Intervention 2 is a",
        "label": "Entailment"
    },
    "f3345897-b99a-4ff2-8bcd-5d1aeb3b698d": {
        "text_answer": "  The statement infant acute undifferentiated leukemia is an acute undifferentiated leukemia that occurs in infancy is not directly related to the intervention MM111 mentioned in the primary trial section Therefore the statement cannot be determined to be entailed or contradictory based on the given information alone  However the statement is a factual description of infant acute undifferentiated leukem",
        "label": "Entailment"
    },
    "32f90f55-6faf-41ed-991a-6f8e9e158200": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial group 2 receives 05gkg of dexmedetomidine not myalgias and in the secondary trial no information is given about the administration of myalgias to any group",
        "label": "Contradiction"
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "text_answer": "  The statement is not entailed in the trial results as given The statement mentions a reduction in tumor diameter but the trial results only report a change in Ki67 expression which is a measure of cell proliferation The statement does not match the outcome measurement reported in the trial Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "6a83fd1d-9dde-419d-8342-ec1be514869e": {
        "text_answer": "  The statement candidates for the primary clinical trial must be Her2 negative based on IHC 0 or 1 evaluation and be able to selfcare without the need for frequent medical supervision is contradictory to the inclusion criteria of the trial as stated in the text   The inclusion criteria clearly state that candidates for the trial must have a histologically confirmed infiltrating primary breast cancer that is Her2 positive either IHC",
        "label": "Entailment"
    },
    "91b35ed1-37f4-440a-a82d-99c639ad7e2a": {
        "text_answer": "  The statement the primary clinical trial had twice as many participants with cholelithiasis than the secondary clinical trial is not entailed in the given trials as cholelithiasis was not reported as an adverse event in either trial Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "text_answer": "  The statement The all recorded AEs in the primary trial occurred to cohort 1 patients is entailed in the given trials as both trials have the same set of adverse events with a total count of 0 or 1 event for each type and all of them occurred in cohort 1",
        "label": "Entailment"
    },
    "5ce47a02-7653-4be0-8747-cc04ae14145a": {
        "text_answer": "  The statement in the primary clinical trial 97 of participants did not encounter any adverse effects is a contradiction to the information provided in the trial results   The trial results state that Overall Number of Participants Analyzed 100 and Measure Type Number Unit of Measure percentage of subjects with percentages given for each arm of the study However there is no mention of the percentage of participants",
        "label": "Contradiction"
    },
    "84246007-e5dd-48da-b548-e0f6403bd67a": {
        "text_answer": "  The secondary trial does not provide any information about shifts in ki67 expression in tumors The trial description mentions several correlative studies including laboratory biomarker analysis enzymelinked immunosorbent assay mass spectrometry bone scan qualityoflife assessment questionnaire administration and pharmacogenomic studies However there is no explicit statement that ki67 expression will be measured Therefore the statement is contrad",
        "label": "Contradiction"
    },
    "a3ab9532-5335-47ab-b19f-33ab64372ce2": {
        "text_answer": "  The statement is not entailed in the trials as they do not provide any information related to individuals working on machinery The trials only report the results of clinical studies on the use of DMCHOCPEN and Ribociclib in patients with various types of cancer The units of measure used in the trials are related to the outcome measurements of tumor diameter and response rates",
        "label": "Contradiction"
    },
    "19a043cf-96b9-4285-9e9c-1405403bf608": {
        "text_answer": "  The statement individuals with histologically proven metastatic small cell lung cancer are not permitted to participate in the primary clinical trial is a contradiction to the inclusion criteria of the trial The trial includes patients with histologically documented metastatic nonsmall cell lung cancer but not small cell lung cancer Therefore the statement is not entailed in the trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "d5abbde0-b23c-4e60-91fc-cb6a7735b68f": {
        "text_answer": "  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is entailed in the trials as the secondary trial had a higher incidence of these adverse events compared to the primary trial However its important to note that the statement only applies to the specific adverse events mentioned in the statement and not to all adverse events The trials do not provide enough information to determine if there",
        "label": "Entailment"
    },
    "7ebbbace-7ced-4e16-bfa7-681b1c6f00f3": {
        "text_answer": "  The statement is contradictory to the given trials In the primary trial participants do not receive Lisdexamfetamine orally instead they receive either CBTI alone or CBTI with Armodafinil In contrast in the secondary trial participants receive different doses of PDR001 but the same dose of MCS110 and there is no mention of Lisdexamfetamine in the trial",
        "label": "Contradiction"
    },
    "5e38b301-c67d-47dc-8117-ad86b9eeb524": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial participants are treated with multiple drugs including chemotherapy targeted therapy and hormonal therapy as well as surgical intervention In contrast the secondary trial also involves the use of multiple drugs everolimus and exemestane but no surgical intervention is mentioned   Therefore the statement that participants in the primary trial are treated with",
        "label": "Contradiction"
    },
    "db15e6cc-ceeb-4f48-b3a1-bca36a6b54f4": {
        "text_answer": "  The statement zero participants in group 1 of the primary trial were discovered to have lesions and over 09 fraction of participants in group 1 of the secondary trial showed symptoms of radiation dermatitis and hyperpigmentation is not directly entailed in the provided trials as there is no common group 1 between the primary and secondary trials The primary trial involves healthy volunteers and breast cancer patients with suspected lesions while the secondary trial focuses on breast",
        "label": "Contradiction"
    },
    "9f5587e3-ff70-42fa-9ddf-e59fc2729d77": {
        "text_answer": "  The statement complete disability is obligatory for participation in the secondary clinical trial in contrast to the primary clinical trial where it isnt a requirement is contradictory to the information provided in the inclusion criteria for both trials   In the primary trial there is no mention of complete disability as a requirement for participation In contrast in the secondary trial there is no mention of complete disability as a requirement for exclusion Therefore the statement is contradictory",
        "label": "Contradiction"
    },
    "361464b0-c0ac-404a-8432-ff8100152bff": {
        "text_answer": "  The statement the primary trial reported an equal number of aes for both groups is contradicted by the given trials as the number of adverse events in Trial 1 is 2 and in Trial 2 is 3 Therefore the statement is contradicted by the given information",
        "label": "Contradiction"
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "text_answer": "  The statement is entailed in the given trials as neither the primary nor the secondary trial includes Xrays transendocardial injections CT scans or MRIs as part of the interventions",
        "label": "Entailment"
    },
    "0c776d98-6a76-407b-9cc8-ded769af766e": {
        "text_answer": "  The statement is entailed in the given trials data as both the primary and secondary trials recorded fewer than 50 total adverse events in their respective cohorts",
        "label": "Entailment"
    },
    "1d20e438-806f-4695-bc8f-d6a0ce1f0299": {
        "text_answer": "  The statement participants of the primary clinical trial must have a normal hepatic function is not explicitly stated in the given inclusion and exclusion criteria However it can be inferred from the exclusion criteria that participants with liver dysfunction are excluded from the trial Therefore the statement is entailed by the given information",
        "label": "Entailment"
    },
    "28002c57-ff24-4b59-9f0e-0dfdbaab7f88": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial intervention involves oral administration of cabergoline while both interventions in the secondary trial involve intravenous IV administration of pixantrone dimaleate There is no mention of topical administration in either trial",
        "label": "Contradiction"
    },
    "55067973-6ec2-4cf7-b98a-6cd2210db8b0": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial both cohorts receive an injection of fluciclatide AH111585 18F for imaging sessions There is no mention of an oral dosage for cohort 1  In the secondary trial both cohorts receive chloroquine injections prior to surgery but these are intraderm",
        "label": "Contradiction"
    },
    "84fe3c19-bee9-4639-9569-455cf74f8c64": {
        "text_answer": "  The statement numerous adverse events were reported by all participants in both cohort 1 and cohort 2 of the primary clinical trial is contradictory to the given information in the trials The trials report that no adverse events were reported by any participant in either cohort 1 or cohort 2 Therefore the statement is contradictory to the trials",
        "label": "Contradiction"
    },
    "c7fd3efb-5319-40f3-aba0-a54c76a50768": {
        "text_answer": "  The statement in the primary clinical trial there were less patients with stable disease in week 12 compared to week 24 is entailed in the trial results as follows  Week 12 SD 12 Week 24 SD 10  The difference in the number of participants with stable disease between week 12 and week 24 is 2 12  10  2 Therefore",
        "label": "Entailment"
    },
    "c70623c3-85f0-4480-a772-349a89de7d43": {
        "text_answer": "  The statement all the adverse events recorded in the primary trial are linked to the cardiovascular system which contrasts with the secondary trial is a contradiction of the given data   The primary trial reports adverse events related to the BloodBone Marrow and Lymphatics systems while the secondary trial reports adverse events related to the BloodBone Marrow system only None of the reported adverse events in either trial are explicitly",
        "label": "Contradiction"
    },
    "0f224562-3266-490d-9b52-10a4d84f5685": {
        "text_answer": "  The given statement is not entailed in the provided trials as there is no mention of unexpected death incidents or hospital admissions in the trials The trials only report the occurrence of adverse events specifically lymphoma and their respective frequencies",
        "label": "Contradiction"
    },
    "9c10ceed-9cc6-473d-87c0-fa0b51353222": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment regimen does not follow a specific cycle arrangement but rather an ongoing regimen with no fixed cycle length In contrast the secondary trial implements an intensive monthly cycle intervention with a fixed cycle length of 21 days This difference in cycle arrangements is consistent with the statement  Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "e85599cc-08a6-4270-a168-cac94d5ce47d": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 involve the preoperative intravenous administration of Dexamethasone Therefore the statement the cohorts of the primary clinical trial are administered dexamethasone preoperationally is entailed by the given trials",
        "label": "Entailment"
    },
    "e6a3ed43-5bb0-40b2-9c4b-8a60e2b201df": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the first intervention involves the administration of fluciclatide to participants In the secondary trial the first intervention also involves the administration of a drug to participants but in this case it is chloroquine However the statement specifically mentions that the first cohort in the secondary trial is introduced to a standard dose of chloroquine which is different from",
        "label": "Entailment"
    },
    "e21cdb34-eb9d-4439-81ff-6dae554954c6": {
        "text_answer": "  The statement there were 11 additional instances of intestinal perforation reported in the secondary clinical trial compared to the primary clinical trial is entailed in the given data if we consider that  1 The primary trial had 0 instances of intestinal perforation 2 The secondary trial had 11 more instances of intestinal perforation than the primary trial making the total number of instances in the secondary trial 11",
        "label": "Entailment"
    },
    "d0a60b09-e029-4c35-b896-3647ce468594": {
        "text_answer": "  The given statement is not entailed in the provided clinical trial information The statement mentions the administration of a her2neu peptide vaccine combined with sargramostim gmcsf on specific days during the trial while the trial information only mentions the administration of chemotherapy and bevacizumab with no mention of a her2neu peptide vaccine or sargramostim Therefore the statement is contradictory",
        "label": "Contradiction"
    },
    "fbda9d7c-12d9-4b04-8047-da25419e1c3b": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description   The trial description specifies the following drugs and dosages epirubicin 100 mgm2 cyclophosphamide 600 mgm2 docetaxel 75 mgm2 and trastuzumab 6 mgkg loading dose and 4 mgkg maintenance dose",
        "label": "Entailment"
    },
    "bf1b6561-6731-457a-801d-8af93bc8857b": {
        "text_answer": "  The statement a patient that has a primary tumour with a diameter of 33cm measured by clinical examination and echography would be eligible for both the primary trial and the secondary trial is entailed in the trials as follows  Primary Trial The inclusion criteria state that the primary tumour must be greater than 2 cm in diameter A tumour with a diameter of 33 cm clearly meets this requirement  Secondary",
        "label": "Entailment"
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "text_answer": "  To determine if the statement is entailed or contradicted in the given trials with entailment or contradiction we need to first understand the context of the trials and the meaning of the statement   The statement The primary trial intervention section requires surgical and imaging procedures implies that the intervention being tested in the primary trial involves both surgical and imaging procedures   Lets examine the trials with entailment and contradiction to see if they",
        "label": "Entailment"
    },
    "68be42cb-7fb2-491a-a6ad-8f37972f9500": {
        "text_answer": "  The statement ccnd3 gene mutation is a change in the nucleotide sequence of the ccnd3 gene Patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer is not directly entailed in the given inclusion and exclusion criteria for the primary trial   The statement mentions the ccnd3 gene mutation and eligibility for the trial based on ER negative breast cancer but",
        "label": "Contradiction"
    },
    "0ef9a5c8-1159-4147-a204-59a3ae183e7d": {
        "text_answer": "  The statement is not directly entailed in the given trials as they focus on the interventions used in each trial rather than the specific conditions being studied thyroid gland lipoadenoma in the primary trial and unspecified in the secondary trial The statement provides additional information about the nature of the condition being studied in the first trial but it does not follow logically from the trials themselves Therefore the statement is neither entailed nor contradictory to the trials",
        "label": "Contradiction"
    },
    "f13676ce-309e-4cf5-866d-542b2a214b27": {
        "text_answer": "  The statement the primary clinical trial showed that the dalotuzumab 20 mgkg group had a 492 greater decrease in the growth factor signature compared to the triple negative group is not entailed in the given trials as there is no direct comparison of the percentage of participants with a decrease in GFS between the two groups in the trials The trials only report the percentage of participants with a decrease in GFS for each group separately Therefore",
        "label": "Contradiction"
    },
    "ce9ff719-a4b1-4506-91ef-eea478339ced": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial clearly states that sunitinib was administered to participants in the study Therefore the statement is contradictory to the facts presented",
        "label": "Entailment"
    },
    "dc545712-7b34-41d2-9166-441ee0366105": {
        "text_answer": "  The statement is entailed in the trials description as both the AlloMSCs and Placebo interventions consist of 20 transendocardial injections each",
        "label": "Entailment"
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial is entailed in the trials exclusion criteria The trial explicitly states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study While the statement uses the term severe anaphylactic reactions instead of grade 3 or 4 allerg",
        "label": "Entailment"
    },
    "b9b32a2d-94f0-413e-95f3-08177622a743": {
        "text_answer": "  The statement A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial is not entailed in the given trial description The trial description explicitly states that No meningeal carcinomatosis is a requirement for eligibility Therefore the statement is contradictory to the trial description",
        "label": "Contradiction"
    },
    "591794ae-5578-4bb4-a527-106947636ddb": {
        "text_answer": "  The statement in both the primary and secondary clinical trials more than 30 of participants experienced several adverse events is contradictory to the given data   The data provided states that in the primary trial 048 of participants experienced adverse events and in the secondary trial no adverse events were reported Neither of these percentages is greater than 30 Therefore the statement is contradictory to the given data",
        "label": "Contradiction"
    },
    "270f0f03-2316-40b0-8e7a-e42c499258da": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement asserts that there were no adverse events in the primary trial and that the most common adverse event in the secondary trial was anaemia which affected more than 5 of patients However the trials provided show that there were no adverse events reported in the primary trial at all while in the secondary trial anaemia affected only 2",
        "label": "Contradiction"
    },
    "fa12778d-4f82-4dd9-8ac0-decbef38472b": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years however at least one patient from both cohorts died in under 2 years is not directly related to the trials provided The trials only report the median survival times for patients undergoing surgery in the midluteal and midfollicular phases of their menstrual cycles The statement about attending school social events less because of hearing is not entailed in the trials Therefore the",
        "label": "Contradiction"
    },
    "32c2c3e7-4421-49e2-b1d0-2e9b125245e1": {
        "text_answer": "  The statement is not entailed in the trial results as the unit of measurement in the statement square millisecond is not related to the trial results which are in terms of percentage of participants experiencing CR or PR according to RECIST criteria Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "b032a728-a998-4b78-945a-048dbc5126f5": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials report percentage change in betaCTX not primary tumor diameter Therefore the trials do not directly compare the primary outcome measure between the two groups and the statement is contradictory to the information given",
        "label": "Contradiction"
    },
    "bf5c5c27-0b57-4397-9ba9-3c2895bcbe5d": {
        "text_answer": "  The statement women aged 18 or older are eligible for the secondary trial and the primary trial is entailed in both trials as it is stated in the inclusion criteria for both trials that participants must be aged 18 or older  The statement villous adenocarcinoma is an adenocarcinoma characterized by the presence of a villous architectural pattern it may arise from a villous adenoma is not directly",
        "label": "Entailment"
    },
    "e200f18a-ae9e-490f-a348-537187a65300": {
        "text_answer": "  The statement the primary trial recorded a higher incidence of palpitations pericardial effusions and abdominal pains than the secondary trial is a contradiction to the given data   The primary trial recorded a total of 40 adverse events out of 106 participants with 1 instance each of palpitations pericardial effusion and abdominal pain The secondary trial recorded no adverse events",
        "label": "Contradiction"
    },
    "d6716be9-247d-4c01-beb3-cd5bbbb6f9ec": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial descriptions The trials specify that 18FFDG and 18FFPPRGD2 PETCT imaging will be used not MRI",
        "label": "Entailment"
    },
    "61a20e23-7b57-4acc-b594-273f4536941c": {
        "text_answer": "  The statement there is no age restriction for candidates in the secondary clinical trial but to be eligible for the primary clinical trial patients need to be less than 30 years old is contradictory to the given trials   The primary trial has an age restriction for candidates less than 30 years old while the secondary trial does not mention any age restriction Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "872c6392-9ba9-4224-a579-de0deb401842": {
        "text_answer": "  The statement there were fewer cases of mucositis oral epileptic seizures and thromboembolic events reported in the primary trial compared to the secondary trial is not directly entailed or contradicted by the given trials as neither trial reports the occurrence of epileptic seizures Therefore we cannot make a definitive conclusion based on the given information alone However we can compare the number of reported cases of mucositis oral and th",
        "label": "Contradiction"
    },
    "ef4f8fe9-1d8e-464f-aa42-c33c073bb493": {
        "text_answer": "  The statement there was one psychiatric adverse event in the primary trial which affected less than 1 of patients is contradictory to the information provided in the trials   The trials report that there were 2 patients 400 with suicidal ideation which is a psychiatric adverse event and it affected more than 1 of patients Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "44cf1331-403a-4711-84e0-93f677307a6c": {
        "text_answer": "  The primary trial and the secondary trial both aim to determine the Maximum Tolerated Dose MTD of an intervention but there are some differences in their design and reporting   The primary trial determines the MTD of Ruxolitinib in combination with paclitaxel based on the number of patients who experience doselimiting toxicity DLT within a cohort The MTD is identified as the level below the coh",
        "label": "Entailment"
    },
    "4a88976f-0af4-449e-97d9-5b3f1ce94668": {
        "text_answer": "  The statement patients who have experienced abdominal fistula gastrointestinal perforation postmenopausal adenocarcinoma stroke transient ischemic attacks or major psychiatric disorders in the past 6 months are not considered for the primary clinical trial is entailed in the trials exclusion criteria as stated in the text provided Therefore the statement is entailed in the trials information",
        "label": "Entailment"
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "text_answer": "  The statement patients with Frontotemporal dementia or Mixed dementia are eligible for the primary trial is contradictory to the inclusion criteria mentioned in the text The inclusion criteria state that subjects must have a Mini Mental State Examination MMSE score of 23 or higher but some evidence of cognitive impairment Frontotemporal dementia and Mixed dementia are both types of dementia",
        "label": "Entailment"
    },
    "2a9e682e-382c-4361-a76f-f4cf5c39819d": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is entailed in the inclusion criteria of the trial as stated below  Histologically confirmed infiltrating primary breast cancer of  20 cm in largest clinical diameter   HER2 positive tumor either IHC 3 or FISH  Therefore the statement is entailed",
        "label": "Entailment"
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "text_answer": "  The statement The majority of patients in the primary trial experienced complete response by week 24 is contradicted by the trial results   Explanation   The trial results indicate that at week 12 there were no participants with complete response CR and at week 24 there were also no participants with CR The number of participants with CR was 0 at both time points   However there were participants with partial",
        "label": "Contradiction"
    },
    "3153ffe1-3625-4900-8a12-861b575959b0": {
        "text_answer": "  The statement is partially entailed in the trials Both interventions involve the use of doxorubicin cyclophosphamide and docetaxel The doses and frequency of administration of doxorubicin cyclophosphamide and the initial docetaxel cycles are the same in both interventions However the second intervention includes three additional cycles of docetaxel Therefore the statement is partially entailed as it",
        "label": "Entailment"
    },
    "eabae980-d833-47b7-8f0e-82242e662880": {
        "text_answer": "  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is neither entailed in the primary trial nor the secondary trial as given in the provided information  Explanation  The primary trial and the secondary trial have different inclusion and exclusion criteria The primary trial is for patients undergoing immediate tissue expander reconstruction following mastectomy while the secondary trial is for patients",
        "label": "Entailment"
    },
    "a8d30960-8533-42a5-949d-3fe706508806": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the trials the administration of dexamethasone is specified as preoperative for both cohorts with no mention of a twohour delay for the second cohort Therefore the statement that the administration is preoperative for the first cohort and two hours postoperative for the second cohort is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "28368708-e1e6-416e-8119-0d2712a89380": {
        "text_answer": "  The statement patients with severe obesity may participate in both the primary clinical trial and the secondary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The criteria for both trials do not mention any specific weight or body mass index BMI requirements Therefore the statement about severe obesity is not explicitly stated or excluded in the given criteria   However it is important to note that",
        "label": "Entailment"
    },
    "0b444449-045a-414d-be8e-1ff558525e83": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial description specifies that enzalutamide is administered orally to both groups 1 and 2 not intravenously as stated in the contradictory statement",
        "label": "Entailment"
    },
    "84a23fa9-2758-4ea6-9eca-ca89b580378a": {
        "text_answer": "  The statement cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine fluorescence in situ hybridization was performed is not explicitly stated in the provided trials However it is mentioned that patients in the primary trial receive a Fluciclatide injection and patients in the secondary trial receive Chloroquine injections",
        "label": "Entailment"
    },
    "745a2452-3a24-4e39-971f-3f7fe661f999": {
        "text_answer": "  The statement All Patients receiving the placebo intervention in the primary trial experienced emesis is a contradiction to the results provided in Trial 2 where 5 out of 20 participants in the placebo group were emesis free during the study period Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "a184cea4-fa4e-4548-a5d7-b3a94ab1130b": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of febrile neutropenia or cholelithiasis in either trial The trials only provide information about adverse events of a different nature gastroesophageal reflux disease and ductal carcinoma in situ in the secondary trial",
        "label": "Contradiction"
    },
    "552c79f8-3f17-4a7d-be66-d4cdc8749a66": {
        "text_answer": "  Lets calculate the amount of MCS110 and PDR001 each patient receives in both interventions in a 21day cycle  Intervention 1  MCS110 1 mgkg every 3 weeks Q3W  PDR001 100 mg every 3 weeks Q3W  Calculate the amount of MCS110 and",
        "label": "Entailment"
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "text_answer": "  The statement is entailed in the Trials In both the primary and secondary trials patients are participating in studies involving the use of 4Demethyl4cholestryloxycarbonylpenclomedine Furthermore the weekly administration of this drug is mentioned in the details of both interventions Therefore the statement that The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4",
        "label": "Entailment"
    },
    "70130418-63df-4ffb-9d78-7416daee50ba": {
        "text_answer": "  The statement all adverse events recorded in the primary clinical trial were solely associated with members of cohort 2 is a contradiction to the given data   Explanation  The data provided in the trials shows that there were no adverse events recorded for any of the participants in either cohort 1 or cohort 2 Therefore it is not accurate to state that all adverse events were associated with members of cohort",
        "label": "Contradiction"
    },
    "1a8cfb13-ebf0-48c4-a452-e26ac7a14863": {
        "text_answer": "  The statement is not entailed in the given trials as the Intervention 1 describes the use of a validated webbased risk assessment tool and decision support for providers based on the risk assessment results While it does not explicitly mention counseling or CBT it does involve some form of risk assessment and potentially preventionfocused interventions Therefore the statement that neither cohort of the primary trial receives any counselling risk assessment or CBT in the",
        "label": "Contradiction"
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "text_answer": "  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is a modification of the inclusion criteria for the trial   The original inclusion criteria state that patients with solid tumors SCBC includes nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer must have measurable",
        "label": "Entailment"
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "text_answer": "  The statement alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   Explanation  The primary trial explicitly excludes participants with a history of alcohol or substance abuse or dependence within the past 2 years However the secondary trial allows participants who drink fewer than ",
        "label": "Entailment"
    },
    "fdb097f0-b7ba-4314-a865-c89b1179aeb4": {
        "text_answer": "  The statement in the primary clinical trial an increase in pleural effusion was observed in 25 of patients belonging to the second cohort is entailed in Trial 2 as it directly reports the observed incidence of increased pleural effusion in the second cohort as 2500 However it is not directly mentioned in Trial 1 but the absence of increased pleural effusion in the first cohort",
        "label": "Entailment"
    },
    "93e1969e-1e96-49b2-874f-6cba2e42a6e4": {
        "text_answer": "  The statement is entailed in the given inclusion criteria of the clinical trial The statement individuals have to be diagnosed with breast cancer and need hormone therapy is a necessary condition for meeting the inclusion criteria of the trial Therefore the statement is entailed by the trials criteria",
        "label": "Entailment"
    },
    "95c7070d-76e7-4618-b95f-56b233dffb16": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial no specific dosing information for MM121 and Paclitaxel is provided However in the secondary trial the HR subgroup receiving Intervention 1 is given a 2 week runin of MM121 20 mgkg weekly followed by 12 weeks of MM1",
        "label": "Entailment"
    },
    "3592e711-ad4f-4f99-afde-3de2106ee5cd": {
        "text_answer": "  The statement the incidence of diarrhoea was higher among participants of the primary clinical trial than it was among the secondary clinical trial subjects is entailed in the given data as the incidence of diarrhoea in the primary trial was 730 2333 compared to 06 000 in the secondary trial",
        "label": "Entailment"
    },
    "595cee41-9cd2-4e9e-8ba5-2b3620985018": {
        "text_answer": "  The primary clinical trial measures the change in units on a scale for the severity of vaginal symptoms specifically vaginal dryness and dyspareunia The secondary clinical trial measures the objective response rate of HER2negative metastatic breast cancer patients using RECIST v10 criteria and FISH testing Neither trial utilizes units such as cm number of participants or time frame explicitly stated in the provided information for their primary outcome measurements  There",
        "label": "Entailment"
    },
    "32cd31d2-605b-4419-89a7-a6881bb792dd": {
        "text_answer": "  The statement alpha thalassemia is a genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule is neither entailed nor contradicted by the given trials as they do not provide any information related to alpha thalassemia The trials only specify the inclusion and exclusion criteria for patients participating in the primary and secondary trials",
        "label": "Entailment"
    },
    "e9941afc-cfd4-4bfa-bbce-eec2b84eb27d": {
        "text_answer": "  The statement the protocol of the primary clinical trial includes a bitherapy regimen for its study duration is entailed in the given trial information   Explanation   The trial consists of two different chemotherapy regimens epirubicin  cyclophosphamide and docetaxel  trastuzumab These regimens are given at different stages of the trial neoadjuvant and adjuvant",
        "label": "Entailment"
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "text_answer": "  The statement the secondary trial requires patients to be over a certain age but the primary trial does not specify an age range for participation is neither entailed nor contradicted by the given trials inclusion and exclusion criteria  Explanation  The primary trials inclusion criteria state that patients presenting for large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston are eligible for participation The exclusion criteria state",
        "label": "Entailment"
    },
    "cbcbfb22-0467-4ba0-b2dc-1f9bd073c27f": {
        "text_answer": "  The statement in the primary trial results there were more patients with stable disease in the end of the third month than in the end of the sixth month but no patients with complete response in the end of third or sixth month is entailed in the trial results as follows  1 The number of participants with stable disease at Week 12 was 12 and at Week 24 was 10 2 There were no participants with complete response",
        "label": "Contradiction"
    },
    "fe1ea6e0-dd6d-44d4-a9db-750c890f08c8": {
        "text_answer": "  The statement There were no patients in the primary trial or the secondary trial that suffered at least 3 different AEs is not directly related to the information provided about the adverse events for the trials involving Lactococcus The statement only mentions the number of different adverse events per patient but it does not specify the number of adverse events experienced by each patient in total Therefore the statement cannot be determined to be entailed or contradicted based on the",
        "label": "Contradiction"
    },
    "ab7fc69a-25c8-4bee-ad2b-526c6ea638e4": {
        "text_answer": "  The statement the majority of patients in the primary trial experienced complete response by week 168 days is not entailed in the given trial results   Explanation   The trial results only report the number of participants with complete response CR partial response PR or stable disease SD at weeks 12 and 24 There is no information provided about the number of participants who experienced CR after week 12 or the",
        "label": "Contradiction"
    },
    "44b41322-9fb1-4a02-b2c5-4faead5489aa": {
        "text_answer": "  The statement Most patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed in the given trials as they do not provide sufficient information to make that determination The trials only list the number and percentage of patients who experienced specific adverse events but they do not provide the total number of patients in each trial or the percentage of patients who did not experience any adverse events Therefore the statement is neither entailed nor contradicted by",
        "label": "Contradiction"
    },
    "278549fe-1d04-44de-88dc-e0661e8f234b": {
        "text_answer": "  The statement the primary clinical trial has fewer total and different kinds of adverse events recorded compared to the secondary trial is entailed in the given trials as follows  1 Fewer total adverse events In the primary trial there were 0 adverse events out of 14 participants while in the secondary trial there were 48 adverse events out of 348 participants The number of adverse events in the primary trial is",
        "label": "Entailment"
    },
    "824add43-b242-4278-9be4-04f1566039cd": {
        "text_answer": "  The statement one injection will be administered to the patients on the eighth day of the study is not directly entailed in the given trial information The trial mentions that the dendritic cell vaccine including the dendritic cells and peptidepulsed DCs and trastuzumab injections are given but it does not explicitly state that one injection is given on the eighth day The statement could be contradictory",
        "label": "Contradiction"
    },
    "bd89597d-82f5-461f-aa6e-ef215afcc6a5": {
        "text_answer": "  The primary trial involves the use of epacadostat in combination with pembrolizumab and sunitinib The secondary trial involves the use of sunitinib as a single agent While both trials involve the use of pembrolizumab the frequency of administration of pembrolizumab in the primary trial is every 3 weeks in combination with epacadostat and sunitinib while in the secondary trial",
        "label": "Entailment"
    },
    "46a79c10-315b-4975-9949-508fc379af87": {
        "text_answer": "  The statement 12 adverse events were observed in the course of the primary clinical trial is a contradiction to the information provided in the trials   The primary trial reported 0 adverse events out of 25 participants while the secondary trial reported 10 adverse events out of 30 participants The total number of adverse events reported in the secondary trial is 10 which is not equal to 12 as stated in the given",
        "label": "Contradiction"
    },
    "6e971275-b508-4627-9380-39dc63e90b3d": {
        "text_answer": "  The statement the primary trial participants do not receive any vaccines is entailed in the given trial information as there is no mention of any vaccines being administered in either Intervention 1 or Intervention 2  The statement rehabilitation center is a healthcare facility designed for improving maintaining or restoring physical strength cognition or mobility is not directly related to the trial information and does not entail or contradict any information provided in the",
        "label": "Entailment"
    },
    "ab6d9f92-0380-4e3a-9bff-032ad4d918ed": {
        "text_answer": "  The statement it was observed that 11000 patients in the primary trial and 3981674 in the secondary trial had an acute myocardial infarction is a contradiction to the given trials as there was no occurrence of acute myocardial infarction reported in any of the trials The trials report a total of 0 acute myocardial infarctions in both the primary and",
        "label": "Contradiction"
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "text_answer": "  The statement Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial is not explicitly stated in the inclusion or exclusion criteria for either trial However the primary trial does list history of clotting disorder hypercoagulable state as an exclusion criterion which could potentially include a history of pulmonary embolisms But the statement goes beyond this",
        "label": "Entailment"
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "text_answer": "  The statement On average both cohorts of the primary trial suffered a deterioration in cognitive function however this was not the case for all patients is not directly entailed in the given trial results   The trials only report the mean standardized composite scores for each group and the statement makes a more general claim about the distribution of cognitive function changes in both groups The trials do not provide sufficient information to determine if the statement is entailed contradicted",
        "label": "Contradiction"
    },
    "f54c9be8-81b3-4544-9e82-b7058b9911f5": {
        "text_answer": "  The statement is entailed in the trials as both trials require participants to meet a certain performance status as a baseline requirement In the primary trial this is measured using the Karnofsky score of 70 or better In the secondary trial this is measured using a Zubrod performance score of 2 or better Therefore the statement is entailed in both trials",
        "label": "Entailment"
    },
    "df43c972-9623-462c-9044-2d632e1daafb": {
        "text_answer": "  The statement patients with papillary carcinoma and controlled blood pressure levels are accepted for the primary clinical trial but are not qualified for the secondary clinical trial is neither entailed nor contradicted by the given trial information  Explanation  The primary clinical trial includes patients with benign breast disease who are amenable to hormonal therapy but excludes those with papillary carcinoma only if they have highrisk lesions or",
        "label": "Entailment"
    },
    "026b062f-0ebf-4e02-9ff8-3bbd12f09ea7": {
        "text_answer": "  The statement is entailed in the trials inclusion criteria The trial explicitly states that one of the inclusion criteria is Any tumor type if tissue tests positive for CCND1 amplification CDK46 mutation CCND2 amplification OR any other functional alteration at the G1S checkpoint Therefore the statement that the primary clinical trial excludes patients diagnosed with tumors that have CCND1 amplification CDK46 mut",
        "label": "Entailment"
    },
    "70e1b8ee-05e4-4427-ba8b-c8762a677b9a": {
        "text_answer": "  The statement the primary trial participants receive whole breast radiation therapy and both cohorts of the secondary trial receive 05 g of fulvestrant in a tablet form to be taken bid is neither entailed nor contradicted by the given trial information   The primary trial participants do receive whole breast radiation therapy as stated in the trial description However the secondary trial participants do not receive 05 g of fulvestrant in a tablet form to",
        "label": "Entailment"
    },
    "f96fa263-12b2-475c-926d-57b8588e85ef": {
        "text_answer": "  The statement the primary clinical trial welcomes patients diagnosed with tx nx mx t0 nx m0 or t1 n1 m1 tumors is not explicitly stated in the given trial criteria However the trial does welcome patients with measurable or nonmeasurable disease which could potentially include some of the mentioned stages Tx T0 T1 N1 M1 Therefore the statement is not directly contradictory",
        "label": "Entailment"
    },
    "e9f1fcfa-40ed-4360-bf37-4260888d241b": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial participants do not receive any medication other than radiation therapy In contrast in both cohorts of the secondary trial participants receive oral medication Enzastaurin and intramuscular injections Fulvestrant Therefore the statement that participants in the primary clinical trial receive whole breast radiation therapy whereas participants in both cohorts of the secondary clinical trial are subjected",
        "label": "Entailment"
    },
    "e21904b2-3e78-4f20-80e3-562a82fc9cfe": {
        "text_answer": "  The statement children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial is neither entailed nor contradicted by the information provided in the inclusion and exclusion criteria for both trials   The primary trial explicitly excludes children as eligible participants while the secondary trial does not mention anything about children being eligible or excluded Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "0ff4990d-1f43-4516-a7b4-62b59526439d": {
        "text_answer": "  The statement All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3 as well as requiring considerable assistance and frequent medical care is not directly entailed in the given inclusion and exclusion criteria of the primary trial   The inclusion criteria state that the primary breast cancer must be HER2 positive either by IHC 3 or FISH However there is no mention of the level of assistance or medical",
        "label": "Contradiction"
    },
    "02ef43dd-1a1c-49c4-8ce0-01f03f733e81": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation  The primary trial does not specify an age range for participation so it does not contradict the statement that 18 years olds are excluded from the secondary trial However the statement does not follow directly from the trials as the secondary trials inclusion criteria explicitly state that participants must be over 18 years old Therefore the statement is not entailed by",
        "label": "Entailment"
    },
    "82080910-276d-4987-8d95-0a39b92ce3ee": {
        "text_answer": "  The statement eligibility for the primary clinical trial requires having colon cancer and a lack of response to prior hormonal treatments is contradictory to the given inclusion and exclusion criteria for the primary trial   The inclusion criteria state that the patient must have breast cancer and a lack of response to prior hormonal treatments The statement provided however mentions colon cancer instead of breast cancer making it contradictory to the given criteria",
        "label": "Entailment"
    },
    "159bf774-0488-4260-94ed-e106c3e02bf7": {
        "text_answer": "  The statement cohort 2 of the primary trial reported fewer incidences of palpitations pericardial effusions and abdominal pains compared to cohort 1 of the secondary trial is a comparison statement between two trials To verify this statement we need to compare the incidence rates of palpitations pericardial effusions and abdominal pains in cohort 1 of the primary trial and coh",
        "label": "Entailment"
    },
    "224ad5d9-659b-474a-b9ff-7cb17e104ddf": {
        "text_answer": "  The statement does not directly entail or contradict the information provided in the trials The statement mentions a specific patient with a longest PFS of 35 months which is not mentioned in the trials The trials only provide median PFS for each group and the longest PFS for an individual patient is not mentioned Therefore the statement is neither entailed nor contradicted by the information in the trials",
        "label": "Entailment"
    },
    "46299940-216a-446b-bab8-6005845f46c6": {
        "text_answer": "  The statement is entailed in the trial results as stated in the mean percentage change in Ki67 expression is 40 63 to 29 The trial results indicate that the administration of tamoxifen as described in the study led to an average reduction of 40 in Ki67 expression which is consistent with the statement",
        "label": "Entailment"
    },
    "f12f052d-fd1b-407b-a2d9-923f00111a45": {
        "text_answer": "  The statement men of reproductive age and women who can bear children are suitable for the primary clinical trial although they must align with further stipulations is entailed in the given inclusion and exclusion criteria of the clinical trial   The inclusion criteria state that Women of childbearing potential WOCBP are allowed but must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after",
        "label": "Entailment"
    },
    "bd7ca920-80f7-4bf8-a09c-3f619056e700": {
        "text_answer": "  The statement there were minimal adverse events observed in the secondary clinical trial as compared to the primary clinical trial is entailed by the given trials data if we assume that the number of adverse events in the secondary trial is less than the number of adverse events in the primary trial and both trials have the same types of adverse events Adverse Events 1 and 2 Based on the given data this assumption holds true since the number of adverse events for",
        "label": "Entailment"
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "text_answer": "  The statement Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen andor progesterone receptor positive and are considering AI therapy are eligible for the primary trial is contradictory to the trials inclusion criteria  Reasoning  The inclusion criteria state that patients must have histologically proven DCIS or stage IIII invasive carcinoma of the breast Stage 4 invasive carcinoma",
        "label": "Entailment"
    },
    "8c002058-a160-4eab-bb58-5874ac1a86d4": {
        "text_answer": "  The statement specific symptoms are predominantly reported as adverse events in the primary clinical trial is entailed in the given data if we define specific symptoms as the individual adverse events listed in the trial The data shows that a total of 16 adverse events were reported out of 51 participants and all of these events are specific symptoms mentioned in the trial Therefore the statement is entailed by the data",
        "label": "Entailment"
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets the following inclusion criteria  Histologically verified diagnosis of solid tumor malignancy of breast  Appropriate diagnostic workup completed including CBCdifferential  Zubrod performance status 02  Age 18 years or older  Signed informed consent  The patient also meets the inclusion criteria for the secondary trial  Signed informed consent form",
        "label": "Entailment"
    },
    "f72c1fc3-cfdb-4aa3-a8a8-968f416e35b7": {
        "text_answer": "  The statement during the primary clinical trial and the secondary clinical trial no adverse events relating to cardiac or psychiatric conditions were observed is entailed in the given trials data as both trials report a total of 0 adverse events for cardiac and psychiatric conditions in each trial",
        "label": "Contradiction"
    },
    "8623aaca-7fb2-44d5-b968-a064007b7112": {
        "text_answer": "  The statement patients with a diagnosis of stage 4 invasive breast carcinoma positive for estrogen andor progesterone receptors and weighing the option of AI therapy are suitable for the primary clinical trial is contradictory to the trials inclusion criteria  Reasoning  The trials inclusion criteria state that patients must have histologically proven DCIS or stage IIII invasive carcinoma of the",
        "label": "Entailment"
    },
    "5df26e2d-1a55-4d02-b95b-1796c872a7ec": {
        "text_answer": "  The statement over 910ths of patients in the secondary trial and the primary trial did not suffer any adverse events is not directly entailed or contradicted by the given data   The data only provides the number and percentage of patients who experienced specific adverse events in each trial It does not provide information on the total number of patients in each trial or the percentage of patients who did not experience any adverse events Therefore it is not",
        "label": "Contradiction"
    },
    "048dc5c5-ef7e-4717-850e-521e58feecf0": {
        "text_answer": "  The statement amyloid resorption induction is amyloid resorption induction involves initiation of activities involved in the breakdown and assimilation of amyloid deposits The primary trial participants receive Epacadostat twice as frequently as secondary trial participants receive sunitinib is not directly entailed in the given trial information   The statement makes assumptions about the nature of amyloid resorption induction and",
        "label": "Contradiction"
    },
    "5ba46a49-9158-4409-815d-0830526da5c4": {
        "text_answer": "  The statement is contradictory to the trial results provided   The trial results indicate that there were 80 participants out of 96 in the Ketorolac 30 mg group who experienced recurrencefree survival and 96 participants out of 107 in the NaCl 09 3mL group who experienced recurrencefree survival   Therefore the statement that 130 participants",
        "label": "Entailment"
    },
    "65130a82-a75f-4faa-85a9-5ec4535aa67b": {
        "text_answer": "  The statement picogram per milliliter per milligram per meter squared per day is a unit of concentration equal to picograms per milliliter divided by milligrams per meter squared per day is a mathematical definition and is not related to the adverse events data provided in the trials Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "text_answer": "  The statement is entailed in the trials as given Both interventions are intravenous infusions that last for 3 hours but they are administered on different days Therefore the statement is an accurate reflection of the information provided in the trials",
        "label": "Entailment"
    },
    "5b19b14f-2049-4c5f-8e3b-5d8dffa5d687": {
        "text_answer": "  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is not explicitly stated in the inclusion or exclusion criteria provided in the text However SCBC small cell lung cancer is not listed among the eligible tumor types in the inclusion criteria Therefore the statement is entailed in the trials exclusion criteria implicitly  Ex",
        "label": "Entailment"
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial Group 2 receives 05ugkg of dexmedetomidine not myalgias and in the secondary trial no intervention related to myalgias is mentioned for either cohort",
        "label": "Contradiction"
    },
    "18c09a69-f72b-42db-b15b-45e369db34e5": {
        "text_answer": "  The statement patients with 45 cerebral metastases in the cerebral cortex will be eligible for the secondary trial however those with this diagnosis will not qualify for the primary trial is a contradiction to the given trial criteria  Explanation  The primary trial explicitly states that each lesion must measure less than 30 cm and there should be one to three presumed brain metastases It also ment",
        "label": "Contradiction"
    },
    "cd2cb8fc-7624-479c-b9ee-e2ca3cf5ea18": {
        "text_answer": "  The statement the variation in ki67 expression in tumors is not evaluated in both the primary and the secondary clinical trial is not directly addressed in the provided information from the trials The primary trial does not mention ki67 expression evaluation and the secondary trial mentions various correlative studies but does not specify ki67 expression among them Therefore the statement is neither entailed nor contradicted by the given trial information",
        "label": "Entailment"
    },
    "6f4c1d2f-4b97-4f77-b25b-004addb58726": {
        "text_answer": "  The statement use of gabapentin or herceptin within the last six months doesnt affect the eligibility for the secondary trial but considers the exclusion from the primary trial is a contradiction with respect to the given inclusion and exclusion criteria for both trials  Explanation  The primary trial excludes participants who have used herceptin in the previous 5 months but it does not mention anything about gabapentin use",
        "label": "Contradiction"
    },
    "b9fd7445-fced-4f32-9efb-7e142d1963e2": {
        "text_answer": "  The statement The same percentage of patients suffered adverse events in both cohorts of the primary trial is not entailed in the given trials as the trials do not provide sufficient information to make that determination The percentage of patients with adverse events is different between the two cohorts 5000 in the first cohort and 4000 in the second cohort Therefore the statement is contradictory to the given",
        "label": "Contradiction"
    },
    "a52b9758-f769-4350-b617-5215621b815b": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In both arms of the trial carboplatin is administered at the same dose AUC 2 to participants Therefore the statement that carboplatin is administered at dissimilar doses between cohorts in the primary clinical trial is not entailed in the trial information and is a contradiction",
        "label": "Contradiction"
    },
    "bad327e8-73f2-4903-a0bf-ed5d08c81f69": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial assess patients progress by the decrease in the size of the tumor following completion of chemotherapy is not entailed in the provided information from the trials   The primary trial assesses the change in serum levels of Follicle Stimulating Hormone FSH from baseline to week 12 while the secondary trial determines the maximum tolerated dose MTD of Ruxol",
        "label": "Contradiction"
    },
    "9bd8875f-ce04-496a-b039-6a84bb2e5548": {
        "text_answer": "  The statement Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure is not directly stated in the provided information from either trial However it is mentioned that the primary trial uses a selfreported outcome measure for vaginal symptoms while the secondary trial uses objective response rate of HER2negative metastatic breast cancer assessed by MRI or CT Therefore the statement is not entailed",
        "label": "Contradiction"
    },
    "602c538d-9b6f-4a94-8423-b7d5427ee15e": {
        "text_answer": "  The statement is not directly related to the given intervention description in the primary trial The statement is about post term pregnancy which is not mentioned or related to the intervention of treated subjects with device placed and treated with partial breast irradiation Therefore the statement is neither entailed nor contradicted by the given intervention description",
        "label": "Entailment"
    },
    "5e094086-297e-44c7-9119-aa451e326e8c": {
        "text_answer": "  The statement women aged 18 or older are eligible for the secondary trial and the primary trial is not directly related to the given inclusion and exclusion criteria for both trials Therefore it cannot be determined if the statement is entailed in the trials with entailment or contradiction based on the provided information alone  However we can determine that the statement is not a contradiction since women aged 18 or older are indeed eligible for both trials according to",
        "label": "Entailment"
    },
    "fc16338c-2505-48c4-ab18-e7de394cab62": {
        "text_answer": "  The statement Africanamerican patients can participate in the primary trial is entailed in the given inclusion criteria for the primary trial as there is no mention of any exclusion based on race  The statement borderline resectable mass is a tumor mass finding that refers to a continuum between resectable and locally advanced unresectable disease is not directly related to the given inclusion and exclusion criteria for the primary trial However the criteria do",
        "label": "Entailment"
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "text_answer": "  The statement candidates for the primary trial must have breast cancer and require hormonal treatment is entailed in the given inclusion criteria of the trial The inclusion criteria explicitly state that candidates must have breast cancer and require hormonal treatment Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "e561775c-d739-405c-ac1e-a8a9ccca4530": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial administers Vitamin B12 sublingually while the secondary trial administers it orally There is no indication of disposition or continuation in either trial",
        "label": "Contradiction"
    },
    "5ed2538b-155d-4527-aa80-b6a19c5a6602": {
        "text_answer": "  The statement is not entailed in the trials provided as the trials report percentage change in serum betaCTX levels at Week 4 not primary tumour diameter",
        "label": "Contradiction"
    },
    "a680a9d1-387f-48e3-8e30-01b306c0b964": {
        "text_answer": "  The statement any patients with a documented allergy to cephalosporin or trimethoprimsulfamethoxazole will not be eligible for the secondary trial and a documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial is entailed in the primary and secondary trial inclusionexclusion criteria as follows  Primary Trial  Exclusion Criteria Patients",
        "label": "Entailment"
    },
    "3d580aba-2e7b-44bc-a094-83f404ebbd6a": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM with a change in units on a scale as its unit of measure The secondary trial measures the objective response rate of HER2negative metastatic breast cancer using percentage of participants as its unit of measure There is no mention of cognitive function scores or CogState in either trial",
        "label": "Contradiction"
    },
    "cf1b44d2-94e8-49b6-adbf-036a44f28402": {
        "text_answer": "  The statement primary clinical trial records a larger number of bronchopneumonia and general physical health deterioration cases than the secondary clinical trial is a comparison statement between the two trials regarding the occurrence of specific adverse events To determine if this statement is entailed or contradicted by the given data we need to compare the number of cases for each adverse event in both trials  According to the given data the secondary trial has one case of bron",
        "label": "Entailment"
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "text_answer": "  The statement 25 of cohort 2 patients in the primary trial suffer Increased pleural effusion is contradictory to the information provided in the trials   Explanation  The trials report the number of patients who experienced each adverse event in each cohort In the first cohort there was one patient out of 13 who experienced increased pleural effusion which is equivalent to 7",
        "label": "Entailment"
    },
    "86dd343d-01be-46f6-aed5-9ad9423aca98": {
        "text_answer": "  The statement is not entailed in the given trials as there is no information provided in the trials regarding the number of adverse events in the primary trial that affected more than 500 patients or more than 60 of patients in any trial The statement only provides information about the percentage of patients affected by specific adverse events in the secondary trial",
        "label": "Contradiction"
    },
    "22a06af0-a4f9-4311-92e0-d2d13a24b9b1": {
        "text_answer": "  The statement the adverse events such as recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were notably more prevalent in the primary clinical trial than the secondary clinical trial is entailed in the given trials data as the primary trial had a higher percentage of adverse events for all the mentioned conditions compared to the secondary trial  Explanation  The statement is ent",
        "label": "Entailment"
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The dosage of Denosumab in Intervention 1 of the primary trial is 120 mg Q4W which is equivalent to 480 mg per 3 months since it is given every 4 weeks   The dosage of Tamoxifen in Intervention 1 of the secondary trial is 10 mg once daily for",
        "label": "Entailment"
    },
    "6e2f3c50-84c2-41e2-8188-a83c94b2704b": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement claims that eyelid oedema upper gastrointestinal haemorrhage and chest pain were the only adverse events observed in patients from the secondary clinical trial but the trials show that the secondary trial recorded a total of 5 adverse events 3 for event type 1 and 2 for event type 2 and only ey",
        "label": "Entailment"
    },
    "bad8129b-64a4-4dfc-bb88-8bcea4fe2dc4": {
        "text_answer": "  The statement cohort 2 of the primary clinical trial experienced significantly fewer incidents of neutropenia compared to cohort 1 of the secondary clinical trial despite receiving larger doses of empegfilgrastim is not directly entailed in the given trials as the trials do not provide sufficient information to make such a comparison The primary trial reports the mean duration of neutropenia for two different doses of empegfilgrastim in the same",
        "label": "Contradiction"
    },
    "603ccef1-eacf-4053-85d3-106eda10ca83": {
        "text_answer": "  The statement patients with detectable malignancies in both breasts are allowed in the primary clinical trial is not entailed in the given inclusion and exclusion criteria The criteria only mention unilateral breast cancer Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "4ac023d3-e86c-47bb-bbd5-1b6907e8cab3": {
        "text_answer": "  The statement is entailed in the trials as it explicitly states that the dose of talazoparib administered varies depending on whether the patient has breast or ovarianperitoneal cancer The trials provide separate interventions for each cancer type with different dosing schedules Therefore the statement is a logical consequence of the information given in the trials",
        "label": "Entailment"
    },
    "ed3e6033-e499-4743-9aca-a275a80a1e4e": {
        "text_answer": "  The statement several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes is not directly entailed or contradicted by the information provided in the trials The trials only report the correlation of Vitamin D levels with the gene expression profile in breast cancer patients but they do not mention the specific results for each participant regarding the gene expression pattern or their Vitamin D levels being normal or not",
        "label": "Contradiction"
    },
    "3c749ffd-27b3-473d-92c9-c4d3899c9689": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials The primary trial and the secondary trial both investigate pathological complete response pCR as their outcome measurement However the trials involve different patient populations and treatment regimens making direct comparison between the trials challenging The small difference in pCR rates between the two arms in the primary trial and the significant difference in pCR rates between the two arms in the secondary trial do not necessarily imply entailment or contrad",
        "label": "Entailment"
    },
    "5ce949a2-19fb-4580-8b0e-f0652dd064e3": {
        "text_answer": "  The statement is contradictory to the information provided in both the primary and secondary trials The primary trial includes patients with a breast tumor of 1 cm in diameter while the secondary trial does not specify the tumor size However the statement mentions a tumor of 200mm 8 inches in diameter which is significantly larger than the size specified in the primary trial and not mentioned at all in the secondary trial Therefore the statement is contradict",
        "label": "Entailment"
    },
    "2f5d2e0a-6378-4b00-b5ed-760d021808c8": {
        "text_answer": "  The statement A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial is not directly related to the information provided in the inclusion and exclusion criteria for the primary and secondary trials The statement about sacral intraspinal meningioma is not mentioned in the trials at all Therefore the statement is neither entailed nor contradicted by the information provided in the trials",
        "label": "Entailment"
    },
    "96ee335e-d938-4b45-a22d-49b03dbb2af0": {
        "text_answer": "  The given statement is not directly related to the trials provided The trials focus on the comparison of the effects of paced respiration and fast shallow breathing on hot flash frequency in menopausal women The statement is about Enterovirus and Poliovirus which are not mentioned in the trials Therefore the statement is neither entailed nor contradicted by the trials",
        "label": "Entailment"
    },
    "38e0b539-6f73-4e11-bb55-0b021f66ee84": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive the same radiation therapy doses with the only difference being the use of Active Breathing Coordination ABC in Cohort 1 The additional two weeks in Cohort 1 is due to the SPECT scans being obtained at baseline and at 6 months followup However the radiation therapy itself is identical in both cohorts Therefore the statement is entailed",
        "label": "Entailment"
    },
    "ee03b5cc-6cfe-4b3a-8429-493f95c97b71": {
        "text_answer": "  The statement a patient whose primary tumor size is not measurable by clinical examination or echography is fit for both the primary clinical trial and the secondary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials   The primary trial includes a criterion for a measurable primary tumor size but it does not explicitly exclude patients with an unmeasurable primary tumor size The secondary trial does not",
        "label": "Entailment"
    },
    "e9c0f175-b715-4b33-86a2-aa21c2990164": {
        "text_answer": "  The statement is entailed in the trials as the patients in cohort 1 receive Active Breathing Coordination ABC during radiation therapy while those in cohort 2 do not Although both groups receive similar radiation therapy doses the presence or absence of ABC is the primary difference between the two cohorts Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "827cb89b-a78f-49e9-b342-d00e7b46e61f": {
        "text_answer": "  The statement is not entailed in the trials provided as they measure different outcome measures The trials report the percentage change in serum betaCTX levels from baseline to Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups No information about primary tumour diameter is given in the trials Therefore the statement is contradictory to the information provided in the trials",
        "label": "Contradiction"
    },
    "4bc6699d-0ac2-4358-9425-1d377151ffa8": {
        "text_answer": "  The statement is entailed in the trials as both trials report the determination of the maximum tolerated dose MTD of an intervention ruxolitinib in the primary trial and MM111 in the secondary trial However it is important to note that the definition and methodology for determining the MTD may differ between the two trials In the primary trial the MTD is determined based on the number of patients who experience dose limiting toxicity ",
        "label": "Entailment"
    },
    "a0ebcb11-7643-4861-b26c-8b1716fd00c1": {
        "text_answer": "  The statement there were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed in the Trials as it is explicitly stated in the Adverse Events 2 section that there were no deaths or hospitalizations in that cohort  However the statement only a single case of Atrial fibrillation is not directly related to the statement about when individuals first began smoking cigarettes regularly Therefore the statement as a whole",
        "label": "Contradiction"
    },
    "13d13c8d-1d58-411f-943b-cbcd836b8d17": {
        "text_answer": "  The statement does not directly entail or contradict the given trial information The statement mentions a mobilization clinical trial setting and a cohort 1 of the primary trial but it does not specify which trial or interventions these terms refer to The trial information provided only mentions two interventions with different doses of ALT801 but it does not mention a mobilization clinical trial setting or any specific cohorts Therefore",
        "label": "Entailment"
    },
    "09f76c97-d8e4-45bd-9365-71e654770e39": {
        "text_answer": "  The statement is entailed in the trials as both trials include the administration of cyclophosphamide Paclitaxel and pegfilgrastim to their patient cohorts However its important to note that the dosing and scheduling of these drugs may differ between the two trials The midline reference in the statement is not directly related to the trials and is an unrelated medical term Therefore the statement is entailed in the trials with respect",
        "label": "Entailment"
    },
    "1ccb499d-d126-4ec6-bed1-c121dfa13d2d": {
        "text_answer": "  The statement is entailed in the Trials as there is a shared inclusion criterion between the two trials  1 Women or patients who are 18 years of age or older  Therefore the statement at least one inclusion criterion is shared between the secondary trial and the primary trial is entailed in the given trials",
        "label": "Entailment"
    },
    "909d54ab-358d-4892-9bd1-e71d6d3bc24c": {
        "text_answer": "  The statement the percentage of cells expressing ki67 increased by 8 after treatment with tak228 plus tamoxifen in the primary clinical trial is a contradiction to the results provided in the trial   The results state that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2 to 38",
        "label": "Contradiction"
    },
    "15f4f1d2-c4db-403e-83ed-85e6958ee7ed": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The statement suggests that there were more adverse events in the secondary trial compared to the primary trial but the trials both report a total of 0 adverse events for each trial Therefore the statement is contradictory to the facts presented",
        "label": "Entailment"
    },
    "0c4d0064-476e-426e-ae13-4f53c07ea0b4": {
        "text_answer": "  The statement ai therapy responsive participants are allowed to partake in the primary clinical trial and secondary clinical trial is not explicitly stated in the given inclusion criteria for either the primary or secondary trials However the primary trial does not list ai therapy responsiveness as an exclusion criterion which implies that participants who are responsive to ai therapy are still eligible for the study Therefore the statement is entailed in the primary trial but there is no mention of it in",
        "label": "Entailment"
    },
    "34208e81-25b5-40a7-ba91-ffdece7c96e1": {
        "text_answer": "  The statement in the findings of the primary clinical trial the number of patients showing stable disease decreased from week 12 to week 24 is entailed in the trial results The number of participants with stable disease at week 12 was 12 and at week 24 it was 10 Therefore the statement is a valid inference from the data provided  However the statement several patients exhibited a complete",
        "label": "Entailment"
    },
    "afa65be8-62bf-4c63-8670-a997a06c6943": {
        "text_answer": "  The given statement unexpected fatalities occurred during the primary clinical trial is not entailed in the provided trials as there is no mention of any fatalities in either trial The trials only report the occurrence of adverse events but not their severity or outcome Therefore the statement is contradictory to the given information",
        "label": "Contradiction"
    },
    "c4ab76ed-d3ce-4368-b081-c39413094966": {
        "text_answer": "  The statement is entailed in the given trials as follows  The statement none of the adverse events occurred during the primary clinical trial is entailed by the fact that the primary trial had no reported adverse events 025  The statement for the secondary clinical trial all adverse events except for skin infections were seen in less than 30 of the patients is also entailed by the data provided in the secondary",
        "label": "Entailment"
    },
    "cac3538f-89a2-4037-9928-4aaa708ae34f": {
        "text_answer": "  The statement is contradictory to the secondary trial as it does not mention the administration of suramin and paclitaxel in its intervention section In the secondary trial the intervention is limited to patients undergoing mastectomy surgery without specification of any medication to be administered",
        "label": "Entailment"
    },
    "abd83d4d-ac75-4626-928d-1b511a61d2b7": {
        "text_answer": "  The statement The patient with the longest PFS in the primary trial survived 35 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS observed in any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "dc3aaeaa-d573-410b-a1f2-a55af755fc83": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial involves the use of multiple types of drugs with specific dosages throughout the study duration Therefore the statement is contradictory to the given information",
        "label": "Entailment"
    },
    "8a3619a4-4224-4451-b7f8-8fc2ff8ec26f": {
        "text_answer": "  The statement individuals who have received antineoplastic chemotherapy androgens estrogens or progestogens therapy within two years prior to the start of the study are not eligible for the primary clinical trial is entailed in the trials exclusion criteria   The trial explicitly states that Any of the following current  4 weeks prior or planned therapies Antineoplastic chemotherapy antiHER",
        "label": "Entailment"
    },
    "710206ba-d90c-4341-a1ae-b937ffc50a2f": {
        "text_answer": "  The statement In the primary trial results there were more patients with stable disease in week 12 than week 24 but 0 patients with complete response in week 12 or 24 is neither entailed nor contradicted by the given trial results   The statement mentions the number of patients with stable disease being greater in week 12 than week 24 but the trial results only provide the exact numbers for each week The statement",
        "label": "Entailment"
    },
    "29fce0a9-c8ac-4851-afbf-a0fbd8357eb9": {
        "text_answer": "  The statement is not entailed in the trial results provided The trial results only report the Ki67 expression at baseline and at 6 weeks for the TAK228 plus Tamoxifen armgroup The statement makes a claim about the percentage of cells with Ki67 expression after 12 months of treatment which is not reported in the trial results",
        "label": "Contradiction"
    },
    "08d2198a-3bd7-453e-8ad1-0e35312cb348": {
        "text_answer": "  The statement at least one patient treated with GTx024 1mg in the primary trial gained over 10 kilos of Lean body Mass is not entailed in the given trial results as there is no participant in the GTx024 1mg group who gained more than 10 kilos of lean body mass based on the reported median and range values The trial results only indicate that the median change in lean body mass for the",
        "label": "Contradiction"
    },
    "d0856f66-d9fb-4bbd-906e-9602d9121c22": {
        "text_answer": "  The statement is entailed in the primary and secondary clinical trial descriptions Both trials include patients with a confirmed histological diagnosis of stage 4 breast adenocarcinoma that are either ER positive PR positive or HER2neu negative Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "9ab1125f-0d0b-4480-b5c2-8a09378a8df4": {
        "text_answer": "  The statement is entailed in the trials as both interventions share the same regimen for tremelimumab and the optional extended treatment for durvalumab The only difference lies in the dose of durvalumab given in each intervention with cohort 1 receiving a lower dose 03 mgkg compared to cohort 2 1 mgkg Therefore the statement is accurate and entailed by the information provided in the trials",
        "label": "Entailment"
    },
    "fb362bcb-d93e-4d35-9127-db0efd9012dc": {
        "text_answer": "  The statement the primary clinical and secondary clinical trials ensured transparency by meticulously recording all adverse events associated with their proceedings is entailed in the given trials data as both trials have reported the total number of adverse events occurring in each trial The statement implies that the trials recorded all adverse events which is consistent with the data provided",
        "label": "Entailment"
    },
    "dcb23a61-648b-4831-92e9-9e61cc596be3": {
        "text_answer": "  The statement worry that breast cancer recurrence would mean losing my breasts is not directly related to the inclusion or exclusion criteria of the primary trial The trials criteria focus on the patients eligibility based on their cancer stage histology and organ function The statement about worrying about losing breasts due to recurrence is a psychological concern and is not mentioned in the trials criteria Therefore the statement is neither entailed nor contradicted",
        "label": "Entailment"
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 In the primary trial there is one test group Pyridoxine and one placebo group Placebo 2 In the secondary trial there are two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride  The statement the primary trial had one test group and one placebo group",
        "label": "Entailment"
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "text_answer": "  The statement 3636 of the primary trial patients suffered an increase in Blood bilirubin is entailed in the given trial data as it is explicitly stated that Blood bilirubin increased 111 909 Since the statement is a consequence of the data it is entailed",
        "label": "Entailment"
    },
    "726f25cd-4611-43a5-b7c6-15f7393b67ee": {
        "text_answer": "  The statement 492 more Participants in the dalotuzumab 20 mgkg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group is not directly entailed in the given trials as they do not provide sufficient information to make that calculation The trials only report the percentage of participants with a decrease in the growth factor signature for each group but they do",
        "label": "Contradiction"
    },
    "3670694c-a13e-4639-bc3d-e51db3bf8149": {
        "text_answer": "  The statement Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention is not directly stated in the provided trial results The results only provide the percentage of participants who were up to date for colorectal breast and cervical cancer screenings before and after the intervention for both the Collaborative Care Intervention CCI and Prevention Care Management PCM",
        "label": "Entailment"
    },
    "a830799d-017f-4656-aed0-d428d5e0c73f": {
        "text_answer": "  The statement every documented adverse event in the primary clinical trial took place among the cohort 1 patients is entailed in the given trials data as all the adverse events listed in both trials are marked as having occurred in Total 03 000 for cohort 2 but none of them are documented to have occurred in cohort 1 in the given trials data Therefore the statement is entailed by",
        "label": "Entailment"
    },
    "2d241b66-d0a0-4012-9d5b-1ef1a74bcd79": {
        "text_answer": "  The primary trial intervention lasted for 10 weeks once a week for 10 weeks while the secondary trial intervention lasted for 24 weeks weekly for 24 weeks   Ten weeks is not three times shorter than 24 weeks but rather about onethird of the duration Therefore the statement is contradictory to the given information",
        "label": "Entailment"
    },
    "67fc355a-1537-479d-b0fc-cd39bdb3cf6d": {
        "text_answer": "  The statement The dosage of Zoledronic Acid in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial is an entailment based on the given information   The dosage of Zoledronic Acid in Intervention 1 of the primary trial is 4 mg Q4W which is equivalent to 16 mg per month",
        "label": "Entailment"
    },
    "ef3e540e-b8dc-4fd5-9eaa-f32a657a57c6": {
        "text_answer": "  The statement is entailed in the Trials as both the Primary and Secondary trials include the requirement that patients have a functional ECOG status less than 2 This is a measure of performance status indicating the patients ability to carry out daily activities and to tolerate treatment Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "9b49f98a-af07-455e-af36-4f6a3f7e3e52": {
        "text_answer": "  The statement pericardial effusions were a less common condition among patients in the primary trial is entailed in the trials   Explanation   The statement implies that the frequency of pericardial effusions is lower in the primary trial compared to the secondary trial To verify this we need to compare the number of patients with pericardial effusions in each trial   In the primary trial there was 1",
        "label": "Entailment"
    },
    "c6e42e3e-8900-43bb-b1de-61f1d1dcf075": {
        "text_answer": "  The statement The results from the primary trial indicate that the Arm A intervention provided the best overall response rate additionally in the secondary trial the Denosumab cohort had a worse Time to First OnStudy SRE than the Zoledronic Acid cohort is not directly entailed in the given trials   The primary trial results indicate that in the Arm A group 676 of participants achieved an overall response ",
        "label": "Contradiction"
    },
    "b181b889-6991-4710-a94c-536591db88fc": {
        "text_answer": "  The statement only candidates who are HER2 negative on their IHC scores and are fully selfcare reliant can participate in the primary clinical trial is contradictory to the inclusion criteria of the trial as stated in the text   The inclusion criteria do not specify that the candidates must be HER2 negative or fully selfcare reliant to participate in the trial Instead the trial includes candidates with histologically confirmed infiltrating primary breast cancer of",
        "label": "Entailment"
    },
    "d3302027-c157-4d58-8653-cf5053658fad": {
        "text_answer": "  The statement did you cough up blood is not directly entailed or contradicted by the information provided in the primary trial The trials only mention the administration of Dexamethasone before surgery and the dosage but they do not provide information about the occurrence or nonoccurrence of coughing up blood in the trial cohorts",
        "label": "Contradiction"
    },
    "e7203466-5ee1-4733-ac54-730489e348b2": {
        "text_answer": "  The statement is contradictory to the information provided in the primary clinical trial description The placebo intervention is not administered orally but rather as 20 transendocardial injections of Buminate solution which is a saline solution used as a control in the study The alloMSCs intervention is also administered via transendocardial injections but with a different solution containing the allogeneic mesenchymal stem cells",
        "label": "Entailment"
    },
    "bb7c2e9b-0a9b-48da-97e8-3a78ca82966f": {
        "text_answer": "  The statement regardless of the type of cancer the majority of patients in the first cohort of the primary clinical trial did not meet the screening timelines post intervention is entailed in the trials provided   Explanation   The trials show that the percentage of participants who were up to date with colorectal breast and cervical cancer screenings increased significantly after the intervention in both the Collaborative Care Intervention CC",
        "label": "Entailment"
    },
    "90432ec4-8df5-408b-8998-39f2a698314d": {
        "text_answer": "  The statement patients who have been bedridden following a recent heart transplant are accepted into the primary clinical trial but are disqualified from the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials  However the primary trial includes the criterion The participant has adequate cardiac function Left ventricular ejection fraction LVEF 50 and does not mention",
        "label": "Entailment"
    },
    "a3b8086c-3eec-402c-8b95-4446b33673b6": {
        "text_answer": "  The statement is entailed in the primary and secondary trials as follows  1 Primary Trial The statement female cancer patients aged 18 and above are eligible for this trial is directly stated in the inclusion criteria of the primary trial 2 Secondary Trial The statement female cancer patients aged 18 and above are eligible for this trial is also stated in the inclusion criteria of the secondary trial However the secondary trial adds",
        "label": "Entailment"
    },
    "6fe2c751-a06e-4679-a13d-3335fe5887e2": {
        "text_answer": "  The statement is not entailed in the given trials as paclitaxel is not mentioned in the trials at all for cohort 2 FULV The trials only specify anastrozole for cohort 1 ANA and fulvestrant for cohort 2 FULV",
        "label": "Contradiction"
    },
    "ed6a6f04-0b3d-4dc7-96fd-2f0547d6fe17": {
        "text_answer": "  The statement a diagnosis of a single cerebral metastasis will lead to an automatic exclusion from the primary trial yet it allows eligibility for the secondary trial is a contradiction   Explanation   The primary trial explicitly states that One to three presumed brain metastases are allowed and there is no mention of an automatic exclusion for a single cerebral metastasis Therefore a diagnosis of a single",
        "label": "Contradiction"
    },
    "213bae99-da68-4307-a7c9-71343afbcd39": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the treatment intervention is defined as a threeweek cycle 21 days for both arms A1 and A2 This is explicitly stated in the description of the treatment schedule  In contrast in the secondary trial there is no mention of a threeweek cycle or any cyclic treatment schedule The treatment interventions are defined as Intraoperative Mammography and",
        "label": "Entailment"
    },
    "97e71457-8a63-4bf3-b1cf-b2743433e7f2": {
        "text_answer": "  The statement daxx gene mutation is a change in the nucleotide sequence of the daxx gene is not directly related to the information provided in the primary trial description Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone The trials describe interventions using a validated webbased risk assessment tool and decision support for providers without mention of any specific genes or mutations being tested or targeted",
        "label": "Entailment"
    },
    "eb93eb13-978c-4f27-8c2b-c3ddddcbafcf": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the number of individuals having mastectomy surgery who were approached for participation in the trial is not specified in the given information Therefore we cannot make any comparison regarding the amount of MM121 and Paclitaxel received by the primary trial candidates and the secondary trial candidates based on this information alone  However in the secondary trial the HR subgroup",
        "label": "Entailment"
    },
    "783f37e2-d649-493a-9d0c-0de214ff8ad2": {
        "text_answer": "  The statement patients who have recently undergone chemotherapy or radiotherapy or those suffering from unstable angina or having neuropathy greater than grade 2 can participate in the secondary clinical trial not in the primary trial even if they meet the other criteria is a contradiction to the information provided in the inclusion and exclusion criteria for both the primary and secondary trials  The primary trial excludes patients who have received chemotherapy or radiotherapy",
        "label": "Contradiction"
    },
    "eae69c88-b4bc-4683-aacf-60d287e4eebc": {
        "text_answer": "  The statement simfibrate is a derivative of clofibrate with antilipidemic activity is not directly related to the information provided in the trials Therefore it cannot be determined if it is entailed or contradicted based on the given data  Regarding the trials the primary trial assesses the safety of a vaccine and the number of participants who received it while the secondary trial evaluates the feasibility of a neoadjuvant therapy",
        "label": "Entailment"
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "text_answer": "  The statement Both cohorts of the primary trial contained the same number of participants is entailed in the given trials as both the Neratinib and Placebo arms had an overall number of participants analyzed of 1420 each",
        "label": "Entailment"
    },
    "f4fd9b7c-ccd9-4131-95d0-2a3a8071faf4": {
        "text_answer": "  The statement 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group cannot be directly verified or falsified based on the given information   The trials only provide the percentage of participants in each group who demonstrated a decrease in the growth factor signature but they do not provide the actual number of participants or the",
        "label": "Entailment"
    },
    "8b2b5b8e-3723-4261-8fd5-a624c9367ef2": {
        "text_answer": "  The statement gastric dysplasia is a morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells is not directly related to the information provided in the trials   The trials only report data on the percentage change in serum betaCTX levels at Week 4 for two different treatment groups AZD0530 175 mg and Zoledronic Acid ",
        "label": "Entailment"
    },
    "386a63a3-cd3f-4f8c-af45-cfe9b26e4bc6": {
        "text_answer": "  The statement the frequencies of both pericardial effusions and corneal deposits were equal in the primary and secondary trials is contradictory to the given data   In the primary trial there was one case of pericardial effusion out of 223 participants 045 However there were no cases of corneal deposits reported in the primary trial   In the secondary trial there was",
        "label": "Contradiction"
    },
    "d3177b24-1a89-40d0-b3a5-e79870dc216e": {
        "text_answer": "  The statement is contradicted by the information provided in the trials The primary trial reported a higher incidence of infection 100 vs 000 asymmetry 323 vs 000 and no mention of nausea in the secondary trial Therefore the statement is contradicted by the trials",
        "label": "Contradiction"
    },
    "bc03d7d7-65ed-4331-a5c9-997968a47547": {
        "text_answer": "  The statement in the primary clinical trial a number of adverse events were observed in patients of cohort 1 is entailed in the given trials as the trials explicitly list the adverse events observed in the patients of cohort 1 for both trials",
        "label": "Entailment"
    },
    "ef73b41f-a188-41e1-af84-8ba9ee13d6c6": {
        "text_answer": "  The statement not a single lifethreatening adverse event was registered among cohort 1 participants in the primary clinical trial is entailed in the trials provided   Explanation   The trials do not report any lifethreatening adverse events for the participants in cohort 1 Dose Level 1  1 Injection  Total Dose 2 x 108 IU as indicated",
        "label": "Entailment"
    },
    "f11744ff-fa1a-4d98-ad4a-03fe1fa9e519": {
        "text_answer": "  The statement participants of the primary clinical trial are not subject to life expectancy pregnancy or age conditions is neither entailed nor contradicted by the given inclusion and exclusion criteria   The criteria do not mention anything about life expectancy pregnancy or age as conditions for inclusion or exclusion Therefore the statement is neither entailed nor contradicted by the given criteria",
        "label": "Entailment"
    },
    "205a0d18-ba5e-4efd-b403-557bf188daa2": {
        "text_answer": "  The statement under 50 of the primary clinical trials participants experienced a decrease in circulating tumor cells after receiving highdose chemotherapy along with purged autologous stem cell products is a contradiction to the results presented in the trial   The trial reports the number of participants with a reduction in CTCs following highdose chemotherapy with purged autologous stem cell products but it does not provide the exact percentage",
        "label": "Contradiction"
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "text_answer": "  The statement Women with Newly diagnosed locally advanced breast cancer confirmed as ER considering a mastectomy are eligible for the primary trial is entailed in the primary trials inclusion criteria   The primary trial includes women with locally advanced recurrent or metastatic breast cancer that is ER and considering a mastectomy for the treatment of measurable disease or lytic or mixed lytic and blastic bone met",
        "label": "Entailment"
    },
    "70310501-6b9e-4283-9981-5f709b9517b6": {
        "text_answer": "  The statement over 015 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as there is no common adverse event category for infections in both trials However we can calculate the number of patients who experienced infections in each trial and compare the results  In the primary trial there were 132 313 patients who experienced in",
        "label": "Contradiction"
    },
    "5677aa15-f929-41ac-97e2-07857e792505": {
        "text_answer": "  The statement is entailed in the trials as the trials involve different patient populations The primary trial focuses on patients receiving HER2specific T cell therapy while the secondary trial focuses on patients receiving trastuzumab emtansine The statement is not contradictory as the trials are evaluating different outcomes and patient populations",
        "label": "Entailment"
    },
    "a1c132f7-d56a-4d89-96eb-b37310cd37d6": {
        "text_answer": "  The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1100 participants is entailed by the given trials since  1 In both trials there were no adverse events reported for the total population or for the neutrophilsgranulocytes ANCAGC subgroup that occurred in more than 1100 participants 2",
        "label": "Entailment"
    },
    "cbe273ac-6267-4827-8ba2-8c8c34d69115": {
        "text_answer": "  The statement patients in the secondary trial experienced anemia pneumonia and stupor more frequently than those in the primary trial however a higher occurrence of febrile infections was noted in the primary trial is not directly entailed in the given trials data   The trials data only provides the number of occurrences of adverse events for each trial but it does not provide enough information to make a definitive statement about the",
        "label": "Contradiction"
    },
    "f2217745-3601-4f6e-b893-11ca72e32556": {
        "text_answer": "  The statement is a contradiction to the given trials   In the primary trial there are only two interventions control normal saline and dexmedetomidine The dosage of dexmedetomidine given in intervention 2 is 05ugkg 5ml There is no mention of a group receiving 45ugkg 45ml of dexmedetomidine",
        "label": "Contradiction"
    },
    "9ddda9ad-0cb3-4ea8-8abe-59b227a8290d": {
        "text_answer": "  The statement the number of participants varied significantly between the two cohorts of the primary clinical trial is not directly entailed in the given trial data However it can be inferred from the data that there is a difference in the percentage of participants with events ie invasive disease recurrence or death between the Neratinib and Placebo arms which could potentially be related to the varying number of participants Therefore the statement is not contradict",
        "label": "Contradiction"
    },
    "2bf60bd1-4d11-4a7d-9d69-7f13e93df39c": {
        "text_answer": "  The statement changes in lymphedema were notably better in acupuncture patients compared to those treated with testosterone cream is not entailed in the provided trials as there is no data presented for the testosterone cream group Therefore it is neither entailed nor contradicted by the information given",
        "label": "Contradiction"
    },
    "75e0a9f9-003d-4bfe-a720-4f84d2d0e7b4": {
        "text_answer": "  The statement is contradictory to the results of the primary clinical trial The trial reports a decrease in Ki67 expression which is a marker of cell proliferation and not an increase in tumor size The statement provided in the question suggests an increase in tumor size which is not supported by the data presented in the trial",
        "label": "Entailment"
    },
    "7a4c195c-e5a6-49b5-b8de-842704bfe7f4": {
        "text_answer": "  The statement is entailed in the given trials description as both Intervention 1 and Intervention 2 do not mention the use of drugs radiotherapy or cognitive behavioral therapy CBT in their descriptions",
        "label": "Entailment"
    },
    "58c1c63d-fcf2-400d-af60-9f33c9820f1b": {
        "text_answer": "  The statement sitalidone is a benzenesulfonamidebased agent with salidiuretic and antihypertensive effects The secondary trial and the primary trial use the same outcome measurement the proportion of patients with pCR Within the Breast Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy is a contradiction to the provided trials ",
        "label": "Contradiction"
    },
    "49a7e9fa-4a0f-4bce-ab0c-c13056e98de2": {
        "text_answer": "  The statement Nobody taking part in the primary trial suffered a UTI is not directly related to the improvement condition stated in the problem The statement only mentions the occurrence or nonoccurrence of urinary tract infections in the trial The improvement condition refers to a superior condition which is not mentioned in the statement Therefore the statement does not entail or contradict the improvement condition It is independent information",
        "label": "Entailment"
    },
    "8665ed72-5c94-4c4f-8dbc-a6950275ca98": {
        "text_answer": "  The statement is entailed in the secondary trial exclusion criteria as follows  1 Chemotherapy or radiotherapy within two weeks The statement explicitly mentions that patients with a history of chemotherapy or radiotherapy within the preceding 2 weeks are not eligible for the secondary trial However it also implies that such patients could still be eligible for the primary trial if they meet all other inclusion criteria This is consistent with the primary trial inclusion criteria that do not have a",
        "label": "Entailment"
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "text_answer": "  The statement Patients in the primary trial will need to receive several injections is entailed in the trial description as patients will receive the following injections  1 Trastuzumab infusion 2 Vinorelbine ditartrate infusion 3 Leukine GMCSF injections for 7 days or until neutrophil count is greater than 1000mm3 4 Ther",
        "label": "Entailment"
    },
    "c20de03b-8eba-4546-8f77-5e54cf25dfb2": {
        "text_answer": "  The statement The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial is a factual statement about the dosages used in the trials However it does not directly entail or contradict the statement about painful joints The trials provide information about the interventions used but they do not provide information about the presence or absence of",
        "label": "Entailment"
    },
    "f82d082e-896d-4d9e-ad92-d64b655dafb8": {
        "text_answer": "  The statement an adult patient diagnosed with ilddpld within the last 9 months with a life expectancy of 16 days would be eligible for the primary trial is contradictory to the trials inclusion criteria   The inclusion criteria state that patients must have a life expectancy of greater than 3 months The patient described in the statement has a life expectancy of only 16 days which is less than the required 3",
        "label": "Entailment"
    },
    "4bfe4376-ffad-4132-8604-b5afbc78429d": {
        "text_answer": "  The statement is not entailed in the given trial information as the trials described in the text refer to different conditions The first trial is about endoflife care for African American patients receiving palliative care while the statement is about pancreaticobiliary malunion and its treatment with radiotherapy Therefore the statement is not entailed in the given trials",
        "label": "Contradiction"
    },
    "0471ee43-16a7-417e-94db-0ef86bd5b0a9": {
        "text_answer": "  The statement a mastectomy for stage iv bc does not necessarily exclude a woman from participatory consideration in either the primary or secondary clinical trial is not directly entailed in the given inclusion and exclusion criteria for both trials  The primary trial excludes patients with prior radiation to the breastchest wall of the ipsilateral breast but it does not mention anything about the stage of breast cancer Therefore a woman with stage iv breast cancer who has",
        "label": "Contradiction"
    },
    "8e19b7e1-e5ac-473f-a4e7-2c8ddfa7a496": {
        "text_answer": "  The statement thyroid cancer pt4b anaplastic carcinoma tnm finding v6 is anaplastic carcinoma extending beyond the capsule of the thyroid gland which is surgically unresectable is not directly related to the information provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone",
        "label": "Entailment"
    },
    "2cff90dc-7bc3-4acb-a250-10de476d1d4c": {
        "text_answer": "  The statement the primary clinical trial would not include an adult diagnosed with diffuse parenchymal lung disease within the prior 3 years is not explicitly stated in the inclusion or exclusion criteria provided However there is no mention of diffuse parenchymal lung disease as a condition that would make a patient eligible or ineligible for the trial Therefore the statement is not entailed in the trial information but it is consistent with the information provided as",
        "label": "Contradiction"
    },
    "b3b142e1-adad-429b-a7de-c852a74edaaa": {
        "text_answer": "  The statement the primary and secondary trials would not discriminate based on an individuals nationality ethnicity mental health status or gender is entailed in the given trials as there is no mention of any exclusion criteria related to nationality ethnicity mental health status or gender in the provided information for both the primary and secondary trials",
        "label": "Entailment"
    },
    "a5eb56c2-6fc0-45da-8a6a-2818cb64a7f0": {
        "text_answer": "  The statement all patients in the primary clinical trial who were given a placebo experienced vomiting is a contradiction to the results presented in the trials   The results indicate that there were 5 participants in the placebo group who were analyzed but no information is provided about the number of participants who experienced vomiting in this group Therefore it is not possible to determine if all participants in the placebo group experienced vomiting based on the given information  ",
        "label": "Contradiction"
    },
    "a60a8f30-02a6-46a4-bb00-bea702d5103d": {
        "text_answer": "  The statement patients with a TNBC tumor of 50cm in diameter are eligible for both the primary trial and the secondary trial is contradictory to the given trials as the primary trial includes a breast tumor that is only 1 cm in diameter while the secondary trial does not mention the size of the breast tumor as an inclusion criterion Therefore the statement is contradictory to the trials as stated",
        "label": "Entailment"
    },
    "d9f28f1f-3a09-4ef9-a80a-9caa02f9069b": {
        "text_answer": "  The statement glandular odontogenic cyst is a developmental odontogenic cyst with epithelial features that simulate salivary gland or glandular differentiation who 2017 is not directly related to the inclusionexclusion criteria of the primary or secondary trials Therefore it cannot be determined if the statement is entailed in the trials or not as they do not share any relevant criteria regarding gland",
        "label": "Entailment"
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "text_answer": "  The statement The patient with the longest PFS in the primary trial survived 35 months without disease progression or death is not directly entailed in the given trials as the trials only report the median PFS for each group not the longest PFS for any individual patient Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "4e56ec6c-1b0c-4d14-b53a-2695fb9dcb7d": {
        "text_answer": "  The statement irradiation doses along with its administration protocol are comprehensively detailed in the primary clinical trial intervention section is entailed in the given trial description if the trial in question is a randomized controlled trial RCT or any other clinical trial where the intervention being tested involves the use of partial breast irradiation In such trials the intervention section would typically provide a detailed description of the irradiation doses and their administration protocol to ensure standardization and re",
        "label": "Entailment"
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "text_answer": "  The statement A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial is contradictory to the trials inclusion criteria as stated No meningeal carcinomatosis Therefore the statement is contradictory to the trials eligibility criteria",
        "label": "Contradiction"
    },
    "953b0337-0c43-42fb-a334-dad6900e2e0f": {
        "text_answer": "  The primary trial does not provide sufficient information to definitively determine if the statement is entailed in the trials or contradictory The trial results only report the mean number of hot flashes per 24 hours for each group but they do not provide information on the number or types of treatment emergent adverse events experienced by participants in each group Therefore it is not possible to make a definitive conclusion based on the given information alone",
        "label": "Entailment"
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "text_answer": "  To verify whether the statement is entailed or contradicted in the given trials we need to examine the details of each trial and the information provided about the use of Paraplatin  However the statement provided does not mention Paraplatin explicitly Instead it mentions Cisplatin which is not mentioned in the trials at all Paraplatin and Cisplatin are both platinumbased chemotherapy drugs but they are not the",
        "label": "Entailment"
    },
    "91e585c8-503f-4253-b749-80caa8ebc3e1": {
        "text_answer": "  The statement Ascites was more common for patients in the primary trial and Pneumocystis jirovecii pneumonia was more common in the secondary trial is entailed in the trials as follows  1 The statement mentions that ascites was more common in the primary trial which is consistent with the data provided as there were 2 cases of ascites out of 223 patients in the primary trial 090",
        "label": "Entailment"
    },
    "577f3aad-32c6-4a0b-8df1-615a9a58fa29": {
        "text_answer": "  The statement the primary clinical trial and the secondary clinical trial noted an identical count of adverse events among their patient groups is entailed in the given data if and only if both trials had the same number of patients and the same types of adverse events were reported in both trials   However based on the given data we cannot make that determination as we only have the number of adverse events reported for each trial and no information about the number of patients or the",
        "label": "Entailment"
    },
    "13765ddf-3be9-411a-ae7a-24a0bdffe2d8": {
        "text_answer": "  The statement is entailed in the Trials as both Intervention 1 and Intervention 2 in both the Primary and Secondary Trials involve the use of 4demethyl4cholestryloxycarbonylpenclomedine in a weekly regimen for patients with CNS involvement from melanoma breast lung cancers or primary malignancies of the CNS who can be previously treated with radiation and systemic therap",
        "label": "Entailment"
    },
    "55bcb170-5b8a-4a7d-b509-f2ab4a2f587a": {
        "text_answer": "  The statement afraid of being rejected is a question about whether an individual is or was afraid of being rejected is not directly related to the given trials The trials only provide information about the occurrence of certain adverse events in two different cohorts of patients The statement does not entail or contradict any information presented in the trials",
        "label": "Entailment"
    },
    "06b2ed93-63bb-4ef0-964c-372ff9077cb4": {
        "text_answer": "  The statement is not entailed in the trials provided as they measure different outcomes The primary trial measures the Summed Pain Intensity Differences SPID at 30 minutes after dosing for each breakthrough pain episode using a visual analog scale while the secondary trial measures the change from baseline to 9 months in bone mineral density BMD of the lumbar spine using dualenergy Xray absorptiometry DEXA The statement mentions",
        "label": "Contradiction"
    },
    "c6408b0b-2cdc-4298-a7d5-9e6fe3d52925": {
        "text_answer": "  The statement is entailed in the Trials   The secondary trial applies a consistent array of inclusion and exclusion benchmarks for all participating individuals This is clear from the provided text as all patients must meet the same eligibility criteria such as ECOG performance status 02 no pregnancy or nursing and no medical conditions that may compromise the objectives of the study  On the other hand the primary trial has two distinct study assemblies",
        "label": "Entailment"
    },
    "4cdd4dc9-e171-438b-8864-1f451af7c15e": {
        "text_answer": "  The statement the educational dvd is not part of the intervention for any cohort in the primary clinical trial is not directly stated in the provided information about the interventions However it can be inferred from the description that the DVD is only mentioned as an intervention for the intervention arm and not for the control arm Therefore the statement is entailed by the information provided  However the statement all cohorts will receive a regular dosage of",
        "label": "Entailment"
    },
    "2b24be38-efe1-4044-92ce-81cace8f239a": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial Armodafinil is given on a daily basis only to the cohort receiving CBTI as an additional intervention INTERVENTION 2 whereas in the secondary trial PDR001 is given with identical dosing schedules to all patients in both interventions INTERVENTION 1 and INTERVENTION 2 but MCS1",
        "label": "Entailment"
    },
    "3ac1baef-7e74-405c-ae5a-897ac2b2fd5f": {
        "text_answer": "  The statement all 100 of patients in the primary trial suffered aes is contradictory to the given trials as the trials report that only 2 out of 35 patients 571 experienced adverse events Therefore the statement is contradictory to the trials",
        "label": "Entailment"
    },
    "c8990938-e3fe-470d-a6d2-d28a3fe89b0b": {
        "text_answer": "  The statement is entailed in the trials The primary trial explicitly requires informed consent while the secondary trial does not have this requirement mentioned in the provided exclusion criteria Therefore the secondary trial not having a requirement for informed consent is a consequence or implication of the information given in the primary trial and thus the statement is entailed",
        "label": "Entailment"
    },
    "5ed2b8ad-5b6d-4397-80c5-48d08c8f51ed": {
        "text_answer": "  The statement is entailed in the trials as follows  Both cohorts 1 and 2 receive the same dosage of CUDC101 which is 275 mgm2 The difference lies in the frequency of administration In cohort 1 CUDC101 is administered for 5 days consecutively every 14 days while in cohort 2 it is",
        "label": "Entailment"
    },
    "3df32fab-15e5-4536-908f-d9c76529702e": {
        "text_answer": "  The statement thirteen individuals participated in the primary clinical trial where they were treated with the enhanced card t cell therapy is not directly entailed in the provided trial information The trial information only mentions the vaccine regimen and the assessment of toxicity without explicitly stating that the therapy being administered is an enhanced card t cell therapy or that thirteen individuals were participating in a trial for that specific therapy Therefore the statement is neither entailed nor contradicted by the",
        "label": "Contradiction"
    },
    "98e89253-c343-4f1f-b2a0-0e09e5cba8ee": {
        "text_answer": "  The statement the participants of cohort 1 of the primary clinical trial did not report adverse events is contradictory to the given results   Results 1 states that all 3 participants in cohort 1 Dose Level 1 experienced adverse events with 1000 of participants being affected Therefore the statement is contradictory to the trial results",
        "label": "Entailment"
    },
    "66362fd1-8e4f-49ad-9098-a67f65cb91c2": {
        "text_answer": "  The statement 5 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed imagable HER2 metastases is entailed in the trial results if the percentage of participants with HER2 metastases is 5 or less   The trial results state that 13 of 49 participants 2",
        "label": "Entailment"
    },
    "2f7bae39-4081-4328-85e2-2a400ec72589": {
        "text_answer": "  The statement patients with a body mass index bmi less than 30 are eligible for both the primary clinical trial and the secondary clinical trial is entailed in the given trials as neither of them have BMI as an exclusion criterion Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "1bc6de92-961a-4a4f-8ead-8f5f6f496d70": {
        "text_answer": "  The statement during the primary clinical trial at least one patient who received gtx024 1mg treatment had over 10 kilos increase in lean body mass is a contradiction to the given trial results   The median change in lean body mass for the GTx024 1mg group was 155 kg with a range of 206 to 1264 kg No participant",
        "label": "Contradiction"
    },
    "3c273853-f394-4550-9969-d476fff275db": {
        "text_answer": "  The statement is contradictory to the given trials as there is no mention of febrile neutropenia or cholelithiasis in either the primary or secondary trials The trials only report the occurrence of adverse events their respective totals and specific types of adverse events",
        "label": "Contradiction"
    },
    "cc2428b1-d508-406f-a59f-186d62e93600": {
        "text_answer": "  Based on the information provided in the trial results the statement in the primary clinical trial the lack of paclitaxel infusions resulted in worsened symptoms for the patients compared to those who received them is contradictory to the results   The results show that the Arm I group Cryotherapy had a median aAUCpa of 14 117 to 68 indicating that on average symptoms improved",
        "label": "Entailment"
    },
    "4c42491a-5ff2-41f8-bb40-6c7fe4dd5c99": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The statement claims that severe nausea and chronic fatigue were the only types of adverse events observed in patients from the secondary clinical trial but the trials do not report any adverse events of this nature in the secondary trial Instead they report the occurrence of eyelid oedema in one patient and chest pain in another   Therefore the statement is",
        "label": "Entailment"
    },
    "27abad83-36b9-47a4-8d11-d08751d1d81a": {
        "text_answer": "  The given statement several of the patients in the primary trial experienced the no pain whatsoever during the 5 years of the study is not entailed in the provided trial information The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups during the 10week study period No information is provided regarding the number of patients who experienced no pain whatsoever during the 5year study duration",
        "label": "Contradiction"
    },
    "001da1c9-0fd7-4a15-baa5-9ee16f2a28bd": {
        "text_answer": "  The statement malignant neoplasm by grade is a term that refers to the categorization of malignant neoplasm by histologic grade Participants must be resistant to AI therapy to participate in the primary trial but this is not necessary to be included in the secondary trial is not entailed in the given trials as there is no mention of histologic grade or resistance to AI therapy in the secondary trial Therefore the statement is contradictory",
        "label": "Contradiction"
    },
    "5a6a1e08-4a0a-45ea-91f5-053182a352cc": {
        "text_answer": "  The statement does not entail or contradict the information provided in the trials   The trials describe interventions for two separate studies The primary trial involves the use of denosumab and the secondary trial involves the use of an intraoperative handheld gamma camera pIHGC and standard of care intraoperative gamma probes GP in lymphoscintigraphy The statement mentions denosumab",
        "label": "Entailment"
    },
    "afa9c5da-71e1-4c40-80fa-bcc02199e395": {
        "text_answer": "  The statement is contradictory to the given data   Explanation   The statement the primary clinical trial was marked by numerous adverse events reported by all patients whereas the secondary clinical trial was free from any adverse events is contradictory to the data provided in the trials   In the primary trial there were no adverse events reported by any of the 42 patients In contrast in the secondary trial there",
        "label": "Contradiction"
    },
    "37321416-91c4-4dd1-952b-6b23865d769c": {
        "text_answer": "  The statement is contradictory to the trials provided The trials describe two interventions both of which involve the use of a compact disc CD for instruction on paced breathing The statement suggests that in the second cohort the instructional method for paced breathing is not a CD and that patients practice only once a day However the trials do not provide any information about the instructional method used in the second cohort that is inconsistent with the use",
        "label": "Entailment"
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "text_answer": "  The statement is entailed in the trials as given   Explanation   In the primary trial neither group receives alisertib MLN8237 as stated In the secondary trial two different doses of alisertib are being tested but neither group in the primary trial receives this intervention Therefore the statement is entailed in the trials as given",
        "label": "Entailment"
    },
    "fe5d5e2f-2b54-48f4-b95b-278456d1db46": {
        "text_answer": "  The statement is contradicted by the given trials   In the primary trial FMX and MM398 are used in combination with different dosing schedules and sequences   In the secondary trial lapatinib and paclitaxel are used in combination with a different dosing schedule compared to the primary trial   Although the same medications are used they are not dispensed at the same doses or on the",
        "label": "Contradiction"
    },
    "a92239f6-9f31-4e7f-a8be-2792789ea5f1": {
        "text_answer": "  Based on the information provided in the input the statement the primary clinical trial does not include trastuzumab in any of its intervention regimens is entailed in the trial description since neither Herceptin Arm 1 nor TaxoterecarboplatinHerceptin Arm 2 contains trastuzumab as a standalone intervention",
        "label": "Entailment"
    },
    "c98e803e-a899-4ed8-aed0-0611eeef943d": {
        "text_answer": "  The statement patients who have experienced a pulmonary embolism within the previous 2 months are not permitted to participate in the primary clinical trial although the secondary clinical trial may allow their participation dependent on the investigators judgement is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade ",
        "label": "Contradiction"
    },
    "49e29ec7-08a2-481d-9fc4-ecb66b09cdfe": {
        "text_answer": "  The statement Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is not directly stated in the given trials However it can be inferred from the inclusion and exclusion criteria of each trial  In the primary trial smokers are explicitly excluded Exclusion Criteria Any history of alcohol or substance abuse or dependence within the past 2 years DSM",
        "label": "Entailment"
    },
    "804aa28f-b791-4a99-98e7-a443456de4b2": {
        "text_answer": "  The statement ct2584 hms is a lipid metabolism modulator which may inhibit angiogenesis thereby possibly having antitumor activity nci is not directly related to the inclusion or exclusion criteria of the primary or secondary trials It is an independent statement about a potential therapeutic agent However the statement does not contradict or entail any of the criteria mentioned in the trials Therefore the statement is neither",
        "label": "Entailment"
    },
    "045ad9d7-6830-4a3d-bba5-4e90ee838977": {
        "text_answer": "  The statement is neither entailed nor contradicted by the information provided in the trials   The trials describe two different interventions one with the use of Active Breathing Coordinator ABC and the other without it Both interventions involve the same doses of radiation therapy and schedule However the statement provided is about a completely different topic  Leptospiraceae a taxonomic family of bacteria Therefore it is neither entailed nor contrad",
        "label": "Entailment"
    },
    "610662cd-053e-4396-a6d6-8aaac67a7440": {
        "text_answer": "  The statement is entailed in the given trials as follows  The primary trial involves the use of a single medication ZD1839 whereas the secondary trial involves the use of a minimum of three distinct medications Zoledronic acid Samarium153 and Pegfilgrastim  Therefore the statement the primary clinical trial involves the use of a single medication zd1839 in contrast the secondary",
        "label": "Entailment"
    },
    "10749f91-8743-4f6a-aa4b-6cc713e927c5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves denosumab which is an injectable medication given every 4 weeks but it is not mentioned in the statement The statement instead compares the administration of palbociclib oral and tezacaftor injection every 90 days in two different trials  The secondary trial involves the use of pIHGC and GP",
        "label": "Entailment"
    },
    "9cd909a2-b826-4e0d-bbbd-3ad52978d1d9": {
        "text_answer": "  The statement the primary clinical trial is solely reserved for individuals who have never undergone Herceptin treatments is a simplification of the inclusion criteria but it is generally entailed in the trials criteria The trial does specify that patients with HER2 FISH negative or unknown status will not receive trastuzumab but are eligible for single agent vinflunine However the statement is not an exact representation of the trials criteria as it does",
        "label": "Entailment"
    },
    "ef0cf72d-6cc3-4589-8016-e96db1b9f33a": {
        "text_answer": "  The statement not a single kind of adverse event registered in the primary clinical trial influenced more than a quarter of the patient group is not directly entailed or contradicted by the given data   The data only provides the number and percentage of patients who experienced each type of adverse event and the total number of adverse events It does not indicate the percentage of patients who experienced any one adverse event that influenced more than a quarter of the patient group Therefore",
        "label": "Contradiction"
    },
    "585bf6db-16c7-4433-8c98-30a6b5a88fc0": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial both Group A and Group B do not receive MLN8237 alisertib as part of their interventions Therefore the statement that alisertib is given in both cohorts in the primary trial is incorrect   On the other hand the secondary trial involves the administration of MLN8237 alisertib",
        "label": "Entailment"
    },
    "31464efc-048a-451b-a02b-5576933a893a": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of captopril or eribulin in either the primary or secondary trials provided",
        "label": "Contradiction"
    },
    "a0e47b7d-7f2d-43ba-8f93-dc5f9dcd648b": {
        "text_answer": "  The statement over 15 of patients in the primary trial and the secondary trial suffered from infections during the study period is not directly entailed in the given trials as the trials do not provide the specific number of patients who suffered from infections However the statement is not contradictory to the trials as well as the trials report the occurrence of infection as one of the adverse events in both trials",
        "label": "Contradiction"
    },
    "ce5dd10f-dad3-46a4-93de-fe57c657f6d9": {
        "text_answer": "  The statement the primary clinical trial noted at least one incident of gastrointestinal adverse event is entailed in Trial 1 and Trial 2 since both trials reported at least one incident of vomiting Trial 1 0149 000 but the denominator is incorrect it should be 148 since there is one less subject in Trial 1 than Trial 2 Trial",
        "label": "Entailment"
    },
    "bb281225-8211-47ed-8789-a42a389fa379": {
        "text_answer": "  The statement Chryseobacterium is a genus of aerobic gram negative rod shaped bacterium in the phylum bacteroidetes and the family flavobacteriaceae is not entailed in the inclusion or exclusion criteria of the primary trial The statement pertains to a different topic which is not related to the eligibility criteria for the breast cancer clinical trial Therefore the statement is neither entailed nor contradictory to the trial",
        "label": "Contradiction"
    },
    "be98ce03-a87b-4fe5-9058-a56259581c41": {
        "text_answer": "  The statement is entailed in the trials as follows  1 The primary trial uses a higher dose of Lenalidomide 5mg orally daily for 57  3 days compared to the secondary trials intervention 1 using Lapatinib 1500mg oral daily for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks The dose of Lenalidomide",
        "label": "Entailment"
    },
    "4db7f58c-f006-48d0-944f-a02b3231615c": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials provide information about the interventions and dosing schedules for each group but they do not explicitly state that the duration or dosing frequency of Alpha Lipoic Acid or Necitumumab remains constant throughout the entire study for each patient in their respective trials  However based on the information provided it can be inferred that  1 Patients in the primary trial may",
        "label": "Contradiction"
    },
    "bcdef75a-f013-4d65-84e1-6004a054d574": {
        "text_answer": "  The statement a patient with a diagnosis of neoplastic meningitis might qualify for the primary clinical trial is contradictory to the given trial criteria as stated in the disease characteristics section No meningeal carcinomatosis Therefore the statement is contradictory to the trial eligibility criteria",
        "label": "Contradiction"
    },
    "6962c2aa-4df2-4479-8744-5784fe8c9fcf": {
        "text_answer": "  The statement only one adverse event has been documented for the patient group in the primary clinical trial is entailed in the given information The information states that there was one adverse event a total of 1 in the patient group 129 or 345 of the group which meets the criteria of the statement",
        "label": "Entailment"
    },
    "a3be9d38-6897-4ead-9ada-790104f2de50": {
        "text_answer": "  The statement individuals who have experienced a myocardial infarction stroke or transient ischemic attack within the last six months can participate in the primary clinical trial is a contradiction to the trials exclusion criteria The trial explicitly states that individuals with a history of myocardial infarction stroke or transient ischemic attacks within the last 6 months are not eligible for participation",
        "label": "Contradiction"
    },
    "12a03716-0ec6-4ffe-abd8-02411c083ee5": {
        "text_answer": "  The statement is contradictory to the information provided in the clinical trial description The trial involves the use of multiple injections including dendritic cell injections GMCSF injections and trastuzumab infusions given through an IV sideport Therefore the statement is contradictory to the facts presented in the trial description",
        "label": "Entailment"
    },
    "156b015d-e2bb-4f38-a312-62e1cf7583d6": {
        "text_answer": "  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is a contradiction to the information provided in the inclusion criteria of the primary trial   The primary trials inclusion criteria state that participants must be resistant to aromatase inhibitors AI therapy but there is no mention of mirtazapine in the inclusion",
        "label": "Contradiction"
    },
    "d3aeafa2-2963-4220-b80d-cd5cde582fe8": {
        "text_answer": "  The statement is contradictory to the results from the primary trial The primary trial reports a decrease in Ki67 expression with tamoxifen treatment with a mean percentage change of 40 63 to 29 The statement however claims an increase of 200 on average which is inconsistent with the trial results",
        "label": "Entailment"
    },
    "d0bfc2f3-c94f-4d4c-ae87-9f9744bd767a": {
        "text_answer": "  The statement The most common adverse event in the secondary trial was Anaemia is entailed in the trials as the trials provide the frequency of adverse events for each trial and the statement correctly identifies the most common adverse event in the secondary trial as Anaemia  However the statement there were no recorded AEs in the primary trial is contradictory to the trials as the trials report that there were no adverse events of",
        "label": "Entailment"
    },
    "9a814107-778f-43ba-bd59-383ae14594ed": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial includes women with locally advanced recurrent or metastatic breast cancer that is ER and has measurable disease or lytic or mixed lytic and blastic bone metastasis The secondary trial includes women with newly diagnosed or recurrent breast cancer who are considering or completing a mastectomy and do not have distant metastatic disease",
        "label": "Entailment"
    },
    "2d007409-93ff-4753-a2e5-c5f94d4fe6dd": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts 72 in Arm A and 84 in Arm B  The secondary trial reports the number of patients that experience Objective Response in the SUNITINIBCAPECITABINE arm  However the statement does not directly compare the two trials or their",
        "label": "Entailment"
    },
    "c51494ed-aee9-4219-b46b-ed47bc261788": {
        "text_answer": "  The statement is entailed in the trials In the primary trial no specific details are given about the dosage of MM121 and Paclitaxel for the intervention group However in the secondary trial the HR subgroup in intervention 1 receives a 2week runin of MM121 with a weekly dose of 20 mgkg followed by 12 weeks of weekly MM12",
        "label": "Entailment"
    },
    "136f0a2e-563c-4085-b390-ac2db90f7aac": {
        "text_answer": "  The statement both cohorts involved in the primary trial demonstrated an average decline in cognitive function although this was not the circumstance for all individuals is not directly entailed in the given trial results   The trials only report the mean standardized composite scores for each group and the statement makes a more generalized claim about the cognitive function of all individuals in both cohorts The trials do not provide sufficient information to determine if the average decline in cognitive function occurred",
        "label": "Contradiction"
    },
    "76eeb32c-d3c0-4ed0-91d4-104417af35e0": {
        "text_answer": "  The statement all patients in the primary clinical trial had recurrencefree survival is contradictory to the information provided in the trial results The results indicate that 98 out of 100 participants had recurrencefree survival but it does not state that all 100 participants had recurrencefree survival Therefore the statement is contradictory to the trial results",
        "label": "Entailment"
    },
    "a402b1c9-c65b-48fb-a2d5-e08c0152e8c3": {
        "text_answer": "  Lets analyze the given information in the primary clinical trials and check if the statement is entailed or contradicted  1 In Intervention 1 the dose of MCS110 given is 1 mgkg every 3 weeks which translates to a dose of 3 mgkg for a 75 kg person in a 3week period This is less than the required 20 mg every 3 weeks  ",
        "label": "Entailment"
    },
    "431b6222-3b82-4eb4-af82-ef98b513e649": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is directly stated in the given trials data therefore it is entailed in the trials  The statement does not directly relate to the performed histopathology differentiation grade code so it is neither entailed nor contradicted by that information",
        "label": "Contradiction"
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "text_answer": "  The statement There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial is entailed in the given trials if we consider the number of occurrences of each adverse event separately   In the primary trial there is 1 case of Biliary colic and 3 cases of Diarrhoea In the secondary trial there is 1 case of Biliary colic and 2 cases",
        "label": "Entailment"
    },
    "a6d3fa8e-c521-4843-b4e7-0a9983acfad0": {
        "text_answer": "  The statement in both the primary trial and the secondary trial pCR is used as the primary efficacy endpoint There is an insignificant discrepancy in results amongst the different cohorts of the primary trial whilst in the secondary trial arm 1 outperformed arm 2 is not directly entailed in the given trials as the trials do not provide sufficient information to make such a definitive statement   The statement mentions that p",
        "label": "Contradiction"
    },
    "71ba0864-5490-4e25-989c-4672afa15599": {
        "text_answer": "  The statement is in contradiction with both primary and secondary trials   The primary trial states that the patient must have an absolute neutrophil count ANC of 1800 cellsmm3 and a platelet count of 60000 cellsmm3 for eligibility The patient in the statement has an ANC of 500l which is below the required threshold",
        "label": "Contradiction"
    },
    "f41f7611-7c20-4f71-8b2d-433e36f840de": {
        "text_answer": "  The statement Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream is not directly entailed or contradicted by the provided trial results   The trials only compare the effects of acupuncture versus a waitlist control group on lymphedema changes There is no information provided about a testosterone cream group in the trials Therefore it is not",
        "label": "Contradiction"
    },
    "3264decd-0cee-4137-a5da-e9a27e3b7791": {
        "text_answer": "  The statement is entailed in the given trials as the primary trial reports results in percentage and the secondary trial reports results in number of participants which are not the same units of measure Therefore the statement is correct",
        "label": "Entailment"
    },
    "5ac3610a-7854-4278-8a51-c1ef8c138ee9": {
        "text_answer": "  The statement less than 10 of the primary trial participants had a Reduction in circulating tumor cells Following months of Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results The trial results only report the number of participants with a reduction in CTCs at one month postAHST not months after the treatment Therefore the statement is contradictory to the trial results",
        "label": "Contradiction"
    },
    "08fb602d-3227-4329-98c8-7dc2a6135f5b": {
        "text_answer": "  The statement the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope which occurred in 14 of the primary trial patients is contradictory to the information provided in the trials  The primary trial reported that syncope occurred in 2 out of 12 patients 1667 which is not equal to 1 out of 4 patients 250",
        "label": "Entailment"
    },
    "76c6b45f-5a4a-47bc-81b1-267a2981b096": {
        "text_answer": "  The statement a candidates Her2 status whether positive or negative is not a requirement for the primary clinical trial is contradictory to the inclusion criteria stated in the trial description The trial specifically requires a histologically confirmed HER2 positive tumor either IHC 3 or FISH for eligibility Therefore the statement is contradictory to the information provided in the trial description",
        "label": "Entailment"
    },
    "95332a34-465b-4777-870b-e60e4c01e706": {
        "text_answer": "  The statement patients in the primary clinical trial saw a higher frequency of ascites whereas those in the secondary clinical trial had higher incidences of pneumocystis jirovecii pneumonia is entailed in the given trials  Explanation  The statement is entailed in the trials because the trials provide the number of occurrences for each adverse event in both trials The statement correctly identifies that the primary trial had",
        "label": "Entailment"
    },
    "f6fbc102-de0c-44d5-943b-4baf66bc0d9b": {
        "text_answer": " The statement in the first cohort of the primary clinical trial all 61 cervical cancer patients were uptodate with their screenings prior to the intervention is not entailed in the provided trial results The trial results only report the percentage of participants who were uptodate with their colorectal breast and cervical cancer screenings before and after the intervention for the Collaborative Care Intervention CCI and",
        "label": "Contradiction"
    },
    "1c72bbf7-1c5b-4326-a9d1-9dc7677aeefd": {
        "text_answer": "  The statement is contradictory to the given trials inclusion and exclusion criteria   The primary trial includes women with locally advanced recurrent or metastatic breast cancer who are ER and have measurable disease or lytic or mixed lytic and blastic bone metastasis However the statement includes women with newly diagnosed or recurrent breast cancer which is not a requirement for the primary trial Additionally the statement includes women with",
        "label": "Entailment"
    },
    "224b15b9-fc1d-4c8b-ae55-ec4731ae5d04": {
        "text_answer": "  The statement is entailed in the trials Although the dosage of CUDC101 is the same for both cohorts the frequency of administration differs Cohort 1 receives the drug for 5 days every 14 days while cohort 2 receives the drug for 3 days every 28 days Therefore cohort 1 receives the drug more frequently as stated in the given condition",
        "label": "Entailment"
    },
    "bd6fc6e9-c2ad-4803-b9ef-5a92d10e4155": {
        "text_answer": "  The statement is entailed in the primary clinical trial as the patient does not meet the inclusion criteria due to the following reasons  1 Histologically or cytologically proven diagnosis of solid tumor malignancy of lung but the patients diagnosis is stage II lung cancer which is not specified in the primary trial 2 Appropriate diagnosis for protocol entry but the patients ANC level is below the required minimum of 180",
        "label": "Entailment"
    },
    "72de2f11-15c9-489a-aec1-5c5e0969f4b7": {
        "text_answer": "  The statement the azd0530 175 mg group of the primary clinical trial did not experience a significant reduction in primary tumour diameter compared to the zoledronic acid 4 mg group is not directly related to the provided trial results as the trials only report the percentage change in betaCTX levels at Week 4 Therefore the statement cannot be entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "0d58d43d-8edc-4846-9d16-b1573f00db28": {
        "text_answer": "  The statement is not directly related to the primary trial interventions as they focus on anastrozole Arm A and fulvestrant Arm B for breast cancer treatment and do not mention paclitaxel or sexual arousal as trial outcomes Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Entailment"
    },
    "ea16ac84-1f11-45c6-a29a-b7159f4b49a1": {
        "text_answer": "  The statement more than half of the patients in the primary clinical trial suffered from adverse events while in the secondary clinical trial this percentage was significantly lower is entailed in the given trials if we consider the percentage of patients with any adverse event In the primary trial 4545 of patients had adverse events while in the secondary trial only 1563 of patients had adverse events Therefore the percentage of patients",
        "label": "Entailment"
    },
    "c69a6bb3-93f7-4597-9359-64fd2541b1aa": {
        "text_answer": "  The statement the primary clinical trial records and reports the number of participants in each subdivision is entailed in the given trials as both trials provide the number of participants analyzed for each armgroup Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "db02f4a9-b294-40e7-861b-d2284c6155e6": {
        "text_answer": "  The statement is contradictory to the information provided in the trials Perjeta pertuzumab is not mentioned in the primary trial at all and it is only mentioned in the secondary trial in relation to the use of novel radiotracers for HER2targeted PETCT imaging The statement incorrectly implies that Perjeta is used in both trials but with different interventions in each trial",
        "label": "Entailment"
    },
    "1b9551eb-0a5d-4d74-a460-a97ea9161f7f": {
        "text_answer": "  The statement there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial is entailed in the given trials as neither of the trials reported any cases of Hypertension Edema or Dyspnea in their adverse events",
        "label": "Entailment"
    },
    "d6c5a9e6-8db3-44f7-b865-4250c057f194": {
        "text_answer": "  The statement is not entailed in the given primary and secondary trial descriptions as there is no mention of lung adenocarcinoma or any specific biomarkers EGFR ALK or ROS1 in either trial The primary trial focuses on breast adenocarcinoma with bone metastases while the secondary trial focuses on breast cancer that is ER positive andor PR positive HER2neu negative and metast",
        "label": "Contradiction"
    },
    "a7f11aff-801c-4f1f-bc03-dc205289964a": {
        "text_answer": "  The statement both primary and secondary clinical trials involved patients who suffered from four different adverse events is not directly entailed in the given trials data However it is not contradictory either since the statement does not specify which adverse events were common to both trials The given trials data only lists the occurrence of specific adverse events for each trial",
        "label": "Contradiction"
    },
    "3e629df7-48b7-4ca1-8987-250629ce3e26": {
        "text_answer": "  The statement is contradictory to the given trials   In the primary trial there is only one test group Intervention 1 and one placebo group Intervention 2 However in the secondary trial there are two test groups Highdose Oxybutynin Chloride Group and Intervention 1 with Pyridoxine and no placebo group mentioned Therefore the statement that the secondary clinical trial was conducted with",
        "label": "Contradiction"
    },
    "4f3ab82f-b17b-45a0-803e-901d0a58bcc6": {
        "text_answer": "  The statement across both the primary trial and the secondary trial only one death was recorded in the adverse events is not directly entailed in the given trials data However it is consistent with the data as both trials report only one death in the adverse events section Therefore the statement is not a contradiction to the trials data  However its important to note that the statement does not follow directly from the information provided in the trials data as",
        "label": "Contradiction"
    },
    "6dddad4e-4cde-4859-a518-897b16bdc042": {
        "text_answer": "  The statement abstinence or moderate drinking is not a criterion of exclusion from the primary clinical trial but the secondary clinical trial mandates a minimum consumption of five alcoholic drinks daily is a contradiction of the given trials inclusionexclusion criteria  In the primary trial the exclusion criteria do not mention anything about alcohol consumption However in the secondary trial the inclusion criteria state that participants must consume fewer than 5 alcoholic drinks",
        "label": "Contradiction"
    },
    "7ccd57f6-2147-4f27-a0a7-f9f7a573a3b5": {
        "text_answer": "  The statement cohort 2 of the secondary clinical trial yielded more positive results than cohort 2 of the primary clinical trial cannot be determined based on the provided information   The primary clinical trial and the secondary clinical trial measure different outcomes The primary clinical trial focuses on breast cancerspecific quality of life using the FACTB instrument while the secondary clinical trial measures the efficacy of a device in addressing positive margins during surgery Therefore",
        "label": "Entailment"
    },
    "86408afa-a3ca-41ee-ac9a-94aa3f2b203d": {
        "text_answer": "  The statement is entailed in the given clinical trial information The text explicitly states that Final eligibility for a clinical trial is determined by the health professionals conducting the trial This implies that even if a patient meets all the inclusion and exclusion criteria the final decision for their participation rests with the health practitioners overseeing the trial",
        "label": "Entailment"
    },
    "7ebe69db-dbde-41d9-b1c8-b866b2bc9e4c": {
        "text_answer": "  The statement infection asymmetry and nausea instances were more in magnitude in the primary clinical trial than they were in the secondary clinical trial is contradicted by the given data   Explanation   The statement implies that there were more instances of infection asymmetry and nausea in the primary trial than in the secondary trial However the data provided shows that there were no instances of nausea reported in either trial and",
        "label": "Contradiction"
    },
    "b447258d-c4d1-4f98-8cc0-9868cd316a3c": {
        "text_answer": "  The statement patients in the primary trial reported conditions of anemia pneumonia and stupor more frequently than those in the secondary trial is contradicted by the given trials data  Explanation  The statement implies that the frequency of anemia pneumonia and stupor is higher in the primary trial compared to the secondary trial However the data provided shows that the frequency of anemia and pneumonia",
        "label": "Contradiction"
    },
    "05772f95-990c-40ee-b29c-b5b2591d0e56": {
        "text_answer": "  The statement is entailed in the primary trial as the patient meets all the inclusion criteria for the primary trial histologically verified diagnosis of solid tumor malignancy of breast appropriate diagnostic workup completed age requirement performance status and signed informed consent The patient also meets the inclusion criteria for the secondary trial histologically verified diagnosis of stage IIbIIIIV breast cancer age requirement life expectancy completion of chemotherapy performance status and signed informed",
        "label": "Entailment"
    },
    "b7028956-b024-401f-b528-554559f8ce17": {
        "text_answer": "  The statement patients with follicular thyroid carcinoma confirmed by thinprep cytology or postmastectomy lymphedema are excluded from both the primary trial and the secondary trial is entailed in the trials as both trials have the same exclusion criteria regarding follicular thyroid carcinoma However the secondary trial does not mention postmastectomy lymphedema as an exclusion criterion",
        "label": "Entailment"
    },
    "d2139fd7-7b3e-405a-a806-ca76d237c11f": {
        "text_answer": "  The statement Any patients with Documented allergy to cephalosporin or trimethoprimsulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial is entailed in the given trials exclusion criteria   The primary trial excludes patients with documented allergies to sulfa antibiotics which",
        "label": "Entailment"
    },
    "039b25b3-517a-4663-9b95-94c941ffa30f": {
        "text_answer": "  The statement is contradictory to the information provided in the trial details   The statement suggests that both cohorts received identical doses of cetuximab but cohort 1 received an additional collaborative care intervention However the trial details clearly state that cohort 1 received a different dose of cetuximab 12 mgkg compared to cohort 2a 20 mgkg Therefore the statement",
        "label": "Entailment"
    },
    "a76b5162-0261-41d2-8d17-c88f5a0e21bc": {
        "text_answer": "  The statement under 10 patients have encountered adverse events in the course of the primary clinical trial is entailed in the given trial data   Explanation   The trial data states that there were 2 adverse events out of 35 patients which is equivalent to a rate of 571 However the statement under 10 patients have encountered adverse events implies that fewer than 10 patients experienced",
        "label": "Entailment"
    },
    "e4b2bcf4-85fa-499c-9d27-e1c3c46174bf": {
        "text_answer": "  The statement is entailed in the trials as both trials involve the use of the same drug empegfilgrastim for the treatment of neutropenia in breast cancer patients undergoing chemotherapy However the primary trial focuses on the duration of CTCAE grade 34 neutropenia after the first chemotherapy cycle using two different dosages 6 mg and 75 mg while the secondary trial investigates the incidence of CTCA",
        "label": "Entailment"
    },
    "37e14df5-fd3b-4c30-bda4-6527febc5e2b": {
        "text_answer": "  The statement those with a confirmed cytological or histological diagnosis of nonsmall cell lung cancer or small cell lung cancer are suitable for the primary clinical trial is entailed in the inclusion criteria of the trial as stated in the text Therefore the statement is entailed in the trial",
        "label": "Entailment"
    },
    "27d0d803-28d5-4b3d-a87e-8fbe577513a9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The primary trial involves oral administration of cabergoline while the secondary trial involves intravenous administration of pixantrone dimaleate There is no mention of dermal patches in either trial",
        "label": "Contradiction"
    },
    "1f755559-38fb-4edc-a41a-91252b1dfb54": {
        "text_answer": "  The statement 14q22 is a chromosome band present on 14q Alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day is neither entailed in the primary trial nor contradictory to it   The statement mentions a chromosome band 14q22 which is not related to the inclusion or exclusion criteria of",
        "label": "Entailment"
    },
    "acf4a907-c58c-46df-aa75-666e643cef4f": {
        "text_answer": "  The statement The intervention in the secondary trial lasts 3 times longer than the intervention detailed in the primary trial is entailed in the trials as the intervention in the primary trial lasted for 10 weeks 45 minutes each session once a week while the intervention in the secondary trial lasted for 24 weeks capsules given weekly Therefore the intervention in the secondary trial is indeed 3 times longer than the intervention in the primary trial  ",
        "label": "Entailment"
    },
    "6d5ac8ed-53a0-4b48-a521-7a9b53e82017": {
        "text_answer": "  The statement is entailed in the given trials as the interventions in both trials involve intravenous injections but the drugs used dosages and frequency of administration are distinct",
        "label": "Entailment"
    },
    "256a6852-2768-4fc9-acae-f5fea437412c": {
        "text_answer": "  The statement There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial is a contradiction to the given data in the trials  The statement does not follow from the trials as the number of cases for Biliary colic is the same 1 in both trials and there are no cases of Clostridium difficile colitis reported in the primary trial  There",
        "label": "Contradiction"
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "text_answer": "  The statement is entailed in the trials   Explanation   The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less is entailed in the trials because the dosage of Cetuximab is the same for both cohorts 400 mgm2 loading dose and ",
        "label": "Entailment"
    },
    "9d447ab6-f75c-40b6-88ca-db2e904ef02d": {
        "text_answer": "  The statement the eligibility for the primary clinical trial imposes no restrictions on mental health bodyweight age karnofskyecog score or prior treatments is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information provided alone  However the criteria do not mention any restrictions related to mental health bodyweight age or prior treatments",
        "label": "Contradiction"
    },
    "624aeeea-894f-4100-86a2-724ef4842002": {
        "text_answer": "  The statement is entailed in the trials as both cohorts receive the same doses of radiation therapy and undergo a SPECT scan at baseline and 6 months followup The statement does not contradict any information provided in the trials",
        "label": "Entailment"
    },
    "647016e6-71d4-4169-801d-e58e9b20171f": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation   The statement asserts that there are 4 more adverse events recorded in the primary trial than the secondary trial However the trials data shows that there are no adverse events recorded in both trials Therefore the statement is contradictory to the facts presented in the trials data  Regarding the CDISCSend Laboratory Animal Species Terminology",
        "label": "Contradiction"
    },
    "5ff5980d-28e1-46a7-9300-20792ad3dffd": {
        "text_answer": "  The statement is entailed in the trials as described Both interventions involve the same regimen for tremelimumab and the optional extended treatment for durvalumab The only difference is the dosage of durvalumab in the biweekly iv infusions which is 03 mgkg less in intervention 1 compared to intervention 2 Therefore the statement accurately reflects the distinction between the two interventions and is entailed by the trial information",
        "label": "Entailment"
    },
    "29b78196-3625-46f2-baa9-45b6ab4b3823": {
        "text_answer": "  The primary trial does not provide information about treatmentemergent adverse events AEs as an outcome measurement The outcome measurement in the primary trial is the change from baseline in patientspecified and reported symptoms on the Measure Yourself Medical Outcome Profile MYMOP  The secondary trial does not mention treatmentemergent AEs as an outcome measurement either The outcome measurement in the secondary trial is the change in Isothiocyanate in",
        "label": "Entailment"
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria it is a",
        "label": "Entailment"
    },
    "f9a077fc-18cf-418a-ac86-ddc89ea4259b": {
        "text_answer": "  The statement is entailed in the trials as follows  In both trials the quantity of docetaxel administered is 100 mgm per cycle and the interval between docetaxel administrations is every 3 weeks The quantity of doxorubicin administered in combination with cyclophosphamide is 60 mgm for doxorubicin and 600 mgm for",
        "label": "Entailment"
    },
    "0c207e39-2335-46a1-8dbd-3be4b8d59a17": {
        "text_answer": "  The statement have a skin rash is not entailed in nor contradictory to the information provided in the primary trial The trial focuses on the use of Active Breathing Coordination ABC during radiation therapy and the acquisition of SPECT scans for determining changes in cardiac perfusion The statement about a skin rash is not mentioned in the trial Therefore it is neither entailed nor contradictory to the trial information",
        "label": "Contradiction"
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "text_answer": "  The statement Both cohorts of the primary trial recorded 0 Aes is entailed by the given trials data as both cohorts had a total of 0 adverse events each which is the same as recording 0 adverse events in total for both cohorts",
        "label": "Entailment"
    },
    "b51a60d1-5112-4972-a303-11b35ba07af1": {
        "text_answer": "  The statement eligibility for both the primary clinical trial and secondary trial requires women to be aged 22 or above is a contradiction to the information provided in the trials inclusion criteria  The primary trial includes patients aged greater than 20 years while the secondary trial includes patients aged 18 or older Therefore the statement that the eligibility for both trials requires women to be aged 22 or above is not entailed in the trials",
        "label": "Contradiction"
    },
    "44bb4ead-0597-4544-9b2c-3d99ff0a099b": {
        "text_answer": "  The statement during the primary clinical trial blood bilirubin levels increased in 3636 of the participants is entailed in the trial data provided The trial data states that Total 411 3636 refers to the total number of participants who experienced an adverse event related to an increase in blood bilirubin levels Therefore the statement is entailed in the trial data",
        "label": "Entailment"
    },
    "caf14d83-76cb-4c21-b5c0-d83966973483": {
        "text_answer": "  The statement is entailed in the trials data provided The statement mentions that the only types of adverse events observed in patients from the secondary trial were Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain and no AEs were recorded in the primary trial The trials data confirms this information as shown in the Adverse Events section for each trial Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "0d984537-a1c8-486f-840d-1a09f2bfa961": {
        "text_answer": "  The statement fewer than a quarter of the patients have registered increased pleural effusion or rapid disease progression is not directly entailed in the given trials as the trials provide the number of patients who experienced each adverse event separately but they do not provide the total number of patients who experienced either adverse event or both However based on the given information it is true that fewer than a quarter of the patients in Trial 1 and fewer than half of",
        "label": "Contradiction"
    },
    "77890255-16cc-4dfb-b374-f2eba38238ce": {
        "text_answer": "  The statement Most the primary trial candidates suffered from some kind of eating disorder during the study duration is not directly related to the adverse events listed in the primary trial Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone The statement may or may not be true but it does not follow logically from the adverse events data provided",
        "label": "Entailment"
    },
    "d0f95f01-4a54-4bdc-9059-50803485a1f5": {
        "text_answer": "  The primary trial includes patients with a breast tumor 1 cm in diameter while the secondary trial includes patients with locally advanced or metastatic breast cancer and measurable disease but the size of the breast tumor is not explicitly stated in the secondary trial However the statement that patients with a breast tumor 311 cm in diameter with confirmed hr positive and her2 negative status are eligible for both trials is not directly entailed in the given trials as",
        "label": "Contradiction"
    },
    "5628cfa9-df1b-4a19-9f6b-c513b1fb73db": {
        "text_answer": "  The primary trial measures the percentage of participants with tumor response according to RECIST criteria after receiving all 24 doses of 852A The secondary trial measures the number of participants with AIMSS but it does not specify how clinical improvement is assessed or recorded  Therefore the statement is not entailed in the trials as the secondary trial does not provide sufficient information about the measurement of clinical improvement",
        "label": "Contradiction"
    },
    "9915c5ea-d327-4cd9-a3e2-26cfa75cadb7": {
        "text_answer": "  The statement Arm 2 of the primary trial had higher Operative Time than Arm 1 therefore the control group performed better than the test group in this regard is a contradiction to the information provided in the trials   The primary trial does not state that the control group Standard Mammography performed better than the test group Intraoperative Mammography based on operative time savings Instead it shows that the test group had a",
        "label": "Contradiction"
    },
    "48262549-7f65-43b7-ac00-f11dfb93e900": {
        "text_answer": "  The statement is entailed in the primary trial as both suramin and paclitaxel are mentioned as interventions for all patients in the primary trial   In the secondary trial the statement is also entailed as the intervention for the secondary trial also includes suramin and paclitaxel However its important to note that in the secondary trial the intervention is applied to a specific population patients undergoing mastectomy surgery but the statement",
        "label": "Entailment"
    },
    "06c2d2d2-93dc-44dd-a729-a11a4397db44": {
        "text_answer": "  The statement is entailed in the trials as described Both interventions involve the same dosing schedule for tremelimumab and the same optional extended treatment for durvalumab The only difference between the interventions is the dosage of durvalumab with cohort 1 receiving a lower dose 03 mgkg and cohort 2 receiving a higher dose 1 mgkg Therefore the statement that the only variances",
        "label": "Entailment"
    },
    "7ae48994-9b72-4bc5-aab2-adcc9f0e1735": {
        "text_answer": "  The statement Any cancer patient diagnosed with either fibromyalgia thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is entailed in the trials eligibility criteria as stated  Primary Trial  Exclusion Criteria Diagnosis of fibromyalgia  Secondary Trial  Exclusion Criteria Diagnosis of thalasemic syndromes",
        "label": "Entailment"
    },
    "adbb33ae-2076-4850-bfd7-967119d8e169": {
        "text_answer": "  The statement is entailed in the primary clinical trial as neither the Vaginal Symptom Measure VSM nor the change in units on a scale have any mention of centimeters number of individuals or time duration  In the secondary clinical trial the outcome measurement is the objective response rate of HER2negative metastatic breast cancer MBC patients which is measured using percentage of participants This measurement does not involve centimeters",
        "label": "Entailment"
    },
    "846578ce-00a5-487a-80d0-c5922f2c0c20": {
        "text_answer": "  To determine if the statement is entailed in the trial results we need to calculate the percentage change in Ki67 expression from baseline to 6 weeks for the TAK228 Plus Tamoxifen arm  Percentage change in Ki67 expression  Ki67 expression at baseline  Ki67 expression at 6 weeks  Ki67 expression at baseline  100  Percentage change in Ki67 expression",
        "label": "Entailment"
    },
    "ba5d4784-f20f-4d77-b133-ab700624da3e": {
        "text_answer": "  The statement the primary trial presented fewer cases of intestinal perforation than the secondary trial is contradicted by the information given in the trials   Explanation   The primary trial reported 0 cases of intestinal perforation out of 17 participants while the secondary trial reported 1 case out of 25 participants Therefore the secondary trial had more cases of intestinal perforation than the primary trial",
        "label": "Contradiction"
    },
    "638143cc-bcdc-422b-8695-ec836f17edae": {
        "text_answer": "  The statement is entailed in the Trials as follows  In the primary trial the participants undergo various treatments including surgery while in the secondary trial the participants do not undergo surgery The statement correctly describes this difference in interventions between the two trials  Therefore the statement is entailed by the given trials",
        "label": "Entailment"
    },
    "d80d13ef-0da7-4203-af51-52c08253aefe": {
        "text_answer": "  The statement trouble moving bowels is a question about whether an individual has or had trouble moving their bowels The primary trial and the secondary trial recorded the same number of adverse events in their cohorts is neither entailed nor contradicted by the given trials data  Explanation  The statement is not entailed by the trials data because the statement makes a broader claim about the nature of the adverse event trouble moving bowels",
        "label": "Entailment"
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity 1 from each cohort is entailed in the trials provided   Explanation   The trials do not explicitly state the number of patients who experienced doselimiting toxicities DLTs in each cohort However they do provide the total number of participants analyzed in each cohort 6",
        "label": "Entailment"
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "text_answer": "  The statement Several recorded AEs in the primary trial occurred to cohort 1 patients is entailed in the given trials as both trials have the same set of patients and all the recorded adverse events are listed for all patients in both trials Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "e6954b69-b723-4a51-8a5b-6e7461028b60": {
        "text_answer": "  The statement getting a ringing or buzzing in ears is not a factor that distinguishes between the Memantine and Placebo interventions in the primary trial  Explanation  The statement is neither entailed nor contradicted by the information provided in the trials Both the Memantine and Placebo interventions are administered at the same frequency and for the same duration of time and there is no mention of any difference in the occurrence of ringing",
        "label": "Entailment"
    },
    "5fbe4001-1044-4684-a2a2-e34bf233fafb": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the given trials data  Explanation  The statement is entailed in the trials data because the primary trial had a higher percentage of occurrence for each of these ad",
        "label": "Entailment"
    },
    "410a0a55-a31f-4a57-9de1-3eacd3da7650": {
        "text_answer": "  The statement the primary clinical trial was devoid of any adverse psychiatric events such as eating disorders or schizophrenia is not directly entailed or contradicted by the given trial data The trial data only reports adverse events that occurred during the study and it does not mention any psychiatric events related to eating disorders or schizophrenia Therefore the statement is neither entailed nor contradicted by the given trial data",
        "label": "Contradiction"
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the participants receive the following interventions 1 Neoadjuvant Therapy doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate needle biopsy therapeutic conventional surgery immun",
        "label": "Entailment"
    },
    "2bc6306e-445f-459e-afab-b445eedd5711": {
        "text_answer": "  The statement doses of paraplatin vary across different interventions is not explicitly stated in the given information Paraplatin is not mentioned in the interventions described in the trial Therefore the statement is neither entailed nor contradicted by the information provided",
        "label": "Entailment"
    },
    "ecb7babe-941e-41bf-89a3-0b8387fdd239": {
        "text_answer": " The statement is not entailed in the trials provided as they measure different outcome measures The trials report the percentage change in serum betaCTX levels from baseline to Week 4 for the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement provided is about a difference in primary tumour diameter between the two groups which is not mentioned in the trials",
        "label": "Contradiction"
    },
    "4d77b4db-8260-4ec9-af60-660f7a2a4833": {
        "text_answer": "  The statement candidates are required to undergo warfarinbased treatment in the primary clinical trial and is also a necessity for inclusion in the secondary clinical trial is a contradiction to the exclusion criteria in both trials   In the primary trial patients who are currently receiving warfarin are excluded In the secondary trial lowdose warfarin less than or equal to 1 mgday is permitted However there is",
        "label": "Contradiction"
    },
    "a3954ec9-3fdd-4183-844d-1a13f70350e8": {
        "text_answer": "  The statement in the primary clinical trial there were no reported cases of adverse events amongst patients while every patient had at least one recorded adverse event in the secondary clinical trial is a contradiction of the given data   Explanation   The primary clinical trial reported no adverse events 000 among the 42 patients while the secondary clinical trial reported at least one adverse event 10000",
        "label": "Contradiction"
    },
    "5c14c797-4995-467f-a993-bc75ad197093": {
        "text_answer": "  The statement is not directly entailed in the given trials as the trials measure different outcome measurements The primary trials measure pathological complete response pCR rates while the secondary trial measures pathological complete response after preoperative therapy Therefore the statement does not follow directly from the trials However the statement does convey some information that could be inferred from the trials The statement implies that the trials involve outcome measurements related to the disappearance of invasive tumor d",
        "label": "Contradiction"
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "text_answer": "  The statement Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is entailed in the trials as follows  In the primary trial severe insomnia is an exclusion criterion under the category of Uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiat",
        "label": "Entailment"
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "text_answer": "  The statement The patient with the longest PFS in the primary trial was in cohort 1 is not directly entailed in the given trials as the trials only report the median PFS for each cohort and do not provide information about the longest PFS observed in each cohort Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "86da40aa-8994-4fb7-8628-098d347b5864": {
        "text_answer": "  The statement Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study is not directly entailed or contradicted by the information provided in the trials The trials only report the average pain intensity scores and the difference between the two intervention groups but they do not provide information on the number of patients who experienced no pain at all during the study",
        "label": "Contradiction"
    },
    "e6b59a72-62ef-4752-8464-902ca8d09119": {
        "text_answer": "  The statement both the primary and the secondary clinical trials registered just one death in the adverse events is entailed in the given data   Explanation   The statement is entailed because the data in the primary trial reports one death 1111 out of nine participants and the data in the secondary trial reports one death 048 out of 208 participants Therefore both trials have reported at least",
        "label": "Entailment"
    },
    "a1e54b35-4b25-4194-8a44-7c8e587a1c83": {
        "text_answer": "  The statement is entailed in the trials as both intervention 1 and intervention 2 involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid around the tumor site Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "e9bc72c1-1933-4ac1-b21b-35bf90b82c48": {
        "text_answer": "  The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is entailed in the Trials as both trials report no deaths and no hospitalizations in their respective cohorts Adverse Events 2 The statement about grade 1 joint effusion being asymptomatic and not requiring intervention from the text is not directly related to the trials and does not affect the entailment relationship",
        "label": "Contradiction"
    },
    "1f400417-bb05-4885-a46b-d348c2353ae9": {
        "text_answer": "  The statement is entailed in the trial description as the participants are indeed subjected to four different pharmaceutical treatments throughout the study The treatments are epirubicin  cyclophosphamide for 4 cycles a 3week break docetaxel for 4 cycles and trastuzumab for 8 treatments loading dose  maintenance dose for 4 cycles each",
        "label": "Entailment"
    },
    "e8e2db51-2ec2-4e88-9096-cbe5d5933286": {
        "text_answer": "  The statement is contradictory to the provided trials as the primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH and the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel There is no common outcome measurement for both trials related to the ratio of patients who exhibit no signs of invasive tumor remaining in the breast after undergoing",
        "label": "Contradiction"
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial is using hormonal interventions Estring and Testosterone Cream for lymphedema treatment The secondary trial is testing an acupuncture intervention for lymphedema treatment  Therefore the statement the primary trial is using hormonal interventions and the secondary trial is testing an acupuncture intervention is entailed in the trials",
        "label": "Entailment"
    },
    "b7d3d4f9-44da-4fba-9005-e650cf0e2bb8": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement discusses the differences in dosing regimens between the two trials for two different interventions Alpha Lipoic Acid and Necitumumab However the statement does not directly compare the two trials or interventions   The primary trial focuses on Alpha Lipoic Acid and its dose escalation throughout the study duration",
        "label": "Entailment"
    },
    "8ffe96d0-134e-438b-884e-8c4f05b57b03": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial involves the use of Yttrium90 Radioembolization which is a type of radiation therapy and surgery is not mentioned The secondary trial involves the use of ibrutinib and MEDI4736 which are not gene therapy or antibody treatments but rather a kinase inhibitor and a monoclonal antibody respectively",
        "label": "Entailment"
    },
    "f9172aa9-f9ea-44cc-9669-f72874fcbef2": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial the interventions do not involve any drugbased treatments mentioned in the statement However the secondary trial is designed to evaluate the effectiveness of multiple doses of a nondrug therapy PF06647020 as stated in the trial description Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "42b44f03-de67-4d76-a566-2669f0768a23": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement the most common adverse event in the secondary trial was anaemia affecting more than 34 patients there were no recorded aes in the primary trial is contradictory to the information in the trials because  1 The statement implies that anaemia was the most common adverse event in the secondary trial",
        "label": "Contradiction"
    },
    "da1010e7-b58a-438b-b93d-cc53b6d4476e": {
        "text_answer": "  The statement 773 the primary trial participants and 101674 the secondary trial participants suffered an acute myocardial infarction is not entailed in the given trials as there is no mention of acute myocardial infarction in either the primary or secondary trials The trials only report the occurrence of various adverse events but not their frequencies Therefore the statement contradicts the given trials as it introdu",
        "label": "Contradiction"
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "text_answer": "  The statement A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial is neither entailed in the primary trial nor contradictory to it   The primary trial focuses on patients undergoing immediate tissue expander reconstruction following mastectomy and the secondary trial focuses on patients who have completed surgery for breast cancer and have certain criteria related to inflammation and fatigue There is no explicit",
        "label": "Entailment"
    },
    "59017303-759d-4b61-a272-efd6364a0b93": {
        "text_answer": "  The statement Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy is entailed in the trial description as it is explicitly stated that Patients will take Vorinostat daily during radiation therapy Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "88d91a58-834e-4e7b-8b8d-f9ef0d075dab": {
        "text_answer": "  The statement children and adolescents can participate in the primary clinical trial but are expressly prohibited from the secondary clinical trial is not explicitly stated in the given inclusion and exclusion criteria for either the primary or secondary trials However the secondary trial does have an age restriction for eligibility stating that women of childbearing potential must commit to the use of effective barrier nonhormonal contraception while on study which implies that children",
        "label": "Entailment"
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "text_answer": "  The statement Neither the secondary trial nor the primary trial use cm Number of Participants or a unit of time as their units of measure is not directly entailed in the given trials as they do not explicitly mention the use or absence of cm Number of Participants or a unit of time as units of measure in the outcome measurements provided However the trials do mention the use of other units of measure such as change in units on a scale 4 to 1",
        "label": "Contradiction"
    },
    "1514ac93-96a8-4d16-a572-d2a829af84c4": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial description specifies that participants receive epirubicin cyclophosphamide docetaxel and trastuzumab which is five different drugs not four Additionally the maximum dose of epirubicin is given as 100 mgm2 but there is no mention of doses for the other drugs in the statement The statement",
        "label": "Contradiction"
    },
    "61c97e3c-0456-4a0f-a261-d8ab75386686": {
        "text_answer": "  The statement in the primary clinical trial cardiacrelated adverse events were not reported in cohort 1 is entailed in the Trials since the Trials do not report any cardiacrelated adverse events ANGINA PECTORIS CARDIAC ARREST CARDIAC FAILURE CARDIAC TAMPONADE in cohort 1 Adverse Events 1 and also",
        "label": "Entailment"
    },
    "1aa7e1a8-707d-4c18-bdec-a750f59ffd1b": {
        "text_answer": "  The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is entailed in the trial results as stated 53 of the 60 participants 90 in the Lapatinib 1000 mg  NabPaclitaxel armgroup experienced either",
        "label": "Entailment"
    },
    "1f30e035-2441-4585-826a-9150678cb094": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is not directly related to the statement about hypophosphatemia and the trials provided Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However we can verify that the statement about the frequency of hypophosphatemia is contradicted by the trials as",
        "label": "Entailment"
    },
    "7b0752c4-ecc6-426a-82c9-e14bb237cfdc": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the last 8 years would be excluded from the primary trial is entailed in the trials exclusion criteria The trial explicitly states that individuals with a history of interstitial lung disease or pneumonitis are ineligible for participation While the term diffuse parenchymal lung disease is not explicitly mentioned in the exclusion criteria interstit",
        "label": "Entailment"
    },
    "34a95632-c79d-4704-8a4a-56c4ddce6070": {
        "text_answer": "  The statement the primary and secondary clinical trial could consider for eligibility a young girl recently diagnosed with ERpositive and HER2positive breast cancer is a contradiction to the inclusion criteria of both trials   The primary trial specifically states that the patients must be female and the secondary trial states that the patients must be 18 years of age or older Therefore a young girl would not meet the age requirement for either trial Additionally",
        "label": "Contradiction"
    },
    "587de897-adb2-4752-bd48-c9240b9bd956": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to compare the percentage of participants with an increase in the growth factor signature GFS in each group   The statement the growth factor signature increased in more participants from the dalotuzumab 20 mgkg group of the primary clinical trial than in those from the triple negative group is a contradiction of the given trials   The trials report that",
        "label": "Entailment"
    },
    "fd0b6abb-37f4-4b91-9b9f-433cbced84a7": {
        "text_answer": "  The statement is entailed in the trials Both cohorts receive CUDC101 at a dose of 275 mgm2 but the frequency of administration differs 5 daysweek for cohort 1 and 3 daysweek for cohort 2 The statement correctly acknowledges that the same amount of CUDC101 is administered in each trial arm but emphasizes the difference in administration frequency",
        "label": "Entailment"
    },
    "2c3adca5-a150-4c23-aa83-2cc8caeb0deb": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism in the last 8 weeks are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary embolism within the last 8 weeks are explicitly excluded However the statement suggests that these patients may be eligible for the secondary",
        "label": "Contradiction"
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial does have a cyclic treatment regimen with a 21day cycle length while the secondary trial does not mention a cyclic treatment regimen at all Therefore the statement that the secondary trial on the other hand does not have a cyclic treatment in place is not entailed in the trials but rather contradicts the information provided",
        "label": "Contradiction"
    },
    "e9602bad-7e97-41b5-9d08-f02f259a75e6": {
        "text_answer": "  The statement is entailed in the trials as both trials include the use of cyclophosphamide in their interventions",
        "label": "Entailment"
    },
    "1fa2d084-6a29-44c1-9e0f-53eb6d932247": {
        "text_answer": "  The statement less than half of the primary trial participants had a Reduction in circulating tumor cells Following Highdose Chemotherapy With Purged Autologous Stem Cell Products is not directly entailed in the provided trial results The trial results only report the number of participants with reduction in CTCs following highdose chemotherapy with purged autologous stem cell products but they do not specify the percentage or proportion of participants in relation to the",
        "label": "Contradiction"
    },
    "ce232ee1-c38c-4eee-bb4a-eaa33f0c75a8": {
        "text_answer": "  The statement a recent diagnosis of an intrabdominal abscess or major psychiatric disorder does not disqualify a patient from participating in the primary clinical trial is not directly stated in the given inclusionexclusion criteria However it is mentioned that No known hypersensitivity to phosphate trehalose or polysorbate and No serious nonhealing wound ulcer or bone fracture are exclusion criteria but",
        "label": "Contradiction"
    },
    "26f39f2a-dad6-40ed-8fa4-5abd8847021f": {
        "text_answer": "  The statement a woman who has not undergone any radical surgical treatment for her stage II bc is strictly ineligible for the secondary trial and the primary trial is contradictory to the information provided in the trials  Explanation  The primary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy including skinsparing mastectomy utilizing bioprosthetic mesh for breast reconstruction who have not undergone",
        "label": "Entailment"
    },
    "b37fc6a3-d231-478b-a18e-aa3439a972f1": {
        "text_answer": "  The given statement is not entailed in the provided trial results as the trial results only report the number of participants with a reduction in CTCs following highdose chemotherapy with purged autologous stem cell products not lowdose standard chemotherapy",
        "label": "Contradiction"
    },
    "e7af2ad2-7001-40c6-93cd-ddfd4d436170": {
        "text_answer": "  The statement the primary clinical trial is open to patients diagnosed with either frontotemporal or mixed dementia is not entailed in the given inclusion and exclusion criteria The criteria only mention some cognitive impairment and a Mini Mental State Examination MMSE score of 23 or above but they do not specify any type of dementia Therefore the statement is contradictory to the information provided in the trials criteria",
        "label": "Contradiction"
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "text_answer": "  The statement Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial the final decision for inclusion will be made by the health professionals conducting the trial is entailed in the given information   The inclusion and exclusion criteria provided in the text specify the minimum requirements for a patient to be eligible for the trial However the statement emphasizes that the final decision for inclusion rests with the health professionals conducting the trial which is consistent with",
        "label": "Entailment"
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "text_answer": "  The statement cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1 is entailed in the trials description since  1 Cohort 1 received 80 mg of Enzalutamide daily two 40 mg capsules 2 Cohort 2 received 160 mg of Enzalutamide daily four 4",
        "label": "Entailment"
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "text_answer": "  The statement is entailed in the trials as both interventions involve the same administration schedule for tremelimumab and the same optional extended treatment for durvalumab The only difference lies in the dosage of durvalumab given in each intervention with cohort 1 receiving a lower dose 03 mgkg compared to cohort 2 1 mgkg Therefore the statement accurately reflects the difference between the two interventions",
        "label": "Entailment"
    },
    "63a2b921-08f3-456f-9710-fc74ec13954e": {
        "text_answer": "  The statement after a month of TAK228 Plus Tamoxifen treatment patients in the primary trial experienced a 10 reduction in the Percentage of cells with Ki67 expression is entailed in the trial results as stated  1 The trial reports a median IQR reduction of Ki67 expression from baseline to 6 weeks of 5 percentage points from 15 to 10 ",
        "label": "Entailment"
    },
    "bbc8e272-7c58-4e53-a78b-4b634add9932": {
        "text_answer": "  The statement is entailed in the given trials as follows  1 The primary trial uses a higher dosage of lenalidomide 5mg orally daily for 57  3 days compared to the secondary trial where lapatinib is used at a dosage of 1500mg orally daily for 6 weeks and then 1500mg orally daily plus weekly paclitaxel for an additional 1",
        "label": "Entailment"
    },
    "a7382edb-9b99-468d-99f2-2030aa61005c": {
        "text_answer": "  The statement is entailed in the Trials as the trials provide information on different patient populations and outcomes The primary trial focuses on the evaluation of toxicity of HER2specific T cells therapy in 19 participants while the secondary trial reports on the percentage of participants with adverse events of primary interest AEPIs in two different cohorts of 2002 and 181 participants receiving trastuzumab emtansine The",
        "label": "Entailment"
    },
    "709bff7a-2384-4cac-ac70-00b4e91a6bce": {
        "text_answer": "  The statement past seven days frequency of anxiety is not related to the primary trial results is neutral and does not entail or contradict the information provided in the trial results The trial results only report the number of participants with clinical benefit complete response partial response or stable disease at week 12 and week 24 and do not mention anxiety or its frequency during the past seven days Therefore the statement is neither entailed nor contradicted by the",
        "label": "Entailment"
    },
    "7c192c20-49e2-4b5c-b4ac-1131b7e9e4d0": {
        "text_answer": "  The statement More Palpitations Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial is a factual statement about the number of adverse events in each trial The statement does not directly entail or contradict the information about the deleterious atm gene mutation provided in the text The trials and the gene mutation are two separate pieces of information Therefore the statement is neither entailed nor",
        "label": "Entailment"
    },
    "608a57fb-72d5-4837-a491-2d0bc83a7776": {
        "text_answer": "  The statement is entailed in the trials as they report different outcome measurements The primary trial reports Time to Progression in months for two different arms of the study while the secondary trial reports the number of participants with Objective Response based on RECIST criteria The statement correctly identifies the different outcome measurements in each trial",
        "label": "Entailment"
    },
    "58f6494f-860a-4f94-9fa1-895637730938": {
        "text_answer": "  The statement is contradictory to the given trials   Explanation   The statement asserts that the dosage of denosumab in intervention 1 of the primary trial is equivalent to the dosage of tamoxifen in intervention 1 of the secondary trial However the dosages are not equivalent   In the primary trial intervention 1 received Zoledronic Acid 4 mg Q4W quarter",
        "label": "Entailment"
    },
    "a08b1e1e-385a-40e6-990d-05b9aebc7335": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial patients received denosumab injections of 120 milligrams every 4 weeks not 240 milligrams every month as stated in the contradictory statement   In the secondary trial patients underwent lymphoscintigraphy with either pIHGC or GP which does not involve den",
        "label": "Entailment"
    },
    "a1eb1305-f49e-4773-aa30-033093afeb64": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trial results we need to compare the percentage of participants with a decrease in the growth factor signature GFS between the ERpositive Luminal B and Triple Negative groups   The statement there was no significant difference in the decrease of the growth factor signature in both the dalotuzumab 20 mgkg group and the triple negative group of the primary clinical trial",
        "label": "Entailment"
    },
    "36c3d1c3-d4dc-49bf-97a8-49608799cc35": {
        "text_answer": "  The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is a separate inclusion criterion that is not explicitly stated in the given inclusion and exclusion criteria for the primary trial   However the statement does contradict the initial inclusion criterion that Patients must have histologically documented metastatic or unresectable nonsmall cell",
        "label": "Entailment"
    },
    "227071c8-f195-4c9c-993d-3f57a9062a6f": {
        "text_answer": "  The statement secondary glioblastoma is a glioblastoma arising from a lower grade astrocytoma is not related to the given trials and their inclusionexclusion criteria Therefore it cannot be entailed or contradicted based on the information provided  Regarding the statement Patients with a Vitamin D deficiency are excluded from the primary trial but may be eligible for the secondary trial this statement is not directly contradictory to",
        "label": "Entailment"
    },
    "a06e0782-9249-48ae-a2a3-70dffa452aab": {
        "text_answer": "  The statement there are no set limitations concerning life expectancy pregnancy or age for individuals participating in the primary clinical trial is not explicitly stated in the given inclusion and exclusion criteria Therefore it cannot be definitively determined if the statement is entailed or contradicted based on the information provided alone However the absence of any mention of life expectancy pregnancy or age as exclusion criteria suggests that there may not be strict limitations in these areas But it",
        "label": "Contradiction"
    },
    "7eb81981-e3ca-42f2-ba8f-d1582e00f54d": {
        "text_answer": "  The statement is contradictory to the given trial information   In the primary trial FMX is given as a single bolus IV injection of 5 mgkg on Day 1 followed by MM398 treatment starting within 7 days of FMX infusion The dosages and intervals for FMX and MM398 are different  In the secondary trial lapatinib and paclitaxel are given in",
        "label": "Entailment"
    },
    "b60cdaf1-5a83-4738-b15d-d857c6d0924a": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial intervention is Radioembolization using TheraSpheres while the secondary trial intervention consists of ibrutinib and MEDI4736 which are pharmaceutical agents and not related to Radioembolization",
        "label": "Entailment"
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "text_answer": "  The statement is contradictory to the given trials as the primary trial intervention is Radioembolization using TheraSpheres while the secondary trial intervention consists of a combination of ibrutinib and MEDI4736",
        "label": "Entailment"
    },
    "7e232984-9a95-44b0-85b0-ecbeb50655b7": {
        "text_answer": "  The statement neither the primary clinical trial nor the secondary clinical trial restricts participation based on a patients nationality ethnicity weight or gender is entailed in the given information There is no mention of any restrictions based on nationality ethnicity weight or gender in the inclusion or exclusion criteria for either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "f5c83e99-e58f-4e5a-9fde-836480522184": {
        "text_answer": "  The statement 07 the primary trial participants and 01674 the secondary trial participants suffered an AE Adverse Event related to squamous differentiation is entailed in the given trials as both trials report that there were no cases of an adverse event related to squamous differentiation in their respective participant groups",
        "label": "Entailment"
    },
    "23727e9e-6589-475f-9c29-0a7880f6d8af": {
        "text_answer": "  The statement all individuals in the primary clinical trial experienced a decline in cognitive performance notably those in the ovarian function suppression group is not directly entailed in the given trial results   The trial results only provide the mean standardized composite cognitive function scores and their standard deviations for the Tamoxifen and Ovarian Function Suppression groups The statement makes a stronger claim that all individuals experienced a decline whereas the trial results only indicate the average",
        "label": "Contradiction"
    },
    "05971ed1-8162-4f52-8361-6fae652d03e2": {
        "text_answer": "  The statement patients in the primary clinical trial who underwent acupuncture experienced more favorable modifications in their lymphedema than those treated with testosterone cream is not directly entailed in the provided trials as there is no data presented on a testosterone cream group in the trials Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "99b57587-ea7a-496f-a7f9-9b2a7837ccc7": {
        "text_answer": "  The statement is contradictory to the primary trial information provided The primary trial does report on changes in pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing SPID30 as the outcome measurement The statement incorrectly asserts that the primary trial does not provide reports on changes in pain intensity Therefore the statement is contradictory to the information in the primary trial  Regarding the secondary",
        "label": "Entailment"
    },
    "af9cfc7a-95f4-494a-b68f-128961cf1a5b": {
        "text_answer": "  The statement a patient diagnosed with a nonneoplastic disorder is eligible for the primary clinical trial is contradictory to the given trial information The trial only includes patients with locally advanced or metastatic breast cancer Therefore a patient diagnosed with a nonneoplastic disorder would not meet the eligibility criteria for this trial",
        "label": "Entailment"
    },
    "55af1301-2370-48bf-8dde-50c589448da1": {
        "text_answer": "  The statement it was unusual for individuals with eating disorders to be candidates in the primary clinical trial is not directly entailed or contradicted by the given trial data The trial data only reports the adverse events observed in the study population but it does not provide information about the participants medical histories or diagnoses including eating disorders Therefore the statement cannot be determined to be entailed or contradicted based on the given trial data alone",
        "label": "Contradiction"
    },
    "7d0d3d69-d8ff-4671-9251-6f7a5f19a5ad": {
        "text_answer": "  The statement All the primary trial participants receive lower doses of drugs than the secondary trial participants is not directly related to the statement about how satisfied with physical attractiveness after gynecologic cancer Therefore it cannot be determined if the statement is entailed or contradicted based on the given information from the trials alone",
        "label": "Entailment"
    },
    "9fcf0873-73d2-48e3-87ac-ee5df19f7810": {
        "text_answer": "  The statement in the primary clinical trial the patient who survived the longest 35 months without disease progression or death was from cohort 1 is not directly entailed in the given trials as the trials only report the median PFS for each cohort and do not provide information about individual patient outcomes or the longest survival time Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "54c9c0a9-c38d-46b1-a96b-1335daaaef85": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial zoledronic acid is given intravenously IV not transdermally In the secondary trial all interventions granisetron hydrochloride prochlorperazine palonosetron hydrochloride and dexamethasone are given intravenously IV or orally not transdermally",
        "label": "Entailment"
    },
    "24493091-48f3-4e50-ae2c-5d23fb12c376": {
        "text_answer": "  The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race ethnic origin or cancer type however for the secondary trial they must have BRCA breast cancer is partially entailed in the given trials   The primary trial includes females aged 18 and above of all racial and ethnic origins who are scheduled to receive the first cycle of a single intravenous dose of doxorub",
        "label": "Entailment"
    },
    "64e0d68e-9fdb-4625-b179-316cf3772ee9": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe two separate interventions one using intravenous bisphosphonate and the other using subcutaneous denosumab There is no mention of multiple routes being used for the same intervention within the same trial Therefore the statement is contradictory to the information provided",
        "label": "Contradiction"
    },
    "fed83886-1413-49c9-91ab-3f1bea54db23": {
        "text_answer": "  The statement the secondary clinical trial was unfortunately halted due to a number of significant adverse events encountered by most participants is entailed in the given data from the secondary trial if we consider a number of significant adverse events encountered by most participants as a synonym for 5 or more adverse events reported in the trial However the data does not provide enough information to determine if these events were significant or severe enough to halt the trial Therefore while the statement",
        "label": "Entailment"
    },
    "7138e72c-d5e7-4c18-ba8c-b71be945ac2d": {
        "text_answer": "  The statement participants in the primary clinical trial receive tailored interventions based on their cancer diagnosis is not entailed in the given trials as there is no mention of cancer diagnosis in the trials provided The trials only mention the age group and the vaccines being administered Therefore the statement is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "4db16d69-4db6-410a-a48a-215903320e43": {
        "text_answer": "  The statement is not directly entailed in the given inclusion and exclusion criteria for the primary trial The statement mentions medical device timetoevent dataset which is not mentioned in the trial criteria However the statement does not contradict the trial criteria as the statement only describes a type of dataset and does not provide any information that would exclude or include patients from the trial",
        "label": "Contradiction"
    },
    "bfe7b8a8-8d7d-404c-b369-9bf059ae079c": {
        "text_answer": "  The statement cancer patients suffering from either epilepsy thalasemic syndromes or anemia are disqualified from the primary and secondary clinical trials is entailed in the given trials as these conditions are listed as exclusion criteria for both trials",
        "label": "Entailment"
    },
    "054618c6-0f9d-46de-94f3-e69e066a8432": {
        "text_answer": "  The statement 5 of the participants in group 1 of the primary trial were found to have lesions and only 30 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is not directly entailed in the given trials as the trials do not provide the same group of participants or the same outcome measurement The primary trial measures the number of lesions detected in healthy volunteers and breast cancer patients undergoing M",
        "label": "Contradiction"
    },
    "3db34e4f-ae01-424d-a8b8-7d1a16e2f898": {
        "text_answer": "  The statement an adult patient diagnosed with diffuse parenchymal lung disease within the past 2 years will be eligible for the primary clinical trial is contradictory to the trials exclusion criteria The trial explicitly states that patients with a history of interstitial lung disease or pneumonitis are ineligible Diffuse parenchymal lung disease is a type of interstitial lung disease Therefore the statement is contradict",
        "label": "Entailment"
    },
    "f300c26a-9ae0-4474-8fb3-34435ecdcf11": {
        "text_answer": "  The statement no participant in the primary clinical trial or the secondary clinical trial receives entericcoated tablets is contradictory to the information provided in the trials   In the primary trial there is no mention of entericcoated tablets being administered to any group However in the secondary trial MLN8237 is described as being given in the form of entericcoated tablets Therefore the statement is",
        "label": "Contradiction"
    },
    "5031f62e-54ed-4635-b136-7f90d6eb2535": {
        "text_answer": "  Both trials report the outcome measurement of Mean Standard Deviation of Tumor Diameter in centimeters cm Therefore the statement that the secondary clinical trial and the primary clinical trial utilize the same units of measure in their results is entailed in the information provided",
        "label": "Entailment"
    },
    "efdd9a96-8d0a-40ae-bcf7-f27abe59658d": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 36 months are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary embolism within the last 36 months are explicitly excluded However the statement suggests that these patients may be eligible for",
        "label": "Contradiction"
    },
    "b89171bc-ed32-4c9b-91ee-545a95b809fc": {
        "text_answer": "  The given statement does not directly entail or contradict the information provided in the interventions described in the primary trial The statement only mentions the absence of specific treatments drugs radiotherapy or CBT in the control group of the trial while the interventions describe the use of a risk assessment tool and decision support for providers The statement does not mention the intervention groups or any potential interaction between the interventions and the mentioned treatments Therefore the statement is neither",
        "label": "Entailment"
    },
    "b0a8feea-e233-4a75-992e-698a978045a5": {
        "text_answer": "  The statement substantial variations were seen in the results of the groups participating in the primary clinical trial is entailed in the trials as the AUC values for the two algorithms in the primary trial differed slightly with the Siemens algorithm having a slightly lower mean probability of 0880 0008 compared to the Lorad algorithms mean probability of 0884 0008  The",
        "label": "Entailment"
    },
    "1d8a752e-8628-40d5-b134-e523b5dead07": {
        "text_answer": " The trials provided do not contain any information regarding the number of patients in each group who reported severe discomfort during the entirety of the 10week study Therefore the statement is neither entailed nor contradicted by the given information",
        "label": "Entailment"
    },
    "7c81475d-c4f3-45cd-8481-400d43c45a7e": {
        "text_answer": "  The statement someone who underwent androgenbased therapy one and a half years prior to the primary clinical trial retains eligibility for the examination is not explicitly stated in the inclusion or exclusion criteria of the primary clinical trial However the criteria do allow for patients who have been on aromatase inhibitors for at least 28 days and are not expected to stop the medication during the study period Androgenbased therapy is not listed as an",
        "label": "Entailment"
    },
    "9e5f5682-6d2b-40df-b271-a0da55928c97": {
        "text_answer": "  The statement oral administration once a day is the method used for both placebo and memantine interventions in the primary clinical trial is entailed in the given trial information   Explanation   The trial information specifies that both the memantine and placebo interventions are administered orally and the dosing frequency for both interventions is twice a day BID However the statement in question simplifies the information by stating",
        "label": "Entailment"
    },
    "40034c62-a8d9-424f-ac22-2d5fcab4dfc0": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description The trial description mentions two different interventions for the patients one involves watching an educational DVD and meeting with a lay health advisor while the other involves receiving usual care without the DVD or the lay health advisor There is no mention of a succeeding cohort undergoing standard radiotherapy treatment instead of the intervention described Therefore the statement is contradictory to the information provided in the trial",
        "label": "Contradiction"
    },
    "711218ac-a329-4d4e-a66b-3c4b2d9116b5": {
        "text_answer": "  The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is entailed by the given data as both trials report no deaths or hospitalizations as adverse events  However the statement object identifier data type is a data type comprised of an integer or pointer that uniquely identifies an object is not related to the trials data and is not entailed or contradicted by the given information  Regarding the",
        "label": "Contradiction"
    },
    "ba6548a1-7dbf-4924-91ed-da83ecb2e8ef": {
        "text_answer": "  The statement general fatigue dimension is a dimension of general fatigue in the multidimensional fatigue inventory is not directly related to the given trials and is entailed neither in the primary nor the secondary trial  Regarding the second part of the statement Diagnosis of 23 cerebral metastases within the brainstem will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary",
        "label": "Entailment"
    },
    "06008bc8-58da-4762-9c98-830f2bd92325": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   Explanation   The statement claims that breast cancer patients in the primary trial receive 7000 mcgweek of talazoparib while ovarianperitoneal cancer patients receive only 175 mcgweek However the trials do not provide enough information to support this claim   In the trials the dosage",
        "label": "Entailment"
    },
    "68fe8d71-5200-4e77-a560-0fb7e67127a6": {
        "text_answer": "  The statement have problems with hearing loss that make me angry is not entailed in nor contradictory to the inclusion and exclusion criteria provided for the primary or secondary trials The trials focus on the eligibility of Japanese female patients with invasive breast cancer and specific conditions related to their cancer diagnosis and treatment The statement about hearing loss and anger is not related to these criteria",
        "label": "Contradiction"
    },
    "cd18deca-a213-4d53-af34-88624163f68e": {
        "text_answer": "  The statement paclitaxel is given to participants in the primary and secondary clinical trials is contradicted by the information provided in the trials   In the primary trial paclitaxel is given as part of the combination therapy with carboplatin but it is not mentioned as a standalone agent or in the secondary trial   In the secondary trial docetaxel is given instead of paclitaxel as part of the combination",
        "label": "Contradiction"
    },
    "f2006562-69ab-4062-a5be-943cb905ee95": {
        "text_answer": "  The statement monoallelic palb2 gene inactivation is any gain loss or exchange of DNA that results in monoallelic loss of function mutations in the palb2 gene is not directly related to the inclusion and exclusion criteria provided in the primary trial The statement pertains to genetic mutations while the criteria focus on eligibility for breast cancer clinical trial participation based on various medical and health conditions The statement about Alzheimer",
        "label": "Entailment"
    },
    "f3f438bb-2af4-44b9-9bf7-28dc232feacb": {
        "text_answer": "  The statement is contradictory to the information provided in the trial description In the trial description capecitabine was administered orally from Days 1 to 14 every 21 days not carboplatin Therefore the statement that carboplatin was administered orally twice a week to all participants in the second cohort of the primary clinical trial is not entailed in the trial description and is contradictory to it",
        "label": "Contradiction"
    },
    "b0410aa1-2da2-4399-b673-45157d3c3fb7": {
        "text_answer": "  The statement in the primary clinical trial there was a rise in blood bilirubin levels in 3636 of the patients is entailed in the trial data provided The trial data states that Blood bilirubin increased 111 3636 Therefore the statement is entailed by the trial data",
        "label": "Entailment"
    },
    "52db4188-de06-4a23-91e2-bc899f33f0e5": {
        "text_answer": "  Lets calculate the amount of MCS110 each patient receives in both interventions in a 3week cycle  Intervention 1  MCS110 1 mgkg  PDR001 100 mg  Total MCS110 dose per cycle 1 mgkg  patient weight kg  Intervention 2  MCS110",
        "label": "Entailment"
    },
    "33c89b93-d655-4154-9712-0803974c65f7": {
        "text_answer": "  The statement in the primary clinical trial the entire initial cohort faced a form of adverse event is not entailed in the given trial results as the trials only report the number of participants with serious and nonserious adverse events for each dose level but they do not indicate that every participant in the trial experienced an adverse event",
        "label": "Contradiction"
    },
    "936d7822-fd4b-42fc-abc5-d5ad838f148c": {
        "text_answer": "  The statement is entailed in the primary trial as individuals diagnosed with metastasized breast cancer confirmed ER and considering hormone therapy meet the inclusion criteria for the primary trial However its important to note that those individuals may also meet the inclusion criteria for the secondary trial depending on other factors such as the presence of measurable disease and the need for reconstruction The statement does not contradict the information provided in the trials",
        "label": "Entailment"
    },
    "b99886d6-98a7-4746-bc6c-1f70c8cdd0c6": {
        "text_answer": "  The statement is entailed in the trials as it accurately reflects the data presented The trials show that no adverse events AEs of type Anemia Febrile neutropenia Polycythaemia Acute coronary syndrome Vertigo Constipation Diarrhea Nausea Stomatitis Upper gastrointestinal haemorrhage or",
        "label": "Entailment"
    },
    "c2c4cbf5-1469-42bf-b243-9080648b458b": {
        "text_answer": "  The statement over 4 months of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 20 reduction in the percentage of cells with ki67 expression is entailed in the trial results as follows  The trial results show that the median IQR of Ki67 expression at baseline was 15 10 to 25 and at 6 weeks it was 10 2",
        "label": "Entailment"
    },
    "cc807530-f293-4c99-921b-f6e303d2b825": {
        "text_answer": "  The statement is entailed in the trials as the primary trial includes patients who do not have a history of breast cancer while the secondary trial specifically excludes patients with a history of breast cancer Therefore the statement that patients who are healthy and not diagnosed with any form of cancer are permitted to join the primary clinical trial but are excluded from the secondary clinical trial is entailed in the trials",
        "label": "Entailment"
    },
    "82c8c33d-a45b-4897-8ac5-407ec39564fd": {
        "text_answer": "  The statement is contradictory to the primary trial as the patient group in the primary trial receives oral pregabalin while the patient group in the secondary trial receives Depocyt intrathecal liposomal cytarabine and Highdose Methotrexate HDMTX which are different interventions",
        "label": "Entailment"
    },
    "a4cc14a3-7e05-4f72-b2f1-c9bb11720917": {
        "text_answer": "  The statement majority of the patients in cohort 1 in the primary clinical trial reported no acute vomiting episodes following the aprepitant dexamethasone cytoxan and kytril treatment is entailed in the trial results as follows  Out of the 20 participants analyzed in cohort 1 there were no reported episodes of vomiting and no rescue medication was required during the first 2",
        "label": "Contradiction"
    },
    "bacab9f7-0d0a-49e1-a503-e959c33bfe6a": {
        "text_answer": "  The statement is entailed in the information provided in the inclusion and exclusion criteria of the clinical trial The criteria clearly state that Final eligibility for a clinical trial is determined by the health professionals conducting the trial This means that even if a patient meets all the stated inclusion and exclusion conditions the final decision on their inclusion rests with the medical professionals running the trial",
        "label": "Entailment"
    },
    "d11e7175-a122-475f-862e-c5215d821f34": {
        "text_answer": "  The statement male patients under the age of 18 can participate in the primary trial regardless of race or ethnic origin or cancer type is not entailed in the inclusion criteria for the primary trial provided The primary trial includes females only  The statement for the secondary trial they must have prostate cancer is not mentioned in the inclusion criteria for the secondary trial provided The secondary trial includes various types of cancers including ovarian breast",
        "label": "Contradiction"
    },
    "99eb2e5a-77d2-4ab1-a25b-b6d8a8bcf412": {
        "text_answer": "  The statement despite fulfilling all the exclusion and inclusion requirements for the primary clinical trial the ultimate choice of participation is at the discretion of a court appointed guardian or representative is neither entailed nor contradictory to the information provided in the given inclusion and exclusion criteria   The statement adds an additional condition for participation in the clinical trial which is not explicitly stated in the provided criteria Therefore it neither contradicts nor is entailed by the",
        "label": "Entailment"
    },
    "c00fd72d-2cbe-4988-a861-60a707684af7": {
        "text_answer": "  The statement the primary clinical trial observed a minimum of one gastrointestinal adverse event is entailed in Trial 1 and Trial 2 since both trials reported a total of 1275 adverse events and among those there were reported cases of nausea Trial 1 067 Trial 2 134 and vomiting Trial 1 ",
        "label": "Entailment"
    },
    "7ade4e76-2f1d-452d-b9e4-499e0aabbe0c": {
        "text_answer": "  The statement a number of instances of swelling hypothermia and confusion have been documented in the adverse events of both the primary clinical trial and the secondary clinical trial is a contradiction to the given data in the trials  The data provided in the trials states that there were no instances of swelling hypothermia or confusion reported in the adverse events section for either trial Therefore the statement that a number of instances of",
        "label": "Contradiction"
    },
    "652e7c7c-998b-4a7d-b170-bcbe79729d93": {
        "text_answer": "  The statement is not entailed in the trials provided as the primary trial uses a change in units on a scale as the unit of measure for the primary outcome while the secondary trial uses percentage of participants as the unit of measure for the secondary outcome The statement only mentions functional physical assessment results and patient selfreported pain levels as the units of measure but it does not match the units of measure used in the trials Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "d8d046cc-99cc-4a31-94de-6dd290f504e7": {
        "text_answer": "  The statement every patient in the primary clinical trial experienced at least five distinct adverse events is contradicted by the information provided in the trials   In the primary trial there were no adverse events reported for any of the 42 patients Therefore no patient experienced five or more distinct adverse events   In contrast in the secondary trial each of the six patients experienced a total of 1 or 2 types of adverse events",
        "label": "Contradiction"
    },
    "9b09c156-bc43-445b-83ca-3831b111056f": {
        "text_answer": "  The statement patient cohorts in the secondary clinical trial displayed marginally more total negative effects than those in the primary clinical trial is a comparison of the total adverse events between the two trials However the given data does not provide enough information to determine if this statement is entailed in the trials or contradictory  The statement implies that there are some adverse events in the secondary trial but the primary trial has none Based on the given data this",
        "label": "Entailment"
    },
    "8b3dbda5-ee27-4d74-b6ab-d4bb1cc5c86b": {
        "text_answer": "  The statement warfarinbased therapy is a mandatory requirement for patients in the primary clinical trial and it disqualifies them from the secondary clinical trial is entailed in the given trials as follows  1 In the primary trial warfarinbased therapy is mentioned as an exclusion criterion 2 In the secondary trial warfarinbased therapy is not mentioned as an inclusion or exclusion criterion 3 Therefore",
        "label": "Entailment"
    },
    "e115c2a9-a31e-4a26-a96b-cd038666ced0": {
        "text_answer": "  The statement is entailed in the trials as follows  The primary trial measures subjective patientreported outcomes using the Vaginal Symptom Measure VSM with a 5point ordinal response scale while the secondary trial measures objective biomarker data using FISH testing for HER2negative metastatic breast cancer These are distinct types of outcome measures with the primary trial focusing on subjective patient experiences and the secondary trial",
        "label": "Entailment"
    },
    "4662f196-5472-4321-846e-c1576bc0be70": {
        "text_answer": "  The statement neither the primary trial participants nor the secondary trial participants experienced cholelithiasis is entailed in the given trials as neither trial reported any cases of cholelithiasis in their adverse events",
        "label": "Entailment"
    },
    "76032781-7c1c-4518-b9c5-13f8d7a5b443": {
        "text_answer": "  The statement the incidence of chest pain was reported to be considerably higher in the secondary clinical trial than in the primary clinical trial is not directly mentioned in the given trials However the statement implies a comparison of the incidence of an adverse event chest pain between the two trials Based on the provided information we cannot make a definitive statement about the incidence of chest pain in the trials Therefore the statement is neither entailed nor contradicted by",
        "label": "Entailment"
    },
    "2c29a565-bdcd-464c-85a4-361ab767c0d9": {
        "text_answer": "  The statement is contradictory to the given trials data   Explanation   The statement the adverse events of the primary and secondary trials each resulted in multiple deaths is contradictory to the trials data because  1 In the primary trial there was only one death reported not otherwise specified out of 9 participants which is not considered multiple deaths 2 In the secondary trial there was one death",
        "label": "Entailment"
    },
    "bd759cf8-b82f-496f-a8f7-1ab39f0d4724": {
        "text_answer": "  The statement have you been in low or very low spirits is a question about whether an individual is or has been in low or very low spirits is not entailed in the inclusion or exclusion criteria of either the primary or secondary trials provided   The primary trial focuses on eligibility criteria for participants with breast cancer or nonHodgkin lymphoma undergoing specific chemotherapy regimens while the secondary trial focuses on inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "7531054e-9cf3-43a1-bba4-19e90a2c5ef0": {
        "text_answer": "  The statement the outcome measures of the primary and secondary clinical trials are directly related despite having different interventions is not directly entailed in the given trials as they do not provide sufficient information to establish a direct relationship between the outcome measures The primary trial measures the percentage of participants with treatmentemergent adverse events in different populations while the secondary trial measures the number of participants with objective response to talazoparib in breast and ovarianperitone",
        "label": "Contradiction"
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "text_answer": "  The statement is contradictory to the given trials as there were no adverse events reported in more than 30 of participants in either the primary or secondary trials The trials only report the occurrence of adverse events in less than 1 of participants in both trials",
        "label": "Contradiction"
    },
    "129d4bb1-11bc-4aa4-b75a-fa8d0832e2ff": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage change in betaCTX between the two groups at Week 4   The percentage change in betaCTX for the AZD0530 175 mg group is 711 95 CI 759 to 654 and for the Zoledronic Acid 4 mg group is 6",
        "label": "Entailment"
    },
    "4a21310d-d0b8-44c7-ac08-ca9164bdc49f": {
        "text_answer": "  The statement is entailed in the given trials as the interventions used in the primary and secondary trials are different In the primary trial Yttrium90 Radioembolization using TheraSphere is used while in the secondary trial a combination of ibrutinib and MEDI4736 is used Therefore the statement is entailed in the trials as it correctly identifies the difference in interventions between the two trials",
        "label": "Entailment"
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "text_answer": "  The statement Any cancer patient diagnosed with either fibromyalgia thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is entailed in the trials inclusion and exclusion criteria   Explanation  The primary trial excludes participants with a diagnosis of fibromyalgia secondary trial inclusion criterion and thalasemic syndromes not explicitly mentioned in the",
        "label": "Entailment"
    },
    "19dbbcf2-63e2-4f96-a672-8c184edb025b": {
        "text_answer": "  The statement stay focused and think clearly under pressure is a question about whether an individual is able to stay focused and think clearly under pressure is not entailed in the given trial descriptions The trials only mention the use of a validated webbased risk assessment tool and decision support for providers in Intervention 1 The control group receives usual care which is not specified in the statement Therefore the statement is neither entailed nor contradicted by the given trial descriptions",
        "label": "Contradiction"
    },
    "3607f455-e990-4306-8b23-52d930ccbdff": {
        "text_answer": "  The statement the occurrence of ascites was higher in the primary clinical trial while the cases of pneumocystis jirovecii pneumonia were more prevalent in the secondary clinical trial is entailed in the Trials if and only if  1 The number of cases of ascites in the primary trial is greater than the number of cases in the secondary trial 2 The number of cases of pneumocystis jiro",
        "label": "Entailment"
    },
    "db2684e9-bcdc-482b-bfe4-4d6b2f6862c0": {
        "text_answer": "  The statement dull red erythema is a response that indicates that the degree of erythematous color change is dull red is not directly related to the adverse events data provided in the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone The trials only report the number of occurrences of adverse events 1 and 2 without specifying the nature or severity of these events",
        "label": "Entailment"
    },
    "40fceb75-d0d5-4926-8d3d-7e5f3c5b7931": {
        "text_answer": "  The statement the incidence of eating disorders was minimal among patients participating in the primary clinical trial is not entailed in the given trial data as there is no mention of any eating disorders among the reported adverse events",
        "label": "Contradiction"
    },
    "b72d4b5e-e31f-47aa-979a-8253ec455cd1": {
        "text_answer": "  The statement The number of hepatotoxicity cases were equal to the cases of hypertension and pancreatectomy is contradictory to the given data in the trial   Explanation   The statement implies that there were three cases of hepatotoxicity hypertension and pancreatectomy each However the given data states that there were three cases of hepatotoxicity one case of",
        "label": "Entailment"
    },
    "fc9a9de5-319a-465e-82ce-3c95b9a42728": {
        "text_answer": "  The statement the primary clinical trial had zero infection cases whilst the secondary clinical trial also reported an absence of infection is entailed in the given trials as both trials report an absence of infection cases in their respective Adverse Events 1 sections",
        "label": "Entailment"
    },
    "3870c72e-cf9d-461b-9dfd-ef407d84e8cf": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial there is no mention of proton therapy being used for radiation therapy The patients undergo whole breast radiation therapy with a dose of 180200 cGy per fraction for 2327 fractions to a total dose of 4600  4860 cGy  In the secondary trial there",
        "label": "Contradiction"
    },
    "83e0c108-bbbe-4b9b-97b6-62ea72e374d8": {
        "text_answer": "  The statement infections and infestations cases in the primary clinical trial occurred in patients from cohort 2 is not directly entailed in the given trials data as there is no mention of the cohort for the adverse events in the trials data provided However it is also not contradictory to the data as the trials data does not specify that there were no infections and infestations in cohort 2 Therefore the statement is neither",
        "label": "Contradiction"
    },
    "8b047df3-cd4b-4c75-97b5-4081f65512eb": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial the dosage of dexmedetomidine given in group 2 is 05ugkg 5ml which is not equivalent to 2mgkg unknown volume In the secondary trial the dosage of dexmedetomidine given in group 2 is not specified but it is mentioned that patients have vitamin D deficiency",
        "label": "Entailment"
    },
    "e92e432c-9e5c-451c-9bb2-ff89a618126c": {
        "text_answer": "  The statement patients with hyperkalemia are disqualified from both the primary and the secondary clinical trials is entailed in the given inclusion and exclusion criteria for the primary trial The primary trial explicitly states that Potassium within the normal range of 3553 mEqL is a requirement for inclusion and Hyperkalemia is defined as a potassium level above 53 m",
        "label": "Entailment"
    },
    "d7f818fb-a383-41c3-ac12-788228db7cf9": {
        "text_answer": "  The statement is entailed in the given trials as follows  In the primary trial the intervention is a single drug ZD1839 In the secondary trial the intervention for Intervention 1 is Zoledronic acid which is a different drug than ZD1839 Additionally Intervention 2 in the secondary trial includes Zoledronic acid Samarium153 and pegfilgrastim which",
        "label": "Entailment"
    },
    "d39e0799-d31d-4759-96ed-716b92f924a6": {
        "text_answer": "  The statement the intervention in the secondary trial lasts three times longer than the intervention detailed in the primary trial is a contradiction to the given information   The intervention in the primary trial lasted for 10 weeks while the interventions in the secondary trial each lasted for 24 weeks However three times longer implies that the intervention in the secondary trial lasted three times the length of the intervention in the primary trial which is not the case",
        "label": "Contradiction"
    },
    "fbe81247-571c-43a1-a2eb-439e579cf229": {
        "text_answer": "  The statement laryngeal fistula ctcae is a disorder characterized by an abnormal communication between the larynx and another organ or anatomic site is not directly related to the adverse events mentioned in the trials The statement describes a medical condition while the trials report the occurrence of adverse events during clinical trials The statement does not entail or contradict the information provided in the trials",
        "label": "Entailment"
    },
    "952fd1e7-65a2-417f-b1b8-188bce187c04": {
        "text_answer": "  The statement is entailed in the Trials The primary trial has consistent inclusion and exclusion criteria for all phases while the secondary trial has different inclusion criteria for each phase Phase I and II and specific inclusion criteria for the secondary trial Therefore the statement is entailed in the Trials as the primary trial has uniform criteria for participant eligibility in every phase while the secondary trials selection criteria vary per participant",
        "label": "Entailment"
    },
    "551bc048-5bac-47a0-a2bf-17844970c8dc": {
        "text_answer": "  The statement Patients in the primary trial will need to receive several injections is entailed in the trial description as patients will receive injections of dendritic cells chemotherapy and trastuzumab A gas cylinder is not mentioned in the trial description so it is not related to the statement and does not contradict it Therefore the statement is entailed in the trial description",
        "label": "Entailment"
    },
    "03c087ae-9ad2-4db3-a913-e6ba85dc15b0": {
        "text_answer": "  The statement candidates who are bedridden for less than 50 of their waking hours are eligible for both primary clinical trial and secondary clinical trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for the primary and secondary trials   The bedridden status is not mentioned as a criterion in either trial Therefore the statement does not follow directly from the information provided in the trials It is an independent condition",
        "label": "Entailment"
    },
    "9c459c1c-bfc4-4fef-ba9f-6052b9622c69": {
        "text_answer": "  The statement calr gene mutation is a change in the nucleotide sequence of the calr gene is not related to the adverse events reported in the trials Therefore it cannot be determined if the statement is entailed or contradicted by the trials as they do not provide enough information to make that determination",
        "label": "Entailment"
    },
    "a79aa893-e44c-4077-8791-47fb56351b5e": {
        "text_answer": "  The statement is a contradiction to the information provided in the trials There is no mention of radiation therapy in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f3e56d1d-af35-462c-ac1e-7e995543f505": {
        "text_answer": "  The statement less than 5 of patients in the primary trial suffered Aes is not directly related to the ages of patients at the end of radiation therapy mentioned in the statement age in days at end of radiation therapy is age of subject in days at the end of radiation therapy   Therefore the statement does not entail or contradict the given trials The trials only provide information about the occurrence of adverse events in the primary trial and",
        "label": "Entailment"
    },
    "88574a43-d4c9-4db7-8f47-307722095b0d": {
        "text_answer": "  The statement is not entailed in the trials provided as they address different outcome measurements and interventions The primary trial examines the effect of sulforaphane supplementation on isothiocyanate levels in urine while the secondary trial investigates the impact of physical therapy on pain reported by participants undergoing chemotherapy The statement is not directly related to the content of either trial",
        "label": "Contradiction"
    },
    "c7e1e07a-e363-47f7-9ec3-21fbd1da79b3": {
        "text_answer": "  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a conditional statement   To determine if this statement is entailed in the trials we need to check if the trials entail the same conditions",
        "label": "Entailment"
    },
    "eca608f4-6f65-4fc9-96cb-d1bb45749048": {
        "text_answer": "  The given statement several of the patients in the primary trial experienced the no pain whatsoever during the 1680 hours of the study is not entailed in the trials provided The trials only report the average pain intensity scores and the difference between the two intervention groups They do not provide any information about the number of patients who experienced no pain at all during the study",
        "label": "Contradiction"
    },
    "a8353a78-23fe-4aba-aaef-06d3fb8dd41a": {
        "text_answer": "  The statement the patient with the longest PFS in the primary trial survived 14 days without disease progression or death is not entailed in the given trials as there is no information provided in the trials about the longest PFS duration in days The trials only report the median PFS in months for each treatment group",
        "label": "Contradiction"
    },
    "cb591a65-2304-40bc-ad66-ddd4f3376bdc": {
        "text_answer": "  The statement peripheral primitive neuroectodermal tumor of bone is a small round cell tumor with neural differentiation arising from the bone It may be associated with pain Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial is not directly entailed in the given inclusion and exclusion criteria for the primary and secondary trials   However the statement that Patients must have no active tobacco use for",
        "label": "Contradiction"
    },
    "c566ae79-b43a-4e83-8336-da8613e19e7f": {
        "text_answer": "  The statement those suffering from Alzheimers disease are not applicable for participation in the primary clinical trial is entailed in the trials exclusion criteria The criteria explicitly state that individuals with dementia including Alzheimers disease are excluded from the trial due to their inability to understand and sign the informed consent and their potential cognitive impairment Therefore the statement is entailed in the trials exclusion criteria",
        "label": "Entailment"
    },
    "b0bedf1c-a1ed-4bf5-9ad1-ac22f0681d03": {
        "text_answer": "  The statement is not entailed in the given trials as neither of them report the number of participants with treatmentemergent adverse events as their outcome measurement The primary trial reports the change from baseline in patientspecified and reported symptoms on the MYMOP questionnaire while the secondary trial reports the change in isothiocyanate in urine samples",
        "label": "Contradiction"
    },
    "a3fb7d8d-5911-41d4-b3da-9a018bb256f6": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the first trial no participants had noticeable lesions at the time of MRI scans In the second trial participants did not have any symptoms of radiation dermatitis or hyperpigmentation Therefore the statement that each participant from the primary trials first group had noticeable lesions with those from the second trials group having any symptoms of radiation",
        "label": "Contradiction"
    },
    "5ccd39fd-215e-4699-8d02-a13d68ec34d3": {
        "text_answer": "  The statement does not follow directly from the given information in the primary trial The trial only provides information about the interventions in each arm and the fact that both arms use Paraplatin but it does not specify the amount or form of Paraplatin used nor does it mention the biospecimen or its characteristics Therefore the statement about the bulk nucleus specimen being a biospecimen consisting of multiple nuclei as a pool and both interventions including",
        "label": "Entailment"
    },
    "1304d51c-38a5-4851-9241-b0cb6993b013": {
        "text_answer": "  The primary clinical trial measures hot flash activity using a daily hot flash score which is a composite entity of both frequency and severity of hot flashes ranging from 0 to infinity The secondary clinical trial measures the overall response rate ORR which is a proportion of participants who achieved a best response of either complete response CR or partial response PR  The units of measurement in the two trials are not identical as they measure different outcomes Therefore the",
        "label": "Entailment"
    },
    "5794c670-e60c-4d2a-8d09-744e644c3e34": {
        "text_answer": "  The statement Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial is entailed in the trials exclusion criteria as it explicitly states History of grade 3 or 4 allergic reactions attributed to trastuzumab as a reason for exclusion Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "cdc43061-760e-4de2-946e-93d74f8ab544": {
        "text_answer": "  The statement Every participant in the primary trial receives the same intervention is entailed in both trials as stated However the statement have trouble going to sleep is a question about whether an individual has or had trouble going to sleep is not directly related to the trials provided It is an unrelated statement and does not entail or contradict the information given in the trials",
        "label": "Entailment"
    },
    "5758ac46-f46b-452f-aa99-5d9c86700447": {
        "text_answer": "  The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is entailed in the Trials   Explanation   The statement is entailed in the Trials because the Trials provide the number of occurrences for each adverse",
        "label": "Entailment"
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "text_answer": "  The statement is entailed in the trial description The participants in the primary trial receive epirubicin 100 mgm2 cyclophosphamide 600 mgm2 docetaxel 75 mgm2 and trastuzumab 6 mgkg loading dose and 4 mgkg maintenance dose throughout the study duration Epirubicin",
        "label": "Entailment"
    },
    "707a6e1b-520e-4052-bbd8-c932c4cc65e2": {
        "text_answer": "  The statement is entailed in the trials as both Intervention 1 and Intervention 2 specify that 18FFDG and 18FFPPRGD2 will be used as radiotracers for PETCT or PETMRI scans in the respective study groups and the statement affirms that the PETCT imaging protocols using these radiotracers will be applied uniformly across all study groups in the",
        "label": "Entailment"
    },
    "0359c605-2a3a-4696-8d14-ba214c571f1b": {
        "text_answer": "  The statement is neither entailed in the primary trial nor contradictory to it The primary trial and the statement refer to different conditions regarding the size of the breast tumor 1 cm vs 100 mm and the type of breast cancer HR HER2 vs TNBC The secondary trial does not mention the size or type of the breast tumor Therefore the statement is neither entailed in the primary trial nor contradictory",
        "label": "Entailment"
    },
    "ed820c4c-4119-4e93-894f-8484407c9ce6": {
        "text_answer": "  The statement is entailed in the trials as both trials involve examining the effects of interventions on study groups with the primary trial comparing two different interventions Hydrophor and MediHoney and the secondary trial comparing two different dosages 90 mg and 110 mg of the same intervention PF05212384  Docetaxel The primary trials focus on the varied effects of radiation therapies",
        "label": "Entailment"
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "text_answer": "  The statement is contradicted by the information provided in the trial descriptions While both cohorts receive NabPaclitaxel at the same dose 125 mgm2 on Days 1 and 8 they receive different doses of the second agent   Arm A Gemcitabine 1000 mgm2 on Days 1 and 8  Arm B Carboplatin AUC",
        "label": "Contradiction"
    },
    "14fdb2fc-e19d-4628-ada4-37ea935a2b4a": {
        "text_answer": "  The statement in the primary trial every adverse event was associated with respiratory complications unlike the secondary trial is a contradiction to the given data   The primary trial data does not indicate that every adverse event was associated with respiratory complications Instead it shows that various adverse events related to blood and bone marrow and lymphatics were present in the trial but there is no mention of respiratory complications",
        "label": "Contradiction"
    },
    "9783fc05-3652-41b2-8ba0-8a276889692a": {
        "text_answer": "  The statement patients with no history of pulmonary embolism over the past decade are ineligible for the primary trial but the secondary trial admission depends on the investigators decision is a contradiction to the information provided in the primary and secondary trials exclusion criteria  The primary trials exclusion criteria list pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4",
        "label": "Contradiction"
    },
    "b6b71c5a-8d4b-4ae1-9b57-45a5c9112543": {
        "text_answer": "  The statement is not entailed in the given trial information as the medication regime described in the statement subcutaneous doses once a fortnight for a year is different from the medication regime in the trial oral lapatinib and oral tamoxifen once daily on days 128",
        "label": "Contradiction"
    },
    "bed229d6-8924-4753-a297-d49d4c128166": {
        "text_answer": "  The statement continuous surface ECG recording for nonhuman species is a continuous electrocardiographic ECG recording utilizing one or more surface leads in a nonhuman species is not entailed in the given inclusion and exclusion criteria for the primary or secondary trials The trials focus on human participants and their eligibility based on various medical conditions performance status and other factors The statement about ECG recording in nonhuman species is unrelated to the",
        "label": "Contradiction"
    },
    "a434b916-659c-46a6-81c3-1654f561a2c2": {
        "text_answer": "  The statement most participants of the primary clinical trial encountered some sort of eating disorder in the course of the research period is contradicted by the given data Anorexia is listed as an adverse event but it only occurred in one participant out of 50 However the statement does not specify that the eating disorder referred to in the statement must be anorexia The other adverse events listed do not relate to eating disorders Therefore based on the",
        "label": "Contradiction"
    },
    "3c96d823-bc6c-4c7e-b490-50a0870076c5": {
        "text_answer": "  The statement is contradictory to the information provided in the trials The trials describe the interventions as being administered via transendocardial injections to the left ventricle using a NOGA Myostar injection catheter not through inhalation Therefore the statement is contradictory to the information provided in the trials",
        "label": "Entailment"
    },
    "f5e483ed-caec-4142-baa9-15ba42da5f03": {
        "text_answer": "  The statement All AE types in the primary trial affected less than 10 of patients is entailed in the given trial data   Explanation   The statement asserts that all adverse event AE types affected less than 10 of patients in the primary trial The trial data shows that the total number of patients who experienced any adverse event was 4 out of 11 which is equivalent to 3",
        "label": "Entailment"
    },
    "a993ae6a-f86f-478e-af30-584181f09531": {
        "text_answer": "  The statement is entailed in the given trial information as both the placebo and memantine interventions are administered twice daily BID for a duration of 81 days days 181 Therefore the frequency and duration of administration are equal for both interventions which is stated in the given trial information and also in the statement",
        "label": "Entailment"
    },
    "f119d419-b22b-4b4d-84ea-f7ab7dba7522": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   The trials provide information about the dosage regimens of PF06647020 in the primary trial and ALT801 in the secondary trial The statement is about occupations related to food preparation and serving There is no direct connection between the trials and the statement",
        "label": "Entailment"
    },
    "d7750102-df82-4668-8c6d-60e73b3241b5": {
        "text_answer": "  The statement is contradictory to the primary trial as it mentions that the secondary trial does not have a cyclic treatment in place while the primary trial does have a cyclic treatment defined as 21day cycles However the statement does not directly address the interventions or the conditions of the trials related to benign pericardial neoplasms Therefore the statement is contradictory to the information provided about the trial designs but it does not",
        "label": "Entailment"
    },
    "d269b697-c96f-4317-99c9-e465c7e935a7": {
        "text_answer": "  The statement the number of participants was identical in both groups of the primary clinical trial is contradictory to the information provided in the trials   The trials state that there were 1420 participants analyzed in each arm Neratinib and Placebo but the statement implies that the number of participants was the same in both groups which is not the case as there are 1420 participants in each group not an identical number in both",
        "label": "Entailment"
    },
    "0a74e0af-2534-45f3-b003-ba68e6e52d94": {
        "text_answer": "  The statement is entailed in the trials as given in the description Both interventions involve the injection of radioactive Tc99M sulfur colloid around the tumor site The difference lies in the use of a handheld gamma camera pIHGC in intervention 1 and the use of standard gamma probes GP in intervention 2 Therefore the statement accurately reflects the difference between the two interventions in the trial",
        "label": "Entailment"
    },
    "c6788d02-11df-4099-a395-c1e3dbc17f35": {
        "text_answer": "  The statement The most common adverse event in the secondary trial was Anaemia affecting more than 5 of patients there were no recorded AEs in the primary trial is a contradiction with the given trials data  Explanation  The statement implies that in the secondary trial Anaemia was the most common adverse event with a frequency greater than 5 and there were no adverse events recorded in the primary trial However",
        "label": "Contradiction"
    },
    "f1dca117-1368-4d17-bdb6-52d1b3816ed5": {
        "text_answer": "  The statement patients that have suffered a pulmonary embolism within the last 1095 days are excluded from the primary trial but may be eligible for the secondary trial depending on the investigators decision is a contradiction to the exclusion criteria in the primary trial   In the primary trial patients with a pulmonary embolism within the last 1095 days are explicitly excluded However the statement suggests that these patients",
        "label": "Contradiction"
    },
    "b1d950c2-dbd9-4cb4-b291-9406d84cd8de": {
        "text_answer": "  The statement ai therapy and mirtazapine responsiveness is not a requirement for patients participating in the primary clinical trial but it is mandatory for the secondary clinical trial is a statement of difference between the two trials   The primary clinical trial and the secondary clinical trial have different inclusion and exclusion criteria The primary clinical trial includes patients with hormone receptorpositive locally advanced or metastatic breast cancer who are resistant to aromatase inhibitor",
        "label": "Entailment"
    },
    "1f63524b-443d-4382-9df4-ea83eda85940": {
        "text_answer": "  The statement normal weighted nonpregnant individuals can participate in the primary clinical trial and the secondary clinical trial is entailed in the given trials as neither trial has any inclusion criteria related to weight or pregnancy status beyond the general requirement of being at least 18 years old and able to give informed consent Therefore the statement is entailed by the trials",
        "label": "Entailment"
    },
    "ad1c4967-3600-4953-a7fb-e48c9f4aa01f": {
        "text_answer": "  The statement is neither entailed in the primary trial nor contradictory to it   The 20yearold female patient with a newly diagnosed ERpositive HER2negative breast cancer could be eligible for the secondary trial as per its inclusion criteria However she would not meet the inclusion criteria for the primary trial due to her age The primary trial only includes female patients who are 18 years of age or older Therefore the",
        "label": "Entailment"
    },
    "6f4a77ce-3f70-4b57-ae45-e9825753d9ee": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial defines each treatment cycle as 21 days and the secondary trial does not mention a treatment cycle or a specific duration for the interventions Therefore the statement that the primary trial uses a 30day cycle for its intervention is not entailed in the trials and is contradictory to the information provided",
        "label": "Contradiction"
    },
    "73a0936e-5144-4b8c-b230-389d8ed451af": {
        "text_answer": "  The statement individuals that have been treated with androgens in the last month are eligible for the primary clinical trial is not entailed in the given inclusion and exclusion criteria The criteria explicitly state that Androgens are excluded as a current or planned therapy Therefore individuals who have been treated with androgens in the last month are not eligible for the trial according to the provided information",
        "label": "Contradiction"
    },
    "37c939aa-c2b0-4fcc-a90a-d7fa36fc8571": {
        "text_answer": "  The statement is entailed in the given trials information   Explanation   The statement neither cohort is subjected to any invasive surgical procedures or given neratinib is consistent with the information provided in the trials description   The trials description specifies that Intervention 1 is a Phase 2 Triplenegative cohort and Intervention 2 is a Phase 2 HER2 H",
        "label": "Entailment"
    },
    "a12ed2c0-b402-445b-b21b-7497389b39ec": {
        "text_answer": "  The statement erbb2 nm 0044484c2264 2278del is a deletion of 15 nucleotides tgagggaaaacaca from the coding sequence of the erbb2 gene from position 2264 through 2278 is not directly mentioned in the inclusion or exclusion criteria of the primary trial Therefore it is neither entailed nor",
        "label": "Entailment"
    },
    "d4bd0ed2-5753-470c-b804-00bbebdfc2d7": {
        "text_answer": "  The statement the primary clinical trial and secondary clinical trial do not accept patients who have a history of pulmonary embolisms and currently possess breast implants is entailed in the given trials as both trials have pulmonary embolisms listed under the exclusion criteria for the primary trial and breast implants listed under the exclusion criteria for both trials",
        "label": "Entailment"
    },
    "44b930a2-5810-41aa-a70c-e7eaa3730bc0": {
        "text_answer": "  The statement 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia is not directly entailed in the given trials as they do not provide sufficient information about the anatomic sites of metastasis for cm1b However the statement is consistent with the information provided in the trials as both trials report the occurrence of Anaemia and Febrile neutrop",
        "label": "Contradiction"
    },
    "7c28d575-cd75-418e-83bb-fae7457d9428": {
        "text_answer": " The statement satisfaction with overall sexual life is a question about how satisfied an individual is or has been with their overall sexual life is not directly related to the information provided in the trials   Regarding the trials the statement Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream is not entailed in the given trials as there is no comparison of the two groups",
        "label": "Contradiction"
    },
    "9a9bd166-1319-4a61-a8c2-e42ee878bf83": {
        "text_answer": "  The statement In total two patients from the primary trial suffered an Incidence of Doselimiting Toxicity 1 from each cohort is not directly entailed in the given trial results However it is consistent with the information provided as both cohorts had one participant each experience a doselimiting toxicity  The second part of the statement cdisc adascog  executive function maze errors is al",
        "label": "Contradiction"
    },
    "b032dff4-0d5d-4ee3-a4b2-c22ab3b8823f": {
        "text_answer": "  The statement participants in both the primary clinical trial and the secondary clinical trial are not required to meet a preliminary performance indicator the trials do not use a performance status scoring system is entailed in the given trials as there is no mention of a performance indicator or performance status scoring system in either the primary or secondary trial inclusion or exclusion criteria",
        "label": "Entailment"
    },
    "dd52a82a-b788-4048-ba8d-525ee119a78f": {
        "text_answer": "  The statement is entailed in the trials as follows  In the primary trial Intervention 1 involves the use of Estring which is a hormonal method for treating lymphedema Intervention 2 also involves a hormonal method albeit a different one with the use of testosterone cream  In the secondary trial Intervention 1 is acupuncture which is not a hormonal method However the control",
        "label": "Entailment"
    },
    "d93422f2-c5ab-4aa0-90a3-478b05a17c4e": {
        "text_answer": "  The statement the cohorts of both the primary clinical trial and the secondary clinical trial reported over 100 total adverse instances is contradictory to the given data in the trials   The primary trial reported 0 adverse events and the secondary trial reported 0 adverse events for Adverse Event 1 and 0 adverse events for Adverse Event 2 Therefore the total number of adverse events reported in both trials is ",
        "label": "Entailment"
    },
    "480133d8-93ea-46f0-86e5-b92c380bb7f9": {
        "text_answer": "  The statement nonnodal regional disease indicator is an indication of whether a subject has nonnodal regional disease is not entailed in the given trials as they do not share enough commonalities to make such a statement entailed The primary trial and the secondary trial have different interventions with the primary trial using FMX and MM398 and the secondary trial using lapatinib and paclitaxel The dosages and frequency of administration",
        "label": "Contradiction"
    },
    "2ac85077-e695-40c7-a9a9-d9901eceaeb2": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   In the primary trial cyclophosphamide is given as part of the AC regimen on days 1 and 2 and then as part of the weekly CarboplatinNabPaclitaxel regimen   In the secondary trial cyclophosphamide is given as part of the neoadjuvant regimen for",
        "label": "Entailment"
    },
    "e4221b6d-f3d7-4299-bcba-19c02be74cdd": {
        "text_answer": "  The statement patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced andor metastatic noncontinuous spinal cord parenchymal is a description of locations of interest is entailed in the given inclusion criteria for the primary trial   The inclusion criteria for both phases of the trial state that participants must have a solid tumor that is locally advanced and",
        "label": "Entailment"
    },
    "a16ff39b-cc99-4214-9af5-910eb9384a97": {
        "text_answer": "  The statement in both the primary trial and the secondary trial there were several adverse events which occurred in more than 90 of participants is contradicted by the given information   The trials do not provide any information about adverse events occurring in more than 90 of participants Instead they report the number of adverse events and the number of participants with neutrophilsgranulocytes ANCAGC abnormal",
        "label": "Contradiction"
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "text_answer": "  The statement in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy can be written as an inequality 3  number of hepatotoxicity cases  number of hypertension and Pancreatectomy cases  10  From the given data we have  Number of hepatotoxicity cases  3",
        "label": "Entailment"
    },
    "f9d0c257-bd9a-484e-bae7-802c0246372c": {
        "text_answer": "  The statement the arm A intervention proved to be the most successful in terms of overall response rate in the primary trial contrarily in the secondary trial the denosumab group showed a lesser performance in time to first onstudy SRE in comparison to the zoledronic acid group is a comparison of two different trials with different outcome measurements   In the primary trial Arm A had an overall response rate of 676 ",
        "label": "Entailment"
    },
    "15a422cf-fc00-4451-bddc-af67f7437e83": {
        "text_answer": "  The statement is entailed in the trials as follows  Both cohorts receive CUDC101 at a dosage of 275 mgm2 In cohort 1 CUDC101 is administered for 5 days in each 14 day cycle while in cohort 2 CUDC101 is administered for 3 days per week for 3 consecutive weeks",
        "label": "Entailment"
    },
    "cdcb40f6-994c-4085-869a-dab87e67ba04": {
        "text_answer": "  The statement in the primary clinical trial 97 of patients reported experiencing adverse events is not directly entailed in the provided trial information The trial results only mention the percentage of subjects who did not experience disease progression or unacceptable toxicity and received all planned treatment courses There is no information given about the percentage of patients who experienced adverse events Therefore the statement is neither entailed nor contradicted by the trial information",
        "label": "Contradiction"
    },
    "8e661d16-bf69-4d02-a437-5a77f12c1bd0": {
        "text_answer": "  The statement is entailed in the Trials as both the primary and secondary trials involve a weekly cycle of 4Demethyl4cholestryloxycarbonylpenclomedine administration for patients with CNS involvement from melanoma breast lung cancers or primary malignancies of the CNS who can be previously treated with radiation and systemic therapies and have other sites of cancer involvement The difference lies in the dosing",
        "label": "Entailment"
    },
    "ac4c15e0-c711-4583-a9d4-1dbc682cd7f7": {
        "text_answer": "  The statement is not entailed in the Trials 1 and 2 as given in the input   Explanation   The statement mentions the occurrence of anaemia and febrile neutropenia in the primary clinical trial which is consistent with Trial 1 However the statement does not mention the occurrence of pancytopenia which is inconsistent with both Trials 1 and 2 as",
        "label": "Contradiction"
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "text_answer": "  The statement 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia is entailed in the Trials as follows  The statement mentions that there is one case of Anaemia and Febrile neutropenia in cohort 1 This is consistent with the data in Trial 1 where there is indeed one case of each",
        "label": "Contradiction"
    },
    "1cab397e-60fd-460d-8f56-978ca8a2bb78": {
        "text_answer": "  To determine if the statement is entailed or contradicted by the given trials we need to calculate the relative frequency of hepatotoxicity hypertension and pancreatectomy cases   The statement says that hepatotoxicity cases were ten times more frequent than hypertension and pancreatectomy cases combined Lets calculate the frequencies   Hepatotoxicity 38  0",
        "label": "Entailment"
    },
    "ed2174d9-375c-4ed0-b880-56d13f6fb069": {
        "text_answer": "  The statement is contradictory to the given trials as there are no adverse events related to ionizing radiationrelated malignant neoplasm mentioned in either the primary or secondary trials The trials only report adverse events related to ANCAGC neutrophilsgranulocytes and the total number of adverse events in each trial is less than 30",
        "label": "Contradiction"
    },
    "ac271988-c319-4b6f-b7bf-f3c86072cf93": {
        "text_answer": "  The statement is entailed in the given trials as there is no mention of ALT801 in the primary trials whereas it is explicitly stated in the secondary trials that participants receive doses of ALT801",
        "label": "Entailment"
    },
    "915adcaa-4b9a-4df9-9803-4c5c0c52bf48": {
        "text_answer": "  The statement is entailed in the given trials as neither Intervention 1 nor Intervention 2 in the primary clinical trial involve paclitaxel Anastrozole is given orally and fulvestrant is given intramuscularly as stated in the trials There is no mention of paclitaxel in the interventions",
        "label": "Entailment"
    },
    "3cdc1ca9-f403-4e4b-878e-678d8dbc6090": {
        "text_answer": "  The statement none of the cohorts in the primary clinical trial observed any occurrences of hypertension dehydration and dyspnea is not directly entailed or contradicted by the given trial data The trial data only reports the occurrences of adverse events related to Disseminated intravascular coagulation Death NOS Edema limbs Fatigue Hepatic failure Alanine aminotransfer",
        "label": "Contradiction"
    },
    "c179d073-c910-42ab-9fde-85e976e52203": {
        "text_answer": "  The statement Morbidly obese patients can be eligible for the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials Morbid obesity is not mentioned as a specific inclusion or exclusion criterion in either trial Therefore the statement is neutral with respect to the given trials",
        "label": "Entailment"
    },
    "7e529d12-16a2-4711-b7f8-b454800447f2": {
        "text_answer": "  The primary trial includes patients with HR HER2 and a breast tumor between 1 cm in diameter The statement does not exactly match the inclusion criteria for the primary trial However it does mention that patients with HR HER2 breast cancer and a tumor size ranging from 02 to 08 cm are eligible for the trial Based on the context it is reasonable to assume that the statement is referring to the primary",
        "label": "Entailment"
    },
    "b71a1480-2037-4a01-8a4f-95a34aa172c2": {
        "text_answer": "  The statement the primary trial documented more instances of mucositis oral thromboembolic events and bladder infection than the secondary trial is contradicted by the given data   Explanation  The statement implies that the primary trial had a greater number of instances of mucositis oral thromboembolic events and bladder infection than the secondary trial However the data provided shows that the primary trial",
        "label": "Contradiction"
    },
    "6690be43-edee-4061-a850-47540cc49bee": {
        "text_answer": "  The statement No two patients in the primary trial suffered the same type of adverse event is not directly related to the information provided about juvenile idiopathic arathritis in the context of the trials Therefore it cannot be determined if the statement is entailed or contradicted based on the given information alone  However it can be verified that in the given primary trial each patient experienced a unique type of adverse event Therefore the statement",
        "label": "Contradiction"
    },
    "13d879d7-e968-4de9-ad06-458eb72759d5": {
        "text_answer": "  The statement is contradictory to the given information The statement suggests that there are 10 recorded adverse events in both trials but the actual information provided states that there were no adverse events in both trials for the given condition Adverse Events 1",
        "label": "Contradiction"
    },
    "c46fb676-9060-4d56-9097-af79bb762f50": {
        "text_answer": "  The statement is entailed in the information provided in the inclusion and exclusion criteria for the clinical trial The criteria clearly outline the conditions that must be met for a patient to be eligible for the trial and the statement emphasizes that the final decision on eligibility rests solely on those criteria regardless of the opinions of the health professionals Therefore the statement is entailed in the information provided",
        "label": "Entailment"
    },
    "14be6911-9b8c-4eb2-bcb9-bb5e892a57d1": {
        "text_answer": "  The statement is entailed in the Trials   Explanation   The primary trial does not involve any drugbased interventions as stated in the trial description It only mentions massage therapy psychosocial assessment and care and qualityoflife assessment   On the other hand the secondary trial tests different doses of a drugbased treatment PF06647020 which is",
        "label": "Entailment"
    },
    "e1cb3a7c-2881-41b9-8dc5-c6a1d311afc6": {
        "text_answer": "  The statement compared to the primary clinical trial the secondary clinical trial observed an increase of 11 adverse events is entailed in the given data   Explanation   The statement implies that there were more adverse events in the secondary trial compared to the primary trial The data provided shows that there were 0 adverse events in the primary trial and 11 adverse events in the secondary trial which is a difference of ",
        "label": "Entailment"
    },
    "2ce0537c-cd90-47dd-83e3-79a690cdc101": {
        "text_answer": "  To determine if the statement 90 more participants in the ERpositive Luminal B group of the primary trial demonstrated a decrease in the growth factor signature than in the Triple Negative group is entailed or contradicted by the given trials we need to calculate the difference in percentage points between the two groups and then determine if the difference is 90 more in the ERpositive Luminal B group  First lets",
        "label": "Entailment"
    },
    "ff1759ba-f09e-4ecf-8316-aac2a78d6c26": {
        "text_answer": "  The statement There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial is entailed in the given trials data   The primary trial had a total of 0 adverse events out of 14 participants 000 while the secondary trial had a total of 48 adverse events out of 348 participants 1379 Therefore the primary",
        "label": "Entailment"
    },
    "db493601-5dae-4077-a455-582cd9e28315": {
        "text_answer": "  The statement qualification for the secondary clinical trial ensures the identical qualification for the primary clinical trial as well is a conditional statement To determine if it is entailed in the trials or contradictory we need to compare the inclusion and exclusion criteria of both trials  Lets examine the inclusion criteria first  Primary Trial Women with nonpalpable malignant lesions requiring image guided localization undergoing lumpect",
        "label": "Entailment"
    },
    "e10d648e-a24d-4358-b81f-77b68fce3dc8": {
        "text_answer": "  The statement is not directly entailed in the given trials as they do not provide sufficient information to make a definitive comparison between the frequency of Biliary colic and Diarrhoea in both trials The trials only provide the total number of adverse events and the number of specific adverse events for each trial However the statement implies that there are more cases of Biliary colic and Diarrhoea in the secondary trial compared to the primary trial based",
        "label": "Contradiction"
    },
    "df709118-7130-4d0e-8150-a05fa7f1a6d1": {
        "text_answer": "  The statement Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen andor progesterone receptor positive and are considering AI therapy are eligible for the primary trial is not entailed in the given inclusion and exclusion criteria  The primary trial is specifically designed for patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone re",
        "label": "Contradiction"
    },
    "077cc008-c777-4fa3-826b-8cc903eab60e": {
        "text_answer": "  The statement is contradictory to the given trials as the trials specify different dosages for each cohort Cohort 1 receives a dosage of 0015 mgkgdose while cohort 2 receives a dosage of 0040 mgkgdose Therefore the statement that both cohort 1 and cohort 2 of the primary clinical trial are administered the same",
        "label": "Entailment"
    },
    "a36a79c9-39aa-493e-a7f9-18771e4a50cf": {
        "text_answer": "  The statement no notable occurrence of pathologic complete response was observed in breast and axillary lymph nodes among trial participants in either cohort of the primary clinical trial after around 7 months postsurgery is not directly entailed in the given trial results as they do not provide the number of participants with pathologic complete response in each cohort However the statement is neutral and does not contradict the information provided in the trials as the",
        "label": "Contradiction"
    },
    "3a027890-3744-44b7-a008-b18f60b0fdd4": {
        "text_answer": "  The given statement none of the patients in the primary trial experienced the worst pain imaginable for 70 days is not directly entailed or contradicted by the information provided in Trials 1 and 2   The trials only report the average pain intensity scores and the change in average pain intensity between the two intervention groups over a 10week period They do not provide information on the distribution of pain intensity scores or the number of patients who experienced the",
        "label": "Contradiction"
    },
    "028e1c85-f23e-411f-bf70-3621480de375": {
        "text_answer": "  The statement the secondary trial patients suffered from anemia pneumonia and stupor more often than patients in the primary trial is entailed in the Trials as follows  The frequency of anemia in the secondary trial is 625 116 while in the primary trial it is 000 034 The difference in frequency is 625  0",
        "label": "Entailment"
    },
    "634ef5d6-4281-4d39-b876-59be4ed256ec": {
        "text_answer": "  The primary clinical trial measures the percentage of participants with ovarian cancer showing tumor response based on RECIST criteria after receiving all 24 doses of 852A The secondary clinical trial measures the number of participants with aromatase inhibitor associated musculoskeletal symptoms AIMSS over a 12month period  The statement is not entailed in the trials as they measure different outcomes The primary trial measures tum",
        "label": "Contradiction"
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "text_answer": "  The statement Africanamerican patients can participate in the primary trial is entailed in the given inclusion criteria for the primary trial as there is no mention of any exclusion based on race or ethnicity",
        "label": "Entailment"
    },
    "42746679-44a5-4854-ba22-6557c0c34ff8": {
        "text_answer": "  The statement is contradictory to the information provided in the trials In the primary trial there is no mention of any injections being given to the participants However in the secondary trial participants receive weekly subcutaneous injections of epoetin beta Therefore the statement that candidates for the secondary trial study group do not receive any injections is contradictory to the information given in the trials",
        "label": "Contradiction"
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "text_answer": "  The statement is contradicted by the given trials   Explanation   The statement claims that only Eyelid oedema Upper gastrointestinal haemorrhage and Chest pain were observed as Adverse Events AEs in the secondary trial and no AEs were recorded in the primary trial However the trials provided show that there were AEs recorded in both trials including Eyelid oed",
        "label": "Contradiction"
    },
    "4138d4cd-bc5a-44db-8dc2-f64fbfb28b94": {
        "text_answer": "  The statement the primary clinical trial noted a number of adverse effects in patients belonging to cohort 1 is entailed in the given trials as the trials explicitly list the adverse events for each cohort However the statement does not provide any specific information about the number or type of adverse events that were entailed or contradicted by the trials so it is not a direct comparison or entailmentcontradiction between the two trials Therefore",
        "label": "Entailment"
    },
    "f51d8422-1f2c-45bf-8de8-ce554a19c011": {
        "text_answer": "  The statement patients with estrogen positive progesterone positive and her2 breast cancer are included in the primary clinical trial is contradictory to the given inclusion criteria The trial only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 It does not include patients with ER positive PR positive and HER2 positive breast cancer Therefore the statement",
        "label": "Entailment"
    },
    "74b24825-1c77-48e6-a1ce-c5b7e60b2b61": {
        "text_answer": "  The statement is a contradiction with respect to the given trials The primary trial involves topical interventions Estring and Testosterone Cream while the secondary trial involves an acupuncture intervention which is not a topical intervention nor an inhalation intervention Therefore the statement is not entailed in the trials",
        "label": "Contradiction"
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "text_answer": "  To determine if the statement is entailed in the trials we need to compare the percentage of participants with Disease Progression or Death in each cohort   The percentage of participants with Disease Progression or Death in the Bevacizumab cohort was 883 and in the Bevacizumab  Capecitabine cohort it was 758   Comparing these percentages",
        "label": "Entailment"
    },
    "e0b061e1-ee74-46e0-a223-de370cfffc8a": {
        "text_answer": "  The statement is contradicted by the given trials as there were no adverse events reported in more than 03 of participants in either the primary or secondary trials The trials report adverse event rates of 048 and 000 for the primary and secondary trials respectively which are both less than 03",
        "label": "Contradiction"
    },
    "9625e56f-5de0-4cbd-8e30-a944bf6d6244": {
        "text_answer": "  The statement is not entailed in the given trials as the trials only specify the dosage and timing of dexamethasone administration for each cohort but they do not explicitly state that one cohort receives the drug postoperatively and the other preoperatively Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "cb88e277-c79d-4bb1-8d63-c637a14d0f48": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   In the primary trial denosumab is administered as a subcutaneous injection every 4 weeks In the secondary trial neither intervention involves an injection However the statement asserts that additionally the secondary trial does not employ any form of injection which is not accurate for the primary intervention in the secondary trial which is the use of the intraoperative handheld",
        "label": "Entailment"
    },
    "af615add-c0e4-4046-9968-9d5805d2620e": {
        "text_answer": "  The statement cancerfree patients are eligible for the primary clinical trial is entailed in the given trial criteria as there is no mention of active cancer or metastatic cancer as inclusion or exclusion criteria in the provided information",
        "label": "Entailment"
    },
    "9477c88f-8957-4925-8c5d-0061409159f8": {
        "text_answer": "  The statement vorinostat capsule ingestion on a daily basis throughout radiation therapy is a requirement for each patient involved in the primary clinical trial is entailed in the given trial information   Explanation   The trial description specifies that patients will take Vorinostat daily during radiation therapy Therefore the statement that vorinostat capsule ingestion on a daily basis throughout radiation therapy is a requirement for each patient involved",
        "label": "Entailment"
    },
    "04e554aa-1522-4fd6-a508-e0f13fa38832": {
        "text_answer": "  The statement 1000 of cohort 1 of the primary trial suffered at least 1 lifethreatening adverse event is not entailed in the given trial results   The trial results only provide the number of participants with serious and nonserious adverse events for each dose level but they do not specify the type or severity of the adverse events for each participant Therefore it is not possible to determine from",
        "label": "Contradiction"
    },
    "e762873d-0ab8-4732-8c17-fdab7712a8e5": {
        "text_answer": "  The statement thromboembolic incidents were experienced by patients in both the primary clinical trial and the secondary clinical trial is entailed in the given trials as there is at least one instance of thromboembolic event reported in each trial 137 in the primary trial and 152 in the secondary trial",
        "label": "Entailment"
    },
    "c9514ddd-0486-4aca-a0b7-4e03a2effc90": {
        "text_answer": "  The given statement during the 10week duration of the primary clinical trial several participants did not report any pain is not directly entailed or contradicted by the provided information in Trials 1 and 2   The trials only report the average pain intensity scores and the difference between the two intervention groups They do not provide information on the number of participants who reported no pain during the trial Therefore it is not possible to determine if the statement",
        "label": "Contradiction"
    },
    "570f69cb-de78-48d6-916b-bcb3ef0a27a7": {
        "text_answer": "  The statement is entailed in the trials as both interventions Inframammary Fold Incision Cohort and Lateral Radial Incision Cohort involve the use of laserassisted fluorescence angiography Spy Elite LifeCell for monitoring perfusion of the involved breast at three separate time points during the surgical procedure Therefore the statement is entailed in the trials",
        "label": "Entailment"
    },
    "54c9f3b4-b90f-4b60-a924-5a26c4097521": {
        "text_answer": "  The statement is neither entailed nor contradicted by the given trials   Explanation   The statement is about body fat measurement and the trials are about different interventions for two different patient cohorts The primary trial deals with oral pregabalin and the secondary trial deals with chemotherapy HDMTX and ITDepocyt There is no direct connection between the statement and the trials",
        "label": "Entailment"
    },
    "f95613c7-63f9-4f97-adbd-176220391993": {
        "text_answer": "  The statement is contradictory to the information provided in the trials   The primary trial states that participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks This is different from the statement that the primary trial requires patients to receive 220 milligrams of denosumab injected subcutaneously every week  Furthermore the secondary trial involves the use of",
        "label": "Entailment"
    },
    "4a7035e5-7fdf-461e-9d63-8e52be720d96": {
        "text_answer": "  The statement is not entailed in the given inclusion and exclusion criteria for either the primary or secondary trials The statement adds additional requirements not mentioned in the provided criteria for both trials The primary trial requires mammography while the secondary trial may require additional imaging modalities such as CT scans but this is not mentioned in the provided criteria The statement also mentions blood tests which is not mentioned in the secondary trials criteria Therefore the statement is contradict",
        "label": "Contradiction"
    },
    "29f65923-503d-402b-b0a3-150f741d8c2b": {
        "text_answer": "  The statement confirmation of a HER2 positive tumor through positive FISH or IHC 3 is mandatory for all individuals considering the primary clinical trial is entailed in the inclusion criteria of the trial The inclusion criteria clearly state that HER2 positive tumor either IHC 3 or FISH is a requirement for participation in the study Therefore the statement is entailed in the trials criteria",
        "label": "Entailment"
    },
    "096f687a-6eec-4648-b8f8-6d423d84f3ae": {
        "text_answer": "  The statement all ae types in the primary trial affected more than 50 of patients is contradictory to the given data The total number of adverse events 4 affected 3636 of patients which is less than 50 Therefore the statement is contradictory to the given data",
        "label": "Entailment"
    },
    "869ef7c8-edf9-4eb0-8654-3bb28fa1b4aa": {
        "text_answer": "  The statement Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial is a statement about the use of Perjeta in the two trials which is not directly related to the information provided about fibrous meningioma Therefore the statement does not entail or contradict the information given about fibrous meningioma in the trials",
        "label": "Entailment"
    },
    "df8057c4-0640-488f-9a63-9036703fbf83": {
        "text_answer": "  The statement all patients in the primary trial receive at least 2ml of mcs110 every 3 weeks is not directly entailed in the given trial information The trials only specify the dosages of MCS110 1 mgkg or 3 mgkg and the dosage and frequency of PDR001 100 mg every 3 weeks They do not provide information about the volume of the administered doses",
        "label": "Contradiction"
    },
    "4aae628e-86f0-4851-9319-0a7d44d488b9": {
        "text_answer": "  The statement primary clinical trial does not accommodate patients with hypokalemia however the secondary clinical trial may accept them is a contradiction based on the information provided in the given trials inclusion and exclusion criteria  The primary trial explicitly lists Potassium within the normal range of 3553 mEqL as an inclusion criterion Therefore patients with hypokalemia potassium levels below 35",
        "label": "Contradiction"
    },
    "9dd72932-f9f7-4ad7-8c3e-15f284d93d89": {
        "text_answer": "  The statement male prostate cancer patients over the age of 55 can participate in the primary clinical trial regardless of race or ethnic origin is entailed in the inclusion criteria of the primary trial as it states Females age 18 years of age or older of all racial and ethnic origins are eligible However the statement however for the secondary clinical trial they must have a confirmed diagnosis of advanced castrationresistant",
        "label": "Entailment"
    },
    "cc6d64c8-a841-4a6b-bf57-df451ad47edb": {
        "text_answer": "  The statement there were severe adverse events AEs reported in cohort 1 of the primary clinical trial is a contradiction to the information given in the trials data provided which states that Total 0147 000 Since there were no severe adverse events reported in the trial according to the data the statement that there were severe adverse events reported is a contradiction to the facts",
        "label": "Contradiction"
    },
    "d803d6fb-f2af-4470-8cf9-7f68d6c53baf": {
        "text_answer": "  The statement is contradictory to the given trials as the trials do not involve orthodontic treatment for correcting malocclusions of the teeth and their surrounding structures The primary trial is using hormonal interventions Estring and Testosterone Cream for managing lymphedema while the secondary trial is testing acupuncture as an intervention for lymphedema management",
        "label": "Entailment"
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "text_answer": "  The statement Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial but this is not necessary to be included in the secondary trial is a statement of contradiction with respect to the given trials   The primary trial has specific inclusion criteria that require participants to be resistant to AI therapy and mirtazapine while the secondary trial does not mention these requirements at all Therefore the secondary trial does not",
        "label": "Contradiction"
    },
    "b2ef7c16-b0e9-48dd-be60-9243443535b7": {
        "text_answer": "  The statement patients diagnosed with nut midline carcinoma castrateresistant prostate cancer or inflammatory breast cancer confirmed by fluorescence in situ hybridization can participate in both the primary clinical trial and the secondary clinical trial is not explicitly stated in the given inclusion or exclusion criteria for either trial However the primary trials inclusion criteria do allow for participation of patients with NUT midline carcinoma and cas",
        "label": "Entailment"
    },
    "0b659007-1edc-43da-aafe-0024c2bb233e": {
        "text_answer": "  The statement Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study is not directly entailed in the provided trial information The trials only report the average pain intensity scores and the difference between the two intervention groups They do not provide specific information about the number of patients who experienced no pain at all during the study",
        "label": "Contradiction"
    },
    "1d828a72-b303-4395-bab6-31865552caff": {
        "text_answer": "  The statement adult mixed glioma is a mixed glioma that occurs during adulthood The secondary trial candidates must be Completely disabled to participate whereas this is not required to be accepted into the primary trial is not entailed in the given trials as there is no mention of adult mixed glioma or disability in the inclusion or exclusion criteria for either the primary or secondary trials",
        "label": "Contradiction"
    },
    "13f17e45-4ce5-4de3-8a67-eee3ca98c4eb": {
        "text_answer": "  The statement is not entailed in the given trials as there is no mention of a cohort 1 using paclitaxel in the provided information The trials only compare Arm A ANA using oral anastrozole and Arm B FULV using intramuscular fulvestrant",
        "label": "Contradiction"
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "text_answer": "  The statement Patients diagnosed with breast cancer may be eligible for all study groups in the primary trial and the secondary trial is neither entailed nor contradicted by the given inclusion and exclusion criteria for both trials  Explanation  The primary trial includes postmenopausal women with early stage breast cancer who have low vitamin D levels and will be treated with an aromatase inhibitor The secondary trial includes healthy participants and HER2",
        "label": "Entailment"
    },
    "6efe0add-df04-4255-a81f-8a542c0b810f": {
        "text_answer": "  The statement patients in the primary clinical trial are not administered any fentanyl sublingual spray during their radiation therapy is a contradiction to the given trial information   The trial description does not mention anything about the use or nonuse of fentanyl sublingual spray during radiation therapy The statement makes a definitive claim about the absence of this medication which is not supported by the provided information",
        "label": "Contradiction"
    },
    "9a276dfa-f4f9-4abe-837e-18cca465967e": {
        "text_answer": "  The statement the primary trial and the secondary trial have 0 recorded adverse events is entailed by the given trials as both trials report having no recorded adverse events for Adverse Events 1 The statement does not make any mention of cytomegalovirus positive status so it is not directly related to that aspect of the trials Therefore the statement is entailed by the trials based on the reported data regarding adverse events",
        "label": "Entailment"
    },
    "19ad39bd-9620-4ff6-8afe-a81348b4fada": {
        "text_answer": "  The statement is a contradiction to the information provided in the primary and secondary trial descriptions In the primary trial patients receive a single injection at the baseline while in the secondary trial patients in the intervention group receive 15 weekly injections These are different dosing schedules making the statement a contradiction",
        "label": "Contradiction"
    },
    "773d939c-db89-4999-9903-89da67345b49": {
        "text_answer": "  The statement some of the patients in the primary clinical trial did not receive sunitinib every day for the entire duration of the study is entailed in the trial description   The trial description states that sunitinib dosing could be interrupted or reduced according to individual tolerance indicating that some patients did not receive sunitinib every day for the entire duration of the study",
        "label": "Entailment"
    },
    "a8f421ec-e3c7-43b4-96da-b6bca22d68ed": {
        "text_answer": "  The statement 0 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 4 weeks of the study is contradictory to the information provided in the trials   The trials do not report any data on pathologic complete response after approximately 4 weeks of the study Instead they report the number of participants with pathologic complete response at the time of surgery which",
        "label": "Entailment"
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "text_answer": "  The statement On average patients from the primary trial survive over 2 years over 50 patients from each cohort survived more than 24 months is not directly entailed in the given trials as they only provide the median survival times and the number of participants analyzed for each group but not the number of patients surviving beyond 24 months Therefore the statement is neither entailed nor contradicted by the given trials",
        "label": "Contradiction"
    },
    "6ee00118-66be-4e39-85a7-2dd1feaca87b": {
        "text_answer": "  Lets calculate the number of cases for hepatotoxicity hypertension and pancreatectomy based on the given information  1 Hepatotoxicity 38  0375  038 cases 2 Hypertension 18  0125  013 cases 3 Pancreatectomy 1",
        "label": "Entailment"
    },
    "d1123c9b-e0d4-412d-bcf6-a69bbb07a0f4": {
        "text_answer": "  The statement throughout the primary clinical trial an instance of doselimiting toxicity was identified in two different patients each from separate cohorts is not directly entailed in the given trial results However it is not contradictory either as the trial results do not provide sufficient information to definitively confirm or deny the statement The trial results only report the number of participants analyzed in each cohort and do not specify whether any of them experienced dose",
        "label": "Contradiction"
    },
    "8bc95ffe-c455-4563-bc81-a7530f6fb500": {
        "text_answer": "  The statement secondary peripheral chondrosarcoma grade 2 is an intermediategrade chondrosarcoma arising within the cartilaginous cap of a preexisting osteochondroma is neither entailed nor contradictory to the given inclusion and exclusion criteria for the clinical trial   The statement pertains to a different type of cancer chondrosarcoma and does not directly relate to the",
        "label": "Entailment"
    },
    "9f08a841-c0c4-42e4-984f-0700bb46f18f": {
        "text_answer": "  Lets calculate the amount of MCS110 administered every 21 days for each intervention  1 Intervention 1    MCS110 1 mgkg every 3 weeks    PDR001 100 mg every 3 weeks     To find the total amount of MCS110 administered every 21 days we need to calculate the dose per 21",
        "label": "Entailment"
    },
    "921d278b-11fe-4f67-883a-cd10b15c20f2": {
        "text_answer": "  The statement grade 1 acoustic nerve disorder nos ctcae is asymptomatic clinical or diagnostic observations only intervention not indicated is not directly related to the adverse events data provided in the trials The statement refers to a grade 1 acoustic nerve disorder which is not listed as an adverse event in either trial Therefore it cannot be determined if the statement is entailed or contradicted based on the given information",
        "label": "Entailment"
    },
    "17ca93e8-5115-4f53-8d4a-b3ce6c43ea58": {
        "text_answer": "The statement simultaneous participation in both the primary and secondary trial is allowed for all patients is not explicitly stated as an inclusion criterion in either the primary or secondary trial However there is no exclusion criterion in either trial that specifically prohibits simultaneous participation in both trials Therefore the statement is neither entailed nor contradicted by the information provided in the trials It would depend on the specific policies and procedures of the research institutions and investigators involved in conducting",
        "label": "Contradiction"
    },
    "04191593-f36e-4fc0-8af5-7591059640a4": {
        "text_answer": "  The statement primary clinical trials first cohort had numerous pancytopenia occurrences with no recorded instances of anemia and febrile neutropenia is contradictory to the information provided in the trials  The first trial reported 18 participants with 1 participant experiencing pancytopenia 1 participant experiencing anemia and 1 participant experiencing febrile neutropenia Therefore the statement",
        "label": "Contradiction"
    }
}